PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Rossier, G; Meier, C; Bauch, C; Summa, V; Sordat, B; Verrey, F; Kuhn, LC				Rossier, G; Meier, C; Bauch, C; Summa, V; Sordat, B; Verrey, F; Kuhn, LC			LAT2, a new basolateral 4F2hc/CD98-associated amino acid transporter of kidney and intestine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; INTERLEUKIN-1-DEPENDENT INTERLEUKIN-2 PRODUCTION; MONOCLONAL-ANTIBODY 4F2; EL4 THYMOMA CELLS; HEAVY-CHAIN; EXPRESSION CLONING; SURFACE-ANTIGEN; RAT-KIDNEY; POSTTRANSCRIPTIONAL REGULATION; TRANSFERRIN RECEPTOR	Glycoprotein-associated amino acid transporters (gpaAT) are permease-related proteins that require heterodimerization to express their function. So far, four vertebrate gpaATs have been shown to associate with 4F2hc/CD98 for functional expression, whereas one gpaAT specifically associates with rBAT. In this study, we characterized a novel gpaAT, LAT2, for which mouse and human cDNAs were identified by expressed sequence tag data base searches. The encoded ortholog proteins are 531 and 535 amino acids long and 92% identical. They share 52 and 48% residues with the gpaATs LAT1 and y(+)LAT1, respectively. When mouse LAT2 and human 4F2hc cRNAs were co-injected into Xenopus oocytes, disulfide-linked heterodimers were formed, and an L-type amino acid uptake was induced, which differed slightly from that produced by LAT1-4F2hc: the apparent affinity for L-phenylalanine was higher, and L-alanine was transported at physiological concentrations. In the presence of an external amino acid substrate, LAT2-4F2hc also mediated amino acid efflux. LAT2 mRNA is expressed mainly in kidney and intestine, whereas LAT1 mRNA is expressed widely. Immunofluorescence experiments showed colocalization of 4F2hc and LAT2 at the basolateral membrane of kidney proximal tubules and small intestine epithelia. In conclusion, LAT2 forms with LAT1 a subfamily of L-type gpaATs, We propose that LAT1 is involved in cellular amino acid uptake, whereas LAT2 plays a role in epithelial amino acid (re)absorption.	Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland; Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland	Swiss Institute Experimental Cancer Research; University of Zurich	Kuhn, LC (corresponding author), Swiss Inst Expt Canc Res, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.			Rossier, Gregoire/0000-0002-0065-5053; Verrey, Francois/0000-0003-3250-9824				BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; Borsani G, 1999, NAT GENET, V21, P297, DOI 10.1038/6815; Broer S, 1995, BIOCHEM J, V312, P863, DOI 10.1042/bj3120863; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTENSEN HN, 1994, J EXP BIOL, V196, P51; FURRIOLS M, 1993, J BIOL CHEM, V268, P27060; GAUGITSCH HW, 1992, J BIOL CHEM, V267, P11267; HAYNES BF, 1981, J IMMUNOL, V126, P1409; HEMLER ME, 1982, J IMMUNOL, V129, P623; HORISBERGER JD, 1991, J BIOL CHEM, V266, P19131; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; LINDSTEN T, 1988, MOL CELL BIOL, V8, P3820, DOI 10.1128/MCB.8.9.3820; LUMADUE JA, 1987, P NATL ACAD SCI USA, V84, P9204, DOI 10.1073/pnas.84.24.9204; LUSCHER B, 1985, J IMMUNOL, V135, P3951; MACDONALD HR, 1985, J IMMUNOL, V135, P3944; Mannion BA, 1998, J BIOL CHEM, V273, P33127, DOI 10.1074/jbc.273.50.33127; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; Nakamura E, 1999, J BIOL CHEM, V274, P3009, DOI 10.1074/jbc.274.5.3009; PARMACEK MS, 1989, NUCLEIC ACIDS RES, V17, P1915, DOI 10.1093/nar/17.5.1915; Pfeiffer R, 1998, FEBS LETT, V439, P157, DOI 10.1016/S0014-5793(98)01359-3; Pfeiffer R, 1999, EMBO J, V18, P49, DOI 10.1093/emboj/18.1.49; PICKEL VM, 1993, P NATL ACAD SCI USA, V90, P7779, DOI 10.1073/pnas.90.16.7779; Puoti A, 1997, P NATL ACAD SCI USA, V94, P5949, DOI 10.1073/pnas.94.11.5949; QUACKENBUSH E, 1987, P NATL ACAD SCI USA, V84, P6526, DOI 10.1073/pnas.84.18.6526; QUACKENBUSH EJ, 1986, J IMMUNOL, V136, P118; SANG JS, 1995, CANCER RES, V55, P1152; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; SEISER C, 1993, J BIOL CHEM, V268, P13074; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; TAYLOR MA, 1987, DEV BIOL, V124, P287, DOI 10.1016/0012-1606(87)90480-5; TEIXEIRA S, 1991, EUR J BIOCHEM, V202, P819, DOI 10.1111/j.1432-1033.1991.tb16438.x; TEIXEIRA S, 1987, J BIOL CHEM, V262, P9574; Torrents D, 1998, J BIOL CHEM, V273, P32437, DOI 10.1074/jbc.273.49.32437; Torrents D, 1999, NAT GENET, V21, P293, DOI 10.1038/6809; WELLS RG, 1992, J BIOL CHEM, V267, P15285; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; Wolf DA, 1996, CANCER RES, V56, P5012; [No title captured]	40	270	280	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34948	34954		10.1074/jbc.274.49.34948	http://dx.doi.org/10.1074/jbc.274.49.34948			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574970	hybrid			2022-12-25	WOS:000083979600064
J	Zhang, YK; Sun, XG; Muraoka, K; Ikeda, A; Miyamoto, S; Shimizu, H; Yoshioka, K; Yamamoto, K				Zhang, YK; Sun, XG; Muraoka, K; Ikeda, A; Miyamoto, S; Shimizu, H; Yoshioka, K; Yamamoto, K			Immunosuppressant FK506 activates NF-kappa B through the proteasome-mediated degradation of I kappa B alpha - Requirement for I kappa B alpha N-terminal phosphorylation but not ubiquitination sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-INDUCED DEGRADATION; KINASE-ALPHA; BETA; TRANSDUCTION; INHIBITOR; PATHWAY; COMPLEX; PROTEIN; MECHANISM; DOMAIN	The immunosuppressant FK506 activates NJ-kappa B through I kappa B alpha degradation in nonlymphoid cells. In the present study, we analyzed mechanisms by which FK506 induces I kappa B alpha degradation. We found that FK506 induces the degradation of both I kappa B alpha and I kappa B beta and that the time courses of the FK506-induced degradation are quite different from degradation induced by interleukin 1 (IL-1). Despite this difference, FK506-induced I kappa B alpha degradation was dependent on the N-terminal Ser-32 and Ser-36 phosphorylation sites and was mediated by proteasomes, as is the case for IL-1-induced I kappa B alpha degradation. We further showed that FK506 induces weak and slow phosphorylation of I kappa B alpha at Ser-32. However, unlike IL-1-induced degradation, IKK-1 and IKK-2 were not activated significantly nor was FK506-induced I kappa B alpha degradation dependent on the N-terminal ubiquitination sites (Lys-21 and Lys-22). These results therefore indicate that FK506 and IL-1 utilize similar but distinct mechanisms to induce the phosphorylation and degradation of I kappa B alpha.	Kanazawa Univ, Canc Res Inst, Dept Mol Pathol, Kanazawa, Ishikawa 9200934, Japan; Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53792 USA	Kanazawa University; University of Wisconsin System; University of Wisconsin Madison	Yamamoto, K (corresponding author), Kanazawa Univ, Canc Res Inst, Dept Mol Pathol, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.							Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRILLANTES AB, 1994, CELL, V77, P512; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Dick LR, 1997, J BIOL CHEM, V272, P182; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DUMONT FJ, 1992, J EXP MED, V176, P751, DOI 10.1084/jem.176.3.751; FIGUEIREDOPEREIRA ME, 1994, J NEUROCHEM, V62, P1989; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; JARIELENCONTRE I, 1995, J BIOL CHEM, V270, P11623, DOI 10.1074/jbc.270.19.11623; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Muraoka K, 1996, J CLIN INVEST, V97, P2433, DOI 10.1172/JCI118690; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Onishi I, 1997, FEBS LETT, V420, P201, DOI 10.1016/S0014-5793(97)01517-2; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Shimada T, 1999, INT IMMUNOL, V11, P1357, DOI 10.1093/intimm/11.8.1357; STUGILL TW, 1988, NATURE, V334, P715; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VERMA IM, 1995, GENE DEV, V9, P2733; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	43	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34657	34662		10.1074/jbc.274.49.34657	http://dx.doi.org/10.1074/jbc.274.49.34657			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574930	hybrid			2022-12-25	WOS:000083979600024
J	Kean, EL; Wei, ZL; Anderson, VE; Zhang, NJ; Sayre, LM				Kean, EL; Wei, ZL; Anderson, VE; Zhang, NJ; Sayre, LM			Regulation of the biosynthesis of N-acetylglucosaminylpyrophosphoryldolichol feedback and product inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOLICHOL PHOSPHATE-MANNOSE; P-P-DOLICHOL; MULTIPLE TRANSMEMBRANE SPANS; LIPID-LINKED OLIGOSACCHARIDE; UDP-GLCNAC; N-ACETYLGLUCOSAMINE-1-P TRANSFERASE; GLCNAC-1-PHOSPHATE TRANSFERASE; EMBRYONIC CHICK; STIMULATION; ACTIVATION	The assembly of the core oligosaccharide region of asparagine-linked glycoproteins proceeds by means of the dolichol pathway, The first step of this pathway, the reaction of dolichol phosphate with UDP-GlcNAc to formN-acetylglucosaminylpyrophosphoryldolichol (GlcNAc-P-P-dolichol), is under investigation as a possible site of metabolic regulation, This report describes feedback inhibition of this reaction by the second intermediate of the pathway, N-acetylglucosaminyl-N-acetylglucosaminylpyrophosphoryldolichol (GlcNAc-GlcNAc-P-P-dolichol), and product inhibition by GlcNAc-P-P-dolichol itself. These influences were revealed when the reactions mere carried out in the presence of showdomycin, a nucleoside antibiotic, present at concentrations that block the cte novo formation of GlcNAc-GlcNAc-P-P-dolichol but not that of GlcNAc-P-P-dolichol. The apparent Ki values for GlcNAc-P-P-dolichol and GlcNAc-GlcNAc-P-P-dolichol under basal conditions were 4.4 and 2.8 mu m, respectively. Inhibition was also observed under conditions where mannosyl-P-dolichol (Man-P-dol) stimulated the biosynthesis of GlcNAc-P-P-dolichol; the apparent gi values for GlcNAc-P-P-dolichol and GlcNAc-GlcNAc-P-P-dolichol were 2.2 and 11 mu M, respectively. Kinetic analysis of the types of inhibition indicated competitive inhibition by GlcNAc-P-P-dolichol toward the substrate UDP-GlcNAc and non-competitive inhibition toward dolichol phosphate, Inhibition by GlcNAc-GlcNAc-P-P-dolichol was uncompetitive toward UDP-GlcNAc and competitive toward dolichol phosphate, A model is presented for the kinetic mechanism of the synthesis of GlcNAc-P-P-dolichol. GlcNAc-P-P-dolichol also exerts a stimulatory effect on the biosynthesis of Man-P-dol, i,e, a reciprocal relationship to that previously observed between these two intermediates of the dolichol pathway. This network of inhibitory and stimulatory influences may be aspects of metabolic control of the pathway and thus of glycoprotein biosynthesis in general.	Case Western Reserve Univ, Dept Ophthalmol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Kean, EL (corresponding author), Case Western Reserve Univ, Dept Ophthalmol, Rm 653,Wearn Bldg,11100 Euclid Ave, Cleveland, OH 44106 USA.		Anderson, Vernon/W-2673-2019; Sayre, Lawrence M/C-8224-2011	Anderson, Vernon Emmett/0000-0002-1699-7621	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036562] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014249] Funding Source: NIH RePORTER; NEI NIH HHS [EY00393] Funding Source: Medline; NIA NIH HHS [AG14249] Funding Source: Medline; NIGMS NIH HHS [GM36562] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1990, J BIOL CHEM, V265, P14691; BANGS JD, 1986, J CELL BIOL, V103, P255, DOI 10.1083/jcb.103.1.255; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; CARSON DD, 1990, J BIOL CHEM, V265, P2947; Cleland W W, 1979, Methods Enzymol, V63, P103; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P188; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P173, DOI 10.1016/0926-6569(63)90226-8; Dan N, 1996, J BIOL CHEM, V271, P30717, DOI 10.1074/jbc.271.48.30717; Dan N, 1997, J BIOL CHEM, V272, P14214, DOI 10.1074/jbc.272.22.14214; FOLCH J, 1957, J BIOL CHEM, V226, P497; HARFORD JB, 1979, ARCH BIOCHEM BIOPHYS, V197, P424, DOI 10.1016/0003-9861(79)90264-9; HAYES GR, 1983, J BIOL CHEM, V258, P5095; HEIFETZ A, 1979, BIOCHEMISTRY-US, V18, P2186, DOI 10.1021/bi00578a008; HEMMING FW, 1995, GLYCOPROTEINS, P127; IMPERIALI B, 1990, TETRAHEDRON LETT, V31, P6485, DOI 10.1016/S0040-4039(00)97097-7; KAUSHAL GP, 1985, J BIOL CHEM, V260, P6303; KEAN EL, 1977, J SUPRAMOL STR CELL, V7, P381, DOI 10.1002/jss.400070310; Kean EL, 1996, GLYCOCONJUGATE J, V13, P675, DOI 10.1007/BF00731456; KEAN EL, 1983, BIOCHIM BIOPHYS ACTA, V750, P268, DOI 10.1016/0005-2760(83)90028-0; KEAN EL, 1991, J BIOL CHEM, V266, P942; Kean EL, 1998, GLYCOCONJUGATE J, V15, P405, DOI 10.1023/A:1006982003957; KEAN EL, 1983, BIOCHIM BIOPHYS ACTA, V752, P488, DOI 10.1016/0005-2760(83)90280-1; KEAN EL, 1986, ARCH BIOCHEM BIOPHYS, V250, P146, DOI 10.1016/0003-9861(86)90711-3; KEAN EL, 1985, J BIOL CHEM, V260, P2561; Kean EL, 1998, GLYCOCONJUGATE J, V15, P11, DOI 10.1023/A:1006931230848; KEAN EL, 1977, EXP EYE RES, V25, P405, DOI 10.1016/0014-4835(77)90108-7; KEAN EL, 1977, J BIOL CHEM, V252, P5622; KEAN EL, 1994, BIOCHEMISTRY-US, V33, P10508, DOI 10.1021/bi00200a036; KEAN EL, 1982, J BIOL CHEM, V257, P7952; KEAN EL, 1992, BIOCHEM CELL BIOL, V70, P413, DOI 10.1139/o92-064; KUKURUZINSKA MA, 1995, BBA-PROTEIN STRUCT M, V1247, P51, DOI 10.1016/0167-4838(94)00201-Q; KUKURUZINSKA MA, 1994, BIOCHEM BIOPH RES CO, V198, P1248, DOI 10.1006/bbrc.1994.1176; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; LEHRMAN M A, 1991, Glycobiology, V1, P553, DOI 10.1093/glycob/1.6.553; LENNON K, 1995, GLYCOBIOLOGY, V5, P633, DOI 10.1093/glycob/5.6.633; LUCAS JJ, 1975, J BIOL CHEM, V250, P1992; PAN YT, 1990, BIOCHEMISTRY-US, V29, P8077, DOI 10.1021/bi00487a013; PRASAD AVK, 1992, EXP EYE RES, V54, P913, DOI 10.1016/0014-4835(92)90155-L; REISSIG JL, 1955, J BIOL CHEM, V217, P959; SCHUTZBACH JS, 1993, J BIOL CHEM, V268, P24190; SHAILUBHAI K, 1988, J BIOL CHEM, V263, P15964	41	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34072	34082		10.1074/jbc.274.48.34072	http://dx.doi.org/10.1074/jbc.274.48.34072			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567375	hybrid			2022-12-25	WOS:000083857500040
J	Kruyt, FAE; Abou-Zahr, F; Mok, H; Youssoufian, H				Kruyt, FAE; Abou-Zahr, F; Mok, H; Youssoufian, H			Resistance to mitomycin C requires direct interaction between the fanconi anemia proteins FANCA and FANCG in the nucleus through an arginine-rich domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS; FAC; LOCALIZATION; CYTOPLASM; CYTOTOXICITY; APOPTOSIS; XRCC9	Fanconi anemia (FA) is a genetically heterogeneous disorder characterized by bone marrow failure, birth defects, and chromosomal instability. Because FA cells are sensitive to mitomycin C (MMC), FA gene products could be involved in cellular defense mechanisms. The FANCA and FANCG proteins deficient in FA groups A and G interact directly with each other. We have localized the mutual interaction domains of these proteins to amino acids 18-29 of FANCA and to two noncontiguous carboxyl-terminal domains of FANCG encompassing amino acids 400-475 and 585-622, Site-directed mutagenesis of FANCA residues 18-29 revealed a novel arginine-rich interaction domain (RRRAWAELLAG). By alanine mutagenesis, Arg(1), Arg(2), and Leu(8) but not Arg(3), Trp(5), and Glu(7) appeared to be critical for binding to FANCG, Similar immunolocalization for FANCA and FANCG suggested that these proteins interact in vivo. Moreover, targeting of FANCA to the nucleus or the cytoplasm with nuclear localization and nuclear export signals, respectively, showed concordance between the localization patterns of FANCA and FANCG, The complementation function of FANCA was abolished by mutations in its FANCG-binding domain. Conversely, stable expression of FANCA mutants encoding intact FANCG interaction domains induced hypersensitivity to MMC in HeLa cells. These results demonstrate that FANCA-FANCG complexes are required for cellular resistance to MMC. Because the FANCC protein deficient in FA group C works within the cytoplasm, we suggest that FANCC and the FANCA-FANCG complexes suppress MMC cytotoxicity within distinct cellular compartments.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Youssoufian, H (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza,S840, Houston, TX 77030 USA.			Kruyt, Frank/0000-0002-2445-9380				Apostolou S, 1996, NAT GENET, V14, P324, DOI 10.1038/ng1196-324; AUERBACH AD, 1998, GENETIC BASIS HUMAN, P317; de Winter JP, 1998, NAT GENET, V20, P281, DOI 10.1038/3093; Fearnhead HO, 1997, GENE DEV, V11, P1266, DOI 10.1101/gad.11.10.1266; Garcia-Higuera I, 1999, MOL CELL BIOL, V19, P4866; Hoatlin ME, 1998, BLOOD, V91, P1418, DOI 10.1182/blood.V91.4.1418; JACHYMCZYK WJ, 1981, MOL GEN GENET, V182, P196, DOI 10.1007/BF00269658; Kruyt FAE, 1998, BLOOD, V92, P3050, DOI 10.1182/blood.V92.9.3050.421k56_3050_3056; Kruyt FAE, 1998, BLOOD, V92, P2229, DOI 10.1182/blood.V92.7.2229.2229_2229_2236; Kupfer GM, 1997, NAT GENET, V17, P487, DOI 10.1038/ng1297-487; Lightfoot J, 1999, HUM MOL GENET, V8, P1007, DOI 10.1093/hmg/8.6.1007; Liu N, 1997, P NATL ACAD SCI USA, V94, P9232, DOI 10.1073/pnas.94.17.9232; LoTenFoe JR, 1996, NAT GENET, V14, P320, DOI 10.1038/ng1196-320; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Mian IS, 1998, MOL GENET METAB, V63, P230, DOI 10.1006/mgme.1997.2652; Naf D, 1998, MOL CELL BIOL, V18, P5952; STRATHDEE CA, 1992, NATURE, V358, P434, DOI 10.1038/358434a0; Waisfisz Q, 1999, P NATL ACAD SCI USA, V96, P10320, DOI 10.1073/pnas.96.18.10320; WEVRICK R, 1993, HUM MOL GENET, V2, P655, DOI 10.1093/hmg/2.6.655; Wright EG, 1999, J PATHOL, V187, P19, DOI 10.1002/(SICI)1096-9896(199901)187:1<19::AID-PATH233>3.0.CO;2-1; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P6712, DOI 10.1073/pnas.91.14.6712; Youssoufian H, 1996, J CLIN INVEST, V97, P2003, DOI 10.1172/JCI118635; YOUSSOUFIAN H, 1994, P NATL ACAD SCI USA, V91, P7975, DOI 10.1073/pnas.91.17.7975	23	46	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34212	34218		10.1074/jbc.274.48.34212	http://dx.doi.org/10.1074/jbc.274.48.34212			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567393	hybrid			2022-12-25	WOS:000083857500058
J	Liu, T; Liu, XX; Wang, HY; Moon, RT; Malbon, CC				Liu, T; Liu, XX; Wang, HY; Moon, RT; Malbon, CC			Activation of rat frizzled-1 promotes Wnt signaling and differentiation of mouse F9 teratocarcinoma cells via pathways that require G alpha(q) and G alpha(o) function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; XENOPUS EMBRYOS; PHOSPHOLIPASE-C; AXIS FORMATION; DEVELOPMENTAL REGULATORS; PRIMITIVE ENDODERM; FAMILY; TRANSCRIPTION; GSK3-BETA; RECEPTORS	The frizzled gene family of putative Wnt receptors encodes proteins that have a seven transmembrane-spanning motif characteristic of G-protein-linked receptors, although no loss-of-function studies have demonstrated a requirement for G-proteins for Wnt signaling by the gene product of frizzled-l. Medium conditioned by mouse F9 teratocarcinoma stem cells stably transfected to express either Xenopus Wnt-5a or Wnt-8 was used to test primitive endoderm formation of F9 stem cells. F9 stem cells expressing the rat Frizzled-l receptors demonstrated endoderm formation in response to conditioned medium containing Wnt-8 but not to medium containing Wnt-5a. Primitive endoderm formation stimulated by Wnt-8 acting on the rat Frizzled-1 receptor was blocked by treatment with pertussis toxin by depletion of either G alpha(o) or G alpha(q) via antisense oligodeoxynucleotides, as well as by inhibitors of protein kinase C (bisindoylmaleimide) and of mitogen-activated protein kinase kinase (PD98059). Our results demonstrate the requirement for G-protein subunits G alpha(o) (a pertussis toxin substrate) and G alpha(q) for signaling by Frizzled-1, and an obligate role for the protein kinase C (likely mediated through stimulation of G alpha(q)) and mitogen-activated protein kinase network at the level of mitogen-activated protein kinase kinase.	SUNY Stony Brook, Dept Pharmacol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Howard Hughes Med Inst, Seattle, WA 98195 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Malbon, CC (corresponding author), SUNY Stony Brook, Dept Pharmacol, Stony Brook, NY 11794 USA.	craig@pharm.sunysb.edu	Moon, Randall/M-5605-2019; malbon, craig/ABF-3604-2020; Moon, Randall T/B-1743-2014	Moon, Randall/0000-0002-9352-1408; Moon, Randall T/0000-0002-9352-1408				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; ANDRADEGORDON P, 1986, BIOCHEMISTRY-US, V25, P4033, DOI 10.1021/bi00362a007; Bahouth SW, 1996, RECEPT SIGNAL TRANS, V6, P141; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bhat KM, 1998, CELL, V95, P1027, DOI 10.1016/S0092-8674(00)81726-2; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; Cox RT, 1998, CURR BIOL, V8, pR140, DOI 10.1016/S0960-9822(98)70081-8; CUI YZ, 1995, DEVELOPMENT, V121, P2177; DU SJ, 1995, MOL CELL BIOL, V15, P2625; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; GALVINPARTON PA, 1990, J BIOL CHEM, V265, P17771; Gao P, 1996, J BIOL CHEM, V271, P9002, DOI 10.1074/jbc.271.15.9002; GAO P, 1995, AM J PHYSIOL-CELL PH, V268, pC1460, DOI 10.1152/ajpcell.1995.268.6.C1460; Gao P, 1996, J BIOL CHEM, V271, P30692, DOI 10.1074/jbc.271.48.30692; Hamada F, 1999, SCIENCE, V283, P1739, DOI 10.1126/science.283.5408.1739; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Kengaku M, 1998, SCIENCE, V280, P1274, DOI 10.1126/science.280.5367.1274; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1994, METHOD ENZYMOL, V237, P345; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MOON RT, 1993, BIOESSAYS, V15, P91, DOI 10.1002/bies.950150204; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muller HAJ, 1999, DEVELOPMENT, V126, P577; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Papkoff J, 1998, BIOCHEM BIOPH RES CO, V247, P851, DOI 10.1006/bbrc.1998.8888; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; ROS M, 1988, J BIOL CHEM, V263, P4362; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Torres MA, 1996, J CELL BIOL, V133, P1123, DOI 10.1083/jcb.133.5.1123; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; Wang YS, 1996, J BIOL CHEM, V271, P4468; WATKINS DC, 1994, BIOCHEM J, V299, P593, DOI 10.1042/bj2990593; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	52	77	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33539	33544		10.1074/jbc.274.47.33539	http://dx.doi.org/10.1074/jbc.274.47.33539			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559239	hybrid			2022-12-25	WOS:000083745200055
J	Castle, M; Nazarian, A; Yi, SS; Tempst, P				Castle, M; Nazarian, A; Yi, SS; Tempst, P			Lethal effects of apidaecin on Escherichia coli involve sequential molecular interactions with diverse targets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE ANTIBACTERIAL PEPTIDE; GRAM-NEGATIVE BACTERIA; SALMONELLA-TYPHIMURIUM; PIG INTESTINE; ANTIMICROBIAL PEPTIDES; BOVINE NEUTROPHILS; BINDING PROTEIN; OUTER-MEMBRANE; DIFFERENT MECHANISMS; ANTIBIOTIC PEPTIDES	Apidaecins, short proline-arginine-rich peptides from insects, are highly bactericidal through a mechanism that includes stereoselective elements but is completely devoid of any pore-forming activity. The spectrum of antibacterial activity, always limited to Gram-negatives, is further dependent on a small number of variable residues and can be manipulated. We show here that mutations in the evolutionary conserved regions result in a more general loss of function, and we have used such analogs to probe molecular interactions in Escherichia coli. First, an assay was developed to measure selectively chiral association with cellular targets. By using this method, we find that apidaecin uptake is energy driven and irreversible and yet can be partially competed by proline in a stereospecific fashion, results upholding a model of a permease/transporter-mediated mechanism. This putative transporter is not the end point of apidaecin action, for failure of certain peptide analogs to kill cells after entering indicates the existence of another downstream target. Tetracycline-induced loss of bactericidal activity and dose-dependent in vivo inhibition of translation by apidaecin point at components of the protein synthesis machinery as likely candidates. These findings provide new insights into the antibacterial mechanism of a unique group of peptides and perhaps, by extension, for distant mammalian relatives such as PR-39.	Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Tempst, P (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.	p-tempst@mskcc.org			NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA08748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGERBERTH B, 1991, EUR J BIOCHEM, V202, P849, DOI 10.1111/j.1432-1033.1991.tb16442.x; AMES GF, 1990, FEMS MICROBIOL REV, V6, P429; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; ANDREWS JC, 1985, J BACTERIOL, V161, P484, DOI 10.1128/JB.161.2.484-492.1985; BARAK Z, 1975, J BACTERIOL, V122, P1200, DOI 10.1128/JB.122.3.1200-1207.1975; Barry A.L., 1991, MANUAL CLIN MICROBIO; BERGER EA, 1973, P NATL ACAD SCI USA, V70, P1514, DOI 10.1073/pnas.70.5.1514; BERGER EA, 1974, J BIOL CHEM, V249, P7747; BESALLE R, 1990, FEBS LETT, V274, P151; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BOMAN HG, 1981, TRENDS BIOCHEM SCI, V6, P306, DOI 10.1146/annurev.mi.41.100187.000535; BOMAN HG, 1993, INFECT IMMUN, V61, P2978, DOI 10.1128/IAI.61.7.2978-2984.1993; BULET P, 1991, J BIOL CHEM, V266, P24520; BULET P, 1993, J BIOL CHEM, V268, P14893; CASTEELS P, 1994, J BIOL CHEM, V269, P26107; CASTEELS P, 1994, BIOCHEM BIOPH RES CO, V199, P339, DOI 10.1006/bbrc.1994.1234; CASTEELS P, 1989, EMBO J, V8, P2387, DOI 10.1002/j.1460-2075.1989.tb08368.x; CASTEELS P, 1993, J BIOL CHEM, V268, P7044; CASTEELSJOSSON K, 1994, J BIOL CHEM, V269, P28569; CASTEELSJOSSON K, 1993, EMBO J, V12, P1569, DOI 10.1002/j.1460-2075.1993.tb05801.x; CHRISTENSEN B, 1988, P NATL ACAD SCI USA, V85, P5072, DOI 10.1073/pnas.85.14.5072; CRUCIANI RA, 1991, P NATL ACAD SCI USA, V88, P3792, DOI 10.1073/pnas.88.9.3792; CRUCIANI RA, 1992, EUR J PHARM-MOLEC PH, V226, P287, DOI 10.1016/0922-4106(92)90045-W; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; Driessen AJM, 1997, MOL MICROBIOL, V24, P881, DOI 10.1046/j.1365-2958.1997.4071742.x; EISENHAUER PB, 1992, INFECT IMMUN, V60, P3556, DOI 10.1128/IAI.60.9.3556-3565.1992; Eliopoulos G.M., 1991, ANTIBIOTICS LAB MED, V3rd Edn, P432; FAYE I, 1975, INFECT IMMUN, V12, P1426, DOI 10.1128/IAI.12.6.1426-1438.1975; FRANK RW, 1990, J BIOL CHEM, V265, P18871; Frohm M, 1996, EUR J BIOCHEM, V237, P86, DOI 10.1111/j.1432-1033.1996.0086n.x; Fulton C, 1997, LANCET, V350, P1750, DOI 10.1016/S0140-6736(05)63574-X; FURLONG CE, 1986, METHOD ENZYMOL, V125, P279; GABAY JE, 1989, P NATL ACAD SCI USA, V86, P5610, DOI 10.1073/pnas.86.14.5610; Ganz T, 1997, Curr Opin Hematol, V4, P53; GARCIABUSTOS JF, 1985, ANTIMICROB AGENTS CH, V27, P791, DOI 10.1128/AAC.27.5.791; GUIJARRO JI, 1995, J BIOL CHEM, V270, P23520, DOI 10.1074/jbc.270.40.23520; GUYER CA, 1986, J BACTERIOL, V168, P775, DOI 10.1128/jb.168.2.775-779.1986; HIGGINS CF, 1986, METHOD ENZYMOL, V125, P365; HIGGINS CF, 1983, J BACTERIOL, V155, P1434, DOI 10.1128/JB.155.3.1434-1438.1983; HOFFMANN JA, 1990, RES IMMUNOL, V141, P910, DOI 10.1016/0923-2494(90)90192-2; HOFFMANN JA, 1995, CURR OPIN IMMUNOL, V7, P4, DOI 10.1016/0952-7915(95)80022-0; HOLTMARK D, 1993, TRENDS GENET, V9, P178; JACKSON MB, 1976, J BIOL CHEM, V251, P5300; JONES DE, 1992, J BIOL CHEM, V267, P23216; KLEINKAUF H, 1987, ANNU REV MICROBIOL, V41, P259, DOI 10.1146/annurev.mi.41.100187.001355; KONISKY J, 1982, ANNU REV MICROBIOL, V36, P125, DOI 10.1146/annurev.mi.36.100182.001013; LEE JY, 1989, P NATL ACAD SCI USA, V86, P9159, DOI 10.1073/pnas.86.23.9159; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; LEHRER RI, 1989, J CLIN INVEST, V84, P553, DOI 10.1172/JCI114198; LEHRER RI, 1991, CELL, V64, P229, DOI 10.1016/0092-8674(91)90632-9; Linton KJ, 1998, MOL MICROBIOL, V28, P5, DOI 10.1046/j.1365-2958.1998.00764.x; LUGTENBERG B, 1983, BIOCHIM BIOPHYS ACTA, V737, P51, DOI 10.1016/0304-4157(83)90014-X; MARTIN JF, 1989, ANNU REV MICROBIOL, V43, P173, DOI 10.1146/annurev.micro.43.1.173; MILLER SI, 1990, INFECT IMMUN, V58, P3706, DOI 10.1128/IAI.58.11.3706-3710.1990; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; OHTA M, 1992, ANTIMICROB AGENTS CH, V36, P1460, DOI 10.1128/AAC.36.7.1460; OKADA M, 1985, J BIOL CHEM, V260, P7174; OPPENHEIM FG, 1988, J BIOL CHEM, V263, P7472; ROMEO D, 1988, J BIOL CHEM, V263, P9573; Russell A.D., 1990, UNDERSTANDING ANTIBA; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; Schulz G.D., 1984, PRINCIPLES PROTEIN S; SELSTED ME, 1993, J BIOL CHEM, V268, P6641; SELSTED ME, 1992, J BIOL CHEM, V267, P4292; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; Shi JH, 1996, ANTIMICROB AGENTS CH, V40, P115, DOI 10.1128/AAC.40.1.115; Singh PK, 1998, P NATL ACAD SCI USA, V95, P14961, DOI 10.1073/pnas.95.25.14961; SKERLAVAJ B, 1990, INFECT IMMUN, V58, P3724, DOI 10.1128/IAI.58.11.3724-3730.1990; Taguchi S, 1996, APPL ENVIRON MICROB, V62, P4652, DOI 10.1128/AEM.62.12.4652-4655.1996; TAME JRH, 1994, SCIENCE, V264, P1578, DOI 10.1126/science.8202710; VAARA M, 1981, FEBS LETT, V129, P145, DOI 10.1016/0014-5793(81)80777-6; VILJANEN P, 1988, INFECT IMMUN, V56, P2324, DOI 10.1128/IAI.56.9.2324-2329.1988; Vunnam S, 1997, J PEPT RES, V49, P59; WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761; WOOD JM, 1988, J MEMBRANE BIOL, V106, P183, DOI 10.1007/BF01872157	75	117	128	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32555	32564		10.1074/jbc.274.46.32555	http://dx.doi.org/10.1074/jbc.274.46.32555			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551808	hybrid			2022-12-25	WOS:000083623000008
J	Mater, MK; Thelen, AP; Pan, DA; Jump, DB				Mater, MK; Thelen, AP; Pan, DA; Jump, DB			Sterol response element-binding protein 1c (SREBP1c) is involved in the polyunsaturated fatty acid suppression of hepatic S14 gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; PYRUVATE-KINASE GENE; RAT-LIVER; CHOLESTEROL-SYNTHESIS; COORDINATE REGULATION; NF-Y; EXPRESSION; ADD1/SREBP1; METABOLISM; MECHANISM	Polyunsaturated fatty acids (PUFA) suppress hepatic lipogenic gene transcription through a peroxisome pro liferator activated receptor alpha (PPAR alpha). and cyclooxygenase-independent mechanism. Recently, the sterol response element-binding protein 1 (SREBP1) was implicated in the nutrient control of lipogenic gene expression. In this report, we have assessed the role SREBP1 plays in the PUFA control of three hepatic genes, fatty acid synthase, L-pyruvate kinase (LPK), and the S14 protein (S14), PUFA suppressed both the hepatic mRNA(SREBP1) through a PPAR alpha-independent mechanism as well as SREBP1c nuclear content (nSREBP1c, 65 kDa), Co-transfection of primary hepatocytes revealed a differential sensitivity of the fatty acid synthase, S14, and LPK promoters to nSREBP1c overexpression. Of the three promoters examined, LPK was the least sensitive to overexpressed nSREBP1c. Promoter deletion and gel shift analyses of the S14 promoter localized a functional SREBP1c cis-regulatory element to an E-box-like sequence ((-139)TCGCCTGAT(-131)) within the S14 PUFA response region. Although overexpression of nSREBP1c significantly reduced PUFA inhibition of S14CAT, overexpression of other factors that induced S14CAT activity, such as steroid receptor co-activator 1 or retinoid X receptor cu, had no effect on S14CAT PUFA sensitivity. These results suggest that PUFA regulates hepatic nSREBP1c, a factor that functionally interacts with the S14 PUFA response region. PUFA regulation of nSREBP1c may account for the PUFA-mediated suppression of hepatic S14 gene transcription.	Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Michigan State University; Michigan State University	Jump, DB (corresponding author), Michigan State Univ, Dept Physiol, 115 Giltner Hall, E Lansing, MI 48824 USA.				NIDDK NIH HHS [DK 43220, R01 DK043220] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043220] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Athanikar JN, 1998, P NATL ACAD SCI USA, V95, P4935, DOI 10.1073/pnas.95.9.4935; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; FLATMARK T, 1988, BIOCHIM BIOPHYS ACTA, V962, P122, DOI 10.1016/0005-2760(88)90103-8; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Fukuda H, 1999, EUR J BIOCHEM, V260, P505, DOI 10.1046/j.1432-1327.1999.00183.x; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; HUA Z, 1996, J BIOL CHEM, V271, P10379; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; JUMP DB, 1993, P NATL ACAD SCI USA, V90, P8454, DOI 10.1073/pnas.90.18.8454; JUMP DB, 1994, J LIPID RES, V35, P1076; Jump DB, 1997, J BIOL CHEM, V272, P27778, DOI 10.1074/jbc.272.44.27778; Jump DB, 1999, ANNU REV NUTR, V19, P63, DOI 10.1146/annurev.nutr.19.1.63; Kaytor EN, 1997, J BIOL CHEM, V272, P7525, DOI 10.1074/jbc.272.11.7525; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kotzka J, 1998, BIOCHEM BIOPH RES CO, V249, P375, DOI 10.1006/bbrc.1998.9161; Li XH, 1997, J LIPID RES, V38, P1277; LIIMATTA M, 1994, MOL ENDOCRINOL, V8, P1147, DOI 10.1210/me.8.9.1147; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; MACDOUGALD OA, 1991, BIOCHEM J, V280, P761, DOI 10.1042/bj2800761; Mater MK, 1998, J LIPID RES, V39, P1327; Mater MK, 1999, J LIPID RES, V40, P1045; Moriizumi S, 1998, GENE EXPRESSION, V7, P103; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; Reeves J.B., 1979, COMPOSITION FOODS FA; Ren B, 1997, J BIOL CHEM, V272, P26827, DOI 10.1074/jbc.272.43.26827; Ren B, 1996, J BIOL CHEM, V271, P17167, DOI 10.1074/jbc.271.29.17167; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Stabile LP, 1998, J LIPID RES, V39, P1951; Tabor DE, 1999, J BIOL CHEM, V274, P20603, DOI 10.1074/jbc.274.29.20603; Thewke DP, 1998, J BIOL CHEM, V273, P21402, DOI 10.1074/jbc.273.33.21402; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Wang SL, 1997, J BIOL CHEM, V272, P19351, DOI 10.1074/jbc.272.31.19351; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Worgall TS, 1998, J BIOL CHEM, V273, P25537, DOI 10.1074/jbc.273.40.25537; Yamada K, 1999, BIOCHEM J, V337, P1, DOI 10.1042/0264-6021:3370001	43	152	158	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32725	32732		10.1074/jbc.274.46.32725	http://dx.doi.org/10.1074/jbc.274.46.32725			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551830	hybrid			2022-12-25	WOS:000083623000030
J	Polyak, SW; Chapman-Smith, A; Brautigan, PJ; Wallace, JC				Polyak, SW; Chapman-Smith, A; Brautigan, PJ; Wallace, JC			Biotin protein ligase from Saccharomyces cerevisiae - The N-terminal domain is required for complete activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI REPRESSOR; HUMAN HOLOCARBOXYLASE SYNTHETASE; COMPLETE GENOME SEQUENCE; ACETYL-COA CARBOXYLASE; PEA PISUM-SATIVUM; HOLOENZYME SYNTHETASE; ARABIDOPSIS-THALIANA; BIRA GENE; RAT-LIVER; PURIFICATION	Catalytically active biotin protein ligase from Saccharomyces cerevisiae (EC 6.3.4.15) was overexpressed in Escherichia coli and purified to near homogeneity in three steps. Kinetic analysis demonstrated that the substrates ATP, biotin, and the biotin-accepting protein bind in an ordered manner in the reaction mechanism. Treatment with any of three proteases of differing specificity in vitro revealed that the sequence between residues 240 and 260 was extremely sensitive to proteolysis, suggesting that it forms an exposed linker between an N-terminal 27-kDa domain and the C-terminal 50-kDa domain containing the active site, The protease susceptibility of this linker region was considerably reduced in the presence of ATP and biotin. A second protease-sensitive sequence, located in the presumptive catalytic site, was protected against digestion by the substrates, Expression of N-terminally truncated variants of the yeast enzyme failed to complement E. coli strains defective in biotin protein Ligase activity, In vitro assays performed with purified N-terminally truncated enzyme revealed that removal of the N-terminal domain reduced BPL activity by greater than 3500-fold, Our data indicate that both the N-terminal domain and the C-terminal domain containing the active site are necessary for complete catalytic function.	Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia	University of Adelaide	Wallace, JC (corresponding author), Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia.	jwallace@biochem.adelaide.edu.au	Polyak, Steven W/A-7488-2019; Polyak, Steven W./G-3185-2011; , John/AAP-5150-2020	Polyak, Steven W/0000-0002-8458-5194; Polyak, Steven W./0000-0002-8458-5194; 				ACHUTAMURTHY PN, 1974, CAN J BIOCHEM CELL B, V52, P800, DOI 10.1139/o74-113; Aoki Y, 1997, PEDIATR RES, V42, P849, DOI 10.1203/00006450-199712000-00021; BARKER DF, 1981, J MOL BIOL, V146, P469, DOI 10.1016/0022-2836(81)90043-7; Beckett D, 1997, METHOD ENZYMOL, V279, P362; BOWER S, 1995, J BACTERIOL, V177, P2572, DOI 10.1128/jb.177.9.2572-2575.1995; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BUONCRISTIANI MR, 1988, J BIOL CHEM, V263, P1013; CAGNON C, 1991, PROTEIN ENG, V4, P843, DOI 10.1093/protein/4.7.843; CAZZULO JJ, 1971, BIOCHEM J, V122, P653, DOI 10.1042/bj1220653; Chapman-Smith A, 1999, J NUTR, V129, p477S, DOI 10.1093/jn/129.2.477S; Chapman-Smith A, 1999, J BIOL CHEM, V274, P1449, DOI 10.1074/jbc.274.3.1449; CHAPMANSMITH A, 1994, BIOCHEM J, V302, P881, DOI 10.1042/bj3020881; CHIBA Y, 1994, ARCH BIOCHEM BIOPHYS, V313, P8, DOI 10.1006/abbi.1994.1351; CHRISTNER JE, 1964, J BIOL CHEM, V239, P3997; Cleland W. W, 1970, ENZYMES, V2, P1; CRONAN JE, 1995, FEMS MICROBIOL LETT, V130, P221, DOI 10.1016/0378-1097(95)00210-V; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; CRONAN JE, 1989, CELL, V58, P427, DOI 10.1016/0092-8674(89)90421-2; DOMBROSKY PM, 1994, ARCH MICROBIOL, V161, P501, DOI 10.1007/BF00307771; Dupuis L, 1996, HUM MOL GENET, V5, P1011, DOI 10.1093/hmg/5.7.1011; EISENBERG MA, 1982, J BIOL CHEM, V239, P2858; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; KNOWLES JR, 1989, ANNU REV BIOCHEM, V58, P195, DOI 10.1146/annurev.bi.58.070189.001211; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE MD, 1964, J BIOL CHEM, V239, P2858; LEE H, 1971, BIOCHIM BIOPHYS ACTA, V242, P519, DOI 10.1016/0005-2744(71)90144-6; LEONDELRIO A, 1995, P NATL ACAD SCI USA, V92, P4626, DOI 10.1073/pnas.92.10.4626; MADAPALL.MM, 1970, BIOCHIM BIOPHYS ACTA, V215, P316, DOI 10.1016/0304-4165(70)90030-9; MATSUDARIA PT, 1988, J BIOL CHEM, V262, P10035; MCALLISTER HC, 1966, J BIOL CHEM, V241, P2855; Morita J, 1998, MOL GENET METAB, V64, P250, DOI 10.1006/mgme.1998.2700; Nenortas E, 1996, J BIOL CHEM, V271, P7559, DOI 10.1074/jbc.271.13.7559; ROGERS TO, 1969, J BACTERIOL, V100, P557, DOI 10.1128/JB.100.2.557-564.1969; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAMOLS D, 1988, J BIOL CHEM, V263, P6461; SHENOY BC, 1988, FASEB J, V2, P2396, DOI 10.1096/fasebj.2.8.3360240; SIEGEL L, 1965, J BIOL CHEM, V240, P1025; Stolz J, 1999, J BIOL CHEM, V274, P18741, DOI 10.1074/jbc.274.26.18741; SUNDARAM TK, 1971, ARCH BIOCHEM BIOPHYS, V143, P609, DOI 10.1016/0003-9861(71)90246-3; SUZUKI Y, 1994, NAT GENET, V8, P122, DOI 10.1038/ng1094-122; Tissot G, 1996, BIOCHEM J, V314, P391, DOI 10.1042/bj3140391; Tissot G, 1998, EUR J BIOCHEM, V258, P586, DOI 10.1046/j.1432-1327.1998.2580586.x; Tissot G, 1997, BIOCHEM J, V323, P179, DOI 10.1042/bj3230179; Val DL, 1995, BIOCHEM J, V312, P817, DOI 10.1042/bj3120817; WALLACE PG, 1994, ANAL BIOCHEM, V222, P404, DOI 10.1006/abio.1994.1509; WILSON KP, 1992, P NATL ACAD SCI USA, V89, P9257, DOI 10.1073/pnas.89.19.9257; XIA WL, 1994, BIOCHEM MOL BIOL INT, V34, P225; Xu Y, 1997, METHOD ENZYMOL, V279, P405; XU Y, 1994, BIOCHEMISTRY-US, V33, P7354, DOI 10.1021/bi00189a041; Xu Y, 1995, BIOCHEMISTRY-US, V34, P16624, DOI 10.1021/bi00051a010; Xu Y, 1996, BIOCHEMISTRY-US, V35, P1783, DOI 10.1021/bi952269e; Zempleni J, 1997, J NUTR, V127, P1776, DOI 10.1093/jn/127.9.1776	52	33	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32847	32854		10.1074/jbc.274.46.32847	http://dx.doi.org/10.1074/jbc.274.46.32847			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551847	hybrid			2022-12-25	WOS:000083623000047
J	Ghosh, N; Piskurich, JF; Wright, G; Hassani, K; Ting, JPY; Wright, KL				Ghosh, N; Piskurich, JF; Wright, G; Hassani, K; Ting, JPY; Wright, KL			A novel element and a TEF-2-like element activate the major histocompatibility complex class II transactivator in B-lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS DNA-REPLICATION; NUCLEAR FACTOR-I; HLA-DRA GENE; INTERFERON-GAMMA; TRANSCRIPTION FACTORS; INDUCIBLE EXPRESSION; INVIVO FOOTPRINT; CELL DEVELOPMENT; BINDING PROTEIN; SV40 ENHANCER	Major histocompatibility complex (MHC) class II molecules play a central role in immune responses, and transcription of this family of genes requires the MHC class II transactivator (CIITA). CIITA has four promoters, which are transcribed in a tissue-specific manner. CIITA promoter III is constitutively active in mature B-lymphocytes. This report now describes the minimal 319-base pair promoter region necessary for maximal transcriptional activity in B-lymphocytes. Ultratiolet light and dimethylsulfate in vivo genomic footprinting analyses reveal five occupied DNA sequence elements present in intact B-lymphocytes, Functional analysis of these elements using promoter deletions and site-specific mutations demonstrates that at least two of the sites occupied in vivo are critical for transcriptional activity. In vitro protein/DNA analysis suggests that one of the sites is a TEF-2-like element and the other is occupied by a novel transcription activator. In addition, nuclear factor-1 associates with the promoter both in vivo and in vitro. In myeloma cell lines, loss of CIITA transcription correlates with a completely unoccupied CIITA promoter III. These findings suggest that CIITA transcription in B-lymphocytes is activated through at least two strong promoter elements, while loss of expression in myeloma cells is mediated through changes in promoter assembly.	Univ S Florida, Coll Med, Dept Biochem & Mol Biol, H Lee Moffitt Canc Ctr, Tampa, FL 33612 USA; Univ N Carolina, Dept Microbiol Immunol, Chapel Hill, NC 27599 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; University of North Carolina; University of North Carolina Chapel Hill	Wright, KL (corresponding author), Univ S Florida, Coll Med, Dept Biochem & Mol Biol, H Lee Moffitt Canc Ctr, 12902 Bruce B Downs Blvd, Tampa, FL 33612 USA.	wrightkl@moffitt.usf.edu			NCI NIH HHS [CA80990] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080990] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENACERRAF B, 1981, SCIENCE, V212, P1229, DOI 10.1126/science.6165083; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHANG CH, 1994, J EXP MED, V180, P1367, DOI 10.1084/jem.180.4.1367; Chang CH, 1996, IMMUNITY, V4, P167, DOI 10.1016/S1074-7613(00)80681-0; CHIN KC, 1994, IMMUNITY, V1, P687, DOI 10.1016/1074-7613(94)90039-6; Creaser PC, 1996, NUCLEIC ACIDS RES, V24, P2597, DOI 10.1093/nar/24.13.2597; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DELLABONA P, 1989, J IMMUNOL, V142, P2902; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EICHBAUM QG, 1994, J EXP MED, V179, P1985, DOI 10.1084/jem.179.6.1985; Frasca L, 1998, CRIT REV IMMUNOL, V18, P569, DOI 10.1615/CritRevImmunol.v18.i6.50; Gao J, 1999, J VIROL, V73, P1411, DOI 10.1128/JVI.73.2.1411-1418.1999; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; HALPER J, 1978, J IMMUNOL, V120, P1480; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; Henderson A, 1998, ANNU REV IMMUNOL, V16, P163, DOI 10.1146/annurev.immunol.16.1.163; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; LATRON F, 1988, P NATL ACAD SCI USA, V85, P2229, DOI 10.1073/pnas.85.7.2229; LEEGWATER PAJ, 1985, EMBO J, V4, P1515, DOI 10.1002/j.1460-2075.1985.tb03811.x; Lennon AM, 1997, IMMUNOGENETICS, V45, P266, DOI 10.1007/s002510050202; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; MERCURIO F, 1989, EMBO J, V8, P1455, DOI 10.1002/j.1460-2075.1989.tb03528.x; MIKI N, 1992, J IMMUNOL, V149, P801; MIYAGOE Y, 1994, J BIOL CHEM, V269, P8268; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; NAGATA K, 1982, P NATL ACAD SCI-BIOL, V79, P6438, DOI 10.1073/pnas.79.21.6438; PFEIFER GP, 1992, MOL CELL BIOL, V12, P1798, DOI 10.1128/MCB.12.4.1798; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; Pfeifer GP, 1997, METHODS, V11, P189, DOI 10.1006/meth.1996.0405; Piskurich JF, 1998, J IMMUNOL, V160, P233; Piskurich JF, 1999, MOL CELL BIOL, V19, P431; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SILACCI P, 1994, J EXP MED, V180, P1329, DOI 10.1084/jem.180.4.1329; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; TARLINTON D, 1993, INT IMMUNOL, V5, P1629, DOI 10.1093/intimm/5.12.1629; TING JPY, 1993, CURR OPIN IMMUNOL, V5, P8, DOI 10.1016/0952-7915(93)90074-3; TORNALETTI S, 1995, J MOL BIOL, V249, P714, DOI 10.1006/jmbi.1995.0331; VILEN BJ, 1992, J BIOL CHEM, V267, P23728; Williams GS, 1998, INT IMMUNOL, V10, P1957, DOI 10.1093/intimm/10.12.1957; WRIGHT KL, 1992, P NATL ACAD SCI USA, V89, P7601, DOI 10.1073/pnas.89.16.7601; WRIGHT KL, 1992, BIOCHEMISTRY-US, V31, P2812, DOI 10.1021/bi00125a023; Yi Q, 1997, BLOOD, V90, P1960, DOI 10.1182/blood.V90.5.1960	49	48	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32342	32350		10.1074/jbc.274.45.32342	http://dx.doi.org/10.1074/jbc.274.45.32342			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542275	hybrid, Green Published			2022-12-25	WOS:000083532100083
J	Ikeda, K; Emoto, N; Raharjo, SB; Nurhantari, Y; Saiki, K; Yokoyama, M; Matsuo, M				Ikeda, K; Emoto, N; Raharjo, SB; Nurhantari, Y; Saiki, K; Yokoyama, M; Matsuo, M			Molecular identification and characterization of novel membrane-bound metalloprotease, the soluble secreted form of which hydrolyzes a variety of vasoactive peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-CONVERTING ENZYME; NEUTRAL ENDOPEPTIDASE; EXPRESSION; PHARMACOLOGY; PROTEIN; CELLS; GENE; KELL; PEX	One class of zinc metalloproteases, represented by neutral endopeptidase 24.11 and endothelin-converting enzyme, has been shown to be involved in proteolytic activation or inactivation of many regulatory peptides. Here, we report molecular cloning and characterization of a novel member of this type II membrane-bound metalloprotease family, termed soluble secreted endopeptidase (SEP). Alternative splicing results in the generation of another transcript, SEPDelta, which lacks a 69-base pair nucleotide segment following the transmembrane helix, Both SEP and SEPDelta mRNA are detected in all mouse tissues examined. Transfection of an SEP cDNA expression construct resulted in the expression of the membrane-bound form of SEP in the early secretory pathway as well as the soluble secreted form of the enzyme in the culture medium. In contrast, transfection of the SEPDelta cDNA only results in the expression of the membrane-bound form. In vitro enzymological analysis of the recombinant soluble form of SEP demonstrated that it hydrolyzes a variety of vasoactive peptides, including endothelin-1, atrial natriuretic peptide, and angiotensin I. This activity of SEP was inhibited by phosphoramidon and the neutral endopeptidase 24.11 specific inhibitor thiorphan, but it was only partially inhibited by the endothelin-converting enzyme specific inhibitor FR901533. These findings suggest that SEP is a novel metalloprotease that possesses a broad substrate specificity and that it may be involved in the metabolism of biologically active peptides intracellulary as well as extracellularly.	Kobe Univ, Sch Med, Div Genet, Int Ctr Med Res, Kobe, Hyogo 6500017, Japan; Kobe Univ, Sch Med, Dept Internal Med 1, Kobe, Hyogo 6500017, Japan; Kobe Pharmaceut Univ, Kobe, Hyogo 6588558, Japan	Kobe University; Kobe University; Kobe Pharmaceutical University	Emoto, N (corresponding author), Kobe Univ, Sch Med, Div Genet, Int Ctr Med Res, 7-5-1 Kusunoki, Kobe, Hyogo 6500017, Japan.			Nurhantari, Yudha/0000-0003-1200-2014; ikeda, Koji/0000-0002-9972-7255; Emoto, Noriaki/0000-0001-6673-2616; raharjo, sunu budhi/0000-0001-5749-8231				Ahn K, 1998, ARCH BIOCHEM BIOPHYS, V359, P258, DOI 10.1006/abbi.1998.0913; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; EHLERS MRW, 1991, P NATL ACAD SCI USA, V88, P1009, DOI 10.1073/pnas.88.3.1009; Emoto N, 1999, J BIOL CHEM, V274, P1509, DOI 10.1074/jbc.274.3.1509; EMOTO N, 1995, J BIOL CHEM, V270, P1526; FRANCIS F, 1995, NAT GENET, V11, P130, DOI 10.1038/ng1095-130; HOOPER NM, 1994, FEBS LETT, V354, P1, DOI 10.1016/0014-5793(94)01079-X; HOOPER NM, 1991, INT J BIOCHEM, V23, P641, DOI 10.1016/0020-711X(91)90032-I; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Johnson GD, 1999, J BIOL CHEM, V274, P4053, DOI 10.1074/jbc.274.7.4053; Korth P, 1999, J HISTOCHEM CYTOCHEM, V47, P447, DOI 10.1177/002215549904700403; LEE S, 1991, P NATL ACAD SCI USA, V88, P6353, DOI 10.1073/pnas.88.14.6353; LU B, 1995, J EXP MED, V181, P2271, DOI 10.1084/jem.181.6.2271; Lu B, 1997, NAT MED, V3, P904, DOI 10.1038/nm0897-904; Ramaraj P, 1998, J CLIN INVEST, V102, P371, DOI 10.1172/JCI3545; RAMCHANDRAN R, 1994, J BIOL CHEM, V269, P2125; ROQUES BP, 1993, PHARMACOL REV, V45, P87; SEN I, 1991, J BIOL CHEM, V266, P21985; Shimada K, 1996, BIOCHEM J, V315, P863, DOI 10.1042/bj3150863; TSURUMI Y, 1994, J ANTIBIOT, V47, P619, DOI 10.7164/antibiotics.47.619; Turner AJ, 1997, FASEB J, V11, P355, DOI 10.1096/fasebj.11.5.9141502; Turner AJ, 1996, BIOCHEM PHARMACOL, V51, P91, DOI 10.1016/0006-2952(95)02036-5; Turner AJ, 1998, TRENDS PHARMACOL SCI, V19, P483, DOI 10.1016/S0165-6147(98)01251-6; Valdenaire O, 1999, MOL BRAIN RES, V64, P211, DOI 10.1016/S0169-328X(98)00321-0; VIJAYARAGHAVAN J, 1990, J BIOL CHEM, V265, P14150; WEI L, 1991, J BIOL CHEM, V266, P5540; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; Yanagisawa H, 1998, DEVELOPMENT, V125, P825; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YANAGISAWA M, 1994, CIRCULATION, V89, P1320, DOI 10.1161/01.CIR.89.3.1320	30	94	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32469	32477		10.1074/jbc.274.45.32469	http://dx.doi.org/10.1074/jbc.274.45.32469			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542292	hybrid			2022-12-25	WOS:000083532100100
J	Pilger, BD; Perozzo, R; Alber, F; Wurth, C; Folkers, G; Scapozza, L				Pilger, BD; Perozzo, R; Alber, F; Wurth, C; Folkers, G; Scapozza, L			Substrate diversity of herpes simplex virus thymidine kinase - Impact of the kinematics of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; THYMIDYLATE KINASE; ADENYLATE KINASE; GENE-THERAPY; AZT ACTIVATION; BINDING-SITE; TYPE-1; ACYCLOVIR; SEQUENCE; RESISTANT	Herpes simplex virus type 1 (HSV 1) thymidine kinase (TK) exhibits an extensive substrate diversity for nucleobases and sugar moieties, in contrast to other TKs, This substrate diversity is the crucial molecular basis of selective antiviral and suicide gene therapy. The mechanisms of substrate binding of HSV I TK were studied by means of site-directed mutagenesis combined with isothermal calorimetric measurements and guided by theoretical calculations and sequence comparison, The results show the link between the exceptionally broad substrate diversity of HSV I TH and the presence of structural features such as the residue triad His-58/ Met-128/Tyr-172. The mutation of Met-128 into a Phe and the double mutant M128F/Y172F result in mutants that have lost their activity. However, by exchanging His to form the triple mutant H58L/M128F/Y172F, the enzyme regains activity, Strikingly, this triple mutant becomes resistant toward acyclovir. Furthermore, we give evidence for the importance of Glu-225 of the flexible LID region for the catalytic reaction. The data presented give new insights to understand mechanisms ruling substrate diversity and thus are crucial for both the development of new antiviral drugs and engineering of mutant TKs apt to accept novel substrate analogs for gene therapeutic approaches.	Swiss Fed Inst Technol, Dept Pharm, CH-8057 Zurich, Switzerland; Int Sch Adv Studies, I-34014 Trieste, Italy; Ist Nazl Fis Mat, I-34014 Trieste, Italy	ETH Zurich; International School for Advanced Studies (SISSA); Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Padua	Scapozza, L (corresponding author), Swiss Fed Inst Technol, Dept Pharm, Winterthurerstr 190, CH-8057 Zurich, Switzerland.			Folkers, Gerd/0000-0002-3620-705X; Scapozza, Leonardo/0000-0003-1079-648X				ABELE G, 1991, Antiviral Chemistry and Chemotherapy, V2, P163; Alber F, 1998, PROTEINS, V31, P453, DOI 10.1002/(SICI)1097-0134(19980601)31:4<453::AID-PROT11>3.0.CO;2-E; BALASUBRAMANIAM NK, 1990, J GEN VIROL, V71, P2979, DOI 10.1099/0022-1317-71-12-2979; BARETTINO D, 1994, NUCLEIC ACIDS RES, V22, P541, DOI 10.1093/nar/22.3.541; Bonini C, 1997, SCIENCE, V276, P1719, DOI 10.1126/science.276.5319.1719; BRADSHAW HD, 1984, MOL CELL BIOL, V4, P2316, DOI 10.1128/MCB.4.11.2316; BROWN DG, 1995, NAT STRUCT BIOL, V2, P876, DOI 10.1038/nsb1095-876; Caruso M, 1997, VIRUS RES, V52, P133, DOI 10.1016/S0168-1702(97)00124-X; CHEN MS, 1979, J VIROL, V30, P942, DOI 10.1128/JVI.30.3.942-945.1979; CHEN MS, 1978, J BIOL CHEM, V253, P1325; Chen SH, 1998, J VIROL, V72, P6710, DOI 10.1128/JVI.72.8.6710-6715.1998; CHENG YC, 1983, P NATL ACAD SCI-BIOL, V80, P2767, DOI 10.1073/pnas.80.9.2767; Christians FC, 1999, NAT BIOTECHNOL, V17, P259, DOI 10.1038/7003; COEN DM, 1989, P NATL ACAD SCI USA, V86, P4736, DOI 10.1073/pnas.86.12.4736; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; CULVER KW, 1994, HUM GENE THER, V5, P343, DOI 10.1089/hum.1994.5.3-343; DARBY G, 1981, NATURE, V289, P81, DOI 10.1038/289081a0; EFSTATHIOU S, 1989, J GEN VIROL, V70, P869, DOI 10.1099/0022-1317-70-4-869; ELION GB, 1977, P NATL ACAD SCI USA, V74, P5716, DOI 10.1073/pnas.74.12.5716; ENGLUND JA, 1990, ANN INTERN MED, V112, P416, DOI 10.7326/0003-4819-76-3-112-6-416; FETZER J, 1994, PROTEIN EXPRES PURIF, V5, P432, DOI 10.1006/prep.1994.1062; FOLKERS G, 1987, MED SCI RES-BIOCHEM, V15, P1495; FURLONG N. BURR, 1963, ANALYT BIOCHEM, V5, P515; FYFE JA, 1983, MOL PHARMACOL, V24, P316; Gaudreau A, 1998, J INFECT DIS, V178, P297, DOI 10.1086/515626; Gerber S, 1996, BIOCHEM BIOPH RES CO, V225, P263, DOI 10.1006/bbrc.1996.1164; Gustafson EA, 1998, ANTIMICROB AGENTS CH, V42, P2923, DOI 10.1128/AAC.42.11.2923; HALPERN ME, 1984, J VIROL, V50, P733, DOI 10.1128/JVI.50.3.733-738.1984; HARRISON PT, 1991, J GEN VIROL, V72, P2583, DOI 10.1099/0022-1317-72-10-2583; INNIS MA, 1990, PCR PROTOCOLS GUIDE, P177; Jacobson JG, 1998, VIROLOGY, V242, P161, DOI 10.1006/viro.1997.9012; KELLER PM, 1981, BIOCHEM PHARMACOL, V30, P3071, DOI 10.1016/0006-2952(81)90495-0; KOONIN EV, 1992, VIRUS GENES, V6, P187, DOI 10.1007/BF01703067; Kussmann-Gerber S, 1998, EUR J BIOCHEM, V255, P472, DOI 10.1046/j.1432-1327.1998.2550472.x; Kussmann-Gerber S, 1999, NUCLEOS NUCLEOT, V18, P311, DOI 10.1080/15257779908043078; LARDER BA, 1983, J BIOL CHEM, V258, P2027; LARDER BA, 1983, J GEN VIROL, V64, P523, DOI 10.1099/0022-1317-64-3-523; Lavie A, 1997, NAT STRUCT BIOL, V4, P601, DOI 10.1038/nsb0897-601; Lavie A, 1998, P NATL ACAD SCI USA, V95, P14045, DOI 10.1073/pnas.95.24.14045; Lavie A, 1998, BIOCHEMISTRY-US, V37, P3677, DOI 10.1021/bi9720787; LIU QY, 1988, VIROLOGY, V163, P638, DOI 10.1016/0042-6822(88)90308-X; MASSON S, 1993, BIOCHEMISTRY-US, V32, P1025, DOI 10.1021/bi00055a005; Michael M, 1997, Pharm Acta Helv, V72, P139, DOI 10.1016/S0031-6865(97)00006-X; Muller CW, 1996, STRUCTURE, V4, P147, DOI 10.1016/S0969-2126(96)00018-4; MUNIR KM, 1992, J BIOL CHEM, V267, P6584; MUNIR KM, 1994, PROTEIN ENG, V7, P83, DOI 10.1093/protein/7.1.83; ROBERTS GB, 1993, BIOCHEM PHARMACOL, V46, P2209, DOI 10.1016/0006-2952(93)90611-Y; ROBERTSON GR, 1988, NUCLEIC ACIDS RES, V16, P11303, DOI 10.1093/nar/16.23.11303; STEINBERG RA, 1994, ANAL BIOCHEM, V219, P155, DOI 10.1006/abio.1994.1246; Tong XW, 1997, ANTICANCER RES, V17, P811; WILD K, 1995, FEBS LETT, V368, P289, DOI 10.1016/0014-5793(95)00680-8; Wild K, 1997, PROTEIN SCI, V6, P2097; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	53	70	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31967	31973		10.1074/jbc.274.45.31967	http://dx.doi.org/10.1074/jbc.274.45.31967			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542226	hybrid			2022-12-25	WOS:000083532100034
J	Hashemi, BB; Penkala, JE; Vens, C; Huls, H; Cubbage, M; Sams, CF				Hashemi, BB; Penkala, JE; Vens, C; Huls, H; Cubbage, M; Sams, CF			T cell activation responses are differentially regulated during clinorotation and in spaceflight	FASEB JOURNAL			English	Article						microgravity culture; clinostat; DNA synthesis; CD69; CD25	PROTEIN-KINASE-C; ANTIGEN-RECEPTOR COMPLEX; LYMPHOCYTES-T; SIGNAL-TRANSDUCTION; INTERLEUKIN-2 PRODUCTION; MESSENGER-RNA; MICROGRAVITY; STIMULATION; EXPRESSION; INDUCTION	Studies of T lymphocyte activation with mitogenic lectins during spaceflight have shown a dramatic inhibition of activation as measured by DNA synthesis at 72 h, but the mechanism of this inhibition is unknown. We have investigated the progression of cellular events during the first 24 h of activation using both spaceflight microgravity culture and a groundbased model system that relies on the low shear culture environment of a rotating clinostat (clinorotation). Stimulation of human peripheral blood mononuclear cells (PBMCs) with soluble anti-CD3 (Leu4) in clinorotation and in microgravity culture shows a dramatic reduction in surface expression of the receptor for IL-2 (CD25) and CD69. An absence of bulk RNA synthesis in clinorotation indicates that stimulation with soluble Leu4 does not induce transition of T cells from G0 to the G1 stage of the cell cycle. However, internalization of the TCR by T cells and normal levels of IL-1 synthesis by monocytes indicate that intercellular interactions that are required for activation occur during clinorotation. Complementation of TCR-mediated signaling by phorbol ester restores the ability of PBMCs to express CD25 in clinorotation, indicating that a PKC associated pathway may be compromised under these conditions. Bypassing the TCR by direct activation of intracellular pathways with a combination of phorbol ester and calcium ionophore in clinorotation resulted in full expression of CD25; however, only partial expression of CD25 occurred in microgravity culture. Though stimulation of purified T cells with Bead-Leu4 in microgravity culture resulted in the engagement and internalization of the TCR, the cells still failed to express CD25. When T cells were stimulated with Bead-Leu4 in microgravity culture, they were able to partially express CD69, a receptor that is constitutively stored in intracellular pools and can be expressed in the absence of new gene expression. Our results suggest that the inhibition of T cell proliferative response in microgravity culture is a result of alterations in signaling events within the first few hours of activation, which are required for the expression of important regulatory molecules.-Hashemi, B. B., Penkala, J. E., Vens, C., Huls, H., Cubbage, M., Sams, C. F. T cell activation responses are differentially regulated during clinorotation and in spaceflight.	NASA, Lyndon B Johnson Space Ctr, Life Sci Res Labs, Houston, TX 77058 USA	National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER	Sams, CF (corresponding author), NASA, Lyndon B Johnson Space Ctr, Life Sci Res Labs, SD3, Houston, TX 77058 USA.							BERRY N, 1989, J IMMUNOL, V143, P1407; CEUPPENS JL, 1989, CELL IMMUNOL, V118, P136, DOI 10.1016/0008-8749(89)90363-8; COGOLI A, 1993, J LEUKOCYTE BIOL, V54, P259, DOI 10.1002/jlb.54.3.259; Cogoli A, 1997, Gravit Space Biol Bull, V10, P5; COGOLI A, 1984, SCIENCE, V225, P228, DOI 10.1126/science.6729481; COGOLI A, 1988, ESA; CogoliGreuter M, 1996, J BIOTECHNOL, V47, P279, DOI 10.1016/0168-1656(96)01380-6; Cooper D, 1998, J LEUKOCYTE BIOL, V63, P550, DOI 10.1002/jlb.63.5.550; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; Darzynkiewicz Z, 1990, Methods Cell Biol, V33, P285; DEGROOT RP, 1991, EXP CELL RES, V197, P87, DOI 10.1016/0014-4827(91)90483-B; DEGROOT RP, 1990, J CELL SCI, V97, P33; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; GIARRUSSO PC, 1988, TISSUE ANTIGENS, V31, P59, DOI 10.1111/j.1399-0039.1988.tb02064.x; GMUNDER FK, 1990, BIOL CELL, V70, P33, DOI 10.1016/0248-4900(90)90358-A; GREGORIO CC, 1994, J CELL BIOL, V125, P345, DOI 10.1083/jcb.125.2.345; GREGORIO CC, 1992, P NATL ACAD SCI USA, V89, P4947, DOI 10.1073/pnas.89.11.4947; Hashemi BB, 1996, J IMMUNOL, V156, P3660; HASHEMI BB, 1994, APPL ENG PHYSICS CHE, P145; HASHEMI BB, 1999, ESA SP, V1222; Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; JENKINS MK, 1994, IMMUNITY, V1, P443, DOI 10.1016/1074-7613(94)90086-8; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; KUPFER A, 1989, ANNU REV IMMUNOL, V7, P309, DOI 10.1146/annurev.immunol.7.1.309; LAI KN, 1991, PATHOLOGY, V23, P224, DOI 10.3109/00313029109063570; LANDIS RC, 1991, J IMMUNOL, V146, P128; LEDBETTER JA, 1981, J EXP MED, V153, P310, DOI 10.1084/jem.153.2.310; LIMOUSE M, 1991, EXP CELL RES, V197, P82, DOI 10.1016/0014-4827(91)90482-A; MANGER B, 1987, J IMMUNOL, V139, P2755; MANIE S, 1990, AM SOC GRAVITATIONAL, V4, P43; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; PARDI R, 1992, J CELL BIOL, V116, P1211, DOI 10.1083/jcb.116.5.1211; PAUZA CD, 1987, MOL CELL BIOL, V7, P342, DOI 10.1128/MCB.7.1.342; REED JC, 1985, P NATL ACAD SCI USA, V82, P4221, DOI 10.1073/pnas.82.12.4221; RIJKEN PJ, 1993, EXP CELL RES, V204, P373, DOI 10.1006/excr.1993.1045; RISSO A, 1991, J IMMUNOL, V146, P4105; RYSER JE, 1982, J IMMUNOL, V128, P1159; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; STEFAN MC, 1983, SCIENCE, V222, P1239; TESTI R, 1989, J IMMUNOL, V142, P1854; THOMPSON CB, 1995, CELL, V81, P979, DOI 10.1016/S0092-8674(05)80001-7; TODD P, 1993, PHYSICAL FORCES MAMM; TSCHOPP A, 1984, J BIOTECHNOL, V1, P287, DOI 10.1016/0168-1656(84)90020-8; Unsworth BR, 1998, NAT MED, V4, P901, DOI 10.1038/nm0898-901; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; Vens C, 1996, J BIOTECHNOL, V47, P203, DOI 10.1016/0168-1656(96)01355-7; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	50	84	93	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1999	13	14					2071	2082		10.1096/fasebj.13.14.2071	http://dx.doi.org/10.1096/fasebj.13.14.2071			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544190				2022-12-25	WOS:000083660700019
J	Takahama, Y; Ochiya, T; Tanooka, H; Yamamoto, H; Sakamoto, H; Nakano, H; Terada, M				Takahama, Y; Ochiya, T; Tanooka, H; Yamamoto, H; Sakamoto, H; Nakano, H; Terada, M			Adenovirus-mediated transfer of HST-1/FGF-4 gene protects mice from lethal irradiation	ONCOGENE			English	Article						HST-/FGF-4; radiation; adenovirus; gene therapy	INTESTINAL STEM-CELLS; GROWTH-FACTOR; TRANSFORMING GENE; LIMB DEVELOPMENT; IN-VIVO; RADIATION; EXPRESSION; INTERLEUKIN-11; PROLIFERATION; CHEMOTHERAPY	Intraperitoneal injection of a replication-deficient adenovirus containing the HST-1 (FGF-4) gene (Adex1HST-1) increased peripheral platelet counts in mice, and also effectively prevented experimentally induced thrombocytopenia. Here, we report the therapeutic potential of Adex1HST-1 on severely injured mice after exposure to otherffise lethal irradiation. Eighteen out of 20 mice that received Adex1HST-1 prior to gamma-irradiation (9 Gy) survived, while all the 20 mice with prior administration of control adenoviruses died after irradiation (P<0.0001). Hematological and histopathological analyses revealed that Adex1HST-1 acts as a potent protector against lethal irradiation, which causes injury of intestinal tract as well as myelosuppression in the bone marrow and spleen. These data demonstrate that the protective effects of administration of Adex1HST-1 against irradiation are superior to any other protective effects of cytokines against a lethal dose of irradiation, and that the pre-administration of Adex1NST-1 may be useful for lessening the side effects of currently used chemo- and radio-therapy against cancer.	Natl Canc Ctr, Res Inst, Chuo Ku, Tokyo 1040045, Japan; Nara Med Univ, Dept Surg 1, Nara 6348522, Japan	National Cancer Center - Japan; Nara Medical University	Terada, M (corresponding author), Natl Canc Ctr, Res Inst, Chuo Ku, 1-1 Tsukiji,5 Chome, Tokyo 1040045, Japan.		Ochiya, Takahiro/AAH-7585-2019					AINSWORTH EJ, 1988, PHARMACOL THERAPEUT, V39, P223; BLUMENTHAL RD, 1995, EXP HEMATOL, V23, P1088; Booth C, 1995, CELL PROLIFERAT, V28, P581, DOI 10.1111/j.1365-2184.1995.tb00046.x; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; Deroanne CF, 1997, CANCER RES, V57, P5590; DU XX, 1994, BLOOD, V83, P33; Farrell CL, 1998, CANCER RES, V58, P933; Galzie Z, 1997, BIOCHEM CELL BIOL, V75, P669, DOI 10.1139/bcb-75-6-669; HANSON WR, 1983, RADIAT RES, V96, P393, DOI 10.2307/3576222; Hu MCT, 1998, MOL CELL BIOL, V18, P6063, DOI 10.1128/MCB.18.10.6063; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; KATOH O, 1992, BIOCHEM BIOPH RES CO, V183, P83, DOI 10.1016/0006-291X(92)91612-T; KONISHI H, 1995, J CLIN INVEST, V96, P1125, DOI 10.1172/JCI118099; Konishi H, 1996, ONCOGENE, V13, P9; Lamb K, 1996, MOL REPROD DEV, V44, P460; Maisin JR, 1998, INT J RADIAT BIOL, V73, P443, DOI 10.1080/095530098142284; NETA R, 1988, PHARMACOL THERAPEUT, V39, P261, DOI 10.1016/0163-7258(88)90070-8; NISWANDER L, 1992, DEVELOPMENT, V114, P755; OCHIYA T, 1995, J CELL BIOL, V130, P997, DOI 10.1083/jcb.130.4.997; POTTEN CS, 1995, INT J CANCER, V62, P356, DOI 10.1002/ijc.2910620321; Potten CS, 1997, BRIT J CANCER, V75, P1454, DOI 10.1038/bjc.1997.249; Quito FL, 1996, BLOOD, V87, P1282, DOI 10.1182/blood.V87.4.1282.bloodjournal8741282; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P12368, DOI 10.1073/pnas.91.26.12368; Sonis ST, 1998, ORAL ONCOL, V34, P39, DOI 10.1016/S1368-8375(97)00053-5; SUZUKI HR, 1992, DEV BIOL, V150, P219, DOI 10.1016/0012-1606(92)90020-H; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; VanBuul PPW, 1997, INT J RADIAT BIOL, V71, P259; Verrees JF, 1996, INT J COLORECTAL DIS, V11, P211, DOI 10.1007/s003840050049; Wambersie A, 1996, Rev Med Brux, V17, P27; WILSON EL, 1991, BLOOD, V77, P954; Wright JA, 1996, HISTOL HISTOPATHOL, V11, P521; YOSHIDA T, 1994, CANCER LETT, V83, P261, DOI 10.1016/0304-3835(94)90328-X	34	16	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	1999	18	43					5943	5947		10.1038/sj.onc.1203171	http://dx.doi.org/10.1038/sj.onc.1203171			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557081				2022-12-25	WOS:000083270700011
J	Pyo, H; Joe, EH; Jung, S; Lee, SH; Jou, I				Pyo, H; Joe, EH; Jung, S; Lee, SH; Jou, I			Gangliosides activate cultured bat brain microglia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; HUMAN NEUROBLASTOMA-CELLS; CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; GROWTH-FACTOR RECEPTOR; NITRIC-OXIDE SYNTHASE; PERITONEAL-MACROPHAGES; CEREBROSPINAL-FLUID; CYTOKINE PRODUCTION; INTERFERON-GAMMA	Microglia, brain resident macrophages, are activated in brain injuries and several neurodegenerative diseases. However, microglial activators that are produced in the brain are not yet defined. In this study, we showed that gangliosides, sialic acid-containing glycosphingolipids, could be a microglial activator. Gangliosides induced production of nitric oxide (NO) and tumor necrosis factor-alpha (TNF-alpha) and expression of cyclooxygenase-a (COX-2). The effect of gangliosides on NO release increased dose-dependently in the range of 10-100 mu g/ml; however, the effect decreased at concentrations higher than 200 mu g/ml. Specific types of gangliosides showed differential effects on microglial activation. Similar to gangliosides, GT1b induced production of NO and TNF-alpha and expression of COX-2. However, GM1 and GD1a induced expression of COX-2 but had little effect on NO and TNF-alpha release. The effect of gangliosides and GT1b an NO release was reduced in the presence of neuraminidase, which removes sialic acid residues from gangliosides and GT1b. Gangliosides activated extracellular signal-regulated kinase significantly but activated c-jun N-terminal kinase/stress-activated protein kinase and p38 relatively weakly. The inhibition of extracellular signal-regulated kinase by PD98059 reduced NO release from both gangliosides- and GT1b-treated microglia whereas inhibition of p38 by SB203580 increased it rather slightly. Gangliosides activated NF-kappa B, and N-acetyl cystein, an inhibitor of NF-kappa B, reduced NO release. These results suggest that gangliosides could be a microglial activator that functions via activation of mitogen-activated protein kinase and NF-kappa B.	Ajou Univ, Sch Med, Dept Pharmacol, Suwon 442749, South Korea; Ajou Univ, Sch Med, Dept Physiol, Suwon 442749, South Korea	Ajou University; Ajou University	Joe, EH (corresponding author), San 5 Woncheon Dong,Paldal Gu, Suwon 442749, South Korea.	ehjoe@madang.ajou.ac.kr; jouilo@madang.ajou.ac.kr						Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bhat NR, 1998, J NEUROSCI, V18, P1633; BLENNOW K, 1991, ARCH NEUROL-CHICAGO, V48, P1032, DOI 10.1001/archneur.1991.00530220048018; BO L, 1994, J NEUROIMMUNOL, V51, P135, DOI 10.1016/0165-5728(94)90075-2; BOCCHINI V, 1988, DEV NEUROSCI-BASEL, V10, P270, DOI 10.1159/000111977; Bonaiuto C, 1997, J NEUROIMMUNOL, V77, P51, DOI 10.1016/S0165-5728(97)00054-4; CHAO CC, 1992, J IMMUNOL, V149, P2736; DAcquisto F, 1997, FEBS LETT, V418, P175, DOI 10.1016/S0014-5793(97)01377-X; DELUDE RL, 1994, J BIOL CHEM, V269, P22253; DERRY DM, 1967, SCIENCE, V158, P1450, DOI 10.1126/science.158.3807.1450; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DING AH, 1988, J IMMUNOL, V141, P2407; Ding Y, 1998, IN VIVO, V12, P357; Dreyfus H, 1997, ANAL BIOCHEM, V249, P67, DOI 10.1006/abio.1997.2143; Fox ES, 1998, J LEUKOCYTE BIOL, V63, P509, DOI 10.1002/jlb.63.4.509; FUKUNAGA K, 1990, J NEUROCHEM, V54, P102, DOI 10.1111/j.1471-4159.1990.tb13288.x; Garofalo T, 1998, J BIOL CHEM, V273, P35153, DOI 10.1074/jbc.273.52.35153; Gisslen M, 1997, J NEUROVIROL, V3, P148, DOI 10.3109/13550289709015804; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Giulian D, 1996, J NEUROSCI, V16, P6021; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; GOUY H, 1994, J IMMUNOL, V152, P3271; Haeffner A, 1997, J IMMUNOL, V158, P1310; Irani DN, 1996, J IMMUNOL, V157, P4333; Kleinert H, 1996, J BIOL CHEM, V271, P6039, DOI 10.1074/jbc.271.11.6039; Kopitz J, 1998, J BIOL CHEM, V273, P11205, DOI 10.1074/jbc.273.18.11205; Kopitz J, 1997, EUR J CELL BIOL, V73, P1; KOPITZ J, 1994, BIOCHEM BIOPH RES CO, V199, P1188, DOI 10.1006/bbrc.1994.1356; KOTANI M, 1993, GLYCOBIOLOGY, V3, P137, DOI 10.1093/glycob/3.2.137; LEE SC, 1993, J IMMUNOL, V150, P2659; McDonald DR, 1998, J NEUROSCI, V18, P4451; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Meuillet E, 1996, GLIA, V17, P206, DOI 10.1002/(SICI)1098-1136(199607)17:3<206::AID-GLIA3>3.0.CO;2-Z; MINGHETTI L, 1995, J NEUROCHEM, V65, P2690; NOJIRI H, 1986, P NATL ACAD SCI USA, V83, P782, DOI 10.1073/pnas.83.3.782; NORIHISA Y, 1994, J IMMUNOL, V152, P485; Oderfeld-Nowak B, 1998, NEUROCHEM RES, V23, P443, DOI 10.1023/A:1022482106152; Pahan K, 1998, FREE RADICAL BIO MED, V24, P39, DOI 10.1016/S0891-5849(97)00137-8; PALLER AS, 1995, EXP CELL RES, V217, P118, DOI 10.1006/excr.1995.1070; Pesheva P, 1998, J NEUROSCI RES, V51, P49, DOI 10.1002/(SICI)1097-4547(19980101)51:1<49::AID-JNR5>3.3.CO;2-2; Pyo H, 1998, NEUROREPORT, V9, P871, DOI 10.1097/00001756-199803300-00020; Rabinovich G, 1996, J LEUKOCYTE BIOL, V59, P363, DOI 10.1002/jlb.59.3.363; Rabinovich GA, 1998, J IMMUNOL, V160, P4831; RENNO T, 1994, J NEUROIMMUNOL, V49, P1, DOI 10.1016/0165-5728(94)90174-0; RENNO T, 1995, J IMMUNOL, V154, P944; SOBUE G, 1988, BRAIN RES, V474, P287, DOI 10.1016/0006-8993(88)90442-8; VanBrocklyn JR, 1997, J NEUROCHEM, V69, P116; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; Yamaguchi S, 1997, GLYCOCONJUGATE J, V14, P707, DOI 10.1023/A:1018517400380; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yatomi Y, 1996, GLYCOBIOLOGY, V6, P347, DOI 10.1093/glycob/6.3.347; ZHOU QG, 1994, J BIOL CHEM, V269, P1959; ZIEGLERHEITBROCK HWL, 1992, J IMMUNOL, V148, P1753	54	105	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34584	34589		10.1074/jbc.274.49.34584	http://dx.doi.org/10.1074/jbc.274.49.34584			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574921	hybrid, Green Published			2022-12-25	WOS:000083979600015
J	Voss, M; Weernink, PAO; Haupenthal, S; Moller, U; Cool, RH; Bauer, B; Camonis, JH; Jakobs, KH; Schmidt, M				Voss, M; Weernink, PAO; Haupenthal, S; Moller, U; Cool, RH; Bauer, B; Camonis, JH; Jakobs, KH; Schmidt, M			Phospholipase D stimulation by receptor tyrosine kinases mediated by protein kinase C and a Ras/Ral signaling cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION-FACTOR; GDP DISSOCIATION STIMULATOR; PHOSPHATIDYLINOSITOL 3-KINASE; DEPENDENT ACTIVATION; RAT ADIPOCYTES; EGF RECEPTOR; V-SRC; INSULIN; PHOSPHORYLATION; CELLS	Stimulation of phospholipase D (PLD) in HEK-293 cells expressing the M-3 muscarinic receptor by phorbol ester-activated protein kinase C (PKC) apparently involves Ral GTPases. We report here that PKC, but not muscarinic receptor-induced PLD stimulation in these cells, is strongly and specifically reduced by expression of dominant-negative RalA, G26A RalA, as well as dominant-negative Ras, S17N Ras. In contrast, overexpression of the Ras-activated Ral-specific guanine nucleotide exchange factor, Ral-GDS, specifically enhanced PKC-induced PLD stimulation, Moreover, recombinant Ral-GDS potentiated Ral-dependent PKC-induced PLD stimulation in membranes. Epidermal growth factor, platelet-derived growth factor, and insulin, ligands for receptor tyrosine kinases (RTKs) endogenously expressed in HEK-293 cells, apparently use the PKC- and Ras/Ral-dependent pathway for PLD stimulation. First, PLD stimulation by the RTK agonists was prevented by PKC inhibition and PKC down-regulation. Second, expression of dominant-negative RalA and Ras mutants strongly reduced RTK-induced PLD stimulation. Third, overexpression of Ral-GDS largely potentiated PLD stimulation by the RTK agonists. Finally, using the Ral binding domain of the Ral effector RLIP as an activation-specific probe for Ral proteins, it is demonstrated that endogenous RalA is activated by phorbol ester and RTK agonists. Taken together, strong evidence is provided that RTK-induced PLD stimulation in HEK-293 cells is mediated by PKC and a Ras/Ral signaling cascade.	Univ Essen Gesamthsch Klinikum, Inst Pharmakol, D-45122 Essen, Germany; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany; INSERM U 248, F-75248 Paris 05, France	University of Duisburg Essen; Max Planck Society; Institut National de la Sante et de la Recherche Medicale (Inserm)	Schmidt, M (corresponding author), Univ Essen Gesamthsch Klinikum, Inst Pharmakol, Hufelandstr 55, D-45122 Essen, Germany.	martina.schmidt@uni-essen.de	Schmidt, Martina/C-5339-2018	Schmidt, Martina/0000-0003-3075-0630; Cool, Robbert/0000-0002-9845-2202				Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; Cockcroft S, 1996, PROG LIPID RES, V35, P345, DOI 10.1016/S0163-7827(96)00009-4; delPeso L, 1997, BIOCHEM J, V322, P519; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; El-Shemerly MYM, 1997, J BIOL CHEM, V272, P30599, DOI 10.1074/jbc.272.49.30599; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Frankel P, 1999, BIOCHEM BIOPH RES CO, V255, P502, DOI 10.1006/bbrc.1999.0234; Hinoi T, 1996, J BIOL CHEM, V271, P19710, DOI 10.1074/jbc.271.33.19710; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JIANG H, 1995, J BIOL CHEM, V270, P6006, DOI 10.1074/jbc.270.11.6006; Karnam P, 1997, J BIOL CHEM, V272, P6136, DOI 10.1074/jbc.272.10.6136; Kim JH, 1998, FEBS LETT, V430, P231, DOI 10.1016/S0014-5793(98)00661-9; Kishida S, 1997, ONCOGENE, V15, P2899, DOI 10.1038/sj.onc.1201473; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Lacal JC, 1997, FEBS LETT, V410, P73, DOI 10.1016/S0014-5793(97)00444-4; Lee TG, 1997, BBA-LIPID LIPID MET, V1347, P199, DOI 10.1016/S0005-2760(97)00083-0; Luo JQ, 1997, BIOCHEM BIOPH RES CO, V235, P854, DOI 10.1006/bbrc.1997.6793; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; Min D, 1998, BIOCHEM BIOPH RES CO, V248, P533, DOI 10.1006/bbrc.1998.8990; Morris AJ, 1996, TRENDS PHARMACOL SCI, V17, P182, DOI 10.1016/0165-6147(96)10016-X; Park SK, 1998, BIOCHEM BIOPH RES CO, V244, P364, DOI 10.1006/bbrc.1998.8275; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Rumenapp U, 1997, EUR J BIOCHEM, V248, P407, DOI 10.1111/j.1432-1033.1997.00407.x; RUMENAPP U, 1995, EUR J BIOCHEM, V234, P240, DOI 10.1111/j.1432-1033.1995.240_c.x; Schmidt M, 1996, J BIOL CHEM, V271, P2422, DOI 10.1074/jbc.271.5.2422; Schmidt M, 1998, J BIOL CHEM, V273, P7413, DOI 10.1074/jbc.273.13.7413; SCHMIDT M, 1994, EUR J BIOCHEM, V225, P667, DOI 10.1111/j.1432-1033.1994.00667.x; Schmidt M, 1999, J BIOL CHEM, V274, P14648, DOI 10.1074/jbc.274.21.14648; Schurmann A, 1999, J BIOL CHEM, V274, P9744, DOI 10.1074/jbc.274.14.9744; Shome K, 1997, CURR BIOL, V7, P387, DOI 10.1016/S0960-9822(06)00186-2; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; Slaaby R, 1998, J BIOL CHEM, V273, P33722, DOI 10.1074/jbc.273.50.33722; Standaert ML, 1996, BIOCHEM J, V313, P1039, DOI 10.1042/bj3131039; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486	47	58	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34691	34698		10.1074/jbc.274.49.34691	http://dx.doi.org/10.1074/jbc.274.49.34691			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574935	hybrid, Green Published			2022-12-25	WOS:000083979600029
J	Munro, TP; Magee, RJ; Kidd, GJ; Carson, JH; Barbarese, E; Smith, LM; Smith, R				Munro, TP; Magee, RJ; Kidd, GJ; Carson, JH; Barbarese, E; Smith, LM; Smith, R			Mutational analysis of a heterogeneous nuclear ribonucleoprotein A2 response element for RNA trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN MESSENGER-RNA; MOLECULAR CHARACTERIZATION; INSITU HYBRIDIZATION; LOCALIZATION; MYELIN; TRANSPORT; NEURONS; OLIGODENDROCYTES; BINDS; TRANSLOCATION	Cytoplasmic transport and localization of mRNA has been reported for a range of oocytes and somatic cells. The heterogeneous nuclear ribonucleoprotein (hnRNP) A2 response element (A2RE) is a 21-nucleotide segment of the myelin basic protein mRNA that is necessary and sufficient for cytoplasmic transport of this message in oligodendrocytes, The predominant A2RE-binding protein in rat brain has previously been identified as hnRNP A2, Here we report that an 11-nucleotide subsegment of the A2RE (A2RE11) was as effective as the full-length A2RE in binding hnRNP A2 and mediating transport of heterologous RNA in oligodendrocytes, Point mutations of the A2RE11 that eliminated binding to hnRNP A2 also markedly reduced the ability of these oligoribonucleotides to support RNA transport, Oligodendrocytes treated with antisense oligonucleotides directed against the translation start site of hnRNP A2 had reduced levels of this protein and disrupted transport of microinjected myelin basic protein RNA. Several A2RE-like sequences from localized neuronal RNAs also bound hnRNP A2 and promoted RNA transport in oligo-dendrocytes, These data demonstrate the specificity of A2RE recognition by hnRNP A2, provide direct evidence for the involvement of hnRNP A2 in cytoplasmic RNA transport, and suggest that this protein may interact with a wide variety of localized messages that possess A2RE-like sequences.	Univ Queensland, Dept Biochem, St Lucia, Qld 4072, Australia; Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Dept Neurol, Farmington, CT 06030 USA	University of Queensland; University of Connecticut; University of Connecticut	Smith, R (corresponding author), Univ Queensland, Dept Biochem, St Lucia, Qld 4072, Australia.		Munro, Trent/AAC-1129-2020; Munro, Trent/B-4856-2009; Smith, Lisa/E-6506-2011	Munro, Trent/0000-0003-1987-2020; Kidd, Grahame/0000-0003-3956-2206; Smith, Lisa/0000-0003-2364-8187	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS015190, R01NS019943, R01NS015190] Funding Source: NIH RePORTER; NINDS NIH HHS [NS15190, NS19943] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ainger K, 1997, J CELL BIOL, V138, P1077, DOI 10.1083/jcb.138.5.1077; AINGER K, 1993, J CELL BIOL, V123, P431, DOI 10.1083/jcb.123.2.431; BARBARESE E, 1995, J CELL SCI, V108, P2781; Bassell G, 1997, CURR OPIN CELL BIOL, V9, P109, DOI 10.1016/S0955-0674(97)80159-7; Bassell GJ, 1999, FASEB J, V13, P447, DOI 10.1096/fasebj.13.3.447; BEHAR L, 1995, INT J DEV NEUROSCI, V13, P113, DOI 10.1016/0736-5748(95)00001-W; BRUCKENSTEIN DA, 1990, NEURON, V5, P809, DOI 10.1016/0896-6273(90)90340-L; Carson JH, 1997, CELL MOTIL CYTOSKEL, V38, P318, DOI 10.1002/(SICI)1097-0169(1997)38:4<318::AID-CM2>3.0.CO;2-#; Carson JH, 1998, CURR OPIN NEUROBIOL, V8, P607, DOI 10.1016/S0959-4388(98)80088-3; COLMAN DR, 1982, J CELL BIOL, V95, P598, DOI 10.1083/jcb.95.2.598; Crino PB, 1996, NEURON, V17, P1173, DOI 10.1016/S0896-6273(00)80248-2; CRIPE L, 1993, P NATL ACAD SCI USA, V90, P2724, DOI 10.1073/pnas.90.7.2724; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; GARNER CC, 1988, NATURE, V336, P674, DOI 10.1038/336674a0; Hazelrigg T, 1998, CELL, V95, P451, DOI 10.1016/S0092-8674(00)81613-X; Hoek KS, 1998, BIOCHEMISTRY-US, V37, P7021, DOI 10.1021/bi9800247; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; Kindler S, 1996, MOL BRAIN RES, V36, P63, DOI 10.1016/0169-328X(95)00237-M; KISLAUSKIS EH, 1993, J CELL BIOL, V123, P165, DOI 10.1083/jcb.123.1.165; KLEIMAN R, 1994, J NEUROSCI, V14, P1130, DOI 10.1523/JNEUROSCI.14-03-01130.1994; Knowles RB, 1996, J NEUROSCI, V16, P7812; KREIBICH G, 1983, METHOD ENZYMOL, V96, P520; Kuhl D, 1998, CURR OPIN NEUROBIOL, V8, P600, DOI 10.1016/S0959-4388(98)80087-1; Lasko P, 1999, FASEB J, V13, P421, DOI 10.1096/fasebj.13.3.421; MCKAY SJ, 1992, NUCLEIC ACIDS RES, V20, P1387, DOI 10.1093/nar/20.6.1387; MCKAY SJ, 1992, NUCLEIC ACIDS RES, V20, P6461, DOI 10.1093/nar/20.24.6461; Mowry KL, 1999, FASEB J, V13, P435, DOI 10.1096/fasebj.13.3.435; Nakielny S, 1997, ANNU REV NEUROSCI, V20, P269, DOI 10.1146/annurev.neuro.20.1.269; STEWARD O, 1992, TRENDS NEUROSCI, V15, P180, DOI 10.1016/0166-2236(92)90170-D; Steward O, 1997, NEURON, V18, P9, DOI 10.1016/S0896-6273(01)80041-6; Steward Oswald, 1995, Current Opinion in Neurobiology, V5, P55, DOI 10.1016/0959-4388(95)80087-5; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; TANEJA KL, 1992, J CELL BIOL, V119, P1245, DOI 10.1083/jcb.119.5.1245; Tiedge H, 1999, SCIENCE, V283, P186, DOI 10.1126/science.283.5399.186; TRAPP BD, 1987, P NATL ACAD SCI USA, V84, P7773, DOI 10.1073/pnas.84.21.7773; VERITY AN, 1988, J NEUROSCI RES, V21, P238, DOI 10.1002/jnr.490210216; WANG SX, 1994, NATURE, V369, P400, DOI 10.1038/369400a0; Weiss B, 1997, NEUROCHEM INT, V31, P321, DOI 10.1016/S0197-0186(96)00105-2; WILHELM JE, 1993, J CELL BIOL, V123, P269, DOI 10.1083/jcb.123.2.269	39	150	154	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34389	34395		10.1074/jbc.274.48.34389	http://dx.doi.org/10.1074/jbc.274.48.34389			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567417	hybrid, Green Accepted			2022-12-25	WOS:000083857500082
J	Watters, D; Kedar, P; Spring, K; Bjorkmann, J; Chen, P; Gatei, M; Birrell, G; Garrone, B; Srinivasa, P; Crane, DI; Lavin, MF				Watters, D; Kedar, P; Spring, K; Bjorkmann, J; Chen, P; Gatei, M; Birrell, G; Garrone, B; Srinivasa, P; Crane, DI; Lavin, MF			Localization of a portion of extranuclear ATM to peroxisomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATAXIA-TELANGIECTASIA CELLS; CYCLE CHECKPOINT PATHWAY; DEFICIENT MICE; GENE-PRODUCT; C-ABL; PROTEIN; CATALASE; PHENOTYPE; DEFECTS; DAMAGE	The gene mutated in the human genetic disorder ataxia-telangiectasia codes for a protein, ATM, the known functions of which include response to DNA damage, cell cycle control, and meiotic recombination. Consistent with these functions, ATM is predominantly present in the nucleus of proliferating cells; however, a significant proportion of the protein has also been detected outside the nucleus in cytoplasmic vesicles. To understand the possible role of extra-nuclear ATM, we initially investigated the nature of these vesicles. In this report we demonstrate that a portion of ATM co-localizes with catalase, that ATM is present in purified mouse peroxisomes, and that there are reduced levels of ATM in the post-mitochondrial membrane fraction of cells from a patient with a peroxisome biogenesis disorder. Furthermore the use of the yeast two-hybrid system demonstrated that ATM interacts directly with a protein involved in the import of proteins into the peroxisome matrix. Because peroxisomes are major sites of oxidative metabolism, we investigated catalase activity and lipid hydroperoxide levels in normal and A-T fibroblasts. Significantly decreased catalase activity and increased lipid peroxidation was observed in several A-T cell lines. The localization of ATM to peroxisomes may contribute to the pleiotropic nature of A-T.	PO Royal Brisbane Hosp, Queensland Inst Med Res, Canc Unit, Herston, Qld 4029, Australia; Griffith Univ, Sch Biomol & Biomed Sci, Nathan, Qld 4111, Australia; Univ Queensland, Royal Brisbane Hosp, Dept Surg, Herston, Qld 4029, Australia	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Griffith University; Royal Brisbane & Women's Hospital; University of Queensland	Watters, D (corresponding author), PO Royal Brisbane Hosp, Queensland Inst Med Res, Canc Unit, Herston, Qld 4029, Australia.		Crane, Denis I/A-7887-2011; Watters, Dianne J/E-6007-2010; Lavin, Martin F/F-5961-2014	Crane, Denis I/0000-0002-5696-1906; Watters, Dianne J/0000-0002-2555-5825; Lavin, Martin F/0000-0002-5940-4769; Spring, Kevin/0000-0003-0601-924X; Birrell, Geoff/0000-0002-6593-1514				Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Barlow C, 1997, NAT GENET, V17, P462, DOI 10.1038/ng1297-462; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; BEERS RF, 1952, J BIOL CHEM, V195, P133; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; CANMAN CE, 1994, CANCER RES, V54, P5054; Chen G, 1996, J BIOL CHEM, V271, P33693, DOI 10.1074/jbc.271.52.33693; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Faber KN, 1998, MOL CELL BIOL, V18, P936, DOI 10.1128/MCB.18.2.936; Gartner J, 1998, NEUROPEDIATRICS, V29, P3, DOI 10.1055/s-2007-973526; Gould SJ, 1996, J CELL BIOL, V135, P85, DOI 10.1083/jcb.135.1.85; Jansen GA, 1997, NAT GENET, V17, P190, DOI 10.1038/ng1097-190; Jung M, 1997, CANCER RES, V57, P24; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; Khanna KK, 1997, J BIOL CHEM, V272, P9489; KHANNA KK, 1995, ONCOGENE, V11, P609; KONDO N, 1993, SCAND J IMMUNOL, V38, P45, DOI 10.1111/j.1365-3083.1993.tb01692.x; Kuljis RO, 1997, P NATL ACAD SCI USA, V94, P12688, DOI 10.1073/pnas.94.23.12688; Lakin ND, 1996, ONCOGENE, V13, P2707; LAVIN MF, 1995, TRENDS BIOCHEM SCI, V20, P382, DOI 10.1016/S0968-0004(00)89083-0; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lim DS, 1998, P NATL ACAD SCI USA, V95, P10146, DOI 10.1073/pnas.95.17.10146; MOSER AB, 1995, J PEDIATR-US, V127, P13, DOI 10.1016/S0022-3476(95)70250-4; NEWMAN LS, 1995, CELL, V82, P773, DOI 10.1016/0092-8674(95)90474-3; Oka A, 1998, NEUROSCI LETT, V252, P195, DOI 10.1016/S0304-3940(98)00576-X; Plug AW, 1997, NAT GENET, V17, P457, DOI 10.1038/ng1297-457; Purdue PE, 1996, J CELL BIOL, V134, P849, DOI 10.1083/jcb.134.4.849; Rhodes N, 1998, GENE DEV, V12, P3686, DOI 10.1101/gad.12.23.3686; Rotman G, 1997, BIOESSAYS, V19, P911, DOI 10.1002/bies.950191011; Rybczynska M, 1996, BBA-LIPID LIPID MET, V1302, P231, DOI 10.1016/0005-2760(96)00067-7; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; SAVITSKY K, 1995, SCIENCE, V268, P1700; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Sheikh FG, 1998, P NATL ACAD SCI USA, V95, P2961, DOI 10.1073/pnas.95.6.2961; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; Subramani S, 1997, NAT GENET, V15, P331, DOI 10.1038/ng0497-331; Titorenko VI, 1998, TRENDS BIOCHEM SCI, V23, P231, DOI 10.1016/S0968-0004(98)01226-2; Trelease RN, 1996, EUR J CELL BIOL, V71, P248; VUILLAUME M, 1986, CANCER RES, V46, P538; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	47	150	153	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34277	34282		10.1074/jbc.274.48.34277	http://dx.doi.org/10.1074/jbc.274.48.34277			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567403	Green Published, hybrid			2022-12-25	WOS:000083857500068
J	Albert, S; Gallwitz, D				Albert, S; Gallwitz, D			Two new members of a family of Ypt/Rab GTPase activating proteins - Promiscuity of substrate recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST; RAS; HYDROLYSIS; COMPLEX; MUTANTS; DOMAIN; RHOA; GAP	Monomeric GTPases of the Ras superfamily have a very slow intrinsic GTPase activity which is accelerated by specific GTPase-activating proteins. In contrast to Ras- and Rho-specific GTPase-activating proteins (GAPs) that have been studied in great detail, little is known about the functioning of GAPs specific for Ypt/Rab transport GTPases. We have identified two novel Ypt/Rab-GAPs because of their sequence relatedness to the three known GAPs Gyp1p, Gyp6p, and Gyp7p. Mdr1/Gyp2p is an efficient GAP for Ypt6p and Sec4p, whereas Msb3/Gyp3p is a potent GAP for Sec4p, Ypt6p, Ypt51p, Ypt31/Ypt32p, and Ypt1p. Although the affinity of Msb3/Gyp3p for its preferred substrate Sec4p is low (K-m = 154 mu M), it accelerates the intrinsic GTPase activity of Sec4p 5 x 10(5)-fold. Msb3/Gyp3p appears to be functionally linked to Cdc42p-regulated pathway(s). The results demonstrate that in yeast there is a large family of Ypt/Rab-GAPs, members of which discriminate poorly between GTPases involved in regulating different steps of exo- and endocytic transport routes.	Max Planck Inst Biophys Chem, Dept Mol Genet, D-37070 Gottingen, Germany	Max Planck Society	Gallwitz, D (corresponding author), Max Planck Inst Biophys Chem, Dept Mol Genet, D-37070 Gottingen, Germany.							Ahmadian MR, 1996, J BIOL CHEM, V271, P16409, DOI 10.1074/jbc.271.27.16409; Albert S, 1999, EMBO J, V18, P5216, DOI 10.1093/emboj/18.19.5216; BI E, IN PRESS MOL BIOL CE; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Cuif MH, 1999, EMBO J, V18, P1772, DOI 10.1093/emboj/18.7.1772; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Du LL, 1998, J BIOL CHEM, V273, P3253, DOI 10.1074/jbc.273.6.3253; DUGGLEBY RG, 1991, BIOCHIM BIOPHYS ACTA, V1080, P231, DOI 10.1016/0167-4838(91)90007-M; Finger FP, 1998, CELL, V92, P559, DOI 10.1016/S0092-8674(00)80948-4; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; Fukui K, 1997, J BIOL CHEM, V272, P4655, DOI 10.1074/jbc.272.8.4655; Gamblin SJ, 1998, CURR OPIN STRUC BIOL, V8, P195, DOI 10.1016/S0959-440X(98)80038-9; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GILBERT D, 1992, SEQAPP VERSION 1 9 A; Joshi A, 1999, J BIOL CHEM, V274, P218, DOI 10.1074/jbc.274.1.218; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Lazar T, 1997, TRENDS BIOCHEM SCI, V22, P468, DOI 10.1016/S0968-0004(97)01150-X; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P243, DOI 10.1016/S0968-0004(97)01073-6; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Schweins T, 1996, BIOCHEMISTRY-US, V35, P14225, DOI 10.1021/bi961118o; STROM M, 1993, NATURE, V361, P736, DOI 10.1038/361736a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOLLMER P, 1995, METHOD ENZYMOL, V257, P118; Vollmer P, 1999, EUR J BIOCHEM, V260, P284, DOI 10.1046/j.1432-1327.1999.00192.x; WAGNER P, 1992, METHOD ENZYMOL, V219, P369; Zhang BL, 1998, BIOCHEMISTRY-US, V37, P5249, DOI 10.1021/bi9718447	29	76	83	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33186	33189		10.1074/jbc.274.47.33186	http://dx.doi.org/10.1074/jbc.274.47.33186			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559187	hybrid			2022-12-25	WOS:000083745200003
J	Thornborrow, EC; Manfredi, JJ				Thornborrow, EC; Manfredi, JJ			One mechanism for cell type-specific regulation of the bax promoter by the tumor suppressor p53 is dictated by the p53 response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; WILD-TYPE; GENE BAX; TRANSCRIPTIONAL ACTIVATION; P53-DEPENDENT APOPTOSIS; INDUCE APOPTOSIS; GENOMIC DNA; MUTANT P53; RAT P53; IN-VIVO	Key to the function of the tumor suppressor p53 is its ability to activate the transcription of its target genes, including those that encode the cyclin-dependent kinase inhibitor p21 and the proapoptotic Bax protein. In contrast to Saos-2 cells in which p53 activated both the p21 and bax promoters, in MDA-MB-453 cells p53 activated the p21 promoter, but failed to activate the bax promoter. Neither phosphorylation of p53 on serines 315 or 392 nor an intact C terminus was required for p53-dependent activation of the bax promoter, demonstrating that this differential regulation of bax could not be explained solely by modifications of these residues. Further, this effect was not due to either p73 or other identified cellular factors competing with p53 for binding to its response element in the bax promoter. p53 expressed in MDA-MB-453 cells also failed to activate transcription through the p53 response element of the bax promoter in isolation, demonstrating that the defect is at the level of the interaction between p53 and its response element. In contrast to other p53 target genes, like p21, in which p53-dependent transcriptional activation is mediated by a response element containing two consensus p53 half-sites, activation by p53 of the bax element was mediated by a cooperative interaction of three adjacent half-sites. In addition, the interaction of p53 with its response element from the bax promoter, as compared with its interaction with its element from the p21 promoter, involves a conformationally distinct form of the protein. Together, these data suggest a potential mechanism for the differential regulation of p53-dependent transactivation of the bax and p21 genes.	Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Manfredi, JJ (corresponding author), Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, Box 1130, New York, NY 10029 USA.				NCI NIH HHS [CA69161] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA069161] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; Bargou RC, 1996, J CLIN INVEST, V97, P2651, DOI 10.1172/JCI118715; BARGOU RC, 1995, INT J CANCER, V60, P854, DOI 10.1002/ijc.2910600622; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Di Como CJ, 1998, ONCOGENE, V16, P2527; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; Flaman JM, 1998, ONCOGENE, V16, P1369, DOI 10.1038/sj.onc.1201889; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FUCHS B, 1995, EUR J BIOCHEM, V228, P625, DOI 10.1111/j.1432-1033.1995.0625m.x; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hecker D, 1996, ONCOGENE, V12, P953; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lohrum M, 1996, ONCOGENE, V13, P2527; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARSTON NJ, 1995, ONCOGENE, V10, P1709; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MIYASHITA T, 1995, CELL, V80, P293; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; Sakakura C, 1996, INT J CANCER, V67, P101, DOI 10.1002/(SICI)1097-0215(19960703)67:1<101::AID-IJC17>3.0.CO;2-H; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shu HKG, 1998, P NATL ACAD SCI USA, V95, P14453, DOI 10.1073/pnas.95.24.14453; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TISHLER RB, 1993, CANCER RES, V53, P2212; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; Wagener C, 1996, INT J CANCER, V67, P138, DOI 10.1002/(SICI)1097-0215(19960703)67:1<138::AID-IJC22>3.0.CO;2-9; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; ZHAN QM, 1994, ONCOGENE, V9, P3743	64	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33747	33756		10.1074/jbc.274.47.33747	http://dx.doi.org/10.1074/jbc.274.47.33747			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559267	hybrid			2022-12-25	WOS:000083745200083
J	Zhu, LP; Ling, S; Yu, XD; Venkatesh, LK; Subramanian, T; Chinnadurai, G; Kuo, TH				Zhu, LP; Ling, S; Yu, XD; Venkatesh, LK; Subramanian, T; Chinnadurai, G; Kuo, TH			Modulation of mitochondrial Ca2+ homeostasis by Bcl-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; ENDOPLASMIC-RETICULUM; INTACT-CELLS; CALCIUM; APOPTOSIS; MEMBRANE; PROTEIN; FAMILY; THAPSIGARGIN; EXPRESSION	We have investigated the role of mitochondrial Ca2+ (Ca-m) homeostasis in cell survival. Disruption of Ca-m homeostasis via depletion of the mitochondrial Ca2+ store was the earliest event that occurred during staurosporine-induced apoptosis in neuroblastoma cells (SH-SY5Y), The decrease of Ca-m preceded activation of the caspase cascade and DNA fragmentation. Overexpression of the anti-apoptosis protein Bcl-2 led to increased Ca-m load, increased mitochondrial membrane potential (Delta Psi(m)), and inhibition of staurosporine-induced apoptosis, On the other hand, ectopic expression of the pro-apoptotic protein Bik led to decreased Ca-m load and decreased Delta Psi(m). Inhibition of calcium uptake into mitochondria by ruthenium red induced a dose-dependent apoptosis as determined by nuclear staining and DNA. ladder assay. Similarly, reducing the Ca-m load by lowering the extracellular calcium concentration also led to apoptosis, We suggest that the anti-apoptotic effect of Bcl-2 is related to its ability to maintain a threshold level of Ca-m and Delta Psi(m) while the pro-apoptotic protein Bik has the opposite effect, Furthermore, both ER and mitochondrial Ca2+ stores are important, and the depletion of either one will result in apoptosis, Thus, our results, for the first time, provide evidence that the maintenance of Ca-m homeostasis is essential for cell survival.	Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; St Louis Univ, Med Ctr, Inst Mol Virol, St Louis, MO 63110 USA	Wayne State University; Saint Louis University	Kuo, TH (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, 540 E Canfield, Detroit, MI 48201 USA.				NATIONAL CANCER INSTITUTE [R01CA073803, R01CA033616] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039481] Funding Source: NIH RePORTER; NCI NIH HHS [CA33616, CA73803] Funding Source: Medline; NHLBI NIH HHS [HL-39481] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; AKERMAN KEO, 1978, BIOCHIM BIOPHYS ACTA, V502, P359, DOI 10.1016/0005-2728(78)90056-7; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bian XP, 1997, AM J PHYSIOL-CELL PH, V272, pC1241, DOI 10.1152/ajpcell.1997.272.4.C1241; BOYD JM, 1995, ONCOGENE, V11, P1921; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Duchen MR, 1998, J CELL BIOL, V142, P975, DOI 10.1083/jcb.142.4.975; FURUYA Y, 1994, CANCER RES, V54, P6167; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GUNTER TE, 1990, AM J PHYSIOL, V258, P755; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HANSFORD RG, 1994, J BIOENERG BIOMEMBR, V26, P495, DOI 10.1007/BF00762734; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; Jayadev S, 1999, J BIOL CHEM, V274, P8261, DOI 10.1074/jbc.274.12.8261; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; Kruman II, 1999, J NEUROCHEM, V72, P529, DOI 10.1046/j.1471-4159.1999.0720529.x; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; Landolfi B, 1998, J CELL BIOL, V142, P1235, DOI 10.1083/jcb.142.5.1235; Lawrie AM, 1996, J BIOL CHEM, V271, P10753, DOI 10.1074/jbc.271.18.10753; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu BF, 1996, J BIOL CHEM, V271, P5536, DOI 10.1074/jbc.271.10.5536; Loo DT, 1998, METHOD CELL BIOL, V57, P251; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marin MC, 1996, ONCOGENE, V12, P2259; McGinnis KM, 1999, J NEUROCHEM, V72, P1899, DOI 10.1046/j.1471-4159.1999.0721899.x; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; NICHOLS BJ, 1995, MOL CELL BIOCHEM, V149, P203, DOI 10.1007/BF01076578; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Preston GA, 1997, CANCER RES, V57, P537; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Rutter GA, 1996, P NATL ACAD SCI USA, V93, P5489, DOI 10.1073/pnas.93.11.5489; Scaduto RC, 1999, BIOPHYS J, V76, P469, DOI 10.1016/S0006-3495(99)77214-0; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Uhlmann EJ, 1998, J BIOL CHEM, V273, P17926, DOI 10.1074/jbc.273.28.17926; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; WINGROVE DE, 1984, J BIOL CHEM, V259, P9390; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZHU WH, 1995, LIFE SCI, V57, P2091, DOI 10.1016/0024-3205(95)02202-T; [No title captured]	50	107	115	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33267	33273		10.1074/jbc.274.47.33267	http://dx.doi.org/10.1074/jbc.274.47.33267			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559201	hybrid			2022-12-25	WOS:000083745200017
J	Coleman, J; Eaton, S; Merkel, G; Skalka, AM; Laue, T				Coleman, J; Eaton, S; Merkel, G; Skalka, AM; Laue, T			Characterization of the self association of avian sarcoma virus integrase by analytical ultracentrifugation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 INTEGRASE; RETROVIRAL INTEGRASE; CATALYTIC DOMAIN; PROTEIN INVITRO; DNA; BINDING	Retroviral integration protein (IN) has been shown to be both necessary and sufficient for the integration of reverse-transcribed retroviral DNA into the host cell DNA. It has been demonstrated that self-assembly of IN is essential for proper function. Analytical ultracentrifugation was used to determine the stoichiometry and free energy of self-association of a full-length IN in various solvents at 23.3 degrees C. Below 8% glycerol, an association stoichiometry of monomer-dimer-tetramer is observed. At salt concentrations above 500 mM, dimer is the dominant species over a wide range of protein concentrations. However, as physiological salt concentrations are approached, tetramer formation is favored. The addition of glycerol to 500 mM NaCl, 20 mM Tris (pH 8.4), 2 mar beta-mercaptoethanol significantly enhances dimer formation with little effect on tetramer formation. Furthermore, as electrostatic shielding is increased by increasing the ionic strength or decreasing the cation size, dimer formation is strengthened while tetramer formation is weakened Taken together, the data support a model in which dimer formation includes favorable buried surface interactions which are opposed by charge-charge repulsion, while favorable electrostatic interactions contribute significantly to tetramer formation.	Univ New Hampshire, Dept Biochem & Mol Biol, Durham, NH 03824 USA; Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA	University System Of New Hampshire; University of New Hampshire; Fox Chase Cancer Center	Laue, T (corresponding author), Univ New Hampshire, Dept Biol & Mol Biol, Biol Sci Bldg, Durham, NH 03824 USA.		Laue, Tom/AAI-5136-2020	Laue, Tom/0000-0003-3571-9368	NATIONAL CANCER INSTITUTE [R01CA071515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R41AI040721, R01AI040385] Funding Source: NIH RePORTER; NCI NIH HHS [CA71515] Funding Source: Medline; NIAID NIH HHS [AI40721, AI40385] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andrake MD, 1996, J BIOL CHEM, V271, P19633, DOI 10.1074/jbc.271.33.19633; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; CHRISTOPHERSON RI, 1979, ANAL BIOCHEM, V100, P184, DOI 10.1016/0003-2697(79)90130-1; COLEMAN JL, 1993, THESIS NEW HAMPSHIRE; DURSCHLAG H, 1986, THERMODYNAMIC DATA B; EIJKELENBOOM APAM, 1995, NAT STRUCT BIOL, V2, P807, DOI 10.1038/nsb0995-807; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; ENGLEMAN A, 1991, CELL, V67, P1211; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4667, DOI 10.1021/bi00519a023; GRANDGENETT DP, 1990, CELL, V60, P3, DOI 10.1016/0092-8674(90)90707-L; Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; JONES KS, 1992, J BIOL CHEM, V267, P16037; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; Laue T. M, 1981, THESIS U CONNECTICUT; LAUE TM, 1984, BIOCHEMISTRY-US, V23, P1339, DOI 10.1021/bi00302a001; LAUE TM, 1992, ANAL ULTRACENTIFUGAT; LAUE TM, SHORT COLUMN EQUILIB; LEAVITT AD, 1992, J VIROL, V66, P2359, DOI 10.1128/JVI.66.4.2359-2368.1992; Lee SP, 1997, BIOCHEMISTRY-US, V36, P173, DOI 10.1021/bi961849o; LIU J, 1994, J BIOL CHEM, V269, P28366; Lubkowski J, 1998, P NATL ACAD SCI USA, V95, P4831, DOI 10.1073/pnas.95.9.4831; Lubkowski J, 1998, J BIOL CHEM, V273, P32685, DOI 10.1074/jbc.273.49.32685; Maignan S, 1998, J MOL BIOL, V282, P359, DOI 10.1006/jmbi.1998.2002; TERRY R, 1988, J VIROL, V62, P2358, DOI 10.1128/JVI.62.7.2358-2365.1988; VINK C, 1993, NUCLEIC ACIDS RES, V21, P1419, DOI 10.1093/nar/21.6.1419; VINK C, 1991, NUCLEIC ACIDS RES, V19, P6691, DOI 10.1093/nar/19.24.6691; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303; YPHANTIS DA, 1960, ANN NY ACAD SCI, V88, P586, DOI 10.1111/j.1749-6632.1960.tb20055.x; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003; 1985, GEL FILTRATION PRACT	33	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32842	32846		10.1074/jbc.274.46.32842	http://dx.doi.org/10.1074/jbc.274.46.32842			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551846	hybrid			2022-12-25	WOS:000083623000046
J	Dho, SE; French, MB; Woods, SA; McGlade, CJ				Dho, SE; French, MB; Woods, SA; McGlade, CJ			Characterization of four mammalian numb protein isoforms - Identification of cytoplasmic and membrane-associated variants of the phosphotyrosine binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; MOUSE CORTICAL NEUROGENESIS; CELL FATE; PTB DOMAIN; ASYMMETRIC LOCALIZATION; EH-DOMAIN; IN-VIVO; SIGNAL-TRANSDUCTION; DROSOPHILA; SPECIFICITY	Numb is a membrane-associated, phosphotyrosine binding (PTB) domain containing protein that functions as an intrinsic determinant of cell fate during Drosophila development. We have identified four isoforms of mammalian Numb with predicted molecular masses of 65, 66, 71, and 72 kDa that are generated by alternative splicing of the Numb mRNA. The different isoforms result from the presence of two sequence inserts within the PTB domain and the central region of the protein. The endogenous expression pattern of these isoforms, examined using specific antisera, varied in different tissues and cell lines, In addition, differentiation of P19 cells with retinoic acid leads to the specific loss of expression of the 71- and 72-kDa Numb proteins, suggesting that the expression of certain forms of Numb protein is regulated in a cell type-specific manner. Expression of Numb proteins fused to green fluorescent protein revealed that the form of the PTB domain with the alternatively spliced insert constitutively associated with the plasma membrane in polarized Madin-Darby canine kidney cells. In contrast, the isoform without the insert was cytoplasmic, suggesting that different PTB domain isoforms may regulate the subcellular localization of Numb proteins. The membrane localization may be due, in part, to differential affinity for acidic phospholipids. The distinct expression and localization patterns of the different mammalian Numb isoforms suggest that they have distinct functional properties.	Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	McGlade, CJ (corresponding author), Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	jmcglade@sickkids.on.ca		French, Michelle/0000-0002-4157-0371				BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Borg JP, 1996, MOL CELL BIOL, V16, P6229; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BREWSTER R, 1995, DEVELOPMENT, V121, P2923; Carbone R, 1997, CANCER RES, V57, P5498; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Chien CT, 1998, MOL CELL BIOL, V18, P598, DOI 10.1128/MCB.18.1.598; Dho SE, 1998, J BIOL CHEM, V273, P9179, DOI 10.1074/jbc.273.15.9179; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Frise E, 1996, P NATL ACAD SCI USA, V93, P11925, DOI 10.1073/pnas.93.21.11925; Gomez MR, 1997, DEVELOPMENT, V124, P4857; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; Howell BW, 1999, MOL CELL BIOL, V19, P5179; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; Juven-Gershon T, 1998, MOL CELL BIOL, V18, P3974, DOI 10.1128/MCB.18.7.3974; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Knoblich JA, 1997, P NATL ACAD SCI USA, V94, P13005, DOI 10.1073/pnas.94.24.13005; Li SC, 1998, NAT STRUCT BIOL, V5, P1075, DOI 10.1038/4185; Li SC, 1997, P NATL ACAD SCI USA, V94, P7204, DOI 10.1073/pnas.94.14.7204; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Paoluzi S, 1998, EMBO J, V17, P6541, DOI 10.1093/emboj/17.22.6541; Park M, 1998, MECH DEVELOP, V75, P117, DOI 10.1016/S0925-4773(98)00098-7; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Sengar AS, 1999, EMBO J, V18, P1159, DOI 10.1093/emboj/18.5.1159; Siegal G, 1999, NAT STRUCT BIOL, V6, P7, DOI 10.1038/4873; Spana EP, 1996, NEURON, V17, P21, DOI 10.1016/S0896-6273(00)80277-9; SPANA EP, 1995, DEVELOPMENT, V121, P3489; Stevenson JM, 1998, J BIOL CHEM, V273, P22761, DOI 10.1074/jbc.273.35.22761; Tang HY, 1997, MOL CELL BIOL, V17, P4294, DOI 10.1128/MCB.17.8.4294; TANG HY, 1999, MOL CELL BIOL, V9, pR70; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; Verdi J, 1996, CURR BIOL, V6, P1134, DOI 10.1016/S0960-9822(02)70680-5; Vervoort M, 1997, CURR OPIN NEUROBIOL, V7, P21, DOI 10.1016/S0959-4388(97)80116-X; Wakamatsu Y, 1999, NEURON, V23, P71, DOI 10.1016/S0896-6273(00)80754-0; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530; Yaich L, 1998, J BIOL CHEM, V273, P10381, DOI 10.1074/jbc.273.17.10381; Zhang ZT, 1997, EMBO J, V16, P6141, DOI 10.1093/emboj/16.20.6141; Zhong WM, 1997, DEVELOPMENT, V124, P1887; Zhong WM, 1996, NEURON, V17, P43, DOI 10.1016/S0896-6273(00)80279-2; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	47	149	160	3	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					33097	33104		10.1074/jbc.274.46.33097	http://dx.doi.org/10.1074/jbc.274.46.33097			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551880	hybrid			2022-12-25	WOS:000083623000080
J	Amano, M; Chihara, K; Nakamura, N; Kaneko, T; Matsuura, Y; Kaibuchi, K				Amano, M; Chihara, K; Nakamura, N; Kaneko, T; Matsuura, Y; Kaibuchi, K			The COOH terminus of Rho-kinase negatively regulates Rho-kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SERINE-THREONINE KINASE; ACTIN STRESS FIBERS; SMALL GTPASE RHO; LIGHT-CHAIN; FOCAL ADHESIONS; CATALYTIC SUBUNITS; MYOSIN PHOSPHATASE; PUTATIVE TARGET; COILED-COIL	Rho-kinase is implicated in the phosphorylation of myosin Light chain downstream of Rho, which is thought to induce smooth muscle contraction and stress fiber formation in non-muscle cells. Here, we examined the mode of action of inhibitors of Rho-kinase. The chemical compounds such as HA1077 and Y-32885 inhibited not only the Rho-kinase activity but also the activity of protein kinase N, one of the targets of Rho, but had less of an effect on the activity of myotonic dystrophy kinase-related Cdc42-binding kinase beta (MRCK beta). The COOH-terminal portion of Rho-kinase containing Rho-binding (RB) and pleckstrin homology (PH) domains (RB/PH (TT)), in which point mutations were introduced to abolish the Rho binding activity, interacted with Rho-kinase and thereby inhibited the Rho-kinase activity, whereas RB/PH (TT) had no effect on the activity of protein kinase N or MRCK beta, suggesting that the COOH-terminal region of Rho-kinase is a possible negative regulatory region of Rho-kinase. The expression of RB/PH (TT) specifically blocked the stress fiber and focal adhesion formation induced by the active form of Rho or Rho-kinase in NIH 3T3 cells, but not that induced by the active form of MRCK beta or myosin light chain. Thus, RB/PH (TT) appears to specifically inhibit Rho kinase in vivo.	Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 6300101, Japan; Natl Inst Infect Dis, Dept Virol 2, Shinjuku Ku, Tokyo 1628640, Japan	Nara Institute of Science & Technology; National Institute of Infectious Diseases (NIID)	Kaibuchi, K (corresponding author), Nara Inst Sci & Technol, Div Signal Transduct, 8916-5 Takayama, Ikoma 6300101, Japan.		Amano, Mutsuki/M-4820-2014	Amano, Mutsuki/0000-0002-0662-1524				Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1998, GENES CELLS, V3, P177, DOI 10.1046/j.1365-2443.1998.00181.x; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BRESNICK AR, 1995, BIOCHEMISTRY-US, V34, P12576, DOI 10.1021/bi00039a012; Cachero TG, 1998, CELL, V93, P1077, DOI 10.1016/S0092-8674(00)81212-X; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; CHRZANOWSKAWODN.M, 1996, J CELL BIOL, V133, P139; Engh RA, 1996, J BIOL CHEM, V271, P26157, DOI 10.1074/jbc.271.42.26157; Fujisawa K, 1996, J BIOL CHEM, V271, P23022, DOI 10.1074/jbc.271.38.23022; Fukata Y, 1999, J CELL BIOL, V145, P347, DOI 10.1083/jcb.145.2.347; Gibson RM, 1997, J BIOL CHEM, V272, P16343, DOI 10.1074/jbc.272.26.16343; Gibson RM, 1997, PROTEIN SCI, V6, P1825, DOI 10.1002/pro.5560060903; Goto H, 1998, J BIOL CHEM, V273, P11728, DOI 10.1074/jbc.273.19.11728; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; KAMISOYAMA H, 1994, BIOCHEMISTRY-US, V33, P840, DOI 10.1021/bi00169a027; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kimura K, 1998, J BIOL CHEM, V273, P5542, DOI 10.1074/jbc.273.10.5542; Kosako H, 1997, J BIOL CHEM, V272, P10333; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Oshiro N, 1998, J BIOL CHEM, V273, P34663, DOI 10.1074/jbc.273.52.34663; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; SWEENEY HL, 1994, P NATL ACAD SCI USA, V91, P1490, DOI 10.1073/pnas.91.4.1490; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249	43	216	227	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32418	32424		10.1074/jbc.274.45.32418	http://dx.doi.org/10.1074/jbc.274.45.32418			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542285	hybrid			2022-12-25	WOS:000083532100093
J	Camerer, E; Rottingen, JA; Gjernes, E; Larsen, K; Skartlien, AH; Iversen, JG; Prydz, H				Camerer, E; Rottingen, JA; Gjernes, E; Larsen, K; Skartlien, AH; Iversen, JG; Prydz, H			Coagulation factors VIIa and Xa induce cell signaling leading to up-regulation of the egr-1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINASE-ACTIVATED RECEPTOR-2; VEIN ENDOTHELIAL-CELLS; CANINE KIDNEY-CELLS; SMOOTH-MUSCLE CELLS; TISSUE FACTOR; THROMBIN-RECEPTOR; MOLECULAR-CLONING; BLOOD-COAGULATION; EPITHELIAL-CELLS; HUMAN PLATELETS	Intracellular signaling induced by the coagulation factors (F) VIIa and Xa is poorly understood. We report here studies on these processes in a human keratinocyte line (HaCaT), which is a constitutive producer of tissue factor (TF) and responds to both FVIIa and FXa with elevation of cytosolic Ca2+, phosphorylation of extracellular signal-regulated kinase (Erk) 1/2, p38(MAPK), and c-Jun N-terminal kinase, and up-regulation of transcription of the early growth response gene-1 (egr-1). Using egr-1 as end point, we observed with both agonists that phosphatidylinositol-specific phospholipase C and the mitogen-activated protein kinase/Erk kinase/Erk pathway were mediators of the responses. The responses to FVIIa were TF-dependent and up-regulation of egr-1 mRNA did not require presence of the TF cytoplasmic domain. Antibodies to EPR-1 and factor V had no effect on the response to FXa. We have provided evidence that TF is not the sole component of the FVIIa receptor. The requirement for proteolytic activity of both FVIIa and FXa suggests that protease-activated receptors may be involved. We now report evidence suggesting that protease-activated receptor 2 or a close homologue may be a necessary but not sufficient component of this particular signal transduction pathway. The up-regulation of egr-1 describes one way by which the initiation of blood coagulation may influence gene transcription. The ability of these coagulation proteases to induce intracellular signals at concentrations at or below the plasma concentrations of their zymogen precursors suggests that these processes may occur also in vivo.	Ctr Biotechnol, N-0371 Oslo, Norway; Univ Oslo, Inst Basic Med Sci, Dept Physiol, Lab Intracellular Signaling, N-0371 Oslo, Norway	University of Oslo	Prydz, H (corresponding author), Ctr Biotechnol, Gaustadalleen 21, N-0371 Oslo, Norway.	hans.prydz@biotek.uio.no	Camerer, Eric/K-4161-2017	Camerer, Eric/0000-0002-6271-7125				Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; Bono F, 1997, J CELL PHYSIOL, V172, P36, DOI 10.1002/(SICI)1097-4652(199707)172:1<36::AID-JCP4>3.0.CO;2-E; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Brass LF, 1997, THROMB HAEMOSTASIS, V78, P234; Camerer E, 1996, BLOOD, V88, P1339, DOI 10.1182/blood.V88.4.1339.bloodjournal8841339; Camerer E, 1996, THROMB RES, V81, P1, DOI 10.1016/0049-3848(95)00209-X; Camerer E, 1996, J BIOL CHEM, V271, P29034, DOI 10.1074/jbc.271.46.29034; Coughlin SR, 1998, ARTERIOSCL THROM VAS, V18, P514, DOI 10.1161/01.ATV.18.4.514; Cui MZ, 1996, J BIOL CHEM, V271, P2731, DOI 10.1074/jbc.271.5.2731; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Fox MT, 1997, FEBS LETT, V417, P267, DOI 10.1016/S0014-5793(97)01298-2; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GAJDUSEK C, 1986, J CELL BIOL, V103, P419, DOI 10.1083/jcb.103.2.419; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Herbert JM, 1998, J CLIN INVEST, V101, P993, DOI 10.1172/JCI1833; HUANG RP, 1994, BIOCHEM BIOPH RES CO, V200, P1271, DOI 10.1006/bbrc.1994.1588; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Khachigian LM, 1997, CIRC RES, V81, P457, DOI 10.1161/01.RES.81.4.457; Ko FN, 1996, J CLIN INVEST, V98, P1493, DOI 10.1172/JCI118938; Nicholson AC, 1996, J BIOL CHEM, V271, P28407, DOI 10.1074/jbc.271.45.28407; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; Ollivier V, 1998, BLOOD, V91, P2698, DOI 10.1182/blood.V91.8.2698.2698_2698_2703; Ott I, 1998, J CELL BIOL, V140, P1241, DOI 10.1083/jcb.140.5.1241; PABORSKY LR, 1991, J BIOL CHEM, V266, P21911; Papapetropoulos A, 1998, P NATL ACAD SCI USA, V95, P4738, DOI 10.1073/pnas.95.8.4738; Pendurthi UR, 1997, P NATL ACAD SCI USA, V94, P12598, DOI 10.1073/pnas.94.23.12598; Poulsen LK, 1998, J BIOL CHEM, V273, P6228, DOI 10.1074/jbc.273.11.6228; Randolph GJ, 1998, BLOOD, V92, P4167, DOI 10.1182/blood.V92.11.4167.423k35_4167_4177; ROTNES JS, 1994, CELL CALCIUM, V15, P467, DOI 10.1016/0143-4160(94)90111-2; ROTNES JS, 1992, CELL CALCIUM, V13, P487, DOI 10.1016/0143-4160(92)90017-M; ROTTINGEN JA, 1995, J BIOL CHEM, V270, P4650, DOI 10.1074/jbc.270.9.4650; Schaeffer P, 1997, CIRC RES, V81, P824; Senden NHM, 1998, J IMMUNOL, V161, P4318; Taniguchi T, 1998, CANCER RES, V58, P4461; Taylor CW, 1998, TRENDS PHARMACOL SCI, V19, P370, DOI 10.1016/S0165-6147(98)01243-7; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V	42	154	165	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32225	32233		10.1074/jbc.274.45.32225	http://dx.doi.org/10.1074/jbc.274.45.32225			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542260	hybrid			2022-12-25	WOS:000083532100068
J	Garnerone, AM; Cabanes, D; Foussard, M; Boistard, P; Batut, J				Garnerone, AM; Cabanes, D; Foussard, M; Boistard, P; Batut, J			Inhibition of the FixL sensor kinase by the FixT protein in Sinorhizobium meliloti	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHIZOBIUM-MELILOTI; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; OXYGEN SENSOR; PHOSPHATASE-ACTIVITIES; NITROGEN-FIXATION; MODULAR STRUCTURE; GENE-EXPRESSION; HEME PROTEIN; PHOSPHORYLATION	Nitrogen fixation in symbiotic rhizobia is subject to multiple levels of gene regulation. In Sinorhizobium meliloti, the alfalfa symbiont, the FixLJ two component regulatory system plays a major role in inducing nitrogen fixation and respiration gene expression in response to the low ambient O-2 concentration of the nodule, Here we report on the mode of action of the FixT protein, a recently identified repressor of nitrogen fixation gene expression in S, meliloti, First, we provide evidence that FixT prevents transcription of the intermediate key regulatory genes nifA and fixK by counteracting the activity of the FixLJ two-component system under otherwise inducing microoxic conditions. Second, we demonstrate that FixT acts as an inhibitor of the sensor hemoprotein kinase FixL, preventing the production or the accumulation of its phosphorylated form. FixT is thus a new example of a regulatory protein that blocks signal transduction in two-component systems at the level of the sensor kinase.	INRA, CNRS, Lab Biol Mol Relat Plantes Microorganismes, F-31326 Castanet Tolosan, France	Centre National de la Recherche Scientifique (CNRS); INRAE	Batut, J (corresponding author), INRA, CNRS, Lab Biol Mol Relat Plantes Microorganismes, BP27, F-31326 Castanet Tolosan, France.		Cabanes, Didier/P-3052-2019; BATUT, Jacques/B-6506-2008; Cabanes, Didier/K-3917-2013	Cabanes, Didier/0000-0002-4001-1332; Cabanes, Didier/0000-0002-4001-1332				Akagawa E, 1995, MICROBIOL-UK, V141, P3241, DOI 10.1099/13500872-141-12-3241; BATUT J, 1989, EMBO J, V8, P1279, DOI 10.1002/j.1460-2075.1989.tb03502.x; DAHL MK, 1992, J BIOL CHEM, V267, P14509; DAVID M, 1988, CELL, V54, P671, DOI 10.1016/S0092-8674(88)80012-6; DEPHILIP P, 1992, MOL GEN GENET, V235, P49, DOI 10.1007/BF00286180; DEPHILIP P, 1990, J BACTERIOL, V172, P4255, DOI 10.1128/jb.172.8.4255-4262.1990; DITTA G, 1987, J BACTERIOL, V169, P3217, DOI 10.1128/jb.169.7.3217-3223.1987; FISCHER HM, 1994, MICROBIOL REV, V58, P352, DOI 10.1128/MMBR.58.3.352-386.1994; Foussard M, 1997, MOL MICROBIOL, V25, P27, DOI 10.1046/j.1365-2958.1997.4501814.x; GALINIER A, 1994, J BIOL CHEM, V269, P23784; GILLESGONZALEZ MA, 1994, BIOCHEMISTRY-US, V33, P8067, DOI 10.1021/bi00192a011; GILLESGONZALEZ MA, 1993, J BIOL CHEM, V268, P16293; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; Gong WM, 1998, P NATL ACAD SCI USA, V95, P15177, DOI 10.1073/pnas.95.26.15177; KAHN D, 1991, MOL MICROBIOL, V5, P987, DOI 10.1111/j.1365-2958.1991.tb00774.x; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LOIS AF, 1993, J BIOL CHEM, V268, P4370; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; Mizuno T, 1997, DNA Res, V4, P161, DOI 10.1093/dnares/4.2.161; MONSON EK, 1992, P NATL ACAD SCI USA, V89, P4280, DOI 10.1073/pnas.89.10.4280; MONSON EK, 1995, J BIOL CHEM, V270, P5243, DOI 10.1074/jbc.270.10.5243; Ogino T, 1998, MOL MICROBIOL, V27, P573, DOI 10.1046/j.1365-2958.1998.00703.x; PEREGO M, 1994, CELL, V79, P1047, DOI 10.1016/0092-8674(94)90035-3; RENALIER MH, 1987, J BACTERIOL, V169, P2231, DOI 10.1128/jb.169.5.2231-2238.1987; REYRAT JM, 1994, J BACTERIOL, V176, P1969, DOI 10.1128/jb.176.7.1969-1976.1994; REYRAT JM, 1993, J BACTERIOL, V175, P6867, DOI 10.1128/jb.175.21.6867-6872.1993; SOUPENE E, 1995, P NATL ACAD SCI USA, V92, P3759, DOI 10.1073/pnas.92.9.3759; Wang L, 1997, GENE DEV, V11, P2569, DOI 10.1101/gad.11.19.2569	29	57	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32500	32506		10.1074/jbc.274.45.32500	http://dx.doi.org/10.1074/jbc.274.45.32500			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542296	hybrid			2022-12-25	WOS:000083532100104
J	Jimenez-Asensio, J; Colvis, CM; Kowalak, JA; Duglas-Tabor, Y; Datiles, MB; Moroni, M; Mura, U; Rao, CM; Balasubramanian, D; Janjani, A; Garland, D				Jimenez-Asensio, J; Colvis, CM; Kowalak, JA; Duglas-Tabor, Y; Datiles, MB; Moroni, M; Mura, U; Rao, CM; Balasubramanian, D; Janjani, A; Garland, D			An atypical form of alpha B-crystallin is present in high concentration in some human cataractous lenses - Identification and characterization of aberrant N- and C-terminal processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; CHAPERONE-LIKE ACTIVITY; BOVINE LENS; 2-DIMENSIONAL ELECTROPHORESIS; PHOSPHORYLATION SITES; MOLECULAR CHAPERONE; MASS-SPECTROMETRY; STRESS PROTEINS; A-CRYSTALLIN; AMINO-ACID	Two unique polypeptides, 22.4 and 16.4 kDa, were prominent in some human cataracts. Both proteins mere identified as modified forms of the small heat shock protein, alpha B-crystallin. The concentration of total alpha B-crystallin in most of these cataracts was significantly increased. The 22.4-kDa protein was subsequently designated as alpha B-g. Mass spectrometric analyses of tryptic and Asp-N digests showed alpha B-g is alpha B-crystallin minus the C-terminal lysine. alpha B-g constituted 10-90% of the total alpha B-crystallin in these cataracts and was preferentially phosphorylated over the typical form of alpha B-crystallin. Human alpha B-g and alpha B-crystallin were cloned and expressed in Escherichia coli. The differences in electrophoretic mobility and the large difference in native pI values suggest some structural differences exist. The chaperone-like activity of recombinant human alpha B-g was comparable to that of recombinant human alpha B-crystallin in preventing the aggregation of lactalbumin induced by dithiothreitol, The mechanism involved in generating alpha B-g is not known, but a premature termination of the alpha B-crystallin gene was ruled out by sequencing the polymerase chain reaction products of the last exon for the alpha B-crystallin gene from lenses containing alpha B-g. The 16.4-kDa protein was an N-terminally truncated fragment of alpha B-g. The high concentration of alpha B-crystallin in these cataracts is the first observation of this kind in human lenses.	NEI, Lab Mechanisms Ocular Dis, NIH, Bethesda, MD 20892 USA; NICHHD, NIH, Bethesda, MD 20892 USA; Univ Pisa, I-56100 Pisa, Italy; Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India; Ctr Cellular & Mol Biol, Hyderabad 500034, Andhra Pradesh, India; LV Prasad Eye Inst, Hyderabad 500034, Andhra Pradesh, India	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Pisa; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB); L. V. Prasad Eye Institute	Garland, D (corresponding author), NEI, Lab Mechanisms Ocular Dis, NIH, Bldg 6,Rm 235, Bethesda, MD 20892 USA.		Datiles, Manuel/S-1206-2019	Datiles, Manuel III B./0000-0003-4660-1664				ANDERSON EI, 1978, EXP EYE RES, V26, P407, DOI 10.1016/0014-4835(78)90128-8; Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; AOYAMA A, 1993, MOL CELL BIOL, V13, P1824, DOI 10.1128/MCB.13.3.1824; Augusteyn RC, 1998, EXP EYE RES, V66, P669, DOI 10.1006/exer.1998.0468; BARRETT AJ, 1998, HDB PROTEOLYTIC ENZY, P1341; Bhat SP, 1999, EUR J CELL BIOL, V78, P143, DOI 10.1016/S0171-9335(99)80016-8; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BINDELS JG, 1983, COMP BIOCHEM PHYS B, V76, P47, DOI 10.1016/0305-0491(83)90169-4; BLOEMENDAL H, 1981, MOL CELLULAR BIOL EY, P279; CARTER JM, 1995, EXP EYE RES, V60, P181, DOI 10.1016/S0014-4835(95)80009-3; Carver JA, 1998, INT J BIOL MACROMOL, V22, P197, DOI 10.1016/S0141-8130(98)00017-8; CHIESA R, 1987, BIOCHEM BIOPH RES CO, V144, P1340, DOI 10.1016/0006-291X(87)91457-4; CHIESA R, 1987, J BIOL CHEM, V262, P1438; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; de Jong W.W., 1988, Advances in Experimental Medicine and Biology, V231, P95; DEJONG WW, 1989, TRENDS BIOCHEM SCI, V14, P365, DOI 10.1016/0968-0004(89)90009-1; DELVECCHIO PJ, 1984, CURR EYE RES, V3, P1213; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; EMMONS T, 1992, EXP EYE RES, V55, P551, DOI 10.1016/S0014-4835(05)80167-8; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; Garland DL, 1996, EXP EYE RES, V62, P285, DOI 10.1006/exer.1996.0034; GOPALAKRISHNAN S, 1992, CURR EYE RES, V11, P929, DOI 10.3109/02713689209033490; GORTHY WC, 1992, CURR EYE RES, V11, P531, DOI 10.3109/02713689209001809; GROENEN PJTA, 1994, EUR J BIOCHEM, V220, P795, DOI 10.1111/j.1432-1033.1994.tb18681.x; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; HARDING JJ, 1976, EXP EYE RES, V22, P1, DOI 10.1016/0014-4835(76)90033-6; HE SM, 1995, J MASS SPECTROM, V30, P424, DOI 10.1002/jms.1190300305; HOENDERS HJ, 1983, J GERONTOL, V38, P278, DOI 10.1093/geronj/38.3.278; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; Ito H, 1997, J BIOL CHEM, V272, P29934, DOI 10.1074/jbc.272.47.29934; IWAKI T, 1993, ACTA NEUROPATHOL, V85, P475; IWAKI T, 1993, AM J PATHOL, V143, P487; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JAKOB U, 1993, J BIOL CHEM, V268, P1517; Kato K, 1997, CELL STRESS CHAPERON, V2, P199, DOI 10.1379/1466-1268(1997)002<0199:MOTAIE>2.3.CO;2; KATO K, 1993, J BIOCHEM-TOKYO, V114, P640, DOI 10.1093/oxfordjournals.jbchem.a124230; KLEMENZ R, 1994, VERH DEUT G, V78, P34; KLEMENZ R, 1993, J CELL BIOL, V120, P639, DOI 10.1083/jcb.120.3.639; Lin PP, 1997, EXP EYE RES, V65, P673, DOI 10.1006/exer.1997.0376; LORAND L, 1992, P NATL ACAD SCI USA, V89, P11161, DOI 10.1073/pnas.89.23.11161; MERCK KB, 1993, J BIOL CHEM, V268, P1046; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Plater ML, 1996, J BIOL CHEM, V271, P28558, DOI 10.1074/jbc.271.45.28558; ROQUEMORE EP, 1992, J BIOL CHEM, V267, P555; SHARMA KK, 1992, EXP EYE RES, V54, P1005, DOI 10.1016/0014-4835(92)90165-O; SMITH JB, 1995, J PROTEIN CHEM, V14, P179, DOI 10.1007/BF01980330; SMITH JB, 1992, PROTEIN SCI, V1, P601, DOI 10.1002/pro.5560010506; Smulders RHPH, 1996, J BIOL CHEM, V271, P29060, DOI 10.1074/jbc.271.46.29060; SPECTOR A, 1985, P NATL ACAD SCI USA, V82, P4712, DOI 10.1073/pnas.82.14.4712; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; STONE KL, 1993, PRACTICAL GUIDE PROT, P45; SWANSON AA, 1985, CURR EYE RES, V4, P43, DOI 10.3109/02713688508999965; TAKEMOTO L, 1994, EXP EYE RES, V59, P239, DOI 10.1006/exer.1994.1103; VOORTER CEM, 1989, FEBS LETT, V259, P50; Wang KY, 1996, EUR J BIOCHEM, V242, P56, DOI 10.1111/j.1432-1033.1996.0056r.x; WISTOW G, 1985, FEBS LETT, V181, P1, DOI 10.1016/0014-5793(85)81102-9	58	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32287	32294		10.1074/jbc.274.45.32287	http://dx.doi.org/10.1074/jbc.274.45.32287			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542268	hybrid			2022-12-25	WOS:000083532100076
J	Kreppel, LK; Hart, GW				Kreppel, LK; Hart, GW			Regulation of a cytosolic and nuclear O-GlcNAc transferase - Role of the tetratricopeptide repeats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-N-ACETYLGLUCOSAMINYLTRANSFERASE; EIF-2 ALPHA-SUBUNIT; LINKED GLYCOSYLATION; CYTOSKELETAL PROTEINS; CYTOPLASMIC PROTEINS; SNAP HELIX; PHOSPHORYLATION; TPR; PURIFICATION; DOMAIN	The O-GlcNAc transferase (OGT) is a unique nuclear and cytosolic glycosyltransferase that contains multiple tetratricopeptide repeats. We have begun to characterize the mechanisms regulating OGT using a combination of deletion analysis and kinetic studies. Here we show that the p110 subunit of the enzyme forms both homo- and heterotrimers that appear to have different binding affinities for UDP-GlcNAc. The multimerization domain of OGT lies within the tetratricopeptide repeat domain and is not necessary for activity. Kinetic analyses of the full-length trimer and the truncated monomer forms of OGT suggest that both forms function through a random bi-bi kinetic mechanism. Both the monomer and trimer have similar specific activities and similar K-m values for peptide substrates. However, they differ in their binding affinities for UDP-GlcNAc, indicating that subunit interactions affect enzyme activity. The findings that recombinant OGT has three distinct K-m values for UDP-GlcNAc and that UDP-GlcNAc concentrations modulates the affinity of OGT for peptides suggest that OGT is exquisitely regulated by the levels of UDP-GlcNAc within the nucleus and cytoplasm.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Hart, GW (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.			Hart, Gerald/0000-0001-7812-4351	NICHD NIH HHS [R01 HD13563] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD013563] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BOYLE JS, 1995, TRENDS GENET, V11, P8, DOI 10.1016/S0168-9525(00)88977-5; CHAKRABORTY A, 1994, BIOCHEMISTRY-US, V33, P6700, DOI 10.1021/bi00187a041; CHOU CF, 1993, J BIOL CHEM, V268, P4465; CHOU CF, 1992, J BIOL CHEM, V267, P3901; DATTA B, 1989, J BIOL CHEM, V264, P20620; Dong DLY, 1996, J BIOL CHEM, V271, P20845, DOI 10.1074/jbc.271.34.20845; DONG DLY, 1994, J BIOL CHEM, V269, P19321; FIELD MC, 1995, GLYCOBIOLOGY, V5, P463, DOI 10.1093/glycob/5.5.463; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; Haltiwanger R S, 1993, Methods Mol Biol, V14, P175; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; Hart GW, 1996, GLYCOBIOLOGY, V6, P711, DOI 10.1093/glycob/6.7.711; Haucke V, 1996, EMBO J, V15, P1231, DOI 10.1002/j.1460-2075.1996.tb00464.x; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; KAPLAN HA, 1984, COMP BIOCHEM PHYS A, V77, P207, DOI 10.1016/0300-9629(84)90048-3; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; KELLY WG, 1993, J BIOL CHEM, V268, P10416; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; KREPPEL LK, 1999, MOL CELLULAR GLYCOBI; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Lubas WA, 1997, J BIOL CHEM, V272, P9316; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; RAMEAU G, 1994, MOL CELL BIOL, V14, P822, DOI 10.1128/MCB.14.1.822; ROQUEMORE EP, 1994, METHOD ENZYMOL, V230, P443; Roquemore EP, 1996, BIOCHEMISTRY-US, V35, P3578, DOI 10.1021/bi951918j; SARNSTRAND B, 1987, ARCH BIOCHEM BIOPHYS, V252, P315, DOI 10.1016/0003-9861(87)90036-1; SCHULTZ J, 1990, MOL CELL BIOL, V10, P4744, DOI 10.1128/MCB.10.9.4744; Shaw P, 1996, ONCOGENE, V12, P921; Snow DM, 1998, INT REV CYTOL, V181, P43, DOI 10.1016/S0074-7696(08)60416-7; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; WICE BM, 1985, J BIOL CHEM, V260, P139; ZHIVKOV V, 1975, COMP BIOCHEM PHYS B, V51, P421, DOI 10.1016/0305-0491(75)90032-2	39	308	332	0	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32015	32022		10.1074/jbc.274.45.32015	http://dx.doi.org/10.1074/jbc.274.45.32015			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542233	hybrid			2022-12-25	WOS:000083532100041
J	Dievart, A; Beaulieu, N; Jolicoeur, P				Dievart, A; Beaulieu, N; Jolicoeur, P			Involvement of Notch1 in the development of mouse mammary tumors	ONCOGENE			English	Article						MMTV; oncogene; provirus; transformation	HUMAN-BREAST-CANCER; NEU ONCOGENE; DROSOPHILA NOTCH; TRANSGENIC MICE; HUMAN HOMOLOG; CELL-LINE; GENE; PROTEIN; DOMAIN; TRANSCRIPTION	The MMTV/neu transgenic (Tg) mice spontaneously develop mammary tumors stochastically after a long latent period, suggesting that the c-neu/erbB2 oncogene is not sufficient for tumor formation. To identify putative collaborator(s) of the c-neu/erbB2, we used the provirus insertional mutagenesis approach with mammary tumors arising in MMTV/neu Tg mice infected with the mouse mammary tumor virus (MMTV), The Notch1 gene was identified as a novel target for MMTV provirus insertional activation. In Notch1-rearranged tumors, the Notch1 gene was interrupted by the MMTV provirus insertion upstream of the exons coding for the TM domain. These insertions led to overexpression of novel 5' truncated similar to 7kb RNA coding for 280 kDa mutant protein harboring only the Notch1 ectodomain, N(EC)(mut), These may be involved in tumor formation. Another consequence of these insertions was the expression of truncated 3' Notch1 transcripts (3.5-4.5 kb) and proteins (86-110 kDa) deleted of most of the extracellular sequences (Notch1(intra)). We found that 3' truncated Notch1(intra) can transform HC11 mouse mammary epithelial cells in vitro. Deletion analysis revealed that the ankyrin-repeats and the domain 1 (aa 1751-1821) are required, while a signal peptide, the two conserved cysteines (C-1652 and C-1685) and the OPA and PEST sequences are dispensable for transformation. These results indicate that the N-terminally truncated Notch1(intra) protein behaves as an oncogene in this system.	Clin Res Inst Montreal, Mol Biol Lab, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Med, Montreal, PQ H3J 3J7, Canada; Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H3J 3J7, Canada; McGill Univ, Dept Expt Med, Montreal, PQ H3G 1A4, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Universite de Montreal; McGill University	Jolicoeur, P (corresponding author), Clin Res Inst Montreal, Mol Biol Lab, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.			Dievart, Anne/0000-0001-9460-4638				ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; ASTER J, 1994, COLD SPRING HARB SYM, V59, P125, DOI 10.1101/SQB.1994.059.01.016; Aster JC, 1997, J BIOL CHEM, V272, P11336; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; Callahan R, 1996, BREAST CANCER RES TR, V39, P33, DOI 10.1007/BF01806076; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Chen YY, 1997, J BIOL CHEM, V272, P14110, DOI 10.1074/jbc.272.22.14110; DELAMO FF, 1993, GENOMICS, V15, P259, DOI 10.1006/geno.1993.1055; DIEDERICH RJ, 1994, DEVELOPMENT, V120, P473; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; Guan E, 1996, J EXP MED, V183, P2025, DOI 10.1084/jem.183.5.2025; HOEMANN CD, 1999, UNPUB; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; KOPAN R, 1993, J CELL BIOL, V121, P631, DOI 10.1083/jcb.121.3.631; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Lu FM, 1996, P NATL ACAD SCI USA, V93, P5663, DOI 10.1073/pnas.93.11.5663; MAJORS JE, 1981, NATURE, V289, P253, DOI 10.1038/289253a0; Milner LA, 1996, P NATL ACAD SCI USA, V93, P13014, DOI 10.1073/pnas.93.23.13014; Moore D H, 1979, Adv Cancer Res, V29, P347, DOI 10.1016/S0065-230X(08)60850-7; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NYE JS, 1994, DEVELOPMENT, V120, P2421; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; REAUME AG, 1992, DEV BIOL, V154, P377, DOI 10.1016/0012-1606(92)90076-S; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; ROSENBERG N, 1997, RETROVIRUS PATHOGENE; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Shawber C, 1996, DEVELOPMENT, V122, P3765; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sun X, 1997, DEVELOPMENT, V124, P3439; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; Washburn T, 1997, CELL, V88, P833, DOI 10.1016/S0092-8674(00)81929-7; WEBSTER MA, 1994, SEMIN CANCER BIOL, V5, P69; Wettstein DA, 1997, DEVELOPMENT, V124, P693	46	177	183	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	1999	18	44					5973	5981		10.1038/sj.onc.1202991	http://dx.doi.org/10.1038/sj.onc.1202991			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557086	Green Submitted			2022-12-25	WOS:000083359100003
J	Lu, Q; Dunlap, K				Lu, Q; Dunlap, K			Cloning and functional expression of novel N-type Ca2+ channel variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SYMPATHETIC NEURONS; CALCIUM-CHANNEL; ALPHA(1) SUBUNIT; MOLECULAR-CLONING; SENSORY NEURONS; ION PERMEATION; RABBIT BRAIN; K+ CHANNELS; BETA-GAMMA; G-PROTEINS	Voltage-dependent Ca2+ channels are structurally and functionally diverse. As Ca2+ currents recorded from embryonic chick dorsal root ganglion (DRG) neurons differ significantly from their mammalian counterparts, information on the primary sequence of the chick channels will help define the structural underpinnings of Ca2+ channel function. Here, we report the cloning and functional expression of full-length Ca2+ channel alpha(1B) subunit cDNAs derived from chick DRGs. Two variable regions (A and B) have been identified in the cytoplasmic linker between repeats I and II; a third (C) in the carboxyl terminus extends the open reading frame by 525 nucleotides. The A and C inserts are absent, and the B insert is present in all other class B clones reported to date. The unique shorter channels appear to predominate in DRG neurons. Results represent a requisite first step in defining the structural elements that underlie variations in function and modulation of Ca2+ channels.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Neurosci, Boston, MA 02111 USA	Tufts University; Tufts University	Dunlap, K (corresponding author), Tufts Univ, Sch Med, Dept Physiol, 136 Harrison Ave, Boston, MA 02111 USA.	kdunlap@opal.tufts.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016483] Funding Source: NIH RePORTER; NINDS NIH HHS [NS16483] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOLAND LM, 1994, J NEUROSCI, V14, P5011; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; COX DH, 1992, J NEUROSCI, V12, P906; COX DH, 1994, J GEN PHYSIOL, V104, P311, DOI 10.1085/jgp.104.2.311; CRUZ LJ, 1986, J BIOL CHEM, V261, P6230; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; DIVERSEPIERLUISSI M, 1995, NEURON, V14, P191, DOI 10.1016/0896-6273(95)90254-6; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; Dunlap KL, 1998, SEMIN NEUROSCI, V9, P198, DOI 10.1006/smns.1997.0119; FUJITA Y, 1993, NEURON, V10, P585, DOI 10.1016/0896-6273(93)90162-K; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; Henning U, 1996, MOL CELL BIOCHEM, V161, P47, DOI 10.1007/BF00240030; HOLZ GG, 1989, J NEUROSCI, V9, P657; HUI A, 1991, NEURON, V7, P35, DOI 10.1016/0896-6273(91)90072-8; IKEDA SR, 1991, J PHYSIOL-LONDON, V439, P181, DOI 10.1113/jphysiol.1991.sp018663; JONES SW, 1989, J GEN PHYSIOL, V94, P169, DOI 10.1085/jgp.94.1.169; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; Lin ZX, 1997, NEURON, V18, P153, DOI 10.1016/S0896-6273(01)80054-4; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NIIDOME T, 1992, FEBS LETT, V308, P7, DOI 10.1016/0014-5793(92)81038-N; Park D, 1998, J NEUROSCI, V18, P6757; PEREZREYES E, 1995, KIDNEY INT, V48, P1111, DOI 10.1038/ki.1995.395; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; RANE SG, 1989, NEURON, V3, P239, DOI 10.1016/0896-6273(89)90037-8; REYNOLDS IJ, 1986, P NATL ACAD SCI USA, V83, P8804, DOI 10.1073/pnas.83.22.8804; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SOLDATOV NM, 1995, J BIOL CHEM, V270, P10540, DOI 10.1074/jbc.270.18.10540; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; STEA A, 1993, NEUROPHARMACOLOGY, V32, P1103, DOI 10.1016/0028-3908(93)90005-N; WAECHTER CJ, 1983, J BIOL CHEM, V258, P5117; WAGNER JA, 1988, J NEUROSCI, V8, P3354; WEI XY, 1994, J BIOL CHEM, V269, P1635; WELLING A, 1993, CIRC RES, V73, P974, DOI 10.1161/01.RES.73.5.974; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; YUE DT, 1990, SCIENCE, V250, P1735, DOI 10.1126/science.2176745; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0	44	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34566	34575		10.1074/jbc.274.49.34566	http://dx.doi.org/10.1074/jbc.274.49.34566			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574919	hybrid			2022-12-25	WOS:000083979600013
J	Maidment, JM; Moore, D; Murphy, GP; Murphy, G; Clark, IM				Maidment, JM; Moore, D; Murphy, GP; Murphy, G; Clark, IM			Matrix metalloproteinase homologues from Arabidopsis thaliana - Expression and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFICATION; CLONING; CDNA	Five genes potentially encoding novel matrix metalloproteinases (MMPs) have been identified on the Arabidopsis thaliana data base. The predicted proteins have a similar domain structure to mammalian MMP-7, with a propeptide and catalytic domain but no C-terminal hemopexin-like domain. Four of the A. thaliana MMPs (At-MMPs) have a predicted C-terminal transmembrane domain. The At-MMPs are differentially expressed in flower, leaf, root, and stem tissues from 14-day-old plants. The cDNA for one of the At-MMPs (At1-MMP) was cloned and expressed in Escherichia coli, Following refolding and purification, the proenzyme At1-MMP was shown to undergo autolytic activation in the presence of an organomercurial with a concomitant decrease in M-r. In contrast to this, trypsin-treatment led to the formation of an inactive product. The activated At1-MMP digested myelin basic protein, but was unable to digest gelatin or casein, Three peptide substrates for MMPs were also cleaved by At1-MMP. The enzyme activity of At1-MMP was inhibited by human tissue inhibitors of metalloproteinases 1 and 2 and the hydroxamate inhibitor BB-94.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; John Innes Ctr, Norwich NR4 7UH, Norfolk, England	University of East Anglia; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Clark, IM (corresponding author), Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.		Clark, Ian M/D-1920-2009					BEVAN M, 1999, NATURE, V391, P419; Cassab GI, 1998, ANNU REV PLANT PHYS, V49, P281, DOI 10.1146/annurev.arplant.49.1.281; CLARK IM, 1989, BIOCHEM J, V263, P201, DOI 10.1042/bj2630201; CLARK IM, 1999, DYNAMICS BONE CARTIL, P137; GRAHAM JS, 1991, PLANT PHYSIOL, V97, P786, DOI 10.1104/pp.97.2.786; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MURPHY G, 1994, J BIOL CHEM, V269, P6632; Nomura K, 1997, BIOCHEMISTRY-US, V36, P7225, DOI 10.1021/bi9629790; Pak JH, 1997, FEBS LETT, V404, P283, DOI 10.1016/S0014-5793(97)00141-5; Pohar N, 1999, GENOMICS, V57, P293, DOI 10.1006/geno.1999.5776; Wada K, 1998, GENE, V211, P57, DOI 10.1016/S0378-1119(98)00076-6	15	81	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34706	34710		10.1074/jbc.274.49.34706	http://dx.doi.org/10.1074/jbc.274.49.34706			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574937	hybrid			2022-12-25	WOS:000083979600031
J	Bunemann, M; Gerhardstein, BL; Gao, TY; Hosey, MM				Bunemann, M; Gerhardstein, BL; Gao, TY; Hosey, MM			Functional regulation of L-type calcium channels via protein kinase A-mediated phosphorylation of the beta(2) subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDENTIFICATION; SKELETAL; CELLS	Activation of protein kinase A (PKA) through the beta-adrenergic receptor pathway is crucial for the positive regulation of cardiac L-type currents; however it is still. unclear which phosphorylation events cause the robust regulation of channel function. In order to study whether or not the recently identified PKA phosphorylation sites on the beta(2) subunit are of functional significance, we coexpressed wild-type (WT) or mutant beta(2) subunits in tsA-201 cells together with an alpha(1C) subunit, alpha(1C)Delta 1905, that lacked the C-terminal 265 amino acids, including the only identified PKA site at Ser-1928. This truncated or,, subunit was similar to the truncated alpha(1C) subunit isolated from cardiac tissue not only in size (similar to 190 kDa), but also with respect to its failure to serve as a PKA substrate. In cells transfected with the WT beta(2) subunit, voltage-activated Ba2+ currents were significantly increased when purified PKA was included in the patch pipette, Furthermore, mutations of Ser-478 and Ser-479 to Ala, but not Ser-459 to Ala, on the beta(2) subunit, completely abolished the PKA-induced increase of currents, The data indicate that the PKA-mediated stimulation of cardiac L-type Ca2+ currents may be at least partially caused by phosphorylation of the beta(2) subunit at Ser-478 and Ser-479.	Northwestern Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Chicago, IL 60611 USA	Northwestern University	Hosey, MM (corresponding author), Northwestern Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 303 E Chicago Ave,S215, Chicago, IL 60611 USA.	mhosey@nwu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023306, R37HL023306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007169] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL23306] Funding Source: Medline; NIDDK NIH HHS [T32-DK07169] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bunemann M, 1998, J BIOL CHEM, V273, P31186, DOI 10.1074/jbc.273.47.31186; CHANG FC, 1988, J BIOL CHEM, V263, P18929; De Waard M, 1996, Ion Channels, V4, P41; DeJongh KS, 1996, BIOCHEMISTRY-US, V35, P10392, DOI 10.1021/bi953023c; Fraser IDC, 1998, EMBO J, V17, P2261, DOI 10.1093/emboj/17.8.2261; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; Gao TY, 1997, J BIOL CHEM, V272, P19401, DOI 10.1074/jbc.272.31.19401; Gerhardstein BL, 1999, BIOCHEMISTRY-US, V38, P10361, DOI 10.1021/bi990896o; HAASE H, 1993, FEBS LETT, V335, P217, DOI 10.1016/0014-5793(93)80733-B; Hase H, 1996, MOL CELL BIOCHEM, V164, P99, DOI 10.1007/BF00408645; Hosey MM, 1996, TRENDS CARDIOVAS MED, V6, P265, DOI 10.1016/S1050-1738(96)00109-0; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; Mitterdorfer J, 1996, BIOCHEMISTRY-US, V35, P9400, DOI 10.1021/bi960683o; Puri TS, 1997, BIOCHEMISTRY-US, V36, P9605, DOI 10.1021/bi970500d; WU JC, 1989, J BIOL CHEM, V264, P7989; ZONG XG, 1995, PFLUG ARCH EUR J PHY, V430, P340, DOI 10.1007/BF00373908	17	143	150	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					33851	33854		10.1074/jbc.274.48.33851	http://dx.doi.org/10.1074/jbc.274.48.33851			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567342	hybrid			2022-12-25	WOS:000083857500007
J	Haugh, JM; Huang, AC; Wiley, HS; Wells, A; Lauffenburger, DA				Haugh, JM; Huang, AC; Wiley, HS; Wells, A; Lauffenburger, DA			Internalized epidermal growth factor receptors participate in the activation of p21(ras) in fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; PHOSPHOTYROSINE-BINDING DOMAIN; MEDIATED CELL MOTILITY; PROTEIN-KINASE KINASE; AUTOPHOSPHORYLATION SITES; SIGNAL-TRANSDUCTION; TYROSINE KINASES; IN-VIVO; SHC; RAS	Regulated activation of the highly conserved Ras GTPase is a central event in the stimulation of cell proliferation, motility, and differentiation elicited by receptor tyrosine kinases, such as the epidermal growth factor receptor (EGFR), In fibroblasts, this involves formation and membrane localization of Shc.Grb2.Sos complexes, which increases the rate of Ras guanine nucleotide exchange. In order to control Pas-mediated cell responses, this activity is regulated by receptor down-regulation and a feedback loop involving the dual specificity kinase mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK), We investigated the role of EGFR endocytosis in the regulation of Ras activation. Of fundamental interest is whether activated receptors in endosomes can participate in the stimulation of Ras guanine nucleotide exchange, because the constitutive membrane localization of Ras may affect its compartmentalization. By exploiting the differences in postendocytic signaling of two EGFR ligands, epidermal growth factor and transforming growth factor-alpha, we found that activated EGFR located at the cell surface and in internal compartments contribute equally to the membrane recruitment and tyrosine phosphorylation of Shc in NR6 fibroblasts expressing wild-type EGFR, Importantly, both the rate of Pas-specific guanine nucleotide exchange and the level of Ras-GTP were depressed to near basal Values on the time scale of receptor trafficking. Using the selective MEK inhibitor PD098059, we were able to block the feed back desensitization pathway and maintain activation of Ras, Under these conditions, the generation of Ras-GTP was not significantly affected by the subcellular location of activated EGFR, In conjunction with our previous analysis of the phospholipase C pathway in the same cell line, this suggests a selective continuation of specific signaling activities and cessation of others upon receptor endocytosis.	MIT, Dept Chem Engn, Cambridge, MA 02139 USA; MIT, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; Univ Utah, Dept Pathol, Salt Lake City, UT 84132 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); University of Alabama System; University of Alabama Birmingham; Utah System of Higher Education; University of Utah	Lauffenburger, DA (corresponding author), MIT, Dept Chem Engn, Cambridge, MA 02139 USA.	lauffen@mit.edu		Wiley, Steven/0000-0003-0232-6867; Haugh, Jason/0000-0002-2476-4027; Wells, Alan/0000-0002-1637-8150				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BAASS PC, 1995, TRENDS CELL BIOL, V5, P465, DOI 10.1016/S0962-8924(00)89116-3; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; Chen P, 1996, J CELL BIOL, V134, P689, DOI 10.1083/jcb.134.3.689; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DEVRIESSMITS AMM, 1995, ONCOGENE, V10, P919; DEVRIESSMITS AMM, 1995, METHOD ENZYMOL, V255, P156; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; EBNER R, 1991, CELL REGUL, V2, P599, DOI 10.1091/mbc.2.8.599; FRENCH AR, 1995, J BIOL CHEM, V270, P4334, DOI 10.1074/jbc.270.9.4334; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; Haugh JM, 1997, BIOPHYS J, V72, P2014, DOI 10.1016/S0006-3495(97)78846-5; Haugh JM, 1998, J THEOR BIOL, V195, P187, DOI 10.1006/jtbi.1998.0791; Haugh JM, 1999, J BIOL CHEM, V274, P8958, DOI 10.1074/jbc.274.13.8958; Holt KH, 1996, J BIOL CHEM, V271, P8300, DOI 10.1074/jbc.271.14.8300; KLARLUND JK, 1995, J BIOL CHEM, V270, P23421, DOI 10.1074/jbc.270.40.23421; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kubiseski TJ, 1997, J BIOL CHEM, V272, P1799, DOI 10.1074/jbc.272.3.1799; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Lotti LV, 1996, MOL CELL BIOL, V16, P1946; LUND KA, 1990, J BIOL CHEM, V265, P15713; MASUI H, 1991, CANCER RES, V51, P6170; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Morrison P, 1996, J BIOL CHEM, V271, P12891, DOI 10.1074/jbc.271.22.12891; Niv H, 1999, J BIOL CHEM, V274, P1606, DOI 10.1074/jbc.274.3.1606; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; Okada S, 1997, J BIOL CHEM, V272, P28042, DOI 10.1074/jbc.272.44.28042; OSTEROP APRM, 1993, EUR J BIOCHEM, V212, P477, DOI 10.1111/j.1432-1033.1993.tb17684.x; Ouyang XM, 1999, J CELL PHYSIOL, V179, P52, DOI 10.1002/(SICI)1097-4652(199904)179:1<52::AID-JCP7>3.0.CO;2-M; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; Pol A, 1998, FEBS LETT, V441, P34, DOI 10.1016/S0014-5793(98)01517-8; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; REDDY CC, 1994, BIOTECHNOL PROGR, V10, P377, DOI 10.1021/bp00028a006; RICCI A, 1995, ONCOGENE, V11, P1519; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; Sasaoka T, 1996, J BIOL CHEM, V271, P8338, DOI 10.1074/jbc.271.14.8338; SCHEELE JS, 1995, P NATL ACAD SCI USA, V92, P1097, DOI 10.1073/pnas.92.4.1097; SOLER C, 1994, ONCOGENE, V9, P2207; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Willumsen BM, 1996, ONCOGENE, V13, P1901; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865; Xie H, 1998, J CELL SCI, V111, P615; Xue LZ, 1998, CELL SIGNAL, V10, P339, DOI 10.1016/S0898-6568(98)00011-4; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	57	125	126	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34350	34360		10.1074/jbc.274.48.34350	http://dx.doi.org/10.1074/jbc.274.48.34350			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567412	hybrid			2022-12-25	WOS:000083857500077
J	Ago, T; Nunoi, H; Ito, T; Sumimoto, H				Ago, T; Nunoi, H; Ito, T; Sumimoto, H			Mechanism for phosphorylation-induced activation of the phagocyte NADPH oxidase protein p47 (phox) - Triple replacement of serines 303, 304, and 328 with aspartates disrupts the SH3 domain-mediated intramolecular interaction in p47 (phox), thereby activating the oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; SRC HOMOLOGY-3 DOMAIN; TYROSINE KINASE HCK; CELL-FREE SYSTEM; HUMAN-NEUTROPHILS; SUPEROXIDE PRODUCTION; COMPONENT P47(PHOX); C-SRC; BINDING	Activation of the superoxide-producing phagocyte NADPH oxidase requires interaction between p47(phox) and p22(phox), which is mediated via the SH3 domains of the former protein. This interaction is considered to be induced by exposure of the domains that are normally masked by an intramolecular interaction with the C-terminal region of p47(phox). Here we locate the intramolecular SH3-binding site at the region of amino acid residues 286-340, where Ser-303, Ser-304, and Ser-328 that are among several serines known to become phosphorylated upon cell stimulation exist. Simultaneous replacement of the three serines in p47(phox) with aspartates or glutamates, each mimicking phosphorylated residues, is sufficient for disruption of the intramolecular interaction and resultant access to p22(phox). Th, triply mutated proteins are also capable of activating the NADPH oxidase without in vitro activators such as arachidonate under cell-free conditions. In a whole-cell system where expression of the wild-type p47(phox) reconstitutes the stimulus-dependent oxidase activity, substitution of the kinase-insensitive residue alanine for Ser-328 as well as for Ser-303/Ser-304 leads to a defective production of superoxide. These findings suggest that phosphorylation of the three serines in p47(phox) induces a conformational change to a state accessible to p22(phox), thereby activating the NADPH oxidase.	Kyushu Univ, Grad Sch Med Sci, Dept Mol & Struct Biol, Higashi Ku, 3-1-1 Maidashi, Fukuoka, Japan; Kumamoto Univ, Sch Med, Dept Pediat, Kumamoto 8608556, Japan; Univ Tokyo, Inst Med Sci, Human Genome Ctr, Minato Ku, Tokyo 1088639, Japan	Kyushu University; Kumamoto University; University of Tokyo	Sumimoto, H (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol & Struct Biol, Higashi Ku, 3-1-1 Maidashi, Fukuoka, Japan.	hsumi@mailserver.med.kyushu-u.ac.jp		Ago, Tetsuro/0000-0003-4560-6594; Ito, Takashi/0000-0001-6097-2803				Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; deMendez I, 1997, MOL CELL BIOL, V17, P2177, DOI 10.1128/MCB.17.4.2177; deMendez I, 1996, EMBO J, V15, P1211, DOI 10.1002/j.1460-2075.1996.tb00462.x; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ElBenna J, 1996, ARCH BIOCHEM BIOPHYS, V334, P395; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; Hata K, 1998, J BIOL CHEM, V273, P4232, DOI 10.1074/jbc.273.7.4232; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; Huang LQ, 1999, J BIOL CHEM, V274, P12803, DOI 10.1074/jbc.274.18.12803; Inanami O, 1998, J BIOL CHEM, V273, P9539, DOI 10.1074/jbc.273.16.9539; Ito T, 1996, FEBS LETT, V385, P229, DOI 10.1016/0014-5793(96)00387-0; Iwata M, 1998, HUM GENET, V103, P419, DOI 10.1007/s004390050844; Johnson JL, 1998, J BIOL CHEM, V273, P35147, DOI 10.1074/jbc.273.52.35147; JONES OTG, 1994, BIOESSAYS, V16, P919, DOI 10.1002/bies.950161211; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LEUSEN JHW, 1994, J EXP MED, V180, P2329, DOI 10.1084/jem.180.6.2329; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Lin HM, 1998, J BIOL CHEM, V273, P19914, DOI 10.1074/jbc.273.31.19914; Mizuki K, 1998, EUR J BIOCHEM, V251, P573, DOI 10.1046/j.1432-1327.1998.2510573.x; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; NAKAMURA M, 1987, BLOOD, V69, P1404; Nguyen JT, 1997, NAT STRUCT BIOL, V4, P256, DOI 10.1038/nsb0497-256; OKAMURA N, 1988, J BIOL CHEM, V263, P6777; Okkenhaug K, 1998, J BIOL CHEM, V273, P21194, DOI 10.1074/jbc.273.33.21194; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Roos D, 1996, BLOOD, V87, P1663; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; SEGAL AW, 1985, NATURE, V316, P547, DOI 10.1038/316547a0; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SMITH RM, 1991, BLOOD, V77, P673; SUGIMOTO Y, 1994, BIO-TECHNOL, V12, P694, DOI 10.1038/nbt0794-694; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; Sumimoto H, 1997, MEMBRANE PROTEINS - STRUCTURE, FUNCTION AND EXPRESSION CONTROL: INTERNATIONAL SYMPOSIUM, P235; Swain SD, 1997, J BIOL CHEM, V272, P29502, DOI 10.1074/jbc.272.47.29502; TERASAWA H, 1994, NAT STRUCT BIOL, V1, P891, DOI 10.1038/nsb1294-891; WITTEKIND M, 1994, BIOCHEMISTRY-US, V33, P13531, DOI 10.1021/bi00250a004; Wu Y, 1998, J BIOL CHEM, V273, P5765, DOI 10.1074/jbc.273.10.5765; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	51	203	205	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33644	33653		10.1074/jbc.274.47.33644	http://dx.doi.org/10.1074/jbc.274.47.33644			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559253	hybrid			2022-12-25	WOS:000083745200069
J	Masuda, T; Inoue, K; Masuda, M; Nagayama, M; Tamaki, A; Ohta, H; Shimada, H; Takamiya, K				Masuda, T; Inoue, K; Masuda, M; Nagayama, M; Tamaki, A; Ohta, H; Shimada, H; Takamiya, K			Magnesium insertion by magnesium chelatase in the biosynthesis of zinc bacteriochlorophyll a in an aerobic acidophilic bacterium Acidiphilium rubrum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTOPORPHYRIN CHELATASE; RHODOBACTER-SPHAEROIDES; MG-CHELATASE; PROTEINS; RECONSTITUTION; EXPRESSION; SYSTEM; GENES; BCHD	To elucidate the mechanism for formation of zinc-containing bacteriochlorophyll a in the photosynthetic bacterium Acidiphilium rubrum, we isolated homologs of magnesium chelatase subunits (bchI, -D, and -H). A, rubrum bchI and -H were encoded by single genes located on the clusters bchP-orf168-bchI-bchD-orf320-crtI and bchF-N-B-H-L as in Rhodobacter capsulatus, respectively, The deduced sequences of A rubrum bchI, -D, and -H had overall identities of 59.8, 40.5, and 50.7% to those from Rba. capsulatus, respectively,When these genes were introduced into bchI, bchD, and bchH mutants of Rba, capsulatus for functional complementation, all mutants were complemented with concomitant synthesis of bacteriochlorophyll a. Analyses of bacteriochlorophyll intermediates showed that A. rubrum cells accumulate magnesium protoporphyrin IX monomethyl ester without detectable accumulation of zinc protoporphyrin IX or its monomethyl ester, These results indicate that a single set of magnesium chelatase homologs in A. rubrum catalyzes the insertion of only Mg2+ into protoporphyrin IX to yield magnesium protoporphyrin IX monomethyl ester, Consequently, it is most likely that zinc-containing bacteriochlorophyll a is formed by a substitution of Zn2+ for Mg2+ at a step in the bacteriochlorophyll biosynthesis after formation of magnesium protoporphyrin IX monomethyl ester.	Tokyo Inst Technol, Fac Biosci & Biotechnol, Dept Biol Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Kanagawa Univ, Fac Sci, Dept Biol Sci, Hiratsuka, Kanagawa 2591293, Japan	Tokyo Institute of Technology; Kanagawa University	Masuda, T (corresponding author), Tokyo Inst Technol, Fac Biosci & Biotechnol, Dept Biol Sci, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.	tmasuda@bio.titech.ac.jp	Ohta, Hiroyuki/B-1840-2014; Masuda, Tatsuru/E-7942-2013	Ohta, Hiroyuki/0000-0002-1068-3242; Masuda, Tatsuru/0000-0002-1585-5832				AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BELANGER FC, 1980, J BIOL CHEM, V255, P1266; BOLLIVAR DW, 1994, J MOL BIOL, V237, P622, DOI 10.1006/jmbi.1994.1260; BUCHLER JW, 1978, PORPHYINS; BUCHLER JW, 1975, PORPHYRINS METALLOPO; DIN GA, 1967, CAN J MICROBIOL, V13, P1413, DOI 10.1139/m67-188; FUESLER TP, 1981, PLANT PHYSIOL, V67, P246, DOI 10.1104/pp.67.2.246; GIBSON LCD, 1995, P NATL ACAD SCI USA, V92, P1941, DOI 10.1073/pnas.92.6.1941; GRIFFITHS WT, 1980, BIOCHEM J, V186, P267, DOI 10.1042/bj1860267; HAMBRIGHT P, 1975, DYNAMIC COORDINATION; HATTA T, 1989, AGR BIOL CHEM TOKYO, V53, P651, DOI 10.1080/00021369.1989.10869349; HELFRICH M, 1992, Z NATURFORSCH C, V47, P231; HSUNG JC, 1975, BIOCHIM BIOPHYS ACTA, V389, P477, DOI 10.1016/0005-2736(75)90158-3; Jensen PE, 1996, J BIOL CHEM, V271, P16662, DOI 10.1074/jbc.271.28.16662; JONES OTG, 1963, BIOCHEM J, V327, P321; Kannangara CG, 1997, MOL GEN GENET, V254, P85, DOI 10.1007/s004380050394; KISHIMOTO N, 1995, SYST APPL MICROBIOL, V18, P85, DOI 10.1016/S0723-2020(11)80453-4; KRUSE E, 1995, EMBO J, V14, P3712, DOI 10.1002/j.1460-2075.1995.tb00041.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMOLA AA, 1974, SCIENCE, V186, P936, DOI 10.1126/science.186.4167.936; Masuda T, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P3233; NEUBERGER A, 1964, BIOCHEM J, V90, P607, DOI 10.1042/bj0900607; Papenbrock J, 1997, PLANT J, V12, P981, DOI 10.1046/j.1365-313X.1997.12050981.x; Petersen BL, 1998, J BACTERIOL, V180, P699, DOI 10.1128/JB.180.3.699-704.1998; PORRA RJ, 1963, BIOCHEM J, V87, P186, DOI 10.1042/bj0870186; Shimada H, 1996, PLANT CELL PHYSIOL, V37, P515, DOI 10.1093/oxfordjournals.pcp.a028974; SHIOI Y, 1995, ANAL BIOCHEM, V231, P225, DOI 10.1006/abio.1995.1524; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; Tamiaki H, 1998, BIOORGAN MED CHEM, V6, P2171, DOI 10.1016/S0968-0896(98)00154-0; Wakao N, 1996, PLANT CELL PHYSIOL, V37, P889, DOI 10.1093/oxfordjournals.pcp.a029029; Walker CJ, 1997, BIOCHEM J, V327, P321; WASIELEWSKI MR, 1984, J AM CHEM SOC, V106, P5043, DOI 10.1021/ja00329a089; WATANABE T, 1991, CHLOROPHYLLS; YANG ZY, 1990, J BACTERIOL, V126, P619; YOUNG DA, 1989, MOL GEN GENET, V218, P1, DOI 10.1007/BF00330558	35	33	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33594	33600		10.1074/jbc.274.47.33594	http://dx.doi.org/10.1074/jbc.274.47.33594			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559247	hybrid			2022-12-25	WOS:000083745200063
J	Remelli, R; Varotto, C; Sandona, D; Croce, R; Bassi, R				Remelli, R; Varotto, C; Sandona, D; Croce, R; Bassi, R			Chlorophyll binding to monomeric light-harvesting complex - A mutation analysis of chromophore-binding residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYSTEM-II COMPLEX; ESCHERICHIA-COLI; HIGHER-PLANTS; PROTEINS; RECONSTITUTION; ABSORPTION; RESOLUTION; SEQUENCE; MODEL; CP29	The chromophore binding properties of the higher plant light-harvesting complex II have been studied by site-directed mutagenesis of pigment-binding residues. Mutant apoproteins were overexpressed in Escherichia coli and then refolded in vitro with purified chromophores to yield holoproteins selectively affected in chlorophyll-binding sites. Biochemical and spectroscopic characterization showed a specific loss of pigments and absorption spectral forms for each mutant, thus allowing identification of the chromophores bound to most of the binding sites. On these bases a map for the occupancy of individual sites by chlorophyll a and chlorophyll b is proposed. In some cases a single mutation led to the loss of more than one chromophore indicating that four chlorophylls and one xanthophyll could be bound by pigment-pigment interactions. Differential absorption spectroscopy allowed identification of the Q(y) transition energy level for each chlorophyll within the complex. It is shown that not only site selectivity is largely conserved between light-harvesting complex II and CP29 but also the distribution of absorption forms among different protein domains, suggesting conservation of energy transfer pathways within the protein and outward to neighbor subunits of the photosystem.	Univ Verona, Fac Sci MM FF NN, I-37134 Verona, Italy	University of Verona	Bassi, R (corresponding author), Univ Verona, Fac Sci MM FF NN, Strada Le Grazie, I-37134 Verona, Italy.	bassi@sci.univr.it	Croce, Roberta/F-1174-2014; Croce, Roberta/N-4067-2014; sandona, dorianna/AAB-9480-2020; Croce, Roberta/ABG-3595-2021; Croce, Roberta/HGU-9554-2022	Croce, Roberta/0000-0003-3469-834X; Croce, Roberta/0000-0003-3469-834X; Croce, Roberta/0000-0003-3469-834X; Varotto, Claudio/0000-0001-5018-087X; bassi, roberto/0000-0002-4140-8446				Bassi R, 1999, P NATL ACAD SCI USA, V96, P10056, DOI 10.1073/pnas.96.18.10056; BASSI R, 1993, EUR J BIOCHEM, V212, P297, DOI 10.1111/j.1432-1033.1993.tb17662.x; Bassi R, 1997, PHYSIOL PLANTARUM, V100, P769, DOI 10.1034/j.1399-3054.1997.1000404.x; BASSI R, 1991, J PHOTOCHEM PHOTOBIO, V6, P381; BOEKEMA EJ, 1995, P NATL ACAD SCI USA, V92, P175, DOI 10.1073/pnas.92.1.175; Connelly JP, 1997, BIOCHEMISTRY-US, V36, P281, DOI 10.1021/bi962467l; Croce R, 1999, FEBS LETT, V456, P1, DOI 10.1016/S0014-5793(99)00907-2; Croce R, 1999, J BIOL CHEM, V274, P29613, DOI 10.1074/jbc.274.42.29613; DAINESE P, 1990, PHOTOCHEM PHOTOBIOL, V51, P693, DOI 10.1111/php.1990.51.6.693; DAINESE P, 1991, J BIOL CHEM, V266, P8136; De Luca C, 1999, J PHOTOCH PHOTOBIO B, V49, P50, DOI 10.1016/S1011-1344(99)00016-0; GILMORE AM, 1991, J CHROMATOGR, V543, P137, DOI 10.1016/S0021-9673(01)95762-0; Giuffra E, 1997, BIOCHEMISTRY-US, V36, P12984, DOI 10.1021/bi9711339; Giuffra E, 1996, EUR J BIOCHEM, V238, P112, DOI 10.1111/j.1432-1033.1996.0112q.x; GOTTESMAN S, 1981, J BACTERIOL, V148, P265, DOI 10.1128/JB.148.1.265-273.1981; GREEN BR, 1991, TRENDS BIOCHEM SCI, V16, P181, DOI 10.1016/0968-0004(91)90072-4; Harrer R, 1998, EUR J BIOCHEM, V255, P196, DOI 10.1046/j.1432-1327.1998.2550196.x; Hirs C. H. W., 1967, METHOD ENZYMOL, V11, P325; HOBE S, 1994, EMBO J, V13, P3423, DOI 10.1002/j.1460-2075.1994.tb06647.x; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; MATSUOKA M, 1987, NUCLEIC ACIDS RES, V15, P6302, DOI 10.1093/nar/15.15.6302; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; Pagano A, 1998, J BIOL CHEM, V273, P17154, DOI 10.1074/jbc.273.27.17154; PAULSEN H, 1990, PLANTA, V181, P204, DOI 10.1007/BF02411539; Peterman EJG, 1995, BIOPHYS J, V69, P2670, DOI 10.1016/S0006-3495(95)80138-4; Pichersky E., 1996, OXYGENIC PHOTOSYNTHE, P507; PLUMLEY FG, 1995, PLANT CELL, V7, P689, DOI 10.2307/3870172; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sandona D, 1998, BBA-BIOENERGETICS, V1365, P207, DOI 10.1016/S0005-2728(98)00068-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUER K, 1966, J AM CHEM SOC, V88, P2681, DOI 10.1021/ja00964a011; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STRAUS SD, 1985, BIOCHEM BIOPH RES CO, V130, P1177, DOI 10.1016/0006-291X(85)91739-5; Trinkunas G, 1997, J PHYS CHEM B, V101, P7313, DOI 10.1021/jp963968j; YUKENBERG PD, 1991, DIRECTED MUTAGENESIS, P27; ZUCCHELLI G, 1994, BIOCHEMISTRY-US, V33, P8982, DOI 10.1021/bi00196a016	37	188	196	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33510	33521		10.1074/jbc.274.47.33510	http://dx.doi.org/10.1074/jbc.274.47.33510			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559236	Green Published, hybrid			2022-12-25	WOS:000083745200052
J	Rojo-Niersbach, E; Furukawa, T; Tanese, N				Rojo-Niersbach, E; Furukawa, T; Tanese, N			Genetic dissection of hTAF(II)130 defines a hydrophobic surface required for interaction with glutamine-rich activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; DROSOPHILA TFIID-COMPLEX; BINDING FACTOR CBF; TRANSCRIPTIONAL ACTIVATION; TRANSACTIVATION DOMAIN; AMINO-ACIDS; DTAF(II)110 COMPONENT; TAF(II)250 SUBUNIT; MOLECULAR-CLONING; CYCLIN GENES	The general transcription factor TFIID is a multiprotein complex consisting of the TATA box-binding protein and multiple TATA box-binding protein-associated factors (TAF(II)s). The central domain of human TAF(II)130 contains four glutamine-rich regions Q1-Q4 that interact with transcriptional activators such as Sp1 and CREB and mediate activation. We screened in yeast random point mutations introduced into Q1-Q4 against the Sp1 activation domain and obtained a distinct set of hTAF(II)130s with alterations in TAF(II)-activator interaction. Here we characterize functionally an hTAF(II)130 mutant containing a phenylalanine to serine change at position 311 (F311S) that is compromised in its ability to associate with Sp1B and CREB-N activation domains. Substitution of phenylalanine with tyrosine but not with isoleucine or tryptophan also reduced hTAF(II)130 interaction, suggesting that the hydrophobic character rather than the specific amino acid at this position is a key determinant of interaction. Deletion of nine amino acids (Delta 9) surrounding Phe(311) abolished the interaction of hTAF(II)130 with Sp1. Overexpression of hTAF(II)130Q1/Q2 and Q1-Q4 strongly inhibited Sp1-dependent transcriptional enhancement in transient transfection assays, whereas expression of either F311S or Delta 9 only partially suppressed Sp1-mediated activation. Thus, a short hydro phobic sequence motif encompassing Phe(311) in hTAF(II)130 represents a critical surface with which Sp1B interacts to activate transcription.	NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA	New York University; New York University	Tanese, N (corresponding author), NYU, Sch Med, Dept Microbiol, 550 1st Ave, New York, NY 10016 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051314] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51314] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amrolia PJ, 1997, P NATL ACAD SCI USA, V94, P10051, DOI 10.1073/pnas.94.19.10051; Bjorklund S, 1999, CELL, V96, P759, DOI 10.1016/S0092-8674(00)80586-3; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Chang MP, 1997, NUCLEIC ACIDS RES, V25, P4861, DOI 10.1093/nar/25.24.4861; Coustry F, 1998, BIOCHEM J, V331, P291, DOI 10.1042/bj3310291; Coustry F, 1996, J BIOL CHEM, V271, P14485, DOI 10.1074/jbc.271.24.14485; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; Damania B, 1996, GENE DEV, V10, P1369, DOI 10.1101/gad.10.11.1369; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; Garabedian Michael J., 1993, Methods (Orlando), V5, P138, DOI 10.1006/meth.1993.1018; GEISBERG JV, 1995, MOL CELL BIOL, V15, P6283; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hahn S, 1998, CELL, V95, P579, DOI 10.1016/S0092-8674(00)81625-6; Hampsey M, 1999, CURR OPIN GENET DEV, V9, P132, DOI 10.1016/S0959-437X(99)80020-3; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lavigne AC, 1999, MOL CELL BIOL, V19, P5486; Lee TI, 1998, GENE DEV, V12, P1398, DOI 10.1101/gad.12.10.1398; Leung DW, 1989, TECHNIQUE, V1, P11; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LING PD, 1993, J VIROL, V67, P2990, DOI 10.1128/JVI.67.6.2990-3003.1993; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Lukac DM, 1997, J VIROL, V71, P7227, DOI 10.1128/JVI.71.10.7227-7239.1997; Mazzarelli JM, 1997, J VIROL, V71, P7978, DOI 10.1128/JVI.71.10.7978-7983.1997; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Olave I, 1998, GENE DEV, V12, P1621, DOI 10.1101/gad.12.11.1621; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Petty KJ, 1996, MOL ENDOCRINOL, V10, P1632, DOI 10.1210/me.10.12.1632; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Sainz MB, 1997, MOL CELL BIOL, V17, P115, DOI 10.1128/MCB.17.1.115; Saluja D, 1998, MOL CELL BIOL, V18, P5734, DOI 10.1128/MCB.18.10.5734; Sauer F, 1997, CURR OPIN GENET DEV, V7, P176, DOI 10.1016/S0959-437X(97)80126-8; SCHWERK C, 1995, J BIOL CHEM, V270, P21331, DOI 10.1074/jbc.270.36.21331; Struhl K, 1998, CELL, V94, P1, DOI 10.1016/S0092-8674(00)81213-1; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; SuzukiYagawa Y, 1997, MOL CELL BIOL, V17, P3284, DOI 10.1128/MCB.17.6.3284; TANAKA M, 1994, MOL CELL BIOL, V14, P6056, DOI 10.1128/MCB.14.9.6056; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985	56	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33778	33784		10.1074/jbc.274.47.33778	http://dx.doi.org/10.1074/jbc.274.47.33778			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559271	hybrid			2022-12-25	WOS:000083745200087
J	Yamahara, T; Shiono, T; Suzuki, T; Tanaka, K; Takio, S; Sato, K; Yamazaki, S; Satoh, T				Yamahara, T; Shiono, T; Suzuki, T; Tanaka, K; Takio, S; Sato, K; Yamazaki, S; Satoh, T			Isolation of a germin-like protein with manganese superoxide dismutase activity from cells of a moss, Barbula unguiculata	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PALEACEA VAR DIPTERA; OXALATE OXIDASE; IRON; EXPRESSION; PLANTS; ENZYME; PURIFICATION; LOCALIZATION; DEFICIENCY; LEAVES	A novel extracellular Mn-superoxide dismutase (SOD) was isolated from a moss, Barbula unguiculata. The SOD was a glycoprotein; the apparent molecular mass of its native form was 120 kDa, as estimated by gel filtration chromatography, and that of its monomer was 22,072 Da, as estimated by time of flight mass spectroscopy. The protein had manganese with a stoichiometry of 0.80 Mn/monomer. The cDNA clone for a gene encoding the extracellular Mn-SOD was isolated. Sequence analysis showed that it has a strong similarity to germin (oxalate oxidase) and germin-like proteins (GLPs) of several plant species and possesses all the characteristic features of members of the germin family. The clone encoding this extracellular Mn-SOD was therefore designated B. unguiculata GLP (BuGLP). BuGLP had no oxalate oxidase activity. In addition, the cDNA for a gene encoding the moss mitochondrial Mn-SOD was isolated. Its amino acid sequence had little similarity to that of BuGLP, even though a close similarity was observed among the mitochondrial Mn-SODs of various organisms. BuGLP was the first germin-like protein that was really demonstrated to be a metalloprotein with Mn-SOD activity but no oxalate oxidase activity.	Hiroshima Univ, Fac Sci, Dept Biol Sci, Higashihiroshima 7398526, Japan; Kumamoto Univ, Fac Sci, Dept Biol Sci, Kumamoto 8608555, Japan; Univ Tokyo, Dept Appl Biol Chem, Bunkyou Ku, Tokyo 1138657, Japan	Hiroshima University; Kumamoto University; University of Tokyo	Satoh, T (corresponding author), Hiroshima Univ, Fac Sci, Dept Biol Sci, Higashihiroshima 7398526, Japan.			Shiono, Takeshi/0000-0002-1118-9991				ASADA K, 1977, ARCH BIOCHEM BIOPHYS, V179, P243, DOI 10.1016/0003-9861(77)90109-6; BAKER CJ, 1995, ANNU REV PHYTOPATHOL, V33, P299, DOI 10.1146/annurev.py.33.090195.001503; BEAMAN BL, 1983, J BIOL CHEM, V258, P91; BORDO D, 1994, J MOL BIOL, V238, P366, DOI 10.1006/jmbi.1994.1298; BOWLER C, 1994, CRIT REV PLANT SCI, V13, P199, DOI 10.1080/713608062; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CROWELL DN, 1991, PLANT PHYSIOL, V96, P1393, DOI 10.1104/pp.96.4.1393; Dunwell JM, 1998, BIOTECHNOL GENET ENG, V15, P1; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Gane PJ, 1998, J MOL EVOL, V46, P488, DOI 10.1007/PL00006329; Gerlach D, 1998, FEMS MICROBIOL LETT, V160, P217, DOI 10.1111/j.1574-6968.1998.tb12914.x; HENRY LEA, 1997, PHOTOSYNTHETIC ORGAN, P377; Hurkman WJ, 1996, PLANT PHYSIOL, V111, P735, DOI 10.1104/pp.111.3.735; Jackson SMJ, 1998, BIOMETALS, V11, P159, DOI 10.1023/A:1009238214394; Kotsira VP, 1998, ARCH BIOCHEM BIOPHYS, V356, P117, DOI 10.1006/abbi.1998.0764; KROLL JS, 1995, MICROBIOL-UK, V141, P2271, DOI 10.1099/13500872-141-9-2271; Kurepa J, 1997, PLANT PHYSIOL BIOCH, V35, P467; LANE BG, 1992, EUR J BIOCHEM, V209, P961, DOI 10.1111/j.1432-1033.1992.tb17369.x; LANE BG, 1993, J BIOL CHEM, V268, P12239; LANE BG, 1994, FASEB J, V8, P294, DOI 10.1096/fasebj.8.3.8143935; MARKLUND SL, 1990, METHOD ENZYMOL, V186, P260; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Ogawa K, 1996, PLANT CELL PHYSIOL, V37, P790, DOI 10.1093/oxfordjournals.pcp.a029014; Oury TD, 1996, LAB INVEST, V75, P617; STEINMAN HM, 1993, J BACTERIOL, V175, P1198, DOI 10.1128/JB.175.4.1198-1202.1993; STRELLER S, 1994, PLANTA, V192, P195, DOI 10.1007/BF01089035; TAKIO S, 1987, J HATTORI BOT LAB, V62, P269; TAKIO S, 1986, J HATTORI BOT LAB, V60, P407; Tanaka K, 1998, PLANT CELL PHYSIOL, V39, P235, DOI 10.1093/oxfordjournals.pcp.a029362; Tanaka K, 1996, PLANT CELL PHYSIOL, V37, P523, DOI 10.1093/oxfordjournals.pcp.a028975; TANAKA K, 1995, J PLANT PHYSIOL, V146, P361, DOI 10.1016/S0176-1617(11)82069-9; Vallelian-Bindschedler L, 1998, PLANT MOL BIOL, V37, P297, DOI 10.1023/A:1005982715972; VANCAMP W, 1990, P NATL ACAD SCI USA, V87, P9903, DOI 10.1073/pnas.87.24.9903; ZACHARIUS RM, 1969, ANAL BIOCHEM, V30, P148, DOI 10.1016/0003-2697(69)90383-2; Zhang ZG, 1996, PLANT MOL BIOL REP, V14, P266, DOI 10.1007/BF02671662; ZHANG ZG, 1995, PLANT J, V8, P139, DOI 10.1046/j.1365-313X.1995.08010139.x	36	81	87	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33274	33278		10.1074/jbc.274.47.33274	http://dx.doi.org/10.1074/jbc.274.47.33274			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559202	hybrid			2022-12-25	WOS:000083745200018
J	Kerkhoff, C; Klempt, M; Kaever, V; Sorg, C				Kerkhoff, C; Klempt, M; Kaever, V; Sorg, C			The two calcium-binding proteins, S100A8 and S100A9, are involved in the metabolism of arachidonic acid in human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; HUMAN MONONUCLEAR PHAGOCYTES; MYELOID DIFFERENTIATION; CELL-GROWTH; EXPRESSION; MRP14; COMPLEX; MACROPHAGES; INHIBITION; PROLIFERATION	Recently, we identified the two myeloid related protein-8 (MRP8) (S100A8) and MRP14 (S100A9) as fatty acid-binding proteins (Klempt, M., Melkonyan, H., Nacken, W., Wiesmann, D., Holtkemper, Il., and Sorg, C. (1997) FEBS Lett. 408, 81-84). Here we present data that the S100A8/A9 protein complex represents the exclusive arachidonic acid-binding proteins in human neutrophils. Binding and competition studies revealed evidence that (i) fatty acid binding was dependent on the calcium concentration; (ii) fatty acid binding was specific for the protein complex formed by S100A8 and S100A9, whereas the individual components were unable to bind fatty acids; (iii) exclusively polyunsaturated fatty acids were bound by S100A8/A9, whereas saturated (palmitic acid, stearic acid) and monounsaturated fatty acids (oleic acid) as well as arachidonic acid-derived eicosanoids (15-hydroxyeicosatetraenoic acid, prostaglandin E-2, thromboxane B-2, leukotriene B-4 were poor competitors). Stimulation of neutrophil-like HL-60 cells with phorbol 12-myristate 13-acetate led to the secretion of S100A8/A9 protein complex, which carried the released arachidonic acid. When elevation of intracellular calcium level was induced by A23187, release of arachidonic acid occurred without secretion of S100A8/A9. In view of the unusual abundance in neutrophilic cytosol (approximately 40% of cytosolic protein) our findings assign an important role for S100A8/A9 as mediator between calcium signaling and arachidonic acid effects. Further investigations have to explore the exact function of the S100A8/A9-arachidonic acid complex both inside and outside of neutrophils.	Univ Munster, Inst Expt Dermatol, D-48149 Munster, Germany; Hannover Med Sch, Inst Mol Pharmacol, D-30623 Hannover, Germany	University of Munster; Hannover Medical School	Kerkhoff, C (corresponding author), Univ Munster, Inst Expt Dermatol, Von Esmarch Str 56, D-48149 Munster, Germany.	kerkhoc@uni-muenster.de	Kaever, Volkhard/G-3280-2013					BHARDWAJ RS, 1992, EUR J IMMUNOL, V22, P1891, DOI 10.1002/eji.1830220732; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRANDTZAEG P, 1987, AM J CLIN PATHOL, V87, P700, DOI 10.1093/ajcp/87.6.700; BRUN JG, 1994, J RHEUMATOL, V21, P733; CALDER PC, 1991, INT J BIOCHEM, V23, P579; Chilton FH, 1996, BBA-LIPID LIPID MET, V1299, P1, DOI 10.1016/0005-2760(95)00169-7; COLLINS SJ, 1987, BLOOD, V70, P1233; De Caterina R, 1998, J LIPID RES, V39, P1062; DeCaterina R, 1996, LIPIDS, V31, pS57, DOI 10.1007/BF02637052; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; EDGEWORTH J, 1991, J BIOL CHEM, V266, P7706; Fasano MB, 1998, CLIN IMMUNOL IMMUNOP, V87, P304, DOI 10.1006/clin.1998.4545; FUJIKAWA M, 1992, IMMUNOLOGY, V75, P330; GLATZ JFC, 1983, ANAL BIOCHEM, V132, P89, DOI 10.1016/0003-2697(83)90429-3; GOEBELER M, 1994, TRANSPLANTATION, V58, P355; Harrison CA, 1999, J BIOL CHEM, V274, P8561, DOI 10.1074/jbc.274.13.8561; Hetland G, 1998, J CLIN PATHOL-MOL PA, V51, P143, DOI 10.1136/mp.51.3.143; HILT DC, 1991, NOVEL CALCIUM BINDIN, P65; HOGG N, 1989, EUR J IMMUNOL, V19, P1053, DOI 10.1002/eji.1830190615; Huang ZH, 1997, CIRC RES, V80, P149, DOI 10.1161/01.RES.80.2.149; HUBBELL T, 1994, BIOCHEMISTRY-US, V33, P3327, DOI 10.1021/bi00177a025; Karim S, 1996, J BIOL CHEM, V271, P12042, DOI 10.1074/jbc.271.20.12042; KELLY JP, 1979, J IMMUNOL, V122, P1556; Kerkhoff C, 1997, BIOCHEM BIOPH RES CO, V237, P632, DOI 10.1006/bbrc.1997.7201; Kerkhoff C, 1998, BBA-MOL CELL RES, V1448, P200, DOI 10.1016/S0167-4889(98)00144-X; Kerkhoff C, 1997, BBA-LIPID LIPID MET, V1346, P163, DOI 10.1016/S0005-2760(97)00030-1; Klempt M, 1997, FEBS LETT, V408, P81, DOI 10.1016/S0014-5793(97)00394-3; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; KLOTZ IM, 1982, SCIENCE, V217, P1247, DOI 10.1126/science.6287580; KRUMP E, 1995, BIOCHEM J, V310, P681, DOI 10.1042/bj3100681; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; LAGASSE E, 1988, MOL CELL BIOL, V8, P2402, DOI 10.1128/MCB.8.6.2402; MADSEN P, 1992, J INVEST DERMATOL, V99, P299, DOI 10.1111/1523-1747.ep12616641; MULLER G, 1993, ARTERIOSCLER THROMB, V13, P1317, DOI 10.1161/01.ATV.13.9.1317; MURAO S, 1990, CELL GROWTH DIFFER, V1, P447; Newton RA, 1998, J IMMUNOL, V160, P1427; Niiro H, 1997, BLOOD, V89, P1621, DOI 10.1182/blood.V89.5.1621.1621_1621_1628; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; Pouliot M, 1998, FASEB J, V12, P1109, DOI 10.1096/fasebj.12.12.1109; Rammes A, 1997, J BIOL CHEM, V272, P9496; RODRIGUEZ CG, 1993, J BIOL CHEM, V268, P24751; ROTH J, 1992, IMMUNOBIOLOGY, V186, P304, DOI 10.1016/S0171-2985(11)80259-7; ROTH J, 1994, BIOCHEM J, V301, P655, DOI 10.1042/bj3010655; ROTH J, 1993, BLOOD, V82, P1875; ROTONDO D, 1994, BBA-MOL CELL RES, V1223, P185, DOI 10.1016/0167-4889(94)90225-9; Roulin K, 1999, EXP CELL RES, V247, P410, DOI 10.1006/excr.1998.4382; SANTOLI D, 1990, J CLIN INVEST, V85, P424, DOI 10.1172/JCI114455; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Siegenthaler G, 1997, J BIOL CHEM, V272, P9371; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sorg C, 1992, Behring Inst Mitt, P126; TEIGELKAMP S, 1991, J BIOL CHEM, V266, P13462; van den Bos C, 1998, PROTEIN EXPRES PURIF, V13, P313, DOI 10.1006/prep.1998.0917; Vogl T, 1999, J AM SOC MASS SPECTR, V10, P1124; WEYMAN C, 1975, LANCET, V2, P33; WEYMAN C, 1977, BIOCHIM BIOPHYS ACTA, V496, P155, DOI 10.1016/0304-4165(77)90123-4; WILKINSON MM, 1988, J CELL SCI, V91, P221; ZWADLO G, 1988, CLIN EXP IMMUNOL, V72, P510	59	132	139	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32672	32679		10.1074/jbc.274.46.32672	http://dx.doi.org/10.1074/jbc.274.46.32672			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551823	hybrid			2022-12-25	WOS:000083623000023
J	Brandt, BH; Roetger, A; Dittmar, T; Nikolai, G; Seeling, M; Merschjann, A; Nofer, JR; Dehmer-Moller, G; Junker, R; Assmann, G; Zaenker, KS				Brandt, BH; Roetger, A; Dittmar, T; Nikolai, G; Seeling, M; Merschjann, A; Nofer, JR; Dehmer-Moller, G; Junker, R; Assmann, G; Zaenker, KS			c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells	FASEB JOURNAL			English	Article						F-actin; gelsolin; epidermal growth factor; HUVEC	EPIDERMAL GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; FACTOR RECEPTOR; EGF RECEPTOR; ANTIBODIES INHIBIT; ERBB-2 PROTEIN; HER-2/NEU GENE; POOR-PROGNOSIS; ONCOGENE; ACTIN	Separate mechanisms for oncogenesis and metastasis have been postulated. We show here that prolonged and invasive cell migration, a key mechanism in cancer metastasis, is linked to c-erbB-2 signaling. Cell lines with c-erbB-2 and EGFR expression and transphosphorylation activity display a high transendothelial invasiveness in an endothelial-extracellular matrix model mimicking a capillary vessel wall, in vitro. Tyrosine-phosphorylated c-erbB-2 receptors and EGFR are localized predominantly in areas of the cell with high membrane extension activity. On the molecular level, there is a subtle cross talk between the transmembrane signaling molecule c-erbB-2 and the actin cytoskeleton at multiple levels, including the generation of the second messenger PIP2 and the mobilization of the actin-regulatory protein gelsolin. Our data strongly suggest that c-erbB-2, especially in a heterodimer with EGFR, is closely involved in signaling pathways, inducing alterations in cell morphology that are required for a human breast cancer cell to become motile and conceivably metastatic.-Brandt, B. H., Roetger, A., Dittmar, T., Nikolai, G., Seeling, M., Merschjann, A., Nofer, J.-R., Dehmer-Moller, G., Junker, R., Assmann, G., Zaenker. K. S. c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells.	Inst Klin Chem & Lab Med, D-48149 Munster, Germany; Univ Witten Herdecke, Inst Immunol, D-58453 Witten, Germany	Witten Herdecke University	Brandt, BH (corresponding author), Inst Klin Chem & Lab Med, Albert Schweitzer Str 33, D-48149 Munster, Germany.	brandt@uni-muenster.de	Junker, Ralf/M-2358-2013; Dittmar, Thomas/T-6679-2019; Dittmar, Thomas/X-3691-2019	Brandt, Burkhard/0000-0003-3681-3049				BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BENZ CC, 1995, GENE, V159, P3, DOI 10.1016/0378-1119(95)00147-X; BILLAH MM, 1982, J BIOL CHEM, V257, P2705; Brandt B, 1998, INT J CANCER, V76, P824, DOI 10.1002/(SICI)1097-0215(19980610)76:6<824::AID-IJC10>3.0.CO;2-2; BUTTON E, 1995, CELL MOTIL CYTOSKEL, V30, P247, DOI 10.1002/cm.970300402; Chen P, 1996, J CELL BIOL, V134, P689, DOI 10.1083/jcb.134.3.689; Cohen BD, 1996, J BIOL CHEM, V271, P30897, DOI 10.1074/jbc.271.48.30897; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; DiGiovanna MP, 1998, ONCOGENE, V17, P1877, DOI 10.1038/sj.onc.1202091; DIGIOVANNA MP, 1995, CANCER RES, V55, P1946; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KORNILOVA ES, 1992, ONCOGENE, V7, P511; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; Kwon HJ, 1997, ONCOGENE, V15, P2625, DOI 10.1038/sj.onc.1201443; MARTH C, 1992, INT J CANCER, V52, P311, DOI 10.1002/ijc.2910520226; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Murali R, 1996, P NATL ACAD SCI USA, V93, P6252, DOI 10.1073/pnas.93.13.6252; Press MF, 1997, J CLIN ONCOL, V15, P2894, DOI 10.1200/JCO.1997.15.8.2894; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; Roetger A, 1998, AM J PATHOL, V153, P1797, DOI 10.1016/S0002-9440(10)65694-5; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; Tan M, 1997, CANCER RES, V57, P1199; Welch MD, 1997, CURR OPIN CELL BIOL, V9, P54, DOI 10.1016/S0955-0674(97)80152-4; Worthylake R, 1997, J BIOL CHEM, V272, P8594, DOI 10.1074/jbc.272.13.8594; Xu FJ, 1997, CLIN CANCER RES, V3, P1629; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YU D, 1995, MOL BASIS ONCOLOGY, P131; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260	42	82	86	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1999	13	14					1939	1949		10.1096/fasebj.13.14.1939	http://dx.doi.org/10.1096/fasebj.13.14.1939			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544177				2022-12-25	WOS:000083660700006
J	Awwad, R; Humphrey, LE; Periyasamy, B; Scovell, W; Li, WH; Coleman, K; Lynch, M; Carboni, J; Brattain, MG; Howell, GM				Awwad, R; Humphrey, LE; Periyasamy, B; Scovell, W; Li, WH; Coleman, K; Lynch, M; Carboni, J; Brattain, MG; Howell, GM			The EGF/TGF alpha response element within the TGF alpha promoter consists of a multi-complex regulatory element	ONCOGENE			English	Article						colon carcinoma; EGF-response element; TGF alpha promotor; transcription; transforming growth factor alpha	GROWTH-FACTOR-ALPHA; HUMAN-COLON CARCINOMA; PROTEIN-KINASE-C; FACTOR-RECEPTOR; MESSENGER-RNA; CELL-LINES; EPITHELIAL-CELLS; PHORBOL ESTER; CANCER-CELLS; EXPRESSION	Autocrine TGF alpha is an important growth effector in the transformed phenotype. Growth stimulation of some colon cancer cells as well as other types of cancer cells is effected by activation of the epidermal growth factor receptor. Importantly, this receptor activation leads to further stimulation of TGF alpha transcription and increased peptide synthesis. However, the molecular mechanism by which TGF alpha transcription is activated is poorly understood. In this paper, we describe the localization of a cis-sequence within the TGF alpha promoter which mediates this stimulation. This region contains parallel cis-acting elements which interact to regulate both basal and EGF-induced TGF alpha expression. The well differentiated colon carcinoma cell line designated FET was employed in these studies. It produces autocrine TGF alpha but requires exogenous EGF in the medium for optimal growth. Addition of EGF to FET cells maintained in the absence of EGF resulted in a 2-3-fold increase of both TGF promoter activity and endogenous TGF alpha mRNA at 4 h. This addition of EGF also stimulated protein synthesis. The use of deletion constructs of the TGF alpha promoter in chimeras with chloramphenicol acetyl transferase localized EGF-responsiveness to between -247 and -201 within the TGF alpha promoter. A 25 bp sequence within this region conferred EGF-responsiveness to heterologous promoter constructs. Further use of deletion/mutation chimeric constructs revealed the presence of at least two interacting cis-elements, one binding a repressor activity and the other, an activator. Gel shift studies indicate the presence of distinct complexes representing activator and repressor binding, which are positively modulated by EGF. The type and amount of complexes formed by these proteins interact to regulate both the basal activity and EGF-responsiveness of the TGF alpha promoter. The interaction of an activator protein with an EGF-responsive repressor may serve to regulate the level of this progression-associated, transforming protein within tight limits.	Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43699 USA; Bristol Myers Squibb Co, Oncol Drug Discovery, Dept Mol Genet, Princeton, NJ 08543 USA; Pfizer Inc, Cent Res, Groton, CT 06340 USA	Bristol-Myers Squibb; Pfizer	Howell, GM (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Surg, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.				NATIONAL CANCER INSTITUTE [R01CA034432, R01CA054807] Funding Source: NIH RePORTER; NCI NIH HHS [CA54807, CA34432] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; BATES SE, 1990, ENDOCRINOLOGY, V126, P596, DOI 10.1210/endo-126-1-596; BJORGE JD, 1989, J BIOL CHEM, V264, P4021; BLASBAND AJ, 1990, MOL CELL BIOL, V10, P2111, DOI 10.1128/MCB.10.5.2111; BOYD DD, 1988, CANCER RES, V48, P2469; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHANTRET I, 1988, CANCER RES, V48, P1936; CHEN XR, 1992, ONCOGENE, V7, P1805; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COFFEY RJ, 1992, CELL GROWTH DIFFER, V3, P347; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DALTON S, 1993, PHILOS T ROY SOC B, V340, P325, DOI 10.1098/rstb.1993.0074; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DERYNCK R, 1987, CANCER RES, V47, P707; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELSHOLTZ HP, 1986, SCIENCE, V234, P1552, DOI 10.1126/science.3491428; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; ENOCH T, 1986, MOL CELL BIOL, V6, P801, DOI 10.1128/MCB.6.3.801; FISCH TM, 1989, MOL CELL BIOL, V9, P1327, DOI 10.1128/MCB.9.3.1327; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HOWELL GM, 1995, J CELL PHYSIOL, V162, P256, DOI 10.1002/jcp.1041620211; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IMANISHI K, 1989, J NATL CANCER I, V81, P220, DOI 10.1093/jnci/81.3.220; JAKOBOVITS EB, 1988, MOL CELL BIOL, V8, P5549, DOI 10.1128/MCB.8.12.5549; Kudlow J E, 1990, Semin Cancer Biol, V1, P293; LEE LW, 1991, CANCER RES, V51, P5238; LEWIS EJ, 1987, MOL CELL BIOL, V7, P3332, DOI 10.1128/MCB.7.9.3332; LEWIS JJ, 1990, SURGERY, V108, P220; MADTES DK, 1988, CELL, V53, P285, DOI 10.1016/0092-8674(88)90390-X; MALDEN LT, 1989, INT J CANCER, V43, P380, DOI 10.1002/ijc.2910430305; Maniatis T, 1982, MOL CLONING LABORATO; MARKOWITZ SD, 1990, J CLIN INVEST, V86, P356, DOI 10.1172/JCI114709; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; MERCHANT JL, 1991, MOL CELL BIOL, V11, P2686, DOI 10.1128/MCB.11.5.2686; Mulder K. M., 1989, CELL MOL BIOL COLON, P45; MULDER KM, 1989, MOL ENDOCRINOL, V3, P1215, DOI 10.1210/mend-3-8-1215; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; RAJA RH, 1991, MOL ENDOCRINOL, V5, P514, DOI 10.1210/mend-5-4-514; SAEKI T, 1991, MOL ENDOCRINOL, V5, P1955, DOI 10.1210/mend-5-12-1955; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SIZELAND AM, 1991, MOL CELL BIOL, V11, P4005, DOI 10.1128/MCB.11.8.4005; SIZELAND AM, 1992, MOL BIOL CELL, V3, P1235, DOI 10.1091/mbc.3.11.1235; SUKHATME VP, 1991, AM J KIDNEY DIS, V17, P615, DOI 10.1016/S0272-6386(12)80333-7; Todaro G J, 1990, Semin Cancer Biol, V1, P257; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WAN CW, 1988, CANCER LETT, V43, P139, DOI 10.1016/0304-3835(88)90226-1; WATKINS LF, 1988, CANCER LETT, V40, P59, DOI 10.1016/0304-3835(88)90262-5; WILCOX JN, 1988, MOL CELL BIOL, V8, P3415, DOI 10.1128/MCB.8.8.3415; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G; ZIOBER BL, 1993, J BIOL CHEM, V268, P691	57	9	9	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 21	1999	18	43					5923	5935		10.1038/sj.onc.1202982	http://dx.doi.org/10.1038/sj.onc.1202982			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557079				2022-12-25	WOS:000083270700009
J	Sambucetti, LC; Fischer, DD; Zabludoff, S; Kwon, PO; Chamberlin, H; Trogani, N; Xu, H; Cohen, D				Sambucetti, LC; Fischer, DD; Zabludoff, S; Kwon, PO; Chamberlin, H; Trogani, N; Xu, H; Cohen, D			Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UROKINASE PLASMINOGEN-ACTIVATOR; ACUTE PROMYELOCYTIC LEUKEMIA; TRANSFORMED NIH3T3 CELLS; TRICHOSTATIN-A; TRANSCRIPTIONAL REPRESSION; COLON-CANCER; WAF1/CIP1 GENE; CARCINOMA CELL; N-COR; BUTYRATE	Histone acetylation is emerging as a major regulatory mechanism thought to modulate gene expression by altering the accessibility of transcription factors to DNA. In this study, treatment of human tumor cells with the histone deacetylase inhibitor, trapoxin (TPX), resulted in selective changes in genes that control the cell cycle. TPX activated p21(waf1) transcription that led to elevated p21(waf1) protein levels in three human tumor cell lines without altering the protein levels of cdk2, cdk4, or cyclin B, In addition, TPX increased cyclin E transcription without increasing the levels of Rb, E2F, dihydrofolate reductase, or glyceraldehyde-3-phosphate dehydrogenase, The elevated levels of p21(waf1) protein led to decreased Rb phosphorylation and cdk2 activity. These effects resulted in G(1) and G(2) cell cycle arrest in H1299 human lung and MDA-MB-435 breast carcinoma cells and apoptosis in A549 lung carcinoma cells. Chromatin immunoprecipitation assays revealed that TPX increased the level of chromatin acetylation associated with histone H3 in the trapoxin-responsive region of the p21(waf1) promoter. This study demonstrates that inhibition of HDAC by TPX increases acetylation of H3-associated chromatin and alters gene expression with marked selectivity.	Novartis Inst Biomed Res, Dept Funct Genomics, Summit, NJ 07901 USA; Novartis Inst Biomed Res, Dept Oncol, Summit, NJ 07901 USA	Novartis; Novartis	Cohen, D (corresponding author), Novartis Inst Biomed Res, Dept Funct Genomics, Summit, NJ 07901 USA.							Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; COGSWELL JP, 1995, EXP CELL RES, V216, P396; Davie JR, 1998, J CELL BIOCHEM, P203; Dong-Le Bourhis X, 1998, BRIT J CANCER, V77, P396, DOI 10.1038/bjc.1998.63; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Espinos E, 1999, MOL CELL BIOL, V19, P3474; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; FUTAMURA M, 1995, ONCOGENE, V10, P1119; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; HARISANOVA NT, 1986, CELL DIFFER DEV, V19, P115, DOI 10.1016/0045-6039(86)90068-0; Hasegawa T, 1999, BIOCHEM BIOPH RES CO, V256, P249, DOI 10.1006/bbrc.1999.0275; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hassig CA, 1997, CHEM BIOL, V4, P783, DOI 10.1016/S1074-5521(97)90111-3; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hitomi M, 1998, ONCOGENE, V17, P959, DOI 10.1038/sj.onc.1202005; HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248; HOSHIKAWA Y, 1991, AGR BIOL CHEM TOKYO, V55, P1491, DOI 10.1080/00021369.1991.10870799; Inokoshi J, 1999, BIOCHEM BIOPH RES CO, V256, P372, DOI 10.1006/bbrc.1999.0316; ITAZAKI H, 1990, J ANTIBIOT, V43, P1524, DOI 10.7164/antibiotics.43.1524; Janson W, 1997, ONCOGENE, V15, P1395, DOI 10.1038/sj.onc.1201304; Kim YB, 1999, ONCOGENE, V18, P2461, DOI 10.1038/sj.onc.1202564; KRUPITZA G, 1995, CARCINOGENESIS, V16, P1199; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Medina V, 1997, CANCER RES, V57, P3697; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Nightingale KP, 1998, EMBO J, V17, P2865, DOI 10.1093/emboj/17.10.2865; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; REEDER JA, 1993, TERATOGEN CARCIN MUT, V13, P75, DOI 10.1002/tcm.1770130204; Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; STIEGLER P, 1998, CANCER RES, V389, P187; SUGITA K, 1992, CANCER RES, V52, P168; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; VanLint C, 1996, GENE EXPRESSION, V5, P245; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5; Xiao HY, 1997, BIOCHEM BIOPH RES CO, V237, P457, DOI 10.1006/bbrc.1997.7158; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; YOSHIDA H, 1992, JPN J CANCER RES, V83, P324, DOI 10.1111/j.1349-7006.1992.tb00109.x; YOSHIDA M, 1988, EXP CELL RES, V177, P122, DOI 10.1016/0014-4827(88)90030-4; YOSHIDA M, 1987, CANCER RES, V47, P3688; YOSHIDA M, 1990, J ANTIBIOT, V43, P1101, DOI 10.7164/antibiotics.43.1101; ZHANG W, 1995, CANCER RES, V55, P668	63	379	393	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34940	34947		10.1074/jbc.274.49.34940	http://dx.doi.org/10.1074/jbc.274.49.34940			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574969	hybrid			2022-12-25	WOS:000083979600063
J	Tarasova, NI; Rice, WG; Michejda, CJ				Tarasova, NI; Rice, WG; Michejda, CJ			Inhibition of G-protein-coupled receptor function by disruption of transmembrane domain interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLECYSTOKININ RECEPTOR; MEMBRANE-PROTEIN; BACTERIORHODOPSIN; FRAGMENTS; PEPTIDES; IDENTIFICATION; RECONSTITUTION; COEXPRESSION; TRAFFICKING; ACTIVATION	G-protein-coupled receptors (GPCR) represent a superfamily of proteins that mediate the function of neurotransmitters and peptide hormones and are involved in viral entry and perception of light, smell, and taste. GPCRs are characterized by the presence of seven transmembrane domains (TMs). We demonstrate here that structural analogs of individual TMs of GPCRs can serve as potent and specific receptor antagonists. Peptides derived from the transmembrane regions of CXCR4 and CCR5 chemokine receptors specifically inhibited receptor signaling and the in vitro replication of human immunodeficiency virus-1 (HIV-1) at concentrations as low as 0.2 mu M. Similarly, peptides mimicking the TMs of cholecystokinin receptor A, were found to abolish ligand binding and signaling through the receptor. Negative charges positioned at the extracellular termini of peptide antagonists appeared to be important for correct spontaneous insertion of the compounds into the cell membrane and for their activity. Targeting of the specific interactions between transmembrane domains of GPCRs is suggested as a general sequence-based method to disrupt receptor function for application in drug design and for structure-function studies of the receptors.	NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Mol Aspects Drug Design Sect, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Lab Antiviral Drug Mechanisms, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Tarasova, NI (corresponding author), NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Mol Aspects Drug Design Sect, POB B, Frederick, MD 21702 USA.			Tarasova, Nadya/0000-0002-4949-0069				AnandSrivastava MB, 1996, J BIOL CHEM, V271, P19324, DOI 10.1074/jbc.271.32.19324; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; Bayle D, 1997, J BIOL CHEM, V272, P19697, DOI 10.1074/jbc.272.32.19697; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Bjorndal A, 1997, J VIROL, V71, P7478; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HUANG KS, 1981, J BIOL CHEM, V256, P3802; Jakubik J, 1999, J BIOL CHEM, V274, P1349, DOI 10.1074/jbc.274.3.1349; KAHN TW, 1992, BIOCHEMISTRY-US, V31, P6144, DOI 10.1021/bi00141a027; KieberEmmons T, 1997, CURR OPIN BIOTECH, V8, P435, DOI 10.1016/S0958-1669(97)80065-1; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; MAGGIO R, 1993, FEBS LETT, V319, P195, DOI 10.1016/0014-5793(93)80066-4; Merkouris M, 1996, MOL PHARMACOL, V50, P985; Osuga Y, 1997, J BIOL CHEM, V272, P25006, DOI 10.1074/jbc.272.40.25006; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; Peitsch MC, 1996, RECEPTOR CHANNEL, V4, P161; Rice W G, 1995, Adv Pharmacol, V33, P389, DOI 10.1016/S1054-3589(08)60675-4; RIDGE KD, 1995, P NATL ACAD SCI USA, V92, P3204, DOI 10.1073/pnas.92.8.3204; Sato M, 1998, J BIOL CHEM, V273, P25203, DOI 10.1074/jbc.273.39.25203; Schoneberg T, 1996, EMBO J, V15, P1283, DOI 10.1002/j.1460-2075.1996.tb00470.x; Silvente-Poirot S, 1998, MOL PHARMACOL, V54, P364, DOI 10.1124/mol.54.2.364; Tarasova NI, 1997, J BIOL CHEM, V272, P14817, DOI 10.1074/jbc.272.23.14817; Tarasova NI, 1998, ADV EXP MED BIOL, V436, P201; Tarasova NI, 1998, J BIOL CHEM, V273, P15883, DOI 10.1074/jbc.273.26.15883; WANK SA, 1995, AM J PHYSIOL-GASTR L, V269, pG628, DOI 10.1152/ajpgi.1995.269.5.G628; WANK SA, 1992, P NATL ACAD SCI USA, V89, P8691, DOI 10.1073/pnas.89.18.8691; Watson S., 1994, G PROTEIN LINKED REC	29	81	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34911	34915		10.1074/jbc.274.49.34911	http://dx.doi.org/10.1074/jbc.274.49.34911			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574965	hybrid			2022-12-25	WOS:000083979600059
J	Zhao, WQ; Chen, H; Xu, H; Moore, E; Meiri, N; Quon, MJ; Alkon, DL				Zhao, WQ; Chen, H; Xu, H; Moore, E; Meiri, N; Quon, MJ; Alkon, DL			Brain insulin receptors and spatial memory - Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; DIABETES-MELLITUS; ALZHEIMERS-DISEASE; CELLS; TRANSDUCTION; DEMENTIA; SHC; ASSOCIATION; METABOLISM; POPULATION	Evidence accumulated from clinical and basic research has indirectly implicated the insulin receptor (IR) in brain cognitive functions, including learning and memory (Wickelgren, I. (1998) Science 280, 517-519), The present study investigates correlative changes in IR expression, phosphorylation, and associated signaling molecules in the rat hippocampus following water maze training. Although the distribution of IR protein matched that of IR mRNA in most forebrain regions, a dissociation of the IR mRNA and protein expression patterns was found in the cerebellar cortex. After training, IR mRNA in the CA1 and dentate gyrus of the hippocampus was up-regulated, and there was increased accumulation of LR protein in the hippocampal crude synaptic membrane fraction. In the CA1 pyramidal neurons, changes in the distribution pattern of LR in particular cellular compartments, such as the nucleus and dendritic regions, was observed only in trained animals. Although IR showed a low level of in vivo tyrosine phosphorylation, an insulin-stimulated increase of in vitro Tyr phosphorylation of IR was detected in trained animals, suggesting that learning may induce IR functional changes, such as enhanced receptor sensitivity. Furthermore, a training-induced co-immunoprecipitation of IR with Shc-66 was detected, along with changes in in vivo Tyr phosphorylation of Shc and mitogen-activated protein kinase, as well as accumulation of Shc-66, Shc-52, and Grb-2 in hippocampal synaptic membrane fractions following training. These findings suggest that IR may participate in memory processing through activation of its receptor Tyr kinase activity, and they suggest possible engagement of Shc/Grb-2/Ras/mitogen-activated protein kinase cascades.	NINDS, Lab Adapt Syst, NIH, Bethesda, MD 20892 USA; NHLBI, Hypertens Endocrine Branch, NIH, Bethesda, MD 20892 USA; Agr Res Org, Volcani Ctr, Inst Anim Sci, IL-50250 Bet Dagan, Israel	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH	Zhao, WQ (corresponding author), NINDS, Lab Adapt Syst, NIH, Bethesda, MD 20892 USA.	wqzhao@helix.nih.gov	Quon, Michael/B-1970-2008	QUON, MICHAEL/0000-0002-5289-3707; Quon, Michael/0000-0002-9601-9915	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL003608] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALKON DL, 1982, SCIENCE, V215, P693, DOI 10.1126/science.7058334; Biessels GJ, 1999, NETH J MED, V54, P35, DOI 10.1016/S0300-2977(98)00134-X; Blum S, 1999, J NEUROSCI, V19, P3535; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; BOYD FT, 1983, AM J PHYSIOL, V245, pC283, DOI 10.1152/ajpcell.1983.245.3.C283; Cavallaro S, 1997, P NATL ACAD SCI USA, V94, P9669, DOI 10.1073/pnas.94.18.9669; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CLARKE DW, 1984, J BIOL CHEM, V259, P1672; COULTER DA, 1989, J NEUROPHYSIOL, V61, P971, DOI 10.1152/jn.1989.61.5.971; Craft S, 1996, NEUROBIOL AGING, V17, P123, DOI 10.1016/0197-4580(95)02002-0; Craft S, 1998, NEUROLOGY, V50, P164, DOI 10.1212/WNL.50.1.164; FIGLEWICZ DP, 1991, BRAIN RES, V550, P101, DOI 10.1016/0006-8993(91)90410-W; FOX GB, 1995, J NEUROCHEM, V65, P2796; GUSEV PA, 1999, ABSTR SOC NEUROSCI, V25, P1623; HEIDENREICH KA, 1983, J BIOL CHEM, V258, P8527; HEIDENREICH KA, 1986, ENDOCRINOLOGY, V118, P1835, DOI 10.1210/endo-118-5-1835; Hong M, 1997, J BIOL CHEM, V272, P19547, DOI 10.1074/jbc.272.31.19547; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KAHN CR, 1993, RECENT PROG HORM RES, V48, P291; KATO H, 1993, J BIOL CHEM, V268, P2655; Lannert H, 1998, BEHAV NEUROSCI, V112, P1199, DOI 10.1037/0735-7044.112.5.1199; Leibson CL, 1997, AM J EPIDEMIOL, V145, P301; MARKS JL, 1991, ADV EXP MED BIOL, V293, P459; MARKS JL, 1988, J NEUROCHEM, V50, P774, DOI 10.1111/j.1471-4159.1988.tb02981.x; MASTERS BA, 1987, BRAIN RES, V417, P247, DOI 10.1016/0006-8993(87)90449-5; MATTHAEI S, 1986, DIABETES, V35, P1181, DOI 10.2337/diabetes.35.10.1181; OLDS JL, 1990, J NEUROSCI, V10, P3707; OLDS JL, 1989, SCIENCE, V245, P866, DOI 10.1126/science.2772638; Orban PC, 1999, TRENDS NEUROSCI, V22, P38, DOI 10.1016/S0166-2236(98)01306-X; Ott A, 1996, DIABETOLOGIA, V39, P1392, DOI 10.1007/s001250050588; PAXINOS G, RAT BRAIN ATLAS; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QUON MJ, 1994, TRENDS ENDOCRIN MET, V5, P369, DOI 10.1016/1043-2760(94)90104-X; RAIZADA MK, 1988, NEUROCHEM RES, V13, P297, DOI 10.1007/BF00972477; Ricketts WA, 1996, J BIOL CHEM, V271, P26165, DOI 10.1074/jbc.271.42.26165; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; ROSTAS JAP, 1986, NEUROCHEM RES, V11, P253, DOI 10.1007/BF00967973; ROTH RA, 1992, J CELL BIOCHEM, V48, P12, DOI 10.1002/jcb.240480104; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sasaoka T, 1996, ENDOCRINOLOGY, V137, P4427, DOI 10.1210/en.137.10.4427; SAUTER A, 1983, BRAIN RES, V260, P330, DOI 10.1016/0006-8993(83)90691-1; Schreurs BG, 1998, J NEUROSCI, V18, P5498, DOI 10.1523/JNEUROSCI.18-14-05498.1998; SCHWARTZ MW, 1992, ENDOCR REV, V13, P387, DOI 10.1210/er.13.3.387; Stolk RP, 1997, DIABETES CARE, V20, P792, DOI 10.2337/diacare.20.5.792; WERTHER GA, 1987, ENDOCRINOLOGY, V121, P1562, DOI 10.1210/endo-121-4-1562; Wickelgren I, 1998, SCIENCE, V280, P517, DOI 10.1126/science.280.5363.517; Woods SC, 1996, NEUROSCI BIOBEHAV R, V20, P139, DOI 10.1016/0149-7634(95)00044-F; ZAHNISER NR, 1984, J NEUROCHEM, V42, P1354, DOI 10.1111/j.1471-4159.1984.tb02795.x	48	417	459	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34893	34902		10.1074/jbc.274.49.34893	http://dx.doi.org/10.1074/jbc.274.49.34893			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574963	hybrid			2022-12-25	WOS:000083979600057
J	Falcone, D; Do, H; Johnson, AE; Andrews, DW				Falcone, D; Do, H; Johnson, AE; Andrews, DW			Negatively charged residues in the IgM stop-transfer effector sequence regulate transmembrane polypeptide integration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN TOPOLOGY; COLI INNER MEMBRANE; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; SIGNAL SEQUENCE; PRION PROTEIN; ER MEMBRANE; AMINO-ACIDS; TERMINAL CHARGE; P-GLYCOPROTEIN	A non-hydrophobic sequence that contributes to the biogenesis of a transmembrane protein is termed a stop-transfer effector (STE), To examine the mechanism of STE-mediated stop-transfer, a series of fusion proteins were constructed containing variants of a putative STE: from murine IgM fused to an otherwise translocated hydrophobic sequence. Unexpectedly, the fraction of molecules adopting transmembrane topology was insensitive to many amino acid substitutions within the STE sequence but varied directly with the number of negative charges. Furthermore, when present at the amino terminus of a reporter, mutants were observed that adopted type I (amino terminus lumenal) and type II (amino terminus cytoplasmic) transmembrane topologies, demonstrating that the STE sequence can be located at either side of the endoplasmic reticulum membrane. Our results suggest that recognition of a broad structural feature formed primarily by negatively charged residues within the STE halts translocation and triggers membrane integration, even when the negative charges end up on the cytoplasmic side of the membrane. Since functional STE sequences photocross-link to two membrane proteins not previously identified at the translocon, these unique proteins are presumably involved in recognizing STE sequences and/or facilitating STE function.	McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; Texas A&M Univ, Dept Med Biochem & Genet, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	McMaster University; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Andrews, DW (corresponding author), McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada.		Johnson, Arthur E/G-3457-2012	Andrews, David/0000-0002-9266-7157	NIGMS NIH HHS [GM 26494] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026494] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrews DW, 1996, TRENDS BIOCHEM SCI, V21, P365; ANDREWS DW, 1992, J BIOL CHEM, V267, P7761; Belin D, 1996, EMBO J, V15, P468, DOI 10.1002/j.1460-2075.1996.tb00379.x; CHENG HL, 1982, NATURE, V296, P410, DOI 10.1038/296410a0; DALBEY RE, 1990, TRENDS BIOCHEM SCI, V15, P253, DOI 10.1016/0968-0004(90)90047-F; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; DUNLOP J, 1995, EMBO J, V14, P3609, DOI 10.1002/j.1460-2075.1995.tb00030.x; Harley CA, 1996, J BIOL CHEM, V271, P24625, DOI 10.1074/jbc.271.40.24625; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Hegde RS, 1997, CELL, V91, P575, DOI 10.1016/S0092-8674(00)80445-6; HIGH S, 1993, J BIOL CHEM, V268, P26745; Izard JW, 1996, J BIOL CHEM, V271, P21579, DOI 10.1074/jbc.271.35.21579; JOHANSSON M, 1993, MOL GEN GENET, V239, P251, DOI 10.1007/BF00281625; Kiefer D, 1997, EMBO J, V16, P2197, DOI 10.1093/emboj/16.9.2197; LANDOLTMARTICORENA C, 1993, J MOL BIOL, V229, P602, DOI 10.1006/jmbi.1993.1066; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; Lu Y, 1998, J BIOL CHEM, V273, P568, DOI 10.1074/jbc.273.1.568; Moss K, 1998, MOL BIOL CELL, V9, P2681, DOI 10.1091/mbc.9.9.2681; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; NAKAHARA DH, 1994, J BIOL CHEM, V269, P7617; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; PILLAI S, 1987, P NATL ACAD SCI USA, V84, P7654, DOI 10.1073/pnas.84.21.7654; ROGERS J, 1981, CELL, V26, P19, DOI 10.1016/0092-8674(81)90029-5; ROTHMAN RE, 1988, J BIOL CHEM, V263, P10470; SAKAGUCHI M, 1992, P NATL ACAD SCI USA, V89, P16, DOI 10.1073/pnas.89.1.16; SATO T, 1990, EMBO J, V9, P2391, DOI 10.1002/j.1460-2075.1990.tb07414.x; SHIRASAWA T, 1993, EMBO J, V12, P1827, DOI 10.1002/j.1460-2075.1993.tb05831.x; SKACH WR, 1993, J BIOL CHEM, V268, P23552; SPIESS M, 1989, J BIOL CHEM, V264, P19117; SPIESS M, 1995, FEBS LETT, V369, P76, DOI 10.1016/0014-5793(95)00551-J; Swameye I, 1997, J VIROL, V71, P9434, DOI 10.1128/JVI.71.12.9434-9441.1997; TERASHIMA M, 1994, EMBO J, V13, P3782, DOI 10.1002/j.1460-2075.1994.tb06689.x; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; vanKlompenburg W, 1997, EMBO J, V16, P4261, DOI 10.1093/emboj/16.14.4261; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; Wahlberg JM, 1997, J CELL BIOL, V137, P555, DOI 10.1083/jcb.137.3.555; WHITLEY P, 1994, EMBO J, V13, P4653, DOI 10.1002/j.1460-2075.1994.tb06788.x; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0; ZHANG JT, 1993, J BIOL CHEM, V268, P15101	41	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33661	33670		10.1074/jbc.274.47.33661	http://dx.doi.org/10.1074/jbc.274.47.33661			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559255	hybrid			2022-12-25	WOS:000083745200071
J	Liu, L; Moesner, P; Kovach, NL; Bailey, R; Hamilton, AD; Sebti, SM; Harlan, JM				Liu, L; Moesner, P; Kovach, NL; Bailey, R; Hamilton, AD; Sebti, SM; Harlan, JM			Integrin-dependent leukocyte adhesion involves geranylgeranylated protein(s)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C; H-RAS; T-LYMPHOCYTES; K-RAS; N-RAS; ACTIVATION; BINDING; INHIBITOR; CELLS; RHO	Integrin-dependent leukocyte adhesion is modulated by alterations in receptor affinity or by post-receptor events. Pretreatment of Jurkat T-cells with the 3-hydroxymethylglutaryl-coenzyme A reductase inhibitor, lovastatin, markedly reduced (IC5- approximate to 1-2 mu M) alpha(4)beta(1)-dependent adhesion to fibronectin (FN) stimulated by phorbol 12-myristate 13-acetate (PMA) which modulates post-receptor events. In contrast, lovastatin did not inhibit Jurkat cell adhesion to FN induced by the beta(1) integrin-activating monoclonal antibody (mAb) 8A2, which directly modulates beta(1) integrin affinity. Similarly, pretreatment of U937 cells with lovastatin inhibited PMA-stimulated, but not mAb 8A2-stimulated, alpha(6)beta(1)-dependent leukocyte adhesion to laminin. The inhibition of lovastatin on PMA-stimulated leukocyte adhesion was not mediated by mitogen-activated protein kinase or phosphatidylinositol 3-kinase pathway. The inhibitory effect of lovastatin on PMA-stimulated leukocyte adhesion was reversed by co-incubation with geranylgeraniol, but not with farnesol, with concurrent reversal of the inhibition of protein prenylation as shown by protein RhoA geranylgeranylation. The selective inhibition of protein geranylgeranylation by the specific protein geranylgeranyltransferase-I inhibitor, GGTI-298, blocked PMA-stimulated leukocyte adhesion but not mAb 8A2-induced leukocyte adhesion. The protein farnesyltransferase inhibitor, FTI-277, had no effect on leukocyte adhesion induced by either stimulus. These results demonstrate that protein geranylgeranylation, but not farnesylation, is required for integrin dependent post-receptor events in leukocyte adhesion.	Univ Washington, Div Hematol, Seattle, WA 98195 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Biochem & Mol Biol, Drug Discovery Program, Tampa, FL 33612 USA	University of Washington; University of Washington Seattle; Yale University; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Liu, L (corresponding author), Univ Washington, Div Hematol, Box 357710, Seattle, WA 98195 USA.				NATIONAL CANCER INSTITUTE [U19CA067771] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NCI NIH HHS [CA67771] Funding Source: Medline; NHLBI NIH HHS [HL18645, HL07321] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aepfelbacher M, 1996, J IMMUNOL, V157, P5070; ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CARBONI JM, 1995, ONCOGENE, V10, P1905; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; D'Souza-Schorey C, 1998, MOL CELL BIOL, V18, P3936, DOI 10.1128/MCB.18.7.3936; DAMBROSIO D, 1994, EUR J IMMUNOL, V24, P616, DOI 10.1002/eji.1830240319; Detmers PA, 1998, J IMMUNOL, V161, P1921; DIDSBURY JR, 1990, BIOCHEM BIOPH RES CO, V171, P804, DOI 10.1016/0006-291X(90)91217-G; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FAULL RJ, 1994, J EXP MED, V179, P1307, DOI 10.1084/jem.179.4.1307; FONTDE MJ, 1997, MOL CELL BIOL, V17, P6068; FRANKLIN RA, 1994, J CLIN INVEST, V93, P2134, DOI 10.1172/JCI117209; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; HERMANOWSKIVOSATKA A, 1992, CELL, V68, P341, DOI 10.1016/0092-8674(92)90475-R; HORI Y, 1991, ONCOGENE, V6, P515; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; JAKOBISIAK M, 1991, P NATL ACAD SCI USA, V88, P3628, DOI 10.1073/pnas.88.9.3628; KHOSRAVIFAR R, 1992, J BIOL CHEM, V267, P24363; Kimura M, 1997, ARTERIOSCL THROM VAS, V17, P1521, DOI 10.1161/01.ATV.17.8.1521; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; LOWY DR, 1989, NATURE, V341, P384, DOI 10.1038/341384a0; McGuire TF, 1997, ONCOGENE, V14, P305, DOI 10.1038/sj.onc.1200819; Niwa S, 1996, INT J IMMUNOPHARMACO, V18, P669, DOI 10.1016/S0192-0561(96)00068-9; Petruzzelli L, 1998, J IMMUNOL, V160, P4208; Salojin K, 1997, J EXP MED, V186, P887, DOI 10.1084/jem.186.6.887; SEBTI SM, 1991, CANCER COMMUN, V3, P141, DOI 10.3727/095535491820873371; Shattil SJ, 1997, J CLIN INVEST, V100, P1, DOI 10.1172/JCI119500; Stewart M, 1996, J CELL BIOCHEM, V61, P554, DOI 10.1002/(SICI)1097-4644(19960616)61:4<554::AID-JCB8>3.0.CO;2-N; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; Vogt A, 1996, ONCOGENE, V13, P1991; Weber C, 1997, J AM COLL CARDIOL, V30, P1212, DOI 10.1016/S0735-1097(97)00324-0; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592	42	66	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33334	33340		10.1074/jbc.274.47.33334	http://dx.doi.org/10.1074/jbc.274.47.33334			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559211	hybrid			2022-12-25	WOS:000083745200027
J	McGraw, DW; Forbes, SL; Kramer, LA; Witte, DP; Fortner, CN; Paul, RJ; Liggett, SB				McGraw, DW; Forbes, SL; Kramer, LA; Witte, DP; Fortner, CN; Paul, RJ; Liggett, SB			Transgenic overexpression of beta(2)-adrenergic receptors in airway smooth muscle alters myocyte function and ablates bronchial hyperreactivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED TRACHEA; GUINEA-PIG; MICE; EXPRESSION; BETA-1-ADRENOCEPTORS; DESENSITIZATION; TRANSDUCTION; RELAXATION; PATTERNS; FAILURE	beta(2)-Adrenergic receptors (beta(2)AR) act to relax airway smooth muscle and can serve to counteract hyperresponsiveness, although the effect may not be ablative even in the presence of exogenous agonist, Within this signaling cascade that ultimately transduces smooth muscle relaxation, a significant "spare receptor" pool has been hypothesized to be present in the airway. In order to modify the relationship between beta(2)AR and downstream effecters, transgenic mice (TG) were created overexpressing beta(2)AR similar to 75-fold in airway smooth muscle using a mouse smooth muscle a-actin promoter. While >90% of these receptors were expressed on the smooth muscle cell surface, the percentage of receptors able to form the agonist-promoted high affinity complex was less than that found with nontransgenic (NTG) cells (R-H = 18 versus 36%). Nevertheless, beta(2)AR signaling was found to be enhanced. Intact airway smooth muscle cells from TG had basal cAMP levels that were greater than NTG cells. A marked increase in agonist-stimulated cAMP levels was found in the TG (similar to 200% stimulation over basal) compared with NTG (similar to 50% over basal) cells. Adenylyl cyclase studies gave similar results and also showed a 10-fold lower EC50 for TC: cells. Tracheal rings from TG mice that were precontracted with acetylcholine had an enhanced responsiveness (relaxation) to beta-agonist, with a 60-fold decrease in the ED50, indicating that the enhanced signaling imposed by overexpression results in an increase in the coordinated function of the intact airway cells. In vivo studies showed a significantly blunted airway resistance response to the inhaled bronchoconstrictor methacholine in the TG mice. Indeed, with beta-agonist pretreatment, the TG mice displayed no response whatsoever to methacholine. These results are consistent with beta(2)AR being the limiting factor in the transduction system. Increases in the initial component of this transduction system (the beta(2)AR) are sufficient to markedly alter signaling and airway smooth muscle function to the extent that bronchial hyperresponsiveness is ablated, consistent with an antiasthma phenotype.	Univ Cincinnati, Coll Med, Dept Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol Genet, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Physiol, Cincinnati, OH 45267 USA; Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center	Liggett, SB (corresponding author), Univ Cincinnati, Coll Med, Dept Med, 231 Bethesda Ave, Cincinnati, OH 45267 USA.	Stephen.Liggett@UC.edu	liggett, stephen b/E-7453-2012	Liggett, Stephen B./0000-0002-0128-3669	NHLBI NIH HHS [HL41496, HL45967, HL54829] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054829, R37HL045967, R01HL045967, P01HL041496, R56HL045967] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVNER BP, 1979, P W PHARMACOL SOC, V22, P177; BAI TR, 1992, LUNG, V170, P125; BARNES PJ, 1985, BRIT J PHARMACOL, V86, P685, DOI 10.1111/j.1476-5381.1985.tb08946.x; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; Dorn GW, 1999, P NATL ACAD SCI USA, V96, P6400, DOI 10.1073/pnas.96.11.6400; FOSTER DN, 1992, J BIOL CHEM, V267, P11995; GREEN SA, 1994, J BIOL CHEM, V269, P26215; GREEN SA, 1995, AM J RESP CELL MOL, V13, P25, DOI 10.1165/ajrcmb.13.1.7598936; GREEN SA, 1996, GENETICS ASTHMA, P67; Hakonarson H, 1998, AM J RESP CRIT CARE, V158, pS115, DOI 10.1164/ajrccm.158.supplement_2.13tac700; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; HENRY PJ, 1990, BRIT J PHARMACOL, V99, P136, DOI 10.1111/j.1476-5381.1990.tb14667.x; HENRY PJ, 1990, BRIT J PHARMACOL, V99, P131, DOI 10.1111/j.1476-5381.1990.tb14666.x; Kao J, 1999, AM J PHYSIOL-LUNG C, V277, pL264, DOI 10.1152/ajplung.1999.277.2.L264; KENAKIN T, 1988, LIFE SCI, V43, P1095, DOI 10.1016/0024-3205(88)90467-5; Laporte JD, 1998, AM J PHYSIOL-LUNG C, V275, pL491, DOI 10.1152/ajplung.1998.275.3.L491; LEMOINE H, 1992, J PHARMACOL EXP THER, V261, P258; LEMOINE H, 1982, N-S ARCH PHARMACOL, V320, P130, DOI 10.1007/BF00506313; LIGGETT SB, 1989, MOL PHARMACOL, V36, P641; LIGGETT SB, 1997, LUNG SCI FDN, P19; McGraw DW, 1998, CELL SIGNAL, V10, P197, DOI 10.1016/S0898-6568(97)00112-5; McGraw DW, 1997, J BIOL CHEM, V272, P7338, DOI 10.1074/jbc.272.11.7338; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; MILLIGAN G, 1995, MOL CELL BIOCHEM, V149, P213, DOI 10.1007/BF01076579; ODONNELL SR, 1972, EUR J PHARMACOL, V19, P371, DOI 10.1016/0014-2999(72)90104-5; PAUL RJ, 1996, GENETICS ASTHMA, P91; Postma DS, 1998, AM J RESP CRIT CARE, V158, pS187, DOI 10.1164/ajrccm.158.supplement_2.13tac170; Rockman HA, 1998, P NATL ACAD SCI USA, V95, P7000, DOI 10.1073/pnas.95.12.7000; SUTLIFF RL, 1998, DEV CARDIOVASC MED, V210, P247; TODA N, 1978, J PHARMACOL EXP THER, V207, P311; Turki J, 1996, P NATL ACAD SCI USA, V93, P10483, DOI 10.1073/pnas.93.19.10483; Wang JW, 1997, J CLIN INVEST, V100, P1425, DOI 10.1172/JCI119663; WEIBEL ER, 1988, PULMONARY DIS DISORD, P20	34	45	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32241	32247		10.1074/jbc.274.45.32241	http://dx.doi.org/10.1074/jbc.274.45.32241			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542262	hybrid			2022-12-25	WOS:000083532100070
J	Hersberger, M; Patarroyo-White, S; Arnold, KS; Innerarity, TL				Hersberger, M; Patarroyo-White, S; Arnold, KS; Innerarity, TL			Phylogenetic analysis of the apolipoprotein B mRNA-editing region - Evidence for a secondary structure between the mooring sequence and the 3 ' efficiency element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; CATALYTIC SUBUNIT; CYTIDINE DEAMINASE; MOLECULAR-CLONING; PROTEIN; SITE; APOBEC-1; BINDING; ENZYME; INVITRO	Apolipoprotein (apo) B mRNA editing is the deamination of C-6666 to uridine, which changes the codon at position 2153 from a genomically encoded glutamine (CAA) to an in-frame stop codon (UAA), The apoB mRNA-editing enzyme complex recognizes the editing region of the apoB pre-mRNA with exquisite precision. Four sequence elements spanning 139 nucleotides (nt) on the apoB mRNA have been identified that specify this precision, In cooperation with the indispensable mooring sequence and spacer element, a 5' efficiency element and a 3' efficiency element enhance editing in vitro, A phylogenetic comparison of 32 species showed minor differences in the apoB mRNA sequence, and the apoB mRNA from 31 species was robustly edited in vitro. However, guinea pig mRNA was poorly edited. Compared with the consensus sequences of these 31 species, guinea pig apoB mRNA has three variations in the 3' efficiency element, and the conversion of these to the consensus sequence increased editing to the levels in the other species. From this information, a model for the secondary structure was formulated in which the mooring sequence and the 3' efficiency element form a double-stranded stem. Thirty-one mammalian apoB mRNA sequences are predicted to form this stem positioning C-6666 two nucleotides upstream of the stem, However, the guinea pig apoB mRNA has a mutation in the 3' efficiency element (C-6743 to U) that predicts an extension of the stem and hence the lower editing efficiency. A test of this model demonstrated that a single substitution at 6743 (U to C) in the guinea pig apoB mRNA, that should reduce the stem, enhanced editing, and mutations in the 3' efficiency element that extended the stem for three base pairs dramatically reduced editing. Furthermore, the addition of a 20-nucleotide 3' efficiency element RNA to a Fis-nucleotide guinea pig apoB mRNA lacking the 3' efficiency element more than doubled the in vitro editing activity. Based on these results, a model is proposed in which the mooring sequence and the 3' efficiency element form a double-stranded stem, thus suggesting a mechanism of how the 3' efficiency element enhances editing.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Hersberger, M (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.	hmr@ikc.unizh.ch		Hersberger, Martin/0000-0002-4472-329X	NHLBI NIH HHS [HL47660] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047660] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANANT S, 1995, J BIOL CHEM, V270, P14762, DOI 10.1074/jbc.270.24.14762; BACKUS JW, 1994, BBA-GENE STRUCT EXPR, V1217, P65; BACKUS JW, 1992, NUCLEIC ACIDS RES, V20, P6007, DOI 10.1093/nar/20.22.6007; BACKUS JW, 1991, NUCLEIC ACIDS RES, V19, P6781, DOI 10.1093/nar/19.24.6781; BOSTROM K, 1990, J BIOL CHEM, V265, P22446; Chan L, 1997, BBA-LIPID LIPID MET, V1345, P11, DOI 10.1016/S0005-2760(96)00156-7; CHEN SH, 1990, J BIOL CHEM, V265, P6811; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; DAVIES MS, 1989, J BIOL CHEM, V264, P13395; DRISCOLL DM, 1994, J BIOL CHEM, V269, P19843; DRISCOLL DM, 1993, MOL CELL BIOL, V13, P7288, DOI 10.1128/MCB.13.12.7288; DRISCOLL DM, 1989, CELL, V58, P519, DOI 10.1016/0092-8674(89)90432-7; GARCIA ZC, 1992, ARTERIOSCLER THROMB, V12, P172, DOI 10.1161/01.ATV.12.2.172; GREEVE J, 1993, J LIPID RES, V34, P1367; HADJIAGAPIOU C, 1994, NUCLEIC ACIDS RES, V22, P1874, DOI 10.1093/nar/22.10.1874; Hersberger M, 1998, J BIOL CHEM, V273, P9435, DOI 10.1074/jbc.273.16.9435; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HODGES PE, 1991, NUCLEIC ACIDS RES, V19, P1197, DOI 10.1093/nar/19.6.1197; Innerarity TL, 1996, J BIOL CHEM, V271, P2353, DOI 10.1074/jbc.271.5.2353; JAMES BD, 1989, METHOD ENZYMOL, V180, P227; JOHNSON DF, 1993, BIOCHEM BIOPH RES CO, V195, P1204, DOI 10.1006/bbrc.1993.2172; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; LAU PP, 1991, J BIOL CHEM, V266, P20550; MACGINNITIE AJ, 1995, J BIOL CHEM, V270, P14768, DOI 10.1074/jbc.270.24.14768; Nakamuta M, 1996, J BIOL CHEM, V271, P25981, DOI 10.1074/jbc.271.42.25981; Nakamuta M, 1999, BIOCHEM BIOPH RES CO, V254, P744, DOI 10.1006/bbrc.1998.9963; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; Navaratnam N, 1998, J MOL BIOL, V275, P695, DOI 10.1006/jmbi.1997.1506; NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3; NAVARATNAM N, 1991, NUCLEIC ACIDS RES, V19, P1741, DOI 10.1093/nar/19.8.1741; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; QIAN X, 1993, ARTERIOSCLER THROMB, V18, P1013; Richardson N, 1998, J BIOL CHEM, V273, P31707, DOI 10.1074/jbc.273.48.31707; SHAH RR, 1991, J BIOL CHEM, V266, P16301; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; Yamanaka S, 1996, J BIOL CHEM, V271, P11506, DOI 10.1074/jbc.271.19.11506; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725; Yang Y, 1997, P NATL ACAD SCI USA, V94, P13075, DOI 10.1073/pnas.94.24.13075; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181; ZUKER M, 1995, NUCLEIC ACIDS RES, V23, P2791, DOI 10.1093/nar/23.14.2791	40	40	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34590	34597		10.1074/jbc.274.49.34590	http://dx.doi.org/10.1074/jbc.274.49.34590			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574922	hybrid			2022-12-25	WOS:000083979600016
J	Leff, MA; Fretland, AJ; Doll, MA; Hein, DW				Leff, MA; Fretland, AJ; Doll, MA; Hein, DW			Novel human N-acetyltransferase 2 alleles that differ in mechanism for slow acetylator phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BLADDER-CANCER; HUMAN LIVER; WILD-TYPE; NAT2; PHARMACOGENETICS; EXPRESSION; GENOTYPE; MUTANT	Three novel human NAT2 alleles (NAT2*5D, NAT2*6D, and NAT2*14G) were identified and characterized in a yeast expression system. The common rapid (NAT2*4) and slow (NAT2*5B) acetylator human NAT2 alleles were also characterized for comparison. The novel recombinant NAT2 allozymes catalyzed both N- and O-acetyltransferase activities at levels comparable with NAT2 5B and significantly below NAT2 4, suggesting that they confer slow acetylation phenotype. In order to investigate the molecular mechanism of slow acetylation in the novel NAT2 alleles, we assessed mRNA and protein expression levels and protein stability. No differences were observed in NAT2 mRNA expression among the novel alleles, NAT2*4 and NAT2*5B. However, NAT2 5B and NAT2 5D, but not NAT2 6D and NAT2 14G protein expression were significantly lower than NAT2 4. In contrast, NAT2 6D was slightly (3.4-fold) and NAT2 14G was substantially (29-fold) less stable than NAT2 4. These results suggest that the 341T-->C(Ile(114)-->Thr) common to the NAT2*5 cluster is sufficient for reduction in NAT2 protein expression, but that mechanisms for slow acetylator phenotype differ for NAT2 alleles that do not contain 341T-->C, such as the NAT2*6 and NAT2*14 clusters. Different mechanisms for slow acetylator phenotype in humans are consistent with multiple slow acetylator phenotypes.	Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA	University of Louisville	Hein, DW (corresponding author), Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA.		Hein, David W/A-9707-2008	Hein, David/0000-0003-3261-9775	NATIONAL CANCER INSTITUTE [R01CA034627] Funding Source: NIH RePORTER; NCI NIH HHS [CA-34627] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE M, 1993, BIOCHEM BIOPH RES CO, V191, P811, DOI 10.1006/bbrc.1993.1289; BLUM M, 1991, P NATL ACAD SCI USA, V88, P5237, DOI 10.1073/pnas.88.12.5237; CARTWRIGHT RA, 1982, LANCET, V2, P842; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DEGUCHI T, 1992, J BIOL CHEM, V267, P18140; DOLL MA, 1995, ANAL BIOCHEM, V231, P413, DOI 10.1006/abio.1995.9978; DUPRET JM, 1994, J BIOL CHEM, V269, P26830; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERGUSON RJ, 1994, DRUG METAB DISPOS, V22, P371; GRANT DM, 1990, J CLIN INVEST, V85, P968, DOI 10.1172/JCI114527; Grant DM, 1997, MUTAT RES-FUND MOL M, V376, P61, DOI 10.1016/S0027-5107(97)00026-2; HEIN DW, 1994, HUM MOL GENET, V3, P729; HEIN DW, 2000, IN PRESS CANC EPIDEM, V9; HEIN DW, 2000, IN PRESS PHARMACOGEN, V10; HICKMAN D, 1995, BIOCHEM PHARMACOL, V50, P697, DOI 10.1016/0006-2952(95)00182-Y; Leff MA, 1999, J PHARMACOL EXP THER, V290, P182; Meyer UA, 1997, ANNU REV PHARMACOL, V37, P269, DOI 10.1146/annurev.pharmtox.37.1.269; RISCH A, 1995, HUM MOL GENET, V4, P231, DOI 10.1093/hmg/4.2.231; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VATSIS KP, 1995, PHARMACOGENETICS, V5, P1, DOI 10.1097/00008571-199502000-00001; WEBER WW, 1985, PHARMACOL REV, V37, P25	21	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34519	34522		10.1074/jbc.274.49.34519	http://dx.doi.org/10.1074/jbc.274.49.34519			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574910	hybrid			2022-12-25	WOS:000083979600004
J	Albanese, C; D'Amico, M; Reutens, AT; Fu, MF; Watanabe, G; Lee, RJ; Kitsis, RN; Henglein, B; Avantaggiati, M; Somasundaram, K; Thimmapaya, B; Pestell, RG				Albanese, C; D'Amico, M; Reutens, AT; Fu, MF; Watanabe, G; Lee, RJ; Kitsis, RN; Henglein, B; Avantaggiati, M; Somasundaram, K; Thimmapaya, B; Pestell, RG			Activation of the cyclin D1 gene by the EPA-associated protein p300 through AP-1 inhibits cellular apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS E1A PROTEINS; WILD-TYPE P53; TUMOR-SUPPRESSOR; TRANSCRIPTIONAL COACTIVATOR; RETINOBLASTOMA PROTEIN; G0-TO-G1 TRANSITION; HISTONE ACETYLATION; MOUSE FIBROBLASTS; DEPENDENT KINASES; TRANSGENIC MICE	The adenovirus E1A protein interferes with regulators of apoptosis and growth by physically interacting with cell cycle regulatory proteins including the retinoblastoma tumor suppressor protein and the coactivator proteins p300/CBP (where CBP is the CREB-binding protein). The p300/CBP proteins occupy a pivotal role in regulating mitogenic signaling and apoptosis, The mechanisms by which cell cycle control genes are directly regulated by p300 remain to be determined. The cyclin D1 gene, which is overexpressed in many different tumor types, encodes a regulatory subunit of a holoenzyme that phosphorylates and inactivates PRE. In the present study E1A12S inhibited the cyclin D1 promoter Fia the amino-terminal p300/CBP binding domain in human choriocarcinoma JEG-3 cells. p300 induced cyclin D1 protein abundance, and p300, but not CBP, induced the cyclin DI promoter. cyclin D1 or p300 overexpression inhibited apoptosis in JEG-3 cells. The CH3 region of p300, which was required for induction of cyclin D1, was also required for the inhibition of apoptosis. p300 activated the cyclin D1 promoter through an activator protein-1 (AP-1) site at -954 and was identified within a DNA-bound complex with c-Jun at the AP-1 site. Apoptosis rates of embryonic fibroblasts derived from mice homozygously deleted of the cyclin D1 gene (cyclin D1(-/-)) were increased compared with wild type control on several distinct matrices. p300 inhibited apoptosis in cyclin D1(+/+) fibroblasts but increased apoptosis in cyclin D1(-/-) cells. The anti-apoptotic function of cyclin D1, demonstrated by sub-G(1) analysis and annexin V staining, may contribute to its cellular transforming and cooperative oncogenic properties.	Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Inst Curie, INSERM U255, F-75005 Paris, France; SUNY Buffalo, Sch Med, Buffalo, NY 14214 USA; Northwestern Univ, Sch Med, Dept Immunol Microbiol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Lurie Canc Ctr, Chicago, IL 60611 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Pestell, RG (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Med, 1300 Morris Pk Ave,Chanin 302, Bronx, NY 10461 USA.				NATIONAL CANCER INSTITUTE [R01CA075503, P30CA013330, R29CA070896] Funding Source: NIH RePORTER; NCI NIH HHS [5-P30-CA13330-26, R01CA75503, R29CA70896-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ANDREE HAM, 1990, J BIOL CHEM, V265, P4923; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; ASKEW DS, 1991, ONCOGENE, V6, P1915; AVANTAGGIATI ML, 1997, CELL, V89, P1174; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Boersma AWM, 1996, CYTOMETRY, V24, P123, DOI 10.1002/(SICI)1097-0320(19960601)24:2<123::AID-CYTO4>3.0.CO;2-K; Botz J, 1996, MOL CELL BIOL, V16, P3401; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; BUCHOU T, 1993, ONCOGENE, V8, P1765; CHEN XB, 1995, CANCER RES, V55, P4257; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Darzynkiewicz Z, 1998, Hum Cell, V11, P3; Darzynkiewicz Z, 1997, CYTOMETRY, V27, P1; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DelSal G, 1996, ONCOGENE, V12, P177; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Han EKH, 1996, CELL GROWTH DIFFER, V7, P699; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HIRAKAWA T, 1991, P NATL ACAD SCI USA, V585, P1519; HUANG TS, 1995, P NATL ACAD SCI USA, V92, P4793, DOI 10.1073/pnas.92.11.4793; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Kalejta RF, 1997, CYTOMETRY, V29, P286, DOI 10.1002/(SICI)1097-0320(19971201)29:4<286::AID-CYTO4>3.0.CO;2-8; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Latham KM, 1996, MOL CELL BIOL, V16, P4445; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Lee JS, 1996, J BIOL CHEM, V271, P17666, DOI 10.1074/jbc.271.30.17666; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Lukas J, 1996, MOL CELL BIOL, V16, P6917; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Lybarger L, 1996, CYTOMETRY, V25, P211, DOI 10.1002/(SICI)1097-0320(19961101)25:3<211::AID-CYTO2>3.0.CO;2-I; Ma CY, 1998, P NATL ACAD SCI USA, V95, P9938, DOI 10.1073/pnas.95.17.9938; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Pestell RG, 1996, MOL ENDOCRINOL, V10, P1084, DOI 10.1210/me.10.9.1084; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; Pestell RG, 1996, CELL GROWTH DIFFER, V7, P1337; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SPITKOVSKY D, 1995, ONCOGENE, V10, P2421; SPITKOVSKY D, 1994, J VIROL, V68, P2206, DOI 10.1128/JVI.68.4.2206-2214.1994; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; SuzukiYagawa Y, 1997, MOL CELL BIOL, V17, P3284, DOI 10.1128/MCB.17.6.3284; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WANG HGH, 1995, J VIROL, V69, P7917, DOI 10.1128/JVI.69.12.7917-7924.1995; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; Watanabe G, 1996, J BIOL CHEM, V271, P22570, DOI 10.1074/jbc.271.37.22570; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Xiong W, 1997, AM J PHYSIOL-LUNG C, V272, pL1205, DOI 10.1152/ajplung.1997.272.6.L1205; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zerfass K, 1996, J VIROL, V70, P2637, DOI 10.1128/JVI.70.4.2637-2642.1996; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	92	165	170	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34186	34195		10.1074/jbc.274.48.34186	http://dx.doi.org/10.1074/jbc.274.48.34186			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567390	hybrid			2022-12-25	WOS:000083857500055
J	Kato-Yamada, Y; Bald, D; Koike, M; Motohashi, K; Hisabori, T; Yoshida, M				Kato-Yamada, Y; Bald, D; Koike, M; Motohashi, K; Hisabori, T; Yoshida, M			epsilon Subunit, an endogenous inhibitor of bacterial F-1-ATPase, also inhibits F0F1-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI ATP SYNTHASE; TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; ESCHERICHIA-COLI; THERMOPHILIC F1-ATPASE; GAMMA-SUBUNIT; H+-ATPASE; ROTATION; COMPLEX; BINDING; BACTERIORHODOPSIN	Since the report by Sternweis and Smith (Sternweis, P. C., and Smith, J. B. (1980) Biochemistry 19, 526-531), the epsilon subunit, an endogenous inhibitor of bacterial F-1-ATPase, has long been thought not to inhibit activity of the holo enzyme, F0F1-ATPase. However, we report here that the epsilon subunit is exerting inhibition in F0F1-ATPase. We prepared a C-terminal half-truncated epsilon subunit (epsilon(Delta C)) of the thermophilic Bacillus PS3 F0F1-ATPase and reconstituted F-1- and F0F1-ATPase containing epsilon(Delta C). Compared with F-1- and F0F1-ATPase containing intact epsilon, those containing epsilon(Delta C) showed uninhibited activity; severalfold higher rate of ATP hydrolysis at low ATP concentration and the start of ATP hydrolysis without an initial lag at high ATP concentration. The F0F1-ATPase containing epsilon(Delta C) was capable of ATP-driven H+ pumping. The time-course of pumping at low ATP concentration was faster than that by the F0F1-ATPase containing intact epsilon. Thus, the comparison with noninhibitory epsilon(Delta C) mutant shed light on the inhibitory role of the intact epsilon subunit in F0F1-ATPase.	Tokyo Inst Technol, Resources Utilizat Res Lab, Yokohama, Kanagawa 2268503, Japan; Teikyo Univ, Biotechnol Res Ctr 3F, Core Res Evolut Sci & Technol, Genet Programming Team 13, Kawasaki, Kanagawa 2160001, Japan	Tokyo Institute of Technology; Japan Science & Technology Agency (JST); Teikyo University	Yoshida, M (corresponding author), Tokyo Inst Technol, Resources Utilizat Res Lab, R-1,4259 Nagatsuta, Yokohama, Kanagawa 2268503, Japan.	myoshida@res.titech.ac.jp	Motohashi, Ken/I-4970-2019; Hisabori, Toru/E-5205-2014	Motohashi, Ken/0000-0002-8414-2836; Hisabori, Toru/0000-0003-2046-0277				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aggeler R, 1997, J BIOL CHEM, V272, P19621, DOI 10.1074/jbc.272.31.19621; Bald D, 1998, J BIOL CHEM, V273, P865, DOI 10.1074/jbc.273.2.865; Bald D, 1999, EUR J BIOCHEM, V262, P563, DOI 10.1046/j.1432-1327.1999.00410.x; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bulygin VV, 1998, J BIOL CHEM, V273, P31765, DOI 10.1074/jbc.273.48.31765; CRUZ JA, 1995, PLANT PHYSIOL, V109, P1379, DOI 10.1104/pp.109.4.1379; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; HASHIMOTO T, 1990, J BIOENERG BIOMEMBR, V22, P27, DOI 10.1007/BF00762843; HASHIMOTO T, 1996, SEIKAGAKU, V68, P775; Hisabori T, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1711; Hisabori T, 1997, EUR J BIOCHEM, V247, P1158, DOI 10.1111/j.1432-1033.1997.01158.x; Kato Y, 1997, J BIOL CHEM, V272, P24906, DOI 10.1074/jbc.272.40.24906; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; KUKI M, 1988, J BIOL CHEM, V263, P17437; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGET PP, 1979, ARCH BIOCHEM BIOPHYS, V197, P83, DOI 10.1016/0003-9861(79)90222-4; MATSUI T, 1995, BBA-BIOENERGETICS, V1231, P139, DOI 10.1016/0005-2728(95)00070-Y; ORT DR, 1992, ANNU REV PLANT PHYS, V43, P269, DOI 10.1146/annurev.pp.43.060192.001413; Pitard B, 1996, EUR J BIOCHEM, V235, P779, DOI 10.1111/j.1432-1033.1996.t01-1-00779.x; PULLMAN ME, 1963, J BIOL CHEM, V238, P3762; RICHARD P, 1995, J BIOL CHEM, V270, P21571, DOI 10.1074/jbc.270.37.21571; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SMITH JB, 1977, BIOCHEMISTRY-US, V16, P306, DOI 10.1021/bi00621a023; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STERNWEIS PC, 1980, BIOCHEMISTRY-US, V19, P526, DOI 10.1021/bi00544a021; Stiggall D L, 1979, Methods Enzymol, V55, P308; Tang CL, 1996, J BIOL CHEM, V271, P3018, DOI 10.1074/jbc.271.6.3018; Uhlin U, 1997, STRUCTURE, V5, P1219, DOI 10.1016/S0969-2126(97)00272-4; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; Wilkens S, 1998, J BIOL CHEM, V273, P26645, DOI 10.1074/jbc.273.41.26645; Xiong H, 1998, BIOCHEMISTRY-US, V37, P16423, DOI 10.1021/bi981522i; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; YOKOYAMA K, 1989, J BIOL CHEM, V264, P21837; YOSHIDA M, 1977, P NATL ACAD SCI USA, V74, P936, DOI 10.1073/pnas.74.3.936; YOSHIDA M, 1975, J BIOL CHEM, V250, P7910; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609	41	73	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					33991	33994		10.1074/jbc.274.48.33991	http://dx.doi.org/10.1074/jbc.274.48.33991			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567363	hybrid			2022-12-25	WOS:000083857500028
J	Sarnago, S; Elorza, A; Mayor, F				Sarnago, S; Elorza, A; Mayor, F			Agonist-dependent phosphorylation of the G protein-coupled receptor kinase 2 (GRK2) by Src tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; C-SRC; ACTIVATION; DESENSITIZATION; BINDING; ENDOCYTOSIS; EXPRESSION; SHC; ACCUMULATION; ASSOCIATION	GRK2 is a member of the G protein-coupled receptor kinase (GRK) family, which phosphorylates the activated form of a variety of G protein-coupled receptors (G;PCR) and plays an important role in GPCR modulation. It has been recently reported that stimulation of the mitogen-activated protein kinase cascade by GPCRs involves tyrosine phosphorylation of docking proteins mediated by members of the Src tyrosine kinase family. In this report, we have investigated the possible role of c-Src in modulating GRK2 function. We demonstrate that c-Src can directly phosphorylate GRK2 on tyrosine residues, as shown by in vitro experiments with purified proteins. The phosphorylation reaction exhibits an apparent K-m for GRK2 of 12 nM, thus suggesting a physiological relevance in living cells. Consistently, overexpression of the constitutively active c-Src Y527F mutant in COS-7 cells leads to tyrosine phosphorylation of coexpressed GRK2, In addition, GRK2 can be detected in phosphotyrosine immunoprecipitates from HEK-293 cells transiently transfected with this Src mutant. Interestingly, phosphotyrosine immunoblots reveal a rapid and transient increase in GRK2 phosphorylation upon agonist stimulation of beta(2)-adrenergic receptors co-transfected with GRK2 and wild type c-Src in COS-7 cells. This tyrosine phosphorylation is maximal within 5 min of isoproterenol stimulation and reaches values of similar to 5-fold over basal conditions. Furthermore, GRK2 phosphorylation on tyrosine residues promotes an increased kinase activity toward its substrates. Our results suggest that GRK2 phosphorylation by c-Src is inherent to GPCR activation and put forward a new mechanism for the regulation of GPCR signaling.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, Dept Biol Mol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Mayor, F (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, Dept Biol Mol, E-28049 Madrid, Spain.	fmayor@cbm.uam.es	Mayor, Federico/N-7644-2016	Mayor Menendez, Federico/0000-0003-1434-8449				Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; AKIYAMA T, 1986, J BIOL CHEM, V261, P4797; Aragay AM, 1998, FEBS LETT, V430, P37, DOI 10.1016/S0014-5793(98)00495-5; Aragay AM, 1998, P NATL ACAD SCI USA, V95, P2985, DOI 10.1073/pnas.95.6.2985; BENOVIC JL, 1989, J BIOL CHEM, V264, P6707; BUSHMAN WA, 1990, P NATL ACAD SCI USA, V87, P7462, DOI 10.1073/pnas.87.19.7462; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; Carman CV, 1998, J BIOL CHEM, V273, P20308, DOI 10.1074/jbc.273.32.20308; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; Choi DJ, 1997, J BIOL CHEM, V272, P17223, DOI 10.1074/jbc.272.27.17223; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; Chuang TT, 1996, TRENDS PHARMACOL SCI, V17, P416, DOI 10.1016/S0165-6147(96)10048-1; Daaka Y, 1997, P NATL ACAD SCI USA, V94, P2180, DOI 10.1073/pnas.94.6.2180; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DebBurman SK, 1996, J BIOL CHEM, V271, P22552, DOI 10.1074/jbc.271.37.22552; DeCorte V, 1997, FEBS LETT, V401, P191, DOI 10.1016/S0014-5793(96)01471-8; Freeman JLR, 1998, J BIOL CHEM, V273, P20653, DOI 10.1074/jbc.273.32.20653; Fuller SJ, 1998, J BIOL CHEM, V273, P18146, DOI 10.1074/jbc.273.29.18146; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HO AK, 1995, J NEUROCHEM, V65, P1597; Jaber M, 1996, P NATL ACAD SCI USA, V93, P12974, DOI 10.1073/pnas.93.23.12974; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; Kovacic B, 1998, J BIOL CHEM, V273, P35185; KURPNICK JG, 1998, ANN REV PHARM TOXICO, V38, P238; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; Lohse MJ, 1996, KIDNEY INT, V49, P1047, DOI 10.1038/ki.1996.153; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Mayor F, 1998, TRENDS CARDIOVAS MED, V8, P234, DOI 10.1016/S1050-1738(98)00008-5; MOYERS JS, 1993, MOL CELL BIOL, V13, P2391, DOI 10.1128/MCB.13.4.2391; Murga C, 1996, J BIOL CHEM, V271, P985, DOI 10.1074/jbc.271.2.985; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; Penela P, 1998, J BIOL CHEM, V273, P35238, DOI 10.1074/jbc.273.52.35238; Pitcher JA, 1998, J BIOL CHEM, V273, P12316, DOI 10.1074/jbc.273.20.12316; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Pronin AN, 1997, J BIOL CHEM, V272, P3806, DOI 10.1074/jbc.272.6.3806; Rockman HA, 1998, P NATL ACAD SCI USA, V95, P7000, DOI 10.1073/pnas.95.12.7000; RuizGomez A, 1997, J BIOL CHEM, V272, P9601; Sato K, 1997, FEBS LETT, V410, P136, DOI 10.1016/S0014-5793(97)00539-5; Taylor CC, 1996, ENDOCRINOLOGY, V137, P5735, DOI 10.1210/en.137.12.5735; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Weng GZ, 1999, SCIENCE, V284, P92, DOI 10.1126/science.284.5411.92; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105	52	89	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34411	34416		10.1074/jbc.274.48.34411	http://dx.doi.org/10.1074/jbc.274.48.34411			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567420	hybrid			2022-12-25	WOS:000083857500085
J	El-Hayek, R; Saiki, Y; Yamamoto, T; Ikemoto, N				El-Hayek, R; Saiki, Y; Yamamoto, T; Ikemoto, N			A postulated role of the near amino-terminal domain of the ryanodine receptor in the regulation of the sarcoplasmic reticulum Ca2+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; CENTRAL CORE DISEASE; SKELETAL-MUSCLE; MALIGNANT HYPERTHERMIA; FEET STRUCTURES; PROTEIN; GENE; CALMODULIN; EXPRESSION; MUTATION	To test the hypothesis that interactions among several putative domains of the ryanodine receptor (RyR) are involved in the regulation of its Ca2+ release channel, we synthesized several peptides corresponding to selected NH2-terminal regions of the RyR, We then examined their effects on ryanodine binding and Ca2+ release activities of the sarcoplasmic reticulum isolated from skeletal and cardiac muscle. Peptides 1-2s, 1-2c, and 1 enhanced ryanodine binding to cardiac RyR and induced a rapid Ca2+ release from cardiac SR in a dose-dependent manner. The order of the potency for the activation of the Ca2+ release channel was 1-2c > 1 > 1-2s, Interestingly, these peptides produced significant activation of the cardiac RyR at near zero or subactivating [Ca2+], indicating that the peptides enhanced the Ca2+ sensitivity of the channel. Peptides 1-2c, 1-2s, and 1 had virtually no effect on skeletal RyR, although occasional and variable extents of activation were observed in ryanodine binding assays performed at 36 degrees C, Peptide 3 affected neither cardiac nor skeletal RyR, We propose that domains 1 and 1-2 of the RyR, to which these activating peptides correspond, would interact with one or more other domains within the RyR (including presumably the Ca2+-binding domain) to regulate the Ca2+ channel.	Boston Biomed Res Inst, Dept Muscle Res, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA	Boston Biomedical Research Institute; Harvard University; Harvard Medical School	Ikemoto, N (corresponding author), Boston Biomed Res Inst, Dept Muscle Res, 20 Staniford St, Boston, MA 02114 USA.	ikemoto@bbri.org			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR016922] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR16922] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aghdasi B, 1997, J BIOL CHEM, V272, P3739, DOI 10.1074/jbc.272.6.3739; CHEN SRW, 1993, J BIOL CHEM, V268, P13414; CHEN SRW, 1994, J BIOL CHEM, V269, P22698; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; ELHAYEK R, 1995, J BIOL CHEM, V270, P15634, DOI 10.1074/jbc.270.26.15634; ELHAYEK R, 1995, J BIOL CHEM, V270, P28696, DOI 10.1074/jbc.270.48.28696; ELHAYEK R, 1995, AM J PHYSIOL-CELL PH, V268, pC1381, DOI 10.1152/ajpcell.1995.268.6.C1381; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FILL M, 1990, BIOPHYS J, V57, P471, DOI 10.1016/S0006-3495(90)82563-7; FRANZINI.C, 1970, J CELL BIOL, V47, P488, DOI 10.1083/jcb.47.2.488; FUJII J, 1991, SCIENCE, V253, P448, DOI 10.1126/science.1862346; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GILLARD EF, 1991, GENOMICS, V11, P751, DOI 10.1016/0888-7543(91)90084-R; GILLARD EF, 1992, GENOMICS, V13, P1247, DOI 10.1016/0888-7543(92)90042-Q; IKEMOTO N, 1988, METHOD ENZYMOL, V157, P469; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P15637; INUI M, 1987, J BIOL CHEM, V262, P1740; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; MACLENNAN DH, 1992, SCIENCE, V256, P789, DOI 10.1126/science.1589759; MACLENNAN DH, 1995, RYANODINE RECEPTORS, P155; MACLENNAN DH, 1994, CALCIUM CELL SIGNAL, P141; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Mickelson JR, 1996, PHYSIOL REV, V76, P537, DOI 10.1152/physrev.1996.76.2.537; MICKELSON JR, 1988, J BIOL CHEM, V263, P9310; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; OTSU K, 1990, J BIOL CHEM, V265, P13472; PHILLIPS MS, 1994, HUM MOL GENET, V3, P2181, DOI 10.1093/hmg/3.12.2181; QUANE KA, 1993, NAT GENET, V5, P51, DOI 10.1038/ng0993-51; QUANE KA, 1994, HUM MOL GENET, V3, P471, DOI 10.1093/hmg/3.3.471; Saiki Y, 1999, BIOCHEMISTRY-US, V38, P3112, DOI 10.1021/bi982250m; SEILER S, 1984, J BIOL CHEM, V259, P8550; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; STERN MD, 1992, FASEB J, V6, P3092, DOI 10.1096/fasebj.6.12.1325933; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; Tong JF, 1997, J BIOL CHEM, V272, P26332, DOI 10.1074/jbc.272.42.26332; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; Wagenknecht T, 1996, BIOPHYS J, V70, P1709, DOI 10.1016/S0006-3495(96)79733-3; Wu YL, 1997, J BIOL CHEM, V272, P25051, DOI 10.1074/jbc.272.40.25051; YAMADA S, 1980, J BIOL CHEM, V255, P3108; Yoshikawa F, 1999, J BIOL CHEM, V274, P328, DOI 10.1074/jbc.274.1.328; ZHANG YL, 1993, NAT GENET, V5, P46, DOI 10.1038/ng0993-46; Zorzato F, 1996, J BIOL CHEM, V271, P22759, DOI 10.1074/jbc.271.37.22759	47	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33341	33347		10.1074/jbc.274.47.33341	http://dx.doi.org/10.1074/jbc.274.47.33341			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559212	hybrid			2022-12-25	WOS:000083745200028
J	Lien, E; Sellati, TJ; Yoshimura, A; Flo, TH; Rawadi, G; Finberg, RW; Carroll, JD; Espevik, T; Ingalls, RR; Radolf, JD; Golenbock, DT				Lien, E; Sellati, TJ; Yoshimura, A; Flo, TH; Rawadi, G; Finberg, RW; Carroll, JD; Espevik, T; Ingalls, RR; Radolf, JD; Golenbock, DT			Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORRELIA-BURGDORFERI LIPOPROTEINS; TUMOR-NECROSIS-FACTOR; FACTOR-KAPPA-B; JARISCH-HERXHEIMER REACTION; OUTER SURFACE LIPOPROTEINS; LYME-DISEASE SPIROCHETE; PROTEIN-KINASE PATHWAYS; TREPONEMA-PALLIDUM; DROSOPHILA TOLL; MEMBRANE LIPOPROTEINS	Toll-like receptors (TLRs) 2 and 4 are signal transducers for lipopolysaccharide, the major proinflammatory constituent in the outer membrane of Gram-negative bacteria. We observed that membrane lipoproteins/lipopeptides from Borrelia burgdorferi, Treponema pallidum, and Mycoplasma fermentans activated cells heterologously expressing TLR2 but not those expressing TLR1 or TLR4. These TLR2-expressing cells were also stimulated by living motile B. burgdorferi, suggesting that TLR2 recognition of lipoproteins is relevant to natural Borrelia infection, Importantly, a TLR2 antibody inhibited bacterial lipoprotein/lipopeptide-induced tumor necrosis factor release from human peripheral blood mononuclear cells, and TLR2-null Chinese hamster macrophages were insensitive to lipoprotein/lipopeptide challenge. The data suggest a role for the native protein in cellular activation by these ligands, In addition, TLR2-dependent responses were seen using whole Mycobacterium avium and Staphylococcus aureus, demonstrating that this receptor can function as a signal transducer for a wide spectrum of bacterial products. We conclude that diverse pathogens activate cells through TLR2 and propose that this molecule is a central pattern recognition receptor in host immune responses to microbial invasion.	Boston Univ, Sch Med, Boston Med Ctr, Maxwell Finland Lab Infect Dis, Boston, MA 02118 USA; Norwegian Univ Sci & Technol, Inst Canc Res & Mol Biol, N-7489 Trondheim, Norway; Inst Pasteur, Dept Bacteriol, F-75724 Paris 15, France; Boston Univ, Sch Med, Dept Med, Boston Vet Affairs Med Ctr, Boston, MA 02130 USA; Dana Farber Canc Inst, Infect Dis Lab, Boston, MA 02115 USA	Boston Medical Center; Boston University; Norwegian University of Science & Technology (NTNU); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Boston University; Harvard University; Dana-Farber Cancer Institute	Golenbock, DT (corresponding author), Boston Univ, Sch Med, Boston Med Ctr, Maxwell Finland Lab Infect Dis, 774 Albany St, Boston, MA 02118 USA.	Douglas.Golenbock@bmc.org	Flo, Trude Helen/E-1311-2013; Sellati, Timothy/ABE-8023-2021; Finberg, Robert W/E-3323-2010	Flo, Trude Helen/0000-0002-2569-0381; Rawadi, Georges/0000-0003-4735-2188; Ingalls, Robin/0000-0003-2197-7198	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI038515, F32AI009973, K08AI001476] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054060, R37GM054060] Funding Source: NIH RePORTER; NIAID NIH HHS [AI38515, AI01476, F32 AI009973] Funding Source: Medline; NIGMS NIH HHS [GM54060] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; BELISLE JT, 1994, J BACTERIOL, V176, P2151, DOI 10.1128/JB.176.8.2151-2157.1994; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; BURMAN WJ, 1996, PROGR RES TREATMENT, P79; Chaudhary PM, 1998, BLOOD, V91, P4020, DOI 10.1182/blood.V91.11.4020.411a44_4020_4027; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; DELUDE RL, 1994, J BIOL CHEM, V269, P22253; DELUDE RL, 1995, P NATL ACAD SCI USA, V92, P9288, DOI 10.1073/pnas.92.20.9288; Delude RL, 1998, J IMMUNOL, V161, P3001; DEOGNY L, 1994, PEPTIDE RES, V7, P91; Ebnet K, 1997, J IMMUNOL, V158, P3285; ESPEVIK T, 1993, EUR J IMMUNOL, V23, P255, DOI 10.1002/eji.1830230140; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; FIKRIG E, 1990, SCIENCE, V250, P553, DOI 10.1126/science.2237407; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Garcia J, 1998, J BIOL CHEM, V273, P34391, DOI 10.1074/jbc.273.51.34391; GOLENBOCK DT, 1993, J BIOL CHEM, V268, P22055; HARDY PH, 1983, P SOC EXP BIOL MED, V174, P47; Heine H, 1999, J IMMUNOL, V162, P6971; Hirschfeld M, 1999, J IMMUNOL, V163, P2382; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Knigge H, 1996, EUR J IMMUNOL, V26, P2299, DOI 10.1002/eji.1830261005; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lien E, 1998, BLOOD, V92, P2084, DOI 10.1182/blood.V92.6.2084.418k26_2084_2092; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; LUKEHART SA, 1994, HARRISONS PRINCIPLES, P726; MA Y, 1993, INFECT IMMUN, V61, P3843, DOI 10.1128/IAI.61.9.3843-3853.1993; Medvedev AE, 1998, J IMMUNOL, V160, P4535; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Morrison TB, 1997, J IMMUNOL, V158, P4838; Muhlradt PF, 1997, J EXP MED, V185, P1951, DOI 10.1084/jem.185.11.1951; NEGUSSIE Y, 1992, J EXP MED, V175, P1207, DOI 10.1084/jem.175.5.1207; Norgard MV, 1996, INFECT IMMUN, V64, P3845, DOI 10.1128/IAI.64.9.3845-3852.1996; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; RADOLF JD, 1991, J IMMUNOL, V147, P1968; RADOLF JD, 1995, J IMMUNOL, V154, P2866; Rawadi G, 1998, J IMMUNOL, V160, P1330; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Savedra R, 1996, J IMMUNOL, V157, P2549; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Sellati TJ, 1999, J IMMUNOL, V163, P2049; Sellati TJ, 1996, INFECT IMMUN, V64, P3180, DOI 10.1128/IAI.64.8.3180-3187.1996; Sellati TJ, 1998, J IMMUNOL, V160, P5455; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; TAKAYAMA K, 1987, INFECT IMMUN, V55, P2311, DOI 10.1128/IAI.55.9.2311-2313.1987; VOGEL SN, 1980, J IMMUNOL, V124, P2004; WEIDEMANN B, 1994, INFECT IMMUN, V62, P4709, DOI 10.1128/IAI.62.11.4709-4715.1994; WEIS JJ, 1994, INFECT IMMUN, V62, P4632, DOI 10.1128/IAI.62.10.4632-4636.1994; Williams MJ, 1997, EMBO J, V16, P6120, DOI 10.1093/emboj/16.20.6120; Wooten RM, 1998, J IMMUNOL, V160, P5485; WRIGHT SD, 1995, J IMMUNOL, V155, P6; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Yoshimura A, 1999, J IMMUNOL, V163, P1; YOUNG EJ, 1982, J INFECT DIS, V146, P606, DOI 10.1093/infdis/146.5.606; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611; ZHANG YH, 1993, J CLIN INVEST, V91, P2076, DOI 10.1172/JCI116430	61	751	793	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33419	33425		10.1074/jbc.274.47.33419	http://dx.doi.org/10.1074/jbc.274.47.33419			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559223	hybrid			2022-12-25	WOS:000083745200039
J	Lopez, MM; Yutani, K; Makhatadze, GI				Lopez, MM; Yutani, K; Makhatadze, GI			Interactions of the major cold shock protein of Bacillus subtilis CspB with single-stranded DNA templates of different base composition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEIC ACID INTERACTIONS; NON-COOPERATIVE BINDING; SOLUTION NMR STRUCTURE; ESCHERICHIA-COLI; TRANSCRIPTION TERMINATION; MESSENGER-RNA; UNTRANSLATED REGION; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; LOW-TEMPERATURE	CspB is a small acidic protein of Bacillus subtilis, the induction of which is increased dramatically in response to cold shock. Although the exact functional role of CspB is unknown, it has been demonstrated that this protein binds single-stranded deoxynucleic acids (ssDNA). We addressed the question of the effect of base composition on the CspB binding to ssDNA by analyzing the thermodynamics of CspB interactions with model oligodeoxynucleotides. Combinations of four different techniques, fluorescence spectroscopy, gel shift mobility assays, isothermal titration calorimetry, and analytical ultracentrifugation, allowed us to show that: 1) CspB can preferentially bind poly-pyrimidine but not poly-purine ssDNA templates; 2) binding to T-based ssDNA template occurs with high affinity (K-d(25 degrees C) approximate to 42 nM) and is salt-independent, whereas binding of CspB to C-based ssDNA template is strongly salt-dependent (no binding is observed at 1 M NaCl), indicating large electrostatic component involved in the interactions; 3) upon binding each CspB covers a stretch of 6-7 thymine bases on T-based ssDNA; and 4) the binding of CspB to T-based ssDNA template is enthalpically driven, indicating the possible involvement of interactions between aromatic side chains on the protein with the thymine bases, The significance of these results with respect to the functional role of CspB in the bacterial cold shock response is discussed.	Texas Tech Univ, Dept Chem & Biochem, Lubbock, TX 79409 USA; Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan	Texas Tech University System; Texas Tech University; Osaka University	Makhatadze, GI (corresponding author), Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA.	makhatadze@psu.edu						ADHYA S, 1978, ANNU REV BIOCHEM, V47, P967, DOI 10.1146/annurev.bi.47.070178.004535; BEAMER LJ, 1992, J MOL BIOL, V227, P177, DOI 10.1016/0022-2836(92)90690-L; Brandi A, 1999, EMBO J, V18, P1653, DOI 10.1093/emboj/18.6.1653; COHEN G, 1968, BIOPOLYMERS, V6, P1077, DOI 10.1002/bip.1968.360060805; EPSTEIN IR, 1978, BIOPHYS CHEM, V8, P327, DOI 10.1016/0301-4622(78)80015-5; Etchegaray JP, 1999, J BACTERIOL, V181, P1827, DOI 10.1128/JB.181.6.1827-1830.1999; Fang L, 1998, J BACTERIOL, V180, P90, DOI 10.1128/JB.180.1.90-95.1998; Fang L, 1997, MOL MICROBIOL, V23, P355, DOI 10.1046/j.1365-2958.1997.2351592.x; Feng WQ, 1998, BIOCHEMISTRY-US, V37, P10881, DOI 10.1021/bi980269j; FERRARI ME, 1994, J MOL BIOL, V236, P106, DOI 10.1006/jmbi.1994.1122; Fried MG, 1996, BIOCHEMISTRY-US, V35, P15295, DOI 10.1021/bi960971k; GOLDSTEIN J, 1990, P NATL ACAD SCI USA, V87, P283, DOI 10.1073/pnas.87.1.283; GRAUMANN P, 1994, FEBS LETT, V338, P157, DOI 10.1016/0014-5793(94)80355-2; Graumann PL, 1999, ARCH MICROBIOL, V171, P135, DOI 10.1007/s002030050690; Graumann PL, 1998, TRENDS BIOCHEM SCI, V23, P286, DOI 10.1016/S0968-0004(98)01255-9; Hanna MM, 1998, J MOL BIOL, V282, P227, DOI 10.1006/jmbi.1998.2005; Henkin TM, 1996, ANNU REV GENET, V30, P35, DOI 10.1146/annurev.genet.30.1.35; HYRE DE, 1995, BIOCHEMISTRY-US, V34, P3212, DOI 10.1021/bi00010a010; INMAN RB, 1964, J MOL BIOL, V9, P624, DOI 10.1016/S0022-2836(64)80171-6; Jezewska MJ, 1997, BIOPHYS CHEM, V64, P253, DOI 10.1016/S0301-4622(96)02221-1; Jezewska MJ, 1996, BIOCHEMISTRY-US, V35, P2117, DOI 10.1021/bi952344l; Jiang WN, 1996, GENES CELLS, V1, P965, DOI 10.1046/j.1365-2443.1996.d01-219.x; Jiang WN, 1997, J BIOL CHEM, V272, P196; Jiang WN, 1996, J BACTERIOL, V178, P4919, DOI 10.1128/jb.178.16.4919-4925.1996; JONES PG, 1987, J BACTERIOL, V169, P2092, DOI 10.1128/jb.169.5.2092-2095.1987; JONES PG, 1994, MOL MICROBIOL, V11, P811, DOI 10.1111/j.1365-2958.1994.tb00359.x; KOBLAN KS, 1992, BIOCHEMISTRY-US, V31, P57, DOI 10.1021/bi00116a010; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P1226, DOI 10.1021/bi00354a006; Kozlov AG, 1998, J MOL BIOL, V278, P999, DOI 10.1006/jmbi.1998.1738; LEE SJ, 1994, MOL MICROBIOL, V11, P833, DOI 10.1111/j.1365-2958.1994.tb00361.x; LIDE DR, 1994, CRC HDB CHEM PHYSICS, P103; LOHMAN TM, 1986, CRIT REV BIOCHEM MOL, V19, P191, DOI 10.3109/10409238609084656; LOHMAN TM, 1991, METHOD ENZYMOL, V208, P258; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; MAKHATADZE GI, 1994, PROTEIN SCI, V3, P2144, DOI 10.1002/pro.5560031127; MAKHATADZE GI, 1993, J MOL BIOL, V232, P639, DOI 10.1006/jmbi.1993.1416; MAKHATADZE GI, 1990, BIOPOLYMERS, V30, P1001, DOI 10.1002/bip.360301102; MASCOTTI DP, 1993, BIOCHEMISTRY-US, V32, P10568, DOI 10.1021/bi00091a006; MASCOTTI DP, 1992, BIOCHEMISTRY-US, V31, P8932, DOI 10.1021/bi00152a033; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MERABET E, 1995, BIOCHEMISTRY-US, V34, P8554, DOI 10.1021/bi00027a005; NEWKIRK K, 1994, P NATL ACAD SCI USA, V91, P5114, DOI 10.1073/pnas.91.11.5114; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; RAFFERTY JB, 1989, NATURE, V341, P705, DOI 10.1038/341705a0; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; RICHARDSON JP, 1993, CRIT REV BIOCHEM MOL, V28, P1, DOI 10.3109/10409239309082571; ROSENBERG M, 1979, ANNU REV GENET, V13, P319, DOI 10.1146/annurev.ge.13.120179.001535; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; SCHINDELIN H, 1992, PROTEINS, V14, P120, DOI 10.1002/prot.340140113; SCHNUCHEL A, 1993, NATURE, V364, P169, DOI 10.1038/364169a0; SCHRODER K, 1995, MOL MICROBIOL, V16, P699, DOI 10.1111/j.1365-2958.1995.tb02431.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Thieringer HA, 1998, BIOESSAYS, V20, P49; WALLACE RB, 1987, METHOD ENZYMOL, V152, P432; Wang N, 1999, J BACTERIOL, V181, P1603, DOI 10.1128/JB.181.5.1603-1609.1999; WILLIMSKY G, 1992, J BACTERIOL, V174, P6326, DOI 10.1128/JB.174.20.6326-6335.1992; WINDER AF, 1971, BIOPOLYMERS, V10, P1243, DOI 10.1002/bip.360100713; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; WISTOW G, 1990, NATURE, V344, P823, DOI 10.1038/344823c0; Wolffe Alan P., 1995, Science Progress, V78, P301; WOLFFE AP, 1992, NEW BIOL, V4, P290; WYMAN G, 1990, BINDING LINKAGE; Yamanaka K, 1998, MOL MICROBIOL, V27, P247, DOI 10.1046/j.1365-2958.1998.00683.x; YANG AS, 1995, J MOL BIOL, V252, P351, DOI 10.1006/jmbi.1995.0502	67	65	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33601	33608		10.1074/jbc.274.47.33601	http://dx.doi.org/10.1074/jbc.274.47.33601			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559248	hybrid			2022-12-25	WOS:000083745200064
J	Michigami, T; Suga, A; Yamazaki, M; Shimizu, C; Cai, GM; Okada, S; Ozono, K				Michigami, T; Suga, A; Yamazaki, M; Shimizu, C; Cai, GM; Okada, S; Ozono, K			Identification of amino acid sequence in the hinge region of human vitamin D receptor that transfers a cytosolic protein to the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; LOCALIZATION SIGNAL; LIVING CELLS; SUBCELLULAR-DISTRIBUTION; GLUCOCORTICOID RECEPTOR; PROGESTERONE-RECEPTOR; BINDING PROTEINS; THYROID-HORMONE; MECHANISMS; ACTIVATION	The localization of human vitamin D receptor (VDR) in the absence of its ligand 1,25-dihydroxyvitamin D-3 was investigated using chimera proteins fused to green fluorescent protein (GFP) at either the N or C terminus, and the nuclear localization signal (NLS) was identified. Plasmids carrying the fusion proteins were transiently or stably introduced into COS7 cells, and the subcellular distribution of the fusion proteins was examined. GFP-tagged wild-type VDRs were located predominantly in nuclei but with a significant cytoplasmic presence, while GFP alone was equally distributed throughout the cells. 10(-8) M 1,25-dihydroxyvitamin D-3 promoted the nuclear import of VDR in a few hours. To identify the NLS, we constructed several mutated VDRs fused to GFP. Mutant VDRs that did not bind to DNA were also localized predominantly in:nuclei, while the deletion of the hinge region resulted in the loss of preference for nucleus. A short segment of 20 amino acids in the hinge region enabled cytoplasmic GFP-tagged alkaline phosphatase to translocate to nuclei. These results indicate that 1) VDR is located predominantly in nuclei with a significant presence in cytoplasm without the ligand and 2) an NLS consisting of 20 amino acids in the hinge region facilitates the transfer of VDR to the nucleus.	Osaka Med Ctr, Dept Environm Med, Osaka 5941101, Japan; Res Inst Maternal & Child Hlth, Osaka 5941101, Japan; Osaka Univ, Grad Sch Med, Dept Pediat, Suita, Osaka 5650871, Japan	Osaka Medical Center for Cancer & Cardiovascular Diseases; Osaka University	Ozono, K (corresponding author), Osaka Med Ctr, Dept Environm Med, 849 Murodo Cho, Osaka 5941101, Japan.		Michigami, Toshimi/AAU-2326-2021					BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BARSONY J, 1990, J CELL BIOL, V111, P2385, DOI 10.1083/jcb.111.6.2385; Barsony J, 1997, J BIOL CHEM, V272, P5774, DOI 10.1074/jbc.272.9.5774; BIDWELL JP, 1994, J CELL BIOCHEM, V54, P494, DOI 10.1002/jcb.240540417; Cai GM, 1998, J CLIN ENDOCR METAB, V83, P3936, DOI 10.1210/jc.83.11.3936; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CLEMENS TL, 1988, ENDOCRINOLOGY, V122, P1224, DOI 10.1210/endo-122-4-1224; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Danila DC, 1999, P NATL ACAD SCI USA, V96, P669, DOI 10.1073/pnas.96.2.669; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; Fejes-Toth G, 1998, P NATL ACAD SCI USA, V95, P2973, DOI 10.1073/pnas.95.6.2973; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GuiochonMantel A, 1996, J STEROID BIOCHEM, V56, P3, DOI 10.1016/0960-0760(95)00268-5; GUIOCHONMANTEL A, 1989, CELL, V57, P1147, DOI 10.1016/0092-8674(89)90052-4; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; Hsieh JC, 1998, J CELL BIOCHEM, V70, P94, DOI 10.1002/(SICI)1097-4644(19980701)70:1<94::AID-JCB10>3.3.CO;2-Q; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; ICHIKAWA K, 1991, LIFE SCI, V49, P1513, DOI 10.1016/0024-3205(91)90323-4; Ishidate T, 1997, FEBS LETT, V409, P237, DOI 10.1016/S0014-5793(97)00455-9; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KAMIMURA S, 1995, J BIOL CHEM, V270, P22160, DOI 10.1074/jbc.270.38.22160; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LEE Y, 1993, J BIOL CHEM, V268, P2021; Lemon BD, 1997, MOL CELL BIOL, V17, P1923, DOI 10.1128/MCB.17.4.1923; LUO ZJ, 1994, EUR J BIOCHEM, V223, P381, DOI 10.1111/j.1432-1033.1994.tb19004.x; LYONS RH, 1987, MOL CELL BIOL, V7, P2451, DOI 10.1128/MCB.7.7.2451; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MILDE P, 1989, J HISTOCHEM CYTOCHEM, V37, P1609, DOI 10.1177/37.11.2553800; Nakajima S, 1998, MOL CELL ENDOCRINOL, V139, P15, DOI 10.1016/S0303-7207(98)00077-X; Nakielny S, 1996, J CELL BIOL, V134, P1365, DOI 10.1083/jcb.134.6.1365; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; Ohyama Y, 1996, J BIOL CHEM, V271, P30381, DOI 10.1074/jbc.271.48.30381; OZONO K, 1990, J BIOL CHEM, V265, P21881; Pike J. W., 1997, Vitamin D., P105; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; ROBERTSON NM, 1993, MOL ENDOCRINOL, V7, P1226, DOI 10.1210/me.7.9.1226; ROSS AC, 1993, FASEB J, V7, P317, DOI 10.1096/fasebj.7.2.8440409; Sackey FNA, 1996, MOL ENDOCRINOL, V10, P1191, DOI 10.1210/me.10.10.1191; Shields JM, 1997, J BIOL CHEM, V272, P18504, DOI 10.1074/jbc.272.29.18504; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; SONE T, 1991, J BIOL CHEM, V266, P23296; Tyagi RK, 1998, MOL ENDOCRINOL, V12, P1684, DOI 10.1210/me.12.11.1684; WALTERS MR, 1980, J BIOL CHEM, V255, P6799; WHITE MP, 1994, ENDOCR REV, V15, P439	49	47	48	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33531	33538		10.1074/jbc.274.47.33531	http://dx.doi.org/10.1074/jbc.274.47.33531			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559238	hybrid			2022-12-25	WOS:000083745200054
J	Tucker, SJ; Ashcroft, FM				Tucker, SJ; Ashcroft, FM			Mapping of the physical interaction between the intracellular domains of an inwardly rectifying potassium channel, Kir6.2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; K+ CHANNELS; MOLECULAR DETERMINANTS; SULFONYLUREA RECEPTOR; ATP; INHIBITION; SUBUNIT; REGIONS	The amino-terminal and carboxyl-terminal domains of inwardly rectifying potassium (Kir) channel subunits are both intracellular. There is increasing evidence that both of these domains are required for the regulation of Kir channels by agents such as G-proteins and nucleotides. Kir6.2 is the pore-forming subunit of the ATP-sensitive K(+) (K(ATP)) channel. Using an in vitro protein-protein interaction assay, we demonstrate that the two intracellular domains of Kir6.2 physically interact with each other, and we map a region within the N terminus that is responsible for this interaction. "Cross-talk" through this interaction may explain how mutations in either the N or C terminus can influence the intrinsic ATP-sensitivity of Kir6.2. Interestingly, the "interaction domain" is highly conserved throughout the superfamily of Kir channels. The N-terminal interaction domain of Kir6.2 can also interact with the C terminus of both Kir6.1 and Kir2.1. Furthermore, a mutation within the conserved region of the N-terminal interaction domain, which disrupts its interaction with the C terminus, severely compromised the ability of both Kir6.2 and Kir2.1 to form functional channels, suggesting that this interaction may be a feature common to all members of the Kir family of potassium channels.	Univ Oxford, Physiol Lab, Oxford OX1 3PT, England	University of Oxford	Tucker, SJ (corresponding author), Univ Oxford, Physiol Lab, Parks Rd, Oxford OX1 3PT, England.	stephen.tucker@physiol.ox.ac.uk	Tucker, Stephen J./ABE-6741-2020; Tucker, Stephen J./ABE-7468-2020	Tucker, Stephen J./0000-0001-8996-2000; Tucker, Stephen J./0000-0001-8996-2000				Babenko AP, 1999, BIOCHEM BIOPH RES CO, V255, P231, DOI 10.1006/bbrc.1999.0172; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Drain P, 1998, P NATL ACAD SCI USA, V95, P13953, DOI 10.1073/pnas.95.23.13953; Fink M, 1996, FEBS LETT, V378, P64, DOI 10.1016/0014-5793(95)01388-1; Gribble FM, 1997, J PHYSIOL-LONDON, V498, P87, DOI 10.1113/jphysiol.1997.sp021843; Huang CL, 1997, FEBS LETT, V405, P291, DOI 10.1016/S0014-5793(97)00197-X; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Jan LY, 1997, J PHYSIOL-LONDON, V505, P267, DOI 10.1111/j.1469-7793.1997.267bb.x; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; Kondo C, 1998, RECEPTOR CHANNEL, V6, P129; Koster JC, 1998, BIOPHYS J, V74, P1821, DOI 10.1016/S0006-3495(98)77892-0; Koster JC, 1999, J PHYSIOL-LONDON, V515, P19, DOI 10.1111/j.1469-7793.1999.019ad.x; Proks P, 1999, J PHYSIOL-LONDON, V514, P19, DOI 10.1111/j.1469-7793.1999.019af.x; Reimann F, 1999, J PHYSIOL-LONDON, V518, P325, DOI 10.1111/j.1469-7793.1999.0325p.x; Reimann F, 1999, CURR OPIN CELL BIOL, V11, P503, DOI 10.1016/S0955-0674(99)80073-8; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Schulte U, 1998, J BIOL CHEM, V273, P34575, DOI 10.1074/jbc.273.51.34575; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; SLESINGER PA, 1995, NEURON, V15, P1145, DOI 10.1016/0896-6273(95)90102-7; Stevens EB, 1997, J PHYSIOL-LONDON, V503, P547, DOI 10.1111/j.1469-7793.1997.547bg.x; Tanabe K, 1999, J BIOL CHEM, V274, P3931, DOI 10.1074/jbc.274.7.3931; Tinker A, 1996, CELL, V87, P857, DOI 10.1016/S0092-8674(00)81993-5; Trapp S, 1998, J GEN PHYSIOL, V112, P325, DOI 10.1085/jgp.112.3.325; Tucker SJ, 1996, AM J PHYSIOL-HEART C, V271, pH379, DOI 10.1152/ajpheart.1996.271.1.H379; Tucker SJ, 1998, EMBO J, V17, P3290, DOI 10.1093/emboj/17.12.3290; Tucker SJ, 1996, J BIOL CHEM, V271, P5866, DOI 10.1074/jbc.271.10.5866; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Varnum MD, 1997, SCIENCE, V278, P110, DOI 10.1126/science.278.5335.110; Woodward R, 1997, J BIOL CHEM, V272, P10823; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	31	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33393	33397		10.1074/jbc.274.47.33393	http://dx.doi.org/10.1074/jbc.274.47.33393			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559219	hybrid			2022-12-25	WOS:000083745200035
J	Azarkina, N; Siletsky, S; Borisov, V; von Wachenfeldt, C; Hederstedt, L; Konstantinov, AA				Azarkina, N; Siletsky, S; Borisov, V; von Wachenfeldt, C; Hederstedt, L; Konstantinov, AA			A cytochrome bb '-type quinol oxidase in Bacillus subtilis strain 168	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AEROBIC RESPIRATORY-CHAIN; CARBON-MONOXIDE BINDING; ESCHERICHIA-COLI; TERMINAL OXIDASE; C-OXIDASE; AZOTOBACTER-VINELANDII; HEME-A; PARACOCCUS-DENITRIFICANS; MENAQUINOL OXIDASE; UBIQUINOL OXIDASE	The aerobic respiratory system of Bacillus subtilis 168 is known to contain three terminal oxidases: cytochrome caa(3), which is a cytochrome c oxidase, and cytochrome aa, and bd, which are quinol oxidases. The presence of a possible fourth oxidase in the bacterium was investigated using a constructed mutant, LUH27, that lacks the aa(3) and caa(3) terminal oxidases and is also deficient in succinate:menaquinone oxidoreductase, The cytochrome bd content of LUH27 can be varied by using different growth conditions. LUH27 membranes virtually devoid of cytochrome bd respired with NADH or exogenous quinol as actively as preparations containing 0.4 nmol of cytochrome bd/mg of protein but were more sensitive to cyanide and aurachin D. The reduced minus oxidized difference spectra of the bd-deficient membranes as well as absorption changes induced by CO and cyanide indicated the presence of a "cytochrome o"-like component; however, the membranes did not contain heme O. The results provide strong evidence for the presence of a terminal oxidase of the bb' type in B. subtilis. The enzyme does not pump protons and combines with CO much faster than typical heme-copper oxidases; in these respects, it resembles a cytochrome bd rather than members of the heme-copper oxidase super-family. The genome sequence of B. subtilis 168 contains gene clusters for four respiratory oxidases. Two of these clusters, cfa and qox are deleted in LUH27. The remaining two, cydAB and ythAB, encode the identified cytochrome bd and a putative second cytochrome bd, respectively, Deletion of ythAB in strain LUH27 or the presence of the yth genes on plasmid did not affect the expression of the bb' oxidase. It is concluded that the novel bb'-type oxidase probably is cytochrome bd encoded by the cyd locus but with heme D being substituted by high spin heme B at the oxygen reactive site, i.e. cytochrome b(558)b(595)b'.	Lund Univ, Dept Microbiol, Solvegatan 12, SE-22362 Lund, Sweden; Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia	Lund University; Lomonosov Moscow State University	Hederstedt, L (corresponding author), Lund Univ, Dept Microbiol, Solvegatan 12, SE-22362 Lund, Sweden.	Lars.Hederstedt@mikrbiol.lu.se	Siletsky, Sergey A./D-8076-2012; Borisov, Vitaliy B/C-9504-2012	Borisov, Vitaliy B/0000-0002-3400-9068; Hederstedt, Lars/0000-0002-6650-6296				AZARKINA NV, 1995, BIOCHEMISTRY-MOSCOW+, V60, P211; BARQUERA B, 1996, EBEC SHORT REP, V9, P79; BERGSMA J, 1982, EUR J BIOCHEM, V128, P151; Bertsova YV, 1997, FEBS LETT, V414, P369, DOI 10.1016/S0014-5793(97)01047-8; Borisov V, 1999, BIOCHEMISTRY-US, V38, P740, DOI 10.1021/bi981908t; COLLINS MD, 1981, MICROBIOL REV, V45, P316, DOI 10.1128/MMBR.45.2.316-354.1981; Cunningham L, 1997, MOL MICROBIOL, V24, P579, DOI 10.1046/j.1365-2958.1997.3561728.x; DEVRIJ W, 1987, EUR J BIOCHEM, V166, P589; FRIDEN H, 1987, FEMS MICROBIOL LETT, V41, P203; GARCIAHORSMAN JA, 1994, BIOCHEMISTRY-US, V33, P3113, DOI 10.1021/bi00176a046; Gilmour R, 1997, J BACTERIOL, V179, P863, DOI 10.1128/jb.179.3.863-870.1997; GRAY KA, 1994, BIOCHEMISTRY-US, V33, P3120, DOI 10.1021/bi00176a047; Grinkevich VA, 1997, BIOCHEMISTRY-MOSCOW+, V62, P718; GueroutFleury AM, 1995, GENE, V167, P335, DOI 10.1016/0378-1119(95)00652-4; HAGERHALL C, 1992, BIOCHEMISTRY-US, V31, P7411, DOI 10.1021/bi00147a028; HEDERSTEDT L, 1986, METHOD ENZYMOL, V126, P399; HILL BC, 1994, BIOCHEMISTRY-US, V33, P15110, DOI 10.1021/bi00254a021; HOCH JA, 1991, METHOD ENZYMOL, V204, P305; Hoffmann T, 1998, J BACTERIOL, V180, P186, DOI 10.1128/JB.180.1.186-189.1998; Johansson P, 1999, MICROBIOL-SGM, V145, P529, DOI 10.1099/13500872-145-3-529; Junemann S, 1997, BIOCHEMISTRY-US, V36, P9323, DOI 10.1021/bi970055m; JUNEMANN S, 1995, J BIOL CHEM, V270, P16213, DOI 10.1074/jbc.270.27.16213; JUNEMANN S, 1995, BIOCHEM SOC T, V23, pS157; Junemann S, 1997, BBA-BIOENERGETICS, V1321, P107, DOI 10.1016/S0005-2728(97)00046-7; KELLY MJS, 1990, J BACTERIOL, V172, P6010, DOI 10.1128/jb.172.10.6010-6019.1990; KITA K, 1984, J BIOL CHEM, V259, P3368; KITA K, 1984, J BIOL CHEM, V259, P3375; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LAURAEUS M, 1991, EUR J BIOCHEM, V197, P699, DOI 10.1111/j.1432-1033.1991.tb15961.x; LAURAEUS M, 1993, J BIOL CHEM, V268, P11470; LAURAEUS M, 1992, BIOCHEMISTRY-US, V31, P10054, DOI 10.1021/bi00156a027; LEMMA E, 1990, ARCH MICROBIOL, V155, P62, DOI 10.1007/BF00291276; LEMMA E, 1991, BIOCHIM BIOPHYS ACTA, V1059, P281, DOI 10.1016/S0005-2728(05)80213-0; LEMMA E, 1993, ARCH MICROBIOL, V159, P574, DOI 10.1007/BF00249037; LEMMA E, 1995, ARCH MICROBIOL, V163, P432, DOI 10.1007/BF00272132; LEUNG D, 1994, FEMS MICROBIOL LETT, V119, P351, DOI 10.1111/j.1574-6968.1994.tb06912.x; LORENCE RM, 1986, BIOCHEMISTRY-US, V25, P2314, DOI 10.1021/bi00357a003; MATSUSHITA K, 1992, J BIOL CHEM, V267, P24748; MEUNIER B, 1995, BIOCHEMISTRY-US, V34, P1076, DOI 10.1021/bi00003a044; MITCHELL R, 1995, BIOCHEMISTRY-US, V34, P7576, DOI 10.1021/bi00023a003; MIYOSHIAKIYAMA T, 1993, BIOCHIM BIOPHYS ACTA, V1141, P283, DOI 10.1016/0005-2728(93)90054-J; MOODY AJ, 1993, BIOCHIM BIOPHYS ACTA, V1141, P321, DOI 10.1016/0005-2728(93)90060-S; MORGAN JE, 1993, BIOCHEMISTRY-US, V32, P11413, DOI 10.1021/bi00093a019; MUNTYAN MS, 1995, BIOCHEM BIOPH RES CO, V207, P55, DOI 10.1006/bbrc.1995.1152; Muntyan MS, 1998, FEBS LETT, V429, P216, DOI 10.1016/S0014-5793(98)00599-7; Nakano MM, 1997, J BACTERIOL, V179, P6749, DOI 10.1128/jb.179.21.6749-6755.1997; PESCHEK GA, 1995, J BIOL CHEM, V270, P27937, DOI 10.1074/jbc.270.46.27937; POOLE RK, 1994, ANTON LEEUW INT J G, V65, P289, DOI 10.1007/BF00872215; Poole RK., 1988, BACTERIAL ENERGY TRA, P231; POWERS L, 1994, BBA-BIOENERGETICS, V1183, P504, DOI 10.1016/0005-2728(94)90078-7; PUUSTINEN A, 1991, P NATL ACAD SCI USA, V88, P6122, DOI 10.1073/pnas.88.14.6122; PUUSTINEN A, 1992, BIOCHEMISTRY-US, V31, P10363, DOI 10.1021/bi00157a026; PUUSTINEN A, 1991, BIOCHEMISTRY-US, V30, P3936, DOI 10.1021/bi00230a019; RAITIO M, 1994, BBA-BIOENERGETICS, V1186, P100, DOI 10.1016/0005-2728(94)90140-6; Sakamoto J, 1996, FEMS MICROBIOL LETT, V143, P151, DOI 10.1016/0378-1097(96)00312-6; Sakamoto J, 1997, J BIOCHEM-TOKYO, V122, P764; SANTANA M, 1992, J BIOL CHEM, V267, P10225; SARASTE M, 1991, EUR J BIOCHEM, V195, P517, DOI 10.1111/j.1432-1033.1991.tb15732.x; Simpson H, 1997, BIOSCIENCE REP, V17, P343, DOI 10.1023/A:1027392830495; SONE N, 1991, FEBS LETT, V288, P154, DOI 10.1016/0014-5793(91)81024-3; SUN J, 1995, BIOCHEMISTRY-US, V34, P12144, DOI 10.1021/bi00038a007; SVENSSON B, 1993, MOL MICROBIOL, V10, P193, DOI 10.1111/j.1365-2958.1993.tb00915.x; TAMEGAI H, 1994, FEBS LETT, V347, P22, DOI 10.1016/0014-5793(94)00500-1; TSUBAKI M, 1995, J BIOL CHEM, V270, P28565, DOI 10.1074/jbc.270.48.28565; VANDEROOST J, 1991, MOL MICROBIOL, V5, P2063; VILLANI G, 1995, BBA-BIOENERGETICS, V1232, P67, DOI 10.1016/0005-2728(95)00112-5; VONWACHENFELDT C, 1992, FEMS MICROBIOL LETT, V100, P91, DOI 10.1016/0378-1097(92)90194-S; VONWACHENFELDT C, 1998, EBEC SHORT REP, V10, P103; Winstedt L, 1998, J BACTERIOL, V180, P6571, DOI 10.1128/JB.180.24.6571-6580.1998; WOOD PM, 1984, BIOCHIM BIOPHYS ACTA, V768, P293, DOI 10.1016/0304-4173(84)90020-X; YU J, 1995, J BACTERIOL, V177, P6751, DOI 10.1128/jb.177.23.6751-6760.1995; Zickermann I, 1997, EUR J BIOCHEM, V246, P618, DOI 10.1111/j.1432-1033.1997.00618.x	72	53	59	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32810	32817		10.1074/jbc.274.46.32810	http://dx.doi.org/10.1074/jbc.274.46.32810			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551842	hybrid			2022-12-25	WOS:000083623000042
J	Kafert, S; Luther, S; Boll, I; Wagner, K; Ganser, A; Eder, M				Kafert, S; Luther, S; Boll, I; Wagner, K; Ganser, A; Eder, M			Functional analysis of a single chain chimeric alpha/beta-granulocyte-macrophage colony-stimulating factor receptor - Importance of a glutamate residue in the transmembrane region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMMON BETA-SUBUNIT; GM-CSF RECEPTOR; GROWTH SIGNAL-TRANSDUCTION; ERYTHROPOIETIN RECEPTOR; CYTOPLASMIC DOMAIN; IL-5 RECEPTORS; POINT MUTATION; TYROSINE PHOSPHORYLATION; EXPRESSION CLONING; NEU ONCOGENE	To analyze the function of each subunit of the receptor for granulocyte-macrophage colony-stimulating factor (GM-CSF), GMR, we previously generated a single-chain chimeric receptor by fusion of the extracellular and transmembrane domain from the alpha-subunit (alpha-GMR) to the intracellular part of the beta-subunit (beta-GMR) introducing an additional glutamate residue at the fusion site (alpha/beta-GMR). me demonstrated the capacity of alpha/beta-GMR to bind GM-CSF with low affinity and to induce GM-CSF-dependent activation of tyrosine kinase activity and proliferation in transfected Ba/F3 cells. To further compare the functions of wild type and chimeric receptors, we now report that this alpha/beta-GMR is sufficient to mediate morphological changes, expression of alpha(4)- and beta(1)-integrin receptor subunits, and serine-phosphorylation of Akt kinase. To analyze the function of the glutamate residue at the fusion region of alpha/beta-GMR various point mutants changing this amino acid and its position were expressed in Ba/F3 cells. None of these mutants was capable of supporting GM-CSF-dependent proliferation; however, when beta-GMR was coexpressed, GM-CSF mediated short and long term proliferation. Interestingly, some mutants but not alpha/beta-GMR can induce proliferation in the presence of an anti-alpha-GMR antibody. These data demonstrate the significance of a glutamate residue in the transmembrane region of alpha/beta-GMR for ligand-induced receptor activation.	Hannover Med Sch, Zentrum Innere Med, Abt Hamatol & Onkol, Dept Hematol & Oncol, D-30623 Hannover, Germany	Hannover Medical School	Eder, M (corresponding author), Hannover Med Sch, Zentrum Innere Med, Abt Hamatol & Onkol, Dept Hematol & Oncol, Carl Neuberg Str 1, D-30623 Hannover, Germany.	Matthias@MH-Hannover.de						ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Bagley CJ, 1997, BLOOD, V89, P1471, DOI 10.1182/blood.V89.5.1471.1471_1471_1482; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BHATIA R, 1994, J CLIN INVEST, V94, P384, DOI 10.1172/JCI117333; CARPENTER CD, 1991, J BIOL CHEM, V266, P5750; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DING DXH, 1994, P NATL ACAD SCI USA, V91, P2537, DOI 10.1073/pnas.91.7.2537; Doyle SE, 1998, BLOOD, V92, P867; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; EDER M, 1994, J BIOL CHEM, V269, P30173; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; JENKINS BJ, 1995, EMBO J, V14, P4276, DOI 10.1002/j.1460-2075.1995.tb00102.x; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lanier LL, 1998, NATURE, V391, P703, DOI 10.1038/35642; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; Matsuguchi T, 1997, J BIOL CHEM, V272, P17450, DOI 10.1074/jbc.272.28.17450; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MUTO A, 1995, BIOCHEM BIOPH RES CO, V208, P368, DOI 10.1006/bbrc.1995.1347; Muto A, 1996, J EXP MED, V183, P1911, DOI 10.1084/jem.183.4.1911; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOGUCHI CT, 1991, BLOOD, V78, P2548; OKUDA K, 1997, BLOOD, V90, P4579; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; RONCO LV, 1995, J IMMUNOL, V154, P3444; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; TAKAKI S, 1994, MOL CELL BIOL, V14, P7404, DOI 10.1128/MCB.14.11.7404; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WEISS M, 1993, BLOOD, V82, P3298; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Woodcock JM, 1997, BLOOD, V90, P3005, DOI 10.1182/blood.V90.8.3005; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	46	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					33064	33071		10.1074/jbc.274.46.33064	http://dx.doi.org/10.1074/jbc.274.46.33064			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551876	hybrid			2022-12-25	WOS:000083623000076
J	Kickhoefer, VA; Stephen, AG; Harrington, L; Robinson, MO; Rome, LH				Kickhoefer, VA; Stephen, AG; Harrington, L; Robinson, MO; Rome, LH			Vaults and telomerase share a common subunit, TEP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; RIBONUCLEOPROTEIN-PARTICLES; MAMMALIAN TELOMERASE; CANCER CELL; PROTEIN; RECONSTITUTION; CRYSTALLINS; DISRUPTION; COMPONENT; CONTAIN	Vaults are large cytoplasmic ribonucleoprotein complexes of undetermined function. Mammalian vaults have two high molecular mass proteins of 193 and 240 kDa. We have identified a partial cDNA encoding the 240-kDa vault protein and determined it is identical to the mammalian telomerase-associated component, TEP1. TEP1 is the mammalian homolog of the Tetrahymena: p80 telomerase protein and has been shown to interact specifically with mammalian telomerase RNA and the catalytic protein subunit hTERT. We show that while TEP1 is a component of the vault particle, vaults have no detectable telomerase activity. Using a yeast three-hybrid assay we demonstrate that several of the human vRNAs interact in a sequence-specific manner with TEP1. The presence of 16 WD40 repeats in the carboxyl terminus of the TEP1 protein is a convenient number for this protein to serve a structural or organizing role in the vault, a particle with eight-fold symmetry. The sharing of the TEP1 protein between vaults and telomerase suggests that TEP1 may play a common role in some aspect of ribonucleoprotein structure, function, or assembly.	Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; Univ Toronto, Dept Med Biophys, Ontario Canc Inst, Amgen Inc, Toronto, ON M5G 2C1, Canada; Amgen Inc, Thousand Oaks, CA 91320 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Amgen	Kickhoefer, VA (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Biol Chem, 33-257 CHS, Los Angeles, CA 90095 USA.		Rome, Leonard H/E-8786-2016; Stephen, Andrew/W-2636-2019	Rome, Leonard H/0000-0002-1236-2063; Stephen, Andrew/0000-0002-8259-621X; Kickhoefer, Valerie/0000-0002-0048-0580; Robinson, Murray/0000-0003-4462-0685	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038097] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38097] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbondanza C, 1998, J CELL BIOL, V141, P1301, DOI 10.1083/jcb.141.6.1301; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; CHUGANI DC, 1993, J CELL SCI, V106, P23; GOOD PD, 1994, GENE, V151, P209, DOI 10.1016/0378-1119(94)90658-0; Hamill DR, 1997, DEV BIOL, V190, P117, DOI 10.1006/dbio.1997.8676; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Herrmann C, 1996, J BIOL CHEM, V271, P13908, DOI 10.1074/jbc.271.23.13908; Herrmann C, 1999, J CELL BIOL, V144, P1163, DOI 10.1083/jcb.144.6.1163; Herrmann C, 1997, GENE, V188, P85, DOI 10.1016/S0378-1119(96)00781-0; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; KEDERSHA NL, 1991, J CELL BIOL, V112, P225, DOI 10.1083/jcb.112.2.225; KEDERSHA NL, 1990, J CELL BIOL, V110, P895, DOI 10.1083/jcb.110.4.895; KEDERSHA NL, 1990, MOL BIOL REP, V14, P121, DOI 10.1007/BF00360441; KEDERSHA NL, 1986, J CELL BIOL, V103, P699, DOI 10.1083/jcb.103.3.699; KICKHOEFER VA, 1994, GENE, V151, P257, DOI 10.1016/0378-1119(94)90667-X; KICKHOEFER VA, 1993, J BIOL CHEM, V268, P7868; Kickhoefer VA, 1996, TRENDS CELL BIOL, V6, P174, DOI 10.1016/0962-8924(96)10014-3; Kickhoefer VA, 1998, J BIOL CHEM, V273, P8971, DOI 10.1074/jbc.273.15.8971; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Kong LB, 1999, STRUCT FOLD DES, V7, P371, DOI 10.1016/S0969-2126(99)80050-1; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Li H, 1998, J BIOL CHEM, V273, P33436, DOI 10.1074/jbc.273.50.33436; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; PHILPOTT CC, 1994, P NATL ACAD SCI USA, V91, P7321, DOI 10.1073/pnas.91.15.7321; PIATIGORSKY J, 1989, CELL, V57, P197, DOI 10.1016/0092-8674(89)90956-2; PIATIGORSKY J, 1989, J COMP PHYSIOL A, V164, P577, DOI 10.1007/BF00614500; Rome L, 1991, Trends Cell Biol, V1, P47, DOI 10.1016/0962-8924(91)90088-Q; SCHEFFER GL, 1995, NAT MED, V1, P578, DOI 10.1038/nm0695-578; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; VASU SK, 1995, J BIOL CHEM, V270, P16588, DOI 10.1074/jbc.270.28.16588; VASU SK, 1993, J BIOL CHEM, V268, P15356; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498	34	121	133	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32712	32717		10.1074/jbc.274.46.32712	http://dx.doi.org/10.1074/jbc.274.46.32712			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551828	hybrid			2022-12-25	WOS:000083623000028
J	Kornfeld, R; Bao, M; Brewer, K; Noll, C; Canfield, W				Kornfeld, R; Bao, M; Brewer, K; Noll, C; Canfield, W			Molecular cloning and functional expression of two splice forms of human N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; EPS15 HOMOLOGY; GROWTH-FACTOR; EH DOMAIN; PROTEIN; PURIFICATION; SIGNAL; LOCALIZATION; SEQUENCE; TRAFFICKING	We have isolated and sequenced human cDNA and mouse genomic DNA clones encoding N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase (phosphodiester alpha-GlcNAcase) which catalyzes the second step in the synthesis of the mannose g-phosphate recognition signal on lysosomal enzymes. The gene is organized into 10 exons. The protein sequence encoded by the clones shows 80% identity between human and mouse phosphodiester alpha-GlcNAcase and no homology to other known proteins. It predicts a type I membrane-spanning glycoprotein of 514 amino acids containing a 24-amino acid signal sequence, a luminal. domain of 422 residues with six potential N-linked glycosylation sites, a single 27-residue transmembrane region, and a 41-residue cytoplasmic tail that contains both a tyrosine-based and an NPF internalization motif. Human brain expressed sequence tags lack a 102-base pair region present in human liver cDNA that corresponds to exon 8 in the genomic DNA and probably arises via alternative splicing. COS cells transfected with the human cDNA expressed 50-100-fold increases in phosphodiester alpha-GlcNAcase activity proving that the cDNA. encodes the subunits of the tetrameric enzyme. Transfection with cDNA lacking the 102-base pair region also gave active enzyme. The complete genomic sequence of human phosphodiester alpha-GlcNAcase was recently deposited in the data base. It showed that our cDNA clone was missing only the 5'-untranslated region and initiator methionine and revealed that the human genomic DNA has the same exon organization as the mouse gene.	Washington Univ, Sch Med, Div Hematol, Dept Med, St Louis, MO 63110 USA; Univ Oklahoma, Hlth Sci Ctr, WK Warren Med Res Inst, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK 73104 USA	Washington University (WUSTL); University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Kornfeld, R (corresponding author), Washington Univ, Sch Med, Div Hematol, Dept Med, 660 S Euclid Ave,Box 8125, St Louis, MO 63110 USA.				NATIONAL CANCER INSTITUTE [R01CA008759, R37CA008759] Funding Source: NIH RePORTER; NCI NIH HHS [CA08759] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschul Stephen F., J MOL BIOL, V215, P403, DOI [10.1016/S0022-2836(05)80360-2, DOI 10.1016/S0022-2836(05)80360-2]; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; de Beer T, 1998, SCIENCE, V281, P1357, DOI 10.1126/science.281.5381.1357; Horton R M, 1997, Methods Mol Biol, V67, P141; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; Kain R, 1998, J BIOL CHEM, V273, P981, DOI 10.1074/jbc.273.2.981; Kornfeld R, 1998, J BIOL CHEM, V273, P23203, DOI 10.1074/jbc.273.36.23203; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEE JK, 1995, ARCH BIOCHEM BIOPHYS, V319, P413, DOI 10.1006/abbi.1995.1312; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; McPherson PS, 1998, BIOCHEM BIOPH RES CO, V244, P701, DOI 10.1006/bbrc.1998.8331; MULLIS KG, 1994, J BIOL CHEM, V269, P1718; MULLIS KG, 1992, ANAL BIOCHEM, V205, P200, DOI 10.1016/0003-2697(92)90424-6; MULLIS KG, 1994, J BIOL CHEM, V269, P1727; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Paoluzi S, 1998, EMBO J, V17, P6541, DOI 10.1093/emboj/17.22.6541; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Tan PK, 1996, J CELL BIOL, V135, P1789, DOI 10.1083/jcb.135.6.1789; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VARKI A, 1981, J BIOL CHEM, V256, P9937; Yamabhai M, 1998, J BIOL CHEM, V273, P31401, DOI 10.1074/jbc.273.47.31401	27	35	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32778	32785		10.1074/jbc.274.46.32778	http://dx.doi.org/10.1074/jbc.274.46.32778			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551838	hybrid			2022-12-25	WOS:000083623000038
J	Koski, C; Saharinen, J; Keski-Oja, J				Koski, C; Saharinen, J; Keski-Oja, J			Independent promoters regulate the expression of two amino terminally distinct forms of latent transforming growth factor-beta binding protein-1 (LTBP-1) in a cell type-specific manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT COMPLEX; EXTRACELLULAR-MATRIX; 8-CYSTEINE REPEAT; GENE-EXPRESSION; HUMAN-PLATELETS; SPLICE VARIANT; MESSENGER-RNA; IDENTIFICATION; FACTOR-BETA-1; GROWTH-FACTOR-BETA-1	Latent transforming growth factor-beta (TGF-beta)-binding proteins (LTBPs) are components of the extracellular matrix and large latent TGF-beta complexes are secreted by various cells. Human LTBP-1 is known to exist in different forms. LTBP-1L (long) has an amino-terminal extension, which is not found in the smaller LTBP-1S isoform. To study the formation and transcriptional regulation of LTBP-1S and LTBP-1L isoforms, we determined the nucleotide sequences of their 5'-flanking regions. The upstream regions of both isoforms are devoid of TATA boxes but contain other putative binding sites for several transcription factors. Genomic sequencing revealed that LTBP-1L transcript is alternatively spliced to an internal splice acceptor inside exon 1 of LTBP-1S and thus defined the genomic organization of the isoforms. Reporter gene analysis of upstream regions indicated the presence of independent, functional promoters, which regulate the transcription of the isoforms by cell-specific manner. Deletion analyses of the promoter regions revealed specific elements modulating their basal and cell type-specific expression. In SV-40 virus-transformed WI-38 lung fibroblasts a regulatory element repressed the transcription of LTBP-1S by a cell-specific manner. In amniotic epithelial cells, transcription of the LTBP-1S reporter gene construct was downregulated by a distal upstream element. mRNA levels of the isoforms of LTBP-1 were stimulated in response to TGF-beta 1 in WI-38 cells. However, since TGF-beta 1 failed to stimulate the transcription of LTBP-1 reporter gene constructs, TGF-beta 1 may mediate the induction of the isoforms by post-transcriptional mechanisms. Chromosomal localization of the LTBP-1 gene was refined to 2p22-24.	Univ Helsinki, Dept Virol, Haartman Inst, FIN-00014 Helsinki, Finland	University of Helsinki	Keski-Oja, J (corresponding author), Univ Helsinki, Dept Virol, Haartman Inst, POB 21,Haartmaninkatu 3, FIN-00014 Helsinki, Finland.							Ahmed W, 1998, CONNECT TISSUE RES, V37, P263, DOI 10.3109/03008209809002444; Biery NJ, 1999, GENOMICS, V56, P70, DOI 10.1006/geno.1998.5697; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; DALLAS SL, 1994, J BIOL CHEM, V269, P6815; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EKLOV S, 1993, CANCER RES, V53, P3193; Ferrigno O, 1997, J BIOL CHEM, V272, P20502, DOI 10.1074/jbc.272.33.20502; GIBSON MA, 1995, MOL CELL BIOL, V15, P6932; Giltay R, 1997, FEBS LETT, V411, P164, DOI 10.1016/S0014-5793(97)00685-6; Gleizes PE, 1996, J BIOL CHEM, V271, P29891, DOI 10.1074/jbc.271.47.29891; Gong WR, 1998, GASTROENTEROLOGY, V114, P352, DOI 10.1016/S0016-5085(98)70488-3; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JAHROUDI N, 1994, MOL CELL BIOL, V14, P999, DOI 10.1128/MCB.14.2.999; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KIM SJ, 1989, J BIOL CHEM, V264, P19373; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KONDRAKHIN YV, 1999, IN PRESS BIOINFORMAT; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MCCARTNEYFRANCIS NL, 1994, J LEUKOCYTE BIOL, V55, P401, DOI 10.1002/jlb.55.3.401; Michel K, 1998, HEPATOLOGY, V27, P1592, DOI 10.1002/hep.510270619; MIYAZONO K, 1992, J BIOL CHEM, V267, P5668; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; MIZOI T, 1993, CANCER RES, V53, P183; MOREN A, 1994, J BIOL CHEM, V269, P32469; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; Oklu R, 1998, FEBS LETT, V425, P281, DOI 10.1016/S0014-5793(98)00257-9; Oklu R, 1998, FEBS LETT, V435, P143, DOI 10.1016/S0014-5793(98)01054-0; Olofsson A, 1995, J BIOL CHEM, V270, P31294, DOI 10.1074/jbc.270.52.31294; OLOFSSON A, 1992, J BIOL CHEM, V267, P19482; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rehn M, 1996, GENOMICS, V32, P436, DOI 10.1006/geno.1996.0139; Ritter SJ, 1998, J BIOL CHEM, V273, P12798, DOI 10.1074/jbc.273.21.12798; Saharinen J, 1996, EMBO J, V15, P245, DOI 10.1002/j.1460-2075.1996.tb00355.x; Saharinen J, 1998, J BIOL CHEM, V273, P18459, DOI 10.1074/jbc.273.29.18459; Saharinen J, 1999, CYTOKINE GROWTH F R, V10, P99, DOI 10.1016/S1359-6101(99)00010-6; SAITTA B, 1990, J BIOL CHEM, V265, P6473; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; STENMAN G, 1994, CYTOGENET CELL GENET, V66, P117, DOI 10.1159/000133680; TAIPALE J, 1995, J BIOL CHEM, V270, P4689, DOI 10.1074/jbc.270.9.4689; Taipale J, 1996, J HISTOCHEM CYTOCHEM, V44, P875, DOI 10.1177/44.8.8756760; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; TSUJI T, 1990, P NATL ACAD SCI USA, V87, P8835, DOI 10.1073/pnas.87.22.8835; VALLE M, 1962, ANN MED EXP BIOL FEN, V40, P342; WAKEFIELD LM, 1988, J BIOL CHEM, V263, P7646; Yin WS, 1998, BIOCHEM BIOPH RES CO, V245, P454, DOI 10.1006/bbrc.1998.8456; YIN WS, 1995, J BIOL CHEM, V270, P10147, DOI 10.1074/jbc.270.17.10147; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855	51	48	50	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32619	32630		10.1074/jbc.274.46.32619	http://dx.doi.org/10.1074/jbc.274.46.32619			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551816	hybrid			2022-12-25	WOS:000083623000016
J	Lewis, DA; Bebenek, K; Beard, WA; Wilson, SH; Kunkel, TA				Lewis, DA; Bebenek, K; Beard, WA; Wilson, SH; Kunkel, TA			Uniquely altered DNA replication fidelity conferred by an amino acid change in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MISPAIR EXTENSION KINETICS; SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; POLYMERASE-BETA; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; HIV-1; MECHANISM; MUTANT; RNA	Arginine 72 in human immunodeficiency virus type I reverse transcriptase (RT), a highly conserved residue among retroviral polymerases and telomerases, forms part of the binding pocket for the nascent base pair. me show here that replacement of Arg(72) by alanine strongly alters fidelity in a highly unusual manner. R72A reverse transcriptase is a frameshift and base substitution anti-mutator polymerase whose increased fidelity results both from increased nucleotide selectivity and from a decreased ability to extend mismatched primer termini. Thus, Arg(72)-substrate interactions in wild-type human immunodeficiency virus type I RT can stabilize incorrect nucleotides allowing misinsertion and promoting extension of mismatched and perhaps misaligned template-primers. In contrast to the higher fidelity at most sites, R72A RT is highly error-prone for misincorporations opposite template T in the sequence context: 5'-C (T) under bar GG. Surprisingly this results mostly from a 1200-fold increase in the apparent K-m for correct dAMP incorporation. Thus, Arg(72) interactions with substrate are critical for the stability of the correct T.dAMP base pair when the 5'-C (T) under bar GG sequence is present in the binding pocket for the nascent base pair. Collectively, the data show that a mutant polymerase may yield higher than normal average replication fidelity, yet paradoxically place specific sequences at very high risk of mutation.	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Kunkel, TA (corresponding author), NIEHS, Struct Biol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	kunkel@niehs.nih.gov	Wilson, Samuel H/E-6644-2019; Kunkel, Thomas A./D-5088-2019	Wilson, Samuel H/0000-0002-1702-5293; Kunkel, Thomas A./0000-0002-9900-1788	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050161, ZIAES050161] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahn J, 1997, BIOCHEMISTRY-US, V36, P1100, DOI 10.1021/bi961653o; Bakhanashvili M, 1996, FEBS LETT, V391, P257, DOI 10.1016/0014-5793(96)00747-8; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; BEARD WA, 1994, J BIOL CHEM, V269, P28091; BEBENEK K, 1993, J BIOL CHEM, V268, P10324; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; BEBENEK K, 1990, J BIOL CHEM, V265, P13878; Bebenek K, 1997, NAT STRUCT BIOL, V4, P194, DOI 10.1038/nsb0397-194; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BECERRA SP, 1993, PROTEIN EXPRES PURIF, V4, P187, DOI 10.1006/prep.1993.1025; Bell JB, 1997, J BIOL CHEM, V272, P7345, DOI 10.1074/jbc.272.11.7345; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BOYER JC, 1992, P NATL ACAD SCI USA, V89, P6919, DOI 10.1073/pnas.89.15.6919; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P804, DOI 10.1021/bi00217a034; CREIGHTON S, 1992, J BIOL CHEM, V267, P2633; Crothers DM, 1998, P NATL ACAD SCI USA, V95, P15163, DOI 10.1073/pnas.95.26.15163; Dornberger U, 1998, J MOL BIOL, V284, P1453, DOI 10.1006/jmbi.1998.2261; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; GOEL R, 1993, BIOCHEMISTRY-US, V32, P13012, DOI 10.1021/bi00211a009; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Kim B, 1996, J BIOL CHEM, V271, P4872, DOI 10.1074/jbc.271.9.4872; Kool ET, 1998, BIOPOLYMERS, V48, P3, DOI 10.1002/(SICI)1097-0282(1998)48:1<3::AID-BIP2>3.0.CO;2-7; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kroutil LC, 1996, BIOCHEMISTRY-US, V35, P1046, DOI 10.1021/bi952178h; Kunkel TA, 1998, NAT STRUCT BIOL, V5, P95, DOI 10.1038/nsb0298-95; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; LIPANOV A, 1993, BIOCHEMISTRY-US, V32, P1373, DOI 10.1021/bi00056a024; LOEB LA, 1982, ANNU REV BIOCHEM, V51, P429, DOI 10.1146/annurev.bi.51.070182.002241; MartinHernandez AM, 1996, EMBO J, V15, P4434, DOI 10.1002/j.1460-2075.1996.tb00816.x; MartinHernandez AM, 1997, NUCLEIC ACIDS RES, V25, P1383, DOI 10.1093/nar/25.7.1383; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Minnick DT, 1999, J BIOL CHEM, V274, P3067, DOI 10.1074/jbc.274.5.3067; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Olson WK, 1998, P NATL ACAD SCI USA, V95, P11163, DOI 10.1073/pnas.95.19.11163; Osheroff WP, 1999, J BIOL CHEM, V274, P20749, DOI 10.1074/jbc.274.30.20749; Pandey VN, 1996, BIOCHEMISTRY-US, V35, P2168, DOI 10.1021/bi9516642; PATEL PH, 1994, P NATL ACAD SCI USA, V91, P549, DOI 10.1073/pnas.91.2.549; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; PETRUSKA J, 1986, P NATL ACAD SCI USA, V83, P1559, DOI 10.1073/pnas.83.6.1559; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; SARAFIANOS SG, 1995, J BIOL CHEM, V270, P19729, DOI 10.1074/jbc.270.34.19729; TEMIN HM, 1993, P NATL ACAD SCI USA, V90, P6900, DOI 10.1073/pnas.90.15.6900; Wainberg MA, 1996, SCIENCE, V271, P1282, DOI 10.1126/science.271.5253.1282; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; YU H, 1992, J BIOL CHEM, V267, P10888	52	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32924	32930		10.1074/jbc.274.46.32924	http://dx.doi.org/10.1074/jbc.274.46.32924			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551858	hybrid			2022-12-25	WOS:000083623000058
J	Petkovic, H; Thamchaipenet, A; Zhou, LH; Hranueli, D; Raspor, P; Waterman, PG; Hunter, IS				Petkovic, H; Thamchaipenet, A; Zhou, LH; Hranueli, D; Raspor, P; Waterman, PG; Hunter, IS			Disruption of an aromatase/cyclase from the oxytetracycline gene cluster of Streptomyces rimosus results in production of novel polyketides with shorter chain lengths	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENGINEERED BIOSYNTHESIS; AROMATIC POLYKETIDE; NUCLEOTIDE-SEQUENCE; CATALYTIC SPECIFICITY; DEDUCED FUNCTIONS; COELICOLOR A3(2); SYNTHASE; CLONING; MANIPULATION; ANTIBIOTICS	Oxytetracycline is a polyketide antibiotic made by Streptomyces rimosus. From DNA sequencing, the gene product of otcD1 is deduced to function as a bifunctional cyclase/aromatase involved in ring closure of the polyketide backbone. Although otcD1 is contiguous with the ketoreductase gene, they are located an unusually large distance from the genes encoding the "minimal polyketide synthase" of the oxytetracycline gene cluster, A recombinant, disrupted in the genomic copy of otcD1, made four novel polyketides, all of shorter chain length (by up to 10 carbons) than oxytetracycline, All four novel structures contained the unusual carboxamido group, typical of oxytetracycline, This implies that the carboxamido group is present at the start of biosynthesis of oxytetracycline, a topic that has been debated in the literature, Loss of the cyclase protein has a profound influence on the length of polyketide chain assembled, implying that OtcD1 plays a greater role in the overall integrity of the quaternary structure of the polyketide complex than hitherto imagined.	Univ Strathclyde, Dept Pharmaceut Sci, Glasgow G1 1XW, Lanark, Scotland; Univ Ljubljana, Biotech FAc, Ljubljana 61000, Slovenia; Kasetsart Univ, Dept Genet, Bangkok 10900, Thailand; PLIVA DD, Res Inst, Anti Infect Res, Zagreb 10000, Croatia	University of Strathclyde; University of Ljubljana; Kasetsart University; Teva Pharmaceutical Industries; Pliva	Hunter, IS (corresponding author), Univ Strathclyde, Dept Pharmaceut Sci, Royal Coll Bldg, Glasgow G1 1XW, Lanark, Scotland.	i.s.hunter@strath.ac.uk	Thamchaipenet, Arinthip/H-7902-2019	Thamchaipenet, Arinthip/0000-0002-8749-0414				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BIBB MJ, 1985, GENE, V38, P215, DOI 10.1016/0378-1119(85)90220-3; BIBB MJ, 1994, GENE, V142, P31, DOI 10.1016/0378-1119(94)90351-4; BINNIE C, 1989, J BACTERIOL, V171, P887, DOI 10.1128/jb.171.2.887-895.1989; BUTLER MJ, 1989, MOL GEN GENET, V215, P231, DOI 10.1007/BF00339722; BUTLER MJ, 1990, DEV IND MICROBIOL, V31, P41; CHOPRA I, 1992, J ANTIMICROB CHEMOTH, V29, P245, DOI 10.1093/jac/29.3.245; DAVIS NK, 1990, MOL MICROBIOL, V4, P1679, DOI 10.1111/j.1365-2958.1990.tb00545.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FERNANDEZMORENO MA, 1992, J BIOL CHEM, V267, P19278; FU H, 1994, J AM CHEM SOC, V116, P4166, DOI 10.1021/ja00089a003; FU H, 1994, J AM CHEM SOC, V116, P6443, DOI 10.1021/ja00093a058; GATENBECK S, 1962, Biochem Biophys Res Commun, V6, P4; HALLAM SE, 1988, GENE, V74, P305, DOI 10.1016/0378-1119(88)90165-5; Hopwood D. A., 1985, GENETIC MANIPULATION; Hopwood DA, 1997, CHEM REV, V97, P2465, DOI 10.1021/cr960034i; HOPWOOD DA, 1992, CIBA F SYMP, V171, P88; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; HRANUELI D, 1979, J GEN MICROBIOL, V114, P295, DOI 10.1099/00221287-114-2-295; Hunter I. S., 1997, BIOTECHNOLOGY ANTIBI, P659; HUTCHINSON CR, 1995, ANNU REV MICROBIOL, V49, P201; KIM ES, 1994, GENE, V141, P141, DOI 10.1016/0378-1119(94)90144-9; Kramer PJ, 1997, J AM CHEM SOC, V119, P635, DOI 10.1021/ja962888q; MALPARTIDA F, 1987, NATURE, V325, P818, DOI 10.1038/325818a0; MCDANIEL R, 1994, P NATL ACAD SCI USA, V91, P11542, DOI 10.1073/pnas.91.24.11542; MCDANIEL R, 1993, J AM CHEM SOC, V115, P11671, DOI 10.1021/ja00078a002; PIGAC J, 1995, APPL ENVIRON MICROB, V61, P352, DOI 10.1128/AEM.61.1.352-356.1995; Ryan MJ, 1996, United States patent, Patent No. 5589385; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sanders J. K. M., 1987, MODERN NMR SPECTROSC; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUMMERS RG, 1992, J BACTERIOL, V174, P1810, DOI 10.1128/jb.174.6.1810-1820.1992; THOMAS R, 1983, J CHEM SOC CHEM COMM, P128, DOI 10.1039/c39830000128; THOMAS R, 1983, J CHEM SOC CHEM COMM, V7, P443; WARD JM, 1986, MOL GEN GENET, V203, P468, DOI 10.1007/BF00422072; WILLIAMS DH, 1997, METHODS ORGANIC CHEM; YE JS, 1994, J BACTERIOL, V176, P6270, DOI 10.1128/jb.176.20.6270-6280.1994; Ylihonko K, 1996, MOL GEN GENET, V251, P113; Yu TW, 1998, J AM CHEM SOC, V120, P7749, DOI 10.1021/ja9803658; YU TW, 1994, J BACTERIOL, V176, P2627, DOI 10.1128/JB.176.9.2627-2634.1994; Zawada RJX, 1997, J BIOL CHEM, V272, P16184, DOI 10.1074/jbc.272.26.16184	42	45	46	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32829	32834						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551844				2022-12-25	WOS:000083623000044
J	Qu, YS; Rogers, JC; Chen, SF; McCormick, KA; Scheuer, T; Catterall, WA				Qu, YS; Rogers, JC; Chen, SF; McCormick, KA; Scheuer, T; Catterall, WA			Functional roles of the extracellular segments of the sodium channel alpha subunit in voltage-dependent gating and modulation by beta 1 subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; NA+-CHANNEL; XENOPUS-OOCYTES; MOLECULAR DETERMINANTS; BETA(1) SUBUNIT; SLOW INACTIVATION; CALCIUM CHANNELS; MESSENGER-RNA; SCORPION TOXIN; BRAIN	Voltage-gated sodium channels consist of a pore-forming a subunit associated with beta 1 subunits and, for brain sodium channels, beta 2 subunits. Although much is known about the structure and function of the a subunit, there is little information on the functional role of the 16 extracellular loops. To search for potential functional activities of these extracellular segments, chimeras were studied in which an individual extracellular loop of the rat heart (rH1) alpha subunit was substituted for the corresponding segment of the rat brain type IIA (rIIA) alpha subunit. In comparison with rH1, wild-type rIIA alpha subunits are characterized by more positive voltage-dependent activation and inactivation, a more prominent slow gating mode, and a more substantial shift to the fast gating mode upon coexpression of beta 1 subunits in Xenopus oocytes. When a subunits were expressed alone, chimeras with substitutions from rH1 in five extracellular loops (IIS5-SS1, IISS2-S6, IIIS1-S2, IIISS2-S6, and TVS3-S4) had negatively shifted activation, and chimeras with substitutions in three of these (IISS2-S6, IIIS1-S2, and IVS3-S4) also had negatively shifted steady-state inactivation. rIIA alpha subunit chimeras with substitutions from rH1 in five extracellular loops (IS5-SS1, ISS2-S6, IISS2-S6, IIIS1-S2, and IVS3-S4) favored the fast gating mode. Like wild-type rIIA alpha subunits, all of the chimeric rIIA alpha subunits except chimera IVSS2-S6 were shifted almost entirely to the fast gating mode when coexpressed with beta 1 subunits. In contrast, substitution of extracellular loop IVSS2-S6 substantially reduced the effectiveness of beta 1 subunits in shifting rIIA. alpha subunits to the fast gating mode. Our results show that multiple extracellular loops influence voltage dependent activation and inactivation and gating mode of sodium channels, whereas segment IVSS2-S6 plays a dominant role in modulation of gating by beta 1 subunits. Evidently, several extracellular loops are important determinants of sodium channel gating and modulation.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Catterall, WA (corresponding author), Univ Washington, Dept Pharmacol, POB 357280, Seattle, WA 98195 USA.				NHLBI NIH HHS [P01 HL44946] Funding Source: Medline; NINDS NIH HHS [R01 NS25704] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025704] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADELMAN WJ, 1969, J GEN PHYSIOL, V54, P589, DOI 10.1085/jgp.54.5.589; ARMSTRONG CM, 1981, PHYSIOL REV, V61, P644, DOI 10.1152/physrev.1981.61.3.644; AULD VJ, 1990, P NATL ACAD SCI USA, V87, P323, DOI 10.1073/pnas.87.1.323; AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; BENNETT PB, 1993, FEBS LETT, V326, P21, DOI 10.1016/0014-5793(93)81752-L; CANNON SC, 1993, PFLUG ARCH EUR J PHY, V423, P155, DOI 10.1007/BF00374974; Catterall WA, 1997, ADV SEC MESS PHOSPH, V31, P159; CATTERALL WA, 1984, SCIENCE, V223, P653, DOI 10.1126/science.6320365; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; Cestele S, 1998, NEURON, V21, P919, DOI 10.1016/S0896-6273(00)80606-6; Chang SY, 1996, BIOPHYS J, V70, P2581, DOI 10.1016/S0006-3495(96)79829-6; Chen CF, 1995, PFLUG ARCH EUR J PHY, V431, P186, DOI 10.1007/BF00410190; CHEN LQ, 1992, FEBS LETT, V309, P253, DOI 10.1016/0014-5793(92)80783-D; CRIBBS LL, 1990, FEBS LETT, V275, P195, DOI 10.1016/0014-5793(90)81470-9; Featherstone DE, 1996, BIOPHYS J, V71, P3098, DOI 10.1016/S0006-3495(96)79504-8; Fozzard HA, 1996, PHYSIOL REV, V76, P887, DOI 10.1152/physrev.1996.76.3.887; GOLDIN AL, 1986, P NATL ACAD SCI USA, V83, P7503, DOI 10.1073/pnas.83.19.7503; Isom LL, 1996, NATURE, V383, P307, DOI 10.1038/383307b0; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; JI S, 1994, J GEN PHYSIOL, V104, P625, DOI 10.1085/jgp.104.4.625; KALLEN RG, 1990, NEURON, V4, P233, DOI 10.1016/0896-6273(90)90098-Z; Kellenberger S, 1996, J BIOL CHEM, V271, P30971, DOI 10.1074/jbc.271.48.30971; KRAFTE DS, 1989, J NEUROSCI METH, V26, P211, DOI 10.1016/0165-0270(89)90118-0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Makielski JC, 1996, MOL PHARMACOL, V49, P30; Makita N, 1996, J NEUROSCI, V16, P7117; MAKITA N, 1994, J BIOL CHEM, V269, P7571; Makita N, 1996, CIRC RES, V78, P244, DOI 10.1161/01.RES.78.2.244; McCormick KA, 1999, J BIOL CHEM, V274, P32638, DOI 10.1074/jbc.274.46.32638; McCormick KA, 1998, J BIOL CHEM, V273, P3954, DOI 10.1074/jbc.273.7.3954; MCPHEE JC, 1995, J BIOL CHEM, V270, P12025, DOI 10.1074/jbc.270.20.12025; MOORMAN JR, 1990, NEURON, V4, P243, DOI 10.1016/0896-6273(90)90099-2; NAKAI J, 1994, P NATL ACAD SCI USA, V91, P1014, DOI 10.1073/pnas.91.3.1014; NARAHASHI T, 1964, J CELL COMPAR PHYSL, V64, P73, DOI 10.1002/jcp.1030640108; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; Nuss HB, 1995, J GEN PHYSIOL, V106, P1171, DOI 10.1085/jgp.106.6.1171; OGATA N, 1992, J MEMBRANE BIOL, V129, P71; PATTON DE, 1994, J BIOL CHEM, V269, P17649; QU YS, 1995, J BIOL CHEM, V270, P25696, DOI 10.1074/jbc.270.43.25696; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; Rogers JC, 1996, J BIOL CHEM, V271, P15950, DOI 10.1074/jbc.271.27.15950; RUDY B, 1978, J PHYSIOL-LONDON, V283, P1; VASSILEV PM, 1988, SCIENCE, V241, P1658, DOI 10.1126/science.2458625; WALLNER M, 1993, FEBS LETT, V336, P535, DOI 10.1016/0014-5793(93)80871-Q; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910; WHITE MM, 1991, MOL PHARMACOL, V39, P604; YANG JS, 1993, NEURON, V11, P915, DOI 10.1016/0896-6273(93)90121-7; ZHANG JF, 1994, NATURE, V372, P97, DOI 10.1038/372097a0; ZHOU J, 1991, NEURON, V7, P755	51	60	60	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32647	32654		10.1074/jbc.274.46.32647	http://dx.doi.org/10.1074/jbc.274.46.32647			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551819	hybrid			2022-12-25	WOS:000083623000019
J	Stangl, H; Hyatt, M; Hobbs, HH				Stangl, H; Hyatt, M; Hobbs, HH			Transport of lipids from high and low density lipoproteins via scavenger receptor-BI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR CHOLESTEROL EFFLUX; ELEMENT-BINDING PROTEIN-2; COENZYME-A REDUCTASE; SELECTIVE UPTAKE; SR-BI; MEDIATED ENDOCYTOSIS; GRANULOSA-CELLS; ESTERS; RAT; OVARY	The scavenger receptor-BI (SR-BI) delivers sterols from circulating lipoproteins to tissues, but the relative potency of individual lipoproteins and the transported cholesterol has not been studied in detail. In this study, we used Chinese hamster ovary cells that express recombinant mouse SR-BI but have no functional low density lipoprotein (LDL) receptors (ldlA7-SRBI cells) to compare the fate of lipids transferred from high or low density lipoproteins to cells by SR-BI. HDL and LDL were equally effective in mediating the transfer of [H-3]cholesterol to cells. Only 5% of the free cholesterol transferred to cells was esterified, in direct contrast to the findings in the cells that express I;DL receptors in which 50% of the transported cholesterol was esterified. Almost all the free cholesterol transferred from lipoproteins to cells was rapidly excreted when the ldlA7-SRBI cells were switched to media containing unlabeled lipoproteins. SR-BI expression was associated with an increase in selective cholesteryl ester uptake from both lipoproteins, but HDL was a more effective donor. HDL and LDL were equally effective in delivering cholesterol to the intracellular regulatory pool via SR-EI. These data indicate that SR-BI is able to exchange cholesterol rapidly between lipoproteins and cell membranes and can mediate the uptake of cholesteryl esters from both classes of lipoproteins.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hobbs, HH (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Eckhardt, Erik/G-1567-2010; Stangl, Herbert/AAT-4379-2021; Stangl, Herbert/R-9441-2019	Stangl, Herbert/0000-0002-7288-7320	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Azhar S, 1998, J LIPID RES, V39, P1616; AZHAR S, 1988, J LIPID RES, V29, P869; AZHAR S, 1990, BIOCHIM BIOPHYS ACTA, V1047, P148, DOI 10.1016/0005-2760(90)90041-U; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CADIGAN KM, 1990, J CELL BIOL, V110, P295, DOI 10.1083/jcb.110.2.295; CALVO D, 1997, ATERIOSCLER THROMB V, V17, P2349; Cheng HH, 1999, J BIOL CHEM, V274, P17171, DOI 10.1074/jbc.274.24.17171; CHUNG BH, 1986, METHOD ENZYMOL, V128, P181; FIELDING CJ, 1995, BIOCHEMISTRY-US, V34, P14237, DOI 10.1021/bi00043a031; Fielding CJ, 1997, J LIPID RES, V38, P1503; Fluiter K, 1997, BIOCHEM J, V326, P515, DOI 10.1042/bj3260515; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GWYNNE JT, 1989, J BIOL CHEM, V264, P8141; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KNECHT TP, 1989, BIOCHIM BIOPHYS ACTA, V1002, P365, DOI 10.1016/0005-2760(89)90351-2; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; LAWRENCE CM, 1995, SCIENCE, V268, P1758, DOI 10.1126/science.7792601; LISCUM L, 1985, J BIOL CHEM, V260, P522; LISCUM L, 1983, J BIOL CHEM, V258, P8450; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Medicherla S, 1996, BIOCHEMISTRY-US, V35, P6243, DOI 10.1021/bi952137l; MORRISON JR, 1994, J BIOL CHEM, V269, P13911; NESTLER JE, 1985, ENDOCRINOLOGY, V117, P502, DOI 10.1210/endo-117-2-502; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; RAJAN VP, 1988, BIOCHIM BIOPHYS ACTA, V959, P206, DOI 10.1016/0005-2760(88)90192-0; REAVEN E, 1995, J LIPID RES, V36, P1602; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; RINNINGER F, 1994, ATHEROSCLEROSIS, V105, P145, DOI 10.1016/0021-9150(94)90044-2; Robins SJ, 1999, HEPATOLOGY, V29, P1541, DOI 10.1002/hep.510290518; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; SCOBEY MW, 1989, GASTROINTEST LIVER P, V20, pG644; SPARROW CP, 1990, BIOCHIM BIOPHYS ACTA, V1043, P203, DOI 10.1016/0005-2760(90)90297-B; Stangl H, 1998, J BIOL CHEM, V273, P31002, DOI 10.1074/jbc.273.47.31002; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; YANG JX, 1995, J BIOL CHEM, V270, P12152, DOI 10.1074/jbc.270.20.12152	40	117	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32692	32698		10.1074/jbc.274.46.32692	http://dx.doi.org/10.1074/jbc.274.46.32692			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551825	hybrid			2022-12-25	WOS:000083623000025
J	Taha, C; Liu, Z; Jin, J; Al-Hasani, H; Sonenberg, N; Klip, A				Taha, C; Liu, Z; Jin, J; Al-Hasani, H; Sonenberg, N; Klip, A			Opposite translational control of GLUT1 and GLUT4 glucose transporter mRNAs in response to insulin - Role of mammalian target of rapamycin, protein kinase B, and phosphatidylinositol 3-kinase in GLUT1 mRNA translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DIABETES-MELLITUS; MESSENGER-RNA TRANSLATION; L6 MUSCLE-CELLS; NECROSIS-FACTOR-ALPHA; INITIATION-FACTOR 4E; 3T3-L1 ADIPOCYTES; SIGNALING PATHWAY; PHAS-I; SECONDARY STRUCTURE; BINDING-PROTEIN	Prolonged exposure of 3T3-L1 adipocytes to insulin increases GLUT1 protein content while diminishing GLUT4, These changes arise in part from changes in mRNA transcription. Here we examined whether there are also specific effects of insulin on GLUT1 and GLUT4 mRNA translation. Insulin enhanced association of GLUT1 mRNA with polyribosomes and decreased association with monosomes, suggesting increased translation. Conversely, insulin arrested the majority of GLUT4 transcripts in monosomes. Insulin inactivates the translational suppressor eukaryotic initiation factor 4E-binding protein-1 (4E-BP1) through the mammalian target of rapamycin (mTOR). Hence, we examined the effect of rapamycin on GLUT1 mRNA translation and protein expression. Rapamycin abrogated the insulin-mediated increase in GLUT1 protein synthesis through partial inhibition of GLUT1 mRNA translation and partial inhibition of the rise in GLUT1 mRNA. 4E-BP1 inhibited GLUT1 mRNA translation in vitro. Because phosphatidylinositol 3-kinase (PI3K) and protein kinase B (PKB), in concert with mTOR, inactivate 4E-BP1, we explored their role in GLUT1 protein expression. Cotransfection of cytomegalovirus promoter-driven, hemagglutinin epitope-tagged GLUT1 with dominant inhibitory mutants of PI3K or PKB inhibited the insulin-elicited increase in hemagglutinin-tagged GLUT1 protein. These results unravel the opposite effects of insulin on GLUT1 and GLUT4 mRNA translation. Increased GLUT1 mRNA translation appears to occur via the PI3K/PKB/mTOR/4E-BP1 cascade.	Hosp Sick Children, Cell Biol Programme, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Cologne, Ctr Mol Med, D-50674 Cologne, Germany	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; McGill University; McGill University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Cologne	Klip, A (corresponding author), Hosp Sick Children, Cell Biol Programme, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.							Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; Boado RJ, 1996, J NEUROCHEM, V67, P1335; BOMMER UA, 1994, CELL MOL BIOL RES, V40, P633; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Ciaraldi TP, 1995, J CLIN INVEST, V96, P2820, DOI 10.1172/JCI118352; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DAVIS BB, 1988, BIOCHEM BIOPH RES CO, V154, P1081, DOI 10.1016/0006-291X(88)90251-3; DEHERREROS AG, 1989, J BIOL CHEM, V264, P9885; Dufner A, 1999, MOL CELL BIOL, V19, P4525; EDERY I, 1983, J BIOL CHEM, V258, P1398; FLORESRIVEROS JR, 1993, P NATL ACAD SCI USA, V90, P512, DOI 10.1073/pnas.90.2.512; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GARVEY WT, 1991, J CLIN INVEST, V87, P1072, DOI 10.1172/JCI115068; GARVEY WT, 1988, J CLIN INVEST, V81, P1528, DOI 10.1172/JCI113485; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Goalstone ML, 1999, BIOCHEM BIOPH RES CO, V254, P243, DOI 10.1006/bbrc.1998.9922; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; Grindstaff KK, 1996, J BIOL CHEM, V271, P23211, DOI 10.1074/jbc.271.38.23211; GULVE EA, 1994, J BIOL CHEM, V269, P18366; GUMA A, 1995, AM J PHYSIOL-ENDOC M, V268, pE613, DOI 10.1152/ajpendo.1995.268.4.E613; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; HAUSDORFF SF, 1994, J BIOL CHEM, V269, P21391; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; Jain RG, 1997, MOL CELL BIOL, V17, P954, DOI 10.1128/MCB.17.2.954; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kimball SR, 1997, AM J PHYSIOL-CELL PH, V272, pC754, DOI 10.1152/ajpcell.1997.272.2.C754; Kimball SR, 1998, AM J PHYSIOL-CELL PH, V274, pC221, DOI 10.1152/ajpcell.1998.274.1.C221; KOIVISTO UM, 1991, J BIOL CHEM, V266, P2615; KOZAK M, 1988, MOL CELL BIOL, V8, P2737, DOI 10.1128/MCB.8.7.2737; LEVENSON RM, 1989, J BIOL CHEM, V264, P11904; Lin TA, 1996, J BIOL CHEM, V271, P30199, DOI 10.1074/jbc.271.47.30199; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MAHER F, 1990, BIOCHEM BIOPH RES CO, V171, P210, DOI 10.1016/0006-291X(90)91378-6; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MITSUMOTO Y, 1991, BIOCHEM BIOPH RES CO, V175, P652, DOI 10.1016/0006-291X(91)91615-J; NIELSEN FC, 1995, NATURE, V377, P358, DOI 10.1038/377358a0; OLEFSKY JM, 1988, AM J MED, V85, P86, DOI 10.1016/0002-9343(88)90401-9; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Pedersen S, 1997, EUR J BIOCHEM, V247, P449, DOI 10.1111/j.1432-1033.1997.00449.x; Raabe T, 1998, J BIOL CHEM, V273, P974, DOI 10.1074/jbc.273.2.974; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; SARGEANT RJ, 1993, BIOCHEM J, V290, P913, DOI 10.1042/bj2900913; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Siomi MC, 1996, MOL CELL BIOL, V16, P3825; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; STEPHENS JM, 1992, J BIOL CHEM, V267, P8336; TAHARA SM, 1981, J BIOL CHEM, V256, P7691; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; WALKER PS, 1990, J BIOL CHEM, V265, P1516; Wang QH, 1999, MOL CELL BIOL, V19, P4008	58	130	132	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					33085	33091		10.1074/jbc.274.46.33085	http://dx.doi.org/10.1074/jbc.274.46.33085			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551878	hybrid			2022-12-25	WOS:000083623000078
J	Xu, L; Tripathy, A; Pasek, DA; Meissner, G				Xu, L; Tripathy, A; Pasek, DA; Meissner, G			Ruthenium red modifies the cardiac and skeletal muscle Ca2+ release channels (ryanodine receptors) by multiple mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM VESICLES; INDUCED CALCIUM RELEASE; ADENINE-NUCLEOTIDE; CA-2+ RELEASE; TERMINAL CISTERNAE; PERMEANT IONS; COMPLEX; INHIBITION; CALMODULIN; RECONSTITUTION	The effects of ruthenium red (RR) on the skeletal and cardiac muscle ryanodine receptors (RyRs) were studied in vesicle-Ca2+ flux, [H-3]ryanodine binding, and single channel measurements. In vesicle-Ca2+ flux measurements, RR was more effective in inhibiting RyRs at 0.2 mu M than 20 mu M free Ca2+. [H-3]Ryanodine binding measurements suggested noncompetitive interactions between RR inhibition and Ca2+ regulatory sites of RyRs. In symmetric 0.25 M KCl. with 10-20 mu M cytosolic Ca2+, cytosolic RR decreased single channel activities at positive and negative holding potentials. In close to fully activated skeletal (20 mu M Ca2+ + 2 mM ATP) and cardiac (200 mu M Ca2+) RyRs, cytosolic RR induced a predominant subconductance at a positive but not negative holding potential. Lumenal RR induced a major subconductance in cardiac RyR at negative but not positive holding potentials and several subconductances in skeletal RyR. The RR-related subconductances of cardiac RyR showed a nonlinear voltage dependence, and more than one RR molecule appeared to be involved in their formation, Cytosolic and lumenal RR also induced subconductances in Ca2+-conducting skeletal and cardiac RyRs recorded at 0 mV holding potential. These results suggest that RR inhibits RyRs and induces subconductances by binding to cytosolic and lumenal sites of skeletal and cardiac RyRs.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Meissner, G (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR018687, R01AR018687] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL27430] Funding Source: Medline; NIAMS NIH HHS [AR18687] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAYLOR SM, 1989, J PHYSIOL-LONDON, V408, P617, DOI 10.1113/jphysiol.1989.sp017480; BRUNDER DG, 1992, J PHYSIOL-LONDON, V445, P759, DOI 10.1113/jphysiol.1992.sp018949; CALVIELLO G, 1989, BIOCHEMISTRY-US, V28, P1301, DOI 10.1021/bi00429a053; CHAMBERLAIN BK, 1984, J BIOL CHEM, V259, P7547; CHEN SRW, 1994, J BIOL CHEM, V269, P22698; CHU A, 1986, BIOCHEMISTRY-US, V25, P8315, DOI 10.1021/bi00373a028; CHU A, 1990, MOL PHARMACOL, V37, P735; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; FEHER JJ, 1989, CIRC RES, V65, P1400, DOI 10.1161/01.RES.65.5.1400; FLEISCHER S, 1985, P NATL ACAD SCI USA, V82, P7256, DOI 10.1073/pnas.82.21.7256; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; JONES LR, 1981, J BIOL CHEM, V256, P1809; JORDAN PC, 1986, ION CHANNEL RECONSTI, P37; Kargacin GJ, 1998, PFLUG ARCH EUR J PHY, V436, P338, DOI 10.1007/s004240050641; KIM DH, 1983, J BIOL CHEM, V258, P9662; LEE HB, 1994, J BIOL CHEM, V269, P13305; MA JJ, 1993, J GEN PHYSIOL, V102, P1031, DOI 10.1085/jgp.102.6.1031; Matlib MA, 1998, J BIOL CHEM, V273, P10223, DOI 10.1074/jbc.273.17.10223; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MEISSNER G, 1983, MOL CELL BIOCHEM, V55, P65; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MIYAMOTO H, 1981, FEBS LETT, V133, P235, DOI 10.1016/0014-5793(81)80513-3; OHNISHI ST, 1979, J BIOCHEM, V86, P1147, DOI 10.1093/oxfordjournals.jbchem.a132609; PALADE P, 1987, J BIOL CHEM, V262, P6135; PARK CS, 1992, NEURON, V9, P307, DOI 10.1016/0896-6273(92)90169-E; PIETROBON D, 1989, J GEN PHYSIOL, V94, P1, DOI 10.1085/jgp.94.1.1; PRODHOM B, 1987, NATURE, V329, P243, DOI 10.1038/329243a0; RADERMACHER M, 1994, J CELL BIOL, V127, P411, DOI 10.1083/jcb.127.2.411; REED KC, 1974, FEBS LETT, V46, P109, DOI 10.1016/0014-5793(74)80346-7; ROUSSEAU E, 1986, BIOPHYS J, V50, P1009, DOI 10.1016/S0006-3495(86)83543-3; SCHILD L, 1991, J GEN PHYSIOL, V97, P117, DOI 10.1085/jgp.97.1.117; SCHOENMAKERS TJM, 1992, BIOTECHNIQUES, V12, P870; SERYSHEVA II, 1995, NAT STRUCT BIOL, V2, P18, DOI 10.1038/nsb0195-18; SMITH JS, 1985, NATURE, V316, P446, DOI 10.1038/316446a0; STRECKER GJ, 1989, BIOPHYS J, V89, P795; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; Tanna B, 1998, J GEN PHYSIOL, V112, P55, DOI 10.1085/jgp.112.1.55; TINKER A, 1992, BIOPHYS J, V61, P1122, DOI 10.1016/S0006-3495(92)81922-7; Tripathy A, 1998, J GEN PHYSIOL, V111, P679, DOI 10.1085/jgp.111.5.679; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; Xu L, 1998, BIOPHYS J, V75, P2302, DOI 10.1016/S0006-3495(98)77674-X; ZIMANYI I, 1991, J PHARMACOL EXP THER, V256, P938	45	92	98	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32680	32691		10.1074/jbc.274.46.32680	http://dx.doi.org/10.1074/jbc.274.46.32680			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551824	Green Published, hybrid			2022-12-25	WOS:000083623000024
J	Amiri, F; Venema, VJ; Wang, XD; Ju, H; Venema, RC; Marrero, MB				Amiri, F; Venema, VJ; Wang, XD; Ju, H; Venema, RC; Marrero, MB			Hyperglycemia enhances angiotensin II-induced janus-activated kinase/STAT signaling in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATES TYROSINE PHOSPHORYLATION; AT(1) RECEPTOR; PROLIFERATION; PATHWAY; TRANSCRIPTION; GROWTH	We have shown previously that angiotensin II (Ang II) activates the janus-activated kinase (JAK)/signal transducers and activators of transcription (STAT) pathway in vascular smooth muscle cells (VSMCs) and that activation of the JAK/STAT pathway is required for Ang II induction of VSMC proliferation. In the present study, we examined the effects of hyperglycemia (HG) on Ang IT-induced JAK/STAT signaling events in cultured VSMCs. HG increases Ang II-induced JAK2 tyrosine phosphorylation and promotes a partial tyrosine phosphorylation of the enzyme under basal conditions. In addition, HG increases both basal. and Ang II-induced complex formation of JAK2 with the Ang II AT, receptor. The extent of STAT1 and STAT3 tyrosine and serine phosphorylation are also increased under HG conditions. Furthermore, the tyrosine phosphorylation and activities of the SHP-1 and SHP-2 tyrosine phosphatases, enzymes that regulate Ang II-induced JAK2 tyrosine phosphorylation, are altered by HG. SHP-1, which is responsible for JAK2 tyrosine dephosphorylation in VSMC, is completely deactivated in HG, resulting in a prolonged duration of JAK2 phosphorylation under HG conditions. HG also enhances Ang II induction of VSMC proliferation. Taken together, these data suggest that HG augments Ang II induction of VSMC proliferation by increasing signal transduction through the JAK/STAT pathway.	Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pediat, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Marrero, MB (corresponding author), Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA.		Tehrani, Fahimeh Ramezani/H-6133-2017	Tehrani, Fahimeh Ramezani/0000-0002-4609-065X	NHLBI NIH HHS [HL62152, HL57201, HL58139] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057201, R29HL057201, R01HL062152, R01HL058139, R29HL058139] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ali MS, 1997, J BIOL CHEM, V272, P12373, DOI 10.1074/jbc.272.19.12373; Ali MS, 1997, J BIOL CHEM, V272, P23382, DOI 10.1074/jbc.272.37.23382; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; King GL, 1996, ENDOCRIN METAB CLIN, V25, P255, DOI 10.1016/S0889-8529(05)70324-8; Liang HY, 1999, J BIOL CHEM, V274, P19846, DOI 10.1074/jbc.274.28.19846; Marrero MB, 1998, AM J PHYSIOL-CELL PH, V275, pC1216, DOI 10.1152/ajpcell.1998.275.5.C1216; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; Marrero MB, 1997, J BIOL CHEM, V272, P24684, DOI 10.1074/jbc.272.39.24684; Natarajan R, 1999, HYPERTENSION, V33, P378, DOI 10.1161/01.HYP.33.1.378; NATARAJAN R, 1992, BIOCHEM BIOPH RES CO, V187, P552, DOI 10.1016/S0006-291X(05)81529-3; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; Schieffer B, 1997, AM J PHYSIOL-CELL PH, V272, pC2019, DOI 10.1152/ajpcell.1997.272.6.C2019; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SOWERS JR, 1995, HYPERTENSION, V26, P869, DOI 10.1161/01.HYP.26.6.869; Venema RC, 1998, J BIOL CHEM, V273, P30795, DOI 10.1074/jbc.273.46.30795; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; XIA P, 1994, DIABETES, V43, P1122, DOI 10.2337/diabetes.43.9.1122	19	73	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32382	32386		10.1074/jbc.274.45.32382	http://dx.doi.org/10.1074/jbc.274.45.32382			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542280	hybrid			2022-12-25	WOS:000083532100088
J	Dickeson, SK; Mathis, NL; Rahman, M; Bergelson, JM; Santoro, SA				Dickeson, SK; Mathis, NL; Rahman, M; Bergelson, JM; Santoro, SA			Determinants of ligand binding specificity of the alpha(1)beta(1) and alpha(2)beta(1) integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-DOMAIN; A-DOMAIN; COLLAGEN RECEPTOR; CRYSTAL-STRUCTURE; ECHOVIRUS-1 INTERACTION; DEPENDENT ADHESION; NEURITE OUTGROWTH; LAMININ RECEPTOR; ALPHA-2 SUBUNIT; CR3 CD11B/CD18	The alpha(1)beta(1) and alpha(2)beta(1) integrins are cell surface collagen receptors, Cells expressing the alpha(1)beta(1) integrin preferentially adhere to collagen TV, whereas cells expressing the alpha(2)beta(1) integrin preferentially adhere to collagen I. Recombinant a, and a, integrin I domains exhibit the same collagen type preferences as the intact integrins, Ttl addition, the alpha(2) integrin I domain binds echovirus 1; the a, I domain does not. To identify the structural components of the I domains responsible for the varying ligand specificities, we have engineered several alpha(1)/alpha(2) integrin I domain chimeras and evaluated their virus and collagen binding activities. Initially, large secondary structural components of the alpha(2) I domain were replaced with corresponding regions of the a, I domain. Following analysis in echovirus 1 and collagen binding assays, chimeras with successively smaller regions of alpha(1) I were constructed and analyzed. The chimeras were analyzed by ELISA with several different alpha(2) integrin monoclonal antibodies to assess their proper folding. Three different regions of the alpha(1) I domain, when present in the alpha(2) I domain, conferred enhanced collagen IV binding activity upon the alpha(2) I domain. These include the alpha 3 and alpha 5 helices and a portion of the as helix. Echovirus 1 binding was lost in a chimera containing the alpha C-alpha 6 loop; higher resolution mapping identified Asn(289) as playing a critical role in echovirus 1 binding. Asn289 had not been implicated in previous echovirus 1 binding studies. Taken together, these data reveal the existence of multiple determinants of ligand binding specificities within the alpha(1) and alpha(2) integrin I domains.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	Washington University (WUSTL); University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Santoro, SA (corresponding author), Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA.		Rahman, Moazur/C-5515-2019	Rahman, Moazur/0000-0003-2892-1250	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063446, R01HL040506] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035667] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL63446, HL40506] Funding Source: Medline; NIAID NIH HHS [AI35667] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERGELSON JM, 1993, J VIROL, V67, P6847, DOI 10.1128/JVI.67.11.6847-6852.1993; BERGELSON JM, 1994, CELL ADHES COMMUN, V2, P455, DOI 10.3109/15419069409004455; BERGELSON JM, 1992, SCIENCE, V255, P1718, DOI 10.1126/science.1553561; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; Calderwood DA, 1997, J BIOL CHEM, V272, P12311, DOI 10.1074/jbc.272.19.12311; Dickeson SK, 1998, CELL MOL LIFE SCI, V54, P556, DOI 10.1007/s000180050184; Dickeson SK, 1998, BIOCHEMISTRY-US, V37, P11280, DOI 10.1021/bi9727848; Dickeson SK, 1997, J BIOL CHEM, V272, P7661, DOI 10.1074/jbc.272.12.7661; Dickeson SK, 1998, CELL ADHES COMMUN, V5, P273, DOI 10.3109/15419069809040297; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Filman DJ, 1998, ACTA CRYSTALLOGR D, V54, P1261, DOI 10.1107/S0907444998002790; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; KERN A, 1994, J BIOL CHEM, V269, P22811; King SL, 1997, J BIOL CHEM, V272, P28518, DOI 10.1074/jbc.272.45.28518; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; RIEU P, 1994, J CELL BIOL, V127, P2081, DOI 10.1083/jcb.127.6.2081; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SANTORO SA, 1995, THROMB HAEMOSTASIS, V74, P813; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TURNER DC, 1987, DEV BIOL, V121, P510, DOI 10.1016/0012-1606(87)90187-4; TURNER DC, 1989, J NEUROSCI, V9, P3287	30	71	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32182	32191		10.1074/jbc.274.45.32182	http://dx.doi.org/10.1074/jbc.274.45.32182			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542255	hybrid			2022-12-25	WOS:000083532100063
J	Soriano, S; Chyung, ASC; Chen, XH; Stokin, GB; Lee, VMY; Koo, EH				Soriano, S; Chyung, ASC; Chen, XH; Stokin, GB; Lee, VMY; Koo, EH			Expression of beta-amyloid precursor protein-CD3 gamma chimeras to demonstrate the selective generation of amyloid beta(1-40) and amyloid beta(1-42) peptides within secretory and endocytic compartments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; PROTEIN-PRECURSOR; NT2N CELLS; PATHWAY; TRAFFICKING; PROTEASOME; CLEAVAGE; DEGRADATION; DERIVATIVES; MECHANISMS	Amyloid beta-protein (A beta) is the main constituent of amyloid fibrils found in senile plaques and cerebral vessels in Alzheimer's disease (AD) and is derived by proteolysis from the beta-amyloid precursor protein (APP), We have analyzed the amyloidogenic processing of APP using chimeric proteins stably transfected in Chinese hamster ovary cells. The extracellular and transmembrane domains of APP were fused to the cytoplasmic region derived from the CD3 gamma chain of the T cell antigen receptor (CD3 gamma), CD3 gamma contains an endoplasmic reticulum (ER) retention motif (RKK), in the absence of which the protein is targeted to lysosomes without going through the cell surface (Letourneur, F., and Klausner, R.D. (1992) Cell 69, 1143-1157). We used the wild-type sequence of CD3 gamma to create an APP chimera predicted to remain in the ER (gamma APP(ER)). Deletion of the RKK motif at the C terminus directed the protein directly to the lysosomes (gamma APP(LYS)). A third chimera was created by removing both lysosomal targeting signals in addition to RKK (gamma APP(Delta Delta)), This last construct does not contain known targeting signals and consequently accumulates at the cell surface. We show by immunofluorescence and by biochemical methods that all three APP chimeras localize to the predicted compartments within the cell, thus providing a useful model to study the processing of APP. We found that A beta(1-40) is generated in the early secretory and endocytic pathways, whereas A beta(1-42) is made mainly in the secretory pathway, More importantly, we provide evidence that, unlike in neuronal models, both ER/intermediate compartment- and endocytic-derived A beta forms can enter the secretable pool. Finally, we directly demonstrate that lysosomal processing is not involved in the generation or secretion of either A beta(1-40) or A beta(1-42).	Univ Calif San Diego, Dept Neurosci 0691, La Jolla, CA 92093 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of California System; University of California San Diego; University of Pennsylvania	Koo, EH (corresponding author), Univ Calif San Diego, Dept Neurosci 0691, 9500 Gilman Dr, La Jolla, CA 92093 USA.	edkoo@ucsd.edu	Stokin, Gorazd Bernard/D-9480-2015	Stokin, Gorazd Bernard/0000-0001-8430-8755	NIA NIH HHS [AG12376] Funding Source: Medline; NINDS NIH HHS [NS01812] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K04NS001812] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012376] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CAPORASO GL, 1994, J NEUROSCI, V14, P3122; Cataldo AM, 1997, J NEUROSCI, V17, P6142; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; COLE GM, 1992, ANN NY ACAD SCI, V674, P103; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Klafki HW, 1996, J BIOL CHEM, V271, P28655, DOI 10.1074/jbc.271.45.28655; Koo EH, 1996, J CELL SCI, V109, P991; KOO EH, 1994, J BIOL CHEM, V269, P17386; KUENTZEL SL, 1993, BIOCHEM J, V15, P367; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; MarquezSterling NR, 1997, J NEUROSCI, V17, P140, DOI 10.1523/JNEUROSCI.17-01-00140.1997; Ono Y, 1997, J BIOCHEM-TOKYO, V121, P585; Peraus GC, 1997, J NEUROSCI, V17, P7714; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; REFOLO LM, 1995, J NEUROSCI RES, V40, P694, DOI 10.1002/jnr.490400515; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; SchraderFischer G, 1997, J NEUROCHEM, V68, P1571; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Yang AJ, 1998, J NEUROSCI RES, V52, P691, DOI 10.1002/(SICI)1097-4547(19980615)52:6<691::AID-JNR8>3.0.CO;2-3	38	77	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32295	32300		10.1074/jbc.274.45.32295	http://dx.doi.org/10.1074/jbc.274.45.32295			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542269	hybrid			2022-12-25	WOS:000083532100077
J	Frank, S; Stallmeyer, B; Kampfer, H; Kolb, N; Pfeilschifter, J				Frank, S; Stallmeyer, B; Kampfer, H; Kolb, N; Pfeilschifter, J			Nitric oxide triggers enhanced induction of vascular endothelial growth factor expression in cultured keratinocytes (HaCaT) and during cutaneous wound repair	FASEB JOURNAL			English	Article						gene expression regulation; skin; inducible nitric oxide synthase	GTP-CYCLOHYDROLASE-I; PERMEABILITY FACTOR; GENE-EXPRESSION; HEALING WOUNDS; HUMAN SKIN; SYNTHASE; CELLS; ARGININE; MITOGEN; PURIFICATION	Recently, we demonstrated a large induction of inducible nitric oxide synthase (iNOS) during cutaneous wound repair. In this study, we investigated the role of nitric oxide (NO) for the expression of vascular endothelial go ivth factor (VEGF), which represents the most important angiogenic factor during the proliferative phase of skin repair. Since keratinocytes are the major source of VEGF production during this process, we used cultured keratinocytes (HaCaT cell line) as an in vitro model to investigate NO action on growth factor-and cytokine-stimulated VEGF expression. Exogenously added NO enhanced transforming growth factor-beta 1-, keratinocyte growth factor-, interleukin-1 beta-, tumor necrosis factor-alpha-, and interferon-gamma-induced VEGF mRNA and protein synthesis in keratinocytes. We could demonstrate that high-level expression of cytokine-induced VEGF mRNA in keratinocytes is dependent on endogenously produced NO, as inhibition of the coinduced iNOS by N-G-monomethyl-L-arginine (L-NMMA) markedly decreased cytokine-triggered VEGF mRNA levels in the cells. We also established an in vivo model in mice to investigate the role of NO during wound healing. During excisional wound repair, mice were treated with L-N-6-(1-iminoethyl)lysine (L-NIL), a selective inhibitor of iNOS enzymatic activity. Compared to control mice, L-NIL-teated animals were characterized by markedly reduced VEGF mRNA levels during the inflammatory phase of repair. Immunohistochemistry demonstrated reduced VEGF protein expression and a completely disorganized pattern of VEGF-expressing keratinocytes within the hyperproliferative epithelium at the wound edge in L-NIL-treated mice. We demonstrate that triggering of VEGF expression is a crucial molecular mechanism underlying NO function during wound healing.-Frank, S., Stallmeyer, B., Kampfer, H., Kolb, N., Pfeilschifter, J. Nitric oxide triggers enhanced induction of vascular endothelial growth factor expression in cultured keratinocytes (HaCaT) and during cutaneous wound repair.	Univ Frankfurt Klinikum, Zentrum Physiol, Inst Allgemeine Pharmakol & Toxikol, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital	Pfeilschifter, J (corresponding author), Univ Frankfurt Klinikum, Zentrum Physiol, Inst Allgemeine Pharmakol & Toxikol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	Pfeilschifter@em.uni-frankfurt.de	Stallmeyer, Birgit/AAE-3020-2020					ALBINA JE, 1990, J IMMUNOL, V144, P3877; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BARBUL A, 1990, SURGERY, V108, P331; Beck KF, 1999, J EXP BIOL, V202, P645; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREIER G, 1992, DEVELOPMENT, V114, P521; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; BROWN LF, 1988, AM J PATHOL, V130, P455; BruchGerharz D, 1996, J EXP MED, V184, P2007, DOI 10.1084/jem.184.5.2007; Chin K, 1997, ONCOGENE, V15, P437, DOI 10.1038/sj.onc.1201201; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark R., 1996, Mezhdunarodnyi Sel'skokhozyaistvennyi Zhurnal, P3; COLEMAN DL, 1982, DIABETES, V31, P1; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; DETMAR M, 1995, J INVEST DERMATOL, V105, P44, DOI 10.1111/1523-1747.ep12312542; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Diefenbach A, 1998, IMMUNITY, V8, P77, DOI 10.1016/S1074-7613(00)80460-4; Frank S, 1999, BIOCHEM J, V338, P367, DOI 10.1042/0264-6021:3380367; Frank S, 1998, J INVEST DERMATOL, V111, P1058, DOI 10.1046/j.1523-1747.1998.00434.x; Frank S, 1998, J INVEST DERMATOL, V111, P1065, DOI 10.1046/j.1523-1747.1998.00433.x; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; GARRIDO C, 1993, GROWTH FACTORS, V8, P109, DOI 10.3109/08977199309046931; Goldsmith PC, 1996, J INVEST DERMATOL, V106, P113, DOI 10.1111/1523-1747.ep12328204; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KIRK SJ, 1993, SURGERY, V114, P155; KLATT P, 1993, J BIOL CHEM, V268, P14781; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KRONCKE KD, 1995, BIOL CHEM H-S, V376, P327; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; MONCADA S, 1991, PHARMACOL REV, V43, P109; MOORE WM, 1994, J MED CHEM, V37, P3886, DOI 10.1021/jm00049a007; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; Nissen NN, 1998, AM J PATHOL, V152, P1445; Ormerod AD, 1998, ARCH DERMATOL RES, V290, P3, DOI 10.1007/s004030050268; Reichner JS, 1999, AM J PATHOL, V154, P1097, DOI 10.1016/S0002-9440(10)65362-X; Remick DG, 1996, J LEUKOCYTE BIOL, V59, P471, DOI 10.1002/jlb.59.4.471; RomeroGraillet C, 1997, J CLIN INVEST, V99, P635, DOI 10.1172/JCI119206; Rowe A, 1997, BRIT J DERMATOL, V136, P18, DOI 10.1046/j.1365-2133.1997.d01-1136.x; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SEIFTER E, 1978, SURGERY, V84, P224; Shimizu Yoshinori, 1997, Journal of Dermatology (Tokyo), V24, P80; Sirsjo A, 1996, BRIT J DERMATOL, V134, P643, DOI 10.1111/j.1365-2133.1996.tb06963.x; Stenger S, 1995, EUR J PHARMACOL, V294, P703, DOI 10.1016/0014-2999(95)00618-4; Tsurumi Y, 1997, NAT MED, V3, P879, DOI 10.1038/nm0897-879; WEINDEL K, 1992, BIOCHEM BIOPH RES CO, V183, P1167, DOI 10.1016/S0006-291X(05)80313-4; Weller R, 1996, J INVEST DERMATOL, V107, P327, DOI 10.1111/1523-1747.ep12363167; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; Wong H. L., 1989, HUMAN MONOCYTES, P383; Xiong M, 1998, AM J PATHOL, V153, P587, DOI 10.1016/S0002-9440(10)65601-5; Yamasaki K, 1998, J CLIN INVEST, V101, P967, DOI 10.1172/JCI2067	57	194	209	1	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1999	13	14					2002	2014		10.1096/fasebj.13.14.2002	http://dx.doi.org/10.1096/fasebj.13.14.2002			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544183	Bronze			2022-12-25	WOS:000083660700012
J	Xi, HK; Eason, DD; Ghosh, D; Dovhey, S; Wright, KL; Blanck, G				Xi, HK; Eason, DD; Ghosh, D; Dovhey, S; Wright, KL; Blanck, G			Co-occupancy of the interferon regulatory element of the class II transactivator (CIITA) Type IV promoter by interferon regulatory factors 1 and 2	ONCOGENE			English	Article						IRF-1; IRF-2; CIITA	RETINOBLASTOMA PROTEIN RESCUE; TRANSCRIPTION FACTOR IRF-2; CELL-ADHESION MOLECULE-1; IFN-GAMMA INDUCIBILITY; DNA-BINDING DOMAIN; GENE-TRANSCRIPTION; IN-VIVO; ACTIVATION DOMAIN; MESSENGER-RNA; FACTOR FAMILY	Class II transactivator (CIITA) activates the expression of major histocompatibility class II genes, which encode antigen-presenting molecules recognized by the T-cell receptor of CD4+ T cells. IFN-gamma induced CIITA transcription in many cell types is directed by the CIITA Type IV promoter. Here we report that the human CIITA Type IV promoter TRF-E binds IRF-1 and can be activated by exogenous expression of IRF-1. Surprisingly, the CIITA Type IV promoter IRF-E is also activated by IRF-2, another member of the IRF family that generally acts as a transcriptional repressor. In addition, we found that IRF-1 and IRF-2 synergistically activate the CIITA Type IV promoter. Electrophoretic mobility shift assays revealed that IRF-1 and IRF-2 can simultaneously occupy the IRF-E of the CIITA Type IV promoter, suggesting a novel mechanism for the role of these two proteins in promoter activation. Our results also indicate that IRF-1 and IRF-2 can cooperatively activate and co-occupy the IRF-E of the guanylate binding protein (GBP) promoter. Finally, CIITA induction by IFN-gamma does not occur in a pancreatic tumor cell line that expresses a mutated IRF-2, representing the first IRF-2 mutation identified in a human tumor cell line.	Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Med Microbiol & Immunol, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Program Immunol, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Blanck, G (corresponding author), Univ S Florida, Coll Med, Dept Biochem & Mol Biol, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.		Blanck, George/A-5365-2012					Aragane Y, 1997, J IMMUNOL, V158, P5393; BENECH P, 1987, MOL CELL BIOL, V7, P4498, DOI 10.1128/MCB.7.12.4498; Birnbaum MJ, 1997, J CELL BIOCHEM, V66, P175, DOI 10.1002/(SICI)1097-4644(19970801)66:2<175::AID-JCB5>3.0.CO;2-N; BLANAR MA, 1989, EMBO J, V8, P1139, DOI 10.1002/j.1460-2075.1989.tb03484.x; BLANCK G, 1990, HUM IMMUNOL, V29, P150, DOI 10.1016/0198-8859(90)90078-4; BRIKEN V, 1995, MOL CELL BIOL, V15, P975; CHA Y, 1994, J BIOL CHEM, V269, P5279; CHANG CH, 1995, J EXP MED, V181, P765, DOI 10.1084/jem.181.2.765; CHANG CH, 1992, IMMUNOGENETICS, V35, P378; CHIN KC, 1994, IMMUNITY, V1, P687, DOI 10.1016/1074-7613(94)90039-6; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Escalante CR, 1998, NATURE, V391, P103, DOI 10.1038/34224; Faggioli L, 1997, EUR J IMMUNOL, V27, P3022, DOI 10.1002/eji.1830271140; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; GRANT CE, 1995, NUCLEIC ACIDS RES, V23, P2137, DOI 10.1093/nar/23.12.2137; HARADA H, 1994, ONCOGENE, V9, P3313; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; Hobart M, 1997, J IMMUNOL, V158, P4260; Jesse TL, 1998, J CELL BIOL, V140, P1265, DOI 10.1083/jcb.140.5.1265; KERN I, 1995, INT IMMUNOL, V7, P1295, DOI 10.1093/intimm/7.8.1295; KINGSTON RE, 1997, CURRENT PROTOCOLS MO; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; Kusumoto M, 1998, J STRUCT BIOL, V121, P363, DOI 10.1006/jsbi.1998.3970; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; LIWEBER M, 1994, J IMMUNOL, V153, P4122; Lu Y, 1997, IMMUNOL CELL BIOL, V75, P325, DOI 10.1038/icb.1997.50; Lu YM, 1996, J IMMUNOL, V156, P2495; Luo W, 1996, J BIOL CHEM, V271, P23445, DOI 10.1074/jbc.271.38.23445; MartinezSoria E, 1996, INT IMMUNOL, V8, P543, DOI 10.1093/intimm/8.4.543; Min W, 1996, J IMMUNOL, V156, P3174; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; NELSON N, 1993, MOL CELL BIOL, V13, P588, DOI 10.1128/MCB.13.1.588; Nozawa H, 1998, INT J CANCER, V77, P522, DOI 10.1002/(SICI)1097-0215(19980812)77:4<522::AID-IJC8>3.0.CO;2-W; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; Piskurich JF, 1999, MOL CELL BIOL, V19, P431; Pongubala JMR, 1997, P NATL ACAD SCI USA, V94, P127, DOI 10.1073/pnas.94.1.127; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; REITH W, 1990, GENE DEV, V4, P1528, DOI 10.1101/gad.4.9.1528; Sambrook J., 1989, MOL CLONING, pA1; Schaefer BC, 1997, MOL CELL BIOL, V17, P873, DOI 10.1128/MCB.17.2.873; SIEGRIST CA, 1995, J EXP MED, V182, P1793, DOI 10.1084/jem.182.6.1793; Spink J, 1997, J BIOL CHEM, V272, P24417, DOI 10.1074/jbc.272.39.24417; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANIGUCHI T, 1995, J CANCER RES CLIN, V121, P516, DOI 10.1007/BF01197763; Taniguchi T, 1997, BBA-REV CANCER, V1333, pM9, DOI 10.1016/S0304-419X(97)00014-0; Ting JPY, 1997, J IMMUNOL, V159, P5457; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; Vaughan PS, 1998, J BIOL CHEM, V273, P194, DOI 10.1074/jbc.273.1.194; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; Wang IM, 1996, MOL CELL BIOL, V16, P6313; Westerheide SD, 1997, J IMMUNOL, V158, P4812; White LC, 1996, IMMUNITY, V5, P365, DOI 10.1016/S1074-7613(00)80262-9; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; WRIGHT KL, 1995, J EXP MED, V181, P1459, DOI 10.1084/jem.181.4.1459; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; Yamagata T, 1996, MOL CELL BIOL, V16, P1283; YAMAMOTO H, 1994, ONCOGENE, V9, P1423; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang LW, 1997, MOL CELL BIOL, V17, P5748, DOI 10.1128/MCB.17.10.5748	68	44	44	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	1999	18	43					5889	5903		10.1038/sj.onc.1202969	http://dx.doi.org/10.1038/sj.onc.1202969			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557076				2022-12-25	WOS:000083270700006
J	Datta, SA; Rao, CM				Datta, SA; Rao, CM			Differential temperature-dependent chaperone-like activity of alpha A- and alpha B-crystallin homoaggregates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; QUATERNARY STRUCTURE; MISSENSE MUTATION; EXPRESSION; GENE; LENS; SUBUNITS; DISEASE; INTERMEDIATE; CATARACT	alpha-Crystallin, a heteromultimeric protein made up of alpha A- and alpha B-crystallins, functions as a molecular chaperone in preventing the aggregation of proteins. We have shown earlier that structural perturbation of alpha-crystallin can enhance its chaperone-like activity severalfold. The two subunits of alpha-crystallin have extensive sequence homology and individually display chaperone-like activity. We have investigated the chaperone-like activity of alpha A- and alpha B-crystallin homoaggregates against thermal and nonthermal modes of aggregation. me find that, against a nonthermal mode of aggregation, alpha B-crystallin shows significant protective ability even at subphysiological temperatures, at which alpha A-crystallin or heteromultimeric alpha-crystallin exhibit very little chaperone-like activity. Interestingly, differences in the protective ability of these homoaggregates against the thermal aggregation of beta(L)-crystallin is negligible. To investigate this differential behavior, me have monitored the temperature-dependent structural changes in both the proteins using fluorescence and circular dichroism spectroscopy. Intrinsic tryptophan fluorescence quenching by acrylamide shows that the tryptophans in alpha B-crystallin are more accessible than the lone tryptophan in alpha A-crystallin even at 25 degrees C. Protein-bound 8-anilinon-aphthalene-1-sulfonate fluorescence demonstrates the higher solvent accessibility of hydrophobic surfaces on alpha B-crystallin. Circular dichroism studies show some tertiary structural changes in alpha A-crystallin above 50 degrees C, alpha B-crystallin, on the other hand, shows significant alteration of tertiary structure by 45 degrees C, Our study demonstrates that despite a high degree of sequence homology and their generally accepted structural similarity, alpha B-crystallin is much more sensitive to temperature-dependent structural perturbation than alpha A- or alpha-crystallin and shows differences in its chaperone-like properties. These differences appear to be relevant to temperature-dependent enhancement of chaperone-like activity of alpha-crystallin and indicate different roles for the two proteins both in alpha-crystallin heteroaggregate and as separate proteins under stress conditions.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Rao, CM (corresponding author), Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India.	mohan@ccmb.ap.nic.in		Datta, Siddhartha/0000-0002-4098-7490				AOYAMA A, 1993, INT J CANCER, V55, P760, DOI 10.1002/ijc.2910550511; BHAT SP, 1991, EUR J BIOCHEM, V202, P775, DOI 10.1111/j.1432-1033.1991.tb16432.x; BLOEMENDAL H, 1981, ANAL BIOCHEM, V117, P327, DOI 10.1016/0003-2697(81)90787-9; Bloemendal M, 1998, INT J BIOL MACROMOL, V22, P239, DOI 10.1016/S0141-8130(98)00021-X; Brady JP, 1997, P NATL ACAD SCI USA, V94, P884, DOI 10.1073/pnas.94.3.884; CARDAMONE M, 1992, BIOCHEM J, V282, P589, DOI 10.1042/bj2820589; CHIESI M, 1990, MOL CELL BIOCHEM, V97, P129; Das BK, 1997, BIOCHEM BIOPH RES CO, V236, P370, DOI 10.1006/bbrc.1997.6950; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; DEJONG WW, 1988, J BIOL CHEM, V263, P5141; DELCOUR J, 1974, BIOCHEM BIOPH RES CO, V57, P134, DOI 10.1016/S0006-291X(74)80367-0; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LI LK, 1973, EXP EYE RES, V15, P179, DOI 10.1016/0014-4835(73)90117-6; Litt M, 1998, HUM MOL GENET, V7, P471, DOI 10.1093/hmg/7.3.471; MAITI M, 1988, FEBS LETT, V236, P109, DOI 10.1016/0014-5793(88)80295-3; MERCK KB, 1992, BIOCHIM BIOPHYS ACTA, V1130, P267, DOI 10.1016/0167-4781(92)90439-7; MERCK KB, 1993, J BIOL CHEM, V268, P1046; Mitton KP, 1997, BIOCHEM BIOPH RES CO, V235, P69, DOI 10.1006/bbrc.1997.6737; Raman B, 1997, J BIOL CHEM, V272, P23559, DOI 10.1074/jbc.272.38.23559; RAMAN B, 1995, FEBS LETT, V365, P133, DOI 10.1016/0014-5793(95)00440-K; RAMAN B, 1994, J BIOL CHEM, V269, P27264; RAMAN B, 1995, J BIOL CHEM, V270, P19888, DOI 10.1074/jbc.270.34.19888; Rao CM, 1998, INT J BIOL MACROMOL, V22, P271; RENKAWEK K, 1992, ACTA NEUROPATHOL, V83, P324, DOI 10.1007/BF00296796; RENKAWEK K, 1994, ACTA NEUROPATHOL, V87, P155, DOI 10.1007/BF00296185; SCOTTING P, 1991, FEBS LETT, V285, P75, DOI 10.1016/0014-5793(91)80728-L; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SIEZEN RJ, 1982, EXP EYE RES, V34, P969, DOI 10.1016/0014-4835(82)90077-X; SIEZEN RJ, 1978, EUR J BIOCHEM, V91, P387, DOI 10.1111/j.1432-1033.1978.tb12691.x; SIEZEN RJ, 1980, EUR J BIOCHEM, V111, P435, DOI 10.1111/j.1432-1033.1980.tb04958.x; Sun TX, 1997, J BIOL CHEM, V272, P6220, DOI 10.1074/jbc.272.10.6220; SUNDARI CS, 1991, BIOCHIM BIOPHYS ACTA, V1065, P35; SUREWICZ WK, 1995, BIOCHEMISTRY-US, V34, P9655, DOI 10.1021/bi00030a001; VANDENOETELAAR PJM, 1990, BIOCHEMISTRY-US, V29, P3488, DOI 10.1021/bi00466a010; VANDEROU.FJ, 1974, EUR J BIOCHEM, V49, P157; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; WALSH MT, 1991, J BIOL CHEM, V266, P20079	44	108	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34773	34778		10.1074/jbc.274.49.34773	http://dx.doi.org/10.1074/jbc.274.49.34773			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574947	hybrid			2022-12-25	WOS:000083979600041
J	Nunoshiba, T; Obata, F; Boss, AC; Oikawa, S; Mori, T; Kawanishi, S; Yamamoto, E				Nunoshiba, T; Obata, F; Boss, AC; Oikawa, S; Mori, T; Kawanishi, S; Yamamoto, E			Role of iron and superoxide for generation of hydroxyl radical, oxidative DNA lesions, and mutagenesis in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROXY-ACID DEHYDRATASE; FE-S CLUSTER; HYDROGEN-PEROXIDE; SUPF GENE; MUTATIONAL SPECIFICITY; STRESS RESPONSES; OXYGEN RADICALS; DAMAGE; MUTANTS; PROTEIN	We measured the generation of hydroxyl radical (OH.) and oxidative DNA lesions in aerobically grown Escherichia coli cells lacking in both superoxide dismutases (SodA SodB) and repressor of iron uptake (Fur) using electroparamagnetic resonance and gas chromatography-mass spectrometry with a selected-ion monitoring method. A specific signal corresponding to OH. generation and an increase in oxidative DNA lesions such as 7,8-dihydro-8-oxoguanine and 1,2-dihydro-2-oxoadenine were detected in the strain deficient in sodA sodB fur. We showed that iron metabolism deregulation in fur mutant produced a 2.5-fold iron overload. The sodA sodB fur strain was about 100-fold higher mutability than the wild-type strain. The mutation spectrum in the strain was found to induce GC --> TA and AT --> CG transversions predominantly. The hypermutability of the strain was suppressed by the tonB mutation which reduces iron transport. Thus, excess iron and excess superoxide were responsible for OH. generation, oxidative DNA lesion formation, and hypermutability in E. coli.	Tohoku Univ, Grad Sch Sci, Inst Biol, Sendai, Miyagi 9808578, Japan; Mie Univ, Sch Med, Dept Hyg, Tsu, Mie 5148507, Japan; Osaka Prefecture Univ, Res Inst Adv Sci & Technol, Osaka 5998570, Japan	Tohoku University; Mie University; Osaka Metropolitan University	Yamamoto, E (corresponding author), Tohoku Univ, Grad Sch Sci, Inst Biol, Sendai, Miyagi 9808578, Japan.	yamamot@mail.cc.tohoku.ac.jp						AKASAKA S, 1992, MOL GEN GENET, V235, P173, DOI 10.1007/BF00279358; AKASAKA S, 1995, BIOCHEM BIOPH RES CO, V213, P74, DOI 10.1006/bbrc.1995.2100; AKASAKA S, 1991, MUTAT RES, V254, P27, DOI 10.1016/0921-8777(91)90037-P; AKASAKA S, 1994, MOL GEN GENET, V243, P500, DOI 10.1007/BF00284197; BABIOR BM, 1992, ADV ENZYMOL RAMB, V65, P49; BAGG A, 1987, BIOCHEMISTRY-US, V26, P5471, DOI 10.1021/bi00391a039; BOCHNER BR, 1980, J BACTERIOL, V143, P926, DOI 10.1128/JB.143.2.926-933.1980; BRAWN K, 1981, ARCH BIOCHEM BIOPHYS, V206, P414, DOI 10.1016/0003-9861(81)90108-9; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DJURIC Z, 1991, CHEM RES TOXICOL, V4, P687, DOI 10.1021/tx00024a014; FARR SB, 1991, MICROBIOL REV, V55, P561, DOI 10.1128/MMBR.55.4.561-585.1991; Flint DH, 1996, J BIOL CHEM, V271, P16068; Flint DH, 1996, J BIOL CHEM, V271, P16053, DOI 10.1074/jbc.271.27.16053; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; IMLAY JA, 1991, J BIOL CHEM, V266, P6957; IMLAY JA, 1988, SCIENCE, V240, P640, DOI 10.1126/science.2834821; IMLAY JA, 1987, J BACTERIOL, V169, P2967, DOI 10.1128/jb.169.7.2967-2976.1987; Inoue M, 1998, J BIOL CHEM, V273, P11069, DOI 10.1074/jbc.273.18.11069; Jiang DY, 1997, J BACTERIOL, V179, P3773, DOI 10.1128/jb.179.11.3773-3782.1997; KAMIYA H, 1995, J BIOL CHEM, V270, P19446, DOI 10.1074/jbc.270.33.19446; Kamiya H, 1997, BIOCHEMISTRY-US, V36, P11125, DOI 10.1021/bi970871u; Kanbashi K, 1997, MUTAT RES-DNA REPAIR, V385, P259, DOI 10.1016/S0921-8777(97)00056-6; KEYER K, 1995, J BACTERIOL, V177, P6782, DOI 10.1128/jb.177.23.6782-6790.1995; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; Kobayashi M, 1998, J BIOL CHEM, V273, P26394, DOI 10.1074/jbc.273.41.26394; KONO Y, 1982, J BIOL CHEM, V257, P5751; LOEWEN PC, 1984, J BACTERIOL, V160, P668, DOI 10.1128/JB.160.2.668-675.1984; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; McCormick ML, 1998, J BACTERIOL, V180, P622, DOI 10.1128/JB.180.3.622-625.1998; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; Mori T, 1998, BIOCHEM BIOPH RES CO, V242, P98, DOI 10.1006/bbrc.1997.7916; Obata F, 1998, J RADIAT RES, V39, P263, DOI 10.1269/jrr.39.263; POSTLE K, 1990, MOL MICROBIOL, V4, P2019, DOI 10.1111/j.1365-2958.1990.tb00561.x; Saito Y, 1997, J BACTERIOL, V179, P3783, DOI 10.1128/jb.179.11.3783-3785.1997; TOUATI D, 1995, J BACTERIOL, V177, P2305, DOI 10.1128/jb.177.9.2305-2314.1995; Yamamoto K, 1997, J RADIAT RES, V38, P1, DOI 10.1269/jrr.38.1; ZHENG LM, 1994, J BIOL CHEM, V269, P18723	37	95	98	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34832	34837		10.1074/jbc.274.49.34832	http://dx.doi.org/10.1074/jbc.274.49.34832			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574955	hybrid			2022-12-25	WOS:000083979600049
J	Sankarapandi, S; Zweier, JL				Sankarapandi, S; Zweier, JL			Evidence against the generation of free hydroxyl radicals from the interaction of copper,zinc-superoxide dismutase and hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; ERYTHROCYTE SUPEROXIDE-DISMUTASE; K-M; COPPER; INACTIVATION; MECHANISM; ENZYME; H2O2; MUTANT; REPERFUSION	Prior spin trapping studies reported that H2O2 is metabolized by copper, zinc-superoxide dismutase (SOD) to form (OH)-O-. that is released from the enzyme, serving as a source of oxidative injury, Although this mechanism has been invoked in a number of diseases, controversy remains regarding whether the hydroxylation of spin traps by SOD is truly derived from free (OH)-O-. or (OH)-O-. scavenged off the Cu2+ catalytic site. To distinguish whether (OH)-O-. is released from the enzyme, a comprehensive EPR investigation of radical production and the kinetics of spin trapping was performed in the presence of a series of structurally different (OH)-O-. scavengers including ethanol, formate, and azide, Although each of these have similar potency in scavenging (OH)-O-. as the spin trap 5,5-dimethyl-1-pyrroline-N-oxide and form secondary radical adducts, each exhibited very different potency in scavenging (OH)-O-. from SOD. Ethanol was 1400-fold less potent than would be expected for reaction with free (OH)-O-.. The anionic scavenger formate, which readily accesses the active site, was still 10-fold less effective than would be predicted for free (OH)-O-., whereas azide was almost 2-fold more potent than would be predicted. Analysis of initial rates of adduct formation indicated that these reactions did not involve free (OH)-O-.. EPR studies of the copper center demonstrated that while high H2O2 concentrations induce release of Cu2+, the magnitude of spin adducts produced by free Cu2+ was negligible compared with that from intact SOD. Further studies with a series of peroxidase substrates demonstrated that characteristic radicals formed by peroxidases were also efficiently,generated by H2O2 and SOD, Thus, SOD and H2O2 oxidize and hydroxylate substrates and spin traps through a peroxidase reaction with bound (OH)-O-. not release of (OH)-O-. from the enzyme.	Johns Hopkins Med Inst, Mol & Cellular Biophys Labs, Dept Med, Div Cardiol, Baltimore, MD 21224 USA; Johns Hopkins Med Inst, Electron Paramagnet Resonance Ctr, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Zweier, JL (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Electron Paramagnet Resonance Ctr, Rm LA-14,5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.				NHLBI NIH HHS [HL-52315, HL-38324] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038324, R01HL038324, P50HL052315] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adak S, 1998, BIOCHEMISTRY-US, V37, P16922, DOI 10.1021/bi980899l; AISEN P, 1978, J BIOL CHEM, V253, P1930; BANNISTER JV, 1987, CRC CR REV BIOCH MOL, V22, P111, DOI 10.3109/10409238709083738; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BLECH DM, 1983, ARCH BIOCHEM BIOPHYS, V224, P579, DOI 10.1016/0003-9861(83)90245-X; BORDERS CL, 1985, ARCH BIOCHEM BIOPHYS, V241, P472, DOI 10.1016/0003-9861(85)90572-7; BRAY RC, 1974, BIOCHEM J, V139, P43, DOI 10.1042/bj1390043; CASTELHANO AL, 1983, CAN J CHEM, V61, P298, DOI 10.1139/v83-053; DJINOVICCARUGO K, 1994, J MOL BIOL, V240, P179, DOI 10.1006/jmbi.1994.1432; ELROYSTEIN O, 1988, CELL, V52, P259, DOI 10.1016/0092-8674(88)90515-6; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; FEE JA, 1972, J BIOL CHEM, V247, P60; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; GETZOFF ED, 1992, NATURE, V358, P347, DOI 10.1038/358347a0; Goto JJ, 1998, J BIOL CHEM, V273, P30104, DOI 10.1074/jbc.273.46.30104; HODGSON EK, 1973, BIOCHEM BIOPH RES CO, V54, P270, DOI 10.1016/0006-291X(73)90918-2; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5299, DOI 10.1021/bi00695a011; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; KALYANARAMAN B, 1984, J BIOL CHEM, V259, P7584; KALYNANARAMAN B, 1987, BIOCHEM BIOPH RES CO, V105, P217; KANOFSKY JR, 1991, PEROXIDASES CHEM BIO, V2, P219; KONNINGSBERGER JC, 1994, CLIN CHIM ACTA, V230, P51; KUPPUSAMY P, 1992, APPL RADIAT ISOTOPES, V44, P367; Liochev SI, 1998, ARCH BIOCHEM BIOPHYS, V352, P237, DOI 10.1006/abbi.1998.0616; LOWN JW, 1981, CAN J CHEM, V59, P390, DOI 10.1139/v81-060; MCCORD JM, 1988, FREE RADICAL BIO MED, V4, P9, DOI 10.1016/0891-5849(88)90005-6; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MOREHOUSE KM, 1987, FEBS LETT, V222, P246, DOI 10.1016/0014-5793(87)80379-4; MOREHOUSE KM, 1988, J BIOL CHEM, V263, P1204; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROTILIO G, 1972, BIOCHEMISTRY-US, V11, P2187, DOI 10.1021/bi00761a028; ROTILIO G, 1973, BIOCHIM BIOPHYS ACTA, V302, P229, DOI 10.1016/0005-2744(73)90151-4; Roubaud V, 1997, ANAL BIOCHEM, V247, P404, DOI 10.1006/abio.1997.2067; SALO DC, 1990, J BIOL CHEM, V265, P11919; Sankarapandi S, 1999, J BIOL CHEM, V274, P1226, DOI 10.1074/jbc.274.3.1226; SATO K, 1992, J BIOL CHEM, V267, P25371; SCOTT MD, 1989, J BIOL CHEM, V264, P2498; Siddique T, 1996, HUM MOL GENET, V5, P1465, DOI 10.1093/hmg/5.Supplement_1.1465; Singh RJ, 1998, P NATL ACAD SCI USA, V95, P6675, DOI 10.1073/pnas.95.12.6675; SYMONYAN MA, 1972, FEBS LETT, V28, P22, DOI 10.1016/0014-5793(72)80667-7; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; Yim HS, 1997, J BIOL CHEM, V272, P8861; YIM MB, 1993, J BIOL CHEM, V268, P4099; YIM MB, 1990, P NATL ACAD SCI USA, V87, P5006, DOI 10.1073/pnas.87.13.5006; Yim MB, 1996, P NATL ACAD SCI USA, V93, P5709, DOI 10.1073/pnas.93.12.5709; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404; ZWEIER JL, 1988, J BIOL CHEM, V263, P1353; ZWEIER JL, 1994, J BIOL CHEM, V269, P24156	50	38	38	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34576	34583		10.1074/jbc.274.49.34576	http://dx.doi.org/10.1074/jbc.274.49.34576			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574920	hybrid			2022-12-25	WOS:000083979600014
J	Nishizawa, M; Kanaya, Y; Toh-e, A				Nishizawa, M; Kanaya, Y; Toh-e, A			Mouse cyclin-dependent kinase (Cdk) 5 is a functional homologue of a yeast Cdk, Pho85 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR PHO4; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; CELL-CYCLE; IN-VIVO; PHOSPHORYLATION; COMPLEX; SYSTEM; ASSOCIATION; RESISTANCE	Mouse cyclin-dependent kinase (Cdk) 5 and yeast Pho85 kinase share similarities in structure as well as in the regulation of their activity. We found that mouse Cdk5 kinase produced in pho85 Delta mutant cells could suppress some of pho85 Delta mutant phenotypes including failure to grow on nonfermentable carbon sources, morphological defects, and growth defect caused by Pho4 or Clb2 overproduction. We also demonstrated that Cdk5 coimmunoprecipitated with Pho85-cyclins including Pcl1, Pcl2, Pcl6, Pcl9, and Pho80, and that the immunocomplex could phosphorylate Pho4, a native substrate of Pho85 kinase. Thus mouse Cdk5 is a functional homologue of yeast Pho85 kinase.	Keio Univ, Sch Med, Dept Microbiol, Shinjuku Ku, Tokyo 1608582, Japan; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Tokyo 1130033, Japan	Keio University; University of Tokyo	Nishizawa, M (corresponding author), Keio Univ, Sch Med, Dept Microbiol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.							Aerne BL, 1998, MOL BIOL CELL, V9, P945, DOI 10.1091/mbc.9.4.945; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; ESPINOZA FH, 1994, SCIENCE, V266, P1388, DOI 10.1126/science.7973730; Espinoza FH, 1998, MOL CELL BIOL, V18, P6365, DOI 10.1128/MCB.18.11.6365; Flick JS, 1998, GENETICS, V148, P33; FUJINO M, 1994, PHOSPHATE IN MICROORGANISMS, P70; Huang DQ, 1996, MOL CELL BIOL, V16, P4357; Huang DQ, 1998, MOL CELL BIOL, V18, P3289, DOI 10.1128/MCB.18.6.3289; Kaffman A, 1998, GENE DEV, V12, P2673, DOI 10.1101/gad.12.17.2673; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; Komeili A, 1999, SCIENCE, V284, P977, DOI 10.1126/science.284.5416.977; Lazaro JB, 1996, NEUROSCI LETT, V218, P21; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; MEASDAY V, 1994, SCIENCE, V266, P1391, DOI 10.1126/science.7973731; Measday V, 1997, MOL CELL BIOL, V17, P1212, DOI 10.1128/MCB.17.3.1212; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; Nishizawa M, 1998, MOL BIOL CELL, V9, P2393, DOI 10.1091/mbc.9.9.2393; NISHIZAWA M, 1994, MOL GEN GENET, V245, P301, DOI 10.1007/BF00290110; Poon RYC, 1997, J BIOL CHEM, V272, P5703, DOI 10.1074/jbc.272.9.5703; Sutton A, 1997, GENETICS, V147, P57; Timblin BK, 1996, GENETICS, V143, P57; TOHE A, 1988, MOL GEN GENET, V214, P162, DOI 10.1007/BF00340196; TOHE A, 1973, J BACTERIOL, V113, P727, DOI 10.1128/JB.113.2.727-738.1973; TSAI LH, 1993, DEVELOPMENT, V119, P1029; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; UESONO Y, 1987, NUCLEIC ACIDS RES, V15, P10299, DOI 10.1093/nar/15.24.10299; Wickert S, 1998, J BACTERIOL, V180, P1887, DOI 10.1128/JB.180.7.1887-1894.1998; [No title captured]	34	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					33859	33862		10.1074/jbc.274.48.33859	http://dx.doi.org/10.1074/jbc.274.48.33859			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567344	hybrid			2022-12-25	WOS:000083857500009
J	Mo, HQ; Rice, KG; Evers, DL; Winter, HC; Peumans, WJ; Van Damme, EJM; Goldstein, IJ				Mo, HQ; Rice, KG; Evers, DL; Winter, HC; Peumans, WJ; Van Damme, EJM; Goldstein, IJ			Xanthosoma sagittifolium tubers contain a lectin with two different types of carbohydrate-binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED OLIGOSACCHARIDES; MANNOSE-SPECIFIC LECTIN; PREPARATIVE PURIFICATION; MONOCOT LECTINS; ARUM-MACULATUM; FAMILY ARACEAE; BULBS; DERIVATIZATION; PROTEINS; CHROMATOGRAPHY	An unusual lectin possessing two distinctly different types of carbohydrate combining sites was purified from tubers of Xanthosoma sagittifolium L. by consecutive passage through two affinity columns, i.e. asialofetuin-Sepharose and invertase-Sepharose. SDS-polyacrylamide gel electrophoresis, N-terminal amino acid sequencing, and gel filtration chromatography of the purified lectin showed that the X sagittifolium lectin is a heterotetrameric protein composed of four 12-kDa subunits (alpha(2)beta(2)) linked by noncovalent bonds. The results obtained by quantitative precipitation and hapten inhibition assays revealed that the lectin has two different types of carbohydrate-combining sites: one type for oligomannoses, which preferentially binds to a cluster of nonreducing terminal alpha 1,3-linked mannosyl residues, and the other type for complex N-linked carbohydrates, which best accommodates a non-sialylated, triantennary oligosaccharide with N-acetyllactosamine (i.e. Gal beta 1,4GlcNAc-) or lacto-N-biose (i.e. Gal beta 1,3GlcNAc-) groups at its three nonreducing termini.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Coll Pharm, Dept Med Chem, Ann Arbor, MI 48109 USA; Katholieke Univ Leuven, Lab Fytopathol & Plantenbescherming, B-3001 Heverlee, Belgium	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; KU Leuven	Goldstein, IJ (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.		Van Damme, Els J/B-4410-2015; Van Damme, Els/U-3904-2019	Van Damme, Els/0000-0001-9848-766X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767, R01GM029470] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 29470, GM 07767] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN AK, 1995, BBA-GEN SUBJECTS, V1244, P129, DOI 10.1016/0304-4165(94)00210-O; Antonyuk L. Ya, 1993, Biokhimiya, V58, P367; CAMMUE BPA, 1986, PLANTA, V169, P583, DOI 10.1007/BF00392110; CHIU MH, 1994, J BIOL CHEM, V269, P16195; DASILVA MLC, 1994, ARCH BIOCHEM BIOPHYS, V312, P151, DOI 10.1006/abbi.1994.1293; DASILVA MLC, 1994, ARCH BIOCHEM BIOPHYS, V315, P460, DOI 10.1006/abbi.1994.1525; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; ETZLER ME, 1986, LETINS PROPERTIES FU, p3P71; Evers DL, 1998, ANAL BIOCHEM, V265, P313, DOI 10.1006/abio.1998.2895; GOLDSTEIN IJ, 1980, NATURE, V285, P66, DOI 10.1038/285066b0; KAKU H, 1990, ARCH BIOCHEM BIOPHYS, V279, P298, DOI 10.1016/0003-9861(90)90495-K; KAMBOJ SS, 1995, IMMUNOL INVEST, V24, P845, DOI 10.3109/08820139509060711; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCH SC, 1974, ANAL BIOCHEM, V60, P149, DOI 10.1016/0003-2697(74)90139-0; MO HQ, 1994, J BIOL CHEM, V269, P7666; MO HQ, 1993, ARCH BIOCHEM BIOPHYS, V306, P431, DOI 10.1006/abbi.1993.1534; ODA Y, 1986, EUR J BIOCHEM, V159, P239, DOI 10.1111/j.1432-1033.1986.tb09859.x; RASCHKE WC, 1971, BIOCHEMISTRY-US, V10, P4130, DOI 10.1021/bi00798a018; RICE KG, 1992, ANAL BIOCHEM, V206, P278, DOI 10.1016/0003-2697(92)90367-G; RUDIGER H, 1988, ADV LECTIN RES, V1, P26; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHANGARY S, 1995, PHYTOCHEMISTRY, V40, P449, DOI 10.1016/0031-9422(95)00229-Z; SHARON N, 1990, FASEB J, V4, P3198, DOI 10.1096/fasebj.4.14.2227211; SHIBUYA N, 1988, J BIOL CHEM, V263, P728; Stubbs HJ, 1997, ANAL BIOCHEM, V247, P357, DOI 10.1006/abio.1997.2070; TAMURA T, 1994, ANAL BIOCHEM, V216, P335, DOI 10.1006/abio.1994.1050; TRIMBLE RB, 1983, J BIOL CHEM, V258, P2562; Van Damme EJM, 1995, LECTINS BIOMEDICAL P, P59; VANDAMME EJM, 1995, PLANT PHYSIOL, V107, P1147, DOI 10.1104/pp.107.4.1147; VANDAMME EJM, 1988, PHYSIOL PLANTARUM, V73, P52, DOI 10.1111/j.1399-3054.1988.tb09192.x; VANDAMME EJM, 1987, PLANT PHYSIOL, V85, P566, DOI 10.1104/pp.85.2.566; VANDAMME EJM, 1991, PHYTOCHEMISTRY, V30, P509, DOI 10.1016/0031-9422(91)83716-X; WARREN L, 1959, J BIOL CHEM, V234, P1971	34	21	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33300	33305		10.1074/jbc.274.47.33300	http://dx.doi.org/10.1074/jbc.274.47.33300			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559206	hybrid			2022-12-25	WOS:000083745200022
J	Navas, TA; Baldwin, DT; Stewart, TA				Navas, TA; Baldwin, DT; Stewart, TA			RIP2 is a Raf1-activated mitogen-activated protein kinase kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INDUCED CELL-DEATH; SIGNAL-TRANSDUCTION; MOUSE MACROPHAGES; PLASMA-MEMBRANE; CD95 FAS/APO-1; AP-1 ACTIVITY; RAF-1 KINASE; MAPK CASCADE; TNF	RIPS is a serine-threonine kinase associated with the tumor necrosis factor (TNF) receptor complex and is implicated in the activation of NF-kappa B and cell death in mammalian cells. However, the function of its kinase domain is still enigmatic as it is not required in engaging these responses. Here we show that RIPE activates the extracellular signal-regulated kinase (ERR) pathway and that the kinase activity of RIPS appears to be important in this process. RIPS activates AP-1 and serum response element regulated expression by inducing the activation of the Elk1 transcription factor. RIPS directly phosphorylates and activates ERK2 in vivo and in vitro. RIP2 in turn is activated through its interaction with Ras-activated Raf1. Kinase-defective point and deletion variants of RIP2 also significantly blocked the activation of ERK2 by TNF alpha but not epidermal growth factor. These results describe a novel pathway of ERK activation and the first catalytic function ascribed to any of the RIP-like kinases associated with the TNF receptor superfamily.	Genentech Inc, Dept Endocrine Res, S San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Biol, S San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Stewart, TA (corresponding author), Genentech Inc, Dept Endocrine Res, 1 DNA Way,MS 37, S San Francisco, CA 94080 USA.							Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Denouel-Galy A, 1998, CURR BIOL, V8, P46, DOI 10.1016/S0960-9822(98)70019-3; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Elion EA, 1998, SCIENCE, V281, P1625, DOI 10.1126/science.281.5383.1625; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hildt E, 1999, J EXP MED, V189, P1707, DOI 10.1084/jem.189.11.1707; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Huwiler A, 1996, P NATL ACAD SCI USA, V93, P6959, DOI 10.1073/pnas.93.14.6959; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lu YM, 1999, J BIOL CHEM, V274, P10047, DOI 10.1074/jbc.274.15.10047; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muller G, 1998, EMBO J, V17, P732, DOI 10.1093/emboj/17.3.732; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; WINSTON BW, 1995, J IMMUNOL, V155, P1525; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yu W, 1998, CURR BIOL, V8, P56, DOI 10.1016/S0960-9822(98)70020-X; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	53	75	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33684	33690		10.1074/jbc.274.47.33684	http://dx.doi.org/10.1074/jbc.274.47.33684			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559258	hybrid			2022-12-25	WOS:000083745200074
J	Xia, P; Vadas, MA; Rye, KA; Barter, PJ; Gamble, JR				Xia, P; Vadas, MA; Rye, KA; Barter, PJ; Gamble, JR			High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway - A possible mechanism for protection against atherosclerosis by HDL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULES; APOLIPOPROTEIN-A-I; CORONARY-ARTERY DISEASE; E-SELECTIN EXPRESSION; ENDOTHELIAL-CELLS; HEART-DISEASE; KAPPA-B; CHOLESTEROL; SPHINGOSINE-1-PHOSPHATE; ATHEROGENESIS	The ability of high density lipoproteins (HDL) to inhibit cytokine-induced adhesion molecule expression has been demonstrated in their protective function against the development of atherosclerosis and associated coronary heart disease. A key event in atherogenesis is endothelial activation induced by a variety of stimuli such as tumor necrosis factor-alpha (TNF), resulting in the expression of various adhesion proteins, We have recently reported that sphingosine I-phosphate, generated by sphingosine kinase activation, is a key molecule in mediating TNF-induced adhesion protein expression. We now show that HDL profoundly inhibit TNF-stimulated sphingosine kinase activity in endothelial cells resulting in a decrease in sphingosine I-phosphate production and adhesion protein expression. HDL also reduced TNF-mediated activation of extracellular signal-regulated kinases and NF-kappa B signaling cascades, Furthermore, HDL enhanced the cellular levels of ceramide which in turn inhibits endothelial activation, Thus, the regulation of sphingolipid signaling in endothelial cells by HDL provides a novel insight into the mechanism of protection against atherosclerosis.	Univ Adelaide, Inst Med & Vet Sci, Div Human Immunol, Adelaide, SA 5000, Australia; Univ Adelaide, Inst Med & Vet Sci, Hanson Ctr Canc Res, Dept Lipid Res, Adelaide, SA 5000, Australia	Institute Medical & Veterinary Science Australia; University of Adelaide; Institute Medical & Veterinary Science Australia; University of Adelaide	Gamble, JR (corresponding author), Univ Adelaide, Inst Med & Vet Sci, Div Human Immunol, Adelaide, SA 5000, Australia.		Vadas, Mathew/R-1378-2019; Xia, Pu/G-3090-2010	Xia, Pu/0000-0003-4705-8878; Gamble, Jennifer/0000-0002-0179-9964				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Allen S, 1998, J CLIN INVEST, V101, P1064, DOI 10.1172/JCI445; Ashby DT, 1998, ARTERIOSCL THROM VAS, V18, P1450, DOI 10.1161/01.ATV.18.9.1450; ASSMANN G, 1992, AM J CARDIOL, V70, P733, DOI 10.1016/0002-9149(92)90550-I; Baker PW, 1999, J LIPID RES, V40, P345; Calabresi L, 1997, BIOCHEM BIOPH RES CO, V238, P61, DOI 10.1006/bbrc.1997.7236; COCKERILL GW, 1995, ARTERIOSCL THROM VAS, V15, P1987, DOI 10.1161/01.ATV.15.11.1987; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; FIELDING CJ, 1995, J LIPID RES, V36, P211; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; Hajjar DP, 1997, J BIOL CHEM, V272, P22975, DOI 10.1074/jbc.272.37.22975; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hwang SJ, 1997, CIRCULATION, V96, P4219; Igarashi Y, 1998, ACTA BIOCHIM POL, V45, P299, DOI 10.18388/abp.1998_4226; JANG YS, 1994, J AM COLL CARDIOL, V24, P1591, DOI 10.1016/0735-1097(94)90162-7; Johnson RC, 1997, J CLIN INVEST, V99, P1037, DOI 10.1172/JCI119231; KOLESNICK RN, 1994, BIOCH CELL BIOL, V72, P741; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Libby P, 1996, ATHEROSCLEROSIS CORO, P585; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MENDEZ AJ, 1994, J CLIN INVEST, V94, P1698, DOI 10.1172/JCI117515; Moudry R, 1997, SHOCK, V7, P175, DOI 10.1097/00024382-199703000-00004; Nageh MF, 1997, ARTERIOSCL THROM VAS, V17, P1517, DOI 10.1161/01.ATV.17.8.1517; Navab M, 1998, CURR OPIN LIPIDOL, V9, P449, DOI 10.1097/00041433-199810000-00009; OBrien KD, 1996, CIRCULATION, V93, P672, DOI 10.1161/01.CIR.93.4.672; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; POSTON RN, 1992, AM J PATHOL, V140, P665; Rakhit S, 1999, BIOCHEM J, V338, P643, DOI 10.1042/0264-6021:3380643; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Ridker PM, 1998, LANCET, V351, P88, DOI 10.1016/S0140-6736(97)09032-6; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; SILVERMAN DI, 1993, AM J MED, V94, P636, DOI 10.1016/0002-9343(93)90217-D; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Vadas MA, 1996, CIRC RES, V79, P1216, DOI 10.1161/01.RES.79.6.1216; VANDERWAL AC, 1992, AM J PATHOL, V141, P161; WALL RT, 1978, J CELL PHYSIOL, V96, P203, DOI 10.1002/jcp.1040960209; Watts JD, 1997, P NATL ACAD SCI USA, V94, P7292, DOI 10.1073/pnas.94.14.7292; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196	42	194	222	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					33143	33147		10.1074/jbc.274.46.33143	http://dx.doi.org/10.1074/jbc.274.46.33143			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551885	hybrid			2022-12-25	WOS:000083623000085
J	Grietzen, KF; Virshup, DM				Grietzen, KF; Virshup, DM			Identification of inhibitory autophosphorylation sites in casein kinase I epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							40 DNA-REPLICATION; SCHIZOSACCHAROMYCES-POMBE; SUBSTRATE DETERMINANTS; PROTEIN-KINASES; PHOSPHORYLATION; EXPRESSION; CYCLE; DELTA; GENE; ISOFORM	Casein kinase I epsilon (CKI epsilon) is a widely expressed protein kinase implicated in the regulation of diverse cellular processes including DNA replication and repair, nuclear trafficking, and circadian rhythm. CKI epsilon and the closely related CKI delta are regulated in part through autophosphorylation of their carboxyl-terminal extensions, resulting in down-regulation of enzyme activity. Treatment of CKI epsilon with any of several serine/threonine phosphatases causes a marked increase in kinase activity that is self-limited. To identify the sites of inhibitory autophosphorylation, a series of carboxyl-terminal dele deletion mutants was constructed by site-directed mutagenesis, Truncations that eliminated specific phosphopeptides present in the wild-type kinase were used to guide construction of specific serine/threonine to alanine mutants, Amino acids Ser-323, Thr-325, Thr-334, Thr-337, Ser-368, Ser-405, Thr-407, and Ser-408 in the carboxyl-terminal tail of CKI epsilon were identified as probable in vivo autophosphorylation sites. A recombinant CKI epsilon protein with serine and threonine to alanine mutations eliminating these autophosphorylation sites was 8-fold more active than wild-type CKI epsilon using I kappa B alpha as a substrate. The identified autophosphorylation sites do not conform to CKI substrate motifs identified in peptide substrates.	Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Div Mol Biol & Genet, Salt Lake City, UT 84132 USA; Univ Utah, Dept Pediat, Div Hematol Oncol, Salt Lake City, UT 84132 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Virshup, DM (corresponding author), Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Div Mol Biol & Genet, 5C334 Hlth Sci Ctr,50 N Med Dr, Salt Lake City, UT 84132 USA.		Virshup, David M/C-1449-2009	Virshup, David M/0000-0001-6976-850X	NCI NIH HHS [CA71074, CA42014] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071074, P30CA042014] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGOSTINIS P, 1989, FEBS LETT, V259, P75, DOI 10.1016/0014-5793(89)81498-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKMAN JL, 1992, P NATL ACAD SCI USA, V89, P9454, DOI 10.1073/pnas.89.20.9454; CARMEL G, 1994, J BIOL CHEM, V269, P7304; CEGIELSKA A, 1994, J VIROL, V68, P269, DOI 10.1128/JVI.68.1.269-275.1994; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; CEGIELSKA A, 1993, MOL CELL BIOL, V13, P1202, DOI 10.1128/MCB.13.2.1202; DHILLON N, 1994, EMBO J, V13, P2777, DOI 10.1002/j.1460-2075.1994.tb06571.x; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; FLOTOW H, 1989, J BIOL CHEM, V264, P9126; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; GRAVES PR, 1995, J BIOL CHEM, V270, P21689, DOI 10.1074/jbc.270.37.21689; Gross SD, 1997, J CELL SCI, V110, P3083; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; HARDIE DG, 1995, PROTEIN PHOSPHORYLAT, P61; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; MILNE DM, 1992, ONCOGENE, V7, P1361; Panek HR, 1997, EMBO J, V16, P4194, DOI 10.1093/emboj/16.14.4194; Rivers A, 1998, J BIOL CHEM, V273, P15980, DOI 10.1074/jbc.273.26.15980; Santos JA, 1996, J CELL SCI, V109, P1847; SONGYANG Z, 1996, MOL CELL BIOL, V16, P4846; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; VANCURA A, 1994, J BIOL CHEM, V269, P1921; VANDERGEER P, 1995, PROTEIN PHOSHORYLATI, P31; WANG PC, 1992, MOL BIOL CELL, V3, P275, DOI 10.1091/mbc.3.3.275; Wang XM, 1996, MOL CELL BIOL, V16, P5375; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	32	102	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32063	32070		10.1074/jbc.274.45.32063	http://dx.doi.org/10.1074/jbc.274.45.32063			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542239	hybrid			2022-12-25	WOS:000083532100047
J	Nozaki, T; Asai, T; Sanchez, LB; Kobayashi, S; Nakazawa, M; Takeuchi, T				Nozaki, T; Asai, T; Sanchez, LB; Kobayashi, S; Nakazawa, M; Takeuchi, T			Characterization of the gene encoding serine acetyltransferase, a regulated enzyme of cysteine biosynthesis from the protist parasites Entamoeba histolytica and Entamoeba dispar - Regulation and possible function of the cysteine biosynthetic pathway in entamoeba	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; ACETYLSERINE THIOL LYASE; ARABIDOPSIS-THALIANA; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; O-ACETYLSERINE; SPINACH-CHLOROPLASTS; KINETIC-PROPERTIES; HYDROGEN-PEROXIDE; IDENTIFICATION	The enteric protist parasites Entamoeba histolytica and Entamoeba dispar possess a cysteine biosynthetic pathway, unlike their mammalian host, and are capable of de novo production of L-cysteine. We cloned and characterized cDNAs that encode the regulated enzyme serine acetyltransferase (SAT) in this pathway from these amoebae by genetic complementation of a cysteine-auxotrophic Escherichia coli strain with the amoebic cDNA libraries. The deduced amino acid sequences of the amoebic SATs exhibited, within the most conserved region, 36-52% identities with the bacterial and plant SATs. The amoebic SATs contain a unique insertion of eight amino acids, also found in the corresponding region of a plasmid-encoded SAT from Synechococcus sp., which showed the highest overall. identities to the amoebic SATs, Phylogenetic reconstruction also revealed a close kinship of the amoebic SATs with cyanobacterial SATs, Biochemical characterization of the recombinant E. histolytica SAT revealed several enzymatic features that distinguished the amoebic enzyme from the bacterial and plant enzymes: 1) inhibition by L-cysteine in a competitive manner with L-serine; 2) inhibition by L-cystine; and 3) no association with cysteine synthase. Genetically engineered amoeba strains that overproduced cysteine synthase and SAT were created. The cysteine synthase-overproducing amoebae had a higher level of cysteine synthase activity and total thiol content and revealed increased resistance to hydrogen peroxide, These results indicate that the cysteine biosynthetic pathway plays an important role in antioxidative defense of these enteric parasites.	Natl Inst Infect Dis, Dept Parasitol, Shinjuku Ku, Tokyo 1628640, Japan; Keio Univ, Sch Med, Dept Trop Med & Parasitol, Shinjuku Ku, Tokyo 1608582, Japan; Rockefeller Univ, New York, NY 10021 USA	National Institute of Infectious Diseases (NIID); Keio University; Rockefeller University	Nozaki, T (corresponding author), Natl Inst Infect Dis, Dept Parasitol, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.	nozaki@nih.go.jp	Kobayashi, seiki/L-4026-2013		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI011942] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11942] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adachi J., 1996, COMPUT SCI MONOGR, V28, P1; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAECKER PA, 1980, ANAL BIOCHEM, V102, P16, DOI 10.1016/0003-2697(80)90310-3; BAKKERGRUNWALD T, 1995, J EUKARYOT MICROBIOL, V42, P346, DOI 10.1111/j.1550-7408.1995.tb01592.x; BEILAN HS, 1983, ANAL BIOCHEM, V128, P169, DOI 10.1016/0003-2697(83)90358-5; Bogdanova N, 1997, PLANT J, V11, P251, DOI 10.1046/j.1365-313X.1997.11020251.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruchhaus I, 1997, BIOCHEM J, V326, P785, DOI 10.1042/bj3260785; BRUCHHAUS I, 1995, MOL BIOCHEM PARASIT, V70, P187, DOI 10.1016/0166-6851(94)00214-8; DENK D, 1987, J GEN MICROBIOL, V133, P515; DIAMOND LS, 1978, T ROY SOC TROP MED H, V72, P431, DOI 10.1016/0035-9203(78)90144-X; DIAMOND LS, 1972, J VIROL, V9, P326, DOI 10.1128/JVI.9.2.326-341.1972; DROUX M, 1992, ARCH BIOCHEM BIOPHYS, V295, P379, DOI 10.1016/0003-9861(92)90531-Z; Droux M, 1998, EUR J BIOCHEM, V255, P235, DOI 10.1046/j.1432-1327.1998.2550235.x; EVANS DJ, 1991, J BACTERIOL, V173, P5457, DOI 10.1128/jb.173.17.5457-5469.1991; FAHEY RC, 1984, SCIENCE, V224, P70, DOI 10.1126/science.6322306; GAGNON Y, 1994, J BIOL CHEM, V269, P7473; GAITONDE MK, 1967, BIOCHEM J, V104, P627, DOI 10.1042/bj1040627; GILLIN FD, 1980, J PROTOZOOL, V27, P220; GILLIN FD, 1984, MOL BIOCHEM PARASIT, V13, P1, DOI 10.1016/0166-6851(84)90096-3; GILLIN FD, 1981, EXP PARASITOL, V52, P9, DOI 10.1016/0014-4894(81)90055-2; GILLIN FD, 1980, J PROTOZOOL, V27, P474, DOI 10.1111/j.1550-7408.1980.tb05402.x; GUARENTE L, 1993, P NATL ACAD SCI USA, V90, P1639, DOI 10.1073/pnas.90.5.1639; HAMANN L, 1995, P NATL ACAD SCI USA, V92, P8975, DOI 10.1073/pnas.92.19.8975; HEDIGER MA, 1985, P NATL ACAD SCI USA, V82, P6414, DOI 10.1073/pnas.82.19.6414; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOCELYN PC, 1987, METHOD ENZYMOL, V143, P44; KADIN H, 1987, METHOD ENZYMOL, V143, P257; Kaneko T, 1997, PLANT CELL PHYSIOL, V38, P1171, DOI 10.1093/oxfordjournals.pcp.a029103; KISHINO H, 1990, J MOL EVOL, V31, P151, DOI 10.1007/BF02109483; KOBAYASHI S, 1998, J EUKARYOT MICROBI S, V45, P3; KREDICH NM, 1969, J BIOL CHEM, V244, P2428; KREDICH NM, 1992, MOL MICROBIOL, V6, P2747, DOI 10.1111/j.1365-2958.1992.tb01453.x; LAI CY, 1992, GENE, V119, P113, DOI 10.1016/0378-1119(92)90074-Y; McNabb DS, 1996, CURR OPIN BIOTECH, V7, P554, DOI 10.1016/S0958-1669(96)80061-9; Mehlotra RK, 1996, CRIT REV MICROBIOL, V22, P295, DOI 10.3109/10408419609105484; MIRELMAN D, 1986, INFECT IMMUN, V54, P827, DOI 10.1128/IAI.54.3.827-832.1986; MURAKOSHI I, 1985, PHYTOCHEMISTRY, V24, P1907, DOI 10.1016/S0031-9422(00)83090-3; Murillo M, 1995, CELL MOL BIOL RES, V41, P425; MURRAY HW, 1981, MOL BIOCHEM PARASIT, V3, P381, DOI 10.1016/0166-6851(81)90038-4; NAKAMURA K, 1988, PLANT CELL PHYSIOL, V29, P689; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; NEUENSCHWANDER U, 1991, PLANT PHYSIOL, V97, P253, DOI 10.1104/pp.97.1.253; NICHOLSON ML, 1995, MOL GEN GENET, V247, P623, DOI 10.1007/BF00290354; NICKEL R, 1994, P NATL ACAD SCI USA, V91, P7095, DOI 10.1073/pnas.91.15.7095; NOAZAKI T, 1998, BIOCHIM BIOPHYS ACTA, V1429, P284; Noji M, 1998, J BIOL CHEM, V273, P32739, DOI 10.1074/jbc.273.49.32739; Nozaki T, 1998, MOL BIOCHEM PARASIT, V97, P33, DOI 10.1016/S0166-6851(98)00129-7; Nozaki T, 1995, MOL BIOCHEM PARASIT, V75, P55, DOI 10.1016/0166-6851(95)02512-X; Olvera A, 1997, Arch Med Res, V28 Spec No, P49; PHILIPPE H, 1993, NUCLEIC ACIDS RES, V21, P5264, DOI 10.1093/nar/21.22.5264; RAETZ CRH, 1995, SCIENCE, V270, P997, DOI 10.1126/science.270.5238.997; REED SL, 1992, INFECT IMMUN, V60, P542, DOI 10.1128/IAI.60.2.542-549.1992; REEVES RE, 1980, EXP PARASITOL, V49, P83, DOI 10.1016/0014-4894(80)90059-4; RENNENBERG H, 1983, PLANT PHYSIOL, V73, P560, DOI 10.1104/pp.73.3.560; Roberts MA, 1996, PLANT MOL BIOL, V30, P1041, DOI 10.1007/BF00020814; Rosenthal B, 1997, J BACTERIOL, V179, P3736, DOI 10.1128/jb.179.11.3736-3745.1997; RUFFET ML, 1994, PLANT PHYSIOL, V104, P597, DOI 10.1104/pp.104.2.597; RUFFET ML, 1995, EUR J BIOCHEM, V227, P500, DOI 10.1111/j.1432-1033.1995.tb20416.x; SAETRE R, 1978, ANAL CHEM, V50, P276, DOI 10.1021/ac50024a027; SAITO K, 1995, J BIOL CHEM, V270, P16321, DOI 10.1074/jbc.270.27.16321; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Singh U, 1997, P NATL ACAD SCI USA, V94, P8812, DOI 10.1073/pnas.94.16.8812; SMABROOK J, 1989, MOL CLONING LAB MANU; SURIN BP, 1988, MOL MICROBIOL, V2, P173, DOI 10.1111/j.1365-2958.1988.tb00019.x; TENNIGKEIT J, 1991, GENE, V98, P113, DOI 10.1016/0378-1119(91)90112-O; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WEINBACH EC, 1976, J PARASITOL, V62, P127, DOI 10.2307/3279066; *WHO, 1995, WORLD HEALTH FORUM, V16, P377	69	100	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32445	32452		10.1074/jbc.274.45.32445	http://dx.doi.org/10.1074/jbc.274.45.32445			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542289	hybrid			2022-12-25	WOS:000083532100097
J	Proudfoot, AEI; Buser, R; Borlat, F; Alouani, S; Soler, D; Offord, RE; Schroder, JM; Power, CA; Wells, TNC				Proudfoot, AEI; Buser, R; Borlat, F; Alouani, S; Soler, D; Offord, RE; Schroder, JM; Power, CA; Wells, TNC			Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTOR; CCR5 EXPRESSION; ANTAGONIST; HIV; MONOCYTES; INFECTION; INTERNALIZATION; INTERLEUKIN-8; INFLAMMATION; ENDOCYTOSIS	Modification of the amino terminus of regulated on activated normal T-cell expressed (RANTES) has been shown to have a significant effect on biological activity and produces proteins with antagonist properties. Two amino-terminally modified RANTES proteins, Met-RANTES and aminooxypentane-RANTES (AOP-RANTES), exhibit differential inhibitory properties on both monocyte and eosinophil chemotaxis, We have investigated their binding properties as well as their ability to activate the RANTES receptors CCR1, CCR3, and CCR5 in cell lines overexpressing these receptors, We show that Met-RANTES has weak activity in eliciting a calcium response in Chinese hamster ovary cells expressing CCR1, CCR3, and CCR5, whereas AOP-RANTES has full agonist activity on CCR5 but is less effective on CCR3 and CCR1, Their ability to induce chemotaxis of the murine pre-B lymphoma cell line, L1.2, transfected with the same receptors, consolidates these results, Monocytes have detectable mRNA for CCR1, CCR2, CCR3, CCR4, and CCR5, and they respond to the ligands for these receptors in chemotaxis but not always in calcium mobilization, AOP-RANTES does not induce calcium mobilization in circulating monocytes but is able to do so as these cells acquire the macrophage phenotype, which coincides with a concomitant up-regulation of CCR5, We have also tested the ability of both modified proteins to induce chemotaxis of freshly isolated monocytes and eosinophils, Cells from most donors do not respond, but occasionally cells from a particular donor do respond, particularly to AOP-RANTES, We therefore hypothesize that the occasional activity of AOP-RANTES to induce leukocyte chemotaxis is due to donor to donor variation of receptor expression.	Serono Pharmaceut Res Inst, Geneva, Switzerland; LeukoSite Inc, Cambridge, MA 02142 USA; Univ Kiel, Dept Dermatol & Allergol, Kiel, Germany; Ctr Med Univ Geneva, Dept Biochim Med, CH-1228 Geneva, Switzerland	University of Kiel; University of Geneva	Proudfoot, AEI (corresponding author), Serono Pharmaceut Res Inst, 14 Chem Aulx,1228 Plan Ouates, Geneva, Switzerland.	amanda.proudfoot@serono.com	Schroeder, Jens M/B-3994-2009	Wells, Timothy/0000-0001-9796-847X				Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Bonecchi R, 1999, J IMMUNOL, V162, P474; Campbell EM, 1998, J IMMUNOL, V161, P7047; Clemons MJ, 1998, BLOOD, V92, P1532, DOI 10.1182/blood.V92.5.1532.417k18_1532_1540; Coulin F, 1997, EUR J BIOCHEM, V248, P507, DOI 10.1111/j.1432-1033.1997.00507.x; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; Gong JH, 1996, J BIOL CHEM, V271, P10521, DOI 10.1074/jbc.271.18.10521; GONG JH, 1995, J EXP MED, V181, P631, DOI 10.1084/jem.181.2.631; Gong JH, 1997, J EXP MED, V186, P131, DOI 10.1084/jem.186.1.131; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; Grewal IS, 1997, J IMMUNOL, V159, P401; Grone HJ, 1999, FASEB J, V13, P1371, DOI 10.1096/fasebj.13.11.1371; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617; Lloyd GM, 1997, J EXP MED, V185, P1371, DOI 10.1084/jem.185.7.1371; Loetscher P, 1996, J EXP MED, V184, P569, DOI 10.1084/jem.184.2.569; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; LUSTINARASIMHAN M, 1995, J BIOL CHEM, V270, P2716, DOI 10.1074/jbc.270.6.2716; Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215; MASSARI FE, 1990, J IMMUNOL, V144, P4628; MOSER B, 1993, J BIOL CHEM, V268, P7125; Naif HM, 1998, J VIROL, V72, P830, DOI 10.1128/JVI.72.1.830-836.1998; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Nieto M, 1997, J EXP MED, V186, P153, DOI 10.1084/jem.186.1.153; PlaterZyberk C, 1997, IMMUNOL LETT, V57, P117, DOI 10.1016/S0165-2478(97)00075-8; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; Proudfoot AEI, 1999, BIOCHEM PHARMACOL, V57, P451; PROUDFOOT AEI, 1995, FEBS LETT, V376, P19, DOI 10.1016/0014-5793(95)01235-X; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Schroder JM, 1997, METHOD ENZYMOL, V288, P266; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Solari R, 1997, J BIOL CHEM, V272, P9617; Sozzani S, 1998, J EXP MED, V187, P439, DOI 10.1084/jem.187.3.439; Wells TNC, 1998, TRENDS PHARMACOL SCI, V19, P376, DOI 10.1016/S0165-6147(98)01247-4; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; ZHANG YJ, 1995, MOL CELL BIOL, V15, P4851	38	126	134	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32478	32485		10.1074/jbc.274.45.32478	http://dx.doi.org/10.1074/jbc.274.45.32478			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542293	hybrid			2022-12-25	WOS:000083532100101
J	Simoneau, JA; Veerkamp, JH; Turcotte, LP; Kelley, DE				Simoneau, JA; Veerkamp, JH; Turcotte, LP; Kelley, DE			Markers of capacity to utilize fatty acids in human skeletal muscle: relation to insulin resistance and obesity and effects of weight loss	FASEB JOURNAL			English	Article						carnitine palmitoyl transferase; fatty acid binding proteins; lipoprotein lipase; maximal aerobic power; fatty acid oxidation	LIPOPROTEIN-LIPASE ACTIVITY; DEPENDENT DIABETES-MELLITUS; BINDING PROTEIN; WOMEN; METABOLISM; OXIDATION; GLUCOSE; SENSITIVITY; MEN; TRIGLYCERIDE	A number of biochemical defects have been identified in glucose metabolism within skeletal muscle in obesity, and positive effects of weight loss on insulin resistance are also well established. Less is known about the capacity of skeletal muscle for the metabolism of fatty acids in obesity-related insulin resistance and of the effects of weight loss, though it is evident that muscle contains increased triglyceride. The current study was therefore undertaken to profile markers of human skeletal muscle for fatty acid metabolism in relation to obesity, in relation to the phenotype of insulin-resistant glucose metabolism, and to examine the effects of weight loss. Fifty-five men and women, lean and obese, with normal glucose tolerance underwent percutaneous biopsy of vastus lateralis skeletal muscle for determination of HADH, CPT, heparin-releasable (Hr) and tissue-extractable (Ext) LPL, CS, COX, PFK, and GAPDH enzyme activities, and content of cytosolic and plasma membrane FABP. Insulin sensitivity was measured using the euglycemic clamp method. DEXA was used to measure FM and FFM. In skeletal muscle of obese individuals, CPT, CS, and COX activities were lower while, conversely, they had a higher or similar content of FABP(C) and FABP(PM) than in lean individuals. Hr and Ext LPL activities were similar in both groups. In multivariate and simple regression analyses, there were significant correlations between insulin resistance and several markers of FA metabolism, notably, CPT and FABP(PM). These data suggest that in obesity-related insulin resistance, the metabolic capacity of skeletal muscle appears to be organized toward fat esterification rather than oxidation and that dietary-induced weight loss does not correct this disposition.-Simoneau, J.-A., Veerkamp, J. H., Turcotte, L. P., Kelley, D. E. Markers of capacity to utilize fatty acids in human skeletal muscle: relation to insulin resistance and obesity and effects of weight loss.	Univ Pittsburgh, Dept Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Div Endocrinol & Metab, Pittsburgh, PA 15213 USA; Univ Laval, Div Kinesiol, Dept Social & Prevent Med, Fac Med, Ste Foy, PQ G1K 7P4, Canada; Catholic Univ Nijmegen, Fac Med Sci, Dept Biochem, NL-6500 HC Nijmegen, Netherlands; Univ So Calif, Dept Exercise Sci, Los Angeles, CA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Laval University; Radboud University Nijmegen; University of Southern California	Kelley, DE (corresponding author), Univ Pittsburgh, Dept Med, E-1140 Biomed Sci Tower, Pittsburgh, PA 15213 USA.	Kelley@msx.dept.-med.pitt.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK046204, R01DK049200] Funding Source: NIH RePORTER; NCRR NIH HHS [5MO1RR00056] Funding Source: Medline; NIDDK NIH HHS [1P30DK46204, R01 DK49200-02] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASS A, 1975, PFLUG ARCH EUR J PHY, V359, P325, DOI 10.1007/BF00581443; BELFRAGE P, 1969, J LIPID RES, V10, P341; BLAAK EE, 1994, AM J PHYSIOL, V267, pE316, DOI 10.1152/ajpendo.1994.267.2.E316; BOGARDUS C, 1985, AM J PHYSIOL, V248, pE286, DOI 10.1152/ajpendo.1985.248.3.E286; Bonen A, 1998, AM J PHYSIOL-ENDOC M, V275, pE471, DOI 10.1152/ajpendo.1998.275.3.E471; BRADY PS, 1993, FASEB J, V7, P1039, DOI 10.1096/fasebj.7.11.8370473; CALLESESCANDON J, 1995, LIFE SCI, V58, P19, DOI 10.1016/0024-3205(95)02251-1; COLBERG SR, 1995, J CLIN INVEST, V95, P1846, DOI 10.1172/JCI117864; Cortright RN, 1997, J NUTR BIOCHEM, V8, P228, DOI 10.1016/S0955-2863(97)89660-X; DAGENAIS GR, 1976, J CLIN INVEST, V58, P421, DOI 10.1172/JCI108486; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; DOHM GL, 1988, J CLIN INVEST, V82, P486, DOI 10.1172/JCI113622; ECKEL RH, 1995, INT J OBESITY, V19, pS16; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; ECKEL RH, 1995, EUR J CLIN INVEST, V25, P396, DOI 10.1111/j.1365-2362.1995.tb01720.x; EVANS DJ, 1984, J CLIN INVEST, V74, P1515, DOI 10.1172/JCI111565; FELBER JP, 1987, DIABETES, V36, P1341, DOI 10.2337/diabetes.36.11.1341; FERRARO R, 1992, J CLIN INVEST, V90, P780, DOI 10.1172/JCI115951; FERRARO RT, 1993, J CLIN INVEST, V92, P441, DOI 10.1172/JCI116586; Fielding BA, 1998, BRIT J NUTR, V80, P495, DOI 10.1017/S0007114598001585; FINEGOOD DT, 1987, DIABETES, V36, P914, DOI 10.2337/diabetes.36.8.914; GAUTHIER JM, 1992, MED SCI SPORT EXER, V24, P1252; Goodpaster BH, 1997, DIABETES, V46, P1579, DOI 10.2337/diabetes.46.10.1579; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; HICKEY MS, 1995, AM J PHYSIOL-ENDOC M, V269, pE150, DOI 10.1152/ajpendo.1995.269.1.E150; HOWALD H, 1990, INT J SPORTS MED, V11, pS10, DOI 10.1055/s-2007-1024847; KELLEY DE, 1994, J CLIN INVEST, V94, P2349, DOI 10.1172/JCI117600; KELLEY DE, 1993, J CLIN ENDOCR METAB, V77, P1287, DOI 10.1210/jc.77.5.1287; KELLEY DE, 1990, AM J PHYSIOL, V258, pE923, DOI 10.1152/ajpendo.1990.258.6.E923; KELLEY DE, 1997, OBES RES, V5, pS12; Kiens B, 1997, BIOCHEM BIOPH RES CO, V231, P463, DOI 10.1006/bbrc.1997.6118; LEAN MEJ, 1988, INT J OBESITY, V12, P15; MANDARINO LJ, 1993, AM J PHYSIOL, V265, pE898, DOI 10.1152/ajpendo.1993.265.6.E898; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; OSCAI LB, 1990, J APPL PHYSIOL, V69, P1571, DOI 10.1152/jappl.1990.69.5.1571; Pan DA, 1997, DIABETES, V46, P983, DOI 10.2337/diabetes.46.6.983; PETTE D, 1986, FED PROC, V45, P2910; Phillips DIW, 1996, METABOLISM, V45, P947, DOI 10.1016/S0026-0495(96)90260-7; POLLARE T, 1991, ARTERIOSCLER THROMB, V11, P1192, DOI 10.1161/01.ATV.11.5.1192; Ruderman NB, 1997, ANN NY ACAD SCI, V827, P221, DOI 10.1111/j.1749-6632.1997.tb51837.x; Saha AK, 1997, AM J PHYSIOL-ENDOC M, V272, pE641, DOI 10.1152/ajpendo.1997.272.4.E641; SEIP RL, 1995, AM J PHYSIOL-ENDOC M, V268, pE229, DOI 10.1152/ajpendo.1995.268.2.E229; SIMONEAU JA, 1995, OBES RES, V3, P23; SIMONEAU JA, 1995, FASEB J, V9, P273, DOI 10.1096/fasebj.9.2.7781930; SIMONEAU JA, 1995, INT J OBESITY, V19, pS9; Simoneau JA, 1999, PROG OBES R, P411; SIMONEAU JA, 1997, HDB OBESITY, P539; TASKINEN MR, 1980, CLIN CHIM ACTA, V104, P107, DOI 10.1016/0009-8981(80)90140-0; Turcotte LP, 1997, MOL CELL BIOCHEM, V166, P153, DOI 10.1023/A:1006846907394; Turcotte LP, 1998, FASEB J, V12, pA231; Turcotte LP, 1999, INT S SPORT, P201; TURCOTTE LP, 1992, AM J PHYSIOL, V262, pE791; VANNIEUWENHOVEN FA, 1995, CIRCULATION, V92, P2848, DOI 10.1161/01.CIR.92.10.2848; VEERKAMP JH, 1995, PROG LIPID RES, V34, P17, DOI 10.1016/0163-7827(94)00005-7; Veerkamp JH, 1996, INT J BIOCHEM CELL B, V28, P473, DOI 10.1016/1357-2725(95)00150-6; VORK MM, 1991, BIOCHIM BIOPHYS ACTA, V1075, P199, DOI 10.1016/0304-4165(91)90267-K; Zechner R, 1997, CURR OPIN LIPIDOL, V8, P77, DOI 10.1097/00041433-199704000-00005; ZURLO F, 1990, AM J PHYSIOL, V259, pE650; ZURLO F, 1994, METABOLISM, V43, P481, DOI 10.1016/0026-0495(94)90081-7	59	358	364	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1999	13	14					2051	2060		10.1096/fasebj.13.14.2051	http://dx.doi.org/10.1096/fasebj.13.14.2051			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544188				2022-12-25	WOS:000083660700017
J	Koritschoner, NP; Bartunek, P; Knespel, S; Blendinger, G; Zenke, M				Koritschoner, NP; Bartunek, P; Knespel, S; Blendinger, G; Zenke, M			The fibroblast growth factor receptor FGFR-4 acts as a ligand dependent modulator of erythroid cell proliferation	ONCOGENE			English	Article						fibroblast growth factor; FGFR-4; bFGF; tyrosine kinase; erythroid cells; hematopoiesis	PROTEIN-TYROSINE KINASE; POLYMERASE CHAIN-REACTION; HUMAN LEUKEMIA-CELLS; PROGENITOR CELLS; SIGNAL-TRANSDUCTION; SELF-RENEWAL; MITOGENIC POTENTIALS; HEMATOPOIETIC-CELLS; MOLECULAR-CLONING; ADAPTER PROTEINS	Receptor and non-receptor tyrosine kinases constitute a large family of proteins that play a pivotal role in hematopoiesis. Here we conducted a comprehensive survey of tyrosine kinase gene expression in primary erythroid progenitor cells from bone marrow by employing a PCR-based strategy that targets the conserved kinase encoding region. We demonstrate that erythroid progenitor cells express several receptor and nonreceptor tyrosine kinases, like c-kit, Jak1, Ryk, FAK, Syk, Arg, Csk and members of the insulin receptor family, Specific changes in the expression profile of tyrosine kinases were observed following differentiation induction. We also report on the identification of a new ligand dependent modulator of erythropoiesis, fibroblast growth factor receptor-4 (FGFR-4), FGFR-4 is effectively expressed in erythroid progenitors and downregulated when cells differentiate. Furthermore, the FGFR-4 ligand, basic fibroblast growth factor (bFGF), enhanced erythroid cell proliferation induced by SCF or insulin, and thus modulated both erythroid proliferation and differentiation in vitro.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Zenke, M (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.		Bartunek, Petr/J-3897-2014	Bartunek, Petr/0000-0002-6202-7650				ARMSTRONG E, 1992, CANCER RES, V52, P2004; Bartunek P, 1996, CYTOKINE, V8, P14, DOI 10.1006/cyto.1996.0003; Bartunek P, 1997, ONCOGENE, V15, P2939, DOI 10.1038/sj.onc.1201457; BEUG H, 1995, METHOD ENZYMOL, V254, P41; Briegel K, 1996, DEVELOPMENT, V122, P3839; BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364; CHOI KG, 1993, P NATL ACAD SCI USA, V90, P5747, DOI 10.1073/pnas.90.12.5747; CHOI KH, 1994, ONCOGENE, V9, P1261; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coulier F, 1997, J MOL EVOL, V44, P43, DOI 10.1007/PL00006120; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DeBerry C, 1997, BIOCHEM J, V327, P73, DOI 10.1042/bj3270073; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; DOLZNIG H, 1995, CELL GROWTH DIFFER, V6, P1341; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; GABRILOVE JL, 1994, BLOOD, V83, P907; GARRIDO C, 1993, VIROLOGY, V192, P578, DOI 10.1006/viro.1993.1074; HALEVY O, 1994, EXP CELL RES, V212, P278, DOI 10.1006/excr.1994.1144; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARRISON ML, 1994, J BIOL CHEM, V269, P955; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; Hoehn GT, 1996, ONCOGENE, V12, P903; Holzenberger M, 1996, DEV BRAIN RES, V97, P76, DOI 10.1016/S0165-3806(96)00133-2; HOVENS CM, 1992, P NATL ACAD SCI USA, V89, P11818, DOI 10.1073/pnas.89.24.11818; Huber TL, 1998, BLOOD, V92, P4128, DOI 10.1182/blood.V92.11.4128.423k46_4128_4137; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; JIA R, 1994, J BIOL CHEM, V269, P1839; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; Madruga J, 1997, ADV EXP MED BIOL, V417, P461; MARCELLE C, 1995, DEV BIOL, V172, P100, DOI 10.1006/dbio.1995.0008; MARCELLE C, 1992, ONCOGENE, V7, P2479; MARCELLE C, 1994, DEVELOPMENT, V120, P683; Mellitzer G, 1996, P NATL ACAD SCI USA, V93, P9600, DOI 10.1073/pnas.93.18.9600; MUTA K, 1994, J CLIN INVEST, V94, P34, DOI 10.1172/JCI117327; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Panzenbock B, 1998, BLOOD, V92, P3658, DOI 10.1182/blood.V92.10.3658.422k18_3658_3668; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; Robinson D, 1998, J BIOMED SCI, V5, P93, DOI 10.1159/000025318; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SASAKI E, 1993, GENE, V128, P257, DOI 10.1016/0378-1119(93)90571-J; SAWADA K, 1989, J CLIN INVEST, V83, P1701, DOI 10.1172/JCI114070; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SIMONEAUX DK, 1995, J IMMUNOL, V154, P1157; STARK KL, 1991, DEVELOPMENT, V113, P641; STEINLEIN P, 1995, CURR BIOL, V5, P191, DOI 10.1016/S0960-9822(95)00040-6; TAMAGNONE L, 1993, ONCOGENE, V8, P2009; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; Vainikka S, 1996, J BIOL CHEM, V271, P1270, DOI 10.1074/jbc.271.3.1270; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; Wang JK, 1997, ONCOGENE, V14, P1767, DOI 10.1038/sj.onc.1201021; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; Wessely O, 1997, EMBO J, V16, P267, DOI 10.1093/emboj/16.2.267; WILKS AF, 1989, GENE, V85, P67, DOI 10.1016/0378-1119(89)90465-4; WILKS AF, 1991, METHOD ENZYMOL, V200, P533; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; YEE K, 1993, BLOOD, V82, P1335; Yuen D, 1998, BLOOD, V91, P3202, DOI 10.1182/blood.V91.9.3202.3202_3202_3209; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	70	17	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	1999	18	43					5904	5914		10.1038/sj.onc.1202979	http://dx.doi.org/10.1038/sj.onc.1202979			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557077				2022-12-25	WOS:000083270700007
J	Blanpain, C; Doranz, BJ; Vakili, J; Rucker, J; Govaerts, C; Baik, SSW; Lorthioir, O; Migeotte, I; Libert, F; Baleux, F; Vassart, G; Doms, RW; Parmentier, M				Blanpain, C; Doranz, BJ; Vakili, J; Rucker, J; Govaerts, C; Baik, SSW; Lorthioir, O; Migeotte, I; Libert, F; Baleux, F; Vassart, G; Doms, RW; Parmentier, M			Multiple charged and aromatic residues in CCR5 amino-terminal domain are involved in high affinity binding of both chemokines and HIV-1 Env protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; DISEASE PROGRESSION; CORECEPTOR USAGE; INTERLEUKIN-8 RECEPTOR; EXTRACELLULAR DOMAIN; MAJOR DETERMINANT; DELETION ALLELE; CXC CHEMOKINES; DISTINCT CCR5; CELL-FUSION	CCR5 is a functional receptor for MIP-1 alpha, MIP-1 beta, RANTES (regulated on activation normal T cell expressed), MCP-2, and MCP-4 and constitutes the main coreceptor for macrophage tropic human and simian immunodeficiency viruses. By using CCR5-CCR2b chimeras, we have shown previously that the second extracellular loop of CCR5 is the major determinant for chemokine binding specificity, whereas the amino-terminal domain plays a major role for human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus coreceptor function. In the present work, by using a panel of truncation and alanine-scanning mutants, we investigated the role of specific residues in the CCR5 amino-terminal domain for chemokine binding, functional response to chemokines, HIV-1 gp120 binding, and coreceptor function. Truncation of the amino-terminal domain resulted in a progressive decrease of the binding affinity for chemokines, which correlated with a similar drop in functional responsiveness. Mutants lacking residues 2-13 exhibited fairly weak responses to high concentrations (500 nM) of RANTES or MIP-1 beta. Truncated mutants also exhibited a reduction in the binding affinity for R5 Env proteins and coreceptor activity. Deletion of 4 or 12 residues resulted in a 50 or 80% decrease in coreceptor function, respectively. Alanine-scanning mutagenesis identified several charged and aromatic residues (Asp-2, Tyr-3, Tyr-10, Asp-11, and Glu-18) that played an important role in both chemokine and Env high affinity binding. The overlapping binding site of chemokines and gp120 on the CCR5 amino terminus, as well as the involvement of these residues in the epitopes of monoclonal antibodies, suggests that these regions are particularly exposed at the receptor surface.	Free Univ Brussels, IRIBHN, B-1070 Brussels, Belgium; Free Univ Brussels, Serv Genet Med, B-1070 Brussels, Belgium; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Inst Pasteur, F-75724 Paris, France	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Pennsylvania; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Parmentier, M (corresponding author), Free Univ Brussels, IRIBHN, ULB Campus,Erasme 808 Rt Lennik, B-1070 Brussels, Belgium.		Blanpain, Cedric/ABD-8392-2021	Migeotte, Isabelle/0000-0002-8972-8211; Parmentier, Marc/0000-0001-8081-4685	PHS HHS [R01 40880] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ahuja SK, 1996, J BIOL CHEM, V271, P225, DOI 10.1074/jbc.271.1.225; Alkhatib G, 1997, J BIOL CHEM, V272, P20420, DOI 10.1074/jbc.272.33.20420; ArenzanaSeisdedos F, 1996, NATURE, V383, P400, DOI 10.1038/383400a0; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; Baba M, 1999, P NATL ACAD SCI USA, V96, P5698, DOI 10.1073/pnas.96.10.5698; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Baik SSW, 1999, VIROLOGY, V259, P267, DOI 10.1006/viro.1999.9779; Bieniasz PD, 1997, EMBO J, V16, P2599, DOI 10.1093/emboj/16.10.2599; Biti R, 1997, NAT MED, V3, P252, DOI 10.1038/nm0397-252; Blanpain C, 1999, BLOOD, V94, P1899; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Doms RW, 1997, VIROLOGY, V235, P179, DOI 10.1006/viro.1997.8703; Doranz BJ, 1997, J VIROL, V71, P6305, DOI 10.1128/JVI.71.9.6305-6314.1997; Dragic T, 1998, J VIROL, V72, P279, DOI 10.1128/JVI.72.1.279-285.1998; Edinger AL, 1999, J VIROL, V73, P4062, DOI 10.1128/JVI.73.5.4062-4073.1999; Edinger AL, 1997, P NATL ACAD SCI USA, V94, P14742, DOI 10.1073/pnas.94.26.14742; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Farzan M, 1998, J VIROL, V72, P1160, DOI 10.1128/JVI.72.2.1160-1164.1998; Gong WH, 1998, J BIOL CHEM, V273, P4289, DOI 10.1074/jbc.273.8.4289; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; Hill CM, 1998, VIROLOGY, V248, P357, DOI 10.1006/viro.1998.9283; Hogaboam CM, 1998, KIDNEY INT, V54, P2152, DOI 10.1046/j.1523-1755.1998.00176.x; LaCasse RA, 1999, SCIENCE, V283, P357, DOI 10.1126/science.283.5400.357; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; Lee B, 1999, P NATL ACAD SCI USA, V96, P5215, DOI 10.1073/pnas.96.9.5215; Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617; LEONG SR, 1994, J BIOL CHEM, V269, P19343; Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Lu ZH, 1997, P NATL ACAD SCI USA, V94, P6426, DOI 10.1073/pnas.94.12.6426; Margolis LB, 1998, J CLIN INVEST, V101, P1876, DOI 10.1172/JCI2015; Martin KA, 1997, SCIENCE, V278, P1470, DOI 10.1126/science.278.5342.1470; Mennicken F, 1999, TRENDS PHARMACOL SCI, V20, P73, DOI 10.1016/S0165-6147(99)01308-5; Michael NL, 1997, NAT MED, V3, P1160, DOI 10.1038/nm1097-1160; Michael NL, 1998, J VIROL, V72, P6040, DOI 10.1128/JVI.72.7.6040-6047.1998; Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; Monteclaro FS, 1997, J BIOL CHEM, V272, P23186, DOI 10.1074/jbc.272.37.23186; Moore BB, 1998, J LAB CLIN MED, V132, P97, DOI 10.1016/S0022-2143(98)90004-X; Rabut GEE, 1998, J VIROL, V72, P3464, DOI 10.1128/JVI.72.4.3464-3468.1998; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; Ross TM, 1998, J VIROL, V72, P1918, DOI 10.1128/JVI.72.3.1918-1924.1998; Rucker J, 1997, METHOD ENZYMOL, V288, P118; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; Ruffing N, 1998, CELL IMMUNOL, V189, P160, DOI 10.1006/cimm.1998.1379; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Samson M, 1997, J BIOL CHEM, V272, P24934, DOI 10.1074/jbc.272.40.24934; Scarlatti G, 1997, NAT MED, V3, P1259, DOI 10.1038/nm1197-1259; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Skelton NJ, 1999, STRUCTURE, V7, P157, DOI 10.1016/S0969-2126(99)80022-7; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Stables J, 1997, ANAL BIOCHEM, V252, P115, DOI 10.1006/abio.1997.2308; Szekanecz Z, 1998, SPRINGER SEMIN IMMUN, V20, P115, DOI 10.1007/BF00832002; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Terkeltaub R, 1998, CURR OPIN LIPIDOL, V9, P397, DOI 10.1097/00041433-199810000-00003; Theodorou I, 1997, LANCET, V349, P1219; Wang WK, 1999, P NATL ACAD SCI USA, V96, P4558, DOI 10.1073/pnas.96.8.4558; Ward SG, 1998, BIOCHEM J, V333, P457, DOI 10.1042/bj3330457; Wells TNC, 1998, TRENDS PHARMACOL SCI, V19, P376, DOI 10.1016/S0165-6147(98)01247-4; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Wu LJ, 1997, J EXP MED, V186, P1373, DOI 10.1084/jem.186.8.1373; Ylisastigui L, 1998, AIDS, V12, P977, DOI 10.1097/00002030-199809000-00003	67	140	156	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34719	34727		10.1074/jbc.274.49.34719	http://dx.doi.org/10.1074/jbc.274.49.34719			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574939	hybrid			2022-12-25	WOS:000083979600033
J	Caldwell, BD; Darlington, DN; Penzes, P; Johnson, RC; Eipper, BA; Mains, RE				Caldwell, BD; Darlington, DN; Penzes, P; Johnson, RC; Eipper, BA; Mains, RE			The novel kinase peptidylglycine alpha-amidating monooxygenase cytosolic interactor protein 2 interacts with the cytosolic routing determinants of the peptide processing enzyme peptidylglycine alpha-amidating monooxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; MANNOSE 6-PHOSPHATE RECEPTOR; FACTOR-II RECEPTOR; CYTOPLASMIC DOMAIN; MESSENGER-RNA; INTRACELLULAR TRAFFICKING; PROPROTEIN CONVERTASE; MEMBRANE-PROTEINS; GENE-EXPRESSION; CELL-SURFACE	The cytosolic domain of the peptide-processing integral membrane protein peptidylglycine alpha-amidating monooxygenase (PAM; EC 1.14.17.3) contains multiple signals determining its subcellular localization. Three PAM cytosolic interactor proteins (P-CIPs) were identified using the yeast two hybrid system (Alam, M. R., Caldwel, B. D., Johnson, R. C., Darlington, D. N., Mains, R, E., and Eipper, B, A. (1996) J. Biol. Chem. 271, 28636-28640); the partial amino acid sequence of P-CIP2 suggested that it was a protein kinase, In situ hybridization and immunocytochemistry show that P-CIP2 is expressed widely throughout the brain; PAM and P-CIP2 are expressed in the same neurons. Based on subcellular fractionation, the 47-kDa P-CIP2 protein is mostly cytosolic P-CIP2 is a highly selective kinase, phosphorylating the cytosolic domain of PAM, but not the corresponding region of furin or carboxypeptidase D, Although P-CIP2 interacts with stathmin, it does not phosphorylate stathmin. Site-directed mutagenesis, phosphoamino acid analysis, and use of synthetic peptides demonstrate that PAM-Ser(949) is the major site phosphorylated by P-CIP2, Based on both in vitro binding experiments and co-immunoprecipitation from cell extracts, P-CIP2 Interacts with PAM proteins containing the wild type cytosolic domain, but not with mutant forms of PAM whose trafficking is disrupted. P-CIP2, through its highly selective phosphorylation of a key site in the cytosolic domain of PAM, appears to play a critical role in the trafficking of this protein.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA	Johns Hopkins University; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Mains, RE (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Rm 907 WBSB,725 N Wolfe St, Baltimore, MD 21205 USA.	dmains@jhmi.edu	Penzes, Peter/L-3987-2016; Darlington, Daniel/CAG-1917-2022	Penzes, Peter/0000-0001-5449-1640; 	NIDDK NIH HHS [DK-32949] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK032949, R56DK032949, R01DK032949] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ainger K, 1997, J CELL BIOL, V138, P1077, DOI 10.1083/jcb.138.5.1077; Alam MR, 1997, J BIOL CHEM, V272, P12667, DOI 10.1074/jbc.272.19.12667; Alam MR, 1996, J BIOL CHEM, V271, P28636, DOI 10.1074/jbc.271.45.28636; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BORJIGIN J, 1994, J BIOL CHEM, V269, P14715; Boyle WJ, 1998, SEL METH EN, P201; Chen HJ, 1997, J BIOL CHEM, V272, P7003, DOI 10.1074/jbc.272.11.7003; Chen LH, 1998, J BIOL CHEM, V273, P33524, DOI 10.1074/jbc.273.50.33524; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; Cuevo RS, 1997, J BIOL CHEM, V272, P3813, DOI 10.1074/jbc.272.6.3813; Daly C, 1997, J NEUROSCI, V17, P2365; Darlington DN, 1997, J HISTOCHEM CYTOCHEM, V45, P1265, DOI 10.1177/002215549704500910; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; DiPaolo G, 1997, J BIOL CHEM, V272, P5175, DOI 10.1074/jbc.272.8.5175; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; Ferrari S, 1998, SEL METH EN, P371; Fraboulet S, 1998, ENDOCRINOLOGY, V139, P894, DOI 10.1210/en.139.3.894; Hanks SK, 1998, SEL METH EN, P39; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRT RP, 1993, CELL, V74, P245, DOI 10.1016/0092-8674(93)90416-N; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; Hunter T, 1998, SEL METH EN, P3; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; JONES BG, 1995, EMBO J, V14, P5869, DOI 10.1002/j.1460-2075.1995.tb00275.x; KEMP BE, 1994, PROTEIN KINASES, P30; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRYIAKIS JM, 1994, PROTEIN KINASES, P85; LAU LF, 1995, J BIOL CHEM, V270, P20036, DOI 10.1074/jbc.270.34.20036; LEBORGNE R, 1993, J BIOL CHEM, V268, P22552; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; MAINS RE, 1990, FRONT NEUROENDOCRIN, V11, P52; MARKLUND U, 1994, J BIOL CHEM, V269, P30626; Maucuer A, 1997, J BIOL CHEM, V272, P23151, DOI 10.1074/jbc.272.37.23151; MAUCUER A, 1995, P NATL ACAD SCI USA, V92, P3100, DOI 10.1073/pnas.92.8.3100; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; Milgram SL, 1996, J BIOL CHEM, V271, P17526, DOI 10.1074/jbc.271.29.17526; Milgram SL, 1996, MOL ENDOCRINOL, V10, P837, DOI 10.1210/me.10.7.837; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; Milgram SL, 1997, J CELL SCI, V110, P695; MILGRAM SL, 1993, J CELL BIOL, V121, P23, DOI 10.1083/jcb.121.1.23; MILNER RJ, 1983, NUCLEIC ACIDS RES, V11, P5497, DOI 10.1093/nar/11.16.5497; MOHR E, 1995, P NATL ACAD SCI USA, V92, P4377, DOI 10.1073/pnas.92.10.4377; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; Ratovitski EA, 1999, J BIOL CHEM, V274, P993, DOI 10.1074/jbc.274.2.993; ROHRER J, 1995, J CELL BIOL, V130, P1297, DOI 10.1083/jcb.130.6.1297; Roquemore EP, 1998, MOL BIOL CELL, V9, P2125, DOI 10.1091/mbc.9.8.2125; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; Seipel K, 1999, J CELL SCI, V112, P1825; SHUM L, 1994, J CELL BIOL, V125, P903, DOI 10.1083/jcb.125.4.903; SMITH RF, 1992, PROTEIN ENG, V5, P35, DOI 10.1093/protein/5.1.35; SMITH RF, 1990, P NATL ACAD SCI USA, V87, P118, DOI 10.1073/pnas.87.1.118; Stephens DJ, 1997, J BIOL CHEM, V272, P14104, DOI 10.1074/jbc.272.22.14104; Steven R, 1998, CELL, V92, P785, DOI 10.1016/S0092-8674(00)81406-3; Stevenson TC, 1998, MOL BIOL CELL, V9, p327A; Steveson TC, 1999, J BIOL CHEM, V274, P21128, DOI 10.1074/jbc.274.30.21128; SUTCLIFFE JG, 1984, SCIENCE, V225, P1308, DOI 10.1126/science.6474179; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; WONG SH, 1993, J BIOL CHEM, V268, P22853; Xin XN, 1997, DNA CELL BIOL, V16, P897, DOI 10.1089/dna.1997.16.897; YUN HY, 1995, J BIOL CHEM, V270, P30075; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745; ZHOU A, 1993, J BIOL CHEM, V268, P1763	73	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34646	34656		10.1074/jbc.274.49.34646	http://dx.doi.org/10.1074/jbc.274.49.34646			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574929	hybrid			2022-12-25	WOS:000083979600023
J	Fink, TL; Francis, SH; Beasley, A; Grimes, KA; Corbin, JD				Fink, TL; Francis, SH; Beasley, A; Grimes, KA; Corbin, JD			Expression of an active, monomeric catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; INHIBITED CAMP-PHOSPHODIESTERASE; DEPENDENT PROTEIN-KINASE; FOS-JUN INTERACTION; LEUCINE ZIPPER; GMP PHOSPHODIESTERASE; HUMAN PLATELETS; DNA-BINDING; AMINO-ACIDS; RAT LUNG	Phosphodiesterases (PDEs) comprise a superfamily of phosphohydrolases that degrade 3',5'-cyclic nucleotides. All known mammalian PDEs are dimeric, but the functional significance of dimerization is unknown, A deletion mutant of cGMP-binding cGMP-specific PDE (PDE5), encoding the 357 carboxyl-terminal amino acids including the catalytic domain, has been generated, expressed, and purified. The K-m of the catalytic fragment for cGMP (5.5 +/- 0.51 mu M) compares well with those of the native bovine lung PDE5 (5.6 mu M) and full-length wild type recombinant PDE5 (2 +/- 0.4 mu M). The catalytic fragment and full-length PDE5 have similar IC50 values for the inhibitors 3-isobutyl-1-methylxanthine (20 mu M) and sildenafil (Viagra (TM)) (4 nm). Based on measured values for Stokes radius (29 Angstrom) and sedimentation coefficient (2.9 S), the PDE5 catalytic fragment has a calculated molecular mass of 35 kDa, which agrees well with that predicted by amino acid content (43.3 kDa) and with that estimated using SDS-polyacrylamide gel electrophoresis (39 kDa), The combined data indicate that the recombinant PDE5 catalytic fragment is monomeric, and retains the essential catalytic features of the dimeric, full-length enzyme. Therefore, the catalytic activity of PDE5 holoenzyme requires neither interaction between the catalytic and regulatory domains nor interactions between subunits of the dimer.	Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	Corbin, JD (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, 702 Light Hall,21st & Garland Ave, Nashville, TN 37232 USA.	tlf8@po.cwru.edu; Sharron.Francis@mcmail.vanderbilt.edu; Jackie.Corbin@mcmail.vanderbilt.edu			NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020593, P60DK020593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041269] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA68485] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline; NIGMS NIH HHS [GM41269] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Boolell M, 1996, Int J Impot Res, V8, P47; CHARBONNEAU H, 1991, BIOCHEMISTRY-US, V30, P7931, DOI 10.1021/bi00246a009; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; Charbonneau H., 1990, CYCLIC NUCLEOTIDE PH, P267; Cheung PP, 1996, BLOOD, V88, P1321, DOI 10.1182/blood.V88.4.1321.bloodjournal8841321; CHEUNG WY, 1971, J BIOL CHEM, V246, P2859; CONTI M, 1995, BIOCHEMISTRY-US, V34, P7979, DOI 10.1021/bi00025a003; CONTI M, 1995, ENDOCR REV, V16, P370, DOI 10.1210/er.16.3.370; COQUIL JF, 1983, BIOCHIM BIOPHYS ACTA, V743, P359, DOI 10.1016/0167-4838(83)90394-1; DEGERMAN E, 1994, BBA-PROTEIN STRUCT M, V1205, P189, DOI 10.1016/0167-4838(94)90233-X; Fisher DA, 1998, BIOCHEM BIOPH RES CO, V246, P570, DOI 10.1006/bbrc.1998.8684; Fisher DA, 1998, J BIOL CHEM, V273, P15559, DOI 10.1074/jbc.273.25.15559; FRANCIS SH, 1980, J BIOL CHEM, V255, P620; FRANCIS SH, 1994, J BIOL CHEM, V269, P22477; FRANCIS SH, 1985, CURR TOP CELL REGUL, V26, P247; FRANCIS SH, 1990, CYCLIC NUCLEOTIDE PH, P117; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GETTYS TW, 1988, J BIOL CHEM, V263, P10359; Granovsky AE, 1998, J BIOL CHEM, V273, P24485, DOI 10.1074/jbc.273.38.24485; HAMET P, 1978, J CYCLIC NUCL PROT, V4, P281; HAMET P, 1988, METHOD ENZYMOL, V159, P710; INOUE H, 1991, J BIOL CHEM, V266, P11896; JIN SLC, 1992, J BIOL CHEM, V267, P18929; KINCAID RL, 1985, J BIOL CHEM, V260, P9009; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; Kovala T, 1997, BIOCHEMISTRY-US, V36, P2968, DOI 10.1021/bi9613483; Leroy MJ, 1996, BIOCHEMISTRY-US, V35, P10194, DOI 10.1021/bi952711t; LINCOLN TM, 1976, P NATL ACAD SCI USA, V73, P2559, DOI 10.1073/pnas.73.8.2559; Lochhead A, 1997, J BIOL CHEM, V272, P18397, DOI 10.1074/jbc.272.29.18397; LOPEZAPARICIO P, 1993, BIOCHEM BIOPH RES CO, V193, P1137, DOI 10.1006/bbrc.1993.1744; MANGANIELLO VC, 1995, ARCH BIOCHEM BIOPHYS, V322, P1, DOI 10.1006/abbi.1995.1429; MARTINS TJ, 1982, J BIOL CHEM, V257, P1973; McAllisterLucas LM, 1995, J BIOL CHEM, V270, P30671, DOI 10.1074/jbc.270.51.30671; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; MEACCI E, 1992, P NATL ACAD SCI USA, V89, P3721, DOI 10.1073/pnas.89.9.3721; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PILLAI R, 1994, J BIOL CHEM, V269, P30676; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RASCON A, 1992, BIOCHIM BIOPHYS ACTA, V1134, P149, DOI 10.1016/0167-4889(92)90038-D; Robison G.A., 1971, CYCLIC AMP, DOI [10.1146/annurev.bi.37.070168.001053, DOI 10.1146/ANNUREV.BI.37.070168.001053]; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Soderling SH, 1998, J BIOL CHEM, V273, P15553, DOI 10.1074/jbc.273.25.15553; Sonnenburg WK, 1995, J BIOL CHEM, V270, P30989, DOI 10.1074/jbc.270.52.30989; STELLWAGEN E, 1984, ADV CYCLIC NUCL PROT, V16, P49; STROOP SD, 1989, J BIOL CHEM, V264, P13718; SUGDEN PH, 1976, BIOCHEM J, V159, P409, DOI 10.1042/bj1590409; Tang KM, 1997, BIOCHEM J, V323, P217; THOMAS MK, 1992, ADV SEC MESS PHOSPH, V25, P45; THOMAS MK, 1990, J BIOL CHEM, V265, P14971; THOMAS MK, 1990, J BIOL CHEM, V265, P14964; Turko IV, 1996, J BIOL CHEM, V271, P22240, DOI 10.1074/jbc.271.36.22240; Turko IV, 1998, BIOCHEMISTRY-US, V37, P4200, DOI 10.1021/bi972448r; Turko IV, 1998, J BIOL CHEM, V273, P6460, DOI 10.1074/jbc.273.11.6460; Wyatt TA, 1998, AM J PHYSIOL-HEART C, V274, pH448, DOI 10.1152/ajpheart.1998.274.2.H448	57	53	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34613	34620		10.1074/jbc.274.49.34613	http://dx.doi.org/10.1074/jbc.274.49.34613			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574925	hybrid			2022-12-25	WOS:000083979600019
J	Pitcher, JA; Tesmer, JJG; Freeman, JLR; Capel, WD; Stone, WC; Lefkowitz, RJ				Pitcher, JA; Tesmer, JJG; Freeman, JLR; Capel, WD; Stone, WC; Lefkowitz, RJ			Feedback inhibition of G protein-coupled receptor kinase 2 (GRK2) activity by extracellular signal-regulated kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; ENDOCYTOSIS; ACTIVATION; SUBUNITS; TUBULIN; BOVINE	G protein-coupled receptor kinase (GRK)-mediated receptor phosphorylation and beta-arrestin binding uncouple G protein-coupled receptors (GPCRs) from their respective G proteins and initiates the process of receptor internalization. In the case of the beta(2)-adrenergic receptor and lysophosphatidic acid receptor, these processes can lead to ERK activation. Here we identify a novel mechanism whereby the activity of GRK2 is regulated by feedback inhibition. GRK2 is demonstrated to be a phosphoprotein in cells. Mass spectrometry and mutational analysis localize the site of phosphorylation on GRK2 to a carboxyl-terminal serine residue (Ser(670)). Phosphorylation at Ser670 impairs the ability of GRK2 to phosphorylate both soluble and membrane-incorporated receptor substrates and dramatically attenuates G beta gamma-mediated activation of this enzyme, Ser(670) is located in a peptide sequence that conforms to an ERK consensus phosphorylation sequence, and in vitro, in the presence of heparin, ERK1 phosphorylates GRK2, Inhibition of ERK activity in HEK293 cells potentiates GRK2 activity, whereas, conversely, ERK activation inhibits GRK2 activity. The discovery that ERK phosphorylates and inactivates GRK2 suggests that ERK participates in a feedback regulatory loop. By negatively regulating GRK-mediated receptor phosphorylation, beta-arrestin-mediated processes such as Src recruitment and clathrin-mediated internalization, which are required for GPCR-mediated ERK activation, are inhibited, thus dampening further ERK activation.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med Cardiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Box 3821, Durham, NC 27710 USA.		Lefkowitz, Robert/AAW-2649-2021; Pitcher, Julie/ABH-2078-2020	Tesmer, John/0000-0003-1125-3727	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; COBB MH, 1995, PROTEIN KINASE FACTS, P214; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Ferguson SSG, 1996, BIOCHEM SOC T, V24, P953, DOI 10.1042/bst0240953; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; KIM CM, 1993, RECEPTOR, V3, P39; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; Lin FT, 1999, J BIOL CHEM, V274, P15971, DOI 10.1074/jbc.274.23.15971; Oppermann M, 1996, P NATL ACAD SCI USA, V93, P7649, DOI 10.1073/pnas.93.15.7649; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; Pitcher JA, 1998, J BIOL CHEM, V273, P12316, DOI 10.1074/jbc.273.20.12316; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; SIMON JR, 1991, MICRON MICROSC ACTA, V22, P405, DOI 10.1016/0739-6260(91)90058-8	15	143	150	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34531	34534		10.1074/jbc.274.49.34531	http://dx.doi.org/10.1074/jbc.274.49.34531			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574913	hybrid			2022-12-25	WOS:000083979600007
J	Gonzalez-Agosti, C; Wiederhold, T; Herndon, ME; Gusella, J; Ramesh, V				Gonzalez-Agosti, C; Wiederhold, T; Herndon, ME; Gusella, J; Ramesh, V			Interdomain interaction of merlin isoforms and its influence on intermolecular binding to NHE-RF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROFIBROMATOSIS-2 TUMOR-SUPPRESSOR; EZRIN/RADIXIN/MOESIN ERM PROTEINS; TERMINAL REGION; NF2 GENE; EZRIN; MEMBRANE; ACTIN; MOESIN; ASSOCIATION; DOMAIN	Merlin, the neurofibromatosis 2 tumor suppressor protein, has two major isoforms with alternate C termini and is related to the ERM (ezrin, radixin, moesin) proteins. Regulation of the ERMs involves intramolecular and/or intermolecular head-to-tail associations between family members. We have determined whether merlin undergoes similar interactions, and our findings indicate that the C terminus of merlin isoform 1 is able to associate with its N-terminal domain in a head-to-tail fashion. However, the C terminus of isoform 2 lacks this property. Similarly, the N terminus of merlin can also associate with C terminus of moesin, We have also explored the effect of merlin self-association on binding to the regulatory cofactor of Na+-H+ exchanger (NHE-RF), an interacting protein for merlin and the ERMs, Merlin isoform 2 captures more NHE-RF than merlin isoform 1 in affinity binding assays, suggesting that in full-length merlin isoform 1, the NHE-RF binding site is masked because of the self-interactions of merlin. Treatment with a phospholipid known to decrease self-association of ERMs enhances the binding of merlin isoform 1 to NHE-RF, Thus, although isoform 1 resembles the ERM proteins, which transition between inactive (closed) and active (open) states, isoform 2 is distinct, existing only in the active (open) state and presumably constitutively more available for interaction with other protein partners.	Massachusetts Gen Hosp, Mol Neurogenet Unit, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Harvard University; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Ramesh, V (corresponding author), Massachusetts Gen Hosp, Mol Neurogenet Unit, Bldg 149,13th St, Charlestown, MA 02129 USA.				NINDS NIH HHS [NS24279] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS024279] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARAKAWA H, 1994, HUM MOL GENET, V3, P565, DOI 10.1093/hmg/3.4.565; BERRYMAN M, 1995, J CELL BIOL, V131, P1231, DOI 10.1083/jcb.131.5.1231; BRESCHER A, 1999, CURR OPIN CELL BIOL, V11, P109; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; GARY R, 1993, P NATL ACAD SCI USA, V90, P10846, DOI 10.1073/pnas.90.22.10846; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; GonzalezAgosti C, 1996, ONCOGENE, V13, P1239; Gronholm M, 1999, J CELL SCI, V112, P895; Gusella JF, 1996, CURR OPIN GENET DEV, V6, P87, DOI 10.1016/S0959-437X(96)90016-7; HAASE VH, 1994, HUM MOL GENET, V3, P407, DOI 10.1093/hmg/3.3.407; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Heiska L, 1998, J BIOL CHEM, V273, P21893, DOI 10.1074/jbc.273.34.21893; HERNDON ME, 1997, LAB GUIDE GLYCOCONJG, P379; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Huang LQ, 1998, BIOCHEM BIOPH RES CO, V248, P548, DOI 10.1006/bbrc.1998.9009; KAISERKUPFER MI, 1989, ARCH OPHTHALMOL-CHIC, V107, P541, DOI 10.1001/archopht.1989.01070010555030; LaJeunesse DR, 1998, J CELL BIOL, V141, P1589, DOI 10.1083/jcb.141.7.1589; LIM WA, 1991, METHOD ENZYMOL, V208, P196; MAGENDANTZ M, 1995, J BIOL CHEM, V270, P25324, DOI 10.1074/jbc.270.43.25324; MARTUZA RL, 1988, NEW ENGL J MED, V318, P684, DOI 10.1056/NEJM198803173181106; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; NIGGLI V, 1995, FEBS LETT, V376, P172, DOI 10.1016/0014-5793(95)01270-1; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; PYKETT MJ, 1994, HUM MOL GENET, V3, P559, DOI 10.1093/hmg/3.4.559; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Reczek D, 1998, J BIOL CHEM, V273, P18452, DOI 10.1074/jbc.273.29.18452; SANANTONIO JD, 1993, BIOCHEMISTRY-US, V32, P4746, DOI 10.1021/bi00069a008; Scoles DR, 1998, NAT GENET, V18, P354, DOI 10.1038/ng0498-354; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; Xu L, 1998, EXP CELL RES, V238, P231, DOI 10.1006/excr.1997.3843; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856	37	74	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34438	34442		10.1074/jbc.274.48.34438	http://dx.doi.org/10.1074/jbc.274.48.34438			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567424	hybrid			2022-12-25	WOS:000083857500089
J	Roques, M; Vidal, H				Roques, M; Vidal, H			A phosphatidylinositol 3-kinase/p70 ribosomal S6 protein kinase pathway is required for the regulation by insulin of the p85 alpha regulatory subunit of phosphatidylinositol 3-kinase gene expression in human muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIABETES-MELLITUS SUBJECTS; GLYCOGEN-SYNTHASE ACTIVITY; SKELETAL-MUSCLE; PHOSPHOINOSITIDE 3-KINASE; PHOSPHOENOLPYRUVATE CARBOXYKINASE; SIGNALING PATHWAYS; MESSENGER-RNA; ACTIVATION; GLUCOSE; NIDDM	Insulin acutely up-regulates p85 alpha phosphatidylinositol 3-kinase (p85 alpha PI 3-K) mRNA levels in human skeletal muscle (Laville, M., Auboeuf, D., Khalfallah, Y., Vega, N., Riou, J, P., and Vidal, H. (1996) J. Clin. Invest. 98, 43-49), In the present work, we attempted to elucidate the mechanism of action of insulin in primary cultures of human muscle cells. Insulin (10(-7) M, 6 h of incubation) induced a a-fold increase in p85aPI3-K mRNA abundances (118 +/- 12 versus 233 +/- 35 amol/mu g total RNA, n = 5, p < 0.01) without changing the expression levels of insulin receptor, IRS-1, glycogen synthase, and Glut 4 mRNAs in differentiated myotubes from healthy subjects. The effect is most probably due to a transcriptional activation of the p85 alpha PI 3-K gene because the half-life of the mRNA was not affected by insulin treatment (4.0 +/- 0.8 versus 3.1 +/- 0.4 h), PD98059 (50 mu M) did not modify the insulin response but increased p85 alpha PI 3-K mRNA levels in the absence of insulin, suggesting that the mitogen-activated protein kinase pathway exerts a negative effect on p85 alpha PI 3-K mRNA expression in the absence of the hormone. On the other hand, the insulin effect was totally abolished by LY294002 (10 mu M) and rapamycin (50 nM). In addition, overexpression of a constitutively active protein kinase B increased p85 alpha PI 3-K mRNA levels. These results indicate that the phosphatidylinositol 3-kinase/PKB/p70S6 kinase pathway is required for the stimulation by insulin of p85 alpha PI 3-K gene expression in human muscle cells.	Univ Lyon 1, Fac Med Rene Laennec, INSERM U449, F-69372 Lyon 08, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Roques, M (corresponding author), Univ Lyon 1, Fac Med Rene Laennec, INSERM U449, F-69372 Lyon 08, France.	roques@laennec.univ-lyon1.fr	Vidal, Hubert/M-6674-2017	Vidal, Hubert/0000-0002-9467-0317				Andreelli F, 1999, DIABETOLOGIA, V42, P358, DOI 10.1007/s001250051163; Auboeuf D, 1997, ANAL BIOCHEM, V245, P141, DOI 10.1006/abio.1996.9986; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Bjornholm M, 1997, DIABETES, V46, P524, DOI 10.2337/diabetes.46.3.524; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Ciaraldi TP, 1995, J CLIN INVEST, V96, P2820, DOI 10.1172/JCI118352; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DENTON RM, 1995, EUR J BIOCHEM, V227, P597, DOI 10.1111/j.1432-1033.1995.tb20179.x; Dickens M, 1998, J BIOL CHEM, V273, P20144, DOI 10.1074/jbc.273.32.20144; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; HARA K, 1995, BIOCHEM BIOPH RES CO, V208, P735, DOI 10.1006/bbrc.1995.1399; Henry RR, 1996, J CLIN INVEST, V98, P1231, DOI 10.1172/JCI118906; HENRY RR, 1995, DIABETES, V44, P936, DOI 10.2337/diabetes.44.8.936; Hurel SJ, 1996, BIOCHEM J, V320, P871, DOI 10.1042/bj3200871; Kruszynska YT, 1998, DIABETES, V47, P1107, DOI 10.2337/diabetes.47.7.1107; Laville M, 1996, J CLIN INVEST, V98, P43, DOI 10.1172/JCI118775; MANDARINO LJ, 1995, AM J PHYSIOL-ENDOC M, V269, pE701; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MESSINA JL, 1992, MOL ENDOCRINOL, V6, P112, DOI 10.1210/me.6.1.112; MOHN KL, 1990, J BIOL CHEM, V265, P21914; Nikoulina SE, 1997, DIABETES, V46, P1017, DOI 10.2337/diabetes.46.6.1017; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Osawa H, 1996, J BIOL CHEM, V271, P16690, DOI 10.1074/jbc.271.28.16690; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; SCHALINJANTTI C, 1994, DIABETOLOGIA, V37, P401, DOI 10.1007/s001250050124; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; TAHA C, 1995, J BIOL CHEM, V270, P24678, DOI 10.1074/jbc.270.42.24678; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; Wagle A, 1998, J BIOL CHEM, V273, P14968, DOI 10.1074/jbc.273.24.14968; Wang D, 1998, J BIOL CHEM, V273, P25420, DOI 10.1074/jbc.273.39.25420; YKIJARVINEN H, 1992, J CLIN ENDOCR METAB, V75, P795, DOI 10.1210/jc.75.3.795; Zierath JR, 1998, MOL CELL BIOCHEM, V182, P153, DOI 10.1023/A:1006861628496; Zimmermann K, 1996, BIOTECHNIQUES, V21, P268	39	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34005	34010		10.1074/jbc.274.48.34005	http://dx.doi.org/10.1074/jbc.274.48.34005			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567366	hybrid			2022-12-25	WOS:000083857500031
J	Xu, BE; Wilsbacher, JL; Collisson, T; Cobb, MH				Xu, BE; Wilsbacher, JL; Collisson, T; Cobb, MH			The N-terminal ERR-binding site of MEK1 is required for efficient feedback phosphorylation by ERK2 in vitro and ERK activation in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE KINASE; HIGH-AFFINITY INTERACTION; PROTEIN-KINASE; MAMMALIAN-CELLS; C-JUN; CASCADE; MOTIF; TRANSFORMATION; CONTAINS; ELK-1	An ERK2-binding site at the N terminus of MEK1 was reported to mediate their stable association. We examined the importance of this binding site in the feedback phosphorylation of MEK1 on Thr(292) and Thr(386) by ERK2, the phosphorylation and activation of ERK2 by MEK1, and the interaction of MEK1 with ERK2 and Raf-1, Deletion of the binding site from MEK1 reduced its phosphorylation by ERK2, but had no effect on its phosphorylation by p21-activated protein kinase-1 (PAK1). A MEK1 N-terminal peptide containing the binding site inhibited MEK1 phosphorylation by ERK2, However, it did not affect MEK1 phosphorylation by p21-activated protein kinase or myelin basic protein phosphorylation by ERK2, Deletion of the N-terminal ERK-binding domain of MEK1 also reduced its ability to phosphorylate ERK2 in vitro, to co-immunoprecipitate with ERK2, and to stimulate ERK2 activation in transfected cells, but it did not alter the association with endogenous Raf-1. Using ERK2-p38 chimeras and an ERK2 deletion mutant, a MEK1-binding site of ERK2 was localized to its N terminus.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Cobb, Melanie/0000-0003-0833-5473	NIDDK NIH HHS [DK34128] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034128, R01DK034128] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bardwell L, 1996, TRENDS BIOCHEM SCI, V21, P373, DOI 10.1016/S0968-0004(96)30032-7; Bardwell L, 1996, MOL CELL BIOL, V16, P3637; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; CHOI KY, 1994, CELL, V78, P499; Cobb M H, 1996, Adv Pharmacol, V36, P49, DOI 10.1016/S1054-3589(08)60576-1; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Dang A, 1998, J BIOL CHEM, V273, P19909, DOI 10.1074/jbc.273.31.19909; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; GARDNER AM, 1994, MOL BIOL CELL, V5, P193, DOI 10.1091/mbc.5.2.193; Gotoh I, 1999, J BIOL CHEM, V274, P11874, DOI 10.1074/jbc.274.17.11874; Holland PM, 1999, CURR BIOL, V9, pR329, DOI 10.1016/S0960-9822(99)80205-X; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LEACHMAN SA, 1992, J BIOL CHEM, V267, P4930; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; Wilsbacher JL, 1999, J BIOL CHEM, V274, P16988, DOI 10.1074/jbc.274.24.16988; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710	35	91	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34029	34035		10.1074/jbc.274.48.34029	http://dx.doi.org/10.1074/jbc.274.48.34029			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567369	hybrid			2022-12-25	WOS:000083857500034
J	Authier, F; Metioui, M; Bell, AW; Mort, JS				Authier, F; Metioui, M; Bell, AW; Mort, JS			Negative regulation of epidermal growth factor signaling by selective proteolytic mechanisms in the endosome mediated by cathepsin B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-DEGRADING ENZYME; ISOLATED LIVER ENDOSOMES; RAT-LIVER; FACTOR RECEPTOR; DEGRADATION PRODUCTS; HEPATOMA-CELLS; PROTEIN-KINASE; FACTOR-ALPHA; LIGAND; GLUCAGON	We have investigated the relevant protease activity in rat liver, which is responsible for most of the receptor-mediated epidermal growth factor (EGF) degradation in vivo. EGF was sequentially cleaved by endosomal proteases at a limited number of sites, which were identified by high performance liquid chromatography and mass spectrometry. EGF proteolysis is initiated by hydrolysis at the C-terminal Glu(51)-Leu(52) bond. Three additional minor cleavage sites were identified at positions Arg(48)-Trp(49), Trp(49)-Trp(50), and Trp(50)-Glu(51) after prolonged incubation. Using nondenaturating immunoprecipitation and cross-linking procedures, the major proteolytic activity was identified as that of the cysteine protease cathepsin-B, The effect of injected EGF on subsequent endosomal EGF receptor (EG;FR) proteolysis was further evaluated by immunoblotting, Using endosomal fractions prepared from EGF-injected rats and incubated in vitro, the EGFR was lost with a time course superimposable with the loss of phosphotyrosine content. The cathepsin-B proinhibitor CA074-Me inhibited both in vivo and in vitro the endosomal degradation of the EGFR and increased the tyrosine phosphorylation states of the EGFR protein and the molecule SHC within endosomes, The data, therefore, describe a unique pathway for the endosomal processing of internalized EGF receptor complexes, which involves the sequential function of cathepsin-B through selective degradation of both the ligand and receptor.	Univ Paris 11, Fac Pharm, INSERM, U510, F-92296 Chatenay Malabry, France; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada; McGill Univ, Shriners Hosp Crippled Children, Joint Dis Lab, Montreal, PQ H3G 1A6, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; McGill University; McGill University	Authier, F (corresponding author), Univ Paris 11, Fac Pharm, INSERM, U510, 5 Rue Jean Baptiste Clement, F-92296 Chatenay Malabry, France.							Authier F, 1996, BIOCHEM J, V319, P149, DOI 10.1042/bj3190149; AUTHIER F, 1994, J BIOL CHEM, V269, P3010; Authier F, 1998, BIOCHEM J, V332, P421, DOI 10.1042/bj3320421; AUTHIER F, 1995, J BIOL CHEM, V270, P15798, DOI 10.1074/jbc.270.26.15798; Authier F, 1996, FEBS LETT, V389, P55, DOI 10.1016/0014-5793(96)00368-7; AUTHIER F, 1995, P NATL ACAD SCI USA, V92, P3859, DOI 10.1073/pnas.92.9.3859; AUTHIER F, 1990, BIOCHEM J, V272, P703, DOI 10.1042/bj2720703; AUTHIER F, 1991, BIOCHEM J, V280, P211, DOI 10.1042/bj2800211; AUTHIER F, 1992, ENDOCRINOLOGY, V131, P447, DOI 10.1210/en.131.1.447; AUTHIER F, 1994, CELLULAR PROTEOLYTIC, V15, P89; BAASS PC, 1995, TRENDS CELL BIOL, V5, P465, DOI 10.1016/S0962-8924(00)89116-3; Baulida J, 1996, J BIOL CHEM, V271, P5251; BERG T, 1995, BIOCHEM J, V307, P313, DOI 10.1042/bj3070313; Blum J S, 1993, Subcell Biochem, V19, P69; BLUM JS, 1991, J BIOL CHEM, V266, P22091; BUTTLE DJ, 1992, ARCH BIOCHEM BIOPHYS, V299, P377, DOI 10.1016/0003-9861(92)90290-D; COHEN S, 1982, P NATL ACAD SCI-BIOL, V79, P6237, DOI 10.1073/pnas.79.20.6237; DECKER SJ, 1989, J BIOL CHEM, V264, P17641; DESBUQUOIS B, 1990, EUR J BIOCHEM, V193, P501, DOI 10.1111/j.1432-1033.1990.tb19365.x; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; DIMENT S, 1988, J BIOL CHEM, V263, P6901; DOHERTY JJ, 1990, J CELL BIOL, V110, P35, DOI 10.1083/jcb.110.1.35; EBNER R, 1991, CELL REGUL, V2, P599, DOI 10.1091/mbc.2.8.599; Fausto N, 1995, FASEB J, V9, P1527, DOI 10.1096/fasebj.9.15.8529831; FIANI ML, 1993, ARCH BIOCHEM BIOPHYS, V307, P225, DOI 10.1006/abbi.1993.1583; FRENCH AR, 1995, J BIOL CHEM, V270, P4334, DOI 10.1074/jbc.270.9.4334; Hamel FG, 1997, MOL CELL ENDOCRINOL, V126, P185, DOI 10.1016/S0303-7207(96)03981-0; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HIWASA T, 1988, FEBS LETT, V233, P367, DOI 10.1016/0014-5793(88)80462-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKS N, 1995, INT J PEPT PROT RES, V46, P306; Mort JS, 1997, INT J BIOCHEM CELL B, V29, P715, DOI 10.1016/S1357-2725(96)00152-5; RENFREW CA, 1991, J BIOL CHEM, V266, P21265; RENFREW CA, 1991, J BIOL CHEM, V266, P4348; ROWAN AD, 1992, J BIOL CHEM, V267, P15993; SHII K, 1986, P NATL ACAD SCI USA, V83, P4147, DOI 10.1073/pnas.83.12.4147; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; STOSCHECK CM, 1988, J CELL BIOCHEM, V38, P51, DOI 10.1002/jcb.240380106; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; WILEY HS, 1985, J BIOL CHEM, V260, P5290; Yates JR, 1998, J MASS SPECTROM, V33, P1	42	70	73	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33723	33731		10.1074/jbc.274.47.33723	http://dx.doi.org/10.1074/jbc.274.47.33723			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559264	hybrid			2022-12-25	WOS:000083745200080
J	Garber, E; Su, LH; Ehrenfels, B; Karpusas, M; Hsu, YM				Garber, E; Su, LH; Ehrenfels, B; Karpusas, M; Hsu, YM			CD154 variants associated with Hyper-IgM syndrome can form oligomers and trigger CD40-mediated signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CD40 LIGAND EXPRESSION; X-LINKED IMMUNODEFICIENCY; B-CELL PROLIFERATION; T-LYMPHOCYTES; MOLECULAR-MODELS; GENE; MUTATIONS; ACTIVATION; MUTAGENESIS; DEFICIENCY	X-linked hyper-IgM syndrome is a rare immunodeficiency disorder resulting from mutations in the gene encoding the CD40 ligand (CD154) molecule. These mutations are very heterogeneous, ranging from a single point mutation to a large deletion in the open reading frame. To investigate the molecular mechanisms that are responsible for the functional defect of these mutants, we examined the biochemical properties of 14 hyper-IgM-related CD154 mutant proteins produced by transient expression in COS7 cells. We show that deletion mutants lacking a significant portion of the tumor necrosis factor homologous domain cannot be stably produced. In contrast, point mutants can be detected as oligomers. Surprisingly, gene products of two point mutants, Thr-all --> Asp and Met-36 --> Arg, can bind to the receptor, CD40. For Thr-211 --> Asp variant, it is comparable to the wild-type protein in its surface expression level, biochemical structure, and functional activities. Thus, it appears that this mutation is a polymorphism of CD154 gene. For Met-36 --> Arg variant, although it is interactive with CD40, it has a much lower surface expression level than wild-type protein. We propose that Met-36 --> Arg mutant represents a prototype of a defective CD154 family whose low cell surface expression of intrinsically active protein is simply insufficient to trigger productive signals through CD40.	Biogen Inc, Dept Prot Engn, Cambridge, MA 02142 USA; Biogen Inc, Dept Mol Genet, Cambridge, MA 02142 USA	Biogen; Biogen	Hsu, YM (corresponding author), Biogen Inc, Dept Prot Engn, 14 Cambridge Ctr, Cambridge, MA 02142 USA.	yen-ming_hsu@biogen.com	Karpusas, Michael/AAP-5547-2021					ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; Bajorath J, 1998, J BIOL CHEM, V273, P24603, DOI 10.1074/jbc.273.38.24603; BAJORATH J, 1995, BIOCHEMISTRY-US, V34, P9884, DOI 10.1021/bi00031a009; BAJORATH J, 1995, BIOCHEMISTRY-US, V34, P1833, DOI 10.1021/bi00006a003; Bajorath J, 1996, PROTEIN SCI, V5, P531; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; Blotta MH, 1996, J IMMUNOL, V156, P3133; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; Brenner B, 1997, FEBS LETT, V417, P301, DOI 10.1016/S0014-5793(97)01306-9; BROWNING JL, 1995, J IMMUNOL, V154, P33; CALLARD RE, 1993, IMMUNOL TODAY, V14, P559, DOI 10.1016/0167-5699(93)90188-Q; CONLEY ME, 1994, J CLIN INVEST, V94, P1404, DOI 10.1172/JCI117476; CONLEY ME, 1992, ANNU REV IMMUNOL, V10, P215; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; Durandy A, 1997, J IMMUNOL, V158, P2576; FARRINGTON M, 1994, P NATL ACAD SCI USA, V91, P1099, DOI 10.1073/pnas.91.3.1099; GAUCHAT JF, 1993, FEBS LETT, V315, P259, DOI 10.1016/0014-5793(93)81175-Y; GRAF D, 1992, EUR J IMMUNOL, V22, P3191, DOI 10.1002/eji.1830221226; GRAF D, 1995, EUR J IMMUNOL, V25, P1749, DOI 10.1002/eji.1830250639; HASLE H, 1994, AM J PEDIAT HEMATOL, V16, P329; HOLLENBAUGH D, 1994, J CLIN INVEST, V94, P616, DOI 10.1172/JCI117377; Hsu YM, 1997, J BIOL CHEM, V272, P911, DOI 10.1074/jbc.272.2.911; KARPUSAS M, 1995, STRUCTURE, V3, P1031, DOI 10.1016/S0969-2126(01)00239-8; Katz F, 1996, HUM MUTAT, V8, P223, DOI 10.1002/(SICI)1098-1004(1996)8:3<223::AID-HUMU5>3.0.CO;2-A; Kirk AD, 1999, NAT MED, V5, P686, DOI 10.1038/9536; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; LEDERMAN S, 1994, J IMMUNOL, V152, P2163; MACCHI P, 1995, AM J HUM GENET, V56, P898; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; Nonoyama S, 1997, HUM GENET, V99, P624, DOI 10.1007/s004390050417; Notarangelo LD, 1996, IMMUNOL TODAY, V17, P511, DOI 10.1016/0167-5699(96)30059-5; OLIVA A, 1995, J ALLERGY CLIN IMMUN, V96, P403, DOI 10.1016/S0091-6749(95)70060-9; Pietravalle F, 1996, EUR J IMMUNOL, V26, P725, DOI 10.1002/eji.1830260333; Pietravalle F, 1996, J BIOL CHEM, V271, P5965, DOI 10.1074/jbc.271.11.5965; RAMESH N, 1993, INT IMMUNOL, V5, P769, DOI 10.1093/intimm/5.7.769; Seyama K, 1998, BLOOD, V92, P2421, DOI 10.1182/blood.V92.7.2421.2421_2421_2434; Seyama K, 1999, J BIOL CHEM, V274, P11310, DOI 10.1074/jbc.274.16.11310; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543; VILLA A, 1994, HUM MUTAT, V3, P73, DOI 10.1002/humu.1380030115; WORM M, 1994, INT IMMUNOL, V6, P1883, DOI 10.1093/intimm/6.12.1883	44	19	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33545	33550		10.1074/jbc.274.47.33545	http://dx.doi.org/10.1074/jbc.274.47.33545			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559240	hybrid			2022-12-25	WOS:000083745200056
J	Harrenga, A; Michel, H				Harrenga, A; Michel, H			The cytochrome c oxidase from Paracoccus denitrificans does not change the metal center ligation upon reduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPPER RESPIRATORY OXIDASES; F-V FRAGMENT; PROTON TRANSLOCATION; ELECTRON-TRANSFER; CRYSTAL-STRUCTURES; LIGAND-EXCHANGE; RESOLUTION; MECHANISM; ANGSTROM; MODEL	Cytochrome c oxidase catalyzes the reduction of oxygen to water. This process is accompanied by the vectorial transport of protons across the mitochondrial or bacterial membrane ("proton pumping"). The mechanism of proton pumping is still a matter of debate. Many proposed mechanisms require structural changes during the reaction cycle of cytochrome c oxidase. Therefore, the structure of the cytochrome c oxidase was determined in the completely oxidized and in the completely reduced states at a temperature of 100 K. No ligand exchanges or other major structural changes upon reduction of the cytochrome c oxidase from Paracoccus denitrificans were observed. The three histidine Cu, ligands are well defined in the oxidized and in the reduced states. These results are hardly compatible with the "histidine cycle" mechanisms formulated previously.	Max Planck Inst Biophys, Abt Mol Membranbiol, D-60528 Frankfurt, Germany	Max Planck Society	Michel, H (corresponding author), Max Planck Inst Biophys, Abt Mol Membranbiol, Heinrich Hoffman Str 7, D-60528 Frankfurt, Germany.	michel@mpibp-frankfiurt.mpg.de						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FergusonMiller S, 1996, CHEM REV, V96, P2889, DOI 10.1021/cr950051s; FRITZSCH G, 1989, BIOCHIM BIOPHYS ACTA, V977, P157, DOI 10.1016/S0005-2728(89)80066-0; GARCIAHORSMAN JA, 1994, J BACTERIOL, V176, P5587, DOI 10.1128/JB.176.18.5587-5600.1994; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kannt A, 1998, BIOPHYS J, V74, P708, DOI 10.1016/S0006-3495(98)73996-7; KLEYMANN G, 1995, BIO-TECHNOL, V13, P155, DOI 10.1038/nbt0295-155; Kornblatt JA, 1998, BIOPHYS J, V75, P435, DOI 10.1016/S0006-3495(98)77531-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Michel H, 1998, P NATL ACAD SCI USA, V95, P12819, DOI 10.1073/pnas.95.22.12819; Michel H, 1998, ANNU REV BIOPH BIOM, V27, P329, DOI 10.1146/annurev.biophys.27.1.329; Mitchell DM, 1996, BIOCHEMISTRY-US, V35, P824, DOI 10.1021/bi951897t; MORGAN JE, 1994, J BIOENERG BIOMEMBR, V26, P599, DOI 10.1007/BF00831534; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; OSTERMEIER C, 1995, NAT STRUCT BIOL, V2, P842, DOI 10.1038/nsb1095-842; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ralle M, 1999, BIOCHEMISTRY-US, V38, P7185, DOI 10.1021/bi982885l; RICH PR, 1995, AUST J PLANT PHYSIOL, V22, P479, DOI 10.1071/PP9950479; ROUSSEAU DL, 1993, J BIOENERG BIOMEMBR, V25, P165, DOI 10.1007/BF00762858; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; WIKSTROM M, 1994, BBA-BIOENERGETICS, V1187, P106, DOI 10.1016/0005-2728(94)90093-0; WIKSTROM MKF, 1977, NATURE, V266, P271, DOI 10.1038/266271a0; WOODRUFF WH, 1993, J BIOENERG BIOMEMBR, V25, P177, DOI 10.1007/BF00762859; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723	30	107	109	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33296	33299		10.1074/jbc.274.47.33296	http://dx.doi.org/10.1074/jbc.274.47.33296			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559205	hybrid			2022-12-25	WOS:000083745200021
J	Pritchard, JB; Sweet, DH; Miller, DS; Walden, R				Pritchard, JB; Sweet, DH; Miller, DS; Walden, R			Mechanism of organic anion transport across the apical membrane of choroid plexus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOLATERAL MEMBRANE; RAT-KIDNEY; P-AMINOHIPPURATE; BRUSH-BORDER; VESICLES; EXCHANGE; ACID; ACCUMULATION; LOCALIZATION; SECRETION	The mechanism and membrane localization of choroid plexus (CP) organic anion transport were determined in apical (or brush border) membrane vesicles isolated from bovine choroid plexus and in intact CP tissue from cow and rat. Brush border membrane vesicles were enriched in Na+,K+-ATPase (20-fold; an apical marker in CP) and demonstrated specific, sodium-coupled transport of proline, glucose, and glutarate. Vesicular uptake of the anionic herbicide 2,4-dichlorophenoxyacetic acid (2,4-D) was markedly stimulated by an inward sodium gradient but only in the presence of glutarate, indicating the presence of apical dicarboxylate/organic anion exchange. Consistent with this interpretation, an imposed outward glutarate gradient stimulated 2,4-D uptake in the absence of sodium. Under both conditions, uptake was dramatically slowed and overshoot was abolished by probenecid. Likewise, apical accumulation of 2,4-D by intact bovine choroid plexus tissue in vitro was stimulated by external glutarate in the presence of sodium. Glutarate stimulation was abolished by 5 mM LiCl. Identical findings were obtained using rat CP tissue, which showed both sodium/glutarate-stimulated 2,4-D (tissue/medium (T/M) similar to 8) and p-aminohippurate (T/M = 2) transport. Finally, since the renal exchanger (rROAT1) has been cloned in rat kidney, a rROAT1-green fluorescent protein construct was used to analyze exchanger distribution directly in transiently transfected rat CP. As predicted by the functional studies, the fluorescently tagged transporter was seen in apical but not basolateral membranes of the CP.	NIEHS, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Pritchard, JB (corresponding author), NIEHS, Lab Pharmacol & Chem, NIH, POB 12233,MD F1-3, Res Triangle Pk, NC 27709 USA.		Sweet, Douglas H/H-7914-2013	Sweet, Douglas H/0000-0002-8911-9184	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES080048, Z01ES048014, Z01ES080054, ZIAES080048] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARANY EH, 1972, ACTA PHYSIOL SCAND, V86, P12, DOI 10.1111/j.1748-1716.1972.tb00222.x; BARANY EH, 1973, ACTA PHYSIOL SCAND, V88, P412, DOI 10.1111/j.1748-1716.1973.tb05470.x; BARANY EH, 1973, ACTA PHYSIOL SCAND, V88, P491, DOI 10.1111/j.1748-1716.1973.tb05478.x; BURCKHARDT G, 1984, PFLUG ARCH EUR J PHY, V401, P254, DOI 10.1007/BF00582592; Cihlar T, 1999, MOL PHARMACOL, V56, P570, DOI 10.1124/mol.56.3.570; CSERR HF, 1971, AM J PHYSIOL, V220, P718, DOI 10.1152/ajplegacy.1971.220.3.718; ERNST SA, 1986, J HISTOCHEM CYTOCHEM, V34, P189, DOI 10.1177/34.2.3003182; Hosoyamada M, 1999, AM J PHYSIOL-RENAL, V276, pF122, DOI 10.1152/ajprenal.1999.276.1.F122; LORENZO AV, 1973, J PHARMACOL EXP THER, V184, P465; Lu R, 1999, AM J PHYSIOL-RENAL, V276, pF295, DOI 10.1152/ajprenal.1999.276.2.F295; NEFF NH, 1967, J PHARMACOL EXP THER, V158, P214; PAPPENHEIMER J, 1961, AM J PHYSIOL, V200, P1; PRITCHARD JB, 1990, J PHARMACOL EXP THER, V255, P969; PRITCHARD JB, 1983, P NATL ACAD SCI-BIOL, V80, P2603, DOI 10.1073/pnas.80.9.2603; PRITCHARD JB, 1988, AM J PHYSIOL, V255, pF597, DOI 10.1152/ajprenal.1988.255.4.F597; PRITCHARD JB, 1980, J PHARMACOL EXP THER, V212, P354; PRITCHARD JB, 1993, PHYSIOL REV, V73, P765, DOI 10.1152/physrev.1993.73.4.765; QUINTON PM, 1973, J CELL BIOL, V58, P724, DOI 10.1083/jcb.58.3.724; Reid G, 1998, KIDNEY BLOOD PRESS R, V21, P233, DOI 10.1159/000025863; RUBIN R, 1968, CANCER RES, V28, P689; SCHMITT C, 1993, PFLUG ARCH EUR J PHY, V423, P280, DOI 10.1007/BF00374407; Segal M., 1998, INTRO BLOOD BRAIN BA, P251; Sekine T, 1997, J BIOL CHEM, V272, P18526, DOI 10.1074/jbc.272.30.18526; SHIMADA H, 1987, AM J PHYSIOL, V253, pF795, DOI 10.1152/ajprenal.1987.253.5.F795; SUZUKI H, 1987, J PHARMACOL EXP THER, V243, P1147; Sweet DH, 1999, AM J PHYSIOL-RENAL, V276, pF864, DOI 10.1152/ajprenal.1999.276.6.F864; Sweet DH, 1997, J BIOL CHEM, V272, P30088, DOI 10.1074/jbc.272.48.30088; ULLRICH KJ, 1984, PFLUG ARCH EUR J PHY, V400, P241, DOI 10.1007/BF00581554; ULLRPORT SI, 1976, J99OD BRAIN BARRIER; Villalobos AR, 1997, J PHARMACOL EXP THER, V282, P1109; Villalobos AR, 1996, J PHARMACOL EXP THER, V278, P582; WHITTICO MT, 1990, J PHARMACOL EXP THER, V255, P615; WHITTICO MT, 1991, J PHARMACOL METHOD, V25, P215, DOI 10.1016/0160-5402(91)90012-T; WOLFF NA, 1997, FEBS LETT, V419, P107	34	69	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33382	33387		10.1074/jbc.274.47.33382	http://dx.doi.org/10.1074/jbc.274.47.33382			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559217	hybrid			2022-12-25	WOS:000083745200033
J	Bacolla, A; Pradhan, S; Roberts, RJ; Wells, RD				Bacolla, A; Pradhan, S; Roberts, RJ; Wells, RD			Recombinant human DNA (cytosine-5) methyltransferase II. Steady-state kinetics reveal allosteric activation by methylated DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; REPRESSOR-OPERATOR SYSTEM; ASSOCIATION KINETICS; DE-NOVO; SEQUENCE SPECIFICITY; COUPLED DIFFUSION; ESCHERICHIA-COLI; MOUSE CELLS; BINDING; MURINE	Initial velocity determinations were conducted with human DNA (cytosine-5) methyltransferase (DNMT1) on unmethylated and hemimethylated DNA templates in order to assess the mechanism of the reaction. Initial velocity data with DNA and S-adenosylmethionine (AdoMet) as variable substrates and product inhibition studies with methylated DNA and S-adenosylhomocysteine (AdoHcy) were obtained and evaluated as double-reciprocal plots. These relationships were linear for plasmid DNA, exon-l from the imprinted small nuclear ribonucleoprotein-associated polypeptide N, (CGG . CCG)(12), (m(5)CGG . CCG)(12), and (CGG . CCG)(73) but were not linear for (CGG . Cm(5)CG)(12). Inhibition by AdoHcy was apparently competitive versus AdoMet and uncompetitive/noncompetitive versus DNA at less than or equal to 20 mu M AdoMet. Addition of the product (methylated DNA) to unmethylated plasmid DNA increased V-max(app) resulting in mixed stimulation and inhibition. Velocity equations indicated a two-step mechanism as follows: first, activation of DNMT1 by methylated DNA that bound to an allosteric site, and second, the addition of AdoMet and DNA to the catalytic site. The preference of DNMT1 for hemimethylated DNA may be the result of positive cooperativity of AdoMet binding mediated by allosteric activation by the methylated CG steps. Fire propose that this activation plays a role in vivo in the regulation of maintenance methylation.	Univ Texas, Texas Med Ctr, Inst Biosci & Technol, Ctr Genome Res, Houston, TX 77030 USA; New England Biolabs Inc, Beverly, MA 01915 USA	Baylor College of Medicine; University of Texas System; University of Texas Health Science Center Houston	Bacolla, A (corresponding author), Univ Texas, Texas Med Ctr, Inst Biosci & Technol, Ctr Genome Res, Houston, TX 77030 USA.	abacolla@ibt.tamu.edu	Bacolla, Albino/AAP-1727-2020; Bacolla, Albino/N-3877-2013	Bacolla, Albino/0000-0003-0206-8423; Bacolla, Albino/0000-0003-0206-8423; Roberts, Richard/0000-0002-4348-0169	NIGMS NIH HHS [GM46127, GM52982] Funding Source: Medline; NINDS NIH HHS [NS37554] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982, R01GM046127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037554] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Araujo FD, 1998, MOL CELL BIOL, V18, P3475, DOI 10.1128/MCB.18.6.3475; Bacolla A, 1997, J BIOL CHEM, V272, P16783, DOI 10.1074/jbc.272.27.16783; BACOLLA A, 1995, J BIOL CHEM, V270, P24556, DOI 10.1074/jbc.270.41.24556; BAKER DJ, 1993, BIOCHEM BIOPH RES CO, V196, P864, DOI 10.1006/bbrc.1993.2329; BERG OG, 1981, BIOCHEMISTRY-US, V20, P6929, DOI 10.1021/bi00527a028; BERG OG, 1977, BIOPHYS CHEM, V7, P33, DOI 10.1016/0301-4622(77)87012-9; BERG OG, 1978, BIOPHYS CHEM, V8, P271, DOI 10.1016/0301-4622(78)80010-6; BERG OG, 1982, BIOPHYS CHEM, V15, P41, DOI 10.1016/0301-4622(82)87015-4; BERG OG, 1976, BIOPHYS CHEM, V4, P367, DOI 10.1016/0301-4622(76)80017-8; BERG OG, 1986, BIOPOLYMERS, V25, P811, DOI 10.1002/bip.360250506; BERG OG, 1984, BIOPOLYMERS, V23, P1869, DOI 10.1002/bip.360231005; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR T, 1988, BIOCHEM SOC T, V16, P944, DOI 10.1042/bst0160944; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; BESTOR TH, 1990, PHILOS T ROY SOC B, V326, P179, DOI 10.1098/rstb.1990.0002; BESTOR TH, 1983, P NATL ACAD SCI-BIOL, V80, P5559, DOI 10.1073/pnas.80.18.5559; Carotti D, 1998, BIOCHEMISTRY-US, V37, P1101, DOI 10.1021/bi971031i; CHENG XD, 1995, ANNU REV BIOPH BIOM, V24, P293, DOI 10.1146/annurev.bb.24.060195.001453; CHRISTMAN JK, 1995, P NATL ACAD SCI USA, V92, P7347, DOI 10.1073/pnas.92.16.7347; Deng J, 1998, J BIOL CHEM, V273, P22869, DOI 10.1074/jbc.273.36.22869; DOERFLER W, 1991, BIOL CHEM H-S, V372, P557; Flynn J, 1996, BIOCHEMISTRY-US, V35, P7308, DOI 10.1021/bi9600512; Flynn J, 1998, J MOL BIOL, V279, P101, DOI 10.1006/jmbi.1998.1761; Gaudet F, 1998, J BIOL CHEM, V273, P32725, DOI 10.1074/jbc.273.49.32725; GRANT RC, 1968, J AM CHEM SOC, V90, P4474, DOI 10.1021/ja01018a060; GRUNWALD S, 1984, INT J BIOCHEM, V16, P883, DOI 10.1016/0020-711X(84)90147-2; HITT MM, 1988, J BIOL CHEM, V263, P4392; Imbert G, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P27; Jeltsch A, 1998, J MOL BIOL, V275, P747, DOI 10.1006/jmbi.1997.1492; JOST JP, 1993, DNA METHYLATION MOL; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; LANDRY D, 1992, METHOD ENZYMOL, V216, P244; Lei H, 1996, DEVELOPMENT, V122, P3195; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, COLD SPRING HARB SYM, V58, P297, DOI 10.1101/SQB.1993.058.01.035; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Lindsay H, 1996, BIOCHEM J, V320, P473, DOI 10.1042/bj3200473; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NOYERWEIDNER M, 1993, DNA METHYLATION MOL, P39; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1998, NUCLEIC ACIDS RES, V26, P2536, DOI 10.1093/nar/26.11.2536; OREND G, 1991, J VIROL, V65, P4301, DOI 10.1128/JVI.65.8.4301-4308.1991; PFEIFER GP, 1985, EMBO J, V4, P2879, DOI 10.1002/j.1460-2075.1985.tb04017.x; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Pradhan S, 1997, NUCLEIC ACIDS RES, V25, P4666, DOI 10.1093/nar/25.22.4666; Ramchandani S, 1998, BIOL CHEM, V379, P535; RAZIN A, 1995, HUM MOL GENET, V4, P1751, DOI 10.1093/hmg/4.suppl_1.1751; Reale A, 1995, BIOCHEM J, V312, P855, DOI 10.1042/bj3120855; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; Roberts R, 1993, NUCLEASES, P35; RUCHIRAWAT M, 1987, MOL CELL BIOCHEM, V76, P45; SEGAL IH, 1975, ENZYME KINETICS BEHA, P505; SMITH SS, 1992, P NATL ACAD SCI USA, V89, P4744, DOI 10.1073/pnas.89.10.4744; Tollefsbol TO, 1997, J MOL BIOL, V269, P494, DOI 10.1006/jmbi.1997.1064; TOLLEFSBOL TO, 1995, J BIOL CHEM, V270, P18543, DOI 10.1074/jbc.270.31.18543; TRASLER JM, 1992, NUCLEIC ACIDS RES, V20, P2541, DOI 10.1093/nar/20.10.2541; TRASLER JM, 1990, MOL CELL BIOL, V10, P1828, DOI 10.1128/MCB.10.4.1828; Tucker KL, 1996, P NATL ACAD SCI USA, V93, P12920, DOI 10.1073/pnas.93.23.12920; Van den Wyngaert I, 1998, FEBS LETT, V426, P283, DOI 10.1016/S0014-5793(98)00362-7; WANG RYH, 1984, NUCLEIC ACIDS RES, V12, P3473, DOI 10.1093/nar/12.8.3473; WILSON GG, 1992, METHOD ENZYMOL, V216, P259; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6961, DOI 10.1021/bi00527a030; Woodcock DM, 1997, J BIOL CHEM, V272, P7810, DOI 10.1074/jbc.272.12.7810; WU JC, 1987, J BIOL CHEM, V262, P4778; XU GR, 1995, BIOCHEM BIOPH RES CO, V207, P544, DOI 10.1006/bbrc.1995.1222; Yoder JA, 1997, J MOL BIOL, V270, P385, DOI 10.1006/jmbi.1997.1125; Yoder JA, 1996, J BIOL CHEM, V271, P31092, DOI 10.1074/jbc.271.49.31092; Yoder JA, 1998, HUM MOL GENET, V7, P279, DOI 10.1093/hmg/7.2.279	69	105	110	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					33011	33019		10.1074/jbc.274.46.33011	http://dx.doi.org/10.1074/jbc.274.46.33011			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551869	hybrid			2022-12-25	WOS:000083623000069
J	Cui, MZ; Penn, MS; Chisolm, GM				Cui, MZ; Penn, MS; Chisolm, GM			Native and oxidized low density lipoprotein induction of tissue factor gene expression in smooth muscle cells is mediated by both Egr-1 and Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; THP-1 MONOCYTIC CELLS; FACTOR MESSENGER-RNA; KAPPA-B-LIKE; LIPOPOLYSACCHARIDE INDUCTION; TRANSCRIPTIONAL REGULATION; EPITHELIAL-CELLS; LYSINE RESIDUES; C ACTIVATION; BINDING	Tissue factor, in association with factor VIIa, initiates the coagulation cascade. We studied the influences of two pathophysiological stimuli, native (unmodified) and oxidized low density lipoprotein, on tissue factor gene expression in a cell important in vascular remodeling and vascular diseases, the smooth muscle cell. Our results demonstrated that both lipoproteins significantly induced tissue factor gene expression in rat aortic smooth muscle cells; oxidized low density lipoprotein was slightly more potent. Both lipoproteins increased tissue factor mRNA in a concentration- and time-dependent manner. Results from nuclear run-on assays and mRNA stability experiments indicated that increased tissue factor mRNA accumulation in response to the lipoproteins was principally controlled at the transcriptional level. By using lipid extracts of low density lipoprotein or methylation of the intact lipoprotein to block receptor recognition, we showed that this lipoprotein induced tissue factor mRNA via both receptor-independent and receptor-augmented pathways. Transfection studies using a series of deleted tissue factor promoters revealed that a -143- to +106-base pair region of the rat tissue factor promoter contained regulatory elements required for lipoprotein-mediated induction. Electrophoretic mobility shift assays showed that the binding activities of the transcription factor Egr-1, but not Spl, were markedly elevated in response to these lipoproteins. Transfection of site-directed mutants of the tissue factor (TF) promoter demonstrated that not only Egr-1 but also Sp1 cis-acting elements in the TF (-143) promoter construct were necessary for optimal TF gene induction. Our data show for the first time that both low density lipoprotein and oxidized low density lipoprotein induce tissue factor gene expression in smooth muscle cells and that this tissue factor gene expression is mediated by both Egr-1 and Sp1 transcription factors.	Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Chisolm, GM (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, 9500 Euclid Ave,NC10, Cleveland, OH 44195 USA.	chisolg@ccf.org		Cui, Mei-Zhen/0000-0003-4745-6999	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029582] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 09911, HL 29582] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; ANNEX BH, 1995, CIRCULATION, V91, P619, DOI 10.1161/01.CIR.91.3.619; BACH RR, 1988, CRC CR REV BIOCH MOL, V23, P339, DOI 10.3109/10409238809082548; BIERHAUS A, 1995, J BIOL CHEM, V270, P26419, DOI 10.1074/jbc.270.44.26419; BRAND K, 1994, ARTERIOSCLER THROMB, V14, P790, DOI 10.1161/01.ATV.14.5.790; BRAND K, 1991, MOL CELL BIOL, V11, P4732, DOI 10.1128/MCB.11.9.4732; BROCK TA, 1985, HYPERTENSION, V7, pI105, DOI 10.1161/01.HYP.7.3_Pt_2.I105; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CAO XM, 1993, J BIOL CHEM, V268, P16949; COFFEY MD, 1995, J CLIN INVEST, V96, P1866, DOI 10.1172/JCI118232; CROSSMAN DC, 1990, J BIOL CHEM, V265, P9782; Cui MZ, 1996, J BIOL CHEM, V271, P2731, DOI 10.1074/jbc.271.5.2731; CUI MZ, 1994, ARTERIOSCLER THROMB, V14, P807, DOI 10.1161/01.ATV.14.5.807; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONOVANPELUSO M, 1994, J BIOL CHEM, V269, P1361; DRAKE TA, 1991, AM J PATHOL, V138, P601; Edgington T S, 1991, Curr Stud Hematol Blood Transfus, P15; FELTS SJ, 1995, BIOCHEMISTRY-US, V34, P12355, DOI 10.1021/bi00038a032; Fields R, 1972, Methods Enzymol, V25, P464, DOI 10.1016/S0076-6879(72)25042-X; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KOSUGI K, 1987, J CELL PHYSIOL, V130, P311, DOI 10.1002/jcp.1041300302; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEWIS JC, 1995, AM J PATHOL, V147, P1029; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDKATZ S, 1988, J BIOL CHEM, V263, P13831; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; MOLL T, 1995, J BIOL CHEM, V270, P3849, DOI 10.1074/jbc.270.8.3849; MOREL DW, 1986, LAB INVEST, V55, P419; MOREL DW, 1983, J LIPID RES, V24, P1070; MORRISSEY JH, 1987, CELL, V50, P129, DOI 10.1016/0092-8674(87)90669-6; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OETH PA, 1994, MOL CELL BIOL, V14, P3772, DOI 10.1128/MCB.14.6.3772; PARRY GCN, 1995, ARTERIOSCL THROM VAS, V15, P612, DOI 10.1161/01.ATV.15.5.612; Penn MS, 1999, CIRCULATION, V99, P1753, DOI 10.1161/01.CIR.99.13.1753; PENN MS, 1994, CIRCULATION, V90, P353; Schecter AD, 1997, J CLIN INVEST, V100, P2276, DOI 10.1172/JCI119765; Schecter AD, 1997, J BIOL CHEM, V272, P28568, DOI 10.1074/jbc.272.45.28568; SCHUH J, 1978, P NATL ACAD SCI USA, V75, P3173, DOI 10.1073/pnas.75.7.3173; Taby O, 1996, THROMB HAEMOSTASIS, V76, P697; TAUBMAN MB, 1993, AM J CARDIOL, V72, pC55, DOI 10.1016/0002-9149(93)90256-C; TAUBMAN MB, 1993, J CLIN INVEST, V91, P547, DOI 10.1172/JCI116234; Taubman MB, 1997, THROMB HAEMOSTASIS, V78, P200; Thiruvikraman SV, 1996, LAB INVEST, V75, P451; VICTOROV AV, 1989, BIOCHIM BIOPHYS ACTA, V984, P119, DOI 10.1016/0005-2736(89)90351-9; VIRCA GD, 1990, BIOTECHNIQUES, V8, P370; WADA H, 1994, INT J CARDIOL, V47, pS21, DOI 10.1016/0167-5273(94)90322-0; WEIS JR, 1991, FASEB J, V5, P2459, DOI 10.1096/fasebj.5.10.2065893; WEISGRABER KH, 1978, J BIOL CHEM, V253, P9053; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; ZELDIS SM, 1972, SCIENCE, V175, P766, DOI 10.1126/science.175.4023.766	54	72	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32795	32802		10.1074/jbc.274.46.32795	http://dx.doi.org/10.1074/jbc.274.46.32795			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551840	hybrid			2022-12-25	WOS:000083623000040
J	Omura, T; Nabekura, J; Akaike, N				Omura, T; Nabekura, J; Akaike, N			Intracellular pathways of V-1 and V-2 receptors activated by arginine vasopressin in rat hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SUBSTANTIA-NIGRA NEURONS; CYCLIC-AMP ACCUMULATION; CA1 PYRAMIDAL NEURONS; ADENYLYL-CYCLASE; BINDING-SITES; AUTORADIOGRAPHIC LOCALIZATION; MOLECULAR-CLONING; INDUCED RESPONSES; TAURINE RESPONSE	To explore the intracellular pathways activated by vasopressin receptors, the effects of arginine vasopressin (AVP) and its analogues mediating glycine (Gly)induced Cl- currents (I-Gly) were examined in acutely dissociated rat hippocampal CA1 neurons using the whole-cell patch recording technique. AVP and its analogues inhibited I-Gly in a concentration-dependent manner. The inhibitory actions of AVP(4-9) (AVP metabolite) and NC-1900 (AVP(4-9) analogue) were reversed by a V-1 receptor antagonist, or pretreatment with 1,2-bis(2-amino- 5-fluorophenoxy)ethane-N,N,N',N'-tetraacetic acid. In contrast, these blocking procedures had no effect on the 1-desamino-8-D-AVP (DDAVP; V-2 agonist) action. A V-1 receptor antagonist did not block the inhibitory action of AVP(4-9) or NC-1900, but blocked that of DDAVP. The inhibitory action of AVP was completely blocked by the co-application of the V-1 and V-2 antagonists. The inhibitory action of NC-1900 was not affected by perfusion with a Ca2+-free external solution, but was strongly blocked by thapsigargin. The intracellular application of heparin or anti-inositol 1,4,5-triphosphate (IP3) also blocked the NC-1900 action. Furthermore, Ca2+/calmodulin (CaM) inhibitors blocked the NC-1900 action, while a CaM-dependent kinase II inhibitor and PKC modulators had no effect. 2',5'-Dideoxyadenosine tan adenylate cyclase inhibitor), H-89, and Rp-cAMPS blocked the inhibitory actions of NC-1900 and DDAVP. These results suggest that the activation of the V-1 receptor in the hippocampal neurons induces the production of IP3 which releases Ca2+ from the IP3-sensitive Ca2+ storage sites. The Ca2+ binds to CaM resulting in the activation of Ca2+/CaM-sensitive adenylate cyclases, The activation of protein kinase A through the adenylate cyclase inhibits I-Gly.	Kyushu Univ, Grad Sch Med, Dept Physiol, Fukuoka 8128582, Japan; Nippon Chemiphar Co Ltd, Res Labs, Misato, Saitama 3410005, Japan	Kyushu University	Akaike, N (corresponding author), Kyushu Univ, Grad Sch Med, Dept Cellular & Syst Physiol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.							AGOPYAN N, 1993, NEUROSCIENCE, V56, P605, DOI 10.1016/0306-4522(93)90360-R; AKAIKE N, 1994, JPN J PHYSIOL, V44, P433, DOI 10.2170/jjphysiol.44.433; AlescioLautier B, 1995, EUR J PHARMACOL, V294, P763, DOI 10.1016/0014-2999(95)00632-X; Baker LP, 1999, J NEUROSCI, V19, P180, DOI 10.1523/JNEUROSCI.19-01-00180.1999; BIEGON A, 1984, NEUROSCI LETT, V44, P229, DOI 10.1016/0304-3940(84)90027-2; BRINTON RD, 1993, DEV BRAIN RES, V71, P101, DOI 10.1016/0165-3806(93)90110-V; BRINTON RD, 1994, BRAIN RES, V661, P274; BRINTON RE, 1989, J NEUROSCI, V9, P752; BRINTON RE, 1984, P NATL ACAD SCI-BIOL, V81, P7248, DOI 10.1073/pnas.81.22.7248; BRINTON RE, 1986, LIFE SCI, V38, P443, DOI 10.1016/0024-3205(86)90069-X; BUIJS RM, 1978, CELL TISSUE RES, V186, P423, DOI 10.1007/BF00224932; BURBACH JPH, 1983, SCIENCE, V221, P1310, DOI 10.1126/science.6351252; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHEN C, 1993, HIPPOCAMPUS, V3, P193, DOI 10.1002/hipo.450030211; CHEPKOVA AN, 1995, BRAIN RES, V701, P255, DOI 10.1016/0006-8993(95)01006-7; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; CHETKOVICH DM, 1993, J NEUROCHEM, V61, P1933, DOI 10.1111/j.1471-4159.1993.tb09836.x; CHURCH AC, 1983, PEPTIDES, V4, P261, DOI 10.1016/0196-9781(83)90124-9; DEKLOET ER, 1985, NEUROSCI LETT, V56, P7, DOI 10.1016/0304-3940(85)90432-X; DEWIED D, 1991, P NATL ACAD SCI USA, V88, P1494, DOI 10.1073/pnas.88.4.1494; DEWIED D, 1988, VASOPRESISN EFFECTS, P97; EBIHARA S, 1992, NEUROSCI RES, V14, P61, DOI 10.1016/S0168-0102(05)80006-9; Everts HGJ, 1997, BRAIN RES, V760, P1, DOI 10.1016/S0006-8993(97)00269-2; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; Harata N, 1997, J PHYSIOL-LONDON, V500, P673, DOI 10.1113/jphysiol.1997.sp022052; HAWTHORN J, 1980, BRAIN RES, V197, P75, DOI 10.1016/0006-8993(80)90435-7; HIRASAWA A, 1994, BIOCHEM BIOPH RES CO, V205, P1702, DOI 10.1006/bbrc.1994.2864; Imanishi T, 1996, NEUROREPORT, V7, P1421, DOI 10.1097/00001756-199605310-00020; INOMATA H, 1993, BRAIN RES, V615, P347, DOI 10.1016/0006-8993(93)90048-R; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JARD S, 1985, FRONTIERS HORMONE RE, V13, P89; KIRK CJ, 1981, BIOCHEM J, V194, P155, DOI 10.1042/bj1940155; Klingler C, 1998, BIOCHEM J, V330, P1023, DOI 10.1042/bj3301023; KRISHTAL OA, 1988, NEUROSCI LETT, V84, P271, DOI 10.1016/0304-3940(88)90519-8; KRUSZYNSKI M, 1980, J MED CHEM, V23, P364, DOI 10.1021/jm00178a003; Liu XB, 1996, J PHARMACOL EXP THER, V277, P796; MAEGAWA H, 1992, LIFE SCI, V51, P285, DOI 10.1016/0024-3205(92)90087-6; MIZUNO Y, 1984, BRAIN RES, V309, P241; MONS N, 1993, SYNAPSE, V14, P51, DOI 10.1002/syn.890140108; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; MOUGINOT D, 1991, J PHYSIOL-LONDON, V437, P109, DOI 10.1113/jphysiol.1991.sp018587; MUHLETHALER M, 1983, P NATL ACAD SCI-BIOL, V80, P6713, DOI 10.1073/pnas.80.21.6713; MUHLETHALER M, 1982, NATURE, V296, P749, DOI 10.1038/296749a0; MURASE K, 1990, BRAIN RES, V525, P84, DOI 10.1016/0006-8993(90)91323-9; Nabekura J, 1996, J NEUROPHYSIOL, V76, P2455, DOI 10.1152/jn.1996.76.4.2455; NEWMAN ME, 1985, FEBS LETT, V181, P203, DOI 10.1016/0014-5793(85)80260-X; NISHIZAKI T, 1995, BRAIN RES, V687, P214, DOI 10.1016/0006-8993(95)00543-Y; Pan H, 1997, J NEUROSCI, V17, P1011; Premont RT, 1996, J BIOL CHEM, V271, P13900, DOI 10.1074/jbc.271.23.13900; Sabatier N, 1998, J PHYSIOL-LONDON, V513, P699, DOI 10.1111/j.1469-7793.1998.699ba.x; SCHONROCK B, 1995, NEUROREPORT, V6, P301, DOI 10.1097/00001756-199501000-00019; SHIRASAKI T, 1991, BRAIN RES, V561, P77, DOI 10.1016/0006-8993(91)90751-G; STEPHENS LR, 1986, J NEUROCHEM, V46, P649, DOI 10.1111/j.1471-4159.1986.tb13016.x; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; VANLEEUWEN FW, 1987, NEUROSCI LETT, V80, P121, DOI 10.1016/0304-3940(87)90640-9; Xu TL, 1996, J PHYSIOL-LONDON, V496, P491, DOI 10.1113/jphysiol.1996.sp021701; YAMAMURA Y, 1992, BRIT J PHARMACOL, V105, P787, DOI 10.1111/j.1476-5381.1992.tb09058.x; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716; Zhang JH, 1997, AM J PHYSIOL-HEART C, V273, pH971, DOI 10.1152/ajpheart.1997.273.2.H971	60	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32762	32770		10.1074/jbc.274.46.32762	http://dx.doi.org/10.1074/jbc.274.46.32762			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551836	hybrid			2022-12-25	WOS:000083623000036
J	Richard, DE; Berra, E; Gothie, E; Roux, D; Pouyssegur, J				Richard, DE; Berra, E; Gothie, E; Roux, D; Pouyssegur, J			p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1 alpha (HIF-1 alpha) and enhance the transcriptional activity of HIF-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; MAP KINASE; FACTOR GENE; O-2 HOMEOSTASIS; 3T3 CELLS; PATHWAY; TRANSACTIVATION; IDENTIFICATION; ANGIOGENESIS; DEGRADATION	Hypoxia-inducible factor-1 (HIF-1) controls the expression of a number of genes such as vascular endothelial growth factor and erythropoietin in low oxygen conditions. However, the molecular mechanisms that underlie the activation of the limiting subunit, HIF-1 alpha, are still poorly resolved, Results showing that endogenous HIF-1 alpha migrated 12 kDa higher than in vitro translated protein led us to evaluate the possible role of phosphorylation on this phenomenon. We report here that HIF-1 alpha is strongly phosphorylated in vivo and that phosphorylation is responsible for the marked differences in the migration pattern of HIF-1 alpha, In vitro, HIF-1 alpha: is phosphorylated by p42 and p44 mitogen-activated protein kinases (MAPKs) and not by p38 MAPK or c-Jun N-terminal kinase, interestingly p42/p44 MAPK stoichiometrically phosphorylate HIF-1 alpha in vitro, as judged by a complete upper shift of HIF-1 alpha. More importantly, we demonstrate that activation of the p42/p44 MAPK pathway in quiescent cells induced the phosphorylation and shift of HIF-1 alpha, which was abrogated in presence of the MEK inhibitor, PD 98059, Finally, we found that in a vascular endothelial growth factor promoter mutated at sites previously shown to be MAPK-sensitive (SP1/AP2-88-66 site), p42/p44 MAPK activation is sufficient to promote the transcriptional activity of HIF-1, This interaction between HIF-1 alpha and p42/p44 MAPK suggests a cooperation between hypoxic and growth factor signals that ultimately leads to the increase in RIF-l-mediated gene expression.	Ctr Antoine Lacassagne, UMR CNRS 6543, Inst Signaling Dev Biol & Canc Res, F-06189 Nice, France	UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne	Richard, DE (corresponding author), Ctr Antoine Lacassagne, UMR CNRS 6543, Inst Signaling Dev Biol & Canc Res, 33 Ave Valombrose, F-06189 Nice, France.		Berra, Edurne/F-9692-2011; Richard, Darren E./K-6760-2019	Berra, Edurne/0000-0002-3820-5744; Richard, Darren/0000-0003-2690-0480				An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Dong QG, 1997, ARTERIOSCL THROM VAS, V17, P1599, DOI 10.1161/01.ATV.17.8.1599; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; ELLIS L, 1986, COLD SPRING HARB SYM, V2, P773; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GLEADLE JM, 1995, AM J PHYSIOL-CELL PH, V268, pC1362, DOI 10.1152/ajpcell.1995.268.6.C1362; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; Ladoux A, 1997, BIOCHEM BIOPH RES CO, V240, P552, DOI 10.1006/bbrc.1997.7708; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; LI H, 1994, J BIOL CHEM, V269, P28098; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; MINCHENKO A, 1994, CELL MOL BIOL RES, V40, P35; Muller JN, 1997, J BIOL CHEM, V272, P23435, DOI 10.1074/jbc.272.37.23435; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; NOMURA M, 1995, J BIOL CHEM, V270, P28316; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Salceda S, 1997, KIDNEY INT, V51, P556, DOI 10.1038/ki.1997.78; SAMUELS ML, 1994, MOL CELL BIOL, V14, P7855, DOI 10.1128/MCB.14.12.7855; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Song XD, 1999, J BIOL CHEM, V274, P1677, DOI 10.1074/jbc.274.3.1677; Vasir B, 1998, DIABETES, V47, P1894, DOI 10.2337/diabetes.47.12.1894; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, BIOCHEM BIOPH RES CO, V216, P669, DOI 10.1006/bbrc.1995.2674; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343	48	669	700	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32631	32637		10.1074/jbc.274.46.32631	http://dx.doi.org/10.1074/jbc.274.46.32631			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551817	hybrid			2022-12-25	WOS:000083623000017
J	Shen, BQ; Lee, DY; Zioncheck, TF				Shen, BQ; Lee, DY; Zioncheck, TF			Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL GROWTH; VEGF; ANGIOGENESIS; GENE; IDENTIFICATION; ACTIVATION; KDR; NEUROPILIN-1; INDUCTION; ISOFORM	The mechanism by which vascular endothelial growth factor (VEGF) regulates endothelial nitric-oxide synthase (eNOS) expression is presently unclear. Here we report that VEGF treatment of bovine adrenal cortex endothelial cells resulted in a B-fold increase in both eNOS protein and activity, Endothelial NOS expression was maximal following 2 days of constant VEGF exposure (500 pM) and declined to base-line levels by day 5, The elevated eNOS protein level was sustained over the time course if VEGF was co-incubated with L-N-G-nitroarginine methyl ester, a competitive eNOS inhibitor. Addition of S-nitroso-N-acetylpenicillamine, a nitric oxide donor, prevented VEGF-induced eNOS up-regulation, These data suggest that nitric oxide participates in a negative feedback mechanism regulating eNOS expression. Various approaches were used to investigate the role of the two high affinity VEGF receptors in eNOS up-regulation. A HDR receptor-selective mutant increased eNOS expression, whereas an Flt-1 receptor-selective mutant did not. Furthermore, VEGF treatment increased eNOS expression in a KDR but not in an Flt-1 receptor-transfected porcine aorta endothelial cell line. SU1498, a selective inhibitor of the KDR receptor tyrosine kinase, blocked eNOS up-regulation thus providing further evidence that the KDR receptor signals for eNOS up-regulation, Finally, treatment of adrenal cortex endothelial cells with VEGF or phorbol ester resulted in protein kinase C activation and elevated eNOS expression, whereas inhibition of protein kinase C with isoform-specific inhibitors abolished VFGF-induced eNOS up-regulation. Taken together, these data demonstrate that VEGF increases eNOS expression via activation of the KDR receptor tyrosine kinase and a downstream protein kinase C signaling pathway.	Genentech Inc, Dept Metab & Pharmacokinet, S San Francisco, CA 94080 USA	Roche Holding; Genentech	Zioncheck, TF (corresponding author), Genentech Inc, Dept Metab & Pharmacokinet, MS 70,1 DNA Way, S San Francisco, CA 94080 USA.							Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371; Athanassiades A, 1998, BIOL REPROD, V59, P643, DOI 10.1095/biolreprod59.3.643; Couffinhal T, 1997, AM J PATHOL, V150, P1673; Cunningham SA, 1999, AM J PHYSIOL-CELL PH, V276, pC176, DOI 10.1152/ajpcell.1999.276.1.C176; Drummond GR, 1998, J CLIN INVEST, V102, P2033, DOI 10.1172/JCI5845; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Hariawala MD, 1996, J SURG RES, V63, P77, DOI 10.1006/jsre.1996.0226; HARRISON DG, 1995, AGENT ACTION SUPPL, V45, P107; HOOD JD, 1998, AM J PHYSIOL, V274, pH1055; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Katoh O, 1998, CANCER RES, V58, P5565; Kelly RA, 1996, CIRC RES, V79, P363, DOI 10.1161/01.RES.79.3.363; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Kroll J, 1998, BIOCHEM BIOPH RES CO, V252, P743, DOI 10.1006/bbrc.1998.9719; LEGRAS TD, 1996, AM J PHYSIOL, V270, pL164; Mandriota SJ, 1996, J BIOL CHEM, V271, P11500, DOI 10.1074/jbc.271.19.11500; Mathews MK, 1997, INVEST OPHTH VIS SCI, V38, P2729; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; MONCADA S, 1991, PHARMACOL REV, V43, P109; Morbidelli L, 1996, AM J PHYSIOL-HEART C, V270, pH411, DOI 10.1152/ajpheart.1996.270.1.H411; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Ohashi Y, 1998, J CLIN INVEST, V102, P2061, DOI 10.1172/JCI4394; ORTEGA N, 1999, FRONT BIOSCI, V4, P141; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; ROBINSON LJ, 1994, GENOMICS, V19, P350, DOI 10.1006/geno.1994.1068; Rudic RD, 1998, J CLIN INVEST, V101, P731, DOI 10.1172/JCI1699; Sase K, 1997, TRENDS CARDIOVAS MED, V7, P28, DOI 10.1016/S1050-1738(96)00121-1; Shen BQ, 1998, J BIOL CHEM, V273, P29979, DOI 10.1074/jbc.273.45.29979; Shen BQ, 1997, AM J PHYSIOL-LUNG C, V272, pL1115, DOI 10.1152/ajplung.1997.272.6.L1115; Shih SC, 1999, J BIOL CHEM, V274, P15407, DOI 10.1074/jbc.274.22.15407; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Spyridopoulos I, 1997, J MOL CELL CARDIOL, V29, P1321, DOI 10.1006/jmcc.1996.0365; TANG JL, 1995, BIOCHEM BIOPH RES CO, V213, P673, DOI 10.1006/bbrc.1995.2184; TERMAN BI, 1991, ONCOGENE, V6, P1677; Tsurumi Y, 1997, NAT MED, V3, P879, DOI 10.1038/nm0897-879; TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858; Uematsu M, 1995, AM J PHYSIOL-CELL PH, V269, pC1371, DOI 10.1152/ajpcell.1995.269.6.C1371; Van Belle E, 1998, CIRCULATION, V97, P381; vanderZee R, 1997, CIRCULATION, V95, P1030; Wellner M, 1999, ARTERIOSCL THROM VAS, V19, P178, DOI 10.1161/01.ATV.19.1.178; Wojta J, 1999, LAB INVEST, V79, P427; Wu HM, 1999, AM J PHYSIOL-HEART C, V276, pH535, DOI 10.1152/ajpheart.1999.276.2.H535; Wu HM, 1996, AM J PHYSIOL-HEART C, V271, pH2735, DOI 10.1152/ajpheart.1996.271.6.H2735; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; Xiao ZS, 1997, J CELL PHYSIOL, V171, P205, DOI 10.1002/(SICI)1097-4652(199705)171:2<205::AID-JCP11>3.3.CO;2-3; Yang RH, 1996, J CARDIOVASC PHARM, V27, P838, DOI 10.1097/00005344-199606000-00011; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451; Ziegler T, 1998, HYPERTENSION, V32, P351, DOI 10.1161/01.HYP.32.2.351	56	252	262	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					33057	33063		10.1074/jbc.274.46.33057	http://dx.doi.org/10.1074/jbc.274.46.33057			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551875	hybrid			2022-12-25	WOS:000083623000075
J	Wang, YH; Johnson, AR; Ye, QZ; Dyer, RD				Wang, YH; Johnson, AR; Ye, QZ; Dyer, RD			Catalytic activities and substrate specificity of the human membrane type 4 matrix metalloproteinase catalytic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXAMATE INHIBITOR; TRANSMEMBRANE DOMAIN; PROGELATINASE-A; TNF-ALPHA; MT-MMPS; STROMELYSIN; COLLAGENASE; ACTIVATION; EXPRESSION; CDNA	Membrane type (MT) matrix metalloproteinases (MMPs) are recently recognized members of the family of Zn2+- and Ca2+-dependent MMPs. To investigate the proteolytic capabilities of human MT4-MMP (i.e. MMP-17), we have cloned DNA encoding its catalytic domain (CD) from a breast carcinoma cDNA library. Human membrane type 4 MMP CD (MT4-MMPCD) protein, expressed as inclusion bodies in Escherichia coli, was purified to homogeneity and refolded in the presence of Zn2+ and Ca2+. While MT4-MMPCD cleaved synthetic MMP substrates Ac-PLG-[2-mercapto-4-methylpentanoyl]-LG-OEt and Mca-PLGL-Dpa-AR-NH2 with modest efficiency, it catalyzed with much higher efficiency the hydrolysis of a pro-tumor necrosis factor-ct converting enzyme synthetic substrate; Mca-PLAQAV-DpaR-SSSR-NH2. Catalytic efficiency with the pro-tumor necrosis factor-a: converting enzyme substrate was maximal at pH 7.4 and was modulated by three ionizable enzyme groups (pK(a3) = 6.2, pK(a2) = 8.3, and pK(a1) = 10.6). MT4-MMPCD cleaved gelatin but was inactive toward type I collagen, type IV collagen, fibronectin, and laminin. Like all known MT-MMPs, MT4-MMPCD was also able to activate 72-kDa progelatinase A to its 68-kDa form. EDTA, 1,10-phenanthroline, reference hydroxamic acid MMP inhibitors, tissue inhibitor of metalloproteinases-l, and tissue inhibitor of metalloproteinases-a all potently blocked MT4-MMPCD enzymatic activity. MT4-MMP is, therefore, a competent Zn2+-dependent MMP with unique specificity among synthetic substrates and the capability to both degrade gelatin and activate progelatinase A.	Warner Lambert Co, Parke Davis Pharmaceut Res Div, Dept Biochem, Ann Arbor, MI 48105 USA	Pfizer	Dyer, RD (corresponding author), Warner Lambert Co, Parke Davis Pharmaceut Res Div, Dept Biochem, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.		Ye, Qizhuang/B-3147-2009					BECKER JW, 1995, PROTEIN SCI, V4, P1966, DOI 10.1002/pro.5560041002; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; CAPUTO CB, 1987, BIOCHEM PHARMACOL, V36, P995, DOI 10.1016/0006-2952(87)90405-9; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; Dhanaraj V, 1996, STRUCTURE, V4, P375, DOI 10.1016/S0969-2126(96)00043-3; DOLLERY CM, 1995, CIRC RES, V77, P863, DOI 10.1161/01.RES.77.5.863; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; Galardy Richard E., 1993, Drugs of the Future, V18, P1109; Giambernardi TA, 1998, MATRIX BIOL, V16, P483, DOI 10.1016/S0945-053X(98)90019-1; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; GRAMS F, 1995, BIOCHEMISTRY-US, V34, P14012, DOI 10.1021/bi00043a007; HARRISON RK, 1992, BIOCHEMISTRY-US, V31, P10757, DOI 10.1021/bi00159a016; Holman CM, 1999, BIOCHEMISTRY-US, V38, P677, DOI 10.1021/bi9822170; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Kroger M, 1997, GENE, V196, P175, DOI 10.1016/S0378-1119(97)00223-0; Liu YY, 1999, ANAL BIOCHEM, V267, P331, DOI 10.1006/abio.1998.3014; Llano E, 1999, CANCER RES, V59, P2570; MacPherson LJ, 1997, J MED CHEM, V40, P2525, DOI 10.1021/jm960871c; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Mucha A, 1998, J BIOL CHEM, V273, P2763, DOI 10.1074/jbc.273.5.2763; Patel IR, 1998, J IMMUNOL, V160, P4570; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Puente XS, 1996, CANCER RES, V56, P944; Rasmussen HS, 1997, PHARMACOL THERAPEUT, V75, P69, DOI 10.1016/S0163-7258(97)00023-5; Rudolph-Owen LA, 1998, CANCER RES, V58, P5500; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Shofuda K, 1997, J BIOL CHEM, V272, P9749; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; VANDOREN SR, 1995, PROTEIN SCI, V4, P2487, DOI 10.1002/pro.5560041205; VanDyk DE, 1997, BIOORG MED CHEM LETT, V7, P1219, DOI 10.1016/S0960-894X(97)00148-0; WALAKOVITS LA, 1992, ARTHRITIS RHEUM, V35, P35, DOI 10.1002/art.1780350106; WEINGARTEN H, 1985, BIOCHEMISTRY-US, V24, P6730, DOI 10.1021/bi00344a064; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; YE QZ, 1995, BIOCHEMISTRY-US, V34, P4702, DOI 10.1021/bi00014a026; YE QZ, 1992, BIOCHEMISTRY-US, V31, P11231, DOI 10.1021/bi00160a038; Ye QZ, 1996, CURR MED CHEM, V3, P407	39	61	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					33043	33049		10.1074/jbc.274.46.33043	http://dx.doi.org/10.1074/jbc.274.46.33043			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551873	hybrid			2022-12-25	WOS:000083623000073
J	Buton, X; Mamdouh, Z; Ghosh, R; Du, H; Kuriakose, G; Beatini, N; Grabowski, GA; Maxfield, FR; Tabas, I				Buton, X; Mamdouh, Z; Ghosh, R; Du, H; Kuriakose, G; Beatini, N; Grabowski, GA; Maxfield, FR; Tabas, I			Unique cellular events occurring during the initial interaction of macrophages with matrix-retained or methylated aggregated low density lipoprotein (LDL) - Prolonged cell-surface contact during which LDL-cholesteryl ester hydrolysis exceeds LDL protein degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; MOUSE PERITONEAL-MACROPHAGES; HUMAN MONOCYTE-MACROPHAGES; TO-RETENTION HYPOTHESIS; COATED PIT FORMATION; SCAVENGER RECEPTOR; FRUSTRATED PHAGOCYTOSIS; ATHEROGENIC LIPOPROTEINS; ATHEROSCLEROTIC LESIONS; HUMAN-FIBROBLASTS	A critical event in atherogenesis is the interaction of arterial wall macrophages with subendothelial lipoproteins, Although most studies have investigated this interaction by incubating cultured macrophages with monomeric lipoproteins dissolved in media, arterial wall macrophages encounter lipoproteins that are mostly bound to subendothelial extracellular matrix, and these lipoproteins are often aggregated or fused. Herein, we utilize a specialized cell-culture system to study the initial interaction of macrophages with aggregated low density lipoprotein (LDL) bound to extracellular matrix. The aggregated LDL remains extracellular for a relatively prolonged period of time and becomes lodged in invaginations in the surface of the macrophages. As expected, the degradation of the protein moiety of the LDL was very slow. Remarkably, however, hydrolysis of the cholesteryl ester (CE) moiety of the LDL was 3-7-fold higher than that of the protein moiety, in stark contrast to the situation with receptor-mediated endocytosis of acetyl-LDL, Similar results were obtained using another experimental system in which the degradation of aggregated LDL protein was delayed by LDL methylation rather than by retention on matrix. Additional experiments indicated the following properties of this interaction: Co) LDL-CE hydrolysis is catalyzed by lysosomal acid lipase; (b) neither scavenger receptors nor the LDL receptor appear necessary for the excess LDL-CE hydrolysis; and Cc) LDL-CE hydrolysis in this system is resistant to cellular potassium depletion, which further distinguishes this process from receptor-mediated endocytosis. In summary, experimental systems specifically designed to mimic the in vivo interaction of arterial wall macrophages with subendothelial Lipoproteins have demonstrated an initial period of prolonged cell-surface contact in which CE hydrolysis exceeds protein degradation.	Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Dept Anat & Cell Biol, New York, NY USA; Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA; Childrens Hosp Res Fdn, Div Human Genet, Cincinnati, OH 45229 USA	Columbia University; Columbia University; Cornell University; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Tabas, I (corresponding author), Columbia Univ, Dept Med, 630 W 168th St, New York, NY 10032 USA.		Maxfield, Fred/M-6747-2019; Maxfield, Fred/A-1718-2011	Maxfield, Fred/0000-0003-4396-8866; 	NHLBI NIH HHS [HL-57560, HL-56984] Funding Source: Medline; NIDDK NIH HHS [DK-36729] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056984, R01HL057560] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036729] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMAD TY, 1985, J LIPID RES, V26, P1160; AVIRAM M, 1995, BIOCHEM BIOPH RES CO, V216, P501, DOI 10.1006/bbrc.1995.2651; BAINTON DF, 1989, AM J PATHOL, V134, P15; BALL RY, 1995, ATHEROSCLEROSIS, V114, P45, DOI 10.1016/0021-9150(94)05463-S; Bergstrand H, 1990, Agents Actions Suppl, V30, P199; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; BOTTALICO LA, 1993, J BIOL CHEM, V268, P8569; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BRUCE C, 1995, J BIOL CHEM, V270, P11532, DOI 10.1074/jbc.270.19.11532; CARPENTIER JL, 1989, J CELL PHYSIOL, V138, P519, DOI 10.1002/jcp.1041380311; CORDIER G, 1981, ANN INST PASTEUR IMM, VD132, P3; CORNICELLI JA, 1983, ARTERIOSCLEROSIS, V3, P560, DOI 10.1161/01.ATV.3.6.560; CUPERS P, 1994, J CELL BIOL, V127, P725, DOI 10.1083/jcb.127.3.725; Du H, 1998, HUM MOL GENET, V7, P1347, DOI 10.1093/hmg/7.9.1347; Fluiter K, 1997, BIOCHEM J, V326, P515, DOI 10.1042/bj3260515; FOGELMAN AM, 1981, J LIPID RES, V22, P1131; GARDINER EE, 1994, EUR J BIOCHEM, V221, P871, DOI 10.1111/j.1432-1033.1994.tb18802.x; GERRITY RG, 1981, AM J PATHOL, V103, P181; Goldberg IJ, 1996, J LIPID RES, V37, P693; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GOLDSTEIN JL, 1981, ARTERIOSCLEROSIS, V1, P210, DOI 10.1161/01.ATV.1.3.210; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; Guyton JR, 1996, ARTERIOSCL THROM VAS, V16, P4, DOI 10.1161/01.ATV.16.1.4; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; HOFF HF, 1995, CURR OPIN LIPIDOL, V6, P317, DOI 10.1097/00041433-199510000-00012; HOFF HF, 1992, J BIOL CHEM, V267, P602; HOFF HF, 1985, ANN NY ACAD SCI, V454, P183, DOI 10.1111/j.1749-6632.1985.tb11857.x; HOFF HF, 1990, EUR HEART J, V11, P105, DOI 10.1093/eurheartj/11.suppl_E.105; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; KHOO JC, 1989, BIOCHIM BIOPHYS ACTA, V1012, P215, DOI 10.1016/0167-4889(89)90099-2; Koval M, 1998, EXP CELL RES, V242, P265, DOI 10.1006/excr.1998.4110; KRUSKAL BA, 1987, J CELL BIOL, V105, P2685, DOI 10.1083/jcb.105.6.2685; Kruth HS, 1997, CURR OPIN LIPIDOL, V8, P246, DOI 10.1097/00041433-199710000-00002; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; Libby Peter, 1993, Current Opinion in Lipidology, V4, P355, DOI 10.1097/00041433-199310000-00003; LISZT F, 1991, EUR J CLIN CHEM CLIN, V29, P123; MAHLEY RW, 1980, J LIPID RES, V21, P970; MYERS JN, 1993, J CELL BIOL, V123, P1389, DOI 10.1083/jcb.123.6.1389; NIEVELSTEIN PFEM, 1991, ARTERIOSCLER THROMB, V11, P1795, DOI 10.1161/01.ATV.11.6.1795; NIEVELSTEINPOST P, 1994, ARTERIOSCLER THROMB, V14, P1151, DOI 10.1161/01.ATV.14.7.1151; Pentikainen MO, 1996, J LIPID RES, V37, P2638; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; Reaven E, 1998, ENDOCRINOLOGY, V139, P2847, DOI 10.1210/en.139.6.2847; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rigotti A, 1997, CURR OPIN LIPIDOL, V8, P181, DOI 10.1097/00041433-199706000-00009; RINNINGER F, 1995, BBA-LIPID LIPID MET, V1255, P141, DOI 10.1016/0005-2760(94)00228-Q; ROSS AC, 1984, J BIOL CHEM, V259, P815; SCHAFFNER T, 1980, AM J PATHOL, V100, P57; Schissel SL, 1996, J CLIN INVEST, V98, P1455, DOI 10.1172/JCI118934; Schissel SL, 1998, J BIOL CHEM, V273, P2738, DOI 10.1074/jbc.273.5.2738; SMITH EB, 1976, ATHEROSCLEROSIS, V25, P71, DOI 10.1016/0021-9150(76)90049-6; SMITH JD, 1995, P NATL ACAD SCI USA, V92, P8264, DOI 10.1073/pnas.92.18.8264; SRIPADA PK, 1987, J LIPID RES, V28, P710; Stangl H, 1998, J BIOL CHEM, V273, P31002, DOI 10.1074/jbc.273.47.31002; STEINBRECHER UP, 1992, ARTERIOSCLER THROMB, V12, P608, DOI 10.1161/01.ATV.12.5.608; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; TABAS I, 1993, J BIOL CHEM, V268, P20419; TABAS I, 1990, J CELL BIOL, V111, P929, DOI 10.1083/jcb.111.3.929; TABAS I, 1995, CURR OPIN LIPIDOL, V6, P260, DOI 10.1097/00041433-199510000-00004; TABAS I, 1999, CHOLESTEROL TRAFFICK; TAKEMURA R, 1986, J CELL BIOL, V102, P55, DOI 10.1083/jcb.102.1.55; Tamminen M, 1999, ARTERIOSCL THROM VAS, V19, P847, DOI 10.1161/01.ATV.19.4.847; TERTOV VV, 1989, BIOCHEM BIOPH RES CO, V163, P489, DOI 10.1016/0006-291X(89)92163-3; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; WEISGRABER KH, 1978, J BIOL CHEM, V253, P9053; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; Williams KJ, 1998, CURR OPIN LIPIDOL, V9, P471, DOI 10.1097/00041433-199810000-00012; WOLF DE, 1985, BIOCHEMISTRY-US, V24, P582, DOI 10.1021/bi00324a006; XU XX, 1991, J BIOL CHEM, V266, P24849; ZHA X, 1996, ARTERIOSCLER THROMB, V90, P1421; Zhang WY, 1997, J BIOL CHEM, V272, P31700, DOI 10.1074/jbc.272.50.31700	77	58	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32112	32121		10.1074/jbc.274.45.32112	http://dx.doi.org/10.1074/jbc.274.45.32112			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542246	hybrid			2022-12-25	WOS:000083532100054
J	Horn, C; Namane, A; Pescher, P; Riviere, M; Romain, F; Puzo, G; Barzu, O; Marchal, G				Horn, C; Namane, A; Pescher, P; Riviere, M; Romain, F; Puzo, G; Barzu, O; Marchal, G			Decreased capacity of recombinant 45/47-kDa molecules (Apa) of Mycobacterium tuberculosis to stimulate T lymphocyte responses related to changes in their mannosylation pattern	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN COMPLEX; 45-KILODALTON GLYCOPROTEIN; MANNOSE RECEPTOR; KDA ANTIGEN; GLYCOSYLATION; RECOGNITION; PROTEINS; CELLS; IDENTIFICATION; CARBOHYDRATE	The Apa molecules secreted by Mycobacterium tuberculosis, Mycobacterium bovis, or BCG have been identified as major immunodominant antigens, Mass spectrometry analysis indicated similar mannosylation, a complete pattern from 1 up to 9 hexose residues/mole of protein, of the native species from the 3 reference strains. The recombinant antigen expressed in M. smegmatis revealed a different mannosylation pattern: species containing 7 to 9 sugar residues/mole of protein were in the highest proportion, whereas species bearing a low number of sugar residues were almost absent. The 45/47-kDa recombinant antigen expressed in E. coli was devoid of sugar residues. The proteins purified from II M.. tuberculosis, M. bovis, or BCG have a high capacity to elicit in vivo potent delayed-type hypersensitivity (DTH) reactions and to stimulate in vitro sensitized T lymphocytes of guinea pigs immunized with living BCG, The recombinant Apa expressed in Mycobacterium smegmatis was 4-fold less potent in vivo in the DTH assay and 10-fold less active in vitro to stimulate sensitized T lymphocytes than the native proteins. The recombinant protein expressed in Escherichia coli was nearly unable to elicit DTH reactions in vivo or to stimulate T lymphocytes in vitro, Thus the observed biological effects were related to the extent of glycosylation of the antigen.	Inst Pasteur, Unite Physiopathol Infect, F-75724 Paris 15, France; Inst Pasteur, Lab Chim Struct Macromol, F-75724 Paris 15, France; CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Marchal, G (corresponding author), Inst Pasteur, Unite Physiopathol Infect, 25 Rue Dr Roux, F-75724 Paris 15, France.	gmarchal@pasteur.fr	Namane, Abdelkader/O-1857-2013	Namane, Abdelkader/0000-0001-7180-7619; Pescher, Pascale/0000-0003-2796-7855				ANDERSEN P, 1994, INFECT IMMUN, V62, P2536, DOI 10.1128/IAI.62.6.2536-2544.1994; BOCK K, 1994, J BIOL CHEM, V269, P7137; Carbone FR, 1997, GLYCOBIOLOGY, V7, P725, DOI 10.1093/glycob/7.6.725-d; DECK B, 1995, J IMMUNOL, V155, P1074; DOBOS KM, 1995, INFECT IMMUN, V63, P2846, DOI 10.1128/IAI.63.8.2846-2853.1995; Dobos KM, 1996, J BACTERIOL, V178, P2498, DOI 10.1128/jb.178.9.2498-2506.1996; DUBOS RJ, 1953, J EXP MED, V97, P207, DOI 10.1084/jem.97.2.207; ESPITIA C, 1989, CLIN EXP IMMUNOL, V77, P378; FURTHMAYR H, 1971, ANAL BIOCHEM, V41, P510, DOI 10.1016/0003-2697(71)90173-4; GARBE T, 1993, INFECT IMMUN, V61, P260, DOI 10.1128/IAI.61.1.260-267.1993; HARLOW E, 1988, ANTIBODIES LAB MAHUA; HAURUM JS, 1994, J EXP MED, V180, P739, DOI 10.1084/jem.180.2.739; Herrmann JL, 1996, EMBO J, V15, P3547, DOI 10.1002/j.1460-2075.1996.tb00724.x; Horn C, 1996, J IMMUNOL METHODS, V197, P151, DOI 10.1016/0022-1759(96)00141-X; HORWITZ MA, 1995, P NATL ACAD SCI USA, V92, P1530, DOI 10.1073/pnas.92.5.1530; KANAI K, 1966, JPN J MED SCI BIOL, V19, P181, DOI 10.7883/yoken1952.19.181; LAQUEYRERIE A, 1995, INFECT IMMUN, V63, P4003, DOI 10.1128/IAI.63.10.4003-4010.1995; MESCHER MF, 1976, J BIOL CHEM, V251, P2005; Mortz E, 1996, J MASS SPECTROM, V31, P1109, DOI 10.1002/(SICI)1096-9888(199610)31:10<1109::AID-JMS400>3.0.CO;2-9; ORME IM, 1988, INFECT IMMUN, V56, P3310, DOI 10.1128/IAI.56.12.3310-3312.1988; PLUMMER TH, 1995, J BIOL CHEM, V270, P13192, DOI 10.1074/jbc.270.22.13192; ROMAIN F, 1993, INFECT IMMUN, V61, P742, DOI 10.1128/IAI.61.2.742-750.1993; ROMAIN F, 1999, IN PRESS INFECT IMMU, V67; Sambrook J., 2002, MOL CLONING LAB MANU; SCHARER LL, 1995, TUBERCULOSIS AIDS RE; Schluger NW, 1998, AM J RESP CRIT CARE, V157, P679, DOI 10.1164/ajrccm.157.3.9708002; Stahl PD, 1998, CURR OPIN IMMUNOL, V10, P50, DOI 10.1016/S0952-7915(98)80031-9; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; STIMSON E, 1995, MOL MICROBIOL, V17, P1201, DOI 10.1111/j.1365-2958.1995.mmi_17061201.x; Tan MCAA, 1997, EUR J IMMUNOL, V27, P2426, DOI 10.1002/eji.1830270942	30	76	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32023	32030		10.1074/jbc.274.45.32023	http://dx.doi.org/10.1074/jbc.274.45.32023			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542234	hybrid			2022-12-25	WOS:000083532100042
J	Li, SL; Schlegel, W; Valente, AJ; Clark, RA				Li, SL; Schlegel, W; Valente, AJ; Clark, RA			Critical flanking sequences of PU.1 binding sites in myeloid-specific promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; TRANSCRIPTION FACTOR PU.1; HEMATOLOGICALLY IMPORTANT MUTATIONS; STIMULATING FACTOR-RECEPTOR; GENE-EXPRESSION; B-LYMPHOCYTES; ETS FAMILY; REQUIRES; MACROPHAGE; C/EBP	The myeloid-specific transcription factor PU.1 is essential for expression of p47(phox), a component of the superoxide-forming phagocyte NADPH oxidase. The consensus PU.1 binding sequence (GAGGAA) is located on the non-coding strand from position -40 to -45 relative to the transcriptional start site of the p47phox promoter. A promoter construct extending to -46 was sufficient to drive tissue-specific expression of the luciferase reporter gene, but extension of the promoter from -46 to -48 resulted in a significant increase in reporter expression. Mutations of the nucleotides G at -46 and/or T at -47 reduced both reporter expression and PU.1 binding, whereas mutations at -48 had no effect, The PU.1 binding avidity of these sequences correlated closely with their capacity to dictate reporter gene transcription. In parallel studies on the functional PU.1 site in the promoter of CD18, mutations of nucleotides G and T at positions -76 and -77 (corresponding to -46 and -47, respectively, of the p47phox promoter) reduced PU.1 binding and nearly abolished the contribution of this element to promoter activity. We conclude that the immediate flanking nucleotides of the PU.1 consensus motif have significant effects on PU.1 binding avidity and activity and that this region is the dominant cis element regulating p47phox expression.	Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA; S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78229 USA; Univ Geneva, Fdn Rech Med, CH-1211 Geneva, Switzerland	University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Geneva	Clark, RA (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.		Clark, Robert/Q-6764-2019	Clark, Robert/0000-0002-4892-3619	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020866, R01AI020866] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20866, R37 AI020866, R01 AI020866] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; BACK AL, 1992, J BIOL CHEM, V267, P5482; Bodger MP, 1998, BRIT J HAEMATOL, V102, P986, DOI 10.1046/j.1365-2141.1998.00863.x; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; Clark RA, 1999, J INFECT DIS, V179, pS309, DOI 10.1086/513849; Cross AR, 1996, BLOOD CELL MOL DIS, V22, P268, DOI 10.1006/bcmd.1996.0109; Cross AR, 1996, BLOOD CELL MOL DIS, V22, P90, DOI 10.1006/bcmd.1996.0013; Egan BS, 1999, J BIOL CHEM, V274, P9098, DOI 10.1074/jbc.274.13.9098; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; EKLUND EA, 1995, J BIOL CHEM, V270, P8267, DOI 10.1074/jbc.270.14.8267; Friedman AD, 1996, CURR TOP MICROBIOL, V211, P149; Gorlach A, 1997, J CLIN INVEST, V100, P1907, DOI 10.1172/JCI119721; Heydemann A, 1997, J BIOL CHEM, V272, P29527, DOI 10.1074/jbc.272.47.29527; Himmelmann A, 1996, BLOOD, V87, P1036, DOI 10.1182/blood.V87.3.1036.bloodjournal8731036; Himmelmann A, 1997, BLOOD, V90, P3984, DOI 10.1182/blood.V90.10.3984; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; KOMINATO Y, 1995, MOL CELL BIOL, V15, P58; Li SL, 1997, J BIOL CHEM, V272, P17802, DOI 10.1074/jbc.272.28.17802; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; NEWBURGER PE, 1994, J CLIN INVEST, V94, P1205, DOI 10.1172/JCI117437; PAHL HL, 1993, J BIOL CHEM, V268, P5014; Paxton LLL, 1997, J BIOL CHEM, V272, P15928, DOI 10.1074/jbc.272.25.15928; PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023; Pio F, 1996, J BIOL CHEM, V271, P23329, DOI 10.1074/jbc.271.38.23329; RAYGALLET D, 1995, ONCOGENE, V11, P303; ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801; Simon MC, 1996, CURR TOP MICROBIOL, V211, P113; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; Smith MF, 1998, J BIOL CHEM, V273, P24272, DOI 10.1074/jbc.273.37.24272; Suzuki S, 1998, P NATL ACAD SCI USA, V95, P6085, DOI 10.1073/pnas.95.11.6085; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Zhang DE, 1996, CURR TOP MICROBIOL, V211, P137; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	36	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32453	32460		10.1074/jbc.274.45.32453	http://dx.doi.org/10.1074/jbc.274.45.32453			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542290	hybrid			2022-12-25	WOS:000083532100098
J	Teixeira, MT; Fabre, E; Dujon, B				Teixeira, MT; Fabre, E; Dujon, B			Self-catalyzed cleavage of the yeast nucleoporin Nup145p precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; NUCLEOCYTOPLASMIC TRANSPORT; SACCHAROMYCES-CEREVISIAE; GLFG NUCLEOPORIN; MESSENGER-RNA; PROTEIN; EXPORT; TRANSFORMATION; RECOMBINATION; MODULATION	Nup145p is a component of the nuclear pore complex of Saccharomyces cerevisiae and is essential for mRNA export. Nup145p and its apparent vertebrate homologue are the only known nucleoporins to be composed of two functionally independent peptide moieties resulting from the post-translational cleavage of a large precursor molecule. In this study, the proteolytic cleavage site of Nup145p has been mapped upstream of an evolutionary conserved serine residue. Cleavage occurs at the same site when a precursor is artificially expressed in Escherichia coli. A hydroxyl-containing residue is critical for the reaction, although a thiol-containing residue offers an acceptable replacement. In vitro kinetics experiments using a purified precursor molecule demonstrate that the cleavage is self-catalyzed and that the catalytic domain lies within the N-terminal moiety. Taken altogether, our data are consistent with a proteolytic mechanism involving an N > 0 acyl rearrangement and a subsequent ester intermediate uncovered in other self-processing proteins.	Inst Pasteur, Dept Biotechnol, CNRS, URA 1300,Unite Genet Mol Levures, F-75724 Paris 15, France; Univ Paris 06, Dept Biotechnol, Inst Pasteur, UPR 927, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Sorbonne Universite	Teixeira, MT (corresponding author), Inst Pasteur, Dept Biotechnol, CNRS, URA 1300,Unite Genet Mol Levures, 25 Rue Dr Roux, F-75724 Paris 15, France.	teresatf@pasteur.fr	Dujon, Bernard A/F-4971-2010; Teixeira, Maria Teresa/A-2100-2011	Teixeira, Maria Teresa/0000-0002-9466-7951; FABRE, Emmanuelle/0000-0002-0009-4604				Allen TD, 1997, SCANNING, V19, P403, DOI 10.1002/sca.4950190603; Ando, 1967, METHOD ENZYMOL, V11, P263; ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; Arthur TM, 1998, J BIOL CHEM, V273, P31381, DOI 10.1074/jbc.273.47.31381; BURNS JA, 1991, J ORG CHEM, V56, P2648, DOI 10.1021/jo00008a014; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; Chong SR, 1998, J BIOL CHEM, V273, P10567, DOI 10.1074/jbc.273.17.10567; Colland F, 1998, MOL MICROBIOL, V27, P819, DOI 10.1046/j.1365-2958.1998.00729.x; Corbett AH, 1997, MICROBIOL MOL BIOL R, V61, P193, DOI 10.1128/.61.2.193-211.1997; Dockendorff TC, 1997, MOL CELL BIOL, V17, P906, DOI 10.1128/MCB.17.2.906; Emtage JLT, 1997, J CELL SCI, V110, P911; FABRE E, 1994, CELL, V78, P275, DOI 10.1016/0092-8674(94)90297-6; Fabre E, 1997, ANNU REV GENET, V31, P277, DOI 10.1146/annurev.genet.31.1.277; Fairhead C, 1996, YEAST, V12, P1439; Fontoura BMA, 1999, J CELL BIOL, V144, P1097, DOI 10.1083/jcb.144.6.1097; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; Guan C, 1998, J BIOL CHEM, V273, P9695, DOI 10.1074/jbc.273.16.9695; Guan CD, 1996, J BIOL CHEM, V271, P1732, DOI 10.1074/jbc.271.3.1732; JENCKS WP, 1960, J BIOL CHEM, V235, P3608; LITTLE JW, 1993, J BACTERIOL, V175, P4943, DOI 10.1128/JB.175.16.4943-4950.1993; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; Marshak DR, 1996, STRATEGIES PROTEIN P; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MEILHOC E, 1990, BIO-TECHNOL, V8, P223, DOI 10.1038/nbt0390-223; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; Perler FB, 1998, NAT STRUCT BIOL, V5, P249, DOI 10.1038/nsb0498-249; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; PORTER JA, 1996, SCIENCE, V274, P256; POWERS MA, 1995, J CELL BIOL, V128, P721, DOI 10.1083/jcb.128.5.721; Powers MA, 1997, J CELL BIOL, V136, P241, DOI 10.1083/jcb.136.2.241; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; Schmidtke G, 1996, EMBO J, V15, P6887, DOI 10.1002/j.1460-2075.1996.tb01081.x; Shao Y, 1996, BIOCHEMISTRY-US, V35, P3810, DOI 10.1021/bi952592h; Sherman F., 1986, METHODS YEAST GENETI; Siniossoglou S, 1996, CELL, V84, P265, DOI 10.1016/S0092-8674(00)80981-2; Teixeira MT, 1997, EMBO J, V16, P5086, DOI 10.1093/emboj/16.16.5086; VANPOELJE PD, 1990, ANNU REV BIOCHEM, V59, P29, DOI 10.1146/annurev.bi.59.070190.000333; WENTE SR, 1994, J CELL BIOL, V125, P955, DOI 10.1083/jcb.125.5.955; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x; Yang Q, 1998, MOL CELL, V1, P223, DOI 10.1016/S1097-2765(00)80023-4	42	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32439	32444		10.1074/jbc.274.45.32439	http://dx.doi.org/10.1074/jbc.274.45.32439			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542288	hybrid			2022-12-25	WOS:000083532100096
J	Yamada, K; Ogawa, H; Honda, S; Harada, N; Okazaki, T				Yamada, K; Ogawa, H; Honda, S; Harada, N; Okazaki, T			A GCM motif protein is involved in placenta-specific expression of human aromatase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT GENE; MESSENGER-RIBONUCLEIC-ACID; TISSUE-SPECIFIC EXPRESSION; TRANSCRIPTION FACTOR; CYTOCHROME-P-450 GENE; CHORIOCARCINOMA CELLS; ENHANCER FUNCTION; DROSOPHILA; PROMOTERS; BINDING	A new cis-element, trophoblast-specific element 2 (TSE2) is located in the placenta-specific enhancer of the human aromatase gene that dictates its tissue-specific expression, In the minimum enhancer region, an element similar to the trophoblast-specific element (TSE), originally described for the human chorionic gonadotropin alpha-subunit gene, also exists (Yamada, K., Harada, N., Honda, S., and Takagi, Y. (1995) J. Biol. Chem, 270, 25064-25069). The co-presence of TSE and TSE2 is required to direct trophoblast-specific expression driven by a heterologous thymidine kinase promoter. A 2562-base pair cDNA clone encoding a 436-amino acid protein that binds to TSE2 was isolated from a human placental cDNA library using a yeast one-hybrid system with the TSE2 as a reporter sequence, The protein was revealed to be identical to hGCMa, a mammalian homologue of the Drosophila GCM (glia cells missing) protein. Expression of hGCMa is restricted to the placenta, The protein also binds to PLE1 in the leptin promoter among other cis-elements reported to confer placenta-specific expression, suggesting that hGCMa is a placenta-specific transcription regulator, possibly involved in the expression of multiple placenta-specific genes.	Fujita Hlth Univ, Inst Comprehens Med Sci, Sch Med, Aichi 4701192, Japan; Fujita Hlth Univ, Japan Sci & Technol Corp, CREST, Sch Med, Aichi 4701192, Japan; Fujita Hlth Univ, Sch Med, Dept Biol, Aichi 4701192, Japan; Fujita Hlth Univ, Sch Med, Dept Biochem, Aichi 4701192, Japan	Fujita Health University; Fujita Health University; Japan Science & Technology Agency (JST); Fujita Health University; Fujita Health University	Yamada, K (corresponding author), Fujita Hlth Univ, Inst Comprehens Med Sci, Sch Med, Aichi 4701192, Japan.	kyamada@fujita-hu.ac.jp						Akiyama Y, 1996, P NATL ACAD SCI USA, V93, P14912, DOI 10.1073/pnas.93.25.14912; Altshuller Y, 1996, FEBS LETT, V393, P201, DOI 10.1016/0014-5793(96)00890-3; Bi S, 1997, J BIOL CHEM, V272, P30583, DOI 10.1074/jbc.272.48.30583; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Firulli AB, 1998, NAT GENET, V18, P266, DOI 10.1038/ng0398-266; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; HARADA N, 1992, ENDOCRINOLOGY, V131, P2306, DOI 10.1210/en.131.5.2306; HARADA N, 1993, P NATL ACAD SCI USA, V90, P11312, DOI 10.1073/pnas.90.23.11312; HARADA N, 1990, BIOCHEM BIOPH RES CO, V166, P365, DOI 10.1016/0006-291X(90)91954-Q; HECKERT LL, 1995, J BIOL CHEM, V270, P26497, DOI 10.1074/jbc.270.44.26497; HOSOYA T, 1995, CELL, V82, P1025, DOI 10.1016/0092-8674(95)90281-3; Jacquemin P, 1997, J BIOL CHEM, V272, P12928, DOI 10.1074/jbc.272.20.12928; JACQUEMIN P, 1994, MOL CELL BIOL, V14, P93, DOI 10.1128/MCB.14.1.93; JAMESON JL, 1989, MOL ENDOCRINOL, V3, P763, DOI 10.1210/mend-3-5-763; JIANG SW, 1995, J BIOL CHEM, V270, P13906, DOI 10.1074/jbc.270.23.13906; Jiang SW, 1997, MOL ENDOCRINOL, V11, P1223, DOI 10.1210/me.11.9.1223; Johnson W, 1997, J BIOL CHEM, V272, P15405, DOI 10.1074/jbc.272.24.15405; JONES BW, 1995, CELL, V82, P1013, DOI 10.1016/0092-8674(95)90280-5; Kamat A, 1999, P NATL ACAD SCI USA, V96, P4575, DOI 10.1073/pnas.96.8.4575; Kanemura Y, 1999, FEBS LETT, V442, P151, DOI 10.1016/S0014-5793(98)01650-0; Kim JS, 1998, P NATL ACAD SCI USA, V95, P12364, DOI 10.1073/pnas.95.21.12364; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; MAHENDROO MS, 1991, J BIOL CHEM, V266, P11276; MEANS GD, 1991, MOL ENDOCRINOL, V5, P2005, DOI 10.1210/mend-5-12-2005; MEANS GD, 1989, J BIOL CHEM, V264, P19385; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; Ogawa H, 1996, NEUROCHEM INT, V29, P553, DOI 10.1016/0197-0186(95)00012-7; PITTMAN RH, 1994, J BIOL CHEM, V269, P19360; Reifegerste R, 1999, MECH DEVELOP, V82, P141, DOI 10.1016/S0925-4773(99)00027-1; RITVOS O, 1992, ENDOCRINOLOGY, V130, P61, DOI 10.1210/en.130.1.61; ROSELLI CE, 1985, ENDOCRINOLOGY, V117, P2471, DOI 10.1210/endo-117-6-2471; Schreiber J, 1997, P NATL ACAD SCI USA, V94, P4739, DOI 10.1073/pnas.94.9.4739; Shi DQ, 1997, J BIOL CHEM, V272, P2334, DOI 10.1074/jbc.272.4.2334; Shi DQ, 1998, J BIOL CHEM, V273, P27331, DOI 10.1074/jbc.273.42.27331; STEGER DJ, 1991, MOL ENDOCRINOL, V5, P243, DOI 10.1210/mend-5-2-243; Sun TJ, 1998, ENDOCRINOLOGY, V139, P1684, DOI 10.1210/en.139.4.1684; THOMPSON EA, 1974, J BIOL CHEM, V249, P5364; TODA K, 1992, EUR J BIOCHEM, V205, P303, DOI 10.1111/j.1432-1033.1992.tb16781.x; Wang ZY, 1998, J BIOL CHEM, V273, P26069, DOI 10.1074/jbc.273.40.26069; YAMADA K, 1995, J BIOL CHEM, V270, P25064, DOI 10.1074/jbc.270.42.25064	44	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32279	32286		10.1074/jbc.274.45.32279	http://dx.doi.org/10.1074/jbc.274.45.32279			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542267	hybrid			2022-12-25	WOS:000083532100075
J	Gustavsson, J; Parpal, S; Karlsson, M; Ramsing, C; Thorn, H; Borg, M; Lindroth, M; Peterson, KH; Magnusson, K; Stralfors, P				Gustavsson, J; Parpal, S; Karlsson, M; Ramsing, C; Thorn, H; Borg, M; Lindroth, M; Peterson, KH; Magnusson, K; Stralfors, P			Localization of the insulin receptor in caveolae of adipocyte plasma membrane	FASEB JOURNAL			English	Article						cholesterol; signal transduction; insulin resistance; diabetes	GLUCOSE-TRANSPORTER GLUT4; 3T3-L1 ADIPOCYTES; GROWTH-FACTOR; TYROSINE KINASE; MEDIATED TRANSPORT; CELL-MEMBRANES; RAT ADIPOCYTES; PROTEIN-KINASE; CHOLESTEROL; TRANSLOCATION	The insulin receptor is a transmembrane protein of the plasma membrane, where it recognizes extracellular insulin and transmits signals into the cellular signaling network. We report that insulin receptors are localized and signal in caveolae microdomains of adipocyte plasma membrane. Immunogold electron microscopy and immunofluorescence microscopy show that insulin receptors are restricted to caveolae and are colocalized with caveolin over the plasma membrane. Insulin receptor was enriched in a caveolae-enriched fraction of plasma membrane. By extraction with beta-cyclodextrin or destruction with cholesterol oxidase, cholesterol reduction attenuated insulin receptor signaling to protein phosphorylation or glucose transport. Insulin signaling was regained by spontaneous recovery or by exogenous replenishment of cholesterol. beta-Cyclodextrin treatment caused a nearly complete annihilation of caveolae invaginations as examined by electron microscopy. This suggests that the receptor is dependent on the caveolae environment for signaling. Insulin stimulation of cells prior to isolation of caveolae or insulin stimulation of the isolated caveolae fraction increased tyrosine phosphorylation of the insulin receptor in caveolae, demonstrating that insulin receptors in caveolae are functional. Our results indicate that insulin receptors are localized to caveolae in the plasma membrane of adipocytes, are signaling in caveolae, and are dependent on caveolae for signaling.-Gustavsson, J., Parpal, S., Karlsson, M., Ramsing, C., Thorn, H., Borg, M., Lindroth, IM., Peterson, K. H., Magnusson, IL-E., Stralfors, P. Localization of the insulin receptor in caveolae of adipocyte plasma membrane.	Linkoping Univ, Fac Hlth Sci, Dept Cell Biol, S-58185 Linkoping, Sweden; Linkoping Univ, Fac Hlth Sci, Dept Med Microbiol, S-58185 Linkoping, Sweden	Linkoping University; Linkoping University	Stralfors, P (corresponding author), Linkoping Univ, Fac Hlth Sci, Dept Cell Biol, S-58185 Linkoping, Sweden.	stralfors@mcb.liu.se	Eckhardt, Erik/G-1567-2010	Magnusson, Karl-Eric/0000-0002-7809-8437; Stralfors, Peter/0000-0002-1196-1806; Parpal, Santiago/0000-0003-2861-0516				ALEMANY S, 1987, NATURE, V330, P77, DOI 10.1038/330077a0; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARPENTIER JL, 1989, DIABETOLOGIA, V32, P627; CARPENTIER JL, 1981, J CELL BIOL, V91, P17, DOI 10.1083/jcb.91.1.17; CERNEUS DP, 1993, J BIOL CHEM, V268, P3150; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; CORLEYMASTICK C, 1995, J CELL BIOL, V129, P1523; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; CUATRECA.P, 1971, J BIOL CHEM, V246, P6532; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FAN JY, 1983, J CELL SCI, V61, P219; FROST SC, 1987, J BIOL CHEM, V262, P9872; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; GAMMELTOFT S, 1988, INSULIN RECEPTORS A, P15; GOLDBERG RI, 1987, J CELL PHYSIOL, V133, P203, DOI 10.1002/jcp.1041330202; Gustavsson J, 1996, MOL MED, V2, P367, DOI 10.1007/BF03401634; HAMILTON JG, 1988, LIPIDS, V23, P1150, DOI 10.1007/BF02535282; HEIDER JG, 1978, J LIPID RES, V19, P514; Inoue G, 1998, J BIOL CHEM, V273, P11548, DOI 10.1074/jbc.273.19.11548; KANDROR KV, 1995, J CELL BIOL, V129, P999, DOI 10.1083/jcb.129.4.999; Keller R., 1993, IEEE Microwave and Guided Wave Letters, V3, P185, DOI 10.1109/75.219809; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; KUBLAOUI B, 1995, J BIOL CHEM, V270, P59, DOI 10.1074/jbc.270.1.59; LAZAR DF, 1994, P NATL ACAD SCI USA, V91, P9665, DOI 10.1073/pnas.91.21.9665; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; MCCLAIN DA, 1988, DIABETES, V37, P806, DOI 10.2337/diabetes.37.6.806; Morris AJ, 1996, P NATL ACAD SCI USA, V93, P8401, DOI 10.1073/pnas.93.16.8401; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; NOVIKOFF AB, 1980, J CELL BIOL, V87, P180, DOI 10.1083/jcb.87.1.180; OKA Y, 1984, J BIOL CHEM, V259, P8125; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; OLEFSKY JM, 1982, METABOLISM, V31, P670, DOI 10.1016/0026-0495(82)90197-4; OLEFSKY JM, 1990, DIABETES, V39, P1009, DOI 10.2337/diabetes.39.9.1009; PARPAL S, 1995, J CELL BIOL, V131, P125, DOI 10.1083/jcb.131.1.125; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; SMITH RM, 1991, J BIOL CHEM, V266, P17522; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; STRALFORS P, 1987, J BIOL CHEM, V262, P11486; Stralfors P, 1997, BIOESSAYS, V19, P327, DOI 10.1002/bies.950190410; STRALFORS P, 1989, EUR J BIOCHEM, V182, P379, DOI 10.1111/j.1432-1033.1989.tb14842.x; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1991, METHOD ENZYMOL, V201, P65; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026	64	291	297	1	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1999	13	14					1961	1971		10.1096/fasebj.13.14.1961	http://dx.doi.org/10.1096/fasebj.13.14.1961			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544179				2022-12-25	WOS:000083660700008
J	Kao, GD; McKenna, WG; Muschel, RJ				Kao, GD; McKenna, WG; Muschel, RJ			P34(Cdc2) kinase activity is excluded from the nucleus during the radiation-induced G(2) arrest in HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; HAMSTER OVARY CELLS; CYCLIN-B EXPRESSION; INDUCED G2 ARREST; TYROSINE PHOSPHORYLATION; IONIZING-RADIATION; INHIBITORY PHOSPHORYLATION; G(2)-PHASE ARREST; CELLULAR-RESPONSE; TUMOR-SUPPRESSOR	The progression of cells from G(2) into mitosis is blocked by exposure to DNA-damaging agents such as ionizing radiation. This G(2) delay is associated with reduced cyclin B1-specific associated histone H1 kinase activity, increased inhibitory phosphorylation of p34(Cdc2), and depressed cyclin B1 levels in HeLa cells. Induction of cyclin B1 or expression of Cdc2AF, a mutant p34(Cdc2) that lacks the sites of inhibitory phosphorylation, only partially reverses the radiation associated G(2) delay, although both maneuvers rapidly result in increased histone H1 kinase activity. To account for the persistent G(2) delay in the face of active p34(Cdc2) kinase, we determined the location of the kinase activity. Although p34(Cdc2) was active in the cytoplasm, the nuclear p34(Cdc2) was inactive. Irradiation led to nuclear accumulation of the inactive tyrosine-phosphorylated form of p34(Cdc2), whereas the active form was seen in the cytoplasm, At later times when cells had resumed cell cycle progression, nuclear kinase activity was detectable. These results give evidence of segregation of cytoplasmic and nuclear kinase activity after DNA damage that has the effect of enhancing checkpoint control Shielding the nucleus from the potentially deleterious effects of kinase activity after DNA damage may help irradiated human cancer cells respond to irradiation.	Univ Penn, Dept Pathol, Philadelphia, PA 19104 USA; Univ Penn, Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Muschel, RJ (corresponding author), Univ Penn, Dept Pathol, 36 & Hamilton Walk,Rm 269 John Morgan Bldg, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047439] Funding Source: NIH RePORTER; NCI NIH HHS [CA 751138] Funding Source: Medline; NIGMS NIH HHS [GM 47439] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bache M, 1999, ANTICANCER RES, V19, P1827; Barratt RA, 1998, CANCER RES, V58, P2639; Barth H, 1996, CANCER RES, V56, P2268; BERNHARD EJ, 1994, RADIAT RES, V140, P393, DOI 10.2307/3579118; Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; Boulikas T, 1996, J CELL BIOCHEM, V60, P61, DOI 10.1002/(SICI)1097-4644(19960101)60:1<61::AID-JCB10>3.0.CO;2-N; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; DavidPfeuty T, 1997, CANCER RES, V57, P4482; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Flaggs G, 1997, CURR BIOL, V7, P977, DOI 10.1016/S0960-9822(06)00417-9; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; HARPER JW, 1993, CELL, V75, P805; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; HERZINGER T, 1995, ONCOGENE, V11, P2151; JACKMAN M, 1995, EMBO J, V14, P1646, DOI 10.1002/j.1460-2075.1995.tb07153.x; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Kao GD, 1997, CANCER RES, V57, P753; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Kaufmann WK, 1998, P SOC EXP BIOL MED, V217, P327; KHARBANDA S, 1994, CANCER RES, V54, P1412; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; LANE DP, 1995, PHILOS T ROY SOC B, V347, P83, DOI 10.1098/rstb.1995.0013; LEVEDAKOU EN, 1995, CANCER RES, V55, P2500; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; LOCK RB, 1990, CANCER RES, V50, P3761; LOCK RB, 1992, CANCER RES, V52, P1817; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Lydall D, 1996, CURR OPIN GENET DEV, V6, P4, DOI 10.1016/S0959-437X(96)90003-9; MAITY A, 1994, RADIOTHER ONCOL, V31, P1, DOI 10.1016/0167-8140(94)90408-1; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; METTING NF, 1995, RADIAT RES, V143, P286, DOI 10.2307/3579215; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; MUNGER K, 1992, CANCER SURV, V12, P197; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; Nishii K, 1996, ONCOGENE, V13, P2225; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; OCONNOR PM, 1992, CELL GROWTH DIFFER, V3, P43; OCONNOR PM, 1993, J BIOL CHEM, V268, P8298; PAULES RS, 1995, CANCER RES, V55, P1763; Pellegata NS, 1996, P NATL ACAD SCI USA, V93, P15209, DOI 10.1073/pnas.93.26.15209; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHERWOOD SW, 1994, EXP CELL RES, V211, P275, DOI 10.1006/excr.1994.1087; SHIMIZU T, 1995, CANCER RES, V55, P228; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SLUDER G, 1995, J CELL BIOL, V129, P1447, DOI 10.1083/jcb.129.6.1447; SMEETS MFMA, 1994, RADIOTHER ONCOL, V33, P217, DOI 10.1016/0167-8140(94)90357-3; STEWART N, 1995, ONCOGENE, V10, P109; TERASIMA T, 1963, BIOPHYS J, V3, P11, DOI 10.1016/S0006-3495(63)86801-0; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; TSAO YP, 1992, CANCER RES, V52, P1823; TuelAhlgren L, 1996, LEUKEMIA LYMPHOMA, V20, P417, DOI 10.3109/10428199609052423; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YU L, 1998, 89 ANN M AM ASS CANC, P1219; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667	63	20	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34779	34784		10.1074/jbc.274.49.34779	http://dx.doi.org/10.1074/jbc.274.49.34779			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574948	hybrid			2022-12-25	WOS:000083979600042
J	Whittaker, MM; Whittaker, JW				Whittaker, MM; Whittaker, JW			Thermally triggered metal binding by recombinant Thermus thermophilus manganese superoxide dismutase, expressed as the apo-enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI-B; AQUIFEX-PYROPHILUS; CRYSTAL-STRUCTURE; IRON; RESOLUTION; BROMOPEROXIDASE; SITE; HB8; PURIFICATION; VANADIUM	Manganese superoxide dismutase from the extremely thermophilic eubacterium Thermus thermophilus has been cloned and expressed at high levels in a mesophilic host (Escherichia coli) as a soluble tetrameric protein mainly present as the metal-free ape-enzyme. Incubation of the purified ape-enzyme with manganese salts at ambient temperature did not restore superoxide dismutase activity, but reactivation could be achieved by heating the protein with Mn(II) at higher temperatures, approaching the physiological growth temperature for T. thermophilus. Heat annealing followed by incubation with manganese at lower temperature fails to reactivate the enzyme, demonstrating that a simple misfolding of the protein is not responsible for the observed behavior. The in vitro metal uptake is nonspecific, and manganese, iron, and vanadium all bind, but only manganese restores catalytic activity. Bound metal ions do not exchange during heat treatment, indicating that the formation of the metal complex is effectively irreversible under these conditions. The metallation process is strongly temperature-dependent, suggesting that substantial activation barriers to metal uptake at ambient temperature are overcome by a thermal transition in the ape-protein structure. A mechanism for SOD metallation is proposed, focusing on interactions at the domain interface.	Oregon Grad Inst Sci & Technol, Dept Biochem & Mol Biol, Beaverton, OR 97006 USA		Whittaker, JW (corresponding author), Oregon Grad Inst Sci & Technol, Dept Biochem & Mol Biol, 20000 NW Walker Rd, Beaverton, OR 97006 USA.	jim@bmb.ogi.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042680] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 42680] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MWW, 1995, BIO-TECHNOL, V13, P662, DOI 10.1038/nbt0795-662; ADAMS MWW, 1993, ANNU REV MICROBIOL, V47, P627, DOI 10.1146/annurev.micro.47.1.627; Beyer W F Jr, 1988, Basic Life Sci, V49, P651; BEYER WF, 1991, J BIOL CHEM, V266, P303; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; Colpas GJ, 1999, BIOCHEMISTRY-US, V38, P4078, DOI 10.1021/bi982435t; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; Dalphin ME, 1999, NUCLEIC ACIDS RES, V27, P293, DOI 10.1093/nar/27.1.293; DEBOER E, 1986, BIOCHIM BIOPHYS ACTA, V872, P104, DOI 10.1016/0167-4838(86)90153-6; DEBOER E, 1986, BIOCHIM BIOPHYS ACTA, V869, P48, DOI 10.1016/0167-4838(86)90308-0; Edward RA, 1998, J AM CHEM SOC, V120, P9684, DOI 10.1021/ja981072h; Edwards RA, 1998, J BIOL INORG CHEM, V3, P161, DOI 10.1007/s007750050217; FEE JA, 1976, J BIOL CHEM, V251, P6157; Flohe L, 1988, Basic Life Sci, V49, P663; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; Gao BF, 1996, GENE, V176, P269, DOI 10.1016/0378-1119(96)00246-6; JUAN JY, 1991, ARCH BIOCHEM BIOPHYS, V286, P257, DOI 10.1016/0003-9861(91)90038-K; KEELE BB, 1970, J BIOL CHEM, V245, P6176; LAH MS, 1995, BIOCHEMISTRY-US, V34, P1646, DOI 10.1021/bi00005a021; Lim JH, 1997, J MOL BIOL, V270, P259, DOI 10.1006/jmbi.1997.1105; Lim JH, 1997, FEBS LETT, V406, P142, DOI 10.1016/S0014-5793(97)00262-7; LUDWIG ML, 1991, J MOL BIOL, V219, P335, DOI 10.1016/0022-2836(91)90569-R; MARCEDORIBEIRO S, 1999, J BIOL INORG CHEM, V4, P209; McCord J M, 1976, Adv Exp Med Biol, V74, P540; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MCCORD JM, 1988, FREE RADICAL BIO MED, V5, P363, DOI 10.1016/0891-5849(88)90109-8; Messerschmidt A, 1996, P NATL ACAD SCI USA, V93, P392, DOI 10.1073/pnas.93.1.392; OSE DE, 1979, ARCH BIOCHEM BIOPHYS, V194, P360, DOI 10.1016/0003-9861(79)90628-3; PARK HJ, 1992, EUR J BIOCHEM, V205, P875, DOI 10.1111/j.1432-1033.1992.tb16852.x; PARKER MW, 1987, PROTEIN ENG, V1, P393, DOI 10.1093/protein/1.5.393; PARKER MW, 1988, FEBS LETT, V229, P377, DOI 10.1016/0014-5793(88)81160-8; POOLE ES, 1995, EMBO J, V14, P151, DOI 10.1002/j.1460-2075.1995.tb06985.x; PRIVALLE CT, 1989, J BIOL CHEM, V264, P2758; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; RINGE D, 1983, PROC R SOC SER B-BIO, V218, P119, DOI 10.1098/rspb.1983.0030; SATO S, 1987, BIOCHIM BIOPHYS ACTA, V912, P178, DOI 10.1016/0167-4838(87)90086-0; SATO S, 1978, J BIOCHEM-TOKYO, V83, P1165, DOI 10.1093/oxfordjournals.jbchem.a132007; SATO S, 1977, EUR J BIOCHEM, V73, P373, DOI 10.1111/j.1432-1033.1977.tb11328.x; STALLINGS WC, 1984, J BIOL CHEM, V259, P695; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; Whittaker JW, 1997, J PHYS CHEM B, V101, P674, DOI 10.1021/jp963049t; WHITTAKER JW, 1991, J AM CHEM SOC, V113, P5528, DOI 10.1021/ja00015a003; Whittaker MM, 1996, BIOCHEMISTRY-US, V35, P6762, DOI 10.1021/bi960088m; Whittaker MM, 1997, BIOCHEMISTRY-US, V36, P8923, DOI 10.1021/bi9704212; Whittaker MM, 1997, J BIOL INORG CHEM, V2, P667, DOI 10.1007/s007750050182; Whittaker MM, 1998, J BIOL CHEM, V273, P22188, DOI 10.1074/jbc.273.35.22188; YAMADA H, 1985, AGR BIOL CHEM TOKYO, V49, P2961, DOI 10.1080/00021369.1985.10867194; YAMAKURA F, 1994, INT CONGR SER, V1058, P115; YOST FJ, 1973, J BIOL CHEM, V248, P4905; Youn HD, 1996, BIOCHEM J, V318, P889, DOI 10.1042/bj3180889	51	34	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34751	34757		10.1074/jbc.274.49.34751	http://dx.doi.org/10.1074/jbc.274.49.34751			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574944	hybrid			2022-12-25	WOS:000083979600038
J	McEwen, RK; Dove, SK; Cooke, FT; Painter, GF; Holmes, AB; Shisheva, A; Ohya, Y; Parker, PJ; Michell, RH				McEwen, RK; Dove, SK; Cooke, FT; Painter, GF; Holmes, AB; Shisheva, A; Ohya, Y; Parker, PJ; Michell, RH			Complementation analysis in PtdInsP kinase-deficient yeast mutants demonstrates that Schizosaccharomyces pombe and murine Fab1p homologues are phosphatidylinositol 3-phosphate 5-kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; VACUOLAR PROTEIN; LIPID KINASE; 3-KINASE; FAMILY; MORPHOLOGY; MEMBRANE; PATHWAY; CELLS	Phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P-2) is widespread in eukaryotic cells. In Saccharomyces cerevisiae, PtdIns(3,5)P-2 synthesis is catalyzed by the PtdIns3P 5 kinase Fab1p, and loss of this activity results in vacuolar morphological defects, indicating that PtdIns(3,5)P-2 is essential for vacuole homeostasis, We have therefore suggested that all Fab1p homologues may be PtdIns3P Ei-kinases involved in membrane trafficking. It is unclear which phosphatidylinositol phosphate kinases (PIPkins) are responsible for PtdIns(3,5)P-2 synthesis in higher eukaryotes. To clarify how PtdIns(3,5)P-2 is synthesized in mammalian and other cells, we determined whether yeast and mammalian Fab1p homologues or mammalian Type I PIPkins (PtdIns4P B-kinases) make Ptdins(3,5)P-2 in vivo. The recently cloned murine (p235) and Schizosaccharomyces pombe FAB1 homologues both restored basal PtdIns(3,5)P-2 synthesis in Delta fab1 cells and made PtdIns(3,5)P-2 in vitro. Only p235 corrected the grow-th and vacuolar defects of fab1 S. cerevisiae, A mammalian Type I PIPkin supported no PtdIns(3,5)P-2 synthesis. Thus, FAB1 and its homologues constitute a distinct class of Type III PIPkins dedicated to PtdIns(S,5)P-2 synthesis, The differential abilities of p235 and of SpFab1p to complement the phenotypic defects of Delta fab1 cells suggests that interaction(s) with other protein factors may be important for spatial and/or temporal regulation of PtdIns(3,5)P-2 synthesis. These results also suggest that p235 may regulate a step in membrane trafficking in mammalian cells that is analogous to its function in yeast.	Univ Birmingham, Sch Biochem, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Ctr Clin Res Immunol & Signalling, Birmingham B15 2TT, W Midlands, England; Imperial Canc Res Fund, Prot Phosphorylat Lab, London WC2A 3PX, England; Univ Cambridge, Cambridge Ctr Mol Recognit, Dept Chem, Cambridge CB2 1EW, England; Wayne State Univ, Sch Med, Dept Physiol, Detroit, MI 48201 USA; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan	University of Birmingham; University of Birmingham; Cancer Research UK; University of Cambridge; Wayne State University; University of Tokyo	McEwen, RK (corresponding author), Univ Birmingham, Sch Biochem, POB 363, Birmingham B15 2TT, W Midlands, England.		Michell, Robert H/AAT-4974-2020; Parker, Peter j/D-5192-2013	Michell, Robert H/0000-0001-9422-9858; parker, peter/0000-0002-6218-2933				AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; Bonangelino CJ, 1997, MOL CELL BIOL, V17, P6847, DOI 10.1128/MCB.17.12.6847; BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Cooke FT, 1998, CURR BIOL, V8, P1219, DOI 10.1016/S0960-9822(07)00513-1; COX S, 1994, CURR OPIN STRUC BIOL, V4, P893, DOI 10.1016/0959-440X(94)90272-0; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Desrivieres S, 1998, J BIOL CHEM, V273, P15787, DOI 10.1074/jbc.273.25.15787; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; DOVE SK, 1999, SIGNAL TRANSDUCTION, P255; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; Hinchliffe KA, 1998, BBA-MOL CELL BIOL L, V1436, P87, DOI 10.1016/S0005-2760(98)00140-4; Homma K, 1998, J BIOL CHEM, V273, P15779, DOI 10.1074/jbc.273.25.15779; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; Madhusudan Elzbieta A. Trafny, 1994, Protein Science, V3, P176; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; PAINTER GF, 1999, J CHEM SOC P1, V8, P923; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; PATTERSON HG, 1994, MOL CELL BIOL, V14, P4002, DOI 10.1128/MCB.14.6.4002; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Rao VD, 1998, CELL, V94, P829, DOI 10.1016/S0092-8674(00)81741-9; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Sbrissa D, 1999, J BIOL CHEM, V274, P21589, DOI 10.1074/jbc.274.31.21589; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SHERMAN F, 1991, P3; Shisheva A, 1999, MOL CELL BIOL, V19, P623; Siddhanta U, 1998, J CELL BIOL, V143, P1647, DOI 10.1083/jcb.143.6.1647; SIKORSKI RJ, 1989, GENETICS, V112, P19; STACK JH, 1994, J BIOL CHEM, V269, P31552; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; STEPHENS L, 1989, BIOCHEM J, V259, P267, DOI 10.1042/bj2590267; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; Stoldt V, 1996, YEAST, V12, P523, DOI 10.1002/(SICI)1097-0061(199605)12:6<523::AID-YEA962>3.3.CO;2-3; Stoyanova S, 1997, BIOCHEM J, V324, P489, DOI 10.1042/bj3240489; TAKEGAWA K, 1995, J CELL SCI, V108, P3745; Tolias KF, 1998, J BIOL CHEM, V273, P18040, DOI 10.1074/jbc.273.29.18040; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; Whiteford CC, 1997, BIOCHEM J, V323, P597, DOI 10.1042/bj3230597; Wurmser AE, 1999, J BIOL CHEM, V274, P9129, DOI 10.1074/jbc.274.14.9129; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756	49	100	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					33905	33912		10.1074/jbc.274.48.33905	http://dx.doi.org/10.1074/jbc.274.48.33905			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567352	hybrid			2022-12-25	WOS:000083857500017
J	Millward, TA; Hess, D; Hemmings, BA				Millward, TA; Hess, D; Hemmings, BA			Ndr protein kinase is regulated by phosphorylation on two conserved sequence motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CELL-CYCLE; PDK1; ACTIVATION; YEAST	Ndr is a nuclear serine/threonine protein kinase that belongs to a subfamily of kinases implicated in the regulation of cell division and cell morphology, This subfamily includes the kinases LATS, Orb6, Cot-1, and Dbf2, We show here that Ndr is potently activated when intact cells are treated with okadaic acid, suggesting that Ndr is normally held in a state of low activity by protein phosphatase 2A. We mapped the regulatory phosphorylation sites of Ndr protein kinase and found that active Ndr is phosphorylated on Ser-281 and Thr-444, Mutation of either site to alanine strongly reduced both basal and okadaic acid-stimulated Ndr activity, while combined mutation abolished Ndr activity completely. Importantly, each of these sites (and also the surrounding sequences) are conserved in the kinase relatives of Ndr, suggesting a general mechanism of activation for kinases of this subfamily. Ser-281 and Thr-444 are also similar to the regulatory phosphorylation sites in several targets of the phosphoinositide-dependent protein kinase PDK1.(1) However, PDK1 does not appear to function as an upstream kinase for Ndr, Thus, Ndr and its close relatives may operate in a novel signaling pathway downstream of an as-yet-unidentified kinase with specificity similar to, but distinct from, PDK1.	Friedrich Miescher Inst, CH-4058 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hemmings, BA (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4058 Basel, Switzerland.	hemmings@fmi.ch						Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Andjelkovic M, 1999, MOL CELL BIOL, V19, P5061; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; Carr SA, 1996, ANAL BIOCHEM, V239, P180, DOI 10.1006/abio.1996.0313; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Jaspersen SL, 1998, MOL BIOL CELL, V9, P2803, DOI 10.1091/mbc.9.10.2803; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Krieg J, 1998, MOL BIOL CELL, V9, P301, DOI 10.1091/mbc.9.2.301; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; MILLWARD T, 1995, P NATL ACAD SCI USA, V92, P5022, DOI 10.1073/pnas.92.11.5022; Millward TA, 1998, EMBO J, V17, P5913, DOI 10.1093/emboj/17.20.5913; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; TOYN JH, 1994, EMBO J, V13, P1103, DOI 10.1002/j.1460-2075.1994.tb06359.x; Verde F, 1998, P NATL ACAD SCI USA, V95, P7526, DOI 10.1073/pnas.95.13.7526; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; YARDEN O, 1992, EMBO J, V11, P2159, DOI 10.1002/j.1460-2075.1992.tb05275.x	28	88	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					33847	33850		10.1074/jbc.274.48.33847	http://dx.doi.org/10.1074/jbc.274.48.33847			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567341	hybrid			2022-12-25	WOS:000083857500006
J	Rosenthal, JA; Chen, H; Slepnev, VI; Pellegrini, L; Salcini, AE; Di Fiore, PP; De Camilli, P				Rosenthal, JA; Chen, H; Slepnev, VI; Pellegrini, L; Salcini, AE; Di Fiore, PP; De Camilli, P			The epsins define a family of proteins that interact with components of the clathrin coat and contain a new protein module	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMIC-ACID DECARBOXYLASE; ARRESTIN/CLATHRIN INTERACTION; TERMINAL DOMAIN; EPS15 HOMOLOGY; EH-DOMAIN; BINDING; ENDOCYTOSIS; DYNAMIN; IDENTIFICATION; YEAST	Epsin (epsin 1) is an interacting partner for the EH domain-containing region of Eps15 and has been implicated in conjunction with Eps15 in clathrin-mediated endocytosis, We report here the characterization of a similar protein (epsin 2), which we have cloned from human and rat brain libraries, Epsin 1 and 2 are most similar in their NH2-terminal region, which represents a module (epsin NH2 terminal homology domain, ENTH domain) found in a variety of other proteins of the data base. The multiple DPW motifs, typical of the central region of epsin 1, are only partially conserved in epsin 2, Both proteins, however, interact through this central region with the clathrin adaptor AP-2, In addition, we show here that both epsin 1 and 2 interact with clathrin, The three NPF motifs of the COOH-terminal region of epsin 1 are conserved in the corresponding region of epsin 2, consistent with the binding of both proteins to Eps15, Epsin 2, like epsin 1, is enriched in brain, is present in a brain-derived clathrin-coated vesicle fraction, is concentrated in the peri-Golgi region and at the cell periphery of transfected cells, and partially colocalizes with clathrin, High overexpression of green fluorescent protein-epsin 2 mislocalizes components of the clathrin coat and inhibits clathrin-mediated endocytosis. The epsins define a new protein family implicated in membrane dynamics at the cell surface.	Yale Univ, Dept Cell Biol, Howard Hughes Med Inst, Sch Med, New Haven, CT 06510 USA; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Bari, Inst Microbiol, I-70124 Bari, Italy	Howard Hughes Medical Institute; Yale University; IRCCS European Institute of Oncology (IEO); Universita degli Studi di Bari Aldo Moro	De Camilli, P (corresponding author), Yale Univ, Dept Cell Biol, Howard Hughes Med Inst, Sch Med, 295 Congress Ave, New Haven, CT 06510 USA.		Di Fiore, Pier Paolo/K-2130-2012; Salcini, Anna Elisabetta/G-4472-2017	Di Fiore, Pier Paolo/0000-0002-2252-0950; Salcini, Anna Elisabetta/0000-0001-5828-2512	NCI NIH HHS [CA46128] Funding Source: Medline; NINDS NIH HHS [NS36251, NS1024-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036251, R37NS036251] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CHANG YC, 1988, J NEUROSCI, V8, P2123; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Chen H, 1999, J BIOL CHEM, V274, P3257, DOI 10.1074/jbc.274.6.3257; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; Guipponi M, 1998, GENOMICS, V53, P369, DOI 10.1006/geno.1998.5521; Hussain NK, 1999, J BIOL CHEM, V274, P15671, DOI 10.1074/jbc.274.22.15671; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Kay BK, 1999, PROTEIN SCI, V8, P435; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; KUBLER E, 1993, EMBO J, V12, P2855, DOI 10.1002/j.1460-2075.1993.tb05947.x; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; MUNN AL, 1994, J CELL BIOL, V127, P373, DOI 10.1083/jcb.127.2.373; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROBINSON PJ, 1994, TRENDS NEUROSCI, V17, P348, DOI 10.1016/0166-2236(94)90179-1; Roos J, 1998, J BIOL CHEM, V273, P19108, DOI 10.1074/jbc.273.30.19108; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Sengar AS, 1999, EMBO J, V18, P1159, DOI 10.1093/emboj/18.5.1159; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; SOLIMENA M, 1991, TRENDS NEUROSCI, V14, P452, DOI 10.1016/0166-2236(91)90044-U; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; SWOFFORD DL, 1991, PAUP PHYLOGENETIC AN; Wendland B, 1996, J CELL BIOL, V135, P1485, DOI 10.1083/jcb.135.6.1485; Witke W, 1998, EMBO J, V17, P967, DOI 10.1093/emboj/17.4.967; Yamabhai M, 1998, J BIOL CHEM, V273, P31401, DOI 10.1074/jbc.273.47.31401	33	146	155	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					33959	33965		10.1074/jbc.274.48.33959	http://dx.doi.org/10.1074/jbc.274.48.33959			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567358	hybrid			2022-12-25	WOS:000083857500023
J	Tanaka, K; Chazenbalk, GD; McLachlan, SM; Rapoport, B				Tanaka, K; Chazenbalk, GD; McLachlan, SM; Rapoport, B			Subunit structure of thyrotropin receptors expressed on the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TSH RECEPTOR; HORMONE-RECEPTOR; EUKARYOTIC CELLS; NATIVE RECEPTOR; INTACT-CELLS; CLEAVAGE; AUTOANTIBODIES; ECTODOMAIN; BINDING; ANTIBODIES	We studied cell surface thyrotropin receptor (TSHR) by biotinylating proteins on the surface of metabolically labeled, intact cells. In addition to TSHR cleaved into A and B subunits, mature single-chain receptors with complex carbohydrate were also present on the cell surface, A low A/B subunit ratio indicated partial shedding of extracellular A subunits from transmembrane B subunits. TSHR cleavage at upstream site 1 (within amino acid residues 305-316) would generate a B subunit of 51-52 kDa. However, only smaller B subunits (40-46 kDa) were detected, corresponding to N termini from residues similar to 370 (site 2) extending downstream to the region of B subunit insertion into the plasma membrane. The intervening C peptide region between sites 1 and 2 could not be purified from TSHR epitope-tagged (c-myc) within this region. However, the small proportion of B subunits recovered with a c-myc antibody were larger (45-52 kDa) than the majority of B subunits recovered with a C-terminal antibody. In conclusion, our study provides the first characterization of cell surface TSHR including their A and B subunits. Single-chain, mature TSHR do exist on the cell surface. The C peptide lost during intramolecular cleavage disintegrates rapidly following cleavage at upstream site 1 of the single-chain TSHR into A and B subunits. N-terminal disintegration of the B subunit pauses at site 2, but then progresses downstream to the vicinity of the plasma membrane, revealing a novel mechanism for A subunit shedding.	Cedars Sinai Res Inst, Autoimmune Dis Unit, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Rapoport, B (corresponding author), Cedars Sinai Med Ctr, 8700 Beverly Blvd,Suite B-131, Los Angeles, CA 90048 USA.				NIDDK NIH HHS [DK19289] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019289] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAN T, 1992, ENDOCRINOLOGY, V131, P815, DOI 10.1210/en.131.2.815; BUCKLAND PR, 1982, FEBS LETT, V145, P245, DOI 10.1016/0014-5793(82)80176-2; Chazenbalk GD, 1997, ENDOCRINOLOGY, V138, P2893, DOI 10.1210/en.138.7.2893; Chazenbalk GD, 1996, ENDOCRINOLOGY, V137, P4586, DOI 10.1210/en.137.11.4586; Couet J, 1996, BIOCHEMISTRY-US, V35, P14800, DOI 10.1021/bi961359w; Couet J, 1996, J BIOL CHEM, V271, P4545; de Bernard S, 1999, J BIOL CHEM, V274, P101, DOI 10.1074/jbc.274.1.101; ENDO T, 1992, BIOCHEM BIOPH RES CO, V187, P887, DOI 10.1016/0006-291X(92)91280-4; FURMANIAK J, 1987, FEBS LETT, V215, P316, DOI 10.1016/0014-5793(87)80169-2; Graves P, 1999, J CLIN ENDOCR METAB, V84, P2177, DOI 10.1210/jc.84.6.2177; Graves PN, 1996, ENDOCRINOLOGY, V137, P3915, DOI 10.1210/en.137.9.3915; GROSSMAN RF, 1995, THYROID, V5, P101, DOI 10.1089/thy.1995.5.101; HARFST E, 1994, MOL CELL ENDOCRINOL, V102, P77, DOI 10.1016/0303-7207(94)90100-7; Kakinuma A, 1997, J CLIN ENDOCR METAB, V82, P2129, DOI 10.1210/jc.82.7.2129; Kakinuma A, 1997, J BIOL CHEM, V272, P28296, DOI 10.1074/jbc.272.45.28296; KAUFMAN KD, 1991, MOL CELL ENDOCRINOL, V78, P107; KOSUGI S, 1992, BIOCHEM BIOPH RES CO, V189, P1754, DOI 10.1016/0006-291X(92)90281-O; LOOSFELT H, 1992, P NATL ACAD SCI USA, V89, P3765, DOI 10.1073/pnas.89.9.3765; MISRAHI M, 1994, EUR J BIOCHEM, V222, P711, DOI 10.1111/j.1432-1033.1994.tb18916.x; Misrahi M, 1997, EUR J ENDOCRINOL, V137, P599, DOI 10.1530/eje.0.1370599; Nicholson LB, 1996, J MOL ENDOCRINOL, V16, P159, DOI 10.1677/jme.0.0160159; POTTER E, 1994, BIOCHEM BIOPH RES CO, V205, P361, DOI 10.1006/bbrc.1994.2673; Rapoport B, 1998, ENDOCR REV, V19, P673, DOI 10.1210/er.19.6.673; RUSSO D, 1991, MOL ENDOCRINOL, V5, P1607, DOI 10.1210/mend-5-11-1607; RUSSO D, 1992, ENDOCRINOLOGY, V130, P2135, DOI 10.1210/en.130.4.2135; Tanaka K, 1998, J BIOL CHEM, V273, P1959, DOI 10.1074/jbc.273.4.1959; Tanaka K, 1999, MOL CELL ENDOCRINOL, V150, P113, DOI 10.1016/S0303-7207(99)00018-0; Tanaka K, 1996, BIOCHEM BIOPH RES CO, V228, P21, DOI 10.1006/bbrc.1996.1611	28	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					33979	33984		10.1074/jbc.274.48.33979	http://dx.doi.org/10.1074/jbc.274.48.33979			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567361	hybrid			2022-12-25	WOS:000083857500026
J	Matsumoto, Y; Kim, K; Hurwitz, J; Gary, R; Levin, DS; Tomkinson, AE; Park, MS				Matsumoto, Y; Kim, K; Hurwitz, J; Gary, R; Levin, DS; Tomkinson, AE; Park, MS			Reconstitution of proliferating cell nuclear antigen-dependent repair of apurinic/apyrimidinic sites with purified human proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; DNA-POLYMERASE-DELTA; AUXILIARY PROTEIN; TERMINAL REGION; PCNA BINDING; REQUIREMENT; INVOLVEMENT; EPSILON; BETA; IDENTIFICATION	An apurinic/apyrimidinic (AP) site is one of the most abundant lesions spontaneously generated in living cells and is also a reaction intermediate in base excision repair. In higher eukaryotes, there are two alternative pathways for base excision repair: a DNA polymerase P-dependent pathway and a proliferating cell nuclear antigen (PCNA)-dependent pathway. Here we have reconstituted PCNA-dependent repair of AP sites with six purified human proteins: AP endonuclease, replication factor C, PCNA, flap endonuclease 1 (FEN1), DNA polymerase delta, and DNA ligase I. The length of nucleotides replaced during the repair reaction (patch size) was predominantly two nucleotides, although longer patches of up to seven nucleotides could be detected. Neither replication protein A nor Ku70/80 enhanced the repair activity in this system. Disruption of the PCNA-binding site of either FEN1 or DNA ligase I significantly reduced efficiency of AP site repair but did not affect repair patch size.	Fox Chase Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19111 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Univ Calif Los Alamos Natl Lab, Life Sci Div M888, Los Alamos, NM 87545 USA; Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA	Fox Chase Cancer Center; Memorial Sloan Kettering Cancer Center; United States Department of Energy (DOE); Los Alamos National Laboratory; University of Texas System; University of Texas Health San Antonio	Matsumoto, Y (corresponding author), Fox Chase Canc Ctr, Dept Radiat Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA.		Gary, Ronald K/A-8650-2008; Park, Min Sung/HCH-2207-2022	Gary, Ronald K/0000-0001-5079-1953; Matsumoto, Yoshihiro/0000-0001-6580-7188	NCI NIH HHS [CA71630, CA63154, CA06927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063154, R29CA071630, P30CA006927, R29CA063154] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; BLANK A, 1994, P NATL ACAD SCI USA, V91, P9047, DOI 10.1073/pnas.91.19.9047; BLIER PR, 1993, J BIOL CHEM, V268, P7594; Cai JS, 1996, P NATL ACAD SCI USA, V93, P12896, DOI 10.1073/pnas.93.23.12896; DeMott MS, 1998, J BIOL CHEM, V273, P27492, DOI 10.1074/jbc.273.42.27492; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; ECKSTEIN F, 1989, TRENDS BIOCHEM SCI, V14, P97, DOI 10.1016/0968-0004(89)90130-8; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Gibbs E, 1996, J BIOL CHEM, V271, P22847, DOI 10.1074/jbc.271.37.22847; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; LEE SH, 1991, J BIOL CHEM, V266, P594; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; Matsumoto Y, 1999, METH MOL B, V113, P289; Miura M, 1996, RADIAT RES, V145, P75, DOI 10.2307/3579198; Montecucco A, 1998, EMBO J, V17, P3786, DOI 10.1093/emboj/17.13.3786; Nagelhus TA, 1997, J BIOL CHEM, V272, P6561, DOI 10.1074/jbc.272.10.6561; Nicholl ID, 1997, BIOCHEMISTRY-US, V36, P7557, DOI 10.1021/bi962950w; Pascucci B, 1999, J BIOL CHEM, V274, P33696, DOI 10.1074/jbc.274.47.33696; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; STIVALA LA, 1993, CARCINOGENESIS, V14, P2569, DOI 10.1093/carcin/14.12.2569; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; TAN CK, 1986, J BIOL CHEM, V261, P2310; TOMKINSON A, 1997, BASE EXCISION REPAIR, P137; WANG YCJ, 1994, J BIOL CHEM, V269, P31923; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Warbrick E, 1998, NUCLEIC ACIDS RES, V26, P3925, DOI 10.1093/nar/26.17.3925; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x	42	149	157	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33703	33708		10.1074/jbc.274.47.33703	http://dx.doi.org/10.1074/jbc.274.47.33703			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559261	hybrid			2022-12-25	WOS:000083745200077
J	Mochizuki, M; Aoyama, H; Shinzawa-Itoh, K; Usui, T; Tsukihara, T; Yoshikawa, S				Mochizuki, M; Aoyama, H; Shinzawa-Itoh, K; Usui, T; Tsukihara, T; Yoshikawa, S			Quantitative reevaluation of the redox active sites of crystalline bovine heart cytochrome c oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2.8 ANGSTROM; COPPER; STATE; IRON; RELEVANCE; BEHAVIOR; MODELS; HEME	Approximately 30% of the iron contained in a bovine heart cytochrome c oxidase preparation was removed by crystallization, giving a molecular extinction coefficient 1.25-1.4 times higher than those reported thus far. Six electron equivalents provided by dithionite were required for complete reduction of the crystalline cytochrome c oxidase preparation. The fully reduced enzyme was oxidized with 4 oxidation equivalents provided by molecular oxygen, giving an absorption spectrum slightly, but significantly, different from that of the original fully oxidized form. Four electron equivalents were required for complete reduction of the O-2-oxidized enzyme. The O-2-oxidized form, when exposed to excess amounts of O-2, was converted to the original oxidized form which required 6 electrons for complete reduction. A slow reduction of the O-2-oxidized form without any external reductant added indicates the existence of internal electron donors for heme irons in the enzyme. These results suggest that the 2 extra oxidation equivalents in the original oxidized form, compared with the O-2-oxidized form, are due to a bound peroxide produced by O-2 and electrons from the internal donors, consistently with a peroxide at the O-2 reduction site in the crystal structure of the enzyme (Yoshikawa, S., Shinzawa-Itoh, K., Nakashima, R., Yaono, R., Yamashita, E., Inoue, N., Yao, M., Fei, M. J., Peters Libeu, C., Mizushima, T., Yamaguchi, H., Tomizaki, T., and Tsukihara, T. (1998) Science 280, 1723-1729).	Japan Sci & Technol Corp, CREST, Himeji Inst Technol, Dept Life Sci, Kamigohri Akoh, Hyogo 6781297, Japan; Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Himeji Inst Technol, Dept Appl Chem, Himeji, Hyogo 6712201, Japan	Japan Science & Technology Agency (JST); University of Hyogo; Osaka University; University of Hyogo	Yoshikawa, S (corresponding author), Japan Sci & Technol Corp, CREST, Himeji Inst Technol, Dept Life Sci, Kamigohri Akoh, Hyogo 6781297, Japan.			Aoyama, Hiroshi/0000-0001-7915-8975				ANTONINI E, 1977, P NATL ACAD SCI USA, V74, P3128, DOI 10.1073/pnas.74.8.3128; BABCOCK GT, 1978, J BIOL CHEM, V253, P2400; BLAIR DF, 1986, J BIOL CHEM, V261, P1524; BURLEIGH BD, 1969, ANAL BIOCHEM, V27, P536, DOI 10.1016/0003-2697(69)90067-0; DESSENS SE, 1982, J AM CHEM SOC, V104, P4357, DOI 10.1021/ja00380a008; FergusonMiller S, 1996, CHEM REV, V96, P2889, DOI 10.1021/cr950051s; FRANCESCHI F, 1996, J CHEM SOC CHEM COMM, P1645; GIBSON QH, 1963, BIOCHEM J, V86, P541, DOI 10.1042/bj0860541; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; LANDRUM JT, 1978, J AM CHEM SOC, V100, P3232, DOI 10.1021/ja00478a055; MALMSTROM BG, 1990, CHEM REV, V90, P1247, DOI 10.1021/cr00105a008; OKUNUKI K, 1958, J BIOCHEM, V45, P847, DOI 10.1093/oxfordjournals.jbchem.a126815; POWERS L, 1985, J INORG BIOCHEM, V23, P207, DOI 10.1016/0162-0134(85)85027-3; SCHROEDL NA, 1977, BIOCHEMISTRY-US, V16, P1327, DOI 10.1021/bi00626a014; SCOTT RA, 1986, BIOCHEMISTRY-US, V25, P5546, DOI 10.1021/bi00367a030; SEITER CHA, 1980, P NATL ACAD SCI-BIOL, V77, P1806, DOI 10.1073/pnas.77.4.1806; STEFFENS GCM, 1993, EUR J BIOCHEM, V213, P1149, DOI 10.1111/j.1432-1033.1993.tb17865.x; TIESJEMA RH, 1973, BIOCHIM BIOPHYS ACTA, V305, P19, DOI 10.1016/0005-2728(73)90227-2; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; VANGELDER BF, 1966, BIOCHIM BIOPHYS ACTA, V118, P36, DOI 10.1016/S0926-6593(66)80142-X; VANNESTE WH, 1966, BIOCHEMISTRY-US, V5, P838, DOI 10.1021/bi00867a005; Washburn E., 1930, INT CRITICAL TABLES; YONETANI T, 1961, J BIOL CHEM, V236, P1680; YOSHIKAWA S, 1977, J BIOL CHEM, V252, P5498; YOSHIKAWA S, 1995, J BIOL CHEM, V270, P4270, DOI 10.1074/jbc.270.9.4270	26	49	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33403	33411		10.1074/jbc.274.47.33403	http://dx.doi.org/10.1074/jbc.274.47.33403			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559221	hybrid			2022-12-25	WOS:000083745200037
J	Piros, ET; Shen, LJ; Huang, XY				Piros, ET; Shen, LJ; Huang, XY			Purification of an EH domain-binding protein from rat brain that modulates the gating of the rat ether-a-go-go channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANAR LIPID BILAYERS; POTASSIUM CHANNEL; TYROSINE-KINASE; XENOPUS OOCYTES; K+ CURRENTS; FUNCTIONAL EXPRESSION; DROSOPHILA; EAG; RECEPTOR; ACTIVATION	Mutations in the gene encoding ether-a-go-go (EAG) potassium channel impair the function of several classes of potassium currents, synaptic transmission, and learning in Drosophila. Absence of EAG abolishes the modulation of a broad group of potassium currents. EAG has been proposed to be a regulatory subunit of different potassium channels. To further explore this regulatory role we searched for signaling molecules that associate with EAG protein. We have purified a similar to 95-kDa protein from rat brain membranes that binds to EAG, When co-expressed in mammalian cells this protein coimmunoprecipites with EAG and alters the gating of EAG channels. Expression of this protein is regulated during neuronal differentiation. The protein is identical to the recently reported rat protein epsin, which is an EH domain-binding protein similar to the Xenopus mitotic phosphoprotein MP90. These results show that proteins of the epsin family are modulators of channel activity that may link signaling pathways, or the cell cycle, to EAG and thus to various potassium channel functions.	Cornell Univ, Coll Med, Dept Physiol, New York, NY 10021 USA	Cornell University	Huang, XY (corresponding author), Cornell Univ, Coll Med, Dept Physiol, New York, NY 10021 USA.	xyhuang@mail.med.cornell.edu						Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; Bruggemann A, 1997, P NATL ACAD SCI USA, V94, P537, DOI 10.1073/pnas.94.2.537; Byrne JH, 1996, J NEUROSCI, V16, P425; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Chen ML, 1996, NEURON, V17, P535, DOI 10.1016/S0896-6273(00)80185-3; Dubin AE, 1998, J NEUROSCI, V18, P5603; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; GRIFFITH LC, 1994, P NATL ACAD SCI USA, V91, P10044, DOI 10.1073/pnas.91.21.10044; Guichet A, 1997, NATURE, V385, P548, DOI 10.1038/385548a0; Hille B., 1992, IONIC CHANNELS EXCIT; Hoshi N, 1998, J BIOL CHEM, V273, P23080, DOI 10.1074/jbc.273.36.23080; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; Jan LY, 1997, J PHYSIOL-LONDON, V505, P267, DOI 10.1111/j.1469-7793.1997.267bb.x; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; KAPLAN WD, 1969, GENETICS, V61, P399; KIJIMA Y, 1993, J BIOL CHEM, V268, P16253; LUDWIG J, 1994, EMBO J, V13, P4451, DOI 10.1002/j.1460-2075.1994.tb06767.x; Pishvaee B, 1998, CELL, V95, P443, DOI 10.1016/S0092-8674(00)81611-6; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; Schopperle WM, 1998, NEURON, V20, P565, DOI 10.1016/S0896-6273(00)80995-2; Stansfeld CE, 1996, P NATL ACAD SCI USA, V93, P9910, DOI 10.1073/pnas.93.18.9910; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; Tang CY, 1998, BIOPHYS J, V75, P1263, DOI 10.1016/S0006-3495(98)74046-9; Terlau H, 1996, PFLUG ARCH EUR J PHY, V432, P301, DOI 10.1007/s004240050137; TIMERMAN AP, 1992, P NATL ACAD SCI USA, V89, P8976, DOI 10.1073/pnas.89.19.8976; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530; WU CF, 1983, SCIENCE, V220, P1076, DOI 10.1126/science.6302847; ZHONG Y, 1993, J NEUROSCI, V13, P4669; ZHONG Y, 1991, SCIENCE, V252, P1562, DOI 10.1126/science.2047864; Zhou BY, 1998, J GEN PHYSIOL, V111, P555, DOI 10.1085/jgp.111.4.555	33	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33677	33683		10.1074/jbc.274.47.33677	http://dx.doi.org/10.1074/jbc.274.47.33677			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559257	hybrid			2022-12-25	WOS:000083745200073
J	Sette, C; Barchi, M; Bianchini, A; Conti, M; Rossi, P; Geremia, R				Sette, C; Barchi, M; Bianchini, A; Conti, M; Rossi, P; Geremia, R			Activation of the mitogen-activated protein kinase ERK1 during meiotic progression of mouse pachytene spermatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-OOCYTE MATURATION; DNA MISMATCH REPAIR; MAP KINASE; CHROMOSOME SYNAPSIS; CELL-CYCLE; CDC25 PHOSPHATASE; DEFICIENT MICE; OKADAIC ACID; PARTHENOGENETIC ACTIVATION; ATAXIA-TELANGIECTASIA	Okadaic acid (OA) causes meiotic progression and chromosome condensation in cultured pachytene spermatocytes and an increase in maturation promoting factor (cyclin B1/cdc2 kinase) activity, as evaluated by H1 phosphorylative activity in anti-cyclin B1 immunoprecipitates, OA also induces a strong increase of phosphorylative activity toward the mitogen-activated protein kinase substrate myelin basic protein (MBP), Immunoprecipitation experiments with anti-extracellular signal-regulated kinase 1 (ERK1) or anti-ERK2 antibodies followed by MBP kinase assays, and direct in-gel kinase assays for MBP, show that p44/ERK1 but not p42/ERK2 is stimulated in OA-treated spermatocytes. OA treatment stimulates phosphorylation of ERK1, but not of ERK2, on a tyrosine residue involved in activation of the enzyme, ERK1 immunoprecipitated from extracts of OA-stimulated spermatocytes induces a stimulation of H1 kinase activity in extracts from control pachytene spermatocytes, whereas immunoprecipitated ERK2 is uneffective. We also show that natural G(2)/M transition in spermatocytes is associated to intracellular redistribution of ERKs, and their association with microtubules of the metaphase spindle. Preincubation of cultured pachytene spermatocytes with PD98059 (a selective inhibitor of ERK-activating kinases MEK1/2) completely blocks the ability of OA to induce chromosome condensation and progression to meiotic metaphases. These results suggest that ERK1 is specifically activated during G(2)/M transition in mouse spermatocytes, that it contributes to the mechanisms of maturation promoting factor activation, and that it is essential for chromosome condensation associated with progression to meiotic metaphases.	Univ Roma Tor Vergata, Dipartimento Sanita Pubbl & Biol Cellulare, Sez Anat, I-00173 Rome, Italy; Stanford Univ, Med Ctr, Dept Obstet & Gynecol, Div Reprod Biol, Stanford, CA 94305 USA	University of Rome Tor Vergata; Stanford University	Geremia, R (corresponding author), Univ Roma Tor Vergata, Dipartimento Sanita Pubbl & Biol Cellulare, Sez Anat, Via O Raimondo 8, I-00173 Rome, Italy.	geremia@uniroma2.it	Sette, Claudio/S-4307-2019; Rossi, Pellegrino/AAA-7072-2019; Barchi, Marco/Q-9378-2019	Sette, Claudio/0000-0003-2864-8266; Barchi, Marco/0000-0003-1104-6234; GEREMIA, Raffaele/0000-0001-9056-6603; ROSSI, PELLEGRINO/0000-0003-4796-327X				ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALEXANDRE H, 1991, DEVELOPMENT, V112, P971; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; Barlow C, 1998, DEVELOPMENT, V125, P4007; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASILLAS AM, 1993, BIOCHEM J, V290, P545, DOI 10.1042/bj2900545; CHAPMAN DL, 1994, DEV BIOL, V165, P500, DOI 10.1006/dbio.1994.1270; Choi T, 1996, P NATL ACAD SCI USA, V93, P4730, DOI 10.1073/pnas.93.10.4730; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; COLLEDGE WH, 1994, NATURE, V370, P65, DOI 10.1038/370065a0; Dix DJ, 1996, P NATL ACAD SCI USA, V93, P3264, DOI 10.1073/pnas.93.8.3264; Dix DJ, 1997, DEVELOPMENT, V124, P4595; Eddy EM, 1998, CURR TOP DEV BIOL, V37, P141; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; Flaggs G, 1997, CURR BIOL, V7, P977, DOI 10.1016/S0960-9822(06)00417-9; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GOTOH Y, 1995, J BIOL CHEM, V270, P25898, DOI 10.1074/jbc.270.43.25898; GRIMALDI P, 1993, MOL ENDOCRINOL, V7, P1217, DOI 10.1210/me.7.9.1217; HACCARD O, 1995, DEV BIOL, V168, P677, DOI 10.1006/dbio.1995.1112; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; Hamilton M, 1998, J BIOL CHEM, V273, P28155, DOI 10.1074/jbc.273.43.28155; HANDEL MA, 1995, DEV GENET, V16, P128, DOI 10.1002/dvg.1020160206; Handel MA, 1998, CURR TOP DEV BIOL, V37, P333, DOI 10.1016/S0070-2153(08)60179-9; HASHIMOTO N, 1994, NATURE, V370, P68, DOI 10.1038/370068a0; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; Huang CYF, 1996, EMBO J, V15, P2169, DOI 10.1002/j.1460-2075.1996.tb00570.x; IZUMI T, 1995, MOL BIOL CELL, V6, P215, DOI 10.1091/mbc.6.2.215; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; Kalab P, 1996, DEVELOPMENT, V122, P1957; Kimura K, 1998, SCIENCE, V282, P487, DOI 10.1126/science.282.5388.487; KOSAKO H, 1994, J BIOL CHEM, V269, P28354; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LEE TH, 1994, MOL BIOL CELL, V5, P323, DOI 10.1091/mbc.5.3.323; Liu D, 1998, NAT GENET, V20, P377, DOI 10.1038/3855; Meistrich M L, 1977, Methods Cell Biol, V15, P15, DOI 10.1016/S0091-679X(08)60207-1; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Page AW, 1997, CURR OPIN GENET DEV, V7, P23, DOI 10.1016/S0959-437X(97)80105-0; Palmer A, 1998, EMBO J, V17, P5037, DOI 10.1093/emboj/17.17.5037; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Pittman DL, 1998, MOL CELL, V1, P697, DOI 10.1016/S1097-2765(00)80069-6; Plug AW, 1997, NAT GENET, V17, P457, DOI 10.1038/ng1297-457; Rhee K, 1997, DEVELOPMENT, V124, P2167; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROSSI P, 1993, DEV BIOL, V155, P68, DOI 10.1006/dbio.1993.1007; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Sagata N, 1997, BIOESSAYS, V19, P13, DOI 10.1002/bies.950190105; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sette C, 1997, DEVELOPMENT, V124, P2267; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; SORRENTINO V, 1988, P NATL ACAD SCI USA, V85, P2191, DOI 10.1073/pnas.85.7.2191; Verlhac MH, 1996, DEVELOPMENT, V122, P815; WILTSHIRE T, 1995, DEV BIOL, V169, P557, DOI 10.1006/dbio.1995.1169; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yoshida K, 1998, MOL CELL, V1, P707, DOI 10.1016/S1097-2765(00)80070-2; Zhu DH, 1997, DEVELOPMENT, V124, P3007	68	72	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33571	33579		10.1074/jbc.274.47.33571	http://dx.doi.org/10.1074/jbc.274.47.33571			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559244	Green Published, hybrid			2022-12-25	WOS:000083745200060
J	Cho, HS; Ha, NC; Choi, G; Kim, HJ; Lee, D; Oh, KS; Kim, KS; Lee, W; Choi, KY; Oh, BH				Cho, HS; Ha, NC; Choi, G; Kim, HJ; Lee, D; Oh, KS; Kim, KS; Lee, W; Choi, KY; Oh, BH			Crystal structure of Delta(5)-3-ketosteroid isomerase from Pseudomonas testosteroni in complex with equilenin settles the correct hydrogen bonding scheme for transition state stabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYZED PROTON ABSTRACTION; CARBON ACIDS; 3-OXO-DELTA(5)-STEROID ISOMERASE; DELTA-5-3-KETOSTEROID ISOMERASE; ENZYMATIC CATALYSIS; SERINE PROTEASES; INTERMEDIATE; MECHANISM; RESIDUES; D38N	Delta(5)-3-Ketosteroid isomerase from Pseudomonas testosteroni has been intensively studied as a prototype to understand an enzyme-catalyzed allylic isomerization, Asp(38) (PKalpha similar to 4.7) was identified as the general base abstracting the steroid C4 beta proton (pK(alpha) similar to 12.7) to form a dienolate intermediate. A key and common enigmatic issue involved in the proton abstraction is the question of how the energy required for the unfavorable proton transfer can be provided at the active site of the enzyme and/or how the thermodynamic barrier can be drastically reduced. Answering this question has been hindered by the existence of two differently proposed enzyme reaction mechanisms. The 2.26 Angstrom crystal structure of the enzyme in complex with a reaction intermediate analogue equilenin reveals clearly that both the Tyr(1.4) OH and Asp(99) COOH provide direct hydrogen bonds to the oxyanion of equilenin, The result negates the catalytic dyad mechanism in which Asp(99) donates the hydrogen bond to Tyr(14), which in turn is hydrogen bonded to the steroid. A theoretical calculation also favors the doubly hydrogen-bonded system over the dyad system. Proton nuclear magnetic resonance analyses of several mutant enzymes indicate that the Tyr(14) OH forms a low barrier hydrogen bond with the dienolic oxyanion of the intermediate.	Pohang Univ Sci & Technol, Sch Environm Engn, Dept Life Sci, Pohang 790784, Kyungbuk, South Korea; Pohang Univ Sci & Technol, Ctr Biofunct Mol, Pohang 790784, Kyungbuk, South Korea; Pohang Univ Sci & Technol, Dept Chem, Natl Creat Res Initiat Ctr Superfunct Mat, Pohang 790784, Kyungbuk, South Korea; Yonsei Univ, Coll Sci, Dept Biochem, Seoul 120749, South Korea	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); Yonsei University	Oh, BH (corresponding author), Pohang Univ Sci & Technol, Sch Environm Engn, Dept Life Sci, Pohang 790784, Kyungbuk, South Korea.		Oh, Byung-Ha/C-2061-2011; Lee, Donghan/B-6893-2011; Kim, Kwang Soo/C-7538-2012	Kim, Kwang Soo/0000-0002-6929-5359; Lee, Donghan/0000-0002-6530-8060				Ash EL, 1997, SCIENCE, V278, P1128, DOI 10.1126/science.278.5340.1128; BEVINS CL, 1984, J AM CHEM SOC, V106, P4957, DOI 10.1021/ja00329a055; BRUNGER AT, 1992, XPLOR VERSION 3 843; Bullock TL, 1996, J MOL BIOL, V260, P422, DOI 10.1006/jmbi.1996.0411; Cho HS, 1998, BIOCHEMISTRY-US, V37, P8325, DOI 10.1021/bi9801614; CLELAND WW, 1994, SCIENCE, V264, P1887, DOI 10.1126/science.8009219; Cleland WW, 1998, J BIOL CHEM, V273, P25529, DOI 10.1074/jbc.273.40.25529; EAMES TCM, 1990, J AM CHEM SOC, V112, P1996, DOI 10.1021/ja00161a054; FREY PA, 1994, SCIENCE, V264, P1927, DOI 10.1126/science.7661899; FRISCH MJ, 1995, GAUSSIAN 94; GERLT JA, 1991, J AM CHEM SOC, V113, P9667, DOI 10.1021/ja00025a039; GERLT JA, 1993, BIOCHEMISTRY-US, V32, P11943, DOI 10.1021/bi00096a001; GERLT JA, 1993, J AM CHEM SOC, V115, P11552, DOI 10.1021/ja00077a062; GERLT JA, 1992, J AM CHEM SOC, V114, P5928, DOI 10.1021/ja00041a004; HAWKINSON DC, 1994, BIOCHEMISTRY-US, V33, P12172, DOI 10.1021/bi00206a021; HOLMAN CM, 1994, BIOCHEMISTRY-US, V33, P2672, DOI 10.1021/bi00175a041; JONES TA, O VERSION 5 9; Kauppi B, 1998, STRUCTURE, V6, P571, DOI 10.1016/S0969-2126(98)00059-8; KIM SW, 1995, J BACTERIOL, V177, P2602, DOI 10.1128/jb.177.9.2602-2605.1995; Kim SW, 1997, BIOCHEMISTRY-US, V36, P14030, DOI 10.1021/bi971546+; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KULIOPULOS A, 1990, BIOCHEMISTRY-US, V29, P10271, DOI 10.1021/bi00496a017; KULIOPULOS A, 1989, BIOCHEMISTRY-US, V28, P149, DOI 10.1021/bi00427a022; LI YK, 1993, BIOCHEMISTRY-US, V32, P1816, DOI 10.1021/bi00058a016; LUNDQVIST T, 1994, STRUCTURE, V2, P937, DOI 10.1016/S0969-2126(94)00095-6; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; Massiah MA, 1998, BIOCHEMISTRY-US, V37, P14701, DOI 10.1021/bi981447b; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Petrounia IP, 1998, BIOCHEMISTRY-US, V37, P700, DOI 10.1021/bi972262s; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; POLLACK RM, 1987, J AM CHEM SOC, V109, P5048, DOI 10.1021/ja00250a061; RADZICKA A, 1995, SCIENCE, V267, P90, DOI 10.1126/science.7809611; SCHEINER S, 1995, J AM CHEM SOC, V117, P6970, DOI 10.1021/ja00131a020; Shan SO, 1996, SCIENCE, V272, P97, DOI 10.1126/science.272.5258.97; TALALAY P, 1955, BIOCHIM BIOPHYS ACTA, V18, P300, DOI 10.1016/0006-3002(55)90079-2; WALSH C, 1984, ENZYMATIC REACTION M; WEINTRAUB H, 1970, EUR J BIOCHEM, V12, P217, DOI 10.1111/j.1432-1033.1970.tb00840.x; WEINTRAUB H, 1977, BIOCHEMISTRY-US, V16, P5045, DOI 10.1021/bi00642a016; Wu ZR, 1997, SCIENCE, V276, P415, DOI 10.1126/science.276.5311.415; XUE L, 1991, BIOCHEMISTRY-US, V30, P4991, DOI 10.1021/bi00234a022; Zhao QJ, 1997, BIOCHEMISTRY-US, V36, P14616, DOI 10.1021/bi971549m; Zhao QJ, 1996, P NATL ACAD SCI USA, V93, P8220, DOI 10.1073/pnas.93.16.8220	42	79	80	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32863	32868		10.1074/jbc.274.46.32863	http://dx.doi.org/10.1074/jbc.274.46.32863			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551849	hybrid			2022-12-25	WOS:000083623000049
J	Cottin, V; Van Linden, A; Riches, DWH				Cottin, V; Van Linden, A; Riches, DWH			Phosphorylation of tumor necrosis factor receptor CD120a (p55) by p42(mapk/erk2) induces changes in its subcellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; KAPPA-B ACTIVATION; SIGNALS CELL-DEATH; ENDOPLASMIC-RETICULUM; TNF RECEPTOR; CYTOPLASMIC DOMAIN; SUBSTRATE RECOGNITION; MOUSE MACROPHAGES; ALPHA; BETA	The interaction of tumor necrosis factor-alpha (TNF alpha) with its receptor sets in motion downstream signaling events including the activation of members of the mitogen-activated protein kinase (MAPK) family. In this study, we show that p42(mapk/erk2) phosphorylates sequences present within the cytoplasmic domain of CD120a (p55). By using a GST-CD120a-(207-425) fusion protein as substrate, phosphorylation was induced following stimulation of mouse macrophages with TNF alpha, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and zymosan particles and was blocked by immunodepletion of p42(mapk/erk2) and by specific inhibition of p42(mapk/erk2) activation with PD098059. Transfection of COS-7 cells with CD120a (p55), wild type p42(mapk/erk2), and constitutively active MEK-1 followed by metabolic labeling with [P-32]orthophosphate indicated that p42(mapk/erk2) phosphorylated the cytoplasmic domain of CD120a (p55) in intact cells. As a consequence of phosphorylation, CD120a (p55) expression at the plasma membrane and Golgi apparatus was lost and the receptor accumulated in intracellular tubular structures associated with the endoplasmic reticulum. Mutation of the four Ser and Thr ERK consensus phosphorylation sites to Ala residues inhibited the ability of the receptor to redistribute to intracellular tubules in a p42(mapk/erk2)-dependent fashion; whereas mutation of the phosphorylation sites to Asp and Glu residues mimicked the effect of receptor phosphorylation. These findings thus indicate that the phosphorylation of CD120a (p55) alters the subcellular localization of the receptor and may thereby result in changes in its signaling properties.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Div Pulm & Crit Care Med, Denver, CO 80262 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, Denver, CO 80206 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health	Riches, DWH (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, Neustadt Rm D405,1400 Jackson St, Denver, CO 80206 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056556, R01HL055549] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 56556, HL55549] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVERY A, 1996, J BIOL CHEM, V271, P10054; Benlimame N, 1998, MOL BIOL CELL, V9, P1773, DOI 10.1091/mbc.9.7.1773; BEYAERT R, 1995, J BIOL CHEM, V270, P23293, DOI 10.1074/jbc.270.40.23293; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOWEN S, 1991, J BIOL CHEM, V266, P1162; BRADLEY JR, 1995, AM J PATHOL, V146, P27; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; Chan ED, 1997, P NATL ACAD SCI USA, V94, P13169, DOI 10.1073/pnas.94.24.13169; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; Darnay BG, 1997, FEBS LETT, V410, P361, DOI 10.1016/S0014-5793(97)00652-2; DARNAY BG, 1994, J BIOL CHEM, V269, P20299; DARNAY BG, 1994, J BIOL CHEM, V269, P19687; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DING AH, 1989, J BIOL CHEM, V264, P3924; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GUY GR, 1993, J BIOL CHEM, V268, P2141; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Haribabu B, 1997, J BIOL CHEM, V272, P28726, DOI 10.1074/jbc.272.45.28726; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hsu MH, 1997, J BIOL CHEM, V272, P29426, DOI 10.1074/jbc.272.47.29426; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Norman BH, 1996, J MED CHEM, V39, P1106, DOI 10.1021/jm950619p; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Riches DWH, 1996, MOL CELLULAR BIOL WO, P95; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Schutze S, 1999, J BIOL CHEM, V274, P10203, DOI 10.1074/jbc.274.15.10203; SIBLEY DR, 1986, P NATL ACAD SCI USA, V83, P9408, DOI 10.1073/pnas.83.24.9408; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; VANARSDALE TL, 1994, J IMMUNOL, V153, P3043; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Winston BW, 1997, J IMMUNOL, V159, P4491; WINSTON BW, 1995, J IMMUNOL, V155, P1525; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu MY, 1997, J BIOL CHEM, V272, P17154, DOI 10.1074/jbc.272.27.17154; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang LR, 1997, J BIOL CHEM, V272, P14762, DOI 10.1074/jbc.272.23.14762; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	59	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32975	32987		10.1074/jbc.274.46.32975	http://dx.doi.org/10.1074/jbc.274.46.32975			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551865	hybrid			2022-12-25	WOS:000083623000065
J	Noguchi, K; Kitanaka, C; Yamana, H; Kokubu, A; Mochizuki, T; Kuchino, Y				Noguchi, K; Kitanaka, C; Yamana, H; Kokubu, A; Mochizuki, T; Kuchino, Y			Regulation of c-Myc through phosphorylation at Ser-62 and Ser-71 by c-Jun N-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; FAS LIGAND EXPRESSION; APOPTOTIC CELL-DEATH; PROTEIN-KINASE; ACTIVATION DOMAIN; RESPONSE ELEMENT; GENE-EXPRESSION; INDUCTION; JNK; GROWTH	The expression of c-myc promotes cell proliferation and also sensitizes cells to various extracellular apoptotic stimuli. However, signal pathways regulating the function of myc proteins during apoptosis are unknown. c-Jun N-terminal kinase (JNK) is activated by various apoptotic stimuli, but neither the target molecule(s) or the action of JNK has been identified in Myc-mediated apoptosis. Here, we found that JNK selectively interacted with, and phosphorylated, c-Myc at Ser-62 and Ser-71 as confirmed with phospho-c-Myc-specific antibodies. Interestingly, dominant negative mutant JNK(APF) impaired the c-Myc-dependent apoptosis, but not mutated c-Myc (S62A/S71A)-dependent apoptosis triggered by UV irradiation. Furthermore, c-Myc (S62A/S71A)-expressing NIH3T3 cells were not sensitized like wild type c-Myc-expressing NIH3T3 cells to JNK-activating apoptotic stimuli, such as UV and Taxol These results indicate that the JNK pathway is selectively involved in the c-Myc-mediated apoptosis and that the apoptotic function of c-myc is directly regulated by JNK pathway through phosphorylation at Ser-62 and Ser-71.	Natl Canc Ctr, Res Inst, Div Biophys, Chuo Ku, Tokyo 1040045, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Kawaguchi, Saitama 3320012, Japan	National Cancer Center - Japan; Japan Science & Technology Agency (JST)	Kuchino, Y (corresponding author), Natl Canc Ctr, Res Inst, Div Biophys, Chuo Ku, Tokyo 1040045, Japan.							Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; Butterfield L, 1997, J BIOL CHEM, V272, P10110; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dong JA, 1997, ONCOGENE, V15, P639, DOI 10.1038/sj.onc.1201237; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Faris M, 1998, J IMMUNOL, V160, P134; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; Khwaja A, 1997, J CELL BIOL, V139, P1017, DOI 10.1083/jcb.139.4.1017; KITANAKA C, 1995, CELL DEATH DIFFER, V2, P123; Lee LF, 1998, J BIOL CHEM, V273, P28253, DOI 10.1074/jbc.273.43.28253; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Nesbit CE, 1998, CELL GROWTH DIFFER, V9, P731; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; PULVERER BJ, 1994, ONCOGENE, V9, P59; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; SETH A, 1993, MOL CELL BIOL, V13, P4125, DOI 10.1128/MCB.13.7.4125; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Sugiyama A, 1999, GENE, V226, P273, DOI 10.1016/S0378-1119(98)00547-2; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899	51	143	162	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32580	32587		10.1074/jbc.274.46.32580	http://dx.doi.org/10.1074/jbc.274.46.32580			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551811	hybrid			2022-12-25	WOS:000083623000011
J	Taylor, JC; Markham, GD				Taylor, JC; Markham, GD			The bifunctional active site of S-adenosylmethionine synthetase - Roles of the active site aspartates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI INORGANIC PYROPHOSPHATASE; ESCHERICHIA-COLI; ALKALINE-PHOSPHATASE; OXYGEN INTERACTIONS; SULFUR-OXYGEN; METHIONINE; BINDING; IONS; COORDINATION; MUTAGENESIS	S-Adenosylmethionine (AdoMet) synthetase catalyzes the biosynthesis of AdoMet in a unique enzymatic reaction. Initially the sulfur of methionine displaces the intact tripolyphosphate chain (PPP;) from ATP, and subsequently PPP, is hydrolyzed to PP, and Pi before product release. The crystal structure of Escherichia coli AdoMet synthetase shows that the active site contains four aspartate residues, Aspartate residues Asp16* and Asp-271 individually provide the sole protein ligand to one of the two required Mg2+ ions (* denotes a residue from a second subunit); aspartates Asp-118 and Asp-238* are proposed to interact with methionine. Each aspartate has been changed to an uncharged asparagine, and the metal binding residues were also changed to alanine, to assess the roles of charge and ligation ability on catalytic efficiency. The resultant enzyme variants all structurally resemble the wild type enzyme as indicated by circular dichroism spectra and are tetramers, However, all have k(cat) reductions of similar to 10(3)-fold in AdoMet synthesis, whereas the MgATP and methionine K-m values change by less than 3- and 8-fold, respectively, In the partial reaction of PPP, hydrolysis, mutants of the Mg2+ binding residues have >700-fold reduced catalytic efficiency (k(cat)/K-m), whereas the D118N and D238*N mutants are impaired less than 35-fold. The catalytic efficiency for PPP, hydrolysis by Mg2+ site mutants is improved by AdoMet, like the wild type enzyme, In contrast AdoMet reduces the catalytic efficiency for PPP, hydrolysis by the D118N and D238*N mutants, indicating that the events involved in AdoMet activation are hindered in these methionyl binding site mutants. Ca2+ uniquely activates the D271A mutant enzyme to 15% of the level of Mg2+, in contrast to the similar to 1% Ca2+ activation of the wild type enzyme. This indicates that the Asp-271 side chain size is a discriminator between the activating ability of Ca2+ and the smaller Mg2+.	Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Markham, GD (corresponding author), Fox Chase Canc Ctr, Inst Canc Res, 7701 Burholme Ave, Philadelphia, PA 19111 USA.				NCI NIH HHS [CA06927] Funding Source: Medline; NIGMS NIH HHS [GM31186] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031186] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Avaeva S, 1996, FEBS LETT, V399, P99, DOI 10.1016/S0014-5793(96)01296-3; Avaeva SM, 1996, FEBS LETT, V392, P91, DOI 10.1016/0014-5793(96)00791-0; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; BISHOP EO, 1981, BIOCHIM BIOPHYS ACTA, V635, P63, DOI 10.1016/0005-2728(81)90007-4; BURLING FT, 1992, J AM CHEM SOC, V114, P2313, DOI 10.1021/ja00033a004; CANTONI GL, 1975, ANNU REV BIOCHEM, V44, P435, DOI 10.1146/annurev.bi.44.070175.002251; CARRELL CJ, 1988, J AM CHEM SOC, V110, P8651, DOI 10.1021/ja00234a011; Chamberlin ME, 1997, AM J HUM GENET, V60, P540; Chamberlin ME, 1996, J CLIN INVEST, V98, P1021, DOI 10.1172/JCI118862; CHIANG PK, 1977, J BIOL CHEM, V252, P4506; CHIFFLET S, 1986, ANAL BIOCHEM, V168, P1; Cleland W W, 1979, Methods Enzymol, V63, P103; Fu ZJ, 1996, J BIOMOL STRUCT DYN, V13, P727, DOI 10.1080/07391102.1996.10508887; Hazelwood S, 1998, AM J MED GENET, V75, P395, DOI 10.1002/(SICI)1096-8628(19980203)75:4<395::AID-AJMG9>3.0.CO;2-P; Katz AK, 1996, J AM CHEM SOC, V118, P5752, DOI 10.1021/ja953943i; Katz AK, 1998, J PHYS CHEM B, V102, P6342, DOI 10.1021/jp9815412; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Markham GD, 1996, STRUCT CHEM, V7, P281, DOI 10.1007/BF02254844; Markham GD, 1999, BIOCHEMISTRY-US, V38, P4433, DOI 10.1021/bi9829579; MARKHAM GD, 1980, J BIOL CHEM, V255, P9082; MARKHAM GD, 1987, J BIOL CHEM, V262, P5609; MARKHAM GD, 1981, J BIOL CHEM, V256, P1903; MARKHAM GD, 1987, J AM CHEM SOC, V109, P599, DOI 10.1021/ja00236a057; Markham GD, 1997, J MOL STRUC-THEOCHEM, V418, P139, DOI 10.1016/S0166-1280(96)05023-3; MARKHAM GD, 1984, BIOCHEMISTRY-US, V23, P470, DOI 10.1021/bi00298a011; Mato JM, 1997, PHARMACOL THERAPEUT, V73, P265, DOI 10.1016/S0163-7258(96)00197-0; MCQUENEY MS, 1995, J BIOL CHEM, V270, P18277, DOI 10.1074/jbc.270.31.18277; MOONWOODY AY, 1996, BIOCHEMISTRY-US, V35, P144; Mudd S. H., 1973, ENZYMES, V8, P121; MUDD SH, 1963, J BIOL CHEM, V238, P2156; MUDD SH, 1963, J BIOL CHEM, V238, P2164; Reczkowski RS, 1998, BIOCHEMISTRY-US, V37, P13499, DOI 10.1021/bi9811011; RECZKOWSKI RS, 1995, J BIOL CHEM, V270, P18484, DOI 10.1074/jbc.270.31.18484; Strater N, 1996, ANGEW CHEM INT EDIT, V35, P2024, DOI 10.1002/anie.199620241; TABOR CW, 1984, ADV ENZYMOL RAMB, V56, P251; Takusagawa F, 1996, J BIOL CHEM, V271, P136, DOI 10.1074/jbc.271.1.136; Takusagawa F, 1996, BIOCHEMISTRY-US, V35, P2586, DOI 10.1021/bi952604z; Tibbitts TT, 1996, J MOL BIOL, V257, P700, DOI 10.1006/jmbi.1996.0195; ZHANG CF, 1993, BIOCHEMISTRY-US, V32, P9866, DOI 10.1021/bi00088a043	39	56	57	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32909	32914		10.1074/jbc.274.46.32909	http://dx.doi.org/10.1074/jbc.274.46.32909			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551856	hybrid			2022-12-25	WOS:000083623000056
J	Schiffer, G; Holtje, JV				Schiffer, G; Holtje, JV			Cloning and characterization of PBP1C, a third member of the multimodular class A penicillin-binding proteins of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; CELL-WALL PEPTIDOGLYCAN; BETA-LACTAM ANTIBIOTICS; MONOFUNCTIONAL GLYCOSYLTRANSFERASE; MUREIN SYNTHESIS; TRANSGLYCOSYLASE; DIVISION; GROWTH; POLYMERIZATION; TRANSPEPTIDASE	All proteins of Escherichia coli that covalently bind penicillin have been cloned except for the penicillin-binding protein (PBP) 1C, For a detailed understanding of the mode of action of beta-lactam antibiotics, cloning of the gene encoding PBP1C was of major importance. Therefore, the structural gene was identified in the E. coli genomic lambda library of Kohara and subcloned, and PBP1C was characterized biochemically. PBP1C is a close homologue to the bifunctional transpeptidases/transglycosylases PBP1A and PBP1B and likewise shows murein polymerizing activity, which can be blocked by the transglycosylase inhibitor moenomycin. Covalently linked to activated Sepharose, PBP1C specifically retained PBP1B and the transpeptidases PBP2 and -3 in addition to the murein hydrolase MltA. The specific interaction with these proteins suggests that PBP1C is assembled into a multienzyme complex consisting of both murein polymerases and hydrolases, Overexpression of PBP1C does not support growth of a PBP1A(tS)/PBP1B double mutant at the restrictive temperature, and PBP1C does not bind to the same variety of penicillin derivatives as PBPs 1A and 1B. Deletion of PBP1C resulted in an altered mode of murein synthesis. It is suggested that PBP1C functions in vivo as a transglycosylase only.	Max Planck Inst Entwicklungsbiol, Biochem Abt, D-72076 Tubingen, Germany	Max Planck Society	Holtje, JV (corresponding author), Max Planck Inst Entwicklungsbiol, Biochem Abt, Spemannstr 35, D-72076 Tubingen, Germany.	joachim-volker.hoeltje@tuebingen.mpg.de						Adam M, 1997, J BACTERIOL, V179, P6005, DOI 10.1128/jb.179.19.6005-6009.1997; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BISHOP RE, 1993, FEMS MICROBIOL LETT, V114, P349, DOI 10.1111/j.1574-6968.1993.tb06597.x; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CASADABAN M, 1980, J MOL BIOL, V13, P179; DEJONGE BLM, 1989, J BACTERIOL, V171, P5783, DOI 10.1128/jb.171.11.5783-5794.1989; DiBerardino M, 1996, FEBS LETT, V392, P184, DOI 10.1016/0014-5793(96)00809-5; EDWARDS DH, 1993, FEMS SYMP, P369; Ghuysen JM, 1996, MICROB DRUG RESIST, V2, P163, DOI 10.1089/mdr.1996.2.163; GLAUNER B, 1988, ANAL BIOCHEM, V172, P451, DOI 10.1016/0003-2697(88)90468-X; GLAUNER B, 1988, J BIOL CHEM, V263, P10088; Goffin C, 1998, MICROBIOL MOL BIOL R, V62, P1079, DOI 10.1128/MMBR.62.4.1079-1093.1998; Goffin C, 1996, J BACTERIOL, V178, P5402, DOI 10.1128/jb.178.18.5402-5409.1996; HARZ H, 1990, ANAL BIOCHEM, V190, P120, DOI 10.1016/0003-2697(90)90144-X; HENDERSON TA, 1995, J BACTERIOL, V177, P2074, DOI 10.1128/jb.177.8.2074-2079.1995; Holtje JV, 1996, MICROBIOL-SGM, V142, P1911, DOI 10.1099/13500872-142-8-1911; Holtje JV, 1998, MICROBIOL MOL BIOL R, V62, P181; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; ISHINO F, 1980, BIOCHEM BIOPH RES CO, V97, P287, DOI 10.1016/S0006-291X(80)80166-5; KATO J, 1985, MOL GEN GENET, V200, P272, DOI 10.1007/BF00425435; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KRAUS W, 1987, J BACTERIOL, V169, P3099, DOI 10.1128/jb.169.7.3099-3103.1987; KULAKAUSKAS S, 1991, J BACTERIOL, V173, P2633, DOI 10.1128/jb.173.8.2633-2638.1991; LABIA R, 1985, J ANTIMICROB CHEMOTH, V15, P9, DOI 10.1093/jac/15.1.9; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; MATSUHASHI M, 1990, RES MICROBIOL, V141, P89, DOI 10.1016/0923-2508(90)90101-U; Matsuhashi M., 1994, BACTERIAL CELL WALL, P55; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P111; NAKAGAWA J, 1984, J BIOL CHEM, V259, P3937; Paik J, 1997, J BACTERIOL, V179, P4061, DOI 10.1128/jb.179.12.4061-4065.1997; PARK JT, 1973, BIOCHEM BIOPH RES CO, V51, P863, DOI 10.1016/0006-291X(73)90006-5; Park JT, 1996, ESCHERICHIA COLI SAL, P48; ROMEIS T, 1994, J BIOL CHEM, V269, P21603; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHALLER K, 1982, J BACTERIOL, V152, P994; SCHMIDT LS, 1981, J BACTERIOL, V145, P632, DOI 10.1128/JB.145.1.632-637.1981; SCHWARZ U, 1981, FEMS MICROBIOL LETT, V10, P107, DOI 10.1111/j.1574-6968.1981.tb06217.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH RF, 1992, PROTEIN ENG, V5, P35, DOI 10.1093/protein/5.1.35; SPRATT BG, 1975, P NATL ACAD SCI USA, V72, P2999, DOI 10.1073/pnas.72.8.2999; SUZUKI H, 1978, P NATL ACAD SCI USA, V75, P664, DOI 10.1073/pnas.75.2.664; SUZUKI H, 1980, FEBS LETT, V110, P245, DOI 10.1016/0014-5793(80)80083-4; TOMASZ A, 1986, REV INFECT DIS, V8, pS260; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANHEIJENOORT J, 1988, ANTIBIOTIC INHIBITIO, P549; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; Vollmer W, 1999, J BIOL CHEM, V274, P6726, DOI 10.1074/jbc.274.10.6726; vonRechenberg M, 1996, MICROB DRUG RESIST, V2, P155, DOI 10.1089/mdr.1996.2.155; WAXMAN DJ, 1983, ANNU REV BIOCHEM, V52, P825, DOI 10.1146/annurev.bi.52.070183.004141; WIENTJES FB, 1991, RES MICROBIOL, V142, P333, DOI 10.1016/0923-2508(91)90049-G; YOUSIF SY, 1985, J GEN MICROBIOL, V131, P2839	54	78	80	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32031	32039		10.1074/jbc.274.45.32031	http://dx.doi.org/10.1074/jbc.274.45.32031			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542235	hybrid			2022-12-25	WOS:000083532100043
J	Wang, J; Zhou, J; Bondy, CA				Wang, J; Zhou, J; Bondy, CA			Igf1 promotes longitudinal bone growth by insulin-like actions augmenting chondrocyte hypertrophy	FASEB JOURNAL			English	Article						glucose transporter; IGF action; insulin; proliferation; epiphysis; short stature	FACTOR-I; SIGNAL-TRANSDUCTION; PLATE; HORMONE; MICE; EXPRESSION; CARTILAGE; RECEPTOR; ZONES; RATS	Longitudinal bone growth, and hence stature, are functions of growth plate chondrocyte proliferation and hypertrophy, Insulin-like growth factor 1 (Igf1) is reputed to augment longitudinal bone growth by stimulating growth plate chondrocyte proliferation. In this study, however, we demonstrate that chondrocyte numbers and proliferation are normal in Igf1 null mice despite a 35% reduction in the rate of long bone growth. Igf1 null hypertrophic chondrocytes differentiate normally in terms of expressing specialized proteins such as collagen X and alkaline phosphatase, but are smaller than wildtype at all levels of the hypertrophic zone, The terminal hypertrophic chondrocytes, which form the scaffold on which long bone growth extends, are reduced in linear dimension by 30% in Igf1 null mice, accounting for most of their decreased longitudinal growth, The expression of the insulin-sensitive glucose transporter, GLUT4, is significantly decreased and the insulin-regulated enzyme glycogen synthase kinase 3 beta (GSK3) is hypo-phosphorylated in ISf1 null chondrocytes, Glycogen levels were significantly decreased and ribosomal RNA levels were reduced by almost 75% in Igf1 null chondrocytes, These data suggest that Igf1 promotes longitudinal bone growth by 'insulin-like' anabolic actions which augment chondrocyte hypertrophy.-Wang, J., Zhou, J., Bendy, C. A. Igf1 promotes longitudinal bone growth by insulin-like actions augmenting chondrocyte hypertrophy.	NICHD, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Bondy, CA (corresponding author), NICHD, Dev Endocrinol Branch, NIH, Bldg 10,Rm 10N262,10 Ctr Dr 1862, Bethesda, MD 20892 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000628] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000628] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BREUR GJ, 1991, J ORTHOPAED RES, V9, P348, DOI 10.1002/jor.1100090306; Breur GJ, 1997, CALCIFIED TISSUE INT, V61, P418, DOI 10.1007/s002239900358; BRIGHTON CT, 1969, J BONE JOINT SURG AM, VA 51, P1383, DOI 10.2106/00004623-196951070-00018; BRIGHTON CT, 1983, J BONE JOINT SURG AM, V65, P663, DOI 10.2106/00004623-198365050-00012; Cheng CM, 1998, J NEUROSCI, V18, P5673; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; DAUGHADAY WH, 1972, NATURE, V235, P107, DOI 10.1038/235107a0; DEMEYTS P, 1994, HORM RES, V42, P152, DOI 10.1159/000184188; GERSTENFELD LC, 1991, J CELL BIOL, V112, P501, DOI 10.1083/jcb.112.3.501; GRANT WT, 1985, J BIOL CHEM, V260, P3798; HUNZIKER EB, 1989, J PHYSIOL-LONDON, V414, P55, DOI 10.1113/jphysiol.1989.sp017676; HUNZIKER EB, 1994, J CLIN INVEST, V93, P1078, DOI 10.1172/JCI117058; HUNZIKER EB, 1987, J BONE JOINT SURG AM, V69A, P162, DOI 10.2106/00004623-198769020-00002; KEMBER NF, 1971, NATURE, V229, P428, DOI 10.1038/229428a0; Kwan KM, 1997, J CELL BIOL, V136, P459, DOI 10.1083/jcb.136.2.459; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; OHLSSON C, 1992, P NATL ACAD SCI USA, V89, P9826, DOI 10.1073/pnas.89.20.9826; Ohlsson C, 1998, ENDOCR REV, V19, P55, DOI 10.1210/er.19.1.55; POWELLBRAXTON L, 1993, GENE DEV, V7, P2609, DOI 10.1101/gad.7.12b.2609; PRITCHERD JJ, 1952, J ANAT, V8, P259; Roberts J, 1997, SCIENCE, V278, P2073, DOI 10.1126/science.278.5346.2073; SHINAR DM, 1993, ENDOCRINOLOGY, V132, P1158, DOI 10.1210/en.132.3.1158; WALKER KVR, 1972, CELL TISSUE KINET, V5, P409, DOI 10.1111/j.1365-2184.1972.tb00379.x; WANG EM, 1995, ENDOCRINOLOGY, V136, P2741, DOI 10.1210/en.136.6.2741; WILSON CM, 1995, FEBS LETT, V368, P19, DOI 10.1016/0014-5793(95)00589-2; Woods KA, 1996, NEW ENGL J MED, V335, P1363, DOI 10.1056/NEJM199610313351805	27	183	188	1	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1999	13	14					1985	1990		10.1096/fasebj.13.14.1985	http://dx.doi.org/10.1096/fasebj.13.14.1985			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544181	Bronze			2022-12-25	WOS:000083660700010
J	Boudot, C; Petitfrere, E; Kadri, Z; Chretien, S; Mayeux, P; Haye, B; Billat, C				Boudot, C; Petitfrere, E; Kadri, Z; Chretien, S; Mayeux, P; Haye, B; Billat, C			Erythropoietin induces glycosylphosphatidylinositol hydrolysis - Possible involvement of phospholipase C-gamma(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; ERYTHROID PROGENITOR CELLS; PROTEIN-TYROSINE KINASE; EPIDERMAL GROWTH-FACTOR; GLYCOSYL-PHOSPHATIDYLINOSITOL; SIGNAL-TRANSDUCTION; INOSITOLPHOSPHATE-GLYCAN; TRYPANOSOMA-BRUCEI; PLASMA-MEMBRANES; INSULIN ACTION	We showed that erythropoietin induced rapid glycosylphosphatidylinositol (GPI) hydrolysis and tyrosine phosphorylation of phospholipase C (PLC)-gamma(2) in FDC-P1 cells transfected with the wild-type erythropoietin-receptor. Erythropoietin-induced tyrosine phosphorylation of PLC-gamma(2) was time- and dose-dependent. By using FDC-P1 cells transfected with an erythropoietin receptor devoid of tyrosine residues, we showed that both effects required the tyrosine residues of intracellular domain on the erythropoietin receptor. Erythropoietin-activated PLC-gamma(2) hydrolyzed purified [H-3]GPI indicating that GPI hydrolysis and PLC-gamma(2) activation under erythropoietin stimulation were correlated. Results obtained on FDC-P1 cells transfected with erythropoietin receptor mutated on tyrosine residues suggest that tyrosines 343, 401, 464, and/or 479 are involved in erythropoietin-induced GPI hydrolysis and tyrosine phosphorylation of PLC-gamma(2), whereas tyrosines 429 and/or 431 seem to be involved in an inhibition of both effects. Thus, our results suggest that erythropoietin regulates C;PI hydrolysis via tyrosine phosphorylation of its receptor and PLC-gamma(2) activation.	Univ Reims, UFR Sci Exactes & Nat, IFR Biomol 53, CNRS UPRESA 6021,Lab Biochim, F-51687 Reims 2, France; Inst Natl Transfus Sanguine, F-75014 Paris, France; Univ Paris 05, Hop Cochin, INSERM U363, Inst Cochin Genet Mol, F-75014 Paris, France	Universite de Reims Champagne-Ardenne; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Billat, C (corresponding author), Univ Reims, UFR Sci Exactes & Nat, IFR Biomol 53, CNRS UPRESA 6021,Lab Biochim, BP 1039, F-51687 Reims 2, France.		Chretien, Stany/M-5166-2018					Bourette RP, 1997, EMBO J, V16, P5880, DOI 10.1093/emboj/16.19.5880; BULOW R, 1986, J BIOL CHEM, V261, P1918; BUTIKOFER P, 1993, J BIOL CHEM, V268, P17794; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CLEMENTE R, 1995, CELL SIGNAL, V7, P411, DOI 10.1016/0898-6568(95)00002-7; Damen JE, 1996, EXP HEMATOL, V24, P1455; Devemy E, 1997, CELL SIGNAL, V9, P41, DOI 10.1016/S0898-6568(96)00095-2; DEVEMY E, 1994, CELL SIGNAL, V6, P523, DOI 10.1016/0898-6568(94)90006-X; DUSANTERFOURT I, 1992, J BIOL CHEM, V267, P10670; EARDLEY DD, 1991, SCIENCE, V251, P78, DOI 10.1126/science.1824727; FARESE RV, 1988, BIOCHEM BIOPH RES CO, V156, P1346, DOI 10.1016/S0006-291X(88)80780-0; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FOUCHIER F, 1990, BIOCHEM J, V269, P321, DOI 10.1042/bj2690321; FOX JA, 1987, P NATL ACAD SCI USA, V84, P2663, DOI 10.1073/pnas.84.9.2663; Gaulton G N, 1994, Semin Immunol, V6, P97, DOI 10.1006/smim.1994.1014; GAULTON GN, 1988, CELL, V53, P963, DOI 10.1016/S0092-8674(88)90509-0; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; HERELD D, 1986, J BIOL CHEM, V261, P3813; Jones DR, 1997, BIOCHEM BIOPH RES CO, V233, P432, DOI 10.1006/bbrc.1997.6475; Jones DR, 1998, INT J BIOCHEM CELL B, V30, P313, DOI 10.1016/S1357-2725(97)00144-1; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOJIMA I, 1990, J BIOL CHEM, V265, P16846; KOURY MJ, 1992, EUR J BIOCHEM, V210, P649, DOI 10.1111/j.1432-1033.1992.tb17466.x; KRANTZ SB, 1991, BLOOD, V77, P419; KUPPE A, 1989, J BACTERIOL, V171, P6077, DOI 10.1128/jb.171.11.6077-6083.1989; MACAULAY SL, 1990, CELL SIGNAL, V2, P9; MARTIN TR, 1980, J CLIN GASTROENTEROL, V2, P21, DOI 10.1097/00004836-198003000-00004; MASONGARCIA M, 1992, AM J PHYSIOL, V262, pC1197; MATO JM, 1987, J BIOL CHEM, V262, P2131; MATO JM, 1998, BIOCHEM BIOPH RES CO, V146, P764; MERIDA I, 1990, P NATL ACAD SCI USA, V87, P9421, DOI 10.1073/pnas.87.23.9421; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIURA O, 1994, BLOOD, V84, P1501; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; QUELLE FW, 1991, J BIOL CHEM, V266, P609; Ralton JE, 1998, J BIOL CHEM, V273, P4245, DOI 10.1074/jbc.273.7.4245; REN HY, 1994, J BIOL CHEM, V269, P19633; REPRESA J, 1991, P NATL ACAD SCI USA, V88, P8016, DOI 10.1073/pnas.88.18.8016; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; SALTIEL AR, 1986, P NATL ACAD SCI USA, V83, P5793, DOI 10.1073/pnas.83.16.5793; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHNEIDER P, 1993, ANAL BIOCHEM, V210, P106, DOI 10.1006/abio.1993.1158; SUZUKI S, 1992, DIABETES, V41, P1373, DOI 10.2337/diabetes.41.11.1373; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; VarelaNieto I, 1996, COMP BIOCHEM PHYS B, V115, P223, DOI 10.1016/0305-0491(96)00087-9; VILA MD, 1990, BIOCHEMISTRY-US, V29, P8735, DOI 10.1021/bi00489a033; Villalba M, 1990, GROWTH FACTORS, V2, P91, DOI 10.3109/08977199009071496; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	50	16	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					33966	33972		10.1074/jbc.274.48.33966	http://dx.doi.org/10.1074/jbc.274.48.33966			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567359	hybrid			2022-12-25	WOS:000083857500024
J	Schriever, AM; Friedrich, T; Pusch, M; Jentsch, TJ				Schriever, AM; Friedrich, T; Pusch, M; Jentsch, TJ			CLC chloride channels in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ELEGANS; GENE-TRANSFER; MESSENGER-RNA; MUTATIONS; MYOTONIA; ORGANIZATION; EXPRESSION; DEPENDENCE; SEQUENCE; DOMINANT	The genome of the nematode Caenorhabditis elegans encodes six putative chloride channels (CeCLC-1 through CeCLC-6) that represent all three known branches of the mammalian CLC gene family, Using promoter fragments to drive the expression of the green fluorescent protein, CeCLC-2, -3, and -4 expression was studied in transgenic C. elegans, CeCLC-4 was specifically expressed in the large H-shaped excretory cell, where it was co-expressed with CeCLC-3, which is also expressed in other cells, including neurons, muscles, and epithelial cells. Also, CeCLC-2 was expressed in several cells of the nervous system, intestinal cells, and vulval muscle cells, Similar to mammalian CLC proteins, only two nematode CLC channels elicited detectable plasma membrane currents in Xenopus oocytes, CeCLC-3 currents were inwardly rectifying and were activated by positive prepulses, Its complex gating behavior can be explained by two gates, at least one of which depends on extracellular anions, In this respect it resembles some mammalian chloride channels with which it also shares a preference of chloride over iodide. C. elegans thus provides new opportunities to understand common mechanisms underlying structure and function in CLC channels and will allow for a genetic dissection of chloride channels in this simple model organism.	Univ Hamburg, Zentrum Mol Neurobiol Hamburg, D-20246 Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf	Jentsch, TJ (corresponding author), Univ Hamburg, Zentrum Mol Neurobiol Hamburg, Martinistr 85, D-20246 Hamburg, Germany.	Jentsch@plexus.uke.uni-hamburg.de	Friedrich, Thomas/AAA-3418-2022	Jentsch, Thomas/0000-0002-3509-2553; Pusch, Michael/0000-0002-8644-8847				Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; BROEKS A, 1995, EMBO J, V14, P1858, DOI 10.1002/j.1460-2075.1995.tb07178.x; BYERLY L, 1979, J PHYSIOL-LONDON, V288, P263; *C EL SEQ CONS, 1998, SCIENCE, V282, P2012; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chen TY, 1996, J GEN PHYSIOL, V108, P237, DOI 10.1085/jgp.108.4.237; Chu SJ, 1997, NUCLEIC ACIDS RES, V25, P4153, DOI 10.1093/nar/25.20.4153; Davis MW, 1995, J NEUROSCI, V15, P8408; Fahlke C, 1998, NATURE, V394, P687, DOI 10.1038/29319; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Friedrich T, 1999, J BIOL CHEM, V274, P896, DOI 10.1074/jbc.274.2.896; Goodman MB, 1998, NEURON, V20, P763, DOI 10.1016/S0896-6273(00)81014-4; GRANATO M, 1994, NUCLEIC ACIDS RES, V22, P1762, DOI 10.1093/nar/22.9.1762; Gunther W, 1998, P NATL ACAD SCI USA, V95, P8075, DOI 10.1073/pnas.95.14.8075; Hechenberger M, 1996, J BIOL CHEM, V271, P33632, DOI 10.1074/jbc.271.52.33632; Jentsch TJ, 1999, PFLUG ARCH EUR J PHY, V437, P783, DOI 10.1007/s004240050847; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; Jordt SE, 1997, EMBO J, V16, P1582, DOI 10.1093/emboj/16.7.1582; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; Lee RYN, 1997, EMBO J, V16, P6066, DOI 10.1093/emboj/16.20.6066; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; LORENZ C, 1994, HUM MOL GENET, V3, P941, DOI 10.1093/hmg/3.6.941; Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362; Ludewig U, 1996, NATURE, V383, P340, DOI 10.1038/383340a0; Matsumura Y, 1999, NAT GENET, V21, P95, DOI 10.1038/5036; MCINTIRE SL, 1993, NATURE, V364, P337, DOI 10.1038/364337a0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Middleton RE, 1996, NATURE, V383, P337, DOI 10.1038/383337a0; NELSON FK, 1984, J EXP ZOOL, V231, P45, DOI 10.1002/jez.1402310107; Ponting CP, 1997, J MOL MED-JMM, V75, P160; PUSCH M, 1995, NATURE, V373, P527, DOI 10.1038/373527a0; Pusch M, 1999, J PHYSIOL-LONDON, V515, P341, DOI 10.1111/j.1469-7793.1999.341ac.x; REINER DJ, 1995, J NEUROSCI, V15, P6094; Rychkov GY, 1996, J PHYSIOL-LONDON, V497, P423, DOI 10.1113/jphysiol.1996.sp021778; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Saviane C, 1999, J GEN PHYSIOL, V113, P457, DOI 10.1085/jgp.113.3.457; SchmidtRose T, 1997, P NATL ACAD SCI USA, V94, P7633, DOI 10.1073/pnas.94.14.7633; Simon DB, 1997, NAT GENET, V17, P171, DOI 10.1038/ng1097-171; Staley K, 1996, NEURON, V17, P543, DOI 10.1016/S0896-6273(00)80186-5; STEINMEYER K, 1994, EMBO J, V13, P737, DOI 10.1002/j.1460-2075.1994.tb06315.x; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0	42	46	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34238	34244		10.1074/jbc.274.48.34238	http://dx.doi.org/10.1074/jbc.274.48.34238			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567397	hybrid			2022-12-25	WOS:000083857500062
J	Travis, AJ; Sui, DX; Riedel, KD; Hofmann, NR; Moss, SB; Wilson, JE; Kopf, GS				Travis, AJ; Sui, DX; Riedel, KD; Hofmann, NR; Moss, SB; Wilson, JE; Kopf, GS			A novel NH2-terminal, nonhydrophobic motif targets a male germ cell-specific hexokinase to the endoplasmic reticulum and plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORIN-BINDING DOMAIN; RAT-BRAIN HEXOKINASE; FIBROUS SHEATH; MOUSE SPERM; PROTEIN; MITOCHONDRIA; SPERMATOZOA; LACKING; TRANSLOCATION; LOCALIZATION	Although three germ cell-specific transcripts of type 1 hexokinase exist in murine male germ cells, only one form, HK1-sc, is found at the protein level. This single isoform localizes to three distinct structures in mouse spermatozoa: the membranes of the head, the mitochondria in the midpiece, and the fibrous sheath in the flagellum (Travis, A. J., Foster, J. A. Rosenbaum, N. A., Visconti, P. E., Gerton, G. L., Kopf, G. S., and Moss, S. B. (1998) Mol. Biol, Cell 9, 263-276), The mechanism by which one protein is targeted to multiple sites within this highly polarized cell poses important questions of protein targeting. Because the study of protein targeting in germ cells is hampered by the lack of established cell lines in culture, constructs containing different domains of the germ cell-specific hexokinase transcripts were linked to a green fluorescent protein and transfected into hexokinase-deficient M+R42 cells. Constructs containing a nonhydrophobic, germ cell-specific domain, present at the amino terminus of the HK1-SC protein, were targeted to the endoplasmic reticulum and the plasma membrane. Mutational analysis of this domain demonstrated that a complex motif, PKIRP-PLTE (with essential residues italicized), represented a novel endoplasmic reticulum-targeting motif, Constructs based on another germ cell-specific hexokinase transcript, HK1-sa, demonstrated the specific proteolytic removal of an amino-terminal domain, resulting in a protein product identical to HK1-SC, Such processing might constitute a regulatory mechanism governing the spatial and/or temporal expression of the protein.	Univ Penn, Med Ctr, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	University of Pennsylvania; Pennsylvania Medicine; Michigan State University	Kopf, GS (corresponding author), Univ Penn, Med Ctr, Ctr Res Reprod & Womens Hlth, Rm 1315,Biomed Res Bldg 2,421 Curie Blvd, Philadelphia, PA 19104 USA.			Hofmann, Nancy/0000-0001-9504-1152	NICHD NIH HHS [T32HD07305, HD-33052] Funding Source: Medline; NIGMS NIH HHS [5T32GM07170] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007305, R01HD033052] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007170] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Addya S, 1997, J CELL BIOL, V139, P589, DOI 10.1083/jcb.139.3.589; ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; CARRERA A, 1994, DEV BIOL, V165, P272, DOI 10.1006/dbio.1994.1252; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; FAIK P, 1989, BIOCHEM J, V260, P153, DOI 10.1042/bj2600153; FAWCETT DW, 1979, SPERMATOZOON MATURAT; GELB BD, 1992, P NATL ACAD SCI USA, V89, P202, DOI 10.1073/pnas.89.1.202; Goldberg E, 1975, Methods Enzymol, V41, P318; Huang LJS, 1999, J CELL BIOL, V145, P951, DOI 10.1083/jcb.145.5.951; KALAB P, 1994, J BIOL CHEM, V269, P3810; Katzen H M, 1967, Adv Enzyme Regul, V5, P335, DOI 10.1016/0065-2571(67)90025-8; KATZEN HM, 1968, ANN NY ACAD SCI, V151, P351, DOI 10.1111/j.1749-6632.1968.tb11900.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; Mori C, 1996, MOL REPROD DEV, V44, P14, DOI 10.1002/(SICI)1098-2795(199605)44:1<14::AID-MRD2>3.0.CO;2-W; MORI C, 1993, BIOL REPROD, V49, P191, DOI 10.1095/biolreprod49.2.191; Mori C, 1998, MOL REPROD DEV, V49, P374, DOI 10.1002/(SICI)1098-2795(199804)49:4&lt;374::AID-MRD4&gt;3.0.CO;2-K; Murakami K, 1997, BLOOD, V89, P762, DOI 10.1182/blood.V89.3.762; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; PEDLEY KC, 1993, BIOCHEM J, V291, P515, DOI 10.1042/bj2910515; POLAKIS PG, 1985, ARCH BIOCHEM BIOPHYS, V236, P328, DOI 10.1016/0003-9861(85)90633-2; Saberan-Djoneidi D, 1998, J BIOL CHEM, V273, P3909, DOI 10.1074/jbc.273.7.3909; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SMITH AD, 1991, ARCH BIOCHEM BIOPHYS, V287, P359, DOI 10.1016/0003-9861(91)90490-A; STOREY BT, 1977, BIOL REPROD, V16, P549; Sui DX, 1997, ARCH BIOCHEM BIOPHYS, V345, P111, DOI 10.1006/abbi.1997.0241; Travis AJ, 1998, MOL BIOL CELL, V9, P263, DOI 10.1091/mbc.9.2.263; Visconti PE, 1996, MOL REPROD DEV, V43, P82; XIE GC, 1988, ARCH BIOCHEM BIOPHYS, V267, P803, DOI 10.1016/0003-9861(88)90090-2	30	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34467	34475		10.1074/jbc.274.48.34467	http://dx.doi.org/10.1074/jbc.274.48.34467			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567428	hybrid			2022-12-25	WOS:000083857500093
J	Arystarkhova, E; Wetzel, RK; Asinovski, NK; Sweadner, KJ				Arystarkhova, E; Wetzel, RK; Asinovski, NK; Sweadner, KJ			The gamma subunit modulates Na+ and K+ affinity of the renal Na,K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; PUMP ACTIVITY; ATPASE; ISOFORMS; NA+,K+-ATPASE; POLYPEPTIDE; EXPRESSION; COMPONENT; INSULIN; OUABAIN	The Na+,K+F-ATPase catalyzes the active transport of ions. It has two necessary subunits, alpha and beta, but in kidney it is also associated with a 7.4-kDa protein, the gamma subunit. Stable transfection was used to determine the effect of gamma on Na,K-ATPase properties. When isolated from either kidney or transfected cells, alpha beta gamma had lower affinities for both Na+ and K-_ than alpha beta. A post-translational modification of gamma selectively eliminated the effect on Naf affinity, suggesting three configurations (alpha beta, alpha beta gamma, and alpha beta gamma*) conferring different stable properties to Na,H-ATPase, In the nephron, segment-specific differences in Na+ affinity have been reported that cannot be explained by the known alpha and beta subunit isoforms of Na,K-ATPase, Immunofluorescence was used to detect gamma in rat renal cortex. Cortical ascending limb and same cortical collecting tubules lacked gamma, correlating with higher Na+ affinities in those segments reported in the literature. Selective expression in different segments of the nephron is consistent with a modulatory role for the gamma subunit in renal physiology.	Massachusetts Gen Hosp, Ctr Neurosci, Lab Membrane Biol, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Sweadner, KJ (corresponding author), Massachusetts Gen Hosp, Ctr Neurosci, Lab Membrane Biol, 149-6118,149 13th St, Charlestown, MA 02129 USA.	sweadner@helix.mgh.harvard.edu			NHLBI NIH HHS [HL36271] Funding Source: Medline; NINDS NIH HHS [NS27653] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036271] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027653] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARYSTARKHOVA E, 1995, J BIOL CHEM, V270, P8785, DOI 10.1074/jbc.270.15.8785; Arystarkhova E, 1996, J BIOL CHEM, V271, P23407, DOI 10.1074/jbc.271.38.23407; BARLETBAS C, 1993, J BIOL CHEM, V268, P11512; BAS CB, 1990, AM J PHYSIOL, V259, pF246; Beguin P, 1997, EMBO J, V16, P4250, DOI 10.1093/emboj/16.14.4250; Bertorello AM, 1995, NEWS PHYSIOL SCI, V10, P253; BIZZOZERO OA, 1995, METHOD ENZYMOL, V250, P361; Blanco G, 1998, AM J PHYSIOL-RENAL, V275, pF633, DOI 10.1152/ajprenal.1998.275.5.F633; BORNSTEIN P, 1970, BIOCHEMISTRY-US, V9, P2408, DOI 10.1021/bi00814a004; BuffinMeyer B, 1996, J PHYSIOL-LONDON, V490, P623, DOI 10.1113/jphysiol.1996.sp021172; DOUCET A, 1992, KIDNEY INT, V41, pS118; EWART HS, 1995, AM J PHYSIOL, V38, pC295; FARMAN N, 1991, AM J PHYSIOL, V260, pC468, DOI 10.1152/ajpcell.1991.260.3.C468; FERAILLE E, 1994, AM J PHYSIOL, V267, pF55, DOI 10.1152/ajprenal.1994.267.1.F55; FERAILLE E, 1995, PFLUG ARCH EUR J PHY, V430, P205, DOI 10.1007/BF00374651; FERAILLE E, 1995, J PHYSIOL-LONDON, V488, P171, DOI 10.1113/jphysiol.1995.sp020955; FORBUSH B, 1978, BIOCHEMISTRY-US, V17, P3667, DOI 10.1021/bi00610a037; Giebisch G, 1998, AM J PHYSIOL-RENAL, V274, pF817, DOI 10.1152/ajprenal.1998.274.5.F817; HARDWICKE PMD, 1981, BIOCHEM BIOPH RES CO, V102, P250, DOI 10.1016/0006-291X(81)91514-X; Jorgensen P L, 1974, Methods Enzymol, V32, P277; MCDONOUGH AA, 1994, AM J PHYSIOL-CELL PH, V267, pC901, DOI 10.1152/ajpcell.1994.267.4.C901; MERCER RW, 1993, J CELL BIOL, V121, P579, DOI 10.1083/jcb.121.3.579; Minor NT, 1998, P NATL ACAD SCI USA, V95, P6521, DOI 10.1073/pnas.95.11.6521; Or E, 1996, BIOCHEMISTRY-US, V35, P6853, DOI 10.1021/bi960093q; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHEINERBOBIS G, 1994, BBA-BIOMEMBRANES, V1193, P226, DOI 10.1016/0005-2736(94)90157-0; Therien AG, 1997, J BIOL CHEM, V272, P32628, DOI 10.1074/jbc.272.51.32628; Therien AG, 1999, J BIOL CHEM, V274, P12252, DOI 10.1074/jbc.274.18.12252; TUMLIN JA, 1994, AM J PHYSIOL, V266, pF240, DOI 10.1152/ajprenal.1994.266.2.F240	29	173	178	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33183	33185		10.1074/jbc.274.47.33183	http://dx.doi.org/10.1074/jbc.274.47.33183			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559186	hybrid			2022-12-25	WOS:000083745200002
J	Cicchetti, G; Maurer, P; Wagener, P; Kocks, C				Cicchetti, G; Maurer, P; Wagener, P; Kocks, C			Actin and phosphoinositide binding by the ActA protein of the bacterial pathogen Listeria monocytogenes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE-RICH REGION; BARBED ENDS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; SIGNAL-TRANSDUCTION; FILAMENT NUCLEATION; SECONDARY STRUCTURE; SURFACE PROTEIN; LIPID PRODUCTS; TAIL FORMATION; HIGH-AFFINITY	The surface protein ActA of the pathogenic bacterium Listeria monocytogenes induces actin-driven movement of bacteria in the cytoplasm of infected host cells and serves as a model for actin-based motility in general. We generated and purified soluble recombinant fragments of ActA and assessed their ability to interact with the acidic phospholipids phosphatidylinositol 4,5-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate, both implicated in the regulation of actin polymerization. Purified ActA consisted of biologically active, elongated molecules with an alpha-helix and beta-sheet content of 11 and 32%, respectively. In the presence of either phosphatidylinositol 4,5-bisphosphate or phosphatidylinositol 3,4,5-trisphosphate, but not phosphatidylcholine, ActA molecules underwent a structural change that raised the alpha-helix content to 19% and lowered the beta-sheet content to 27%. Go-sedimentation experiments with phosphatidylcholine vesicles containing different acidic phospholipids demonstrated that ActA binds preferentially to D-3 phosphoinositides. The D-3 phosphoinositide binding activity was mapped to a small subregion in the N-terminal domain of ActA. This subregion comprised 19 amino acids and showed homology to cecropins. In addition, we found that amino acids 33 to 74 of ActA mediated actin binding by the whole, folded ActA molecule. These findings shed new light on ActA function.	Univ Cologne, Inst Genet, D-50674 Cologne, Germany; Univ Cologne, Med Einrichtungen, Inst Biochem, D-50931 Cologne, Germany	University of Cologne; University of Cologne	Kocks, C (corresponding author), Univ Cologne, Inst Genet, Zulpicher Str 47, D-50674 Cologne, Germany.			Cicchetti, Gregor/0000-0002-3984-3756				AlvarezDominguez C, 1997, INFECT IMMUN, V65, P78; AULLO P, 1993, EMBO J, V12, P921, DOI 10.1002/j.1460-2075.1993.tb05733.x; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; Bechinger B, 1997, J MEMBRANE BIOL, V156, P197, DOI 10.1007/s002329900201; BEYERT N, 1994, NUCLEIC ACIDS RES, V22, P1643, DOI 10.1093/nar/22.9.1643; Bi EF, 1999, CURR BIOL, V9, pR160, DOI 10.1016/S0960-9822(99)80102-X; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; Cameron LA, 1999, P NATL ACAD SCI USA, V96, P4908, DOI 10.1073/pnas.96.9.4908; Coligan JE, 1995, CURRENT PROTOCOLS PR; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; Cossart P, 1998, EMBO J, V17, P3797, DOI 10.1093/emboj/17.14.3797; David V, 1998, J CELL SCI, V111, P2877; DiNubile MJ, 1997, CELL MOTIL CYTOSKEL, V37, P211, DOI 10.1002/(SICI)1097-0169(1997)37:3<211::AID-CM3>3.0.CO;2-9; DOMANN E, 1992, EMBO J, V11, P1981, DOI 10.1002/j.1460-2075.1992.tb05252.x; FRIEDERICH E, 1995, EMBO J, V14, P2731, DOI 10.1002/j.1460-2075.1995.tb07274.x; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOUIN E, 1995, INFECT IMMUN, V63, P2729, DOI 10.1128/IAI.63.7.2729-2737.1995; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HENIKOFF S, 1991, NUCLEIC ACIDS RES, V19, P6565, DOI 10.1093/nar/19.23.6565; Herrmann H, 1996, J MOL BIOL, V264, P933, DOI 10.1006/jmbi.1996.0688; Ireton K, 1996, SCIENCE, V274, P780, DOI 10.1126/science.274.5288.780; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; KOCKS C, 1995, MOL MICROBIOL, V18, P413, DOI 10.1111/j.1365-2958.1995.mmi_18030413.x; LASA I, 1995, MOL MICROBIOL, V18, P425, DOI 10.1111/j.1365-2958.1995.mmi_18030425.x; Lasa I, 1997, EMBO J, V16, P1531, DOI 10.1093/emboj/16.7.1531; Lasa I, 1998, BBA-MOL CELL RES, V1402, P217, DOI 10.1016/S0167-4889(98)00009-3; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; Lu PJ, 1996, BIOCHEMISTRY-US, V35, P14027, DOI 10.1021/bi961878z; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; MARCHAND JB, 1995, J CELL BIOL, V130, P331, DOI 10.1083/jcb.130.2.331; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Missy K, 1998, J BIOL CHEM, V273, P30279, DOI 10.1074/jbc.273.46.30279; Mourrain P, 1997, P NATL ACAD SCI USA, V94, P10034, DOI 10.1073/pnas.94.19.10034; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; Purich DL, 1997, BIOCHEM BIOPH RES CO, V231, P686, DOI 10.1006/bbrc.1997.6158; RAGHUNATHAN V, 1992, FEBS LETT, V297, P46, DOI 10.1016/0014-5793(92)80324-A; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; Roth MG, 1999, TRENDS CELL BIOL, V9, P174, DOI 10.1016/S0962-8924(99)01535-4; RUHNAU K, 1989, J MOL BIOL, V210, P141, DOI 10.1016/0022-2836(89)90296-9; RUPPERT C, 1993, J CELL BIOL, V120, P1393, DOI 10.1083/jcb.120.6.1393; SMITH GA, 1995, MOL MICROBIOL, V17, P945, DOI 10.1111/j.1365-2958.1995.mmi_17050945.x; Smith GA, 1996, J CELL BIOL, V135, P647, DOI 10.1083/jcb.135.3.647; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Thain A, 1996, TRENDS GENET, V12, P209, DOI 10.1016/S0168-9525(96)90022-0; THERIOT JA, 1994, CELL, V76, P505, DOI 10.1016/0092-8674(94)90114-7; TILNEY LG, 1990, J CELL BIOL, V111, P2979, DOI 10.1083/jcb.111.6.2979; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; Welch MD, 1997, NATURE, V385, P265, DOI 10.1038/385265a0; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; Xian WJ, 1995, BIOPHYS J, V69, P2695, DOI 10.1016/S0006-3495(95)80140-2; Yarar D, 1999, CURR BIOL, V9, P555, DOI 10.1016/S0960-9822(99)80243-7	53	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33616	33626		10.1074/jbc.274.47.33616	http://dx.doi.org/10.1074/jbc.274.47.33616			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559250	hybrid			2022-12-25	WOS:000083745200066
J	Schlegel, A; Wang, CG; Katzenellenbogen, BS; Pestell, RG; Lisanti, MP				Schlegel, A; Wang, CG; Katzenellenbogen, BS; Pestell, RG; Lisanti, MP			Caveolin-1 potentiates estrogen receptor alpha (ER alpha) signaling - Caveolin-1 drives ligand-independent nuclear translocation and activation of ER alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONCOGENICALLY TRANSFORMED-CELLS; SMOOTH-MUSCLE CELLS; MAP KINASE CASCADE; IN-VIVO; PLASMA-MEMBRANE; SCAFFOLDING DOMAIN; BREAST-CANCER; GENE FAMILY; PROTEIN; CHOLESTEROL	Estrogen receptor alpha (ER alpha) is a soluble protein that mediates the effects of the gonadal estrogens such as 17 beta-estradiol. Upon ligand binding, a cytoplasmic pool of ER alpha translocates to the nucleus, where it acts as a transcription factor, driving the expression of genes that contain estrogen-response elements. The activity of ERa is regulated by a number of proteins, including cytosolic chaperones and nuclear cofactors, Here, we show that caveolin-1 potentiates ER alpha-mediated signal transduction, Coexpression of caveolin-1 and ER alpha resulted in ligand-independent translocation of ER alpha to the nucleus as shown by both cell fractionation and immunofluorescence microscopic studies. Similarly, caveolin-1 augmented both ligand-independent and ligand-dependent ER alpha signaling as measured using a estrogen-response element-based luciferase reporter assay, Caveolin-1-mediated activation of ER alpha was sensitive to a well known ER antagonist, 4-hydroxytamoxifen. However, much higher concentrations of tamoxifen were required to mediate inhibition in the presence of caveolin-1. Interestingly, caveolin-1 expression also synergized with a constitutively active, ligand-independent ER alpha mutant, dramatically illustrating the potent stimulatory effect of caveolin-1 in this receptor system. Taken together, our results identify caveolin-1 as a new positive regulator of ER alpha signal transduction.	Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Univ Illinois, Coll Med, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; Univ Illinois, Coll Med, Dept Cell & Struct Biol, Urbana, IL 61801 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Lisanti, MP (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013	Lisanti, Michael/0000-0003-2034-1382; Schlegel, Amnon/0000-0003-4060-2252	NCI NIH HHS [R01-CA-80250, R29-CA70897] Funding Source: Medline; NIGMS NIH HHS [T32-GM07288] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080250, R01CA070897] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Carman CV, 1999, J BIOL CHEM, V274, P8858, DOI 10.1074/jbc.274.13.8858; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Engelman JA, 1998, AM J HUM GENET, V63, P1578, DOI 10.1086/302172; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Fielding CJ, 1999, BIOCHEMISTRY-US, V38, P2506, DOI 10.1021/bi981012o; FIELDING PE, 1995, BIOCHEMISTRY-US, V34, P14288, DOI 10.1021/bi00044a004; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Gilbert A, 1999, J CELL SCI, V112, P1101; Graf GA, 1999, J BIOL CHEM, V274, P12043, DOI 10.1074/jbc.274.17.12043; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Lazennec G, 1997, MOL ENDOCRINOL, V11, P1375, DOI 10.1210/me.11.9.1375; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PICARD D, 1990, CELL REGUL, V1, P291, DOI 10.1091/mbc.1.3.291; Prall OWJ, 1998, J STEROID BIOCHEM, V65, P169, DOI 10.1016/S0960-0760(98)00021-1; Razani B, 1999, J BIOL CHEM, V274, P26353, DOI 10.1074/jbc.274.37.26353; Rochefort H, 1998, J STEROID BIOCHEM, V65, P163, DOI 10.1016/S0960-0760(98)00010-7; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Schlegel A, 1999, J BIOL CHEM, V274, P22660, DOI 10.1074/jbc.274.32.22660; SEVERS NJ, 1988, J CELL SCI, V90, P341; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Thyberg J, 1998, LAB INVEST, V78, P825; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; Venema VJ, 1997, J BIOL CHEM, V272, P28187, DOI 10.1074/jbc.272.45.28187; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7; Weis KE, 1996, MOL ENDOCRINOL, V10, P1388, DOI 10.1210/me.10.11.1388	48	129	132	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33551	33556		10.1074/jbc.274.47.33551	http://dx.doi.org/10.1074/jbc.274.47.33551			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559241	hybrid			2022-12-25	WOS:000083745200057
J	Seth, P; Wu, X; Huang, W; Leibach, FH; Ganapathy, V				Seth, P; Wu, X; Huang, W; Leibach, FH; Ganapathy, V			Mutations in novel organic cation transporter (OCTN2), an organic cation/carnitine transporter, with differential effects on the organic cation transport function and the carnitine transport function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDENTIFICATION; COTRANSPORTER; RESIDUES	Novel organic cation transporter (OCTN2) is an organic cation/carnitine transporter, and two missense mutations, L352R and P478L, in OCTN2 have been identified as the cause for primary carnitine deficiency. In the present study, we assessed the influence of these two mutations on the carnitine transport function and the organic cation transport function of OCTN2, The L352R mutation resulted in a complete loss of both transport functions. In contrast, the P478L mutation resulted in a complete loss of only the carnitine transport function but significantly stimulated the organic cation transport function. Studies with human OCTN2/rat OCTN2 chimeric transporters indicated that the carnitine transport site and the organic cation transport site were not identical. Because carnitine transport is Na+-dependent whereas organic cation transport is Na+-independent, we investigated the possibility that the P478L mutation affected Na+ binding. The Na+ activation kinetics were found to be similar for the P478L mutant and wild type OCTN2. We then mutated nine different tyrosine residues located in or near transmembrane domains and assessed the transport function of these mutants. One of these mutations, Y211F, was found to have differential influence on the two transport activities of OCTN2 as did the P478L mutation. However, the Na+ activation kinetics were not affected. These findings are of clinical relevance to patients with primary carnitine deficiency because whereas each and every mutation in these patients is expected to result in the loss of the carnitine transport function, all of these mutations may not interfere with the organic cation transport function.	Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Ganapathy, V (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.				NICHD NIH HHS [HD 33347] Funding Source: Medline; NIDA NIH HHS [DA 10045] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA010045] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BIEBER LL, 1988, ANNU REV BIOCHEM, V57, P261, DOI 10.1146/annurev.bi.57.070188.001401; GANAPATHY V, 1989, J PHARMACOL EXP THER, V251, P9; HAMILTON JW, 1986, GASTROENTEROLOGY, V91, P10, DOI 10.1016/0016-5085(86)90432-4; Kerner J, 1998, ANNU REV NUTR, V18, P179, DOI 10.1146/annurev.nutr.18.1.179; Koepsell H, 1999, J MEMBRANE BIOL, V167, P103, DOI 10.1007/s002329900475; KOIZUMI T, 1988, LAB ANIM, V22, P83, DOI 10.1258/002367788780746511; KULANTHAIVEL P, 1989, BIOCHIM BIOPHYS ACTA, V985, P139, DOI 10.1016/0005-2736(89)90358-1; Lamhonwah AM, 1998, BIOCHEM BIOPH RES CO, V252, P396, DOI 10.1006/bbrc.1998.9679; Lu KM, 1998, BIOCHEM BIOPH RES CO, V252, P590, DOI 10.1006/bbrc.1998.9708; Nezu JI, 1999, NAT GENET, V21, P91, DOI 10.1038/5030; PEERCE BE, 1985, J BIOL CHEM, V260, P6026; Prasad PD, 1996, BBA-BIOMEMBRANES, V1284, P109, DOI 10.1016/0005-2736(96)00126-5; REBOUCHE CJ, 1984, ARCH BIOCHEM BIOPHYS, V235, P393, DOI 10.1016/0003-9861(84)90212-1; Roque AS, 1996, BBA-BIOMEMBRANES, V1282, P274, DOI 10.1016/0005-2736(96)00068-5; STEIGER B, 1995, BIOCHEM J, V309, P643; Tamai I, 1998, J BIOL CHEM, V273, P20378, DOI 10.1074/jbc.273.32.20378; Tang NLS, 1999, HUM MOL GENET, V8, P655, DOI 10.1093/hmg/8.4.655; Wang YH, 1999, P NATL ACAD SCI USA, V96, P2356, DOI 10.1073/pnas.96.5.2356; WRIGHT EM, 1984, J BIOL CHEM, V259, P4993; Wu X, 1998, BIOCHEM BIOPH RES CO, V246, P589, DOI 10.1006/bbrc.1998.8669; Wu X, 1999, J PHARMACOL EXP THER, V290, P1482	21	68	71	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33388	33392		10.1074/jbc.274.47.33388	http://dx.doi.org/10.1074/jbc.274.47.33388			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559218	hybrid			2022-12-25	WOS:000083745200034
J	Veenhoff, LM; Poolman, B				Veenhoff, LM; Poolman, B			Substrate recognition at the cytoplasmic and extracellular binding site of the lactose transport protein of Streptococcus thermophilus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+ SYMPORT PROTEIN; ESCHERICHIA-COLI; GLUCOSE TRANSPORTERS; SUGAR BINDING; D-GALACTOSE; SPECIFICITY; SYSTEM; RECONSTITUTION; PERMEASE; RECEPTOR	The lactose transport protein (LacS) of Streptococcus thermophilus catalyzes the uptake of lactose in an exchange reaction with intracellularly formed galactose, The interactions between the substrate and the cyto plasmic and extracellular binding site of LacS have been characterized by assaying binding and transport of a range of sugars in proteoliposomes, in which the purified protein was reconstituted with a unidirectional orientation. Specificity for galactoside binding is given by the spatial configuration of the C-2, C-3, C-4, and C-6 hydroxyl groups of the galactose moiety, Except for a C-4 methoxy substitution, replacement of the hydroxyl groups for bulkier groups is not tolerated at these positions. Large hydrophobic or hydrophilic substitutions on the galactose C-1 alpha or beta position did not impair transport. In fact, the hydrophobic groups increased the binding affinity but decreased transport rates compared with galactose, Binding and transport characteristics of deoxygalactosides from either side of the membrane showed that the cytoplasmic and extracellular binding site interact differently with galactose, Compared with galactose, the IC50 values for 2-deoxy- and 6-deoxygalactose at the cytoplasmic binding site were increased 150- and 20-fold, respectively, whereas they were the same at the extracellular binding site. From these and other experiments, we conclude that the binding sites and translocation pathway of LacS are spacious along the C-1 to C-4 axis of the galactose moiety and are restricted along the C-2 to C-6 axis. The differences in affinity at the cytoplasmic and extracellular binding site ensure that the transport via LacS is highly asymmetrical for the two opposing directions of translocation.	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Microbiol, NL-9751 NN Haren, Netherlands	University of Groningen	Poolman, B (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Biochem, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.		Poolman, Bert/D-1882-2012	Veenhoff, Liesbeth/0000-0002-0158-4728				BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; BARNETT JEG, 1975, BIOCHEM J, V145, P417, DOI 10.1042/bj1450417a; Chaudhuri BN, 1999, J MOL BIOL, V286, P1519, DOI 10.1006/jmbi.1999.2571; COLVILLE CA, 1993, BIOCHEM J, V294, P753, DOI 10.1042/bj2940753; EISENTHAL R, 1989, BIOCHIM BIOPHYS ACTA, V985, P81, DOI 10.1016/0005-2736(89)90107-7; ELLIKER PR, 1956, J DAIRY SCI, V39, P1611, DOI 10.3168/jds.S0022-0302(56)94896-2; FOUCAUD C, 1992, J BIOL CHEM, V267, P22087; KLEINZELLER A, 1980, BIOCHIM BIOPHYS ACTA, V600, P513, DOI 10.1016/0005-2736(80)90453-8; Knol J, 1998, BIOCHEMISTRY-US, V37, P16410, DOI 10.1021/bi981596u; Knol J, 1996, J BIOL CHEM, V271, P15358, DOI 10.1074/jbc.271.26.15358; LOSTAO MP, 1994, J MEMBRANE BIOL, V142, P160; MERRITT EA, 1994, MOL MICROBIOL, V13, P745, DOI 10.1111/j.1365-2958.1994.tb00467.x; OLSEN SG, 1989, J BIOL CHEM, V264, P15982; OLSEN SG, 1993, J BACTERIOL, V175, P6269, DOI 10.1128/JB.175.19.6269-6275.1993; OTTO R, 1982, J BACTERIOL, V149, P733, DOI 10.1128/JB.149.2.733-738.1982; POOLMAN B, 1989, J BACTERIOL, V171, P244, DOI 10.1128/jb.171.1.244-253.1989; POOLMAN B, 1995, P NATL ACAD SCI USA, V92, P778, DOI 10.1073/pnas.92.3.778; Poolman B, 1996, MOL MICROBIOL, V19, P911, DOI 10.1046/j.1365-2958.1996.397949.x; Quiocho FA, 1997, STRUCTURE, V5, P997, DOI 10.1016/S0969-2126(97)00253-0; Spooner PJR, 1999, BIOCHEMISTRY-US, V38, P9634, DOI 10.1021/bi990745l; VYAS MN, 1994, BIOCHEMISTRY-US, V33, P4762, DOI 10.1021/bi00182a003; WALMSLEY AR, 1993, EUR J BIOCHEM, V215, P43, DOI 10.1111/j.1432-1033.1993.tb18005.x; WALMSLEY AR, 1994, J BIOL CHEM, V269, P17009	23	31	31	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33244	33250		10.1074/jbc.274.47.33244	http://dx.doi.org/10.1074/jbc.274.47.33244			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559198	hybrid, Green Published			2022-12-25	WOS:000083745200014
J	Azam, TA; Ishihama, A				Azam, TA; Ishihama, A			Twelve species of the nucleoid-associated protein from Escherichia coli - Sequence recognition specificity and DNA binding affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; RESPONSIVE REGULATORY PROTEIN; MULTIPLE ANTIBIOTIC-RESISTANCE; HISTONE-LIKE PROTEINS; PHAGE Q-BETA; RNA-POLYMERASE; TRANSCRIPTIONAL ACTIVATION; CHROMOSOMAL REPLICATION; CURVED DNA; HFQ GENE	The genome of Escherichia coli is composed of a single molecule of circular DNA with the length of about 47,000 kilobase pairs, which is associated with about 10 major DNA-binding proteins, altogether forming the nucleoid. We expressed and purified 12 species of the DNA-binding protein, i.e. CbpA (curved DNA-binding protein A), CbpB or Rob (curved DNA-binding protein B or right arm of the replication origin binding protein), DnaA (DNA-binding protein A), Dps (DNA-binding protein from starved cells), Fis (factor for inversion stimulation), Hfq (host factor for phage Q(beta)), H-NS (histone-libe nucleoid structuring protein), HU (heat-unstable nucleoid protein), IciA (inhibitor of chromosome initiation A), IHF (integration host factor), Lrp (leucine-responsive regulatory protein), and StpA (suppressor of td(-) phenotype A). The sequence specificity of DNA binding was determined for all the purified nucleoid proteins using gel-mobility shift assays. Five proteins (CbpB, DnaA, Fis, IHF, and Lrp) were found to bind to specific DNA sequences, while the remaining seven proteins (CbpA, Dps, Hfq, H-NS, HU, IciA, and StpA) showed apparently sequence-nonspecific DNA binding activities. Four proteins, CbpA, Hfq, H-NS, and IciA, showed the binding preference for the curved DNA From the apparent dissociation constant (k(d)) determined using the sequence-specific or nonspecific DNA probes, the order of DNA binding affinity were determined to be: HU > IHF > Lrp > CbpB(Rob) > Fis > H-NS > StpA > CbpA > IciA > Hfq/Dps, ranging from 25 nM (HU binding to the noncurved DNA) to 250 nM (Hfq binding to the non curved DNA), under the assay conditions employed.	Natl Inst Genet, Dept Mol Genet, Mishima, Shizuoka 4118540, Japan; Japan Sci & Technol Corp, Kawaguchi, Saitama 3320012, Japan	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Japan Science & Technology Agency (JST)	Ishihama, A (corresponding author), Natl Inst Genet, Dept Mol Genet, Mishima, Shizuoka 4118540, Japan.							ALMIRON M, 1992, GENE DEV, V6, P2646, DOI 10.1101/gad.6.12b.2646; ARIZA RR, 1995, J BACTERIOL, V177, P1655, DOI 10.1128/jb.177.7.1655-1661.1995; ATLUNG T, 1985, MOL GEN GENET, V200, P442, DOI 10.1007/BF00425729; Blomfield IC, 1997, MOL MICROBIOL, V23, P705, DOI 10.1046/j.1365-2958.1997.2241615.x; BONNEFOY E, 1994, J MOL BIOL, V242, P116, DOI 10.1006/jmbi.1994.1563; BONNEFOY E, 1991, EMBO J, V10, P687, DOI 10.1002/j.1460-2075.1991.tb07998.x; BRAUN RE, 1985, CELL, V40, P159, DOI 10.1016/0092-8674(85)90319-8; Brown L, 1996, J BACTERIOL, V178, P3763, DOI 10.1128/jb.178.13.3763-3770.1996; CALVO JM, 1994, MICROBIOL REV, V58, P466, DOI 10.1128/MMBR.58.3.466-490.1994; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CASTAING B, 1995, J BIOL CHEM, V270, P10291, DOI 10.1074/jbc.270.17.10291; CRAIG NL, 1984, CELL, V39, P707, DOI 10.1016/0092-8674(84)90478-1; CUI YH, 1995, J BACTERIOL, V177, P4872, DOI 10.1128/jb.177.17.4872-4880.1995; Cusick ME, 1998, MOL MICROBIOL, V28, P847, DOI 10.1046/j.1365-2958.1998.00848.x; DARI R, 1993, TRENDS BIOCHEM SCI, V18, P260, DOI 10.1016/0968-0004(93)90177-O; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; ERNSTING BR, 1993, J BACTERIOL, V175, P7160, DOI 10.1128/JB.175.22.7160-7169.1993; FINKEL SE, 1992, MOL MICROBIOL, V6, P3257, DOI 10.1111/j.1365-2958.1992.tb02193.x; Franze de Fernandez M T, 1972, J Biol Chem, V247, P824; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; GILADI H, 1992, J MOL BIOL, V227, P985, DOI 10.1016/0022-2836(92)90514-K; GOOSEN N, 1995, MOL MICROBIOL, V16, P1, DOI 10.1111/j.1365-2958.1995.tb02386.x; Gourse RL, 1996, ANNU REV MICROBIOL, V50, P645, DOI 10.1146/annurev.micro.50.1.645; HIGGINS CF, 1990, MOL MICROBIOL, V4, P2007, DOI 10.1111/j.1365-2958.1990.tb00559.x; HWANG DS, 1990, CELL, V63, P325, DOI 10.1016/0092-8674(90)90165-B; HWANG DS, 1992, J BIOL CHEM, V267, P2209; Ishihama A, 1999, GENES CELLS, V4, P135, DOI 10.1046/j.1365-2443.1999.00247.x; Ishihama A, 1997, CURR OPIN GENET DEV, V7, P582, DOI 10.1016/S0959-437X(97)80003-2; Ishihama A., 1997, NUCL ACIDS MOL BIOL, V11, P53; Jair KW, 1996, J BACTERIOL, V178, P2507, DOI 10.1128/jb.178.9.2507-2513.1996; KAJITANI M, 1994, J BACTERIOL, V176, P531, DOI 10.1128/JB.176.2.531-534.1994; KAJITANI M, 1991, NUCLEIC ACIDS RES, V19, P1063, DOI 10.1093/nar/19.5.1063; KAKEDA M, 1995, MOL GEN GENET, V248, P629, DOI 10.1007/BF02423459; LaurentWinter C, 1997, EUR J BIOCHEM, V244, P767, DOI 10.1111/j.1432-1033.1997.00767.x; Lee YS, 1997, J BIOL CHEM, V272, P83; LOSSO MA, 1986, EUR J BIOCHEM, V155, P27, DOI 10.1111/j.1432-1033.1986.tb09454.x; Martin RG, 1997, J BACTERIOL, V179, P7410, DOI 10.1128/jb.179.23.7410-7419.1997; Martinez A, 1997, J BACTERIOL, V179, P5188, DOI 10.1128/jb.179.16.5188-5194.1997; Messer W, 1997, MOL MICROBIOL, V24, P1, DOI 10.1046/j.1365-2958.1997.3171678.x; Muffler A, 1996, GENE DEV, V10, P1143, DOI 10.1101/gad.10.9.1143; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; Nash Howard A., 1996, P149; NEWMAN EB, 1992, CELL, V68, P617, DOI 10.1016/0092-8674(92)90135-Y; Pan CQ, 1996, J MOL BIOL, V264, P675, DOI 10.1006/jmbi.1996.0669; Pettijohn D.E., 1996, ESCHERICHIA COLI SAL, P158; PONTIGGIA A, 1993, MOL MICROBIOL, V7, P343, DOI 10.1111/j.1365-2958.1993.tb01126.x; PRUSS GJ, 1989, CELL, V56, P521, DOI 10.1016/0092-8674(89)90574-6; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; ROUVIEREYANIV J, 1979, CELL, V17, P265, DOI 10.1016/0092-8674(79)90152-1; SCHAPER S, 1995, J BIOL CHEM, V270, P17622, DOI 10.1074/jbc.270.29.17622; Shimizu M, 1995, BBA-GENE STRUCT EXPR, V1264, P330, DOI 10.1016/0167-4781(95)00173-5; SKARSTAD K, 1993, J BIOL CHEM, V268, P5365; SKARSTAD K, 1994, BBA-GENE STRUCT EXPR, V1217, P111, DOI 10.1016/0167-4781(94)90025-6; Sutton MD, 1997, J BIOL CHEM, V272, P23017, DOI 10.1074/jbc.272.37.23017; Szalewska-Palasz A, 1998, P NATL ACAD SCI USA, V95, P4241, DOI 10.1073/pnas.95.8.4241; Takada A, 1997, BIOCHEM BIOPH RES CO, V236, P576, DOI 10.1006/bbrc.1997.7013; TALUKDER AA, IN PRESS J BACTERIOL; TANAKA H, 1993, J BIOCHEM-TOKYO, V113, P568, DOI 10.1093/oxfordjournals.jbchem.a124084; TANAKA K, 1991, AGR BIOL CHEM TOKYO, V55, P3139, DOI 10.1080/00021369.1991.10859737; TSUI HCT, 1994, MOL MICROBIOL, V13, P35, DOI 10.1111/j.1365-2958.1994.tb00400.x; UEGUCHI C, 1994, P NATL ACAD SCI USA, V91, P1054, DOI 10.1073/pnas.91.3.1054; VARGAS LM, 1989, SCIENCE, V244, P1457; WANG Q, 1993, J MOL BIOL, V229, P306, DOI 10.1006/jmbi.1993.1036; WANG Q, 1993, EMBO J, V12, P2495, DOI 10.1002/j.1460-2075.1993.tb05904.x; WANG SQ, 1995, BIOCHEMISTRY-US, V34, P13082, DOI 10.1021/bi00040a020; Wei T, 1996, NUCLEIC ACIDS RES, V24, P1865, DOI 10.1093/nar/24.10.1865; Wiese DE, 1997, J MOL BIOL, V270, P152, DOI 10.1006/jmbi.1997.1057; Williams RM, 1997, FEMS MICROBIOL LETT, V156, P175, DOI 10.1016/S0378-1097(97)00397-2; YAMADA H, 1990, J BIOCHEM-TOKYO, V108, P420, DOI 10.1093/oxfordjournals.jbchem.a123216; YMAADA H, 1993, MOL GEN GENET, V237, P118; ZHANG A, 1995, RNA, V1, P783; Zhang AX, 1996, EMBO J, V15, P1340, DOI 10.1002/j.1460-2075.1996.tb00476.x; ZUBER F, 1994, MOL MICROBIOL, V12, P231, DOI 10.1111/j.1365-2958.1994.tb01012.x	74	342	357	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					33105	33113		10.1074/jbc.274.46.33105	http://dx.doi.org/10.1074/jbc.274.46.33105			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551881	hybrid			2022-12-25	WOS:000083623000081
J	McCormick, KA; Srinivasan, J; White, K; Scheuer, T; Catterall, WA				McCormick, KA; Srinivasan, J; White, K; Scheuer, T; Catterall, WA			The extracellular domain of the beta 1 subunit is both necessary and sufficient for beta 1-like modulation of sodium channel gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR STRUCTURAL PROTEIN; ALPHA-SUBUNIT; RAT-BRAIN; MOLECULAR DETERMINANTS; SCORPION TOXIN; INACTIVATION; EXPRESSION; MOVEMENT; GLYCOPROTEIN; ACTIVATION	The type IIA voltage-gated sodium Na+ channel from rat brain is composed of a large, pore-forming alpha subunit and the auxiliary subunits beta 1 and beta 2. When expressed in Xenopus oocytes, the beta 1 subunit modulates the gating properties of the type IIA alpha subunit, resulting in acceleration of both inactivation and recovery from inactivation and in a negative shift in the voltage dependence of fast inactivation. The beta 1 subunit is composed of an extracellular domain with a single immunoglobulin-libe fold, a single transmembrane segment, and a small intracellular domain. A series of chimeras with exchanges of domains between the Na+ channel beta 1 and beta 2 subunits and between pi and the structurally related protein myelin P0 were constructed and analyzed by two-microelectrode voltage clamp in Xenopus oocytes. Only chimeras containing the pi extracellular domain were capable of beta 1-like modulation of Na+ channel gating. Neither the transmembrane segment nor the intracellular domain was required for modulation, although mutation of Glu(158) within the transmembrane domain altered the voltage dependence of steady-state inactivation. A truncated beta 1 subunit was engineered in which the pi extracellular domain was fused to a recognition sequence for attachment of a glycosylphosphatidylinositol membrane anchor. The beta 1(ec)-glycosylphosphatidylinositol protein fully reproduced modulation of Na+ channel inactivation and recovery from inactivation by wild-type beta 1. Our findings demonstrate that extracellular domain of the beta 1 subunit is both necessary and sufficient for the modulation of Na+ channel gating.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	McCormick, KA (corresponding author), Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025704, F32NS009842] Funding Source: NIH RePORTER; NINDS NIH HHS [NS09842-03, NS25704] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		An RH, 1998, CIRC RES, V83, P141, DOI 10.1161/01.RES.83.2.141; ARMSTRONG CM, 1973, J GEN PHYSIOL, V62, P375, DOI 10.1085/jgp.62.4.375; ARMSTRONG CM, 1973, NATURE, V242, P459, DOI 10.1038/242459a0; AULD VJ, 1990, P NATL ACAD SCI USA, V87, P323, DOI 10.1073/pnas.87.1.323; AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; CATTERALL WA, 1992, PHYSIOL REV, V72, P15; Cestele S, 1998, NEURON, V21, P919, DOI 10.1016/S0896-6273(00)80606-6; Cha A, 1999, NEURON, V22, P73, DOI 10.1016/S0896-6273(00)80680-7; Chen CF, 1995, PFLUG ARCH EUR J PHY, V431, P186, DOI 10.1007/BF00410190; GOLDIN AL, 1986, P NATL ACAD SCI USA, V83, P7503, DOI 10.1073/pnas.83.19.7503; Isom LL, 1996, NATURE, V383, P307, DOI 10.1038/383307b0; ISOM LL, 1995, J BIOL CHEM, V270, P3306, DOI 10.1074/jbc.270.7.3306; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; JASIN M, 1991, J VIROL, V65, P440, DOI 10.1128/JVI.65.1.440-444.1991; KAM W, 1985, P NATL ACAD SCI USA, V82, P8715, DOI 10.1073/pnas.82.24.8715; Kellenberger S, 1996, J BIOL CHEM, V271, P30971, DOI 10.1074/jbc.271.48.30971; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEMKE G, 1985, CELL, V40, P501, DOI 10.1016/0092-8674(85)90198-9; Makita N, 1996, CIRC RES, V78, P244, DOI 10.1161/01.RES.78.2.244; McCormick KA, 1998, J BIOL CHEM, V273, P3954, DOI 10.1074/jbc.273.7.3954; MCPHEE JC, 1995, J BIOL CHEM, V270, P12025, DOI 10.1074/jbc.270.20.12025; MORAN P, 1991, J BIOL CHEM, V266, P1250; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; PATTON DE, 1994, J BIOL CHEM, V269, P17649; Qu YS, 1999, J BIOL CHEM, V274, P32647, DOI 10.1074/jbc.274.46.32647; Rogers JC, 1996, J BIOL CHEM, V271, P15950, DOI 10.1074/jbc.271.27.15950; Shah R. M., 1996, Society for Neuroscience Abstracts, V22, P63; Shapiro L, 1996, NEURON, V17, P435, DOI 10.1016/S0896-6273(00)80176-2; SLANETZ AE, 1991, EUR J IMMUNOL, V21, P179, DOI 10.1002/eji.1830210127; Tang CY, 1997, J GEN PHYSIOL, V109, P301, DOI 10.1085/jgp.109.3.301; TSE AGD, 1985, SCIENCE, V230, P1003, DOI 10.1126/science.2865810; VASSILEV PM, 1988, SCIENCE, V241, P1658, DOI 10.1126/science.2458625; Wallace RH, 1998, NAT GENET, V19, P366, DOI 10.1038/1252; West AP, 1997, J BIOL CHEM, V272, P25468, DOI 10.1074/jbc.272.41.25468; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910; Yang NB, 1996, NEURON, V16, P113, DOI 10.1016/S0896-6273(00)80028-8	38	68	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32638	32646		10.1074/jbc.274.46.32638	http://dx.doi.org/10.1074/jbc.274.46.32638			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551818	hybrid			2022-12-25	WOS:000083623000018
J	Ozono, K; Saito, M; Miura, D; Michigami, T; Nakajima, S; Ishizuka, S				Ozono, K; Saito, M; Miura, D; Michigami, T; Nakajima, S; Ishizuka, S			Analysis of the molecular mechanism for the antagonistic action of a novel 1 alpha,25-dihydroxyvitamin D-3 analogue toward vitamin D receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-RESPONSIVE ELEMENTS; ESTROGEN-RECEPTOR; 24-HYDROXYLASE GENE; THYROID-HORMONE; RETINOIC ACID; DNA-BINDING; COACTIVATOR; DOMAIN; TRANSCRIPTION; ANTIESTROGEN	We have recently reported that 23(S)-25-dehydro-1 alpha-hydroxyvitamin D-3-26,23-lactone (TEI-9647) efficiently blocks the differentiation of HL-60 cells induced by 1 alpha,25-dihydroxyvitamin D-3 (1 alpha,25(OH)(2)D-3) (Miura, D., Manabe, H., Ozone, K., Saito, M., Gao, Q., Norman, A. W., and Ishizuka, S. (1999) J. Biol. Chem. 274, 16392-16399). To clarify the molecular mechanisms of this antagonism, we examined whether TEI-9647 antagonizes the genomic effects of 1 alpha,25(OH)(2)D-3. 10(-7) to 10(-9) M TEI-9647 inhibited the transactivation effect of 10(-8) m 1 alpha,25(OH)(2)D-3 in a dose-dependent manner, while TEI-9647 alone did not activate the reporter activity driven by SV40 promoter containing two vitamin D response elements in Saos-2 cells. The antagonistic effect of TEI-9647 was also observed using the rat 24-hydroxylase gene promoter, but the effect was weaker in HeLa and COS-7 cells than in Saos-2 cells. TEI-9647 also exhibited antagonism in an assay system where the VDR fused to the GAL4 DNA-binding domain and the reporter plasmid containing the GAL4 binding site were used in Saos-2 cells, but did not in HeLa cells, TEI-9647 reduced the interaction between VDR and RXR alpha according to the results obtained from the mammalian two-hybrid system in Saos-2 cells, but did not in HeLa cells. The two-hybrid system also revealed that the interaction between VDR and SRC-1 was reduced by TEI-9647 in Saos-2 cells. These results demonstrate that the novel 1 alpha,25(OH)(2)D-3 analogue, TEI-9647, is the first synthetic ligand for the VDR that efficiently antagonizes the action of 1 alpha,25(OH)(2)D-3, although the extent of its antagonism depends on cell type.	Med Ctr, Dept Environm Med, Osaka 5941101, Japan; Res Inst Maternal & Child Hlth, Osaka 5941101, Japan; Teijin Inst Biomed Res, Tokyo 1918512, Japan		Ozono, K (corresponding author), Med Ctr, Dept Environm Med, 840 Murodo Cho, Osaka 5941101, Japan.		Michigami, Toshimi/AAU-2326-2021					BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; Barsony J, 1997, J BIOL CHEM, V272, P5774, DOI 10.1074/jbc.272.9.5774; BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CHEN KS, 1995, BBA-GENE STRUCT EXPR, V1263, P1, DOI 10.1016/0167-4781(95)00060-T; CLEMENS TL, 1988, ENDOCRINOLOGY, V122, P1224, DOI 10.1210/endo-122-4-1224; Devin-Leclerc J, 1998, MOL ENDOCRINOL, V12, P842, DOI 10.1210/me.12.6.842; DUSSO AS, 1991, ENDOCRINOLOGY, V128, P1687, DOI 10.1210/endo-128-4-1687; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Gill RK, 1998, MOL ENDOCRINOL, V12, P57, DOI 10.1210/mend.12.1.0048; Grese TA, 1997, P NATL ACAD SCI USA, V94, P14105, DOI 10.1073/pnas.94.25.14105; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; Hsieh JC, 1998, J CELL BIOCHEM, V70, P94, DOI 10.1002/(SICI)1097-4644(19980701)70:1<94::AID-JCB10>3.3.CO;2-Q; HUGHES MR, 1988, SCIENCE, V242, P1702, DOI 10.1126/science.2849209; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KRAUS WL, 1995, MOL CELL BIOL, V15, P1847; Lala DS, 1996, NATURE, V383, P450, DOI 10.1038/383450a0; Lee MO, 1996, J BIOL CHEM, V271, P11897, DOI 10.1074/jbc.271.20.11897; Lemon BD, 1997, MOL CELL BIOL, V17, P1923, DOI 10.1128/MCB.17.4.1923; Li YC, 1997, P NATL ACAD SCI USA, V94, P9831, DOI 10.1073/pnas.94.18.9831; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; MacGregor JI, 1998, PHARMACOL REV, V50, P151; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Masuyama H, 1997, MOL ENDOCRINOL, V11, P1507, DOI 10.1210/me.11.10.1507; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; MICHIGAMI T, 1998, BONE, V23, pS257; Miura D, 1999, J BIOL CHEM, V274, P16392, DOI 10.1074/jbc.274.23.16392; Nakajima S, 1998, MOL CELL ENDOCRINOL, V139, P15, DOI 10.1016/S0303-7207(98)00077-X; Nakajima S, 1997, BIOCHEM BIOPH RES CO, V232, P806, DOI 10.1006/bbrc.1997.6376; NAKAJIMA S, 1994, MOL ENDOCRINOL, V8, P159, DOI 10.1210/me.8.2.159; NORMAN AW, 1993, J BIOL CHEM, V268, P20022; Norman AW, 1998, J BONE MINER RES, V13, P1360, DOI 10.1359/jbmr.1998.13.9.1360; Ohyama Y, 1996, J BIOL CHEM, V271, P30381, DOI 10.1074/jbc.271.48.30381; OHYAMA Y, 1994, J BIOL CHEM, V269, P10545; ONATE SA, 1995, SCIENCE, V270, P1354; Peleg S, 1998, MOL ENDOCRINOL, V12, P525, DOI 10.1210/me.12.4.525; Pike J. W., 1997, Vitamin D., P105; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; SONE T, 1991, MOL ENDOCRINOL, V5, P1578, DOI 10.1210/mend-5-11-1578; Takeyama KI, 1999, MOL CELL BIOL, V19, P1049; VandenBemd GJCM, 1996, P NATL ACAD SCI USA, V93, P10685, DOI 10.1073/pnas.93.20.10685; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391; Zhao XY, 1997, MOL ENDOCRINOL, V11, P366, DOI 10.1210/me.11.3.366	45	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32376	32381		10.1074/jbc.274.45.32376	http://dx.doi.org/10.1074/jbc.274.45.32376			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542279	hybrid			2022-12-25	WOS:000083532100087
J	Jiang, YX; Rom, WN; Yie, TA; Chi, CX; Tchou-Wong, KM				Jiang, YX; Rom, WN; Yie, TA; Chi, CX; Tchou-Wong, KM			Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-negative IGF-I receptor	ONCOGENE			English	Article						IGF-IR; glandular differentiation; lung carcinoma cells	GROWTH-FACTOR-I; MOUSE EMBRYO FIBROBLASTS; SIGNAL-TRANSDUCTION; INSULIN; APOPTOSIS; CANCER; TRANSFORMATION; TUMORIGENESIS; INHIBITION; VIVO	Overexpression or activation of insulin-like growth factor I receptor (IGF-IR) has been observed in many human cancers including breast, lung, colon and gastric carcinomas, We demonstrate that inhibition of the endogenous insulin-like growth factor I receptor by stable expression of a dominant-negative IGF-IR represses the transforming activity in vitro and tumorigenicity of human lung carcinoma cells A549 in vivo, The suppression of tumorigenicity in nude mice is correlated with the induction of glandular differentiation. In addition, functional inhibition of the endogenous receptor dramatically increases the sensitivity of A549 cells to a variety of apoptotic signals including UV irradiation and proteasome inhibitors. These effects are due to the formation of a stable heterocomplex of the dominant-negative receptor with the endogenous wild type receptor which reduces the kinase activity of the latter by twofold. Thus, inhibition of the IGF-IR signaling pathway not only suppresses tumorigenicity but also enhances sensitivity to apoptosis-inducing agents. Antagonizing IGF-IR signaling by promoting tumor differentiation and enhancing sensitivity to apoptotic death are potential cancer therapeutic approaches.	NYU, Med Ctr, Dept Med, Div Pulm & Crit Care Med, New York, NY 10016 USA; NYU, Med Ctr, Dept Environm Med, Div Pulm & Crit Care Med, New York, NY 10016 USA; NYU, Dept Pathol, Div Pulm & Crit Care Med, New York, NY 10016 USA; NYU, Med Ctr, Dept Microbiol, Div Pulm & Crit Care Med, New York, NY 10016 USA	New York University; New York University; New York University; New York University	Tchou-Wong, KM (corresponding author), NYU, Med Ctr, Dept Med, Div Pulm & Crit Care Med, 550 1st Ave,MSB 147, New York, NY 10016 USA.			Rom, William/0000-0002-8793-7028	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000096] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062055, R01HL059832] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR00096] Funding Source: Medline; NHLBI NIH HHS [R01-HL62055, R01-HL59832] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; DAmbrosio C, 1997, CANCER RES, V57, P3264; DAmbrosio C, 1996, CANCER RES, V56, P4013; FREED KA, 1989, J MOL ENDOCRINOL, V3, P183, DOI 10.1677/jme.0.0030183; ImajohOhmi S, 1995, BIOCHEM BIOPH RES CO, V217, P1070, DOI 10.1006/bbrc.1995.2878; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LEE TC, 1993, CANCER RES, V53, P2858; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LEROITH D, 1995, ANN INTERN MED, V122, P54, DOI 10.7326/0003-4819-122-1-199501010-00009; LIU DL, 1993, J VIROL, V67, P9, DOI 10.1128/JVI.67.1.9-18.1993; MACAULY VM, 1988, BRIT J CANCER, V57, P91, DOI 10.1038/bjc.1988.16; Nakamura S, 1997, EXP CELL RES, V235, P287, DOI 10.1006/excr.1997.3683; NAKANISHI Y, 1988, J CLIN INVEST, V82, P354, DOI 10.1172/JCI113594; NEUENSCHWANDER S, 1995, ENDOCRINOLOGY, V136, P4298, DOI 10.1210/en.136.10.4298; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; RANDAZZO PA, 1990, EXP CELL RES, V190, P25, DOI 10.1016/0014-4827(90)90139-2; Resnicoff M, 1996, J Exp Ther Oncol, V1, P385; RESNICOFF M, 1994, CANCER RES, V54, P4848; RESNICOFF M, 1995, CANCER RES, V55, P2463; Rininsland F, 1997, P NATL ACAD SCI USA, V94, P5854, DOI 10.1073/pnas.94.11.5854; RUBIN R, 1995, LAB INVEST, V73, P311; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SHIMIHARA K, 1996, BIOCHEM J, V317, P385; Singleton JR, 1996, CANCER RES, V56, P4522; SPEIRS V, 1991, BRIT J CANCER, V64, P693, DOI 10.1038/bjc.1991.383; Turner BC, 1997, CANCER RES, V57, P3079; Valentinis B, 1997, MOL CELL BIOL, V17, P3744, DOI 10.1128/MCB.17.7.3744; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; Wu YL, 1996, J CELL PHYSIOL, V168, P499, DOI 10.1002/(SICI)1097-4652(199609)168:3<499::AID-JCP2>3.0.CO;2-K; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; Zong CS, 1997, J BIOL CHEM, V272, P1500, DOI 10.1074/jbc.272.3.1500	36	45	51	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	1999	18	44					6071	6077		10.1038/sj.onc.1202984	http://dx.doi.org/10.1038/sj.onc.1202984			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557096				2022-12-25	WOS:000083359100013
J	Tamarappoo, BK; Yang, BX; Verkman, AS				Tamarappoo, BK; Yang, BX; Verkman, AS			Misfolding of mutant aquaporin-2 water channels in nephrogenic diabetes insipidus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CHEMICAL CHAPERONES; ENDOPLASMIC-RETICULUM; CONFORMATIONAL MATURATION; PROTEIN; CFTR; PHENOTYPE; MUTATIONS; MECHANISM; GLYCEROL	We reported that several aquaporin-2 (AQP2) point mutants that cause nephrogenic diabetes insipidus (NDI) are retained in the endoplasmic reticulum (ER) of transfected mammalian cells and degraded but can be rescued by chemical chaperones to function as plasma membrane water channels (Tamarappoo, B. K., and Verkman, A. S. (1998) J. Clin. Invest. 101, 2257-2267). To test whether mutant AQP2 proteins are misfolded, AQP2 folding was assessed by comparative detergent extractability and limited proteolysis, and AQP2 degradation kinetics was measured by label-pulse-chase and immunoprecipitation, In ER membranes from transfected CHO cells containing [S-35]methionine-labeled AQP2, mutants T126M and A147T were remarkably detergent-resistant; for example wild-type AQP2 was >95% solubilized by 0.5% CHAPS whereas T126M was <10% solubilized, E258K, an NDI-causing AQP2 mutant which is retained in the Gels, is highly detergent soluble like wild-type AQP2. The mutants and wild-type AQP2 were equally susceptible to digestion by trypsin, thermolysin, and proteinase K. Stopped-flow light scattering measurements indicated that T126M AQP2 at the ER was fully functional as a water channel. Pulse-chase studies indicated that the increased degradation rates for T126M (t(1/2) 2.5 h) and A147T (2 h) compared with wildtype AQP2 (4 h) involve a brefeldin A-resistant, ER-dependent degradation mechanism. After growth of cells for 48 h in the chemical chaperone glycerol, AQP2 mutants T126M and A147T became properly targeted and relatively detergent-soluble. These results provide evidence that NDI-causing mutant AQP2 proteins are mis folded, but functional, and that chemical chaperones both correct the trafficking and folding defects. Strategies to facilitate protein folding might thus have therapeutic efficacy in NDI.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, F32DK009484, R37DK035124] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59198] Funding Source: Medline; NIDDK NIH HHS [DK09484, DK35124] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai LQ, 1996, J BIOL CHEM, V271, P5171; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; Brown CR, 1997, J CLIN INVEST, V99, P1432, DOI 10.1172/JCI119302; Brown CR, 1996, CELL STRESS CHAPERON, V1, P117, DOI 10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2; Brown D, 1998, AM J PHYSIOL-RENAL, V275, pF328, DOI 10.1152/ajprenal.1998.275.3.F328; BROWN D, 1989, AM J PHYSIOL, V256, pF1, DOI 10.1152/ajprenal.1989.256.1.F1; Canfield MC, 1997, HUM MOL GENET, V6, P1865, DOI 10.1093/hmg/6.11.1865; DEEN PMT, 1995, J CLIN INVEST, V95, P2291, DOI 10.1172/JCI117920; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; FUJIWARA TM, 1995, ANNU REV MED, V46, P331; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4677, DOI 10.1021/bi00519a024; HAMMOND C, 1995, CURR OPIN CELL BIOL, V3, P592; Huppa JB, 1997, IMMUNITY, V7, P113, DOI 10.1016/S1074-7613(00)80514-2; JUNG JS, 1994, J BIOL CHEM, V269, P14648; Kamsteeg EJ, 1999, EMBO J, V18, P2394, DOI 10.1093/emboj/18.9.2394; LE AQ, 1992, J BIOL CHEM, V267, P1072; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; Mulders SM, 1997, J AM SOC NEPHROL, V8, P242; Mulders SM, 1998, J CLIN INVEST, V102, P57, DOI 10.1172/JCI2605; PASYK EA, 1995, J BIOL CHEM, V270, P12347, DOI 10.1074/jbc.270.21.12347; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; Qu BH, 1996, J BIOL CHEM, V271, P7261, DOI 10.1074/jbc.271.13.7261; Qu BH, 1997, J BIOL CHEM, V272, P15739, DOI 10.1074/jbc.272.25.15739; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Tamarappoo BK, 1998, J CLIN INVEST, V101, P2257, DOI 10.1172/JCI2303; Tatzelt J, 1996, EMBO J, V15, P6363, DOI 10.1002/j.1460-2075.1996.tb01027.x; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Ward DT, 1999, ANNU REV PHYSIOL, V61, P683, DOI 10.1146/annurev.physiol.61.1.683; Welch WJ, 1996, CELL STRESS CHAPERON, V1, P109, DOI 10.1379/1466-1268(1996)001<0109:IOMACC>2.3.CO;2; YU G, 1997, J BIOL CHEM, V272, P20800; Zhang F, 1998, NAT STRUCT BIOL, V5, P180, DOI 10.1038/nsb0398-180	34	92	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34825	34831		10.1074/jbc.274.49.34825	http://dx.doi.org/10.1074/jbc.274.49.34825			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574954	hybrid			2022-12-25	WOS:000083979600048
J	Rahlfs, S; Aufurth, S; Muller, V				Rahlfs, S; Aufurth, S; Muller, V			The Na+-F1F0-ATPase operon from Acetobacterium woodii - Operon structure and presence of multiple copies of atpE which encode proteolipids of 8-and 18-kDa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATE SYNTHASE; NA+-TRANSLOCATING F1F0-ATPASE; VACUOLAR-TYPE ATPASE; ESCHERICHIA-COLI; PROPIONIGENIUM-MODESTUM; NUCLEOTIDE-SEQUENCE; F1F0 ATPASE; H+-ATPASE; CAENORHABDITIS-ELEGANS; F1F0-TYPE ENZYME	Eight genes (atpI, atpB, atpE(1), atpE(2), atpE(3), atpF(4), atpH, and atpA) upstream of and contiguous with the previously described genes atpG, atpD, and atpC were cloned from chromosomal DNA of Acetobacterium woodii. Northern blot analysis revealed that the eleven atp genes are transcribed as a polycistronic message, The atp operon encodes the Na+-F1F0-ATPase of A. woodii, as evident from a comparison of the biochemically derived N termini of the subunits with the amino acid sequences deduced from the DNA sequences. The molecular analysis revealed that all of the F1F0-encoding genes from Escherichia coli have homologs in the Na+-F1F0-ATPase operon from A. woodii, despite the fact that only six subunits were found in previous preparations of the enzyme from A. woodii. These results unequivocally prove that the Na+-ATPase from A. woodii is an enzyme of the F1F0 class. Most interestingly, the gene encoding the proteolipid underwent quadruplication. Two gene copies (atpE(2) and atpE(3)) encode identical 8-kDa proteolipids. Two additional gene copies were fused to form the atpE(1) gene. Heterologous expression experiments as well as immunolabeling studies with native membranes revealed that atpE(1) encodes a duplicated 18-kDa proteolipid. This is the first demonstration of multiplication nd fusion of proteolipid-encoding genes in F1F0-ATPase operons, Furthermore, AtpE(1) is the first duplicated proteolipid ever found to be encoded by an F1F0-ATPase operon.	Univ Munich, Lehrstuhl Mikrobiol, D-80638 Munich, Germany; Univ Gottingen, Inst Mikrobiol & Genet, D-37077 Gottingen, Germany	University of Munich; University of Gottingen	Muller, V (corresponding author), Univ Munich, Lehrstuhl Mikrobiol, Maria Ward Str 1A, D-80638 Munich, Germany.		Mueller, Volker/ABE-4305-2021	Mueller, Volker/0000-0001-7955-5508				BRUSILOW WSA, 1989, J BIOL CHEM, V264, P1528; CAIN BD, 1986, J BIOL CHEM, V261, P43; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CLARKE DJ, 1979, EUR J BIOCHEM, V98, P597, DOI 10.1111/j.1432-1033.1979.tb13222.x; Das A, 1997, J BACTERIOL, V179, P3746, DOI 10.1128/jb.179.11.3746-3755.1997; Das A, 1997, J BACTERIOL, V179, P1714, DOI 10.1128/jb.179.5.1714-1720.1997; DeckersHebestreit G, 1996, ANNU REV MICROBIOL, V50, P791, DOI 10.1146/annurev.micro.50.1.791; Dimroth P, 1997, BBA-BIOENERGETICS, V1318, P11, DOI 10.1016/S0005-2728(96)00127-2; ESSER U, 1990, NUCLEIC ACIDS RES, V18, P5887, DOI 10.1093/nar/18.19.5887; Fillingame RH, 1998, BBA-BIOENERGETICS, V1365, P135, DOI 10.1016/S0005-2728(98)00053-X; FORSTER A, 1995, BBA-BIOENERGETICS, V1229, P393, DOI 10.1016/0005-2728(95)00037-J; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; FUTAI M, 1994, BBA-BIOENERGETICS, V1187, P165, DOI 10.1016/0005-2728(94)90104-X; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HEISE R, 1991, FEBS LETT, V295, P119, DOI 10.1016/0014-5793(91)81400-3; HEISE R, 1993, FEMS MICROBIOL LETT, V112, P261, DOI 10.1111/j.1574-6968.1993.tb06460.x; HEISE R, 1989, J BACTERIOL, V171, P5473, DOI 10.1128/jb.171.10.5473-5478.1989; HEISE R, 1992, EUR J BIOCHEM, V206, P553, DOI 10.1111/j.1432-1033.1992.tb16959.x; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; HOMMA M, 1985, J BACTERIOL, V163, P464, DOI 10.1128/JB.163.2.464-471.1985; KAIM G, 1990, NUCLEIC ACIDS RES, V18, P6697, DOI 10.1093/nar/18.22.6697; KAIM G, 1992, EUR J BIOCHEM, V207, P463, DOI 10.1111/j.1432-1033.1992.tb17072.x; KAKINUMA Y, 1993, BIOCHEM BIOPH RES CO, V195, P1063, DOI 10.1006/bbrc.1993.2152; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; KRUMHOLZ LR, 1989, NUCLEIC ACIDS RES, V17, P7993, DOI 10.1093/nar/17.19.7993; KRUMHOLZ LR, 1992, FEMS MICROBIOL LETT, V91, P37, DOI 10.1111/j.1574-6968.1992.tb05180.x; LILL H, 1991, PLANT MOL BIOL, V17, P641, DOI 10.1007/BF00037050; LUDWIG W, 1990, EUR J BIOCHEM, V193, P395, DOI 10.1111/j.1432-1033.1990.tb19352.x; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MCCARTHY JEG, 1990, MOL MICROBIOL, V4, P1233, DOI 10.1111/j.1365-2958.1990.tb00702.x; MCCARTHY JEG, 1985, EMBO J, V4, P519, DOI 10.1002/j.1460-2075.1985.tb03659.x; Muller V, 1995, ARCH MICROBIOL, V164, P363, DOI 10.1007/s002030050276; Muller V, 1999, J BIOENERG BIOMEMBR, V31, P15, DOI 10.1023/A:1005451311009; Muller V., 1994, ACETOGENESIS, P127; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; OHTA S, 1988, BIOCHIM BIOPHYS ACTA, V933, P141, DOI 10.1016/0005-2728(88)90064-3; Oka T, 1998, J BIOL CHEM, V273, P22570, DOI 10.1074/jbc.273.35.22570; Oka T, 1997, J BIOL CHEM, V272, P24387, DOI 10.1074/jbc.272.39.24387; Rahlfs S, 1997, FEBS LETT, V404, P269, DOI 10.1016/S0014-5793(97)00088-4; Rahlfs S, 1999, FEBS LETT, V453, P35, DOI 10.1016/S0014-5793(99)00576-1; REIDLINGER J, 1994, FEBS LETT, V356, P17, DOI 10.1016/0014-5793(94)01222-9; REIDLINGER J, 1994, EUR J BIOCHEM, V223, P275, DOI 10.1111/j.1432-1033.1994.tb18992.x; Ruppert C, 1999, J BIOL CHEM, V274, P25281, DOI 10.1074/jbc.274.36.25281; Ruppert C, 1998, J BACTERIOL, V180, P3448, DOI 10.1128/JB.180.13.3448-3452.1998; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P369; SPRUTH M, 1995, BBA-BIOENERGETICS, V1229, P96, DOI 10.1016/0005-2728(94)00192-8; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; TSCHECH A, 1984, ARCH MICROBIOL, V137, P163, DOI 10.1007/BF00414460; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X	52	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					33999	34004		10.1074/jbc.274.48.33999	http://dx.doi.org/10.1074/jbc.274.48.33999			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567365	hybrid			2022-12-25	WOS:000083857500030
J	Sun, TX; Akhtar, NJ; Liang, JJN				Sun, TX; Akhtar, NJ; Liang, JJN			Thermodynamic stability of human lens recombinant alpha A- and alpha B-crystallins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONE-LIKE ACTIVITY; HEAT-SHOCK-PROTEIN; GAMMA-II-CRYSTALLIN; CALF EYE-LENS; QUATERNARY STRUCTURE; CONFORMATIONAL STABILITY; MOLECULAR CHAPERONE; DOMAIN; FLUORESCENCE; TRANSPARENCY	Lens alpha-crystallin is a 600-800-kDa heterogeneous oligomer protein consisting of two subunits, alpha A and alpha B. The homogeneous oligomers (alpha A- and alpha B-crystallins) have been prepared by recombinant DNA technology and shown to differ in the following biophysical/biochemical properties: hydrophobicity, chaperone-like activity, subunit exchange rate, and thermal stability. In this study, we studied their thermodynamic stability by unfolding in guanidine hydrochloride. The unfolding was probed by three spectroscopic parameters: absorbance at 235 nm, Trp fluorescence intensity at 320 nm, and far-UV circular dichroism at 223 nm, Global analysis indicated that a three-state model better describes the unfolding behavior than a two-state model, an indication that there are stable intermediates for both alpha A- and alpha B-crystallins, In terms of standard free energy (Delta G(NU)(H2O)), alpha A-crystallin is slightly more stable than alpha B-crystallin, The significance of the intermediates may be related to the functioning of alpha-crystallins as chaperone-like molecules.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Ophthalm Res, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Liang, JJN (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Ophthalm Res, 221 Longwood Ave, Boston, MA 02115 USA.				NEI NIH HHS [EY05803] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; ANDLEY UP, 1982, BIOCHEMISTRY-US, V21, P1853, DOI 10.1021/bi00537a023; AUGUSTEYN RC, 1987, FEBS LETT, V222, P1, DOI 10.1016/0014-5793(87)80180-1; BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; Bloemendal M, 1998, INT J BIOL MACROMOL, V22, P239, DOI 10.1016/S0141-8130(98)00021-X; CARVER JA, 1993, BIOCHIM BIOPHYS ACTA, V1164, P22, DOI 10.1016/0167-4838(93)90107-3; CARVER JA, 1994, EXP EYE RES, V59, P231, DOI 10.1006/exer.1994.1101; CASPERS GJ, 1995, J MOL EVOL, V40, P238, DOI 10.1007/BF00163229; Das BK, 1997, BIOCHEM BIOPH RES CO, V236, P370, DOI 10.1006/bbrc.1997.6950; Das BK, 1998, INT J BIOL MACROMOL, V23, P191, DOI 10.1016/S0141-8130(98)00048-8; Das BK, 1997, CURR EYE RES, V16, P303, DOI 10.1076/ceyr.16.4.303.10691; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; Eftink MR, 1997, METHOD ENZYMOL, V278, P258; Eftink MR, 1995, METHOD ENZYMOL, V259, P487; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; Gesierich U, 1996, FEBS LETT, V393, P151, DOI 10.1016/0014-5793(96)00867-8; GOROVITS BM, 1995, J BIOL CHEM, V270, P28551, DOI 10.1074/jbc.270.48.28551; GOROVITS BM, 1995, BIOCHEMISTRY-US, V34, P13928, DOI 10.1021/bi00042a026; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; Haley DA, 1998, J MOL BIOL, V277, P27, DOI 10.1006/jmbi.1997.1611; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Horwitz J, 1998, INT J BIOL MACROMOL, V22, P263, DOI 10.1016/S0141-8130(98)00024-5; Horwitz J, 1998, METHOD ENZYMOL, V290, P365, DOI 10.1016/S0076-6879(98)90032-5; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; JEANICKE R, 1986, METHOD ENZYMOL, V131, P218; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MAITI M, 1988, FEBS LETT, V236, P109, DOI 10.1016/0014-5793(88)80295-3; MANDAL K, 1985, BIOCHIM BIOPHYS ACTA, V832, P156, DOI 10.1016/0167-4838(85)90327-9; MANDAL K, 1987, BIOCHIM BIOPHYS ACTA, V911, P277, DOI 10.1016/0167-4838(87)90068-9; MATTHEWS CR, 1987, METHOD ENZYMOL, V154, P498; MAYR EM, 1994, J MOL BIOL, V235, P84, DOI 10.1016/S0022-2836(05)80017-8; Muchowski PJ, 1997, J BIOL CHEM, V272, P2578; Muchowski PJ, 1999, J MOL BIOL, V289, P397, DOI 10.1006/jmbi.1999.2759; ORTWERTH BJ, 1992, EXP EYE RES, V55, P777, DOI 10.1016/0014-4835(92)90004-C; Plater ML, 1996, J BIOL CHEM, V271, P28558, DOI 10.1074/jbc.271.45.28558; RAMAN B, 1995, J BIOL CHEM, V270, P19888, DOI 10.1074/jbc.270.34.19888; RUDOLPH R, 1990, P NATL ACAD SCI USA, V87, P4625, DOI 10.1073/pnas.87.12.4625; Sharma KK, 1998, J BIOL CHEM, V273, P8965, DOI 10.1074/jbc.273.15.8965; SIEBENDRITT R, 1991, BIOL CHEM H-S, V372, P23, DOI 10.1515/bchm3.1991.372.1.23; SIEZEN RJ, 1982, EXP EYE RES, V34, P969, DOI 10.1016/0014-4835(82)90077-X; SIEZEN RJ, 1980, EUR J BIOCHEM, V111, P435, DOI 10.1111/j.1432-1033.1980.tb04958.x; Smulders RHPH, 1998, INT J BIOL MACROMOL, V22, P187, DOI 10.1016/S0141-8130(98)00016-6; SMULDERS RHPH, 1995, EUR J BIOCHEM, V232, P834, DOI 10.1111/j.1432-1033.1995.834zz.x; SPECTOR A, 1984, INVEST OPHTH VIS SCI, V25, P130; Sun TX, 1998, FEBS LETT, V430, P401, DOI 10.1016/S0014-5793(98)00707-8; Sun TX, 1997, J BIOL CHEM, V272, P6220, DOI 10.1074/jbc.272.10.6220; Sun TX, 1998, J BIOL CHEM, V273, P286, DOI 10.1074/jbc.273.1.286; THOMSON JA, 1989, J BIOL CHEM, V264, P11614; TRINKL S, 1994, PROTEIN SCI, V3, P1392, DOI 10.1002/pro.5560030905; Utiyama H, 1986, Methods Enzymol, V131, P51; VANDENOETELAAR PJM, 1989, BIOCHIM BIOPHYS ACTA, V995, P91, DOI 10.1016/0167-4838(89)90238-0; WALSH MT, 1991, J BIOL CHEM, V266, P20079; WANG KY, 1995, EXP EYE RES, V61, P115; WISTOW G, 1985, FEBS LETT, V181, P1, DOI 10.1016/0014-5793(85)81102-9	57	47	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34067	34071		10.1074/jbc.274.48.34067	http://dx.doi.org/10.1074/jbc.274.48.34067			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567374	hybrid			2022-12-25	WOS:000083857500039
J	Der Perng, M; Muchowski, PJ; van den IJssel, P; Wu, GJS; Hutcheson, AM; Clark, JI; Quinlan, RA				Der Perng, M; Muchowski, PJ; van den IJssel, P; Wu, GJS; Hutcheson, AM; Clark, JI; Quinlan, RA			The cardiomyopathy and lens cataract mutation in alpha B-crystallin alters its protein structure, chaperone activity, and interaction with intermediate filaments in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; MOLECULAR CHAPERONE; A-CRYSTALLIN; POSTTRANSLATIONAL MODIFICATIONS; MISSENSE MUTATION; THERMAL-STABILITY; MYOPATHY; DOMAIN; STRESS; IDENTIFICATION	Desmin-related myopathy and cataract are both caused by the R120G mutation in alpha B-crystallin, Desmin-related myopathy is one of several diseases characterized by the coaggregation of intermediate filaments with alpha B-crystallin, and it identifies intermediate filaments as important physiological substrates for alpha B-crystallin, Using recombinant human alpha B-crystallin, the effects of the disease-causing mutation R120G upon the structure and the chaperone activities of alpha B-crystallin are reported, The secondary, tertiary, and quaternary structural features of alpha B-crystallin are all altered by the mutation as deduced by near- and far-UV circular dichroism spectroscopy, size exclusion chromatography, and chymotryptic digestion assays. The R120G alpha B-crystallin is also less stable than wild type alpha B-crystallin to heat-induced denaturation, These structural changes coincide with a significant reduction in the in vitro chaperone activity of the mutant alpha B-crystallin protein, as assessed by temperature-induced protein aggregation assays. The mutation also significantly altered the interaction of alpha B-crystallin with intermediate filaments. It abolished the ability of alpha B-crystallin to prevent those filament filament interactions required to in duce gel formation while increasing alpha B-crystallin binding to assembled intermediate filaments. These activities are closely correlated to the observed disease pathologies characterized by filament aggregation accompanied by alpha B-crystallin binding. These studies provide important insight into the mechanism of alpha B-crystallin-induced aggregation of intermediate filaments that causes disease.	Univ Dundee, Inst Med Sci, Dept Biochem, Dundee DD1 5EH, Scotland; Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA	University of Dundee; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Quinlan, RA (corresponding author), Univ Dundee, Inst Med Sci, Dept Biochem, Dundee DD1 5EH, Scotland.		Quinlan, Roy/A-1348-2012	Quinlan, Roy/0000-0003-0644-4123	NATIONAL EYE INSTITUTE [T32EY007031, R01EY004542] Funding Source: NIH RePORTER; NEI NIH HHS [EY0452, T32 EY07031, R01 EY004542] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BENNARDINI F, 1992, CIRC RES, V71, P288, DOI 10.1161/01.RES.71.2.288; Berengian AR, 1997, BIOCHEMISTRY-US, V36, P9951, DOI 10.1021/bi9712347; Berengian AR, 1999, J BIOL CHEM, V274, P6305, DOI 10.1074/jbc.274.10.6305; Blakytny R, 1997, BBA-PROTEIN STRUCT M, V1343, P299, DOI 10.1016/S0167-4838(97)00145-3; Bova MP, 1999, P NATL ACAD SCI USA, V96, P6137, DOI 10.1073/pnas.96.11.6137; CARTER JM, 1995, EXP EYE RES, V60, P181, DOI 10.1016/S0014-4835(95)80009-3; CHERIAN M, 1995, BIOCHEM BIOPH RES CO, V208, P675, DOI 10.1006/bbrc.1995.1391; Cherian M, 1997, J BIOL CHEM, V272, P29099, DOI 10.1074/jbc.272.46.29099; COLLIER NC, 1986, EXP EYE RES, V43, P103, DOI 10.1016/S0014-4835(86)80049-5; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; DEJONG WW, 1984, EUR J BIOCHEM, V141, P131; Djabali K, 1997, J CELL SCI, V110, P2759; GOEBEL HH, 1993, VIRCHOWS ARCH B, V64, P127, DOI 10.1007/BF02915105; Goldfarb LG, 1998, NAT GENET, V19, P402, DOI 10.1038/1300; Haley DA, 1998, J MOL BIOL, V277, P27, DOI 10.1006/jmbi.1997.1611; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Horwitz J, 1998, INT J BIOL MACROMOL, V22, P263, DOI 10.1016/S0141-8130(98)00024-5; Horwitz J, 1998, METHOD ENZYMOL, V290, P365, DOI 10.1016/S0076-6879(98)90032-5; INAGUMA Y, 1993, J BIOCHEM-TOKYO, V114, P378, DOI 10.1093/oxfordjournals.jbchem.a124184; IWAKI T, 1994, J CELL BIOL, V125, P1385, DOI 10.1083/jcb.125.6.1385; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1074, P201, DOI 10.1016/0304-4165(91)90062-L; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kumar LVS, 1999, J BIOL CHEM, V274, P24137, DOI 10.1074/jbc.274.34.24137; LIANG J, 1989, INVEST OPHTH VIS SCI, V30, P2065; LIANG JN, 1985, BIOCHIM BIOPHYS ACTA, V832, P197, DOI 10.1016/0167-4838(85)90332-2; Litt M, 1998, HUM MOL GENET, V7, P471, DOI 10.1093/hmg/7.3.471; LOWE J, 1992, J PATHOL, V166, P61, DOI 10.1002/path.1711660110; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; Magin TM, 1998, J CELL BIOL, V140, P1441, DOI 10.1083/jcb.140.6.1441; MAITI M, 1988, FEBS LETT, V236, P109, DOI 10.1016/0014-5793(88)80295-3; Muchowski PJ, 1999, J BIOL CHEM, V274, P30190, DOI 10.1074/jbc.274.42.30190; Muchowski PJ, 1999, INVEST OPHTH VIS SCI, V40, P951; Muchowski PJ, 1998, P NATL ACAD SCI USA, V95, P1004, DOI 10.1073/pnas.95.3.1004; Muchowski PJ, 1997, J BIOL CHEM, V272, P2578; Muchowski PJ, 1999, J MOL BIOL, V289, P397, DOI 10.1006/jmbi.1999.2759; Munoz-Marmol AM, 1998, P NATL ACAD SCI USA, V95, P11312, DOI 10.1073/pnas.95.19.11312; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; Perng MD, 1999, J CELL SCI, V112, P2099; Porter RM, 1998, J BIOL CHEM, V273, P32265, DOI 10.1074/jbc.273.48.32265; Quinlan R, 1995, PROTEIN PROFILE, V2, P801; Quinlan R, 1999, NAT MED, V5, P25, DOI 10.1038/4704; Quinlan RA, 1996, TRENDS CELL BIOL, V6, P123, DOI 10.1016/0962-8924(96)20001-7; RALTON JE, 1994, J CELL SCI, V107, P1935; Raman B, 1997, J BIOL CHEM, V272, P23559, DOI 10.1074/jbc.272.38.23559; RAMAN B, 1995, FEBS LETT, V365, P133, DOI 10.1016/0014-5793(95)00440-K; RAO PV, 1994, J BIOL CHEM, V269, P13266; Smulders RHPH, 1996, J BIOL CHEM, V271, P29060, DOI 10.1074/jbc.271.46.29060; SMULDERS RHPH, 1995, EUR J BIOCHEM, V232, P834, DOI 10.1111/j.1432-1033.1995.834zz.x; Sun TX, 1998, FEBS LETT, V430, P401, DOI 10.1016/S0014-5793(98)00707-8; Sun TX, 1997, J BIOL CHEM, V272, P6220, DOI 10.1074/jbc.272.10.6220; SUREWICZ WK, 1995, BIOCHEMISTRY-US, V34, P9655, DOI 10.1021/bi00030a001; TAKEMOTO L, 1993, BIOCHEM J, V294, P435, DOI 10.1042/bj2940435; van den IJssel P, 1999, CURR BIOL, V9, pR103, DOI 10.1016/S0960-9822(99)80061-X; vanBoekel MAM, 1996, OPHTHALMIC RES, V28, P32, DOI 10.1159/000267940; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Wisniewski T, 1998, NEUROCHEM RES, V23, P385, DOI 10.1023/A:1022465702518; WISTOW G, 1985, FEBS LETT, V181, P1, DOI 10.1016/0014-5793(85)81102-9	59	144	149	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33235	33243		10.1074/jbc.274.47.33235	http://dx.doi.org/10.1074/jbc.274.47.33235			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559197	Green Accepted, hybrid			2022-12-25	WOS:000083745200013
J	Karchner, SI; Powell, WH; Hahn, ME				Karchner, SI; Powell, WH; Hahn, ME			Identification and functional characterization of two highly divergent aryl hydrocarbon receptors (AHR1 and AHR2) in the teleost Fundulus heteroclitus - Evidence for a novel subfamily of ligand-binding basic helix loop helix-Per-ARNT-Sim (bHLH-PAS) factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; CLOSE SEQUENCE SIMILARITY; NUCLEAR TRANSLOCATOR ARNT; MESSENGER-RNAS; DNA-BINDING; TRANSCRIPTION FACTOR; DIOXIN RECEPTOR; CELL-CYCLE; PHYLOGENETIC ANALYSIS; BIPHENYL CONGENERS	The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor through which 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related compounds cause altered gene expression and toxicity. The AKR belongs to an emerging multigene family of transcription factors possessing basic helix loop helix (bHLH) and Per-ARNT-Sim (PAS) domains. Most bHLH-PAS proteins occur as duplicates or "paralog groups" in mammals, but only a single mammalian AHR has been identified. Here we report the cDNA cloning of two distinct AHRs, designated FhAHR1 and FhAHR2, from a single vertebrate species, the teleost Fundulus heteroclitus (Atlantic killifish). Both Fundulus AHR proteins possess bHLH and PAS domains that are closely related to those of the mammalian AHR. FhAHR1 and FhAHR2 are highly divergent (40% overall amino acid identity; 61% identity in the N-terminal half), suggesting that they arose from a gene duplication predating the divergence of mammals and fish. Photoaffinity labeling with 2-azido-3-[I-125]iodo-7,8-dibromodibenzo-p-dioxin and velocity sedimentation analysis using 2,3,7,8-[1,6-H-3]TCDD showed that both FhAHR1 and FhAHR2 exhibit specific, high-affinity binding of dioxins. Both AHRs also showed specific, TCDD- and ARNT-dependent interactions with a mammalian xenobiotic response element. The two Fundulus AHR genes displayed different tissue-specific patterns of expression; FhAHR1 transcripts were primarily expressed in brain, heart, ovary, and testis, while FhAHR2 transcripts were equally abundant in many tissues. Phylogenetic analysis demonstrated that Fundulus AHR1 is an ortholog of mammalian AHRs, while AHR2 forms in Fundulus and other fish are paralogous to Fundulus AHR1 and the mammalian AHRs and thus represent a novel vertebrate subfamily of ligand-binding AHRs.	Woods Hole Oceanog Inst, Dept Biol, Woods Hole, MA 02543 USA	Woods Hole Oceanographic Institution	Hahn, ME (corresponding author), Woods Hole Oceanog Inst, Dept Biol, MS 32, Woods Hole, MA 02543 USA.	mhahn@whoi.edu	Hahn, Mark/AAV-7516-2020	Hahn, Mark/0000-0003-4358-2082; Powell, Wade H./0000-0002-3727-2822	NIEHS NIH HHS [F32 ES05800, R01 ES006272-08, R01 ES006272, ES06272, F32 ES05644, F32 ES005800] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F32ES005800, R29ES006272, R01ES006272, F32ES005644] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABBOTT BD, 1995, DEV DYNAM, V204, P133, DOI 10.1002/aja.1002040204; Abnet CC, 1999, J BIOL CHEM, V274, P15159, DOI 10.1074/jbc.274.21.15159; Amores A, 1998, SCIENCE, V282, P1711, DOI 10.1126/science.282.5394.1711; Andreola F, 1997, CANCER RES, V57, P2835; ARMSTRON.PB, 1965, BIOL BULL, V128, P143, DOI 10.2307/1539545; BANK PA, 1995, ARCH BIOCHEM BIOPHYS, V317, P439, DOI 10.1006/abbi.1995.1186; Besselink HT, 1998, TOXICOL SCI, V43, P161; BHATTACHARYA D, 1993, MOL BIOL EVOL, V10, P689; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CARVER LA, 1994, NUCLEIC ACIDS RES, V22, P3038, DOI 10.1093/nar/22.15.3038; COOMBS DH, 1985, ANAL BIOCHEM, V148, P254, DOI 10.1016/0003-2697(85)90654-2; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; DENISON MS, 1986, J BIOL CHEM, V261, P3987; DENISON MS, 1992, J BIOCHEM TOXICOL, V7, P249, DOI 10.1002/jbt.2570070408; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DOLWICK KM, 1993, MOL PHARMACOL, V44, P911; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; Dong LQ, 1996, J BIOL CHEM, V271, P7942, DOI 10.1074/jbc.271.14.7942; DOTTAVIOMARTIN D, 1978, ANAL BIOCHEM, V87, P562, DOI 10.1016/0003-2697(78)90706-6; Duncan DM, 1998, GENE DEV, V12, P1290, DOI 10.1101/gad.12.9.1290; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; EMA M, 1994, J BIOL CHEM, V269, P27337; Ema M, 1996, MOL CELL BIOL, V16, P5865; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; Fan CM, 1996, MOL CELL NEUROSCI, V7, P1, DOI 10.1006/mcne.1996.0001; Ferguson M.M., 1991, Biochemistry and Molecular Biology of Fishes, V1, P25; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; FernandezSalguero PM, 1996, TOXICOL APPL PHARM, V140, P173, DOI 10.1006/taap.1996.0210; Force A, 1999, GENETICS, V151, P1531; Fujii-Kuriyama Y, 1997, FASEB J, V11, pA780; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; Fukunaga BN, 1996, J BIOL CHEM, V271, P3743; GASIEWICZ TA, 1979, TOXICOL APPL PHARM, V51, P329, DOI 10.1016/0041-008X(79)90475-7; Ge NL, 1998, J BIOL CHEM, V273, P22708, DOI 10.1074/jbc.273.35.22708; GOOCH JW, 1989, TOXICOL APPL PHARM, V98, P422, DOI 10.1016/0041-008X(89)90171-3; Guiney PD, 1997, TOXICOL APPL PHARM, V143, P256, DOI 10.1006/taap.1996.8051; HAHN ME, 1995, BIOCHEM J, V310, P383, DOI 10.1042/bj3100383; HAHN ME, 1994, ARCH BIOCHEM BIOPHYS, V310, P218, DOI 10.1006/abbi.1994.1160; Hahn ME, 1998, COMP BIOCHEM PHYS C, V120, P67, DOI 10.1016/S0742-8413(98)00007-3; Hahn ME, 1997, P NATL ACAD SCI USA, V94, P13743, DOI 10.1073/pnas.94.25.13743; Hahn ME, 1998, COMP BIOCHEM PHYS C, V121, P23, DOI 10.1016/S0742-8413(98)10028-2; HAHN ME, 1998, REV TOXICOL, V2, P395; HAHN ME, 1996, INTERCONNECTIONS HUM, P9; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Hirose K, 1996, MOL CELL BIOL, V16, P1706; Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895; JAIN S, 1994, J BIOL CHEM, V269, P31518; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; LANDERS JP, 1991, J BIOL CHEM, V266, P9471; LI W, 1994, ARCH BIOCHEM BIOPHYS, V315, P279, DOI 10.1006/abbi.1994.1501; MA Q, 1995, J BIOL CHEM, V270, P12697, DOI 10.1074/jbc.270.21.12697; Ma Q, 1996, MOL CELL BIOL, V16, P2144; Maier A, 1998, ENVIRON HEALTH PERSP, V106, P421, DOI 10.2307/3434070; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MARUYAMA IN, 1995, NUCLEIC ACIDS RES, V23, P3796, DOI 10.1093/nar/23.18.3796; MASON ME, 1982, EUR J BIOCHEM, V123, P209, DOI 10.1111/j.1432-1033.1982.tb06518.x; Mimura J, 1999, GENE DEV, V13, P20, DOI 10.1101/gad.13.1.20; Misof BY, 1996, MOL PHYLOGENET EVOL, V5, P309, DOI 10.1006/mpev.1996.0026; Morrison HG, 1998, COMP BIOCHEM PHYS C, V121, P231, DOI 10.1016/S0742-8413(98)10044-0; Nacci D, 1999, MAR BIOL, V134, P9, DOI 10.1007/s002270050520; OKEY AB, 1979, J BIOL CHEM, V254, P1636; PERDEW GH, 1995, J BIOCHEM TOXICOL, V10, P95, DOI 10.1002/jbt.2570100206; PETERSON RE, 1993, CRIT REV TOXICOL, V23, P283, DOI 10.3109/10408449309105013; POLAND A, 1994, MOL PHARMACOL, V46, P915; POLAND A, 1986, J BIOL CHEM, V261, P6352; POLAND A, 1976, J BIOL CHEM, V251, P4936; POLAND A, 1991, MOL PHARMACOL, V39, P20; Powell WH, 1999, ARCH BIOCHEM BIOPHYS, V361, P156, DOI 10.1006/abbi.1998.0992; Powell-Coffman JA, 1998, P NATL ACAD SCI USA, V95, P2844, DOI 10.1073/pnas.95.6.2844; POWERS DA, 1989, SCIENCE, V246, P352, DOI 10.1126/science.2678474; POWERS DA, 1986, AM ZOOL, V26, P131; PRINCE R, 1995, ENVIRON TOXICOL CHEM, V14, P579, DOI 10.1002/etc.5620140405; Rasmussen AS, 1999, P NATL ACAD SCI USA, V96, P2177, DOI 10.1073/pnas.96.5.2177; Rowlands JC, 1996, MOL PHARMACOL, V50, P538; Roy NK, 1997, ARCH BIOCHEM BIOPHYS, V344, P373, DOI 10.1006/abbi.1997.0238; SCHMIDT JV, 1993, J BIOL CHEM, V268, P22203; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; Sharman AC, 1996, NETH J ZOOL, V46, P47, DOI 10.1163/156854295X00050; Sun WM, 1997, J BIOL CHEM, V272, P31845, DOI 10.1074/jbc.272.50.31845; Swanson HI, 1998, MOL PHARMACOL, V54, P671; Swanson HI, 1996, J BIOL CHEM, V271, P31657, DOI 10.1074/jbc.271.49.31657; SWOFFORD DL, 2001, PHYLOGENETIC ANAL US; Takahashi Y, 1996, EUR J BIOCHEM, V242, P512, DOI 10.1111/j.1432-1033.1996.0512r.x; Tanguay RL, 1999, BBA-GENE STRUCT EXPR, V1444, P35, DOI 10.1016/S0167-4781(98)00252-8; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; TSUI HW, 1981, CAN J PHYSIOL PHARM, V59, P927, DOI 10.1139/y81-143; WALKER MK, 1991, CAN J FISH AQUAT SCI, V48, P875, DOI 10.1139/f91-104; WALKER MK, 1991, AQUAT TOXICOL, V21, P219, DOI 10.1016/0166-445X(91)90074-J; Wang WD, 1998, FISH PHYSIOL BIOCHEM, V18, P49, DOI 10.1023/A:1007790214142; Weiss C, 1996, EXP CELL RES, V226, P154, DOI 10.1006/excr.1996.0214; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103; Wittbrodt J, 1998, BIOESSAYS, V20, P511, DOI 10.1002/(SICI)1521-1878(199806)20:6&lt;511::AID-BIES10&gt;3.0.CO;2-3; Zaher H, 1998, MOL PHARMACOL, V54, P313, DOI 10.1124/mol.54.2.313; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	98	128	142	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33814	33824		10.1074/jbc.274.47.33814	http://dx.doi.org/10.1074/jbc.274.47.33814			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559277	hybrid			2022-12-25	WOS:000083745200093
J	Rich, CB; Fontanilla, MR; Nugent, M; Foster, JA				Rich, CB; Fontanilla, MR; Nugent, M; Foster, JA			Basic fibroblast growth factor decreases elastin gene transcription through an AP1/cAMP-response element hybrid site in the distal promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA LEVELS; RAT LUNG; DEVELOPMENTAL-CHANGES; PULMONARY FIBROBLASTS; INSITU HYBRIDIZATION; FOS PROTEINS; FACTOR-I; C-JUN; EXPRESSION; AP-1	Previous studies demonstrated that basic fibroblast growth factor (bFGF) decreases elastin gene transcription in pulmonary fibroblasts. In this study we pursue the identification of the element and the trans-acting factors responsible. Gel shift analyses show that bFGF increases protein binding to a sequence located at -564 to -558 base pairs (bp), which possesses homology to both AP1 and cAMP-response consensus elements yet displays a unique affinity for heterodimer binding. Site-directed mutation of the -564- to -558-bp sequence results in an increase in promoter activity and abrogates the effect of bFGF. Western blot analysis shows that bFGF induces a sustained increase in the steady-state levels of Fra 1, and co-transfection of a Fra 1 expression vector with an elastin promoter reporter construct results in an inhibition of elastin promoter activity. Overall the results suggest that bFGF represses elastin gene transcription by increasing the amount of the Fra 1 that subsequently binds to the -564- to -558-bp as a heterodimer with c-Jun to form an inhibitory complex. We propose that the identified bFGF response element can serve to down-regulate elastin transcription in elastogenic cells and, conversely, can serve to up-regulate elastogenesis in cells where endogenous bFGF signaling is attenuated or altered.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Foster, JA (corresponding author), Boston Univ, Sch Med, Dept Biochem, 80 E Concord St, Boston, MA 02118 USA.	jfoster@med-biochem.bu.edu		Nugent, Matthew/0000-0002-8630-4712	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046902] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 46902] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBIN RJ, 1987, PULMONARY EMPHYSEM 5, P283; BERK JL, 1991, J BIOL CHEM, V266, P3192; Boudreaux JM, 1996, J BIOL CHEM, V271, P7508, DOI 10.1074/jbc.271.13.7508; BRETTELL LM, 1994, AM J RESP CELL MOL, V10, P306, DOI 10.1165/ajrcmb.10.3.8117449; BRUCE MC, 1991, AM J RESP CELL MOL, V5, P344, DOI 10.1165/ajrcmb/5.4.344; Buczek-Thomas JA, 1999, J BIOL CHEM, V274, P25167, DOI 10.1074/jbc.274.35.25167; CVEKL A, 1994, MOL CELL BIOL, V14, P7363, DOI 10.1128/MCB.14.11.7363; FOSTER JA, 1988, LAB INVEST, V58, P667; FOSTER JA, 1990, J BIOL CHEM, V265, P15544; GENERSCH E, 1995, EMBO J, V14, P791, DOI 10.1002/j.1460-2075.1995.tb07057.x; Griffiths MR, 1998, BIOCHEM J, V335, P19, DOI 10.1042/bj3350019; James MF, 1998, DEV DYNAM, V213, P170, DOI 10.1002/(SICI)1097-0177(199810)213:2<170::AID-AJA2>3.0.CO;2-D; JENSEN DE, 1995, J BIOL CHEM, V270, P6555, DOI 10.1074/jbc.270.12.6555; KAHARI VM, 1992, J BIOL CHEM, V267, P26134; KAHARI VM, 1990, J BIOL CHEM, V265, P9485; KILBOURNE EJ, 1995, J BIOL CHEM, V270, P7004, DOI 10.1074/jbc.270.12.7004; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Leonard DA, 1998, NAT STRUCT BIOL, V5, P877, DOI 10.1038/2316; McGowan SE, 1997, AM J RESP CELL MOL, V17, P25, DOI 10.1165/ajrcmb.17.1.2686; MCGOWAN SE, 1993, AMJ RESP CELL MOL BI, V3, P369; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Newberry EP, 1997, MOL ENDOCRINOL, V11, P1129, DOI 10.1210/me.11.8.1129; NOGUCHI A, 1990, PEDIATR RES, V28, P379, DOI 10.1203/00006450-199010000-00015; NOGUCHI A, 1991, AM J RESP CELL MOL, V5, P571, DOI 10.1165/ajrcmb/5.6.571; PIERCE RA, 1995, AM J PHYSIOL-LUNG C, V268, pL491, DOI 10.1152/ajplung.1995.268.3.L491; Rich CB, 1996, J BIOL CHEM, V271, P23043, DOI 10.1074/jbc.271.38.23043; RYSECK RP, 1991, ONCOGENE, V6, P533; Sambrook J., 1989, MOL CLONING, pA1; SANDHAUS RA, 1987, PULMONARY EMPHYSEMA, P227; SHIBAHARA S, 1981, BIOCHEMISTRY-US, V20, P6577, DOI 10.1021/bi00526a009; SNIDER GL, 1991, ANN NY ACAD SCI, V624, P45, DOI 10.1111/j.1749-6632.1991.tb17005.x; SWEE MH, 1995, J BIOL CHEM, V270, P14899, DOI 10.1074/jbc.270.25.14899; TAN Y, 1994, MOL CELL BIOL, V14, P7546, DOI 10.1128/MCB.14.11.7546; VANDELEST CHA, 1995, EUR RESPIR J, V8, P238, DOI 10.1183/09031936.95.08020238; Weinstein M, 1998, DEVELOPMENT, V125, P3615; WOLFE BL, 1993, J BIOL CHEM, V268, P12418	37	30	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33433	33439		10.1074/jbc.274.47.33433	http://dx.doi.org/10.1074/jbc.274.47.33433			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559225	hybrid			2022-12-25	WOS:000083745200041
J	Wenzel-Seifert, K; Arthur, JM; Liu, HY; Seifert, R				Wenzel-Seifert, K; Arthur, JM; Liu, HY; Seifert, R			Quantitative analysis of formyl peptide receptor coupling to G(i)alpha(1) G(i),alpha(2), and G(i)alpha(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-BINDING; G-PROTEIN-ACTIVATION; INFECTED INSECT CELLS; HUMAN LEUKEMIA-CELLS; FUSION PROTEIN; SIGNAL-TRANSDUCTION; ESCHERICHIA-COLI; HL-60 CELLS; SF9 CELLS; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE	The human formyl peptide receptor (FPR) is a prototypical Gi protein-coupled receptor, but little is known about quantitative aspects of FPR-G(i) protein coupling. To address this issue, we fused the FPR to G(i)alpha(1), G(i)alpha(2), and G(i)alpha(3) and expressed the fusion proteins in Sf9 insect cells. Fusion of a receptor to G alpha ensures a defined 1:1 stoichiometry of the signaling partners. By analyzing high affinity agonist binding, the kinetics of agonist- and inverse agonist-regulated guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S) binding and GTP hydrolysis and photolabeling of G alpha, we demonstrate highly efficient coupling of the FPR to fused G(i)alpha(1), G(i)alpha(2), and G(i)alpha(3) without cross-talk of the receptor to insect cell G proteins. The FPR displayed high constitutive activity when coupled to all three G(i)alpha isoforms. The K-d values of high affinity agonist binding were similar to 100-fold lower than the EC50 (concentration that gives half-maximal stimulation) values of agonist for GTPase activation. Based on the B-max values of agonist saturation binding and ligand-regulated GTP gamma S binding, it was previously proposed that the FPR activates G proteins catalytically, i.e. one FPR activates several Gi proteins. Analysis of agonist saturation binding, ligand-regulated GTP gamma S saturation binding and quantitative immunoblotting with membranes expressing FPR-G(i)alpha fusion proteins and nonfused FPR now reveals that FPR agonist binding greatly underestimates the actual FPR expression level. Our data show the following: (i) the FPR couples to G(i)alpha(1), G(i)alpha(2), and G(i)alpha(3) with similar efficiency; (ii) the FPR can exist in a state of low agonist affinity that couples efficiently to G proteins; and (iii) in contrast to the previously held view, the FPR appears to activate Gi proteins linearly and not catalytically.	Univ Kansas, Dept Pharmacol & Toxicol, Lawrence, KS 66045 USA; Univ Kansas, Higuchi Biosci Ctr, Lawrence, KS 66045 USA; Univ Louisville, Dept Med, Kidney Dis Program, Louisville, KY 40202 USA	University of Kansas; University of Kansas; University of Louisville	Wenzel-Seifert, K (corresponding author), Univ Kansas, Dept Pharmacol & Toxicol, 5003 Malott Hall, Lawrence, KS 66045 USA.		Seifert, Roland/G-3189-2013	Arthur, John/0000-0003-4342-4762				Albrecht E, 1998, J PHARMACOL EXP THER, V286, P896; Arthur JM, 1997, AM J PHYSIOL-RENAL, V273, pF129, DOI 10.1152/ajprenal.1997.273.1.F129; BERTIN B, 1992, J BIOL CHEM, V267, P8200; BERTIN B, 1994, P NATL ACAD SCI USA, V91, P8827, DOI 10.1073/pnas.91.19.8827; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOMMAKANTI RK, 1995, BIOCHEMISTRY-US, V34, P6720, DOI 10.1021/bi00020a017; Burt AR, 1998, J BIOL CHEM, V273, P10367, DOI 10.1074/jbc.273.17.10367; BUTKERAIT P, 1995, J BIOL CHEM, V270, P18691, DOI 10.1074/jbc.270.31.18691; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CARTY DJ, 1990, J BIOL CHEM, V265, P6268; Clawges HM, 1997, BIOCHEMISTRY-US, V36, P12930, DOI 10.1021/bi970112b; CUPO JF, 1989, BIOCHIM BIOPHYS ACTA, V982, P31, DOI 10.1016/0005-2736(89)90170-3; Damaj BB, 1996, J BIOL CHEM, V271, P12783, DOI 10.1074/jbc.271.22.12783; DIDSBURY JR, 1987, FEBS LETT, V219, P259, DOI 10.1016/0014-5793(87)81228-0; DIETRICH A, 1992, FEBS LETT, V313, P220, DOI 10.1016/0014-5793(92)81195-R; DILLON SB, 1988, VIRCHOWS ARCH B, V55, P65; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Gao JL, 1999, J EXP MED, V189, P657, DOI 10.1084/jem.189.4.657; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; GIERSCHIK P, 1991, EUR J BIOCHEM, V197, P725, DOI 10.1111/j.1432-1033.1991.tb15964.x; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; GIERSCHIK P, 1989, EUR J BIOCHEM, V183, P97, DOI 10.1111/j.1432-1033.1989.tb14901.x; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; Grunewald S, 1996, BIOCHEMISTRY-US, V35, P15162, DOI 10.1021/bi960757w; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; Hornquist CE, 1997, J IMMUNOL, V158, P1068; JACOBS AA, 1995, J LEUKOCYTE BIOL, V57, P679, DOI 10.1002/jlb.57.4.679; Jiang HP, 1996, J BIOL CHEM, V271, P13430, DOI 10.1074/jbc.271.23.13430; JONES DT, 1987, J BIOL CHEM, V262, P14241; Kenakin T, 1996, PHARMACOL REV, V48, P413; KLINKER JF, 1994, BIOCHEM PHARMACOL, V48, P1857, DOI 10.1016/0006-2952(94)90583-5; Klinker JF, 1996, GEN PHARMACOL, V27, P33, DOI 10.1016/0306-3623(95)00107-7; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; Kular G, 1997, BIOCHEM J, V325, P299, DOI 10.1042/bj3250299; LAW SF, 1993, J BIOL CHEM, V268, P10721; LEFF P, 1995, TRENDS PHARMACOL SCI, V16, P89, DOI 10.1016/S0165-6147(00)88989-0; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; Leopoldt D, 1997, N-S ARCH PHARMACOL, V356, P216, DOI 10.1007/PL00005044; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; LINDER ME, 1990, J BIOL CHEM, V265, P8243; MURPHY PM, 1987, FEBS LETT, V221, P81, DOI 10.1016/0014-5793(87)80356-3; MUSGRAVE IF, 1995, BIOCHEM PHARMACOL, V49, P187, DOI 10.1016/S0006-2952(94)00432-3; OFFERMANS S, 1990, FEBS LETT, V260, P14, DOI 10.1016/0014-5793(90)80054-M; Prossnitz ER, 1997, PHARMACOL THERAPEUT, V74, P73, DOI 10.1016/S0163-7258(96)00203-3; QUEHENBERGER O, 1992, J BIOL CHEM, V267, P19757; RANSNAS LA, 1988, J BIOL CHEM, V263, P9482; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; RUDOLPH U, 1995, NAT GENET, V10, P143, DOI 10.1038/ng0695-143; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; Sautel M, 1998, FEBS LETT, V436, P46, DOI 10.1016/S0014-5793(98)01094-1; SCHEPERS TM, 1992, J BIOL CHEM, V267, P159; Seifert R, 1998, EUR J BIOCHEM, V255, P369, DOI 10.1046/j.1432-1327.1998.2550369.x; Seifert R, 1999, EUR J BIOCHEM, V260, P661, DOI 10.1046/j.1432-1327.1999.00161.x; Seifert R, 1998, J BIOL CHEM, V273, P5109, DOI 10.1074/jbc.273.9.5109; Seifert R, 1999, TRENDS PHARMACOL SCI, V20, P383, DOI 10.1016/S0165-6147(99)01368-1; SEIFERT R, 1991, REV PHYSIOL BIOCH P, V117, P1; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; STEPHENS L, 1993, J BIOL CHEM, V268, P17162; Wenzel-Seifert K, 1998, J BIOL CHEM, V273, P24181, DOI 10.1074/jbc.273.37.24181; WENZELSEIFERT K, 1993, J IMMUNOL, V150, P4591; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; WIELAND T, 1995, N-S ARCH PHARMACOL, V351, P329, DOI 10.1007/BF00169072; Wise A, 1997, BIOCHEM J, V325, P17, DOI 10.1042/bj3250017; Wise A, 1999, BIOCHEMISTRY-US, V38, P2272, DOI 10.1021/bi982054f	66	86	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33259	33266		10.1074/jbc.274.47.33259	http://dx.doi.org/10.1074/jbc.274.47.33259			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559200	hybrid			2022-12-25	WOS:000083745200016
J	Mischiati, C; Borgatti, M; Bianchi, N; Rutigliano, C; Tomassetti, M; Feriotto, G; Gambari, R				Mischiati, C; Borgatti, M; Bianchi, N; Rutigliano, C; Tomassetti, M; Feriotto, G; Gambari, R			Interaction of the human NF-kappa B p52 transcription factor with DNA-PNA hybrids mimicking the NF-kappa B binding sites of the human immunodeficiency virus type 1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; PEPTIDE NUCLEIC-ACIDS; LONG TERMINAL REPEAT; RNA POLYMERASE-II; GENE-EXPRESSION; FACTOR DECOY; BIOSENSOR TECHNOLOGY; KINETIC-ANALYSIS; IN-VITRO; HIV-1	We determined whether peptide nucleic acids (PNAs) are able to interact with NF-kappa B p52 transcription factor. The binding of NP-kappa B p52 to DNA-DNA, DNA-PNA, PNA-DNA, and PNA-PNA hybrid molecules carrying the NP-KB binding sites of human immunodeficiency type I long terminal repeat was studied by (i) biospecific interaction analysis (BIA) using surface plasmon resonance technology, (ii) electrophoretic mobility shift, (iii) DNase I footprinting, and (iv) UV cross-linking assays. Our results demonstrate that NF-kappa B p52 does not efficiently bind to PNA-PNA hybrids. However, a DNA-PNA hybrid molecule was found to be recognized by NF-kappa B p52, although the molecular complexes generated exhibited low stability. From the theoretical point of view, our results suggest that binding of NF-kappa B p52 protein to target DNA motifs is mainly due to contacts with bases; interactions with the DNA backbone are, however, important for stabilization of the protein-DNA complex. From the practical point of view, our results suggest that DNA-PNA hybrid can be recognized by NF-kappa B p52 protein, although with an efficiency lower than DNA-DNA NF-kappa B target molecules; therefore, our results should encourage studies on modified PNAs in order to develop potential agents for the decoy approach in gene therapy.	Univ Ferrara, Dept Biochem & Mol Biol, I-44100 Ferrara, Italy; Univ Ferrara, Ctr Biotechnol, I-44100 Ferrara, Italy	University of Ferrara; University of Ferrara	Gambari, R (corresponding author), Univ Ferrara, Dept Biochem & Mol Biol, Via L Borsari 46, I-44100 Ferrara, Italy.	gam@dns.unife.it	Gambari, Roberto/F-9555-2015; Bianchi, Nicoletta/H-1902-2015; Mischiati, Carlo/AAF-2016-2020; Borgatti, Monica/G-2611-2015	Gambari, Roberto/0000-0001-9205-6033; Bianchi, Nicoletta/0000-0001-9280-6017; Borgatti, Monica/0000-0001-8470-2496; Mischiati, Carlo/0000-0002-0029-2205				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BERG OG, 1988, TRENDS BIOCHEM SCI, V13, P207, DOI 10.1016/0968-0004(88)90085-0; BETTS L, 1995, SCIENCE, V270, P1838, DOI 10.1126/science.270.5243.1838; Bianchi N, 1997, BIOCHEM J, V326, P919, DOI 10.1042/bj3260919; BONDESON K, 1993, ANAL BIOCHEM, V214, P245, DOI 10.1006/abio.1993.1484; Cheskis B, 1996, BIOCHEMISTRY-US, V35, P3309, DOI 10.1021/bi952283r; CLUSEL C, 1993, NUCLEIC ACIDS RES, V21, P3405, DOI 10.1093/nar/21.15.3405; CLUSEL C, 1995, GENE EXPRESSION, V4, P301; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0; EGHOLM M, 1992, J AM CHEM SOC, V114, P1895, DOI 10.1021/ja00031a062; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FERIOTTO G, 1994, EUR J PHARM-MOLEC PH, V267, P143, DOI 10.1016/0922-4106(94)90165-1; FERIOTTO G, 1994, BIOCHEM J, V299, P451, DOI 10.1042/bj2990451; Galio L, 1997, ANAL BIOCHEM, V253, P70, DOI 10.1006/abio.1997.2367; Gambari R, 1997, INT J ONCOL, V11, P145; GAMBARI R, 1994, BIOCHEM PHARMACOL, V47, P599, DOI 10.1016/0006-2952(94)90121-X; GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001; Good L, 1997, ANTISENSE NUCLEIC A, V7, P431, DOI 10.1089/oli.1.1997.7.431; HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; Hyrup B, 1996, BIOORGAN MED CHEM, V4, P5, DOI 10.1016/0968-0896(95)00171-9; Iwase R, 1997, Nucleic Acids Symp Ser, P203; Jensen KK, 1997, BIOCHEMISTRY-US, V36, P5072, DOI 10.1021/bi9627525; Khaled AR, 1998, CLIN IMMUNOL IMMUNOP, V86, P170, DOI 10.1006/clin.1997.4486; Knudsen H, 1996, NUCLEIC ACIDS RES, V24, P494, DOI 10.1093/nar/24.3.494; Kozlov IA, 1997, ANTISENSE NUCLEIC A, V7, P279, DOI 10.1089/oli.1.1997.7.279; Larsen HJ, 1996, NUCLEIC ACIDS RES, V24, P458, DOI 10.1093/nar/24.3.458; LI YC, 1994, J BIOL CHEM, V269, P30616; Lim CS, 1997, NUCLEIC ACIDS RES, V25, P575, DOI 10.1093/nar/25.3.575; LOCKER J, 1993, GENE TRANSCRIPTION P, P321; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; MCSHAN WM, 1992, J BIOL CHEM, V267, P5712; Misra HS, 1998, BIOCHEMISTRY-US, V37, P1917, DOI 10.1021/bi971524n; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Morishita R, 1997, NAT MED, V3, P894, DOI 10.1038/nm0897-894; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; NILSSON P, 1995, ANAL BIOCHEM, V224, P400, DOI 10.1006/abio.1995.1057; Ono S, 1998, HUM GENE THER, V9, P1003, DOI 10.1089/hum.1998.9.7-1003; PEFFER NJ, 1993, P NATL ACAD SCI USA, V90, P10648, DOI 10.1073/pnas.90.22.10648; PETERSEN KH, 1995, BIOORG MED CHEM LETT, V5, P1119, DOI 10.1016/0960-894X(95)00177-U; Peyman A, 1997, ANGEW CHEM INT EDIT, V36, P2809, DOI 10.1002/anie.199728091; ROULSTON A, 1995, MICROBIOL REV, V59, P481, DOI 10.1128/MMBR.59.3.481-505.1995; SAGAMI I, 1986, MOL CELL BIOL, V6, P4259, DOI 10.1128/MCB.6.12.4259; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; Sharma HW, 1996, ANTICANCER RES, V16, P61; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Tomita N, 1998, J HYPERTENS, V16, P993, DOI 10.1097/00004872-199816070-00013; UHLMANN E, 1990, CHEM REV, V90, P543, DOI 10.1021/cr00102a001; VADGAMA P, 1992, ANALYST, V117, P1657, DOI 10.1039/an9921701657; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WINGENDER E, 1988, NUCLEIC ACIDS RES, V16, P1879, DOI 10.1093/nar/16.5.1879; WITTUNG P, 1994, NUCLEIC ACIDS RES, V22, P5371, DOI 10.1093/nar/22.24.5371; WOOD SJ, 1993, MICROCHEM J, V47, P330, DOI 10.1006/mchj.1993.1051; Yamashita J, 1998, J BIOL CHEM, V273, P15993, DOI 10.1074/jbc.273.26.15993	57	74	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					33114	33122		10.1074/jbc.274.46.33114	http://dx.doi.org/10.1074/jbc.274.46.33114			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551882	hybrid			2022-12-25	WOS:000083623000082
J	Altiok, S; Batt, D; Altiok, N; Papautsky, A; Downward, J; Roberts, TM; Avraham, H				Altiok, S; Batt, D; Altiok, N; Papautsky, A; Downward, J; Roberts, TM; Avraham, H			Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-kinase/AKT in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; DNA-DAMAGE; CYCLE; GENE; AKT; EXPRESSION; DIFFERENTIATION; REQUIREMENT; INVOLVEMENT; INHIBITION	The breast cancer susceptibility gene BRCA1 encodes a nuclear phosphoprotein that acts as a tumor suppressor, Phosphorylation of BRCA1 has been implicated in altering its function, however, the pathway(s) that leads to the phosphorylation of BRCA1 has not been described, Here, a signaling pathway by which heregulin induces cell cycle-independent phosphorylation of BRCA1 was delineated. We showed that heregulin stimulation induced the phosphorylation of BRCA1 and concomitant activation of the serine/threonine kinase AKT in T47D human breast cancer cells. Heregulin-induced phosphorylation of BRCA1 was abrogated by phosphatidylinositol 3-kinase (PI3K) inhibitors and by a dominant-negative AKT, In the absence of heregulin, the ectopic expression of the constitutively active p110 subunit of PI3K: was sufficient to induce BRCA1 phosphorylation. Furthermore, the purified glutathione S-transferase/AKT kinase phosphorylated BRCA1 in vitro. We have also shown that the phosphorylation of BRCA1 by ABT occurs on the residue Thr-509, which is located in the nuclear localization signal. These results reveal a novel signaling pathway that links extracellular signals to the phosphorylation of BRCA1 in breast cancer cells.	Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, Boston, MA 02115 USA; Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Childrens Hosp, Div Neurosci, Boston, MA 02115 USA; Imperial Canc Res Fund, Signal Transduct Lab, London WC2A 3PX, England	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Cancer Research UK	Avraham, H (corresponding author), Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, 3rd Fl,4 Blackfan Circle, Boston, MA 02115 USA.			Downward, Julian/0000-0002-2331-4729; ALTIOK, NEDRET/0000-0001-5989-8482	NATIONAL CANCER INSTITUTE [R01CA076226] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055445, R01HL051456] Funding Source: NIH RePORTER; NCI NIH HHS [CA76226] Funding Source: Medline; NHLBI NIH HHS [HL55445, HL51456] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Altiok N, 1997, EMBO J, V16, P717, DOI 10.1093/emboj/16.4.717; Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Coffer PJ, 1998, BIOCHEM J, V335, P1; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; EASTON DF, 1995, AM J HUM GENET, V56, P265; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; HYNES NE, 1993, SEMIN CANCER BIOL, V4, P19; Krane IM, 1996, ONCOGENE, V12, P1781; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Lewis GD, 1996, CANCER RES, V56, P1457; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shao NS, 1996, ONCOGENE, V13, P1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Tang CK, 1996, CANCER RES, V56, P3350; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801	29	103	108	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32274	32278		10.1074/jbc.274.45.32274	http://dx.doi.org/10.1074/jbc.274.45.32274			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542266	hybrid			2022-12-25	WOS:000083532100074
J	Kubicka, S; Kuhnel, F; Zender, L; Rudolph, KL; Plumpe, J; Manns, M; Trautwein, C				Kubicka, S; Kuhnel, F; Zender, L; Rudolph, KL; Plumpe, J; Manns, M; Trautwein, C			p53 represses CAAT enhancer-binding protein (C/EBP)-dependent transcription of the albumin gene - A molecular mechanism involved in viral liver infection with implications for hepatocarcinogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; HEPATOCELLULAR-CARCINOMA; DNA-BINDING; WILD-TYPE; FUNCTION MUTATIONS; ACTIVATION DOMAIN; PRODUCT P53; PROMOTER; MODULATION; NF-IL6	p53 is a transcription factor that is activated by genotoxic stress and mediates cell cycle arrest and apoptosis. Here we demonstrate that infection of mouse liver with recombinant E1/E3-deleted adenovirus leads to p53 activation and simultaneously to the down-regulation of albumin gene expression. In vitro transcription assays indicate that transcriptional mechanisms mediated through the albumin promoter are responsible for reduced albumin mRNA levels during viral infection. Albumin expression is maintained in the liver by a combination of liver-enriched transcription factors such as CAAT enhancer binding protein (C/EBP)alpha and C/EBP beta, We show that p53 wild type and tumor-derived p53 mutations repress C/EBP-mediated transactivation of the albumin promoter. The binding of C/EBP alpha or -beta to its cognate sequence in the albumin promoter is not inhibited by p53 expression, Deletion analysis and domain swapping experiments show that repression of C/EBP beta-mediated transactivation is dependent on the N-terminal domain of p53 and the transactivation domain, leucine zipper domain, and the inhibitory domain II (amino acids 163-191) of C/EBP beta, Our results provide a molecular explanation for the p53-mediated down-regulation of liver-specific gene expression after viral infection. Additionally, as overexpression of p53 mutants is frequently found in undifferentiated hepatocellular carcinomas, the same mechanisms may contribute to the lack of liver-specific gene transcription in these tumors.	Med Hsch Hannover, Dept Gastroenterol & Hepatol, D-30625 Hannover, Germany	Hannover Medical School	Kubicka, S (corresponding author), Med Hsch Hannover, Dept Gastroenterol & Hepatol, Carl Neubergstr 1, D-30625 Hannover, Germany.			Rudolph, Karl Lenhard/0000-0002-4839-2862				Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; BUCK M, 1994, EMBO J, V13, P851, DOI 10.1002/j.1460-2075.1994.tb06328.x; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Dugimont T, 1998, ONCOGENE, V16, P2395, DOI 10.1038/sj.onc.1201742; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hayashi H, 1995, HEPATOLOGY, V22, P1702; HSIAO M, 1994, AM J PATHOL, V145, P702; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; Hussain SP, 1998, CANCER RES, V58, P4023; Iotsova V, 1996, ONCOGENE, V13, P2331; KUBICKA S, 1995, J HEPATOL, V23, P412, DOI 10.1016/0168-8278(95)80199-5; Kubicka S, 1997, HEPATOLOGY, V25, P867, DOI 10.1002/hep.510250414; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; LEVRAT F, 1993, EXP CELL RES, V209, P307, DOI 10.1006/excr.1993.1315; Li J, 1997, P NATL ACAD SCI USA, V94, P10885, DOI 10.1073/pnas.94.20.10885; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MARGULIES L, 1993, J BIOL CHEM, V268, P15096; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; ODA T, 1992, CANCER RES, V52, P6358; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PIETRANGELO A, 1992, J CLIN INVEST, V89, P1755, DOI 10.1172/JCI115778; POLL V, 1990, CELL, V63, P643; PONCHEL F, 1994, CANCER RES, V54, P2064; RAGIMOV N, 1993, ONCOGENE, V8, P1183; SANG BC, 1994, ONCOGENE, V9, P853; SELIVANOVA G, 1995, ADV CANCER RES, V66, P143, DOI 10.1016/S0065-230X(08)60253-5; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; Soriano HE, 1998, HEPATOLOGY, V27, P392, DOI 10.1002/hep.510270212; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUN Y, 1993, P NATL ACAD SCI USA, V90, P2827, DOI 10.1073/pnas.90.7.2827; TANAKA S, 1993, CANCER RES, V53, P2884; TERAMOTO T, 1994, CANCER RES, V54, P231; Trautwein C, 1996, J BIOL CHEM, V271, P22262, DOI 10.1074/jbc.271.36.22262; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; UNSAL H, 1994, P NATL ACAD SCI USA, V91, P822, DOI 10.1073/pnas.91.2.822; WANG L, 1995, J BIOL CHEM, V270, P23159, DOI 10.1074/jbc.270.39.23159; Watkins PJ, 1996, CANCER RES, V56, P1063; Webster NJG, 1996, CANCER RES, V56, P2781; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; Yin L, 1998, HEPATOLOGY, V27, P73, DOI 10.1002/hep.510270113	57	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32137	32144		10.1074/jbc.274.45.32137	http://dx.doi.org/10.1074/jbc.274.45.32137			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542249	hybrid			2022-12-25	WOS:000083532100057
J	Darke, PL; Jacobs, AR; Waxman, L; Kuo, LC				Darke, PL; Jacobs, AR; Waxman, L; Kuo, LC			Inhibition of hepatitis C virus NS2/3 processing by NS4A peptides - Implications for control of viral processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTRUCTURAL PROTEINS; CRYSTAL-STRUCTURE; COFACTOR PEPTIDE; ESCHERICHIA-COLI; NS2-3 PROTEASE; NS3 PROTEASE; IN-VITRO; NON-A; GENOME; ORGANIZATION	The NS2/3 protease of hepatitis C virus is responsible for a single cleavage in the viral polyprotein between the nonstructural proteins NS2 and NS3, The minimal protein region necessary to catalyze this cleavage includes most of NS2 and the N-terminal one-third of NS3, Autocleavage reactions using NS2/3 protein translated in vitro are used here to investigate the inhibitory potential of peptides likely to affect the reaction, Peptides representing the cleaved sequence have no effect upon reaction rates, and the reaction rate is insensitive to dilution, Both results are consistent with prior suggestions that the NS2/3 cleavage is an intramolecular reaction. Surprisingly, peptides containing the 12-amino acid region of NS4A responsible for binding to NS3 inhibit the NS2/3 reaction with K-i values as low as 3 mu M. Unrelated peptide sequences of similar composition are not inhibitory, and neither are peptides containing incomplete segments of the NS4A region that binds to NS3, Inhibition of NS2/3 by NS4A peptides can be rationalized from the organizing effect of NS4A on the N terminus of NS3 (the NS2/3 cleavage point) as suggested by the known three-dimensional structure of the NS3 protease domain. (Yan, Y., Li, Y., Munshi, S., Sardana, V., Cole, J. L., Sardana, M., Steinkuhler, C., Tomei, L., De Francesco, R., Kuo, L. C., and Chen, Z. (1998) Protein Sci. 7, 837-847). These findings may imply a sequential order to proteolytic maturation events in hepatitis C virus.	Merck Res Labs, Dept Antiviral Res, West Point, PA 19486 USA	Merck & Company	Darke, PL (corresponding author), Merck Res Labs, Dept Antiviral Res, WP26-344, West Point, PA 19486 USA.							Bianchi E, 1997, BIOCHEMISTRY-US, V36, P7890, DOI 10.1021/bi9631475; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; DSOUZA EDA, 1994, J GEN VIROL, V75, P3469, DOI 10.1099/0022-1317-75-12-3469; Gallinari P, 1999, BIOCHEMISTRY-US, V38, P5620, DOI 10.1021/bi982892+; Gallinari P, 1998, J VIROL, V72, P6758, DOI 10.1128/JVI.72.8.6758-6769.1998; Gorbalenya AE, 1996, PERSPECT DRUG DISCOV, V6, P64, DOI 10.1007/BF02174046; GRAKOUI A, 1993, P NATL ACAD SCI USA, V90, P10583, DOI 10.1073/pnas.90.22.10583; HIJIKATA M, 1993, P NATL ACAD SCI USA, V90, P10773, DOI 10.1073/pnas.90.22.10773; HIJIKATA M, 1993, J VIROL, V67, P4665, DOI 10.1128/JVI.67.8.4665-4675.1993; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; KOMODA Y, 1994, GENE, V145, P221; KRAUSSLICH HG, 1992, J VIROL, V66, P567; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; Lohmann V, 1996, J HEPATOL, V24, P11; Love RA, 1996, CELL, V87, P331, DOI 10.1016/S0092-8674(00)81350-1; MIZUSHIMA H, 1994, J VIROL, V68, P2731, DOI 10.1128/JVI.68.4.2731-2734.1994; MIZUSHIMA H, 1994, J VIROL, V68, P6215, DOI 10.1128/JVI.68.10.6215-6222.1994; Neddermann P, 1997, BIOL CHEM, V378, P469; Pieroni L, 1997, J VIROL, V71, P6373, DOI 10.1128/JVI.71.9.6373-6380.1997; Pryor KD, 1997, PROTEIN EXPRES PURIF, V10, P309, DOI 10.1006/prep.1997.0759; REED KE, 1995, J VIROL, V69, P4127, DOI 10.1128/JVI.69.7.4127-4136.1995; SANTOLINI E, 1995, J VIROL, V69, P7461, DOI 10.1128/JVI.69.12.7461-7471.1995; SELBY MJ, 1993, J GEN VIROL, V74, P1103, DOI 10.1099/0022-1317-74-6-1103; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; Wu Z, 1998, TRENDS BIOCHEM SCI, V23, P92, DOI 10.1016/S0968-0004(98)01180-3; Yan YW, 1998, PROTEIN SCI, V7, P837	28	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34511	34514		10.1074/jbc.274.49.34511	http://dx.doi.org/10.1074/jbc.274.49.34511			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574908	hybrid			2022-12-25	WOS:000083979600002
J	Asai, A; Qiu, JH; Narita, Y; Chi, S; Saito, N; Shinoura, N; Hamada, H; Kuchino, Y; Kirino, T				Asai, A; Qiu, JH; Narita, Y; Chi, S; Saito, N; Shinoura, N; Hamada, H; Kuchino, Y; Kirino, T			High level calcineurin activity predisposes neuronal cells to apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSIENT FOREBRAIN ISCHEMIA; NERVE GROWTH-FACTOR; NF-KAPPA-B; GLUTAMATE NEUROTOXICITY; CARDIAC-HYPERTROPHY; CEREBRAL-ISCHEMIA; MAMMALIAN-CELLS; NMDA-RECEPTOR; PC12 CELLS; T-CELLS	Calcineurin is a Ca2+/calmodulin-dependent protein phosphatase that is abundantly expressed in several specific areas of the brain, which are exceptionally vulnerable to stroke, epilepsy, and neurodegenerative diseases. In this study, we assessed the effects of high level activity of calcineurin on neuronal cells. Virus-mediated high level constitutive activity of calcineurin rendered neuronal cells susceptible to apoptosis induced by serum reduction or by a brief exposure to calcium ionophore. Adenovirus-mediated, high level forced activity of calcineurin induced cytochrome c/caspase-3-dependent apoptosis in neurons. Preincubation with the calcineurin inhibitors cyclosporin A and FK506 reduced susceptibility to apoptosis. High level constitutive expression of Bcl-2 or CrmA or incubation with a specific caspase-3 inhibitor inhibited the calcineurin-induced apoptosis. These data indicate that high level constitutive activity of calcineurin predisposes neuronal cells to cytochrome c/caspase-3 dependent apoptosis even under sublethal conditions.	Univ Tokyo, Fac Med, Dept Neurosurg, Lab Neurosci & Neurooncol,Bunkyo Ku, Tokyo 1138655, Japan; Inst Canc, Ctr Canc Chemotherapy, Dept Mol Biotherapy Res, Toshima Ku, Tokyo 1708455, Japan; Natl Canc Ctr, Res Inst, Div Biophys, Chuo Ku, Tokyo 1040045, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi 3320012, Japan	University of Tokyo; National Cancer Center - Japan; Japan Science & Technology Agency (JST)	Asai, A (corresponding author), Univ Tokyo, Fac Med, Dept Neurosurg, Lab Neurosci & Neurooncol,Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.							ALBERS GW, 1992, ARCH NEUROL-CHICAGO, V49, P418, DOI 10.1001/archneur.1992.00530280112031; Ankarcrona M, 1996, FEBS LETT, V394, P321, DOI 10.1016/0014-5793(96)00959-3; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CHOI DW, 1987, J NEUROSCI, V7, P369; CRAIN BJ, 1988, NEUROSCIENCE, V27, P387; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; FISCHER I, 1991, EXP CELL RES, V194, P195, DOI 10.1016/0014-4827(91)90354-W; FREUND TF, 1990, EXP BRAIN RES, V83, P55; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3689; GOTO S, 1986, BRAIN RES, V397, P161, DOI 10.1016/0006-8993(86)91381-8; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GREENE LA, 1983, J CELL BIOL, V96, P76, DOI 10.1083/jcb.96.1.76; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; JORGENSEN MB, 1982, ACTA NEUROL SCAND, V66, P536; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MANALAN AS, 1983, P NATL ACAD SCI-BIOL, V80, P4291, DOI 10.1073/pnas.80.14.4291; MELDRUM B, 1985, CLIN SCI, V68, P113, DOI 10.1042/cs0680113; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MORLEY P, 1994, BRAIN PATHOL, V4, P37; NAKAMURA Y, 1994, CANCER RES, V54, P5757; OLNEY JW, 1978, KAINIC ACID TOOL NEU, P37; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PICKUP DJ, 1986, P NATL ACAD SCI USA, V83, P7698, DOI 10.1073/pnas.83.20.7698; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SHARKEY J, 1994, NATURE, V371, P336, DOI 10.1038/371336a0; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; Shinoura N, 1998, HUM GENE THER, V9, P2683, DOI 10.1089/hum.1998.9.18-2683; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; SMITH ML, 1984, ACTA NEUROPATHOL, V64, P319, DOI 10.1007/BF00690397; Stefanis L, 1996, J BIOL CHEM, V271, P30663, DOI 10.1074/jbc.271.48.30663; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; SWAN JH, 1988, J CEREBR BLOOD F MET, V8, P64, DOI 10.1038/jcbfm.1988.9; TOCCI MJ, 1989, J IMMUNOL, V143, P718; TONG G, 1995, SCIENCE, V267, P1510, DOI 10.1126/science.7878472; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wakimoto H, 1997, JPN J CANCER RES, V88, P296, DOI 10.1111/j.1349-7006.1997.tb00381.x; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813; ZHAO Y, 1995, J IMMUNOL, V154, P6346	57	136	148	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34450	34458		10.1074/jbc.274.48.34450	http://dx.doi.org/10.1074/jbc.274.48.34450			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567426	hybrid			2022-12-25	WOS:000083857500091
J	Carman, CV; Parent, JL; Day, PW; Pronin, AN; Sternweis, PM; Wedegaertner, PB; Gilman, AG; Benovic, JL; Kozasa, T				Carman, CV; Parent, JL; Day, PW; Pronin, AN; Sternweis, PM; Wedegaertner, PB; Gilman, AG; Benovic, JL; Kozasa, T			Selective regulation of G alpha(q/11) by an RGS domain in the G protein-coupled receptor kinase, GRK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; ALPHA-SUBUNITS; TRANSITION-STATE; P115 RHOGEF; SF9 CELLS; PHOSPHORYLATION; BINDING; BETA; HYDROLYSIS; MECHANISM	G protein-coupled receptor kinases (GRKs) are well characterized regulators of G protein-coupled receptors, whereas regulators of G protein signaling (RGS) proteins directly control the activity of G protein alpha subunits. Interestingly, a recent report (Siderovski, D. P., Hessel, A., Chung, S., Mak, T. W., and Tyers, M. (1996) Curr. Biol. 6, 211-212) identified a region within the N terminus of GRKs that contained homology to RGS domains. Given that RGS domains demonstrate AlF4--dependent binding to G protein alpha subunits, we tested the ability of G proteins from a crude bovine brain extract to bind to GRK affinity columns in the absence or presence of AlF4-. This revealed the specific ability of bovine brain G alpha(q/11) to bind to both GRK2 and GRK3 in an AlF4--dependent manner. In contrast, G alpha(s), G alpha(i), and G alpha(12/13) did not bind to GRK2 or GRK3 despite their presence in the extract. Additional studies revealed that bovine brain G alpha(q/11) could also bind to an N-terminal construct of GRK2, while no binding of G alpha(q/11) G alpha(s), G alpha(i), or G alpha(12/13) to comparable constructs of GRK5 or GRK6 was observed. Experiments using purified G alpha(q) revealed significant binding of both G alpha(q) GDP/AlF4- and G alpha(q)(GTP gamma S), but not G alpha(q)(GDP), to GRK2. Activation-dependent binding was also observed in both COS-1 and HEK293 cells as GRK2 significantly co-immunoprecipitated constitutively active G alpha(q)(R183C) but not mild type G alpha(q). ln vitro analysis revealed that GRK2 possesses weak GAP activity toward G alpha(q) that is dependent on the presence of a G protein-coupled receptor. However, GRK2 effectively inhibited G alpha(q)-mediated activation of phospholipase C-beta both in. vitro and in cells, possibly through sequestration of activated G alpha(q). These data suggest that a subfamily of the GRKs may be bifunctional regulators of G protein-coupled receptor signaling operating directly on both receptors and G proteins.	Thomas Jefferson Univ, Kimmel Canc Inst, Dept Mol Pharmacol & Biochem, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	Jefferson University; Jefferson University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Benovic, JL (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Dept Mol Pharmacol & Biochem, 233 S 10th St, Philadelphia, PA 19107 USA.		Carman, Christopher/L-8108-2016; Carman, Christopher V./AAX-8995-2020	Carman, Christopher/0000-0001-7358-2548; Carman, Christopher V./0000-0001-7358-2548	NCI NIH HHS [5-T32-CA09662] Funding Source: Medline; NIGMS NIH HHS [GM34497, GM44944] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944, R01GM034497, R37GM034497] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aragay AM, 1999, J BIOL CHEM, V274, P4807, DOI 10.1074/jbc.274.8.4807; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; Bunemann M, 1998, J BIOL CHEM, V273, P31186, DOI 10.1074/jbc.273.47.31186; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; Carman CV, 1999, J BIOL CHEM, V274, P8858, DOI 10.1074/jbc.274.13.8858; Carman CV, 1998, J BIOL CHEM, V273, P20308, DOI 10.1074/jbc.273.32.20308; CHEN CY, 1993, J BIOL CHEM, V268, P7825; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; Dicker F, 1999, P NATL ACAD SCI USA, V96, P5476, DOI 10.1073/pnas.96.10.5476; Diviani D, 1996, J BIOL CHEM, V271, P5049; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; Freeman JLR, 1998, J BIOL CHEM, V273, P20653, DOI 10.1074/jbc.273.32.20653; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; Huang LJS, 1997, P NATL ACAD SCI USA, V94, P11184, DOI 10.1073/pnas.94.21.11184; Ingi T, 1998, J NEUROSCI, V18, P7178; KIM CM, 1993, RECEPTOR, V3, P39; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; Murga C, 1996, J BIOL CHEM, V271, P985, DOI 10.1074/jbc.271.2.985; Natochin M, 1998, J BIOL CHEM, V273, P6731, DOI 10.1074/jbc.273.12.6731; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; Pitcher JA, 1998, J BIOL CHEM, V273, P12316, DOI 10.1074/jbc.273.20.12316; Pitcher JA, 1996, J BIOL CHEM, V271, P24907, DOI 10.1074/jbc.271.40.24907; Pronin AN, 1997, J BIOL CHEM, V272, P18273, DOI 10.1074/jbc.272.29.18273; Siderovski DP, 1996, CURR BIOL, V6, P211, DOI 10.1016/S0960-9822(02)00454-2; Srinivasa SP, 1998, J BIOL CHEM, V273, P1529, DOI 10.1074/jbc.273.3.1529; Stoffel RH, 1997, J MEMBRANE BIOL, V157, P1, DOI 10.1007/s002329900210; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tobin AB, 1997, PHARMACOL THERAPEUT, V75, P135, DOI 10.1016/S0163-7258(97)00053-3; Umemori H, 1997, SCIENCE, V276, P1878, DOI 10.1126/science.276.5320.1878; Viard P, 1999, FASEB J, V13, P685, DOI 10.1096/fasebj.13.6.685; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; ZENG Y, 1994, SCIENCE, V263, P1609; Zerangue N, 1998, CURR BIOL, V8, pR313, DOI 10.1016/S0960-9822(98)70196-4	50	275	278	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34483	34492		10.1074/jbc.274.48.34483	http://dx.doi.org/10.1074/jbc.274.48.34483			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567430	hybrid			2022-12-25	WOS:000083857500095
J	Claussen, M; Rudt, F; Pieler, T				Claussen, M; Rudt, F; Pieler, T			Functional modules in ribosomal protein L5 for ribonucleoprotein complex formation and nucleocytoplasmic transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; NUCLEAR-LOCALIZATION SIGNALS; NUCLEOLAR-TARGETING SIGNAL; GENE-TRANSCRIPTION FACTOR; 5S RNA; KARYOPHERIN-BETA; U SNRNPS; HNRNP A1; DEVELOPMENTAL EXPRESSION; BIOCHEMICAL-RESEARCH	Ribosomal protein L5 forms a small, extraribosomal complex with 5 S ribosomal RNA, referred to as the 5 S ribonucleoprotein complex, which shuttles between nucleus and cytoplasm in Xenopus oocytes, Mapping elements in L5 that mediate nuclear protein import defines three separate such activities (L5-nuclear localization sequence (NLS)-1, -2, and -3), which are functional in both oocytes and somatic cells, RNA binding activity involves N-terminal as well as C-terminal elements of L5, In contrast to the full length protein, none of the individual NLSs carrying L5 fragments are able to allow for the predominating accumulation in the nucleoli that is observed with the full-length protein. The separate L5-NLSs differ in respect to two activities. Firstly, only L5-NLS-1 and -3, not L5-NLS-2, are capable of promoting the nuclear transfer of a heterologous, covalently attached ribonucleoprotein complex. Secondly, only L5-NLS-1 is able to bind strongly to a variety of different import receptors; those that recognize L5-NLS-2 and -3 have yet to be identified.	Univ Gottingen, Inst Biochem & Zellbiol, D-37073 Gottingen, Germany	University of Gottingen	Pieler, T (corresponding author), Univ Gottingen, Inst Biochem & Zellbiol, Humboldtallee 23, D-37073 Gottingen, Germany.							ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; ALLISON LA, 1991, DEV BIOL, V144, P129, DOI 10.1016/0012-1606(91)90485-L; ALLISON LA, 1995, DEV BIOL, V168, P284, DOI 10.1006/dbio.1995.1080; Annilo T, 1998, BIOCHEM BIOPH RES CO, V249, P759, DOI 10.1006/bbrc.1998.9187; Antoine M, 1997, J BIOL CHEM, V272, P29475, DOI 10.1074/jbc.272.47.29475; BURGLIN TR, 1987, GENE DEV, V1, P97, DOI 10.1101/gad.1.1.97; COCHRANE AW, 1990, J VIROL, V64, P881, DOI 10.1128/JVI.64.2.881-885.1990; Corbett AH, 1997, MICROBIOL MOL BIOL R, V61, P193, DOI 10.1128/.61.2.193-211.1997; CREANCIER L, 1993, MOL BIOL CELL, V4, P1239, DOI 10.1091/mbc.4.12.1239; Dahlberg JE, 1998, CURR OPIN CELL BIOL, V10, P400, DOI 10.1016/S0955-0674(98)80017-3; DANG CV, 1989, J BIOL CHEM, V264, P18019; Dasso M, 1998, AM J HUM GENET, V63, P311, DOI 10.1086/301990; DESHMUKH M, 1995, J BIOL CHEM, V270, P30148; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; DUNDR M, 1995, J CELL SCI, V108, P2811; Dundr M, 1997, CHROMOSOMA, V105, P407, DOI 10.1007/BF02510477; FISCHER U, 1991, J CELL BIOL, V113, P705, DOI 10.1083/jcb.113.4.705; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; FISCHER U, 1994, J CELL BIOL, V125, P971, DOI 10.1083/jcb.125.5.971; FISCHER U, 1993, EMBO J, V12, P573, DOI 10.1002/j.1460-2075.1993.tb05689.x; Fridell RA, 1997, J CELL SCI, V110, P1325; Gorlich D, 1995, COLD SPRING HARB SYM, V60, P695, DOI 10.1101/SQB.1995.060.01.075; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HEINE MA, 1993, MOL BIOL CELL, V4, P1189, DOI 10.1091/mbc.4.11.1189; HONDA BM, 1980, CELL, V22, P119, DOI 10.1016/0092-8674(80)90160-9; Huber J, 1998, EMBO J, V17, P4114, DOI 10.1093/emboj/17.14.4114; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; IMAMOTO N, 1995, FEBS LETT, V368, P415; Izaurralde E, 1998, RNA, V4, P351; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; JOHO KE, 1990, CELL, V61, P293, DOI 10.1016/0092-8674(90)90809-S; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KUBOTA S, 1989, BIOCHEM BIOPH RES CO, V162, P963, DOI 10.1016/0006-291X(89)90767-5; Liu JL, 1997, J VIROL, V71, P3188, DOI 10.1128/JVI.71.4.3188-3196.1997; Lutz P, 1996, J VIROL, V70, P3449, DOI 10.1128/JVI.70.6.3449-3460.1996; MAEDA Y, 1992, EMBO J, V11, P3695, DOI 10.1002/j.1460-2075.1992.tb05454.x; MAIRY M, 1971, DEV BIOL, V24, P143, DOI 10.1016/0012-1606(71)90092-3; MARKMEYER P, 1990, GENE, V93, P129, DOI 10.1016/0378-1119(90)90146-I; MARSHALLSAY C, 1994, EMBO J, V13, P222, DOI 10.1002/j.1460-2075.1994.tb06252.x; MATTAJ IW, 1987, EMBO J, V6, P2409, DOI 10.1002/j.1460-2075.1987.tb02519.x; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Mears WE, 1996, J VIROL, V70, P7445, DOI 10.1128/JVI.70.11.7445-7453.1996; Melchior F, 1998, TRENDS CELL BIOL, V8, P175, DOI 10.1016/S0962-8924(98)01252-5; Michael WM, 1996, J BIOL CHEM, V271, P11571, DOI 10.1074/jbc.271.19.11571; MICHAUD N, 1992, J CELL BIOL, V116, P851, DOI 10.1083/jcb.116.4.851; MORELAND RB, 1985, P NATL ACAD SCI USA, V82, P6561, DOI 10.1073/pnas.82.19.6561; Moroianu J, 1998, J CELL BIOCHEM, V70, P231; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; MOROIANU J, 1994, BIOCHEM BIOPH RES CO, V203, P1765, DOI 10.1006/bbrc.1994.2391; Murdoch KJ, 1996, EXP CELL RES, V227, P332, DOI 10.1006/excr.1996.0282; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Palacios I, 1997, EMBO J, V16, P6783, DOI 10.1093/emboj/16.22.6783; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; PICARD B, 1980, EUR J BIOCHEM, V109, P359, DOI 10.1111/j.1432-1033.1980.tb04802.x; PICARD B, 1979, P NATL ACAD SCI USA, V76, P241, DOI 10.1073/pnas.76.1.241; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; Rudt F, 1996, EMBO J, V15, P1383, DOI 10.1002/j.1460-2075.1996.tb00480.x; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Russo G, 1997, J BIOL CHEM, V272, P5229, DOI 10.1074/jbc.272.8.5229; SCHAAP PJ, 1991, J MOL BIOL, V221, P225; Schlenstedt G, 1997, EMBO J, V16, P6237, DOI 10.1093/emboj/16.20.6237; SCHMIDT C, 1995, MOL BIOL CELL, V6, P1875, DOI 10.1091/mbc.6.12.1875; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; Schwamborn K, 1998, EXP CELL RES, V244, P206, DOI 10.1006/excr.1998.4177; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SIOMI H, 1990, J VIROL, V64, P1803, DOI 10.1128/JVI.64.4.1803-1807.1990; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Siomi MC, 1997, J CELL BIOL, V138, P1181, DOI 10.1083/jcb.138.6.1181; STEITZ JA, 1988, J CELL BIOL, V106, P545, DOI 10.1083/jcb.106.3.545; UNDERWOOD MR, 1990, EMBO J, V9, P91, DOI 10.1002/j.1460-2075.1990.tb08084.x; WEIGHARDT F, 1995, J CELL SCI, V108, P545; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; WORMINGTON WM, 1989, MOL CELL BIOL, V9, P5281, DOI 10.1128/MCB.9.12.5281; Wozniak RW, 1998, TRENDS CELL BIOL, V8, P184, DOI 10.1016/S0962-8924(98)01248-3; YAN C, 1993, J CELL BIOL, V123, P1081, DOI 10.1083/jcb.123.5.1081; Yaseen NR, 1997, P NATL ACAD SCI USA, V94, P4451, DOI 10.1073/pnas.94.9.4451; Zirwes RF, 1997, P NATL ACAD SCI USA, V94, P11387, DOI 10.1073/pnas.94.21.11387; Zirwes RF, 1997, MOL BIOL CELL, V8, P231, DOI 10.1091/mbc.8.2.231	89	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					33951	33958		10.1074/jbc.274.48.33951	http://dx.doi.org/10.1074/jbc.274.48.33951			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567357	hybrid			2022-12-25	WOS:000083857500022
J	Kagawa, A; Azuma, H; Akaike, M; Kanagawa, Y; Matsumoto, T				Kagawa, A; Azuma, H; Akaike, M; Kanagawa, Y; Matsumoto, T			Aspirin reduces apolipoprotein(a) (Apo(a)) production in human hepatocytes by suppression of apo(a) gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY HEART-DISEASE; PLASMA LIPOPROTEIN(A) CONCENTRATIONS; NF-KAPPA-B; SODIUM-SALICYLATE; MESSENGER-RNA; SERUM LIPOPROTEIN(A); ENDOTHELIAL-CELLS; LP(A) EXCESS; PLASMINOGEN; LIVER	High serum lipoprotein(a) (Lp(a)) is a risk factor for vascular disorders, Our preliminary observations suggest that, in some patients with coronary heart disease with high serum Lp(a) levels, administration of aspirin reduced Lp(a) levels. Therefore, we aimed to analyze the effects of aspirin on the production of apo(a), the expression of apolipoprotein(a) (apo(a)) mRNA and the transcriptional activity of apo(a) gene promoter. Aspirin (5 mM) reduced the apo(a) levels in culture medium of human hepatocytes and suppressed apo(a) mRNA expression to 73% and 85% of the controls, respectively. Aspirin also reduced the transcriptional activity of apo(a) gene transfected into HepG2 hepatoma cells in a dose-dependent manner, with a maximal effect at 5 mM (44.3 +/- 1.5% of the control). Sodium salicylate (5 mM) also reduced apo(a) gene transcription, whereas indomethacin (10 mu M) had no effect. Deletion analysis of apo(a) gene promoter showed that promoter region extending from -30 to +138 is critical for the effect of aspirin, Furthermore, enhanced production, mRNA expression, and gene transcription of apo(a) by interleukin-6 were also inhibited by aspirin. These results demonstrate that aspirin reduces apo(a) production from hepatocytes via reduction of the transcriptional activity of apo(a) gene with suppression of apo(a) mRNA expression. The suppression of apo(a) production by aspirin may at least in part play a role in the anti-atherogenic effect of aspirin in vascular disorders.	Univ Tokushima, Sch Med, Dept Internal Med 1, Tokushima 7708503, Japan	Tokushima University	Azuma, H (corresponding author), Univ Tokushima, Sch Med, Dept Internal Med 1, Kuramotocho 3, Tokushima 7708503, Japan.							AZROLAN N, 1991, J BIOL CHEM, V266, P13866; Azuma H, 1996, BIOCHEM BIOPH RES CO, V227, P570, DOI 10.1006/bbrc.1996.1547; Biasucci LM, 1996, CIRCULATION, V94, P874, DOI 10.1161/01.CIR.94.5.874; BOERWINKLE E, 1992, J CLIN INVEST, V90, P52, DOI 10.1172/JCI115855; Bostom AG, 1996, JAMA-J AM MED ASSOC, V276, P544, DOI 10.1001/jama.276.7.544; CUSHING GL, 1989, ARTERIOSCLEROSIS, V9, P593, DOI 10.1161/01.ATV.9.5.593; Dong ZG, 1997, J BIOL CHEM, V272, P9962; GENEST J, 1991, AM J CARDIOL, V67, P1039, DOI 10.1016/0002-9149(91)90862-F; GONZALEZGRONOW M, 1989, BIOCHEMISTRY-US, V28, P2374, DOI 10.1021/bi00432a005; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; GRAINGER DJ, 1993, SCIENCE, V260, P1655, DOI 10.1126/science.8503012; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Huang CS, 1997, J BIOL CHEM, V272, P26325, DOI 10.1074/jbc.272.42.26325; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; MAEDA S, 1989, ATHEROSCLEROSIS, V78, P145, DOI 10.1016/0021-9150(89)90218-9; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; Oberle S, 1998, CIRC RES, V82, P1016, DOI 10.1161/01.RES.82.9.1016; OrthGomer K, 1997, CIRCULATION, V95, P329; PATRONO C, 1994, NEW ENGL J MED, V330, P1287; PEPIN JM, 1991, J LIPID RES, V32, P317; RADER DJ, 1994, J CLIN INVEST, V93, P2758, DOI 10.1172/JCI117292; RADER DJ, 1993, J CLIN INVEST, V91, P443, DOI 10.1172/JCI116221; RAMHARACK R, 1995, J LIPID RES, V36, P1294; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Rouy D, 1998, J BIOL CHEM, V273, P1247, DOI 10.1074/jbc.273.2.1247; SINGH RB, 1991, NUTRITION, V7, P125; Stein JH, 1997, ARCH INTERN MED, V157, P1170, DOI 10.1001/archinte.157.11.1170; TRIEU VN, 1995, J BIOL CHEM, V270, P15471, DOI 10.1074/jbc.270.26.15471; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0; WADE DP, 1994, J BIOL CHEM, V269, P19757; WADE DP, 1991, ATHEROSCLEROSIS, V91, P63, DOI 10.1016/0021-9150(91)90187-8; WADE DP, 1993, P NATL ACAD SCI USA, V90, P1369, DOI 10.1073/pnas.90.4.1369; WEBER C, 1995, CIRCULATION, V91, P1914, DOI 10.1161/01.CIR.91.7.1914; WEISSMANN G, 1991, SCI AM, V264, P84, DOI 10.1038/scientificamerican0191-84; WHITE AL, 1994, J BIOL CHEM, V269, P9060; WHITE AL, 1993, J LIPID RES, V34, P509; ZENKER G, 1986, STROKE, V17, P942, DOI 10.1161/01.STR.17.5.942	41	40	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34111	34115		10.1074/jbc.274.48.34111	http://dx.doi.org/10.1074/jbc.274.48.34111			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567380	hybrid			2022-12-25	WOS:000083857500045
J	Kryukov, GV; Kryukov, VM; Gladyshev, VN				Kryukov, GV; Kryukov, VM; Gladyshev, VN			New mammalian selenocysteine-containing proteins identified with an algorithm that searches for selenocysteine insertion sequence elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELENIUM; EUKARYOTES; SELENOPROTEINS; PURIFICATION; EXPRESSION; EFFICIENCY; MECHANISM; CODON; MOTIF; UGA	Mammalian selenium-containing proteins identified thus far contain selenium in the form of a selenocysteine residue encoded by UGA, These proteins lack common amino acid sequence motifs, but 3'-untranslated regions of selenoprotein genes contain a common stem-loop structure, selenocysteine insertion sequence (SECTS) element, that is necessary for decoding UGA as selenocysteine rather than a stop signal. We describe here a computer program, SECISearch, that identifies mammalian selenoprotein genes by recognizing SECIS elements on the basis of their primary and secondary structures and free energy requirements, When SECISearch was applied to search human dbEST, two new mammalian selenoproteins, designated SelT and SelR, were identified. We determined their cDNA sequences and expressed them in a monkey cell line as fusion proteins with a green fluorescent protein. Incorporation of selenium into new proteins was confirmed by metabolic labeling with Se-75, and expression of SelT was additionally documented in immunoblot assays, SelT and SelR did not have homology to previously characterized proteins, but their putative homologs were detected in various organisms. SelR homologs were present in every organism characterized by complete genome sequencing, The data suggest applicability of SECISearch for identification of new selenoprotein genes in nucleotide data bases.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; Russian Acad Sci, Inst Biochem & Physiol Microorganisms, Lab Genet Enzymol, Pushchino 142292, Moscow, Russia	University of Nebraska System; University of Nebraska Lincoln; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences	Gladyshev, VN (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.		Gladyshev, Vadim N/J-6187-2013; Gladyshev, Vadim N/A-9894-2013; Kryukov, Gregory V/A-9592-2008	Gladyshev, Vadim/0000-0002-0372-7016; Kryukov, Gregory/0000-0002-6131-9483				Baum MK, 1998, NUTR REV, V56, pS135; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; BOCK A, 1991, TRENDS BIOCHEM SCI, V16, P463, DOI 10.1016/0968-0004(91)90180-4; Bosl MR, 1997, P NATL ACAD SCI USA, V94, P5531, DOI 10.1073/pnas.94.11.5531; Buettner C, 1999, J BIOL CHEM, V274, P21598, DOI 10.1074/jbc.274.31.21598; Burk RF, 1999, BIOESSAYS, V21, P231, DOI 10.1002/(SICI)1521-1878(199903)21:3<231::AID-BIES7>3.3.CO;2-4; BURK RF, 1993, ANNU REV NUTR, V13, P65, DOI 10.1146/annurev.nu.13.070193.000433; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; Gladyshev VN, 1999, P NATL ACAD SCI USA, V96, P835, DOI 10.1073/pnas.96.3.835; Gladyshev VN, 1999, BIOCHEM BIOPH RES CO, V259, P244, DOI 10.1006/bbrc.1999.0765; Gladyshev VN, 1999, J BIOMED SCI, V6, P151, DOI 10.1007/BF02255899; Gladyshev VN, 1998, J BIOL CHEM, V273, P8910, DOI 10.1074/jbc.273.15.8910; Grundner-Culemann E, 1999, RNA, V5, P625, DOI 10.1017/S1355838299981542; Guimaraes MJ, 1996, P NATL ACAD SCI USA, V93, P15086, DOI 10.1073/pnas.93.26.15086; Hatfield D, 1999, COMPREHENSIVE NATURA, P353; Hill KE, 1996, BBA-MOL CELL RES, V1313, P29, DOI 10.1016/0167-4889(96)00047-X; Larsen PR, 1997, BIOCHEM SOC T, V25, P588, DOI 10.1042/bst0250588; Lee BJ, 1996, MOL CELLS, V6, P509; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; Martin GW, 1996, RNA, V2, P171; Mushegian AR, 1996, P NATL ACAD SCI USA, V93, P10268, DOI 10.1073/pnas.93.19.10268; SAWERS G, 1991, J BACTERIOL, V173, P4983, DOI 10.1128/jb.173.16.4983-4993.1991; SIEDLER F, 1993, BIOCHEMISTRY-US, V32, P7488, DOI 10.1021/bi00080a021; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; StGermain DL, 1997, THYROID, V7, P655; Sun QA, 1999, J BIOL CHEM, V274, P24522, DOI 10.1074/jbc.274.35.24522; SUNDE RA, 1994, SELENIUM BIOL HUMAN, P146; Ursini F, 1997, BIOMED ENVIRON SCI, V10, P327; VENDELAND SC, 1993, J BIOL CHEM, V268, P17103; Walczak R, 1996, RNA, V2, P367; Walczak R, 1998, RNA, V4, P74; Wen W, 1998, J BIOL CHEM, V273, P28533, DOI 10.1074/jbc.273.43.28533; Wilting R., 1997, Journal of Molecular Biology, V266, P637, DOI 10.1006/jmbi.1996.0812; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	34	202	221	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					33888	33897		10.1074/jbc.274.48.33888	http://dx.doi.org/10.1074/jbc.274.48.33888			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567350	hybrid, Green Published			2022-12-25	WOS:000083857500015
J	Underwood, R; Chiravuri, M; Lee, H; Schmitz, T; Kabcenell, AK; Yardley, K; Huber, BT				Underwood, R; Chiravuri, M; Lee, H; Schmitz, T; Kabcenell, AK; Yardley, K; Huber, BT			Sequence, purification, and cloning of an intracellular serine protease, quiescent cell proline dipeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDASE-IV; CLEAVAGE; CARBOXYPEPTIDASE; PROTEINASES; SPECIFICITY; ACTIVATION; FAMILIES	We recently observed that specific inhibitors of postproline cleaving aminodipeptidases cause apoptosis in quiescent lymphocytes in a process independent of CD26/dipeptidyl peptidase IV. These results led to the isolation and cloning of a new protease that we have termed quiescent cell proline dipeptidase (QPP), QPP activity was purified from CD26(-) Jurkat T cells. The protein was identified by labeling with [H-3]diisopropylfluorophosphate and subjected to tryptic digestion and partial amino acid sequencing. The peptide sequences were used to identify expressed sequence tag clones. The cDNA of QPP contains an open reading frame of 1476 base pairs, coding for a protein of 492 amino acids. The amino acid sequence of QPP reveals similarity with prolylcarboxypeptidase. The putative active site residues serine, aspartic acid, and histidine of QPP show an ordering of the catalytic triad similar to that seen in the post-proline cleaving exopeptidases prolylcarboxypeptidase and CD26/dipeptidyl peptidase IV. The post-proline cleaving activity of QPP has an unusually broad pH range in that it is able to cleave substrate molecules at acidic pH as web as at neutral pH, QPP has also been detected in nonlymphocytic cell lines, indicating that this enzyme activity may play an important role in other tissues as well.	Tufts Univ, Sch Med, Dept Pathol, Program Immunol, Boston, MA 02111 USA; Boehringer Ingelheim Pharmaceut Inc, Dept Immunol Dis, Ridgefield, CT 06877 USA	Tufts University; Boehringer Ingelheim	Yardley, K (corresponding author), Tufts Univ, Sch Med, Dept Pathol, Program Immunol, 136 Harrison Ave, Boston, MA 02111 USA.				NIAID NIH HHS [AI36696, AI43469] Funding Source: Medline; NIAMS NIH HHS [T32AR07570] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036696, R01AI043469] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007570] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARRETT AJ, 1995, ARCH BIOCHEM BIOPHYS, V318, P247, DOI 10.1006/abbi.1995.1227; BLUM JS, 1991, J BIOL CHEM, V266, P22091; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Chiravuri M, 1999, J IMMUNOL, V163, P3092; FLENTKE GR, 1991, P NATL ACAD SCI USA, V88, P1556, DOI 10.1073/pnas.88.4.1556; HEINS J, 1988, BIOCHIM BIOPHYS ACTA, V954, P161, DOI 10.1016/0167-4838(88)90067-2; Huang K, 1996, BBA-GEN SUBJECTS, V1290, P149, DOI 10.1016/0304-4165(96)00013-X; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MENTLEIN R, 1989, J NEUROCHEM, V52, P1284, DOI 10.1111/j.1471-4159.1989.tb01877.x; Morimoto C, 1998, IMMUNOL REV, V161, P55, DOI 10.1111/j.1600-065X.1998.tb01571.x; Oravecz T, 1997, J EXP MED, V186, P1865, DOI 10.1084/jem.186.11.1865; Proost P, 1999, J BIOL CHEM, V274, P3988, DOI 10.1074/jbc.274.7.3988; Rawlings ND, 1996, BBA-PROTEIN STRUCT M, V1298, P1, DOI 10.1016/S0167-4838(96)00153-7; SEIDL R, 1991, PREP BIOCHEM, V21, P141, DOI 10.1080/10826069108018009; Shioda T, 1998, P NATL ACAD SCI USA, V95, P6331, DOI 10.1073/pnas.95.11.6331; TAN FL, 1993, J BIOL CHEM, V268, P16631; VANHOOF G, 1995, FASEB J, V9, P736, DOI 10.1096/fasebj.9.9.7601338; von Bonin A, 1998, IMMUNOL REV, V161, P43	18	92	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34053	34058		10.1074/jbc.274.48.34053	http://dx.doi.org/10.1074/jbc.274.48.34053			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567372	hybrid			2022-12-25	WOS:000083857500037
J	Valle, C; Festucci, A; Calogero, A; Macri, P; Mecozzi, B; Liberti, P; Ciolio, D				Valle, C; Festucci, A; Calogero, A; Macri, P; Mecozzi, B; Liberti, P; Ciolio, D			Stage-specific expression of a Schistosoma mansoni polypeptide similar to the vertebrate regulatory protein stathmin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE FAMILY; SURFACE-MEMBRANE; PHOSPHORYLATION; PHOSPHOPROTEIN; SCG10; BRAIN; P19; IDENTIFICATION; INVITRO	The ubiquitous vertebrate protein stathmin is expressed and phosphorylated in response to a variety of external and internal signals. Stathmin, in turn, controls cell growth and differentiation through its capacity to regulate microtubule assembly dynamics. This is the first report on the molecular cloning and characterization of a stathmin-like protein (SmSLP) in an invertebrate, the human blood fluke Schistosoma mansoni. SmSLP is first synthesized at high levels in the intermediate molluscan host and completely disappears 48 h after penetration into the mammalian host. The protein is preferentially iodinated in intact immature parasites using the Bolton-Hunter reagent, can be quantitatively extracted in high salt buffers, and remains soluble after boiling. Native SmSLP was partially sequenced, and its complete structure was derived from the cloning and sequencing of its cDNA, The sequence is up to 26% identical to vertebrate stathmin sequences and contains two potential phosphorylation sites. Native SmSLP is indeed phosphorylated because phosphatase digestion shifts its mobility in electrofocusing gels. SmSLP associates with tubulin, as suggested by immune co-precipitation results. Irt vitro experiments demonstrated that SmSLP inhibits tubulin assembly and causes the depolymerization of preassembled microtubules, thus probably fulfilling regulatory roles in critical steps of schistosome development.	Natl Res Council, Inst Cell Biol, I-00137 Rome, Italy		Ciolio, D (corresponding author), Natl Res Council, Inst Cell Biol, 43 Viale Marx, I-00137 Rome, Italy.		valle, cristiana/J-7302-2018; Calogero, Aldo E./AAA-9538-2021	valle, cristiana/0000-0002-0914-6511; Calogero, Aldo E./0000-0001-6950-335X				Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; CIOLI D, 1976, INT J PARASITOL, V6, P349, DOI 10.1016/0020-7519(76)90058-8; COOPER HL, 1991, J IMMUNOL, V146, P3689; Davies SJ, 1998, J BIOL CHEM, V273, P11234, DOI 10.1074/jbc.273.18.11234; DiPaolo G, 1997, J BIOL CHEM, V272, P5175, DOI 10.1074/jbc.272.8.5175; FLURKEY WH, 1993, BIOCHEM BIOPH RES CO, V196, P589, DOI 10.1006/bbrc.1993.2290; GASKIN F, 1974, J MOL BIOL, V89, P737, DOI 10.1016/0022-2836(74)90048-5; HAILAT N, 1990, ONCOGENE, V5, P1615; Horwitz SB, 1997, J BIOL CHEM, V272, P8129, DOI 10.1074/jbc.272.13.8129; KUSEL JR, 1984, PARASITOLOGY, V89, P483, DOI 10.1017/S0031182000056717; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsson N, 1997, MOL CELL BIOL, V17, P5530, DOI 10.1128/MCB.17.9.5530; LIBERTI P, 1986, MOL BIOCHEM PARASIT, V18, P55, DOI 10.1016/0166-6851(86)90050-2; MAUCUER A, 1993, J BIOL CHEM, V268, P16420; OKAZAKI T, 1993, GENOMICS, V18, P360, DOI 10.1006/geno.1993.1477; Osman A, 1999, MOL BIOCHEM PARASIT, V100, P27, DOI 10.1016/S0166-6851(99)00029-8; Pearson WR, 1996, METHOD ENZYMOL, V266, P227; RAMALHOPINTO FJ, 1974, EXP PARASITOL, V36, P360, DOI 10.1016/0014-4894(74)90076-9; Sambrook J., 2002, MOL CLONING LAB MANU; SCHUBART UK, 1989, DNA-J MOLEC CELL BIO, V8, P389, DOI 10.1089/dna.1.1989.8.389; SCHUBART UK, 1987, J BIOL CHEM, V262, P11871; Schussler P, 1997, PARASITOLOGY, V115, P629, DOI 10.1017/S003118209700173X; SOBEL A, 1989, J BIOL CHEM, V264, P3765; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; STEIN R, 1988, NEURON, V1, P463, DOI 10.1016/0896-6273(88)90177-8	25	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					33869	33874		10.1074/jbc.274.48.33869	http://dx.doi.org/10.1074/jbc.274.48.33869			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567347	hybrid			2022-12-25	WOS:000083857500012
J	Das, KP; Choo-Smith, LP; Petrash, JM; Surewicz, WK				Das, KP; Choo-Smith, LP; Petrash, JM; Surewicz, WK			Insight into the secondary structure of non-native proteins bound to a molecular chaperone alpha-crystallin - An isotope-edited infrared spectroscopic study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; FOURIER SELF-DECONVOLUTION; X-RAY-ANALYSIS; B-CRYSTALLIN; QUATERNARY STRUCTURE; LENS CRYSTALLINS; A-CRYSTALLIN; RESOLUTION; SUBSTRATE; TISSUES	alpha-Crystallin, the major lens protein, acts as a molecular chaperone by preventing the aggregation of proteins damaged by heat and other stress conditions. To characterize the backbone conformation of protein folding intermediates that are recognized by the chaperone, we prepared the uniformly C-13-labeled alpha A-crystallin. The labeling greatly reduced the overlapping between the conformation-sensitive amide I bands of alpha-crystallin and unlabeled substrate proteins. This procedure has allowed us to gain insight into the secondary structure of alpha-crystallin-bound species, an understanding which has previously been unattainable. Analysis of the infrared spectra of two substrate proteins (gamma- and beta(L)-crystallins) indicates that heat-destabilized conformers captured by alpha-crystallin are characterized by a high proportion of native-like secondary structure, In contrast to the chaperone-bound species, the same proteins subjected to heat treatment in the absence of alpha-crystallin preserve very little native secondary structure. These data show that cu-crystallin specifically recognizes very early intermediates on the denaturation pathway of proteins. These aggregation-prone species are characterized by native-like secondary structure but compromised tertiary interactions. The experimental approach described in this study can be further applied to probe the backbone conformation of proteins bound to chaperones other than a-crystallin.	Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; Washington Univ, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA	Case Western Reserve University; Washington University (WUSTL)	Surewicz, WK (corresponding author), Case Western Reserve Univ, Dept Pathol, 2085 Adelbert Rd, Cleveland, OH 44106 USA.			Das, Kali/0000-0001-7686-9077	NEI NIH HHS [EY11694] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011694] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; BAX B, 1990, NATURE, V347, P776, DOI 10.1038/347776a0; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; BYLER M, 1986, BIOPOLYMERS, V26, P469; DAS KP, 1995, BIOCHEM J, V311, P367, DOI 10.1042/bj3110367; Das KP, 1996, J BIOL CHEM, V271, P10449, DOI 10.1074/jbc.271.18.10449; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; FRASER PE, 1991, BIOPHYS J, V60, P1190, DOI 10.1016/S0006-3495(91)82154-3; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; Haley DA, 1998, J MOL BIOL, V277, P27, DOI 10.1006/jmbi.1997.1611; HARIS PI, 1992, BIOCHEMISTRY-US, V31, P6279, DOI 10.1021/bi00142a016; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOENDERS HJ, 1981, MOL CELLULAR BIOL EY, P279; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; HORWITZ J, 1993, INVEST OPHTH VIS SCI, V34, P10; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JAKOB U, 1993, J BIOL CHEM, V268, P1517; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; KAUPPINEN JK, 1981, APPL SPECTROSC, V35, P271, DOI 10.1366/0003702814732634; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LAMBA OP, 1993, BIOCHIM BIOPHYS ACTA, V1163, P113, DOI 10.1016/0167-4838(93)90172-N; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Lindner RA, 1998, EUR J BIOCHEM, V258, P170, DOI 10.1046/j.1432-1327.1998.2580170.x; LOWE J, 1992, J PATHOL, V166, P61, DOI 10.1002/path.1711660110; RAMAN B, 1994, J BIOL CHEM, V269, P27264; Rao PV, 1995, BBA-GEN SUBJECTS, V1245, P439, DOI 10.1016/0304-4165(95)00125-5; Sax C M, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P155; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; SUREWICZ WK, 1993, BIOCHEMISTRY-US, V32, P389, DOI 10.1021/bi00053a001; SUREWICZ WK, 1995, BIOCHEMISTRY-US, V34, P9655, DOI 10.1021/bi00030a001; TADESSE L, 1991, J AM CHEM SOC, V113, P7036, DOI 10.1021/ja00018a052; WANG KY, 1994, J BIOL CHEM, V269, P13601; WISTOW G, 1983, J MOL BIOL, V170, P175, DOI 10.1016/S0022-2836(83)80232-0; ZHANG M, 1994, BIOCHEMISTRY-US, V33, P10833	36	55	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33209	33212		10.1074/jbc.274.47.33209	http://dx.doi.org/10.1074/jbc.274.47.33209			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559193	hybrid			2022-12-25	WOS:000083745200009
J	Bae, GU; Seo, DW; Kwon, HK; Lee, HY; Hong, S; Lee, ZW; Ha, KS; Lee, HW; Han, JW				Bae, GU; Seo, DW; Kwon, HK; Lee, HY; Hong, S; Lee, ZW; Ha, KS; Lee, HW; Han, JW			Hydrogen peroxide activates p70(S6k) signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; P70 S6 KINASE; EPIDERMAL GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; DIFFERENTIAL REGULATION; RIBOSOMAL PROTEIN-S6; SELECTIVE INHIBITORS; TRANSCRIPTION FACTOR; INSULIN STIMULATION; MESSENGER-RNA	We investigated a possible role of reactive oxygen species (ROS) in p70(S6k) activation, which plays an important role in the progression of cells from G(0)/G(1) to S phase of the cell cycle by translational up-regulation of a family of mRNA transcripts that encode for components of the protein synthetic machinery. Treatment of mouse epidermal cell JB6 with H2O2 generated extracellularly by glucose/glucose oxidase led to the activation of p70(S6k) and p90(Rsk) and to phosphorylation of p42(MAPK)/p44(MAPK) The activation of p70(S6k) and p90(Rsk) was dose-dependent and transient, maximal activities being in extracts treated for 15 and 30 min, respectively. Further characterization of ROS-induced activation of p70S6k using specific inhibitors for p70S6k Signaling pathway, rapamycin, and wortmannin revealed that ROS acted upstream of the rapamycin-sensitive component FRAP/RAFT and wortmannin-sensitive component phosphatidylinositol 3-kinase, because both inhibitors caused the inhibition of ROS-induced p70(S6k) activity. In addition, Ca2+ chelation also inhibited ROS-induced activation of p70S6k, indicating that Ca2+ is a mediator of p70(S6k) activation by ROS. However, down-regulation of 12-O-tetradecanoylphorbol-13-acetate (TPA)-responsive protein kinase C (PKC) by chronic pretreatment with TPA or a specific PHC inhibitor Re-31-8220 did not block the activation of p70S6k by ROS, indicating that the activation of TPA-responsive PHC was not required for stimulation of p70(S6k) activity by H2O2 in JB6 cells. Exposure of JB6 cells to platelet-derived growth factor or epidermal growth factor led to a rapid increase in H2O2, phosphorylation, and activation of p70(S6k), which were antagonized by the pretreatment of catalase. Taken together, the results suggest that ROS act as a messenger in growth factor-induced p70(S6k) signaling pathway.	Sungkyunkwan Univ, Coll Pharm, Dept Biochem, Suwon 440746, South Korea; Sungkyunkwan Univ, Coll Life Sci & Nat Resources, Dept Genet Engn, Suwon 440746, South Korea; Konyang Univ, Coll Med, Dept Pharmacol, Nonsan 320711, South Korea; Korea Basic Sci Inst, Biomol Res Grp, Taejon 305333, South Korea	Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU); Konyang University; Konyang University Hospital; Korea Basic Science Institute (KBSI)	Han, JW (corresponding author), Sungkyunkwan Univ, Coll Pharm, Dept Biochem, Suwon 440746, South Korea.	jhhan@yurim.skku.ac.kr		Ha, Kwon-Soo/0000-0002-4219-1787; Seo, Dong-Wan/0000-0003-4971-834X				AEBI H, 1984, METHOD ENZYMOL, V105, P121; Akimoto K, 1998, BIOCHEM J, V335, P417, DOI 10.1042/bj3350417; ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; AMES BN, 1988, IARC SCI PUBL, V89, P407; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Conus NM, 1998, J BIOL CHEM, V273, P4776, DOI 10.1074/jbc.273.8.4776; CRAWFORD D, 1988, ONCOGENE, V3, P27; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; DOWNWARD J, 1995, NATURE, V376, P553, DOI 10.1038/376553a0; FERRARI S, 1994, CRIT REV BIOCHEM MOL, V29, P385, DOI 10.3109/10409239409083485; Gindhart T D, 1985, Carcinog Compr Surv, V8, P341; Graves LM, 1997, J BIOL CHEM, V272, P1920, DOI 10.1074/jbc.272.3.1920; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; JEFFERIES HBJ, 1994, J BIOL CHEM, V269, P4367; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; KOZMA SC, 1994, SEMIN CANCER BIOL, V5, P255; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LARSSON R, 1988, J BIOL CHEM, V263, P17452; Lee ZW, 1998, J BIOL CHEM, V273, P12710, DOI 10.1074/jbc.273.21.12710; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; NIXON JS, 1992, BIOCHEM SOC T, V20, P419, DOI 10.1042/bst0200419; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; OLIVIER AR, 1988, P NATL ACAD SCI USA, V85, P4720, DOI 10.1073/pnas.85.13.4720; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; Stabel S., 1993, INTRACELLULAR MESSEN, P167; STEWART MJ, 1994, BIOESSAYS, V16, P809, DOI 10.1002/bies.950161107; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; SZATROWSKI TP, 1991, CANCER RES, V51, P794; TWOMEY B, 1990, BIOCHEM BIOPH RES CO, V171, P1087, DOI 10.1016/0006-291X(90)90795-O; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744	59	121	124	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32596	32602		10.1074/jbc.274.46.32596	http://dx.doi.org/10.1074/jbc.274.46.32596			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551813	hybrid			2022-12-25	WOS:000083623000013
J	Cassano, S; Di Lieto, A; Cerillo, R; Avvedimento, EV				Cassano, S; Di Lieto, A; Cerillo, R; Avvedimento, EV			Membrane-bound cAMP-dependent protein kinase controls cAMP-induced differentiation in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; CYCLIC-AMP; II-BETA; GENE-EXPRESSION; REGULATORY SUBUNIT; HYDROXYLASE GENE; A-KINASE; TRANSCRIPTION; LOCALIZATION; STIMULATION	The A126 cell line, a derivative of PC12, is defective in cAMP-induced transcription and does not differentiate in the presence of cAMP. In these cells overexpression of a cAMP-dependent protein kinase (PKA) anchor protein, AKAP75, and of the PKA catalytic subunit substantially increased the fraction of PKAIII bound to the membrane, stimulated the transcription of cAMP-induced genes, and induced terminal differentiation. Conversely, wild type PC12 cells expressing a derivative of the AKAP75 protein, AKAP45, which binds the PKA regulatory subunits RII, but fails to locate them to the membranes, induced translocation of PKAII to the cytosol, These cells did not efficiently accumulate PRA catalytic subunit in the nuclei when stimulated with CAMP, did not transcribe cAMP-induced genes, and failed to differentiate when exposed to cAMP. These data indicate that membrane-bound PKA positively controls the transcription of cAMP-induced genes and differentiation in PC12 cells.	Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Mol & Cellulare, CNR,Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Catanzaro Magna Graecia, Fac Med & Chirurg, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Magna Graecia University of Catanzaro	Cassano, S (corresponding author), Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Mol & Cellulare, CNR,Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy.			CASSANO, SILVANA/0000-0001-9868-7936				Cassano S, 1996, J BIOL CHEM, V271, P29870, DOI 10.1074/jbc.271.47.29870; Corbitt J, 1998, J NEUROCHEM, V71, P478; DAMON DH, 1990, J CELL BIOL, V110, P1333, DOI 10.1083/jcb.110.4.1333; Feliciello A, 1997, CURR BIOL, V7, P1011, DOI 10.1016/S0960-9822(06)00424-6; Feliciello A, 1998, J BIOL CHEM, V273, P23361, DOI 10.1074/jbc.273.36.23361; Feliciello A, 1996, J BIOL CHEM, V271, P25350, DOI 10.1074/jbc.271.41.25350; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; GLANTZ SB, 1992, MOL BIOL CELL, V3, P1215, DOI 10.1091/mbc.3.11.1215; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HENDERSON LP, 1994, J NEUROSCI, V14, P1153, DOI 10.1523/JNEUROSCI.14-03-01153.1994; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; KAANG BK, 1992, P NATL ACAD SCI USA, V89, P1133, DOI 10.1073/pnas.89.3.1133; KIM KS, 1994, J NEUROSCI, V14, P7200; LEISER M, 1986, J BIOL CHEM, V261, P1904; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; POSSENTI R, 1992, P NATL ACAD SCI USA, V89, P3815, DOI 10.1073/pnas.89.9.3815; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; Sambrook J., 2002, MOL CLONING LAB MANU; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; URSINI MV, 1988, BIOCHEM BIOPH RES CO, V150, P287, DOI 10.1016/0006-291X(88)90518-9; VANBUSKIRK R, 1985, MOL CELL BIOL, V5, P1984, DOI 10.1128/MCB.5.8.1984	29	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32574	32579		10.1074/jbc.274.46.32574	http://dx.doi.org/10.1074/jbc.274.46.32574			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551810	hybrid			2022-12-25	WOS:000083623000010
J	Chalfant, ML; Denton, JS; Langloh, AL; Karlson, KH; Loffing, J; Benos, DJ; Stanton, BA				Chalfant, ML; Denton, JS; Langloh, AL; Karlson, KH; Loffing, J; Benos, DJ; Stanton, BA			The NH2 terminus of the epithelial sodium channel contains an endocytic motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE NA+ CHANNEL; SHAKER POTASSIUM CHANNEL; BETA-SUBUNIT; ALPHA-SUBUNIT; ACETYLCHOLINE-RECEPTOR; LIDDLE SYNDROME; ION CHANNELS; CELL-SURFACE; ENAC; IDENTIFICATION	An epithelial sodium channel (ENaC) is composed of three homologous subunits: alpha, beta, and gamma. To elucidate the function of the cytoplasmic, NH2 terminus of rat ENaC (rENaC) subunits, a series of mutant cDNAs was constructed and the cRNAs for all three subunits were expressed in Xenopus oocytes. Amiloride-sensitive Na+ currents (I-Na) were measured by the two-electrode voltage clamp technique. Deletion of the cytoplasmic, NH2 terminus of alpha (Delta 2-109), beta (Delta 2-49), or gamma-rENaC (Delta 2-53) dramatically reduced I-Na. A series of progressive, NH2 terminal deletions of alpha-rENaC were constructed to identify motifs that regulate I-Na. Deletion of amino acids 2-46 had no effect on I-Na: however, deletion of amino acids 2-51, 2-55, 2-58, and 2-67 increased I-Na by similar to 4-fold. By contrast, deletion of amino acids 2-79, 2-89, 2-100, and 2-109 eliminated I-Na. To evaluate the mechanism whereby Delta 2-67-alpha-rENaC increased I-Na, single channels were evaluated by patch clamp. The single-channel conductance and open probability of alpha,beta,gamma-rENaC and Delta 2-67-alpha,beta,gamma-rENaC were similar. However, the number of active channels in the membrane increased from 6 +/- 1 channels per patch with alpha,beta,gamma-rENaC to 11 +/- 1 channels per patch with Delta 2-67-alpha,beta,gamma-rENaC. Laser scanning confocal microscopy confirmed that there were more Delta 2-67-alpha,beta,gamma-rENaC channels in the plasma membrane than alpha,beta,gamma-rENaC channels. Deletion of amino acids 2-67 in alpha-rENaC reduced the endocytic retrieval of channels from the plasma membrane and increased the half-life of the channel in the membrane from 1.1 +/- 0.2 to 3.5 +/- 1.1 h. We conclude that the cytoplasmic, NH2 terminus of alpha-, beta-, and gamma-rENaC is required for channel activity, The cytoplasmic, NH2 terminus of alpha-rENaC contains two key motifs. One motif regulates the endocytic retrieval of the channel from the plasma membrane. The second motif is required for channel activity.	Dartmouth Med Sch, Dept Physiol, Hanover, NH 03755 USA; Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35233 USA; Univ Zurich, Inst Anat, CH-8057 Zurich, Switzerland	Dartmouth College; University of Alabama System; University of Alabama Birmingham; University of Zurich	Stanton, BA (corresponding author), Dartmouth Med Sch, Dept Physiol, 615 Remsen Bldg, Hanover, NH 03755 USA.		Loffing, Johannes/ABG-9973-2020	Loffing, Johannes/0000-0002-9415-6588	NIDDK NIH HHS [DK-51067, DK-07301, DK-34533] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051067, R01DK034533] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams CM, 1997, J BIOL CHEM, V272, P27295, DOI 10.1074/jbc.272.43.27295; Awayda MS, 1997, AM J PHYSIOL-CELL PH, V273, pC1889; Benos DJ, 1996, KIDNEY INT, V49, P1632, DOI 10.1038/ki.1996.237; BENOS DJ, 1999, IN PRESS J PHYSL; Berdiev BK, 1998, BIOPHYS J, V75, P2292, DOI 10.1016/S0006-3495(98)77673-8; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Canessa CM, 1996, NEWS PHYSIOL SCI, V11, P195; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Chalfant ML, 1999, AM J PHYSIOL-CELL PH, V276, pC477, DOI 10.1152/ajpcell.1999.276.2.C477; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Fyfe GK, 1998, SEMIN NEPHROL, V18, P138; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Geering K, 1996, J CELL BIOL, V133, P1193, DOI 10.1083/jcb.133.6.1193; Grunder S, 1997, EMBO J, V16, P899, DOI 10.1093/emboj/16.5.899; Horisberger JD, 1998, CURR OPIN CELL BIOL, V10, P443, DOI 10.1016/S0955-0674(98)80056-2; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; Ismailov II, 1997, J BIOL CHEM, V272, P21075, DOI 10.1074/jbc.272.34.21075; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LIGHT DB, 1988, AM J PHYSIOL, V255, pF278, DOI 10.1152/ajprenal.1988.255.2.F278; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; McNicholas CM, 1997, J GEN PHYSIOL, V109, P681, DOI 10.1085/jgp.109.6.681; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; Prince LS, 1998, BIOCHEM J, V336, P705, DOI 10.1042/bj3360705; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; SHEN NV, 1993, NEURON, V11, P67; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Tamura H, 1996, J CLIN INVEST, V97, P1780, DOI 10.1172/JCI118606; Thomas CP, 1998, AM J PHYSIOL-CELL PH, V274, pC1312, DOI 10.1152/ajpcell.1998.274.5.C1312; Tucker SJ, 1996, J BIOL CHEM, V271, P5866, DOI 10.1074/jbc.271.10.5866; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; Voilley N, 1997, COMP BIOCHEM PHYS A, V118, P193, DOI 10.1016/S0300-9629(97)00066-2; VOILLEY N, 1994, P NATL ACAD SCI USA, V91, P247, DOI 10.1073/pnas.91.1.247; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	40	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32889	32896		10.1074/jbc.274.46.32889	http://dx.doi.org/10.1074/jbc.274.46.32889			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551853	hybrid			2022-12-25	WOS:000083623000053
J	Hammarstrom, P; Persson, M; Freskgard, PO; Martensson, LG; Andersson, D; Jonsson, BH; Carlsson, U				Hammarstrom, P; Persson, M; Freskgard, PO; Martensson, LG; Andersson, D; Jonsson, BH; Carlsson, U			Structural mapping of an aggregation nucleation site in a molten globule intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CARBONIC-ANHYDRASE; PYRENE EXCIMER FLUORESCENCE; INCLUSION-BODY FORMATION; PROBING SUBSTRUCTURE; FOLDING INTERMEDIATE; TRYPTOPHAN RESIDUES; PROTEIN; RENATURATION; SCATTERING; SPECTRUM	Protein aggregation plays an important role in biotechnology and also causes numerous diseases. Human carbonic anhydrase II is a suitable model protein for studying the mechanism of aggregation. We found that a molten globule state of the enzyme formed aggregates. The intermolecular interactions involved in aggregate formation were localized in a direct way by measuring excimer formation between each of 20 site-specific pyrene-labeled cysteine mutants. The contact area of the aggregated protein was very specific, and all sites included in the intermolecular interactions were located in the large beta-sheet of the protein, within a limited region between the central beta-strands 4 and 7. This substructure is very hydrophobic, which underlines the importance of hydrophobic interactions between specific beta-sheet containing regions in aggregate formation.	Linkoping Univ, Dept Phys Measurement Technol, SE-58183 Linkoping, Sweden; Linkoping Univ, Dept Chem, SE-58183 Linkoping, Sweden; Umea Univ, Dept Biochem, SE-90187 Umea, Sweden; Novo Nordisk AS, Tissue Factor Factor VII Res, DK-2760 Malov, Denmark	Linkoping University; Linkoping University; Umea University; Novo Nordisk	Carlsson, U (corresponding author), Linkoping Univ, Dept Phys Measurement Technol, SE-58183 Linkoping, Sweden.		Freskgård, Per-Ola/AAY-4194-2021	Martensson, Lars-Goran/0000-0002-7642-9263				BERGENHEM N, 1989, INT J PEPT PROT RES, V33, P140; Betts S, 1997, ADV PROTEIN CHEM, V50, P243, DOI 10.1016/S0065-3233(08)60323-X; Billsten P, 1997, FEBS LETT, V402, P67, DOI 10.1016/S0014-5793(96)01431-7; CARLSSON U, 1995, CURR OPIN STRUC BIOL, V5, P482, DOI 10.1016/0959-440X(95)80032-8; CLELAND JL, 1990, BIOCHEMISTRY-US, V29, P11072, DOI 10.1021/bi00502a009; CLELAND JL, 1991, ACS SYM SER, V470, P169; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; Denisov VP, 1999, NAT STRUCT BIOL, V6, P253, DOI 10.1038/6692; ERIKSSON AE, 1988, PROTEINS, V4, P274, DOI 10.1002/prot.340040406; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; FRANSSON C, 1992, FEBS LETT, V296, P90, DOI 10.1016/0014-5793(92)80410-I; FRESKGARD PO, 1994, BIOCHEMISTRY-US, V33, P14281, DOI 10.1021/bi00251a041; FRESKGARD PO, 1991, FEBS LETT, V289, P117, DOI 10.1016/0014-5793(91)80922-P; HAKANSSON K, 1992, J MOL BIOL, V227, P1192, DOI 10.1016/0022-2836(92)90531-N; Hammarstrom P, 1997, FEBS LETT, V420, P63, DOI 10.1016/S0014-5793(97)01488-9; HAUGLAND RP, 1996, HDB FLUORESCENT PROB, P57; HENDERSON LE, 1976, J BIOL CHEM, V251, P5457; ISHII Y, 1986, BIOPHYS J, V50, P75, DOI 10.1016/S0006-3495(86)83440-3; Jaenicke R, 1997, ADV PROTEIN CHEM, V50, P1, DOI 10.1016/S0065-3233(08)60318-6; Jonasson P, 1997, BIOCHEMISTRY-US, V36, P5142, DOI 10.1021/bi961882a; KHALIFAH RG, 1977, BIOCHEMISTRY-US, V16, P2241, DOI 10.1021/bi00629a031; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Lehrer S S, 1995, Subcell Biochem, V24, P115; LONDON J, 1974, EUR J BIOCHEM, V47, P409, DOI 10.1111/j.1432-1033.1974.tb03707.x; MARTENSSON LG, 1992, BIOCHIM BIOPHYS ACTA, V1118, P179; MARTENSSON LG, 1993, BIOCHEMISTRY-US, V32, P224, DOI 10.1021/bi00052a029; MARTENSSON LG, 1995, BIOCHEMISTRY-US, V34, P1011, DOI 10.1021/bi00003a036; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; Nozaki Y, 1972, Methods Enzymol, V26, P43; Persson M, 1999, BIOCHEMISTRY-US, V38, P432, DOI 10.1021/bi981442e; PERSSON M, 1995, BBA-PROTEIN STRUCT M, V1247, P195, DOI 10.1016/0167-4838(94)00227-8; Persson M, 1996, BBA-PROTEIN STRUCT M, V1298, P191, DOI 10.1016/S0167-4838(96)00125-2; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; SAFAR J, 1994, BIOCHEMISTRY-US, V33, P8375, DOI 10.1021/bi00193a027; Semisotnov GV, 1996, J MOL BIOL, V262, P559, DOI 10.1006/jmbi.1996.0535; Silow M, 1997, P NATL ACAD SCI USA, V94, P6084, DOI 10.1073/pnas.94.12.6084; SVENSSON M, 1995, BIOCHEMISTRY-US, V34, P8606, DOI 10.1021/bi00027a010; UVERSKY VN, 1993, BIOCHEMISTRY-US, V32, P13288, DOI 10.1021/bi00211a042; WETLAUFER DB, 1995, PROTEIN SCI, V4, P1535, DOI 10.1002/pro.5560040811	39	54	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32897	32903		10.1074/jbc.274.46.32897	http://dx.doi.org/10.1074/jbc.274.46.32897			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551854	hybrid			2022-12-25	WOS:000083623000054
J	Meighan-Mantha, RL; Hsu, DKW; Guo, Y; Brown, SAN; Feng, SLY; Peifley, KA; Alberts, GF; Copeland, NG; Gilbert, DJ; Jenkins, NA; Richards, CM; Winkles, JA				Meighan-Mantha, RL; Hsu, DKW; Guo, Y; Brown, SAN; Feng, SLY; Peifley, KA; Alberts, GF; Copeland, NG; Gilbert, DJ; Jenkins, NA; Richards, CM; Winkles, JA			The mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; NIH 3T3 CELLS; SITE-DIRECTED MUTAGENESIS; MESSENGER-RNA EXPRESSION; SIGNAL-TRANSDUCTION; MOUSE FIBROBLASTS; CYCLE PROGRESSION; ALDOSE REDUCTASE; LIGAND-BINDING; INTEGRIN	The binding of polypeptide growth factors to their appropriate cell surface transmembrane receptors triggers numerous biochemical responses, including the transcriptional. activation of specific genes. We have used a differential display approach to identify fibroblast growth factor-1-inducible genes in murine NIH 3T3 cells. Here, we report that the fibroblast growth factorinducible-14 (Fn14) gene is a growth factor-regulated, immediate-early response gene expressed in a developmental stage- and adult tissue-specific manner in vivo. This gene, located on mouse chromosome 17, is predicted to encode an 129-amino acid type Ia membrane protein with no significant sequence similarity to any known protein. me have used two experimental approaches, direct fluorescence microscopy and immunoprecipitation analysis of biotinylated cell surface proteins, to demonstrate that Fn14 is located on the plasma membrane. To examine the biological consequences of constitutive Fn14 expression, we isolated NIH 3T3 cell lines expressing variable levels of epitope-tagged Fn14 and analyzed their phenotypic properties in vitro. These experiments revealed that Fn14 expression decreased cellular adhesion to the extracellular matrix proteins fibronectin and vitronectin and also reduced serum-stimulated cell growth and migration. These results indicate that Fn14 is a novel plasma membrane-spanning molecule that may play a role in cell-matrix interactions.	Amer Red Cross, Holland Lab, Dept Vasc Biol, Rockville, MD 20855 USA; NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Mammalian Genet Lab, Frederick, MD 21702 USA; George Washington Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20037 USA; George Washington Univ, Med Ctr, Inst Biomed Sci, Washington, DC 20037 USA	American Red Cross; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; George Washington University; George Washington University	Winkles, JA (corresponding author), Amer Red Cross, Holland Lab, Dept Vasc Biol, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.	winkles@usa.redcross.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039727, R29HL039727] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL039727, HL-39727] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBRECHTBUEHLER G, 1976, J CELL BIOL, V69, P275, DOI 10.1083/jcb.69.2.275; ALBRECHTBUEHLER G, 1976, J CELL BIOL, V71, P370, DOI 10.1083/jcb.71.2.370; ASUNDI VK, 1995, J BIOL CHEM, V270, P26404, DOI 10.1074/jbc.270.44.26404; Belkin AM, 1998, J BIOL CHEM, V273, P15234, DOI 10.1074/jbc.273.24.15234; BORMANN BJ, 1992, ANNU REV BIOPH BIOM, V21, P223, DOI 10.1146/annurev.bb.21.060192.001255; Burgess W. H., 1996, P154; BURGESS WH, 1990, J CELL BIOL, V111, P2129, DOI 10.1083/jcb.111.5.2129; Carey DJ, 1997, BIOCHEM J, V327, P1; Chase D, 1998, BIOCHEM J, V333, P655, DOI 10.1042/bj3330655; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; Coulier F, 1997, J MOL EVOL, V44, P43, DOI 10.1007/PL00006120; Defilippi P, 1997, ONCOGENE, V14, P1933, DOI 10.1038/sj.onc.1201027; DIKE LE, 1988, P NATL ACAD SCI USA, V85, P6792, DOI 10.1073/pnas.85.18.6792; Donohue P J, 1997, Methods Mol Biol, V85, P25; DONOHUE PJ, 1994, J BIOL CHEM, V269, P8604; Donohue PJ, 1997, EXP CELL RES, V234, P139, DOI 10.1006/excr.1997.3598; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; Donohue PJ, 1996, BIOCHEM J, V319, P9, DOI 10.1042/bj3190009; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Granes F, 1999, EXP CELL RES, V248, P439, DOI 10.1006/excr.1999.4437; Greenwood JA, 1998, MICROSC RES TECHNIQ, V43, P420, DOI 10.1002/(SICI)1097-0029(19981201)43:5<420::AID-JEMT8>3.0.CO;2-B; Haas J, 1996, CURR BIOL, V6, P315, DOI 10.1016/S0960-9822(02)00482-7; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hsu DKW, 1996, J BIOL CHEM, V271, P13786, DOI 10.1074/jbc.271.23.13786; HSU DKW, 1993, BIOCHEM BIOPH RES CO, V197, P1483, DOI 10.1006/bbrc.1993.2644; Hsu DKW, 1997, BIOCHEM J, V328, P593, DOI 10.1042/bj3280593; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KLEIN S, 1993, MOL BIOL CELL, V4, P973, DOI 10.1091/mbc.4.10.973; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lin TH, 1997, J BIOL CHEM, V272, P8849; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; PIETERS J, 1993, J CELL SCI, V106, P831; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Rooney RJ, 1998, MAMM GENOME, V9, P320, DOI 10.1007/s003359900758; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SANKAR S, 1995, AM J PATHOL, V147, P601; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; TAUTZ D, 1983, ANAL BIOCHEM, V132, P14, DOI 10.1016/0003-2697(83)90419-0; Tchorzewski MT, 1998, J SURG RES, V77, P99, DOI 10.1006/jsre.1998.5351; Thiel S, 1999, BIOCHEM J, V339, P15, DOI 10.1042/0264-6021:3390015; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vaughan KT, 1996, GENOMICS, V36, P29, DOI 10.1006/geno.1996.0422; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; WINKLES JA, 1993, AM J PATHOL, V143, P518; Winkles JA, 1998, PROG NUCLEIC ACID RE, V58, P41; Woodard AS, 1998, J CELL SCI, V111, P469; Woods A, 1998, TRENDS CELL BIOL, V8, P189, DOI 10.1016/S0962-8924(98)01244-6; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219; Zukowska-Grojec Z, 1998, CIRC RES, V83, P187, DOI 10.1161/01.RES.83.2.187	61	179	200	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					33166	33176		10.1074/jbc.274.46.33166	http://dx.doi.org/10.1074/jbc.274.46.33166			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551889	hybrid			2022-12-25	WOS:000083623000089
J	Reddy, S; Yang, WB; Taylor, DG; Shen, XQ; Oxender, D; Kust, G; Leff, T				Reddy, S; Yang, WB; Taylor, DG; Shen, XQ; Oxender, D; Kust, G; Leff, T			Mitogen-activated protein kinase regulates transcription of the ApoCIII gene - Involvement of the orphan nuclear receptor HNF4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE-RICH LIPOPROTEINS; APOLIPOPROTEIN-C-III; CIII GENE; APO-CIII; DNA POLYMORPHISMS; TRANSGENIC MICE; YOUNG MODY1; HYPERTRIGLYCERIDEMIA; PROMOTER; METABOLISM	The transcriptional regulation of the apoCIII gene by hormonal and metabolic signals plays a significant role in determining plasma triglyceride levels, In the current work me demonstrate that the apoCIII gene is regulated by the mitogen-activated protein (MAP) kinase signaling pathway, In HepG2 cells, repression of MAP kinase activity by treatment with the mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD98059 caused a 5-8-fold increase in apoCIII transcriptional activity, Activation of MAP kinase by phorbol ester treatment caused a 3-5-fold reduction in apoCIII transcription. The region of the apoCIII promoter responsible for this regulation was mapped in transiently transfected HepG2 cells to a 6-base pair element located at -740, The major protein binding to this site was identified as the nuclear hormone receptor HNF4, An increase in HNF4 mRNA and protein levels was observed in HepG2 cells after treatment with PD98059, indicating that the MAP kinase pathway regulates the expression of the HNF4 gene. These findings demonstrate that, the apoCIII gene can be regulated by signals acting through the MAP kinase pathway and that this regulation is mediated, at least in part, by changes in the amount of HNF4.	Parke Davis Res, Dept Cell Biol, Ann Arbor, MI 48105 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	Pfizer; University of Michigan System; University of Michigan	Leff, T (corresponding author), Parke Davis Res, Dept Cell Biol, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.		Leff, Todd/U-9084-2018	Leff, Todd/0000-0001-6923-3900				AALTOSETALA K, 1987, ATHEROSCLEROSIS, V66, P145, DOI 10.1016/0021-9150(87)90190-0; AaltoSetala K, 1996, J LIPID RES, V37, P1802; AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; AHN YI, 1991, HUM HERED, V41, P281, DOI 10.1159/000154014; Boylan JM, 1998, J BIOL CHEM, V273, P3784, DOI 10.1074/jbc.273.6.3784; CARLSON LA, 1976, ATHEROSCLEROSIS, V23, P563, DOI 10.1016/0021-9150(76)90016-2; CHEN M, 1994, J LIPID RES, V35, P1918; DAMMERMAN M, 1993, P NATL ACAD SCI USA, V90, P4562, DOI 10.1073/pnas.90.10.4562; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GINSBERG HN, 1986, J CLIN INVEST, V78, P1287, DOI 10.1172/JCI112713; GRUBER PJ, 1994, NUCLEIC ACIDS RES, V22, P2417, DOI 10.1093/nar/22.12.2417; Hadzopoulou-Cladaras M, 1998, BIOCHEMISTRY-US, V37, P14078, DOI 10.1021/bi9804176; HAVEL RJ, 1995, METABOLIC MOL BASES, P1841; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; ITO Y, 1990, SCIENCE, V249, P90; JIANG GQ, 1995, MOL CELL BIOL, V15, P5131; KRAUSS RM, 1973, CIRC RES, V33, P403, DOI 10.1161/01.RES.33.4.403; Lavrentiadou SN, 1999, BIOCHEMISTRY-US, V38, P964, DOI 10.1021/bi981068i; Li WW, 1995, J CLIN INVEST, V96, P2601, DOI 10.1172/JCI118324; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MAEDA N, 1994, J BIOL CHEM, V269, P23610; MALMENDIER CL, 1989, ATHEROSCLEROSIS, V77, P139, DOI 10.1016/0021-9150(89)90075-0; OGAMI K, 1990, J BIOL CHEM, V265, P9808; REES A, 1985, J CLIN INVEST, V76, P1090, DOI 10.1172/JCI112062; REISHER SR, 1993, P NATL ACAD SCI USA, V90, P5757, DOI 10.1073/pnas.90.12.5757; SLADEK FM, 1993, RECEPTOR, V3, P223; Stoffel M, 1997, P NATL ACAD SCI USA, V94, P13209, DOI 10.1073/pnas.94.24.13209; TAS S, 1989, CLIN CHEM, V35, P256; Taylor DG, 1996, NUCLEIC ACIDS RES, V24, P2930, DOI 10.1093/nar/24.15.2930; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; WANG CS, 1985, J CLIN INVEST, V75, P384, DOI 10.1172/JCI111711; WINDLER E, 1985, J LIPID RES, V26, P556; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; ZENG Q, 1995, HUM GENET, V95, P371	35	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					33050	33056		10.1074/jbc.274.46.33050	http://dx.doi.org/10.1074/jbc.274.46.33050			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551874	hybrid			2022-12-25	WOS:000083623000074
J	Yang, DS; Yip, CM; Huang, THJ; Chakrabartty, A; Fraser, PE				Yang, DS; Yip, CM; Huang, THJ; Chakrabartty, A; Fraser, PE			Manipulating the amyloid-beta aggregation pathway with chemical chaperones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC-FORCE MICROSCOPY; SYNCHROTRON X-RAY; ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; PRION PROTEIN; FIBRILLOGENESIS; PHENOTYPE; FIBRIL; PATHOGENESIS; INTERMEDIATE	Amyloid-beta (A beta) assembly into fibrillar structures is a defining characteristic of Alzheimer's disease that is initiated by a conformational transition from random coil to beta-sheet and a nucleation-dependent aggregation process. We have investigated the role of organic osmolytes as chemical chaperones in the amyloid pathway using glycerol to mimic the effects of naturally occurring molecules, Osmolytes such as the naturally occurring trimethylamine N-oxide and glycerol correct folding defects by preferentially hydrating partially denatured proteins and entropically stabilize native conformations and polymeric states. Trimethylamine N-oxide and glycerol were found to rapidly accelerate the A beta random coil-to-beta-sheet conformational change necessary for fiber formation. This was accompanied by an immediate conversion of amorphous unstructured aggregates into uniform globular and possibly nucleating structures. Osmolyte-facilitated changes in A beta hydration also affected the final stages of amyloid formation and mediated transition from the protofibrils to mature fibers that are observed in vivo, These findings suggest that hydration forces can be used to control fibril assembly and may have implications for the accumulation of A beta within intracellular compartments such as the endoplasmic reticulum and in, vitro modeling of the amyloid pathway.	Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Chem Engn & Appl Chem, Toronto, ON M5S 3H2, Canada; Univ Toronto, Inst Biomet & Biomed Engn, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 3H2, Canada; Univ Toronto, Ontario Canc Inst, Toronto, ON M5S 3H2, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Fraser, PE (corresponding author), Univ Toronto, Ctr Res Neurodegenerat Dis, 6 Queens Pk Crescent W, Toronto, ON M5S 3H2, Canada.			Chakrabartty, Avi/0000-0001-7002-8381; Yip, Christopher/0000-0003-4507-556X				Blake C, 1996, STRUCTURE, V4, P989, DOI 10.1016/S0969-2126(96)00104-9; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Brown CR, 1997, J CLIN INVEST, V99, P1432, DOI 10.1172/JCI119302; Brown CR, 1996, CELL STRESS CHAPERON, V1, P117, DOI 10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2; BURG MB, 1995, AM J PHYSIOL, V268, P983; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; DebBurman SK, 1997, P NATL ACAD SCI USA, V94, P13938, DOI 10.1073/pnas.94.25.13938; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; GarzonRodriguez W, 1997, J BIOL CHEM, V272, P21037, DOI 10.1074/jbc.272.34.21037; Harper JD, 1997, CHEM BIOL, V4, P951, DOI 10.1016/S1074-5521(97)90303-3; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Huang THJ, 1997, J MOL BIOL, V269, P214; INOUYE H, 1993, BIOPHYS J, V64, P502, DOI 10.1016/S0006-3495(93)81393-6; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Kisilevsky R, 1997, CRIT REV BIOCHEM MOL, V32, P361, DOI 10.3109/10409239709082674; Kowalewski T, 1999, P NATL ACAD SCI USA, V96, P3688, DOI 10.1073/pnas.96.7.3688; Lai ZH, 1996, BIOCHEMISTRY-US, V35, P6470, DOI 10.1021/bi952501g; Lomakin A, 1997, P NATL ACAD SCI USA, V94, P7942, DOI 10.1073/pnas.94.15.7942; McLaurin J, 1998, J MOL BIOL, V278, P183, DOI 10.1006/jmbi.1998.1677; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; Sackett DL, 1997, AM J PHYSIOL-REG I, V273, pR669, DOI 10.1152/ajpregu.1997.273.2.R669; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; Stine WB, 1996, J PROTEIN CHEM, V15, P193, DOI 10.1007/BF01887400; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; Tamarappoo BK, 1998, J CLIN INVEST, V101, P2257, DOI 10.1172/JCI2303; Tatzelt J, 1996, EMBO J, V15, P6363, DOI 10.1002/j.1460-2075.1996.tb01027.x; TIMASHEFF SN, 1993, ANNU REV BIOPH BIOM, V22, P67, DOI 10.1146/annurev.bb.22.060193.000435; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Wang AJ, 1997, BIOCHEMISTRY-US, V36, P9101, DOI 10.1021/bi970247h; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085	34	210	218	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32970	32974		10.1074/jbc.274.46.32970	http://dx.doi.org/10.1074/jbc.274.46.32970			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551864	hybrid			2022-12-25	WOS:000083623000064
J	Vanden Berghe, W; De Bosscher, K; Boone, E; Plaisance, S; Haegeman, G				Vanden Berghe, W; De Bosscher, K; Boone, E; Plaisance, S; Haegeman, G			The nuclear factor-kappa B engages CBP/p300 and histone acetyltransferase activity for transcriptional activation of the interleukin-6 gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; STEROID-RECEPTOR COACTIVATOR-1; DEPENDENT TRANSCRIPTION; SIGNAL-TRANSDUCTION; PROTEIN-SYNTHESIS; FACTOR-ALPHA; NF-Y; ACETYLATION; DEACETYLASE; CHROMATIN	Expression of the pleiotropic cytokine interleukin (IL)-6 can be stimulated by the proinflammatory cytokine tumor necrosis factor (TNF) and the microbial alkaloid staurosporine (STS). In this report, the transcriptional mechanisms were thoroughly investigated. Whereas transcription factors binding to the activator protein-1-, cAMP-responsive element-, and CAAT enhancer-binding protein-responsive sequences are necessary for gene activation by STS, nuclear factor (NF)-kappa B alone is responsible and sufficient for inducibility by TNF, which reveals distinct signaling pathways for both compounds. At the cofactor level, cAMP-responsive element-binding protein-binding protein (CBP) or p300 potentiate basal and induced IL-6 promoter activation via multiple protein-protein interactions with all transcription factors bound to the promoter DNA. However, the strongest promoter activation relies on the p65 NF-kappa B subunit, which specifically engages CBP/p300 for maximal transcriptional stimulation by its histone acetyltransferase activity. Moreover, treatment of chromatin-integrated promoter constructions with the histone deacetylase inhibitor trichostatin A exclusively potentiates TNF-dependent (ie. NF-kappa B-mediated) gene activation, while basal or STS-stimulated IL-6 promoter activity remains completely unchanged. Similar observations were recorded with other natural NF-kappa B-driven promoters, namely IL-8 and endothelial leukocyte adhesion molecule (ELAM). We conclude that, within an "enhanceosome-like" structure, NF-kappa B is the central mediator of TNF-induced IL-6 gene expression, involving CBP/p300 and requiring histone acetyltransferase activity.	Univ Ghent, Dept Mol Biol, B-9000 Ghent, Belgium; Flanders Interuniv Inst Biotechnol, B-9000 Ghent, Belgium	Ghent University	Haegeman, G (corresponding author), Univ Ghent, Dept Mol Biol, KL Ledeganckstr 35, B-9000 Ghent, Belgium.	guy.haegeman@dmb.rug.ac.be	Vanden Berghe, Wim/HGE-4696-2022; Plaisance, Stephane/B-3488-2009; Berghe, Wim Vanden/S-6425-2018; Plaisance, Stephane/ABI-6307-2020	Plaisance, Stephane/0000-0002-1651-241X; Berghe, Wim Vanden/0000-0003-0161-7355; Plaisance, Stephane/0000-0002-1651-241X; De Bosscher, Karolien/0000-0001-5059-9718				Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; Bestor TH, 1998, NATURE, V393, P311, DOI 10.1038/30613; BEYAERT R, 1993, CANCER RES, V53, P2623; Bjorklund S, 1999, CELL, V96, P759, DOI 10.1016/S0092-8674(00)80586-3; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Bruening W, 1998, NUCLEIC ACIDS RES, V26, P486, DOI 10.1093/nar/26.2.486; Calkhoven CF, 1996, BIOCHEM J, V317, P329, DOI 10.1042/bj3170329; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; DENDORFER U, 1994, MOL CELL BIOL, V14, P4443, DOI 10.1128/MCB.14.7.4443; Eckner R, 1996, BIOL CHEM, V377, P685; Espinos E, 1999, MOL CELL BIOL, V19, P3474; Gadient RA, 1997, PROG NEUROBIOL, V52, P379, DOI 10.1016/S0301-0082(97)00021-X; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Hampsey M, 1999, CURR OPIN GENET DEV, V9, P132, DOI 10.1016/S0959-437X(99)80020-3; Han J, 1999, NAT CELL BIOL, V1, pE39, DOI 10.1038/10032; Hsieh JJD, 1999, P NATL ACAD SCI USA, V96, P23, DOI 10.1073/pnas.96.1.23; Ikeda K, 1999, MOL CELL BIOL, V19, P855; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Keller ET, 1996, FRONT BIOSCI, V1, P340, DOI DOI 10.2741/A136; Koj A, 1996, BBA-MOL BASIS DIS, V1317, P84, DOI 10.1016/S0925-4439(96)00048-8; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Li Q, 1998, EMBO J, V17, P6300, DOI 10.1093/emboj/17.21.6300; Liu YZ, 1998, J BIOL CHEM, V273, P32400, DOI 10.1074/jbc.273.49.32400; Magnaghi-Jaulin L, 1999, SEMIN CELL DEV BIOL, V10, P197, DOI 10.1006/scdb.1999.0301; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Medina V, 1997, CANCER RES, V57, P3697; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Minucci S, 1997, P NATL ACAD SCI USA, V94, P11295, DOI 10.1073/pnas.94.21.11295; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Myers CA, 1998, MOL CELL BIOL, V18, P2184, DOI 10.1128/MCB.18.4.2184; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Parekh BS, 1999, MOL CELL, V3, P125, DOI 10.1016/S1097-2765(00)80181-1; Parker D, 1998, MOL CELL, V2, P353, DOI 10.1016/S1097-2765(00)80279-8; Perissi V, 1999, P NATL ACAD SCI USA, V96, P3652, DOI 10.1073/pnas.96.7.3652; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Plaisance S, 1997, MOL CELL BIOL, V17, P3733, DOI 10.1128/MCB.17.7.3733; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; Sheridan PL, 1997, GENE DEV, V11, P3327, DOI 10.1101/gad.11.24.3327; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	64	290	297	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32091	32098		10.1074/jbc.274.45.32091	http://dx.doi.org/10.1074/jbc.274.45.32091			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542243	hybrid			2022-12-25	WOS:000083532100051
J	Scalabrino, G; Nicolini, G; Buccellato, FR; Peracchi, M; Tredici, G; Manfridi, A; Pravettoni, G				Scalabrino, G; Nicolini, G; Buccellato, FR; Peracchi, M; Tredici, G; Manfridi, A; Pravettoni, G			Epidermal growth factor as a local mediator of the neurotrophic action of vitamin B-12 (cobalamin) in the rat central nervous system	FASEB JOURNAL			English	Article						cerebrospinal fluid; epidermal growth factor; subacute combined degeneration; totally gastrectomized rat	TOTALLY GASTRECTOMIZED RATS; SUBACUTE COMBINED DEGENERATION; VASOACTIVE-INTESTINAL-PEPTIDE; NECROSIS-FACTOR-ALPHA; ORNITHINE DECARBOXYLASE; NEUROPEPTIDE RECEPTORS; SPINAL-CORDS; GLIAL-CELLS; BRAIN; DEFICIENCY	We have recently demonstrated that the myelinolytic lesions in the spinal cord (SC) of rats made deficient in vitamin B-12 (cobalamin) (Cbl) through total gastrectomy (TG) are tumor necrosis factor-alpha (TNF-alpha)-mediated. We investigate whether or not permanent Cbl deficiency, induced in the rat either through TG or by chronic feeding of a Cbl-deficient diet, might modify the levels of three physiological neurotrophic factors-epidermal growth factor (EGF), vasoactive intestinal peptide (VIP), and somatostatin (SS)-in the cerebrospinal fluid (CSF) of these rats. We also investigated the ability of the central nervous system (CNS) in these Cbl-deficient rats to synthesize EGF mRNA and of the SC to take up labeled Cbl in vivo. Cbl-deficient rats, however the vitamin deficiency is induced, show a selective decrease in EGF CSF levels and an absence of EGF mRNA in neurons and glia in various CNS areas. In contrast, radiolabeled Cbl is almost exclusively taken up by the SC white matter, but to a much higher degree in totally gastrectomized (TGX) rats. Chronic administration of Chl to TGX rats restores to normal both the EGF CSF level and EGF mRNA expression in the various CNS areas examined. This in vivo study presents the first evidence that the neurotrophic action of Cbl in the CNS of TGX rats is mediated by stimulation of the EGF synthesis in the CNS itself, It thus appears that Cbl inversely regulates the expression of EGF and TNF-alpha genes in the CNS of TGX rats.-Scalabrino, G., Nicolini, G., Buccellato, F. R., Peracchi, M., Tredici, G., Manfridi, A., Pravettoni, G, Epidermal growth factor as a local mediator of the neurotrophic action of vitamin B-12 (cobalamin) in the rat central nervous system.	Univ Milan, Inst Gen Pathol, Fac Med, I-20133 Milan, Italy; Univ Milan, Inst Human Anat, Fac Med, I-20133 Milan, Italy; Univ Milan, Inst Med Sci, Fac Med, I-20133 Milan, Italy; Univ Milan, Inst Human Physiol 2, Fac Med, I-20133 Milan, Italy; Gife Lab, Lugano, Switzerland	University of Milan; University of Milan; University of Milan; University of Milan	Scalabrino, G (corresponding author), Univ Milan, Inst Gen Pathol, Fac Med, Via Mangiagalli 31, I-20133 Milan, Italy.		manfridi, alfredo/D-3398-2013; NIcolini, Gabriella/AAK-9155-2020; Pravettoni, Gabriella/AAC-3500-2022; Pravettoni, Gabriella/C-6915-2011	Pravettoni, Gabriella/0000-0002-4843-4663; NICOLINI, GABRIELLA/0000-0002-6241-4538				BARRECA T, 1988, ACTA ENDOCRINOL-COP, V117, P130, DOI 10.1530/acta.0.1170130; Beck W S, 1991, Adv Intern Med, V36, P33; BRENNEMAN DE, 1995, INT J DEV NEUROSCI, V13, P187, DOI 10.1016/0736-5748(95)00014-8; Buccellato FR, 1999, FASEB J, V13, P297, DOI 10.1096/fasebj.13.2.297; BURGESS AW, 1989, BRIT MED BULL, V45, P401, DOI 10.1093/oxfordjournals.bmb.a072331; CHANARIN I, 1992, J CLIN PATHOL, V45, P277, DOI 10.1136/jcp.45.4.277; Connor B, 1998, BRAIN RES REV, V27, P1, DOI 10.1016/S0165-0173(98)00004-6; Defacque H, 1999, J CELL PHYSIOL, V178, P109, DOI 10.1002/(SICI)1097-4652(199901)178:1<109::AID-JCP14>3.3.CO;2-O; DUNCAN DB, 1955, BIOMETRICS, V11, P1, DOI 10.2307/3001478; EPELBAUM J, 1986, PROG NEUROBIOL, V27, P63, DOI 10.1016/0301-0082(86)90012-2; ERMISCH A, 1993, PHYSIOL REV, V73, P489, DOI 10.1152/physrev.1993.73.3.489; FISCHER DA, 1989, ANNU REV PHYSIOL, V51, P67; Gressens P, 1997, J CLIN INVEST, V100, P390, DOI 10.1172/JCI119545; HAN VKM, 1992, ENDOCRINOLOGY, V131, P1134, DOI 10.1210/en.131.3.1134; Hefti F, 1997, ANNU REV PHARMACOL, V37, P239, DOI 10.1146/annurev.pharmtox.37.1.239; HERBERT V, 1985, LAB INVEST, V52, P3; Hoffmann M, 1998, CANCER IMMUNOL IMMUN, V47, P167, DOI 10.1007/s002620050517; HOKFELT T, 1980, NATURE, V284, P515, DOI 10.1038/284515a0; HUFF KR, 1990, INT J DEV NEUROSCI, V8, P255, DOI 10.1016/0736-5748(90)90031-V; KAR S, 1995, J COMP NEUROL, V354, P253, DOI 10.1002/cne.903540208; Koli K, 1996, ADV CANCER RES, V70, P63, DOI 10.1016/S0065-230X(08)60872-6; Kordek R, 1996, P NATL ACAD SCI USA, V93, P9754, DOI 10.1073/pnas.93.18.9754; KRISCH B, 1994, INT REV CYTOL, V148, P119, DOI 10.1016/S0074-7696(08)62407-9; Labourdette G., 1995, P441; MARTIN DL, 1992, GLIA, V5, P81, DOI 10.1002/glia.440050202; MAZZONI IE, 1992, DRUG DEVELOP RES, V26, P111, DOI 10.1002/ddr.430260202; MCMILLIAN MK, 1994, TRENDS NEUROSCI, V17, P138, DOI 10.1016/0166-2236(94)90086-8; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; METZ J, 1992, ANNU REV NUTR, V12, P59, DOI 10.1146/annurev.nu.12.070192.000423; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; MORRISON RS, 1987, SCIENCE, V238, P72, DOI 10.1126/science.3498986; MULLER JM, 1995, MOL NEUROBIOL, V10, P115, DOI 10.1007/BF02740671; PANT SS, 1968, ACTA NEUROL SCAN S35, V44, P8; Peracchi M, 1997, AM J GASTROENTEROL, V92, P1884; PEZACKA EH, 1992, BIOCHEM BIOPH RES CO, V184, P832, DOI 10.1016/0006-291X(92)90665-8; PLATASALAMAN CR, 1991, PEPTIDES, V12, P653, DOI 10.1016/0196-9781(91)90115-6; Powers J, 1996, MOL CHEM NEUROPATHOL, V27, P31, DOI 10.1007/BF02815031; QURESHI AA, 1994, CRIT REV ONCOL HEMAT, V17, P133, DOI 10.1016/1040-8428(94)90022-1; Reichlin S., 1998, WILLIAMS TXB ENDOCRI, P165; Rothwell NJ, 1997, BRIT J PHARMACOL, V121, P841, DOI 10.1038/sj.bjp.0701248; Said SI, 1996, J CLIN INVEST, V97, P2163, DOI 10.1172/JCI118655; SCALABRINO G, 1995, LAB INVEST, V72, P114; SCALABRINO G, 1990, LAB INVEST, V62, P297; Scalabrino G, 1997, EXP NEUROL, V144, P258, DOI 10.1006/exnr.1996.6376; Scalabrino G, 1998, BRIT J HAEMATOL, V100, P615; SNIDER WD, 1989, ANN NEUROL, V26, P489, DOI 10.1002/ana.410260402; SWANSON LW, 1995, TRENDS NEUROSCI, V18, P471, DOI 10.1016/0166-2236(95)92766-J; Tredici G, 1998, J SUBMICR CYTOL PATH, V30, P165; Tredici G, 1998, J NEUROL SCI, V156, P18, DOI 10.1016/S0022-510X(98)00005-7; VIEIRAMAKINGS E, 1991, BIOCHEM J, V275, P585, DOI 10.1042/bj2750585; WASS JAH, 1995, ENDOCRINOLOGY, P266; WEIR DG, 1995, BAILLIERE CLIN HAEM, V8, P479, DOI 10.1016/S0950-3536(05)80217-3; WILLIAMS MA, 1977, PRACTICAL METHODS EL, V6, P85; Yamada M, 1997, PROG NEUROBIOL, V51, P19, DOI 10.1016/S0301-0082(96)00046-9; YOUNG M, 1995, AM J PHYSIOL-ENDOC M, V269, pE657, DOI 10.1152/ajpendo.1995.269.4.E657; YOUNG M, 1994, J CLIN INVEST, V93, P2578, DOI 10.1172/JCI117269; Yuen EC, 1996, ANN NEUROL, V40, P346, DOI 10.1002/ana.410400304	57	50	50	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1999	13	14					2083	2090		10.1096/fasebj.13.14.2083	http://dx.doi.org/10.1096/fasebj.13.14.2083			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544191				2022-12-25	WOS:000083660700020
J	Hwang, SR; Steineckert, B; Yasothornsrikul, S; Sei, CA; Toneff, T; Rattan, J; Hook, VYH				Hwang, SR; Steineckert, B; Yasothornsrikul, S; Sei, CA; Toneff, T; Rattan, J; Hook, VYH			Molecular cloning of endopin 1, a novel serpin localized to neurosecretory vesicles of chromaffin cells - Inhibition of basic residue-cleaving proteases by endopin 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ADRENAL-MEDULLA; HUMAN ALPHA-1-ANTICHYMOTRYPSIN; PROHORMONE CONVERTASES; ENKEPHALIN PRECURSOR; SECRETORY VESICLES; PURIFICATION; ALPHA-1-ANTITRYPSIN; PROENKEPHALIN; GRANULES; FURIN	Serpins represent a diverse class of endogenous protease inhibitors that regulate important biological functions. In consideration of the importance of regulated proteolysis within secretory vesicles for the production of peptide hormones and neurotransmitters, this study revealed the molecular identity of a novel serpin, endopin 1, that is localized to neurosecretory vesicles of neuropeptide-containing chromaffin cells (chromaffin granules). Endopin 1 of 68-70 kDa was present within isolated chromaffin granules. Stimulated cosecretion of endopin 1 with chromaffin granule components, [Met]enkephalin and a cysteine protease known as "pro-hormone thiol protease," demonstrated localization of endopin 1 to functional secretory vesicles. Punctate, discrete immunofluorescence cellular localization of endopin 1 in chromaffin cells was consistent with its secretory vesicle localization. Endopin 1 contains a unique reactive site loop with Arg as the predicted P1 residue, suggesting inhibition of basic residue-cleaving proteases; indeed, trypsin was potently inhibited (K7(i(app)) of 5 nM), and plasmin was moderately inhibited. Although endopin 1 possesses homology with alpha(1)-antichymotrypsin, chymotrypsin was not inhibited. Moreover, endopin 1 inhibited the chromaffin granule prohormone thiol protease (involved in proenkephalin processing), These results suggest a role for the novel serpin, endopin 1, in regulating basic residue-cleaving proteases within neurosecretory vesicles of chromaffin cells.	Univ Calif San Diego, Dept Med Neurosci, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Hook, VYH (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	vhook@ucsd.edu						ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; AZARYAN AV, 1995, J NEUROCHEM, V65, P1771; AZARYAN AV, 1995, J BIOL CHEM, V270, P8201, DOI 10.1074/jbc.270.14.8201; BALLINGER MD, 1995, BIOCHEMISTRY-US, V34, P13312, DOI 10.1021/bi00041a006; BAO JJ, 1987, BIOCHEMISTRY-US, V26, P7755, DOI 10.1021/bi00398a033; Benjannet S, 1997, J BIOL CHEM, V272, P26210, DOI 10.1074/jbc.272.42.26210; CARMICHAEL SW, 1990, NEUROSCIENCE, V34, P433, DOI 10.1016/0306-4522(90)90152-T; CHANDRA T, 1983, BIOCHEMISTRY-US, V22, P5055, DOI 10.1021/bi00291a001; Chang WSW, 1997, PROTEIN SCI, V6, P89; CHRISTENSEN S, 1994, BIOCHEM J, V303, P383, DOI 10.1042/bj3030383; Eskeland NL, 1996, J CLIN INVEST, V98, P148, DOI 10.1172/JCI118760; FESTOFF BW, 1990, SERINE PROTEASES THE, P1; FLEMINGER G, 1983, P NATL ACAD SCI-BIOL, V80, P6418, DOI 10.1073/pnas.80.20.6418; FURUYA S, 1989, J ELECTRON MICROSC, V38, P143; GAINER H, 1985, NEUROENDOCRINOLOGY, V40, P171, DOI 10.1159/000124070; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GOLD R, 1975, BIOCHIM BIOPHYS ACTA, V410, P421, DOI 10.1016/0005-2744(75)90246-6; HILL RE, 1984, NATURE, V311, P175, DOI 10.1038/311175a0; HILL RM, 1995, J NEUROCHEM, V65, P2318; Hook VYH, 1999, ENDOCRINOLOGY, V140, P3744, DOI 10.1210/en.140.8.3744; HOOK VYH, 1994, FASEB J, V8, P1269, DOI 10.1096/fasebj.8.15.8001739; HOOK VYH, 1993, J BIOL CHEM, V268, P20570; HOOK VYH, 1985, P NATL ACAD SCI USA, V82, P4745, DOI 10.1073/pnas.82.14.4745; HOOK VYH, 1998, MOL B INT U, V2, P89; HUTTNER WB, 1995, CURR BIOL, V5, P242, DOI 10.1016/S0960-9822(95)00049-2; HWANG SR, 1994, P NATL ACAD SCI USA, V91, P9579, DOI 10.1073/pnas.91.20.9579; HWANG SR, 1995, FEBS LETT, V368, P471, DOI 10.1016/0014-5793(95)00709-I; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; KAWABATA SI, 1988, EUR J BIOCHEM, V172, P17, DOI 10.1111/j.1432-1033.1988.tb13849.x; KHOURI HE, 1991, BIOCHEMISTRY-US, V30, P8929, DOI 10.1021/bi00101a003; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRIEGER TJ, 1991, J BIOL CHEM, V266, P8376; LISTON D, 1984, SCIENCE, V225, P734, DOI 10.1126/science.6547780; LITTLETON JT, 1995, TRENDS NEUROSCI, V18, P177; Loh Y. P., 1993, MECHANISMS INTRACELL, P179; LOH YP, 1985, J BIOL CHEM, V260, P7194; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; MARSHALL CJ, 1993, PHILOS T ROY SOC B, V342, P101, DOI 10.1098/rstb.1993.0141; Mikus P, 1996, J BIOL CHEM, V271, P10048, DOI 10.1074/jbc.271.17.10048; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MORITA T, 1977, J BIOCHEM-TOKYO, V82, P1495, DOI 10.1093/oxfordjournals.jbchem.a131840; NUCK R, 1990, GLYCOCONJUGATE J, V7, P279, DOI 10.1007/BF01073372; POTEMPA J, 1995, BIOCHEM J, V306, P191, DOI 10.1042/bj3060191; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; RUBIN H, 1990, J BIOL CHEM, V265, P1199; Schick C, 1998, BIOCHEMISTRY-US, V37, P5258, DOI 10.1021/bi972521d; SCHILLER MR, 1995, BIOCHEMISTRY-US, V34, P7988, DOI 10.1021/bi00025a004; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SIEGEL RE, 1985, NEUROPEPTIDES, V6, P543, DOI 10.1016/0143-4179(85)90117-9; SPRUCE BA, 1988, J BIOL CHEM, V263, P19788; STEINER DF, 1992, J BIOL CHEM, V267, P23435; Takahashi A, 1996, J BIOL CHEM, V271, P32487, DOI 10.1074/jbc.271.51.32487; TAKEDA A, 1995, FEBS LETT, V359, P78, DOI 10.1016/0014-5793(94)01456-B; TEZAPSIDIS N, 1995, J BIOL CHEM, V270, P13285, DOI 10.1074/jbc.270.22.13285; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; VANNOSTRAND WE, 1990, J BIOL CHEM, V265, P9591; Yasothornsrikul S, 1998, J NEUROCHEM, V70, P153	57	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34164	34173		10.1074/jbc.274.48.34164	http://dx.doi.org/10.1074/jbc.274.48.34164			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567388	hybrid			2022-12-25	WOS:000083857500053
J	Wesche, J; Rapak, A; Olsnes, S				Wesche, J; Rapak, A; Olsnes, S			Dependence of ricin toxicity on translocation of the toxin A-chain from the endoplasmic reticulum to the cytosol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; I HEAVY-CHAINS; EUKARYOTIC RIBOSOMES; PROTEIN-DEGRADATION; PSEUDOMONAS EXOTOXIN; RETROGRADE TRANSPORT; SECRETORY PATHWAY; ESCHERICHIA-COLI; DIPHTHERIA-TOXIN; ER DEGRADATION	Ricin acts by translocating to the cytosol the enzymatically active toxin A-chain, which inactivates ribosomes. Retrograde intracellular transport and translocation of ricin was studied under conditions that alter the sensitivity of cells to the toxin. For this purpose tyrosine sulfation of mutant A-chain in the Golgi apparatus, glycosylation in the endoplasmic reticulum (ER) and appearance of A-chain in the cytosolic fraction was monitored. introduction of an ER retrieval signal, a C-terminal KDEL sequence, into the A-chain increased the toxicity and resulted in more efficient glycosylation, indicating enhanced transport from Golgi to ER. Calcium depletion inhibited neither sulfation nor glycosylation but inhibited translocation and toxicity, suggesting that the toxin is translocated to the cytosol by the pathway used by misfolded proteins that are targeted to the proteasomes for degradation. Slightly acidified medium had a similar effect. The proteasome inhibitor, lactacystin, sensitized cells to ricin and increased the amount of ricin A-chain in the cytosol, Anti-Sec61 alpha precipitated sulfated and glycosylated ricin A-chain, suggesting that retrograde toxin translocation involves Sec61p, The data indicate that retrograde translocation across the ER membrane is required for intoxication.	Norwegian Radium Hosp, Inst Canc Res, N-0310 Oslo, Norway	University of Oslo	Olsnes, S (corresponding author), Norwegian Radium Hosp, Inst Canc Res, N-0310 Oslo, Norway.	olsnes@radium.uio.no	Rapak, Andrzej/ABE-6262-2021	Rapak, Andrzej/0000-0003-4897-0287; Wesche, Jorgen/0000-0002-9200-9162				Barrero MJ, 1997, J BIOL CHEM, V272, P27694, DOI 10.1074/jbc.272.44.27694; Beaumelle B, 1997, J BIOL CHEM, V272, P22097, DOI 10.1074/jbc.272.35.22097; BEAUMELLE B, 1993, J BIOL CHEM, V268, P23661; Bhakdi S, 1996, ARCH MICROBIOL, V165, P73, DOI 10.1007/s002030050300; BHAKDI S, 1993, MED MICROBIOL IMMUN, V182, P167; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; Day PJ, 1996, BIOCHEMISTRY-US, V35, P11098, DOI 10.1021/bi960880n; Durr G, 1998, MOL BIOL CELL, V9, P1149, DOI 10.1091/mbc.9.5.1149; ENDO Y, 1987, J BIOL CHEM, V262, P8128; ENDO Y, 1987, J BIOL CHEM, V262, P5908; Gill DL, 1996, BIOSCIENCE REP, V16, P139, DOI 10.1007/BF01206203; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Hazes B, 1997, BIOCHEMISTRY-US, V36, P11051, DOI 10.1021/bi971383p; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Holmberg L, 1996, J MOL BIOL, V259, P81, DOI 10.1006/jmbi.1996.0303; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; Kim JH, 1998, P NATL ACAD SCI USA, V95, P2997, DOI 10.1073/pnas.95.6.2997; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEITINGER B, 1994, J BIOL CHEM, V269, P8115; Lord JM, 1998, J CELL BIOL, V140, P733; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; OLSNES S, 1973, BIOCHEMISTRY-US, V12, P3121, DOI 10.1021/bi00740a028; OLSNES S, 1973, MOL BIOL REP, V1, P15, DOI 10.1007/BF00357400; OLSNES S, 1972, FEBS LETT, V20, P327, DOI 10.1016/0014-5793(72)80098-X; OLSNES S, 1972, FEBS LETT, V28, P48, DOI 10.1016/0014-5793(72)80674-4; OLSNES S, 1974, NATURE, V249, P627, DOI 10.1038/249627a0; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Rapak A, 1997, P NATL ACAD SCI USA, V94, P3783, DOI 10.1073/pnas.94.8.3783; ROSA P, 1992, J BIOL CHEM, V267, P12227; SANDVIG K, 1982, J BIOL CHEM, V257, P7495; SANDVIG K, 1982, J BIOL CHEM, V257, P7504; SANDVIG K, 1991, J CELL BIOL, V115, P971, DOI 10.1083/jcb.115.4.971; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; SEETHARAM S, 1991, J BIOL CHEM, V266, P17376; Suzuki T, 1998, J BIOL CHEM, V273, P10083, DOI 10.1074/jbc.273.17.10083; Tagge E, 1996, J HISTOCHEM CYTOCHEM, V44, P159, DOI 10.1177/44.2.8609372; TAKEDA Y, 1993, MICROBIOL IMMUNOL, V37, P591, DOI 10.1111/j.1348-0421.1993.tb01681.x; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; TONNESSEN TI, 1990, AM J PHYSIOL, V258, pC1117, DOI 10.1152/ajpcell.1990.258.6.C1117; VANDEURS B, 1986, J CELL BIOL, V102, P37, DOI 10.1083/jcb.102.1.37; VANDEURS B, 1989, INT REV CYTOL, V117, P131; WALES R, 1993, J BIOL CHEM, V268, P23986; WALES R, 1992, EXP CELL RES, V203, P1, DOI 10.1016/0014-4827(92)90032-4; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WILSON DW, 1993, J BIOL CHEM, V268, P7465; YOSHIDA T, 1991, EXP CELL RES, V192, P389, DOI 10.1016/0014-4827(91)90056-Z	54	169	177	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34443	34449		10.1074/jbc.274.48.34443	http://dx.doi.org/10.1074/jbc.274.48.34443			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567425	hybrid			2022-12-25	WOS:000083857500090
J	Xu, FH; Li, HQ; Jin, TR				Xu, FH; Li, HQ; Jin, TR			Cell type-specific autoregulation of the Caudal-related homeobox gene Cdx-2/3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEODOMAIN PROTEIN CDX-2/3; OCTAMER-BINDING-PROTEINS; TRANSCRIPTION FACTORS; ISLET CELLS; PROMOTER; EXPRESSION; ACTIVATION; ELEMENTS; GROWTH; MOTIF	The caudal-related homeobox gene Cdx-2/3 is a critical "master" control gene in embryogenesis, Mice heterozygous for a null mutation in Cdx-2/3 exhibit multiple malfunctions including tail abnormalities, stunted growth, a homeotic shift in vertebrae, and the development of multiple intestinal adenomatous polyps, indicating that Cdx-2/3 is haplo-insufficient. In vitro studies have identified more than a half-dozen downstream target genes expressed in pancreatic and intestinal cells for this transcription factor, We have examined the transcriptional properties of the mouse Cdx-2/3 promoter, This promoter could be autoregulated in pancreatic and intestinal cells that express endogenous Cdx-2/3. In contrast, Cdx-2/3 transfection represses the Cdx-2/3 promoter in fibroblasts, which do not express endogenous Cdx-2/3, Since Cdx-2/3 activates proglucagon gene promoter in both pancreatic and intestinal cells and in fibroblasts, we suggest that some, yet to be identified, cell type-specific components are required for activating selected target gene promoters of Cdx-2/3, including the Cdx-2/3 promoter itself. Cdx-2/3 binds to the TATA box and another AT-rich motif, designated as DES, within an evolutionarily conserved proximal element of the Cdx-2/3 promoter. The DBS motif is critical for the autoregulation, whereas the TATA box may act as an attenuating element for the autoregulatory loop. Finally, overexpression of Cdx-2/3 in a pancreatic cell line activated the expression of the endogenous Cdx-2/3. Taken together, our results indicate that the dose-dependent phenotype of Cdx-2/3 expression on its downstream targets in vivo could be regulated initially via a transcriptional network involving cell type-specific autoregulation of the Cdx-2/3 promoter.	Univ Toronto, Toronto Hosp, Oncol Res Lab, Toronto, ON M5G 2M1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto	Jin, TR (corresponding author), Univ Toronto, Toronto Hosp, Oncol Res Lab, 67 Coll St, Toronto, ON M5G 2M1, Canada.							Boncinelli E, 1997, CURR OPIN GENET DEV, V7, P331, DOI 10.1016/S0959-437X(97)80146-3; Care A, 1996, MOL CELL BIOL, V16, P4842; Chang CP, 1997, MOL CELL BIOL, V17, P81, DOI 10.1128/MCB.17.1.81; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; CHOUINARD S, 1991, DEVELOPMENT, V113, P1267; Colnot S, 1998, J BIOL CHEM, V273, P31939, DOI 10.1074/jbc.273.48.31939; DRUCKER DJ, 1994, MOL ENDOCRINOL, V8, P1646, DOI 10.1210/me.8.12.1646; Drummond F, 1997, ANN HUM GENET, V61, P393, DOI 10.1017/S0003480097006465; Drummond F, 1996, EUR J BIOCHEM, V236, P670, DOI 10.1111/j.1432-1033.1996.t01-1-00670.x; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Fishman MC, 1997, CELL, V91, P153, DOI 10.1016/S0092-8674(00)80397-9; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Hawley RG, 1997, CANCER RES, V57, P337; JAMES R, 1994, J BIOL CHEM, V269, P15229; Jin TR, 1999, INT J CANCER, V81, P104, DOI 10.1002/(SICI)1097-0215(19990331)81:1<104::AID-IJC18>3.0.CO;2-Q; Jin TR, 1996, MOL CELL BIOL, V16, P19; Jin TR, 1997, MOL ENDOCRINOL, V11, P203, DOI 10.1210/me.11.2.203; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Lambert M, 1996, EUR J BIOCHEM, V236, P778, DOI 10.1111/j.1432-1033.1996.00778.x; Laser B, 1996, J BIOL CHEM, V271, P28984, DOI 10.1074/jbc.271.46.28984; Muragaki Y, 1996, SCIENCE, V272, P548, DOI 10.1126/science.272.5261.548; Okladnova O, 1998, MOL BRAIN RES, V60, P177, DOI 10.1016/S0169-328X(98)00167-3; PEERS B, 1995, MOL CELL BIOL, V15, P7091; Phelan ML, 1997, J BIOL CHEM, V272, P8635, DOI 10.1074/jbc.272.13.8635; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SERFLING E, 1989, TRENDS GENET, V5, P131, DOI 10.1016/0168-9525(89)90049-8; Smith RC, 1997, GENE DEV, V11, P1674, DOI 10.1101/gad.11.13.1674; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; Suda Y, 1997, MECH DEVELOP, V69, P125, DOI 10.1016/S0925-4773(97)00161-5; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Taylor JK, 1997, NUCLEIC ACIDS RES, V25, P2293, DOI 10.1093/nar/25.12.2293; Taylor JK, 1997, DNA CELL BIOL, V16, P1419, DOI 10.1089/dna.1997.16.1419; Trinh KY, 1999, J BIOL CHEM, V274, P6011, DOI 10.1074/jbc.274.9.6011; Troelsen JT, 1997, BIOCHEM J, V322, P833, DOI 10.1042/bj3220833; WU K, 1993, J CELL BIOCHEM, V52, P449, DOI 10.1002/jcb.240520409; Yamamoto H, 1999, J BONE MINER RES, V14, P240, DOI 10.1359/jbmr.1999.14.2.240; Yu Y, 1997, NATURE, V385, P552, DOI 10.1038/385552a0	41	58	60	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34310	34316		10.1074/jbc.274.48.34310	http://dx.doi.org/10.1074/jbc.274.48.34310			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567407	hybrid			2022-12-25	WOS:000083857500072
J	Conrad, PW; Freeman, TL; Beitner-Johnson, D; Millhorn, DE				Conrad, PW; Freeman, TL; Beitner-Johnson, D; Millhorn, DE			EPAS1 trans-activation during hypoxia requires p42/p44 MAPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR 1-ALPHA; TYROSINE-HYDROXYLASE GENE; PAS DOMAIN PROTEIN-1; TRANSCRIPTION FACTOR; PC12 CELLS; MEMBRANE DEPOLARIZATION; PATHWAYS TARGET; CAROTID-BODY; K+ CURRENT; FACTOR-I	Hypoxia is a common environmental stress that regulates gene expression and cell function. A number of hypoxia-regulated transcription factors have been identified and have been shown to play critical roles in mediating cellular responses to hypoxia, One of these is the endothelial PAS-domain protein 1 (EPAS1/HIF2-alpha/HLF/HRF). This protein is 48% homologous to hypoxia-inducible factor 1-alpha (HIF1-alpha). To date, virtually nothing is known about the signaling pathways that lead to either EPAS1 or HIF1-alpha activation. Here we show that EPAS1 is phosphorylated when PC12 cells are exposed to hypoxia and that p42/p44 MAPK is a critical mediator of EPAS1 activation. Pretreatment of PC12 cells with the MEK inhibitor, PD98059, completely blocked hypoxia-induced trans-activation of a hypoxia response element (HRE) reporter gene by transfected EPAS1. Likewise, expression of a constitutively active MEK1 mimicked the effects of hypoxia on HRE reporter gene expression. However, pretreatment with PD98059 had no effect on EPAS1 phosphorylation during hypoxia, suggesting that MAPK targets other proteins that are critical for the trans-activation of EPAS1, We further show that hypoxia-induced trans-activation of EPAS1 is independent of Pas. Finally, pretreatment with calmodulin antagonists nearly completely blocked both the hypoxia-induced phosphorylation of MAPK and the EPAS1 trans-activation of HRE-Luc. These results demonstrate that the MAPK pathway is a critical mediator of EPAS1 activation and that activation of MAPK and EPAS1 occurs through a calmodulin-sensitive pathway and not through the GTPase, Pas. These results are the first to identify a specific signaling pathway involved in EPAS1 activation.	Univ Cincinnati, Coll Med, Dept Mol & Cellular Physiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Millhorn, DE (corresponding author), Univ Cincinnati, Coll Med, Dept Mol & Cellular Physiol, POB 67-0576, Cincinnati, OH 45267 USA.	david.millhorn@uc.edu			NHLBI NIH HHS [R37HL33831, R01HL59945, HL07571] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL033831, R01HL059945] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Beitner-Johnson D, 1998, J BIOL CHEM, V273, P19834, DOI 10.1074/jbc.273.31.19834; BERNSTEIN LR, 1994, J BIOL CHEM, V269, P9401; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; Conforti L, 1997, J PHYSIOL-LONDON, V502, P293, DOI 10.1111/j.1469-7793.1997.293bk.x; Conrad PW, 1999, J BIOL CHEM, V274, P23570, DOI 10.1074/jbc.274.33.23570; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; CZYZYKKRZESKA MF, 1992, J NEUROCHEM, V58, P1538, DOI 10.1111/j.1471-4159.1992.tb11376.x; Egea J, 1998, J NEUROCHEM, V70, P2554; Egea J, 1999, J BIOL CHEM, V274, P75, DOI 10.1074/jbc.274.1.75; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; FIAMME I, 1997, MECH DEVELOP, V63, P51; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; JewellMotz EA, 1996, J BIOL CHEM, V271, P18082, DOI 10.1074/jbc.271.30.18082; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; KRAMMER EB, 1978, P NATL ACAD SCI USA, V75, P2507, DOI 10.1073/pnas.75.5.2507; Kumar GK, 1998, AM J PHYSIOL-CELL PH, V274, pC1592, DOI 10.1152/ajpcell.1998.274.6.C1592; Liu YZ, 1998, J BIOL CHEM, V273, P32400, DOI 10.1074/jbc.273.49.32400; LOPEZBARNEO J, 1988, SCIENCE, V241, P580, DOI 10.1126/science.2456613; Maletic-Savatic M, 1998, J NEUROSCI, V18, P6814; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Millhorn DE, 1996, ADV EXP MED BIOL, V410, P135; Mishra RR, 1998, MOL BRAIN RES, V59, P74, DOI 10.1016/S0169-328X(98)00139-9; NORRIS ML, 1995, J BIOL CHEM, V270, P23774, DOI 10.1074/jbc.270.40.23774; O'Rourke JF, 1999, J BIOL CHEM, V274, P2060, DOI 10.1074/jbc.274.4.2060; Pracyk JB, 1997, SURGERY, V122, P404, DOI 10.1016/S0039-6060(97)90033-7; PURVES MJ, 1966, J PHYSIOL-LONDON, V185, P60, DOI 10.1113/jphysiol.1966.sp007972; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SCHILLING K, 1991, P NATL ACAD SCI USA, V88, P5665, DOI 10.1073/pnas.88.13.5665; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Taylor SC, 1998, BIOCHEM BIOPH RES CO, V248, P13, DOI 10.1006/bbrc.1998.8905; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; WADMAN IA, 1994, ONCOGENE, V9, P3713; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 1997, BIOL CHEM, V378, P609; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Zhu WH, 1996, AM J PHYSIOL-CELL PH, V271, pC658, DOI 10.1152/ajpcell.1996.271.2.C658	48	136	144	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33709	33713		10.1074/jbc.274.47.33709	http://dx.doi.org/10.1074/jbc.274.47.33709			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559262	hybrid			2022-12-25	WOS:000083745200078
J	Millman, JS; Andrews, DW				Millman, JS; Andrews, DW			A site-specific, membrane-dependent cleavage event defines the membrane binding domain of FtsY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION PARTICLE; ENDOPLASMIC-RETICULUM MEMBRANE; ESCHERICHIA-COLI SRP; SEQUENCE RECOGNITION; NG DOMAIN; PROTEIN; RECEPTOR; SUBUNIT; MUTATIONS; RIBONUCLEOPROTEIN	Targeting of many polytopic proteins to the inner membrane of prokaryotes occurs via an essential signal recognition particle-like pathway. Unlike the general secretory pathway, the proteins involved in this pathway and their activities appear in many respects to mirror closely those of their eukaryotic homologues, However, the Escherichia coli signal recognition particle receptor, FtsY, differs significantly at the amino terminus from the eukaryote homologue alpha-subunit of the signal recognition particle receptor. In addition, there is no prokaryote homologue of the transmembrane beta-subunit of the receptor. Therefore, FtsY must assemble on the membrane in a unique manner. Using assays designed to accurately discriminate membrane-bound proteins from aggregated material, we found that in contrast to a previous report, only amino acids 1-284 of FtsY are necessary and sufficient for membrane assembly. These amino acids together constitute a bona fide membrane binding domain that includes both the regions originally designated A and N based on sequence comparisons. Furthermore, we found that a membrane-bound factor mediates specific cleavage of some membrane-bound FtsY molecules between the N and G regions previously believed to be functionally linked to generate a novel membrane-bound isoform composed of only the AN domain.	McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada	McMaster University	Andrews, DW (corresponding author), McMaster Univ, Dept Biochem, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.			Andrews, David/0000-0002-9266-7157; Millman, Jonathan/0000-0002-1766-2348				AKIYAMA Y, 1994, J BIOL CHEM, V269, P5218; AKIYAMA Y, 1994, J BIOL CHEM, V269, P5225; ANDREWS D, 1989, BIOTECHNIQUES, V7, P960; Andrews DW, 1996, TRENDS BIOCHEM SCI, V21, P365; ANDREWS DW, 1989, J CELL BIOL, V108, P797, DOI 10.1083/jcb.108.3.797; Arvidson CG, 1999, J BACTERIOL, V181, P731, DOI 10.1128/JB.181.3.731-739.1999; BarPeled M, 1996, ANAL BIOCHEM, V241, P140, DOI 10.1006/abio.1996.0390; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; CAMMACK KA, 1965, BIOCHEM J, V96, P671, DOI 10.1042/bj0960671; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; deLeeuw E, 1997, FEBS LETT, V416, P225, DOI 10.1016/S0014-5793(97)01238-6; Freymann DM, 1997, NATURE, V385, P361, DOI 10.1038/385361a0; GILL DR, 1990, MOL MICROBIOL, V4, P575; Gribaldo S, 1998, J MOL EVOL, V47, P508, DOI 10.1007/PL00006407; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; HONDA K, 1993, J BACTERIOL, V175, P4885, DOI 10.1128/JB.175.15.4885-4894.1993; Hughes MJG, 1996, BIOTECHNIQUES, V20, P188; JANIAK F, 1994, BIOCHEM J, V300, P191, DOI 10.1042/bj3000191; LAUFFER L, 1985, NATURE, V318, P334, DOI 10.1038/318334a0; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; MACFARLANE J, 1995, EUR J BIOCHEM, V233, P766, DOI 10.1111/j.1432-1033.1995.766_3.x; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; Montoya G, 1997, NATURE, V385, P365, DOI 10.1038/385365a0; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7421, DOI 10.1073/pnas.81.23.7421; Newitt JA, 1997, EUR J BIOCHEM, V245, P720, DOI 10.1111/j.1432-1033.1997.00720.x; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; Powers T, 1997, EMBO J, V16, P4880, DOI 10.1093/emboj/16.16.4880; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; Sambrook J., 2002, MOL CLONING LAB MANU; Samuelsson T, 1997, BIOCHEM BIOPH RES CO, V231, P839, DOI 10.1006/bbrc.1997.6199; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Seluanov A, 1997, J BIOL CHEM, V272, P2053; STRUCK JCR, 1988, NUCLEIC ACIDS RES, V16, P7740, DOI 10.1093/nar/16.15.7740; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; YOUNG JC, 1995, J BIOL CHEM, V270, P15650, DOI 10.1074/jbc.270.26.15650; Zelazny A, 1997, P NATL ACAD SCI USA, V94, P6025, DOI 10.1073/pnas.94.12.6025	42	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33227	33234		10.1074/jbc.274.47.33227	http://dx.doi.org/10.1074/jbc.274.47.33227			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559196	hybrid			2022-12-25	WOS:000083745200012
J	Roseberry, AG; Hosey, MM				Roseberry, AG; Hosey, MM			Trafficking of M-2 muscarinic acetylcholine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; PLASMA-MEMBRANE; MEDIATED ENDOCYTOSIS; DOWN-REGULATION; BETA-ARRESTINS; INTERNALIZATION; RESENSITIZATION; DESENSITIZATION; SEQUESTRATION	Internalization is an important mechanism regulating the agonist-dependent responses of G-protein-coupled receptors, The internalization of the M-2 muscarinic cholinergic receptors (mAChR) in HEK293 cells has been demonstrated to occur by an unknown mechanism that is independent of arrestins and dynamin, In this study we examined various aspects of the trafficking of the M-2 mAChR in HEK293 cells to characterize this unknown pathway of internalization. Internalization of the M-2 mAChR was rapid and extensive, but prolonged incubation with agonist did not lead to appreciable down-regulation (a decrease in total receptor number) of the receptors, Recovery of M-2 mAChRs to the cell surface following agonist-mediated internalization was a very slow process that contained protein synthesis-dependent and -independent components. The protein synthesis-dependent component of the recovery of receptors to the cell surface did not appear to reflect a requirement for synthesis of new receptors, as no changes in total receptor number were observed either in the presence or absence of cycloheximide, Phosphorylation of the M-2 mAChR did not appear to influence the rate or extent of the recovery of receptors to the cell surface, as the recovery of a phosphorylation-deficient mutant M-2 mAChR, the N,CAla-8 mutant, was similar to the recovery of the wild type M-2 mAChR, Finally, the constitutive, nonagonist-dependent internalization and recycling of the M-2 mAChR was very slow and also contained protein synthesis-dependent and -independent components, suggesting that a similar pathway controls the recovery from agonist-dependent and -independent internalization. Overall, these data demonstrated a variety of previously unappreciated facets involved in the regulation of M-2 mAChRs.	Northwestern Univ, Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA	Northwestern University	Hosey, MM (corresponding author), Northwestern Univ, Sch Med, Dept Mol Pharmacol & Biol Chem, 303 E Chicago Ave,S215, Chicago, IL 60611 USA.			Roseberry, Aaron/0000-0003-0468-0333				Bogatkewitsch GS, 1996, MOL PHARMACOL, V50, P424; Bohm SK, 1997, BIOCHEM J, V322, P1; Bunemann M, 1999, J PHYSIOL-LONDON, V517, P5, DOI 10.1111/j.1469-7793.1999.0005z.x; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Gomeza J, 1999, P NATL ACAD SCI USA, V96, P1692, DOI 10.1073/pnas.96.4.1692; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; HEIN L, 1994, J BIOL CHEM, V269, P27719; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Innamorati G, 1998, P NATL ACAD SCI USA, V95, P2222, DOI 10.1073/pnas.95.5.2222; Koenig JA, 1996, MOL PHARMACOL, V49, P351; KOENIG JA, 1994, J BIOL CHEM, V269, P17174; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; KOENIG JA, 1994, BRIT J PHARMACOL, V111, P1023, DOI 10.1111/j.1476-5381.1994.tb14846.x; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1997, J BIOL CHEM, V272, P18125, DOI 10.1074/jbc.272.29.18125; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Trejo J, 1998, P NATL ACAD SCI USA, V95, P13698, DOI 10.1073/pnas.95.23.13698; Tsuga H, 1998, J BIOL CHEM, V273, P5323, DOI 10.1074/jbc.273.9.5323; YOUNG JM, 1972, J PHARM PHARMACOL, V24, P950, DOI 10.1111/j.2042-7158.1972.tb08925.x; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	28	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33671	33676		10.1074/jbc.274.47.33671	http://dx.doi.org/10.1074/jbc.274.47.33671			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559256	hybrid			2022-12-25	WOS:000083745200072
J	Cheung, PY; Churchich, JE				Cheung, PY; Churchich, JE			Recognition of protein substrates by protein-disulfide isomerase - A sequence of the b ' domain responds to substrate binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL MALATE-DEHYDROGENASE; MISFOLDED PROTEINS; GROEL; THIOREDOXIN; RHODANESE; ATP	Refolding of partially folded mitochondrial malate de hydrogenase (mMDH) is assisted by protein-disulfide isomerase (PDI). The addition of a 20-fold molar excess of PDI over denatured protein (0.1 mu M) accelerates the recovery of catalytic activity. PDI fluorescence measurements show that 1 mol of PDI binds 1 mol of denatured mMDH when their concentrations approach 1 mu M. The binding of PDI, derivatized with the fluorescence probe iodoacetamide fluorescein, to partially folded mMDH is characterized by a dissociation constant of 0.2 mu M. It is shown that the fluorescence probe is covalently attached to a SH residue located in the b' domain. Based on the fluorescence measurements of native and derivatized PDI, it is suggested that recognition of the unfolded substrate involves conformational changes propagated to several domains of PDI.	Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Hong Kong, Peoples R China	Hong Kong Polytechnic University	Churchich, JE (corresponding author), Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Hong Kong, Peoples R China.							Churchich JE, 1997, J BIOL CHEM, V272, P19645, DOI 10.1074/jbc.272.32.19645; Dai Y, 1997, J BIOL CHEM, V272, P27572, DOI 10.1074/jbc.272.44.27572; DELORENZ.F, 1966, J BIOL CHEM, V241, P1562; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; Gilbert HF, 1998, METHOD ENZYMOL, V290, P26, DOI 10.1016/S0076-6879(98)90005-2; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; Guthapfel R, 1996, J BIOL CHEM, V271, P2663, DOI 10.1074/jbc.271.5.2663; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; HUTCHINSON JP, 1994, BIOCHEM J, V302, P405, DOI 10.1042/bj3020405; JOHN DCA, 1993, EMBO J, V12, P1587, DOI 10.1002/j.1460-2075.1993.tb05803.x; Klappa P, 1998, EMBO J, V17, P927, DOI 10.1093/emboj/17.4.927; Klappa P, 1998, EUR J BIOCHEM, V254, P63, DOI 10.1046/j.1432-1327.1998.2540063.x; Koivunen P, 1999, EMBO J, V18, P65, DOI 10.1093/emboj/18.1.65; LAMBERT N, 1983, BIOCHEM J, V213, P225, DOI 10.1042/bj2130225; Li WK, 1997, EUR J BIOCHEM, V246, P127, DOI 10.1111/j.1432-1033.1997.t01-1-00127.x; MAKINO Y, 1993, FEBS LETT, V336, P363, DOI 10.1016/0014-5793(93)80838-L; MORJANA NA, 1993, P NATL ACAD SCI USA, V90, P2107, DOI 10.1073/pnas.90.6.2107; Ranson NA, 1997, J MOL BIOL, V266, P656, DOI 10.1006/jmbi.1996.0815; SONG JL, 1995, EUR J BIOCHEM, V231, P312, DOI 10.1111/j.1432-1033.1995.tb20702.x; SONGJL, 1997, BIOCH J, V273, P9637; Todd MJ, 1998, METHOD ENZYMOL, V290, P135, DOI 10.1016/S0076-6879(98)90012-X	21	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32757	32761		10.1074/jbc.274.46.32757	http://dx.doi.org/10.1074/jbc.274.46.32757			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551835	hybrid			2022-12-25	WOS:000083623000035
J	Leissring, MA; Parker, I; LaFerla, FM				Leissring, MA; Parker, I; LaFerla, FM			Presenilin-2 mutations modulate amplitude and kinetics of inositol 1,4,5-trisphosphate-mediated calcium signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; AMYLOID-BETA-PEPTIDE; ENDOPLASMIC-RETICULUM; NEURONAL EXPRESSION; PC12 CELLS; FIBROBLASTS; APOPTOSIS; GENE; BRAIN; LOCALIZATION	Mutations in the two presenilin genes (PS1, PS2) account for the majority of early-onset familial Alzheimer's disease (FAD) cases. Converging evidence from a variety of experimental systems, including fibroblasts from FAD patients and transgenic animals, indicates that PSI mutations modulate intracellular calcium signaling pathways. Despite the potential relevance of these changes to the pathogenesis of FAD, a comparable effect for PS2 has not yet been demonstrated experimentally. We examined the effects of wild-type PS2, and both of the identified FAD mutations in PS2, on intracellular calcium signaling in Xenopus oocytes. Inositol 1,4,5-trisphosphate (IP3)-evoked calcium signals were significantly potentiated in cells expressing either of the PS2 mutations relative to wild-type PS2-expressing cells and controls. Decay rates of calcium signals were also significantly accelerated in mutant PS2-expressing cells in a manner dependent upon IF, concentration, The finding that mutations in both PS1 and PS2 modulate intracellular calcium signaling suggests that these disturbances may represent a common pathogenic mechanism of presenilin-associated FAD.	Univ Calif Irvine, Dept Neurobiol & Behav, Gillespie Neurosci Facil 1109, Lab Mol Neuropathogenesis, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Neurobiol & Behav, Cellular & Mol Neurobiol Lab, Irvine, CA 92697 USA; Univ Calif Irvine, Ctr Neurobiol Learning & Memory, Irvine, CA 92697 USA; Univ Calif Irvine, Inst Brain Aging & Dementia, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	LaFerla, FM (corresponding author), Univ Calif Irvine, Dept Neurobiol & Behav, Gillespie Neurosci Facil 1109, Lab Mol Neuropathogenesis, Irvine, CA 92697 USA.		LEISSRING, MALCOLM/AAW-5361-2021	LEISSRING, MALCOLM/0000-0001-7185-4255	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048071, R37GM048071] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-48071] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Begley JG, 1999, J NEUROCHEM, V72, P1030, DOI 10.1046/j.1471-4159.1999.0721030.x; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Buxbaum JD, 1998, NAT MED, V4, P1177, DOI 10.1038/2673; Callamaras N, 1998, Methods Enzymol, V291, P380; Cribbs DH, 1996, AM J PATHOL, V148, P1797; Cruts M, 1998, HUM MOL GENET, V7, P43, DOI 10.1093/hmg/7.1.43; Deng GM, 1996, FEBS LETT, V397, P50, DOI 10.1016/S0014-5793(96)01142-8; DISTERHOFT JF, 1994, ANN NY ACAD SCI, V747, P382; Etcheberrigaray R, 1998, NEUROBIOL DIS, V5, P37, DOI 10.1006/nbdi.1998.0176; Gibson GE, 1997, NEUROBIOL AGING, V18, P573, DOI 10.1016/S0197-4580(97)00149-8; Gibson GE, 1996, BBA-MOL BASIS DIS, V1316, P71, DOI 10.1016/0925-4439(96)00002-6; Guo Q, 1999, NAT MED, V5, P101, DOI 10.1038/4789; Guo Q, 1996, NEUROREPORT, V8, P379, DOI 10.1097/00001756-199612200-00074; Guo Q, 1997, J NEUROSCI, V17, P4212; Hong CS, 1999, J NEUROSCI, V19, P637; ITO E, 1994, P NATL ACAD SCI USA, V91, P534, DOI 10.1073/pnas.91.2.534; KHACHATURIAN ZS, 1987, NEUROBIOL AGING, V8, P345, DOI 10.1016/0197-4580(87)90073-X; Kim T.-W., 1998, Society for Neuroscience Abstracts, V24, P757; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; Leissring MA, 1999, J NEUROCHEM, V72, P1061, DOI 10.1046/j.1471-4159.1999.0721061.x; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; MATTSON MP, 1991, MOL CHEM NEUROPATHOL, V15, P117, DOI 10.1007/BF03159951; Mattson MP, 1998, J NEUROCHEM, V70, P1; Meyers MB, 1998, J BIOL CHEM, V273, P18930, DOI 10.1074/jbc.273.30.18930; MEYERS MB, 1995, J BIOL CHEM, V270, P26411, DOI 10.1074/jbc.270.44.26411; QUERFURTH HW, 1994, BIOCHEMISTRY-US, V33, P4550, DOI 10.1021/bi00181a016; Querfurth HW, 1997, J NEUROCHEM, V69, P1580; Renbaum P, 1998, CELL MOL LIFE SCI, V54, P910, DOI 10.1007/s000180050220; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Saura CA, 1999, J BIOL CHEM, V274, P13818, DOI 10.1074/jbc.274.20.13818; Sun XP, 1998, J PHYSIOL-LONDON, V509, P67, DOI 10.1111/j.1469-7793.1998.067bo.x; Tsujimura A, 1997, BIOCHEM BIOPH RES CO, V231, P392, DOI 10.1006/bbrc.1996.6043; Vito P, 1996, J BIOL CHEM, V271, P31025, DOI 10.1074/jbc.271.49.31025; Walter J, 1998, BIOCHEMISTRY-US, V37, P5961, DOI 10.1021/bi971763a; YAO Y, 1993, J PHYSIOL-LONDON, V468, P275, DOI 10.1113/jphysiol.1993.sp019771; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436	37	117	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32535	32538		10.1074/jbc.274.46.32535	http://dx.doi.org/10.1074/jbc.274.46.32535			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551803	hybrid			2022-12-25	WOS:000083623000003
J	Quintas, A; Saraiva, MJM; Brito, RMM				Quintas, A; Saraiva, MJM; Brito, RMM			The tetrameric protein transthyretin dissociates to a non-native monomer in solution - A novel model for amyloidogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL AMYLOIDOTIC POLYNEUROPATHY; CRYSTAL-STRUCTURE; PREALBUMIN; BINDING; VARIANT; FLUORESCENCE; DENATURATION; STABILITY; PATHWAY; FAP	In amyloidosis, normally innocuous soluble proteins polymerize to form insoluble fibrils, Amyloid fibril formation and deposition have been associated with a wide range of diseases, including spongiform encephalopathies, Alzheimer's disease, and familial amyloid polyneuropathies (FAP), In certain forms of FAP, the amyloid fibrils are mostly constituted by variants of transthyretin (TTR), a homotetrameric plasma protein implicated in the transport of thyroxine and retinol, The most common amyloidogenic TTR variant is V30M-TTR, and L55P-TTR is the variant associated with the most aggressive form of FAP, Recently, we reported that TTR dissociates to a monomeric species at pH 7.0 and nearly physiological ionic strengths (Quintas, A, Saraiva, M, J,, and Brito, R, M, (1997) PEES Lett, 418, 297-300). Here, we show that the tetramer dissociation is apparently irreversible; and based on intrinsic tryptophan fluorescence and fluorescence quenching experiments, we show that the monomeric species formed upon tetramer dissociation is non-native. We also show, based on 1-anilino-8-naph-thalenesulfonate binding studies, that this monomeric species appears not to behave like a molten globule, These data allowed us to propose a model for TTR amyloidogenesis based on tetramer dissociation occurring naturally under commonly observed physiological solution conditions.	Univ Coimbra, Dept Quim, Fac Ciencias & Tecnol, P-3049 Coimbra, Portugal; Univ Coimbra, Ctr Neurociencias Coimbra, P-3004517 Coimbra, Portugal; Inst Super Ciencias Saude Sul, P-2825 Monte De Caparica, Portugal; Univ Porto, Inst Mol & Cellular Biol, Amyloid Unit, P-4050 Porto, Portugal; Univ Porto, Inst Ciencias Biomed Abel Salazar, P-4050 Porto, Portugal; Univ Coimbra, Ctr Neurociencias Coimbra, P-3004517 Coimbra, Portugal; Inst Super Ciencias Saude Sul Quinta Granja, P-2825 Monte De Caparica, Portugal	Universidade de Coimbra; Universidade de Coimbra; Universidade do Porto; Universidade do Porto; Universidade de Coimbra	Brito, RMM (corresponding author), Univ Coimbra, Dept Quim, Fac Ciencias & Tecnol, P-3049 Coimbra, Portugal.		Saraiva, Maria João/K-3907-2013; Quintas, Alexandre/J-6436-2012	Saraiva, Maria João/0000-0002-3360-6899; Quintas, Alexandre/0000-0002-5188-0453; Brito, Rui/0000-0001-9128-2557				ADAMS D, 1996, J NEUROL, V243, P73; Almeida MR, 1997, ENDOCRINE, V6, P309, DOI 10.1007/BF02820508; Alves IL, 1997, EUR J BIOCHEM, V249, P662, DOI 10.1111/j.1432-1033.1997.00662.x; BLAKE CCF, 1978, J MOL BIOL, V121, P339, DOI 10.1016/0022-2836(78)90368-6; CHENG SY, 1977, BIOCHEMISTRY-US, V16, P3707, DOI 10.1021/bi00635a031; COLON W, 1992, BIOCHEMISTRY-US, V31, P8654, DOI 10.1021/bi00151a036; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; FURUYA H, 1991, BIOCHEMISTRY-US, V30, P2415, DOI 10.1021/bi00223a017; Goldsteins G, 1997, BIOCHEMISTRY-US, V36, P5346, DOI 10.1021/bi961649c; GUSTAVSSON A, 1991, BIOCHEM BIOPH RES CO, V175, P1159, DOI 10.1016/0006-291X(91)91687-8; HAMILTON JA, 1993, J BIOL CHEM, V268, P2416; Inouye H, 1998, AMYLOID, V5, P163, DOI 10.3109/13506129809003842; Lai ZH, 1996, BIOCHEMISTRY-US, V35, P6470, DOI 10.1021/bi952501g; Lashuel HA, 1998, BIOCHEMISTRY-US, V37, P17851, DOI 10.1021/bi981876+; Lehrer S S, 1978, Methods Enzymol, V49, P222; MCCUTCHEN SL, 1995, BIOCHEMISTRY-US, V34, P13527, DOI 10.1021/bi00041a032; MCCUTCHEN SL, 1993, BIOCHEMISTRY-US, V32, P12119, DOI 10.1021/bi00096a024; Miranker AD, 1996, CURR OPIN STRUC BIOL, V6, P31, DOI 10.1016/S0959-440X(96)80092-3; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Quintas A, 1997, FEBS LETT, V418, P297, DOI 10.1016/S0014-5793(97)01398-7; Saraiva M J, 1996, J Peripher Nerv Syst, V1, P179; SARAIVA MJM, 1984, J CLIN INVEST, V74, P104, DOI 10.1172/JCI111390; Sebastiao MP, 1998, J BIOL CHEM, V273, P24715, DOI 10.1074/jbc.273.38.24715; STRYER L, 1968, SCIENCE, V162, P526, DOI 10.1126/science.162.3853.526; TERRY CJ, 1993, EMBO J, V12, P735, DOI 10.1002/j.1460-2075.1993.tb05707.x; VANJAARSVELD PP, 1973, J BIOL CHEM, V248, P4698; VATASSERY GT, 1991, CLIN CHIM ACTA, V197, P19, DOI 10.1016/0009-8981(91)90344-C	27	142	142	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32943	32949		10.1074/jbc.274.46.32943	http://dx.doi.org/10.1074/jbc.274.46.32943			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551861	hybrid			2022-12-25	WOS:000083623000061
J	Shimizu, K; Chiba, S; Kumano, K; Hosoya, N; Takahashi, T; Kanda, Y; Hamada, Y; Yazaki, Y; Hirai, H				Shimizu, K; Chiba, S; Kumano, K; Hosoya, N; Takahashi, T; Kanda, Y; Hamada, Y; Yazaki, Y; Hirai, H			Mouse Jagged1 physically interacts with Notch2 and other Notch receptors - Assessment by quantitative methods	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; DOMAINS IN-VIVO; CAENORHABDITIS-ELEGANS; INTRACELLULAR DOMAIN; LIGAND INTERACTIONS; SIGNALING LIGAND; C-ELEGANS; DROSOPHILA; GENE; EXPRESSION	The Delta/Serrate/LAG-2 (DSL) domain containing proteins are considered to be ligands for Notch receptors, However, the physical interaction between DSL proteins and Notch receptors is poorly understood, In this study, we cloned a cDNA for mouse Jagged1 (mJagged1), To identify the receptor interacting with mJagged1 and to gain insight into its binding characteristics, we established two experimental systems using fusion proteins comprising various extracellular parts of mJagged1, a "cell" binding assay and a "solid-phase" binding assay. mJagged1 physically bound to mouse Notch2 (mNotch2) on the cell surface and to a purified extracellular portion of mNotch2, respectively, in a Ca2+-dependent manner. Scatchard analysis of mJagged1 binding to BaF3 cells and to the soluble Notch2 protein demonstrated dissociation constants of 0.4 and 0.7 nM, respectively, and that the number of mJagged1-binding sites on BaF3 is 5,548 per cell. Furthermore, deletion mutant analyses showed that the DSL domain of mJagged1 is a minimal binding unit and is indispensable for binding to mNotch2, The epidermal growth factor-like repeats of mJagged1 modulate the affinity of the interaction, with the first and second repeats playing a major role, Finally, solid-phase binding assay showed that Jagged1 binds to Notch1 and Notch3 in addition to Notch2, suggesting that mJagged1 is a ligand for multiple Notch receptors.	Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Cell Therapy & Transplantat Med, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Transfus & Immunohematol, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Cardiol, Tokyo 1138655, Japan; Natl Inst Basic Biol, Okazaki, Aichi 4448585, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Hirai, H (corresponding author), Tokyo Univ Hosp, Dept Cell Therapy & Transplantat Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.		Hosoya, Noriko/AAA-1447-2022	Hosoya, Noriko/0000-0002-1418-0677; Takahashi, Tokiharu/0000-0002-5785-8660				ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Bray S, 1998, CELL, V93, P499, DOI 10.1016/S0092-8674(00)81180-0; Cohen B, 1997, NAT GENET, V16, P283, DOI 10.1038/ng0797-283; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; Fitzgerald K, 1995, DEVELOPMENT, V121, P4275; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; Henderson ST, 1997, MOL BIOL CELL, V8, P1751, DOI 10.1091/mbc.8.9.1751; HENDERSON ST, 1994, DEVELOPMENT, V120, P2913; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; KATAKURA Y, 1999, IN PRESS CYTOTECHNOL, V31; Klein T, 1998, DEVELOPMENT, V125, P2951; KOPAN R, 1993, J CELL BIOL, V121, P631, DOI 10.1083/jcb.121.3.631; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; LARDELLI M, 1994, MECH DEVELOP, V46, P123, DOI 10.1016/0925-4773(94)90081-7; Li LH, 1998, IMMUNITY, V8, P43, DOI 10.1016/S1074-7613(00)80457-4; LIEBER T, 1992, NEURON, V9, P847, DOI 10.1016/0896-6273(92)90238-9; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Lindsell CE, 1996, MOL CELL NEUROSCI, V8, P14, DOI 10.1006/mcne.1996.0040; LIU YC, 1993, P NATL ACAD SCI USA, V90, P8957, DOI 10.1073/pnas.90.19.8957; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Luo B, 1997, MOL CELL BIOL, V17, P6057, DOI 10.1128/MCB.17.10.6057; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; Milner LA, 1996, P NATL ACAD SCI USA, V93, P13014, DOI 10.1073/pnas.93.23.13014; NYE JS, 1995, CURR BIOL, V5, P966, DOI 10.1016/S0960-9822(95)00189-8; NYE JS, 1994, DEVELOPMENT, V120, P2421; OHASHI H, 1994, BIOSCI BIOTECH BIOCH, V58, P758, DOI 10.1271/bbb.58.758; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Rand MD, 1997, PROTEIN SCI, V6, P2059; REAUME AG, 1992, DEV BIOL, V154, P377, DOI 10.1016/0012-1606(92)90076-S; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; Rebay Ilaria, 1993, Comptes Rendus de l'Academie des Sciences Serie III Sciences de la Vie, V316, P1097; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shawber C, 1996, DEV BIOL, V180, P370, DOI 10.1006/dbio.1996.0310; Sidow A, 1997, NATURE, V389, P722, DOI 10.1038/39587; SIMPSON P, 1995, NATURE, V375, P736, DOI 10.1038/375736a0; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAX FE, 1994, NATURE, V368, P150, DOI 10.1038/368150a0; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; Washburn T, 1997, CELL, V88, P833, DOI 10.1016/S0092-8674(00)81929-7; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414	54	196	213	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32961	32969		10.1074/jbc.274.46.32961	http://dx.doi.org/10.1074/jbc.274.46.32961			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551863	hybrid			2022-12-25	WOS:000083623000063
J	Woo, PL; Ching, DX; Guan, Y; Firestone, GL				Woo, PL; Ching, DX; Guan, Y; Firestone, GL			Requirement for Ras and phosphatidylinositol 3-kinase signaling uncouples the glucocorticoid-induced junctional organization and transepithelial electrical resistance in mammary tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE UVOMORULIN; POLARIZED EPITHELIAL-CELLS; ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR-ALPHA; TIGHT JUNCTIONS; TYROSINE PHOSPHORYLATION; PDZ DOMAIN; MDCK CELLS; C-ZETA; OCCLUDIN	In Con8 rat mammary epithelial tumor cells, the synthetic glucocorticoid dexamethasone stimulates the remodeling of the apical junction (tight and adherens junctions) and the transepithelial electrical resistance (TER), which reflects tight junction sealing. Indirect immunofluorescence revealed that dexamethasone induced the recruitment of endogenous Ras and the p85 regulatory subunit of phosphatidylinositol (PI) I-kinase to regions of cell-cell contact, concurrently with the stimulation of TER. Expression of dominant-negative RasN17 abolished the dexamethasone stimulation in TER, whereas, dexamethasone induced the reorganization of tight junction and adherens junction proteins, ZO-1 and beta-catenin, as well as F-actin, to precise regions of cell-cell contact in a Res-independent manner. Confocal microscopy revealed that RasN17 and the p85 regulatory subunit of PI 3-kinase co-localized with ZO-1 and F-actin at the tight junction and adherens junction, respectively. Treatment with either of the PI S-kinase inhibitors, wortmannin or LY294002, or the MEK inhibitor PD 098059, which prevents MAPK signaling, attenuated the dexamethasone stimulation of TER without affecting apical junction remodeling. Similar to dominant-negative RasN17, disruption of both Ras effector pathways using a combination of inhibitors abolished the glucocorticoid stimulation of TER. Thus, the glucocorticoiddependent remodeling of the apical junction and tight junction sealing can be uncoupled by their dependence on Ras and/or PI S-kinase-dependent pathways, implicating a new role for Ras and PI 3-kinase cell signaling events in the steroid control of cell-cell interactions.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Canc Res Lab, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Firestone, GL (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 591 LSA, Berkeley, CA 94720 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK042799, R01DK042799] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09041] Funding Source: Medline; NIDDK NIH HHS [DK-42799] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; BALDA MS, 1991, J MEMBRANE BIOL, V122, P193, DOI 10.1007/BF01871420; BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; BUSE P, 1995, J BIOL CHEM, V270, P6505, DOI 10.1074/jbc.270.12.6505; Cereijido M, 1998, ANNU REV PHYSIOL, V60, P161, DOI 10.1146/annurev.physiol.60.1.161; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; Dempsey PJ, 1997, J CELL BIOL, V138, P747, DOI 10.1083/jcb.138.4.747; Denker BM, 1996, J BIOL CHEM, V271, P25750, DOI 10.1074/jbc.271.42.25750; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; Dodane V, 1996, J MEMBRANE BIOL, V149, P199, DOI 10.1007/s002329900020; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FENG ZW, 1995, J CELL BIOL, V131, P1095, DOI 10.1083/jcb.131.4.1095; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; Gopalakrishnan S, 1998, AM J PHYSIOL-CELL PH, V275, pC798, DOI 10.1152/ajpcell.1998.275.3.C798; GOYA L, 1993, MOL ENDOCRINOL, V7, P1121, DOI 10.1210/me.7.9.1121; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Jou TS, 1998, J CELL BIOL, V142, P101, DOI 10.1083/jcb.142.1.101; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lora L, 1997, GASTROENTEROLOGY, V113, P1347, DOI 10.1053/gast.1997.v113.pm9322530; Lu Q, 1998, MOL CELL BIOL, V18, P3257, DOI 10.1128/MCB.18.6.3257; MADARA JL, 1992, ANN NY ACAD SCI, V664, P47, DOI 10.1111/j.1749-6632.1992.tb39748.x; Madara JL, 1998, ANNU REV PHYSIOL, V60, P143, DOI 10.1146/annurev.physiol.60.1.143; MANDEL LJ, 1993, NATURE, V361, P552, DOI 10.1038/361552a0; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; NUSRAT A, 1995, P NATL ACAD SCI USA, V92, P10629, DOI 10.1073/pnas.92.23.10629; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Ranganathan R, 1997, CURR BIOL, V7, pR770, DOI 10.1016/S0960-9822(06)00401-5; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Sakakibara A, 1997, J CELL BIOL, V137, P1393, DOI 10.1083/jcb.137.6.1393; SCHOENENBERGER CA, 1991, J CELL BIOL, V112, P8738; SILICIANO JD, 1988, J CELL BIOL, V107, P2389, DOI 10.1083/jcb.107.6.2389; SINGER KL, 1994, J BIOL CHEM, V269, P16108; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEDA H, 1995, CELL STRUCT FUNCT, V20, P387, DOI 10.1247/csf.20.387; Therrien M, 1998, CELL, V95, P343, DOI 10.1016/S0092-8674(00)81766-3; WarnCramer BJ, 1996, J BIOL CHEM, V271, P3779; WEBER E, 1994, J CELL BIOL, V125, P583, DOI 10.1083/jcb.125.3.583; Wong V, 1997, J CELL BIOL, V136, P399, DOI 10.1083/jcb.136.2.399; Wong V, 1999, J BIOL CHEM, V274, P5443, DOI 10.1074/jbc.274.9.5443; Wong V, 1997, AM J PHYSIOL-CELL PH, V273, pC1859, DOI 10.1152/ajpcell.1997.273.6.C1859; Woo PL, 1996, J BIOL CHEM, V271, P404, DOI 10.1074/jbc.271.1.404; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Xu YR, 1997, J BIOL CHEM, V272, P13463, DOI 10.1074/jbc.272.21.13463; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785; ZAHRAOUI A, 1994, J CELL BIOL, V124, P101, DOI 10.1083/jcb.124.1.101; ZETTL KS, 1992, P NATL ACAD SCI USA, V89, P9069, DOI 10.1073/pnas.89.19.9069	66	47	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32818	32828		10.1074/jbc.274.46.32818	http://dx.doi.org/10.1074/jbc.274.46.32818			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551843	hybrid			2022-12-25	WOS:000083623000043
J	Yang, J; Kramer, JM				Yang, J; Kramer, JM			Proteolytic processing of Caenorhabditis elegans SQT-1 cuticle collagen is inhibited in right roller mutants whereas cross-linking is inhibited in left roller mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-PROTEIN CONVERTASES; C-ELEGANS; ORGANISMAL MORPHOLOGY; GENES; MUTATIONS; ENCODES; ELECTROPHORESIS; PEPTIDES; MATRIX; FAMILY	The sqt-1 gene encodes a C. elegans cuticle collagen that when defective can cause dramatic alterations of organismal morphology. Specific antisera were used to examine the assembly of wild-type and mutant SQT-1 in the cuticle. Wild-type SQT-1 chains associate into dimer, tetramer, and higher oligomers that are cross-linked by non-reducible, presumably tyrosine-derived, covalent bonds. The SQT-1 pattern differs from the bulk of cuticle collagens which are found in trimer and larger forms. sqt-1 mutations that cause left-handed helical twisting of animals remove a conserved carboxyl-domain cysteine and inhibit formation of these non-reducible bonds. SQT-1 monomers accumulate and novel trimer-sized products form. A conserved tyrosine immediately adjacent to the affected cysteine suggests that disulfide bond formation is required for this tyrosine to form a cross-link. sqt-1 mutations that cause right-handed helical twisting affect conserved arginines in a predicted cleavage site for a subtilisin-like protease. These mutant SQT-1 molecules retain residues an the amino side of the predicted cleavage site and are larger than wild-type by the amount expected if cleavage failed to occur. The conservation of this site in all nematode cuticle collagens indicates that they are all synthesized as procollagens that are processed by subtilisin-like proteases.	Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA	Northwestern University	Kramer, JM (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, 303 Chicago Ave, Chicago, IL 60611 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022028] Funding Source: NIH RePORTER; NICHD NIH HHS [HD22028] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BRENNER S, 1974, GENETICS, V77, P71; Byers PH, 1997, AM J MED GENET, V72, P94, DOI 10.1002/(SICI)1096-8628(19971003)72:1<94::AID-AJMG20>3.0.CO;2-O; Colige A, 1997, P NATL ACAD SCI USA, V94, P2374, DOI 10.1073/pnas.94.6.2374; COX GN, 1980, GENETICS, V95, P317; COX GN, 1992, J PARASITOL, V78, P1, DOI 10.2307/3283678; COX GN, 1981, DEV BIOL, V86, P456, DOI 10.1016/0012-1606(81)90204-9; COX GN, 1981, J CELL BIOL, V90, P7, DOI 10.1083/jcb.90.1.7; FETTERER RH, 1993, J PARASITOL, V79, P160, DOI 10.2307/3283502; FREYTAG JW, 1979, BIOCHEMISTRY-US, V18, P4761, DOI 10.1021/bi00588a042; FUJIMOTO D, 1981, BIOCHEM BIOPH RES CO, V99, P637, DOI 10.1016/0006-291X(81)91792-7; FURTHMAYR H, 1971, ANAL BIOCHEM, V41, P510, DOI 10.1016/0003-2697(71)90173-4; Harlow E., 1988, ANTIBODIES LAB MANUA; HAYASHI T, 1980, J BIOCHEM, V87, P803, DOI 10.1093/oxfordjournals.jbchem.a132809; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KRAMER JM, 1993, GENETICS, V135, P1035; KRAMER JM, 1994, ANNU REV GENET, V28, P95; KRAMER JM, 1988, CELL, V55, P555, DOI 10.1016/0092-8674(88)90214-0; KRAMER JM, 1994, FASEB J, V8, P329, DOI 10.1096/fasebj.8.3.8143939; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; KUSCH M, 1986, GENETICS, V113, P621; LEVY AD, 1993, MOL BIOL CELL, V4, P803, DOI 10.1091/mbc.4.8.803; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; PARK YS, 1994, DEV BIOL, V163, P112, DOI 10.1006/dbio.1994.1127; PETERS K, 1991, GENETICS, V129, P95; Sambrook J., 1989, MOL CLONING; SEIDAH NG, 1993, BIOCHEM SOC T, V21, P685, DOI 10.1042/bst0210685; SEIDAH NG, 1994, METHOD ENZYMOL, V244, P175; THACKER C, 1995, GENE DEV, V9, P956, DOI 10.1101/gad.9.8.956; TILLET E, 1995, EUR J BIOCHEM, V228, P160, DOI 10.1111/j.1432-1033.1995.tb20245.x; WOOD WB, 1988, NEMAODE CAENORHABDIT; YANG J, 1994, MOL CELL BIOL, V14, P2722, DOI 10.1128/MCB.14.4.2722	31	17	20	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32744	32749		10.1074/jbc.274.46.32744	http://dx.doi.org/10.1074/jbc.274.46.32744			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551833	hybrid			2022-12-25	WOS:000083623000033
J	Yeh, DC; Duncan, JA; Yamashita, S; Michel, T				Yeh, DC; Duncan, JA; Yamashita, S; Michel, T			Depalmitoylation of endothelial nitric-oxide synthase by acyl-protein thioesterase 1 is potentiated by Ca2+-calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-MODULATED PALMITOYLATION; MYELIN PROTEOLIPID PROTEIN; TYROSINE KINASE; ALPHA-SUBUNITS; IN-VITRO; ACYLATION; CAVEOLAE; MYRISTOYLATION; AUTOACYLATION; LOCALIZATION	Protein palmitoylation represents an important mechanism governing the dynamic subcellular localization of many signaling proteins, Palmitoylation of endothelial nitric-oxide synthase (eNOS) promotes its targeting to plasmalemmal caveolae; agonist-promoted depalmitoylation leads to eNOS translocation, Depalmitoylation and translocation of eNOS modulate the agonist response, but the pathways that regulate eNOS palmitoylation and depalmitoylation are poorly understood. We now show that the newly characterized acylprotein thioesterase 1 (APT1) regulates eNOS depalmitoylation. Immunoblot analyses indicate that APT1 is expressed in bovine aortic endothelial cells, which express eNOS. APT1 overexpression appears to accelerate the depalmitoylation of eNOS in COS-7 cells cotransfected with eNOS and APT1 cDNAs. Additionally, purified recombinant APT1 depalmitoylates eNOS assayed in biological membranes isolated from endothelial cells biosynthetically labeled with [H-3]palmitate or COS-7 cells transfected with eNOS cDNA. More important, the APT1-catalyzed depalmitoylation of palmitoyl-eNOS is potentiated by Ca2+-calmodulin (CaM), a key allosteric activator of eNOS. In contrast, APT1-catalyzed depalmitoylation of the G protein G alpha(s) is unaffected by Ca2+-CaM. Furthermore, caveolin, a palmitoylated membrane protein, does not appear to be a substrate for APT1. Taken together, these results support a role for APT1 in the regulation of eNOS depalmitoylation and suggest that Ca2+-CaM activation of eNOS renders the enzyme more susceptible to APT1-catalyzed depalmitoylation.	Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; W Roxbury Vet Affairs Med Ctr, Cardiol Sect, Boston, MA 02132 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Gunma Univ, Sch Med, Dept Biochem, Gunma, Japan	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Gunma University	Michel, T (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, Thorn Bldg,Rm 1210A,75 Francis St, Boston, MA 02115 USA.	michel@calvin.bwh.harvard.edu						Bano MC, 1998, BIOCHEM J, V330, P723, DOI 10.1042/bj3300723; BHARADWAJ M, 1995, J NEUROCHEM, V65, P1805; BIZZOZERO OA, 1987, J BIOL CHEM, V262, P13550; Boutin JA, 1997, CELL SIGNAL, V9, P15, DOI 10.1016/S0898-6568(96)00100-3; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; Duncan JA, 1996, J BIOL CHEM, V271, P23594, DOI 10.1074/jbc.271.38.23594; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Hayashi MK, 1997, ARCH BIOCHEM BIOPHYS, V340, P376, DOI 10.1006/abbi.1997.9906; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LEE E, 1994, METHOD ENZYMOL, V237, P146; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; MUMBY SM, 1991, METHOD ENZYMOL, V195, P215; NATHAN C, 1994, J BIOL CHEM, V269, P13725; OBRIEN PJ, 1987, J BIOL CHEM, V262, P5210; QANBAR R, 1994, FASEB J, V8, pA1355; ROBINSON LJ, 1995, P NATL ACAD SCI USA, V92, P11776, DOI 10.1073/pnas.92.25.11776; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; ROSS NW, 1988, J NEUROSCI RES, V21, P35, DOI 10.1002/jnr.490210106; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; Song KS, 1997, CELL MOL BIOL, V43, P293; Stamler, 1996, METHODS NITRIC OXIDE, P249; Sugimoto H, 1996, J BIOL CHEM, V271, P7705, DOI 10.1074/jbc.271.13.7705; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6	29	145	146	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					33148	33154		10.1074/jbc.274.46.33148	http://dx.doi.org/10.1074/jbc.274.46.33148			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551886	hybrid			2022-12-25	WOS:000083623000086
J	Chung, HY; Brazil, MI; Soe, TT; Maxfield, FR				Chung, HY; Brazil, MI; Soe, TT; Maxfield, FR			Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid beta-peptide by microglial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR MESSENGER-RNA; TRANSGENIC MICE; SCAVENGER RECEPTOR; CULTURED-CELLS; SENILE PLAQUES; DOWN-SYNDROME; PROTEIN; DISEASE; SURFACE; DEPOSITION	Microglia are phagocytic cells that are the main inflammatory response cells of the central nervous system, In Alzheimer's disease brain, activated microglia are concentrated in regions of compact amyloid deposits that contain the 39-43-amino acid A beta peptide. We examined the uptake, degradation, and release of small aggregates of fibrillar A beta (fA beta) or soluble A beta (sA beta) by microglia, We found that although some degradation of fA beta was observed over 3 days, no further degradation was observed over the next 9 days, Instead, there was a slow release of intact A beta. The poor degradation was not due to inhibition of lysosomal function, since the rate of alpha 2-macroglobulin degradation was not affected by the presence of fA beta in the late endosomes/lysosomes. In contrast to fA beta, internalization of sA beta was not saturable. After internalization, sA beta was released rapidly from microglia, and very little was degraded. These data show that fA beta and sA beta interact differently with microglia but that after internalization a large fraction of both are released without degradation.	Cornell Univ, Dept Biochem, Weill Med Coll, New York, NY 10021 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA	Cornell University; Columbia University	Maxfield, FR (corresponding author), Cornell Univ, Dept Biochem, Weill Med Coll, 1300 York Ave,Rm E215, New York, NY 10021 USA.		Maxfield, Fred/A-1718-2011; Maxfield, Fred/M-6747-2019	Maxfield, Fred/0000-0003-4396-8866	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034761] Funding Source: NIH RePORTER; NINDS NIH HHS [NS34761] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANATI RB, 1993, GLIA, V9, P199, DOI 10.1002/glia.440090305; BAUER J, 1991, FEBS LETT, V282, P335, DOI 10.1016/0014-5793(91)80508-Z; BESTERMAN JM, 1981, J CELL BIOL, V91, P716, DOI 10.1083/jcb.91.3.716; BORDEN LA, 1990, J BIOL CHEM, V265, P8497; BURDICK D, 1992, J BIOL CHEM, V267, P546; del Rio Hortega P, 1932, CYTOLOGY CELLULAR PA, P481; DOVEY HF, 1993, NEUROREPORT, V4, P1039, DOI 10.1097/00001756-199308000-00011; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; ElKhoury J, 1996, NATURE, V382, P716; FRACKOWIAK J, 1992, ACTA NEUROPATHOL, V84, P225; Frautschy SA, 1998, AM J PATHOL, V152, P307; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Geuze HJ, 1998, IMMUNOL TODAY, V19, P282, DOI 10.1016/S0167-5699(98)01269-9; GHOSH RN, 1995, J CELL BIOL, V128, P549, DOI 10.1083/jcb.128.4.549; GIULIAN D, 1995, J NEUROSCI, V15, P7712; Giulian D, 1996, J NEUROSCI, V16, P6021; GIULIAN D, 1995, NEUROCHEM INT, V27, P119, DOI 10.1016/0197-0186(95)00067-I; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOEDERT M, 1987, EMBO J, V6, P3627, DOI 10.1002/j.1460-2075.1987.tb02694.x; Goldgaber D, 1990, Adv Neurol, V51, P163; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1991, J NEUROSCI, V11, P3783; HALVERSON K, 1990, BIOCHEMISTRY-US, V29, P2639, DOI 10.1021/bi00463a003; Harper JD, 1997, CHEM BIOL, V4, P951, DOI 10.1016/S1074-5521(97)90303-3; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; ITAGAKI S, 1989, J NEUROIMMUNOL, V24, P173, DOI 10.1016/0165-5728(89)90115-X; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Iwatsubo T, 1996, AM J PATHOL, V149, P1823; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; KNAUER MF, 1992, P NATL ACAD SCI USA, V89, P7437, DOI 10.1073/pnas.89.16.7437; Kusumoto Y, 1998, P NATL ACAD SCI USA, V95, P12277, DOI 10.1073/pnas.95.21.12277; LEBLANC AC, 1991, FEBS LETT, V292, P171, DOI 10.1016/0014-5793(91)80861-V; Lemere CA, 1996, NEUROBIOL DIS, V3, P16, DOI 10.1006/nbdi.1996.0003; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Lomakin A, 1997, P NATL ACAD SCI USA, V94, P7942, DOI 10.1073/pnas.94.15.7942; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MAYOR S, 1995, MOL BIOL CELL, V6, P929, DOI 10.1091/mbc.6.7.929; Mukherjee S, 1998, BIOPHYS J, V75, P1915, DOI 10.1016/S0006-3495(98)77632-5; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Mukherjee S, 1999, J CELL BIOL, V144, P1271, DOI 10.1083/jcb.144.6.1271; Paresce DM, 1997, J BIOL CHEM, V272, P29390, DOI 10.1074/jbc.272.46.29390; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; Rodriguez A, 1997, J CELL BIOL, V137, P93, DOI 10.1083/jcb.137.1.93; ROZEMULLER JM, 1992, NEUROSCI LETT, V140, P137, DOI 10.1016/0304-3940(92)90087-N; SALZMAN NH, 1988, J CELL BIOL, V106, P1083, DOI 10.1083/jcb.106.4.1083; SALZMAN NH, 1989, J CELL BIOL, V109, P2067; SAVAGE MJ, 1995, J EXP CLIN INVEST, V2, P234; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; SCOTT SA, 1993, EXP NEUROL, V121, P113, DOI 10.1006/exnr.1993.1076; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TABAS I, 1994, J BIOL CHEM, V269, P22547; TERRY RD, 1994, ALZHEIMER DIS, P9; TYCKO B, 1983, ANN NY ACAD SCI, V421, P424, DOI 10.1111/j.1749-6632.1983.tb18136.x; VIGOPELFREY C, 1993, J NEUROCHEM, V61, P1965, DOI 10.1111/j.1471-4159.1993.tb09841.x; WAITE J, 1992, NEUROBIOL AGING, V13, P595, DOI 10.1016/0197-4580(92)90062-3; WISNIEWSKI HM, 1992, ACTA NEUROPATHOL, V84, P117, DOI 10.1007/BF00311383; YAMASHIRO DJ, 1989, J CELL PHYSIOL, V139, P377, DOI 10.1002/jcp.1041390221; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yang AJ, 1998, J NEUROSCI RES, V52, P691, DOI 10.1002/(SICI)1097-4547(19980615)52:6<691::AID-JNR8>3.0.CO;2-3	67	177	194	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32301	32308		10.1074/jbc.274.45.32301	http://dx.doi.org/10.1074/jbc.274.45.32301			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542270	hybrid			2022-12-25	WOS:000083532100078
J	Francki, A; Bradshaw, AD; Bassuk, JA; Howe, CC; Couser, WG; Sage, EH				Francki, A; Bradshaw, AD; Bassuk, JA; Howe, CC; Couser, WG; Sage, EH			SPARC regulates the expression of collagen type I and transforming growth factor-beta 1 in mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; FACTOR-BETA; EXTRACELLULAR-MATRIX; GENE-EXPRESSION; ENDOTHELIAL-CELLS; ANGIOGENESIS INVITRO; DEPENDENT PATHWAY; PROTEIN-SYNTHESIS; RAT; PROLIFERATION	The matricellular protein SPARC is expressed at high levels in cells that participate in tissue remodeling and is thought to regulate mesangial cell proliferation and extracellular matrix production in the kidney glomerulus in a rat model of glomerulonephritis (Pichler, R. H., Bassuk, J. A., Hugo, C., Reed, RI. J., Eng, E., Gordon, K. L., Pippin, J., Alpers, C. E., Couser, W. G., Sage, E. H., and Johnson, R. J. (1997) Am. J. Pathol. 148, 1153-1167). A potential mechanism by which SPARC controls both cell cycle and matrix production has been attributed to its regulation of a pleiotropic growth factor. In this study we used primary mesangial cell cultures from wild-type mice and from mice with a targeted disruption of the SPARC gene. SPARC-null cells displayed diminished expression of collagen type I mRNA and protein, relative to wild-type cells, by the criteria of immunocytochemistry, immunoblotting, and the reverse transcription-polymerase chain reaction. The SPARC-null cells also showed significantly decreased steady-state levels of transforming growth factor-beta 1 (TGF-beta 1) mRNA and secreted TGF-beta 1 protein. Addition of recombinant SPARC to SPARC-null cells restored the expression of collagen type I mRNA to 70% and TGF-beta 1 mRNA to 100% of wildtype levels. We conclude that SPARC regulates the expression of collagen type I and TGF-beta 1 in kidney mesangial cells. Since increased mitosis and matrix deposition by mesangial cells are characteristics of glomerulopathies, we propose that SPARC is one of the factors that maintains the balance between cell proliferation and matrix production in the glomerulus.	Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; Univ Washington, Dept Urol, Seattle, WA 98195 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Univ Washington, Div Nephrol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; The Wistar Institute; University of Washington; University of Washington Seattle	Sage, EH (corresponding author), Hope Heart Inst, Dept Vasc Biol, 528 18th Ave, Seattle, WA 98122 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040711] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 18645] Funding Source: Medline; NIDDK NIH HHS [DK 47459] Funding Source: Medline; NIGMS NIH HHS [GM 40711] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRASS CK, 1995, KIDNEY INT, V47, P25, DOI 10.1038/ki.1995.3; Bassuk JA, 1996, ARCH BIOCHEM BIOPHYS, V325, P8, DOI 10.1006/abbi.1996.0002; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bradshaw AD, 1999, MOL BIOL CELL, V10, P1569, DOI 10.1091/mbc.10.5.1569; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; ENGELMANN GL, 1993, CARDIOVASC RES, V27, P1598, DOI 10.1093/cvr/27.9.1598; FLOEGE J, 1991, AM J KIDNEY DIS, V17, P673, DOI 10.1016/S0272-6386(12)80349-0; FLOEGE J, 1993, AM J PATHOL, V142, P637; Frank R, 1996, J INVEST DERMATOL, V106, P36, DOI 10.1111/1523-1747.ep12327182; FUNK SE, 1991, P NATL ACAD SCI USA, V88, P2648, DOI 10.1073/pnas.88.7.2648; Gilbert RE, 1998, KIDNEY INT, V54, P1052, DOI 10.1046/j.1523-1755.1998.00081.x; Gooden MD, 1999, J CELL BIOCHEM, V74, P152, DOI 10.1002/(SICI)1097-4644(19990801)74:2<152::AID-JCB2>3.0.CO;2-4; Goswami PC, 1997, CELL PROLIFERAT, V30, P271, DOI 10.1111/j.1365-2184.1997.tb00940.x; Grande JP, 1997, J LAB CLIN MED, V130, P476, DOI 10.1016/S0022-2143(97)90124-4; IruelaArispe ML, 1996, DEV DYNAM, V207, P171, DOI 10.1002/(SICI)1097-0177(199610)207:2<171::AID-AJA5>3.0.CO;2-E; IWANO M, 1994, CLIN EXP IMMUNOL, V97, P309; JOHNSON RJ, 1992, J EXP MED, V175, P1413, DOI 10.1084/jem.175.5.1413; Kagami S, 1996, EXP CELL RES, V229, P1, DOI 10.1006/excr.1996.0336; Kupprion C, 1998, J BIOL CHEM, V273, P29635, DOI 10.1074/jbc.273.45.29635; LANE TF, 1992, J BIOL CHEM, V267, P16736; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; Lenz O, 1998, J AM SOC NEPHROL, V9, P2040; Lloyd GM, 1997, J EXP MED, V185, P1371, DOI 10.1084/jem.185.7.1371; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Motamed K, 1998, J CELL BIOCHEM, V70, P543, DOI 10.1002/(SICI)1097-4644(19980915)70:4<543::AID-JCB10>3.0.CO;2-I; Norose K, 1998, INVEST OPHTH VIS SCI, V39, P2674; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; Pichler RH, 1996, AM J PATHOL, V148, P1153; Poncelet AC, 1998, AM J PHYSIOL-RENAL, V275, pF458; Porte H, 1998, CLIN CANCER RES, V4, P1375; RADEKE HH, 1992, CLIN INVESTIGATOR, V70, P825; RAINES EW, 1992, P NATL ACAD SCI USA, V89, P1281, DOI 10.1073/pnas.89.4.1281; REED MJ, 1994, J CELL PHYSIOL, V158, P169, DOI 10.1002/jcp.1041580121; REED MJ, 1993, J HISTOCHEM CYTOCHEM, V41, P1467, DOI 10.1177/41.10.8245406; Rosenblatt S, 1997, BIOCHEM J, V324, P311, DOI 10.1042/bj3240311; Sasaki T, 1998, EMBO J, V17, P1625, DOI 10.1093/emboj/17.6.1625; SATO N, 1993, AM J PATHOL, V142, P1119; Satoh M, 1996, J CELL BIOL, V133, P469, DOI 10.1083/jcb.133.2.469; Shankavaram UT, 1997, J CELL PHYSIOL, V173, P327, DOI 10.1002/(SICI)1097-4652(199712)173:3<327::AID-JCP4>3.3.CO;2-R; TREMBLE PM, 1993, J CELL BIOL, V121, P1433, DOI 10.1083/jcb.121.6.1433; UNEMORI E N, 1991, Current Opinion in Rheumatology, V3, P953, DOI 10.1097/00002281-199112000-00010; Varedi M, 1997, J CELL PHYSIOL, V172, P192, DOI 10.1002/(SICI)1097-4652(199708)172:2<192::AID-JCP6>3.0.CO;2-J; WOLTHUIS A, 1993, AM J PATHOL, V143, P1209; WRANA JL, 1991, EUR J BIOCHEM, V197, P519, DOI 10.1111/j.1432-1033.1991.tb15940.x; Yamamoto T, 1996, KIDNEY INT, V49, P461, DOI 10.1038/ki.1996.65; ZIYADEH FN, 1994, J CLIN INVEST, V93, P536, DOI 10.1172/JCI117004	47	155	160	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32145	32152		10.1074/jbc.274.45.32145	http://dx.doi.org/10.1074/jbc.274.45.32145			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542250	hybrid			2022-12-25	WOS:000083532100058
J	Collavin, L; Lazarevic, D; Utrera, R; Marzinotto, S; Monte, M; Schneider, C				Collavin, L; Lazarevic, D; Utrera, R; Marzinotto, S; Monte, M; Schneider, C			wt p53 dependent expression of a membrane-associated isoform of adenylate kinase	ONCOGENE			English	Article						p53 tumor suppressor; adenylate kinase; Va15 fibroblasts	NUCLEOSIDE-DIPHOSPHATE KINASE; WILD-TYPE P53; G-PROTEIN; GROWTH SUPPRESSION; DNA-DAMAGE; ARREST; NM23; PHOSPHOTRANSFERASE; FIBROBLASTS; INDUCTION	Six novel p53-inducible transcripts were recently cloned from Val5, a murine cell line stably expressing a temperature-sensitive p53 allele. One of the isolated clones represented a novel isoform of cytosolic adenylate kinase (AK1), a highly conserved monomeric enzyme involved in cellular homeostasis of adenine nucleotides. The corresponding protein, which we named AK1 beta, was specifically induced upon activation of wt p53 in Val5 cells. The AK1 beta protein differs from cytoplasmic AK1 by having 18 extra amino acids at the N-terminus. The extra residues in AK1 beta provide a consensus signal for N-terminal myristoylation; as expected, AK1 beta was shown to localize to the plasma membrane. The human AK1 gene contains several consensus p53 binding sites and we report that p53-dependent induction of the alternative AK1 beta transcript also occurs in human cells. By using antisense ablation experiments in Val5 fibroblasts we show that AK1 beta plays a relevant role in the establishment of reversible cell-cycle arrest as induced by p53 in these cells. These findings suggest that within a p53-dependent genetic program, a specific isoform of adenylate kinase has a previously undescribed growth regulatory function, which might not necessarily require its best characterized biochemical activity.	Lab Nazl Consorzio Interuniv Biotecnol, I-34012 Trieste, Italy; Univ Udine, Dipartimento Sci & Tecnol Biomed, I-33100 Udine, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine	Schneider, C (corresponding author), Lab Nazl Consorzio Interuniv Biotecnol, AREA Sci Pk,Padriciano 99, I-34012 Trieste, Italy.		Lazarevic, Dejan/AAN-1861-2020; Collavin, Licio/A-5312-2010	Collavin, Licio/0000-0001-6815-5381; Monte, Martin/0000-0002-5068-563X; lazarevic, dejan/0000-0003-4527-290X				Bates GD, 1996, J MANAGE ENG, V12, P12; Bhatnagar RS, 1997, TRENDS CELL BIOL, V7, P14, DOI 10.1016/S0962-8924(97)10044-7; Bourdon JC, 1997, ONCOGENE, V14, P85, DOI 10.1038/sj.onc.1200804; Boyer P.D, 1973, ENZYMES, P279; Buckbinder L, 1997, P NATL ACAD SCI USA, V94, P7868, DOI 10.1073/pnas.94.15.7868; BUCKBINDER L, 1994, P NATL ACAD SCI USA, V91, P10640, DOI 10.1073/pnas.91.22.10640; BYEON IJL, 1995, BIOCHEMISTRY-US, V34, P3172, DOI 10.1021/bi00010a006; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; DelSal G, 1996, ONCOGENE, V12, P177; DELSAL G, 1995, MOL CELL BIOL, V15, P7152; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DREUSICKE D, 1988, J MOL BIOL, V199, P359, DOI 10.1016/0022-2836(88)90319-1; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x; Engel M, 1998, J BIOL CHEM, V273, P20058, DOI 10.1074/jbc.273.32.20058; GERSTEIN M, 1993, J MOL BIOL, V229, P494, DOI 10.1006/jmbi.1993.1048; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GUTIERREZ JA, 1995, J BACTERIOL, V177, P390, DOI 10.1128/jb.177.2.390-400.1995; Hall A, 1998, SCIENCE, V280, P2074, DOI 10.1126/science.280.5372.2074; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Kaufman M, 1996, BIOCHEM J, V316, P35, DOI 10.1042/bj3160035; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOEGL M, 1994, BIOCHEM J, V303, P749, DOI 10.1042/bj3030749; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; Komarova EA, 1998, ONCOGENE, V17, P1089, DOI 10.1038/sj.onc.1202303; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LASCU I, 1992, J BIOL CHEM, V267, P12775; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Lu Q, 1996, P NATL ACAD SCI USA, V93, P5720, DOI 10.1073/pnas.93.12.5720; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; Madden SL, 1997, ONCOGENE, V15, P1079, DOI 10.1038/sj.onc.1201091; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATSUURA S, 1989, J BIOL CHEM, V264, P10148; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Ohnishi T, 1996, J BIOL CHEM, V271, P14510, DOI 10.1074/jbc.271.24.14510; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RENZING J, 1995, ONCOGENE, V10, P1865; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SCHULZ GE, 1974, NATURE, V250, P142, DOI 10.1038/250142a0; Shankar S, 1996, J BACTERIOL, V178, P1777, DOI 10.1128/jb.178.7.1777-1781.1996; TANABE T, 1993, J BIOCHEM-TOKYO, V113, P200, DOI 10.1093/oxfordjournals.jbchem.a124026; Utrera R, 1998, EMBO J, V17, P5015, DOI 10.1093/emboj/17.17.5015; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; VIKHANSKAYA F, 1994, NUCLEIC ACIDS RES, V22, P1012, DOI 10.1093/nar/22.6.1012; WATANABE K, 1986, BIOCHEM BIOPH RES CO, V134, P527, DOI 10.1016/S0006-291X(86)80452-1; XIONG Y, 1993, NATURE, V366, P704; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	59	45	46	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 21	1999	18	43					5879	5888		10.1038/sj.onc.1202970	http://dx.doi.org/10.1038/sj.onc.1202970			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557075				2022-12-25	WOS:000083270700005
J	Cieslik, K; Lee, CM; Tang, JL; Wu, KK				Cieslik, K; Lee, CM; Tang, JL; Wu, KK			Transcriptional regulation of endothelial nitric-oxide synthase by an interaction between casein kinase 2 and protein phosphatase 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; DNA-BINDING ACTIVITY; ATHEROGENIC LIPOPROTEINS; GENE-EXPRESSION; CULTURED HUMAN; MESSENGER-RNA; LYSOPHOSPHATIDYLCHOLINE; CELLS; INDUCTION; SP1	We previously demonstrated that lysophosphatidylcholine up-regulated endothelial nitric-oxide synthase promoter activity by increasing Spl binding via the action of protein serine/threonine phosphatase 2A (Cieslik, K., Zembowicz, A., Tang, J.-L., and Wu, K.K. (1998) J. Biol. Chem. 278, 14885-14890). To characterize the regulation of basal endothelial nitric-oxide synthase promoter activity and the signaling pathway through which lysophosphatidylcholine augments endothelial nitric-oxide synthase transcription, we used a casein kinase 2 inhibitor coupled with immunoprecipitation to demonstrate that basal Spl binding and endothelial nitric-oxide synthase promoter activity were controlled by casein kinase 2 complexed with protein serine/threonine phosphatase 2A, Casein kinase 2 catalyzed protein serine/threonine phosphatase 2A phosphorylation thereby inhibiting its activity. Lysophosphatidylcholine selectively activated p42/p44 mitogen-activated protein kinase, Purified extracellular regulated Kinase 2 blocked casein kinase 2 activity and increased protein serine/threonine phosphatase 2A activity, resulting in an increased Spl binding and endothelial nitric-oxide synthase promoter activity. These results indicate that Spl binding to its cognate site on the endothelial nitric-oxide synthase promoter and its transactivation of endothelial nitric-oxide synthase is regulated by post-translational Spl phosphorylation and dephosphorylation through a dynamic interaction between casein kinase 2 and protein serine/threonine phosphatase 2A.	Univ Texas, Sch Med, Vasc Biol Res Ctr, Houston, TX 77030 USA; Univ Texas, Sch Med, Div Hematol, Houston, TX 77030 USA; Acad Sinica, Inst Biomed Sci, Vasc Biol Program, Taipei 115, Taiwan; Natl Taiwan Univ Hosp, Coll Med, Taipei 115, Taiwan	University of Texas System; University of Texas System; Academia Sinica - Taiwan; National Taiwan University; National Taiwan University Hospital	Wu, KK (corresponding author), Univ Texas, Sch Med, Vasc Biol Res Ctr, 6431 Fannin,MSB 5-016, Houston, TX 77030 USA.		Cieslik, Katarzyna/AAO-1982-2021; Wu, Kenneth Kun-Yu/B-1070-2010; Lee, Chii-Ming/M-7799-2015	Cieslik, Katarzyna/0000-0002-2167-7921; Lee, Chii-Ming/0000-0002-1075-5787; TANG, JIH-LUH/0000-0003-4021-3281	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS023327] Funding Source: NIH RePORTER; NINDS NIH HHS [P50 NS-23327] Funding Source: Medline; PHS HHS [R01-50675] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Arnet UA, 1996, J BIOL CHEM, V271, P15069, DOI 10.1074/jbc.271.25.15069; Bassa BV, 1998, J AM SOC NEPHROL, V9, P488; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Fang XJ, 1997, J BIOL CHEM, V272, P13683, DOI 10.1074/jbc.272.21.13683; FAVRE B, 1997, J BIOL CHEM, V272, P13586; Fuhrer DK, 1996, BIOCHEM BIOPH RES CO, V224, P289, DOI 10.1006/bbrc.1996.1023; GUO H, 1993, J BIOL CHEM, V268, P11193; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; HIRATA K, 1995, CIRC RES, V76, P958, DOI 10.1161/01.RES.76.6.958; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KUGIYAMA K, 1992, CIRC RES, V71, P1422, DOI 10.1161/01.RES.71.6.1422; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; KUME N, 1994, J CLIN INVEST, V93, P907, DOI 10.1172/JCI117047; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MONCADA S, 1991, PHARMACOL REV, V43, P109; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Nadaud S, 1996, CIRC RES, V79, P857, DOI 10.1161/01.RES.79.4.857; NAKANO T, 1994, P NATL ACAD SCI USA, V91, P1069, DOI 10.1073/pnas.91.3.1069; OHGUSHI M, 1993, ARTERIOSCLER THROMB, V13, P1525, DOI 10.1161/01.ATV.13.10.1525; PARTHASARATHY S, 1985, P NATL ACAD SCI USA, V82, P3000, DOI 10.1073/pnas.82.9.3000; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; SESSA WC, 1994, CIRC RES, V74, P349, DOI 10.1161/01.RES.74.2.349; TANG JL, 1995, BIOCHEM BIOPH RES CO, V213, P673, DOI 10.1006/bbrc.1995.2184; WEINER CP, 1994, P NATL ACAD SCI USA, V91, P5212, DOI 10.1073/pnas.91.11.5212; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Wu K K, 1995, Adv Pharmacol, V33, P179, DOI 10.1016/S1054-3589(08)60669-9; Wu KK, 1998, P ASSOC AM PHYSICIAN, V110, P163; ZEMBOWICZ A, 1995, J CLIN INVEST, V96, P1688, DOI 10.1172/JCI118211; ZEMBOWICZ A, 1995, J BIOL CHEM, V270, P17006, DOI 10.1074/jbc.270.28.17006; ZHANG R, 1995, J BIOL CHEM, V270, P15320, DOI 10.1074/jbc.270.25.15320	37	47	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34669	34675		10.1074/jbc.274.49.34669	http://dx.doi.org/10.1074/jbc.274.49.34669			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574932	hybrid			2022-12-25	WOS:000083979600026
J	Fu, TJ; Peng, JM; Lee, G; Price, DH; Flores, O				Fu, TJ; Peng, JM; Lee, G; Price, DH; Flores, O			Cyclin K functions as a CDK9 regulatory subunit and participates in RNA polymerase II transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL DOMAIN KINASE; FACTOR P-TEFB; HIV-1 TAT; IN-VITRO; ELONGATION; ACTIVATION; BINDING	Important progress in the understanding of elongation control by RNA polymerase II (RNAPII) has come from the recent identification of the positive transcription elongation factor b (P-TEFb) and the demonstration that this factor is a protein kinase that phosphorylates the carboxyl-terminal domain (CTD) of the RNAPII largest subunit, The P-TEFb complex isolated from mammalian cells contains a catalytic subunit (CDK9), a cyclin subunit (cyclin T1 or cyclin T2), and additional, yet unidentified, polypeptides of unknown function, To identify additional factors involved in P-TEFb function we performed a yeast two-hybrid screen using CDK9 as bait and found that cyclin K interacts with CDK9 in vivo, Biochemical analyses indicate that cyclin K functions as a regulatory subunit of CDK9, The CDK9-cyclin K complex phosphorylated the CTD of RNAPII and functionally substituted for P-TEFb comprised of CDK9 and cyclin T in in vitro transcription reactions.	Tularik Inc, Dept Biol, S San Francisco, CA 92080 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa	Flores, O (corresponding author), Merck Res Labs, Dept Antiviral Res, W Point, PA 19446 USA.		Peng, Junmin/N-2614-2018; Price, David H/F-6173-2010	Peng, Junmin/0000-0003-0472-7648; Price, David/0000-0002-5597-385X	NIAID NIH HHS [AI46391] Funding Source: Medline; NIGMS NIH HHS [GM 35500] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035500] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bieniasz PD, 1998, EMBO J, V17, P7056, DOI 10.1093/emboj/17.23.7056; Casse C, 1999, J BIOL CHEM, V274, P16097, DOI 10.1074/jbc.274.23.16097; Edwards MC, 1998, MOL CELL BIOL, V18, P4291, DOI 10.1128/MCB.18.7.4291; Flores OL, 1999, P NATL ACAD SCI USA, V96, P7208, DOI 10.1073/pnas.96.13.7208; Garber ME, 1998, GENE DEV, V12, P3512, DOI 10.1101/gad.12.22.3512; Garriga J, 1998, ONCOGENE, V17, P3093, DOI 10.1038/sj.onc.1202548; Herrmann CH, 1998, J VIROL, V72, P9881, DOI 10.1128/JVI.72.12.9881-9888.1998; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Peng J, 1998, COLD SPRING HARB SYM, V63, P365, DOI 10.1101/sqb.1998.63.365; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Xie Z, 1998, J BIOL CHEM, V273, P3771, DOI 10.1074/jbc.273.6.3771; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	19	188	198	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34527	34530		10.1074/jbc.274.49.34527	http://dx.doi.org/10.1074/jbc.274.49.34527			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574912	hybrid			2022-12-25	WOS:000083979600006
J	Nishikawa, Y; Wang, ZQ; Kerns, J; Wilcox, CS; Carr, BI				Nishikawa, Y; Wang, ZQ; Kerns, J; Wilcox, CS; Carr, BI			Inhibition of hepatoma cell growth in vitro by arylating and non-arylating K vitamin analogs - Significance of protein tyrosine phosphatase inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR; MENADIONE 2-METHYL-1,4-NAPHTHOQUINONE; ISOLATED HEPATOCYTES; ALKYLATING-AGENTS; KINASE PATHWAY; CYTO-TOXICITY; DNA-SYNTHESIS; CYCLE ARREST; IN-VIVO; PHOSPHORYLATION	We recently found that a thioether analog of K vitamin (Cpd 5) inhibited the activity of protein-tyrosine phosphatases (PTPases) and induced protein-tyrosine phosphorylation in a human hepatoma cell line (Hep3B), We have now examined the structural requirements for induction of protein-tyrosine phosphorylation and PTPase inhibition by several K vitamin analogs. Thioether analogs with sulfhydryl arylation capacity, especially those with a hydroxy (Cpd 5) or a methoxy group at the end of the side chain, induced protein-tyrosine phosphorylation, but non-arylating analogs, such as those with an all-carbon or O-ether side chain, did not. Among the receptor-tyrosine kinases, epidermal growth factor receptors were tyrosine-phosphorylated by treatment with thioether analogs, whereas insulin and hepatocyte growth factor receptors were not. An increase in tyrosine-phosphorylated ERK2 mitogen-activated protein kinase was also observed. The activity of purified T cell PTPase was inhibited only by the thioether analogs, but not by non-arylating analogs. Furthermore, the epidermal growth factor receptor dephosphorylation activity of Hep3B cell lysates was inhibited by Cpd 5 treatment. A similar induction of protein-tyrosine phosphorylation by Cpd 5 was seen in other human hepatoma cell lines together with growth inhibition. However, one cell line (HepG2), which was relatively resistant to growth inhibition by Cpd 5, did not increase its phosphorylation levels upon Cpd 5 treatment. These results suggest that cell growth inhibition by thioether analogs is closely associated with inhibition of PTPases by sulfhydryl arylation and with tyrosine phosphorylation of selected proteins.	Univ Pittsburgh, Thomas E Starzl Transplantat Inst, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Carr, BI (corresponding author), Univ Pittsburgh, Thomas E Starzl Transplantat Inst, BST E1552,200 Lothrop St, Pittsburgh, PA 15213 USA.			Carr, Brian/0000-0002-6111-5077				Band CJ, 1997, J BIOL CHEM, V272, P138; Bandyopadhyay D, 1997, J BIOL CHEM, V272, P1639, DOI 10.1074/jbc.272.3.1639; BECKWITH M, 1991, J IMMUNOL, V147, P2411; Bromberg JF, 1998, CELL GROWTH DIFFER, V9, P505; BROWN PC, 1991, ARCH BIOCHEM BIOPHYS, V285, P187, DOI 10.1016/0003-9861(91)90348-M; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CASELLI A, 1994, J BIOL CHEM, V269, P24878; CHAPMAN JH, 1950, J CHEM SOC, P579, DOI 10.1039/jr9500000579; CHLEBOWSKI RT, 1985, CANCER TREAT REP, V69, P527; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; COKER KJ, 1994, P NATL ACAD SCI USA, V91, P6967, DOI 10.1073/pnas.91.15.6967; EISHEN CM, 1994, J IMMUNOL, V153, P1947; Falet H, 1996, FEBS LETT, V383, P165, DOI 10.1016/0014-5793(96)00232-3; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; FLINT AJ, 1997, P NATL ACAD SCI USA, V94, P1630; GANT TW, 1988, CHEM-BIOL INTERACT, V65, P157, DOI 10.1016/0009-2797(88)90052-X; Gulli LF, 1996, CELL GROWTH DIFFER, V7, P173; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Hunter T, 1996, BIOCHEM SOC T, V24, P307, DOI 10.1042/bst0240307; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; KERNS J, 1995, BIOORG CHEM, V23, P101, DOI 10.1006/bioo.1995.1008; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Liu F, 1997, BIOCHEM J, V327, P139, DOI 10.1042/bj3270139; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; NELSON RL, 1984, MOL CELL BIOL, V4, P1003, DOI 10.1128/MCB.4.6.1003; NGO EO, 1991, BIOCHEM PHARMACOL, V42, P1961, DOI 10.1016/0006-2952(91)90596-W; Ni R, 1997, HEPATOLOGY, V26, P559; Ni RZ, 1998, J BIOL CHEM, V273, P9906, DOI 10.1074/jbc.273.16.9906; NISHIKAWA Y, 1995, J BIOL CHEM, V270, P28304, DOI 10.1074/jbc.270.47.28304; NOTO V, 1989, CANCER, V63, P901, DOI 10.1002/1097-0142(19890301)63:5<901::AID-CNCR2820630518>3.0.CO;2-G; NUTTER LM, 1992, J BIOL CHEM, V267, P2474; PRASAD KN, 1981, LIFE SCI, V29, P1387, DOI 10.1016/0024-3205(81)90683-4; Pregel MJ, 1997, J BIOL CHEM, V272, P23552, DOI 10.1074/jbc.272.38.23552; Puius YA, 1997, P NATL ACAD SCI USA, V94, P13420, DOI 10.1073/pnas.94.25.13420; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; RAGO R, 1990, ANAL BIOCHEM, V191, P31; Rice RL, 1997, BIOCHEMISTRY-US, V36, P15965, DOI 10.1021/bi971338h; ROSS D, 1985, CHEM-BIOL INTERACT, V55, P177, DOI 10.1016/S0009-2797(85)80126-5; ROSS D, 1986, ARCH BIOCHEM BIOPHYS, V248, P460, DOI 10.1016/0003-9861(86)90499-6; Ruff SJ, 1997, J BIOL CHEM, V272, P1263, DOI 10.1074/jbc.272.2.1263; SCHICK MR, 1993, J IMMUNOL, V151, P1918; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6162; SELVA E, 1993, J BIOL CHEM, V268, P2250; Skorey K, 1997, J BIOL CHEM, V272, P22472, DOI 10.1074/jbc.272.36.22472; STONE RL, 1994, J BIOL CHEM, V269, P31323; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; THOR H, 1982, J BIOL CHEM, V257, P2419; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; WILSON I, 1987, CHEM-BIOL INTERACT, V61, P229, DOI 10.1016/0009-2797(87)90003-2; WU FYH, 1993, ONCOGENE, V8, P2237; Yin TG, 1997, J BIOL CHEM, V272, P1032, DOI 10.1074/jbc.272.2.1032; Zhao ZZ, 1996, J BIOL CHEM, V271, P22251, DOI 10.1074/jbc.271.36.22251	55	51	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34803	34810		10.1074/jbc.274.49.34803	http://dx.doi.org/10.1074/jbc.274.49.34803			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574951	hybrid			2022-12-25	WOS:000083979600045
J	Hama, H; Schnieders, EA; Thorner, J; Takemoto, JY; DeWald, DB				Hama, H; Schnieders, EA; Thorner, J; Takemoto, JY; DeWald, DB			Direct involvement of phosphatidylinositol 4-phosphate in secretion in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID TRANSFER PROTEIN; OXYSTEROL BINDING-PROTEIN; GOLGI-COMPLEX; TRANSPORT VESICLES; PLASMA-MEMBRANE; COAT PROTEINS; GENE; 4-KINASE; PATHWAY; REQUIREMENT	The SEC14 gene encodes an essential phosphatidylinositol (PtdIns) transfer protein required for formation of Golgi-derived secretory vesicles in yeast. Suppressor mutations that rescue temperature-sensitive sec14 mutants provide an approach for determining the role of Sec14p in secretion. One suppressor, sac1-22, causes accumulation of PtdIns(4)P. SAC1 encodes a phosphatase that can hydrolyze PtdIns(4)P and certain other phosphoinositides. These findings suggest that PtdIns(4)P is limiting in sec14 cells and that elevation of PtdIns(4)P production can suppress the secretory defect. Correspondingly, we found that PtdIns(4)P levels were decreased significantly in sec14-3 mutants shifted to 37 degrees C and that sec14-3 cells could grow at an otherwise non-permissive temperature (34 degrees C) when carrying a plasmid overexpressing PIK1, encoding one of two essential PtdIns 4-kinases. This effect is specific because overexpression of the other PtdIns 4-kinase gene (STT4) or a PtdIns 3-kinase gene (VPS34) did not rescue sec14-3 cells. To further address Pik1p function in secretion, two different pik1(ts) mutants were examined. Upon shift to restrictive temperature (37 degrees C), the PtdIns(4)P levels dropped by about 60% in both pik1(ts) strains within 1 h. During the same period, cells displayed a reduction (40-50%) in release of a secreted enzyme (invertase), However, similar treatment did not effect maturation of a vacuolar enzyme (carboxypeptidase Y). These findings indicate that, first, PtdIns(4)P limitation is a major contributing factor to the secretory defect in sec14 cells; second, Sec14p function is coupled to the action of Pik1p, and; third, PtdIns(4)P has an important role in the Golgi-to-plasma membrane stage of secretion.	Utah State Univ, Dept Biol, Logan, UT 84322 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, Berkeley, CA 94720 USA	Utah System of Higher Education; Utah State University; University of California System; University of California Berkeley	DeWald, DB (corresponding author), Utah State Univ, Dept Biol, Logan, UT 84322 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007232, R37GM021841, R01GM021841] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM21841, GM07232] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; Bryant NJ, 1998, MICROBIOL MOL BIOL R, V62, P230, DOI 10.1128/MMBR.62.1.230-247.1998; Burd CG, 1998, SEMIN CELL DEV BIOL, V9, P527, DOI 10.1006/scdb.1998.0255; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CLEVES AE, 1989, J CELL BIOL, V109, P2939, DOI 10.1083/jcb.109.6.2939; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; Currie RA, 1997, CURR BIOL, V7, P184, DOI 10.1016/S0960-9822(97)70089-7; DAUM G, 1990, EXPERIENTIA, V46, P586, DOI 10.1007/BF01939697; Daum G, 1998, YEAST, V14, P1471, DOI 10.1002/(SICI)1097-0061(199812)14:16<1471::AID-YEA353>3.0.CO;2-Y; Desrivieres S, 1998, J BIOL CHEM, V273, P15787, DOI 10.1074/jbc.273.25.15787; Dickson RC, 1997, J BIOL CHEM, V272, P29620, DOI 10.1074/jbc.272.47.29620; Dickson RC, 1998, ANNU REV BIOCHEM, V67, P27, DOI 10.1146/annurev.biochem.67.1.27; Fang M, 1996, EMBO J, V15, P6447, DOI 10.1002/j.1460-2075.1996.tb01036.x; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; FLANAGAN CA, 1992, J BIOL CHEM, V267, P24117; GARCIABUSTOS JF, 1994, EMBO J, V13, P2352, DOI 10.1002/j.1460-2075.1994.tb06519.x; GOVINDAN B, 1995, J CELL BIOL, V128, P1055, DOI 10.1083/jcb.128.6.1055; Guo SL, 1999, J BIOL CHEM, V274, P12990, DOI 10.1074/jbc.274.19.12990; HAMA H, INPRESS METHODS COMP; Hendricks KB, 1999, NAT CELL BIOL, V1, P234, DOI 10.1038/12058; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HJELMSTAD RH, 1987, J BIOL CHEM, V262, P3909; Homma K, 1998, J BIOL CHEM, V273, P15779, DOI 10.1074/jbc.273.25.15779; HORAZDOVSKY BF, 1995, CURR OPIN CELL BIOL, V7, P544, DOI 10.1016/0955-0674(95)80012-3; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; Janmey PA, 1998, PHYSIOL REV, V78, P763, DOI 10.1152/physrev.1998.78.3.763; JIANG B, 1994, YEAST, V10, P341, DOI 10.1002/yea.320100307; Jones SM, 1998, J BIOL CHEM, V273, P10349, DOI 10.1074/jbc.273.17.10349; KAISER CA, 1997, MOL CELLULAR BIOL YE, V3, P91; KAUFFMANNZEH A, 1995, SCIENCE, V268, P1188, DOI 10.1126/science.7761838; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; Kearns MA, 1998, EMBO J, V17, P4004, DOI 10.1093/emboj/17.14.4004; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Luo WJ, 1997, J CELL BIOL, V138, P731, DOI 10.1083/jcb.138.4.731; Martin TFJ, 1997, BIOCHEM SOC T, V25, P1137, DOI 10.1042/bst0251137; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; NOVICK P, 1989, GENETICS, V121, P659; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Panaretou C, 1997, J BIOL CHEM, V272, P2477; PREUSS D, 1992, MOL BIOL CELL, V3, P789, DOI 10.1091/mbc.3.7.789; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SALAMA SR, 1990, J BACTERIOL, V172, P4510, DOI 10.1128/jb.172.8.4510-4521.1990; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHNIEDERS EA, 1996, BIOCH GENETIC ANAL P; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SKINNER HB, 1995, P NATL ACAD SCI USA, V92, P112, DOI 10.1073/pnas.92.1.112; SKINNER HB, 1993, EMBO J, V12, P4775, DOI 10.1002/j.1460-2075.1993.tb06166.x; Sreenivas A, 1998, J BIOL CHEM, V273, P16635, DOI 10.1074/jbc.273.27.16635; Srinivasan S, 1997, EUR J CELL BIOL, V74, P350; Stock SD, 1999, J BIOL CHEM, V274, P12979, DOI 10.1074/jbc.274.19.12979; Stolz LE, 1998, GENETICS, V148, P1715; Trotter PJ, 1998, J BIOL CHEM, V273, P13189, DOI 10.1074/jbc.273.21.13189; TSUKAGOSHI Y, 1987, EUR J BIOCHEM, V169, P477, DOI 10.1111/j.1432-1033.1987.tb13635.x; Wendland B, 1998, J CELL BIOL, V141, P71, DOI 10.1083/jcb.141.1.71; Westphal V, 1996, J BIOL CHEM, V271, P11865, DOI 10.1074/jbc.271.20.11865; Wiedemann C, 1998, J NEUROSCI, V18, P5594; Wiedemann C, 1996, EMBO J, V15, P2094, DOI 10.1002/j.1460-2075.1996.tb00563.x; Wurmser AE, 1999, J BIOL CHEM, V274, P9129, DOI 10.1074/jbc.274.14.9129; Xie ZG, 1998, P NATL ACAD SCI USA, V95, P12346, DOI 10.1073/pnas.95.21.12346; YOSHIDA S, 1994, MOL GEN GENET, V242, P631, DOI 10.1007/BF00283416; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166	65	243	245	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34294	34300		10.1074/jbc.274.48.34294	http://dx.doi.org/10.1074/jbc.274.48.34294			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567405	hybrid			2022-12-25	WOS:000083857500070
J	Calonge, MJ; Massague, J				Calonge, MJ; Massague, J			Smad4/DPC4 silencing and hyperactive Ras jointly disrupt transforming growth factor-beta antiproliferative responses in colon cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN COLORECTAL CANCERS; TUMOR-SUPPRESSOR GENE; FAMILY MEDIATOR SMAD1; TGF-BETA; EPITHELIAL-CELLS; PANCREATIC-CARCINOMA; SIGNALING PATHWAYS; MAMMALIAN-CELLS; CYCLE ARREST; DPC4 GENE	Smad4/DPC4 is a tumor suppressor gene frequently mutated or deleted in pancreatic and metastatic colon cancers. Smad4 acts as a cofactor that binds transforming growth factor-beta (TGF-beta) receptor-activated Smad2 and Smad3 generating transcriptional complexes. Using SW480.7 colon carcinoma cells, defective in Smad4 function, we have investigated whether this loss plays a role in the resistance of colon cancer cells to the antiproliferative effects of TGF-beta. SW480.7 cells contain only one Smad4 allele, which we found encodes a wild type protein that is not expressed. We generated SW480.7 cells conditionally expressing Smad4 via an ecdysone-inducible system. Smad4 expression in these cells failed to rescue TGF-beta antiproliferative and gene responses (c-myc down-regulation and induction of p21/Cip1 and plasminogen activator inhibitor-1). SW480.7 cells contain an activated Ki-ras oncogene. Hyperactivation of Ras can inhibit Smad nuclear accumulation by their phosphorylation at mitogen-activated protein kinase sites. Co-transfection into SW480.7 cells of Smad4 together with a Ras phosphorylation-resistant Smad3 (but not with wild type Smad2, Smad3, adenomatous polyposis coli (APC), or TGF-beta type II receptor) restored the TGF-beta antiproliferative response. These results suggest that loss of Smad4 function by both deletion and silencing and inhibition of Smad2/3 function by a hyperactive Ras pathway jointly prevent TGF-beta antiproliferative responses in SW480.7 colon cancer cells.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Massague, J (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave,Box 116, New York, NY 10021 USA.			Massague, Joan/0000-0001-9324-8408				ALEXANDROW MG, 1995, CANCER RES, V55, P1452; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Filmus Jorge, 1993, Current Opinion in Oncology, V5, P123; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; GEISER AG, 1992, J BIOL CHEM, V267, P2588; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; Grady WM, 1999, CANCER RES, V59, P320; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HOUCK KA, 1989, ONCOGENE, V4, P19; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Jonson T, 1999, GENE CHROMOSOME CANC, V24, P62, DOI 10.1002/(SICI)1098-2264(199901)24:1<62::AID-GCC9>3.0.CO;2-4; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KNUDSON AG, 1975, P NATL ACAD SCI USA, V72, P5116, DOI 10.1073/pnas.72.12.5116; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; Liu B, 1999, MOL CELL BIOL, V19, P424; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; LONGSTREET M, 1992, ONCOGENE, V7, P1549; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MacKay SLD, 1998, ANN SURG, V227, P781, DOI 10.1097/00000658-199806000-00001; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MICHELSON AM, 1983, P NATL ACAD SCI-BIOL, V80, P472, DOI 10.1073/pnas.80.2.472; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Moskaluk CA, 1997, DIAGN MOL PATHOL, V6, P85, DOI 10.1097/00019606-199704000-00003; MULDER KM, 1990, J CELL PHYSIOL, V145, P501, DOI 10.1002/jcp.1041450316; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Powell SM, 1997, CANCER RES, V57, P4221; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Riggins GJ, 1997, CANCER RES, V57, P2578; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Rozenblum E, 1997, CANCER RES, V57, P1731; Schutte M, 1996, CANCER RES, V56, P2527; Schwarte-Waldhoff I, 1999, ONCOGENE, V18, P3152, DOI 10.1038/sj.onc.1202641; SCHWARZ LC, 1988, CANCER RES, V48, P6999; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; VALVERIUS EM, 1989, CANCER RES, V49, P6269; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	52	127	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33637	33643		10.1074/jbc.274.47.33637	http://dx.doi.org/10.1074/jbc.274.47.33637			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559252	hybrid			2022-12-25	WOS:000083745200068
J	Dumay, H; Rubbi, L; Sentenac, A; Marck, C				Dumay, H; Rubbi, L; Sentenac, A; Marck, C			Interaction between yeast RNA polymerase III and transcription factor TFIIIC via ABC10 alpha and tau 131 subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; SACCHAROMYCES-CEREVISIAE; COMMON SUBUNITS; DNA-BINDING; MUTATION; GENE; INITIATION; TOPOGRAPHY; COMPONENT; ARCHAEON	Yeast TFIIIC mediates transcription of class III genes by promoting the assembly of a stable TFIIIB-DNA complex that is sufficient for RNA polymerase III recruitment and function. Unexpectedly, we found an interaction in vivo and in vitro between the TFIIIB-recruiting subunit of TFIIIC, tau 131, and ABC10 alpha, a small essential subunit common to the three forms of nuclear RNA polymerases. This interaction was mapped to the C-terminal region of ABC10 alpha. A thermosensitive mutation in the C terminus region of ABC10 alpha (rpc10-30) was found to be selectively suppressed by overexpression of a mutant form of tau 131 (tau 131-Delta TPR2) that lacks the second TPR repeat. Remarkably, the rpc10-30 mutation weakened the ABC10 alpha-tau 131 interaction, and the suppressive mutation, tau 131-Delta TPR2 increased the interaction between the two proteins in the two-hybrid assay. These results point to the potential importance of a functional contact between TFIIIC and RNA polymerase III.	CEA Saclay, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Marck, C (corresponding author), CEA Saclay, Serv Biochim & Genet Mol, Batiment 142, F-91191 Gif Sur Yvette, France.	marck@jonas.saclay.cea.fr	DUMAY-ODELOT, Hélène/M-7751-2014	DUMAY-ODELOT, Helene/0000-0002-7245-084X				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arrebola R, 1998, MOL CELL BIOL, V18, P1; BARTHOLOMEW B, 1993, MOL CELL BIOL, V13, P942, DOI 10.1128/MCB.13.2.942; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BRAUN BR, 1992, J MOL BIOL, V228, P1063, DOI 10.1016/0022-2836(92)90315-B; Brun I, 1997, EMBO J, V16, P5730, DOI 10.1093/emboj/16.18.5730; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CARLES C, 1991, J BIOL CHEM, V266, P24092; CHAUSSIVERT N, 1995, J BIOL CHEM, V270, P15353, DOI 10.1074/jbc.270.25.15353; Chedin S, 1998, COLD SPRING HARB SYM, V63, P381, DOI 10.1101/sqb.1998.63.381; CHIANNILKULCHAI N, 1992, J BIOL CHEM, V267, P23099; DEPREZ E, 1999, IN PRESS MOL CELL BI; DIECI G, 1995, EMBO J, V14, P3766, DOI 10.1002/j.1460-2075.1995.tb00046.x; Flores A, 1999, P NATL ACAD SCI USA, V96, P7815, DOI 10.1073/pnas.96.14.7815; GABRIELSEN OS, 1989, J BIOL CHEM, V264, P7505; HARRIS SD, 1991, GENETICS, V127, P279; Hsieh YJ, 1999, MOL CELL BIOL, V19, P4944; HUET J, 1994, NUCLEIC ACIDS RES, V22, P3433; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; LALO D, 1993, P NATL ACAD SCI USA, V90, P5524, DOI 10.1073/pnas.90.12.5524; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; LANGER D, 1995, P NATL ACAD SCI USA, V92, P5768, DOI 10.1073/pnas.92.13.5768; LEFEBVRE O, 1994, J BIOL CHEM, V269, P23374; LEFEBVRE O, 1992, P NATL ACAD SCI USA, V89, P10512, DOI 10.1073/pnas.89.21.10512; Manaud N, 1998, MOL CELL BIOL, V18, P3191, DOI 10.1128/MCB.18.6.3191; MARCK C, 1993, P NATL ACAD SCI USA, V90, P4027, DOI 10.1073/pnas.90.9.4027; Moir RD, 1997, MOL CELL BIOL, V17, P7119, DOI 10.1128/MCB.17.12.7119; PAPAVASSILIOU AG, 1992, NUCLEIC ACIDS RES, V20, P4365, DOI 10.1093/nar/20.16.4365; PARSONS MC, 1990, J BIOL CHEM, V265, P5095; PARSONS MC, 1992, J BIOL CHEM, V267, P2894; Persinger J, 1996, J BIOL CHEM, V271, P33039, DOI 10.1074/jbc.271.51.33039; RAMEAU G, 1994, MOL CELL BIOL, V14, P822, DOI 10.1128/MCB.14.1.822; Rubbi L, 1999, J BIOL CHEM, V274, P31485, DOI 10.1074/jbc.274.44.31485; Ruth J, 1996, EMBO J, V15, P1941, DOI 10.1002/j.1460-2075.1996.tb00545.x; SADHALE PP, 1994, MOL CELL BIOL, V14, P6164, DOI 10.1128/MCB.14.9.6164; SCHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHPAKOVSKI GV, 1995, MOL CELL BIOL, V15, P4702; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; SWANSON RN, 1991, P NATL ACAD SCI USA, V88, P4887, DOI 10.1073/pnas.88.11.4887; THUILLIER V, 1995, EMBO J, V14, P351, DOI 10.1002/j.1460-2075.1995.tb07009.x; Treich Isabelle, 1992, Gene Expression, V2, P31; Wang ZX, 1997, GENE DEV, V11, P1315, DOI 10.1101/gad.11.10.1315; WERNER M, 1993, J BIOL CHEM, V268, P20721; White R.J., 1998, RNA POLYM	49	28	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33462	33468		10.1074/jbc.274.47.33462	http://dx.doi.org/10.1074/jbc.274.47.33462			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559229	hybrid			2022-12-25	WOS:000083745200045
J	Kleppe, R; Uhlemann, K; Knappskog, PM; Haavik, J				Kleppe, R; Uhlemann, K; Knappskog, PM; Haavik, J			Urea-induced denaturation of human phenylalanine hydroxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TYROSINE-HYDROXYLASE; PROTEIN STABILITY; FLUORESCENCE; AGGREGATION; PHENYLKETONURIA; DEGRADATION; ENZYME; CHROMATOGRAPHY; SPECTROSCOPY	Human phenylalanine hydroxylase was expressed and purified from Escherichia coli as a fusion protein with maltose-binding protein. After removal of the fusion partner, the effects of increasing urea concentrations on enzyme activity, aggregation, unfolding, and refolding were examined. At pH 7.50, purified human phenylalanine hydroxylase is transiently activated in the presence of 0-4 M urea but slowly inactivated at higher denaturant concentrations. Intrinsic tryptophan fluorescence spectroscopy showed that the enzyme is denatured through at least two distinct transitions. The presence of phenylalanine (L-Phe) shifts the transition midpoint of the first transition from 1.4 to 2.7 M urea, whereas the second transition is unaffected by this substrate. Apparently the free energy of denaturation was almost identical for the free enzyme and for the enzyme-substrate complex, but significant differences in d Delta G(D)/d[urea] (m(D) values) were observed for the first denaturation transition. In the absence of substrate, a high rate of non-covalent aggregation was observed for the enzyme in the presence of 1-4 M urea. All three tryptophan residues in the enzyme (Trp-120, Trp 187, and Trp-326) were mutated to phenylalanine, either as single mutations or in combination, in order to identify the residues involved in the spectroscopic transitions. A gradual dissociation of the native tetrameric enzyme to increasingly denatured dimeric and monomeric forms was demonstrated by size exclusion chromatography in the presence of denaturants.	Univ Bergen, Dept Biochem & Mol Biol, N-5009 Bergen, Norway; Univ Bergen, Haukeland Hosp, Dept Med Genet, N-5021 Bergen, Norway	University of Bergen; University of Bergen; Haukeland University Hospital	Haavik, J (corresponding author), Univ Bergen, Dept Biochem & Mol Biol, N-5009 Bergen, Norway.	jan.haavik@pki.uib.no	Haavik, Jan/ABE-1535-2020	Kleppe, Rune/0000-0002-6086-755X; Haavik, Jan/0000-0001-7865-2808				AMIR D, 1988, BIOCHEMISTRY-US, V27, P8889, DOI 10.1021/bi00425a003; Baskakov IV, 1998, BIOCHEMISTRY-US, V37, P18010, DOI 10.1021/bi981849j; BIERZYNSKI A, 1982, EUR J BIOCHEM, V206, P15; Bjorgo E, 1998, EUR J BIOCHEM, V257, P1, DOI 10.1046/j.1432-1327.1998.2570001.x; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; Chehin R, 1998, FEBS LETT, V422, P225, DOI 10.1016/S0014-5793(97)01596-2; CORBETT RJT, 1984, BIOCHEMISTRY-US, V23, P1888, DOI 10.1021/bi00303a047; DEYOUNG LR, 1993, BIOCHEMISTRY-US, V32, P3877, DOI 10.1021/bi00066a006; DILL KA, 1991, ANNU REV BIOCHEM, V60, P795, DOI 10.1146/annurev.bi.60.070191.004051; DOSKELAND A, 1982, NEUROCHEM RES, V7, P407, DOI 10.1007/BF00965494; EFTINK MR, 1994, BIOPHYS J, V66, P482, DOI 10.1016/S0006-3495(94)80799-4; Eiken HG, 1996, HUM MUTAT, V7, P228, DOI 10.1002/(SICI)1098-1004(1996)7:3<228::AID-HUMU7>3.0.CO;2-6; Erlandsen H, 1997, NAT STRUCT BIOL, V4, P995, DOI 10.1038/nsb1297-995; Fusetti F, 1998, J BIOL CHEM, V273, P16962, DOI 10.1074/jbc.273.27.16962; HAAVIK J, 1992, EUR J BIOCHEM, V210, P23, DOI 10.1111/j.1432-1033.1992.tb17386.x; IbarraMolero B, 1996, BIOCHEMISTRY-US, V35, P14689, DOI 10.1021/bi961836a; Jaenicke R, 1997, ADV PROTEIN CHEM, V50, P1, DOI 10.1016/S0065-3233(08)60318-6; JOHNSON CM, 1995, BIOCHEMISTRY-US, V34, P6795, DOI 10.1021/bi00020a026; Kappock TJ, 1995, J BIOL CHEM, V270, P30532, DOI 10.1074/jbc.270.51.30532; Kappock TJ, 1996, CHEM REV, V96, P2659, DOI 10.1021/cr9402034; Knappskog PM, 1996, EUR J BIOCHEM, V242, P813, DOI 10.1111/j.1432-1033.1996.0813r.x; KNAPPSKOG PM, 1995, BIOCHEMISTRY-US, V34, P11790, DOI 10.1021/bi00037a017; Kobe B, 1999, NAT STRUCT BIOL, V6, P442, DOI 10.1038/8247; KWOK SCM, 1985, BIOCHEMISTRY-US, V24, P556, DOI 10.1021/bi00324a002; Lacowicz JR, 1983, PRINCIPLES FLUORESCE; LEDLEY FD, 1988, J PEDIATR-US, V113, P463, DOI 10.1016/S0022-3476(88)80629-2; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; Levy HL, 1999, P NATL ACAD SCI USA, V96, P1811, DOI 10.1073/pnas.96.5.1811; LOHSE DL, 1993, BIOCHEM BIOPH RES CO, V197, P1543, DOI 10.1006/bbrc.1993.2653; MARTINEZ A, 1995, BIOCHEM J, V306, P589, DOI 10.1042/bj3060589; OKANO Y, 1991, NEW ENGL J MED, V324, P1232, DOI 10.1056/NEJM199105023241802; Pace C N, 1986, Methods Enzymol, V131, P266; PARNIAK MA, 1989, CHEM BIOL PTERIDINES, P656; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; SHORTLE D, 1995, ADV PROTEIN CHEM, V46, P217, DOI 10.1016/S0065-3233(08)60336-8; Shortle D, 1996, FASEB J, V10, P27, DOI 10.1096/fasebj.10.1.8566543; STIGTER D, 1993, FLUID PHASE EQUILIBR, V82, P237, DOI 10.1016/0378-3812(93)87148-T; UVERSKY VN, 1993, BIOCHEMISTRY-US, V32, P13288, DOI 10.1021/bi00211a042; Waters PJ, 1998, HUM MUTAT, V12, P344, DOI 10.1002/(SICI)1098-1004(1998)12:5<344::AID-HUMU8>3.0.CO;2-D	39	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33251	33258		10.1074/jbc.274.47.33251	http://dx.doi.org/10.1074/jbc.274.47.33251			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559199	hybrid			2022-12-25	WOS:000083745200015
J	Rossignol, R; Malgat, M; Mazat, JP; Letellier, T				Rossignol, R; Malgat, M; Mazat, JP; Letellier, T			Threshold effect and tissue specificity - Implication for mitochondrial cytopathies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN MITOCHONDRIA; KEARNS-SAYRE SYNDROME; CYTOCHROME-C-OXIDASE; RED FIBERS MERRF; OXIDATIVE-PHOSPHORYLATION; MYOCLONIC EPILEPSY; DIABETES-MELLITUS; LACTIC-ACIDOSIS; POINT MUTATION; DNA DELETIONS	Mitochondrial cytopathies present a tissue specificity characterized by the fact that even if a mitochondrial DNA mutation is present in all tissues, only some will be affected and induce a pathology. Several mechanisms have been proposed to explain this phenomenon such as the appearance of a sporadic mutation in a given stem cell during embryogenesis or mitotic segregation, giving different degrees of heteroplasmy in tissues. However, these mechanisms cannot be the only ones involved in tissue specificity. In this paper, we propose an additional mechanism contributing to tissue specificity. It is based on the metabolic expression of the defect in oxidative phosphorylation (OXPHOS) complexes that can present a biochemical threshold. The value of this threshold for a given OXPHOS complex can vary according to the tissue; thus different tissues will display different sensitivities to a defect in an OXPHOS complex. To verify this hypothesis and to illustrate the pathological consequences of the variation in biochemical thresholds, we studied their values for seven OXPHOS complexes in mitochondria isolated from five different rat tissues. Two types of behavior in the threshold curves can be distinguished corresponding to two modes of OXPHOS response to a deficiency. We propose a classification of tissues according to their type of OXPHOS response to a complex deficiency and therefore to their threshold values.	Univ Bordeaux 2, INSERM, EMI 9929, F-33076 Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Letellier, T (corresponding author), Univ Bordeaux 2, INSERM, EMI 9929, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	tletel@u-bordeaux2.fr	Rossignol, Rodrigue/K-7821-2014					BALLINGER SW, 1994, CURR TOP BIOENERG, V17, P59; BEZIAT F, 1993, NUCLEIC ACIDS RES, V21, P387, DOI 10.1093/nar/21.3.387; BIRCHMACHIN MA, 1989, PEDIATR RES, V25, P553, DOI 10.1203/00006450-198905000-00025; BOURGERON T, 1993, J BIOL CHEM, V268, P19369; CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; Chomyn A, 1998, AM J HUM GENET, V62, P745, DOI 10.1086/301813; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; CLARK JB, 1970, J BIOL CHEM, V245, P4724; Davey GP, 1998, J BIOL CHEM, V273, P12753, DOI 10.1074/jbc.273.21.12753; Davey GP, 1996, J NEUROCHEM, V66, P1617; DEBISE R, 1993, BIOCHEM BIOPH RES CO, V196, P355, DOI 10.1006/bbrc.1993.2256; DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008; DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602; DOUSSIERE J, 1984, BIOCHIM BIOPHYS ACTA, V766, P492, DOI 10.1016/0005-2728(84)90265-2; ENTER C, 1991, HUM GENET, V88, P233; Gattermann N, 1997, BLOOD, V90, P4961, DOI 10.1182/blood.V90.12.4961.4961_4961_4972; GELLERICH FN, 1990, FEBS LETT, V274, P167, DOI 10.1016/0014-5793(90)81355-R; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GROEN AK, 1982, J BIOL CHEM, V257, P2754; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HEINRICH R, 1974, EUR J BIOCHEM, V42, P89, DOI 10.1111/j.1432-1033.1974.tb03318.x; HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0; HOLZHUTTER HG, 1990, COMPUT APPL BIOSCI, V6, P23; INUI K, 1992, J PEDIATR-US, V120, P62, DOI 10.1016/S0022-3476(05)80599-2; Jacobs HT, 1997, ANN MED, V29, P483, DOI 10.3109/07853899709007472; Johnson  D., 1967, METHOD ENZYMOL, V10, P94, DOI DOI 10.1016/0076-6879(67)10018-9; KACSER H, 1981, GENETICS, V97, P639; KACSER H, 1973, RATE CONTROL BIOL PR, P65; KOBAYASHI Y, 1991, AM J HUM GENET, V49, P590; Korzeniewski B, 1996, ACTA BIOTHEOR, V44, P263, DOI 10.1007/BF00046532; KUNZ W, 1988, FEBS LETT, V233, P17, DOI 10.1016/0014-5793(88)81347-4; LAUBER J, 1991, NUCLEIC ACIDS RES, V19, P1393, DOI 10.1093/nar/19.7.1393; LESTIENNE P, 1988, LANCET, V1, P885; LETELLIER T, 1994, BIOCHEM J, V302, P171, DOI 10.1042/bj3020171; Letellier T, 1998, MOL CELL BIOCHEM, V184, P409, DOI 10.1023/A:1006826927220; LETELLIER T, 1993, BIOCHIM BIOPHYS ACTA, V1141, P58, DOI 10.1016/0005-2728(93)90189-M; Mazat JP, 1997, MOL CELL BIOCHEM, V174, P143, DOI 10.1023/A:1006875517267; MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001; MORGANHUGHES JA, 1977, BRAIN, V100, P617, DOI 10.1093/brain/100.4.617; MORGANHUGHES JA, 1986, MYOLOGY, P1709; NONAKA I, 1992, CURR OPIN NEUROL NEU, V5, P622; ONISHI H, 1993, J NEUROL SCI, V114, P205, DOI 10.1016/0022-510X(93)90299-E; REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3; REDER C, 1988, J THEOR BIOL, V135, P175, DOI 10.1016/S0022-5193(88)80073-0; REMES AM, 1993, NEUROLOGY, V43, P1015, DOI 10.1212/WNL.43.5.1015; ROTIG A, 1989, LANCET, V1, P902; Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755; SEIBEL P, 1990, BIOCHEM BIOPH RES CO, V173, P561, DOI 10.1016/S0006-291X(05)80071-3; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; TANAKA M, 1990, LANCET, V336, P1452, DOI 10.1016/0140-6736(90)93162-I; TAYLOR RW, 1993, BIOCHIM BIOPHYS ACTA, V1181, P261, DOI 10.1016/0925-4439(93)90030-5; TAYLOR RW, 1994, J BIOL CHEM, V269, P3523; Villani G, 1997, P NATL ACAD SCI USA, V94, P1166, DOI 10.1073/pnas.94.4.1166; WALLACE DC, 1986, SOMAT CELL MOLEC GEN, V12, P41, DOI 10.1007/BF01560726; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231; WALLACE DC, 1993, TRENDS GENET, V9, P128, DOI 10.1016/0168-9525(93)90207-X; WALLACE DC, 1995, HUMAN GENE MAPPING 1, P910; Wharton DC., 1967, METHOD ENZYMOL, P245; ZEVIANI M, 1991, AM J HUM GENET, V48, P203; ZEVIANI M, 1990, ANN NEUROL, V28, P94, DOI 10.1002/ana.410280118; Zhou L, 1997, J NEUROSCI, V17, P7746	62	214	219	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33426	33432		10.1074/jbc.274.47.33426	http://dx.doi.org/10.1074/jbc.274.47.33426			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559224	hybrid			2022-12-25	WOS:000083745200040
J	Wilson, GM; Sun, Y; Lu, HP; Brewer, G				Wilson, GM; Sun, Y; Lu, HP; Brewer, G			Assembly of AUF1 oligomers on U-rich RNA targets by sequential dimer association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; NECROSIS-FACTOR-ALPHA; MYC MESSENGER-RNA; FLUORESCENCE ANISOTROPY; 3'-UNTRANSLATED REGION; AUUUA MOTIFS; PROTEIN-DNA; DEGRADATION; BINDING; ELEMENT	Many labile mammalian mRNAs are targeted for rapid cytoplasmic turnover by the presence of A + U-rich elements (AREs) within their 3'-untranslated regions, These elements are selectively recognized by AUF1, a component of a multisubunit complex that may participate in the initiation of mRNA decay, In this study, we have investigated the recognition of AREs by AUF1 in vitro using oligoribonucleotide substrates. Gel mobility shift assays demonstrated that U-rich RNA targets were specifically bound by AUF1, generating two distinct RNA-protein complexes in a concentration-dependent manner. Chemical cross-linking revealed the interaction of AUF1 dimers to form tetrameric structures involving protein-protein interactions in the presence of high affinity RNA targets. From these data, a model of AUF1 association with AREs involving sequential dimer binding was developed. Using fluorescent RNA substrates, binding parameters of AUF1 dimer-ARE and tetramer-ARE equilibria were evaluated in solution by fluorescence anisotropy measurements. Using two AUF1 deletion mutants, sequences C-terminal to the RNA recognition motifs are shown to contribute to the formation of the AUF1 tetramer ARE complex but are not obligate for RNA binding activity. Kinetic studies demonstrated rapid turnover of AUF1 ARE complexes in solution, suggesting that these interactions are very dynamic in character. Taken together, these data support a model where ARE-dependent oligomerization of AUF1 may function to nucleate the formation of a trans-acting, RNA-destabilizing complex in vivo.	Wake Forest Univ, Bowman Gray Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center	Brewer, G (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, 675 Hoes Ln, Piscataway, NJ 08854 USA.		Wilson, Gerald/AAF-3874-2019	Wilson, Gerald/0000-0002-1273-7507	NATIONAL CANCER INSTITUTE [R01CA052443] Funding Source: NIH RePORTER; NCI NIH HHS [CA 52443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHARON T, 1993, MOL CELL BIOL, V13, P1971, DOI 10.1128/MCB.13.3.1971; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; Brewer G, 1998, J BIOL CHEM, V273, P34770, DOI 10.1074/jbc.273.52.34770; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CHECOVICH WJ, 1995, NATURE, V375, P254, DOI 10.1038/375254a0; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CURATOLA AM, 1995, MOL CELL BIOL, V15, P6331; DeMaria CT, 1997, J BIOL CHEM, V272, P27635, DOI 10.1074/jbc.272.44.27635; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; FASMAN GD, 1976, CRC HDB BIOCH MOL BI, P589; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Frankel AD, 1998, CELL, V92, P149, DOI 10.1016/S0092-8674(00)80908-3; Hel Z, 1996, MOL CELL BIOL, V16, P5579; Henics T, 1999, J BIOL CHEM, V274, P17318, DOI 10.1074/jbc.274.24.17318; Heyduk T, 1996, METHOD ENZYMOL, V274, P492; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; JAMESON DM, 1995, METHOD ENZYMOL, V246, P283; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; Lundblad JR, 1996, MOL ENDOCRINOL, V10, P607, DOI 10.1210/me.10.6.607; OTTO MR, 1994, BIOPHYS J, V67, P2511, DOI 10.1016/S0006-3495(94)80741-6; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; Peng SSY, 1996, MOL CELL BIOL, V16, P1490; PEPPEL K, 1991, J EXP MED, V173, P349, DOI 10.1084/jem.173.2.349; Raabe T, 1998, J BIOL CHEM, V273, P974, DOI 10.1074/jbc.273.2.974; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; Scaringe SA, 1998, J AM CHEM SOC, V120, P11820, DOI 10.1021/ja980730v; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STOECKLIN G, 1994, J BIOL CHEM, V269, P28591; Tholanikunnel BG, 1997, J BIOL CHEM, V272, P11471; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; WEBER G, 1952, BIOCHEM J, V51, P145, DOI 10.1042/bj0510145; Wilson GM, 1999, METHODS, V17, P74, DOI 10.1006/meth.1998.0709; Wilson GM, 1999, PROG NUCLEIC ACID RE, V62, P257; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WINSTALL E, 1995, MOL CELL BIOL, V15, P3796; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	44	85	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33374	33381		10.1074/jbc.274.47.33374	http://dx.doi.org/10.1074/jbc.274.47.33374			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559216	hybrid			2022-12-25	WOS:000083745200032
J	Fernandez-Chacon, R; de Toledo, GA; Hammer, RE; Sudhof, TC				Fernandez-Chacon, R; de Toledo, GA; Hammer, RE; Sudhof, TC			Analysis of SCAMP1 function in secretory vesicle exocytosis by means of gene targeting in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARRIER MEMBRANE-PROTEINS; MAST-CELLS; CAPACITANCE MEASUREMENTS; GRANULE MEMBRANES; FUSION PORE; RELEASE; PRODUCTS; SYNAPTOPHYSIN	Secretory carrier membrane proteins (SCAMPs) comprise a family of ubiquitous membrane proteins of transport vesicles with no known function. Their universal presence in all cells suggests a fundamental role in membrane traffic, SCAMPs are particularly highly expressed in organelles that undergo regulated exocytosis, such as synaptic vesicles and mast cell granules. Of the three currently known SCAMPs, SCAMPI is the most abundant. To investigate the possible functions of SCAMPI, we generated mice that lack SCAMP1, SCAMP1-deficient mice are viable and fertile. They exhibit no changes in the overall architecture or the protein composition of the brain or alterations in peripheral organs. Capacitance measurements in mast cells demonstrated that exocytosis could be triggered reliably by GTP gamma S in SCAMP1-deficient cells. The initial overall capacitance of mast cells was similar between wild type and mutant mice, but the final cell capacitance after completion of exocytosis, was significantly smaller in SCAMP1-deficient cells than in wild type cells, Furthermore, there was an increased proportion of reversible fusion events, which may have caused the decrease in the overall capacitance change observed after exocytosis, Our data show that SCAMP1 is not essential for exocytosis, as such, and does not determine the stability or size of secretory vesicles, but is required for the full execution of stable exocytosis in mast cells, This phenotype could be the result of a function of SCAMP1 in the formation of stable fusion pores during exocytosis or of a role of SCAMPI in the regulation of endocytosis after formation of fusion pores.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Sevilla, Fac Med, Dept Fisiol Med & Biofis, E-41009 Seville, Spain	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Sevilla	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Rm NA4-118,6000 Harry Hines Blvd, Dallas, TX 75235 USA.		Alvarez de Toledo, Guillermo/I-2888-2015; Fernandez-Chacon, Rafael/E-6303-2010; IBIS, FISIOLOGIA/O-9485-2015	Alvarez de Toledo, Guillermo/0000-0001-7193-2663; Fernandez-Chacon, Rafael/0000-0002-9845-9885				ALMERS W, 1987, J PHYSIOL-LONDON, V386, P205, DOI 10.1113/jphysiol.1987.sp016530; BRAND SH, 1991, J BIOL CHEM, V266, P18949; BRAND SH, 1993, EMBO J, V12, P3753, DOI 10.1002/j.1460-2075.1993.tb06053.x; BRUMELL JH, 1995, J IMMUNOL, V155, P5750; CAMERON RS, 1986, J CELL BIOL, V103, P1299, DOI 10.1083/jcb.103.4.1299; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; DETOLEDO GA, 1990, J CELL BIOL, V110, P1033, DOI 10.1083/jcb.110.4.1033; FERNANDEZ JM, 1984, NATURE, V312, P453, DOI 10.1038/312453a0; FERNANDEZCHACON R, 1995, FEBS LETT, V363, P221, DOI 10.1016/0014-5793(95)00319-5; Fischer Y, 1997, J BIOL CHEM, V272, P7085, DOI 10.1074/jbc.272.11.7085; FYKSE EM, 1993, J NEUROSCI, V13, P4997; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Guo ZH, 1998, CELL, V94, P537, DOI 10.1016/S0092-8674(00)81594-9; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; JOHNSTON PA, 1989, J BIOL CHEM, V264, P1268; LAURIE SM, 1993, J BIOL CHEM, V268, P19110; LINDAU M, 1991, Q REV BIOPHYS, V24, P75, DOI 10.1017/S0033583500003279; LINDAU M, 1991, BIOCHIM BIOPHYS ACTA, V1071, P429, DOI 10.1016/0304-4157(91)90006-I; McMahon HT, 1996, P NATL ACAD SCI USA, V93, P4760, DOI 10.1073/pnas.93.10.4760; Milgram SL, 1997, J CELL SCI, V110, P695; MONCK JR, 1990, P NATL ACAD SCI USA, V87, P7804, DOI 10.1073/pnas.87.20.7804; Oberhauser AF, 1996, P NATL ACAD SCI USA, V93, P14349, DOI 10.1073/pnas.93.25.14349; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; Sambrook J., 2002, MOL CLONING LAB MANU; Singleton DR, 1997, J CELL SCI, V110, P2099; Wen GP, 1998, MAMM GENOME, V9, P536, DOI 10.1007/s003359900814; Wu TT, 1998, MOL BIOL CELL, V9, P1661, DOI 10.1091/mbc.9.7.1661	27	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32551	32554		10.1074/jbc.274.46.32551	http://dx.doi.org/10.1074/jbc.274.46.32551			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551807	hybrid			2022-12-25	WOS:000083623000007
J	Cadefau, JA; Parra, J; Tauler, A; Cusso, R				Cadefau, JA; Parra, J; Tauler, A; Cusso, R			Contractile activity modifies Fru-2,6-P-2 metabolism in rabbit fast twitch skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-FREQUENCY STIMULATION; FRUCTOSE 2,6-BISPHOSPHATE; HEXOKINASE-II; 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE; RAT-LIVER; EXPRESSION; ISOZYMES; 6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE; PURIFICATION; RESPONSES	Modification of muscular contractile patterns by denervation and chronic low frequency stimulation induces structural, physiological, and biochemical alterations in fast twitch skeletal muscles. Fructose 2,6-bisphosphate is a potent activator of 6-phosphofructo-1-kinase, a key regulatory enzyme of glycolysis in animal tissues. The concentration of Fru-2,6-P-2, depends on the activity of the bifunctional enzyme, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK-2/FBPase-2), which catalyzes the synthesis and degradation of this metabolite. This enzyme has several isoforms, the relative abundance of which depends on the tissue metabolic properties. Skeletal muscle expresses two of these isoforms; it mainly contains the muscle isozyme (RI-type) and a small amount of the liver isozyme (L-type), whose expression is under hormonal control. Moreover, contractile activity regulates expression of muscular proteins related with glucose metabolism. Fast twitch rabbit skeletal muscle denervation or chronic low frequency stimulation can provide information about the regulation of this enzyme. Our results show an increase in Fru-2,6-P-2, concentration after 2 days of denervation or stimulation. In denervated muscle, this increase is mediated by a rise in liver PFK-2/FBPase-2 isozyme, while in stimulated muscle it is mediated by a rise in muscle PFK-2/FBPase-2 isozyme, In conclusion, our results show that contractile activity could alter the expression of PFK-2/FBPase-2.	Univ Barcelona, Fac Med, Dept Ciencias Fisiol 1, E-08036 Barcelona, Spain; Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Dept Biochem & Mol Biol, Div 4, E-08036 Barcelona, Spain	University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Cadefau, JA (corresponding author), Univ Barcelona, Fac Med, Dept Ciencias Fisiol 1, C Casanova 143, E-08036 Barcelona, Spain.		Cadefau, Joan Aureli/G-2906-2016; Cadefau, Joan AurelI/M-7934-2018; Tauler, Albert/D-5183-2014	Cadefau, Joan Aureli/0000-0001-6020-189X; Cadefau, Joan AurelI/0000-0001-6020-189X; Tauler, Albert/0000-0003-0193-0667				ANDRES V, 1990, DIFFERENTIATION, V43, P98, DOI 10.1111/j.1432-0436.1990.tb00435.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CADEFAU JA, 1993, PFLUG ARCH EUR J PHY, V424, P529, DOI 10.1007/BF00374918; CARROLL NV, 1956, J BIOL CHEM, V220, P583; CASTELLO A, 1993, J BIOL CHEM, V268, P14998; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CREPIN KM, 1989, BIOCHEM J, V264, P151, DOI 10.1042/bj2640151; CREPIN KM, 1992, J BIOL CHEM, V267, P21698; CREPIN KM, 1988, FEBS LETT, V227, P136, DOI 10.1016/0014-5793(88)80884-6; CREPIN KM, 1989, EUR J BIOCHEM, V183, P433, DOI 10.1111/j.1432-1033.1989.tb14946.x; DALBIS A, 1994, EUR J BIOCHEM, V223, P249, DOI 10.1111/j.1432-1033.1994.tb18989.x; ELMAGHRABI MR, 1982, P NATL ACAD SCI-BIOL, V79, P315, DOI 10.1073/pnas.79.2.315; GREEN HJ, 1991, FEBS LETT, V282, P107, DOI 10.1016/0014-5793(91)80455-C; Gundersen K, 1998, ACTA PHYSIOL SCAND, V162, P333, DOI 10.1046/j.1365-201X.1998.0336e.x; GUTMANN E, 1976, ANNU REV PHYSIOL, V38, P177, DOI 10.1146/annurev.ph.38.030176.001141; Handberg A, 1996, AM J PHYSIOL-ENDOC M, V271, pE50, DOI 10.1152/ajpendo.1996.271.1.E50; HOFMANN S, 1994, EUR J BIOCHEM, V219, P307, DOI 10.1111/j.1432-1033.1994.tb19942.x; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; Jones JP, 1997, BIOCHEM BIOPH RES CO, V238, P53, DOI 10.1006/bbrc.1997.7241; KITAMURA K, 1989, J BIOL CHEM, V264, P9799; Kraus W E, 1994, Exerc Sport Sci Rev, V22, P313; MINATOGAWA Y, 1984, BIOCHEM J, V223, P73, DOI 10.1042/bj2230073; Passonneau J.V., 1972, FLEXIBLE SYSTEM ENZY; PETTE D, 1992, REV PHYSIOL BIOCH P, V120, P115, DOI 10.1007/BFb0036123; Pette D, 1997, Int Rev Cytol, V170, P143, DOI 10.1016/S0074-7696(08)61622-8; PILKIS SJ, 1995, ANNU REV BIOCHEM, V64, P799, DOI 10.1146/annurev.bi.64.070195.004055; ROSA JL, 1990, BIOCHEM J, V270, P645, DOI 10.1042/bj2700645; ROSEN KM, 1990, BIOTECHNIQUES, V8, P398; SCHWARZ G, 1983, PFLUG ARCH EUR J PHY, V398, P130, DOI 10.1007/BF00581060; SIMARD C, 1985, COMP BIOCH PHYSL, V2, P539; SIMONEAU JA, 1989, PFLUG ARCH EUR J PHY, V413, P679, DOI 10.1007/BF00581821; Spitz F, 1998, J BIOL CHEM, V273, P14975, DOI 10.1074/jbc.273.24.14975; TANIYAMA M, 1988, BIOCHEM BIOPH RES CO, V157, P949, DOI 10.1016/S0006-291X(88)80966-5; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; VANSCHAFTINGEN E, 1986, EUR J BIOCHEM, V159, P359; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V124, P143; VENTURA F, 1991, NATO ASI SER H, V56, P131; WEBER FE, 1988, FEBS LETT, V238, P71, DOI 10.1016/0014-5793(88)80227-8; WINDER WW, 1992, AM J PHYSIOL, V262, pE919, DOI 10.1152/ajpendo.1992.262.6.E919	39	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31961	31966		10.1074/jbc.274.45.31961	http://dx.doi.org/10.1074/jbc.274.45.31961			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542225	hybrid			2022-12-25	WOS:000083532100033
J	Chen, DH; Xu, XP; Zhu, LJ; Angervo, M; Li, QX; Bagchi, MK; Bagchi, IC				Chen, DH; Xu, XP; Zhu, LJ; Angervo, M; Li, QX; Bagchi, MK; Bagchi, IC			Cloning and uterus/oviduct-specific expression of a novel estrogen-regulated gene (ERG1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER RIBONUCLEIC-ACID; IMMATURE RAT UTERUS; DIFFERENTIAL DISPLAY; RECEPTOR SUPERFAMILY; MOUSE UTERUS; C-FOS; GROWTH; IDENTIFICATION; PROTEIN; RNA	The steroid hormone estrogen profoundly influences growth and differentiation programs in the reproductive tract of cycling and pregnant mamals, It is thought that estrogen exerts its cellular effects by regulating the expression of specific target genes. We utilized a messenger RNA differential display method to identify the genes whose expression is modulated by estrogen in the preimplantation rat uterus, Here we report the cloning of a novel gene (ERG1) that is tightly regulated by estrogen in two key reproductive tissues, the uterus and oviduct. Spatio-temporal analyses reveal that ERG1 mRNA is expressed in a highly stage-specific manner in the uterus and oviduct, and its expression is restricted to the surface epithelium of both of these tissues, Nucleotide sequence analysis of the full-length ERG1 cDNA indicates that it has an open reading frame of 1821 nuceotides encoding a putative protein of 607 amino acids with a single transmembrane domain and a short cytoplasmic tail. The extracellular part of the protein contains several distinct structural motifs. These include a zona pellucida binding domain, which is present in a number of proteins such as the zona pellucida sperm binding proteins, and uromodulin, In addition, there is a repeat of a motif called CUB domain, which exists in a number of genes involved in development and differentiation such as bone morphogenetic protein 1 (BMP1), Although the precise function of ERG1 eludes us presently, its unique pattern of expression in the uterus and oviduct and its regulation by estrogen, a principal reproductive hormone, lead us to speculate that this novel gene plays an important role in events during the reproductive cycle and early pregnancy.	Populat Council, New York, NY 10021 USA; Rockefeller Univ, New York, NY 10021 USA	Population Council; Rockefeller University	Bagchi, IC (corresponding author), Populat Council, 1230 York Ave, New York, NY 10021 USA.		Chen, Dahu/AAX-6349-2021		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD034760, R01HD034527] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050257] Funding Source: NIH RePORTER; NICHD NIH HHS [UO1 HD-34760, R01 HD-34527] Funding Source: Medline; NIDDK NIH HHS [R01-DK-50257] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIELLO LP, 1994, P NATL ACAD SCI USA, V91, P6231, DOI 10.1073/pnas.91.13.6231; Allen E, 1928, J MORPHOL PHYSIOL, V46, P479, DOI 10.1002/jmor.1050460205; Allen E, 1928, AM J ANAT, V42, P467, DOI 10.1002/aja.1000420207; ANDERSON JN, 1975, ENDOCRINOLOGY, V96, P160, DOI 10.1210/endo-96-1-160; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; BAULIEU EE, 1991, TRENDS ENDOCRIN MET, V2, P233, DOI 10.1016/1043-2760(91)90030-Q; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BORK P, 1992, FEBS LETT, V300, P237, DOI 10.1016/0014-5793(92)80853-9; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; BORK P, 1991, FEBS LETT, V282, P9, DOI 10.1016/0014-5793(91)80433-4; CHIAPPETTA C, 1992, J STEROID BIOCHEM, V41, P113, DOI 10.1016/0960-0760(92)90037-J; CROXATTO HB, 1996, REPROD ENDOCRINOLOGY, V1, P385; CULLINANBOVE K, 1993, ENDOCRINOLOGY, V133, P829, DOI 10.1210/en.133.2.829; DIAUGUSTINE RP, 1988, ENDOCRINOLOGY, V122, P2355, DOI 10.1210/endo-122-6-2355; DONNELLY KM, 1991, MOL ENDOCRINOL, V5, P356, DOI 10.1210/mend-5-3-356; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FINN CA, 1971, BIOL UTERUS, P246; GHAHARY A, 1989, ENDOCRINOLOGY, V125, P597, DOI 10.1210/endo-125-2-597; Harper Michael J. K., 1994, P123; JENSEN EV, 1972, ANNU REV BIOCHEM, V41, P203, DOI 10.1146/annurev.bi.41.070172.001223; Kasik JW, 1998, BIOCHEM J, V330, P947; KATZENELLENBOGE.BS, 1975, BIOCHEMICAL ACTION H, V3, P187; Katzenellenbogen BS, 1997, ENDOCRINOLOGY, V138, P861, DOI 10.1210/en.138.3.861; KAYE AM, 1972, BIOCHIM BIOPHYS ACTA, V261, P475, DOI 10.1016/0304-4165(72)90072-4; KIRKLAND JL, 1979, BIOL REPROD, V21, P269, DOI 10.1095/biolreprod21.2.269; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LINGHAM RB, 1988, MOL ENDOCRINOL, V2, P230, DOI 10.1210/mend-2-3-230; LOOSEMITCHELL DS, 1988, MOL ENDOCRINOL, V2, P946, DOI 10.1210/mend-2-10-946; MURPHY LJ, 1987, MOL ENDOCRINOL, V1, P445, DOI 10.1210/mend-1-7-445; MURPHY LJ, 1987, ENDOCRINOLOGY, V120, P1882, DOI 10.1210/endo-120-5-1882; NELSON KG, 1992, ENDOCRINOLOGY, V131, P1657, DOI 10.1210/en.131.4.1657; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PENNICA D, 1987, SCIENCE, V236, P83, DOI 10.1126/science.3453112; PSYCHOYOS A, 1973, VITAM HORM, V31, P205; PSYCHOYOS A, 1973, HDB PHYSL, P187; QUARMBY VE, 1984, ENDOCRINOLOGY, V114, P694, DOI 10.1210/endo-114-3-694; TRAVERS MT, 1987, FEBS LETT, V211, P27, DOI 10.1016/0014-5793(87)81267-X; UTANS U, 1994, P NATL ACAD SCI USA, V91, P6463, DOI 10.1073/pnas.91.14.6463; WAKELING AE, 1988, J STEROID BIOCHEM, V30, P141, DOI 10.1016/0022-4731(88)90086-6; WEISZ A, 1988, MOL ENDOCRINOL, V2, P816, DOI 10.1210/mend-2-9-816; WIEST WG, 1970, ENDOCRINOLOGY, V87, P43, DOI 10.1210/endo-87-1-43; YOSHINAGA K, 1969, ENDOCRINOLOGY, V85, P103, DOI 10.1210/endo-85-1-103	42	18	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32215	32224		10.1074/jbc.274.45.32215	http://dx.doi.org/10.1074/jbc.274.45.32215			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542259	hybrid			2022-12-25	WOS:000083532100067
J	Dong, LA; Wang, WL; Wang, F; Stoner, M; Reed, JC; Harigai, M; Samudio, I; Kladde, MP; Vyhlidal, C; Safe, S				Dong, LA; Wang, WL; Wang, F; Stoner, M; Reed, JC; Harigai, M; Samudio, I; Kladde, MP; Vyhlidal, C; Safe, S			Mechanisms of transcriptional activation of bcl-2 gene expression by 17 beta-estradiol in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR SP1; HUMAN FOLLICULAR LYMPHOMA; ELEMENT-BINDING PROTEIN; CATHEPSIN-D GENE; CHROMOSOMAL BREAKPOINT; INDEPENDENT ACTIVATION; RESPONSIVE ELEMENT; INDUCED APOPTOSIS; DOWN-REGULATION; LINE MCF-7	bcl-2 gene expression is induced by 17 beta-estradiol (E2) in T47D and MCF-7 human breast cancer cells, and the mechanism of E2 responsiveness was further investigated by analysis of the bcl-2 gene promoter. The -1602 to -1534 distal region (bcl-2j) of the promoter was E2-responsive; however, in gel mobility shift assays, the estrogen receptor alpha (ERalpha) did not bind [P-32]bcl-2j, whereas Spl protein formed a retarded band complex. Further analysis demonstrated that the upstream region (-1603 to -1579) of the bcl-2 gene promoter contained two GC/GA-rich sites at -1601 (5'-GGGCTGG-3') and -1588 (3'-GGAGGG-5') that bound Spl protein. Subsequent studies confirmed that transactivation by E2 was dependent on ERalpha/Sp1 interactions with both GC-rich sites, and this was confirmed by in uitro footprinting. In contrast, a 21-base pair E2-responsive downstream region (-1578 to -1534) did not bind Spl or ER, protein; however, analysis of a complex binding pattern with nuclear extracts showed that ATF-1 and CREB-1 bound to this motif, These data coupled,with results of transient transfection studies demonstrated that transcriptional activation by E2 of the -1578 to -1534 region of the bcl-2 gene promoter was dependent on induction of cAMP and subsequent activation through a cAMP response element, Thus, hormone regulation of bcl-2 gene expression in breast cancer cells involves multiple enhancer elements and E2-mediated transactivation does not require direct binding of the estrogen receptor with promoter DNA.	Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Burnham Inst, La Jolla, CA 92037 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Sanford Burnham Prebys Medical Discovery Institute	Safe, S (corresponding author), Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA.		Samudio, Ismael/D-3581-2013	Samudio, Ismael/0000-0001-8676-1035	NATIONAL CANCER INSTITUTE [R01CA076636] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009106] Funding Source: NIH RePORTER; NCI NIH HHS [CA76636] Funding Source: Medline; NIEHS NIH HHS [ES09106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adam L, 1997, CANCER RES, V57, P1023; ALDERSON LM, 1995, CANCER RES, V55, P999; ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; AUGEREAU P, 1994, MOL ENDOCRINOL, V8, P693, DOI 10.1210/me.8.6.693; Baba M, 1996, INT J ONCOL, V8, P355; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BRONNER MP, 1995, AM J PATHOL, V146, P20; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; CRAIG RW, 1995, SEMIN CANCER BIOL, V6, P35, DOI 10.1006/scbi.1995.0005; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; DOGLIONI C, 1994, VIRCHOWS ARCH, V424, P47; Duan R, 1998, ENDOCRINOLOGY, V139, P1981, DOI 10.1210/en.139.4.1981; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; ElTanani MKK, 1996, MOL CELL ENDOCRINOL, V124, P71, DOI 10.1016/S0303-7207(96)03930-5; ElTanani MKK, 1997, MOL ENDOCRINOL, V11, P928, DOI 10.1210/me.11.7.928; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALDAR S, 1994, CANCER RES, V54, P2095; HENRIKSEN R, 1995, BRIT J CANCER, V72, P1324, DOI 10.1038/bjc.1995.509; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Kaiser UB, 1998, J BIOL CHEM, V273, P12943, DOI 10.1074/jbc.273.21.12943; Kandouz M, 1996, INT J CANCER, V68, P120, DOI 10.1002/(SICI)1097-0215(19960927)68:1<120::AID-IJC21>3.0.CO;2-E; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kladde MP, 1996, METHOD ENZYMOL, V274, P214; Kladde MP, 1996, EMBO J, V15, P6290, DOI 10.1002/j.1460-2075.1996.tb01019.x; Kobayashi S, 1997, BREAST CANCER RES TR, V42, P173, DOI 10.1023/A:1005760013810; Krajewski S, 1997, CLIN CANCER RES, V3, P199; KRISHNAN V, 1994, J BIOL CHEM, V269, P15912; Kumar R, 1996, CLIN CANCER RES, V2, P1215; Lapointe J, 1999, ENDOCRINOLOGY, V140, P416, DOI 10.1210/en.140.1.416; LEEK RD, 1994, BRIT J CANCER, V69, P135, DOI 10.1038/bjc.1994.22; Lundblad JR, 1998, J BIOL CHEM, V273, P19251, DOI 10.1074/jbc.273.30.19251; Margana RK, 1997, J BIOL CHEM, V272, P3083, DOI 10.1074/jbc.272.5.3083; McDonnell TJ, 1996, EXPERIENTIA, V52, P1008, DOI 10.1007/BF01920110; MIYASHITA T, 1994, CANCER RES, V54, P3131; NAKASU S, 1994, ACTA NEUROPATHOL, V88, P520; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Piche A, 1998, CANCER RES, V58, P2134; Porter W, 1997, MOL ENDOCRINOL, V11, P1569, DOI 10.1210/me.11.11.1569; Qin CH, 1999, ENDOCRINOLOGY, V140, P2501, DOI 10.1210/en.140.6.2501; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Roder K, 1997, J BIOL CHEM, V272, P21616, DOI 10.1074/jbc.272.34.21616; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Schanke JT, 1998, MOL ENDOCRINOL, V12, P405, DOI 10.1210/me.12.3.405; Scholz A, 1998, J BIOL CHEM, V273, P4360, DOI 10.1074/jbc.273.8.4360; SUMANTRAN VN, 1995, CANCER RES, V55, P2507; Sun GL, 1998, MOL ENDOCRINOL, V12, P882, DOI 10.1210/me.12.6.882; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; WAGNER SA, 1993, SCIENCE, V266, P395; Wang F, 1998, NUCLEIC ACIDS RES, V26, P3044, DOI 10.1093/nar/26.12.3044; WANG TTY, 1995, CANCER RES, V55, P2487; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; Xie W, 1999, ENDOCRINOLOGY, V140, P219, DOI 10.1210/en.140.1.219; Yamagata T, 1997, MOL CELL BIOL, V17, P4272, DOI 10.1128/MCB.17.8.4272; Yamaguchi A, 1997, INT J ONCOL, V10, P581; ZHANG DE, 1994, J BIOL CHEM, V269, P11425; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	61	231	241	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32099	32107		10.1074/jbc.274.45.32099	http://dx.doi.org/10.1074/jbc.274.45.32099			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542244	hybrid			2022-12-25	WOS:000083532100052
J	Ober, D; Hartmann, T				Ober, D; Hartmann, T			Deoxyhypusine synthase from tobacco - cDNA isolation, characterization, and bacterial expression of an enzyme with extended substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 5A; HYPUSINE-CONTAINING PROTEIN; MOLECULAR-CLONING; SACCHAROMYCES-CEREVISIAE; HOMOSPERMIDINE SYNTHASE; PYRROLIZIDINE ALKALOIDS; LIQUID-CHROMATOGRAPHY; FUNCTIONAL EXPRESSION; SYM-HOMOSPERMIDINE; HAMSTER EPIDIDYMIS	Deoxyhypusine synthase catalyzes the formation of a deoxyhypusine residue in the translation eukaryotic initiation factor 5A (eIF5A) precursor protein by transferring an aminobutyl moiety from spermidine onto a conserved lysine residue within the eIF5A polypeptide chain. This reaction commences the activation of the initiation factor in fungi and vertebrates, A mechanistically identical reaction is known in the biosynthetic pathway leading to pyrrolizidine alkaloids in plants. Deoxyhypusine synthase from tobacco was cloned and expressed in active form in Escherichia coli. It catalyzes the formation of a deoxyhypusine residue in the tobacco eIF5A substrate as shown by gas chromatography coupled with a mass spectrometer. The enzyme also accepts free putrescine as the aminobutyl acceptor, instead of lysine bound in the eIF5A polypeptide chain, yielding homospermidine. Conversely, it accepts homospermidine instead of spermidine as the aminobutyl donor, whereby the reactions with putrescine and homospermidine proceed at the same rate as those involving the authentic substrates. The conversion of deoxyhypusine synthase-catalyzed eIF5A deoxyhypusinylation pinpoints a function for spermidine in plant metabolism. Furthermore, and quite unexpectedly, the substrate spectrum of deoxyhypusine synthase hints at a biochemical basis behind the sparse and skew occurrence of both homospermidine and its pyrrolizidine derivatives across distantly related plant taxa.	Tech Univ Braunschweig, Inst Pharmazeut Biol, D-38106 Braunschweig, Germany	Braunschweig University of Technology	Hartmann, T (corresponding author), Tech Univ Braunschweig, Inst Pharmazeut Biol, Mendelssohnstr 1, D-38106 Braunschweig, Germany.							Abid MR, 1997, J BIOCHEM-TOKYO, V121, P769; BARTIG D, 1992, J CHROMATOGR, V606, P43, DOI 10.1016/0021-9673(92)85255-R; BARTIG D, 1990, SYST APPL MICROBIOL, V13, P112, DOI 10.1016/S0723-2020(11)80156-6; BOTTCHER F, 1994, CAN J CHEM, V72, P80, DOI 10.1139/v94-013; BOTTCHER F, 1993, PHYTOCHEMISTRY, V32, P679, DOI 10.1016/S0031-9422(00)95154-9; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Chen KY, 1997, BIOL SIGNAL, V6, P105; COOPER HL, 1983, P NATL ACAD SCI-BIOL, V80, P1854, DOI 10.1073/pnas.80.7.1854; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; EVANS PT, 1989, ANNU REV PLANT PHYS, V40, P235, DOI 10.1146/annurev.pp.40.060189.001315; Galston AW, 1997, BOT ACTA, V110, P197, DOI 10.1111/j.1438-8677.1997.tb00629.x; GALSTON AW, 1985, PLANT HORMONES, P158; GORDON ED, 1987, J BIOL CHEM, V262, P16585; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Graser G, 1998, PHYTOCHEMISTRY, V47, P1017, DOI 10.1016/S0031-9422(97)00600-6; HAMANA K, 1988, FEMS MICROBIOL LETT, V50, P11; Hamana K, 1998, CAN J BOT, V76, P130, DOI 10.1139/cjb-76-1-130; HAMANA K, 1979, FEBS LETT, V99, P325, DOI 10.1016/0014-5793(79)80983-7; HAMANA K, 1992, CRIT REV MICROBIOL, V18, P261, DOI 10.3109/10408419209113518; Hartmann T, 1999, PLANTA, V207, P483, DOI 10.1007/s004250050508; Hartmann T., 1995, CHEM BIOL PERSPECT, V9, P155; Henikoff JG, 1996, METHOD ENZYMOL, V266, P88; HUSEK P, 1992, ANAL CHIM ACTA, V259, P185, DOI 10.1016/0003-2670(92)85367-F; IN JG, 1997, PLANT PHYSIOL, V115, P864; JOE YA, 1995, J BIOL CHEM, V270, P22386, DOI 10.1074/jbc.270.38.22386; KAISER FE, 1974, J CHROMATOGR, V94, P113, DOI 10.1016/S0021-9673(01)92361-1; KANG HA, 1994, J BIOL CHEM, V269, P3934; KEMPER WM, 1976, J BIOL CHEM, V251, P5551; KLIER H, 1995, FEBS LETT, V364, P207, DOI 10.1016/0014-5793(95)00394-O; KRISTIAK J, 1993, J PHYS IV, V3, P265, DOI 10.1051/jp4:1993441; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liao DI, 1998, STRUCTURE, V6, P23, DOI 10.1016/S0969-2126(98)00004-5; MAGDOLEN V, 1994, MOL GEN GENET, V244, P646, DOI 10.1007/BF00282755; MATSUZAKI S, 1982, BIOCHEM BIOPH RES CO, V107, P307, DOI 10.1016/0006-291X(82)91705-3; MATSUZAKI S, 1987, BIOCHEM INT, V15, P817; MEHTA AM, 1994, PLANT PHYSIOL, V106, P1413, DOI 10.1104/pp.106.4.1413; PARK MH, 1993, BIOFACTORS, V4, P95; Park MH, 1997, BIOL SIGNAL, V6, P115; PARK MH, 1988, J BIOL CHEM, V263, P15264; PARK MH, 1991, J BIOL CHEM, V266, P7988; PAY A, 1991, PLANT MOL BIOL, V17, P927, DOI 10.1007/BF00037075; Peat TS, 1998, STRUCT FOLD DES, V6, P1207, DOI 10.1016/S0969-2126(98)00120-8; SANO A, 1984, BIOCHIM BIOPHYS ACTA, V800, P135; SANO A, 1985, POLYAMINES BASIC CLI, P81; Sasaki K, 1996, FEBS LETT, V384, P151, DOI 10.1016/0014-5793(96)00310-9; SCHERER P, 1983, J BACTERIOL, V154, P1315, DOI 10.1128/JB.154.3.1315-1322.1983; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TAO Y, 1995, J BIOL CHEM, V270, P383, DOI 10.1074/jbc.270.1.383; TAO Y, 1995, J BIOL CHEM, V270, P23984, DOI 10.1074/jbc.270.41.23984; Tholl D, 1996, EUR J BIOCHEM, V240, P373, DOI 10.1111/j.1432-1033.1996.0373h.x; Walden R, 1997, PLANT PHYSIOL, V113, P1009, DOI 10.1104/pp.113.4.1009; Wolff EC, 1999, YEAST, V15, P43; WOLFF EC, 1990, J BIOL CHEM, V265, P4793; WOLFF EC, 1995, J BIOL CHEM, V270, P8660, DOI 10.1074/jbc.270.15.8660; Wolff EC, 1997, J BIOL CHEM, V272, P15865, DOI 10.1074/jbc.272.25.15865; YAN SCB, 1989, TRENDS BIOCHEM SCI, V14, P264, DOI 10.1016/0968-0004(89)90060-1; Yan YP, 1996, BIOCHEM J, V315, P429, DOI 10.1042/bj3150429; Yoneyama T, 1998, J EXP BOT, V49, P521, DOI 10.1093/jexbot/49.320.521	59	76	83	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32040	32047		10.1074/jbc.274.45.32040	http://dx.doi.org/10.1074/jbc.274.45.32040			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542236	hybrid			2022-12-25	WOS:000083532100044
J	Pavlova, NV; Yuziuk, JA; Nakagawa, H; Kiso, M; Li, SC; Li, YT				Pavlova, NV; Yuziuk, JA; Nakagawa, H; Kiso, M; Li, SC; Li, YT			2-Keto-3-deoxy-D-glycero-D-galacto-nononic acid (KDN)- and N-acetylneuraminic acid-cleaving sialidase (KDN-sialidase) and KDN-cleaving hydrolase (KDNase) from the hepatopancreas of oyster, Crassostrea virginica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEAMINATED NEURAMINIC ACID; RAINBOW-TROUT EGGS; 3-DEOXY-D-GLYCERO-D-GALACTO-2-NONULOSONIC ACID; POLY(ALPHA-2,8-DEAMINONEURAMINIC ACID); FLUOROMETRIC ASSAY; MAMMALIAN-TISSUES; EXPRESSION; IDENTIFICATION; PURIFICATION; GLYCOPROTEIN	KDN (2-keto-3-deoxy-D-glycero-D-galacto-nononic acid), a sialic acid analog, has been found to be widely distributed in nature. Despite the structural similarity between KDN and Neu5Ac, alpha-ketosides of KDN me refractory to conventional sialidases. Ne found that the hepatopancreas of the oyster, Crassostrea virginica, contains two KDN-cleaving sialidases but is devoid of conventional sialidase. The major sialidase, KDN-sialidase, effectively cleaves alpha-ketosidically linked KDN and also slowly cleaves the alpha-ketosides of Neu5Ac. The minor sialidase, KDNase, is specific for alpha-ketosides of KDN. Ne were able to separate these two KDN-cleaving enzymes using hydrophobic interaction and cation-exchange chromatographies. The rate of hydrolysis of 4-methylumbelliferyl-alpha-KDN (MU-KDN) by KDN-sialidase is 30 times faster than that of MU-Neu5Ac in the presence of 0.2 M NaCl, whereas in the absence of NaCl this ratio is only 8. KDNase hydrolyzes MU-KDN over 500 times faster than MU-Neu5Ac and is not affected by NaCl. KDN-sialidase purified to electrophoretically homogeneous form was found to have a molecular mass of 25 kDa and an isoelectric point of 8.4. One of the three tryptic peptides derived from KDN-sialidase contains the consensus motif, SXDXGXTW, that has been found in all conventional sialidases. Kinetic analysis of the inhibition of the hydrolysis of MU-KDN and MU-Neu5Ac by 2,3-dehydro-2-deoxy-KDN (KDN2-en) and 2,3-dehydro-2-deoxy-(Neu5Ac2-en) suggests that KDN-sialidase contains two separate active sites for the hydrolysis of KDN and Neu5Ac. Both KDN-sialidase and KDNase effectively hydrolyze KDN-G(M3), KDN alpha 2-->3Gal beta 1-->4Glc, KDN alpha 2-->6Gal beta 1-->4Glc, KDN alpha 2-->6-N-acetylgalactosaminitol, KDN alpha 2-->6(KDN alpha 2-->3)N-acetylgalactosaminitol and KDN alpha 2-->6(GlcNAc beta 1-->3)N-acetylgalactosaminitol. However, only KDN-sialidase also slowly hydrolyzes G(M3), Neu5Ac alpha 2-->3Gal beta 1-->4Glc, and Neu5Ac alpha 2-->6Gal beta 1-->4Glc. These two KDN-cleaving sialidases should be useful for studying the structure and function of KDN-containing glycoconjugates.	Tulane Univ, Sch Med, Dept Biochem, New Orleans, LA 70112 USA; Saga Univ, Fac Agr, Div Biometry & Appl Sci, Saga 840, Japan; Gifu Univ, Dept Bioorgan Chem, Gifu 50111, Japan	Tulane University; Saga University; Gifu University	Li, YT (corresponding author), Tulane Univ, Sch Med, Dept Biochem, 1430 Tulane Ave, New Orleans, LA 70112 USA.	yli@tmcpop.tmc.tulane.edu			NINDS NIH HHS [NS 09626] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009626] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANGATA T, 1994, GLYCOBIOLOGY, V4, P517, DOI 10.1093/glycob/4.4.517; BOEKER EA, 1982, BIOCHEM J, V203, P117, DOI 10.1042/bj2030117; Corfield A.P., 1981, PERSPECTIVES INHERIT, V4, P3; DOUCET JP, 1988, ANAL BIOCHEM, V168, P265, DOI 10.1016/0003-2697(88)90317-X; FERRARI J, 1994, GLYCOBIOLOGY, V4, P367, DOI 10.1093/glycob/4.3.367; HARRIS G, 1954, CHEM IND-LONDON, P249; HEUERMANN D, 1991, GLYCOCONJUGATE J, V8, P95, DOI 10.1007/BF00731018; Inoue S, 1996, J BIOL CHEM, V271, P24341, DOI 10.1074/jbc.271.40.24341; Inoue S, 1998, J BIOL CHEM, V273, P27199, DOI 10.1074/jbc.273.42.27199; INOUE S, 1988, BIOCHEM BIOPH RES CO, V153, P172, DOI 10.1016/S0006-291X(88)81204-X; IWASAKI M, 1987, BIOCHEMISTRY-US, V26, P1452, DOI 10.1021/bi00379a036; JASPARD E, 1993, J BIOL CHEM, V268, P9496; KIMURA M, 1994, J BIOL CHEM, V269, P32138; KITAJIMA K, 1994, J BIOL CHEM, V269, P21415; KNIREL YA, 1989, CARBOHYD RES, V188, P145, DOI 10.1016/0008-6215(89)84067-4; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; LI YT, 1994, ARCH BIOCHEM BIOPHYS, V310, P243, DOI 10.1006/abbi.1994.1163; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIYAGI T, 1993, J BIOL CHEM, V268, P26435; MOORE GL, 1969, ANAL BIOCHEM, V32, P122, DOI 10.1016/0003-2697(69)90111-0; MYERS RW, 1980, ANAL BIOCHEM, V101, P166, DOI 10.1016/0003-2697(80)90056-1; NADANO D, 1986, J BIOL CHEM, V261, P1550; NAKAGAWA H, 1987, J BIOCHEM-TOKYO, V101, P855, DOI 10.1093/oxfordjournals.jbchem.a121952; NAKAMURA M, 1991, CHEM PHARM BULL, V39, P3140; Nishino S, 1996, J BIOL CHEM, V271, P2909, DOI 10.1074/jbc.271.6.2909; POTIER M, 1979, ANAL BIOCHEM, V94, P287, DOI 10.1016/0003-2697(79)90362-2; Qu BX, 1996, P NATL ACAD SCI USA, V93, P8995, DOI 10.1073/pnas.93.17.8995; RIVERASAGREDO A, 1992, EUR J BIOCHEM, V209, P415, DOI 10.1111/j.1432-1033.1992.tb17304.x; ROGGENTIN P, 1989, GLYCOCONJUGATE J, V6, P349, DOI 10.1007/BF01047853; Rosenberg A, 1976, BIOL ROLES SIALIC AC, P295; SONG Y, 1991, J BIOL CHEM, V266, P21929; STRECKER G, 1992, FEBS LETT, V298, P39, DOI 10.1016/0014-5793(92)80018-C; Terada T, 1997, J BIOL CHEM, V272, P5452, DOI 10.1074/jbc.272.9.5452; TERADA T, 1993, J CARBOHYD CHEM, V12, P425, DOI 10.1080/07328309308019398; TRONSMO A, 1993, ANAL BIOCHEM, V208, P74, DOI 10.1006/abio.1993.1010; Yuziuk JA, 1996, BIOCHEM J, V315, P1041, DOI 10.1042/bj3151041; Ziak M, 1996, P NATL ACAD SCI USA, V93, P2759, DOI 10.1073/pnas.93.7.2759; Ziak M, 1999, J AM SOC NEPHROL, V10, P203	38	8	8	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31974	31980		10.1074/jbc.274.45.31974	http://dx.doi.org/10.1074/jbc.274.45.31974			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542227	hybrid			2022-12-25	WOS:000083532100035
J	Zeremski, M; Hill, JE; Kwek, SSS; Grigorian, IA; Gurova, KV; Garkavtsev, IV; Diatchenko, L; Koonin, EV; Gudkov, AV				Zeremski, M; Hill, JE; Kwek, SSS; Grigorian, IA; Gurova, KV; Garkavtsev, IV; Diatchenko, L; Koonin, EV; Gudkov, AV			Structure and regulation of the mouse ing1 gene - Three alternative transcripts encode two PHD finger proteins that have opposite effects on p53 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANDIDATE TUMOR-SUPPRESSOR; REGION; MDM2; DEGRADATION; FIBROBLASTS; PROMOTES; RNA	The human ING1 gene encodes nuclear protein p33(,)(ING1) CII previously shown to cooperate with p53 in cell growth control (Garkavtsev, I., Grigorian, I. A., Ossovskaya, V. S., Chernov, M. V., Chumakov, P, M., and Gudkov, A. V, (1998) Nature 391, 295-298), p33(ING1) belongs to a small family of proteins from human, mouse, and yeast of approximately the same size that show significant similarity to one another within the C-terminaI PHD finger domain and also contain an additional N-terminal region with subtle but reliably detectable sequence conservation Mouse ing1 is transcribed from three differently regulated promoters localized within a 4-kilobase pair region of genomic DNA The resulting transcripts share a long common region encoded by a common exon and differ in their 5'-exon sequences. Two transcripts are translated into the same protein of 185 amino acids, the mouse equivalent of the human p33(ING1), while the third transcript encodes a longer protein that has 94 additional N-terminal amino acids. Overexpression of the longer protein interferes with the accumulation of p53 protein and activation of p53-responsive promoters after DNA damage. Between the two products of ing1, only the longer one forms a complex with p53 detectable by immunoprecipitation, These results indicate that a single gene, ing1, encodes both p53-suppressing and p53-activating proteins that are regulated by alternative promoters.	Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA; CLONTECH Labs Inc, Palo Alto, CA 94303 USA; Genome Therapeut Corp, Dept Funct Gen, Waltham, MA 02154 USA; Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Gudkov, AV (corresponding author), Univ Illinois, Coll Med, Dept Mol Genet, M-C 669,900 S Ashland Ave, Chicago, IL 60607 USA.			Gudkov, Andrei/0000-0003-2548-0154; Hill, Jason/0000-0003-2512-1661	NATIONAL CANCER INSTITUTE [R01CA060730, R01CA075179] Funding Source: NIH RePORTER; NCI NIH HHS [CA60730, CA75179] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; CHENCHIK A, 1998, GENE CLONING ANAL RT, P305; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Cui JQ, 1998, ONCOL REP, V5, P585; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Garkavtsev I, 1997, HYBRIDOMA, V16, P537, DOI 10.1089/hyb.1997.16.537; Garkavtsev I, 1997, MOL CELL BIOL, V17, P2014, DOI 10.1128/MCB.17.4.2014; Garkavtsev I, 1997, CYTOGENET CELL GENET, V76, P176, DOI 10.1159/000134539; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; GUDKOV AV, 1989, INT J CANCER, V44, P1052, DOI 10.1002/ijc.2910440619; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Helbing CC, 1997, CANCER RES, V57, P1255; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NEUWALD AF, 1995, PROTEIN SCI, V4, P1618, DOI 10.1002/pro.5560040820; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; QUELLE DE, 1995, CELL, V83, P993; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sambrook J., 2002, MOL CLONING LAB MANU; SCHINDLER U, 1993, PLANT J, V4, P1357; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SMALE S.T., 1994, TRANSCRIPTION MECHAN, P63; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; STASSEN MJ, 1995, MECH DEVELOP, V52, P209, DOI 10.1016/0925-4773(95)00402-M; THLIVERIS A, 1994, CANCER RES, V54, P2991; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259	31	65	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32172	32181		10.1074/jbc.274.45.32172	http://dx.doi.org/10.1074/jbc.274.45.32172			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542254	hybrid			2022-12-25	WOS:000083532100062
J	Aguilar, Z; Akita, RW; Finn, RS; Ramos, BL; Pegram, MD; Kabbinavar, FF; Pietras, RJ; Pisacane, P; Sliwkowski, MX; Slamon, DJ				Aguilar, Z; Akita, RW; Finn, RS; Ramos, BL; Pegram, MD; Kabbinavar, FF; Pietras, RJ; Pisacane, P; Sliwkowski, MX; Slamon, DJ			Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells	ONCOGENE			English	Article						heregulin; NDF; HER-2; growth factor; epithelial cells	EPIDERMAL GROWTH-FACTOR; ACETYLCHOLINE-RECEPTOR SYNTHESIS; CANCER-CELLS; EGF RECEPTOR; TUMOR-CELLS; TYROSINE PHOSPHORYLATION; BASEMENT-MEMBRANE; NEU ONCOGENE; ERBB-FAMILY; LIGAND	The heregulins are a family of ligands with ability to induce phosphorylation of the p185(HER-2/neu) receptor. Various investigators have reported a variety of responses of mouse and human breast and ovarian cells to this family of ligands including growth stimulation, growth inhibition, apoptosis and induction of differentiation in cells expressing the HER-2/neu receptor. Some of the disparity in the literature has been attributed to variations in the cell lines studied, ligand dose applied, methodologies utilized or model system evaluated (i.e. in vitro or in vivo). To evaluate the effects of heregulin on normal and malignant human breast and ovarian epithelial cells expressing known levels of the HER-2/ neu receptor, this report presents the use of several different assays, performed both in vitro and in vivo, in vitro proliferation assays, direct cell counts, clonogenicity under anchorage-dependent and aochorage-independent conditions, as well as the in vivo effects of heregulin on human cells growing in nude mice to address heregulin activity. Using a total of five different biologic assays in nine different cell lines, across two different epithelia and over a one log heregulin dose range, we obtained results that clearly indicate a growth-stimulatory role for this ligand in human breast and ovarian epithelial cells, We find no evidence that heregulin has any growth-inhibitory effects in human epithelial cells. We also quantitated the amount of each member of the type I receptor tyrosine kinase family (RTK I, i.e. HER-1, HER-2, HER-3 and HER-4) in the cell lines employed and correlated this to their respective heregulin responses. These data demonstrate that HER-2/neu overexpression itself affects the expression of other RTK I members and that cells expressing the highest levels of HER-2/neu have the greatest response to HRG.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA; Genentech Inc, San Francisco, CA 94080 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Roche Holding; Genentech	Slamon, DJ (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA.			Pietras, Richard/0000-0002-2846-3192	NATIONAL CANCER INSTITUTE [P01CA032737] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA32737] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Alimandi M, 1997, EMBO J, V16, P5608, DOI 10.1093/emboj/16.18.5608; BACUS SS, 1993, CANCER RES, V53, P5251; Bacus SS, 1996, ONCOGENE, V12, P2535; BARCELLOSHOFF MH, 1989, DEVELOPMENT, V105, P223; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; CHAZIN VR, 1992, ONCOGENE, V7, P1859; CORFAS G, 1993, P NATL ACAD SCI USA, V90, P1624, DOI 10.1073/pnas.90.4.1624; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; Daly JM, 1997, CANCER RES, V57, P3804; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FRESHNEY RI, 1985, ANTICANCER RES, V5, P111; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Grasso AW, 1997, ONCOGENE, V15, P2705, DOI 10.1038/sj.onc.1201447; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUANG SS, 1992, J BIOL CHEM, V267, P11508; HUDZIAK RM, 1988, P NATL ACAD SCI USA, V85, P5102, DOI 10.1073/pnas.85.14.5102; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KARUNAGARAN D, 1995, J BIOL CHEM, V270, P9982, DOI 10.1074/jbc.270.17.9982; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; KITA YA, 1994, FEBS LETT, V349, P139, DOI 10.1016/0014-5793(94)00644-X; Kopp DM, 1997, J NEUROSCI, V17, P6697; Krane IM, 1996, ONCOGENE, V12, P1781; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; LEMOINE NR, 1990, ONCOGENE, V5, P237; Leung HY, 1997, BRIT J UROL, V79, P212, DOI 10.1046/j.1464-410X.1997.30412.x; LEVI ADO, 1995, J NEUROSCI, V15, P1329; Lewis GD, 1996, CANCER RES, V56, P1457; LU HS, 1995, J BIOL CHEM, V270, P4784, DOI 10.1074/jbc.270.9.4784; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARIKOVSKY M, 1995, ONCOGENE, V10, P1403; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; Meiners S, 1998, ONCOGENE, V16, P9, DOI 10.1038/sj.onc.1201486; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NATALI PG, 1990, INT J CANCER, V45, P457, DOI 10.1002/ijc.2910450314; Niemann C, 1998, J CELL BIOL, V143, P533, DOI 10.1083/jcb.143.2.533; PAIK S, 1991, METHOD ENZYMOL, V198, P290; PARASKEVA C, 1990, ANTICANCER RES, V10, P1189; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRESS MF, 1993, CANCER RES, V53, P4960; PRESS MF, 1990, ONCOGENE, V5, P953; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; Raabe TD, 1997, J NEUROSCI RES, V50, P755; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Schaefer G, 1997, ONCOGENE, V15, P1385, DOI 10.1038/sj.onc.1201317; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V267, P8056; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; Stampfer M R, 1994, Cancer Treat Res, V71, P29; TARAHOVSKI A, 1991, BIOCHEMISTRY-US, V30, P3543; Weiss FU, 1997, J CELL PHYSIOL, V173, P187, DOI 10.1002/(SICI)1097-4652(199711)173:2<187::AID-JCP19>3.0.CO;2-D; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YARDEN Y, 1991, BIOCHEMISTRY-US, V30, P3543, DOI 10.1021/bi00228a027; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562	72	126	131	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	1999	18	44					6050	6062		10.1038/sj.onc.1202993	http://dx.doi.org/10.1038/sj.onc.1202993			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557094	Green Published			2022-12-25	WOS:000083359100011
J	Jonkers, J; Weening, JJ; van der Valk, M; Bobeldijk, R; Berns, A				Jonkers, J; Weening, JJ; van der Valk, M; Bobeldijk, R; Berns, A			Overexpression of Frat1 in transgenic mice leads to glomerulosclerosis and nephrotic syndrome, and provides direct evidence for the involvement of Frat1 in lymphoma progression	ONCOGENE			English	Article						insertional mutagenesis; Moloney leukemia virus; transgenic mice; T cell lymphoma; oncogenes; glomerulosclerosis	E-MU-MYC; MURINE LEUKEMIA-VIRUS; EPITHELIAL TRANSFORMATION; METANEPHRIC MESENCHYME; DEVELOPING KIDNEY; B-CELL; C-MYC; N-MYC; GENE; DNA	The proto-oncogene Frat1 was originally identified as a common site of proviral insertion in transplanted tumors of Moloney murine leukemia virus (M-MuLV)-infected E mu-Pim1 transgenic mice. Contrary to most common insertion sites implicated in mouse T cell lymphomagenesis, retroviral insertional mutagenesis of Frat1 constitutes a relatively late event in M-MuLV-induced tumor development, suggesting that proviral activation of Frat1 contributes to progression of T cell lymphomas rather than their genesis, To substantiate this notion we have generated transgenic mice that overexpress Frat1 in various organs, including lymphoid tissues, Frat1 trans; genic mice develop focal glomerulosclerosis and a nephrotic syndrome, but they do not exhibit an increased incidence of spontaneous lymphomas, Conversely, these mice are highly susceptible to M-MuLV-induced lymphomagenesis, and Frat/Pim1 bitransgenic animals develop lymphomas with increased frequency compared to Pim1 transgenic littermates, These data support a role for Frat1 in tumor progression.	Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	Berns, A (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		Jonkers, Jos/AAG-3246-2019	Jonkers, Jos/0000-0002-9264-9792				AARDEN LA, 1979, NY ACAD SCI US, V254, P505; ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Alkema MJ, 1997, ONCOGENE, V15, P899, DOI 10.1038/sj.onc.1201262; BERNS A, 1994, COLD SPRING HARB SYM, V59, P435, DOI 10.1101/SQB.1994.059.01.049; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Brady HJM, 1996, EMBO J, V15, P1221, DOI 10.1002/j.1460-2075.1996.tb00463.x; COUSER WG, 1994, WESTERN J MED, V160, P440; CUYPERS HT, 1984, CELL, V37, P141; HARRISON PTC, 1984, LAB ANIM, V18, P325, DOI 10.1258/002367784780865324; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; Izui S, 1994, Int Rev Immunol, V11, P211, DOI 10.3109/08830189409061728; JAENISCH R, 1975, P NATL ACAD SCI USA, V72, P4008, DOI 10.1073/pnas.72.10.4008; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Jonkers J, 1997, EMBO J, V16, P441, DOI 10.1093/emboj/16.3.441; Kispert A, 1998, DEVELOPMENT, V125, P4225; Kispert A, 1996, DEVELOPMENT, V122, P3627; Klein J B, 1993, Curr Opin Nephrol Hypertens, V2, P225, DOI 10.1097/00041552-199303000-00008; Kotzin BL, 1996, CELL, V85, P303, DOI 10.1016/S0092-8674(00)81108-3; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NISHIMURA M, 1994, J EXP MED, V179, P1053, DOI 10.1084/jem.179.3.1053; RENAULD JC, 1994, ONCOGENE, V9, P1327; Sambrook J., 2002, MOL CLONING LAB MANU; Sheehan D.C., 1980, THEORY PRACTICE HIST; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; TAYA Y, 1986, EMBO J, V5, P1215, DOI 10.1002/j.1460-2075.1986.tb04349.x; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANDERPUTTEN H, 1979, CELL, V18, P109, DOI 10.1016/0092-8674(79)90359-3; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; WEENING JJ, 1986, KIDNEY INT, V29, P789, DOI 10.1038/ki.1986.68; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961	38	23	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 28	1999	18	44					5982	5990		10.1038/sj.onc.1202995	http://dx.doi.org/10.1038/sj.onc.1202995			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557087				2022-12-25	WOS:000083359100004
J	Koide, T; Asada, S; Nagata, K				Koide, T; Asada, S; Nagata, K			Substrate recognition of collagen-specific molecular chaperone HSP47 - Structural requirements and binding regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS PROTEIN HSP47; ENDOPLASMIC-RETICULUM; PROLYL HYDROXYLASE; PURIFICATION; PROCOLLAGEN; EXPRESSION; GLOMERULONEPHRITIS; GLYCOPROTEIN; ASSOCIATION; PH	Prior to secretion, procollagen molecules are correctly folded to triple helices in the endoplasmic reticulum (ER). HSP47 specifically associates with procollagen in the ER during its folding and/or modification processes and is thought to function as a collagen-specific molecular chaperone (Nagata, K, (1996) Trends Bio chem. Sci, 21, 23-26), However, structural requirements for substrate recognition and regulation of the binding have not yet been elucidated. Here, we show that a typical collagen model sequence, (Pro-Pro-Gly)(n), possesses sufficient structural information required for recognition by HSP47. A structure-activity relationship study using synthetic analogs of (Pro-Pro-Gly)(n) has revealed the requirements in both chain length and primary structure for the interaction. The substrate recognition of HSP47 has also been shown to be similar but distinct from that of prolyl 4-hydroxylase, an ER resident enzyme, Further, it has shown that the interaction of HSP47 with the substrate peptides is abolished by prolyl 4-hydroxylation of the second Pro residues in Pro-Pro-Gly triplets and that the fully prolyl 4-hydroxylated peptide, (Pro-Hyp-Gly)(n), does not interact with HSP47, We thus have proposed a model in which HSP47 dissociates from procollagen during the process of prolyl 4-hydroxylation in the ER.	Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Sakyo Ku, Kyoto 6068397, Japan; Kyoto Univ, Dept Cell Biol, Inst Frontier Med Sci, Sakyo Ku, Kyoto 6068397, Japan	Japan Science & Technology Agency (JST); Kyoto University	Nagata, K (corresponding author), Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Sakyo Ku, Kyoto 6068397, Japan.							Asada S, 1999, CELL STRUCT FUNCT, V24, P187, DOI 10.1247/csf.24.187; ATREYA PL, 1991, J BIOL CHEM, V266, P2852; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; BERG RA, 1970, J BIOL CHEM, V245, P5759; BOEDTKER H, 1956, J AM CHEM SOC, V78, P4267, DOI 10.1021/ja01598a024; CHOPRA RK, 1982, P NATL ACAD SCI-BIOL, V79, P7180, DOI 10.1073/pnas.79.23.7180; Davids JW, 1995, BIOORG CHEM, V23, P427, DOI 10.1006/bioo.1995.1029; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; KEDERSHA NL, 1981, COLLAGEN REL RES, V1, P345; KIVIRIKKO KI, 1967, J BIOL CHEM, V242, P4007; KIVIRIKKO KI, 1992, POSTTRANSLATIONAL MO, P2; Loones MT, 1998, CELL STRESS CHAPERON, V3, P237, DOI 10.1379/1466-1268(1998)003<0237:HACDDE>2.3.CO;2; MASUDA H, 1994, J CLIN INVEST, V94, P2481, DOI 10.1172/JCI117617; Masuda H, 1998, CELL STRESS CHAPERON, V3, P256, DOI 10.1379/1466-1268(1998)003<0256:EALOCB>2.3.CO;2; Nagata K, 1996, TRENDS BIOCHEM SCI, V21, P23, DOI 10.1016/0968-0004(96)80881-4; NAKAI A, 1992, J CELL BIOL, V117, P903, DOI 10.1083/jcb.117.4.903; NATSUME T, 1994, J BIOL CHEM, V269, P31224; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; PROCKOP DJ, 1979, NEW ENGL J MED, V301, P13, DOI 10.1056/NEJM197907053010104; Razzaque MS, 1997, J PATHOL, V183, P24; SAGA S, 1987, J CELL BIOL, V105, P517, DOI 10.1083/jcb.105.1.517; SAKAKIBARA S, 1968, B CHEM SOC JPN, V41, P1273, DOI 10.1246/bcsj.41.1273; Satoh M, 1996, J CELL BIOL, V133, P469, DOI 10.1083/jcb.133.2.469; Sauk JJ, 1998, CONNECT TISSUE RES, V37, P105, DOI 10.3109/03008209809028904; Sunamoto M, 1998, LAB INVEST, V78, P967; TAKECHI H, 1992, EUR J BIOCHEM, V206, P323, DOI 10.1111/j.1432-1033.1992.tb16930.x; TUDERMAN L, 1975, EUR J BIOCHEM, V52, P9, DOI 10.1111/j.1432-1033.1975.tb03967.x; Wilson R, 1998, J BIOL CHEM, V273, P9637, DOI 10.1074/jbc.273.16.9637; ZU X, 1996, SCIENCE, V272, P1606	30	49	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34523	34526		10.1074/jbc.274.49.34523	http://dx.doi.org/10.1074/jbc.274.49.34523			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574911	hybrid			2022-12-25	WOS:000083979600005
J	Weber, A; Pennise, CR; Fowler, VM				Weber, A; Pennise, CR; Fowler, VM			Tropomodulin increases the critical concentration of barbed end-capped actin filaments by converting ADP center dot P-i-actin to ADP-actin at all pointed filament ends	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRIATED-MUSCLE; F-ACTIN; BINDING; TROPOMYOSIN; PROTEIN; POLYMERIZATION; KINETICS; DEPOLYMERIZATION; THYMOSIN-BETA-4; NUCLEATION	The pointed end capping protein, tropomodulin, increases the critical concentration of barbed end capped actin, i.e. it lowers the apparent affinity of pointed ends for actin monomers, We show here that this is due to the conversion of pointed end ADP . P-i-actin (low critical concentration) to ADP-actin (high critical concentration) when 70-98% of the ends are capped by tropomodulin, We propose that this is due to the low affinity of tropomodulin for pointed ends (K-d similar to 0.3 mu M), which allows tropomodulin to rapidly exchange binding sites and transiently block access of actin monomers to all pointed ends. This leaves time for ATP hydrolysis and phosphate release to go to completion between successive monomer additions to the pointed end. When the affinity of tropomodulin for pointed ends was increased about 1000-fold by the presence of tropomyosin (K-d < 0.05 nM), capping of 95% of the ends by tropomodulin did not alter the critical concentration. However, the critical concentration did increase when the tropomodulin concentration was raised to the high values effective in the absence of tropomyosin, This may reflect transient tropomodulin binding to tropomyosin-free actin molecules at the pointed ends of the tropomyosin-actin filaments without a high affinity tropomodulin cap, i.e. the ends that determine the value of the actin critical concentration.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	Scripps Research Institute; University of Pennsylvania	Fowler, VM (corresponding author), Scripps Res Inst, Dept Cell Biol, MB24,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NHLBI NIH HHS [HL15835] Funding Source: Medline; NIGMS NIH HHS [GM34225, GM53029] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL015835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053029, R01GM034225] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almenar-Queralt A, 1999, J BIOL CHEM, V274, P28466, DOI 10.1074/jbc.274.40.28466; ASAKURA S, 1961, ARCH BIOCHEM BIOPHYS, V92, P140, DOI 10.1016/0003-9861(61)90228-4; BABCOCK GG, 1994, J BIOL CHEM, V269, P27510; BROSCHAT KO, 1990, J BIOL CHEM, V265, P21323; BRYAN J, 1988, J CELL BIOL, V106, P1553, DOI 10.1083/jcb.106.5.1553; CARLIER MF, 1988, J BIOL CHEM, V263, P817; CARLIER MF, 1991, J BIOL CHEM, V266, P1; CARLIER MF, 1986, BIOCHEMISTRY-US, V25, P7789, DOI 10.1021/bi00372a001; DE LA CRUZ EM, 1995, BIOCHEMISTRY-US, V34, P5452, DOI 10.1021/bi00016a016; Dye CA, 1998, DEVELOPMENT, V125, P1845; Fowler VM, 1996, CURR OPIN CELL BIOL, V8, P86, DOI 10.1016/S0955-0674(96)80052-4; FOWLER VM, 1990, J CELL BIOL, V111, P471, DOI 10.1083/jcb.111.2.471; Fowler VM, 1997, SOC GEN PHY, V52, P79; KASAI M, 1965, BIOCHIM BIOPHYS ACTA, V94, P494, DOI 10.1016/0926-6585(65)90058-0; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Littlefield R, 1998, ANNU REV CELL DEV BI, V14, P487, DOI 10.1146/annurev.cellbio.14.1.487; Melki R, 1996, BIOCHEMISTRY-US, V35, P12038, DOI 10.1021/bi961325o; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; NORTHROP J, 1986, J BIOL CHEM, V261, P9274; Oosawa F., 1975, THERMODYNAMICS POLYM; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; SUNG LA, 1994, BIOCHEM BIOPH RES CO, V201, P627, DOI 10.1006/bbrc.1994.1747; WEBER A, 1994, J CELL BIOL, V127, P1627, DOI 10.1083/jcb.127.6.1627; WEBER A, 1987, BIOCHEMISTRY-US, V26, P2537, DOI 10.1021/bi00383a020; WEBER A, 1992, BIOCHEMISTRY-US, V31, P6179, DOI 10.1021/bi00142a002; WEGNER A, 1979, J MOL BIOL, V131, P839, DOI 10.1016/0022-2836(79)90204-3; YOUNG CL, 1990, BIOCHEMISTRY-US, V29, P2232, DOI 10.1021/bi00461a005; [No title captured]	30	69	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34637	34645		10.1074/jbc.274.49.34637	http://dx.doi.org/10.1074/jbc.274.49.34637			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574928	hybrid			2022-12-25	WOS:000083979600022
J	Fliss, AE; Rao, J; Melville, MW; Cheetham, ME; Caplan, AJ				Fliss, AE; Rao, J; Melville, MW; Cheetham, ME; Caplan, AJ			Domain requirements of DnaJ-like (Hsp40) molecular chaperones in the activation of a steroid hormone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; FINGER-LIKE DOMAIN; SACCHAROMYCES-CEREVISIAE; ANDROGEN RECEPTOR; HUMAN HOMOLOG; HSP70; YEAST; YDJ1; BINDING; ATPASE	DnaJ-like proteins function in association with Hsp70 molecular chaperones to facilitate protein folding. We previously demonstrated that a yeast DnaJ-like protein, Ydj1p, was important for activation of heterologously expressed steroid hormone receptors (Caplan, A. J., Langley, E., Wilson, E, M,, and Vidal, J, (1995) J. Biol. Chem, 270, 5251-5257), In the present study, we analyzed Ydj1p function by assaying hormone binding to the human androgen receptor (AR) heterologously expressed in yeast. We analyzed hormone binding in strains that were wild type or deleted for the YDJ1 gene. In the deletion mutant, the AR did not bind hormone to the same extent as the wild type. Introduction of mutant forms of Ydj1p to the deletion strain revealed that the J domain is necessary but not sufficient for Ydj1p action, and that other domains of the protein are also functionally important, Of three human DnaJ-like proteins introduced into the deletion mutant, only Hdj2, which displays full domain conservation with Ydj1p, suppressed the hormone binding defect of the deletion mutant. By comparison of the domains shared by these three human proteins, and with mutants of Ydj1p that were functional, it was deduced that the cysteine-rich zinc binding domain is important for Hdj2/Ydj1p action in hormone receptor function, A model for the mechanism of DnaJ-like protein action is discussed.	CUNY Mt Sinai Sch Med, Dept Cell Biol & Anat, New York, NY 10029 USA; Univ Washington, Dept Microbiol, Seattle, WA 98195 USA; UCL, Inst Ophthalmol, Dept Pathol, London EC1V 9EL, England	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Washington; University of Washington Seattle; University of London; University College London	Caplan, AJ (corresponding author), CUNY Mt Sinai Sch Med, Dept Cell Biol & Anat, 1 Gustave L Levy Pl, New York, NY 10029 USA.	caplan@msvax.mssm.edu	Cheetham, Michael/B-4672-2011; Caplan, Avrom/GPT-0824-2022	Cheetham, Michael/0000-0001-6429-654X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49065] Funding Source: Medline; NIGMS NIH HHS [T32 GM07270] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATENCIO DP, 1992, MOL CELL BIOL, V12, P283, DOI 10.1128/MCB.12.1.283; ATENCIO J, 1994, THESIS U CALIFORNIA; Banecki B, 1996, J BIOL CHEM, V271, P14840, DOI 10.1074/jbc.271.25.14840; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; CAPLAN AJ, 1995, J BIOL CHEM, V270, P5251, DOI 10.1074/jbc.270.10.5251; Caplan AJ, 1999, TRENDS CELL BIOL, V9, P262, DOI 10.1016/S0962-8924(99)01580-9; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CHEETHAM ME, 1992, BIOCHEM J, V284, P469, DOI 10.1042/bj2840469; Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; Cheetham ME, 1996, BIOCHEM J, V319, P103, DOI 10.1042/bj3190103; CHELLAIAH A, 1993, BIOCHIM BIOPHYS ACTA, V1174, P111, DOI 10.1016/0167-4781(93)90103-K; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; Dey B, 1996, MOL BIOL CELL, V7, P91, DOI 10.1091/mbc.7.1.91; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; Fang YF, 1996, J BIOL CHEM, V271, P28697, DOI 10.1074/jbc.271.45.28697; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; GEITZ RD, 1995, YEAST, V11, P3555; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; King C, 1997, BIOCHEMISTRY-US, V36, P4067, DOI 10.1021/bi9625307; Kosano H, 1998, J BIOL CHEM, V273, P32973, DOI 10.1074/jbc.273.49.32973; LEVY EJ, 1995, FEBS LETT, V368, P435, DOI 10.1016/0014-5793(95)00704-D; Lu Z, 1998, J BIOL CHEM, V273, P5970, DOI 10.1074/jbc.273.10.5970; Lu Z, 1998, J BIOL CHEM, V273, P27824, DOI 10.1074/jbc.273.43.27824; Melville MW, 1999, J BIOL CHEM, V274, P3797, DOI 10.1074/jbc.274.6.3797; OH S, 1993, BIOCHIM BIOPHYS ACTA, V1174, P114, DOI 10.1016/0167-4781(93)90104-L; OHTSUKA K, 1993, BIOCHEM BIOPH RES CO, V197, P235, DOI 10.1006/bbrc.1993.2466; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; PURVIS IJ, 1991, GENE, V106, P35, DOI 10.1016/0378-1119(91)90563-Q; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; Terada K, 1997, J CELL BIOL, V139, P1089, DOI 10.1083/jcb.139.5.1089; Tsai J, 1996, J BIOL CHEM, V271, P9347, DOI 10.1074/jbc.271.16.9347; UNGERWICKELL E, 1985, EMBO J, V2, P1401; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0	37	39	41	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34045	34052		10.1074/jbc.274.48.34045	http://dx.doi.org/10.1074/jbc.274.48.34045			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567371	hybrid			2022-12-25	WOS:000083857500036
J	Jardim, A; Bergeson, SE; Shih, S; Carter, N; Lucas, RW; Merlin, G; Myler, PJ; Stuart, K; Ullman, B				Jardim, A; Bergeson, SE; Shih, S; Carter, N; Lucas, RW; Merlin, G; Myler, PJ; Stuart, K; Ullman, B			Xanthine phosphoribosyltransferase from Leishmania donovani - Molecular cloning, biochemical characterization, and genetic analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE; PURINE METABOLISM; TRITRICHOMONAS-FETUS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; EXPRESSION; PARASITE; SEQUENCE; NUCLEOSIDASES; CHROMOSOME	Xanthine phosphoribosyltransferase (XPRT) from Leishmania donovani is a unique enzyme that lacks a mammalian counterpart and is, therefore, a potential target for antiparasitic therapy. To investigate the enzyme at the molecular and biochemical level, a cDNA encoding the L, donovani XPRT was isolated by functional complementation of a purine auxotroph of Escherichia coli that also harbors deficiencies in the prokaryotic phosphoribosyltransferase (PRT) activities. The cDNA was then used to isolate the XPRT genomic clone. XPRT encodes a 241-amino acid protein exhibiting similar to 33% amino acid identity with the L. donovani hypoxanthine-guanine phosphoribosyltransferase (HGPRT) and significant homology with other HGPRT family members. Southern blot analysis revealed that XPRT was a single copy gene that co-localized with HGPRT within a 4.3-kilobase pair (kb) EcoRI fragment, implying that the two genes arose as a result of an ancestral duplication event. Sequencing of this EcoRI fragment confirmed that HGPRT and XPRT were organized in a head-to-tail arrangement separated by an similar to 2.2-kb intergenic region, Both the 3.2-kb XPRT mRNA and XPRT enzyme were significantly up-regulated in Delta hgprt and Delta hgprt/Delta aprt L. donovani mutants. Genetic obliteration of the XPRT locus by targeted gene replacement indicated that XPRT was not an essential gene under most conditions and that the Delta xprt null strain was competent of salvaging all purines except xanthine, XPRT was overexpressed in E, coli and the recombinant protein purified to homogeneity, Kinetic analysis revealed that the XPRT preferentially phosphoribosylated xanthine but could also recognize hypoxanthine and guanine, K-m values of 7.1, 448.0, and >100 mu M and k(cat) values of 3.5, 2.6, and similar to 0.003 s(-1) were calculated for xanthine, hypoxanthine, and guanine, respectively. The XPRT gene and XPRT protein provide the requisite molecular and biochemical reagents for subsequent studies to validate XPRT as a potential therapeutic target.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Univ Bordeaux 2, Lab Parasitol Mol, CNRS, UPRESA 5016, F-33076 Bordeaux, France; Seattle Biomed Res Inst, Seattle, WA 98109 USA	Oregon Health & Science University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Center for Infectious Disease Research	Ullman, B (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA.		Myler, Peter John/AAR-9535-2021	Myler, Peter/0000-0002-0056-0513	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI023682, R01AI023682] Funding Source: NIH RePORTER; NIAID NIH HHS [AI23682] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABLIG W, 1988, GENE, V73, P141; Allen T, 1995, MOL BIOCHEM PARASIT, V74, P99, DOI 10.1016/0166-6851(95)02475-1; ALLEN TE, 1995, MOL BIOCHEM PARASIT, V73, P133, DOI 10.1016/0166-6851(94)00105-V; BECK JT, 1993, MOL BIOCHEM PARASIT, V60, P187, DOI 10.1016/0166-6851(93)90130-P; Berens Randolph L., 1995, P89, DOI 10.1016/B978-012473345-9/50007-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Clayton C, 1998, MOL BIOCHEM PARASIT, V97, P221, DOI 10.1016/S0166-6851(98)00115-7; COMEAU AM, 1986, MOL BIOCHEM PARASIT, V21, P161, DOI 10.1016/0166-6851(86)90019-8; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; Donald RGK, 1996, J BIOL CHEM, V271, P14010, DOI 10.1074/jbc.271.24.14010; EADS JC, 1994, CELL, V78, P325, DOI 10.1016/0092-8674(94)90301-8; EELLS JT, 1983, NEUROCHEM RES, V8, P1451; FREEDMAN DJ, 1993, MOL BIOCHEM PARASIT, V62, P37, DOI 10.1016/0166-6851(93)90175-W; FUNG K, 1991, MOL BIOCHEM PARASIT, V45, P261, DOI 10.1016/0166-6851(91)90093-L; GIACOMELLO A, 1978, J BIOL CHEM, V253, P6038; GOTTLIEB M, 1985, SCIENCE, V227, P72, DOI 10.1126/science.2981117; GROGL M, 1992, AM J TROP MED HYG, V47, P117, DOI 10.4269/ajtmh.1992.47.117; HASSAN HF, 1985, EXP PARASITOL, V59, P139, DOI 10.1016/0014-4894(85)90066-9; HENDRICKSON N, 1993, MOL BIOCHEM PARASIT, V59, P15, DOI 10.1016/0166-6851(93)90003-G; Hwang HY, 1997, J BIOL CHEM, V272, P19488, DOI 10.1074/jbc.272.31.19488; Hwang HY, 1996, J BIOL CHEM, V271, P30840, DOI 10.1074/jbc.271.48.30840; Jardim A, 1997, J BIOL CHEM, V272, P8967, DOI 10.1074/jbc.272.14.8967; JOCHIMSEN B, 1975, MOL GEN GENET, V143, P85, DOI 10.1007/BF00269424; KING A, 1987, NUCLEIC ACIDS RES, V15, P10469, DOI 10.1093/nar/15.24.10469; KOSZALKA GW, 1979, J BIOL CHEM, V254, P8185; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFON SW, 1982, BIOCHEM PHARMACOL, V31, P231, DOI 10.1016/0006-2952(82)90216-7; LANGFORD CK, 1992, EXP PARASITOL, V74, P360, DOI 10.1016/0014-4894(92)90161-3; LEE MGS, 1988, NUCLEIC ACIDS RES, V16, P9567, DOI 10.1093/nar/16.20.9567; MARR JJ, 1983, J CELL BIOCHEM, V22, P187, DOI 10.1002/jcb.240220307; MILLER RL, 1972, BIOCHEMISTRY-US, V11, P4723, DOI 10.1021/bi00775a014; MILLER SI, 1988, MOL CELL BIOL, V8, P2597, DOI 10.1128/MCB.8.6.2597; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; MUSHEGIAN AR, 1994, PROTEIN SCI, V3, P1081, DOI 10.1002/pro.5560030711; OPPERDOES FR, 1993, BIOCHIMIE, V75, P231, DOI 10.1016/0300-9084(93)90081-3; SACCI JB, 1990, EXP PARASITOL, V71, P158, DOI 10.1016/0014-4894(90)90018-8; Sambrook J., 2002, MOL CLONING LAB MANU; Schumacher MA, 1996, NAT STRUCT BIOL, V3, P881, DOI 10.1038/nsb1096-881; Shih S, 1998, J BIOL CHEM, V273, P1534, DOI 10.1074/jbc.273.3.1534; Sommer JM, 1996, MOL BIOCHEM PARASIT, V78, P185, DOI 10.1016/S0166-6851(96)02623-0; Somoza JR, 1996, BIOCHEMISTRY-US, V35, P7032, DOI 10.1021/bi953072p; Tao W, 1996, BIOCHEMISTRY-US, V35, P14, DOI 10.1021/bi951898l; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUTTLE JV, 1980, J BIOL CHEM, V255, P909; Ullman B, 1997, INT J PARASITOL, V27, P203, DOI 10.1016/S0020-7519(96)00150-6; WANG CC, 1981, P NATL ACAD SCI-BIOL, V78, P6618, DOI 10.1073/pnas.78.11.6618; WILSON K, 1991, NUCLEIC ACIDS RES, V19, P5787, DOI 10.1093/nar/19.20.5787	48	46	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34403	34410		10.1074/jbc.274.48.34403	http://dx.doi.org/10.1074/jbc.274.48.34403			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567419	hybrid			2022-12-25	WOS:000083857500084
J	Komalavilas, P; Shah, PK; Jo, HJ; Lincoln, TM				Komalavilas, P; Shah, PK; Jo, HJ; Lincoln, TM			Activation of mitogen-activated protein kinase pathways by cyclic GMP and cyclic GMP-dependent protein kinase in contractile vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; NITRIC-OXIDE; MAP KINASE; DNA-SYNTHESIS; SIGNAL-TRANSDUCTION; ANGIOTENSIN-II; ENDOTHELIAL-CELLS; MESANGIAL CELLS; MAMMALIAN-CELLS; PROLIFERATION	Vascular smooth muscle cells (VSMC) exist in either a contractile or a synthetic phenotype in vitro and in vivo. The molecular mechanisms regulating phenotypic modulation are unknown. Previous studies have suggested that the serine/threonine protein kinase mediator of nitric oxide (NO) and cyclic GMP (cGMP) signaling, the cGMP-dependent protein kinase (PKG) promotes modulation to the contractile phenotype in cultured rat aortic smooth muscle cells (RASMC). Because of the potential importance of the mitogen-activated protein kinase (MAP kinase) pathways in VSMC proliferation and phenotypic modulation, the effects of PKG expression in PKG-deficient and PKG-expressing adult RASMC on MAP kinases were examined. In PKG-expressing adult RASMC, 8-para-chlorophenylthio-cGMP activated extracellular signal- regulated kinases (ERK1/2) and c-Jun N-terminal kinase (JNK). The major effect of PKG activation was increased activation by MAP kinase kinase (MEK). The cAMP analog, 8-Br-cAMP inhibited ERK1/2 activation in PKG-deficient and PKG-expressing RASMC but had no effect on JNK activity. The effects of PKG on ERK and JNK activity were additive with those of platelet-derived growth factor (PDGF), suggesting that PKG activates MEK through a pathway not used by PDGF. The stimulatory effects of cGMP on ERK and JNK activation mere also observed in low-passaged, contractile RASMC still expressing endogenous PKG, suggesting that the effects of PKG expression were not artifacts of cell transfections. These results suggest that in contractile adult RASMC, NO-cGMP signaling increases MAP kinase activity. Increased activation of these MAP kinase pathways may be one mechanism by which cGMP and PKG activation mediate c-fos induction and increased proliferation of contractile adult RASMC.	Univ Alabama Birmingham, Div Mol & Cellular Pathol, Dept Pathol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Komalavilas, P (corresponding author), Univ Alabama Birmingham, Div Mol & Cellular Pathol, Dept Pathol, Birmingham, AL 35294 USA.	padmini@path.uab.edu	ekambaram, padmini/D-3530-2015; Jo, Hanjoong/L-6216-2019	Jo, Hanjoong/0000-0003-1833-372X	NHLBI NIH HHS [HL34646, HL53426] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053426, R01HL034646] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAM LP, 1992, FEBS LETT, V302, P223, DOI 10.1016/0014-5793(92)80446-N; ADAM LP, 1996, BIOCH SMOOTH MUSCLE, P167; Begum N, 1998, J BIOL CHEM, V273, P25164, DOI 10.1074/jbc.273.39.25164; Berk BC, 1997, CIRC RES, V80, P607, DOI 10.1161/01.RES.80.5.607; Boerth NJ, 1997, J VASC RES, V34, P245, DOI 10.1159/000159231; Brown C, 1999, CIRC RES, V84, P655, DOI 10.1161/01.RES.84.6.655; CAMPBELL GR, 1985, EXP MOL PATHOL, V42, P139, DOI 10.1016/0014-4800(85)90023-1; Chiche JD, 1998, J BIOL CHEM, V273, P34263, DOI 10.1074/jbc.273.51.34263; CHILDS TJ, 1992, J BIOL CHEM, V267, P22853; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; CORNWELL TL, 1994, J VASC RES, V31, P330, DOI 10.1159/000159061; CORNWELL TL, 1994, AM J PHYSIOL-CELL PH, V267, pC1405, DOI 10.1152/ajpcell.1994.267.5.C1405; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Dey NB, 1998, CIRC RES, V82, P139; Dhaunsi GS, 1996, CARDIOVASC RES, V31, P37, DOI 10.1016/S0008-6363(95)00148-4; Drab M, 1997, FASEB J, V11, P905, DOI 10.1096/fasebj.11.11.9285489; DUFF JL, 1995, J BIOL CHEM, V270, P7161, DOI 10.1074/jbc.270.13.7161; FINGERLE J, 1989, P NATL ACAD SCI USA, V86, P8412, DOI 10.1073/pnas.86.21.8412; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; Gorenne I, 1998, AM J PHYSIOL-HEART C, V275, pH131, DOI 10.1152/ajpheart.1998.275.1.H131; GOWN AM, 1986, AM J PATHOL, V125, P191; GRUETTER CA, 1980, J PHARMACOL EXP THER, V214, P9; Gudi T, 1996, J BIOL CHEM, V271, P4597; HABY C, 1994, J NEUROCHEM, V62, P496; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HASSID A, 1994, AM J PHYSIOL, V267, pH1040, DOI 10.1152/ajpheart.1994.267.3.H1040; Hayashi K, 1999, J CELL BIOL, V145, P727, DOI 10.1083/jcb.145.4.727; Hood J, 1998, J BIOL CHEM, V273, P23504, DOI 10.1074/jbc.273.36.23504; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; ISHIDA Y, 1992, FEBS LETT, V310, P41, DOI 10.1016/0014-5793(92)81142-9; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; JONZON B, 1985, J CELL PHYSIOL, V124, P451, DOI 10.1002/jcp.1041240314; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KARIYA K, 1989, ATHEROSCLEROSIS, V80, P143, DOI 10.1016/0021-9150(89)90022-1; KATOCH SS, 1995, AM J PHYSIOL-HEART C, V269, pH222, DOI 10.1152/ajpheart.1995.269.1.H222; KHALIL RA, 1993, AM J PHYSIOL, V265, pC406, DOI 10.1152/ajpcell.1993.265.2.C406; Komalavilas P, 1996, J BIOL CHEM, V271, P21933, DOI 10.1074/jbc.271.36.21933; LERMIOGLU F, 1991, BIOCHEM J, V274, P323, DOI 10.1042/bj2740323; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LINCOLN TM, 1990, AM J PHYSIOL, V258, pC399, DOI 10.1152/ajpcell.1990.258.3.C399; LINCOLN TM, 1994, CYCLIC GMPBIOCH PHYS; MAJESKY MW, 1992, CIRC RES, V71, P759, DOI 10.1161/01.RES.71.4.759; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MORISAKI N, 1988, ATHEROSCLEROSIS, V71, P165, DOI 10.1016/0021-9150(88)90140-2; MOSSE PRL, 1985, LAB INVEST, V53, P556; NAKAKI T, 1990, EUR J PHARM-MOLEC PH, V189, P347, DOI 10.1016/0922-4106(90)90031-R; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; Pollman MJ, 1996, CIRC RES, V79, P748, DOI 10.1161/01.RES.79.4.748; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROSS R, 1995, ANN NY ACAD SCI, V748, P1; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHWARTZ SM, 1990, PHYSIOL REV, V70, P1177, DOI 10.1152/physrev.1990.70.4.1177; Sciorati C, 1997, BRIT J PHARMACOL, V122, P687, DOI 10.1038/sj.bjp.0701413; Smolenski A, 1998, N-S ARCH PHARMACOL, V358, P134, DOI 10.1007/PL00005234; SOUNESS JE, 1992, BIOCHEM PHARMACOL, V44, P857, DOI 10.1016/0006-2952(92)90116-Z; SOUTHGATE K, 1990, ATHEROSCLEROSIS, V82, P113, DOI 10.1016/0021-9150(90)90150-H; Sugimoto T, 1996, J BIOL CHEM, V271, P544, DOI 10.1074/jbc.271.1.544; Suhasini M, 1998, MOL CELL BIOL, V18, P6983, DOI 10.1128/MCB.18.12.6983; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; WATSON MH, 1993, CIRC RES, V73, P109, DOI 10.1161/01.RES.73.1.109; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; WYATT TA, 1998, AM J PHYSIOL, V274, pH449; Yu SM, 1997, CIRCULATION, V95, P1269; ZEILIG CE, 1977, P NATL ACAD SCI USA, V74, P1052, DOI 10.1073/pnas.74.3.1052	67	119	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34301	34309		10.1074/jbc.274.48.34301	http://dx.doi.org/10.1074/jbc.274.48.34301			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567406	hybrid			2022-12-25	WOS:000083857500071
J	Meacham, GC; Browne, BL; Zhang, WY; Kellermayer, R; Bedwell, DM; Cyr, DM				Meacham, GC; Browne, BL; Zhang, WY; Kellermayer, R; Bedwell, DM; Cyr, DM			Mutations in the yeast Hsp40 chaperone protein Ydj1 cause defects in Axl1 biogenesis and pro-a-factor processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC DNAJ HOMOLOG; HEAT-SHOCK PROTEINS; BUD-SITE SELECTION; SACCHAROMYCES-CEREVISIAE; MOLECULAR CHAPERONES; MATING PHEROMONE; STRESS PROTEINS; IN-VIVO; HSP70; TRANSLOCATION	The heat shock protein (Hsp) 70/Hsp40 chaperone system plays an essential role in cell physiology, but few of its in vivo functions are known, We report that biogenesis of Axl1p, an insulinase-like endoprotease from yeast, is dependent upon the cytosolic Hsp40 protein Ydj1p, Axil is responsible for cleavage of the P2 processing intermediate of pro-a-factor, a mating pheromone, to its mature form. Mutant ydj1 strains exhibited a severe mating defect, which correlated with a 90% reduction in a-factor secretion. Reduced levels of a-factor export were caused by defects in the endoproteolytic processing of P2, which led to its intracellular accumulation. Defective P2 processing correlated with the reduction in the steady state level of active Axl1p, Two mechanisms were uncovered to explain why Axl1p activity was diminished in ydj1 strains. First, AXL1 mRNA levels were reduced ydj1 strains. Second, the half-life of newly synthesized Axl1p was greatly diminished in ydj1 strains. Collectively, these data indicate Ydj1p functions to promote AXL1 mRNA accumulation and in addition appears to facilitate the proper folding of nascent Axl1p, This study is the first to suggest a role Sor Pdj1p in RNA metabolism and identifies Axl1p as an in vivo substrate of the Hsp70/Ydj1p chaperone system.	Univ Alabama Birmingham, Sch Med, Dept Cell Biol, Med Ctr, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Sch Med, Dept Microbiol, Med Ctr, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Sch Dent, Dept Microbiol, Med Ctr, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Sch Dent, Dept Cell Biol, Med Ctr, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Cyr, DM (corresponding author), Univ Alabama Birmingham, Sch Med, Dept Cell Biol, Med Ctr, 652 McCallum Bas Hlth Sci Bldg, Birmingham, AL 35294 USA.	dcyr@cellbio.bhs.uab.edu		Bedwell, David/0000-0002-6605-818X; Cyr, Douglas/0000-0002-4928-3414	NIDDK NIH HHS [R01DK50032, DKP5053090] Funding Source: Medline; NIGMS NIH HHS [R01GM56981, R01 GM056981] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK053090] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056981] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMES N, 1995, SCIENCE, V270, P464, DOI 10.1126/science.270.5235.464; ANG D, 1991, J BIOL CHEM, V266, P24233; ATENCIO DP, 1992, MOL CELL BIOL, V12, P283, DOI 10.1128/MCB.12.1.283; Becker J, 1996, MOL CELL BIOL, V16, P4378; BONETTI B, 1995, J MOL BIOL, V251, P334, DOI 10.1006/jmbi.1995.0438; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; Brizzio V, 1996, J CELL BIOL, V135, P1727, DOI 10.1083/jcb.135.6.1727; Brodsky JL, 1998, BIOCHEMISTRY-US, V37, P18045, DOI 10.1021/bi980900g; Browne BL, 1996, J BACTERIOL, V178, P1712, DOI 10.1128/jb.178.6.1712-1719.1996; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; CAPLAN AJ, 1995, J BIOL CHEM, V270, P5251, DOI 10.1074/jbc.270.10.5251; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; Chen P, 1997, J CELL BIOL, V136, P251, DOI 10.1083/jcb.136.2.251; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; CYR DM, 1995, FEBS LETT, V359, P129, DOI 10.1016/0014-5793(95)00024-4; CYR DM, 1992, J BIOL CHEM, V267, P20927; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; CYR DM, 1994, J BIOL CHEM, V269, P9798; CYR DM, 1997, GUIDEBOOK MOL CHAPER, P89; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; Dey B, 1996, MOL BIOL CELL, V7, P91, DOI 10.1091/mbc.7.1.91; Fedorov AN, 1997, J BIOL CHEM, V272, P32715, DOI 10.1074/jbc.272.52.32715; FUJITA A, 1994, NATURE, V372, P567, DOI 10.1038/372567a0; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Henics T, 1999, J BIOL CHEM, V274, P17318, DOI 10.1074/jbc.274.24.17318; JACKSON CL, 1990, CELL, V63, P1039, DOI 10.1016/0092-8674(90)90507-B; JULIUS D, 1984, CELL, V36, P309, DOI 10.1016/0092-8674(84)90224-1; Kim S, 1998, P NATL ACAD SCI USA, V95, P12860, DOI 10.1073/pnas.95.22.12860; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; Kuchler K, 1990, CURR OPIN CELL BIOL, V2, P617, DOI 10.1016/0955-0674(90)90102-K; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; Lee DH, 1996, MOL CELL BIOL, V16, P4773; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Lu Z, 1998, J BIOL CHEM, V273, P5970, DOI 10.1074/jbc.273.10.5970; Lu Z, 1998, J BIOL CHEM, V273, P27824, DOI 10.1074/jbc.273.43.27824; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; Meacham GC, 1999, EMBO J, V18, P1492, DOI 10.1093/emboj/18.6.1492; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; Miseta A, 1999, J BIOL CHEM, V274, P5939, DOI 10.1074/jbc.274.9.5939; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; Netzer WJ, 1998, TRENDS BIOCHEM SCI, V23, P68, DOI 10.1016/S0968-0004(97)01171-7; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P732; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIKORSKI RS, 1989, GENETICS, V122, P19; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STEINER DF, 1992, J BIOL CHEM, V267, P23435; Teter SA, 1999, CELL, V97, P755, DOI 10.1016/S0092-8674(00)80787-4; Tsai J, 1996, J BIOL CHEM, V271, P9347, DOI 10.1074/jbc.271.16.9347; Yaglom JA, 1996, MOL CELL BIOL, V16, P3679; ZIEGELHOFFER T, 1995, J BIOL CHEM, V270, P10412, DOI 10.1074/jbc.270.18.10412	54	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34396	34402		10.1074/jbc.274.48.34396	http://dx.doi.org/10.1074/jbc.274.48.34396			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567418	hybrid			2022-12-25	WOS:000083857500083
J	Petukhova, G; Stratton, SA; Sung, P				Petukhova, G; Stratton, SA; Sung, P			Single strand DNA binding and annealing activities in the yeast recombination factor Rad59	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN-A; SACCHAROMYCES-CEREVISIAE; EXCHANGE; CATALYSIS	Saccharomyces cerevisiae RAD59 gene is required for homologous recombination processes and normal level of resistance to ionizing radiation. To study the biochemical functions of Rad59, it was overproduced in yeast and purified to near homogeneity. Rad59 binds DNA, showing much higher affinity for ssDNA than dsDNA. Rad59 also anneals complementary DNA strands, and order of addition experiments indicate that maximal annealing efficiency is achieved when both complementary DNA strands are present upon addition of Rad59, Thus, Rad59 resembles its homolog Rad52 in being able to bind ssDNA and anneal complementary DNA strands. However, unlike Rad52, DNA annealing by Rad59 is not accelerated by the ssDNA binding factor RPA. DNA binding and strand annealing are likely to be important for the biological functions of Rad59 in general recombination and in the single-strand annealing pathway of recombination.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio	Sung, P (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, 7703 Floyd Curl Dr, San Antonio, TX 78245 USA.				NIA NIH HHS [T32 AG00165] Funding Source: Medline; NIEHS NIH HHS [R01 ES07061] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000165] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bai Y, 1996, GENE DEV, V10, P2025, DOI 10.1101/gad.10.16.2025; BAI Y, 1999, IN PRESS GENETICS; MELLOR J, 1983, GENE, V24, P1, DOI 10.1016/0378-1119(83)90126-9; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Shinohara A, 1998, GENES CELLS, V3, P145, DOI 10.1046/j.1365-2443.1998.00176.x; Sugiyama T, 1998, P NATL ACAD SCI USA, V95, P6049, DOI 10.1073/pnas.95.11.6049; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194	16	65	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					33839	33842		10.1074/jbc.274.48.33839	http://dx.doi.org/10.1074/jbc.274.48.33839			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567339	hybrid			2022-12-25	WOS:000083857500004
J	Schulenberg, B; Aggeler, R; Murray, J; Capaldi, RA				Schulenberg, B; Aggeler, R; Murray, J; Capaldi, RA			The gamma epsilon-c subunit interface in the ATP synthase of Escherichia coli - Cross-linking of the epsilon subunit to the c subunit ring does not impair enzyme function, that of gamma to c subunits leads to uncoupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; F-0 PARTS; ADENOSINE-TRIPHOSPHATASE; F0F1-ATP SYNTHASE; H+-ATPASE; F1; F1-ATPASE; ROTATION; RECONSTITUTION; STOICHIOMETRY	Mutants with a cysteine residue in the gamma subunit at position 207 and the epsilon subunit at position 31 were expressed in combination with a c-dimer construct, which contains a single cysteine at position 42 of the second c subunit, These mutants are called gamma Y207C/cc'Q42C and epsilon E31C/cc'Q42C, respectively. Cross-linking of epsilon to the c subunit ring was obtained almost to completion without significant effect on any enzyme function, i.e. ATP hydrolysis, ATP synthesis, and ATP hydrolysis-driven proton translocation were all close to that of wild type. The gamma subunit could also be linked to the c subunit ring in more than 90% yield, but this affected coupling. Thus, ATP hydrolysis was increased 2.5-fold, ATP synthesis was dramatically decreased, and ATP hydrolysis-driven proton translocation was abolished, as measured by the 9-amino-6-chloro-2-methoxyacridinequenching method. These results for epsilon E31C/cc'Q42C indicate that the c subunit ring rotates with the central stalk element. That the gamma-epsilon cross-linked enzyme retains ATPase activity also argues for a gamma epsilon-c subunit rotor. However, the uncoupling induced by cross-linking of gamma to the c subunit ring points to important conformational changes taking place in the gamma epsilon-c subunit interface during this. Blocking these structural changes by cross-linking leads to a proton leak within the F-o.	Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA	University of Oregon	Capaldi, RA (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.				NHLBI NIH HHS [HL 24526] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024526] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1992, J BIOL CHEM, V267, P21355; Aggeler R, 1997, J BIOL CHEM, V272, P19621, DOI 10.1074/jbc.272.31.19621; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; AGGELER R, 1987, BIOCHEMISTRY-US, V26, P7107, DOI 10.1021/bi00396a036; Battey, 1986, BASIC METHODS MOL BI; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; Bottcher B, 1998, J MOL BIOL, V281, P757, DOI 10.1006/jmbi.1998.1957; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Bulygin VV, 1998, J BIOL CHEM, V273, P31765, DOI 10.1074/jbc.273.48.31765; Dimroth P, 1999, P NATL ACAD SCI USA, V96, P4924, DOI 10.1073/pnas.96.9.4924; Dmitriev OY, 1999, P NATL ACAD SCI USA, V96, P7785, DOI 10.1073/pnas.96.14.7785; DOWNER NW, 1976, BIOCHEMISTRY-US, V15, P2930, DOI 10.1021/bi00658a036; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; FOSTER DL, 1979, J BIOL CHEM, V254, P8230; Hermolin J, 1999, J BIOL CHEM, V274, P17011, DOI 10.1074/jbc.274.24.17011; Jones PC, 1998, J BIOL CHEM, V273, P29701, DOI 10.1074/jbc.273.45.29701; Ketchum CJ, 1998, J BIOL CHEM, V273, P22292, DOI 10.1074/jbc.273.35.22292; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4134, DOI 10.1021/bi00313a019; Maniatis T., 1982, MOL CLONING LAB MANU; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; Rodgers AJW, 1998, J BIOL CHEM, V273, P29406, DOI 10.1074/jbc.273.45.29406; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SCHNEIDER E, 1987, MICROBIOL REV, V51, P477, DOI 10.1128/MMBR.51.4.477-497.1987; Schulenberg B, 1997, EUR J BIOCHEM, V249, P134, DOI 10.1111/j.1432-1033.1997.t01-1-00134.x; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; Tang CL, 1996, J BIOL CHEM, V271, P3018, DOI 10.1074/jbc.271.6.3018; Watts SD, 1997, J BIOL CHEM, V272, P15065, DOI 10.1074/jbc.272.24.15065; Wilkens S, 1998, BBA-BIOENERGETICS, V1365, P93, DOI 10.1016/S0005-2728(98)00048-6; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609	38	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34233	34237		10.1074/jbc.274.48.34233	http://dx.doi.org/10.1074/jbc.274.48.34233			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567396	hybrid			2022-12-25	WOS:000083857500061
J	Sooy, K; Schermerhorn, T; Noda, M; Surana, M; Rhoten, WB; Meyer, M; Fleischer, N; Sharp, GWG; Christakos, S				Sooy, K; Schermerhorn, T; Noda, M; Surana, M; Rhoten, WB; Meyer, M; Fleischer, N; Sharp, GWG; Christakos, S			Calbindin-D-28k controls [Ca2+](i) and insulin release - Evidence obtained from calbindin-D-28k knockout mice and beta cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; RAT PANCREATIC-ISLETS; VITAMIN-D DEFICIENCY; FUNCTIONAL CONSIDERATIONS; 1,25 DIHYDROXYVITAMIN-D3; INTRACELLULAR CA2+; MOLECULAR-BIOLOGY; CHANNEL CURRENTS; TRANSGENIC MOUSE; SECRETION	The role of the calcium-binding protein, calbindin-D-28k in potassium/depolarization-stimulated increases in the cytosolic free Ca2+ concentration ([Ca2+](i)) and insulin release was investigated in pancreatic islets from calbindin-D-28k nullmutant mice (knockouts; KO) or wild type mice and beta cell lines stably transfected and overexpressing calbindin. Using single islets from KO mice and stimulation with 45 mM KCl, the peak of [Ca2+](i) was 3.5-fold greater in islets from KO mice compared with wild type islets (p < 0.01) and [Ca2+](i) remained higher during the plateau phase. In addition to the increase in [Ca2+](i) in response to KCl there was also a significant increase in insulin release in islets isolated from KO mice. Evidence for modulation by calbindin of [Ca2+](i) and insulin release was also noted using beta cell lines. Rat calbindin was stably expressed in beta TC-3 and beta HC-13 cells. In response to depolarizing concentrations of K+, insulin release was decreased by 45-47% in calbindin expressing beta TC cells and was decreased by 70-80% in calbindin expressing beta HC cells compared with insulin release from vector transfected beta TC or beta HC cells (p < 0.01). In addition, the K+-stimulated intracellular calcium peak was markedly inhibited in calbindin expressing beta HC cells compared with vector transfected cells (225 nM versus 1,100 nm, respectively). Buffering of the depolarization-induced rise in [Ca2+](i) was also observed in calbindin expressing beta TC cells. In summary, our findings, using both isolated islets from calbindin-D-28k KO mice and beta cell lines, establish a role for calbindin in the modulation of depolarization-stimulated insulin release and suggest that calbindin can control the rate of insulin release via regulation of [Ca2+](i).	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; Grad Sch Biomed Sci, Newark, NJ 07103 USA; Cornell Univ, New York State Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA; Marshall Univ, Sch Med, Dept Anat Cell & Neurobiol, Huntington, WV USA; Max Planck Inst, Dept Neurochem, D-82152 Martinsried, Germany; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Ctr Diabet Res & Training, Bronx, NY 10461 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Cornell University; Marshall University; Max Planck Society; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Christakos, S (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, 185 S Orange Ave, Newark, NJ 07103 USA.		Schermerhorn, Thomas/AAC-5116-2022; Noda, Mitsuhiko/W-3905-2019	Schermerhorn, Thomas/0000-0002-6800-0969; Noda, Mitsuhiko/0000-0003-0413-4631	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK055050, R01DK054243, R01DK038961] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 55050, DK54243, DK38961] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Airaksinen MS, 1997, P NATL ACAD SCI USA, V94, P1488, DOI 10.1073/pnas.94.4.1488; ARKHAMMAR P, 1994, J BIOL CHEM, V269, P2743; Ausubel FM, 1992, CURRENT PROTOCOLS MO; Bourlon PM, 1996, J ENDOCRINOL, V148, P223, DOI 10.1677/joe.0.1480223; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRONNER F, 1989, AM J PHYSIOL, V257, pF707, DOI 10.1152/ajprenal.1989.257.5.F707; CELIO MR, 1990, NEUROSCIENCE, V35, P375, DOI 10.1016/0306-4522(90)90091-H; CHARD PS, 1995, P NATL ACAD SCI USA, V92, P5144, DOI 10.1073/pnas.92.11.5144; CHARD PS, 1993, J PHYSIOL-LONDON, V472, P341, DOI 10.1113/jphysiol.1993.sp019950; CHERTOW BS, 1983, ENDOCRINOLOGY, V113, P1511, DOI 10.1210/endo-113-4-1511; Christakos S., 1997, Vitamin D., P209; CHRISTAKOS S, 1989, ENDOCR REV, V10, P3, DOI 10.1210/edrv-10-1-3; CHRISTAKOS S, 1987, METHOD ENZYMOL, V139, P534; CHRISTAKOS S, 1979, BIOCHEM BIOPH RES CO, V89, P56, DOI 10.1016/0006-291X(79)90942-2; CHRISTAKOS S, 1995, ENDOCRINE REV MONOGR, V4, P108; CLARK SA, 1980, CELL TISSUE RES, V209, P515; CLARK SA, 1981, DIABETES, V30, P382, DOI 10.2337/diabetes.30.5.382; DAMBRA R, 1990, ENDOCRINOLOGY, V126, P2815, DOI 10.1210/endo-126-6-2815; EFRAT S, 1993, DIABETES, V42, P901, DOI 10.2337/diabetes.42.6.901; EPSTEIN PN, 1989, CELL, V58, P1067, DOI 10.1016/0092-8674(89)90505-9; Guo Q, 1998, P NATL ACAD SCI USA, V95, P3227, DOI 10.1073/pnas.95.6.3227; HEIMBERG H, 1993, EMBO J, V12, P2873, DOI 10.1002/j.1460-2075.1993.tb05949.x; HEIZMANN CW, 1991, TRENDS BIOCHEM SCI, V16, P98, DOI 10.1016/0968-0004(91)90041-S; Jan CR, 1996, J BIOL CHEM, V271, P15478, DOI 10.1074/jbc.271.26.15478; JOHNSON JA, 1994, AM J PHYSIOL, V267, pE356, DOI 10.1152/ajpendo.1994.267.3.E356; KADOWAKI S, 1984, J CLIN INVEST, V73, P759, DOI 10.1172/JCI111269; KIKUCHI M, 1974, DIABETES, V23, P550, DOI 10.2337/diab.23.6.550; KOMATSU M, 1995, P NATL ACAD SCI USA, V92, P10728, DOI 10.1073/pnas.92.23.10728; Krueger KA, 1999, DIABETES, V48, P499, DOI 10.2337/diabetes.48.3.499; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; LEE S, 1994, ENDOCRINOLOGY, V134, P1602, DOI 10.1210/en.134.4.1602; LI ZH, 1995, J PHYSIOL-LONDON, V488, P601, DOI 10.1113/jphysiol.1995.sp020993; Liang Y, 1996, AM J PHYSIOL-ENDOC M, V270, pE846, DOI 10.1152/ajpendo.1996.270.5.E846; LIEDO PM, 1992, NEURON, V9, P943; MALAISSE WJ, 1980, CANCER RES, V40, P3827; MATTSON MP, 1991, NEURON, V6, P41, DOI 10.1016/0896-6273(91)90120-O; Noda M, 1996, DIABETES, V45, P1766, DOI 10.2337/diabetes.45.12.1766; NORMAN AW, 1980, SCIENCE, V209, P823, DOI 10.1126/science.6250216; OKAZAKI K, 1994, J BIOL CHEM, V269, P6149; PANSINI AR, 1984, J BIOL CHEM, V259, P9735; POLLOCK AS, 1995, J BIOL CHEM, V270, P16291, DOI 10.1074/jbc.270.27.16291; RADVANYI F, 1993, MOL CELL BIOL, V13, P4223, DOI 10.1128/MCB.13.7.4223; Reddy D, 1997, P NATL ACAD SCI USA, V94, P1961, DOI 10.1073/pnas.94.5.1961; REGAZZI R, 1990, J BIOL CHEM, V265, P15003; RHOTEN WB, 1985, ENDOCRINOLOGY, V117, P674, DOI 10.1210/endo-117-2-674; RHOTEN WB, 1994, ENDOCRINE, V2, P989; RIBAR TJ, 1995, J BIOL CHEM, V270, P28688, DOI 10.1074/jbc.270.48.28688; RIBAR TJ, 1995, ENDOCRINOLOGY, V136, P106, DOI 10.1210/en.136.1.106; RORSMAN P, 1989, NATURE, V341, P233, DOI 10.1038/341233a0; ROTH J, 1982, ENDOCRINOLOGY, V110, P2216, DOI 10.1210/endo-110-6-2216; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; SONNENBERG J, 1984, ENDOCRINOLOGY, V115, P640, DOI 10.1210/endo-115-2-640; SORENSON RL, 1991, DIABETES, V40, P1365, DOI 10.2337/diabetes.40.11.1365; VELASCO JM, 1989, Q J EXP PHYSIOL CMS, V74, P367, DOI 10.1113/expphysiol.1989.sp003280; WASSERMA.RH, 1966, SCIENCE, V152, P791, DOI 10.1126/science.152.3723.791; WATKINS DT, 1991, DIABETES, V40, P1063, DOI 10.2337/diabetes.40.8.1063; Weaver CD, 1996, J BIOL CHEM, V271, P12977, DOI 10.1074/jbc.271.22.12977; YADA T, 1989, J BIOL CHEM, V264, P2455	58	90	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34343	34349		10.1074/jbc.274.48.34343	http://dx.doi.org/10.1074/jbc.274.48.34343			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567411	hybrid			2022-12-25	WOS:000083857500076
J	Choi, CY; Kim, YH; Kwon, HJ; Kim, Y				Choi, CY; Kim, YH; Kwon, HJ; Kim, Y			The homeodomain protein NK-3 recruits Groucho and a histone deacetylase complex to repress transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEOBOX GENES; N-COR; COREPRESSOR; DOMAIN; CHROMATIN; REGULATOR; MSIN3A; FAMILY; HAIRY; ACTS	Transcriptional repression by sequence-specific DNA binding factors is mediated by the recruitment of a corepressor complex to the promoter region. The NK-3 homeodomain protein is a transcriptional repressor that recruits the nuclear protein kinase, homeodomain interacting protein kinase 2 (HIPK2). Here we show that HIPK2 is a component of a corepressor complex containing Groucho and a histone deacetylase complex. Groucho, like HIPK2, acts as a corepressor for NK-3 and binds to NK-3 and HlPK2. Moreover, HIPK2 appears to regulate the corepressor activity of Groucho. Transcriptional repression by NK-3 and Groucho is relieved by the histone deacetylase inhibitor trichostatin A, and both NK-3 and Groucho directly interact with the histone deacetylase HDAC1 that is associated with mSin3A in vivo. Recruitment of the histone deacetylase complex by NK-3 decreases the acetylated histones that are associated with the target gene promoter. These results indicate that NK-3 represses transcription by recruiting a complex containing Groucho and a histone deacetylase complex that leads to histone modification on chromatin and suggest that HIPK2 may play a regulatory role in the corepressor complex formation.	NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA; Georgetown Univ, Dept Radiat Med, Washington, DC 20007 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Georgetown University	Kim, Y (corresponding author), NHLBI, Mol Cardiol Lab, NIH, Bldg 10,Rm 8N228, Bethesda, MD 20892 USA.		권, 호정/AAS-3642-2021					Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Chen GQ, 1998, MOL CELL BIOL, V18, P7259, DOI 10.1128/MCB.18.12.7259; Crane-Robinson C, 1998, TRENDS GENET, V14, P477, DOI 10.1016/S0168-9525(98)01621-7; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Jimenez G, 1997, GENE DEV, V11, P3072, DOI 10.1101/gad.11.22.3072; Kadosh D, 1998, MOL CELL BIOL, V18, P5121, DOI 10.1128/MCB.18.9.5121; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; KIM YS, 1989, P NATL ACAD SCI USA, V86, P7716, DOI 10.1073/pnas.86.20.7716; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lee YM, 1997, J BIOL CHEM, V272, P17531, DOI 10.1074/jbc.272.28.17531; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	23	138	140	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33194	33197		10.1074/jbc.274.47.33194	http://dx.doi.org/10.1074/jbc.274.47.33194			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559189	hybrid			2022-12-25	WOS:000083745200005
J	Nagarajan, RP; Zhang, JM; Li, W; Chen, Y				Nagarajan, RP; Zhang, JM; Li, W; Chen, Y			Regulation of Smad7 promoter by direct association with Smad3 and Smad4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-INDUCED TRANSCRIPTION; MAD-RELATED PROTEIN; TGF-BETA; SIGNALING PATHWAYS; BINDING-PROTEIN; RECEPTOR; CELLS; GENE; PHOSPHORYLATION; ACTIVATION	Smad7 is a regulatory Smad protein that is able to antagonize signal transduction by transforming growth factor-beta (TGF-beta) and activin receptors. To characterize the regulation of Smad7 at the transcriptional level, we isolated the promoter region of the mouse Smad7 gene. When the Smad7 promoter luciferase reporter gene (-408 and +112 bp) was expressed in human hepatoma (HepG2) cells, its transcriptional activity was increased following TGF-beta or activin treatment. In addition, this region of the Smad7 promoter was stimulated by ectopic expression of Smad3 as well as constitutively active TGF-beta and activin receptors, indicating that Smad7 transcription was modulated by the signaling downstream those two receptors. A gel mobility shift assay indicated that a DNA fragment spanning -408 to -126 base pairs (bp) was able to directly bind purified Smad4. Furthermore, a consensus Smad3-Smad4 binding element (SEE) was discovered in this region of the promoter with a palindromic sequence of GTCTAGAC. A 33-bp Smad7 promoter fragment containing this SEE was able to bind Smad3 and Smad4. In human embryonic kidney 293 cells, the expression of constitutively active TGF-beta type I receptor was able to induce the formation of a Smad3- and Smad4-containing nuclear protein complex that bound the SEE. In HepG2 cells, TGF-beta 1 treatment could induce the formation of an endogenous SEE-binding complex. Taken together, these data provided the first evidence that Smad7 transcription is regulated by TGF-beta and activin signaling through direct binding of Smad3 and Smad4 to the Smad7 promoter.	Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Chen, Y (corresponding author), Indiana Univ, Sch Med, Dept Med & Mol Genet, IB130,975 W Walnut St, Indianapolis, IN 46202 USA.		N, Rajendra Prasad/X-1743-2019	N, Rajendra Prasad/0000-0002-3937-8735				Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Attisano L, 1996, MOL CELL BIOL, V16, P1066; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Bhushan A, 1998, DEV BIOL, V200, P260, DOI 10.1006/dbio.1998.8965; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen Y, 1997, P NATL ACAD SCI USA, V94, P12938, DOI 10.1073/pnas.94.24.12938; Chen Y, 1996, P NATL ACAD SCI USA, V93, P12992, DOI 10.1073/pnas.93.23.12992; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Ishisaki A, 1998, J BIOL CHEM, V273, P24293, DOI 10.1074/jbc.273.38.24293; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu B, 1999, MOL CELL BIOL, V19, P424; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakayama T, 1998, DEVELOPMENT, V125, P857; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Takase M, 1998, BIOCHEM BIOPH RES CO, V244, P26, DOI 10.1006/bbrc.1998.8200; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Yamamoto N, 1997, BIOCHEM BIOPH RES CO, V238, P574, DOI 10.1006/bbrc.1997.7325; Zauberman A, 1997, ONCOGENE, V15, P1705, DOI 10.1038/sj.onc.1201348; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	46	196	208	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33412	33418		10.1074/jbc.274.47.33412	http://dx.doi.org/10.1074/jbc.274.47.33412			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559222	hybrid			2022-12-25	WOS:000083745200038
J	Shibatani, T; Kramer, G; Hardesty, B; Horowitz, PM				Shibatani, T; Kramer, G; Hardesty, B; Horowitz, PM			Domain separation precedes global unfolding of rhodanese	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE LIVER RHODANESE; CONFORMATIONAL-CHANGES; EXPRESSION; PROTEINS; TERMINUS	The enzyme rhodanese was investigated for the conformational transition associated with its urea unfolding. When rhodanese was treated with 0 or 3 M urea, the activity was not significantly affected. 4.25 M urea treatment led to a time-dependent loss of activity in 60 min. Rhodanese was completely inactivated within 2 min in 6 M urea. The 1,1'-bi(4-anilino)naphthalene-5,5'-disulfonic acid fluorescence intensity was not significantly increased during 0, 3, and 6 M urea equilibrations, and the fluorescence was dramatically increased with 4.25 M urea, indicating that hydrophobic surfaces are exposed. After 0 and 3 RI urea equilibration, rhodanese was not significantly proteolyzed with trypsin, Treatment with 4.25 M urea led to simultaneous formation of major 12-, 15.9-, 17-, and 21.2-kDa fragments, followed by progressive emergence of smaller peptides, The N termini of the 17- and 21.2-kDa bands were those of intact rhodanese, The N terminus of the 15.9-kDa band starts at the end of the interdomain tether, The 12-kDa band beans with either residue 183 or residue 187, The size and sequence information suggest that the 17- and 15.9-kDa bands correspond to the two domains. The 21.2- and 12-kDa bands appear to be generated through one-site tryptic cleavage, It is concluded that urea disrupts interaction between the two domains, increasing the accessibility of the interdomain tether that can be digested by trypsin, The released domains have increased proteolytic susceptibility and produce smaller peptides, which may represent subdomains of rhodanese.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA; Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Austin	Horowitz, PM (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.				NIGMS NIH HHS [GM25177] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HOROWITZ P, 1983, J BIOL CHEM, V258, P1614; HOROWITZ PM, 1987, J BIOL CHEM, V262, P14544; HOROWITZ PM, 1993, J BIOL CHEM, V268, P2500; HOROWITZ PM, 1992, J BIOL CHEM, V267, P19464; KOJ A, 1975, FEBS LETT, V57, P42, DOI 10.1016/0014-5793(75)80148-7; LUO GX, 1993, J BIOL CHEM, V268, P10246; MENDOZA JA, 1991, J BIOL CHEM, V266, P13587; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MERRILL GA, 1993, J BIOL CHEM, V268, P15611; MILLER DM, 1991, J BIOL CHEM, V266, P4686; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PLOEGMAN JH, 1978, J MOL BIOL, V123, P557, DOI 10.1016/0022-2836(78)90207-3; PLOEGMAN JH, 1979, J MOL BIOL, V127, P149, DOI 10.1016/0022-2836(79)90236-5; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; Trevino RJ, 1998, J BIOL CHEM, V273, P27841, DOI 10.1074/jbc.273.43.27841; TRUMPOWER BL, 1974, BIOCHEM BIOPH RES CO, V57, P532, DOI 10.1016/0006-291X(74)90965-6; WASYLEWSKI Z, 1982, BIOCHIM BIOPHYS ACTA, V701, P12, DOI 10.1016/0167-4838(82)90305-3	21	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33795	33799		10.1074/jbc.274.47.33795	http://dx.doi.org/10.1074/jbc.274.47.33795			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559274	hybrid			2022-12-25	WOS:000083745200090
J	Asahi, M; Kimura, Y; Kurzydlowski, R; Tada, M; MacLennan, DH				Asahi, M; Kimura, Y; Kurzydlowski, R; Tada, M; MacLennan, DH			Transmembrane helix M6 in sarco(endo)plasmic reticulum Ca2+-ATPase forms a functional interaction site with phospholamban - Evidence for physical, interactions at other sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; CA2+ TRANSPORT; MYOCARDIAL-CONTRACTILITY; CYTOPLASMIC DOMAIN; BINDING; ATPASE; PUMP; MUTAGENESIS; ASSOCIATION; MECHANISM	In an earlier study (Kimura, Y., Kurzydlowski, K., Tada, M., and MacLennan, D. H. (1997) J. Biol. Chem. 272, 15061-15064), mutation of amino acids on one face of the phospholamban (PLN) transmembrane helix led to loss of PLN inhibition of sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) molecules. This helical face was proposed to form a site of PLN interaction with a transmembrane helix in SERCA molecules. To determine whether predicted transmembrane helices M4, M5, M6, or Mg in SERCA1a interact with PLN, SERCA1a mutants were co expressed with wild-type PLN and effects on Ca2+ dependence of Ca2+ transport were measured. Wild-type inhibitory interactions shifted apparent Ca2+ affinity of SERCA1a by an average of -0.34 pCa units, but four of the seven mutations in M4 led to a more inhibitory shift in apparent Ca2+ affinity, averaging -0.53 pCa units. Seven mutations in M5 led to an average shift of -0.32 pCa units and seven mutations in M8 led to an average shift of -0.30 pCa units. Among 11 mutations in M6, 1, Q791A, increased the inhibitory shift (-0.59 pCa units) and 5, V795A (-0.11), L802A (-0.07), L802V (-0.04), T805A (-0.11), and F809A (-0.12), reduced the inhibitory shift, consistent with the view that Val(795), Leu(802), Thr(805), and Phe(809), located on one face of a predicted M6 helix, form a site in SERCA1a for interaction with PLN. Those mutations in M4, M6, or M8 of SERCA1a that enhanced PLN inhibitory function did not enhance PLN physical association with SERCA1a, but mutants V795A and L802A in M6, which decreased PLN inhibitory function, decreased physical association, as measured by co-immunoprecipitation. In related studies, those PLN mutants that gained inhibitory function also increased levels of co-immunoprecipitation of wild-type SERCAla and those that lost inhibitory function also reduced association, correlating functional interaction sites with physical interaction sites. Thus, both functional and physical data confirm that PLN interacts with M6 SERCAla.	Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Yamaguchi Univ, Sch Med, Dept Pharmacol, Ube, Yamaguchi 7558505, Japan; Osaka Univ, Sch Med, Dept Med & Pathophysiol, Suita, Osaka 5650891, Japan	University of Toronto; Yamaguchi University; Osaka University	MacLennan, DH (corresponding author), Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.	david.maclennan@utoronto.ca						ADAMS PD, 1995, NAT STRUCT BIOL, V2, P154, DOI 10.1038/nsb0295-154; ARKIN IT, 1995, J MOL BIOL, V248, P824, DOI 10.1006/jmbi.1995.0263; Autry JM, 1997, J BIOL CHEM, V272, P15872, DOI 10.1074/jbc.272.25.15872; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURK SE, 1989, J BIOL CHEM, V264, P18561; CANTILINA T, 1993, J BIOL CHEM, V268, P17018; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; Cornea RL, 1997, BIOCHEMISTRY-US, V36, P2960, DOI 10.1021/bi961955q; FUJII J, 1987, J CLIN INVEST, V79, P301, DOI 10.1172/JCI112799; HUGHES G, 1994, BIOCHEM J, V303, P511, DOI 10.1042/bj3030511; JONES LR, 1993, J BIOL CHEM, V268, P11486; JONES LR, 1985, J BIOL CHEM, V260, P7721; Kimura Y, 1996, J BIOL CHEM, V271, P21726, DOI 10.1074/jbc.271.36.21726; Kimura Y, 1997, J BIOL CHEM, V272, P15061, DOI 10.1074/jbc.272.24.15061; Kimura Y, 1998, J BIOL CHEM, V273, P14238, DOI 10.1074/jbc.273.23.14238; KINGSTON RE, 1990, CURRENT PROTOCOLS MO; Koss KL, 1996, CIRC RES, V79, P1059, DOI 10.1161/01.RES.79.6.1059; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; MacLennan DH, 1997, ANN NY ACAD SCI, V834, P175, DOI 10.1111/j.1749-6632.1997.tb52249.x; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; Mayer EJ, 1996, J BIOL CHEM, V271, P1669, DOI 10.1074/jbc.271.3.1669; MORTISHIRESMITH RJ, 1995, BIOCHEMISTRY-US, V34, P7603, DOI 10.1021/bi00023a006; REDDY LG, 1995, J BIOL CHEM, V270, P9390, DOI 10.1074/jbc.270.16.9390; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; Rice WJ, 1997, J BIOL CHEM, V272, P31412, DOI 10.1074/jbc.272.50.31412; SASAKI T, 1992, J BIOL CHEM, V267, P1674; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; Soulie S, 1999, BIOCHEMISTRY-US, V38, P5813, DOI 10.1021/bi983039d; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; TOYOFUKU T, 1993, J BIOL CHEM, V268, P2809; TOYOFUKU T, 1994, J BIOL CHEM, V269, P22929; TOYOFUKU T, 1992, J BIOL CHEM, V267, P14490; WU KD, 1995, AM J PHYSIOL-CELL PH, V269, pC775, DOI 10.1152/ajpcell.1995.269.3.C775; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959; ZUBRZYCKAGAARN E, 1984, J BIOENERG BIOMEMBR, V16, P441, DOI 10.1007/BF00743238	40	81	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32855	32862		10.1074/jbc.274.46.32855	http://dx.doi.org/10.1074/jbc.274.46.32855			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551848	hybrid			2022-12-25	WOS:000083623000048
J	Ruehr, ML; Zakhary, DR; Damron, DS; Bond, M				Ruehr, ML; Zakhary, DR; Damron, DS; Bond, M			Cyclic AMP-dependent protein kinase binding to A-kinase anchoring proteins in living cells by fluorescence resonance energy transfer of green fluorescent protein fusion proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNIT RII; INDICATORS; CALMODULIN; DOMAIN	A-kinase anchoring proteins tether cAMP-dependent protein kinase (PRA) to specific subcellular locations. The purpose of this study was to use fluorescence resonance energy transfer to monitor binding events in Living cells between the type II regulatory subunit of PKA (RII) and the RII-binding domain of the human thyroid RII anchoring protein (Ht31), a peptide containing the PKA-binding domain of an A-kinase anchoring protein. RII was linked to enhanced yellow fluorescent protein (EYFP), Ht31 was baked to enhanced cyan fluorescent protein (ECFP), and these constructs were coexpressed in Chinese hamster ovary cells. Upon excitation of the donor fluorophore, Ht31.ECFP, an increase in emission of the acceptor fluorophore, RII.EYFP, and a decrease in emission from Ht31.ECFP were observed. The emission ratio (acceptor/donor) was increased 2-fold (p < 0.05) in cells expressing Ht31.ECFP and RII.EYFP compared with cells expressing Ht31.ECFP, the inactive form of Ht31, and RII.EYFP. These results provide the first in vivo demonstration of RII/Ht31 interaction in Living cells and confirm previous in vitro findings of RII/Ht31 binding. Using surface plasmon resonance, we also showed that the green fluorescent protein tags did not significantly alter the binding of Ht31 to RII. Thus, fluorescence resonance energy transfer can be used to directly monitor protein-protein interactions of the PKA signaling pathway in living cells.	Cleveland Clin Fdn, Dept Mol Cardiol NB50, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Ctr Anesthesiol Res, Cleveland, OH 44195 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Case Western Reserve University	Bond, M (corresponding author), Cleveland Clin Fdn, Dept Mol Cardiol NB50, Lerner Res Inst, Cleveland, OH 44195 USA.	bondm@ccf.org		Zakhary, Daniel/0000-0002-5328-6757	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010273, R01HL056256] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007678] Funding Source: NIH RePORTER; NHLBI NIH HHS [F32 HL10273, R01 HL56256] Funding Source: Medline; NIDDK NIH HHS [T32 DK07678] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Banky P, 1998, J BIOL CHEM, V273, P35048, DOI 10.1074/jbc.273.52.35048; BENSON RC, 1979, J HISTOCHEM CYTOCHEM, V27, P44, DOI 10.1177/27.1.438504; CARR DW, 1992, J BIOL CHEM, V267, P13376; CARR DW, 1991, J BIOL CHEM, V266, P14188; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; Hausken ZE, 1996, BIOCHEM SOC T, V24, P986, DOI 10.1042/bst0240986; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Lester LB, 1997, P NATL ACAD SCI USA, V94, P14942, DOI 10.1073/pnas.94.26.14942; LOHMANN SM, 1984, P NATL ACAD SCI-BIOL, V81, P6723, DOI 10.1073/pnas.81.21.6723; Mahajan NP, 1998, NAT BIOTECHNOL, V16, P547, DOI 10.1038/nbt0698-547; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; Newlon MG, 1999, NAT STRUCT BIOL, V6, P222; Newlon MG, 1997, J BIOL CHEM, V272, P23637, DOI 10.1074/jbc.272.38.23637; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pollok BA, 1999, TRENDS CELL BIOL, V9, P57, DOI 10.1016/S0962-8924(98)01434-2; Romoser VA, 1997, J BIOL CHEM, V272, P13270, DOI 10.1074/jbc.272.20.13270; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Tsunoda S, 1998, CURR OPIN GENET DEV, V8, P419, DOI 10.1016/S0959-437X(98)80112-3; Williams DR, 1997, J BIOL CHEM, V272, P8427, DOI 10.1074/jbc.272.13.8686; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134; Yang JC, 1998, J CELL BIOL, V142, P511, DOI 10.1083/jcb.142.2.511; Zakhary DR, 1999, CIRCULATION, V99, P505, DOI 10.1161/01.CIR.99.4.505; Zhao JK, 1998, J BIOL CHEM, V273, P30448, DOI 10.1074/jbc.273.46.30448	28	26	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					33092	33096		10.1074/jbc.274.46.33092	http://dx.doi.org/10.1074/jbc.274.46.33092			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551879	hybrid			2022-12-25	WOS:000083623000079
J	Jung, YS; Gao-Sheridan, HS; Christiansen, J; Dean, DR; Burgess, BK				Jung, YS; Gao-Sheridan, HS; Christiansen, J; Dean, DR; Burgess, BK			Purification and biophysical characterization of a new [2Fe-2S] ferredoxin from Azotobacter vinelandii, a putative [Fe-S] cluster assembly/repair protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; IRON-SULFUR CLUSTERS; MAGNETIC CIRCULAR-DICHROISM; ELEMENT BINDING-PROTEIN; ESCHERICHIA-COLI; CLOSTRIDIUM-PASTEURIANUM; NITROGEN-FIXATION; 4FE-4S CLUSTER; 2<4FE-4S> FERREDOXIN; NUCLEOTIDE-SEQUENCE	During the purification of site-directed mutant variants of Azotobacter vinelandii ferredoxin I (FdI), a pink protein, which was not observed in native FdI preparations, appeared to associate specifically with variants that had mutations in ligands to FdI [Fe-S] clusters. That protein, which me designate FdIV has now been purified. NH2-terminal sequence analysis revealed that the protein is the product of a previously described gene, herein designated fdxD, that is in the A. vinelandii iscSUA operon that encodes proteins involved in iron-sulfur cluster assembly or repair. An apoprotein molecular mass of 12,434.03 +/- 0.21 Da was determined by mass spectrometry consistent with the known gene sequence, The monomeric protein was shown to contain a single [2Fe-2S](2+/+) cluster by UV/visible, CD, and EPR spectroscopies with a reduction potential of -344 mV versus the standard hydrogen electrode. When overexpressed in Escherichia coli, recombinant FdIV holoprotein was successfully assembled. However, the polypeptide of the recombinant protein was modified in some way such that the apoprotein molecular mass increased by 52 Da. Antibodies raised against FdIV and EPR spectroscopy were used to examine the relative levels of FdIV and FdI in various A. vinelandii strains leading to the conclusion that FdIV levels appear to be specifically increased under conditions where another protein, NADPH:ferredoxin reductase is also up-regulated. In that case, the fpr gene is known to be activated in response to oxidative stress. This suggests that the fdxD gene and other genes in the iron-sulfur cluster assembly or repair operon might be similarly up-regulated in response to oxidative stress.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Virginia Polytech Inst & State Univ, Dept Biochem, Blacksburg, VA 24061 USA	University of California System; University of California Irvine; Virginia Polytechnic Institute & State University	Burgess, BK (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045209] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-45209] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; Atta M, 1998, BIOCHEMISTRY-US, V37, P15974, DOI 10.1021/bi9812928; BAUR J R, 1990, Biofactors, V2, P197; Beinert H, 1996, FEBS LETT, V382, P218, DOI 10.1016/0014-5793(96)00140-8; BEINERT H, 1990, FASEB J, V4, P2483, DOI 10.1096/fasebj.4.8.2185975; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Beinert H, 1996, CHEM REV, V96, P2335, DOI 10.1021/cr950040z; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BOHME H, 1989, PLANT MOL BIOL, V12, P667, DOI 10.1007/BF00044157; BRODERICK JB, 1997, J AM CHEM SOC, V119, P7936; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; CAMMACK R, 1992, ADV INORG CHEM, V38, P281, DOI 10.1016/S0898-8838(08)60066-5; Chatelet C, 1999, J BIOL INORG CHEM, V4, P311, DOI 10.1007/s007750050317; CHEN JC, 1992, BIOCHIM BIOPHYS ACTA, V1131, P122, DOI 10.1016/0167-4781(92)90111-C; CHENG H, 1994, BIOCHEMISTRY-US, V33, P3155, DOI 10.1021/bi00177a003; Clark MA, 1998, CURR MICROBIOL, V36, P158, DOI 10.1007/PL00006760; COGHLAN VM, 1989, P NATL ACAD SCI USA, V86, P835, DOI 10.1073/pnas.86.3.835; CROUSE BR, 1994, J BIOL CHEM, V269, P21030; CUPP JR, 1988, J BIOL CHEM, V263, P17418; DAVASSE V, 1992, BIOCHEM BIOPH RES CO, V185, P341, DOI 10.1016/S0006-291X(05)80991-X; Farinas E, 1998, PROTEIN SCI, V7, P1939, DOI 10.1002/pro.5560070909; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Flint DH, 1996, CHEM REV, V96, P2315, DOI 10.1021/cr950041r; Frey P A, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P1; Gao-Sheridan HS, 1998, J BIOL CHEM, V273, P5514, DOI 10.1074/jbc.273.10.5514; GAOSHERIDANS HS, 1998, THESIS U CALIFORNIA; Gaudu P, 1996, P NATL ACAD SCI USA, V93, P10094, DOI 10.1073/pnas.93.19.10094; Golinelli MP, 1998, BIOCHEMISTRY-US, V37, P10429, DOI 10.1021/bi9806394; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HIDALGO E, 1995, J BIOL CHEM, V270, P20908, DOI 10.1074/jbc.270.36.20908; Holm RH, 1996, CHEM REV, V96, P2239, DOI 10.1021/cr9500390; HOWARD JB, 1991, ADV PROTEIN CHEM, V42, P199; Hugo N, 1998, J BIOL CHEM, V273, P9622, DOI 10.1074/jbc.273.16.9622; IISMAA SE, 1991, J BIOL CHEM, V266, P21563; ISAS JM, 1994, J BIOL CHEM, V269, P19404; JACOBSON BL, 1993, BIOCHEMISTRY-US, V32, P6788, DOI 10.1021/bi00077a033; JACOBSON MR, 1989, J BACTERIOL, V171, P1017, DOI 10.1128/jb.171.2.1017-1027.1989; JOERGER RD, 1988, J BACTERIOL, V170, P1475, DOI 10.1128/jb.170.4.1475-1487.1988; JOHNSON MK, 1994, ENCY INORGANIC CHEM, V4, P1896; JOUANNEAU Y, 1992, BIOCHEM J, V286, P267; Jung YS, 1999, J BIOL CHEM, V274, P2978, DOI 10.1074/jbc.274.5.2978; Kemper MA, 1998, BIOCHEMISTRY-US, V37, P12829, DOI 10.1021/bi9810499; KHOROSHILOVA N, 1995, P NATL ACAD SCI USA, V92, P2499, DOI 10.1073/pnas.92.7.2499; KNOELL HE, 1974, EUR J BIOCHEM, V50, P245, DOI 10.1111/j.1432-1033.1974.tb03893.x; Lazazzera BA, 1996, J BIOL CHEM, V271, P2762, DOI 10.1074/jbc.271.5.2762; LE O, 1993, J BACTERIOL, V175, P7707, DOI 10.1128/JB.175.23.7707-7710.1993; LINDAHL PA, 1990, J CLUST SCI, V1, P29; LOVENBERG W, 1963, IRON SULFUR PROTEINS, V1; MARTIN AE, 1990, P NATL ACAD SCI USA, V87, P598, DOI 10.1073/pnas.87.2.598; MATSUBARA H, 1992, ADV INORG CHEM, V38, P223, DOI 10.1016/S0898-8838(08)60065-3; Meyer J, 1997, BIOCHEMISTRY-US, V36, P13374, DOI 10.1021/bi971775w; MITTAL S, 1988, ARCH BIOCHEM BIOPHYS, V264, P383, DOI 10.1016/0003-9861(88)90303-7; MORGAN TV, 1988, J BIOL CHEM, V263, P1370; MORTENSON LE, 1962, BIOCHEM BIOPH RES CO, V7, P448, DOI 10.1016/0006-291X(62)90333-9; MOSHIRI F, 1994, MOL MICROBIOL, V14, P101, DOI 10.1111/j.1365-2958.1994.tb01270.x; Nicolet Y, 1999, STRUCTURE, V7, P13, DOI 10.1016/S0969-2126(99)80005-7; PEISACH J, 1971, J BIOL CHEM, V246, P5877; Peters JW, 1998, SCIENCE, V282, P1853, DOI 10.1126/science.282.5395.1853; PETERSON JA, 1990, J BIOL CHEM, V265, P6066; PETILLOT Y, 1995, ANAL BIOCHEM, V228, P56, DOI 10.1006/abio.1995.1314; RAINA R, 1993, MOL GEN GENET, V236, P459, DOI 10.1007/BF00277149; RAINA R, 1988, MOL GEN GENET, V214, P121, DOI 10.1007/BF00340189; REICHARD P, 1993, J BIOL CHEM, V268, P8383; Reyntjens B, 1997, J BIOL INORG CHEM, V2, P595, DOI 10.1007/s007750050174; RODRIGUEZQUINONES F, 1993, J BACTERIOL, V175, P2926; ROUAULT TA, 1992, BIOMETALS, V5, P131, DOI 10.1007/BF01061319; SCHERINGS G, 1977, EUR J BIOCHEM, V77, P621, DOI 10.1111/j.1432-1033.1977.tb11706.x; SHEN B, 1995, P NATL ACAD SCI USA, V92, P10064, DOI 10.1073/pnas.92.22.10064; SHEN BH, 1993, J BIOL CHEM, V268, P25928; SHETHNA YI, 1968, BIOCHEM BIOPH RES CO, V31, P862, DOI 10.1016/0006-291X(68)90531-7; Siuzdak G., 1996, MASS SPECTROMETRY BI, P56; Staples CR, 1996, BIOCHEMISTRY-US, V35, P11425, DOI 10.1021/bi961007p; STEPHENS PJ, 1991, BIOCHEMISTRY-US, V30, P3200, DOI 10.1021/bi00227a007; STEPHENS PJ, 1978, BIOCHEMISTRY-US, V17, P4770, DOI 10.1021/bi00615a026; Sundin GW, 1996, MOL MICROBIOL, V20, P965, DOI 10.1111/j.1365-2958.1996.tb02538.x; TA DT, 1992, J BIOL CHEM, V267, P11120; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TSUKIHARA T, 1990, J MOL BIOL, V216, P399, DOI 10.1016/S0022-2836(05)80330-4; UHLMANN H, 1992, BIOCHEM BIOPH RES CO, V188, P1131, DOI 10.1016/0006-291X(92)91349-U; VAZQUEZ A, 1994, PROTEIN EXPRES PURIF, V5, P96, DOI 10.1006/prep.1994.1014; Vidakovic MS, 1996, J BIOL CHEM, V271, P14734, DOI 10.1074/jbc.271.25.14734; WIENTJENS R, 1993, THESIS AGR U WAGENIN; Yannone SM, 1998, J BIOL INORG CHEM, V3, P253, DOI 10.1007/s007750050229; YOCH DC, 1972, J BIOL CHEM, V247, P4514; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	86	57	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32402	32410		10.1074/jbc.274.45.32402	http://dx.doi.org/10.1074/jbc.274.45.32402			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542283	hybrid			2022-12-25	WOS:000083532100091
J	Suzuki, T; Ohsugi, Y; Uchida-Toita, M; Akiyama, T; Yoshida, M				Suzuki, T; Ohsugi, Y; Uchida-Toita, M; Akiyama, T; Yoshida, M			Tax oncoprotein of HTLV-1 binds to the human homologue of Drosophila discs large tumor suppressor protein, hDLG, and perturbs its function in cell growth control	ONCOGENE			English	Article						HTLV-1; Tax; adult T cell leukaemia; DLG; PDZ domain	VIRUS TYPE-I; NF-KAPPA-B; TRANSCRIPTIONAL ACTIVATION; TRANSACTIVATOR TAX; CREB BINDING; NUCLEAR TRANSLOCATION; GENE-EXPRESSION; T-LYMPHOCYTES; PDZ DOMAINS; LEUKEMIA	HTLV-1 Tax oncoprotein interacts with various cellular factors and modulates transcription and the cell cycle. To identify more cellular targets, we employed the yeast two hybrid system with Tax using a human cDNA library, and isolated a cDNA encoding the human counterpart of Drosophila discs large tumor suppressor protein, hDLG. Tax binding to hDLG was confirmed in vitro and also in HTLV-l-infected T-cells. Furthermore, hDLG was found to be efficiently phosphorylated in Tax-transfected cells and HTLV-l-infected T-cells. The C-terminus of Tax and the PDZ domain of hDLG were responsible for the binding of Tax to hDLG. The C-terminal peptide of Tax prevented the binding of hDLG to APC tumor suppressor gene product, suggesting inhibition of hDLG function by Tax. Over-expression of hDLG in NIH3T3 cells by microinjection induced a reduction of BrdU incorporation into DNA, but coexpression of Tax suppressed this inhibitory effect of hDLG. These results suggest that hDLG arrested the cell cycle and that Tax canceled this inhibitory action of hDLG through targeting hDLG. Therefore, Tax affects this novel regulatory pathway of the cell cycle alteration, of which seems to play a role in the development of human cancer.	Univ Tokyo, Inst Med Sci, Dept Cellular & Mol Biol, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Inst Mol & Cellular Biol, Dept Mol Genet Informat, Minato Ku, Tokyo 1088639, Japan	University of Tokyo; University of Tokyo	Yoshida, M (corresponding author), Banyu Tsukuba Res Inst, 3-Okubo, Tsukuba, Ibaraki 3002611, Japan.							BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Hanada T, 1997, J BIOL CHEM, V272, P26899, DOI 10.1074/jbc.272.43.26899; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lemasson I, 1997, J VIROL, V71, P1975, DOI 10.1128/JVI.71.3.1975-1983.1997; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POLAKIS P, 1995, CURR OPIN GENET DEV, V5, P66, DOI 10.1016/S0959-437X(95)90055-1; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SUZUKI T, 1994, ONCOGENE, V9, P3099; SUZUKI T, 1995, ONCOGENE, V10, P1199; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; Szabo I, 1996, J BIOL CHEM, V271, P20465, DOI 10.1074/jbc.271.34.20465; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yoshida M, 1993, Trends Microbiol, V1, P131, DOI 10.1016/0966-842X(93)90127-D; YOSHIDA M, 1995, J CANCER RES CLIN, V121, P521, DOI 10.1007/BF01197764; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	40	109	112	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	1999	18	44					5967	5972		10.1038/sj.onc.1203008	http://dx.doi.org/10.1038/sj.onc.1203008			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557085				2022-12-25	WOS:000083359100002
J	Ishii, N; Tada, M; Hamou, MF; Janzer, RC; Meagher-Villemure, K; Wiestler, OD; de Tribolet, N; Van Meir, EG				Ishii, N; Tada, M; Hamou, MF; Janzer, RC; Meagher-Villemure, K; Wiestler, OD; de Tribolet, N; Van Meir, EG			Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor	ONCOGENE			English	Article						TP53; prognosis; glioma; tumor recurrence; clonal evolution; irradiation	P53 FUNCTIONAL ASSAY; GENE-MUTATIONS; PROGRESSION; GLIOMA; IMMUNOREACTIVITY	It is important to understand how lon grade tumors recur and progress to malignant lesions since this dramatically shortens patient survival. Here, we evaluated the concept that malignant progression and poor prognosis of low grade astrocytic tumors are TP53 dependent through clonal expansion of mutated cells. TP53 status was established in primary and recurrent tumors from 36 patients with WHO grade II astrocytic tumors and two tumor types were found. Tumors from 14 patients (39%; type 1) had TP53 mutated cells, and 92% of these recurred with 57% progressing to malignancy. The evolution of TP53 mutated cells before and after progression was examined using a clonal analysis procedure in yeast. Malignant progression was accompanied by an increased percentage of mutant TP53 (red) yeast colonies resulting from monoclonal expansion of cells with mutated TP53. The presence of TP53 mutations in WHO grade II astrocytic tumors was associated with malignant progression (P = 0.034, chi(2) test) and shorter progression-free survival (PFS; 47.6+/-9.6 months for TP53-mutated tumors vs 67.8+/-8.2 months for TP53-wild type tumors, P<0.05, log-rank test). Tumors from 22 patients (61%; type 2) were without TP53 mutations, and 64% of these recurred without a change in TP53 status, although 41% progressed to malignancy. This suggests that TP53 mutation is not an initiating or progression event in the majority of low grade astrocytic tamers. Our study also indicates that irradiation for WHO grade II astrocytic tumors might be associated with Door outcome (P<0.0001) and this was independent of TP53 status. These findings have important implications in the clinical management of patients with low grade astocytoma and provide new support to the clonal evolution model for tumor progression.	Emory Univ, Winship Canc Ctr, Mol Neurooncol Lab, Atlanta, GA 30322 USA; CHU Vaudois, Dept Neurosurg, Lab Tumor Biol & Genet, CH-1011 Lausanne, Switzerland; Hokkaido Univ, Sch Med, Dept Neurosurg, Sapporo, Hokkaido 060, Japan; CHU Vaudois, Div Neuropathol, CH-1011 Lausanne, Switzerland; Univ Bonn, Med Ctr, Dept Neuropathol, D-53105 Bonn, Germany; Emory Univ, Dept Neurol Surg, Mol Neurooncol Lab, Atlanta, GA 30322 USA	Emory University; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Hokkaido University; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Bonn; Emory University	Van Meir, EG (corresponding author), Emory Univ, Winship Canc Ctr, Mol Neurooncol Lab, 1365-B Clifton Rd NE,Room B5103, Atlanta, GA 30322 USA.			Van Meir, Erwin G./0000-0003-2444-7707				ALSARRAJ S, 1995, BRIT J NEUROSURG, V9, P143, DOI 10.1080/02688699550041476; *CBTRUS, 1997, ANN REP, P20; CHEN TC, 1995, BENIGN CEREBRAL GLIO, V2, P118; CHOZICK BS, 1994, NEUROSURGERY, V35, P831, DOI 10.1227/00006123-199411000-00005; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Fulci G, 1998, BRAIN PATHOL, V8, P599, DOI 10.1111/j.1750-3639.1998.tb00187.x; HALL PA, 1994, J PATHOL, V172, P1, DOI 10.1002/path.1711720103; HAYASHI Y, 1991, BIOCHEM BIOPH RES CO, V180, P1145, DOI 10.1016/S0006-291X(05)81186-6; Ishii N, 1998, INT J CANCER, V76, P797, DOI 10.1002/(SICI)1097-0215(19980610)76:6<797::AID-IJC5>3.3.CO;2-1; IUZZOLINO P, 1994, BRIT J CANCER, V69, P586, DOI 10.1038/bjc.1994.107; Kleihues P, 1993, HISTOLOGICAL TYPING; KRAUS JA, 1994, GENE CHROMOSOME CANC, V10, P143, DOI 10.1002/gcc.2870100211; Kyritsis AP, 1995, CLIN CANCER RES, V1, P1617; Maintz D, 1997, J NEUROPATH EXP NEUR, V56, P1098, DOI 10.1097/00005072-199710000-00003; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; REIFENBERGER G, 1997, PATHOLOGY GENETICS T, P45; REIFENBERGER J, 1994, AM J PATHOL, V145, P1175; SALCMAN M, 1995, BENIGN CEREBRAL GLIO, V2, P213; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; VANMEYEL DJ, 1994, JNCI-J NATL CANCER I, V86, P1011, DOI 10.1093/jnci/86.13.1011; VECHT CJ, 1993, J NEUROL NEUROSUR PS, V56, P1259, DOI 10.1136/jnnp.56.12.1259; Waridel F, 1997, ONCOGENE, V14, P163, DOI 10.1038/sj.onc.1200812; Watanabe K, 1997, CLIN CANCER RES, V3, P523	23	67	69	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 21	1999	18	43					5870	5878		10.1038/sj.onc.1203241	http://dx.doi.org/10.1038/sj.onc.1203241			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557074				2022-12-25	WOS:000083270700004
J	Boonen, GJJC; van Oirschot, BA; van Diepen, A; Mackus, WJM; Verdonck, LF; Rijksen, G; Medema, RH				Boonen, GJJC; van Oirschot, BA; van Diepen, A; Mackus, WJM; Verdonck, LF; Rijksen, G; Medema, RH			Cyclin D3 regulates proliferation and apoptosis of leukemic T cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA-PROTEIN; MONOCLONAL-ANTIBODIES; KINASE-ACTIVITY; LYMPHOCYTES-T; DEATH; INHIBITION; ANTIGEN; COMPLEX; IDENTIFICATION; INACTIVATION	Activation of the T cell receptor in leukemic T cell lines or T cell hybridomas causes growth inhibition. A similar growth inhibition is seen when protein kinase C is activated through addition of phorbol myristate acetate, This inhibition is due to an arrest of cell cycle progression in G(1) combined with an induction of apoptosis, Here we have investigated the mechanism by which these stimuli induce inhibition of proliferation in Jurkat and H9 leukemic T cell lines. We show that expression of cyclin D3 is reduced by each of these stimuli, resulting in a concomitant reduction in cyclin D-associated kinase activity. This reduction in cyclin DS-expression is crucial to the observed G(1) arrest, since ectopic expression of cyclin D3 can abrogate the G(1) arrest seen with each of these stimuli. Moreover, ectopic expression of cyclin D3 also prevents the induction of programmed cell death by phorbol myristate acetate and T-cell receptor activation, leading us to conclude that cyclin D3 not only plays a crucial role in progression through the G(1) phase; but is also involved in regulating apoptosis of T cells.	Univ Utrecht Hosp, Dept Haematol, Jordan Lab Hemato Oncol, NL-3508 GA Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Medema, RH (corresponding author), Univ Utrecht Hosp, Dept Haematol, Jordan Labs, POB 85500,Rm G03647, NL-3508 GA Utrecht, Netherlands.		Medema, Rene H/E-2981-2013; Medema, Rene H/G-5415-2011	Medema, Rene/0000-0002-6754-0381				AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; Boonen GJJC, 1999, EUR J IMMUNOL, V29, P789; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; JONES LA, 1990, SCIENCE, V250, P1726, DOI 10.1126/science.2125368; Kalejta RF, 1997, CYTOMETRY, V29, P286, DOI 10.1002/(SICI)1097-0320(19971201)29:4<286::AID-CYTO4>3.0.CO;2-8; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; Lissy NA, 1998, IMMUNITY, V8, P57, DOI 10.1016/S1074-7613(00)80458-6; LUKAS J, 1995, ONCOGENE, V10, P2125; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; MERCEP M, 1988, J IMMUNOL, V140, P324; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MIYATAKE S, 1995, J EXP MED, V182, P401, DOI 10.1084/jem.182.2.401; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; SHI YF, 1991, J IMMUNOL, V146, P3340; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; TAKAHASHI S, 1989, EUR J IMMUNOL, V19, P1911, DOI 10.1002/eji.1830191023; TAM SW, 1994, ONCOGENE, V9, P2663; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; ZHU LQ, 1995, J IMMUNOL, V154, P192	31	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34676	34682		10.1074/jbc.274.49.34676	http://dx.doi.org/10.1074/jbc.274.49.34676			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574933	hybrid			2022-12-25	WOS:000083979600027
J	Krimm, I; Goyer, A; Issakidis-Bourguet, E; Miginiac-Maslow, M; Lancelin, JM				Krimm, I; Goyer, A; Issakidis-Bourguet, E; Miginiac-Maslow, M; Lancelin, JM			Direct NMR observation of the thioredoxin-mediated reduction of the chloroplast NADP-malate dehydrogenase provides a structural basis for the relief of autoinhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT REGULATORY SITE; H-1-NMR SPECTRA; SPECTROSCOPY; EXCHANGE; IDENTIFICATION; MACROMOLECULES; MUTAGENESIS; ACTIVATION; RELAXATION; PROTEINS	The chloroplastic NADP-dependent malate dehydrogenase (NADP-MDH) catalyzing the reduction of oxaloacetate into L-malate is regulated by light. Its activation results from the thioredoxin-mediated reduction of two disulfides, located, respectively, in N- and C-terminal sequence extensions typical of all NADP-dependent Light-regulated forms. Site-directed mutagenesis studies and the resolution of the three-dimensional structure of the oxidized (inactive) Sorghum vulgare enzyme showed that the C-terminal Cys(365)-Cys(377) disulfide constrains the C-terminal extension to fold into the active site where it acts as an internal inhibitor. In the present study, two-dimensional proton NMR spectra of an engineered NADP-MDH rendered monomeric by a 33-amino acid deletion at the N terminus (38 kDa) revealed that a 15-amino acid-long C-terminal peptide (Ala(375) to C-terminal Val(389)) acquired an increased mobility upon reduction, allowing its direct sequence-specific NMR assignment. The location of the flexible peptide in the sequence suggests that the first part of the C-terminal peptide is still folded near the core of the enzyme, so that cysteines 365 and 377 remain in proximity to allow for an efficient reoxidation/inactivation of the enzyme.	Univ Lyon 1, CNRS, Lab RMN Biomol, F-69622 Villeurbanne, France; Ecole Super Chim Phys Elect Lyon, F-69622 Villeurbanne, France; Univ Paris 11, CNRS, Inst Biotechnol Plantes, UMR 8618, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Lancelin, JM (corresponding author), Univ Lyon 1, CNRS, Lab RMN Biomol, Batiment 308G, F-69622 Villeurbanne, France.		Lancelin, Jean-marc/AAC-5686-2019; Goyer, Aymeric/AAW-2617-2021; Krimm, Isabelle/O-4972-2014	Krimm, Isabelle/0000-0002-5981-109X; Issakidis-Bourguet, Emmanuelle/0000-0002-6144-4364; Goyer, Aymeric/0000-0003-0714-6750				BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Carr PD, 1999, STRUCTURE, V7, P461, DOI 10.1016/S0969-2126(99)80058-6; CRETIN C, 1990, EUR J BIOCHEM, V192, P299, DOI 10.1111/j.1432-1033.1990.tb19227.x; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; DECOTTIGNIES P, 1988, J BIOL CHEM, V263, P11780; Goyer A, 1999, FEBS LETT, V444, P165, DOI 10.1016/S0014-5793(99)00051-4; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; ISSAKIDIS E, 1994, J BIOL CHEM, V269, P3511; ISSAKIDIS E, 1992, J BIOL CHEM, V267, P21577; Jacquot JP, 1997, NEW PHYTOL, V136, P543, DOI 10.1046/j.1469-8137.1997.00784.x; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Johansson K, 1999, BIOCHEMISTRY-US, V38, P4319, DOI 10.1021/bi982876c; LIPPENS G, 1995, J BIOMOL NMR, V5, P327, DOI 10.1007/BF00211762; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; MiginiacMaslow M, 1997, AUST J PLANT PHYSIOL, V24, P529, DOI 10.1071/PP97004; Mittard V, 1997, EUR J BIOCHEM, V243, P374, DOI 10.1111/j.1432-1033.1997.0374a.x; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Pons JL, 1996, J BIOMOL NMR, V8, P445, DOI 10.1007/BF00228146; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Riessland R, 1997, BIOL CHEM, V378, P983, DOI 10.1515/bchm.1997.378.9.983; Ruelland E, 1998, J BIOL CHEM, V273, P33482, DOI 10.1074/jbc.273.50.33482; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Wuthrich K, 1986, NMR PROTEINS NUCL AC	26	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34539	34542		10.1074/jbc.274.49.34539	http://dx.doi.org/10.1074/jbc.274.49.34539			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574915	hybrid			2022-12-25	WOS:000083979600009
J	Lerner-Marmarosh, N; Gimi, K; Urbatsch, IL; Gros, P; Senior, AE				Lerner-Marmarosh, N; Gimi, K; Urbatsch, IL; Gros, P; Senior, AE			Large scale purification of detergent-soluble P-glycoprotein from Pichia pastoris cells and characterization of nucleotide binding properties of wild-type, Walker A, and Walker B mutant proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE; ATPASE ACTIVITY; SUBSTRATE-SPECIFICITY; SITES; MUTATIONS; TRANSPORTER; HYDROLYSIS; RESIDUES; OVEREXPRESSION; EXPRESSION	P-glycoprotein (Pgp; mouse MDR3) was expressed in Pichia pastoris, grown in fermenter culture, and purified. The final pure product is of high specific ATPase activity and is soluble at low detergent concentration. 120 g of cells yielded 6 mg of pure Pgp; >4 kg of cells were obtained from a single fermenter run, Properties of the pure protein were similar to those of previous preparations, except there was significant ATPase activity in absence of added lipid. Mutant mouse MDR3 P-glycoproteins were purified by the same procedure after growth of cells in flask culture, with similar yields and purity. This procedure should open up new avenues of structural, biophysical, and biochemical studies of Pgp. Equilibrium nucleotide-binding parameters of wildtype mouse MDR3 Pgp were studied using 2'-(3')-O-(2,4,6-trinitrophenyl) adeno sine tri- and diphosphate. Both analogs were found to bind with K-d in the low micromolar range, to a single class of site, with no evidence of cooperativity. ATP displacement of the analogs was seen. Similar binding was seen with K429R/K1072R and D551N/D1196N mutant mouse MDR3 Pgp, showing that these Walker A and B mutations had no significant effect on affinity or stoichiometry of nucleotide binding. These residues, known to be critical for catalysis, are concluded to be involved primarily in stabilization of the catalytic transition state in Pgp.	Univ Rochester, Ctr Med, Dept Biochem & Biophys, Rochester, NY 14642 USA; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	University of Rochester; McGill University	Senior, AE (corresponding author), Univ Rochester, Ctr Med, Dept Biochem & Biophys, 601 Elmwood Ave,Box 712, Rochester, NY 14642 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050156] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50156] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BAUBICHONCORTAY H, 1994, J BIOL CHEM, V269, P22983; Beaudet L, 1998, METHOD ENZYMOL, V292, P397; Beaudet L, 1998, BIOCHEMISTRY-US, V37, P9073, DOI 10.1021/bi972656j; BECHHANSEN NT, 1976, J CELL PHYSIOL, V88, P23, DOI 10.1002/jcp.1040880104; Bolhuis H, 1996, EMBO J, V15, P4239, DOI 10.1002/j.1460-2075.1996.tb00798.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Dayan G, 1996, J BIOL CHEM, V271, P11652, DOI 10.1074/jbc.271.20.11652; Demeule M, 1998, BIOCHEMISTRY-US, V37, P18110, DOI 10.1021/bi981992c; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; Forgac M, 1999, J BIOL CHEM, V274, P1301, DOI 10.1074/jbc.274.3.1301; GOTTESMAN MM, 1993, CANCER RES, V53, P747; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; Gros P, 1993, Int Rev Cytol, V137C, P169; Hafkemeyer P, 1998, BIOCHEMISTRY-US, V37, P16400, DOI 10.1021/bi980871+; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIRATSUKA T, 1973, BIOCHIM BIOPHYS ACTA, V320, P635, DOI 10.1016/0304-4165(73)90143-8; Hrycyna CA, 1998, BIOCHEMISTRY-US, V37, P13660, DOI 10.1021/bi9808823; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; HYREYNA CA, 1998, J BIOL CHEM, V273, P16631; Liu RH, 1997, BIOCHEMISTRY-US, V36, P2836, DOI 10.1021/bi9627119; Liu RH, 1996, BIOCHEMISTRY-US, V35, P11865, DOI 10.1021/bi960823u; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; Mao QC, 1997, BBA-BIOMEMBRANES, V1327, P107, DOI 10.1016/S0005-2736(97)00050-3; Oluwatosin YE, 1997, J BIOL CHEM, V272, P28149, DOI 10.1074/jbc.272.44.28149; Ramachandra M, 1998, BIOCHEMISTRY-US, V37, P5010, DOI 10.1021/bi973045u; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; Sankaran B, 1997, BIOCHEMISTRY-US, V36, P6847, DOI 10.1021/bi970034s; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Senior AE, 1998, ARCH BIOCHEM BIOPHYS, V357, P121, DOI 10.1006/abbi.1998.0778; SENIOR AE, 1995, J BIOENERG BIOMEMBR, V27, P31, DOI 10.1007/BF02110328; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1998, BIOCHEMISTRY-US, V37, P831, DOI 10.1021/bi9719962; SHAPIRO AB, 1995, J BIOENERG BIOMEMBR, V27, P7, DOI 10.1007/BF02110325; Sharom FJ, 1997, J MEMBRANE BIOL, V160, P161, DOI 10.1007/s002329900305; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stein WD, 1997, PHYSIOL REV, V77, P545, DOI 10.1152/physrev.1997.77.2.545; Szabo K, 1998, J BIOL CHEM, V273, P10132, DOI 10.1074/jbc.273.17.10132; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; Urbatsch IL, 1998, BIOCHEMISTRY-US, V37, P4592, DOI 10.1021/bi9728001; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; Weber J, 1996, J BIOL CHEM, V271, P3474	46	126	129	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34711	34718		10.1074/jbc.274.49.34711	http://dx.doi.org/10.1074/jbc.274.49.34711			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574938	hybrid			2022-12-25	WOS:000083979600032
J	Olin, KL; Potter-Perigo, S; Barrett, PHR; Wight, TN; Chait, A				Olin, KL; Potter-Perigo, S; Barrett, PHR; Wight, TN; Chait, A			Lipoprotein lipase enhances the binding of native and oxidized low density lipoproteins to versican and biglycan synthesized by cultured arterial smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	70th Scientific Session of the American-Heart-Association	NOV 09-13, 1997	ORLANDO, FL	Amer Heart Assoc			CORONARY ATHEROSCLEROTIC PLAQUES; CHONDROITIN SULFATE PROTEOGLYCAN; HEPARAN-SULFATE; GROWTH-FACTOR; EXTRACELLULAR-MATRIX; OXIDATIVE MODIFICATION; ENDOTHELIAL-CELLS; DECORIN; APOLIPOPROTEIN; MACROPHAGES	Retention of low density lipoproteins (LDL) by vascular proteoglycans and their subsequent oxidation are important in atherogenesis, Lipoprotein lipase (LPL) can bind LDL and proteoglycans, although the effect of different proteoglycans to influence the ability of LPL to act as a bridge in the formation of LDL-proteoglycan complexes is unknown. Using an electrophoretic gel mobility shift assay, [S-35]SO4-labeled versican and biglycan, two extracellular proteoglycans secreted by vascular cells, bound native LDL in a saturable fashion, The addition of bovine milk LPL dose-dependently increased the binding of native LDL to both versican and biglycan, approaching saturation at 30-40 mu g/ml LPL for versican and 20 mu g/ml LPL for biglycan. LDL was oxidized by several methods, including copper, 2,2-azobis(2-amidinopropane)-2HCl and hypochlorite, Extensively copper- and hypochlorite-oxidized LDL bound poorly to versican and biglycan, Proteoglycan binding to LDL was correlated inversely with the extent of LDL; however, the addition of LPL to oxidized LDL together with biglycan or versican allowed the oxidized LDL to bind the proteoglycans in an LPL dose-dependent manner. Addition of LPL had a greater relative effect on the binding of extensively oxidized LDL to proteoglycans compared with native LDL, LPL had a slightly greater effect on increasing the binding of native and oxidized LDL to biglycan than versican, Thus, LPL in the artery wall might increase the atherogenicity of oxidized LDL, since it enables its binding to vascular biglycan and versican.	Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Western Australia, Dept Med, Perth, WA 6001, Australia	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Western Australia	Chait, A (corresponding author), Univ Washington, Dept Med, Box 356426, Seattle, WA 98195 USA.		Barrett, Hugh/ABF-1714-2020; Barrett, Hugh/B-2745-2011	Barrett, Hugh/0000-0003-3223-6125; 	NHLBI NIH HHS [HL07028] Funding Source: Medline; NIDDK NIH HHS [DK02456, DK07247] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007247, R13DK107247] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Auerbach BJ, 1996, J BIOL CHEM, V271, P1329, DOI 10.1074/jbc.271.3.1329; Babaev VR, 1999, J CLIN INVEST, V103, P1697, DOI 10.1172/JCI6117; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; Benlian P, 1996, NEW ENGL J MED, V335, P848, DOI 10.1056/NEJM199609193351203; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; CAMEJO G, 1993, J BIOL CHEM, V268, P14131; CAMEJO G, 1988, ARTERIOSCLEROSIS, V8, P368, DOI 10.1161/01.ATV.8.4.368; CAMEJO G, 1990, EUR HEART J, V11, P164, DOI 10.1093/eurheartj/11.suppl_E.164; CHAIT A, 1980, P NATL ACAD SCI-BIOL, V77, P4084, DOI 10.1073/pnas.77.7.4084; Chang MY, 1998, J BIOL CHEM, V273, P15985, DOI 10.1074/jbc.273.26.15985; CHOI SY, 1995, J BIOL CHEM, V270, P8081, DOI 10.1074/jbc.270.14.8081; DeBruin TWA, 1996, EUR J CLIN INVEST, V26, P631, DOI 10.1111/j.1365-2362.1996.tb02146.x; EDWARDS IJ, 1993, J LIPID RES, V34, P1155; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; ELSAADANI M, 1989, J LIPID RES, V30, P627; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; Evanko SP, 1998, AM J PATHOL, V152, P533; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; Gutierrez P, 1997, CARDIOVASC PATHOL, V6, P271, DOI 10.1016/S1054-8807(97)00001-X; Halpert I, 1996, P NATL ACAD SCI USA, V93, P9748, DOI 10.1073/pnas.93.18.9748; HASCALL VC, 1982, METHOD ENZYMOL, V82, P769; HAZELL LJ, 1993, BIOCHEM J, V290, P165, DOI 10.1042/bj2900165; HEINECKE JW, 1986, J CLIN INVEST, V77, P757, DOI 10.1172/JCI112371; HERTTUALA SY, 1991, P NATL ACAD SCI USA, V88, P10143; Hurt-Camejo E, 1998, Methods Mol Biol, V110, P267; HURTCAMEJO E, 1992, ARTERIOSCLER THROMB, V12, P569, DOI 10.1161/01.ATV.12.5.569; Iverius P H, 1986, Methods Enzymol, V129, P691; JARVELAINEN HT, 1991, J BIOL CHEM, V266, P23274; Jukema JW, 1996, CIRCULATION, V94, P1913, DOI 10.1161/01.CIR.94.8.1913; KAWAMURA M, 1994, J CLIN INVEST, V94, P771, DOI 10.1172/JCI117396; KINSELLA MG, 1986, J CELL BIOL, V102, P679, DOI 10.1083/jcb.102.3.679; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; Lookene A, 1996, BIOCHEMISTRY-US, V35, P12155, DOI 10.1021/bi960008e; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARGELIN D, 1989, INT J BIOCHEM, V21, P761, DOI 10.1016/0020-711X(89)90208-5; Merkel M, 1998, P NATL ACAD SCI USA, V95, P13841, DOI 10.1073/pnas.95.23.13841; MULDER M, 1992, BIOCHEM BIOPH RES CO, V185, P582, DOI 10.1016/0006-291X(92)91664-C; NOGUCHI N, 1994, BBA-LIPID LIPID MET, V1213, P176, DOI 10.1016/0005-2760(94)90024-8; O'Brien KD, 1998, CIRCULATION, V98, P519, DOI 10.1161/01.CIR.98.6.519; OBrien KD, 1996, CIRCULATION, V94, P1216, DOI 10.1161/01.CIR.94.6.1216; OBRIEN KD, 1992, J CLIN INVEST, V89, P1544, DOI 10.1172/JCI115747; ODETTI P, 1992, DIABETES, V41, P153, DOI 10.2337/diabetes.41.2.153; OLIN K, 1997, CIRCULATION S, V96, P40; Olivecrona Thomas, 1993, Current Opinion in Lipidology, V4, P187, DOI 10.1097/00041433-199306000-00003; Olsson U, 1997, ARTERIOSCL THROM VAS, V17, P149, DOI 10.1161/01.ATV.17.1.149; Oorni K, 1997, J BIOL CHEM, V272, P21303, DOI 10.1074/jbc.272.34.21303; RADHAKRISHNAMURTHY B, 1990, EUR HEART J, V11, P148, DOI 10.1093/eurheartj/11.suppl_E.148; REICHL D, 1991, EUR J CLIN INVEST, V21, P631; RIESSEN R, 1994, AM J PATHOL, V144, P962; SAITO H, 1968, J BIOL CHEM, V243, P1536; SAXENA U, 1993, BIOCHEM BIOPH RES CO, V194, P769, DOI 10.1006/bbrc.1993.1888; SAXENA U, 1992, J CLIN INVEST, V89, P373, DOI 10.1172/JCI115595; SCHONHERR E, 1993, ARTERIOSCLER THROMB, V13, P1026, DOI 10.1161/01.ATV.13.7.1026; SCHONHERR E, 1991, J BIOL CHEM, V266, P17640; Schonherr E, 1997, ARCH BIOCHEM BIOPHYS, V339, P353, DOI 10.1006/abbi.1996.9854; Semenkovich CF, 1998, J LIPID RES, V39, P1141; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; TangChristensen M, 1996, AM J PHYSIOL-REG I, V271, pR848, DOI 10.1152/ajpregu.1996.271.4.R848; TORNVALL P, 1995, ARTERIOSCL THROM VAS, V15, P1086, DOI 10.1161/01.ATV.15.8.1086; vanBarlingen HHJJ, 1996, J LIPID RES, V37, P754; WIGHT TN, 1996, ATHEROSCLEROSIS CORO, P421; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YANAGISHITA M, 1987, METHOD ENZYMOL, V138, P279; YAO LY, 1994, MATRIX BIOL, V14, P213, DOI 10.1016/0945-053X(94)90185-6; YEO TK, 1992, CONNECT TISSUE RES, V27, P265, DOI 10.3109/03008209209007001; YOUNG SG, 1994, W J MED, V160, P183	68	85	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34629	34636		10.1074/jbc.274.49.34629	http://dx.doi.org/10.1074/jbc.274.49.34629			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	260XW	10574927	hybrid			2022-12-25	WOS:000083979600021
J	Li, YZ; Mechin, MC; van de Werve, G				Li, YZ; Mechin, MC; van de Werve, G			Diabetes affects similarly the catalytic subunit and putative glucose-6-phosphate translocase of glucose-6-phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER GLUCOSE-6-PHOSPHATASE; GENE-EXPRESSION; HEPATOMA-CELLS; MESSENGER-RNA; GLUCOSE; INSULIN; PROTEIN; SEQUENCE; MICROSOMES; TRANSPORT	The effect of streptozocin diabetes on the expression of the catalytic subunit (p36) and the putative glucose-6-phosphate translocase (p46) of the glucose-6-phosphatase system (G6Pase) was investigated in rats. In addition to the documented effect of diabetes to increase p36 mRNA and protein in the liver and kidney, a similar to 2-fold increase in the mRNA abundance of p46 was found in liver, kidney, and intestine, and a similar increase was found in the p46 protein level in liver. In HepG2 cells, glucose caused a dose-dependent (1-25 mar) increase (up to B-fold) in p36 and p46 mRNA and a lesser increase in p46 protein, whereas insulin (1 mu M) suppressed p36 mRNA, reduced p46 mRNA level by half, and decreased p46 protein by about 33%. Cyclic AMP (100 mu M) increased p36 and p46 mRNA by >2- and 1.5-fold, respectively, but not p46 protein. These data suggest that insulin deficiency and hyperglycemia might each be responsible for up-regulation of G6Pase in diabetes. It is concluded that enhanced hepatic glucose output in insulin-dependent diabetes probably involves dysregulation of both the catalytic subunit and the putative glucose-6-phosphate translocase of the liver G6Pase system.	CHUM, Hop Notre Dame, Ctr Rech, Dept Nutr,Lab Endocrinol Metab, Montreal, PQ H2L 4M1, Canada; CHUM, Hop Notre Dame, Ctr Rech, Dept Biochem,Grp Rech Transport Membranaire, Montreal, PQ H2L 4M1, Canada	Universite de Montreal; Universite de Montreal	van de Werve, G (corresponding author), CHUM, Hop Notre Dame, Ctr Rech, Dept Nutr,Lab Endocrinol Metab, 8e Mailloux,1560 Sherbrooke E, Montreal, PQ H2L 4M1, Canada.							Argaud D, 1996, DIABETES, V45, P1563, DOI 10.2337/diabetes.45.11.1563; Argaud D, 1997, J BIOL CHEM, V272, P12854, DOI 10.1074/jbc.272.19.12854; Arion WJ, 1998, J BIOL CHEM, V273, P6223, DOI 10.1074/jbc.273.11.6223; BARZILAI N, 1993, J BIOL CHEM, V268, P25019; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURCHELL A, 1985, DIABETOLOGIA, V28, P852, DOI 10.1007/BF00291077; Gerin I, 1997, FEBS LETT, V419, P235, DOI 10.1016/S0014-5793(97)01463-4; Herling AW, 1998, AM J PHYSIOL-GASTR L, V274, pG1087, DOI 10.1152/ajpgi.1998.274.6.G1087; LANGE AJ, 1994, BIOCHEM BIOPH RES CO, V201, P302, DOI 10.1006/bbrc.1994.1702; LAVOIE L, 1993, DIABETES, V42, P363, DOI 10.2337/diabetes.42.2.363; Lin BC, 1998, J BIOL CHEM, V273, P31656, DOI 10.1074/jbc.273.48.31656; LIU ZQ, 1994, BIOCHEM BIOPH RES CO, V205, P680, DOI 10.1006/bbrc.1994.2719; Massillon D, 1996, J BIOL CHEM, V271, P9871, DOI 10.1074/jbc.271.17.9871; Mechin MC, 1996, INFECT IMMUN, V64, P3555; Mithieux G, 1996, DIABETES, V45, P891, DOI 10.2337/diabetes.45.7.891; Nordlie R C, 1974, Curr Top Cell Regul, V8, P33; Rajas F, 1999, GASTROENTEROLOGY, V117, P132, DOI 10.1016/S0016-5085(99)70559-7; Sambrook J., 2002, MOL CLONING LAB MANU; Schmoll D, 1996, FEBS LETT, V383, P63, DOI 10.1016/0014-5793(96)00224-4; Seoane J, 1997, J BIOL CHEM, V272, P26972, DOI 10.1074/jbc.272.43.26972; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; STDENIS JF, 1995, J BIOL CHEM, V270, P21092, DOI 10.1074/jbc.270.36.21092; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; Xie W, 1999, BIOCHEM J, V343, P393, DOI [10.1042/0264-6021:3430393, 10.1042/bj3430393]	24	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					33866	33868		10.1074/jbc.274.48.33866	http://dx.doi.org/10.1074/jbc.274.48.33866			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567346	hybrid			2022-12-25	WOS:000083857500011
J	MacFarlane, WM; Chapman, JC; Shepherd, RM; Hashmi, MN; Kamimura, N; Cosgrove, KE; O'Brien, RE; Barnes, PD; Hart, AW; Docherty, HM; Lindley, KJ; Aynsley-Green, A; James, RFL; Docherty, K; Dunne, MJ				MacFarlane, WM; Chapman, JC; Shepherd, RM; Hashmi, MN; Kamimura, N; Cosgrove, KE; O'Brien, RE; Barnes, PD; Hart, AW; Docherty, HM; Lindley, KJ; Aynsley-Green, A; James, RFL; Docherty, K; Dunne, MJ			Engineering a glucose-responsive human insulin-secreting cell line from islets of langerhans isolated from a patient with persistent hyperinsulinemic hypoglycemia of infancy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; TRANSCRIPTION FACTOR IUF1; SULFONYLUREA RECEPTOR; FAMILIAL HYPERINSULINISM; GENE; RAT; NESIDIOBLASTOSIS; EXPRESSION; MUTATIONS; CHANNELS	Persistent hyperinsulinemic hypoglycemia of infancy (PHHI) is a neonatal disease characterized by dysregulation of insulin secretion accompanied by profound hypoglycemia, We have discovered that islet cells, isolated from the pancreas of a PHHI patient, proliferate in culture while maintaining a beta cell-like phenotype, The PHHI-derived cell line (NES2Y) exhibits insulin secretory characteristics typical of islet cells derived from these patients, i,e, they have no K-ATP channel activity and as a consequence secrete insulin at constitutively high levels in the absence of glucose, In addition, they exhibit impaired expression of the homeodomain transcription factor PDX1, which is a key component of the signaling pathway linking nutrient metabolism to the regulation of insulin gene expression. To repair these defects NES2Y cells were triple-transfected with cDNAs encoding the two components of the K-ATP channel (SUR1 and Kir6.2) and PDX1, One selected clonal cell line (NISK9) had normal K-ATP channel activity, and as a result of changes in intracellular Ca2+ homeostasis ([Ca2+](i)) secreted insulin within the physiological range of glucose concentrations. This approach to engineering PHHI-derived islet cells may be of use in gene therapy for PHHI and in cell engineering techniques for administering insulin for the treatment of diabetes mellitus.	Univ Sheffield, Inst Mol Physiol, Sheffield S10 2TN, S Yorkshire, England; Univ Sheffield, Dept Biomed Sci, Sheffield S10 2TN, S Yorkshire, England; Univ Aberdeen, Inst Med Sci, Dept Mol & Cell Biol, Aberdeen, Scotland; Univ London, Inst Child Hlth, London WC1N 1EH, England; Univ Leicester, Leicester Royal Infirm, Dept Surg, Leicester LE2 7LX, Leics, England	University of Sheffield; University of Sheffield; University of Aberdeen; University of London; University College London; University of Leicester	Dunne, MJ (corresponding author), Univ Sheffield, Inst Mol Physiol, Western Bank, Sheffield S10 2TN, S Yorkshire, England.			Hart, Alan/0000-0001-7463-2535; Cosgrove, Karen/0000-0002-5162-0985; Docherty, Kevin/0000-0001-6765-2060				ASHCROFT FM, 1992, INSULIN MOL BIOL PAT, P97; AYNSLEYGREEN A, 1981, DEV MED CHILD NEUROL, V23, P372; AYNSLEYGREEN A, 1981, ARCH DIS CHILD, V56, P496, DOI 10.1136/adc.56.7.496; BEST L, 1992, BIOCHEM PHARMACOL, V43, P2483, DOI 10.1016/0006-2952(92)90330-L; Dunne MJ, 1997, NEWS PHYSIOL SCI, V12, P197; Dunne MJ, 1997, NEW ENGL J MED, V336, P703, DOI 10.1056/NEJM199703063361005; DUNNE MJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P67, DOI 10.1016/0304-4157(91)90012-L; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; GAZDAR AF, 1980, P NATL ACAD SCI-BIOL, V77, P3519, DOI 10.1073/pnas.77.6.3519; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; Glaser B, 1999, TRENDS ENDOCRIN MET, V10, P55, DOI 10.1016/S1043-2760(98)00102-7; GLASER B, 1994, NAT GENET, V7, P185, DOI 10.1038/ng0694-185; Glaser B, 1998, NEW ENGL J MED, V338, P226, DOI 10.1056/NEJM199801223380404; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Kane C, 1996, NAT MED, V2, P1344, DOI 10.1038/nm1296-1344; Kukuvitis A, 1997, J CLIN ENDOCR METAB, V82, P1192, DOI 10.1210/jc.82.4.1192; Macfarlane WM, 1997, FEBS LETT, V413, P304, DOI 10.1016/S0014-5793(97)00874-0; MACFARLANE WM, 1994, BIOCHEM J, V303, P625, DOI 10.1042/bj3030625; McClenaghan NH, 1996, DIABETES, V45, P1132, DOI 10.2337/diabetes.45.8.1132; MELLOUL D, 1993, P NATL ACAD SCI USA, V90, P3865, DOI 10.1073/pnas.90.9.3865; Miki T, 1997, P NATL ACAD SCI USA, V94, P11969, DOI 10.1073/pnas.94.22.11969; Miki T, 1998, P NATL ACAD SCI USA, V95, P10402, DOI 10.1073/pnas.95.18.10402; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Nestorowicz A, 1998, HUM MOL GENET, V7, P1119, DOI 10.1093/hmg/7.7.1119; RANDLE PJ, 1993, DIABETOLOGIA, V36, P269, DOI 10.1007/BF00400227; RICORDI C, 1989, DIABETES, V38, P140, DOI 10.2337/diab.38.1.S140; Ryan F, 1998, ARCH DIS CHILD, V79, P445, DOI 10.1136/adc.79.5.445; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; SANTER R, 1995, J PEDIATR-US, V126, P1017, DOI 10.1016/S0022-3476(95)70238-5; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SATO Y, 1992, DIABETES, V41, P438, DOI 10.2337/diabetes.41.4.438; Shepherd RM, 1996, BRIT J PHARMACOL, V119, P911, DOI 10.1111/j.1476-5381.1996.tb15759.x; Stanley CA, 1998, NEW ENGL J MED, V338, P1352, DOI 10.1056/NEJM199805073381904; Straub SG, 1998, DIABETES, V47, P1053, DOI 10.2337/diabetes.47.7.1053; Straub SG, 1998, DIABETES, V47, P758, DOI 10.2337/diabetes.47.5.758; THOMAS PM, 1995, AM J HUM GENET, V56, P416; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; Thornton PS, 1998, J PEDIATR-US, V132, P9, DOI 10.1016/S0022-3476(98)70477-9; Verkarre V, 1998, J CLIN INVEST, V102, P1286, DOI 10.1172/JCI4495	40	53	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34059	34066		10.1074/jbc.274.48.34059	http://dx.doi.org/10.1074/jbc.274.48.34059			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567373	hybrid			2022-12-25	WOS:000083857500038
J	Rao, S; Garrett-Sinha, LA; Yoon, J; Simon, MC				Rao, S; Garrett-Sinha, LA; Yoon, J; Simon, MC			The Ets factors PU.1 and Spi-B regulate the transcription in vivo of P2Y10, a lymphoid restricted heptahelical receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS-TYROSINE-KINASE; CHAIN GENE ENHANCER; BETA-GAMMA-SUBUNITS; DNA-BINDING; CELL DEVELOPMENT; ATP RECEPTOR; PROTEIN; EXPRESSION; PROMOTER; DOMAIN	To investigate the in vivo functions of PU.1 and Spi-B, two highly related Ets transcription factors, we previously generated PU.1(+/+)Spi-B-/- and PU.1(+/-)Spi(-/-) mice and demonstrated a significant decrease in B-cell receptor (BCR) signaling in mutants. Major components of BCR signaling appear to be expressed at normal levels in these mice, implying that PU.1 and Spi-B cooperate in the transcription of additional target genes important for antigen receptor signaling. We used subtractive hybridization to identify novel in vivo PU.1/Spi-B target genes and determined that the expression of a heptahelical receptor, P2Y10, is dramatically reduced in PU.1(+/-)Spi-B-/- B-cells. Further analysis shows that P2Y10 expression is restricted to lymphoid cells and parallels that of Spi-B in B-lymphocytes. Lastly, the P2Y10 promoter contains a PU.1/Spi-B binding site functionally required for efficient transcription in B-cells. Thus, P2Y10 is likely to be a direct in vivo transcriptional target for PU.1 and Spi-B and provides a unique model to explore transcriptional regulation by this Ets factor subfamily, Furthermore, P2Y10 suggests an intriguing connection between heterotrimeric G-proteins and BCR signaling.	Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago; University of Chicago	Simon, MC (corresponding author), Univ Chicago, Howard Hughes Med Inst, 5841 S Maryland Ave,MC 1028, Chicago, IL 60637 USA.	csimon@medicine.bsd.uchicago.edu	Garrett-Sinha, Lee Ann/K-5911-2019; Simon, Celeste/AAG-3941-2021	Garrett-Sinha, Lee Ann/0000-0001-7806-4352				Abrams CS, 1996, BBA-MOL CELL RES, V1314, P233, DOI 10.1016/S0167-4889(96)00109-7; Anderson KL, 1998, BLOOD, V91, P3702, DOI 10.1182/blood.V91.10.3702; Bemark M, 1999, J BIOL CHEM, V274, P10259, DOI 10.1074/jbc.274.15.10259; Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; Bogdanov YD, 1997, J BIOL CHEM, V272, P12583, DOI 10.1074/jbc.272.19.12583; CHEN HM, 1995, BLOOD, V85, P2918, DOI 10.1182/blood.V85.10.2918.bloodjournal85102918; Dang W, 1998, MOL CELL BIOL, V18, P1477, DOI 10.1128/MCB.18.3.1477; DESIDERIO S, 1995, CURR BIOL, V5, P605, DOI 10.1016/S0960-9822(95)00121-7; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Eichbaum Q, 1997, BLOOD, V90, P4135, DOI 10.1182/blood.V90.10.4135; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; Erman B, 1998, MOL CELL BIOL, V18, P1322, DOI 10.1128/MCB.18.3.1322; Fredholm BB, 1997, TRENDS PHARMACOL SCI, V18, P79, DOI 10.1016/S0165-6147(96)01038-3; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; Garrett-Sinha LA, 1999, IMMUNITY, V10, P399, DOI 10.1016/S1074-7613(00)80040-0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HARDEN TK, 1995, ANNU REV PHARMACOL, V35, P541, DOI 10.1146/annurev.pharmtox.35.1.541; Heydemann A, 1996, MOL CELL BIOL, V16, P1676; Himmelmann A, 1996, BLOOD, V87, P1036, DOI 10.1182/blood.V87.3.1036.bloodjournal8731036; Himmelmann A, 1997, BLOOD, V90, P3984, DOI 10.1182/blood.V90.10.3984; Hromas Robert, 1993, Blood, V82, P2998; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; Lacaud G, 1998, IMMUNITY, V9, P827, DOI 10.1016/S1074-7613(00)80648-2; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; Li Q, 1997, BIOCHEM BIOPH RES CO, V236, P455, DOI 10.1006/bbrc.1997.6984; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; Ma YC, 1998, P NATL ACAD SCI USA, V95, P12197, DOI 10.1073/pnas.95.21.12197; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; Martin V, 1999, J BIOL CHEM, V274, P8597, DOI 10.1074/jbc.274.13.8597; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; Nicholas RA, 1996, MOL PHARMACOL, V50, P224; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; Omori SA, 1997, J IMMUNOL, V159, P1800; PARMACEK MS, 1994, MOL CELL BIOL, V14, P1870, DOI 10.1128/MCB.14.3.1870; PETTERSSON M, 1987, GENE DEV, V1, P962, DOI 10.1101/gad.1.9.962; PONGUBALA JMR, 1991, MOL CELL BIOL, V11, P1040, DOI 10.1128/MCB.11.2.1040; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; Pongubala JMR, 1997, P NATL ACAD SCI USA, V94, P127, DOI 10.1073/pnas.94.1.127; Rao S, 1999, J BIOL CHEM, V274, P11115, DOI 10.1074/jbc.274.16.11115; RAYGALLET D, 1995, ONCOGENE, V11, P303; Reya T, 1998, CURR OPIN IMMUNOL, V10, P158, DOI 10.1016/S0952-7915(98)80244-6; Rickert RC, 1997, NUCLEIC ACIDS RES, V25, P1317, DOI 10.1093/nar/25.6.1317; Scott EW, 1997, IMMUNITY, V6, P437, DOI 10.1016/S1074-7613(00)80287-3; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; Su GH, 1996, J EXP MED, V184, P203, DOI 10.1084/jem.184.1.203; Su GH, 1997, EMBO J, V16, P7118, DOI 10.1093/emboj/16.23.7118; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; Wan Y, 1997, J BIOL CHEM, V272, P17209, DOI 10.1074/jbc.272.27.17209; Webb TE, 1996, MOL PHARMACOL, V50, P258; Webb TE, 1996, BIOCHEM BIOPH RES CO, V219, P105, DOI 10.1006/bbrc.1996.0189; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I; Ying H, 1998, J IMMUNOL, V160, P2287; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Zhuang Y, 1996, MOL CELL BIOL, V16, P2898	64	31	32	1	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34245	34252		10.1074/jbc.274.48.34245	http://dx.doi.org/10.1074/jbc.274.48.34245			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567398	hybrid			2022-12-25	WOS:000083857500063
J	Bodnar, RJ; Gu, MY; Li, ZY; Englund, GD; Du, XP				Bodnar, RJ; Gu, MY; Li, ZY; Englund, GD; Du, XP			The cytoplasmic domain of the platelet glycoprotein Ib alpha is phosphorylated at Serine 609	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; DEPENDENT PROTEIN-KINASE; ACTIN-BINDING PROTEIN; MEMBRANE GLYCOPROTEIN; IX COMPLEX; T-CELLS; ARTERY SUBENDOTHELIUM; SIGNALING PROTEIN; IIB-IIIA; 14-3-3-PROTEINS	The a chain of the platelet von Willebrand factor receptor, glycoprotein (GP) Ib, is not known to be phosphorylated. Here, we report that the cytoplasmic domain of GPIb alpha is phosphorylated at Ser(609); this was detected by immunoblotting with an anti-phosphopeptide antibody, anti-pS609, that specifically recognizes the GPIb alpha C-terminal sequence S(606)GHSL(610) only when Ser(609) is phosphorylated. Immunoabsorption with anti-pS(609) removed almost all of the GPIb alpha from platelet lysates, indicating a high proportion of GPIb alpha phosphorylation. Anti-pS609 inhibited GPIb-IX binding to the intracellular signaling molecule, 14-3-3 zeta. Dephosphorylation of GPIb-IX with potato acid phosphatase inhibited anti-pS609 binding and also 14-3-3 zeta binding. A synthetic phosphopeptide corresponding to the GPIb alpha C-terminal sequence (SIRYSGHpSL), but not a nonphosphorylated identical peptide, abolished GPIb-IX binding to 14-3-3 zeta. Thus, phosphorylation at Ser(609) of GPIb alpha is important for 14-3-3 zeta binding to GPIb-IX. In certain regions of spreading platelets, particularly at the periphery, there was a reduction in GPIb alpha staining by anti-pS609 as observed under a confocal microscope, indicating that a subpopulation of GPIb alpha molecules in these regions is dephosphorylated. These data suggest that phosphorylation and dephosphorylation at Ser(609) of GPIb alpha regulates GPIb-IX interaction with 14-3-3 and may play important roles in the process of platelet adhesion and spreading.	Univ Illinois, Dept Pharmacol, Coll Med, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Du, XP (corresponding author), Univ Illinois, Dept Pharmacol, Coll Med, M-C868,835 S Wolcott Ave, Chicago, IL 60612 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL052547] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52547] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACS P, 1995, BIOCHEM BIOPH RES CO, V216, P103, DOI 10.1006/bbrc.1995.2597; Andrews RK, 1998, BIOCHEMISTRY-US, V37, P638, DOI 10.1021/bi970893g; ANDREWS RK, 1992, J BIOL CHEM, V267, P18605; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; Calverley DC, 1998, BLOOD, V91, P1295, DOI 10.1182/blood.V91.4.1295; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Cunningham JG, 1996, J BIOL CHEM, V271, P11581, DOI 10.1074/jbc.271.19.11581; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; Dong JF, 1997, BIOCHEMISTRY-US, V36, P12421, DOI 10.1021/bi970636b; DU XP, 1994, J BIOL CHEM, V269, P18287; DU XP, 1995, J BIOL CHEM, V270, P26146, DOI 10.1074/jbc.270.44.26146; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; Du XP, 1996, J BIOL CHEM, V271, P7362, DOI 10.1074/jbc.271.13.7362; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; FOX JEB, 1985, J BIOL CHEM, V260, P1970; FOX JEB, 1987, J BIOL CHEM, V262, P12627; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; FURUKAWA Y, 1993, BIOCHEM BIOPH RES CO, V194, P144, DOI 10.1006/bbrc.1993.1796; Gu MY, 1998, J BIOL CHEM, V273, P33465, DOI 10.1074/jbc.273.50.33465; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; LOPEZ JA, 1994, BLOOD COAGUL FIBRIN, V5, P97; Meller N, 1996, MOL CELL BIOL, V16, P5782; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; RUAN CG, 1987, BLOOD, V69, P570; SAKARIASSEN KS, 1979, NATURE, V279, P636, DOI 10.1038/279636a0; SAKARIASSEN KS, 1986, BRIT J HAEMATOL, V63, P681, DOI 10.1111/j.1365-2141.1986.tb07552.x; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; WARDELL MR, 1989, J BIOL CHEM, V264, P15656; Ware J, 1998, THROMB HAEMOSTASIS, V79, P466; WEISS HJ, 1986, BLOOD, V67, P322; WYLER B, 1986, BIOCHEM J, V234, P373, DOI 10.1042/bj2340373; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717	42	52	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33474	33479		10.1074/jbc.274.47.33474	http://dx.doi.org/10.1074/jbc.274.47.33474			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559231	hybrid			2022-12-25	WOS:000083745200047
J	Ji, Y; Wang, N; Ramakrishnan, R; Sehayek, E; Huszar, D; Breslow, JL; Tall, AR				Ji, Y; Wang, N; Ramakrishnan, R; Sehayek, E; Huszar, D; Breslow, JL; Tall, AR			Hepatic scavenger receptor BI promotes rapid clearance of high density lipoprotein free cholesterol and its transport into bile	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE CAVEOLAE; APOLIPOPROTEIN-A-I; SR-BI; BILIARY CHOLESTEROL; ESTERIFIED CHOLESTEROL; TARGETED MUTATION; SELECTIVE UPTAKE; LIPID TRANSFER; LIVER; METABOLISM	The clearance of free cholesterol from plasma lipoproteins by tissues is of major quantitative importance, but it is not known whether this is passive or receptor-mediated. Based on our finding that scavenger receptor BI (SR-BI) promotes free cholesterol (FC) exchange between high density lipoprotein (HDL) and cells, we tested whether SR-BI would effect FC movement in vivo using [C-14]FC- and [H-3]cholesteryl ester (CE)-labeled HDL in mice with increased (SR-BI transgenic (Tg)) or decreased (SR-BI attenuated (att)) hepatic SR-BI expression. The initial clearance of RBL FC was increased in SR-BI Tg mice by 72% and decreased in SR-BI att mice by 53%, but was unchanged in apoA-I knockout mice compared with wild-type mice. Transfer of FC to non-HDL and esterification of FC were minor and could not explain differences. The hepatic uptake of FC was increased in SR-BI Tg mice by 34% and decreased in SR-BI att mice by 22%. CE clearance and uptake gave similar results, but with much slower rates. The uptake of HDL FC and CE by SR-BI Tg primary hepatocytes was increased by 2.2- and 2.6-fold (1-h incubation), respectively, compared with control hepatocytes. In SR-BI Tg mice, the initial biliary secretion of [C-14]FC was markedly increased, whereas increased [H-3]FC appeared after a slight delay. Thus, in the mouse, a major portion of the clearance of HDL FC from plasma is mediated by SR-BI.	Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA; Columbia Univ, Dept Pediat, New York, NY 10032 USA; Rockefeller Univ, Lab Biochem Genet & Metab, New York, NY 10032 USA; Millennium Pharmaceut Inc, Cambridge, MA 02139 USA	Columbia University; Columbia University; Rockefeller University; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Tall, AR (corresponding author), Columbia Univ, Dept Med, Div Mol Med, 630 W 168th St, New York, NY 10032 USA.		Tall, Alan/AAT-8528-2021; Breslow, Jan L/B-7544-2008		NHLBI NIH HHS [HL54591, HL58033] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058033, P01HL054591] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Arai T, 1999, J BIOL CHEM, V274, P2366, DOI 10.1074/jbc.274.4.2366; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOTHAM KM, 1995, PROG LIPID RES, V34, P71, DOI 10.1016/0163-7827(94)00007-9; BRAVO E, 1989, BIOCHIM BIOPHYS ACTA, V1003, P315, DOI 10.1016/0005-2760(89)90238-5; BRAVO E, 1990, BIOCHIM BIOPHYS ACTA, V1045, P74, DOI 10.1016/0005-2760(90)90205-C; BRAVO E, 1994, BBA-LIPID LIPID MET, V1215, P93, DOI 10.1016/0005-2760(94)90096-5; CONNELLYM A, 1999, J BIOL CHEM, V274, P41; de la Llera-Moya M, 1999, J LIPID RES, V40, P575; Elferink RPJO, 1997, FASEB J, V11, P19, DOI 10.1096/fasebj.11.1.9034162; Fidge NH, 1999, J LIPID RES, V40, P187; Fielding CJ, 1999, BIOCHEMISTRY-US, V38, P2506, DOI 10.1021/bi981012o; FIELDING PE, 1995, BIOCHEMISTRY-US, V34, P14288, DOI 10.1021/bi00044a004; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; GLOMSET JA, 1968, J LIPID RES, V9, P155; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; Graf GA, 1999, J BIOL CHEM, V274, P12043, DOI 10.1074/jbc.274.17.12043; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; HALLORAN LG, 1978, SURGERY, V84, P1; Honkakoski P, 1998, BIOCHEM J, V330, P889, DOI 10.1042/bj3300889; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; Le N A, 1986, Methods Enzymol, V129, P384; MORTON RE, 1981, J BIOL CHEM, V256, P1992; PORTMAN OW, 1980, BIOCHIM BIOPHYS ACTA, V619, P545, DOI 10.1016/0005-2760(80)90106-X; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; RINNINGER F, 1987, J LIPID RES, V28, P1313; Robins SJ, 1997, J CLIN INVEST, V99, P380, DOI 10.1172/JCI119170; Rothblat GH, 1999, J LIPID RES, V40, P781; SCHWARTZ CC, 1981, BIOCHIM BIOPHYS ACTA, V663, P143, DOI 10.1016/0005-2760(81)90201-0; SCHWARTZ CC, 1975, GASTROENTEROLOGY, V69, P1379; SCHWARTZ CC, 1978, SCIENCE, V200, P62, DOI 10.1126/science.204996; SCHWARTZ CC, 1978, J CLIN INVEST, V61, P408, DOI 10.1172/JCI108952; SCHWARTZ CC, 1982, J CLIN INVEST, V70, P105, DOI 10.1172/JCI110582; SCOBEY MW, 1989, AM J PHYSIOL, V257, pG644, DOI 10.1152/ajpgi.1989.257.4.G644; Sehayek E, 1998, P NATL ACAD SCI USA, V95, P10194, DOI 10.1073/pnas.95.17.10194; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; STEIN Y, 1975, BIOCHIM BIOPHYS ACTA, V380, P106, DOI 10.1016/0005-2760(75)90049-1; Steinberg D, 1996, SCIENCE, V271, P460, DOI 10.1126/science.271.5248.460; Tall AR, 1998, EUR HEART J, V19, pA31; Ueda Y, 1999, J BIOL CHEM, V274, P7165, DOI 10.1074/jbc.274.11.7165; Varban ML, 1998, P NATL ACAD SCI USA, V95, P4619, DOI 10.1073/pnas.95.8.4619; VERKADE HJ, 1995, HEPATOLOGY, V21, P1174; Wang N, 1998, J BIOL CHEM, V273, P32920, DOI 10.1074/jbc.273.49.32920; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; Webb NR, 1998, J BIOL CHEM, V273, P15241, DOI 10.1074/jbc.273.24.15241; WILLIAMSON R, 1992, P NATL ACAD SCI USA, V89, P7134, DOI 10.1073/pnas.89.15.7134	53	230	235	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33398	33402		10.1074/jbc.274.47.33398	http://dx.doi.org/10.1074/jbc.274.47.33398			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559220	hybrid			2022-12-25	WOS:000083745200036
J	Hofsteenge, J; Blommers, M; Hess, D; Furmanek, A; Miroshnichenko, O				Hofsteenge, J; Blommers, M; Hess, D; Furmanek, A; Miroshnichenko, O			The four terminal components of the complement system are C-mannosylated on multiple tryptophan residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE ATTACK COMPLEX; AMINO-ACID-SEQUENCE; O-LINKED GLYCOSYLATION; FAST-ATOM-BOMBARDMENT; RNASE U-S; THROMBOSPONDIN FAMILY; PROTEIN GLYCOSYLATION; MASS-SPECTROMETRY; CELL-ADHESION; I REPEATS	C-Mannosylation is a unique form of protein glycosylation, involving the C-glycosidic attachment of a mannosyl residue to the indole moiety of Trp. In the two examples found so far, human RNase 2 and interleukin-12, only the first Trp in the recognition motif WXXW is specifically C-mannosylated. To establish the generality of protein C-mannosylation, and to learn more about its mechanism, the terminal components of the human complement system (C6, C7, C8,and C9), which contain multiple and complex recognition motifs, were examined. Together with C5b they form the cytolytic agent, the membrane attack complex These are the first proteins that are C-mannosylated on more than one Trp residue as follows: six in C6, four in C7, C8 alpha; and C8 beta, and two in C9. Thus, hom the 113 Trp residues in the complete membrane attack complex 50 were found to undergo C-mannosylation. The other important finding is that in C6, C7, C8, and C9 Trp residues without a second Trp (or another aromatic residue) at the +3 position can be C-mannosylated. This shows that they must contain an additional C-mannosylation signal. Whether this is encoded in the primary or tertiary structure is presently unknown. Finally, all modified Trp residues are part of the highly conserved core of the thrombospondin type 1 repeats present in these proteins. Since this module has been found in a large number of other proteins, the results suggest further candidates for C-mannosylation.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland; Novartis Pharma AG, CH-4002 Basel, Switzerland; Natl Acad Sci Ukraine, AV Palladin Biochem Inst, UA-252030 Kiev, Ukraine	Friedrich Miescher Institute for Biomedical Research; Novartis; National Academy of Sciences Ukraine; Palladin Institute of Biochemistry of NASU	Hofsteenge, J (corresponding author), Friedrich Miescher Inst, POB 2543, CH-4002 Basel, Switzerland.		Nita-Lazar, Aleksandra/N-3740-2018	Nita-Lazar, Aleksandra/0000-0002-8523-605X				ADAMS J, 1993, CURR BIOL, V3, P188, DOI 10.1016/0960-9822(93)90270-X; Adams RH, 1996, MECH DEVELOP, V57, P33, DOI 10.1016/0925-4773(96)00525-4; BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BECCHI M, 1989, BIOMED ENVIRON MASS, V18, P122, DOI 10.1002/bms.1200180207; Crombie R, 1998, J EXP MED, V187, P25, DOI 10.1084/jem.187.1.25; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; DEBEER T, 1995, BIOCHEMISTRY-US, V34, P11785, DOI 10.1021/bi00037a016; DISCIPIO RG, 1988, J BIOL CHEM, V263, P549; DISCIPIO RG, 1984, P NATL ACAD SCI-BIOL, V81, P7298, DOI 10.1073/pnas.81.23.7298; DISCIPIO RG, 1989, J BIOL CHEM, V264, P16197; Doucey MA, 1999, GLYCOBIOLOGY, V9, P435, DOI 10.1093/glycob/9.5.435; Doucey MA, 1998, MOL BIOL CELL, V9, P291, DOI 10.1091/mbc.9.2.291; DOUCEY MA, 1998, THESIS U L PASTEUR S; Gobron S, 1996, J CELL SCI, V109, P1053; GOTTSCHALK A, 1966, GLYCOPROTEINS, P1; GOTTSCHALK A, 1966, GLYCOPROTEINS     ED, P273; GOUNDIS D, 1988, NATURE, V335, P82, DOI 10.1038/335082a0; GRATHWOHL C, 1976, BIOPOLYMERS, V15, P2025, DOI 10.1002/bip.1976.360151012; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; HAEFLIGER JA, 1987, BIOCHEMISTRY-US, V26, P3551, DOI 10.1021/bi00386a045; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; Higashijima S, 1997, DEV BIOL, V192, P211, DOI 10.1006/dbio.1997.8760; Hilton DJ, 1996, J BIOL CHEM, V271, P4699; HOFSTEENGE J, 1991, J BIOL CHEM, V266, P24198; HOFSTEENGE J, 1994, BIOCHEMISTRY-US, V33, P13524, DOI 10.1021/bi00250a003; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; Krieg J, 1998, MOL BIOL CELL, V9, P301, DOI 10.1091/mbc.9.2.301; Krieg J, 1997, J BIOL CHEM, V272, P26687, DOI 10.1074/jbc.272.42.26687; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LHAV J, 1993, THROMBOSPONDIN; LI QM, 1992, BIOL MASS SPECTROM, V21, P213, DOI 10.1002/bms.1200210406; LIS H, 1993, EUR J BIOCHEM, V218, P1, DOI 10.1111/j.1432-1033.1993.tb18347.x; Loffler A, 1996, BIOCHEMISTRY-US, V35, P12005, DOI 10.1021/bi9610515; MAVES KK, 1993, IMMUNOL RES, V12, P233, DOI 10.1007/BF02918255; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; Mosimann SC, 1996, J MOL BIOL, V260, P540, DOI 10.1006/jmbi.1996.0420; MULLEREBERHARD HJ, 1986, ANNU REV IMMUNOL, V4, P503, DOI 10.1146/annurev.iy.04.040186.002443; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; NISHIKAWA T, 1998, SYN LETT, V1, P123; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; PISANO A, 1993, GLYCOBIOLOGY, V3, P429, DOI 10.1093/glycob/3.5.429; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RAO AG, 1987, BIOCHEMISTRY-US, V26, P3556, DOI 10.1021/bi00386a046; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; Shiratsuchi T, 1997, CYTOGENET CELL GENET, V79, P103, DOI 10.1159/000134693; SILVERSMITH RE, 1986, BIOCHEMISTRY-US, V25, P852, DOI 10.1021/bi00352a017; SMITH KF, 1991, BIOCHEMISTRY-US, V30, P8000, DOI 10.1021/bi00246a018; STANLEY KK, 1985, EMBO J, V4, P375, DOI 10.1002/j.1460-2075.1985.tb03639.x; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; TSCHOPP J, 1984, J BIOL CHEM, V259, P7857; TSCHOPP J, 1984, J BIOL CHEM, V259, P1922; TSCHOPP J, 1982, NATURE, V298, P534, DOI 10.1038/298534a0; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; Umemiya T, 1997, DEV BIOL, V186, P165, DOI 10.1006/dbio.1997.8591; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; Vliegenthart JFG, 1998, CURR OPIN STRUC BIOL, V8, P565, DOI 10.1016/S0959-440X(98)80145-0; WEIXING L, 1993, J BIOL CHEM, V268, P16179; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; WUERZNER R, 1995, IMMUNOLOGY, V85, P214; [No title captured]	62	86	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32786	32794		10.1074/jbc.274.46.32786	http://dx.doi.org/10.1074/jbc.274.46.32786			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551839	hybrid			2022-12-25	WOS:000083623000039
J	Laffargue, M; Raynal, P; Yart, A; Peres, C; Wetzker, R; Roche, S; Payrastre, B; Chap, H				Laffargue, M; Raynal, P; Yart, A; Peres, C; Wetzker, R; Roche, S; Payrastre, B; Chap, H			An epidermal growth factor receptor/Gab1 signaling pathway is required for activation of phosphoinositide 3-kinase by lysophosphatidic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SMOOTH-MUSCLE CELLS; BETA-GAMMA-SUBUNITS; PHOSPHATIDYLINOSITOL 3-KINASE; KINASE ACTIVATION; EGF-RECEPTOR; TYROSINE KINASE; MEDIATED ACTIVATION; RAS ACTIVATION; ION-CHANNEL	Phosphoinositide 3-kinase (PI3K) has been shown to play an essential role in G protein-induced signaling even in non-myeloid cells where few agonists of G protein-coupled receptors are known to activate PI3K. We have identified adherent cell lines where lysophosphatidic acid (LPA) strongly and rapidly activates the accumulation of PI3K lipid products. The process is not modified by expression of a kinase-dead mutant of the G beta gamma-responsive PI3K p110 gamma. In contrast, it is inhibited by genistein or expression of a dominant negative mutant of p85 and potentiated by overexpressing wild-type p110 alpha or -beta but not -gamma. By using a specific chemical inhibitor of the epidermal growth factor receptor (EGFR) and expression of a dominant negative mutant, we have observed that recruitment of p85/p110 PI3Ks occurs through transactivation of the EGFR by LPA and downstream mobilization of the docking protein Gab1 that associates with p85 upon LPA stimulation. Finally, we show that LPA cannot activate PI3K in cell lines lacking the EGFR/Gab1 pathway, including cells that transactivate the PDGF receptor. Altogether, these results demonstrate that activation of PI3K by LPA is conditioned by the ability of LPA to transactivate an EGFR/Gab1 signaling pathway.	Hop Purpan, INSERM U326, IFR 30, F-31059 Toulouse, France; Univ Jena, Max Planck Res Unit, D-07747 Jena, Germany; CRBM, CNRS UPR 1086, F-34293 Montpellier, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Friedrich Schiller University of Jena; Max Planck Society; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Raynal, P (corresponding author), Hop Purpan, INSERM U326, IFR 30, F-31059 Toulouse, France.		Peres, Carlos A./B-1276-2013; YART, Armelle/A-5656-2016; Peres, Carlos Augusto/N-8275-2019; Raynal, Patrick/O-1926-2018; Laffargue, Muriel/AAE-7849-2021; Peres, Carlos A./ABE-8361-2020; Wetzker, Reinhard/AAD-8713-2019	Peres, Carlos A./0000-0002-1588-8765; YART, Armelle/0000-0002-2412-9840; Peres, Carlos A./0000-0002-1588-8765; , Bernard/0000-0002-8693-0190; Laffargue, Muriel/0000-0003-1833-639X; Raynal, Patrick/0000-0002-6731-3007; roche, serge/0000-0003-3413-3859				Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Ferby IM, 1996, J BIOL CHEM, V271, P11684, DOI 10.1074/jbc.271.20.11684; FERBY IM, 1994, J BIOL CHEM, V269, P30485; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Habib AA, 1998, J BIOL CHEM, V273, P6885, DOI 10.1074/jbc.273.12.6885; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; Hu ZW, 1996, J BIOL CHEM, V271, P8977, DOI 10.1074/jbc.271.15.8977; Ireton K, 1996, SCIENCE, V274, P780, DOI 10.1126/science.274.5288.780; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Kranenburg O, 1997, EMBO J, V16, P3097, DOI 10.1093/emboj/16.11.3097; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Lopez-Ilasaca M, 1998, J BIOL CHEM, V273, P2505, DOI 10.1074/jbc.273.5.2505; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Roche S, 1998, MOL CELL BIOL, V18, P7119, DOI 10.1128/MCB.18.12.7119; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SAKANAKA C, 1994, BIOCHEM BIOPH RES CO, V205, P18, DOI 10.1006/bbrc.1994.2623; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Takeda H, 1999, EMBO J, V18, P386, DOI 10.1093/emboj/18.2.386; Tang XW, 1997, J BIOL CHEM, V272, P14193, DOI 10.1074/jbc.272.22.14193; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; ZHANG J, 1995, J BIOL CHEM, V270, P6589, DOI 10.1074/jbc.270.12.6589; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767	43	73	75	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32835	32841		10.1074/jbc.274.46.32835	http://dx.doi.org/10.1074/jbc.274.46.32835			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551845	hybrid			2022-12-25	WOS:000083623000045
J	Cestra, G; Castagnoli, L; Dente, L; Minenkova, O; Petrelli, A; Migone, N; Hoffmuller, U; Schneider-Mergener, J; Cesareni, G				Cestra, G; Castagnoli, L; Dente, L; Minenkova, O; Petrelli, A; Migone, N; Hoffmuller, U; Schneider-Mergener, J; Cesareni, G			The SH3 domains of endophilin and amphiphysin bind to the proline-rich region of synaptojanin 1 at distinct sites that display an unconventional binding specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULOSE MEMBRANE SUPPORTS; SRC HOMOLOGY-3 DOMAIN; PEPTIDE LIBRARIES; SYNAPSIN-I; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; SPOT-SYNTHESIS; DYNAMIN BINDS; IDENTIFICATION; ENDOCYTOSIS	The proline-rich domain of synaptojanin 1, a synaptic protein with phosphatidylinositol phosphatase activity, binds to amphiphysin and to a family of recently discovered proteins known as the SH3p4/8/13, the SH3-GL, or the endophilin family. These interactions are mediated by SH3 domains and are believed to play a regulatory role in synaptic vesicle recycling, We have precisely mapped the target peptides on human synaptojanin that are recognized by the SH3 domains of endophilins and amphiphysin and proven that they are distinct. By a combination of different approaches, selection of phage displayed peptide libraries, substitution analyses of peptides synthesized on cellulose membranes, and a peptide scan spanning a 252-residue long synaptojanin fragment, we have concluded that amphiphysin binds to two sites, PIRPSR and PTIPPR, whereas endophilin has a distinct preferred binding site, PKRPPPPR, The comparison of the results obtained by phage display and substitution analysis permitted the identification of proline and arginine at positions 4 and 6 in the PIRPSR and PTIPPR target sequence as the major determinants of the recognition specificity mediated by the SH3 domain of amphiphysin I. More complex is the structural rationalization of the preferred endophilin ligands where SH3 binding cannot be easily interpreted in the framework of the "classical" type I or type II SH3 binding models. Our results suggest that the binding repertoire of SH3 domains may be more complex than originally predicted.	Univ Rome, Dept Biol, I-00133 Rome, Italy; Humboldt Univ, Univ Frankfurt Charite, D-10117 Berlin, Germany; Univ Turin, Dipartimento Genet Biol & Biochim, I-10126 Turin, Italy	Sapienza University Rome; Humboldt University of Berlin; University of Turin	Cesareni, G (corresponding author), Univ Rome, Dept Biol, Via Della Ric Sci, I-00133 Rome, Italy.	Cesareni@uniroma2.it	Cesareni, Gianni/AAW-1382-2020; cestra, gianluca/AAL-4736-2021	Castagnoli, Luisa/0000-0001-5283-8671; DENTE, LUCIANA/0000-0002-9617-0922				Anderson BL, 1998, J CELL BIOL, V141, P1357, DOI 10.1083/jcb.141.6.1357; CHEADLE C, 1994, J BIOL CHEM, V269, P24034; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; FELICI F, 1991, J MOL BIOL, V222, P301, DOI 10.1016/0022-2836(91)90213-P; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Frank R, 1996, Methods Mol Biol, V66, P149; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; Giachino C, 1997, GENOMICS, V41, P427, DOI 10.1006/geno.1997.4645; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Kramer A, 1997, CELL, V91, P799, DOI 10.1016/S0092-8674(00)80468-7; Kramer A, 1998, METH MOL B, V87, P25; KRAMER A, 1993, PEPTIDE RES, V6, P314; Kramer A, 1998, PROTEIN ENG, V11, P941, DOI 10.1093/protein/11.10.941; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Micheva KD, 1997, J BIOL CHEM, V272, P27239, DOI 10.1074/jbc.272.43.27239; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; Nemoto Y, 1997, J BIOL CHEM, V272, P30817, DOI 10.1074/jbc.272.49.30817; Okamoto PM, 1997, J BIOL CHEM, V272, P11629; Onofri F, 1997, P NATL ACAD SCI USA, V94, P12168, DOI 10.1073/pnas.94.22.12168; Owen DJ, 1998, EMBO J, V17, P5273, DOI 10.1093/emboj/17.18.5273; Pelicci G, 1996, ONCOGENE, V13, P633; Qualmann B, 1999, MOL BIOL CELL, V10, P501, DOI 10.1091/mbc.10.2.501; RICKLES FR, 1995, THROMB HAEMOSTASIS, V74, P391; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Singer-Kruger B, 1998, J CELL SCI, V111, P3347; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Srinivasan S, 1997, EUR J CELL BIOL, V74, P350; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	43	94	104	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32001	32007		10.1074/jbc.274.45.32001	http://dx.doi.org/10.1074/jbc.274.45.32001			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542231	hybrid			2022-12-25	WOS:000083532100039
J	Kamata, T; Liddington, RC; Takada, Y				Kamata, T; Liddington, RC; Takada, Y			Interaction between collagen and the alpha(2) I-domain of integrin alpha(2)beta(1) - Critical role of conserved residues in the metal ion-dependent adhesion site (MIDAS) region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; COMPLEMENT RECEPTOR TYPE-3; AMINO-ACID SEQUENCE; FACTOR A1 DOMAIN; CRYSTAL-STRUCTURE; LIGAND-BINDING; DIRECTED MUTAGENESIS; ALPHA-2-BETA-1 VLA-2; VONWILLEBRAND-FACTOR; MOLECULAR-CLONING	A docking model of the cu, I-domain and collagen has been proposed based on their crystal structures (Emsley, J., Ring, S., Bergelson, J., and Liddington, R. C. (1997) J. Biol. Chem. 272, 28512-28517). In this model, several amino acid residues in the I domain make direct contact with collagen (Asn-154, Asp-219, Leu-220, Glu-256, His-258, Tyr-285, Asn-289, Leu-291, Asn-295, and Lys-298), and the protruding C-helix of alpha(2) (residues 284-288) determines ligand specificity. Because most of the pro posed critical residues are not conserved, different I-domains are predicted to bind to collagen differently. We found that deleting the entire C-helix or mutating the predicted critical residues had no effect on collagen binding to whole alpha(2)beta(1), with the exception that mutating Asn-154, Asp-219, and His-258 had a moderate effect. We performed further studies and found that mutating the conserved surface-exposed residues in the metal ion-dependent adhesion site (MIDAS) (Tyr-157 and Gln-215) significantly blocks collagen binding. me have revised the docking model based on the mutagenesis data. In the revised model, conserved Tyr-157 makes contact with collagen in addition to the previously proposed Asn-154, Asp-219, His-258, and Tyr-285 residues. These results suggest that the collagen-binding I-domains (e.g. alpha(1), alpha(2), and alpha(10)) bind to collagen in a similar fashion.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Burnham Inst, La Jolla, CA 92037 USA	Scripps Research Institute; Sanford Burnham Prebys Medical Discovery Institute	Takada, Y (corresponding author), Scripps Res Inst, Dept Vasc Biol, 10550 N Torrey Pines Rd,VB-1,Pines Rd, La Jolla, CA 92037 USA.			takada, yoshikazu/0000-0001-5481-9589	NIGMS NIH HHS [GM49899, GM47157] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047157, R01GM049899] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNAOUT MA, 1988, J CELL BIOL, V106, P2153, DOI 10.1083/jcb.106.6.2153; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; Bienkowska J, 1997, J BIOL CHEM, V272, P25162, DOI 10.1074/jbc.272.40.25162; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; Calderwood DA, 1997, J BIOL CHEM, V272, P12311, DOI 10.1074/jbc.272.19.12311; CAMBILLAU C, 1984, J MOL GRAPHICS, V2, P53, DOI 10.1016/0263-7855(84)80036-3; Camper L, 1998, J BIOL CHEM, V273, P20383, DOI 10.1074/jbc.273.32.20383; Celikel R, 1998, NAT STRUCT BIOL, V5, P189, DOI 10.1038/nsb0398-189; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; CORBI AL, 1988, J BIOL CHEM, V263, P12403; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Emsley J, 1998, J BIOL CHEM, V273, P10396, DOI 10.1074/jbc.273.17.10396; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; Huizinga EG, 1997, STRUCTURE, V5, P1147, DOI 10.1016/S0969-2126(97)00266-9; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KERN A, 1994, J BIOL CHEM, V269, P22811; Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; PYTELA R, 1988, EMBO J, V7, P1371, DOI 10.1002/j.1460-2075.1988.tb02953.x; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; SANTORO SA, 1995, THROMB HAEMOSTASIS, V74, P813; Sasaki T, 1998, EMBO J, V17, P1625, DOI 10.1093/emboj/17.6.1625; SHAW SK, 1994, J BIOL CHEM, V269, P6016; Symersky J, 1997, NAT STRUCT BIOL, V4, P833, DOI 10.1038/nsb1097-833; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TENCHINI ML, 1993, CELL ADHES COMMUN, V1, P55, DOI 10.3109/15419069309095681; TUCKWELL D, 1995, J CELL SCI, V108, P1629; VanderVieren M, 1995, IMMUNITY, V3, P683, DOI 10.1016/1074-7613(95)90058-6	35	43	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32108	32111		10.1074/jbc.274.45.32108	http://dx.doi.org/10.1074/jbc.274.45.32108			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542245	hybrid			2022-12-25	WOS:000083532100053
J	Lienard, H; Bruhns, P; Malbec, O; Fridman, WH; Daeron, M				Lienard, H; Bruhns, P; Malbec, O; Fridman, WH; Daeron, M			Signal regulatory proteins negatively regulate immunoreceptor-dependent cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE SHP-1; AFFINITY IGE RECEPTOR; FC-GAMMA RECEPTOR; INHIBITORY RECEPTOR; STEEL FACTOR; MAST-CELLS; ASSOCIATION; LEUKEMIA; PHOSPHORYLATION; EXPRESSION	Signal regulatory proteins of the alpha subtype (SIRP alpha) are ubiquitous molecules of the immunoglobulin superfamily that negatively regulate protein tyrosine kinase receptor-dependent cell proliferation. Their intracytoplasmic domain contains four motifs that resemble immunoreceptor tyrosine-based inhibition motifs (ITIMs) and that, when tyrosyl-phosphorylated, recruit cytoplasmic SH2 domain-bearing protein tyrosine phosphatases (SHPs). ITIMs are borne by molecules that negatively regulate cell activation induced by receptors bearing immunoreceptor tyrosine-based activation motifs (ITAMs), Because SIRP alpha are coexpressed with ITAM-bearing receptors in hematopoietic cells, we investigated whether SIRP alpha could negatively regulate ITAM-dependent cell activation. We found SIRPa transcripts in human mast cells, and we show that a chimeric molecule having the transmembrane and intracytoplasmic domains of SIRP alpha could inhibit IgE-induced mediator secretion and cytokine synthesis by mast cells. Inhibition required that the SIRP alpha chimera was coaggregated with ITAM-bearing high affinity IgE receptors (Fc epsilon RI). It was correlated with the tyrosyl phosphorylation of the SIRP alpha chimera and the recruitment of SHP-1 and SHP-2. The phosphorylation of Fc epsilon RI ITAMs was decreased; the mobilization of intracellular Ca2+ and the influx of extracellular Ca2+ were reduced, and the activation of the mitogen-activated protein kinases Erk1 and Erk2 was abolished. SIRP alpha can therefore negatively regulate not only receptor tyrosine kinase-dependent cell proliferation but also ITAM-dependent cell activation.	Inst Curie, INSERM, U255, Lab Immunol Cellulaire & Clin, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Daeron, M (corresponding author), Inst Curie, INSERM, U255, Lab Immunol Cellulaire & Clin, 26 Rue Ulm, F-75005 Paris, France.		Bruhns, Pierre/F-5567-2013	Bruhns, Pierre/0000-0002-4709-8936; fridman, wolf herman/0000-0002-1332-0973				Adams S, 1998, J IMMUNOL, V161, P1853; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; Binstadt BA, 1996, IMMUNITY, V5, P629, DOI 10.1016/S1074-7613(00)80276-9; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; Bruhns P, 1999, J IMMUNOL, V162, P3168; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; Cherif-Zahar B, 1998, BLOOD, V92, P2535, DOI 10.1182/blood.V92.7.2535.2535_2535_2540; DAERON M, 1992, J IMMUNOL, V149, P1365; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; DAERON M, 1997, IMMUNOLOGIST, V5, P79; Fong DC, 1996, IMMUNOL LETT, V54, P83, DOI 10.1016/S0165-2478(96)02654-5; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Furusawa T, 1998, J BIOCHEM-TOKYO, V123, P101; Gadina M, 1998, J IMMUNOL, V160, P4657; Ghannadan M, 1998, J INVEST DERMATOL, V111, P689, DOI 10.1046/j.1523-1747.1998.00359.x; Heldin Carl-Henrik, 1996, Cytokine and Growth Factor Reviews, V7, P3, DOI 10.1016/1359-6101(96)00002-0; Jiang PH, 1999, J BIOL CHEM, V274, P559, DOI 10.1074/jbc.274.2.559; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KISHI K, 1985, LEUKEMIA RES, V9, P381, DOI 10.1016/0145-2126(85)90060-8; LATOUR S, 1992, J IMMUNOL, V149, P2155; LIU FT, 1980, J IMMUNOL, V124, P2728; Malbec O, 1998, J IMMUNOL, V160, P1647; Malbec O, 1999, J IMMUNOL, V162, P4424; MATOZAKI T, 1994, BIOCHEM BIOPH RES CO, V204, P874, DOI 10.1006/bbrc.1994.2541; Moretta A, 1997, IMMUNOL REV, V155, P105, DOI 10.1111/j.1600-065X.1997.tb00943.x; Ohnishi H, 1996, J BIOL CHEM, V271, P25569, DOI 10.1074/jbc.271.41.25569; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; Parkos CA, 1996, J CELL BIOL, V132, P437, DOI 10.1083/jcb.132.3.437; PFEFFERKORN LC, 1994, J IMMUNOL, V153, P3228; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; Reinhold MI, 1997, J EXP MED, V185, P1, DOI 10.1084/jem.185.1.1; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; Saito H, 1996, J IMMUNOL, V157, P343; Scharenberg AM, 1996, CELL, V87, P961, DOI 10.1016/S0092-8674(00)81790-0; SCHOLL PR, 1993, P NATL ACAD SCI USA, V90, P8847, DOI 10.1073/pnas.90.19.8847; Stofega MR, 1998, J BIOL CHEM, V273, P7112, DOI 10.1074/jbc.273.12.7112; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Timms JF, 1998, MOL CELL BIOL, V18, P3838, DOI 10.1128/MCB.18.7.3838; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; Veillette A, 1998, J BIOL CHEM, V273, P22719, DOI 10.1074/jbc.273.35.22719; Vivier E, 1997, IMMUNOL TODAY, V18, P286, DOI 10.1016/S0167-5699(97)80025-4; WAGTMANN N, 1995, IMMUNITY, V2, P439, DOI 10.1016/1074-7613(95)90025-X; Waterhouse P, 1996, IMMUNOL REV, V153, P183, DOI 10.1111/j.1600-065X.1996.tb00925.x	47	57	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32493	32499		10.1074/jbc.274.45.32493	http://dx.doi.org/10.1074/jbc.274.45.32493			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542295	hybrid			2022-12-25	WOS:000083532100103
J	Park, JS; Park, SJ; Peng, XD; Wang, M; Yu, MA; Lee, SH				Park, JS; Park, SJ; Peng, XD; Wang, M; Yu, MA; Lee, SH			Involvement of DNA-dependent protein kinase in UV-induced replication arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; SIMIAN VIRUS-40 DNA; CELL NUCLEAR ANTIGEN; RNA-POLYMERASE-II; SV40 T-ANTIGEN; RADIATION-INDUCED PHOSPHORYLATION; BINDING-PROTEIN; ATAXIA-TELANGIECTASIA; PHOSPHATIDYLINOSITOL 3-KINASE; IONIZING-RADIATION	Cells exposed to UV irradiation are predominantly arrested at S-phase as web as at the G(1)/S boundary while repair occurs. It is not known how UV irradiation induces S-phase arrest and yet permits DNA repair; however, UV-induced inhibition of replication is efficiently reversed by the addition of replication protein A (RPA), suggesting a role for RPA in this regulatory event. Here, we show evidence that DNA-dependent protein kinase (DNA-PK), plays a role in W-induced replication arrest, DNA synthesis of M059K (DNA-PK catalytic subunit-positive (DNA-PKcs(+))), as measured by [H-3]thymidine incorporation, was significantly arrested by 4 h following UV irradiation, whereas M059J (DNA-PKcs(-)) cells were much less affected. Similar results were obtained with the in vitro replication reactions where immediate replication arrest occurred in DNA-PKcs(+) cells following UV irradiation, and only a gradual decrease in replication activity was observed in DNA-PKcs(-) cells. Reversal of replication arrest was observed at 8 h following UV irradiation in DNA-PKcs(+) cells but not in DNA-PKcs(-) cells. Reversal of W-induced replication arrest was also observed in vitro by the addition of a DNA-PK inhibitor, wortmannin, or by immunodepletion of DNA-PKcs, supporting a positive role for DNA-PK in damage-induced replication arrest. The RPA-containing fraction from UV-irradiated DNA-PKcs(+) cells poorly supported DNA replication, whereas the replication activity of the RPA-containing fraction from DNA-PKcs(-) cells was not affected by UV, suggesting that DNA-PKcs may be involved in UV-induced replication arrest through modulation of RPA activity. Together, our results strongly suggest a role for DNA-PK in S-phase (replication) arrest in response to UV irradiation.	Indiana Univ, Ctr Canc, Dept Biochem & Mol Biol, Sch Med,Walther Oncol Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Lee, SH (corresponding author), Indiana Univ, Ctr Canc, Dept Biochem & Mol Biol, Sch Med,Walther Oncol Ctr, Indianapolis, IN 46202 USA.	slee@iupui.edu	Yu, Michelle/CAH-1357-2022		NIGMS NIH HHS [GM52358] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052358] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramova NA, 1997, P NATL ACAD SCI USA, V94, P7186, DOI 10.1073/pnas.94.14.7186; BOUBNOV NV, 1995, MOL CELL BIOL, V15, P5700; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; Cheng XB, 1996, RADIOTHER ONCOL, V39, P43, DOI 10.1016/0167-8140(96)01712-4; Chibazakura T, 1997, EUR J BIOCHEM, V247, P1166, DOI 10.1111/j.1432-1033.1997.01166.x; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; COLLINS KL, 1993, EMBO J, V12, P4555, DOI 10.1002/j.1460-2075.1993.tb06144.x; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; Drissi R, 1998, BIOCHEM J, V330, P181, DOI 10.1042/bj3300181; DVIR A, 1993, J BIOL CHEM, V268, P10440; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Fried LM, 1996, P NATL ACAD SCI USA, V93, P13825, DOI 10.1073/pnas.93.24.13825; Galloway AM, 1999, ONCOGENE, V18, P1361, DOI 10.1038/sj.onc.1202433; GANNON J V, 1990, New Biologist, V2, P84; Gasior SL, 1998, GENE DEV, V12, P2208, DOI 10.1101/gad.12.14.2208; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Henricksen LA, 1996, NUCLEIC ACIDS RES, V24, P3107, DOI 10.1093/nar/24.15.3107; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; Jackson SP, 1997, INT J BIOCHEM CELL B, V29, P935, DOI 10.1016/S1357-2725(97)00006-X; Jin SF, 1997, CANCER SURV, V29, P221; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KUHN A, 1995, GENE DEV, V9, P193, DOI 10.1101/gad.9.2.193; LABHART P, 1995, P NATL ACAD SCI USA, V92, P2934, DOI 10.1073/pnas.92.7.2934; LEE SH, 1995, J BIOL CHEM, V270, P12801, DOI 10.1074/jbc.270.21.12801; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lin RZ, 1997, J BIOL CHEM, V272, P31196, DOI 10.1074/jbc.272.49.31196; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; Longhese MP, 1996, NUCLEIC ACIDS RES, V24, P3533, DOI 10.1093/nar/24.18.3533; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; McConnell K, 1996, CURR OPIN CELL BIOL, V8, P325, DOI 10.1016/S0955-0674(96)80005-6; MELENDY T, 1993, J BIOL CHEM, V268, P3389; Morgan SE, 1997, CANCER RES, V57, P3386; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; Muller C, 1998, NUCLEIC ACIDS RES, V26, P1382, DOI 10.1093/nar/26.6.1382; Muller C, 1997, ONCOGENE, V15, P2343, DOI 10.1038/sj.onc.1201402; MURAKAMI Y, 1993, J BIOL CHEM, V268, P11008; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; Orren DK, 1997, MOL BIOL CELL, V8, P1129, DOI 10.1091/mbc.8.6.1129; PAN ZQ, 1995, P NATL ACAD SCI USA, V92, P4636, DOI 10.1073/pnas.92.10.4636; PETERSON SR, 1995, J BIOL CHEM, V270, P1449, DOI 10.1074/jbc.270.3.1449; POLTORATSKY VP, 1995, J IMMUNOL, V155, P4529; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; Rotman G, 1997, BIOESSAYS, V19, P911, DOI 10.1002/bies.950191011; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; Shen HX, 1997, ONCOL RES, V9, P295; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMALE ST, 1986, MOL CELL BIOL, V6, P4077, DOI 10.1128/MCB.6.11.4077; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STIGGER E, 1994, P NATL ACAD SCI USA, V91, P579, DOI 10.1073/pnas.91.2.579; Stigger E, 1998, J BIOL CHEM, V273, P9337, DOI 10.1074/jbc.273.15.9337; Treuner K, 1999, J BIOL CHEM, V274, P15556, DOI 10.1074/jbc.274.22.15556; Vairapandi M, 1996, ONCOGENE, V12, P2579; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wang Y, 1998, RADIAT RES, V149, P284, DOI 10.2307/3579962; Wang Y, 1999, J BIOL CHEM, V274, P22060, DOI 10.1074/jbc.274.31.22060; Weaver DT, 1997, NATURE, V388, P428, DOI 10.1038/41225; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; Yuan ZM, 1997, J BIOL CHEM, V272, P23485, DOI 10.1074/jbc.272.38.23485	70	52	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32520	32527		10.1074/jbc.274.45.32520	http://dx.doi.org/10.1074/jbc.274.45.32520			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542299	hybrid			2022-12-25	WOS:000083532100107
J	Nelson, EL; Strobl, S; Subleski, J; Prieto, D; Kopp, WC; Nelson, PJ				Nelson, EL; Strobl, S; Subleski, J; Prieto, D; Kopp, WC; Nelson, PJ			Cycling of human dendritic cell effector phenotypes in response to TNF-alpha: modification of the current 'maturation' paradigm and implications for in vivo immunoregulation	FASEB JOURNAL			English	Article						antigen presenting cells; cytokines; chemokines; and dendritic cell activation	NECROSIS-FACTOR-ALPHA; COLONY-STIMULATING FACTOR; IN-VITRO; T-CELLS; HUMAN BLOOD; IMMUNE-RESPONSE; CYTOKINE; PROGENITORS; GENERATION; ACTIVATION	Dendritic cells (DCs) are potent antigen presenting cells reported to undergo irreversible functional 'maturation' in response to inflammatory signals such as TNF-alpha. The current paradigm holds that this DC maturation event is required for full functional capacity and represents terminal differentiation of this cell type, culminating in apoptotic cell death. This provides a possible mechanism for avoiding dysregulated immunostimulatory activity, but imposes constraints on the capacity of DCs to influence subsequent immune responses and to participate in immunological memory. We report that the cell surface and functional effects induced by TNF-alpha are reversible and reinducible. These effects are accompanied by a concordant modulation of cytokine mRNA expression that includes the induction of proinflammatory factors (IL-15, IL-12, LT-a!, LT-beta, TNF-alpha, RANTES) which is coincident with the down-regulation of counter-regulatory cytokines (IL-10, TGF-beta 1, TGF-beta 2, IL-1 RA, MCP-1). The resultant net effect is a dendritic cell activation state characterized by a transient proinflammatory posture. These results demonstrate that 1) human DCs do not undergo terminal 'maturation' in response to TNF-alpha, 2) DC phenotypes are more pleiotropic than previously thought, and 3) DCs are potential immunoregulatory effector cells with implications for control of immune responses in both in vivo and in vitro systems.-Nelson, E. L., Strobl, S., Subleski, J., Prieto, D., Kopp, W. C., Nelson, P. J. Cycling of human dendritic cell effector phenotypes in response to TNF-alpha: modification of the current 'maturation' paradigm and implications for in vivo immunoregulation. Cycling of human dendritic cell effector phenotypes in response to TNF-alpha modification of the current 'maturation' paradigm and implications for in vivo immunoregulation.	NCI, Immunotherapy Lab, FCRDC, Div Clin Sci, Frederick, MD 21702 USA; NCI, Clin Support Lab, FCRDC, Div Clin Sci, Frederick, MD 21702 USA; Univ Munich, Med Poliklin, D-8000 Munich, Germany	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Munich	Nelson, EL (corresponding author), NCI, Immunotherapy Lab, FCRDC, Div Clin Sci, Bldg 1050,Boyles St, Frederick, MD 21702 USA.	enelson@mail.ncifcrf.gov		Nelson, Edward/0000-0001-7887-032X	NCI NIH HHS [N01-CO-56000] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BELL EB, 1979, IMMUNOLOGY, V38, P797; Bender A, 1996, J IMMUNOL METHODS, V196, P121, DOI 10.1016/0022-1759(96)00079-8; Caux C, 1996, J EXP MED, V184, P695, DOI 10.1084/jem.184.2.695; Cella M, 1997, CURR OPIN IMMUNOL, V9, P10, DOI 10.1016/S0952-7915(97)80153-7; Chapuis F, 1997, EUR J IMMUNOL, V27, P431, DOI 10.1002/eji.1830270213; Chen BG, 1998, BLOOD, V91, P4652, DOI 10.1182/blood.V91.12.4652.412a03_4652_4661; CUMBERBATCH M, 1995, IMMUNOLOGY, V84, P31; de Saint-Vis B, 1998, J IMMUNOL, V160, P1666; DiRosa F, 1996, J EXP MED, V183, P2153, DOI 10.1084/jem.183.5.2153; Enk AH, 1997, INT J CANCER, V73, P309, DOI 10.1002/(SICI)1097-0215(19971104)73:3<309::AID-IJC1>3.0.CO;2-3; GALEY A, 1995, IMMUNITY, V3, P459; Ghanekar S, 1996, J IMMUNOL, V157, P4028; Hart DNJ, 1997, BLOOD, V90, P3245, DOI 10.1182/blood.V90.9.3245; Herbst B, 1996, BLOOD, V88, P2541, DOI 10.1182/blood.V88.7.2541.bloodjournal8872541; JAFFE R, 1993, PEDIATR PATHOL, V13, P821, DOI 10.3109/15513819309048268; Jonuleit H, 1997, J IMMUNOL, V158, P2610; KNIGHT SC, 1982, EUR J IMMUNOL, V12, P1057, DOI 10.1002/eji.1830121214; Langerhans P, 1868, VIRCHOWS ARCH PATHOL, V44, P325, DOI [DOI 10.1007/BF01959006, 10.1007/BF01959006]; Morse MA, 1997, ANN SURG, V226, P6, DOI 10.1097/00000658-199707000-00002; Peters JH, 1996, IMMUNOL TODAY, V17, P273, DOI 10.1016/0167-5699(96)80544-5; PUGH CW, 1983, J EXP MED, V157, P1758, DOI 10.1084/jem.157.6.1758; Reddy A, 1997, BLOOD, V90, P3640, DOI 10.1182/blood.V90.9.3640; REID CDL, 1993, ADV EXP MED BIOL, V329, P257; Rescigno M, 1997, J LEUKOCYTE BIOL, V61, P415, DOI 10.1002/jlb.61.4.415; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; Romani N, 1996, J IMMUNOL METHODS, V196, P137, DOI 10.1016/0022-1759(96)00078-6; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Santiago-Schwarz F, 1998, BLOOD, V92, P745, DOI 10.1182/blood.V92.3.745.415k35_745_755; Schuler G, 1997, INT ARCH ALLERGY IMM, V112, P317, DOI 10.1159/000237474; Siena S, 1995, EXP HEMATOL, V23, P1463; Sozzani S, 1998, J IMMUNOL, V161, P1083; STEINMAN RM, 1973, J EXP MED, V137, P1142, DOI 10.1084/jem.137.5.1142; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; Steptoe RJ, 1996, CLIN EXP IMMUNOL, V105, P397, DOI 10.1046/j.1365-2249.1996.d01-779.x; Thomas R, 1996, IMMUNOL TODAY, V17, P559, DOI 10.1016/S0167-5699(96)20030-1; VanderMeide PH, 1996, BIOTHERAPY, V8, P243, DOI 10.1007/BF01877210; Winzler C, 1997, J EXP MED, V185, P317, DOI 10.1084/jem.185.2.317; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Wu JH, 1996, J IMMUNOL, V157, P3404; ZHOU LJ, 1995, BLOOD, V86, P3295, DOI 10.1182/blood.V86.9.3295.bloodjournal8693295; Zhou LJ, 1996, P NATL ACAD SCI USA, V93, P2588, DOI 10.1073/pnas.93.6.2588; Zitvogel L, 1996, J EXP MED, V183, P87, DOI 10.1084/jem.183.1.87	46	37	39	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1999	13	14					2021	2030		10.1096/fasebj.13.14.2021	http://dx.doi.org/10.1096/fasebj.13.14.2021			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544185				2022-12-25	WOS:000083660700014
J	Schlake, T; Schupp, I; Kutsche, K; Mincheva, A; Lichter, P; Boehm, T				Schlake, T; Schupp, I; Kutsche, K; Mincheva, A; Lichter, P; Boehm, T			Predetermined chromosomal deletion encompassing the Nf-1 gene	ONCOGENE			English	Article						neurofibromatosis-1; cre recombinase; chromosome engineering	EMBRYONIC STEM-CELLS; ESCHERICHIA-COLI; SITE; DNA; RECOMBINATION; TRANSLOCATION; EXPRESSION; MICE	Complex chromosomal rearrangements (deletions, inversions, translocations) are a hallmark of human tumour cells, Yet, the generation of animal models for gross chromosomal abnormalities still presents a formidable challenge. Here, we describe a versatile procedure for chromosomal engineering that was used to generate an ES cell line with a megabase deletion encompassing the tumour suppressor gene neurofibromatosis-l (Nf-l) on mouse chromosome 11, which is often deleted in tumours of neural crest origin. Homologous recombination into sites flanking Nf-1 was used to introduce artificial sequences (triple-helix, loxP, vector backbone) that can be employed for in vitro recovery of intervening sequences or the generation of in viva deletions. This strategy may be developed into a scheme by which large chromosomal regions with precisely defined end points may be excised from mammalian cells and reintroduced after suitable in vitro modification.	Max Planck Inst Immunobiol, Dept Dev Immunol, D-79108 Freiburg, Germany; Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Max Planck Society; Helmholtz Association; German Cancer Research Center (DKFZ)	Boehm, T (corresponding author), Max Planck Inst Immunobiol, Dept Dev Immunol, Stuebeweg 51, D-79108 Freiburg, Germany.							Gagneten S, 1997, NUCLEIC ACIDS RES, V25, P3326, DOI 10.1093/nar/25.16.3326; HOCHMAN L, 1983, VIROLOGY, V131, P11, DOI 10.1016/0042-6822(83)90528-7; JOHANSSON B, 1993, GENE CHROMOSOME CANC, V8, P205, DOI 10.1002/gcc.2870080402; KEMPKES B, 1995, P NATL ACAD SCI USA, V92, P5875, DOI 10.1073/pnas.92.13.5875; Li ZW, 1996, P NATL ACAD SCI USA, V93, P6158, DOI 10.1073/pnas.93.12.6158; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; Montgomery JC, 1998, MAMM GENOME, V8, pS215, DOI 10.1007/s003359900656; NEHLS M, 1995, MAMM GENOME, V6, P321, DOI 10.1007/BF00364794; Nehls M, 1996, SCIENCE, V272, P886, DOI 10.1126/science.272.5263.886; NEHLS MC, 1994, MAMM GENOME, V5, P183, DOI 10.1007/BF00352354; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; SHENG Y, 1995, NUCLEIC ACIDS RES, V23, P1990, DOI 10.1093/nar/23.11.1990; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376; VANDEURSEN J, 1995, P NATL ACAD SCI USA, V92, P7376, DOI 10.1073/pnas.92.16.7376; VISKOCHIL D, 1993, ANNU REV NEUROSCI, V16, P183, DOI 10.1146/annurev.ne.16.030193.001151; Zhang YM, 1998, NAT GENET, V20, P123, DOI 10.1038/2417; Zhu H, 1999, NUCLEIC ACIDS RES, V27, P910, DOI 10.1093/nar/27.3.910	18	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	1999	18	44					6078	6082		10.1038/sj.onc.1203021	http://dx.doi.org/10.1038/sj.onc.1203021			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557097				2022-12-25	WOS:000083359100014
J	Morinaka, K; Koyama, S; Nakashima, S; Hinoi, T; Okawa, K; Iwamatsu, A; Kikuchi, A				Morinaka, K; Koyama, S; Nakashima, S; Hinoi, T; Okawa, K; Iwamatsu, A; Kikuchi, A			Epsin binds to the EH domain of POB1 and regulates receptor-mediated endocytosis	ONCOGENE			English	Article						Epsin; POB1; EH domain; endocytosis	NUCLEOTIDE DISSOCIATION STIMULATOR; TYROSINE KINASE SUBSTRATE; RAS-INDUCED TRANSFORMATION; INSULIN-RECEPTOR; SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; ACTIN CYTOSKELETON; NERVE-TERMINALS; EPS15 HOMOLOGY; DUAL ROLE	POB1 has been identified as a RalBP1-binding protein and has the Eps15 homology (EH) domain. The EH domain-containing proteins have been suggested to be involved in clathrin-dependent endocytosis. To clarify the function of POB1, we purified a protein which binds to the EH domain of POB1 from bovine brain cytosol and identified it as Epsin, which is known to bind to the EH domain of Eps15. Epsin has three Asn-Pro-Phe (NPF) motifs in the C-terminal region, which are known to form the core sequence for the binding to the EH domain. The EH domain of POB1 interacted directly with the region containing the NPF motifs of Epsin. Expression of Epsin in CHO-IR cells inhibited internalization of insulin although it affected neither insulin-binding nor autophosphorylation activities of the insulin receptor. Taken together with the observations that Epsin is involved in internalization of the receptors for epidermal growth factor and transferrin, these results suggest that Epsin is a binding partner of POB1 and their binding regulates receptor-mediated endocytosis.	Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan	Hiroshima University; Kirin Brewery Company Limited	Kikuchi, A (corresponding author), Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.		Hinoi, Takao/AAI-1443-2020	Hinoi, Takao/0000-0003-0462-6177				ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BACKER JM, 1989, J BIOL CHEM, V264, P1694; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Biener Y, 1996, J BIOL CHEM, V271, P29489, DOI 10.1074/jbc.271.46.29489; Carbone R, 1997, CANCER RES, V57, P5498; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Coda L, 1998, J BIOL CHEM, V273, P3003, DOI 10.1074/jbc.273.5.3003; de Beer T, 1998, SCIENCE, V281, P1357, DOI 10.1126/science.281.5381.1357; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; DiFiore PP, 1997, TRENDS BIOCHEM SCI, V22, P411, DOI 10.1016/S0968-0004(97)01127-4; EMKEY R, 1991, J BIOL CHEM, V266, P9703; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Haffner C, 1997, FEBS LETT, V419, P175, DOI 10.1016/S0014-5793(97)01451-8; Hamer I, 1997, J BIOL CHEM, V272, P21685, DOI 10.1074/jbc.272.35.21685; HARI J, 1987, J BIOL CHEM, V262, P15341; HEIZMANN CW, 1991, TRENDS BIOCHEM SCI, V16, P98, DOI 10.1016/0968-0004(91)90041-S; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; Kay BK, 1999, PROTEIN SCI, V8, P435; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kishida S, 1997, ONCOGENE, V15, P2899, DOI 10.1038/sj.onc.1201473; Koshiba S, 1999, FEBS LETT, V442, P138, DOI 10.1016/S0014-5793(98)01644-5; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEVY JR, 1987, ENDOCRINOLOGY, V121, P2075, DOI 10.1210/endo-121-6-2075; Matsubara K, 1999, ONCOGENE, V18, P1303, DOI 10.1038/sj.onc.1202425; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; McPherson PS, 1998, BIOCHEM BIOPH RES CO, V244, P701, DOI 10.1006/bbrc.1998.8331; MORRIS SA, 1993, EMBO J, V12, P667, DOI 10.1002/j.1460-2075.1993.tb05700.x; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Okazaki M, 1996, CANCER RES, V56, P2387; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; Paoluzi S, 1998, EMBO J, V17, P6541, DOI 10.1093/emboj/17.22.6541; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; Tang HY, 1997, MOL CELL BIOL, V17, P4294, DOI 10.1128/MCB.17.8.4294; Tang HY, 1996, MOL CELL BIOL, V16, P4897; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Wendland B, 1998, J CELL BIOL, V141, P71, DOI 10.1083/jcb.141.1.71; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530; Yamabhai M, 1998, J BIOL CHEM, V273, P31401, DOI 10.1074/jbc.273.47.31401; Yamaguchi A, 1997, J BIOL CHEM, V272, P31230, DOI 10.1074/jbc.272.50.31230	50	58	63	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 21	1999	18	43					5915	5922		10.1038/sj.onc.1202974	http://dx.doi.org/10.1038/sj.onc.1202974			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557078				2022-12-25	WOS:000083270700008
J	Chen, JW; Luo, YL; Hwang, MJ; Peng, FC; Ling, KH				Chen, JW; Luo, YL; Hwang, MJ; Peng, FC; Ling, KH			Territrem B, a tremorgenic mycotoxin that inhibits acetylcholinesterase with a noncovalent yet irreversible binding mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPERGILLUS-TERREUS; MOLECULAR-DYNAMICS; PHYSICOCHEMICAL PROPERTIES; CHEMICAL-STRUCTURE; CRYSTAL-STRUCTURE; SERINE PROTEASES; ACUTE TOXICITY; TRANSITION; COMPLEX; BUTYRYLCHOLINESTERASE	Territrem B (TRB) is a fungal metabolite isolated from Aspergillus terreus shown previously to be a potent and irreversible inhibitor of acetylcholinesterase (AChE), In the present study, a number of binding and inhibition assays were carried out to further characterize the inhibitory effect of TRB, The results indicate that the binding of TRB (a) is much more selective than a well characterized selective inhibitor of AChE, BW284C51, (b) adopts a one-to-one stoichiometry with the enzyme, (c) cannot be undone by an AChE-regenerating oxime agent, which contrasts the ability of 8 M urea to release AChE-bound TRB, (d) is enhanced by high concentration NaCl but prevented, unless preincubated, by Triton X-100, and (e) exhibits quasi-first order kinetics with an overall inhibition constant of 0.01 nM(-1) min(-1). Together these results suggest a very different irreversible binding (a noncovalent type) from that of the covalent type, which involves typical irreversible AChE inhibitors such as diisopropylfluorophosphate and neostigmine, According to the prediction of a molecular modeling study, the distinct AChE, inhibitory characteristics of TRB may arise from the inhibitor being noncovalently trapped within a unique active-site gorge structure of the enzyme. It was predicted that an optimal TRB AChE binding would position a narrowing connection of the TRB structure at a constricted area near the entrance of the gorge, thereby providing a structural basis for the observed irreversible binding.	Acad Sinica, Inst Biomed Sci, Div Struct Biol, Taipei 115, Taiwan; Natl Taiwan Univ, Coll Med, Inst Biochem, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Inst Toxicol, Taipei 100, Taiwan	Academia Sinica - Taiwan; National Taiwan University; National Taiwan University	Hwang, MJ (corresponding author), Acad Sinica, Inst Biomed Sci, Div Struct Biol, 128 Yen Chiou Yuan Rd,Sec 2, Taipei 115, Taiwan.	mjhwang@ibms.sinica.edu.tw	Hwang, Ming-jing/E-9210-2012	Hwang, Ming-jing/0000-0002-9657-5663; PENG, FU-CHUO/0000-0003-4385-8499				ABRAMSON SN, 1989, MOL PHARMACOL, V36, P349; ANTOSIEWICZ J, 1995, BIOCHEMISTRY-US, V34, P4211, DOI 10.1021/bi00013a009; ARVANOV VL, 1993, NEUROSCI LETT, V152, P69, DOI 10.1016/0304-3940(93)90485-4; BARAK D, 1995, BIOCHEMISTRY-US, V34, P15444, DOI 10.1021/bi00047a008; Barnard E.A., 1974, PERIPHERAL NERVOUS S, P201; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; Cervenansky C., 1991, P303; Chen Jen-Wei, 1996, Journal of Biomedical Science, V3, P54, DOI 10.1007/BF02253579; CYGLER M, 1993, PROTEIN SCI, V2, P366; Degen SJ, 1999, BIOORG MED CHEM LETT, V9, P973, DOI 10.1016/S0960-894X(99)00115-8; DING HQ, 1992, J CHEM PHYS, V97, P4309, DOI 10.1063/1.463935; DOWD PF, 1992, ENTOMOL EXP APPL, V65, P57, DOI 10.1007/BF00189717; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Enyedy IJ, 1998, J AM CHEM SOC, V120, P8043, DOI 10.1021/ja973131h; FOX BW, 1968, INT J APPL RADIAT IS, V19, P717, DOI 10.1016/0020-708X(68)90109-9; GILSON MK, 1994, SCIENCE, V263, P1276, DOI 10.1126/science.8122110; GORDON MA, 1978, MOL PHARMACOL, V14, P266; Harel M, 1996, J AM CHEM SOC, V118, P2340, DOI 10.1021/ja952232h; Harel M, 1995, STRUCTURE, V3, P1355, DOI 10.1016/S0969-2126(01)00273-8; HAREL M, 1992, P NATL ACAD SCI USA, V89, P10827, DOI 10.1073/pnas.89.22.10827; HARPER JW, 1985, BIOCHEMISTRY-US, V24, P1831, DOI 10.1021/bi00329a005; HARPER JW, 1985, BIOCHEMISTRY-US, V24, P7200, DOI 10.1021/bi00346a028; HSU TH, 1982, CRYSTALLOGR STRUCT C, V11, P199; IVERSON F, 1969, BIOCHEMISTRY-US, V8, P1889, DOI 10.1021/bi00833a018; KITZ R, 1962, J BIOL CHEM, V237, P3245; Kryger G, 1999, STRUCTURE, V7, P297, DOI 10.1016/S0969-2126(99)80040-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE SS, 1992, J NAT PROD, V55, P251; Ling K H, 1987, Mycotoxin Res, V3, P7, DOI 10.1007/BF03191979; LING KH, 1982, APPL ENVIRON MICROB, V44, P860, DOI 10.1128/AEM.44.4.860-863.1982; LING KH, 1991, DRUG METAB DISPOS, V19, P587; LING KH, 1994, J TOXICOL-TOXIN REV, V13, P243, DOI 10.3109/15569549409089963; LING KH, 1984, APPL ENVIRON MICROB, V47, P98, DOI 10.1128/AEM.47.1.98-100.1984; LING KH, 1979, APPL ENVIRON MICROB, V37, P358, DOI 10.1128/AEM.37.3.358-361.1979; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NOCHI S, 1995, BIOL PHARM BULL, V18, P1145; OMURA S, 1995, J ANTIBIOT, V48, P745, DOI 10.7164/antibiotics.48.745; Ordentlich A, 1996, J BIOL CHEM, V271, P11953, DOI 10.1074/jbc.271.20.11953; Otoguro K, 1997, PHARMACOL THERAPEUT, V76, P45, DOI 10.1016/S0163-7258(97)00093-4; PENG FC, 1985, APPL ENVIRON MICROB, V49, P721, DOI 10.1128/AEM.49.3.721-723.1985; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; RADIC Z, 1993, BIOCHEMISTRY-US, V32, P12074, DOI 10.1021/bi00096a018; Raves ML, 1997, NAT STRUCT BIOL, V4, P57, DOI 10.1038/nsb0197-57; RIPOLL DR, 1993, P NATL ACAD SCI USA, V90, P5128, DOI 10.1073/pnas.90.11.5128; Sepcic K, 1998, BBA-PROTEIN STRUCT M, V1387, P217, DOI 10.1016/S0167-4838(98)00125-3; SHAFFERMAN A, 1992, EMBO J, V11, P3561, DOI 10.1002/j.1460-2075.1992.tb05439.x; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; Taylor P, 1998, NEUROLOGY, V51, pS30, DOI 10.1212/WNL.51.1_Suppl_1.S30; Tung S.-S., 1971, Journal of the Formosan Medical Association, V70, P251; Wlodek ST, 1997, J AM CHEM SOC, V119, P9513, DOI 10.1021/ja971226d; Zhou HX, 1998, P NATL ACAD SCI USA, V95, P9280, DOI 10.1073/pnas.95.16.9280	52	34	40	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34916	34923		10.1074/jbc.274.49.34916	http://dx.doi.org/10.1074/jbc.274.49.34916			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574966	hybrid			2022-12-25	WOS:000083979600060
J	Dornan, J; Page, AP; Taylor, P; Wu, SY; Winter, AD; Husi, H; Walkinshaw, MD				Dornan, J; Page, AP; Taylor, P; Wu, SY; Winter, AD; Husi, H; Walkinshaw, MD			Biochemical and structural characterization of a divergent loop cyclophilin from Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS-ISOMERASE; NEMATODE BRUGIA-MALAYI; CYCLOSPORINE-A; HOMOLOG NINAA; MOLECULAR REPLACEMENT; CRYSTAL-STRUCTURE; PROLYL ISOMERASE; INFECTIVE LARVAE; BINDING-PROTEIN; TOXOCARA-CANIS	Cyclophilin 3 (CYP-3) is one of the most abundantly expressed cyclophilin isoforms in the free living nematode Caenorhabditis elegans, The detailed post-embryonic expression pattern of the cyp-3 transcript is unusual, peaking during early larval development. The spatial expression pattern was examined via reporter gene analysis demonstrating that the cyp-3 transcript is exclusively expressed in the single anterior excretory cell. Recombinant cyclophilin 3 has been purified, crystallized and solved to a resolution of 1.8 Angstrom. The peptidyl-prolyl isomerase activity of CYP-3 has been characterized against the substrate N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide, and gives a k(cat)/K-m value of 2.4 x 10(6) M-1 s(-1). The immunosuppressive drug cyclosporin A binds and inhibits CYP-3 with an IC50 value of 16 nM, comparable with the range of values found for human cyclophilin A The x-ray structure shows that the overall fold and active site geometry is similar to other cyclophilin structures. There are however a number of distinctive features, and we use this structure and amino acid sequence alignment analysis to identify a subgroup of "divergent-loop cyclophilins". This subgroup has a number of uniquely conserved features: an additional loop between residues 48 and 54 (KSGKPLH); two cysteine residues (Cys(40) and Cys(168)) that are in close proximity but remain in the unoxidized form, and two Other conserved residues, His(54) and Glu(83). We suggest that these features are functionally important for the role played by this class of cyclophilins during cellular responses to stress caused by changes in the redox environment or by upregulation of cellular activity. This study represents a detailed biological, biochemical, and structural characterization of a single cyclophilin isoform in the model organism Caenorhabditis elegans.	Univ Edinburgh, Inst Cell & Mol Biol, Struct Biochem Grp, Edinburgh EH9 3JR, Midlothian, Scotland; Univ Glasgow, Anderson Coll, Wellcome Ctr Mol Parasitol, Glasgow G11 6NU, Lanark, Scotland	University of Edinburgh; University of Glasgow	Walkinshaw, MD (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Struct Biochem Grp, Med Swann Bldg,Kings Bldg,Mayfield Rd, Edinburgh EH9 3JR, Midlothian, Scotland.		walkinshaw, malcolm/AAB-7497-2019	walkinshaw, malcolm/0000-0001-5955-9325				Altschul SF, 1996, METHOD ENZYMOL, V266, P460; BACHINGER HP, 1987, J BIOL CHEM, V262, P17144; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; BRAUN W, 1995, FASEB J, V9, P63, DOI 10.1096/fasebj.9.1.7529736; CHAPPELL LH, 1992, PARASITOLOGY, V105, pS25, DOI 10.1017/S0031182000075338; Cho H, 1997, BIOCHEMISTRY-US, V36, P382, DOI 10.1021/bi9624604; Chou IT, 1997, PLANT MOL BIOL, V35, P873, DOI 10.1023/A:1005930024796; Duina AA, 1998, J BIOL CHEM, V273, P18974, DOI 10.1074/jbc.273.30.18974; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FRESKGARD PO, 1992, SCIENCE, V258, P466, DOI 10.1126/science.1357751; GALAT A, 1995, PROG BIOPHYS MOL BIO, V63, P67, DOI 10.1016/0079-6107(94)00009-X; Gothel SF, 1998, BIOCHEMISTRY-US, V37, P13392, DOI 10.1021/bi981253w; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1986, J BIOL CHEM, V261, P8547; Helekar SA, 1997, P NATL ACAD SCI USA, V94, P5432, DOI 10.1073/pnas.94.10.5432; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; Jaschke A, 1998, J MOL BIOL, V277, P763, DOI 10.1006/jmbi.1998.1644; Johnstone IL, 1996, MOL BIOCHEM PARASIT, V80, P103, DOI 10.1016/0166-6851(96)02682-5; KALLEN J, 1991, NATURE, V353, P276, DOI 10.1038/353276a0; KE HM, 1991, P NATL ACAD SCI USA, V88, P9483, DOI 10.1073/pnas.88.21.9483; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; Leverson JD, 1998, MOL CELL, V1, P203, DOI 10.1016/S1097-2765(00)80021-0; LIU J, 1990, P NATL ACAD SCI USA, V87, P4028, DOI 10.1073/pnas.87.11.4028; Meza-Zepeda LA, 1998, J EXP BOT, V49, P1451, DOI 10.1093/jexbot/49.325.1451; Mikol V, 1998, PROTEIN SCI, V7, P1310, DOI 10.1002/pro.5560070606; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NELSON FK, 1984, J EXP ZOOL, V231, P45, DOI 10.1002/jez.1402310107; ONDEK B, 1992, J BIOL CHEM, V267, P16460; PAGE AP, 1992, EXP PARASITOL, V75, P56, DOI 10.1016/0014-4894(92)90122-Q; Page AP, 1996, BIOCHEM J, V317, P179, DOI 10.1042/bj3170179; PAGE AP, 1992, EXP PARASITOL, V75, P72, DOI 10.1016/0014-4894(92)90123-R; PAGE AP, 1995, PARASITOL TODAY, V11, P385, DOI 10.1016/0169-4758(95)80007-7; PAGE AP, 1995, BIOCHEMISTRY-US, V34, P11545, DOI 10.1021/bi00036a030; Page AP, 1998, MOL BIOCHEM PARASIT, V95, P215, DOI 10.1016/S0166-6851(98)00096-6; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PFLUGL GM, 1994, J MOL BIOL, V244, P385, DOI 10.1006/jmbi.1994.1738; RASSOW J, 1995, MOL CELL BIOL, V15, P2654; SHELDRICK GM, 1997, SHELX97 SHELXWAT; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; Taylor P, 1998, FEBS LETT, V425, P361, DOI 10.1016/S0014-5793(98)00264-6; Taylor P, 1997, PROG BIOPHYS MOL BIO, V67, P155, DOI 10.1016/S0079-6107(97)00014-X; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WHITE J, 1998, NEMATODE CAENORHABDI, P81; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718; 1999, SCIENCE, V283, P35	50	47	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34877	34883		10.1074/jbc.274.49.34877	http://dx.doi.org/10.1074/jbc.274.49.34877			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574961	hybrid			2022-12-25	WOS:000083979600055
J	Matsuda, S; Suzuki-Fujimoto, T; Minowa, A; Ueno, H; Katamura, K; Koyasu, S				Matsuda, S; Suzuki-Fujimoto, T; Minowa, A; Ueno, H; Katamura, K; Koyasu, S			Temperature-sensitive ZAP70 mutants degrading through a proteasome-independent pathway - Restoration of a kinase domain mutant by Cdc37	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; T-CELL RECEPTOR; HEAT-SHOCK PROTEINS; TANDEM SH2 DOMAINS; SIGNAL-TRANSDUCTION; LYMPHOCYTE-ACTIVATION; ANTIGEN RECEPTOR; ZAP-70; IMMUNODEFICIENCY; PHOSPHORYLATION	CD8 deficiency is an autosomal recessive form of severe combined immunodeficiency diseases characterized by the absence of CD8(+) T lymphocytes and impaired T cell functions. We identified two novel missense mutations in the zap70 genes of a CD8-deficiency patient. One mutation (P80Q) affects a residue in an SH2 domain and another (M572L) in the kinase subdomain XI. Both mutations cause a degradation of ZAP70 protein in a temperature-sensitive manner through an ATP-dependent and proteasome-independent pathway. We further demonstrated that Cdc37, a protein kinase-specific chaperone, bound to M572L but not P80Q mutant and restored the expression of the M572L mutant when overexpressed. The restoration of M572L mutant by Cdc37 required the function of HSP90. These results indicate that Cdc37 in conjunction with HSP90 functions as a molecular chaperone for a temperature-sensitive kinase domain mutant of ZAP70.	Keio Univ, Sch Med, Dept Immunol, Shinjuku Ku, Tokyo 1608582, Japan; Kyoto Univ, Grad Sch Med, Dept Pediat, Sakyo Ku, Kyoto 6068507, Japan	Keio University; Kyoto University	Koyasu, S (corresponding author), Keio Univ, Sch Med, Dept Immunol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.		Koyasu, Shigeo/J-5583-2015; Ueno, Hideki/L-1237-2016	Koyasu, Shigeo/0000-0001-9585-3038; Ueno, Hideki/0000-0001-7747-0738				ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; Geier E, 1999, SCIENCE, V283, P978, DOI 10.1126/science.283.5404.978; Gelfand E W, 1983, Birth Defects Orig Artic Ser, V19, P65; GIEBEL LB, 1991, J CLIN INVEST, V87, P1119, DOI 10.1172/JCI115075; GOTOH Y, 1994, ONCOGENE, V9, P1891; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Isakov N, 1996, J BIOL CHEM, V271, P15753, DOI 10.1074/jbc.271.26.15753; Katamura K, 1999, CLIN EXP IMMUNOL, V115, P124; Kimura Y, 1997, GENE DEV, V11, P1775, DOI 10.1101/gad.11.14.1775; KOYASU S, 1994, P NATL ACAD SCI USA, V91, P6693, DOI 10.1073/pnas.91.14.6693; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Matsuda S, 1998, J BIOL CHEM, V273, P12378, DOI 10.1074/jbc.273.20.12378; MONAFO WJ, 1992, CLIN EXP IMMUNOL, V90, P390; Morimoto RI, 1997, ESSAYS BIOCHEM, V32, P17; Ochs HD, 1996, MEDICINE, V75, P287, DOI 10.1097/00005792-199611000-00001; Ozaki T, 1995, DNA CELL BIOL, V14, P1017, DOI 10.1089/dna.1995.14.1017; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Qian DP, 1996, J EXP MED, V183, P611, DOI 10.1084/jem.183.2.611; ROIFMAN CM, 1989, J EXP MED, V170, P2177, DOI 10.1084/jem.170.6.2177; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SunderPlassmann R, 1997, EUR J IMMUNOL, V27, P2001, DOI 10.1002/eji.1830270826; vanOers NSC, 1996, J EXP MED, V183, P1053, DOI 10.1084/jem.183.3.1053; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YONEZAWA N, 1988, EUR J BIOCHEM, V177, P1, DOI 10.1111/j.1432-1033.1988.tb14337.x	32	53	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34515	34518		10.1074/jbc.274.49.34515	http://dx.doi.org/10.1074/jbc.274.49.34515			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574909	hybrid			2022-12-25	WOS:000083979600003
J	Satoh, M; Shaheen, VM; Kao, PN; Okano, T; Shaw, M; Yoshida, H; Richards, HB; Reeves, WH				Satoh, M; Shaheen, VM; Kao, PN; Okano, T; Shaw, M; Yoshida, H; Richards, HB; Reeves, WH			Autoantibodies define a family of proteins with conserved double-stranded RNA-binding domains as well as DNA binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English; English	Article							NF-KAPPA-B; MONOCLONAL-ANTIBODIES; KINASE PKR; ANTIGEN; EXPRESSION; INTERFERON; CELLS; PURIFICATION; AUTOIMMUNITY; ACTIVATION	Cellular responses to viral infection are signaled by double-stranded (ds) RNA, which is not found in substantial amounts in uninfected cells. Although cellular dsRNA-binding proteins have been described, their characterization is incomplete. We show that dsRNA-binding proteins are prominent autoantigens. Sera from B6 and B10.S mice with pristane-induced lupus and human autoimmune sera immunoprecipitated a novel set of 130-, 110-, 90-, 80-, and 45-kDa proteins. The proteins were all major cellular poly(IC)-binding factors. N-terminal amino acid sequences of p110 and p90 were identical and matched nuclear factor (NF) 90 and M phase phosphoprotein 4. p45 and p90 were identified as the NF45 . NF90 complex, which binds the interleukin-a promoter as well as certain highly structured viral RNAs. NF90 . NF45 and M phase phosphoprotein 4 belong to a large group of proteins with conserved dsRNA-binding motifs. Besides binding dsRNA, NF90 . NF45, p110, and p130 had single-stranded and dsDNA binding activity. Some sera contained autoantibodies whose binding was inhibited by poly(IC) but not single-stranded DNA or vice versa, suggesting that the DNA- and RNA-binding sites are different. These autoantibodies will be useful probes of the function of dsRNA-binding proteins. Their interaction with dsRNA, an immunological adjuvant, also could promote autoimmunity.	Univ N Carolina, Dept Med & Microbiol & Immunol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Stanford Univ, Med Ctr, Div Pulm & Crit Care Med, Stanford, CA 94305 USA; Kitasato Univ, Clin Immunol Lab, Sch Allied Hlth Sci, Sagamihara, Kanagawa 228, Japan	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Stanford University; Kitasato University	Reeves, WH (corresponding author), Univ Florida, Div Clin Immunol & Rheumatol, POB 100221, Gainesville, FL 32610 USA.	reevewh@medicine.ufl.edu	Satoh, Minoru/E-2421-2011		NIAMS NIH HHS [R01-AR44731, P60-AR30701, AR40391] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044731, R01AR040391, P60AR030701] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BASS BL, 1994, CURR BIOL, V4, P301, DOI 10.1016/S0960-9822(00)00069-5; CHAN EKL, 1987, J EXP MED, V166, P1627, DOI 10.1084/jem.166.6.1627; CHOU CH, 1992, J EXP MED, V175, P1677, DOI 10.1084/jem.175.6.1677; CORTHESY B, 1994, J BIOL CHEM, V269, P20682; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; Dempsey LA, 1998, J BIOL CHEM, V273, P29224, DOI 10.1074/jbc.273.44.29224; DONG XW, 1994, J EXP MED, V179, P1243, DOI 10.1084/jem.179.4.1243; FUJINAMI RS, 1983, P NATL ACAD SCI-BIOL, V80, P2346, DOI 10.1073/pnas.80.8.2346; Gianani R, 1996, P NATL ACAD SCI USA, V93, P2257, DOI 10.1073/pnas.93.6.2257; Herbert A, 1997, P NATL ACAD SCI USA, V94, P8421, DOI 10.1073/pnas.94.16.8421; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; KAO PN, 1994, J BIOL CHEM, V269, P20691; KAPLAN ME, 1968, LANCET, V1, P561; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Labrador M, 1998, CLIN EXP IMMUNOL, V114, P301; Langland JO, 1999, BIOCHEMISTRY-US, V38, P6361, DOI 10.1021/bi982410u; LERNER MR, 1979, P NATL ACAD SCI USA, V76, P5495, DOI 10.1073/pnas.76.11.5495; Liao HJ, 1998, P NATL ACAD SCI USA, V95, P8514, DOI 10.1073/pnas.95.15.8514; MatsumotoTaniura N, 1996, MOL BIOL CELL, V7, P1455, DOI 10.1091/mbc.7.9.1455; Nanduri S, 1998, EMBO J, V17, P5458, DOI 10.1093/emboj/17.18.5458; ONODERA T, 1981, J EXP MED, V153, P1457, DOI 10.1084/jem.153.6.1457; PATTERSON JB, 1995, MOL CELL BIOL, V15, P5376, DOI 10.1128/mcb.15.10.5376; Perrin L, 1999, J BIOL CHEM, V274, P6315, DOI 10.1074/jbc.274.10.6315; REEVES WH, 1994, RHEUM DIS CLIN N AM, V20, P1; Reeves WH, 1997, ANTIBODIES, P33; Satoh M, 1996, J CLIN INVEST, V97, P2619, DOI 10.1172/JCI118711; SATOH M, 1994, J EXP MED, V180, P2341, DOI 10.1084/jem.180.6.2341; Satoh M, 1996, J IMMUNOL, V157, P3200; Segal BM, 1997, J IMMUNOL, V158, P5087; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; Suzuki K, 1999, P NATL ACAD SCI USA, V96, P2285, DOI 10.1073/pnas.96.5.2285; XIAO QR, 1994, NUCLEIC ACIDS RES, V22, P2512	34	37	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34598	34604		10.1074/jbc.274.49.34598	http://dx.doi.org/10.1074/jbc.274.49.34598			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574923	Green Published, hybrid			2022-12-25	WOS:000083979600017
J	Hanasaki, K; Ono, T; Saiga, A; Morioka, Y; Ikeda, M; Kawamoto, K; Higashino, K; Nakano, K; Yamada, K; Ishizaki, J; Arita, H				Hanasaki, K; Ono, T; Saiga, A; Morioka, Y; Ikeda, M; Kawamoto, K; Higashino, K; Nakano, K; Yamada, K; Ishizaki, J; Arita, H			Purified group X secretory phospholipase A(2) induced prominent release of arachidonic acid from human myeloid leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-MOLECULAR-WEIGHT; PANCREATIC PHOSPHOLIPASE-A2; CYTOSOLIC PHOSPHOLIPASE-A2; PROSTAGLANDIN PRODUCTION; RECOMBINANT EXPRESSION; P388D(1) MACROPHAGES; INDUCED ARTHRITIS; SYNOVIAL-FLUID; BINDING-SITE; RAT SPLEEN	Group X secretory phospholipase A, (sPLA(2)-X) possesses several structural features characteristic of both group IB and IIA sPLA(2)s (sPLA(2)-IB and -IIA) and is postulated to be involved in inflammatory responses owing to its restricted expression in the spleen and thymus, Here, we report the purification of human recombinant COOH-terminal His-tagged sPLA(2)-X, the preparation of its antibody, and the purification of native sPLA(2)-X. The affinity-purified sPLA(2)-X protein migrated as various molecular species of 13-18 kDa on SDS-polyacrylamide gels, and N-glycosidase F treatment caused shifts to the 13- and 14-kDa bands. NH2-terminal amino acid sequencing analysis revealed that the 13-kDa form is a putative mature sPLA(2)-X and the 14-kDa protein possesses a propeptide of 11 amino acid residues attached at the NH, termini of the mature protein, Separation with reverse-phase high performance liquid chromatography revealed that N-linked carbohydrates are not required for the enzymatic activity and pro-sPLA(2)-X has a relatively weak potency compared with the mature protein. The mature sPLA(2)-X induced the release of arachidonic acid from phosphatidylcholine more efficiently than other human sPLA(2) groups (IB, IIA, IID, and V) and elicited a prompt and marked release of arachidonic acid from human monocytic THP-1 cells compared with sPLA2-IB and -IIA with concomitant production of prostaglandin E-2. A prominent release of arachidonic acid was also observed in sPLA(2)-X-treated human U937 and HL60 cells. Immunohistochemical analysis of human lung preparations revealed its expression in alveolar epithelial cells. These results indicate that human sPLA(2)-X is a unique N-glycosylated sPLA(2) that releases arachidonic acid from human myeloid leukemia cells more efficiently than sPLA(2)-IB and -IIA.	Shionogi & Co Ltd, Shionogi Res Labs, Fukushima Ku, Osaka 5530002, Japan	Shionogi & Company Limited	Hanasaki, K (corresponding author), Shionogi & Co Ltd, Shionogi Res Labs, Fukushima Ku, Sagisu 5-12-4, Osaka 5530002, Japan.		morioka, yasuhide/AAC-9514-2019	morioka, yasuhide/0000-0001-7878-2557				ARITA H, 1989, PROG LIPID RES, V28, P273, DOI 10.1016/0163-7827(89)90002-7; ARITA H, 1991, J BIOL CHEM, V266, P19139; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; BALSINDE J, 1994, P NATL ACAD SCI USA, V91, P11060, DOI 10.1073/pnas.91.23.11060; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BRACKERTZ D, 1977, ARTHRITIS RHEUM, V20, P841, DOI 10.1002/art.1780200314; CHEN J, 1994, J BIOL CHEM, V269, P2365; CHEN J, 1994, J BIOL CHEM, V269, P23018; Chen YJ, 1998, BBA-LIPID LIPID MET, V1394, P57, DOI 10.1016/S0005-2760(98)00098-8; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CRESTANI B, 1994, J CLIN INVEST, V94, P731, DOI 10.1172/JCI117392; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; DEHAAS GH, 1968, BIOCHIM BIOPHYS ACTA, V159, P118, DOI 10.1016/0005-2744(68)90249-0; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; Fonteh AN, 1998, BBA-LIPID LIPID MET, V1393, P253, DOI 10.1016/S0005-2760(98)00079-4; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; Grass DS, 1996, J CLIN INVEST, V97, P2233, DOI 10.1172/JCI118664; GREEN JA, 1991, INFLAMMATION, V15, P355, DOI 10.1007/BF00917352; GRONROOS JM, 1992, DIGESTION, V52, P232, DOI 10.1159/000200958; Hagishita S, 1996, J MED CHEM, V39, P3636, DOI 10.1021/jm960395q; HALBAN PA, 1994, BIOCHEM J, V299, P1; Han SK, 1998, BIOCHEM J, V331, P353, DOI 10.1042/bj3310353; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; HANASAKI K, 1995, J BIOL CHEM, V270, P7543, DOI 10.1074/jbc.270.13.7543; HANASAKI K, 1992, J BIOL CHEM, V267, P6414; Hanasaki K, 1997, J BIOL CHEM, V272, P32792, DOI 10.1074/jbc.272.52.32792; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; Ishizaki J, 1999, J BIOL CHEM, V274, P24973, DOI 10.1074/jbc.274.35.24973; Kasai T, 1998, J IMMUNOL, V161, P6469; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Koduri RS, 1998, J BIOL CHEM, V273, P32142, DOI 10.1074/jbc.273.48.32142; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KUBIN M, 1994, BLOOD, V83, P1847; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; NAKANO T, 1994, BIOCHEM BIOPH RES CO, V198, P10, DOI 10.1006/bbrc.1994.1002; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; OHARA O, 1995, PROG LIPID RES, V34, P117, DOI 10.1016/0163-7827(94)00009-B; ONO T, 1988, J BIOL CHEM, V263, P5732; Reddy ST, 1996, J BIOL CHEM, V271, P186, DOI 10.1074/jbc.271.1.186; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; REYNOLDS LJ, 1992, ANAL BIOCHEM, V204, P190, DOI 10.1016/0003-2697(92)90160-9; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SHARP JD, 1991, J BIOL CHEM, V266, P14850; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Tischfield JA, 1996, GENOMICS, V32, P328, DOI 10.1006/geno.1996.0126; TOJO H, 1988, J BIOL CHEM, V263, P5724; TOJO H, 1993, J LIPID RES, V34, P837; VADAS P, 1986, LAB INVEST, V55, P391; Valentin E, 1999, J BIOL CHEM, V274, P19152, DOI 10.1074/jbc.274.27.19152; VARKI A, 1992, Current Opinion in Cell Biology, V4, P257, DOI 10.1016/0955-0674(92)90041-A; WOOLEY PH, 1985, J IMMUNOL, V135, P2443; YAKOTA Y, 1999, BIOCHIM BIOPHYS ACTA, V1438, P213; YUAN YP, 1995, BLOOD, V86, P4166, DOI 10.1182/blood.V86.11.4166.bloodjournal86114166; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1	60	148	157	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34203	34211		10.1074/jbc.274.48.34203	http://dx.doi.org/10.1074/jbc.274.48.34203			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567392	hybrid			2022-12-25	WOS:000083857500057
J	Kabe, Y; Goto, M; Shima, D; Imai, T; Wada, T; Morohashi, K; Shirakawa, M; Hirose, S; Handa, H				Kabe, Y; Goto, M; Shima, D; Imai, T; Wada, T; Morohashi, K; Shirakawa, M; Hirose, S; Handa, H			The role of human MBF1 as a transcriptional coactivator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; BINDING PROTEIN; ACTIVATION; PROMOTERS; AD4BP; CYP11A	Multiprotein bridging factor 1 (MBF1) is a coactivator which mediates transcriptional activation by interconnecting the general transcription factor TATA element-binding protein and gene-specific activators such as the Drosophila nuclear receptor FTZ-F1 or the yeast basic leucine zipper protein GCN4, The human homolog of MBF1 (hMBF1) has been identified but its function, especially in transcription, remains unclear. Here we report the cDNA cloning and functional analysis of hMBF1. Two isoforms, which we term hMBF1 alpha and hMBF1 beta, have been identified. hMBF1 alpha mRNA was detected in a number of tissues, whereas hMBF1 beta exhibited tissue-specific expression. Both isoforms bound to TBP and Ad4BP/SF-1, a mammalian counterpart of FTZ-F1, and mediated Ad4BP/SF-1-dependent transcriptional activation. While hMBF1 was detected in the cytoplasm by immunostaining, coexpression of the nuclear protein Ad4BP/SF-1 with hMBF1 induced accumulation of hMBF1 in the nucleus, suggesting that hMBF1 is localized in the nucleus through its binding to Ad4BP/SF-1. hMBF1 also bound to ATF1, a member of the basic leucine zipper protein family, and mediated its activity as a transcriptional activator. These data establish that the coactivator MBF1 is functionally conserved in eukaryotes.	Tokyo Inst Technol, Frontier Collaborat Res Ctr, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Natl Inst Basic Biol, Okazaki, Aichi 4448585, Japan; Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan; Natl Inst Genet, Dept Dev Biol, Mishima, Shizuoka 4118540, Japan	Tokyo Institute of Technology; Tokyo Institute of Technology; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Nara Institute of Science & Technology; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Handa, H (corresponding author), Tokyo Inst Technol, Frontier Collaborat Res Ctr, Midori Ku, 4259 Nagatsuta Cho, Yokohama, Kanagawa 2268501, Japan.		Hirose, Susumu/I-8865-2019	Imai, Takeshi/0000-0002-9503-7353				Dragoni I, 1998, J BIOL CHEM, V273, P31119, DOI 10.1074/jbc.273.47.31119; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; HONDA S, 1993, J BIOL CHEM, V268, P7494; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LI FQ, 1994, MOL CELL BIOL, V14, P3013, DOI 10.1128/MCB.14.5.3013; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOROHASHI K, 1993, MOL ENDOCRINOL, V7, P1196, DOI 10.1210/me.7.9.1196; Morohashi K, 1997, GENES CELLS, V2, P95, DOI 10.1046/j.1365-2443.1997.1060304.x; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; Morohashi K, 1999, BLOOD, V93, P1586; Morohashi KI, 1996, FASEB J, V10, P1569, DOI 10.1096/fasebj.10.14.9002548; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TAKAYAMA K, 1994, J BIOCHEM-TOKYO, V116, P193, DOI 10.1093/oxfordjournals.jbchem.a124493; Takemaru K, 1997, P NATL ACAD SCI USA, V94, P7251, DOI 10.1073/pnas.94.14.7251; Takemaru K, 1998, MOL CELL BIOL, V18, P4971, DOI 10.1128/MCB.18.9.4971; TREIZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190; UEDA H, 1990, GENE DEV, V4, P624, DOI 10.1101/gad.4.4.624; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; WATANABE H, 1988, MOL CELL BIOL, V8, P1290, DOI 10.1128/MCB.8.3.1290; WATANABE N, 1994, EUR J BIOCHEM, V222, P825, DOI 10.1111/j.1432-1033.1994.tb18929.x; Yamaguchi Y, 1998, NUCLEIC ACIDS RES, V26, P3854, DOI 10.1093/nar/26.16.3854; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328	26	75	82	3	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34196	34202		10.1074/jbc.274.48.34196	http://dx.doi.org/10.1074/jbc.274.48.34196			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567391	hybrid			2022-12-25	WOS:000083857500056
J	Kakita, T; Hasegawa, K; Morimoto, T; Kaburagi, S; Wada, H; Sasayama, S				Kakita, T; Hasegawa, K; Morimoto, T; Kaburagi, S; Wada, H; Sasayama, S			p300 protein as a coactivator of GATA-5 in the transcription of cardiac-restricted atrial natriuretic factor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; EMBRYONIC-DEVELOPMENT; ACTIVATION DOMAIN; DEVELOPING HEART; E1A ONCOPROTEIN; ADENOVIRUS E1A; DNA-SYNTHESIS; CBP; DIFFERENTIATION; MUSCLE	A cellular target of adenovirus E1A oncoprotein, p300 is a transcriptional coactivator and a negative regulator of cellular proliferation. A previous study suggests that the p300 family is also involved in cell type-specific transcription in cardiac myocytes, However, nothing is known about which cardiac transcription factor(s) interact with and transactivate through these proteins. The transcription factors GATA-4/5/6 have been implicated as key regulators of cardiogenesis, and they participate in the transcription of many cardiac-specific genes. Here we show that E1A represses the GATA-5-dependent transactivation of a promoter derived from the cardiac-restricted atrial natriuretic factor gene. This repression is correlated with the interaction of E1A with p300, indicating that p300 participates in GATA-5-dependent transactivation, EIA markedly down-regulates endogenous atrial natriuretic factor expression, as well as disrupts the interaction between p300 and GATA-5. A small fragment of p300 containing the carboxyl-terminal cysteine/histidine-rich domain, sufficient to interact with GATA-5, prevents transcriptional activation by GATA-5 as a dominant-negative mutant. Consistent with its role as a coactivator, p300 markedly potentiates GATA-5-activated transcription. These results implicate p300 as an important component of myocardial cell differentiation and provide an insight into the relationship between mechanisms that mediate cell type-specific transcription and cell cycle regulation during cardiogenesis.	Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Hasegawa, K (corresponding author), Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Sakyo Ku, 54 Kawara Cho, Kyoto 6068507, Japan.			Wada, Hiromichi/0000-0002-8980-224X				ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CLAYCOMB WC, 1975, J BIOL CHEM, V250, P32229; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; GIORDANO A, 1991, ONCOGENE, V6, P481; GOLDSTEIN MA, 1974, SCIENCE, V183, P212, DOI 10.1126/science.183.4121.212; Grepin C, 1997, DEVELOPMENT, V124, P2387; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; GREPIN C, 1995, MOL CELL BIOL, V15, P4095; Hasegawa K, 1997, J BIOL CHEM, V272, P20049, DOI 10.1074/jbc.272.32.20049; HEIKINHEIMO M, 1994, DEV BIOL, V164, P361, DOI 10.1006/dbio.1994.1206; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; Janknecht R, 1996, ONCOGENE, V12, P1961; Jiang YM, 1996, DEV BIOL, V174, P258, DOI 10.1006/dbio.1996.0071; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KANNABIRAN C, 1993, J VIROL, V67, P507, DOI 10.1128/JVI.67.1.507-515.1993; KELLEY C, 1993, DEVELOPMENT, V118, P817; KIRSHENBAUM LA, 1995, J BIOL CHEM, V270, P7791, DOI 10.1074/jbc.270.14.7791; KUO CT, 1997, GENE DEV, V10, P1284; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LITVIN J, 1992, TRENDS CARDIOVAS MED, V2, P27, DOI 10.1016/1050-1738(92)90041-P; Liu Y, 1996, J CELL BIOL, V133, P325, DOI 10.1083/jcb.133.2.325; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Morrisey EE, 1997, DEV BIOL, V183, P21, DOI 10.1006/dbio.1996.8485; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; RUMYANTSEV PP, 1977, INT REV CYTOL, V51, P187; Sang Nianli, 1995, Molecular and Cellular Differentiation, V3, P1; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	52	79	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34096	34102		10.1074/jbc.274.48.34096	http://dx.doi.org/10.1074/jbc.274.48.34096			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567378	Green Submitted, hybrid			2022-12-25	WOS:000083857500043
J	Masumoto, J; Taniguchi, S; Ayukawa, K; Sarvotham, H; Kishino, T; Niikawa, N; Hidaka, E; Katsuyama, T; Higuchi, T; Sagara, J				Masumoto, J; Taniguchi, S; Ayukawa, K; Sarvotham, H; Kishino, T; Niikawa, N; Hidaka, E; Katsuyama, T; Higuchi, T; Sagara, J			ASC, a novel 22-kDa protein, aggregates during apoptosis of human promyelocytic leukemia HL-60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID; DIFFERENTIATION; EXPRESSION; DEATH; RECRUITMENT; INTERACTS; INHIBITOR; DOMAIN; KINASE; MOESIN	The cytoskeletal and/or nuclear matrix molecules responsible for morphological changes associated with apoptosis were identified using monoclonal antibodies (mAbs). We developed mAbs against Triton X-100-insoluble components of HL-60 cells pretreated with all-trans retinoic acid. In particular, one mAb recognized a 22-kDa protein that exhibited intriguing behavior by forming an aggregate and appearing as a speck during apoptosis induced by retinoic acid and other anti-tumor drugs. Cloning and sequencing of its cDNA revealed that this protein comprises 195 amino acids and that its C-terminal half has a caspase recruitment domain (CARD) motif, characteristic of numerous proteins involved in apoptotic signaling. We referred to this protein as ASC (apoptosis-associated Speck-like protein containing a CARD). The ASC gene was mapped on chromosome 16p11.2-12. The antisense oligonucleotides of ASC were found to reduce the expression of ASC, and consequently, etoposide-mediated apoptosis of HL-60 cells was suppressed. Our results indicate that ASC is a novel member of the CARD-containing adaptor protein family.	Shinshu Univ, Sch Med, Res Ctr Aging & Adaptat, Dept Mol Oncol & Angiol, Matsumoto, Nagano 3908621, Japan; Shinshu Univ, Sch Med, Dept Lab Med, Matsumoto, Nagano 3908621, Japan; Nagasaki Univ, Sch Med, Dept Human Genet, Nagasaki 8528523, Japan	Shinshu University; Shinshu University; Nagasaki University	Sagara, J (corresponding author), Shinshu Univ, Sch Med, Res Ctr Aging & Adaptat, Dept Mol Oncol & Angiol, Asahi 3-1-1, Matsumoto, Nagano 3908621, Japan.							Aksentijevich I, 1997, CELL, V90, P797; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; COLLINS SJ, 1987, BLOOD, V70, P1233; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; Hengartner MO, 1996, CURR OPIN GENET DEV, V6, P34, DOI 10.1016/S0959-437X(96)90007-6; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KISHINO T, 1994, CYTOGENET CELL GENET, V66, P167, DOI 10.1159/000133692; Koseki T, 1998, P NATL ACAD SCI USA, V95, P5156, DOI 10.1073/pnas.95.9.5156; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; Masumoto J, 1998, HISTOCHEM CELL BIOL, V110, P33, DOI 10.1007/s004180050262; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; NAGY L, 1995, MOL CELL BIOL, V15, P3540; PARK JR, 1994, BLOOD, V84, P440; Perkins C, 1998, CANCER RES, V58, P4561; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; TELFORD WG, 1994, J IMMUNOL METHODS, V172, P1, DOI 10.1016/0022-1759(94)90373-5; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974	26	401	435	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					33835	33838		10.1074/jbc.274.48.33835	http://dx.doi.org/10.1074/jbc.274.48.33835			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567338	hybrid			2022-12-25	WOS:000083857500003
J	Pascucci, B; Stucki, M; Jonsson, ZO; Dogliotti, E; Hubscher, U				Pascucci, B; Stucki, M; Jonsson, ZO; Dogliotti, E; Hubscher, U			Long patch base excision repair with purified human proteins - DNA ligase I as patch size mediator for DNA polymerases delta and epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; REPLICATION FACTOR-C; AUXILIARY PROTEINS; MAMMALIAN-CELLS; CALF THYMUS; BETA; RECONSTITUTION; IDENTIFICATION; REQUIREMENT; PATHWAY	Among the different base excision repair pathways known, the long patch base excision repair of apurinic/apyrimidinic sites is an important mechanism that requires proliferating cell nuclear antigen. We have reconstituted this pathway using purified human proteins. Our data indicated that efficient repair is dependent on six components including AP endonuclease, replication factor C, proliferating cell nuclear antigen, DNA polymerases delta or epsilon, flap endonuclease 1, and DNA Ligase I. Fine mapping of the nucleotide replacement events showed that repair patches extended up to a maximum of 10 nucleotides 3' to the lesion. However, almost 70% of the repair synthesis was confined to 2-4-nucleotide patches and DNA ligase I appeared to be responsible for limiting the repair patch length. Moreover, both proliferating cell nuclear antigen and flap endonuclease 1 are required for the production and ligation of long patch repair intermediates suggesting an important role of this complex in both excision and resynthesis steps.	Univ Zurich, Inst Vet Biochem, CH-8057 Zurich, Switzerland; Ist Super Sanita, Comparat Toxicol & Ecotoxicol Lab, I-00161 Rome, Italy	University of Zurich; Istituto Superiore di Sanita (ISS)	Hubscher, U (corresponding author), Univ Zurich, Inst Vet Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	dogliott@iss.it; hubscher@vetbio.unizh.ch	Jónsson, Zophonías Oddur/AAO-1354-2020; Stucki, Manuel/H-4739-2017; Jónsson, Zophonías/E-1960-2015	Jónsson, Zophonías Oddur/0000-0001-5798-9647; PASCUCCI, BARBARA/0000-0002-8383-8751				CULLMANN G, 1993, GENE, V134, P191, DOI 10.1016/0378-1119(93)90093-I; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; Fortini P, 1999, J BIOL CHEM, V274, P15230, DOI 10.1074/jbc.274.21.15230; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; FROSINA G, 1994, BIOCHEM J, V304, P699, DOI 10.1042/bj3040699; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; Hubscher U, 1999, PRACT APPROACH SER, V199, P119; HUBSCHER U, 1979, P NATL ACAD SCI USA, V76, P6284, DOI 10.1073/pnas.76.12.6284; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Longley MJ, 1997, J BIOL CHEM, V272, P10917; Maga G, 1999, J MOL BIOL, V285, P259, DOI 10.1006/jmbi.1998.2314; Matsumoto Y, 1999, J BIOL CHEM, V274, P33703, DOI 10.1074/jbc.274.47.33703; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Mossi R, 1998, J BIOL CHEM, V273, P14322, DOI 10.1074/jbc.273.23.14322; Mossi R, 1998, EUR J BIOCHEM, V254, P209, DOI 10.1046/j.1432-1327.1998.254209.x; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; PODUST LM, 1995, MOL CELL BIOL, V15, P3072; PODUST V, 1992, CHROMOSOMA, V102, pS133, DOI 10.1007/BF02451797; PODUST VN, 1993, NUCLEIC ACIDS RES, V21, P841, DOI 10.1093/nar/21.4.841; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; PRICE A, 1991, BIOCHEMISTRY-US, V30, P8631, DOI 10.1021/bi00099a020; Schurtenberger P, 1998, J MOL BIOL, V275, P123, DOI 10.1006/jmbi.1997.1435; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1999, CARCINOGENESIS, V20, P1049, DOI 10.1093/carcin/20.6.1049; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; WEISER T, 1991, J BIOL CHEM, V266, P10420; WOLD MS, 1989, J BIOL CHEM, V264, P2801; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036	42	158	165	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33696	33702		10.1074/jbc.274.47.33696	http://dx.doi.org/10.1074/jbc.274.47.33696			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559260	Green Accepted, hybrid			2022-12-25	WOS:000083745200076
J	Karrer, KM; VanNuland, TA				Karrer, KM; VanNuland, TA			Nucleosome positioning is independent of histone H1 in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA GENES; TETRAHYMENA-THERMOPHILA; SACCHAROMYCES-CEREVISIAE; CHROMATIN STRUCTURE; LINKER HISTONES; DNA; INVITRO; TRANSCRIPTION; ALIGNMENT; STABILITY	Nucleosome positioning in the somatic macronuclear genome of the ciliated protozoan Tetrahymena thermophila was analyzed by indirect end labeling Nucleosomes were positioned nonrandomly in three different regions of the Tetrahymena genome. Nucleosome repeat length varied between adjacent nucleosomes. Nucleosome positioning in a histone H1 knockout strain was indistinguishable hom that in a strain with wild type histone H1.	Marquette Univ, Dept Biol, Milwaukee, WI 53233 USA	Marquette University	Karrer, KM (corresponding author), Marquette Univ, Dept Biol, Wehr Life Sci Bldg,530 N 15th St, Milwaukee, WI 53233 USA.	kathleen.karrer@marquette.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM052656] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52656] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLIS CD, 1980, CELL, V20, P55; ALMER A, 1986, EMBO J, V5, P2681, DOI 10.1002/j.1460-2075.1986.tb04551.x; BENEZRA R, 1986, CELL, V44, P697, DOI 10.1016/0092-8674(86)90835-4; BLACKBURN EH, 1981, P NATL ACAD SCI-BIOL, V78, P2263, DOI 10.1073/pnas.78.4.2263; BUDARF ML, 1986, J BIOL CHEM, V261, P363; CAPOWSKI EE, 1989, MOL CELL BIOL, V9, P2598, DOI 10.1128/MCB.9.6.2598; ENGLANDER EW, 1995, J BIOL CHEM, V270, P10091, DOI 10.1074/jbc.270.17.10091; Gorovsky M A, 1975, Methods Cell Biol, V9, P311, DOI 10.1016/S0091-679X(08)60080-1; GOROVSKY MA, 1977, COLD SPRING HARB SYM, V42, P493; HAYASHI T, 1987, J BIOCHEM-TOKYO, V102, P369, DOI 10.1093/oxfordjournals.jbchem.a122063; JEONG SW, 1991, J MOL BIOL, V222, P1131, DOI 10.1016/0022-2836(91)90597-Y; Landsman D, 1996, TRENDS BIOCHEM SCI, V21, P287, DOI 10.1016/S0968-0004(96)30030-3; LAUDERDALE JD, 1992, NUCLEIC ACIDS RES, V20, P6589, DOI 10.1093/nar/20.24.6589; LINDER C, 1994, MOL CELL BIOL, V14, P2822, DOI 10.1128/MCB.14.4.2822; PALEN TE, 1984, CELL, V36, P933, DOI 10.1016/0092-8674(84)90043-6; Patterton HG, 1998, J BIOL CHEM, V273, P7268, DOI 10.1074/jbc.273.13.7268; PRATT K, 1983, J PROTOZOOL, V30, P592, DOI 10.1111/j.1550-7408.1983.tb01428.x; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHEN XT, 1995, CELL, V82, P47, DOI 10.1016/0092-8674(95)90051-9; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; STEIN A, 1983, NATURE, V302, P548, DOI 10.1038/302548a0; STEIN A, 1997, PROG NUCL ACIDS RES, V54, P333; SUN JM, 1990, EMBO J, V9, P1651, DOI 10.1002/j.1460-2075.1990.tb08285.x; UVARDY J, 1984, J MOL BIOL, V172, P385; van Holde KE., 1989, SPRINGER SERIES MOL; WELLS JM, 1994, MOL CELL BIOL, V14, P5939, DOI 10.1128/MCB.14.9.5939; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; WU M, 1988, P NATL ACAD SCI USA, V85, P2205, DOI 10.1073/pnas.85.7.2205; WU M, 1994, MOL CELL BIOL, V14, P10, DOI 10.1128/MCB.14.1.10; WU M, 1986, P NATL ACAD SCI USA, V83, P8674, DOI 10.1073/pnas.83.22.8674; ZAUG AJ, 1980, CELL, V19, P331, DOI 10.1016/0092-8674(80)90507-3; Zlatanova J, 1996, PROG NUCLEIC ACID RE, V52, P217, DOI 10.1016/S0079-6603(08)60968-X	33	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					33020	33024		10.1074/jbc.274.46.33020	http://dx.doi.org/10.1074/jbc.274.46.33020			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551870	hybrid			2022-12-25	WOS:000083623000070
J	Maiti, N; Widjaja, L; Banerjee, R				Maiti, N; Widjaja, L; Banerjee, R			Proton transfer from histidine 244 may facilitate the 1,2 rearrangement reaction in coenzyme B-12-dependent methylmalonyl-CoA mutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; HYDROGEN-ATOM ABSTRACTION; CARBON BOND HOMOLYSIS; AB-INITIO; ADENOSYLCOBALAMIN; MECHANISM; SUBSTRATE; B-12; 1,2-DIHYDROXYETHANE; SPECTROSCOPY	Methylmalonyl-CoA mutase is an adenosylcobalamin-dependent enzyme that catalyzes the 1,2 rearrangement of methylmalonyl-CoA to succinyl-CoA This reaction results in the interchange of a carbonyl-CoA group and a hydrogen atom on vicinal carbons. The crystal structure of the enzyme reveals the presence of an aromatic cluster of residues in the active site that includes His-244, Tyr-243, and Tyr-89 in the large subunit, Of these, His-244 is within hydrogen bonding distance to the carbonyl oxygen of the carbonyl-Cob moiety of the substrate. The location of these aromatic residues suggests a possible role for them in catalysis either in radical stabilization and/or by direct participation in one or more steps in the reaction. The mechanism by which the initially formed substrate radical isomerizes to the product radical during the rearrangement of methylmalonyl-CoA to succinyl-CoA is unknown. Ab initio molecular orbital theory calculations predict that partial proton transfer can contribute significantly to the lowering of the barrier for the rearrangement reaction. In this study, we report the kinetic characterization of the H244G mutant, which results in an acute sensitivity of the enzyme to oxygen, indicating the important role of this residue in radical stabilization Mutation of His-244 leads to an similar to 300-fold lowering in the catalytic efficiency of the enzyme and loss of one of the two titratable pK(a) values that govern the activity of the wild type enzyme. These data suggest that protonation of His-244 increases the reaction sate in wild type enzyme and provides experimental support for ab initio molecular orbital theory calculations that predict rate enhancement of the rearrange ment reaction by the interaction of the migrating group with a general acid. However, the magnitude of the rate enhancement is significantly lower than that predicted by the theoretical studies.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Banerjee, R (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045776, R29DK045776] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45776] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abend A, 1997, EUR J BIOCHEM, V249, P180, DOI 10.1111/j.1432-1033.1997.00180.x; Banerjee R, 1997, CHEM BIOL, V4, P175, DOI 10.1016/S1074-5521(97)90286-6; CANNATA JJB, 1965, J BIOL CHEM, V240, P3249; DOWD P, 1975, J AM CHEM SOC, V97, P4754, DOI 10.1021/ja00849a048; EDWARD JT, 1978, CAN J CHEM, V59, P931; George P, 1997, J AM CHEM SOC, V119, P7065, DOI 10.1021/ja963424v; GEORGE P, 1995, J AM CHEM SOC, V117, P10131, DOI 10.1021/ja00145a032; GOLDING BT, 1976, J AM CHEM SOC, V98, P6331, DOI 10.1021/ja00436a044; HALPERN J, 1985, SCIENCE, V227, P869, DOI 10.1126/science.2857503; He M, 1998, J AM CHEM SOC, V120, P1133, DOI 10.1021/ja971415w; KEEP NH, 1993, BIOCHEM J, V295, P387, DOI 10.1042/bj2950387; KELLERMEYER RW, 1964, J BIOL CHEM, V239, P2562; Licht SS, 1999, BIOCHEMISTRY-US, V38, P1221, DOI 10.1021/bi981885i; LUDWIG M, 1999, CHEM BIOCH B12; Ludwig ML, 1997, ANNU REV BIOCHEM, V66, P269, DOI 10.1146/annurev.biochem.66.1.269; Mancia F, 1998, STRUCTURE, V6, P711, DOI 10.1016/S0969-2126(98)00073-2; Mancia F, 1996, STRUCTURE, V4, P339, DOI 10.1016/S0969-2126(96)00037-8; Mancia F, 1999, BIOCHEMISTRY-US, V38, P7999, DOI 10.1021/bi9903852; Marsh ENG, 1998, BIOCHEMISTRY-US, V37, P11864, DOI 10.1021/bi980512e; MCKIE N, 1990, BIOCHEM J, V269, P293, DOI 10.1042/bj2690293; Meier TW, 1996, BIOCHEMISTRY-US, V35, P11791, DOI 10.1021/bi961250o; MERKELBACH II, 1985, J AM CHEM SOC, V107, P4037, DOI 10.1021/ja00299a046; Miles E W, 1977, Methods Enzymol, V47, P431; PADMAKUMAR R, 1995, J BIOL CHEM, V270, P9295, DOI 10.1074/jbc.270.16.9295; Padmakumar R, 1997, BIOCHEMISTRY-US, V36, P3713, DOI 10.1021/bi962503g; PADMAKUMAR R, 1995, J AM CHEM SOC, V117, P7033, DOI 10.1021/ja00131a039; POLGAR L, 1974, FEBS LETT, V47, P15, DOI 10.1016/0014-5793(74)80415-1; Retey J., 1982, B12, VII, P357; Smith DM, 1999, J AM CHEM SOC, V121, P1383, DOI 10.1021/ja983512a; Thoma NH, 1998, BIOCHEMISTRY-US, V37, P14386, DOI 10.1021/bi981375o; Thoma NH, 1998, BIOCHEM SOC T, V26, P293, DOI 10.1042/bst0260293; ZHAO Y, 1994, EUR J BIOCHEM, V225, P891, DOI 10.1111/j.1432-1033.1994.0891b.x; ZHAO Y, 1992, ANGEW CHEM INT EDIT, V31, P215, DOI 10.1002/anie.199202151	33	37	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32733	32737		10.1074/jbc.274.46.32733	http://dx.doi.org/10.1074/jbc.274.46.32733			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551831	hybrid			2022-12-25	WOS:000083623000031
J	Pal, S; Chandra, S; Chowdhury, S; Sarkar, D; Ghosh, AN; Das Gupta, C				Pal, S; Chandra, S; Chowdhury, S; Sarkar, D; Ghosh, AN; Das Gupta, C			Complementary role of two fragments of domain V of 23 S ribosomal RNA in protein folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOMES; MOLECULAR CHAPERONES; DENATURED PROTEINS; IN-VITRO; REACTIVATION; RHODANESE; FLUORESCENCE; ACTIVATION; SUBUNIT; BINDING	We have shown that the domain V of bacterial 23 S rRNA could fold denatured proteins to their active state. This segment of 23 S rRNA could further be split into two parts. One part containing mainly the central loop of domain V could bind denatured human carbonic anhydrase I stably. This association could be reversed by adding the other part of domain V. The released enzyme was directed in such a way by the central loop of domain V that it could now fold by itself to active form. This agrees with our earlier observation that proteins fold within the cell posttranslationally, a process that is completed after release of the newly synthesized polypeptide from the ribosome.	Univ Calcutta, Coll Sci & Technol, Dept Biophys Mol Biol & Genet, Calcutta 700009, W Bengal, India; Brown Univ, Div Biol & Med, Providence, RI 02912 USA; Natl Inst Cholera & Enter Dis, Calcutta 700010, W Bengal, India	University of Calcutta; Brown University; Indian Council of Medical Research (ICMR); ICMR - National Institute of Cholera & Enteric Diseases (NICED)	Das Gupta, C (corresponding author), Univ Calcutta, Coll Sci & Technol, Dept Biophys Mol Biol & Genet, 92 Acharya Prafulla Chandra Rd, Calcutta 700009, W Bengal, India.		Sarkar, Dibyendu/F-9269-2010					BARLOW JH, 1987, NUCLEIC ACIDS RES, V15, P2386, DOI 10.1093/nar/15.5.2386; BERA AK, 1994, BIOCHEM MOL BIOL INT, V32, P315; BERA AK, 1994, CURR SCI INDIA, V66, P230; Chattopadhyay S, 1996, P NATL ACAD SCI USA, V93, P8284, DOI 10.1073/pnas.93.16.8284; Chattopadhyay S, 1999, BBA-PROTEIN STRUCT M, V1429, P293, DOI 10.1016/S0167-4838(98)00179-4; CHATTOPADHYAY S, 1994, BIOCHEM J, V300, P717, DOI 10.1042/bj3000717; Choi KM, 1998, NUCLEIC ACIDS RES, V26, P887, DOI 10.1093/nar/26.4.887; DAS B, 1992, BIOCHEM BIOPH RES CO, V183, P774, DOI 10.1016/0006-291X(92)90550-5; Das B, 1996, EUR J BIOCHEM, V235, P613, DOI 10.1111/j.1432-1033.1996.00613.x; Ellis RJ, 1996, FASEB J, V10, P20, DOI 10.1096/fasebj.10.1.8566542; FEDEROV AN, 1997, J BIOL CHEM, V272, P32715; FEDOROV AN, 1995, P NATL ACAD SCI USA, V92, P1227, DOI 10.1073/pnas.92.4.1227; FEDOROV AN, 1992, J MOL BIOL, V228, P351, DOI 10.1016/0022-2836(92)90825-5; Gething MJ, 1995, COLD SPRING HARB SYM, V60, P417, DOI 10.1101/SQB.1995.060.01.046; HANSEN WJ, 1994, J BIOL CHEM, V269, P26610; Hardesty B, 1995, BIOCHEM CELL BIOL, V73, P1199, DOI 10.1139/o95-129; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; Komar AA, 1997, J BIOL CHEM, V272, P10646; KOVALIC D, 1995, BIOCHEMISTRY-US, V34, P15838, DOI 10.1021/bi00048a029; Kudlicki W, 1997, FOLD DES, V2, P101, DOI 10.1016/S1359-0278(97)00014-X; Kudlicki W, 1997, J BIOL CHEM, V272, P32206, DOI 10.1074/jbc.272.51.32206; KUDLICKI W, 1994, J BIOL CHEM, V269, P16549; KUDLICKI W, 1994, J MOL BIOL, V244, P319, DOI 10.1006/jmbi.1994.1732; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; MAIZELS N, 1993, RNA WORLD, P577; Netzer WJ, 1998, TRENDS BIOCHEM SCI, V23, P68, DOI 10.1016/S0968-0004(97)01171-7; NETZER WJ, 1997, NATURE, V355, P33; Nitta I, 1998, SCIENCE, V281, P666, DOI 10.1126/science.281.5377.666; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; Pal D, 1997, NUCLEIC ACIDS RES, V25, P5047, DOI 10.1093/nar/25.24.5047	32	34	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32771	32777		10.1074/jbc.274.46.32771	http://dx.doi.org/10.1074/jbc.274.46.32771			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551837	hybrid			2022-12-25	WOS:000083623000037
J	Sayeski, PP; Ali, MS; Safavi, A; Lyles, M; Kim, SO; Frank, SJ; Bernstein, KE				Sayeski, PP; Ali, MS; Safavi, A; Lyles, M; Kim, SO; Frank, SJ; Bernstein, KE			A catalytically active Jak2 is required for the angiotensin II-dependent activation of Fyn	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SMOOTH-MUSCLE CELLS; AT(1) RECEPTOR; C-SRC; COMPLEX-FORMATION; CARDIAC MYOCYTES; JANUS KINASE-2; MESSENGER-RNA; BINDING; PATHWAY	Recent work with interleukins has shown a convergence of tyrosine phosphorylation signal transduction cascades at the level of the Janus and Src families of tyrosine kinases. Here we demonstrate that activation of the seven-transmembrane AT, receptor by angiotensin II induces a physical association between Jak2 and Fyn, in vivo. This association requires the catalytic activity of Jak2 but not Fyn. Deletion studies indicate that the region of Jak2 that binds Fyn is located between amino acids 1 and 240. Studies of the Fyn SH2 and SH3 domains demonstrate that the SH2 domain plays the primary role in Jak2/Fyn association. Not surprisingly, this domain shows a marked preference for tyrosine-phosphorylated Jak2. Surface plasmon resonance estimated the dissociation equilibrium constant (lid) Of this association to be 2.36 nM. Last, in vivo studies in vascular smooth muscle cells show that, in response to angiotensin II, Jak2 activation is required for Fyn activation and induction of the c-fos gene. The significance of these data is that Jak2, in addition to serving as a critical angiotensin II activated signal transduction kinase, also functions as a docking protein and participates in the activation of Fyn by providing phosphotyrosine residues that bind the SH2 domain of Fyn.	Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Univ Alabama Birmingham, Dept Med, Div Endocrinol & Metab, Birmingham, AL 35294 USA	Emory University; University of Alabama System; University of Alabama Birmingham	Bernstein, KE (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, 1639 Pierce Dr,7107 WMB, Atlanta, GA 30322 USA.	kbernst@emory.edu		Bernstein, Kenneth/0000-0001-8097-3272	NIDDK NIH HHS [DK45215, DK44280, DK39777] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044280, P50DK045215, R37DK039777, R01DK039777] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe J, 1999, J BIOL CHEM, V274, P21003, DOI 10.1074/jbc.274.30.21003; AGGER R, 1995, GENE, V158, P307, DOI 10.1016/0378-1119(95)00040-D; Ali MS, 1998, BIOCHEM BIOPH RES CO, V249, P672, DOI 10.1006/bbrc.1998.9054; Ali MS, 1997, J BIOL CHEM, V272, P23382, DOI 10.1074/jbc.272.37.23382; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BHAT GJ, 1995, J BIOL CHEM, V270, P19059, DOI 10.1074/jbc.270.32.19059; Briscoe J, 1996, TRENDS CELL BIOL, V6, P336, DOI 10.1016/0962-8924(96)10028-3; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; DHAR A, 1994, J BIOL CHEM, V269, P9123; DUHE RJ, 1995, J BIOL CHEM, V270, P23084, DOI 10.1074/jbc.270.39.23084; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; FUERST TR, 1989, J MOL BIOL, V206, P333, DOI 10.1016/0022-2836(89)90483-X; Fuhrer DK, 1996, BIOCHEM BIOPH RES CO, V224, P289, DOI 10.1006/bbrc.1996.1023; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; IHLE JN, 1984, TRENDS BIOCHEM SCI, V19, P222; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; KAWAHARA Y, 1988, BIOCHEM BIOPH RES CO, V150, P52, DOI 10.1016/0006-291X(88)90485-8; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; Lock P, 1996, CELL, V84, P23, DOI 10.1016/S0092-8674(00)80989-7; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; McWhinney CD, 1997, J MOL CELL CARDIOL, V29, P2513, DOI 10.1006/jmcc.1997.0489; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Mohi MG, 1998, MOL BIOL CELL, V9, P3299, DOI 10.1091/mbc.9.12.3299; Rui LY, 1999, J BIOL CHEM, V274, P10590, DOI 10.1074/jbc.274.15.10590; Rui LY, 1997, MOL CELL BIOL, V17, P6633, DOI 10.1128/MCB.17.11.6633; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; Sayeski PP, 1998, REGUL PEPTIDES, V78, P19, DOI 10.1016/S0167-0115(98)00137-2; Sayeski PP, 1998, CIRC RES, V82, P1279, DOI 10.1161/01.RES.82.12.1279; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; WANG XY, 1995, J BIOL CHEM, V270, P27999; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZHAO YM, 1995, J BIOL CHEM, V270, P13814, DOI 10.1074/jbc.270.23.13814; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0	44	28	29	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					33131	33142		10.1074/jbc.274.46.33131	http://dx.doi.org/10.1074/jbc.274.46.33131			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551884	hybrid			2022-12-25	WOS:000083623000084
J	Gordon, J; Sengupta, TK; Phillips, CA; O'Malley, SM; Williams, KR; Spicer, EK				Gordon, J; Sengupta, TK; Phillips, CA; O'Malley, SM; Williams, KR; Spicer, EK			Identification of the RNA binding domain of T4 RegA protein by structure-based mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; GENE-44 MESSENGER-RNA; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; ALPHA-HELIX; BACTERIOPHAGE-T4; SPECIFICITY; RECOGNITION; COMPLEX; REGION	The T4 translational repressor RegA protein folds into two structural domains, as revealed by the crystal structure (Kang, C.-H., Chan, R., Berger, I., Lockshin, C., Green, L,, Gold, L,, and Rich, A. (1995) Science 268, 1170-1173). Domain I of the RegA protein contains a four-stranded beta-sheet and two alpha-helices. Domain II contains a four-stranded beta-sheet and an unusual 3/10 helix, Since beta-sheet residues play a role in a number of protein-RNA interactions, one or both of the beta-sheet regions in Reg-A protein may be involved in RNA binding, To test this possibility, mutagenesis of residues on both beta-sheets was performed, and the effects on the RNA binding affinities of RegA protein were measured. Additional sites for mutagenesis were selected from molecular modeling of RegA protein. The RNA binding affinities of three purified mutant RegA proteins were evaluated by fluorescence quenching equilibrium binding assays. The activities of the remainder of the mutant proteins were evaluated by quantitative RNA gel mobility shift assays using lysed cell supernatants, The results of this mutagenesis study ruled out the participation of beta-sheet residues. Instead, the RNA binding site was found to be a surface pocket formed by residues on two loops and an alpha-helix. Thus, RegA protein appears to use a unique structural motif in binding RNA, which may be related to its unusual RNA recognition properties.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA	Medical University of South Carolina; Howard Hughes Medical Institute; Yale University; Yale University	Spicer, EK (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29425 USA.		Sengupta, Tapas K/P-7126-2014; Williams, Kenneth/B-5986-2016	Williams, Kenneth/0000-0001-7792-9588				ADARI HY, 1985, P NATL ACAD SCI USA, V82, P1901, DOI 10.1073/pnas.82.7.1901; Allain FHT, 1996, NATURE, V380, P646, DOI 10.1038/380646a0; Allen SV, 1999, ANAL BIOCHEM, V269, P32, DOI 10.1006/abio.1999.4025; Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BRANDON C, 1998, INTRO PROTEIN STRUCT, P129; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; DRAPER DE, 1995, ANNU REV BIOCHEM, V64, P593, DOI 10.1146/annurev.bi.64.070195.003113; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FRIED MG, 1983, NUCLEIC ACIDS RES, V11, P141, DOI 10.1093/nar/11.1.141; HALL KB, 1994, BIOCHEMISTRY-US, V33, P10076, DOI 10.1021/bi00199a035; Jain C, 1996, CELL, V87, P115, DOI 10.1016/S0092-8674(00)81328-8; JESSEN TH, 1991, EMBO J, V10, P3447, DOI 10.1002/j.1460-2075.1991.tb04909.x; JOHNSON BH, 1994, BIOTECHNOLOGY, V12, P114; JOZWIK CE, 1992, P NATL ACAD SCI USA, V89, P5053, DOI 10.1073/pnas.89.11.5053; KANG CH, 1995, SCIENCE, V268, P1170, DOI 10.1126/science.7761833; KARAM J, 1981, P NATL ACAD SCI-BIOL, V78, P4669, DOI 10.1073/pnas.78.8.4669; MCSWIGGEN JA, 1988, J MOL BIOL, V199, P609, DOI 10.1016/0022-2836(88)90305-1; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; OMALLEY SM, 1995, J BIOL CHEM, V270, P5107, DOI 10.1074/jbc.270.10.5107; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Phillips CA, 1996, NUCLEIC ACIDS RES, V24, P4319, DOI 10.1093/nar/24.21.4319; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; Sambrook J., 2002, MOL CLONING LAB MANU; Shamoo Y, 1997, NAT STRUCT BIOL, V4, P215, DOI 10.1038/nsb0397-215; SZEWCZAK AA, 1991, J BIOL CHEM, V266, P17832; TAN RY, 1993, CELL, V73, P1031, DOI 10.1016/0092-8674(93)90280-4; UNNITHAN S, 1990, NUCLEIC ACIDS RES, V18, P7083, DOI 10.1093/nar/18.23.7083; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; WEBSTER KR, 1992, J BIOL CHEM, V267, P26097; WEBSTER KR, 1989, NUCLEIC ACIDS RES, V17, P10047, DOI 10.1093/nar/17.23.10047; WEBSTER KR, 1991, BIOTECHNIQUES, V11, P658; WEBSTER KR, 1990, J BIOL CHEM, V265, P19007; WINTER RB, 1987, P NATL ACAD SCI USA, V84, P7822, DOI 10.1073/pnas.84.22.7822	35	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32265	32273		10.1074/jbc.274.45.32265	http://dx.doi.org/10.1074/jbc.274.45.32265			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542265	hybrid			2022-12-25	WOS:000083532100073
J	Rani, MRS; Leaman, DW; Han, YL; Leung, S; Croze, E; Fish, EN; Wolfman, A; Ransohoff, RM				Rani, MRS; Leaman, DW; Han, YL; Leung, S; Croze, E; Fish, EN; Wolfman, A; Ransohoff, RM			Catalytic ally active TYK2 is essential for interferon-beta-mediated phosphorylation of STAT3 and interferon-alpha receptor-1 (IFNAR-1) but not for activation of phosphoinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; EPIDERMAL GROWTH-FACTOR; SIGNALING PATHWAY; PHOSPHATIDYLINOSITOL 3-KINASE; TARGETED DISRUPTION; DEPENDENT ACTIVATION; BINDING; TRANSDUCTION; COMPLEXES; SUBUNIT	TYK2, a Janus kinase, plays both structural and catalytic roles in type I interferon (IFN) signaling. We recently reported (Rani, M. R. S., Gauzzi, C., Pellegrini, S., Fish, E., Wei, T., and Ransohoff, R. M. (1999) J. Biol. Chem. 274, 1891-1897) that catalytically active TYK2 was necessary for IFN-beta to induce the beta-R1 gene. We now report IFN-beta-mediated activation of STATs and other components in UI (TYK2-null) cell lines that were complemented with kinase-negative (U1.KR930) or wildtype TYK2 (U1.wt), We found that IFN-beta induced phosphorylation on tyrosine of STAT3 in U1.wt cells but not in U1.KR930 cells, whereas STAT1 and STATE were activated in both cell lines. Additionally, IFN-beta-mediated phosphorylation of interferon-alpha receptor-1 (IFNAR-1) was defective in IFN-beta treated U1.KR930 cells, but evident in U1.wt cells, In U1A-derived cells, the p85/p110 phosphoinositol 3-kinase isoform was associated with IFNAR-1 but not STAT3, and the association was ligand-independent. Further, IFN-beta treatment stimulated IFNAR-1-associated phosphoinositol kinase activity equally in either U1.wt or U1.KR930 cells. Our results indicate that catalytically active TYK2 is required for IFN-beta-mediated tyrosine phosphorylation of STAT3 and IFNAR-1 in intact cells.	Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 3E2, Canada; Berlex Biosci, Richmond, CA 94804 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Toronto	Ransohoff, RM (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, NC30, Cleveland, OH 44195 USA.				NCI NIH HHS [1PO1 CA62220] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Burfoot MS, 1997, J BIOL CHEM, V272, P24183, DOI 10.1074/jbc.272.39.24183; COFFER P, 1995, ONCOGENE, V10, P985; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; Croze E, 1996, J BIOL CHEM, V271, P33165, DOI 10.1074/jbc.271.52.33165; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Gauzzi MC, 1996, J BIOL CHEM, V271, P20494, DOI 10.1074/jbc.271.34.20494; Ghislain JJ, 1996, J BIOL CHEM, V271, P12408, DOI 10.1074/jbc.271.21.12408; Han YL, 1997, MOL ENDOCRINOL, V11, P1180, DOI 10.1210/me.11.8.1180; Han YL, 1999, J INTERF CYTOK RES, V19, P731, DOI 10.1089/107999099313578; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Lewerenz M, 1998, J MOL BIOL, V282, P585, DOI 10.1006/jmbi.1998.2026; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Qureshi SA, 1996, MOL CELL BIOL, V16, P288; Rani MRS, 1999, J BIOL CHEM, V274, P1891, DOI 10.1074/jbc.274.4.1891; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; Richter MF, 1998, J BIOL CHEM, V273, P24723, DOI 10.1074/jbc.273.38.24723; Runkel L, 1998, J BIOL CHEM, V273, P8003, DOI 10.1074/jbc.273.14.8003; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Uddin S, 1997, J IMMUNOL, V158, P2390; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; UZE G, 1995, J INTERF CYTOK RES, V15, P3, DOI 10.1089/jir.1995.15.3; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; Yang CH, 1998, P NATL ACAD SCI USA, V95, P5568, DOI 10.1073/pnas.95.10.5568; Yang CH, 1996, J BIOL CHEM, V271, P8057, DOI 10.1074/jbc.271.14.8057; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	33	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32507	32511		10.1074/jbc.274.45.32507	http://dx.doi.org/10.1074/jbc.274.45.32507			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542297	hybrid			2022-12-25	WOS:000083532100105
J	Cardier, JE; Schulte, T; Kammer, H; Kwak, S; Cardier, M				Cardier, JE; Schulte, T; Kammer, H; Kwak, S; Cardier, M			Fas (CD95, APO-1) antigen expression and function in murine liver endothelial cells: implications for the regulation of apoptosis in liver endothelial cells	FASEB JOURNAL			English	Article						Fas-L; LEC-1; liver; HUVEC	TUMOR-NECROSIS-FACTOR; STAPHYLOCOCCAL-ENTEROTOXIN-B; ANTIBODY-MEDIATED APOPTOSIS; FACTOR RECEPTOR; NATURAL-KILLER; DIFFERENTIAL EXPRESSION; HEPATOCYTE APOPTOSIS; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; SURFACE ANTIGEN	The Fas (CD95, APO-1) receptor is a membrane-associated polypeptide that can mediate apoptosis in various cell types. Although Fas receptor is expressed in endothelial cells (EC), little is known about its function in these cells. The expression of Fas by liver endothelial cells (LEC) suggests that upon stimulation, apoptosis may occur in these cells. We show that Fas is highly and constitutively expressed in cloned murine liver endothelial cells (LEC-1). In contrast, Fast expression was not detected at the protein and mRNA level in these cells. Our results show that Fas ligation in LEC-1 induces apoptotic cell death, indicating that Fas receptor is functional in these cells. The doses of Fas agonist required to induce LEC-1 apoptosis were higher than those used previously in other cells, including hepatocytes, suggesting that LEC-1 are highly resistant to the Fas apoptotic pathway. TNF treatment of LEC-1 induced up-regulation of Fas receptor on these cells. In contrast, TNF did not induce the expression of Fast on LEC-1. An increased susceptibility to Fas-mediated apoptosis was observed in TNF-treated LEC-1. Enhanced susceptibility to Fas-mediated apoptosis was also observed in LEC-1 pretreated with actinomycin D, suggesting that transcription of message coding for protective proteins is necessary to protect these cells against Fas-mediated apoptosis. Up regulation of VCAM-1 and ICAM-1 was observed in LEC-1 treated with a dose of Fas agonist that does not induce apoptosis. To our knowledge, this is the first report that Fas mediates apoptosis in LEG, suggesting that apoptosis of these cells may participate in the liver damage observed in animals after receiving anti-Fas mAb or soluble Fast. Our findings also suggest that the Fas/FasL system may transduce activating signals independently of cell death in LEG1.-Cardier, J. E., Schulte, T., Kammer, H., Kwak, J., Cardier, M. Fas (CD95, APO-1) antigen expression and function in murine liver endothelial cells: implications for the regulation of apoptosis in liver endothelial cells.	Inst Venezolano Invest Cient, Lab Fisiopatol, Ctr Med Expt, Caracas 1020A, Venezuela; Hipple Canc Res Ctr, Dayton, OH 45439 USA; Hosp Risquez, Caracas, Venezuela	Venezuelan Institute Science Research	Cardier, JE (corresponding author), Inst Venezolano Invest Cient, Lab Fisiopatol, Ctr Med Expt, Apartado Postal 21827, Caracas 1020A, Venezuela.		Cardier, Jose/ABD-6349-2020					AGGARWAL BB, 1995, FEBS LETT, V364, P5, DOI 10.1016/0014-5793(95)00339-B; ALDERSON MR, 1993, J EXP MED, V178, P2231, DOI 10.1084/jem.178.6.2231; Biancone L, 1997, J EXP MED, V186, P147, DOI 10.1084/jem.186.1.147; Cardier JE, 1998, BLOOD, V91, P923, DOI 10.1182/blood.V91.3.923.923_923_929; Cardier JE, 1997, HEPATOLOGY, V26, P165; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; DEBATIN KM, 1994, EUR J IMMUNOL, V24, P753, DOI 10.1002/eji.1830240339; Dong CM, 1996, LAB INVEST, V74, P921; ESSER P, 1995, BIOCHEM BIOPH RES CO, V213, P1026, DOI 10.1006/bbrc.1995.2231; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Gallop JR, 1995, CERN REPORT, V95, P1; GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Hartmann K, 1997, J IMMUNOL, V159, P4006; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HEWETT JA, 1993, AM J PHYSIOL, V265, pG1011, DOI 10.1152/ajpgi.1993.265.6.G1011; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; LEIST M, 1995, J IMMUNOL, V154, P1307; LEIST M, 1994, J IMMUNOL, V153, P1778; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; Longthorne VL, 1997, EMBO J, V16, P3805, DOI 10.1093/emboj/16.13.3805; MACHIZUKI K, 1996, J HEPATOL, V24, P1; Mitra D, 1997, BLOOD, V89, P1224, DOI 10.1182/blood.V89.4.1224; Mohan RR, 1997, EXP EYE RES, V65, P575, DOI 10.1006/exer.1997.0371; Muschen M, 1998, HEPATOLOGY, V27, P200, DOI 10.1002/hep.510270131; NAGAKI M, 1994, GASTROENTEROLOGY, V106, P450, DOI 10.1016/0016-5085(94)90604-1; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NI R, 1994, EXP CELL RES, V215, P332, DOI 10.1006/excr.1994.1349; OEHM A, 1992, J BIOL CHEM, V267, P10709; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Orange JS, 1997, J VIROL, V71, P9248, DOI 10.1128/JVI.71.12.9248-9258.1997; Oshimi Y, 1996, J IMMUNOL, V157, P2909; PILARO AM, 1994, J IMMUNOL, V153, P333; Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991; Rafi AQ, 1998, J IMMUNOL, V161, P3077; RENSINGEHL A, 1995, J INFLAMM, V45, P161; RICHARDSON BC, 1994, EUR J IMMUNOL, V24, P2640, DOI 10.1002/eji.1830241111; ROTHSTEIN TL, 1995, NATURE, V374, P163, DOI 10.1038/374163a0; SUDA T, 1995, J IMMUNOL, V154, P3806; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; Tanaka M, 1996, NAT MED, V2, P317, DOI 10.1038/nm0396-317; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Tsutsui H, 1996, J IMMUNOL, V157, P3967; Urayama S, 1997, BIOCHEM BIOPH RES CO, V239, P782, DOI 10.1006/bbrc.1997.7535; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; VIDALVANACLOCHA F, 1993, HEPATOLOGY, V18, P328; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WELLER M, 1994, J CLIN INVEST, V94, P954, DOI 10.1172/JCI117462; WONG GHW, 1994, J IMMUNOL, V152, P1751; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	54	61	61	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1999	13	14					1950	1960		10.1096/fasebj.13.14.1950	http://dx.doi.org/10.1096/fasebj.13.14.1950			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544178				2022-12-25	WOS:000083660700007
J	Davis, PL; Miron, A; Andersen, LM; Iglehart, JD; Marks, JR				Davis, PL; Miron, A; Andersen, LM; Iglehart, JD; Marks, JR			Isolation and initial characterization of the BRCA2 promoter	ONCOGENE			English	Article						BRCA2; transcription; promoter	SUSCEPTIBILITY GENE BRCA2; TRANSCRIPTION FACTOR USF; MAMMARY EPITHELIAL-CELLS; SPORADIC BREAST-CANCER; MAJOR LATE PROMOTER; DNA-REPAIR; C-MYC; COOPERATIVE INTERACTION; OVARIAN CANCERS; MAMMALIAN-CELLS	The hereditary breast cancer susceptibility gene, BRCA2, is considered to be a tumor suppressor gene that may be involved in the cellular response to DNA damage, The transcript for this gene is cell cycle regulated with mRNA levels reaching a peak just before the onset of DNA synthesis. In order to define the mechanisms by which BRCA2 is transcriptionally regulated, we have begun to study upstream regulatory sequences, In this report, we define a minimal promoter region that has strong activity in human breast epithelial cells, Deletions of this sequence narrowed the strong basal activity to a region extending from - 66 to + 129 with respect to the BRCA2 transcriptional start site. This sequence demonstrated cell cycle regulated activity with kinetics similar to the endogenous transcript. Examination of the sequence revealed several consensus binding sites for transcription factors including an E-box, E2F and Ets recognition motifs. Electrohoretic mobility shift assays revealed specific protein binding to two sequences upstream of the start site; the palindromic E-box and an Ets/E2F site, Site-directed mutagenesis of either of these sites reduced both the basal activity in log phase cells and the cell cycle regulated activity of the promoter. Mutational inactivation of both sites within the same construct effectively eliminated promoter activity. Antibodies to candidate transcription factors used in super shift experiments revealed specific interactions between the BRCA2 promoter and the basic region/helix-loop-helix containing USE-I and 2 proteins and Elf-1, an Ets domain protein, Binding of these factors depended upon the presence of intact recognition sequences. The USF factors were shown to bind predominantly as a heterodimeric complex of USF-1 and 2 while Elf-1 bound the promoter when it was not occupied by USF, Co-transfection studies with USP proteins and the varicella tester IE62 protein provide evidence for the involvement of endogenous and exogenous USF in the activation of the BRCA2 promoter. We propose that interactions between USF-1, USF-2 and Elf-1 play an important role in the transcriptional regulation of the BRCA2 gene.	Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Canc Genet Lab, Durham, NC 27710 USA	Duke University; Duke University	Marks, JR (corresponding author), Duke Univ, Med Ctr, Dept Surg, Box 3873, Durham, NC 27710 USA.				NCI NIH HHS [CA-73802, CA-68438] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA068438, R01CA073802] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AYER DE, 1988, MOL CELL BIOL, V8, P2021, DOI 10.1128/MCB.8.5.2021; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; Bertwistle D, 1997, CANCER RES, V57, P5485; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; Collins N, 1997, BRIT J CANCER, V76, P1150, DOI 10.1038/bjc.1997.526; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Davis P, 1996, ONCOGENE, V13, P1315; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; Dobrovic A, 1997, CANCER RES, V57, P3347; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; Katagiri T, 1998, GENE CHROMOSOME CANC, V21, P217, DOI 10.1002/(SICI)1098-2264(199803)21:3<217::AID-GCC5>3.0.CO;2-2; Krainer M, 1997, NEW ENGL J MED, V336, P1416, DOI 10.1056/NEJM199705153362003; Lancaster JM, 1996, NAT GENET, V13, P238, DOI 10.1038/ng0696-238; Lecine P, 1996, MOL CELL BIOL, V16, P6829; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; Marks JR, 1997, ONCOGENE, V14, P115, DOI 10.1038/sj.onc.1200808; MEIER JL, 1994, MOL CELL BIOL, V14, P6896, DOI 10.1128/MCB.14.10.6896; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Phillips KW, 1997, LAB INVEST, V76, P419; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Rellahan BL, 1998, J IMMUNOL, V160, P2794; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Spillman MA, 1996, ONCOGENE, V13, P1639; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Teng DHF, 1996, NAT GENET, V13, P241, DOI 10.1038/ng0696-241; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; TYLER JK, 1993, NUCLEIC ACIDS RES, V21, P513, DOI 10.1093/nar/21.3.513; Vaughn JP, 1996, CANCER RES, V56, P4590; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Zhang HB, 1998, CELL, V92, P433, DOI 10.1016/S0092-8674(00)80936-8	60	51	52	2	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 28	1999	18	44					6000	6012		10.1038/sj.onc.1202990	http://dx.doi.org/10.1038/sj.onc.1202990			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557089				2022-12-25	WOS:000083359100006
J	Parekh, D; Ziegler, W; Yonezawa, K; Hara, K; Parker, PJ				Parekh, D; Ziegler, W; Yonezawa, K; Hara, K; Parker, PJ			Mammalian TOR controls one of two kinase pathways acting upon nPKC delta and nPKC epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; IN-VIVO; PHOSPHATIDYLINOSITOL 3-KINASE; PERMISSIVE ACTIVATION; PROTEIN-KINASES; IV KINASE; C-ALPHA; PHOSPHORYLATION; IDENTIFICATION; RAPAMYCIN	There are three conserved phosphorylation sites in protein kinase C (PKC) isotypes that have been termed priming sites and play an important role in PKC function. The requirements and pathways involved in novel (nPKC) phosphorylation have been investigated here. The evidence presented for nPKC delta shows that there are two independent kinase pathways that act upon the activation loop (Thr-505) and a C-terminal hydrophobic site (Ser-662) and that the phosphorylation of the Ser-662 site is protected from dephosphorylation by the Thr-505 phosphorylation. Both phosphorylations require C1 domain-dependent allosteric activation of PKC. The third site (Ser-643) appears to be an autophosphorylation site. The serum-dependent phosphorylation of the Thr-505 and Ser-662 sites increases nPKC delta activity up to 80-fold. Phosphorylation at the Ser-662 site is independently controlled by a pathway involving mammalian TOR (mTOR) because the rapamycin-induced block of its phosphorylation is overcome by co-expression of a rapamycin-resistant mutant of mTOR. Consistent with this role of mTOR, amino acid deprivation selectively inhibits the serum-induced phosphorylation of the Ser-662 site in nPKC delta. It is established that nPKC epsilon behaves in a manner similar to nPKC delta with respect to phosphorylation at its C-terminal hydrophobic site, Ser-729. The results define the regulatory inputs to nPKC delta and nPKC epsilon and establish these PKC isotypes downstream of mTOR and on an amino acid sensing pathway. The multiple signals integrated in PKC are discussed.	Imperial Canc Res Fund, Prot Phosphorylat Lab, London WC2A 3PX, England; Kobe Univ, Biosignal Res Ctr, Nada Ku, Kobe, Hyogo 6578501, Japan	Cancer Research UK; Kobe University	Parker, PJ (corresponding author), Imperial Canc Res Fund, Prot Phosphorylat Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Parker, Peter j/D-5192-2013	Ziegler, Wolfgang H./0000-0003-4529-1916; parker, peter/0000-0002-6218-2933				Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; FERRARI S, 1993, J BIOL CHEM, V268, P16091; Garcia-Paramio P, 1998, BIOCHEM J, V333, P631, DOI 10.1042/bj3330631; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LEE JSC, 1994, J BIOL CHEM, V269, P2158; Lester LB, 1997, RECENT PROG HORM RES, V52, P409; Li WQ, 1997, J BIOL CHEM, V272, P24550, DOI 10.1074/jbc.272.39.24550; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; OKUNO S, 1994, J BIOCHEM, V116, P923, DOI 10.1093/oxfordjournals.jbchem.a124617; OLIVIER AR, 1991, EUR J BIOCHEM, V200, P805, DOI 10.1111/j.1432-1033.1991.tb16248.x; ORR JW, 1994, J BIOL CHEM, V269, P27715; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; Shigemitsu K, 1999, J BIOL CHEM, V274, P1058, DOI 10.1074/jbc.274.2.1058; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; TSUTAKAWA SE, 1995, J BIOL CHEM, V270, P26807, DOI 10.1074/jbc.270.45.26807; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; Ziegler WH, 1999, CURR BIOL, V9, P522, DOI 10.1016/S0960-9822(99)80236-X	40	155	158	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34758	34764		10.1074/jbc.274.49.34758	http://dx.doi.org/10.1074/jbc.274.49.34758			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574945	hybrid			2022-12-25	WOS:000083979600039
J	Pennathur, S; Jackson-Lewis, V; Przedborski, S; Heinecke, JW				Pennathur, S; Jackson-Lewis, V; Przedborski, S; Heinecke, JW			Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and o,o '-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridien-treated mice, a model of oxidative stress in Parkinson's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL NITRIC-OXIDE; HUMAN ATHEROSCLEROTIC INTIMA; HYDROXYL RADICAL PRODUCTION; CATALYZED OXIDATION; CARBON-DIOXIDE; NEURODEGENERATIVE DISEASES; NEUROTOXIN 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; P-HYDROXYPHENYLACETALDEHYDE; HORSERADISH-PEROXIDASE; HYDROGEN-PEROXIDE	Oxidative stress is implicated in the death of dopaminergic neurons in Parkinson's disease and in the 1-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine (MPTP) model of Parkinson's disease. Oxidative species that might mediate this damage include hydroxyl radical, tyrosyl radical, or reactive nitrogen species such as peroxynitrite, In mice, we showed that MPTP markedly increased levels of o,o'-dityrosine and 3-nitrotyrosine in the striatum and midbrain but not in brain regions resistant to MPTP. These two stable compounds indicate that tyrosyl radical and reactive nitrogen species have attacked tyrosine residues, In contrast, MPTP failed to alter levels of ortho-tyrosine in any brain region we studied. This marker accumulates when hydroxyl radical oxidizes protein-bound phenylalanine residues. We also showed that treating whole-brain proteins with hydroxyl radical markedly increased levels of ortho-tyrosine in vit, o. Under identical conditions, tyrosyl radical, produced by the heme protein myeloperoxidase, selectively increased levels of o,o'-dityrosine, whereas peroxynitrite increased levels of S-nitrotyrosine and, to a lesser extent, of ortho-tyrosine. These in vivo and in vitro findings implicate reactive nitrogen species and tyrosyl radical in MPTP neurotoxicity but argue against a deleterious role for hydroxyl radical in this model. They also show that reactive nitrogen species and tyrosyl radical (and consequently protein oxidation) represent an early and previously unidentified biochemical event in MPTP-induced brain injury. This finding may be significant for understanding the pathogenesis of Parkinson's disease and developing neuroprotective therapies.	Washington Univ, Sch Med, Dept Internal Med, Div Atherosclerosis Nutr & Lipid Res, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Columbia Univ, Dept Neurol, Movement Disorder Div, New York, NY 10032 USA; Columbia Univ, Dept Pathol, New York, NY 10032 USA	Washington University (WUSTL); Washington University (WUSTL); Columbia University; Columbia University	Heinecke, JW (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Atherosclerosis Nutr & Lipid Res, Box 8046,660 S Euclid Ave, St Louis, MO 63110 USA.				NIA NIH HHS [AG15013, AG12293] Funding Source: Medline; NIDDK NIH HHS [DK02456] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG015013, R01AG012293] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Ara J, 1998, P NATL ACAD SCI USA, V95, P7659, DOI 10.1073/pnas.95.13.7659; Baynes J.W., 1996, CURR OPIN ENDOCRINOL, V3, P277, DOI DOI 10.1097/00060793-199608000-00001; Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; Beal MF, 1997, NEUROSCIENTIST, V3, P21, DOI 10.1177/107385849700300112; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; DEXTER DT, 1987, LANCET, V2, P219; DYER DG, 1993, J CLIN INVEST, V91, P2463, DOI 10.1172/JCI116481; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Eiserich JP, 1996, J BIOL CHEM, V271, P19199, DOI 10.1074/jbc.271.32.19199; Fahn S., 1988, CECILS TXB MED, P2143; FRIDOVICH I, 1983, ANNU REV PHARMACOL, V23, P239, DOI 10.1146/annurev.pa.23.040183.001323; Halliwell B., 1991, FREE RADICALS BIOL M; Hantraye P, 1996, NAT MED, V2, P1017, DOI 10.1038/nm0996-1017; HASEGAWA E, 1990, BIOCHEM BIOPH RES CO, V170, P1049, DOI 10.1016/0006-291X(90)90498-C; Hazen SL, 1996, J BIOL CHEM, V271, P23080, DOI 10.1074/jbc.271.38.23080; Hazen SL, 1997, J BIOL CHEM, V272, P16990, DOI 10.1074/jbc.272.27.16990; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Hazen SL, 1996, J BIOL CHEM, V271, P1861, DOI 10.1074/jbc.271.4.1861; Heinecke JW, 1997, BIOFACTORS, V6, P145, DOI 10.1002/biof.5520060208; Heinecke JW, 1999, METHOD ENZYMOL, V300, P124; Heinecke JW, 1998, ATHEROSCLEROSIS, V141, P1, DOI 10.1016/S0021-9150(98)00173-7; HORNYKIEWICZ O, 1987, PARKINSONS DIS, P19; HUGGINS TG, 1993, J BIOL CHEM, V268, P12341; JACKSONLEWIS V, 1995, NEURODEGENERATION, V4, P257, DOI 10.1016/1055-8330(95)90015-2; Kaur H, 1998, J NEUROCHEM, V70, P2220; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; Kohutnicka M, 1998, IMMUNOPHARMACOLOGY, V39, P167, DOI 10.1016/S0162-3109(98)00022-8; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P1433, DOI 10.1074/jbc.272.3.1433; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; LEIS JR, 1993, J CHEM SOC CHEM COMM, P1298, DOI 10.1039/c39930001298; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; Lymar SV, 1996, BIOCHEMISTRY-US, V35, P7855, DOI 10.1021/bi960331h; McCormick ML, 1998, J BIOL CHEM, V273, P32030, DOI 10.1074/jbc.273.48.32030; Nagra RM, 1997, J NEUROIMMUNOL, V78, P97, DOI 10.1016/S0165-5728(97)00089-1; Patel RP, 1999, BBA-BIOENERGETICS, V1411, P385, DOI 10.1016/S0005-2728(99)00028-6; POIRIER J, 1985, BIOCHEM BIOPH RES CO, V131, P4573; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; Przedborski S, 1998, CURR OPIN NEUROL, V11, P335, DOI 10.1097/00019052-199808000-00009; RIEDERER P, 1989, J NEUROCHEM, V52, P515, DOI 10.1111/j.1471-4159.1989.tb09150.x; ROSSETTI ZL, 1988, BIOCHEM PHARMACOL, V37, P4573, DOI 10.1016/0006-2952(88)90674-0; RUPNIAK NMJ, 1992, ANN NEUROL, V32, P103, DOI 10.1002/ana.410320118; Sampson JB, 1998, ARCH BIOCHEM BIOPHYS, V356, P207, DOI 10.1006/abbi.1998.0772; SANCHEZRAMOS JR, 1994, NEURODEGENERATION, V3, P197; SCHULZ JB, 1995, J NEUROCHEM, V64, P936, DOI 10.1046/j.1471-4159.1995.64020936.x; SELL DR, 1989, J BIOL CHEM, V264, P21597; SMITH TS, 1994, NEUROREPORT, V5, P2598, DOI 10.1097/00001756-199412000-00048; Smith TS, 1997, BRAIN RES, V765, P183, DOI 10.1016/S0006-8993(97)00429-0; SOKOLOVS.M, 1966, BIOCHEMISTRY-US, V5, P3582, DOI 10.1021/bi00875a029; Squadrito GL, 1998, FREE RADICAL BIO MED, V25, P392, DOI 10.1016/S0891-5849(98)00095-1; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; SWARTZ HM, 1992, ANN NEUROL, V32, pS69, DOI 10.1002/ana.410320712; Togasaki D. M., 1996, Society for Neuroscience Abstracts, V22, P1495; Uppu RM, 1996, ARCH BIOCHEM BIOPHYS, V327, P335, DOI 10.1006/abbi.1996.0131; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; WellsKnecht MC, 1997, J CLIN INVEST, V100, P839, DOI 10.1172/JCI119599; WELLSKNECHT MC, 1993, J BIOL CHEM, V268, P12348; WINK DA, 1994, P NATL ACAD SCI USA, V91, P6604, DOI 10.1073/pnas.91.14.6604; ZANG LY, 1992, J BIOL CHEM, V267, P23601	62	228	231	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34621	34628		10.1074/jbc.274.49.34621	http://dx.doi.org/10.1074/jbc.274.49.34621			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574926	hybrid			2022-12-25	WOS:000083979600020
J	Tan, Y; Ruan, H; Demeter, MR; Comb, MJ				Tan, Y; Ruan, H; Demeter, MR; Comb, MJ			p90(RSK) blocks bad-mediated cell death via a protein kinase C-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; MYC-INDUCED APOPTOSIS; NERVE GROWTH-FACTOR; PHORBOL ESTER; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; LEUKEMIA-CELLS; S6 KINASE; BCL-2 EXPRESSION; SURVIVAL FACTOR	Although activation of protein kinase C (PKC) is known to promote cell survival and protect against cell death, the PKC targets and pathways that serve this function have remained elusive. Here we demonstrate that two potent activators of PKC, 12-O-tetradecanoyl-phorbol-13-acetate and bryostatin, both stimulate phosphorylation of Bad at Ser(112), a site known to regulate apoptotic cell death by interleukin-3. PKC inhibitors but not PI 3-kinase/Akt inhibitors block 12-O-tetradecanoyl-phorbol-13-acetate-stimulated Bad phosphorylation, PRC isoforms tested in vitro were unable to phosphorylate Bad at Ser(112), suggesting that PRC acts indirectly to activate a downstream Bad kinase, p90(RSK) and family members RSK-2 and RSK-3 are activated by phorbol ester and phosphorylate Bad at Ser(112) both in vitro and in vivo. p90(RSK) stimulates binding of Bad to 14-3-3 and blocks Bad-mediated cell death in a Ser(112)-dependent manner. These findings suggest that p90(RSK) can function in a PKC-dependent pathway to promote cell survival via phosphorylation and inactivation of Bad-mediated cell death.	New England Biolabs Inc, Cell Signaling Lab, Beverly, MA 01915 USA		Tan, Y (corresponding author), New England Biolabs Inc, Cell Signaling Lab, 32 Tozer Rd, Beverly, MA 01915 USA.	tan@neb.com			NIDA NIH HHS [DA05706] Funding Source: Medline	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Barr LF, 1997, CELL GROWTH DIFFER, V8, P381; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; COULDWELL WT, 1994, FEBS LETT, V345, P43, DOI 10.1016/0014-5793(94)00415-3; CZERNIK AJ, 1991, METHOD ENZYMOL, V201, P264; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; ERIKSON E, 1987, MOL CELL BIOL, V7, P3147, DOI 10.1128/MCB.7.9.3147; Evans TC, 1998, PROTEIN SCI, V7, P2256, DOI 10.1002/pro.5560071103; Eves EM, 1998, MOL CELL BIOL, V18, P2143, DOI 10.1128/MCB.18.4.2143; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; FORBES IJ, 1992, EXP CELL RES, V198, P367, DOI 10.1016/0014-4827(92)90393-M; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; GROVE JR, 1993, BIOCHEMISTRY-US, V32, P7727, DOI 10.1021/bi00081a018; Gubina E, 1998, BLOOD, V91, P823, DOI 10.1182/blood.V91.3.823.823_823_829; HAIMOVITZFRIEDMAN A, 1994, CANCER RES, V54, P2591; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; JARVIS WD, 1994, CANCER RES, V54, P1707; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LEE HJJ, 1995, J BIOL CHEM, V270, P15979, DOI 10.1074/jbc.270.27.15979; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LOTEM J, 1991, BLOOD, V78, P953; LUCAS M, 1995, GEN PHARMACOL, V26, P881, DOI 10.1016/0306-3623(94)00295-X; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mayne GC, 1998, J BIOL CHEM, V273, P24115, DOI 10.1074/jbc.273.37.24115; MCCABE JM, 1994, PROTEIN KINASE, P290; Minshall C, 1996, J IMMUNOL, V156, P939; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Murata M, 1997, CELL MOL LIFE SCI, V53, P737, DOI 10.1007/s000180050093; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; RAO P, 1994, CANCER RES, V54, P777; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; SANCHEZMARGALET V, 1993, EXP CELL RES, V209, P160, DOI 10.1006/excr.1993.1297; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Vik TA, 1997, BIOCHEM BIOPH RES CO, V235, P398, DOI 10.1006/bbrc.1997.6794; WAKADE AR, 1988, J NEUROCHEM, V51, P975, DOI 10.1111/j.1471-4159.1988.tb01835.x; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; Whitman SP, 1997, J BIOL CHEM, V272, P23481, DOI 10.1074/jbc.272.38.23481; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	63	212	214	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34859	34867		10.1074/jbc.274.49.34859	http://dx.doi.org/10.1074/jbc.274.49.34859			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574959	hybrid			2022-12-25	WOS:000083979600053
J	Yoshida, K; Kharbanda, S; Kufe, D				Yoshida, K; Kharbanda, S; Kufe, D			Functional interaction between SHPTP1 and the Lyn tyrosine kinase in the apoptotic response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; C-ABL; IONIZING-RADIATION; STRESS-RESPONSE; PHOSPHATIDYLINOSITOL 3-KINASE; CELLS; 1-BETA-D-ARABINOFURANOSYLCYTOSINE; PHOSPHORYLATION; ASSOCIATION; DOMAINS	The Lyn protein-tyrosine kinase is activated in the cellular response to DNA-damaging agents. Here we demonstrate that Lyn associates constitutively with the SHPTP1 protein-tyrosine phosphatase. The SH3 domain of Lyn interacts directly with SHPTP1. The results show that Lyn phosphorylates SHPTP1 at the C-terminal Tyr-564 site. Lyn-mediated phosphorylation of SHPTP1 stimulates SHPTP1 tyrosine phosphatase activity. We also demonstrate that treatment of cells with 1-beta-D-arabinofuranosylcytosine and other genotoxic agents induces Lyn-dependent phosphorylation and activation of SHPTP1. The significance of the Lyn-SHPTP1 interaction is supported by the demonstration that activation of Lyn contributes in part to the apoptotic response to ara-C treatment and that SHPTP1 attenuates this response. These findings support a functional interaction between Lyn and SHPTP1 in the response to DNA damage.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA029431] Funding Source: NIH RePORTER; NCI NIH HHS [CA29431] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; GOGA A, 1995, ONCOGENE, V11, P791; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KHARBANDA S, 1994, ONCOGENE, V9, P3005; KHARBANDA S, 1994, J BIOL CHEM, V269, P20739; Kharbanda S, 1996, CANCER RES, V56, P3617; Kharbanda S, 1997, BIOCHIM BIOPHYS ACTA, V1333, pO1; Kumar S, 1998, J BIOL CHEM, V273, P25654, DOI 10.1074/jbc.273.40.25654; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PEI DH, 1993, P NATL ACAD SCI USA, V90, P1092, DOI 10.1073/pnas.90.3.1092; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; YUAN ZM, 1995, BIOCHEMISTRY-US, V34, P1058, DOI 10.1021/bi00003a041; Yuan ZM, 1996, ONCOGENE, V13, P939; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1997, J BIOL CHEM, V272, P23485, DOI 10.1074/jbc.272.38.23485; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Yuan ZM, 1998, J BIOL CHEM, V273, P3799, DOI 10.1074/jbc.273.7.3799	27	48	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34663	34668		10.1074/jbc.274.49.34663	http://dx.doi.org/10.1074/jbc.274.49.34663			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574931	hybrid			2022-12-25	WOS:000083979600025
J	Ensenat, D; Yao, ZB; Wang, XHS; Kori, R; Zhou, GS; Lee, SC; Tan, TH				Ensenat, D; Yao, ZB; Wang, XHS; Kori, R; Zhou, GS; Lee, SC; Tan, TH			A novel Src homology 3 domain-containing adaptor protein, HIP-55, that interacts with hematopoietic progenitor kinase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERMINAL CENTER KINASE; N-TERMINAL KINASE; ACTIN-BINDING-PROTEIN; SIGNAL-TRANSDUCTION; ACTIVATION; PATHWAY; HPK1; CASCADE; FAMILY; KHS	Hematopoietic progenitor kinase 1 (HPK1) is a member of the mitogen-activated protein kinase kinase kinase kinase (MAP4K) family and an upstream activator of the c-Jun N-terminal kinase (JNK) signaling cascade. HPK1 interacts, through its proline-rich domains, with growth factor receptor-bound 2 (Grb2), CT10-regulated kinase (Crk), and Crk-like (CrkL) adaptor proteins. We identified a novel HPK1-interacting protein of 55 kDa (HIP-55), similar to the mouse SH3P7 protein, containing an N-terminal actin-binding domain and a C-terminal Src homology 3 domain. We found that HPK1 bound to HIP-55 both in vitro and in vivo. When co-transfected, HIP-55 increased HPK1's kinase activity as well as JNK1's kinase activity. A dominant-negative HPK1 mutant blocked activation of JNK1 by HIP-55 showing that HIP-55 activates the JNK1 signaling pathway via HPK1. Our results identify a novel protein, HIP-55, that binds to HPK1 and regulates the JNK1 signaling cascade.	Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA; Amgen Inc, Dept Biol, Boulder, CO 80301 USA	Baylor College of Medicine; Amgen	Tan, TH (corresponding author), Baylor Coll Med, Dept Microbiol & Immunol, M929,1 Baylor Plaza, Houston, TX 77030 USA.	ttan@bcm.tmc.edu	Tan, Tse-Hua/ABD-7080-2021; Tan, Tse-Hua/E-3983-2010	Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038649, R01AI042532] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM018509] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI38649, R01-AI42532] Funding Source: Medline; NIGMS NIH HHS [5 F32 GM018509] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anafi M, 1997, J BIOL CHEM, V272, P27804, DOI 10.1074/jbc.272.44.27804; BENNER GE, 1995, J BIOL CHEM, V270, P21121, DOI 10.1074/jbc.270.36.21121; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; DEHOSTOS EL, 1993, CELL MOTIL CYTOSKEL, V26, P181, DOI 10.1002/cm.970260302; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; HATZ P, 1994, J BIOL CHEM, V269, P16802; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Lappalainen P, 1998, MOL BIOL CELL, V9, P1951, DOI 10.1091/mbc.9.8.1951; Ling P, 1999, MOL CELL BIOL, V19, P1359; Oehrl W, 1998, ONCOGENE, V17, P1893, DOI 10.1038/sj.onc.1202108; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; SHIRAO T, 1988, MOL BRAIN RES, V4, P71, DOI 10.1016/0169-328X(88)90020-4; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133	26	57	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					33945	33950		10.1074/jbc.274.48.33945	http://dx.doi.org/10.1074/jbc.274.48.33945			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567356	hybrid			2022-12-25	WOS:000083857500021
J	Kimzey, AL; Dynan, WS				Kimzey, AL; Dynan, WS			Identification of a human T-cell leukemia virus type I tax peptide in contact with DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CREB BINDING-PROTEIN; HTLV-I; TRANSACTIVATOR TAX; TRANSCRIPTIONAL ACTIVATOR; MOLECULAR MECHANISM; PHOTOCROSS-LINKING; CROSS-LINKING; BZIP PROTEINS; IKK-ALPHA	The human T-cell leukemia virus Tax protein directs binding of a host factor, cAMP response element binding protein, to an extended recognition sequence in the proviral promoter. Prior cross-linking experiments have revealed that Tax makes restricted contact with this DNA at two symmetric positions, 14 nucleotides apart on opposite strands of the DNA. Tax lacks a conventional DNA binding domain, and the sequences in Tax that are in contact with DNA have not been previously identified. Analysis of cross-linked peptides now shows that the contact occurs between Tax residues 89 and 110, corresponding to a protease-sensitive linker joining two protein structural domains. The linker assumes a protease-resistant conformation in the cross-linked complex. Point mutations within the linker prevent cross-linking and interfere with Tax function. These data suggest that entry of Tax into the ternary complex may be coupled to folding of an unstructured protein domain, which then makes base-specific contacts with DNA.	Med Coll Georgia, Inst Mol Med & Genet, Gene Regulat Program, Augusta, GA 30912 USA; Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	University System of Georgia; Augusta University; University of Colorado System; University of Colorado Boulder	Dynan, WS (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Gene Regulat Program, 1120 15th St, Augusta, GA 30912 USA.			Dynan, William/0000-0002-4045-5662				ANDERSON MG, 1994, NUCLEIC ACIDS RES, V22, P3194, DOI 10.1093/nar/22.15.3194; ARMSTRONG AP, 1993, P NATL ACAD SCI USA, V90, P7303, DOI 10.1073/pnas.90.15.7303; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; BRAUWEILER A, 1995, J BIOL CHEM, V270, P12814, DOI 10.1074/jbc.270.21.12814; BURGIN AB, 1990, EMBO J, V9, P4111, DOI 10.1002/j.1460-2075.1990.tb07633.x; Caron C, 1997, P NATL ACAD SCI USA, V94, P3662, DOI 10.1073/pnas.94.8.3662; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Clemens KE, 1996, MOL CELL BIOL, V16, P4656; COLIGAN JE, 1997, CURR PROT PROTEIN SC, V2; Ferreira OC, 1997, BLOOD REV, V11, P91, DOI 10.1016/S0268-960X(97)90015-1; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; GIAM CZ, 1986, P NATL ACAD SCI USA, V83, P7192, DOI 10.1073/pnas.83.19.7192; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Kimzey AL, 1998, J BIOL CHEM, V273, P13768, DOI 10.1074/jbc.273.22.13768; KIMZEY AL, 1999, THESIS U COLORADO; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; LANGRANGE T, 1996, P NATL ACAD SCI USA, V93, P10620; Laurance ME, 1997, J BIOL CHEM, V272, P2646, DOI 10.1074/jbc.272.5.2646; Lenzmeier BA, 1998, MOL CELL BIOL, V18, P721, DOI 10.1128/MCB.18.2.721; Lundblad JR, 1998, J BIOL CHEM, V273, P19251, DOI 10.1074/jbc.273.30.19251; MATTHEWS MAH, 1992, MOL CELL BIOL, V12, P1986, DOI 10.1128/MCB.12.5.1986; MAYER AN, 1995, GENE, V153, P1, DOI 10.1016/0378-1119(94)00752-E; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; Meisenheimer KM, 1997, CRIT REV BIOCHEM MOL, V32, P101, DOI 10.3109/10409239709108550; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; MOOS M, 1998, CURRENT PROTOCOLS MO; Nicot C, 1998, J VIROL, V72, P6777, DOI 10.1128/JVI.72.8.6777-6784.1998; PACAUCCARALERTKUN S, 1994, MOL CELL BIOL, V14, P456, DOI 10.1128/MCB.14.1.456; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; Reddy TR, 1997, ONCOGENE, V14, P2785, DOI 10.1038/sj.onc.1201119; SEELER JS, 1993, VIROLOGY, V196, P442, DOI 10.1006/viro.1993.1500; SEMMES OJ, 1995, J VIROL, V69, P1827, DOI 10.1128/JVI.69.3.1827-1833.1995; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; SEMMES OJ, 1992, VIROLOGY, V188, P754, DOI 10.1016/0042-6822(92)90530-3; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; Tang Y, 1998, J BIOL CHEM, V273, P27339, DOI 10.1074/jbc.273.42.27339; Tie F, 1996, J VIROL, V70, P8368, DOI 10.1128/JVI.70.12.8368-8374.1996; TSUCHIYA H, 1994, ONCOGENE, V9, P337; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; Woodard RL, 1999, J BIOL CHEM, V274, P478, DOI 10.1074/jbc.274.1.478; YANG SW, 1994, P NATL ACAD SCI USA, V91, P12183, DOI 10.1073/pnas.91.25.12183; Yin MJ, 1996, J MOL BIOL, V264, P20, DOI 10.1006/jmbi.1996.0620; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; YIN MJ, 1995, J VIROL, V69, P6209, DOI 10.1128/JVI.69.10.6209-6218.1995; Yin MJ, 1996, MOL CELL BIOL, V16, P3156	54	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34226	34232		10.1074/jbc.274.48.34226	http://dx.doi.org/10.1074/jbc.274.48.34226			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567395	hybrid			2022-12-25	WOS:000083857500060
J	Yao, Y; Huang, L; Krutchinsky, A; Wong, ML; Standing, KG; Burlingame, AL; Wang, CC				Yao, Y; Huang, L; Krutchinsky, A; Wong, ML; Standing, KG; Burlingame, AL; Wang, CC			Structural and functional characterizations of the proteasome-activating protein PA26 from Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REG-ALPHA PA28-ALPHA; 20S PROTEASOME; HOMOLOGOUS SUBUNITS; ESCHERICHIA-COLI; 20-S PROTEASOME; BETA-SUBUNIT; KINASE; PURIFICATION; REGULATOR; DEGRADATION	The activated 20 S proteasome, which has been found only in mammalian cells, is composed of two heptamer rings of an activator protein on each end of the 20 S proteasome and is inducible by interferon-gamma, A 20 S proteasome has been recently identified in a protozoan pathogen Trypanosoma brucei, but there has been no experimental evidence yet for the presence of a 26 S proteasome. Instead, an activated form of 20 S proteasome was isolated from this organism, which has significantly enhanced peptidase activities. It consists of an additional activator protein with an estimated molecular mass of 26 kDa (PA26) (To, W, Y,, and Wang, C, C, (1997) FEES Lett, 404, 253-262), The profile and sequences of tryptic peptides from PA26 were determined by mass spectrometry; no matches were found in the data base. The peptide sequences were used in reverse transcriptase-polymerase chain reaction to isolate a full-length cDNA clone encoding PA26, The protein sequence thus derived from it indicates little sequence identity with those of mammalian activator proteins PA28 alpha, beta, or gamma, There is only a single copy of PA26 gene in T, brucei, Purified recombinant PA26 polymerizes spontaneously to form heptamer ring with an outer diameter of 8.5 nm, The ring binds and activates 20 S proteasomes from T, brucei as well as rat, whereas human PA28 alpha can neither bind nor activate T, brucei 20 S proteasome. The former is thus apparently more ubiquitous than PA28 in its capability of binding to and activating 20 S proteasomes. Its presence in T, brucei may also suggest a more ancient origin of proteasome activator proteins and a much wider involvement in protein degradation among other eukaryotic organisms than was originally envisaged.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Manitoba, Dept Phys, Winnipeg, MB R3T 2N2, Canada	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of Manitoba	Wang, CC (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.	ccwang@cgl.ucsf.edu	Standing, Kenneth/E-2416-2011; Huang, Lan/C-3618-2011		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021786] Funding Source: NIH RePORTER; NCRR NIH HHS [R01 RR-01614] Funding Source: Medline; NIAID NIH HHS [R01 AI-21786] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAM KMG, 1971, MED VET PROTOZOOLOGY; AHN JY, 1995, FEBS LETT, V366, P37, DOI 10.1016/0014-5793(95)00492-R; BAKHIET M, 1993, SCAND J IMMUNOL, V37, P165, DOI 10.1111/j.1365-3083.1993.tb01753.x; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; CAMPBELL DA, 1984, NATURE, V311, P350, DOI 10.1038/311350a0; Ciechanover A, 1998, P NATL ACAD SCI USA, V95, P2727, DOI 10.1073/pnas.95.6.2727; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; CRAIG SP, 1991, P NATL ACAD SCI USA, V88, P2500, DOI 10.1073/pnas.88.6.2500; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; Donelson JE, 1996, CURR OPIN GENET DEV, V6, P699, DOI 10.1016/S0959-437X(96)80023-2; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; Goldberg AL, 1997, BIOL CHEM, V378, P131; Grant S, 1996, CLIN CANCER RES, V2, P1915; GRAY CW, 1994, J MOL BIOL, V236, P7, DOI 10.1006/jmbi.1994.1113; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEISE N, 1995, EXP MYCOL, V19, P111, DOI 10.1006/emyc.1995.1013; Hertz CJ, 1998, J IMMUNOL, V161, P6775; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hua SB, 1997, J BIOL CHEM, V272, P10797, DOI 10.1074/jbc.272.16.10797; Hua SB, 1996, MOL BIOCHEM PARASIT, V78, P33, DOI 10.1016/S0166-6851(96)02599-6; Huang L, 1999, MOL BIOCHEM PARASIT, V102, P211, DOI 10.1016/S0166-6851(99)00096-1; JOCHIMSEN B, 1975, MOL GEN GENET, V143, P85, DOI 10.1007/BF00269424; Johnston SC, 1997, PROTEIN SCI, V6, P2469; KARL R, 1999, ANAL CHEM, V71, P2871; KEITH K, 1990, MOL BIOCHEM PARASIT, V43, P107, DOI 10.1016/0166-6851(90)90135-9; Knowlton JR, 1997, NATURE, V390, P639, DOI 10.1038/37670; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MA CP, 1992, J BIOL CHEM, V267, P10515; MEDINAACOSTA E, 1993, MOL BIOCHEM PARASIT, V59, P327, DOI 10.1016/0166-6851(93)90231-L; Milne KG, 1999, J BIOL CHEM, V274, P1465, DOI 10.1074/jbc.274.3.1465; MOTT JD, 1994, J BIOL CHEM, V269, P31466; OLSSON T, 1993, CELL, V72, P715, DOI 10.1016/0092-8674(93)90400-K; PaturiauxHanocq F, 1997, BIOCHEM J, V324, P885, DOI 10.1042/bj3240885; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; REALINI C, 1994, FEBS LETT, V348, P109, DOI 10.1016/0014-5793(94)00569-9; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; Song XL, 1997, J BIOL CHEM, V272, P27994, DOI 10.1074/jbc.272.44.27994; TANG XJ, 1994, RAPID COMMUN MASS SP, V8, P750, DOI 10.1002/rcm.1290080918; To WY, 1997, FEBS LETT, V404, P253, DOI 10.1016/S0014-5793(97)00116-6; WAHL GM, 1987, METHOD ENZYMOL, V152, P572; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Zhang ZG, 1998, J BIOL CHEM, V273, P9501, DOI 10.1074/jbc.273.16.9501; Zhang ZG, 1999, BIOCHEMISTRY-US, V38, P5651, DOI 10.1021/bi990056+; Zhang ZG, 1998, J BIOL CHEM, V273, P30660, DOI 10.1074/jbc.273.46.30660; Zuhl F, 1997, FEBS LETT, V418, P189, DOI 10.1016/S0014-5793(97)01370-7; Zuhl F, 1997, FEBS LETT, V400, P83, DOI 10.1016/S0014-5793(96)01403-2	53	49	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					33921	33930		10.1074/jbc.274.48.33921	http://dx.doi.org/10.1074/jbc.274.48.33921			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567354	hybrid			2022-12-25	WOS:000083857500019
J	Boutaud, O; Brash, AR				Boutaud, O; Brash, AR			Purification and catalytic activities of the two domains of the allene oxide synthase-lipoxygenase fusion protein of the coral Plexaura homomalla	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EGGS; SOYBEAN LIPOXYGENASE; SUICIDE INACTIVATION; MOLECULAR-CLONING; ACID METABOLISM; BIOSYNTHESIS; IDENTIFICATION; HYDROPEROXIDE; PATHWAY; ASSAY	The conversion of fatty acid hydroperoxides to allene epoxides is catalyzed by a cytochrome P450 in plants and, in coral, by a 43-kDa catalase-related hemoprotein fused to the lipoxygenase that synthesizes the 8R-hydroperoxyeicosatetraenoic acid (8R-HPETE) substrate. We have expressed the separate lipoxygenase and allene oxide synthase (AOS) domains of the coral protein in Escherichia coli (BL21 cells) and purified the proteins; this system gives high expression (1.5 and 0.3 mu mol/liter, respectively) of catalytically active enzymes. Both domains show fast reaction kinetics. Catalytic activity of the lipoxygenase domain is stimulated 5-fold by high concentrations of monovalent cations (500 mM Na+, Li+, or K+), and an additional 5-fold by 10 mM Ca2+. The resulting rates of reaction are approximate to 300 turnovers/s, 1-2 orders of magnitude faster than mammalian lipoxygenases. This makes the coral lipoxygenase well suited for partnership with the AOS domain, which shows maximum rates of approximate to 1400 turnovers/s in the conversion of 8R-HPETE to the allene oxide. Some unusual catalytic activities of the two domains are described. The lipoxygenase domain converts 20.3 omega 6 partly to the bis-allylic hydroperoxide (10-hydroperoxyeicosa-8,11,14-trienoic acid). Metabolism of the preferred substrate of the AOS domain, 8R-HPETE, is inhibited by the enantiomer 8S-HPETE. Although the AOS domain has homology to catalase in primary structure, it is completely lacking in catalatic action on H2O2; catalase itself, as expected from its preference for small hydroperoxides, is ineffective in allene oxide synthesis from 8R-HPETE.	Vanderbilt Univ, Sch Med, Dept Pharmacol, Med Ctr, Nashville, TN 37232 USA	Vanderbilt University	Brash, AR (corresponding author), Vanderbilt Univ, Sch Med, Dept Pharmacol, Med Ctr, 23rd Ave & Pierce, Nashville, TN 37232 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049502, R01GM053638] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30-ES00267] Funding Source: Medline; NIGMS NIH HHS [GM-49502, GM-53638] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER BJ, 1985, J AM CHEM SOC, V107, P2976, DOI 10.1021/ja00296a026; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOEYNAEMS JM, 1980, ANAL BIOCHEM, V104, P259, DOI 10.1016/0003-2697(80)90073-1; BRASH AR, 1995, ARCH BIOCHEM BIOPHYS, V321, P485, DOI 10.1006/abbi.1995.1421; Brash AR, 1996, METHOD ENZYMOL, V272, P250, DOI 10.1016/S0076-6879(96)72030-X; Brash AR, 1996, J BIOL CHEM, V271, P20949, DOI 10.1074/jbc.271.34.20949; BRASH AR, 1987, J BIOL CHEM, V262, P15829; BRASH AR, 1991, J BIOL CHEM, V266, P22926; BUNDY GL, 1985, ADV PROSTAG THROMB L, V14, P229; COREY EJ, 1985, TETRAHEDRON LETT, V26, P4171, DOI 10.1016/S0040-4039(00)98982-2; COREY EJ, 1973, J AM CHEM SOC, V95, P2054, DOI 10.1021/ja00787a079; COREY EJ, 1988, TETRAHEDRON LETT, V29, P2555, DOI 10.1016/S0040-4039(00)86110-9; DODGE JT, 1963, ARCH BIOCHEM BIOPHYS, V100, P119, DOI 10.1016/0003-9861(63)90042-0; GIBIAN MJ, 1987, ANAL BIOCHEM, V163, P343, DOI 10.1016/0003-2697(87)90234-X; GILLOT I, 1991, DEV BIOL, V146, P396, DOI 10.1016/0012-1606(91)90241-T; Hamberg M, 1998, J BIOL CHEM, V273, P13080, DOI 10.1074/jbc.273.21.13080; HAMBERG M, 1992, BIOCHIM BIOPHYS ACTA, V1165, P1, DOI 10.1016/0005-2760(92)90069-8; HAMBERG M, 1993, ARCH BIOCHEM BIOPHYS, V305, P115, DOI 10.1006/abbi.1993.1400; HAMBERG M, 1992, LIPIDS, V27, P487, DOI 10.1007/BF02536128; HAMBERG M, 1989, J AM OIL CHEM SOC, V66, P1445, DOI 10.1007/BF02661968; HOFFMAN BJ, 1995, PROTEIN EXPRES PURIF, V6, P646, DOI 10.1006/prep.1995.1085; IMAI T, 1993, J BIOL CHEM, V268, P19681; JONES DA, 1991, J BIOL CHEM, V266, P23510; KIM MR, 1991, ARCH BIOCHEM BIOPHYS, V288, P270, DOI 10.1016/0003-9861(91)90194-N; Kishimoto K, 1996, BBA-LIPID LIPID MET, V1300, P56, DOI 10.1016/0005-2760(95)00241-3; Koljak R, 1997, SCIENCE, V277, P1994, DOI 10.1126/science.277.5334.1994; KUHN H, 1990, J BIOL CHEM, V265, P16300; KUHN H, 1993, BIOCHIM BIOPHYS ACTA, V1169, P80, DOI 10.1016/0005-2760(93)90085-N; Matsui K, 1996, FEBS LETT, V394, P21, DOI 10.1016/0014-5793(96)00924-6; MEIJER L, 1984, CAH BIOL MAR, V25, P457; ORNING L, 1992, J BIOL CHEM, V267, P22733; PACEASCIAK CR, 1990, BIOL OXIDATION SYSTE, V2, P725; PEERS KE, 1983, CHEM PHYS LIPIDS, V32, P49, DOI 10.1016/0009-3084(83)90069-5; RABINOVITCHCHABLE H, 1992, BIOCHEM BIOPH RES CO, V188, P858, DOI 10.1016/0006-291X(92)91135-D; SCHEWE T, 1986, ADV ENZYMOL RAMB, V58, P191; SILVERMAN RB, 1988, MECHANISM BASED ENZY, V1; SOK DE, 1989, BIOCHEM BIOPH RES CO, V162, P1357, DOI 10.1016/0006-291X(89)90823-1; SONG WC, 1991, ARCH BIOCHEM BIOPHYS, V290, P427, DOI 10.1016/0003-9861(91)90562-W; SONG WC, 1991, SCIENCE, V253, P781, DOI 10.1126/science.1876834; SONG WC, 1993, P NATL ACAD SCI USA, V90, P8519, DOI 10.1073/pnas.90.18.8519; SONG WC, 1991, PROSTAGLANDINS LEUKO, P89; STEINHAR.RA, 1974, P NATL ACAD SCI USA, V71, P1915, DOI 10.1073/pnas.71.5.1915; VARVAS K, 1994, TETRAHEDRON LETT, V35, P8267, DOI 10.1016/0040-4039(94)88299-1; Varvas K, 1999, J BIOL CHEM, V274, P9923, DOI 10.1074/jbc.274.15.9923; Vliegenthart J. F. G., 1982, FREE RADICAL BIO MED, P29	45	65	66	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33764	33770		10.1074/jbc.274.47.33764	http://dx.doi.org/10.1074/jbc.274.47.33764			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559269	hybrid			2022-12-25	WOS:000083745200085
J	Hampson, DR; Huang, XP; Pekhletski, R; Peltekova, V; Hornby, G; Thomsen, C; Thogersen, H				Hampson, DR; Huang, XP; Pekhletski, R; Peltekova, V; Hornby, G; Thomsen, C; Thogersen, H			Probing the ligand-binding domain of the mGluR4 subtype of metabotropic glutamate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR DOMAIN; AGONIST SELECTIVITY; X-RAY; CLONING; PROTEIN; LOCALIZATION; EXPRESSION; FAMILY	Metabotropic glutamate receptors (mGluRs) are G-protein-coupled glutamate receptors that subserve a number of diverse functions in the central nervous system. The large extracellular amino-terminal domains (ATDs) of mGluRs are homologous to the periplasmic binding proteins in bacteria. In this study, a region in the ATD of the mGluR4 subtype of mGluR postulated to contain the ligand-binding pocket was explored by site-directed mutagenesis using a molecular model of the tertiary structure of the ATD as a guiding tool. Although the conversion of Arg(78), Ser(159), or Thr(182) to Ala did not affect the level of protein expression or cell-surface expression, all three mutations severely impaired the ability of the receptor to bind the agonist L-[H-3] amino-4-phosphonobutyric acid. Mutation of other residues within or in close proximity to the proposed binding pocket produced either no effect (Ser(157) and Ser(160)) or a relatively modest effect (Ser(181)) on ligand affinity compared with the Arg(78), Ser(159), and Thr(182) mutations. Based on these experimental findings, together with information obtained from the model in which the glutamate analog L-serine O-phosphate (L-SOP) was "docked" into the binding pocket, we suggest that the hydroxyl groups on the side chains of Ser(159) and Thr(182) of mGluR4 form hydrogen bonds with the Lu-carboxyl and alpha-amino groups on L-SOP, respectively, whereas Arg(78) forms an electrostatic interaction with the acidic side chains of L-SOP or glutamate. The conservation of Arg7(8,) Ser(159), and Thr(182) in all members of the mGluR family indicates that these amino acids may be fundamental recognition motifs for the binding of agonists to this class of receptors.	Univ Toronto, Fac Pharm, Toronto, ON M5S 2S2, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5S 2S2, Canada; Novo Nordisk AS, Dept Mol Pharmacol, Malov 2760, Denmark; Novo Nordisk AS, Dept Med Chem, Malov 2760, Denmark	University of Toronto; University of Toronto; Novo Nordisk; Novo Nordisk	Hampson, DR (corresponding author), Univ Toronto, Fac Pharm, 19 Russell St, Toronto, ON M5S 2S2, Canada.	d.hampson@utoronto.ca						BLUNDELL TL, 1987, NATURE, V326, P347, DOI 10.1038/326347a0; Bradley SR, 1999, J COMP NEUROL, V407, P33; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Chamberlain D, 1997, BIOCHEMISTRY-US, V36, P8020, DOI 10.1021/bi9703251; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Eriksen L, 1995, BRIT J PHARMACOL, V116, P3279, DOI 10.1111/j.1476-5381.1995.tb15136.x; Galvez T, 1999, J BIOL CHEM, V274, P13362, DOI 10.1074/jbc.274.19.13362; Gerlai R, 1998, BEHAV NEUROSCI, V112, P525; Gomeza J, 1996, MOL PHARMACOL, V50, P923; Han GM, 1999, J BIOL CHEM, V274, P10008, DOI 10.1074/jbc.274.15.10008; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; KLUNK WE, 1991, MOL CHEM NEUROPATHOL, V15, P51, DOI 10.1007/BF03161056; Kubo Y, 1998, SCIENCE, V279, P1722, DOI 10.1126/science.279.5357.1722; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; Macek TA, 1996, J NEUROPHYSIOL, V76, P3798, DOI 10.1152/jn.1996.76.6.3798; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; MOON MA, 1999, CELL, V96, P541; Ng GYK, 1999, J BIOL CHEM, V274, P7607, DOI 10.1074/jbc.274.12.7607; Nicoletti F, 1996, TRENDS NEUROSCI, V19, P267, DOI 10.1016/S0166-2236(96)20019-0; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; Pekhletski R, 1996, J NEUROSCI, V16, P6364; Petralia RS, 1996, NEUROSCIENCE, V71, P949, DOI 10.1016/0306-4522(95)00533-1; Pickering DS, 1995, P NATL ACAD SCI USA, V92, P12090, DOI 10.1073/pnas.92.26.12090; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; Shigemoto R, 1997, J NEUROSCI, V17, P7503, DOI 10.1523/jneurosci.17-19-07503.1997; Stowell JN, 1999, NEURON, V22, P525, DOI 10.1016/S0896-6273(00)80707-2; Sutcliffe MJ, 1996, BIOPHYS J, V70, P1575, DOI 10.1016/S0006-3495(96)79724-2; Sutcliffe MJ, 1998, METHOD ENZYMOL, V293, P589; TAKAHASHI K, 1993, J BIOL CHEM, V268, P19341; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; Thomsen C, 1998, NEUROPHARMACOLOGY, V37, P1465, DOI 10.1016/S0028-3908(98)00138-5; Thomsen C, 1997, NEUROPHARMACOLOGY, V36, P21, DOI 10.1016/S0028-3908(96)00153-0; Toms NJ, 1996, BRIT J PHARMACOL, V119, P851, DOI 10.1111/j.1476-5381.1996.tb15750.x; Tones MA, 1995, NEUROREPORT, V7, P117, DOI 10.1097/00001756-199512290-00028; Wroblewska B, 1997, J NEUROCHEM, V69, P174	39	64	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33488	33495		10.1074/jbc.274.47.33488	http://dx.doi.org/10.1074/jbc.274.47.33488			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559233	Green Submitted, hybrid			2022-12-25	WOS:000083745200049
J	Hayes, AL; Smith, C; Foxwell, BMJ; Brennan, FM				Hayes, AL; Smith, C; Foxwell, BMJ; Brennan, FM			CD45-induced tumor necrosis factor alpha production in monocytes is phosphatidylinositol 3-kinase-dependent and nuclear factor-kappa B-independent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; CD45 PHOSPHOTYROSINE PHOSPHATASE; CD40-CD40 LIGAND INTERACTION; CELL ANTIGEN RECEPTOR; N-TERMINAL KINASE; HUMAN T-CELLS; SIGNAL-TRANSDUCTION; BACTERIAL LIPOPOLYSACCHARIDE; TYROSINE KINASE; RHEUMATOID-ARTHRITIS	The pro-inflammatory cytokine tumor necrosis factor (TNF)-alpha plays a pivotal role in the pathogenesis of rheumatoid arthritis. The mechanisms involved in regulating monocyte/macrophage TNF alpha production are not yet fully understood but are thought to involve both soluble factors and cell/cell contact with other cell types. Ligation of certain cell surface receptors, namely CD45, CD44, and CD58, can induce the production of TNF alpha in monocytes. In this paper, we investigate further the signaling pathways utilized by cell surface receptors (specifically CD45) to induce monocyte TNF alpha and compare the common/unique pathways involved with that of lipopolysaccharide. The results indicate that monocyte TNF alpha induced upon CD45 ligation or lipopolysaccharide stimulation is differentially modulated by phosphatidylinositol 3-kinase and nuclear factor-kappa B but similarly regulated by p38 mitogen-activated protein kinase. These results demonstrate that both common and unique signaling pathways are utilized by different stimuli for the induction of TNF alpha. These observations may have a major bearing on approaches to inhibiting TNF alpha production in disease where the cytokine has a pathogenic role.	Kennedy Inst, London W6 8LH, England	University of Oxford	Brennan, FM (corresponding author), Kennedy Inst, 1 Aspenlea Rd, London W6 8LH, England.	f.brennan@cxwms.ac.uk						Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; BEATY CD, 1994, EUR J IMMUNOL, V24, P1278, DOI 10.1002/eji.1830240606; Benatar T, 1996, J EXP MED, V183, P329, DOI 10.1084/jem.183.1.329; BIFFEN M, 1994, EMBO J, V13, P1920, DOI 10.1002/j.1460-2075.1994.tb06461.x; BRABLETZ T, 1991, NUCLEIC ACIDS RES, V19, P61, DOI 10.1093/nar/19.1.61; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; CAVAILLON J-M, 1990, Cytokine, V2, P313, DOI 10.1016/1043-4666(90)90061-W; CAVAILLON JM, 1990, INFECT IMMUN, V58, P2375, DOI 10.1128/IAI.58.7.2375-2382.1990; CLARK EA, 1989, IMMUNOL TODAY, V10, P225, DOI 10.1016/0167-5699(89)90257-0; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P27, DOI 10.1146/annurev.iy.09.040191.000331; ENGELBERTS I, 1991, LYMPHOKINE CYTOK RES, V10, P69; Finch A, 1997, FEBS LETT, V418, P144, DOI 10.1016/S0014-5793(97)01364-1; Foxwell B, 1998, P NATL ACAD SCI USA, V95, P8211, DOI 10.1073/pnas.95.14.8211; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GENG Y, 1993, J IMMUNOL, V151, P6692; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; GOLDFELD AE, 1994, J EXP MED, V180, P763, DOI 10.1084/jem.180.2.763; GOLDFELD AE, 1991, J EXP MED, V174, P73, DOI 10.1084/jem.174.1.73; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; GRUBER MF, 1994, J IMMUNOL, V152, P1354; Hambleton J, 1996, P NATL ACAD SCI USA, V93, P2774, DOI 10.1073/pnas.93.7.2774; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HerreraVelit P, 1996, J IMMUNOL, V156, P1157; ISLER P, 1993, EUR CYTOKINE NETW, V4, P15; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KANNER SB, 1992, BIOCHEM SOC T, V20, P178, DOI 10.1042/bst0200178; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KRUYS V, 1992, P NATL ACAD SCI USA, V89, P673, DOI 10.1073/pnas.89.2.673; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; LEDBETTER JA, 1988, P NATL ACAD SCI USA, V85, P8628, DOI 10.1073/pnas.85.22.8628; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; LIU J, 1993, IMMUNOL TODAY, V14, P290, DOI 10.1016/0167-5699(93)90048-P; LIU MK, 1994, J IMMUNOL, V153, P2642; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; MANIE S, 1993, EUR CYTOKINE NETW, V4, P7; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; PAI SY, 1994, EUR J IMMUNOL, V24, P2364, DOI 10.1002/eji.1830241016; Parry SL, 1997, J IMMUNOL, V158, P3673; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; QUI Y, 1998, P NATL ACAD SCI USA, V95, P3644; ROLAPLESZCZYNSKI M, 1993, J LIPID MEDIATOR, V6, P175; Saklatvala J, 1999, BIOCHEM SOC SYMP, P63; Sebbag M, 1997, EUR J IMMUNOL, V27, P624, DOI 10.1002/eji.1830270308; SGROI D, 1995, P NATL ACAD SCI USA, V92, P4026, DOI 10.1073/pnas.92.9.4026; SHAPIRA L, 1994, J IMMUNOL, V153, P1818; SHIROO M, 1992, EMBO J, V11, P4887, DOI 10.1002/j.1460-2075.1992.tb05595.x; SHU U, 1995, EUR J IMMUNOL, V25, P1125, DOI 10.1002/eji.1830250442; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; TRINCHIERI G, 1991, IMMUNOL RES, V10, P89, DOI 10.1007/BF02918157; TROWBRIDGE IS, 1991, BIOCHIM BIOPHYS ACTA, V1095, P46, DOI 10.1016/0167-4889(91)90043-W; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; WAGNER DH, 1994, EUR J IMMUNOL, V24, P3148, DOI 10.1002/eji.1830241235; WEBB DSA, 1990, SCIENCE, V249, P1295, DOI 10.1126/science.1697984; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; WHITESIDE ST, 1992, NUCLEIC ACIDS RES, V20, P1531, DOI 10.1093/nar/20.7.1531; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Wrighton CJ, 1996, J EXP MED, V183, P1013, DOI 10.1084/jem.183.3.1013	72	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33455	33461		10.1074/jbc.274.47.33455	http://dx.doi.org/10.1074/jbc.274.47.33455			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559228	hybrid			2022-12-25	WOS:000083745200044
J	Molina-Heredia, FP; Diaz-Quintana, A; Hervas, M; Navarro, JA; De la Rosa, MA				Molina-Heredia, FP; Diaz-Quintana, A; Hervas, M; Navarro, JA; De la Rosa, MA			Site-directed mutagenesis of cytochrome c(6) from Anabaena species PCC 7119 - Identification of surface residues of the hemeprotein involved in photosystem I reduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLASH ABSORPTION-SPECTROSCOPY; ELECTRON-TRANSFER; SYNECHOCYSTIS PCC-6803; MONORAPHIDIUM-BRAUNII; REACTION-MECHANISM; PLASTOCYANIN; PCC-7119; PROTEINS; PURIFICATION; PHOTOLYSIS	A number of surface residues of cytochrome c(6) from the cyanobacterium Anabaena sp, PCC 7119 have been modified by site-directed mutagenesis. Changes were made in six amino acids, two near the heme group (Val-25 and Lys-29) and four in the positively charged patch (Lys-62, Arg-64, Lys-66, and Asp-72). The reactivity of mutants toward the membrane-anchored complex photosystem I was analyzed by laser flash absorption spectroscopy. The experimental results indicate that cytochrome c(6) possesses two areas involved in the redox interaction with photosystem I: 1) a positively charged patch that may drive its electrostatic attractive movement toward photosystem I to form a transient complex and 2) a hydrophobic region at the edge of the heme pocket that may provide the contact surface for the transfer of electrons to P-700. The isofunctionality of these two areas with those found in plastocyanin (which acts as an alternative electron carrier playing the same role as cytochrome c(6)) are evident.	Univ Sevilla, Inst Bioquim Vegetal & Fotosintesis, Seville 41092, Spain; CSIC, Ctr Isla de la Cartuja, Seville 41092, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-JA-USE - Centro de Investigaciones Cientificas Isla de La Cartuja (CICIC)	De la Rosa, MA (corresponding author), Univ Sevilla, Inst Bioquim Vegetal & Fotosintesis, Americo Vespucio S-N, Seville 41092, Spain.		Hervas, Manuel/K-9279-2014; Díaz-Quintana, Antonio/A-1946-2011; navarro, jose a/B-6354-2015; De la Rosa, Miguel/B-2545-2014; Molina-Heredia, Fernando P./F-7877-2015	Hervas, Manuel/0000-0003-4523-8891; Díaz-Quintana, Antonio/0000-0001-8973-8009; navarro, jose a/0000-0002-0536-6074; De la Rosa, Miguel/0000-0003-1187-5737; Molina-Heredia, Fernando P./0000-0002-3637-0519				ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; Beissinger M, 1998, EMBO J, V17, P27, DOI 10.1093/emboj/17.1.27; BOTTIN H, 1985, BIOCHEMISTRY-US, V24, P6453, DOI 10.1021/bi00344a022; CAMPOS AP, 1993, EUR J BIOCHEM, V216, P329, DOI 10.1111/j.1432-1033.1993.tb18150.x; CHITNIS PR, 1995, PHOTOSYNTH RES, V44, P23, DOI 10.1007/BF00018294; De la Cerda B, 1999, J BIOL CHEM, V274, P13292, DOI 10.1074/jbc.274.19.13292; DelaCerda B, 1997, BIOCHEMISTRY-US, V36, P10125, DOI 10.1021/bi9708601; DIAZ A, 1994, EUR J BIOCHEM, V222, P1001, DOI 10.1111/j.1432-1033.1994.tb18951.x; Drepper F, 1996, BIOCHEMISTRY-US, V35, P1282, DOI 10.1021/bi951471e; ERVAS M, 1994, BIOCHIM BIOPHYS ACTA, V1184, P235; FRAZAO C, 1995, STRUCTURE, V3, P1159, DOI 10.1016/S0969-2126(01)00252-0; GIAMMONA DA, 1984, THESIS U CALIFORNIA; HAEHNEL W, 1994, EMBO J, V13, P1028, DOI 10.1002/j.1460-2075.1994.tb06351.x; Hervas M, 1996, BIOCHEMISTRY-US, V35, P2693, DOI 10.1021/bi951876z; HERVAS M, 1995, BIOCHEMISTRY-US, V34, P11321, DOI 10.1021/bi00036a004; Hippler M, 1996, EMBO J, V15, P6374, DOI 10.1002/j.1460-2075.1996.tb01028.x; HO KK, 1984, BIOCHIM BIOPHYS ACTA, V766, P310, DOI 10.1016/0005-2728(84)90246-9; HOSHINO T, 1980, J BACTERIOL, V141, P1055, DOI 10.1128/JB.141.3.1055-1063.1980; KERFELD CA, 1995, J MOL BIOL, V250, P627, DOI 10.1006/jmbi.1995.0404; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MATHIS P, 1981, ISRAEL J CHEM, V21, P316; MEDINA M, 1993, EUR J BIOCHEM, V213, P1133, DOI 10.1111/j.1432-1033.1993.tb17863.x; Medina M, 1997, J BIOL INORG CHEM, V2, P225, DOI 10.1007/s007750050128; MEYER TE, 1993, BIOCHEMISTRY-US, V32, P4552, DOI 10.1021/bi00068a010; Molina-Heredia FP, 1998, BIOCHEM BIOPH RES CO, V243, P302, DOI 10.1006/bbrc.1997.7953; MOORE GR, 1984, BIOCHIM BIOPHYS ACTA, V764, P331, DOI 10.1016/0005-2728(84)90104-X; Navarro JA, 1997, J BIOL INORG CHEM, V2, P11, DOI 10.1007/s007750050101; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; NORDLING M, 1991, FEBS LETT, V291, P327, DOI 10.1016/0014-5793(91)81313-W; ORTEGA JM, 1988, EUR J BIOCHEM, V199, P239; PEARLMAN DA, 1995, AMBER VERSION 4 1; ROGNER M, 1990, J BIOL CHEM, V265, P6189; Sambrook J., 2002, MOL CLONING LAB MANU; Sigfridsson K, 1996, BIOCHEMISTRY-US, V35, P1249, DOI 10.1021/bi9520141; Ullmann GM, 1997, BIOCHEMISTRY-US, V36, P16187, DOI 10.1021/bi971241v; WATKINS JA, 1994, PROTEIN SCI, V3, P2104, DOI 10.1002/pro.5560031124; XU QA, 1994, J BIOL CHEM, V269, P3205	38	39	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33565	33570		10.1074/jbc.274.47.33565	http://dx.doi.org/10.1074/jbc.274.47.33565			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559243	Green Published, hybrid			2022-12-25	WOS:000083745200059
J	Sun, YP; Zhang, JY; Kraeft, SK; Auclair, D; Chang, MS; Liu, Y; Sutherland, R; Salgia, R; Griffin, JD; Ferland, LH; Chen, LB				Sun, YP; Zhang, JY; Kraeft, SK; Auclair, D; Chang, MS; Liu, Y; Sutherland, R; Salgia, R; Griffin, JD; Ferland, LH; Chen, LB			Molecular cloning and characterization of human trabeculin-alpha a giant protein defining a new family of actin-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BULLOUS PEMPHIGOID ANTIGEN; INTERMEDIATE FILAMENTS; STRUCTURAL-ANALYSIS; MEMBRANE SKELETON; FOCAL ADHESIONS; STRESS FIBERS; SPECTRIN; PHOSPHORYLATION; CYTOSKELETON; DROSOPHILA	We describe the molecular cloning and characterization of a novel giant human cytoplasmic protein, trabeculin-alpha (M-r = 614,000), Analysis of the deduced amino acid sequence reveals homologies with several putative functional domains, including a pair of alpha-actinin-like actin binding domains; regions of homology to plakins at either end of the giant polypeptide; 29 copies of a spectrin-like motif in the central region of the protein; two potential Ca2+-binding EF-hand motifs; and a Ser-rich region containing a repeated GSRX motif, With similarities to both plakins and spectrins, trabeculin-alpha appears to have evolved as a hybrid of these two families of proteins. The functionality of the actin binding domains located near the N terminus was confirmed with an F-actin binding assay using glutathione S-transferase fusion proteins comprising amino acids 9-486 of the deduced peptide. Northern and Western blotting and immunofluorescence studies suggest that trabeculin is ubiquitously expressed and is distributed throughout the cytoplasm, though the protein was found to be greatly up-regulated upon differentiation of myoblasts into myotubes. Finally, the presence of cDNAs similar to, yet distinct from, trabeculin-alpha in both human and mouse suggests that trabeculins may form a new subfamily of giant actin-binding/cytoskeletal cross-linking proteins.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Chen, LB (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	drchen@shore.net		CHANG, MAU-SUN/0000-0002-3703-2386				Allen PG, 1999, BIOESSAYS, V21, P451, DOI 10.1002/(SICI)1521-1878(199906)21:6<451::AID-BIES1>3.0.CO;2-B; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; Bernier G, 1996, GENOMICS, V38, P19, DOI 10.1006/geno.1996.0587; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; BYERS TJ, 1995, FEBS LETT, V368, P500, DOI 10.1016/0014-5793(95)00722-L; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; DAHL SC, 1994, J CELL BIOL, V125, P1057, DOI 10.1083/jcb.125.5.1057; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; DUBREUIL RR, 1991, BIOESSAYS, V13, P219, DOI 10.1002/bies.950130504; Foisner R, 1996, MOL BIOL CELL, V7, P273, DOI 10.1091/mbc.7.2.273; Foisner R, 1991, CURR OPIN CELL BIOL, V3, P75, DOI 10.1016/0955-0674(91)90168-X; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; GREEN KJ, 1992, INT J BIOL MACROMOL, V14, P145, DOI 10.1016/S0141-8130(05)80004-2; Gregory SL, 1998, J CELL BIOL, V143, P1271, DOI 10.1083/jcb.143.5.1271; Grum VL, 1999, CELL, V98, P523, DOI 10.1016/S0092-8674(00)81980-7; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HARTWIG JH, 1994, PROTEIN PROFILE, V1, P711; KAWASAKI H, 1995, PROTEIN PROFILE, V2, P305; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LO SH, 1994, J BIOL CHEM, V269, P22310; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; LO SH, 1994, J CELL BIOL, V125, P1067, DOI 10.1083/jcb.125.5.1067; MANNO S, 1995, J BIOL CHEM, V270, P5659, DOI 10.1074/jbc.270.10.5659; Nagase T, 1998, DNA Res, V5, P277, DOI 10.1093/dnares/5.5.277; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Pascual J, 1997, BIOESSAYS, V19, P811, DOI 10.1002/bies.950190911; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Prokop A, 1998, J CELL BIOL, V143, P1283, DOI 10.1083/jcb.143.5.1283; Prout M, 1997, GENETICS, V146, P275; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ruhrberg C, 1997, CURR OPIN GENET DEV, V7, P392, DOI 10.1016/S0959-437X(97)80154-2; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; Squire JM, 1997, CURR OPIN STRUC BIOL, V7, P247, DOI 10.1016/S0959-440X(97)80033-4; STAPPENBECK TS, 1994, J BIOL CHEM, V269, P29351; SVOBODA K, 1992, BIOPHYS J, V63, P784, DOI 10.1016/S0006-3495(92)81644-2; Tang HY, 1996, J BIOL CHEM, V271, P9716, DOI 10.1074/jbc.271.16.9716; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; Yang YM, 1999, CELL, V98, P229, DOI 10.1016/S0092-8674(00)81017-X; Zucman-Rossi J, 1996, GENOMICS, V38, P247, DOI 10.1006/geno.1996.0625	45	39	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33522	33530		10.1074/jbc.274.47.33522	http://dx.doi.org/10.1074/jbc.274.47.33522			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559237	hybrid			2022-12-25	WOS:000083745200053
J	Eilers, AL; Billin, AN; Liu, J; Ayer, DE				Eilers, AL; Billin, AN; Liu, J; Ayer, DE			A 13-amino acid amphipathic alpha-helix is required for the functional interaction between the transcriptional repressor Mad1 and mSin3A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL DOMAIN; HISTONE DEACETYLASE; TRANSACTIVATION DOMAIN; N-COR; SECONDARY STRUCTURE; BINDING PROTEIN; COMPLEX; MYC; MAX; SIN3	Members of the Mad family of bHLHZip proteins heterodimerize with Max and function to repress the transcriptional and transforming activities of the Myc protooncogene. Mad:Max heterodimers repress transcription by recruiting a large multi-protein complex containing the histone deacetylases, HDAC1 and HDAC2, to DNA. The interaction between Mad proteins and HDAC1/2 is mediated by the corepressor mSin3A and requires sequences at the amino terminus of the Mad proteins, termed the SID, for SinS interaction domain, and the second of four paired amphipathic alpha-helices (PAH2) in mSin3A To better understand the requirements for the interaction between the SID and PAH2, we have performed mutagenesis and structural studies on the SID. These studies show that amino acids 8-20 of Mad1. are sufficient for SID:PAH2 interaction. Further, this minimal 13-residue SID peptide forms an amphipathic cu-helix in solution, and residues on the hydrophobic face of the SID helix are required for interaction with PAH2. Finally, the minimal SID can function as an autonomous and portable repression domain, demonstrating that it is sufficient to target a functional mSin3AH/DAC corepressor complex.	Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Ayer, DE (corresponding author), Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, 2000 Circle Hope, Salt Lake City, UT 84112 USA.	don.ayer@hci.utah.edu		Ayer, Donald/0000-0002-5595-3269; Billin, Andrew/0000-0001-7752-0934	NCI NIH HHS [3P30CA42014] Funding Source: Medline; NIGMS NIH HHS [GM5568-01, R01 GM055668] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055668] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cairns BR, 1998, TRENDS BIOCHEM SCI, V23, P20, DOI 10.1016/S0968-0004(97)01160-2; Davie JR, 1998, CURR OPIN GENET DEV, V8, P173, DOI 10.1016/S0959-437X(98)80138-X; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hassig CA, 1997, CURR OPIN CHEM BIOL, V1, P300, DOI 10.1016/S1367-5931(97)80066-X; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Hua QX, 1998, BIOCHEMISTRY-US, V37, P5858, DOI 10.1021/bi9800808; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; JASANOFF A, 1994, BIOCHEMISTRY-US, V33, P2129, DOI 10.1021/bi00174a020; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kasten MM, 1996, MOL CELL BIOL, V16, P4215; Kentsis A, 1998, BIOCHEMISTRY-US, V37, P14613, DOI 10.1021/bi981641y; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Moore DD, 1995, GLOB MOB SURV; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Parker D, 1998, MOL CELL, V2, P353, DOI 10.1016/S1097-2765(00)80279-8; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; UM M, 1995, MOL CELL BIOL, V15, P5007; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; WANG HM, 1990, MOL CELL BIOL, V10, P5927, DOI 10.1128/MCB.10.11.5927; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; WU CSC, 1981, BIOCHEMISTRY-US, V20, P566, DOI 10.1021/bi00506a019; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	52	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32750	32756		10.1074/jbc.274.46.32750	http://dx.doi.org/10.1074/jbc.274.46.32750			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551834	hybrid			2022-12-25	WOS:000083623000034
J	Ghibelli, L; Coppola, S; Fanelli, C; Rotilio, G; Civitareale, P; Scovassi, AI; Ciriolo, MR				Ghibelli, L; Coppola, S; Fanelli, C; Rotilio, G; Civitareale, P; Scovassi, AI; Ciriolo, MR			Glutathione depletion causes cytochrome c release even in the absence of cell commitment to apoptosis	FASEB JOURNAL			English	Article						caspase 3; redox modulation; PARP; apoptotic cytochrome c release; puromycin	PERMEABILITY TRANSITION; GSH EXTRUSION; ION-CHANNEL; BAX; MITOCHONDRIA; FRAGMENTATION; TRANSLOCATION; ACTIVATION; CASPASE-3; PROTEASE	We demonstrate here that the release of mature cytochrome c from mitochondria is a cellular response to the depletion of glutathione, the main intracellular antioxidant, independently from the destiny of the cells, i.e., apoptosis or survival. On the one hand, cytosolic cytochrome c was detected in cells where the inhibition of glutathione synthesis led to glutathione depletion without impairing viability or in tight concomitance with glutathione depletion prior to puromycin-induced apoptosis. Removal of the apoptogenic agent prior to apoptosis, but after glutathione extrusion and cytochrome c release, led to recovery of preapoptotic cells, which resume healthy features, i.e., restoration of normal glutathione levels and disappearance of cytosolic cytochrome c. On the other hand, in an example of apoptosis occurring without glutathione depletion, no translocation of cytochrome c from mitochondria to cytosol was detected. Unlike the other instances of apoptosis, in this case caspase 3 was not activated, thus suggesting the following oxidant-related apoptotic pathway: glutathione depletion, cytochrome c release, and caspase 3 activation. These results show that cytochrome c release is not a terminal event leading cells to apoptosis, but rather is the consequence of a redox disequilibrium that, under some circumstances, may be associated with apoptosis.-Ghibelli, L., Coppola, S., Fanelli, C., Rotilio, G., Civitareale, P., Scovassi, A. I., Ciriolo, M. R. Glutathione depletion causes cytochrome c release even in the absence of cell commitment to apoptosis.	Univ Roma Tor Vergata, Dipartimento Biol, I-00133 Rome, Italy; CNR, Ist Genet Biochim & Evoluzionist, I-27100 Pavia, Italy; Univ Chieti, Dipartimento Sci Biomed, I-66013 Chieti, Italy	University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); G d'Annunzio University of Chieti-Pescara	Ghibelli, L (corresponding author), Univ Roma Tor Vergata, Dipartimento Biol, Via Ric Sci, I-00133 Rome, Italy.		Scovassi, Anna Ivana/F-2458-2010; Ciriolo, Maria Rosa/K-6572-2016; Coppola, Simona/A-6638-2015	Scovassi, Anna Ivana/0000-0003-3484-9881; Coppola, Simona/0000-0001-7851-9409; Ciriolo, Maria Rosa/0000-0002-7863-9029				Dini L, 1996, EXP CELL RES, V223, P340, DOI 10.1006/excr.1996.0089; Donzelli M, 1999, ONCOGENE, V18, P439, DOI 10.1038/sj.onc.1202309; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Ghibelli L, 1995, FEBS LETT, V377, P9, DOI 10.1016/0014-5793(95)01284-2; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; Ghibelli L, 1998, FASEB J, V12, P479, DOI 10.1096/fasebj.12.6.479; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; MARZULLI D, 1995, ARCH BIOCHEM BIOPHYS, V319, P36, DOI 10.1006/abbi.1995.1264; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; SHAH GM, 1995, ANAL BIOCHEM, V227, P1, DOI 10.1006/abio.1995.1245; Tang DG, 1998, BIOCHEM BIOPH RES CO, V242, P380, DOI 10.1006/bbrc.1997.7969; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thomas A, 1996, ONCOGENE, V12, P1055; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; Yang JC, 1998, BIOCHEM BIOPH RES CO, V250, P454, DOI 10.1006/bbrc.1998.9333; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	28	122	125	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1999	13	14					2031	2036		10.1096/fasebj.13.14.2031	http://dx.doi.org/10.1096/fasebj.13.14.2031			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544186				2022-12-25	WOS:000083660700015
J	Hong, SJ; Ugulava, N; Guergova-Kuras, M; Crofts, AR				Hong, SJ; Ugulava, N; Guergova-Kuras, M; Crofts, AR			The energy landscape for ubihydroquinone oxidation at the Q(o) site of the bc(1) complex in Rhodobacter sphaeroides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; CYTOCHROME-C OXIDOREDUCTASE; MITOCHONDRIAL BC1 COMPLEX; ELECTRON-TRANSFER CHAIN; RHODOPSEUDOMONAS-SPHAEROIDES; BOVINE HEART; UBIQUINOL-CYTOCHROME-C2 OXIDOREDUCTASE; INHIBITOR BINDING; QUINOL OXIDATION; B(6)F COMPLEX	Activation energies for partial reactions involved in oxidation of quinol by the bc(1) complex were independent of pH in the range 5.5-8.9. Formation of enzyme-substrate complex required two substrates, ubihydroquinone binding from the lipid phase and the extrinsic domain of the iron-sulfur protein. The activation energy for ubihydroquinone oxidation was independent of the concentration of either substrate, showing that the activated step was in a reaction after formation of the enzyme-substrate complex. At all pH values, the partial reaction with the limiting rate and the highest activation energy was oxidation of bound ubihydroquinone. The pH dependence of the rate of ubihydroquinone oxidation reflected the pK on the oxidized iron-sulfur protein and requirement for the deprotonated form in formation of the enzyme-substrate complex. We discuss different mechanisms to explain the properties of the bifurcated reaction, and we preclude models in which the high activation barrier is in the second electron transfer or is caused by deprotonation of QH(2). Separation to products after the first electron transfer and movement of semiquinone formed in the Q(o) site would allow rapid electron transfer to heme b(L). This would also insulate the semiquinone from oxidation by the iron-sulfur protein, explaining the efficiency of bifurcation.	Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Crofts, AR (corresponding author), Univ Illinois, Ctr Biophys & Computat Biol, 388 Morrill Hall,505 S Goodwin, Urbana, IL 61801 USA.	crufts@life.uiuc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035438] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35438] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1985, ENZYMES BIOL MEMBRAN, DOI DOI 10.1007/978-1-4684-4604-3_10; BOWYER JR, 1980, BIOCHIM BIOPHYS ACTA, V592, P445, DOI 10.1016/0005-2728(80)90091-2; Brandt U, 1996, BBA-BIOENERGETICS, V1275, P41, DOI 10.1016/0005-2728(96)00048-5; Brandt U, 1998, BBA-BIOENERGETICS, V1365, P261, DOI 10.1016/S0005-2728(98)00078-4; BRANDT U, 1991, J BIOL CHEM, V266, P19958; BRANDT U, 1991, EUR J BIOCHEM, V195, P163, DOI 10.1111/j.1432-1033.1991.tb15690.x; Brandt U, 1997, BIOCHEMISTRY-US, V36, P11234, DOI 10.1021/bi970968g; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; Brandt U, 1996, FEBS LETT, V387, P1, DOI 10.1016/0014-5793(96)00436-X; Brasseur G, 1996, BBA-BIOENERGETICS, V1275, P61, DOI 10.1016/0005-2728(96)00051-5; BRUGNA M, 1998, 11 INT C BIOCH BUD S; Cramer WA, 1996, ANNU REV PLANT PHYS, V47, P477, DOI 10.1146/annurev.arplant.47.1.477; Crofts A.R., 1999, PHOTOTROPHIC PROKARY, P229; Crofts AR, 1998, CURR OPIN STRUC BIOL, V8, P501, DOI 10.1016/S0959-440X(98)80129-2; CROFTS AR, 1989, PHOTOSYNTH RES, V22, P69, DOI 10.1007/BF00114768; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V723, P202, DOI 10.1016/0005-2728(83)90120-2; Crofts AR, 1999, P NATL ACAD SCI USA, V96, P10021, DOI 10.1073/pnas.96.18.10021; CROFTS AR, 1995, PHOTOSYNTHESIS LIGHT, V2, P493; CROFTS AR, 1999, IN PRESS BIOCHEMISTR; CROFTS AR, 1998, PHOTOSYNTHESIS MECH, V3, P1481; DEGLIESPOSTI M, 1993, BIOCHIM BIOPHYS ACTA, V1143, P243, DOI 10.1016/0005-2728(93)90197-N; Denke E, 1998, J BIOL CHEM, V273, P9085, DOI 10.1074/jbc.273.15.9085; DEVAULT D, 1980, Q REV BIOPHYS, V13, P387, DOI 10.1017/S003358350000175X; DEVRIES S, 1979, BIOCHIM BIOPHYS ACTA, V546, P316, DOI 10.1016/0005-2728(79)90049-5; Ding H, 1995, BIOCHEMISTRY-US, V34, P15979, DOI 10.1021/bi00049a012; DING HG, 1992, BIOCHEMISTRY-US, V31, P3144, DOI 10.1021/bi00127a015; Dutton P L, 1978, Methods Enzymol, V54, P411; GATTI DL, 1989, J MOL BIOL, V205, P421, DOI 10.1016/0022-2836(89)90352-5; GENNIS RB, 1993, J BIOENERG BIOMEMBR, V25, P195, DOI 10.1007/BF00762582; GLASER EG, 1984, BIOCHIM BIOPHYS ACTA, V766, P322, DOI 10.1016/0005-2728(84)90248-2; Gray HB, 1996, ANNU REV BIOCHEM, V65, P537, DOI 10.1146/annurev.bi.65.070196.002541; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; JACKSON JB, 1971, EUR J BIOCHEM, V18, P120, DOI 10.1111/j.1432-1033.1971.tb01222.x; JACKSON JB, 1969, FEBS LETT, V4, P185, DOI 10.1016/0014-5793(69)80230-9; Junemann S, 1998, J BIOL CHEM, V273, P21603, DOI 10.1074/jbc.273.34.21603; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; Kuras R, 1998, BIOCHEMISTRY-US, V37, P16280, DOI 10.1021/bi9813476; LINK TA, 1993, J BIOENERG BIOMEMBR, V25, P221, DOI 10.1007/BF00762584; Link TA, 1997, FEBS LETT, V412, P257, DOI 10.1016/S0014-5793(97)00772-2; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; MARCUS RA, 1965, J CHEM PHYS, V43, P679, DOI 10.1063/1.1696792; MEINHARDT SW, 1983, BIOCHIM BIOPHYS ACTA, V723, P219, DOI 10.1016/0005-2728(83)90121-4; MEINHARDT SW, 1982, FEBS LETT, V149, P223, DOI 10.1016/0014-5793(82)81105-8; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; MOSER CC, 1995, J BIOENERG BIOMEMBR, V27, P263, DOI 10.1007/BF02110096; RICH PR, 1981, BIOCHIM BIOPHYS ACTA, V637, P28, DOI 10.1016/0005-2728(81)90206-1; Sharp RE, 1999, BIOCHEMISTRY-US, V38, P3440, DOI 10.1021/bi982639+; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; SNOZZI M, 1984, BIOCHIM BIOPHYS ACTA, V766, P451, DOI 10.1016/0005-2728(84)90261-5; TAKAMIYA K, 1979, J BIOL CHEM, V254, P1307; Ugulava NB, 1998, FEBS LETT, V440, P409, DOI 10.1016/S0014-5793(98)01493-8; VANDOREN SR, 1993, BIOCHEMISTRY-US, V32, P8083, DOI 10.1021/bi00083a005; VENTUROLI G, 1988, BIOCHIM BIOPHYS ACTA, V935, P258, DOI 10.1016/0005-2728(88)90222-8; Williams RJP, 1997, J BIOL INORG CHEM, V2, P373, DOI 10.1007/s007750050146; Witthuhn VC, 1997, BIOCHEMISTRY-US, V36, P903, DOI 10.1021/bi961648k; WOOD PM, 1988, BIOCHEM J, V253, P287, DOI 10.1042/bj2530287; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YUN CH, 1991, BIOCHEMISTRY-US, V30, P6747, DOI 10.1021/bi00241a017; YUN CH, 1990, EUR J BIOCHEM, V194, P399, DOI 10.1111/j.1432-1033.1990.tb15633.x; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	60	81	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					33931	33944		10.1074/jbc.274.48.33931	http://dx.doi.org/10.1074/jbc.274.48.33931			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567355	hybrid			2022-12-25	WOS:000083857500020
J	Li, XH; Murphy, KM; Palka, KT; Surabhi, RM; Gaynor, RB				Li, XH; Murphy, KM; Palka, KT; Surabhi, RM; Gaynor, RB			The human T-cell leukemia virus type-1 Tax protein regulates the activity of the I kappa B kinase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC PHOSPHORYLATION; IKK-ALPHA; TRANSACTIVATOR TAX; DNA-BINDING; INDUCED APOPTOSIS; RAT FIBROBLASTS; BZIP PROTEINS; ACTIVATION; BETA; TRANSCRIPTION	Two cytokine-inducible kinases, IKK alpha and IKK beta, are components of a 700-kDa kinase complex that specifically phosphorylates I kappa B. Phosphorylation of I kappa B by IKK leads to its ubiquitination and subsequent degradation, resulting in the nuclear translocation of NF-kappa B. The oncogenic protein Tax, encoded by human T-cell leukemia virus type-1 (HTLV-1), stimulates IKK activity to result in constitutive nuclear levels of NF-kappa B. In an attempt to gain insights into the mechanism by which Tax mediates constitutive activation of the NF-kappa B pathway, we analyzed the chromatographic distribution of IKK proteins using cellular extracts prepared from three T lymphocytes either lacking or containing Tax. IKK kinase activity and the distribution of proteins in the IKK complex were characterized, In extracts prepared from cells containing Tax, the activity of both IKK alpha and IKK beta present in the 700-kDa IKK complex were increased. Surprisingly, cell lines expressing Tax also contained an additional peak of IKK beta, but not IKK alpha activity, that migrated at 300 kDa rather than at 700 kDa, We noted that extracts containing Tax had extremely low levels of I kappa B beta, but not I kappa B alpha, and contained predominantly a truncated form of the MAP3K MEKK1. These results suggest that Tax may target several components of the NF-kappa B pathway leading to constitutive activation of this important regulator of cellular gene expression.	Univ Texas, SW Med Ctr, Dept Med, Div Hematol Oncol,Simmons Canc Ctr, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gaynor, RB (corresponding author), Univ Texas, SW Med Ctr, Dept Med, Div Hematol Oncol,Simmons Canc Ctr, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.							Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Coscoy L, 1998, VIROLOGY, V248, P332, DOI 10.1006/viro.1998.9298; Deacon K, 1999, J BIOL CHEM, V274, P16604, DOI 10.1074/jbc.274.23.16604; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Devalaraja MN, 1999, CANCER RES, V59, P1372; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GarciaMartinez LF, 1997, EMBO J, V16, P2836, DOI 10.1093/emboj/16.10.2836; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KOEFFLER HP, 1984, BLOOD, V64, P482; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li XH, 1999, GENE EXPRESSION, V7, P233; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nicot C, 1998, J VIROL, V72, P6777, DOI 10.1128/JVI.72.8.6777-6784.1998; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; Schlesinger TK, 1998, FRONT BIOSCI, V3, P1181; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; Suyang H, 1996, MOL CELL BIOL, V16, P5444; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Tie F, 1996, J VIROL, V70, P8368, DOI 10.1128/JVI.70.12.8368-8374.1996; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; YAN MH, 1994, NATURE, V372, P798; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Yin MJ, 1996, MOL CELL BIOL, V16, P3156; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355	76	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34417	34424		10.1074/jbc.274.48.34417	http://dx.doi.org/10.1074/jbc.274.48.34417			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567421	hybrid			2022-12-25	WOS:000083857500086
J	Nosaka, K; Onozuka, M; Nishino, H; Nishimura, H; Kawasaki, Y; Ueyama, H				Nosaka, K; Onozuka, M; Nishino, H; Nishimura, H; Kawasaki, Y; Ueyama, H			Molecular cloning and expression of a mouse thiamin pyrophosphokinase cDNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; BRAIN; GENE; METABOLISM; TRANSPORT; SEQUENCES; CELLS; THI80; ACID	Thiamin pyrophosphokinase (EC 2.7.6.2) catalyzes the pyrophosphorylation of thiamin with adenosine 5'-triphosphate to form thiamin pyrophosphate. A mouse thiamin pyrophosphokinase cDNA clone (mTPK1) was isolated using a combination of mouse expressed sequence tag database analysis, a two-step polymerase chain reaction procedure, and functional complementation screening with a Saccharomyces cerevisiae thiamin pyrophosphokinase-deficient mutant (thi80). The predicted protein contained 243 amino acid residues with a calculated molecular weight of 27,068, When the intact mTPK1 open reading frame was expressed as a glutathione S-transferase fusion protein in Escherichia coli lacking thiamin pyrophosphokinase, marked enzyme activity was detected in the bacterial cells. The corresponding 2.5-kilobase pair mRNA was expressed in a tissue-dependent manner and was found at relatively high levels in the kidney and liver, indicating that the mode of expression of mTPK1 genes differs with cell type. The expression of mTPK1 genes in cultured mouse neuroblastoma and normal liver cells was unaffected by the thiamin concentration in the medium (10 mu M versus 3.0 nM). This is the first report on identification of the primary sequence for mammalian thiamin pyrophosphokinase.	Kyoto Prefectural Univ, Dept Chem, Kita Ku, Kyoto 6038334, Japan; Kyoto Prefectural Univ, Dept Biochem, Kita Ku, Kyoto 6038334, Japan; Kyoto Prefectural Univ, Radioisotope Lab, Kita Ku, Kyoto 6038334, Japan; Doshisha Womens Coll, Dept Food Microbiol, Kamigyo Ku, Kyoto 6020893, Japan; Shiga Univ Med Sci, Dept Biochem Med, Otsu, Shiga 5202192, Japan	Kyoto Prefectural University; Kyoto Prefectural University; Kyoto Prefectural University; Shiga University of Medical Science	Nosaka, K (corresponding author), Kyoto Prefectural Univ, Dept Chem, Kita Ku, Kyoto 6038334, Japan.							BETTENDORFF L, 1994, J BIOL CHEM, V269, P14379; COOPER JR, 1979, NEUROCHEM RES, V4, P223, DOI 10.1007/BF00964146; Diaz GA, 1999, NAT GENET, V22, P309, DOI 10.1038/10385; EGI Y, 1992, BIOCHIM BIOPHYS ACTA, V1160, P171, DOI 10.1016/0167-4838(92)90004-W; FANKHAUSER H, 1995, J BIOL CHEM, V270, P28457; Fleming JC, 1999, NAT GENET, V22, P305, DOI 10.1038/10379; FRIEDRICH W, 1988, VITAMINS, P339; HAAS RH, 1988, ANNU REV NUTR, V8, P483, DOI 10.1146/annurev.nu.08.070188.002411; HAMADA M, 1969, Seikagaku, V41, P837; HANSCHE PE, 1978, GENETICS, V88, P673; KAWASAKI Y, 1990, J BACTERIOL, V172, P6145, DOI 10.1128/jb.172.10.6145-6147.1990; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Labay V, 1999, NAT GENET, V22, P300, DOI 10.1038/10372; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDER IG, 1975, METABOLIC PATHWAYS, V7, P57; Makino K, 1997, ONCOGENE, V14, P2425, DOI 10.1038/sj.onc.1201087; MATSUDA T, 1981, P NATL ACAD SCI-BIOL, V78, P5886, DOI 10.1073/pnas.78.9.5886; NISHIMURA H, 1991, J BACTERIOL, V173, P2716, DOI 10.1128/jb.173.8.2716-2719.1991; NISHINO H, 1971, BIOCHEM BIOPH RES CO, V45, P363, DOI 10.1016/0006-291X(71)90827-8; NOSAKA K, 1993, J BIOL CHEM, V268, P17440; NOSAKA K, 1989, FEMS MICROBIOL LETT, V60, P55, DOI 10.1016/0378-1097(89)90077-3; Pekovich SR, 1998, J NUTR, V128, P683, DOI 10.1093/jn/128.4.683; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RINDI G, 1992, VITAMINS BIOFACTORS, P379; Rose MD., 1990, METHODS YEAST GENETI; ROSE RC, 1988, BIOCHIM BIOPHYS ACTA, V947, P335, DOI 10.1016/0304-4157(88)90014-7; Sambrook J., 2002, MOL CLONING LAB MANU; SANIOTO SML, 1977, INT J VITAM NUTR RES, V47, P315; Schellenberger A, 1998, BBA-PROTEIN STRUCT M, V1385, P177, DOI 10.1016/S0167-4838(98)00067-3; SCHWEINGRUBER ME, 1986, J BIOL CHEM, V261, P5877; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; TREBUKHINA RV, 1981, J NUTR, V111, P505, DOI 10.1093/jn/111.3.505; Wakabayashi Y., 1978, VITAMINS, V52, P223	33	20	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34129	34133		10.1074/jbc.274.48.34129	http://dx.doi.org/10.1074/jbc.274.48.34129			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567383	hybrid			2022-12-25	WOS:000083857500048
J	Roger, F; Martin, PY; Rousselot, M; Favre, H; Feraille, E				Roger, F; Martin, PY; Rousselot, M; Favre, H; Feraille, E			Cell shrinkage triggers the activation of mitogen-activated protein kinases by hypertonicity in the rat kidney medullary thick ascending limb of the Henle's loop - Requirement of p38 kinase for the regulatory volume increase response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; GROWTH-FACTOR; MAP KINASE; S6 KINASE; SIGNAL-TRANSDUCTION; GLYCOGEN-SYNTHASE; PATHWAY; STRESS; INDUCTION; JNK	The kidney medulla is exposed to very high interstitial osmolarity leading to the activation of mitogen-activated protein kinases (MAPK). However, the respective roles of increased intracellular osmolality and of cell shrinkage in MAPK activation are not known. Similarly, the participation of MAPK in the regulatory volume increase (RVI) following cell shrinkage remains to be investigated. In the rat medullary thick ascending limb of Henle (MTAL), extracellular hypertonicity produced by addition of NaCl or sucrose increased the phosphorylation level of extracellular signal-regulated kinase (ERK) and p38 kinase and to a lesser extent c-Jun NH2-terminal kinase with sucrose only. Both hypertonic solutions decreased the MTAL cellular volume in a dose-and time-dependent manner. In contrast, hypertonic urea had no effect, The extent of MAPK activation was correlated with the extent of MTAL cellular volume decrease. Increasing intracellular osmolality without modifying cellular volume did not activate MAPK, whereas cell shrinkage without variation in osmolality activated both ERK and p38, In the presence of 600 mosmol/liter NaCl, the maximal cell shrinkage was observed after 10 min at 37 degrees C and the MTAL cellular volume was reduced to 70% of its initial value. Then, RVI occurred and the cellular volume progressively recovered to reach about 90% of its initial value after 30 min. SB203580, a specific inhibitor of p38, almost completely inhibited the cellular volume recovery, whereas inhibition of ERK did not alter RVI. In conclusion, in rat MTAL: 1) cell shrinkage, but not intracellular hyperosmolality, triggers the activation of both ERK and p38 kinase in response to extracellular hypertonicity; and 2) RVI is dependent on p38 kinase activation.	Fdn Rech Med, Div Nephrol, CH-1211 Geneva 4, Switzerland	University of Geneva	Feraille, E (corresponding author), Fdn Rech Med, Div Nephrol, 64 Ave Roseraie, CH-1211 Geneva 4, Switzerland.	feraille@cmu.unige.ch		Feraille, Eric/0000-0003-1656-8365				Berl T, 1997, AM J PHYSIOL-RENAL, V272, pF305, DOI 10.1152/ajprenal.1997.272.3.F305; BURG MB, 1995, AM J PHYSIOL-RENAL, V268, pF983, DOI 10.1152/ajprenal.1995.268.6.F983; CHANG PY, 1995, J BIOL CHEM, V270, P29928; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; FERBY IM, 1994, J BIOL CHEM, V269, P30485; FLORDELLIS CS, 1995, J BIOL CHEM, V270, P3491, DOI 10.1074/jbc.270.8.3491; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; ITOH T, 1994, J CLIN INVEST, V93, P2387, DOI 10.1172/JCI117245; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; KNEPPER MA, 1996, KIDNEY, P532; Krump E, 1997, J BIOL CHEM, V272, P17303, DOI 10.1074/jbc.272.28.17303; Kultz D, 1998, J BIOL CHEM, V273, P13645, DOI 10.1074/jbc.273.22.13645; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; Liu HG, 1999, J BIOL CHEM, V274, P10557, DOI 10.1074/jbc.274.15.10557; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; PARKER JC, 1993, AM J PHYSIOL, V265, pC1191, DOI 10.1152/ajpcell.1993.265.5.C1191; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Sheikh-Hamad D, 1998, J BIOL CHEM, V273, P1832, DOI 10.1074/jbc.273.3.1832; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SUN AM, 1990, KIDNEY INT, V38, P1019, DOI 10.1038/ki.1990.308; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; TERADA Y, 1994, J BIOL CHEM, V269, P31296; Watts BA, 1998, AM J PHYSIOL-RENAL, V275, pF478, DOI 10.1152/ajprenal.1998.275.4.F478; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wojtaszek PA, 1998, J CLIN INVEST, V102, P1874, DOI 10.1172/JCI4384; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Zhang Z, 1996, AM J PHYSIOL-RENAL, V271, pF1234, DOI 10.1152/ajprenal.1996.271.6.F1234	35	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34103	34110		10.1074/jbc.274.48.34103	http://dx.doi.org/10.1074/jbc.274.48.34103			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567379	hybrid			2022-12-25	WOS:000083857500044
J	Shen, YMA; Chertihin, OI; Biltonen, RL; Sando, JJ				Shen, YMA; Chertihin, OI; Biltonen, RL; Sando, JJ			Lipid-dependent activation of protein kinase C-alpha by normal alcohols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID UNSATURATION; MOLECULAR MECHANISMS; MEMBRANE-BINDING; PHORBOL ESTERS; ANESTHETICS; CALCIUM; PHASE; PHOSPHORYLATION; INHIBITION; VESICLES	Significant stimulation of protein kinase C-alpha (PKC alpha) by n-alcohols was observed in characterized lipid systems composed of phosphatidylcholine/phosphatidylserine/dioleoylglycerol (PC/PS/DO), The logarithm of the alcohol concentrations to achieve half-maximal PKC stimulation (ED50) and of the maximal PKC stimulation by alcohols were both linear functions of alcohol chain length, consistent with the Meyer-Overton effect. Binding of phorbol esters to PKC was not significantly affected by octanol, Octanol increased, up to 4-fold, the affinity of PKC binding to the lipid bilayers in both the absence and presence of DO. However, octanol increased PKC activity much more significantly than it enhanced binding of the enzyme to the lipid bilayers, suggesting that the stimulation of PKC is not merely a reflection of the increase in PKC bilayer binding affinity. P-31 NMR experiments did not reveal formation of non-lamellar phases with octanol, Differential scanning calorimetry suggested that alcohols, like diacylglycerol, induce formation of compositionally distinct domains and the maximal enzyme activity with alcohol resided roughly in the putative domain-coexistence region. These results suggest that alcohols are mimicking diacylglycerol in activating PKC, not by binding to the high affinity phorbol ester binding site, but by altering lipid structure and by enhancing PCK-bilayer binding.	Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Charlottesville, VA 22903 USA; Univ Virginia, Hlth Sci Ctr, Biophys Program, Charlottesville, VA 22903 USA; Univ Virginia, Hlth Sci Ctr, Ctr Canc, Charlottesville, VA 22903 USA	University of Virginia; University of Virginia; University of Virginia	Sando, JJ (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Box 448, Charlottesville, VA 22908 USA.	jjs@virginia.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031184, P01GM047525, R01GM059205] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM31184, R01 GM 59205, P01 GM 47525] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P5002, DOI 10.1021/bi00390a018; BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P7961, DOI 10.1021/bi00246a013; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P115, DOI 10.1021/bi00375a017; BOLEN EJ, 1992, BIOCHEMISTRY-US, V31, P5945, DOI 10.1021/bi00140a034; BOTTNER M, 1993, BIOPHYS J, V65, P2041, DOI 10.1016/S0006-3495(93)81254-2; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Dibble ARG, 1996, BIOPHYS J, V71, P1877, DOI 10.1016/S0006-3495(96)79387-6; DIMITRIJEVIC SM, 1995, MOL PHARMACOL, V48, P259; DODSON BA, 1984, MOL CELL BIOCHEM, V64, P97; EPAND RM, 1991, BIOSCIENCE REP, V11, P59, DOI 10.1007/BF01118606; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; Giorgione JR, 1998, BIOCHEMISTRY-US, V37, P2384, DOI 10.1021/bi970873e; GOLDBERG EM, 1994, BIOPHYS J, V66, P382, DOI 10.1016/S0006-3495(94)80788-X; HEMMINGS HC, 1994, ANESTHESIOLOGY, V81, P147, DOI 10.1097/00000542-199407000-00021; Hemmings HC, 1996, ANESTHESIOLOGY, V84, P652, DOI 10.1097/00000542-199603000-00021; HEMMINGS HC, 1989, FASEB J, V3, P1583, DOI 10.1096/fasebj.3.5.2493406; HILLE B, 1980, PROGR ANESTHESIOLOGY, V2, P1; Hinderliter AK, 1997, BIOCHEMISTRY-US, V36, P6141, DOI 10.1021/bi962715d; HO CJ, 1994, BBA-BIOMEMBRANES, V1193, P307, DOI 10.1016/0005-2736(94)90167-8; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; JORGENSEN K, 1991, BIOCHIM BIOPHYS ACTA, V1067, P241, DOI 10.1016/0005-2736(91)90050-I; KAMINOH Y, 1988, BIOCHIM BIOPHYS ACTA, V946, P215, DOI 10.1016/0005-2736(88)90395-1; LESTER DS, 1991, EUR J PHARM-MOLEC PH, V206, P301, DOI 10.1016/0922-4106(91)90114-W; Medkova M, 1998, BIOCHEMISTRY-US, V37, P4892, DOI 10.1021/bi972495j; MORI T, 1980, J BIOL CHEM, V255, P8378; MORIS ME, 1992, PROTEIN KINASE C CUR, P157; MORRISON WR, 1964, ANAL BIOCHEM, V7, P218, DOI 10.1016/0003-2697(64)90231-3; MOSIOR M, 1993, BIOCHEMISTRY-US, V32, P65, DOI 10.1021/bi00052a010; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; ODA A, 1995, AM J PHYSIOL-CELL PH, V269, pC118, DOI 10.1152/ajpcell.1995.269.1.C118; ORR JW, 1994, J BIOL CHEM, V269, P8383; ROWE ES, 1994, BIOPHYS J, V67, P1888, DOI 10.1016/S0006-3495(94)80671-X; SANDO JJ, 1983, P NATL ACAD SCI-BIOL, V80, P2642, DOI 10.1073/pnas.80.9.2642; Sando JJ, 1998, J BIOL CHEM, V273, P34022, DOI 10.1074/jbc.273.51.34022; Sando JJ, 1996, BIOCHEM J, V317, P583, DOI 10.1042/bj3170583; SANDO JJ, 1992, CELL SIGNAL, V4, P595, DOI 10.1016/0898-6568(92)90041-6; SENISTERRA G, 1993, ARCH BIOCHEM BIOPHYS, V300, P378, DOI 10.1006/abbi.1993.1051; SHEARMAN MS, 1989, PHARMACOL REV, V41, P211; Slater SJ, 1997, J BIOL CHEM, V272, P6167, DOI 10.1074/jbc.272.10.6167; SLATER SJ, 1993, NATURE, V364, P82, DOI 10.1038/364082a0; Slater SJ, 1996, J BIOL CHEM, V271, P4627; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; TRUDELL JR, 1991, ANN NY ACAD SCI, V625, P743, DOI 10.1111/j.1749-6632.1991.tb33907.x; TRUDELL JR, 1989, BIOCHEM BIOPH RES CO, V162, P45, DOI 10.1016/0006-291X(89)91959-1; UEDA I, 1984, ANESTH ANALG, V63, P929; Walker J M, 1989, Adv Exp Med Biol, V255, P29; YANG L, 1995, BIOCHEMISTRY-US, V34, P1500, DOI 10.1021/bi00005a005; ZHANG FL, 1992, BIOCHEMISTRY-US, V31, P2005, DOI 10.1021/bi00122a016	50	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34036	34044		10.1074/jbc.274.48.34036	http://dx.doi.org/10.1074/jbc.274.48.34036			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567370	hybrid			2022-12-25	WOS:000083857500035
J	Baird, JW; Nibbs, RJB; Komai-Koma, M; Connolly, JA; Ottersbach, K; Clark-Lewis, I; Liew, FY; Grahamn, GJ				Baird, JW; Nibbs, RJB; Komai-Koma, M; Connolly, JA; Ottersbach, K; Clark-Lewis, I; Liew, FY; Grahamn, GJ			ESkine, a novel beta-chemokine, is differentially spliced to produce secretable and nuclear targeted isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; RECEPTOR ALPHA-CHAIN; HEMATOPOIETIC DEVELOPMENT; LOCOMOTOR CAPACITY; HUMAN-LYMPHOCYTES; OPPOSITE STRAND; GENE-EXPRESSION; GROWTH-FACTOR; IN-VITRO; INVITRO	Using the murine embryonal stem cell system, we have identified a novel gene encoding a highly divergent member of the beta-chemokine family of proinflammatory mediators and have called this protein ESkine. Much of the coding sequence for ESkine overlaps with the 3'-end of a novel interleukin 11 receptor alpha-like sequence on murine chromosome 4. ESkine is produced as two splice variants. One of these variants encodes a classical chemokine with an associated signal peptide, while the other variant (PESKY) possesses the main body of the chemokine but has replaced the signal peptide with an alternative stretch of amino acids that allows for nuclear targeting of this isoform. This differential splicing arises as a result of alternative 5' exon usage. These differentially spliced forms are expressed at discrete tissue loci. Thus, while ESkine is highly expressed in the placenta, PESKY is mainly expressed in the Testes and brain and weakly in the developing embryo. Studies on the proinflammatory properties of ESkine reveal it to be active in inducing polarization of CD4(+) T cells but to be inactive on other hemopoietic cellular populations.	Beatson Inst Canc Res, Canc Res Campaign Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Univ Glasgow, Dept Immunol, Glasgow G11 3QU, Lanark, Scotland; Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada	Beatson Institute; University of Glasgow; University of British Columbia	Grahamn, GJ (corresponding author), Beatson Inst Canc Res, Canc Res Campaign Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.		Graham, Gerard/D-1240-2009	Nibbs, Robert/0000-0002-8150-0044; Ottersbach, Katrin/0000-0002-6880-4895; Graham, Gerard/0000-0002-7801-204X				ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; ADELMAN JP, 1987, SCIENCE, V235, P1514, DOI 10.1126/science.3547652; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Bilinski P, 1998, GENE DEV, V12, P2234, DOI 10.1101/gad.12.14.2234; Bilinski P, 1996, BIOCHEM J, V320, P359, DOI 10.1042/bj3200359; BURKERT U, 1991, NEW BIOL, V3, P698; ClarkLewis I, 1997, METHOD ENZYMOL, V287, P233; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Graham GJ, 1997, INT J EXP PATHOL, V78, P197, DOI 10.1046/j.1365-2613.1997.270361.x; Graham GJ, 1996, EMBO J, V15, P6506, DOI 10.1002/j.1460-2075.1996.tb01041.x; HASTON WS, 1985, J IMMUNOL METHODS, V81, P229, DOI 10.1016/0022-1759(85)90208-X; HASTON WS, 1982, J CELL BIOL, V92, P747, DOI 10.1083/jcb.92.3.747; Hieshima K, 1997, J BIOL CHEM, V272, P5846, DOI 10.1074/jbc.272.9.5846; Hole N, 1996, BLOOD, V88, P1266, DOI 10.1182/blood.V88.4.1266.bloodjournal8841266; Hole N, 1997, BAILLIERE CLIN HAEM, V10, P467, DOI 10.1016/S0950-3536(97)80021-2; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; KEIFER P, 1994, EMBO J, V13, P4126; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KOMAIKOMA M, 1995, J IMMUNOL, V155, P1110; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; Mock BA, 1998, MAMM GENOME, V8, pS68, DOI 10.1007/s003359900649; MOREL Y, 1989, P NATL ACAD SCI USA, V86, P6582, DOI 10.1073/pnas.86.17.6582; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; NAGY A, 1990, DEVELOPMENT, V110, P815; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Newman I, 1996, IMMUNOLOGY, V87, P428, DOI 10.1046/j.1365-2567.1996.491565.x; Nibbs RJB, 1997, J BIOL CHEM, V272, P12495, DOI 10.1074/jbc.272.19.12495; Oravecz T, 1997, J EXP MED, V186, P1865, DOI 10.1084/jem.186.11.1865; Proost P, 1998, J BIOL CHEM, V273, P7222, DOI 10.1074/jbc.273.13.7222; Robb L, 1997, GENOMICS, V40, P387, DOI 10.1006/geno.1996.4579; Robb L, 1996, J BIOL CHEM, V271, P13754, DOI 10.1074/jbc.271.23.13754; Robertson E. J., 1987, TERATOCARCINOMAS EMB; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; ShakinEshleman SH, 1996, J BIOL CHEM, V271, P6363, DOI 10.1074/jbc.271.11.6363; Shioda T, 1998, P NATL ACAD SCI USA, V95, P6331, DOI 10.1073/pnas.95.11.6331; SPOONCER E, 1984, NATURE, V310, P228, DOI 10.1038/310228a0; Vicari AP, 1997, IMMUNITY, V7, P291, DOI 10.1016/S1074-7613(00)80531-2; WANG Z, 1991, P NATL ACAD SCI USA, V88, P11505, DOI 10.1073/pnas.88.24.11505; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; WILES MV, 1991, DEVELOPMENT, V111, P259; WILKINSON PC, 1986, IMMUNOLOGY, V57, P281; WILKINSON PC, 1995, J EXP MED, V181, P1255, DOI 10.1084/jem.181.3.1255; WILKINSON PC, 1992, J IMMUNOL, V149, P2689; WILLIAMS T, 1986, NATURE, V322, P275, DOI 10.1038/322275a0	47	45	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33496	33503		10.1074/jbc.274.47.33496	http://dx.doi.org/10.1074/jbc.274.47.33496			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559234	hybrid			2022-12-25	WOS:000083745200050
J	Koizumi, S; Lipp, P; Berridge, MJ; Bootman, MD				Koizumi, S; Lipp, P; Berridge, MJ; Bootman, MD			Regulation of ryanodine receptor opening by lumenal Ca2+ underlies quantal Ca2+ release in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; SENSITIVE CALCIUM STORES; STEADY-STATE MECHANISM; LUMINAL CA2+; SARCOPLASMIC-RETICULUM; INTRACELLULAR STORES; TRISPHOSPHATE RECEPTORS; PERMEABILIZED HEPATOCYTES; CHROMAFFIN CELLS; HELA-CELLS	Graded or "quantal" Ca2+ release from intracellular stores has been observed in various cell types following activation of either ryanodine receptors (RyR) or inositol 1,4,5-trisphosphate receptors (InsP(3)R). The mechanism causing the release of Ca2+ stores in direct proportion to the strength of stimulation is unresolved. We investigated the properties of quantal Ca2+ release evoked by activation of RyR in PC12 cells, and in particular whether the sensitivity of RyR to the agonist caffeine was altered by lumenal Ca2+. Quantal Ca2+ release was observed in cells stimulated with 1 to 40 mM caffeine, a range of caffeine concentrations giving a >10-fold change in lumenal Ca2+ content. The Ca2+ load of the caffeine-sensitive stores was modulated by allowing them to refill for varying times after complete discharge with maximal caffeine, or by depolarizing the cells with K+ to enhance their normal steady-state loading. The threshold for RyR activation was sensitized similar to 10-fold as the Ca2+ load increased from a minimal to a maximal loading. In addition, the fraction of Ca2+ released by low caffeine concentrations increased. Our data suggest that RyR are sensitive to lumenal Ca2+ over the full range of Ca2+ loads that can be achieved in an intact PC12 cell, and that changes in RyR sensitivity may be responsible for the termination of Ca2+ release underlying the quantal effect.	Babraham Inst, Mol Signalling Lab, Cambridge CB2 4AT, England; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Natl Inst Hlth Sci, Div Pharmacol, Setagaya Ku, Tokyo 158, Japan	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Cambridge; National Institute of Health Sciences - Japan	Lipp, P (corresponding author), Babraham Inst, Mol Signalling Lab, Babraham Hall, Cambridge CB2 4AT, England.		Bootman, Martin/AAB-3330-2019; Koizumi, Schuichi/E-8568-2010	Bootman, Martin/0000-0002-6447-3451; Koizumi, Schuichi/0000-0001-6184-3106				Alonso MT, 1999, J CELL BIOL, V144, P241, DOI 10.1083/jcb.144.2.241; Barrero MJ, 1997, J BIOL CHEM, V272, P27694, DOI 10.1074/jbc.272.44.27694; Beecroft MD, 1997, BIOCHEM J, V326, P215, DOI 10.1042/bj3260215; Bennett DL, 1996, J BIOL CHEM, V271, P6356, DOI 10.1074/jbc.271.11.6356; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOOTMAN MD, 1994, J BIOL CHEM, V269, P24783; BOOTMAN MD, 1994, MOL CELL ENDOCRINOL, V98, P157, DOI 10.1016/0303-7207(94)90134-1; BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; CHEEK TR, 1994, BIOCHEM J, V301, P879, DOI 10.1042/bj3010879; CHEEK TR, 1993, J BIOL CHEM, V268, P27076; Combettes L, 1996, EMBO J, V15, P2086, DOI 10.1002/j.1460-2075.1996.tb00562.x; DETTBARN C, 1994, MOL PHARMACOL, V46, P502; Dettbarn C, 1997, MOL PHARMACOL, V52, P1124, DOI 10.1124/mol.52.6.1124; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; HENZI V, 1992, NEUROSCIENCE, V46, P251, DOI 10.1016/0306-4522(92)90049-8; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; KOIZUMI S, 1995, BRIT J PHARMACOL, V115, P1502, DOI 10.1111/j.1476-5381.1995.tb16643.x; Koizumi S, 1999, NEURON, V22, P125, DOI 10.1016/S0896-6273(00)80684-4; Lipp P, 1996, PROG BIOPHYS MOL BIO, V65, P265, DOI 10.1016/S0079-6107(96)00014-4; LOOMISHUSSELBEE JW, 1993, BIOCHEM J, V289, P861, DOI 10.1042/bj2890861; Lukyanenko V, 1999, J PHYSIOL-LONDON, V518, P173, DOI 10.1111/j.1469-7793.1999.0173r.x; Marchant JS, 1998, BIOCHEMISTRY-US, V37, P11524, DOI 10.1021/bi980808k; Meszaros LG, 1998, CELL CALCIUM, V23, P43, DOI 10.1016/S0143-4160(98)90073-2; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; Miller LDP, 1996, J NEUROPHYSIOL, V76, P554, DOI 10.1152/jn.1996.76.1.554; Missiaen L, 1997, BIOCHEM J, V323, P123, DOI 10.1042/bj3230123; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MISSIAEN L, 1994, MOL CELL ENDOCRINOL, V98, P147, DOI 10.1016/0303-7207(94)90133-3; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; Missiaen L, 1999, PFLUG ARCH EUR J PHY, V437, P691, DOI 10.1007/s004240050833; Mogami H, 1997, CELL, V88, P49, DOI 10.1016/S0092-8674(00)81857-7; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NEHER E, 1992, J PHYSIOL-LONDON, V450, P273, DOI 10.1113/jphysiol.1992.sp019127; NELSON TE, 1990, FEBS LETT, V263, P292, DOI 10.1016/0014-5793(90)81396-6; NUNN DL, 1992, MOL PHARMACOL, V41, P115; OLDERSHAW KA, 1992, J BIOL CHEM, V267, P16312; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; ONDRIAS K, 1990, CIRC RES, V67, P1167, DOI 10.1161/01.RES.67.5.1167; Parys JB, 1996, PFLUG ARCH EUR J PHY, V432, P359, DOI 10.1007/s004240050145; PARYS JB, 1995, BIOCHEM BIOPH RES CO, V209, P451, DOI 10.1006/bbrc.1995.1523; PARYS JB, 1993, J BIOL CHEM, V268, P25206; PozzoMiller LD, 1997, J NEUROSCI, V17, P8729; RENARDROONEY DC, 1993, J BIOL CHEM, V268, P23601; SAYERS LG, 1993, BIOCHEM J, V289, P883, DOI 10.1042/bj2890883; Sienaert I, 1996, J BIOL CHEM, V271, P27005, DOI 10.1074/jbc.271.43.27005; SITSAPESAN R, 1995, J MEMBRANE BIOL, V146, P133, DOI 10.1007/BF00238004; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; Steenbergen JF, 1996, J BIOL CHEM, V271, P1821, DOI 10.1074/jbc.271.4.1821; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; Tanimura A, 1996, J CELL BIOL, V132, P607, DOI 10.1083/jcb.132.4.607; Tanimura A, 1998, CELL STRUCT FUNCT, V23, P129, DOI 10.1247/csf.23.129; TAYLOR CW, 1990, BIOCHEM J, V266, P189, DOI 10.1042/bj2660189; Wilcox RA, 1996, CELL CALCIUM, V20, P243, DOI 10.1016/S0143-4160(96)90030-5; Zahradnikova A, 1996, BIOPHYS J, V71, P2996, DOI 10.1016/S0006-3495(96)79492-4	58	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33327	33333		10.1074/jbc.274.47.33327	http://dx.doi.org/10.1074/jbc.274.47.33327			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559210	hybrid			2022-12-25	WOS:000083745200026
J	Wang, Z; Danielsen, AJ; Maihle, NJ; McManus, MJ				Wang, Z; Danielsen, AJ; Maihle, NJ; McManus, MJ			Tyrosine phosphorylation of caldesmon is required for binding to the Shc center dot Grb2 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CALDESMON; EPIDERMAL GROWTH-FACTOR; ROUS-SARCOMA VIRUS; ACTIN-BINDING; CALMODULIN-BINDING; V-ERBB; SIGNAL-TRANSDUCTION; FUNCTIONAL DOMAINS; NONMUSCLE CELLS; FACTOR RECEPTOR	S3-v-erbB is a retroviral oncogene that encodes a ligand-independent, transforming mutant of the epidermal growth factor receptor. This oncogene has been shown to be sarcomagenic in vivo and to transform fibroblasts in vitro. Our previous studies (McManus, M.J., Lingle, W, L,, Salisbury, J, L,, and Maihle, N, J, (1997) Proc. Natl Acad. Sci, U.S.A, 94, 11351-11356) showed that expression of S3-v-erbB in primary fibroblasts results in the tyrosine phosphorylation of caldesmon (CaD), an actin- and calmodulin-binding protein. This phosphorylation is transformation-associated, and the phosphorylated form of CaD is associated with a signaling complex consisting of Shc, Grb2, and Sos in transformed fibroblasts, To identify the tyrosine phosphorylation site(s) in the CaD molecule and to further elucidate the functional role of CaD tyrosine phosphorylation in S3-v-ErbB oncogenic signaling, we have generated a series of mutant CaDs in which one or more tyrosine residues have been replaced with phenylalanine. Using a CaD null cell line, DF1 cells (an immortalized chicken embryo fibroblast cell line), and transient transfection assays, we demonstrated that Tyr-27 and Tyr-393 are the major sites of tyrosine phosphorylation on CaD, Interestingly, Tyr-27 is located within the myosin binding domain of CaD, and Tyr-393 is adjacent to one of the major actin binding and actomyosin ATPase inhibitory domains. Our studies also show that the tyrosine phosphorylation of CaD enhances its binding to the Shc.Grb2 complex. Specifically, replacement of Tyr-27, but not of Tyr-165 or Tyr-393, significantly reduces the ability of CaD to interact with the Shc Grb2 complex, Together, these studies demonstrate that the major sites of tyrosine phosphorylation on CaD are located in the myosin and actin binding domains of CaD and that Tyr-27 is the major tyrosine phosphorylation site through which CaD interacts with the Shc Grba complex.	Mayo Clin & Mayo Fdn, Tumor Biol Program, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Maihle, NJ (corresponding author), Mayo Clin & Mayo Fdn, Tumor Biol Program, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.	maihle@mayo.edu			NATIONAL CANCER INSTITUTE [R01CA079808, R29CA075238] Funding Source: NIH RePORTER; NCI NIH HHS [CA01627, CA79808, CA75238] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boerner J. L., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P370; BRETSCHER A, 1985, J CELL BIOL, V100, P1656, DOI 10.1083/jcb.100.5.1656; BRYAN J, 1989, J BIOL CHEM, V264, P13873; BURGESS AW, 1996, REGULATION RAS SIGNA, P75; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CASTELLINO F, 1995, J CELL BIOL, V131, P1223, DOI 10.1083/jcb.131.5.1223; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; CHILDS TJ, 1992, J BIOL CHEM, V267, P22853; CONNOLLY DC, 1994, J VIROL, V68, P6804, DOI 10.1128/JVI.68.10.6804-6810.1994; COOPER JA, 1981, MOL CELL BIOL, V1, P165, DOI 10.1128/MCB.1.2.165; HAYMAN MJ, 1991, CANCER CELL-MON REV, V3, P302; HEGMANN TE, 1991, CELL MOTIL CYTOSKEL, V20, P109, DOI 10.1002/cm.970200204; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Himly M, 1998, VIROLOGY, V248, P295, DOI 10.1006/viro.1998.9290; HUGHES S, 1984, VIROLOGY, V136, P89, DOI 10.1016/0042-6822(84)90250-2; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; IKEBE M, 1988, J BIOL CHEM, V263, P3055; IKEBE M, 1990, J BIOL CHEM, V265, P17607; Ishikawa R, 1998, J BIOL CHEM, V273, P26991, DOI 10.1074/jbc.273.41.26991; ISHIKAWA R, 1992, CELL MOTIL CYTOSKEL, V23, P244, DOI 10.1002/cm.970230404; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; Lamb NJC, 1996, EUR J CELL BIOL, V69, P36; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAIHLE NJ, 1989, BIOCHIM BIOPHYS ACTA, V948, P287, DOI 10.1016/0304-419X(89)90003-6; MARSTON SB, 1994, J BIOL CHEM, V269, P8134; MARSTON SB, 1991, BIOCHEM J, V279, P1; MARSTON SB, 1985, ADV PROTEIN PHOSPHAT, V2, P171; Matsumura F, 1993, CURR OPIN CELL BIOL, V5, P70, DOI 10.1016/S0955-0674(05)80010-9; McManus MJ, 1997, P NATL ACAD SCI USA, V94, P11351, DOI 10.1073/pnas.94.21.11351; MCMANUS MJ, 1995, J VIROL, V69, P3631, DOI 10.1128/JVI.69.6.3631-3638.1995; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; REDWOOD CS, 1993, J BIOL CHEM, V268, P10969; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Schaefer-Klein J, 1998, VIROLOGY, V248, P305, DOI 10.1006/viro.1998.9291; Shtutman M, 1998, MOL BIOL CELL, V9, p462A; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SOBUE K, 1985, P NATL ACAD SCI USA, V82, P5025, DOI 10.1073/pnas.82.15.5025; SOBUE K, 1985, BIOCHEM BIOPH RES CO, V132, P645, DOI 10.1016/0006-291X(85)91181-7; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUTHERLAND C, 1989, J BIOL CHEM, V264, P578; SUTHERLAND C, 1994, J MUSCLE RES CELL M, V15, P440, DOI 10.1007/BF00122118; SZPACENKO A, 1986, FEBS LETT, V202, P182, DOI 10.1016/0014-5793(86)80683-4; VELU TJ, 1989, MOL CELL BIOL, V9, P1772, DOI 10.1128/MCB.9.4.1772; VOROTNIKOV AV, 1994, J MUSCLE RES CELL M, V15, P37, DOI 10.1007/BF00123831; Wang Z, 1997, P NATL ACAD SCI USA, V94, P11899, DOI 10.1073/pnas.94.22.11899; Wang Z, 1996, J BIOL CHEM, V271, P25707, DOI 10.1074/jbc.271.41.25707; Wang Z, 1996, J BIOL CHEM, V271, P2234, DOI 10.1074/jbc.271.4.2234; Wang Z, 1997, J BIOL CHEM, V272, P16896, DOI 10.1074/jbc.272.27.16896; WARREN KS, 1994, J CELL BIOL, V125, P359, DOI 10.1083/jcb.125.2.359; YAMASHIRO S, 1990, NATURE, V344, P675, DOI 10.1038/344675a0; YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0; ZHAN Q, 1991, J BIOL CHEM, V266, P21810	54	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33807	33813		10.1074/jbc.274.47.33807	http://dx.doi.org/10.1074/jbc.274.47.33807			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559276	hybrid			2022-12-25	WOS:000083745200092
J	Stewart, L; Ireton, GC; Champoux, JJ				Stewart, L; Ireton, GC; Champoux, JJ			A functional linker in human topoisomerase I is required for maximum sensitivity to camptothecin in a DNA relaxation assay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC TOPOISOMERASE; CATALYTIC ACTIVITY; DRUG CAMPTOTHECIN; INHIBITORS; SITE; MECHANISM; CLEAVAGE; BINDING; IDENTIFICATION; FRAGMENT	Human topoisomerase I is composed of four major domains: the highly charged NH2-terminal region, the conserved core domain, the positively charged linker domain, and the highly conserved COOH-terminal domain. Near complete enzyme activity can be reconstituted by combining recombinant polypeptides that approximate the core and COOH-terminal domains, although DNA binding is reduced somewhat for the reconstituted enzyme (Stewart, L, Ireton, G. C., and Champoux, J. J. (1997) J. Mol Biol. 269, 355-372), A reconstituted enzyme comprising the core domain plus a COOH-terminal fragment containing the complete linker region exhibits the same biochemical properties as a reconstituted enzyme lacking the linker altogether, and thus detachment of the linker from the core domain renders the linker non-functional. The rate of religation by the reconstituted enzyme is increased relative to the forms of the enzyme containing the linker indicating that in the intact enzyme the linker slows religation. Relaxation of plasmid DNA by full-length human topoisomerase I or a 70-kDa form of the enzyme that is missing only the non-essential NH2-terminal domain (topo70) is inhibited similar to 16-fold by the anticancer compound, camptothecin, whereas the reconstituted enzyme is nearly resistant to the inhibitory effects of the drug despite similar affinities for the drug by the two forms of the enzyme. Eased on these results and in light of the crystal structure of human topoisomerase I, we propose that the linker plays a role in hindering supercoil relaxation during the normal relaxation reaction and that camptothecin inhibition of DNA relaxation depends on a direct effect of the drug on DNA rotation that is also dependent on the linker.	Univ Washington, Dept Microbiol, Sch Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Champoux, JJ (corresponding author), Univ Washington, Dept Microbiol, Sch Med, Box 357242, Seattle, WA 98195 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049156] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49156] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELSON HT, 1973, BIOCHEM BIOPH RES CO, V50, P1048; ALSNER J, 1992, J BIOL CHEM, V267, P12408; ANDOH T, 1987, P NATL ACAD SCI USA, V84, P5565, DOI 10.1073/pnas.84.16.5565; BJORNSTI MA, 1989, CANCER RES, V49, P6318; BURGIN AB, 1995, NUCLEIC ACIDS RES, V23, P2973, DOI 10.1093/nar/23.15.2973; Champoux JJ, 1998, PROG NUCLEIC ACID RE, V60, P111, DOI 10.1016/S0079-6603(08)60891-0; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; CHRISTIANSEN K, 1987, J MOL BIOL, V193, P517, DOI 10.1016/0022-2836(87)90264-6; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; ENG WK, 1988, MOL PHARMACOL, V34, P755; HERTZBERG RP, 1990, J BIOL CHEM, V265, P19287; HERTZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629, DOI 10.1021/bi00437a018; HORWITZ SB, 1971, MOL PHARMACOL, V7, P632; HSIANG YH, 1988, CANCER RES, V48, P1722; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; JAXEL C, 1989, CANCER RES, V49, P1465; KIKUCHI A, 1993, MOLECULAR BIOLOGY OF DNA TOPOISOMERASES AND ITS APPLICATION CHEMOTHERAPY, P121; KJELDSEN E, 1988, J MOL BIOL, V202, P333, DOI 10.1016/0022-2836(88)90462-7; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487; MADDEN KR, 1995, EMBO J, V14, P5399, DOI 10.1002/j.1460-2075.1995.tb00224.x; MADDEN KR, 1992, CANCER RES, V52, P525; MAG M, 1991, NUCLEIC ACIDS RES, V19, P1537; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; Pommier Y, 1998, BIOCHIMIE, V80, P255, DOI 10.1016/S0300-9084(98)80008-4; Pommier Y., 1991, DNA TOPOISOMERASES C, P121; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Rothenberg ML, 1997, ANN ONCOL, V8, P837, DOI 10.1023/A:1008270717294; Stewart L, 1997, J MOL BIOL, V269, P355, DOI 10.1006/jmbi.1997.1056; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P15449, DOI 10.1021/bi00255a027; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; Stivers JT, 1997, BIOCHEMISTRY-US, V36, P5212, DOI 10.1021/bi962880t; SVEJSTRUP JQ, 1991, J MOL BIOL, V222, P669, DOI 10.1016/0022-2836(91)90503-X; WALL ME, 1966, J AM CHEM SOC, V88, P3888, DOI 10.1021/ja00968a057; Wang HK, 1997, MED RES REV, V17, P367, DOI 10.1002/(SICI)1098-1128(199707)17:4<367::AID-MED3>3.0.CO;2-U; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang XY, 1998, BIOCHEMISTRY-US, V37, P2691, DOI 10.1021/bi972707c	40	71	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32950	32960		10.1074/jbc.274.46.32950	http://dx.doi.org/10.1074/jbc.274.46.32950			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551862	hybrid			2022-12-25	WOS:000083623000062
J	Chau, ASS; Shibuya, EK				Chau, ASS; Shibuya, EK			Inactivation of p42 mitogen-activated protein kinase is required for exit from M-phase after cyclin destruction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS EGG EXTRACTS; SPINDLE-ASSEMBLY CHECKPOINT; MAP KINASE; CELL-CYCLE; PATHWAY; MITOSIS; CDC25; ARREST; PHOSPHORYLATION; KINETOCHORES	By using cycling Xenopus egg extracts, we have previously found that if mitogen-activated protein kinase (p42 MAPK) is activated on entry into mitosis (M-phase), the extract is arrested with condensed chromosomes and spindle microtubules. Here we show that these arrested extracts have high levels of M-phase promoting factor (MPF, Cyclin B/Cdc2) activity, stabilized levels of Cyclin B, and sustained M-phase-specific phosphorylations, We also examined the role of p42 MAPK in DNA damage checkpoint-arrested extracts that were induced to enter M-phase by the addition of Cdc25C protein. In these extracts, Cdc25C protein triggers the abrupt, premature activation of MPF and entry into M-phase. MPF activity then drops suddenly due to Cyclin B proteolysis, just as p42 MAPK is activated. Unexpectedly, however, M-phase is sustained, as judged by maintenance of M-phase-specific phosphorylations and condensed chromosomes. To determine if this M-phase arrest depended on p42 MAPK activation, we added PD98059 (PD), an inhibitor of p42 MAPK activation, to egg extracts with exogenous Cdc25, Both untreated and PH-treated extracts entered RI-phase simultaneously, with a sharp peak of MPF activity, However, only PH-treated extracts subsequently exited from RI-phase and entered interphase. In PH-treated extracts, p42 MAPK was not activated, and the transition to interphase was accompanied by the formation of decondensed nuclei and the disappearance of M-phase-specific phosphorylation of proteins. These results show that although entry into M-phase requires the activation of MPF, exit from M-phase even after cyclin destruction, is dependent on the inactivation of p42 MAPK.	Univ Alberta, Dept Cell Biol, Mol Mechanisms Growth Control Gr, Edmonton, AB T6G 2H7, Canada	University of Alberta	Shibuya, EK (corresponding author), Univ Alberta, Dept Cell Biol, Mol Mechanisms Growth Control Gr, 6-30 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.							Abrieu A, 1997, EMBO J, V16, P6407, DOI 10.1093/emboj/16.21.6407; Abrieu A, 1996, J CELL SCI, V109, P239; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bitangcol JC, 1998, MOL BIOL CELL, V9, P451, DOI 10.1091/mbc.9.2.451; BOTTORFF D, 1995, MOL CELL BIOL, V15, P5113; Chau ASS, 1998, BIOL CELL, V90, P565, DOI 10.1016/S0248-4900(99)80014-8; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; Kumagai A, 1998, MOL BIOL CELL, V9, P345, DOI 10.1091/mbc.9.2.345; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SHIBUYA EK, 1992, EMBO J, V11, P3963, DOI 10.1002/j.1460-2075.1992.tb05490.x; Takenaka K, 1997, J CELL BIOL, V136, P1091, DOI 10.1083/jcb.136.5.1091; VANDERVELDEN HMW, 1993, MOL CELL BIOL, V13, P1480, DOI 10.1128/MCB.13.3.1480; VIGERS GPA, 1991, J CELL BIOL, V112, P545, DOI 10.1083/jcb.112.4.545; Walter SA, 1997, MOL BIOL CELL, V8, P2157, DOI 10.1091/mbc.8.11.2157; Wells WAE, 1996, TRENDS CELL BIOL, V6, P228, DOI 10.1016/0962-8924(96)10018-0; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547	28	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32085	32090		10.1074/jbc.274.45.32085	http://dx.doi.org/10.1074/jbc.274.45.32085			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542242	hybrid			2022-12-25	WOS:000083532100050
J	Inoue, T; Kamiyama, J; Sakai, T				Inoue, T; Kamiyama, J; Sakai, T			Sp1 and NF-Y synergistically mediate the effect of vitamin D-3 in the p27(Kip1) gene promoter that lacks vitamin D response elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE INHIBITOR P27; TRANSCRIPTION-FACTOR; BINDING PROTEINS; FUNCTIONAL-CHARACTERIZATION; HORMONE-RECEPTOR; LEUKEMIA-CELLS; DNA; DIFFERENTIATION; EXPRESSION; PHOSPHORYLATION	Vitamin D-3 promotes myeloid leukemic cell lines to differentiate terminally into monocytes/macrophages. It has been reported that overexpression of the cdk inhibitor p27(Kip1) results in the differentiation of the myelomonocytic U937 cell line and that this gene is the target of vitamin D-3. To identify the sequences required for the positive regulation of p27(Kip1) transcription by man p27(Kip1) 3.6-kilobase 5'-flanking region of the human was examined by transiently transfecting luciferase reporter constructs into U937 cells. The transcriptional activity of this construct was activated by vitamin D-3. Deletion and mutational analysis revealed that both a GGGCGG sequence (-545/-539) and a CCAAT sequence (-525/-520) were necessary to induce p27(Kip1) gene expression. Importantly, the region containing both of these elements conferred positive responsiveness to vitamin D-3 to a heterologous promoter. Gel shift assays showed that Spl binds to the GGGCGG sequence and that NF-Y binds to the CCAAT sequence. Consistent with the roles of these transcription factors, treatment with vitamin DQ Stimulated the DNA binding activities of these factors to each element and induced the change of one NF-Y subunit. We conclude that vitamin D-3 stimulates transcription of the p27(Kip1) gene by a novel mechanism involving Spl and NF-Y, but not the vitamin D receptor, during the early stages of U937 cell differentiation.	Kyoto Prefectural Univ Med, Dept Prevent Med, Kamigyo Ku, Kyoto 6028566, Japan	Kyoto Prefectural University of Medicine	Sakai, T (corresponding author), Kyoto Prefectural Univ Med, Dept Prevent Med, Kamigyo Ku, Kyoto 6028566, Japan.							ALROY I, 1995, MOL CELL BIOL, V15, P5789; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BHATIA M, 1995, J BIOL CHEM, V270, P15962, DOI 10.1074/jbc.270.27.15962; BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; Currie RA, 1998, J BIOL CHEM, V273, P1430, DOI 10.1074/jbc.273.3.1430; DEMAY MB, 1990, P NATL ACAD SCI USA, V87, P369, DOI 10.1073/pnas.87.1.369; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Ezura Y, 1997, J BIOL CHEM, V272, P29865, DOI 10.1074/jbc.272.47.29865; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; Hauses M, 1998, J BIOL CHEM, V273, P31844, DOI 10.1074/jbc.273.48.31844; Ishimaru F, 1997, BLOOD, V89, P4136, DOI 10.1182/blood.V89.11.4136; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Jehan F, 1997, P NATL ACAD SCI USA, V94, P10138, DOI 10.1073/pnas.94.19.10138; KAMEI Y, 1993, BIOCHEM BIOPH RES CO, V193, P948, DOI 10.1006/bbrc.1993.1717; Kamiyama J, 1999, FEBS LETT, V455, P281, DOI 10.1016/S0014-5793(99)00899-6; KRIWACKI RW, 1992, P NATL ACAD SCI USA, V89, P9759, DOI 10.1073/pnas.89.20.9759; Li Q, 1998, EMBO J, V17, P6300, DOI 10.1093/emboj/17.21.6300; LI XY, 1992, J BIOL CHEM, V267, P8984; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; Marziali G, 1999, BLOOD, V93, P519, DOI 10.1182/blood.V93.2.519.402a01_519_526; Minami S, 1997, FEBS LETT, V411, P1, DOI 10.1016/S0014-5793(97)00660-1; MINGHETTI PP, 1988, FASEB J, V2, P3043, DOI 10.1096/fasebj.2.15.2847948; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Orita T, 1997, J BIOL CHEM, V272, P23216, DOI 10.1074/jbc.272.37.23216; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAHL HL, 1991, EXP HEMATOL, V19, P1038; Schrader M, 1997, BIOCHEM BIOPH RES CO, V230, P646, DOI 10.1006/bbrc.1996.6025; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; VANHUIJSDUIJNEN RAMH, 1987, NUCLEIC ACIDS RES, V15, P7265, DOI 10.1093/nar/15.18.7265; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; ZHANG DE, 1994, J BIOL CHEM, V269, P11425; Zhang Y, 1997, BBA-GENE STRUCT EXPR, V1353, P307, DOI 10.1016/S0167-4781(97)00063-8	41	136	138	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32309	32317		10.1074/jbc.274.45.32309	http://dx.doi.org/10.1074/jbc.274.45.32309			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542271	hybrid			2022-12-25	WOS:000083532100079
J	Mercuri, FA; Doege, KJ; Arner, EC; Pratta, MA; Last, K; Fosang, AJ				Mercuri, FA; Doege, KJ; Arner, EC; Pratta, MA; Last, K; Fosang, AJ			Recombinant human aggrecan G1-G2 exhibits native binding properties and substrate specificity for matrix metalloproteinases and aggrecanase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARTILAGE PROTEOGLYCAN DEGRADATION; NEUTROPHIL COLLAGENASE MMP-8; HUMAN ARTICULAR-CARTILAGE; GLOBULAR PROTEIN DOMAINS; HUMAN SYNOVIAL-FLUID; INTERGLOBULAR DOMAIN; KERATAN SULFATE; LINK PROTEIN; MONOCLONAL-ANTIBODIES; N-GLYCOSYLATION	A recombinant human aggrecan G1-G2 fragment comprising amino acids Val(1)-Arg(656) has been expressed in Sf21 cells using a baculovirus expression system. The recombinant G1-G2 (rG1-G2) was purified to homogeneity by hyaluronan-Sepharose affinity chromatography followed by high performance liquid chromatography gel filtration, and gave a single band of M-r 90,000-95,000 by silver stain or immunoblotting with monoclonal antibody 1-C-6. The expressed G1-G2 bound to both hyaluronan and link protein indicating that the immunoglobulin-fold motif and proteoglycan tandem repeat loops of the G1 domain were correctly folded, Further analysis of secondary structure by rotary shadowing electron microscopy confirmed a double globe appearance, but revealed that the rG1-G2 was more compact than its native counterpart. The size of rG1-G2 by SDS-polyacrylamide gel electorphoresis was unchanged following digestion with keratanase and keratanase II and reduced by only 2-5 kDa following digestion with either O-glycosidase or N-glycosidase F. Recombinant G1-G2 was digested with purified matrix metalloproteinases (MMP), isolated aggrecanase, purified atrolysin C, or proteinases present in conditioned medium from cartilage explant cultures, and the products analyzed on SDS gels by silver stain and immunoblotting, Neoepitope antibodies recognizing the N-terminal F(342)FGVG C-terminal DIPEN341 sequences were used to confirm MMP cleavage at the Asn(341) down arrow Phe bond, while neoepitope antibodies recognizing the N-terminal A(374)RGSV or C-terminal ITEGE(373) sequences were used to confirm aggrecanase cleavage at the Glu(373) down arrow Ala bond. Cleavage at the authentic MMP and aggrecanase sites revealed that these proteinases have the same specificity for rG1-G2 as for native aggrecan. Incubation of rG1-G2 with conditioned medium from porcine cartilage cultures revealed that active soluble aggrecanase but no active MMPs, was released following stimulation with interleukin-1 alpha or retinoic acid, Atrolysin C, which cleaves native bovine aggrecan at both the aggrecanase and MMP sites, efficiently cleaved rG1-G2 at the aggrecanase site but failed to cleave at the MMP site. In contrast, native glycosylated G1-G2 with or without keratanase treatment was cleaved by atrolysin C at both the aggrecanase and MMP sites. The results suggest that the presence or absence per se of keratan sulfate on native G1-G2 does not affect the activity of atrolysin C toward the two sites.	Univ Melbourne, Dept Paediat, Royal Childrens Hosp, Orthopaed Mol Biol Res Unit, Parkville, Vic 3052, Australia; Shriners Hosp Crippled Children, Tampa Unit, Tampa, FL 33612 USA; DuPont Pharmaceut Co, Expt Stn E400, Wilmington, DE 19880 USA	Royal Children's Hospital Melbourne; University of Melbourne; DuPont	Fosang, AJ (corresponding author), Univ Melbourne, Dept Paediat, Royal Childrens Hosp, Orthopaed Mol Biol Res Unit, Parkville, Vic 3052, Australia.			Last, Karena/0000-0002-4396-8404; Mercuri, Francesca/0000-0003-1026-2672; Fosang, Amanda/0000-0002-5523-5427				Arner EC, 1997, J BIOL CHEM, V272, P9294; Arner EC, 1999, J BIOL CHEM, V274, P6594, DOI 10.1074/jbc.274.10.6594; ARNER EC, 1997, T ORTHOP RES SOC, V22, P103; BARRY FP, 1995, J BIOL CHEM, V270, P20516, DOI 10.1074/jbc.270.35.20516; BARRY FP, 1992, BIOCHEM J, V286, P761, DOI 10.1042/bj2860761; BJARNASON JB, 1978, BIOCHEMISTRY-US, V17, P3395, DOI 10.1021/bi00609a033; BONNET F, 1985, BIOCHEM J, V228, P77, DOI 10.1042/bj2280077; BUTTNER FH, 1998, T ORTHOP RES SOC, V23, P84; CAMPBELL MA, 1989, BIOCHEM J, V259, P21, DOI 10.1042/bj2590021; CATERSON B, 1986, ARTICULAR CARTILAGE, P59; Chiang N, 1998, ARCH BIOCHEM BIOPHYS, V352, P207, DOI 10.1006/abbi.1998.0620; DAVIDSON DJ, 1993, J CLIN INVEST, V92, P249, DOI 10.1172/JCI116557; DAVIS TR, 1993, IN VITRO CELL DEV-AN, V29A, P842, DOI 10.1007/BF02631361; DAVIS TR, 1995, IN VITRO CELL DEV-AN, V31, P659; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; FLANNERY CR, 1993, T ORTHOP RES SOC, V18, P190; FLANNERY CR, 1995, T ORTHOP RES SOC, V20, P102; FOSANG AJ, 1989, BIOCHEM J, V261, P801, DOI 10.1042/bj2610801; FOSANG AJ, 1994, BIOCHEM J, V304, P347, DOI 10.1042/bj3040347; FOSANG AJ, 1991, J BIOL CHEM, V266, P15579; FOSANG AJ, 1995, BIOCHEM J, V310, P337, DOI 10.1042/bj3100337; FOSANG AJ, 1992, J BIOL CHEM, V267, P19470; Fosang AJ, 1996, J CLIN INVEST, V98, P2292, DOI 10.1172/JCI119040; FOSANG AJ, 1993, BIOCHEM J, V295, P273, DOI 10.1042/bj2950273; FOSANG AJ, 1991, BIOCHEM J, V273, P369, DOI 10.1042/bj2730369; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; Fosang AJ, 1998, FEBS LETT, V430, P186, DOI 10.1016/S0014-5793(98)00667-X; GRABENHORST E, 1993, EUR J BIOCHEM, V215, P189, DOI 10.1111/j.1432-1033.1993.tb18022.x; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; Gu JG, 1997, BIOCHEM BIOPH RES CO, V232, P91, DOI 10.1006/bbrc.1997.6230; HASCALL VC, 1974, J BIOL CHEM, V249, P4242; Hughes CE, 1997, J BIOL CHEM, V272, P20269, DOI 10.1074/jbc.272.32.20269; HUGHES CE, 1992, J BIOL CHEM, V267, P16011; HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799; Hughes CE, 1998, J BIOL CHEM, V273, P30576, DOI 10.1074/jbc.273.46.30576; HUTTON S, 1996, T ORTHOP RES SOC, V21, P150; ILIC MZ, 1995, ARCH BIOCHEM BIOPHYS, V322, P22, DOI 10.1006/abbi.1995.1431; ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L; JARVIS DL, 1995, VIROLOGY, V212, P500, DOI 10.1006/viro.1995.1508; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; KOKLITIS PA, 1991, BIOCHEM J, V276, P217, DOI 10.1042/bj2760217; Krishnan P, 1999, J BIOL CHEM, V274, P10945, DOI 10.1074/jbc.274.16.10945; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARK MW, 1995, BIOCHEM J, V307, P245, DOI 10.1042/bj3070245; Lark MW, 1997, J CLIN INVEST, V100, P93, DOI 10.1172/JCI119526; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; Lopez M, 1997, GLYCOBIOLOGY, V7, P635, DOI 10.1093/glycob/7.5.635; LOULAKIS P, 1992, BIOCHEM J, V284, P589, DOI 10.1042/bj2840589; MANNEBERG M, 1994, PROTEIN SCI, V3, P30; MEHMET H, 1986, EUR J BIOCHEM, V157, P385, DOI 10.1111/j.1432-1033.1986.tb09680.x; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; MORGELIN M, 1989, J BIOL CHEM, V264, P12080; MORRIS NP, 1986, J BIOL CHEM, V261, P5638; MURPHY G, 1992, J BIOL CHEM, V267, P9612; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; PAULSSON M, 1987, BIOCHEM J, V245, P763, DOI 10.1042/bj2450763; RATCLIFFE A, 1986, BIOCHEM J, V238, P571, DOI 10.1042/bj2380571; Reboul P, 1996, J CLIN INVEST, V97, P2011, DOI 10.1172/JCI118636; Russo S, 1998, FEBS LETT, V436, P11, DOI 10.1016/S0014-5793(98)00951-X; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; SANDY JD, 1991, J BIOL CHEM, V266, P8683; SINGER II, 1995, J CLIN INVEST, V95, P2178, DOI 10.1172/JCI117907; STEVENS JW, 1984, J CELL BIOCHEM, V26, P247, DOI 10.1002/jcb.240260405; Sztrolovics R, 1997, BIOCHEM J, V326, P235, DOI 10.1042/bj3260235; Tortorella MD, 1998, J BIOL CHEM, V273, P5846, DOI 10.1074/jbc.273.10.5846; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; TORTORELLA MD, 1995, T ORTHOP RES SOC, V20, P341; VALHMU WB, 1995, BIOCHEM J, V309, P535, DOI 10.1042/bj3090535; WARD RV, 1991, BIOCHEM J, V278, P179, DOI 10.1042/bj2780179; Watanabe H, 1997, J BIOL CHEM, V272, P28057, DOI 10.1074/jbc.272.44.28057; WITTER J, 1987, ARTHRITIS RHEUM-US, V30, P519, DOI 10.1002/art.1780300506; XUE CB, 1997, Patent No. 9718207; YEH JC, 1993, BIOCHEMISTRY-US, V32, P11087, DOI 10.1021/bi00092a019	76	32	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32387	32395		10.1074/jbc.274.45.32387	http://dx.doi.org/10.1074/jbc.274.45.32387			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542281	hybrid			2022-12-25	WOS:000083532100089
J	Tucker, SC; Wisdom, R				Tucker, SC; Wisdom, R			Site-specific heterodimerization by paired class homeodomain proteins mediates selective transcriptional responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SPECIFICITY; MOUSE GENOME; COOPERATIVE INTERACTIONS; CRYSTAL-STRUCTURE; HOX PROTEINS; IN-VIVO; GENE; DROSOPHILA; DOMAIN; HOMEOPROTEIN	Alx4 is a paired class homeodomain protein involved in defining anterior/posterior polarity in the developing limb bud. The paired class of homeodomain proteins cooperatively bind palindromic DNA elements as homodimers or as heterodimers with other paired homeodomain proteins, Previous characterization demonstrates that the strength of the cooperativity as well as the preference for targets is dictated largely by the identity of amino acid 50 of the homeodomain, Here we compare and contrast the DNA binding properties of a glutamine 50 paired homeodomain protein, Alx4, and a lysine 50 paired homeodomain protein, Goosecoid. We demonstrate that Alx4 homodimers, Gsc homodimers, and Alx4/Gsc heterodimers each have distinct DNA binding properties, and each can discriminate between highly related palindromic elements. Using reporter gene assays, we show that Alx4 activates transcription in a site-specific manner, and that Gsc is capable of antagonizing Alx4-mediated activation only from promoter elements that support heterodimer formation. These data demonstrate that paired homeodomain proteins with different DNA binding properties are able to form heterodimeric complexes with unique DNA binding and transcriptional activities. Thus, heterodimerization regulates the DNA binding specificity of these transcription factors and may partially explain how paired homeodomain proteins direct specific developmental functions.	Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA	Vanderbilt University	Wisdom, R (corresponding author), Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [T32CA009582, R01CA064118] Funding Source: NIH RePORTER; NCI NIH HHS [2T32 CA09582, R01CA64118] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Biggin MD, 1997, DEVELOPMENT, V124, P4425; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BRANDON EP, 1995, CURR BIOL, V5, P873, DOI 10.1016/S0960-9822(95)00177-1; BRANDON EP, 1995, CURR BIOL, V5, P625, DOI 10.1016/S0960-9822(95)00127-8; BRANDON EP, 1995, CURR BIOL, V5, P758, DOI 10.1016/S0960-9822(95)00152-7; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; CHANG DT, 1994, DEVELOPMENT, V120, P3339; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DUBOULE D, 1994, GUIDEBOOK HOMEOBOX G, P3; Duncan I, 1996, BIOESSAYS, V18, P91, DOI 10.1002/bies.950180203; GAUNT SJ, 1993, DEVELOPMENT, V117, P769; GEHRING WJ, 1993, GENE, V135, P215, DOI 10.1016/0378-1119(93)90068-E; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; HIRI CC, 1993, NAT GENET, V3, P241; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; Lu Q, 1996, MOL CELL BIOL, V16, P1632; LUESSINK B, 1995, MECH DEVELOP, V52, P51; Mailhos C, 1998, DEVELOPMENT, V125, P937; Miskiewicz P, 1996, DEVELOPMENT, V122, P2709; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; Pflugrad A, 1997, DEVELOPMENT, V124, P1699; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; Qu SM, 1997, DEVELOPMENT, V124, P3999; Qu SM, 1999, DEVELOPMENT, V126, P359; Qu SM, 1997, GENE, V203, P217, DOI 10.1016/S0378-1119(97)00497-6; Qu SM, 1998, DEVELOPMENT, V125, P2711; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RIVERAPEREZ JA, 1995, DEVELOPMENT, V121, P3005; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; SAUNDERS JW, 1968, EPITHELIAL MESSENCHY; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; Smith ST, 1996, DEVELOPMENT, V122, P3141; ten Berge D, 1998, DEV BIOL, V199, P11, DOI 10.1006/dbio.1998.8921; TICKLE C, 1994, ANNU REV CELL BIOL, V10, P121; TREISMAN J, 1989, CELL, V59, P553; TuckerKellogg L, 1997, STRUCTURE, V5, P1047, DOI 10.1016/S0969-2126(97)00256-6; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VORTKAMP A, 1991, NATURE, V352, P539, DOI 10.1038/352539a0; Watabe T, 1995, GENE DEV, V9, P3038, DOI 10.1101/gad.9.24.3038; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; WILSON DS, 1995, CURR BIOL, V5, P32, DOI 10.1016/S0960-9822(95)00010-8; Yamada G, 1997, BIOCHEM BIOPH RES CO, V233, P161, DOI 10.1006/bbrc.1997.6315; YAMADA G, 1995, DEVELOPMENT, V121, P2917; ZHAO GQ, 1994, MECH DEVELOP, V48, P245, DOI 10.1016/0925-4773(94)90063-9; ZHAO GQ, 1993, P NATL ACAD SCI USA, V90, P8633, DOI 10.1073/pnas.90.18.8633	53	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32325	32332		10.1074/jbc.274.45.32325	http://dx.doi.org/10.1074/jbc.274.45.32325			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542273	hybrid			2022-12-25	WOS:000083532100081
J	Smith, LM; Wise, SC; Hendricks, DT; Sabichi, AL; Bos, T; Reddy, P; Brown, PH; Birrer, MJ				Smith, LM; Wise, SC; Hendricks, DT; Sabichi, AL; Bos, T; Reddy, P; Brown, PH; Birrer, MJ			cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype	ONCOGENE			English	Article						cJun; AP-1; breast cancer; tumorigenicity; invasion; hormone resistance	RAT EMBRYO CELLS; C-JUN; AP-1 ACTIVITY; DNA-BINDING; GLUCOCORTICOID RECEPTOR; MALIGNANT PROGRESSION; INDEPENDENT GROWTH; MESSENGER-RNA; EXPRESSION; PROTEIN	We have previously demonstrated decreased Jun/AP-1 activity in the breast cancer cell line MCF-7 when compared to normal or immortalized mammary epithelial cells. In this paper, we overexpress Jun in MCF-7 cells (MCF7Jun) and demonstrate that it results in diverse biologic and biochemical changes, which mimic those seen clinically in breast cancer. Overexpression of Jun causes significant alterations in the composition of AP-1, decreased junB and increased fr a-l expression and results in an increased biologic aggressiveness. MCF7Jun cells exhibit increased cellular motility, increased expression of a matrix degrading enzyme MMP-9, increased in vitro chemoinvasion and tumor formation in nude mice in the absence of exogenous estrogens. Furthermore, MCF7Jun cells are unresponsive to the growth stimulating effects of estrogen and growth inhibitory effects of tamoxifen. Analysis of the estrogen receptor (ER) expression and activity showed that the MCF7Jun cells have no detectable ER. MCF-7 cells overexpressing mutant forms of cJun were responsive to the growth stimulatory effects of estrogen indicating that full-length cJun is required to acquire the estrogen-independent phenotype in breast cancer cells.	NCI, Med Branch, Dept Cell & Canc Biol, NIH, Rockville, MD 20850 USA; Eastern Virginia Med Sch, Dept Microbiol & Immunol, Norfolk, VA USA; Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Eastern Virginia Medical School; University of Texas System; University of Texas Health San Antonio	Birrer, MJ (corresponding author), 9610 Med Ctr Dr,Room 300, Rockville, MD 20850 USA.							ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BIGNON E, 1989, J MED CHEM, V32, P2092, DOI 10.1021/jm00129a013; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; Chen TK, 1996, MOL CARCINOGEN, V15, P215, DOI 10.1002/(SICI)1098-2744(199603)15:3<215::AID-MC7>3.0.CO;2-G; CLARKE R, 1989, J ENDOCRINOL, V122, P331, DOI 10.1677/joe.0.1220331; CLARKE R, 1989, P NATL ACAD SCI USA, V86, P3649, DOI 10.1073/pnas.86.10.3649; CLARKE R, 1990, ANN ONCOL, V1, P401, DOI 10.1093/oxfordjournals.annonc.a057790; DARBON JM, 1986, BIOCHEM PHARMACOL, V35, P2683, DOI 10.1016/0006-2952(86)90175-9; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DICKSON RB, 1995, MOL BIOL CANC MED, P241; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; Dumont JA, 1996, CELL GROWTH DIFFER, V7, P351; Fialka I, 1996, J CELL BIOL, V132, P1115, DOI 10.1083/jcb.132.6.1115; HolstHansen C, 1996, CLIN EXP METASTAS, V14, P297; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Johnston SRD, 1999, CLIN CANCER RES, V5, P251; Lambert PA, 1997, SURGERY, V122, P372, DOI 10.1016/S0039-6060(97)90029-5; LEONESSA F, 1992, ACTA ONCOL, V31, P115, DOI 10.3109/02841869209088890; McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342; RITKE MK, 1994, BIOCHEM PHARMACOL, V48, P525, DOI 10.1016/0006-2952(94)90282-8; SACEDA M, 1991, J BIOL CHEM, V266, P17809; SATO H, 1993, ONCOGENE, V8, P395; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Smith LM, 1997, CANCER RES, V57, P3046; STANIER RY, 1976, MICROBIAL WORLD, P276; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; Szabo E, 1996, CANCER RES, V56, P305; Tang ZQ, 1997, MOL CELL BIOL, V17, P1274, DOI 10.1128/MCB.17.3.1274; THOMPSON EW, 1993, CLIN EXP METASTAS, V11, P15, DOI 10.1007/BF00880062; TZUKERMAN M, 1991, MOL ENDOCRINOL, V5, P1983, DOI 10.1210/mend-5-12-1983; Uht RM, 1997, ENDOCRINOLOGY, V138, P2900, DOI 10.1210/en.138.7.2900; VIG E, 1994, MOL ENDOCRINOL, V8, P1336, DOI 10.1210/me.8.10.1336; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; Yang LM, 1997, CANCER RES, V57, P4652; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972	44	181	190	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 28	1999	18	44					6063	6070		10.1038/sj.onc.1202989	http://dx.doi.org/10.1038/sj.onc.1202989			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557095				2022-12-25	WOS:000083359100012
J	Fachinger, G; Deutsch, U; Risau, W				Fachinger, G; Deutsch, U; Risau, W			Functional interaction of vascular endothelial-protein-tyrosine phosphatase with the Angiopoietin receptor Tie-2	ONCOGENE			English	Article						receptor-type tyrosine phosphatase; vascular endothelium; Tie-2; interaction	GROWTH-FACTOR; EMBRYONIC ANGIOGENESIS; KINASE TIE2; IN-VITRO; EXPRESSION; CELLS; VASCULOGENESIS; GENE; LETHALITY; LIGANDS	During development of the vertebrate vascular system essential signals are transduced via protein-tyrosine phosphorylation. Null-mutations of receptor-tyrosine kinase (RTK) genes expressed in endothelial (ECs) display early lethal vascular phenotypes, we aimed to identify endothelial protein-tyrosine phosphatases (PTPs), which should have similar importance in EC-biology. A murine receptor-type PTP was identified by a degenerated PCR cloning approach from endothelial cells (VE-PTP). By in situ hybridization this phosphatase was found to be specifically expressed in vascular ECs throughout mouse development. In experiments using GST-fusion proteins, as well as in transient transfections, trapping mutants of VE-PTP co-precipitated with the Angiopoietin receptor Tie-2, but not with the Vascular Endothelial Growth Factor receptor 2 (VEGFR-2/Flk-1). In addition, VE-PTP dephosphorylates Tie-2 but not VEGFR-2. We conclude that VE-PTP is a Tie-2 specific phosphatase expressed in ECs, and VE-PTP phosphatase activity serves to specifically modulate Angiopoietin/Tie-2 function. Based on its potential role as a regulator of blood vessel morphogenesis and maintenance, VE-PTP is a candidate gene for inherited vascular malformations similar to the Tie-2 gene.	Max Planck Inst Physiol & Clin Res, WG Kerckhoff Inst, Dept Mol Cell Biol, D-61231 Bad Nauheim, Germany	Max Planck Society	Deutsch, U (corresponding author), Max Planck Inst Physiol & Clin Res, WG Kerckhoff Inst, Dept Mol Cell Biol, Pk Str 1, D-61231 Bad Nauheim, Germany.			Deutsch, Urban/0000-0003-4265-6262				Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233; BRADYKALNAY SM, 1995, CURR OPIN CELL BIOL, V7, P650, DOI 10.1016/0955-0674(95)80106-5; BREIER G, 1992, DEVELOPMENT, V114, P521; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Esser S, 1998, J CELL BIOL, V140, P947, DOI 10.1083/jcb.140.4.947; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GAITS F, 1995, BIOCHEM J, V311, P97, DOI 10.1042/bj3110097; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Jallal B, 1997, J BIOL CHEM, V272, P12158, DOI 10.1074/jbc.272.18.12158; Kataoka H, 1997, DEV GROWTH DIFFER, V39, P729; Koblizek TI, 1997, EUR J BIOCHEM, V244, P774, DOI 10.1111/j.1432-1033.1997.00774.x; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Korpelainen EI, 1998, CURR OPIN CELL BIOL, V10, P159, DOI 10.1016/S0955-0674(98)80137-3; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Schaapveld R, 1997, MOL BIOL REP, V24, P247, DOI 10.1023/A:1006870016238; SCHEPENS J, 1992, MOL BIOL REP, V16, P241, DOI 10.1007/BF00419663; SCHLAEGER TM, 1998, THESIS PHILIPPS U MA; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514	38	147	172	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 21	1999	18	43					5948	5953		10.1038/sj.onc.1202992	http://dx.doi.org/10.1038/sj.onc.1202992			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557082				2022-12-25	WOS:000083270700012
J	Porter, JE; Perez, DM				Porter, JE; Perez, DM			Characteristics for a salt-bridge switch mutation of the alpha(1b) adrenergic receptor - Altered pharmacology and rescue of constitutive activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION; BINDING; IDENTIFICATION; CHROMOPHORE; RHODOPSIN; AGONISTS	Agonist-dependent activation of the alpha(1b)-adrenergic receptor is postulated to be initiated by disruption of an interhelical salt-bridge constraint between an aspartic acid (Asp-125) and a lysine residue (Lys-331) in transmembrane domains three and seven, respectively. Single point mutations that disrupt the charges of either of these residues results in constitutive activity. To validate this hypothesis, we used site-directed mutagenesis to switch the position of these amino acids to observe, if possible, regeneration of the salt-bridge reverses that the constitutive activity of the single point mutations. The transiently expressed switch mutant receptor displayed an altered pharmacological profile, The affinity of selective Agonist-dependent activation of the alpha(1)-adrenergic receptor is postulated to be initiated by disruption of an interhelical salt-bridge constraint between an aspartic acid (Asp-125) and a lysine residue (Lys-331) in transmembrane domains three and seven, respectively. Single point mutations that disrupt the charges of either of these residues results in constitutive activity. To validate this hypothesis, we used site-directed mutagenesis to switch the position of these amino acids to observe, if possible, regeneration of the salt-bridge reverses that the constitutive activity of the single point mutations. The transiently expressed switch mutant receptor displayed an altered pharmacological profile, The affinity of selective alpha(1b)-adrenergic receptor antagonists for the switch mutant (D125K/K331D) was no different from the wild-type alpha(1b)-adrenergic receptor, suggesting that both receptors are maintaining similar tertiary structures in the cell membrane. However, there was a significant 4-6-fold decrease in the affinity of protonated amine receptor agonists and a 3-6-fold increase in the affinity of carboxylated catechol derivatives for the switch mutant compared with the wild-type alpha(1b)-adrenergic receptor. This pharmacology is consistent with a reversed charge at position 125 in transmembrane domain three. Interestingly, the ability of either a negatively or positively charged agonist to generate soluble inositol phosphates was similar for both types of receptors, Finally, the switch mutant (D125K/K331D) displayed similar basal signaling activity as the wild-type receptor, reversing the constitutive activity of the single point mutations (D125K and K331D), This suggests an ionic constraint has been reformed in the snitch mutant analogous to the restraint previously described for the wild-type alpha(1b)-adrenergic receptor. These results strongly establish the disruption of an electrostatic interaction as an initial step in the agonist-dependent activation of alpha(1)-adrenergic receptors.	Cleveland Clin Fdn, Dept Mol Cardiol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Perez, DM (corresponding author), Cleveland Clin Fdn, Dept Mol Cardiol, Lerner Res Inst, 9500 Euclid Ave,NB50, Cleveland, OH 44195 USA.				NHLBI NIH HHS [R01HL52544, R01HL61438] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061438, R01HL052544] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Befort K, 1999, J BIOL CHEM, V274, P18574, DOI 10.1074/jbc.274.26.18574; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAEMEN FJM, 1978, NATURE, V276, P847, DOI 10.1038/276847a0; ELLING CE, 1999, I PRESS P NATL ACAD, V96; HWA J, 1996, AUTONOMIC NERVOUS SY, P49; MOTULSKY HJ, 1987, FASEB J, V1, P365, DOI 10.1096/fasebj.1.5.3315805; PEREZ DM, 1991, MOL PHARMACOL, V40, P876; Porter JE, 1996, J BIOL CHEM, V271, P28318, DOI 10.1074/jbc.271.45.28318; Porter JE, 1998, MOL PHARMACOL, V53, P766, DOI 10.1124/mol.53.4.766; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; Sambrook J., 2002, MOL CLONING LAB MANU; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; WANG CD, 1991, MOL PHARMACOL, V40, P168; Zhao MM, 1996, MOL PHARMACOL, V50, P1118; ZHUKOVSKY EA, 1991, SCIENCE, V251, P558, DOI 10.1126/science.1990431	16	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34535	34538		10.1074/jbc.274.49.34535	http://dx.doi.org/10.1074/jbc.274.49.34535			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574914	hybrid			2022-12-25	WOS:000083979600008
J	Yanai, K; Hirota, K; Taniguchi-Yanai, K; Shigematsu, Y; Shimamoto, Y; Saito, T; Chowdhury, S; Takiguchi, M; Arakawa, M; Nibu, Y; Sugiyama, F; Yagami, K; Fukamizu, A				Yanai, K; Hirota, K; Taniguchi-Yanai, K; Shigematsu, Y; Shimamoto, Y; Saito, T; Chowdhury, S; Takiguchi, M; Arakawa, M; Nibu, Y; Sugiyama, F; Yagami, K; Fukamizu, A			Regulated expression of human angiotensinogen gene by hepatocyte nuclear factor 4 and chicken ovalbumin upstream promoter-transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-PRESSURE REGULATION; ENHANCER CORE ELEMENT; COUP-TF; ESSENTIAL-HYPERTENSION; BINDING-PROTEINS; THYROID-HORMONE; INITIATION SITE; INCREASED RISK; DNA-BINDING; TATA BOX	We previously identified various upstream and downstream regulatory elements and factors important for hepatic expression of the human angiotensinogen (ANG) gene, the precursor of vasoactive octapeptide angiotensin II. In the present study, to further investigate the molecular mechanism of human ANG transcriptional regulation, we generated transgenic mice carrying the fusion gene composed of the 1.3-kilobase promoter of the human ANG gene, its downstream enhancer, and the chloramphenicol acetyltransferase reporter gene. Because expression of the chloramphenicol acetyltransferase gene was observed strongly in the liver and weakly in the kidney, we suspected that hepatocyte nuclear factor (HNF) 4 with a tissue expression pattern similar to that of the reporter gene would regulate ANG transcription. In vitro assays indicated that HNF4 bound to the promoter elements and strongly activated the ANG transcription, but that chicken ovalbumin upstream promoter transcription factor (COUP-TF), a transcriptional repressor, dramatically repressed human ANG transcription through the promoter elements and the downstream enhancer core elements. Furthermore, COUP-TF dramatically decreased the human ANG transcription in the mouse liver by the Hellos Gene Gun system in vivo, These results suggest that an interplay between HNF4 and COUP-TF could be important in hepatic human ANG transcription.	Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Lab Anim Ctr, Tsukuba, Ibaraki 3058577, Japan; Chiba Univ, Sch Med, Dept Biochem, Chiba 2600856, Japan	University of Tsukuba; University of Tsukuba; University of Tsukuba; Chiba University	Fukamizu, A (corresponding author), Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan.		Nibu, Yutaka/J-4136-2019; fukamizu, akiyoshi/J-5350-2012	Nibu, Yutaka/0000-0002-4696-7503; fukamizu, akiyoshi/0000-0002-8786-6020				ARGRIMSSON R, 1993, NAT GENET, V4, P114; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Cairns W, 1996, J BIOL CHEM, V271, P25269, DOI 10.1074/jbc.271.41.25269; CLARK AR, 1993, BIOCHEM J, V296, P521, DOI 10.1042/bj2960521; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; COOPER DN, 1992, ANN MED, V24, P427, DOI 10.3109/07853899209166991; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; CRABTREE GR, 1992, TRANSCRIPTIONAL REGU, V2, P1063; DESIMONE V, 1992, BIOCHIM BIOPHYS ACTA, V1132, P119, DOI 10.1016/0167-4781(92)90001-G; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doria A, 1996, HYPERTENSION, V27, P1134, DOI 10.1161/01.HYP.27.5.1134; FUKAMIZU A, 1995, TRENDS ENDOCRIN MET, V6, P279, DOI 10.1016/1043-2760(95)00156-5; GALSON DL, 1995, MOL CELL BIOL, V15, P2135; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GOULD AB, 1971, CARDIOVASC RES, V5, P86, DOI 10.1093/cvr/5.1.86; GRIENDLING KK, 1993, CIRCULATION, V87, P1816, DOI 10.1161/01.CIR.87.6.1816; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; HOGAN B, 1986, MANIPULATING MOUSE E; Ishigami T, 1997, HYPERTENSION, V30, P1325, DOI 10.1161/01.HYP.30.6.1325; ISHIGAMI T, 1995, CIRCULATION, V91, P951, DOI 10.1161/01.CIR.91.4.951; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; JOHNSON PF, 1990, CELL GROWTH DIFFER, V1, P47; KAMITANI A, 1995, HYPERTENSION, V25, P950, DOI 10.1161/01.HYP.25.5.950; KATSUYA T, 1995, LANCET, V345, P1600, DOI 10.1016/S0140-6736(95)90115-9; KIM HS, 1995, P NATL ACAD SCI USA, V92, P2735, DOI 10.1073/pnas.92.7.2735; KIMURA A, 1993, J BIOL CHEM, V268, P11125; KIMURA S, 1992, EMBO J, V11, P821, DOI 10.1002/j.1460-2075.1992.tb05119.x; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LAI E, 1991, TRENDS BIOCHEM SCI, V16, P427, DOI 10.1016/0968-0004(91)90169-V; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MIYATA KS, 1993, J BIOL CHEM, V268, P19169; Morishita R, 1996, HYPERTENSION, V27, P502, DOI 10.1161/01.HYP.27.3.502; MULLER MM, 1988, EUR J BIOCHEM, V176, P485, DOI 10.1111/j.1432-1033.1988.tb14306.x; NIBU Y, 1994, J BIOL CHEM, V269, P28598; NIBU Y, 1994, BIOCHEM BIOPH RES CO, V205, P1102, DOI 10.1006/bbrc.1994.2779; REID IA, 1978, ANNU REV PHYSIOL, V40, P377, DOI 10.1146/annurev.ph.40.030178.002113; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SAGAMI I, 1986, MOL CELL BIOL, V6, P4259, DOI 10.1128/MCB.6.12.4259; Sato N, 1997, HYPERTENSION, V30, P321, DOI 10.1161/01.HYP.30.3.321; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEMENZA GL, 1994, HUM MUTAT, V3, P180, DOI 10.1002/humu.1380030304; Shibata H, 1997, MOL ENDOCRINOL, V11, P714, DOI 10.1210/me.11.6.714; SHIMADA S, 1995, ENDOCRINE, V3, P543, DOI 10.1007/BF02738831; SLADEK FM, 1994, LIVER GENE EXPRESSIO, P207; SLADEK FM, 1990, GENE DEV, V4, P2352; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; WARD K, 1993, NAT GENET, V4, P59, DOI 10.1038/ng0593-59; Yanai K, 1996, J BIOL CHEM, V271, P15981, DOI 10.1074/jbc.271.27.15981; Yanai K, 1997, BIOCHEM BIOPH RES CO, V237, P158, DOI 10.1006/bbrc.1997.7000; Yanai K, 1997, FEBS LETT, V412, P285, DOI 10.1016/S0014-5793(97)00802-8; Yanai K, 1997, J BIOL CHEM, V272, P30558, DOI 10.1074/jbc.272.48.30558; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; Yoshida Y, 1997, BIOCHEM BIOPH RES CO, V234, P695, DOI 10.1006/bbrc.1997.6682	55	27	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34605	34612		10.1074/jbc.274.49.34605	http://dx.doi.org/10.1074/jbc.274.49.34605			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574924	hybrid			2022-12-25	WOS:000083979600018
J	Collet, JF; Stroobant, V; Van Schaftingen, E				Collet, JF; Stroobant, V; Van Schaftingen, E			Mechanistic studies of phosphoserine phosphatase, an enzyme related to P-type ATPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING DOMAIN; SITE-DIRECTED MUTAGENESIS; L-2-HALOACID DEHALOGENASE; SARCOPLASMIC-RETICULUM; PHOSPHOENZYME INTERMEDIATE; FUNCTIONAL CONSEQUENCES; DATABASE SEARCH; ACTIVE-SITE; PROTEIN; IDENTIFICATION	Phosphoserine phosphatase belongs to a new class of phosphotransferases forming an acylphosphate during catalysis and sharing three motifs with P-type ATPases and haloacid dehalogenases, The phosphorylated residue was identified as the first aspartate in the first motif (DXDXT) by mass spectrometry analysis of peptides derived from the phosphorylated enzyme treated with NaBH4 or alkaline [O-18]H2O. Incubation of native phosphoserine phosphatase with phosphoserine in [O-18]H2O did not result in O-18 incorporation in residue Asp-20, indicating that the phosphoaspartate is hydrolyzed, as in P-type ATPases, by attack of the phosphorus atom. Mutagenesis studies bearing on conserved residues indicated that four conservative changes either did not affect (S109T) or caused a moderate decrease in activity (G178A, D179E, and D183E), Other mutations inactivated the enzyme by >80% (S109A and G180A) or even by greater than or equal to 99% (D179N, D183N, K158A, and K158R), Mutations G178A and D179N decreased the affinity for phosphoserine, suggesting that these residues participate in the binding of the substrate. Mutations of Asp-179 decreased the affinity for Mg2+, indicating that this residue interacts with the cation, Thus, investigated residues appear to play an important role in the reaction mechanism of phosphoserine phosphatase, as is known for equivalent residues in P-type ATPases and haloacid dehalogenases.	Christian de Duve Inst Cellular Pathol, Chim Physiol Lab, B-1200 Brussels, Belgium; Catholic Univ Louvain, B-1200 Brussels, Belgium; Ludwig Inst Canc Res, B-1200 Brussels, Belgium	Universite Catholique Louvain; Ludwig Institute for Cancer Research	Van Schaftingen, E (corresponding author), UCL 7539, Ave Hippocrate 75, B-1200 Brussels, Belgium.	vanschaftingen@bchm.ucl.ac.be	Van+Schaftingen, Emile/AAF-5532-2020; Collet, Jean Francois/F-2105-2010	Collet, Jean-Francois/0000-0001-8069-7036; Van Schaftingen, Emile/0000-0002-6199-7647				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; Auer M, 1998, NATURE, V392, P840, DOI 10.1038/33967; Baker AS, 1998, BIOCHEMISTRY-US, V37, P9305, DOI 10.1021/bi972677d; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; Collet JF, 1998, J BIOL CHEM, V273, P14107, DOI 10.1074/jbc.273.23.14107; Collet JF, 1997, FEBS LETT, V408, P281, DOI 10.1016/S0014-5793(97)00438-9; Hisano T, 1996, J BIOL CHEM, V271, P20322, DOI 10.1074/jbc.271.34.20322; INESI G, 1992, ADV ENZYMOL RAMB, V65, P185; Jaeken J, 1996, ARCH DIS CHILD, V74, P542, DOI 10.1136/adc.74.6.542; Jaeken J, 1997, J MED GENET, V34, P594, DOI 10.1136/jmg.34.7.594; KOONIN EV, 1994, J MOL BIOL, V244, P125, DOI 10.1006/jmbi.1994.1711; KURIHARA T, 1995, J BIOCHEM, V117, P1317, DOI 10.1093/oxfordjournals.jbchem.a124861; Li YF, 1998, J BIOL CHEM, V273, P15035, DOI 10.1074/jbc.273.24.15035; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LIU JQ, 1995, J BIOL CHEM, V270, P18309, DOI 10.1074/jbc.270.31.18309; MACLENNAN DH, 1992, ACTA PHYSIOL SCAND, V146, P141; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; MCCIARD RW, 1979, ANAL BIOCHEM, V96, P500; Pirard M, 1997, FEBS LETT, V411, P251, DOI 10.1016/S0014-5793(97)00704-7; PLAPP BV, 1995, METHOD ENZYMOL, V249, P91; POST RL, 1973, J BIOL CHEM, V248, P6993; Ridder IS, 1999, BIOCHEM J, V339, P223, DOI 10.1042/0264-6021:3390223; Ridder IS, 1997, J BIOL CHEM, V272, P33015, DOI 10.1074/jbc.272.52.33015; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; SEAL SN, 1987, J BIOL CHEM, V262, P13496; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Thaller MC, 1998, PROTEIN SCI, V7, P1647, DOI 10.1002/pro.5560070722; VeigadaCunha M, 1996, J BIOL CHEM, V271, P6292, DOI 10.1074/jbc.271.11.6292; VINCENT JB, 1992, TRENDS BIOCHEM SCI, V17, P105, DOI 10.1016/0968-0004(92)90246-6; WEBB MR, 1981, J BIOL CHEM, V256, P4884; WO YYP, 1992, BIOCHEMISTRY-US, V31, P1712, DOI 10.1021/bi00121a019; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	35	101	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					33985	33990		10.1074/jbc.274.48.33985	http://dx.doi.org/10.1074/jbc.274.48.33985			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567362	hybrid			2022-12-25	WOS:000083857500027
J	Hu, QH; Deshpande, S; Irani, K; Ziegelstein, RC				Hu, QH; Deshpande, S; Irani, K; Ziegelstein, RC			[Ca2+](i) oscillation frequency regulates agonist-stimulated NF-kappa B transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AORTIC ENDOTHELIAL-CELLS; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; INTRACELLULAR CALCIUM; CA-2+ OSCILLATIONS; CA2+ OSCILLATIONS; GENE-EXPRESSION; INDICATORS; ACTIVATION; MECHANISM; HISTAMINE	In nonexcitable cells, stimulation by high agonist concentrations typically produces a biphasic increase in cytosolic Ca2+ ([Ca2+](i)), This response is characterized by a transient initial increase because of intracellular Ca2+ release followed by a sustained elevation which varies in amplitude depending on the nature of the stimulus. In contrast, low-level stimulation often evokes oscillatory changes in [Ca2+](i), The specific information provided by repetitive [Ca2+], spikes appears to be encoded in the frequency rather than in the amplitude of [Ca2+](i) oscillations. The specific, membrane-permeable inositol 1,4,5-trisphosphate (Ins-1,4,5-P-3) receptor blocker Xestospongin C (XeC, 2-20 mu M) was used to affect [Ca2+], signaling in human aortic endothelial cells (HAEC) during an established response to low-level (1 mu M) histamine stimulation. XeC produced a dose-dependent decrease in the frequency of [Ca2+], oscillations during histamine stimulation without affecting oscillation amplitude. Histamine stimulated a 14-fold increase in NF-kappa B-chloramphenicol acetyltransferase reporter gene activity that was dose-dependently decreased by XeC, Thus, during low-level agonist stimulation, [Ca2+](i) oscillation frequency regulates nuclear transcription in HAEC.	Johns Hopkins Univ, Sch Med, Johns Hopkins Bayview Med Ctr, Dept Med,Div Cardiol, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	Ziegelstein, RC (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Bayview Med Ctr, Dept Med,Div Cardiol, 4940 Eastern Ave, Baltimore, MD 21224 USA.	rziegel@jhmi.edu		Irani, Kaikobad/0000-0001-9194-7387	NHLBI NIH HHS [HL-52315] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052315] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aoki Y, 1998, AM J PHYSIOL-LUNG C, V274, pL1030, DOI 10.1152/ajplung.1998.274.6.L1030; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; CARTER TD, 1991, BIOCHEM J, V278, P697, DOI 10.1042/bj2780697; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; FEWTRELL C, 1993, ANNU REV PHYSIOL, V55, P427, DOI 10.1146/annurev.physiol.55.1.427; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HORIUTI K, 1988, J PHYSIOL-LONDON, V398, P131, DOI 10.1113/jphysiol.1988.sp017034; Hu QH, 1998, CIRCULATION, V97, P268, DOI 10.1161/01.CIR.97.3.268; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; JACOB R, 1988, NATURE, V335, P40, DOI 10.1038/335040a0; Kanno T, 1996, J IMMUNOL, V157, P5277; LATTANZIO FA, 1991, BIOCHEM BIOPH RES CO, V177, P184, DOI 10.1016/0006-291X(91)91966-G; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; POLLOCK WK, 1988, BIOCHEM J, V256, P371, DOI 10.1042/bj2560371; RINK TJ, 1989, CELL CALCIUM, V10, P385, DOI 10.1016/0143-4160(89)90064-X; Shatrov VA, 1997, BIOCHEM BIOPH RES CO, V234, P121, DOI 10.1006/bbrc.1997.6598; SNEYD J, 1995, FASEB J, V9, P1463, DOI 10.1096/fasebj.9.14.7589988; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Tanimura A, 1996, J CELL BIOL, V132, P607, DOI 10.1083/jcb.132.4.607; TSE FW, 1994, P NATL ACAD SCI USA, V91, P9750, DOI 10.1073/pnas.91.21.9750; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; ZIEGELSTEIN RC, 1993, AM J PHYSIOL, V265, pH1424, DOI 10.1152/ajpheart.1993.265.4.H1424	26	104	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					33995	33998		10.1074/jbc.274.48.33995	http://dx.doi.org/10.1074/jbc.274.48.33995			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567364	hybrid			2022-12-25	WOS:000083857500029
J	Kingsley-Kallesen, ML; Kelly, D; Rizzino, A				Kingsley-Kallesen, ML; Kelly, D; Rizzino, A			Transcriptional regulation of the transforming growth factor-beta 2 promoter by cAMP-responsive element-binding protein (CREB) and activating transcription factor-1 (ATF-1) is modulated by protein kinases and the coactivators p300 and CREB-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							EMBRYONAL CARCINOMA-CELLS; NF-KAPPA-B; ACID-INDUCED DIFFERENTIATION; RNA-POLYMERASE-II; RETINOIC-ACID; CYCLIC-AMP; TGF-BETA; GROWTH-FACTOR-BETA-2 GENE; FACTOR USF; F9 CELLS	Transcription of the transforming growth factor-beta 2 (TGF-beta 2) gene is dependent on a cAMP-response element/activating transcription factor (CRE/ATF) site that is bound by CREB and ATF-1 as well as an E-box motif that is bound by upstream stimulatory factors 1 and 2 (USF1 and USF2), To identify additional factors involved in the expression of the TGF-beta 2 gene, we employed F9 embryonal carcinoma (EC) cells, which express TGF-beta 2 only after the cells differentiate. We show that overexpression of the transcription factors, CREB, ATF-1, USF1, and USF2 dramatically increases TGF-beta 2 promoter activity in F9-differentiated cells. We further show that the coactivators p300 and CBP up-regulate the TGF-beta 2 promoter when CREB and ATF-1 are expressed in conjunction with protein kinases that phosphorylate CREB on serine 133 and ATF-1 on serine 63, Importantly, we identify the presence of serine 133-phosphorylated CREB in the nucleus of F9-differentiated cells but not in the nucleus of F9 EC cells. This phosphorylated form is present in whole cell extracts of both the parental and differentiated cells, suggesting that nuclear accumulation of serine 133-phosphorylated CREB is regulated duping differentiation of F9 EC cells and is likely to play an important role in the activation of the TGF-beta 2 gene.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Rizzino, A (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, 986805 Nebraska Med Ctr, Omaha, NE 68198 USA.				NCI NIH HHS [CA 79491, CA 36727, CA 74771] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074771, P30CA036727, R01CA079491] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; BERNSTINE EG, 1973, P NATL ACAD SCI USA, V70, P3899, DOI 10.1073/pnas.70.12.3899; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; BUCHNER K, 1995, EUR J BIOCHEM, V228, P211; BURT DW, 1991, DNA CELL BIOL, V10, P723, DOI 10.1089/dna.1991.10.723; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dallas PB, 1997, J VIROL, V71, P1726, DOI 10.1128/JVI.71.2.1726-1731.1997; DIFAGAGNA FD, 1995, J VIROL, V69, P2765, DOI 10.1128/JVI.69.5.2765-2775.1995; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; FLANDERS KC, 1991, DEVELOPMENT, V113, P183; GALIBERT MD, 1997, J IMMUNOL, V159, P176; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; GALVINPARTON PA, 1990, J BIOL CHEM, V265, P17771; Gao P, 1996, J BIOL CHEM, V271, P9002, DOI 10.1074/jbc.271.15.9002; GATHERER D, 1990, DEVELOPMENT, V110, P445; GEISER AG, 1991, MOL CELL BIOL, V11, P84, DOI 10.1128/MCB.11.1.84; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Guo B, 1997, BIOCHEMISTRY-US, V36, P14447, DOI 10.1021/bi971781s; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Hogan PG, 1999, NATURE, V398, P200, DOI 10.1038/18327; Jans DA, 1998, BIOESSAYS, V20, P400, DOI 10.1002/(SICI)1521-1878(199805)20:5<400::AID-BIES7>3.0.CO;2-R; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; JUAN LJ, 1994, EMBO J, V13, P6031, DOI 10.1002/j.1460-2075.1994.tb06949.x; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; Kawasaki H, 1998, GENE DEV, V12, P233, DOI 10.1101/gad.12.2.233; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; KELLY D, 1990, CYTOTECHNOLOGY, V4, P227, DOI 10.1007/BF00563783; KELLY D, 1992, DEV BIOL, V153, P172, DOI 10.1016/0012-1606(92)90102-M; Kelly D, 1998, J BIOL CHEM, V273, P21115, DOI 10.1074/jbc.273.33.21115; KELLY D, 1995, MOL REPROD DEV, V40, P135, DOI 10.1002/mrd.1080400202; Khuri FR, 1996, CELL GROWTH DIFFER, V7, P595; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KIM SJ, 1989, J BIOL CHEM, V264, P402; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KRAFT AS, 1983, J BIOL CHEM, V258, P9178; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAFYATIS R, 1990, J BIOL CHEM, V265, P19128; Lee JS, 1996, J BIOL CHEM, V271, P17666, DOI 10.1074/jbc.271.30.17666; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; Liu L, 1999, MOL CELL BIOL, V19, P1202; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MALDONADO F, 1988, NUCLEIC ACIDS RES, V16, P8189, DOI 10.1093/nar/16.16.8189; MALIPIERO U, 1990, BIOCHEM BIOPH RES CO, V171, P1145, DOI 10.1016/0006-291X(90)90804-V; MASSON N, 1992, MOL CELL BIOL, V12, P1096, DOI 10.1128/MCB.12.3.1096; MEIER JL, 1994, MOL CELL BIOL, V14, P6896, DOI 10.1128/MCB.14.10.6896; MILLAN FA, 1991, DEVELOPMENT, V111, P131; MILLER DA, 1989, MOL ENDOCRINOL, V3, P1108, DOI 10.1210/mend-3-7-1108; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; MUMMERY CL, 1990, DEV BIOL, V137, P161, DOI 10.1016/0012-1606(90)90017-D; MURAKAMI A, 1993, NUCLEIC ACIDS RES, V21, P5351, DOI 10.1093/nar/21.23.5351; Noma T, 1991, GROWTH FACTORS, V4, P247, DOI 10.3109/08977199109043910; NORRIS JL, 1992, GENE DEV, V6, P1654, DOI 10.1101/gad.6.9.1654; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Oike Y, 1999, BLOOD, V93, P2771; OREILLY MA, 1992, J BIOL CHEM, V267, P19938; PELTON RW, 1989, DEVELOPMENT, V106, P759; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PLET A, 1985, DIFFERENTIATION, V30, P159, DOI 10.1111/j.1432-0436.1985.tb00527.x; PLET A, 1982, J BIOL CHEM, V257, P889; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; RICKLES RJ, 1989, MOL CELL BIOL, V9, P1691, DOI 10.1128/MCB.9.4.1691; Rippe RA, 1997, J BIOL CHEM, V272, P1753, DOI 10.1074/jbc.272.3.1753; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; Sanford LP, 1997, DEVELOPMENT, V124, P2659; SCHMID P, 1991, MOL CELL BIOL, V11, P84; Scholtz B, 1996, J BIOL CHEM, V271, P32375, DOI 10.1074/jbc.271.50.32375; SCHOLTZ B, 1995, MOL REPROD DEV, V41, P140, DOI 10.1002/mrd.1080410204; Schwartz R, 1996, J VIROL, V70, P6955, DOI 10.1128/JVI.70.10.6955-6966.1996; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shimomura A, 1996, J BIOL CHEM, V271, P17957, DOI 10.1074/jbc.271.30.17957; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; SLAGER HG, 1991, DEV BIOL, V145, P205, DOI 10.1016/0012-1606(91)90120-R; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; Takahashi Y, 1997, J BIOL CHEM, V272, P30025, DOI 10.1074/jbc.272.48.30025; Tanaka Y, 1997, P NATL ACAD SCI USA, V94, P10215, DOI 10.1073/pnas.94.19.10215; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	104	54	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34020	34028		10.1074/jbc.274.48.34020	http://dx.doi.org/10.1074/jbc.274.48.34020			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567368	hybrid			2022-12-25	WOS:000083857500033
J	Pittman, RH; Andrews, MT; Setzer, DR				Pittman, RH; Andrews, MT; Setzer, DR			A feedback loop coupling 5 S rRNA synthesis to accumulation of a ribosomal protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-OOCYTES; RNA GENES; TRANSCRIPTION COMPLEXES; RIBONUCLEIC-ACID; ZINC FINGERS; BINDING; TFIIIA; L5; LAEVIS; TRANSPORT	We have shown that elevated expression of ribosomal protein L5 in Xenopus embryos results in the ectopic activation of 5 S rRNA genes that are normally inactive. This transcriptional stimulation mimics the effect of overexpressing transcription factor IIIA (TFIIIA), the 5 S rRNA gene-specific transcription factor. The results support a model in which a network of nucleic acid-protein interactions involving 5 S rRNA, the 5 S rRNA gene, TFIIIA, and L5 mediates both feedback inhibition of 5 S rRNA synthesis and coupling of 5 S rRNA synthesis to accumulation of a ribosomal protein, L5. We propose that these mechanisms contribute to the homeostatic control of ribosome assembly.	Case Western Reserve Univ, Sch Med, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA; N Carolina State Univ, Dept Genet, Raleigh, NC 27695 USA	Case Western Reserve University; University of North Carolina; North Carolina State University	Setzer, DR (corresponding author), Case Western Reserve Univ, Sch Med, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA.				NICHD NIH HHS [HD24673, HD07194] Funding Source: Medline; NIGMS NIH HHS [GM48035] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD024673] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048035] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1991, DEV BIOL, V144, P129, DOI 10.1016/0012-1606(91)90485-L; ALLISON LA, 1995, DEV BIOL, V168, P284, DOI 10.1006/dbio.1995.1080; ALLISON LA, 1993, MOL CELL BIOL, V13, P6819, DOI 10.1128/MCB.13.11.6819; ANDREWS MT, 1987, CELL, V51, P445, DOI 10.1016/0092-8674(87)90640-4; BROW DA, 1987, J BIOL CHEM, V262, P13953; COZZARELLI NR, 1983, CELL, V34, P829, DOI 10.1016/0092-8674(83)90540-8; DARBY MK, 1988, P NATL ACAD SCI USA, V85, P5516, DOI 10.1073/pnas.85.15.5516; FORD PJ, 1971, NATURE, V233, P561, DOI 10.1038/233561a0; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; HUBER PW, 1986, J BIOL CHEM, V261, P3002; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; MAIRY M, 1971, DEV BIOL, V24, P143, DOI 10.1016/0012-1606(71)90092-3; Nieuwkoop P. D., 1956, NORMAL TABLES XENOPU; PECULIS BA, 1992, J CELL BIOL, V116, P1, DOI 10.1083/jcb.116.1.1; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; Pieler T, 1997, SEMIN CELL DEV BIOL, V8, P79, DOI 10.1006/scdb.1996.0125; RAWLINGS SL, 1996, J BIOL CHEM, V271, P868; ROLLINS MB, 1993, MOL CELL BIOL, V13, P4776, DOI 10.1128/MCB.13.8.4776; Rudt F, 1996, EMBO J, V15, P1383, DOI 10.1002/j.1460-2075.1996.tb00480.x; SCHLISSEL MS, 1984, CELL, V37, P903, DOI 10.1016/0092-8674(84)90425-2; SCRIPTURE JB, 1995, J BIOL CHEM, V270, P27358, DOI 10.1074/jbc.270.45.27358; Setzer DR, 1996, RNA, V2, P1254; SETZER DR, 1985, J BIOL CHEM, V260, P2483; STEITZ JA, 1988, J CELL BIOL, V106, P545, DOI 10.1083/jcb.106.3.545; WORMINGTON WM, 1989, MOL CELL BIOL, V9, P5281, DOI 10.1128/MCB.9.12.5281; WORMINGTON WM, 1986, P NATL ACAD SCI USA, V83, P8639, DOI 10.1073/pnas.83.22.8639	26	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33198	33201		10.1074/jbc.274.47.33198	http://dx.doi.org/10.1074/jbc.274.47.33198			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559190	hybrid			2022-12-25	WOS:000083745200006
J	Seki, M; Akiyama, M; Sugaya, Y; Ohtsubo, E; Maki, H				Seki, M; Akiyama, M; Sugaya, Y; Ohtsubo, E; Maki, H			Strand asymmetry of +1 frameshift mutagenesis at a homopolymeric run by DNA polymerase III holoenzyme of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MISMATCH REPAIR; SPONTANEOUS MUTATION; CATALYTIC SUBUNIT; FIDELITY; REPLICATION; SPECIFICITY; MISINCORPORATION; PURIFICATION; SEQUENCE; INVITRO	We have recently shown that single-base frameshifts were predominant among mutations induced within the rpsL target sequence upon oriC plasmid DNA replication in vitro. We found that the occurrence of +1 frameshifts at a run of 6 residues of dA/dT could be increased proportionally by increasing the concentration of dATP present in the in vitro replication. Using single-stranded circular DNA containing either the coding sequence of the rpsL gene or its complementary sequence, the +1 frameshift mutagenesis by DNA polymerase III holoenzyme of Escherichia coli was extensively examined. A(6) --> A(7) frameshifts occurred 30 to 90 times more frequently during DNA synthesis with the noncoding sequence (dT tract) template than with the coding sequence (dA tract). Excess dATP enhanced the occurrence of +1 frameshifts during DNA synthesis with the dT tract template, but no other dNTPs showed such an effect. In the presence of 0.1 mM dATP, the A(6) --> A(7) mutagenesis with the dT tract template was not inhibited by 1.5 mM dCTP, which is complementary to the residue immediately upstream of the dT tract. These results strongly suggested that the A(6) --> A(7) frameshift mutagenesis possesses an asymmetric strand nature and that slippage errors leading to the +1 frameshift are made during chain elongation within the tract rather than by misincorporation of nucleotides opposite residues next to the tract.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Dept Mol Biol, Nara 6300101, Japan; Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	Nara Institute of Science & Technology; Stanford University; University of Tokyo	Maki, H (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, Dept Mol Biol, Takayama Cho 8916-5, Nara 6300101, Japan.	maki@bs.aist-nara.ac.jp						BEBENEK K, 1992, J BIOL CHEM, V267, P3589; BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; BEBENEK K, 1990, J BIOL CHEM, V265, P13878; BISHOP DK, 1989, P NATL ACAD SCI USA, V86, P3713, DOI 10.1073/pnas.86.10.3713; CREIGHTON S, 1995, J BIOL CHEM, V270, P4759, DOI 10.1074/jbc.270.9.4759; DEBOER JG, 1988, GENETICS, V118, P181; DICKERSON RE, 1994, P NATL ACAD SCI USA, V91, P3579, DOI 10.1073/pnas.91.9.3579; Dlakic M, 1996, P NATL ACAD SCI USA, V93, P3847, DOI 10.1073/pnas.93.9.3847; ECHOLS H, 1983, P NATL ACAD SCI-BIOL, V80, P2189, DOI 10.1073/pnas.80.8.2189; FERSHT AR, 1981, P NATL ACAD SCI-BIOL, V78, P4251, DOI 10.1073/pnas.78.7.4251; FERSHT AR, 1979, P NATL ACAD SCI USA, V76, P4946, DOI 10.1073/pnas.76.10.4946; Fujii S, 1999, J MOL BIOL, V289, P835, DOI 10.1006/jmbi.1999.2802; FUNNELL BE, 1986, J BIOL CHEM, V261, P5616; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; KUNKEL TA, 1986, J BIOL CHEM, V261, P3581; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; MAKI H, 1991, J BIOL CHEM, V266, P5055; MAKI H, 1988, J BIOL CHEM, V263, P6570; Mo JY, 1996, J BIOL CHEM, V271, P18947, DOI 10.1074/jbc.271.31.18947; MO JY, 1991, J MOL BIOL, V222, P925, DOI 10.1016/0022-2836(91)90586-U; Pham PT, 1999, J BIOL CHEM, V274, P3705, DOI 10.1074/jbc.274.6.3705; RIPLEY LS, 1990, ANNU REV GENET, V24, P189, DOI 10.1146/annurev.ge.24.120190.001201; SAIN B, 1980, MOL GEN GENET, V180, P35, DOI 10.1007/BF00267350; SCHAAPER RM, 1987, P NATL ACAD SCI USA, V84, P6220, DOI 10.1073/pnas.84.17.6220; SLOANE DL, 1988, NUCLEIC ACIDS RES, V16, P6465, DOI 10.1093/nar/16.14.6465; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; Tran HT, 1997, MOL CELL BIOL, V17, P2859, DOI 10.1128/MCB.17.5.2859	28	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33313	33319		10.1074/jbc.274.47.33313	http://dx.doi.org/10.1074/jbc.274.47.33313			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559208	hybrid			2022-12-25	WOS:000083745200024
J	Takesono, A; Cismowski, MJ; Ribas, C; Bernard, M; Chung, P; Hazard, S; Duzic, E; Lanier, SM				Takesono, A; Cismowski, MJ; Ribas, C; Bernard, M; Chung, P; Hazard, S; Duzic, E; Lanier, SM			Receptor-independent activators of heterotrimeric G-protein signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNEIN LIGHT-CHAIN; BETA-GAMMA-SUBUNITS; CYTOPLASMIC DYNEIN; ALPHA-SUBUNITS; IDENTIFICATION; TCTEX-1; DOMAINS	Heterotrimeric G-protein signaling systems are activated via cell surface receptors possessing the seven-membrane span motif, Several observations suggest the existence of other modes of stimulus input to heterotrimeric G-proteins, As part of an overall effort to identify such proteins we developed a functional screen based upon the pheromone response pathway in Saccharomyces cerevisiae, We identified two mammalian proteins, AGS2 and AGS3 (activators of G-protein Signaling), that activated the pheromone response pathway at the level of heterotrimeric G-proteins in the absence of a typical receptor. beta-galactosidase reporter assays in yeast strains expressing different G alpha subunits (Gpa1, G(s)alpha, G(i)alpha(2(Gpal(1-41))), G(i)alpha(3(Gpa1(1-41))), G alpha(16(Gpa1(1-41)))) indicated that AGS proteins selectively activated G-protein heterotrimers. AGS3 was only active in the G(i)alpha(2) and G(i)alpha(3) genetic backgrounds, whereas AGS2 was active in each of the genetic backgrounds except Gpa1, In protein interaction studies, AGS2 selectively associated with G beta gamma, whereas AGS3 bound G alpha and exhibited a preference for G alpha GDP versus G alpha GTP gamma S, Subsequent studies indicated that the mechanisms of G-protein activation by AGS2 and AGS3 were distinct from that of a typical G-protein-coupled receptor. AGS proteins provide unexpected mechanisms for input to heterotrimeric G-protein signaling pathways. AGS2 and AGS3 may also serve as novel binding partners for G alpha and G beta gamma that allow the subunits to subserve functions that do not require initial heterotrimer formation.	Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29425 USA; Cadus Pharmaceut Corp, Tarrytown, NY 10591 USA	Medical University of South Carolina	Lanier, SM (corresponding author), Med Univ S Carolina, Dept Pharmacol, 173 Ashley Ave, Charleston, SC 29425 USA.		Bernard, Michael/AAW-3944-2021; Cismowski, Mary/E-2897-2011	Lanier, Stephen/0000-0002-2740-7607	NINDS NIH HHS [R01-NS24821] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024821] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bailey TL, 1997, J COMPUT BIOL, V4, P45, DOI 10.1089/cmb.1997.4.45; Campbell KS, 1998, J IMMUNOL, V161, P1728; Cismowski MJ, 1999, NAT BIOTECHNOL, V17, P878, DOI 10.1038/12867; Denker SP, 1996, J CELL BIOL, V133, P1027, DOI 10.1083/jcb.133.5.1027; Fischer D, 1997, P NATL ACAD SCI USA, V94, P11929, DOI 10.1073/pnas.94.22.11929; Harrison A, 1998, J CELL BIOL, V140, P1137, DOI 10.1083/jcb.140.5.1137; HOLBROOK SR, 1993, BIOTECHNIQUES, V14, P984; Jamora C, 1999, CELL, V98, P59, DOI 10.1016/S0092-8674(00)80606-6; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; King SM, 1996, J BIOL CHEM, V271, P32281, DOI 10.1074/jbc.271.50.32281; Klein C, 1998, NAT BIOTECHNOL, V16, P1334, DOI 10.1038/4310; Lagriffoul A, 1996, J BIOL CHEM, V271, P31508, DOI 10.1074/jbc.271.49.31508; Lin HC, 1998, P NATL ACAD SCI USA, V95, P5057, DOI 10.1073/pnas.95.9.5057; Luo Y, 1999, J BIOL CHEM, V274, P10685, DOI 10.1074/jbc.274.16.10685; Mochizuki N, 1996, GENE, V181, P39, DOI 10.1016/S0378-1119(96)00456-8; Nagano F, 1998, J BIOL CHEM, V273, P30065, DOI 10.1074/jbc.273.46.30065; Roychowdhury S, 1997, J BIOL CHEM, V272, P31576, DOI 10.1074/jbc.272.50.31576; Sato M, 1996, J BIOL CHEM, V271, P30052, DOI 10.1074/jbc.271.47.30052; SATO M, 1995, J BIOL CHEM, V270, P15269, DOI 10.1074/jbc.270.25.15269; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SCHULTZ J, 1995, CURR OPIN GENET DEV, V5, P31, DOI 10.1016/S0959-437X(95)90050-0; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Tai AW, 1998, J BIOL CHEM, V273, P19639, DOI 10.1074/jbc.273.31.19639; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Wu GY, 1998, J BIOL CHEM, V273, P7197, DOI 10.1074/jbc.273.13.7197	26	226	235	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33202	33205		10.1074/jbc.274.47.33202	http://dx.doi.org/10.1074/jbc.274.47.33202			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559191	hybrid			2022-12-25	WOS:000083745200007
J	Chen, CF; Chen, PL; Zhong, Q; Sharp, ZD; Lee, WH				Chen, CF; Chen, PL; Zhong, Q; Sharp, ZD; Lee, WH			Expression of BRC repeats in breast cancer cells disrupts the BRCA2-Rad51 complex and leads to radiation hypersensitivity and loss of G(2)/M checkpoint control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUSCEPTIBILITY GENE BRCA2; HUMAN RAD51 PROTEIN; STRAND TRANSFER; P53; MICE; DIFFERENTIATION; REPAIR; PROLIFERATION; MUTATIONS; LETHALITY	BRCA2 is a breast tumor suppressor with a potential function in the cellular response to DNA damage. BRCA2 binds to Rad51 through its BRC repeats. In support of the biological significance of this interaction, we found that the complex of BRCA2 and Rad51 in breast cancer MCF-7 cells was diminished upon conditional expression of a wild-type, but not a mutated, BRC4 repeat using the tetracycline-inducible system. Cells expressing a wild-type BRC4 repeat showed hypersensitivity to gamma-irradiation, an inability to form Rad51 radiation-induced foci, and a failure of radiation-induced G(2)/M, but not G(I)/S, checkpoint control. These results strongly suggest that the interaction between BRCA2 and Rad51 mediated by BRC repeats is critical for the cellular response to DNA damage.	Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Lee, WH (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Mol Med, 7703 Floyd Curl Dr, San Antonio, TX 78245 USA.		Zhong, Qing/GLT-4858-2022	Zhong, Qing/0000-0001-6979-955X; Chen, Chi-Fen/0000-0002-6391-821X	NCI NIH HHS [CA30195, CA58183] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA030195, P50CA058183] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbott DW, 1998, J NATL CANCER I, V90, P978, DOI 10.1093/jnci/90.13.978; Baumann P, 1997, EMBO J, V16, P5198, DOI 10.1093/emboj/16.17.5198; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Bignell G, 1997, HUM MOL GENET, V6, P53, DOI 10.1093/hmg/6.1.53; Bork P, 1996, NAT GENET, V13, P22, DOI 10.1038/ng0596-22; Brugarolas J, 1997, NAT MED, V3, P721, DOI 10.1038/nm0797-721; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Friedman LS, 1998, CANCER RES, V58, P1338; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Lim DS, 1996, MOL CELL BIOL, V16, P7133; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Vaughn JP, 1996, CANCER RES, V56, P4590; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10321, DOI 10.1073/pnas.93.19.10321; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	35	161	170	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32931	32935		10.1074/jbc.274.46.32931	http://dx.doi.org/10.1074/jbc.274.46.32931			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551859	hybrid			2022-12-25	WOS:000083623000059
J	Spencer, AG; Thuresson, E; Otto, JC; Song, I; Smith, T; DeWitt, DL; Garavito, RM; Smith, WL				Spencer, AG; Thuresson, E; Otto, JC; Song, I; Smith, T; DeWitt, DL; Garavito, RM; Smith, WL			The membrane binding domains of prostaglandin endoperoxide H synthases 1 and 2 - Peptide mapping and mutational analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; CYCLOOXYGENASE ACTIVE-SITE; ENDOPROTEINASE-ASP-N; ENDOPLASMIC-RETICULUM; SUBCELLULAR-LOCALIZATION; SELECTIVE-INHIBITION; CRYSTAL-STRUCTURE; ARACHIDONIC-ACID; GENE DISRUPTION; HEME-BINDING	Prostaglandin endoperoxide H synthases I and 2 (PGHS-1 and -2) are the major targets of nonsteroidal anti-inflammatory drugs. Both isozymes are integral membrane proteins but lack transmembrane domains. X-ray crystallographic studies have led to the hypothesis that PGHS-1 and -2 associate with only one face of the membrane bilayer through a novel, monotopic membrane binding domain (MBD) that is comprised of four short, consecutive, amphipathic cr-helices (helices A-D) that include residues 74-122 in ovine PGHS-1 (oPGHS-1) and residues 59-108 in human PGHS-2 (hPGHS-2). Previous biochemical studies from our laboratory showed that the MBD of oPGHS-1 lies somewhere between amino acids 25 and 166. In studies reported here, membrane-associated forms of oPGHS-1 and hPGHS-2 were labeled using the hydrophobic, photoactivable reagent 3-trifluoro-3-(m-[I-125]iodophenyl) diazirine, isolated, and cleaved with AspN and/or GluC, and the photolabeled peptides were sequenced. The results establish that the MBDs of oPGHS-1 and hPGHS-2 reside within residues 74-140 and 59-111, respectively, and thus provide direct provide biochemical support for the hypothesis that PGHS-1 and -2 do associate with membranes through a monotopic MBD. me also prepared HelA, HelB, and HelC mutants of oPGHS-1, in which, for each helix, three or four hydrophobic residues expected to protrude into the membrane were replaced with small, neutral residues. When expressed in COS-l cells, HelA and HelC mutants exhibited little or no catalytic activity and were present, at least in part, as misfolded aggregates. The HelB mutant retained about 20% of the cyclooxygenase activity of native oPGHS-1 and partitioned in subcellular fractions Like native oPGHS-1; however, the HeLB mutant exhibited an extra site of N-glycosylation at Asn(104) When this glycosylation site was eliminated (HelB/N104Q mutation), the mutant lacked cyclooxygenase activity, Thus, our mutational analyses indicate that the amphipathic character of each helix is important for the assembly and folding of oPGHS-1 to a cyclooxygenase active form.	Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA; Univ Seoul, Dept Life Sci, Seoul 130743, South Korea	Michigan State University; University of Seoul	Smith, WL (corresponding author), Michigan State Univ, Dept Biochem, Rm 513,Biochem Bldg, E Lansing, MI 48824 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK022042, R37DK022042] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK22042] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; BLANTON MP, 1992, BIOCHEMISTRY-US, V31, P3738, DOI 10.1021/bi00130a003; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; Booden MA, 1999, J BIOL CHEM, V274, P1423, DOI 10.1074/jbc.274.3.1423; BRUNNER J, 1981, BIOCHEMISTRY-US, V20, P7174, DOI 10.1021/bi00528a019; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DEWITT DL, 1981, J BIOL CHEM, V256, P375; EVETT GE, 1993, ARCH BIOCHEM BIOPHYS, V306, P169, DOI 10.1006/abbi.1993.1496; FOEGH ML, 1989, PROSTAGLANDINS CLIN, P131; Fushman D, 1998, J BIOL CHEM, V273, P2835, DOI 10.1074/jbc.273.5.2835; Guan ZH, 1998, J BIOL CHEM, V273, P12901, DOI 10.1074/jbc.273.21.12901; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HAVERSTICK DM, 1987, P NATL ACAD SCI USA, V84, P4475, DOI 10.1073/pnas.84.13.4475; HULKOWER KI, 1994, ARTHRITIS RHEUM-US, V37, P653, DOI 10.1002/art.1780370508; INGROSSO D, 1989, BIOCHEM BIOPH RES CO, V162, P1528, DOI 10.1016/0006-291X(89)90848-6; JONES DA, 1993, J BIOL CHEM, V268, P9049; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ RJ, 1987, PROSTAGLANDINS, V34, P225, DOI 10.1016/0090-6980(87)90246-2; KULMACZ RJ, 1994, J BIOL CHEM, V269, P5527; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LANEUVILLE O, 1995, J BIOL CHEM, V270, P19330, DOI 10.1074/jbc.270.33.19330; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Li Y, 1998, J BIOL CHEM, V273, P29830, DOI 10.1074/jbc.273.45.29830; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; Movileanu L, 1997, BIOSYSTEMS, V40, P263, DOI 10.1016/S0303-2647(96)01650-4; OTTO JC, 1993, J BIOL CHEM, V268, P18234; OTTO JC, 1994, J BIOL CHEM, V269, P19868; Otto JC, 1996, J BIOL CHEM, V271, P9906, DOI 10.1074/jbc.271.17.9906; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; RAZ A, 1990, ADV PROSTAG THROMB L, V20, P22; REGIER MK, 1993, ARCH BIOCHEM BIOPHYS, V301, P439, DOI 10.1006/abbi.1993.1168; Rieke CJ, 1999, J BIOL CHEM, V274, P17109, DOI 10.1074/jbc.274.24.17109; RUAN KH, 1993, J BIOL CHEM, V268, P19483; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schulz GE, 1996, CURR OPIN STRUC BIOL, V6, P485, DOI 10.1016/S0959-440X(96)80113-8; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; STRITTMATTER P, 1982, J BIOL CHEM, V257, P1883; Szczesna-Skorupa E, 1998, P NATL ACAD SCI USA, V95, P14793, DOI 10.1073/pnas.95.25.14793; TETAZ T, 1990, BIOCHEM INT, V22, P561; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; VANDEROUDERAA FJG, 1982, METHOD ENZYMOL, V86, P60; Wendt KU, 1997, SCIENCE, V277, P1811, DOI 10.1126/science.277.5333.1811; Wendt KU, 1999, J MOL BIOL, V286, P175, DOI 10.1006/jmbi.1998.2470; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742	58	74	74	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32936	32942		10.1074/jbc.274.46.32936	http://dx.doi.org/10.1074/jbc.274.46.32936			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551860	hybrid			2022-12-25	WOS:000083623000060
J	Delerive, P; De Bosscher, K; Besnard, S; Vanden Berghe, W; Peters, JM; Gonzalez, FJ; Fruchart, JC; Tedgui, A; Haegeman, G; Staels, B				Delerive, P; De Bosscher, K; Besnard, S; Vanden Berghe, W; Peters, JM; Gonzalez, FJ; Fruchart, JC; Tedgui, A; Haegeman, G; Staels, B			Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappa B and AP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY-ARTERY DISEASE; CBP-INDUCED STIMULATION; CREB-BINDING PROTEIN; GLUCOCORTICOID RECEPTOR; C-JUN; NUCLEAR FACTOR; PPAR-GAMMA; LIPOPROTEIN METABOLISM; FUNCTIONAL ANTAGONISM; ANDROGEN RECEPTOR	Interleukin-6 (IL-6) is a pleiotropic cytokine, whose plasma levels are elevated in inflammatory diseases such as atherosclerosis. We have previously reported that peroxisome proliferator-activated receptor alpha (PPAR alpha) Ligands (fibrates) lower elevated plasma concentrations of IL-6 in patients with atherosclerosis and inhibit IL-1-stimulated IL-6 secretion by human aortic smooth muscle cells (SMC). Here, we show that aortic explants isolated from PPAR alpha-null mice display an exacerbated response to inflammatory stimuli, such as li popolysaccharide (LPS), as demonstrated by increased IL-6 secretion. Furthermore, fibrate treatment represses IL-6 mRNA levels in LPS-stimulated aortas of PPAR alpha wild-type, but not of PPAR alpha-null mice, demonstrating a role for PPAR alpha in this fibrate action. in human aortic SMC, fibrates inhibit IL-1-induced IL-6 gene expression. Furthermore, activation of PPAR alpha represses both c-Jun- and p65-induced transcription of the human IL-6 promoter. Transcriptional interference between PPAR alpha and both c-Jun and p65 occurs reciprocally, since c-Jun and p65 also inhibit PPAR alpha-mediated activation of a PPAR response element-driven promoter. This transcriptional interference occurs independent of the promoter context as demonstrated by cotransfection experiments using PPAR alpha, p65, and c-Jun Gal4 chimeras. Overexpression of the transcriptional coactivator cAMP-responsive element-binding protein-binding protein (CBP) does not relieve PPAR alpha-mediated transcriptional repression of p65 and c-Jun, Finally, glutathione S-transferase pull-down experiments demonstrate that PPAR alpha physically interacts with c-dun, p65, and CBP. Altogether these data indicate that fibrates inhibit the vascular inflammatory response via PPAR alpha by interfering with the NF-kappa B and AP-1 transactivation capacity involving direct protein-protein interaction with p65 and c-Jun.	Inst Pasteur, Dept Atherosclerose, U325 INSERM, F-59019 Lille, France; Univ Lille 2, Fac Pharm, F-59000 Lille, France; Univ Ghent, Mol Biol Lab, B-9000 Ghent, Belgium; VIB, B-9000 Ghent, Belgium; INSERM U141, F-75745 Paris 10, France; NCI, Dept Mol Carcinogenesis, NIH, Bethesda, MD 20892 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille; Ghent University; Flanders Institute for Biotechnology (VIB); Institut National de la Sante et de la Recherche Medicale (Inserm); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Staels, B (corresponding author), Inst Pasteur, Dept Atherosclerose, U325 INSERM, 1 Rue Pr Calmette, F-59019 Lille, France.	bart.staels@pasteur-lille.fr	Peters, Jeffrey/D-8847-2011; Vanden Berghe, Wim/HGE-4696-2022; Berghe, Wim Vanden/S-6425-2018; Staels, Bart/N-9497-2016	Berghe, Wim Vanden/0000-0003-0161-7355; Staels, Bart/0000-0002-3784-1503; De Bosscher, Karolien/0000-0001-5059-9718; Peters, Jeffrey/0000-0003-2782-2998	NATIONAL CANCER INSTITUTE [ZIABC005708, Z01BC005708] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bannister AJ, 1995, ONCOGENE, V11, P2509; BELMIN J, 1995, AM J PHYSIOL-HEART C, V268, pH2288, DOI 10.1152/ajpheart.1995.268.6.H2288; Biswas P, 1998, BLOOD, V91, P258, DOI 10.1182/blood.V91.1.258.258_258_265; BROCKMANN D, 1995, J BIOL CHEM, V270, P10754, DOI 10.1074/jbc.270.18.10754; Bubulya A, 1996, J BIOL CHEM, V271, P24583, DOI 10.1074/jbc.271.40.24583; Caelli T, 1997, INT J PATTERN RECOGN, V11, P1, DOI 10.1142/S0218001497000652; CASTELL JV, 1989, FEBS LETT, V242, P237, DOI 10.1016/0014-5793(89)80476-4; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; Colville-Nash PR, 1998, J IMMUNOL, V161, P978; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Dowell P, 1997, J BIOL CHEM, V272, P33435, DOI 10.1074/jbc.272.52.33435; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Frick MH, 1997, CIRCULATION, V96, P2137; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Gottlicher M, 1998, J MOL MED-JMM, V76, P480, DOI 10.1007/s001090050242; HINEGARDNER RT, 1971, ANAL BIOCHEM, V39, P197, DOI 10.1016/0003-2697(71)90476-3; Hollenberg AN, 1996, J BIOL CHEM, V271, P28516, DOI 10.1074/jbc.271.45.28516; IKEDA U, 1992, ATHEROSCLEROSIS, V92, P213, DOI 10.1016/0021-9150(92)90280-T; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Madej A, 1998, INT J CLIN PHARM TH, V36, P345; Marx N, 1999, CIRCULATION, V99, P3125, DOI 10.1161/01.CIR.99.24.3125; Marx N, 1998, AM J PATHOL, V153, P17, DOI 10.1016/S0002-9440(10)65540-X; Mehta JL, 1998, J AM COLL CARDIOL, V31, P1217, DOI 10.1016/S0735-1097(98)00093-X; Munoz C, 1996, BLOOD, V88, P3482, DOI 10.1182/blood.V88.9.3482.bloodjournal8893482; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; RAY A, 1994, J BIOL CHEM, V269, P12940; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rogatsky I, 1998, P NATL ACAD SCI USA, V95, P2050, DOI 10.1073/pnas.95.5.2050; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Ruotolo G, 1998, J AM COLL CARDIOL, V32, P1648, DOI 10.1016/S0735-1097(98)00442-2; Rus HG, 1996, ATHEROSCLEROSIS, V127, P263, DOI 10.1016/S0021-9150(96)05968-0; Saitoh Kiyoshi, 1995, Folia Pharmacologica Japonica, V106, P41, DOI 10.1254/fpj.106.41; SAKAI M, 1995, CANCER RES, V55, P5370; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Staels B, 1998, CIRCULATION, V98, P2088, DOI 10.1161/01.CIR.98.19.2088; STAELS B, 1992, ARTERIOSCLER THROMB, V12, P286, DOI 10.1161/01.ATV.12.3.286; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Tilg H, 1997, IMMUNOL TODAY, V18, P428, DOI 10.1016/S0167-5699(97)01103-1; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Wissink S, 1997, J BIOL CHEM, V272, P22278, DOI 10.1074/jbc.272.35.22278; Xing Z, 1998, J CLIN INVEST, V101, P311, DOI 10.1172/JCI1368; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	61	900	930	1	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32048	32054		10.1074/jbc.274.45.32048	http://dx.doi.org/10.1074/jbc.274.45.32048			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542237	hybrid			2022-12-25	WOS:000083532100045
J	Di Paolo, C; Hefti, HP; Meli, M; Landis, H; Pavlovic, J				Di Paolo, C; Hefti, HP; Meli, M; Landis, H; Pavlovic, J			Intramolecular backfolding of the carboxyl-terminal end of MxA protein is a prerequisite for its oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIVIRAL ACTIVITY; INFLUENZA-VIRUS; GTPASE ACTIVITY; DYNAMIN; INTERFERON; INHIBITION; EXPRESSION; TRANSCRIPTION; RESISTANCE; CELLS	Mx proteins are large GTPases, which play a pivotal role in the interferon type I-mediated response against viral infections. The human MxA inhibits the replication of several RNA viruses and is organized in oligomeric structures. Using two different experimental approaches, the mammalian two-hybrid system and an interaction dependent nuclear translocation approach, three domains in the carboxyl-terminal moiety were identified that are involved in the oligomerization of MxA. The first consists of a carboxyl-terminal amphipathic helix (LZ1), which binds to a more proximal part of the same molecule, This intramolecular backfolding is a prerequisite for the formation of an intermolecular complex, This intermolecular interaction is mediated by two domains, a poorly defined region generated by the intramolecular interaction and a domain located between amino acids 363 and 415. Go-expression of wild-type MxA with various mutant fragments thereof revealed that the presence of the carboxyl-terminal region comprising the amphipathic helices LZ1 and LZ2 is necessary and sufficient to exert a dominant negative effect. This finding suggests that the functional interference of the carboxyl-terminal region is due to competition for binding of an as yet unidentified cellular or viral target molecules.	Univ Zurich, Inst Med Virol, CH-8028 Zurich, Switzerland	University of Zurich	Pavlovic, J (corresponding author), Univ Zurich, Inst Med Virol, Gloriastr 30, CH-8028 Zurich, Switzerland.		Pavlovic, Jovan/G-9669-2015	Pavlovic, Jovan/0000-0003-4428-2487				BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; Carr JF, 1997, J BIOL CHEM, V272, P28030, DOI 10.1074/jbc.272.44.28030; CHIANG CM, 1993, PEPTIDE RES, V6, P62; DREIDING P, 1985, VIROLOGY, V140, P192, DOI 10.1016/0042-6822(85)90460-X; FRESE M, 1995, J VIROL, V69, P3904, DOI 10.1128/JVI.69.6.3904-3909.1995; Frese M, 1996, J VIROL, V70, P915, DOI 10.1128/JVI.70.2.915-923.1996; GARBER EA, 1993, VIROLOGY, V194, P715, DOI 10.1006/viro.1993.1312; GAUTIER C, 1989, NUCLEIC ACIDS RES, V17, P8389, DOI 10.1093/nar/17.20.8389; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; ISRAEL A, 1979, ANN INST PASTEUR MIC, VB130, P85; Kanerva M, 1996, VIROLOGY, V224, P55, DOI 10.1006/viro.1996.0506; Landis H, 1998, J VIROL, V72, P1516, DOI 10.1128/JVI.72.2.1516-1522.1998; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; Melen K, 1997, J BIOL CHEM, V272, P32353, DOI 10.1074/jbc.272.51.32353; MELEN K, 1992, J BIOL CHEM, V267, P25898; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; NAKAYAMA M, 1993, J BIOL CHEM, V268, P15033; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; PAVLOVIC J, 1990, J VIROL, V64, P3370, DOI 10.1128/JVI.64.7.3370-3375.1990; PITOSSI F, 1993, J VIROL, V67, P6726, DOI 10.1128/JVI.67.11.6726-6732.1993; Ponten A, 1997, J VIROL, V71, P2591, DOI 10.1128/JVI.71.4.2591-2599.1997; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SCHNEIDERSCHAULIES S, 1994, J VIROL, V68, P6910, DOI 10.1128/JVI.68.11.6910-6917.1994; SCHNORR JJ, 1993, J VIROL, V67, P4760, DOI 10.1128/JVI.67.8.4760-4768.1993; Schumacher B, 1998, J BIOL CHEM, V273, P28365, DOI 10.1074/jbc.273.43.28365; SCHWEMMLE M, 1995, VIROLOGY, V206, P545, DOI 10.1016/S0042-6822(95)80071-9; SCHWEMMLE M, 1995, J BIOL CHEM, V270, P13518, DOI 10.1074/jbc.270.22.13518; Staeheli P, 1990, Adv Virus Res, V38, P147, DOI 10.1016/S0065-3527(08)60862-3; STAEHELI P, 1986, CELL, V44, P147, DOI 10.1016/0092-8674(86)90493-9; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TUMA PL, 1995, J BIOL CHEM, V270, P26707, DOI 10.1074/jbc.270.44.26707; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310; Zhao H, 1996, VIROLOGY, V220, P330, DOI 10.1006/viro.1996.0321; ZURCHER T, 1992, EMBO J, V11, P1657, DOI 10.1002/j.1460-2075.1992.tb05212.x; ZURCHER T, 1992, J VIROL, V66, P5059	41	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32071	32078		10.1074/jbc.274.45.32071	http://dx.doi.org/10.1074/jbc.274.45.32071			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542240	hybrid, Green Accepted			2022-12-25	WOS:000083532100048
J	Hutchison, RS; Steenhuis, JJ; Yocum, CF; Razeghifard, MR; Barry, BA				Hutchison, RS; Steenhuis, JJ; Yocum, CF; Razeghifard, MR; Barry, BA			Deprotonation of the 33-kDa, extrinsic, manganese-stabilizing subunit accompanies photooxidation of manganese in photosystem II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC OXYGEN-EVOLUTION; DIFFERENCE FT-IR; TRANSFORM INFRARED-SPECTROSCOPY; ELECTRON-PARAMAGNETIC-RES; SYNECHOCYSTIS SP PCC-6803; 33 KDA PROTEIN; WATER OXIDATION; O-2-EVOLVING SYSTEM; STRUCTURAL-CHANGES; STATE TRANSITIONS	Photosystem II catalyzes photosynthetic water oxidation. The oxidation of water to molecular oxygen requires four sequential oxidations; the sequentially oxidized forms of the catalytic site are called the S states. An extrinsic subunit, the manganese-stabilizing protein (MSP), promotes the efficient turnover of the S states. MSP can be removed and rebound to the reaction center; removal and reconstitution is associated with a decrease in and then a restoration of enzymatic activity. We have isotopically edited MSP by uniform C-13 labeling of the Escherichia coli-expressed protein and have obtained the Fourier transform infrared spectrum associated with the S-1 to S-2 transition in the presence either of reconstituted C-12 or C-13 MSP, C-13 labeling of MSP is shown to cause 30-60 cm(-1) shifts in a subset of vibrational lines. The derived, isotope-edited vibrational spectrum is consistent with a deprotonation of glutamic/ aspartic acid residues on MSP during the S, to S, transition; the base, which accepts this proton(s), is not located on MSP. This finding suggests that this subunit plays a role as a stabilizer of a charged transition state and, perhaps, as a general acid/base catalyst of oxy gen evolution. These results provide a molecular explanation for known MSP effects on oxygen evolution.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Gortner Lab 140, St Paul, MN 55108 USA; Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Barry, BA (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, Gortner Lab 140, St Paul, MN 55108 USA.							Ahlbrink R, 1998, BIOCHEMISTRY-US, V37, P1131, DOI 10.1021/bi9719152; AKERLUND HE, 1981, FEBS LETT, V124, P229, DOI 10.1016/0014-5793(81)80143-3; BALDWIN MJ, 1994, J AM CHEM SOC, V116, P11349, DOI 10.1021/ja00104a014; BARRY B, 1987, BIOCHEMISTRY-US, V26, P59, DOI 10.1021/bi00375a009; BARRY BA, 1995, METHOD ENZYMOL, V258, P303; BELLAMY LJ, 1980, INFRARED SPECTRA COM, P183; Benson TE, 1997, BIOCHEMISTRY-US, V36, P796, DOI 10.1021/bi962220o; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; Betts SD, 1997, BIOCHEMISTRY-US, V36, P4047, DOI 10.1021/bi962413b; Betts SD, 1996, BIOCHEMISTRY-US, V35, P6302, DOI 10.1021/bi953066t; BRAIMAN MS, 1988, ANNU REV BIOPHYS BIO, V17, P541; BRICKER TM, 1992, BIOCHEMISTRY-US, V31, P4623, DOI 10.1021/bi00134a012; BRITT RD, 1996, OXYGENIC PHOTOSYNTHE, V4, P137; BURNAP RL, 1991, BIOCHEMISTRY-US, V30, P440, DOI 10.1021/bi00216a020; BURNAP RL, 1994, BIOCHEMISTRY-US, V33, P13712, DOI 10.1021/bi00250a023; BURNAP RL, 1992, BIOCHEMISTRY-US, V31, P7404, DOI 10.1021/bi00147a027; Christensen T, 1997, EUR J BIOCHEM, V250, P638, DOI 10.1111/j.1432-1033.1997.00638.x; Chu HA, 1999, BIOCHEMISTRY-US, V38, P4533, DOI 10.1021/bi982807y; DIOUMAEV AK, 1995, J AM CHEM SOC, V117, P10572, DOI 10.1021/ja00147a020; Fierobe HP, 1998, BIOCHEMISTRY-US, V37, P3753, DOI 10.1021/bi972232p; FLETT MS, 1962, SPECTROCHIM ACTA, V18, P1537, DOI 10.1016/S0371-1951(62)80282-3; Haumann M, 1997, FEBS LETT, V410, P243, DOI 10.1016/S0014-5793(97)00596-6; Haumann M, 1997, PHOTOSYNTH RES, V51, P193, DOI 10.1023/A:1005861917596; Herman RC, 1939, J CHEM PHYS, V7, P460, DOI 10.1063/1.1750472; Hutchison RS, 1998, BIOCHEMISTRY-US, V37, P5643, DOI 10.1021/bi9724467; JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140; Karge M, 1997, BIOCHEMISTRY-US, V36, P8904, DOI 10.1021/bi962342g; Kim S, 1998, BBA-BIOENERGETICS, V1366, P330, DOI 10.1016/S0005-2728(98)00134-0; Kim SY, 1998, BIOPHYS J, V74, P2588, DOI 10.1016/S0006-3495(98)77965-2; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; KUWABARA T, 1985, BIOCHIM BIOPHYS ACTA, V806, P283, DOI 10.1016/0005-2728(85)90107-0; Lancaster CRD, 1996, BIOPHYS J, V70, P2469, DOI 10.1016/S0006-3495(96)79820-X; Lydakis-Simantiris N, 1997, BBA-BIOENERGETICS, V1322, P129, DOI 10.1016/S0005-2728(97)00072-8; MACDONALD GM, 1995, J BIOL CHEM, V270, P8420, DOI 10.1074/jbc.270.15.8420; MACDONALD GM, 1992, BIOCHEMISTRY-US, V31, P9848, DOI 10.1021/bi00155a043; MAYES SR, 1991, BIOCHIM BIOPHYS ACTA, V1060, P1, DOI 10.1016/S0005-2728(05)80112-4; MAYFIELD SP, 1987, EMBO J, V6, P313, DOI 10.1002/j.1460-2075.1987.tb04756.x; McIntosh LP, 1996, BIOCHEMISTRY-US, V35, P9958, DOI 10.1021/bi9613234; Miura T, 1997, J BIOL CHEM, V272, P3788, DOI 10.1074/jbc.272.6.3788; MIYAO M, 1984, FEBS LETT, V168, P118, DOI 10.1016/0014-5793(84)80218-5; MIYAO M, 1983, FEBS LETT, V164, P375, DOI 10.1016/0014-5793(83)80320-2; MIYAO M, 1984, FEBS LETT, V170, P350, DOI 10.1016/0014-5793(84)81342-3; MIYAO M, 1987, BIOCHIM BIOPHYS ACTA, V890, P151, DOI 10.1016/0005-2728(87)90016-8; Nakamoto K., 1986, INFRARED RAMAN SPECT, P191; NAVERRETE JTL, 1994, BIOPOLYMERS, V34, P1065; NOGUCHI T, 1995, BBA-BIOENERGETICS, V1228, P189, DOI 10.1016/0005-2728(94)00171-Z; NOGUCHI T, 1992, BIOCHEMISTRY-US, V31, P5953, DOI 10.1021/bi00141a001; ONO T, 1984, FEBS LETT, V168, P281, DOI 10.1016/0014-5793(84)80263-X; ONO T, 1985, BIOCHIM BIOPHYS ACTA, V806, P331, DOI 10.1016/0005-2728(85)90240-3; ONO T, 1983, FEBS LETT, V164, P252; Pan K, 1998, BIOCHEMISTRY-US, V37, P1357, DOI 10.1021/bi971835y; PHILBRICK JB, 1991, J BIOL CHEM, V266, P13370; RAMIREZ FJ, 1995, SPECTROCHIM ACTA A, V51, P293, DOI 10.1016/0584-8539(94)00188-H; Razeghifard MR, 1997, BIOCHEMISTRY-US, V36, P14474, DOI 10.1021/bi970116g; ROTHSCHILD KJ, 1992, J BIOENERG BIOMEMBR, V24, P147, DOI 10.1007/BF00762674; SAUER K, 1992, MANGANESE REDOX ENZY, P141; SCHOWEN KB, 1982, METHOD ENZYMOL, V87, P551; Seidler A, 1996, EUR J BIOCHEM, V242, P485, DOI 10.1111/j.1432-1033.1996.0485r.x; Seidler A, 1996, BBA-BIOENERGETICS, V1277, P35, DOI 10.1016/S0005-2728(96)00102-8; SEIDLER A, 1995, PHOTOSYNTHESIS LIGHT, V2, P259; Short SA, 1996, J BIOL CHEM, V271, P4978; Steenhuis JJ, 1996, J AM CHEM SOC, V118, P11927, DOI 10.1021/ja961691v; Steenhuis JJ, 1999, J BIOL CHEM, V274, P14609, DOI 10.1074/jbc.274.21.14609; Steenhuis JJ, 1998, J PHYS CHEM B, V102, P4, DOI 10.1021/jp9730609; Steenhuis JJ, 1997, J PHYS CHEM B, V101, P6652, DOI 10.1021/jp971260e; STYRING S, 1988, BIOCHIM BIOPHYS ACTA, V933, P378, DOI 10.1016/0005-2728(88)90046-1; SUSI H, 1986, METHOD ENZYMOL, V130, P290; VASS I, 1992, BIOCHIM BIOPHYS ACTA, V1102, P195, DOI 10.1016/0005-2728(92)90100-G; VASS I, 1987, BIOCHIM BIOPHYS ACTA, V892, P224, DOI 10.1016/0005-2728(87)90178-2; Yamomoto Y., 1981, FEBS LETT, V133, P265; Zhang HM, 1998, BIOCHEMISTRY-US, V37, P5511, DOI 10.1021/bi971787h	71	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31987	31995		10.1074/jbc.274.45.31987	http://dx.doi.org/10.1074/jbc.274.45.31987			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542229	hybrid			2022-12-25	WOS:000083532100037
J	Tseng, CP; Ely, BD; Pong, RC; Wang, Z; Zhou, J; Hsieh, JT				Tseng, CP; Ely, BD; Pong, RC; Wang, Z; Zhou, J; Hsieh, JT			The role of DOC-2/DAB2 protein phosphorylation in the inhibition of AP-1 activity - An underlying mechanism of its tumor-suppressive function in prostate cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C-DELTA; NUCLEAR-LOCALIZATION SIGNAL; DIFFERENTIAL REGULATION; GROWTH-CONTROL; PHORBOL ESTER; DISABLED GENE; CELL-LINE; OVEREXPRESSION; EXPRESSION; EPSILON	DOC-2/DAB2, a novel phosphoprotein with signal-transducing capability, inhibits human prostatic cancer cells (Tseng, C.-P., Ely, B. D., Li, Y., Pong, R.-C., and Hsieh, J.-T. (1998) Endocrinology 139, 3542-3553). However, its mechanism of action is not understood completely, This study delineates the functional significance of DOC-2/DAB2 protein phosphorylation and demonstrates that in vivo activation of protein kinase C (PKC) by 12-O-tetradecanoylphorbol-13-acetate (TPA) induces DOC-2/DAB2 phosphorylation, including a serine residue at position 24, Mutation of Ser(24) to Ala reduced DOC-2/DAB2 phosphorylation by PKC, Using a synthetic Ser(24) peptide (APS(24)KKEKKKGSEKTD) or recombinant DOC-2/DAB2 as substrates, PKC beta II, PKC gamma, and PKC delta (but not casein kinase II) directly phosphorylated Ser24 in vitro. This indicates that DOC-2/DAB2 is a PKC-specific substrate. Since expression of wild-type DOC-2/DAB2, but not the S24A mutant, inhibited TPA-induced AP-I activity in prostatic epithelial cells, phosphorylation of Ser(24) appears to play a critical role in modulating TPA-induced AP-1 activity. Taken together, these data suggest that PKC-regulated phosphorylation of DOC-2/DAB2 protein may help its growth inhibitory function.	Univ Texas, SW Med Ctr, Dept Urol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hsieh, JT (corresponding author), Univ Texas, SW Med Ctr, Dept Urol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.				NCI NIH HHS [CA59939] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA059939] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; FRIEDERICH E, 1992, CELL, V70, P81, DOI 10.1016/0092-8674(92)90535-K; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; Fulop V, 1998, ONCOGENE, V17, P419, DOI 10.1038/sj.onc.1201955; GOLDSTEIN DR, 1995, CARCINOGENESIS, V16, P1121, DOI 10.1093/carcin/16.5.1121; GOODE N, 1992, J BIOL CHEM, V267, P16878; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; KIELBASSA K, 1995, J BIOL CHEM, V270, P6156, DOI 10.1074/jbc.270.11.6156; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KRAUSS RS, 1989, ONCOGENE, V4, P991; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; LEHEL C, 1994, J BIOL CHEM, V269, P4761; LEUKEL M, 1995, EUR J CELL BIOL, V68, P133; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; ROBBINS DJ, 1992, MOL BIOL CELL, V3, P299, DOI 10.1091/mbc.3.3.299; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; TAGAWA T, 1995, J CELL BIOL, V130, P255, DOI 10.1083/jcb.130.2.255; TSENG CP, 1994, CARCINOGENESIS, V15, P707, DOI 10.1093/carcin/15.4.707; Tseng CP, 1998, ENDOCRINOLOGY, V139, P3542, DOI 10.1210/en.139.8.3542; Tseng CP, 1996, GENE, V169, P287, DOI 10.1016/0378-1119(95)00816-0; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678	30	50	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31981	31986		10.1074/jbc.274.45.31981	http://dx.doi.org/10.1074/jbc.274.45.31981			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542228	hybrid			2022-12-25	WOS:000083532100036
J	Delaughter, MC; Taffet, GE; Fiorotto, ML; Entman, ML; Schwartz, RJ				Delaughter, MC; Taffet, GE; Fiorotto, ML; Entman, ML; Schwartz, RJ			Local insulin-like growth factor I expression induces physiologic, then pathologic, cardiac hypertrophy in transgenic mice	FASEB JOURNAL			English	Article						IGF-I; SIS2 transgene; systolic function; hypertension	MYOCYTE PROLIFERATION; VENTRICULAR HYPERTROPHY; HEART-FAILURE; UP-REGULATION; HORMONE; PERFORMANCE; CARDIOMYOCYTES; INFARCTION; INDUCTION; SYSTEM	In the present study we determined the long-term effects of persistent, local insulin-like growth factor I (IGF-I) expression on cardiac function in the SIS2 transgenic mouse. Cardiac mass/tibial length was increased in SIS2 mice by 10 wk of age; this cardiac hypertrophy became more pronounced later in life, Peak aortic outflow velocity, a correlate of cardiac output, was increased at 10 wk in SIS2 mice but was decreased at 52 wk, 72 wk SIS2 mouse hearts exhibited wide variability in the extent of cardiac hypertrophy and enlargement of individual cardiac myofibers, Sirius red staining revealed increased fibrosis in 72 wk SIS:! hearts, Persistent local ICE-I expression is sufficient to initially induce an analog of physiological cardiac hypertrophy in which peak aortic outflow velocity is increased relative to controls in the absence of any observed detrimental histological changes. However, this hypertrophy progresses to a pathological condition characterized by decreased systolic performance and increased fibrosis, Our results confirm the shortterm systolic performance benefit of increased ICE-I, but our demonstration that ICE-I ultimately diminishes systolic performance raises doubt about the therapeutic value of chronic ICE-I administration. Considering these findings, limiting temporal exposure to ICE-I seems the most likely means of delivering IGF-I's potential benefits while avoiding its deleterious side effects.-Delaughter, M. C,, Taffet, G. E., Fiorotto, M, L., Entman, M, L., Schwartz, R. J. Local insulinlike growth factor I expression induces physiologic, then pathologic, cardiac hypertrophy in transgenic mice.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Huffington Ctr Aging, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, USDA ARS, Childrens Nutr Res Ctr, Houston, TX 77030 USA; Baylor Coll Med, Dept Cardiovasc Sci, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; United States Department of Agriculture (USDA); Baylor College of Medicine	Schwartz, RJ (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.				NHLBI NIH HHS [HL42550] Funding Source: Medline; NIA NIH HHS [5 T32 AG000183] Funding Source: Medline; NIDDK NIH HHS [2 T32 DK07696] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL042550] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000183] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BUERKE M, 1995, P NATL ACAD SCI USA, V92, P8031, DOI 10.1073/pnas.92.17.8031; Butt RP, 1997, J MOL CELL CARDIOL, V29, P1141, DOI 10.1006/jmcc.1996.0347; CHANSON P, 1990, ANN INTERN MED, V113, P921, DOI 10.7326/0003-4819-113-12-921; COHICK WS, 1993, ANNU REV PHYSIOL, V55, P131, DOI 10.1146/annurev.ph.55.030193.001023; COLEMAN ME, 1995, J BIOL CHEM, V270, P12109, DOI 10.1074/jbc.270.20.12109; DIEZ J, 1994, J HUM HYPERTENS, V8, pS21; Donath MY, 1998, J CLIN ENDOCR METAB, V83, P3177, DOI 10.1210/jc.83.9.3177; DONATH MY, 1994, P NATL ACAD SCI USA, V91, P1686, DOI 10.1073/pnas.91.5.1686; DONOHUE TJ, 1994, CIRCULATION, V89, P799, DOI 10.1161/01.CIR.89.2.799; DUERR RL, 1995, J CLIN INVEST, V95, P619, DOI 10.1172/JCI117706; FAZIO S, 1994, J CLIN ENDOCR METAB, V79, P441, DOI 10.1210/jc.79.2.441; Fazio S, 1996, NEW ENGL J MED, V334, P809, DOI 10.1056/NEJM199603283341301; ITO H, 1993, CIRCULATION, V87, P1715, DOI 10.1161/01.CIR.87.5.1715; KAJSTURA J, 1994, EXP CELL RES, V215, P273, DOI 10.1006/excr.1994.1343; KARDAMI E, 1990, MOL CELL BIOCHEM, V92, P129; Lombardi G, 1997, J PEDIATR ENDOCR MET, V10, P553; Reiss K, 1996, P NATL ACAD SCI USA, V93, P8630, DOI 10.1073/pnas.93.16.8630; REISS K, 1994, J CELL PHYSIOL, V158, P160, DOI 10.1002/jcp.1041580120; REISS K, 1994, EXP CELL RES, V213, P463, DOI 10.1006/excr.1994.1224; Sacca L, 1997, CARDIOVASC RES, V36, P3, DOI 10.1016/S0008-6363(97)00127-2; Stromer H, 1996, CIRC RES, V79, P227, DOI 10.1161/01.RES.79.2.227; Taffet GE, 1996, AM J PHYSIOL-HEART C, V270, pH2204; Wang L, 1998, CIRC RES, V83, P516, DOI 10.1161/01.RES.83.5.516; Wang L, 1998, ENDOCRINOLOGY, V139, P1354, DOI 10.1210/en.139.3.1354; YANG RH, 1995, CIRCULATION, V92, P262, DOI 10.1161/01.CIR.92.2.262	25	125	129	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1999	13	14					1923	1929		10.1096/fasebj.13.14.1923	http://dx.doi.org/10.1096/fasebj.13.14.1923			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544175				2022-12-25	WOS:000083660700004
J	Murphy, KM; Streips, UN; Lock, RB				Murphy, KM; Streips, UN; Lock, RB			Bax membrane insertion during Fas(CD95)-induced apoptosis precedes cytochrome c release and is inhibited by Bcl-2	ONCOGENE			English	Article						Fas; Bax; Bcl-2; caspase; cytochrome c	FAS-MEDIATED APOPTOSIS; INDUCED CELL-DEATH; NECROSIS-FACTOR; MITOCHONDRIAL RELEASE; CPP32-LIKE PROTEASES; SIGNALING COMPLEX; CD95 FAS/APO-1; ICE-LIKE; ACTIVATION; PROTEIN	Ligation of the Fas cell surface receptor leads to activation of caspases and subsequent apoptosis. Members of the Bcl-2 family of proteins control the cellular commitment to apoptosis, although their role in Fas-induced apoptosis is ill-defined. In this report we demonstrate that the pro-apoptotic protein, Bax, translocates from the cytosol specifically to the mitochondria following Fas ligation in MCF10A1 breast epithelial cells. Bax translocation was dependent on caspase activation, and preceded the release of cytochrome c and loss of mitochondrial respiratory activity. Bax translocation occurred in concert with activation of downstream caspases as determined by cleavage of a synthetic substrate, proteolysis of poly(ADP-ribose) polymerase, and processing of procaspase-3 and -7, Overexpression of the anti-apoptotic protein, Bcl-2, prevented Bax insertion, cytochrome c release, complete processing of procaspase-3 and -7, and full activation of DEVD-specific cleavage activity. These data establish a role for Bax mitochondrial insertion during Fas-mediated apoptosis, and support a model in which Bax insertion amplifies the Fas apoptotic cascade through cytochrome c release and complete processing of caspases-3 and -7. In addition, our findings indicate that prevention of Bax insertion into the mitochondria represents a novel mechanism by which Bcl-2 inhibits Fas-induced apoptosis.	Sydney Childrens Hosp, Childrens Canc Inst Asutralia Med Res, Randwick, NSW 2031, Australia; Univ Louisville, Dept Microbiol & Immunol, Louisville, KY 40292 USA	University of Louisville	Lock, RB (corresponding author), Sydney Childrens Hosp, Childrens Canc Inst Asutralia Med Res, Randwick, NSW 2031, Australia.		Lock, Richard/G-4253-2013	Lock, Richard/0000-0002-3436-9071				Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cory S, 1998, BBA-REV CANCER, V1377, pR25, DOI 10.1016/S0304-419X(98)00003-1; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Keane MM, 1996, CANCER RES, V56, P4791; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lock RB, 1996, CANCER RES, V56, P4006; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Rosen A, 1997, J CELL BIOCHEM, V64, P50, DOI 10.1002/(SICI)1097-4644(199701)64:1<50::AID-JCB8>3.0.CO;2-Z; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	49	83	86	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 28	1999	18	44					5991	5999		10.1038/sj.onc.1203001	http://dx.doi.org/10.1038/sj.onc.1203001			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557088				2022-12-25	WOS:000083359100005
J	Nagata, Y; Anan, T; Yoshida, T; Mizukami, T; Taya, Y; Fujiwara, T; Kato, H; Saya, H; Nakao, M				Nagata, Y; Anan, T; Yoshida, T; Mizukami, T; Taya, Y; Fujiwara, T; Kato, H; Saya, H; Nakao, M			The stabilization mechanism of mutant-type p53 by impaired ubiquitination: the loss of wild-type p53 function and the hsp90 association	ONCOGENE			English	Article						p53; ubiquitin-proteasome; mdm2; hsp90; conformation; phosphorylation	TUMOR-SUPPRESSOR GENE; HEAT-SHOCK-PROTEIN; DNA-DAMAGE; CELL-LINE; MOLECULAR CHAPERONE; PROTEASOME PATHWAY; CRYSTAL-STRUCTURE; DEGRADATION; MDM2; PHOSPHORYLATION	Mutant-type p53 (mt p53) is largely accumulated in cancer cells due to its increased stability, To elucidate the mechanism of mt p53 stabilization, we analysed the turnover of p53 mutated at codon 248 whose alteration is most frequently found in human cancers. Proteasome inhibition induced the accumulation of ubiquitinated mt p53, indicating that the ubiquitinated forms were essentially unstable and degraded by the proteasome, The presence of a small amount of the ubiquitinated mt p53 relative to the abundant non-ubiquitinated form suggested that the mt p53 ubiquitination was a rate-limiting process in the slow turnover, Two phenomena destabilizing mt p53 via the ubiquitin-proteasome degradation were proved to be independent, First, the coexpression of wild-type p53 (wt p53) promoted mt p53 destabilization as feedback regulation. Second, geldanamycin also induced mt p53 destabilization through the dissociation of the protein from hsp90 but not through the restoration of wt p53 function. Neither the mutant-specific conformation nor the N-terminal phosphorylation seemed to contribute directly to the mt p53 stabilization, Further, a two-dimensional gel electrophoresis revealed that most of the post-translationally modified mt p53 was equally subjected to ubiquitination and subsequent proteasomal degradation, These findings are evidence that mt p53 stabilization depends on the impaired ubiquitination due to both the loss of wt p53 function and the hsp90 association.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8600811, Japan; Kurume Univ, Sch Med, Dept Pediat & Child Hlth, Kurume, Fukuoka 8300011, Japan; Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Tokyo 1940023, Japan; Ctr Canc, Res Inst, Chuo Ku, Tokyo 1040045, Japan; Okayama Univ, Sch Med, Dept Surg 1, Okayama 7000914, Japan	Kumamoto University; Kurume University; Kyowa Kirin Ltd; Okayama University	Nakao, M (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Honjo, Kumamoto 8600811, Japan.		Saya, Hideyuki/J-4325-2013					AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; Blagosklonny MV, 1997, ONCOGENE, V15, P1889, DOI 10.1038/sj.onc.1201374; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; BROWN JP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Chen LH, 1998, P NATL ACAD SCI USA, V95, P195, DOI 10.1073/pnas.95.1.195; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CORDONCARDO C, 1994, CANCER RES, V54, P794; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRITSCHE M, 1993, ONCOGENE, V8, P307; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Hall PA, 1996, J PATHOL, V180, P1; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; KASTAN MB, 1991, CANCER RES, V51, P6304; KONDO S, 1995, ONCOGENE, V10, P2001; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Landers JE, 1997, CANCER RES, V57, P3562; LEGROS Y, 1994, ONCOGENE, V9, P3689; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; Maki CG, 1996, CANCER RES, V56, P2649; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MIYAJI H, 1990, CYTOTECHNOLOGY, V3, P133, DOI 10.1007/BF00143675; Miyake H, 1998, ONCOGENE, V16, P933, DOI 10.1038/sj.onc.1201602; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Pagano M, 1997, FASEB J, V11, P1067, DOI 10.1096/fasebj.11.13.9367342; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Roth JA, 1997, J NATL CANCER I, V89, P21, DOI 10.1093/jnci/89.1.21; Save V, 1998, J PATHOL, V184, P348; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Selkirk James K., 1994, Applied and Theoretical Electrophoresis, V4, P11; Sharma SV, 1998, ONCOGENE, V16, P2639, DOI 10.1038/sj.onc.1201790; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; VOJTESEK B, 1995, ONCOGENE, V10, P389; Whitesell L, 1998, MOL CELL BIOL, V18, P1517, DOI 10.1128/MCB.18.3.1517; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	53	84	86	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 28	1999	18	44					6037	6049		10.1038/sj.onc.1202978	http://dx.doi.org/10.1038/sj.onc.1202978			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557093				2022-12-25	WOS:000083359100010
J	Stacker, SA; Vitali, A; Caesar, C; Domagala, T; Groenen, LC; Nice, E; Achen, MG; Wilks, AF				Stacker, SA; Vitali, A; Caesar, C; Domagala, T; Groenen, LC; Nice, E; Achen, MG; Wilks, AF			A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; SIGNAL-TRANSDUCTION; NITRIC-OXIDE; TUMOR-CELLS; BINDING; EXPRESSION; IDENTIFICATION; KDR; ANGIOGENESIS; LIGAND	Vascular endothelial growth factor (VEGF) is a major mediator of vasculogenesis and angiogenesis both during development and in pathological conditions. VEGF has a variety of effects on vascular endothelium, including the ability to stimulate endothelial cell mitogenesis, and the potent induction of vascular permeability. These activities are at least in part mediated by binding to two high affinity receptors, VEGFR-1 and VEGFR-2, In this study we have made mutations of mouse VEGF in order to define the regions that are required for VEGFR-2-mediated functions, Development of a bioassay, which responds only to signals generated by cross-linking of VEGFR-2, has allowed evaluation of these mutants for their ability to activate VEGFR-2, One mutant (VEGF0), which had amino acids 83-89 of VEGF substituted with the analogous region of the related placenta growth factor, demonstrated significantly reduced VEGFR-2 binding compared with wild type VEGF, indicating that this region was required for VEGF-VEGFR-2 interaction, Intriguingly, when this mutant was evaluated in a Miles assay for its ability to induce vascular permeability, no difference was found when compared with wild type VEGF, In addition we have shown that the VEGF homology domain of the structurally related growth factor VEGF-D is capable of binding to and activating VEGFR-2 but has no vascular permeability activity, indicating that VEGFR-2 binding does not correlate with permeability activity for all VEGF family members; These data suggest different mechanisms for VEGF-mediated mitogenesis and vascular permeability and raise the possibility of an alternative receptor mediating vascular permeability.	Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia	Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Stacker, SA (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, POB 2008, Melbourne, Vic 3050, Australia.		Wilks, Andrew F/R-5542-2019; Nice, Edouard C/B-1026-2011	Stacker, Steven/0000-0003-4096-9273; Achen, Marc/0000-0002-3791-803X; Wilks, Andrew F/0000-0002-8554-2399				Achen MG, 1997, GROWTH FACTORS, V15, P69, DOI 10.3109/08977199709002113; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BREIER G, 1992, DEVELOPMENT, V114, P521; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Damert A, 1997, CANCER RES, V57, P3860; Dvorak AM, 1996, J LEUKOCYTE BIOL, V59, P100, DOI 10.1002/jlb.59.1.100; DVORAK HF, 1979, J IMMUNOL, V122, P166; Feng D, 1996, J EXP MED, V183, P1981, DOI 10.1084/jem.183.5.1981; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FERRARA N, 1997, REGULATION ANGIOGENE, P209; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GitayGoren H, 1996, J BIOL CHEM, V271, P5519, DOI 10.1074/jbc.271.10.5519; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Joukov V, 1998, J BIOL CHEM, V273, P6599, DOI 10.1074/jbc.273.12.6599; Joukov V, 1996, EMBO J, V15, P290; Kabrun N, 1997, DEVELOPMENT, V124, P2039; Kevil CG, 1998, J BIOL CHEM, V273, P15099, DOI 10.1074/jbc.273.24.15099; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Koblizek TI, 1997, EUR J BIOCHEM, V244, P774, DOI 10.1111/j.1432-1033.1997.00774.x; KOHN S, 1992, LAB INVEST, V67, P596; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MILES AA, 1952, J PHYSIOL-LONDON, V118, P228, DOI 10.1113/jphysiol.1952.sp004789; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Murohara T, 1998, CIRCULATION, V97, P99, DOI 10.1161/01.CIR.97.1.99; NICE E, 1994, J CHROMATOGR A, V660, P169, DOI 10.1016/0021-9673(94)85110-7; OELRICHS RB, 1993, ONCOGENE, V8, P11; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; OSTMAN A, 1991, J BIOL CHEM, V266, P10073; PACIFICI RE, 1994, J BIOL CHEM, V269, P1571; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; SEETHARAM L, 1995, ONCOGENE, V10, P135; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Siemeister G, 1998, P NATL ACAD SCI USA, V95, P4625, DOI 10.1073/pnas.95.8.4625; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Stacker SA, 1999, GROWTH FACTORS, V17, P1, DOI 10.3109/08977199909001058; Stacker SA, 1999, J BIOL CHEM, V274, P32127, DOI 10.1074/jbc.274.45.32127; STACKER SA, 1991, J IMMUNOL, V146, P648; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VASSBOTN FS, 1993, MOL CELL BIOL, V13, P4066, DOI 10.1128/MCB.13.7.4066; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071; YEO KT, 1993, CANCER RES, V53, P2912	55	96	106	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34884	34892		10.1074/jbc.274.49.34884	http://dx.doi.org/10.1074/jbc.274.49.34884			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574962	hybrid			2022-12-25	WOS:000083979600056
J	Baechtold, H; Kuroda, M; Sok, J; Ron, D; Lopez, BS; Akhmedov, AT				Baechtold, H; Kuroda, M; Sok, J; Ron, D; Lopez, BS; Akhmedov, AT			Human 75-kDa DNA-pairing protein is identical to the pro-oncoprotein TLS/FUS and is able to promote D-loop formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; RNA-BINDING PROTEIN; HUMAN RAD51 PROTEIN; HUMAN MYELOID-LEUKEMIA; COLI RECT PROTEIN; ESCHERICHIA-COLI; C-ABL; CHROMOSOMAL TRANSLOCATION; HOMOLOGOUS RECOMBINATION; TYROSINE KINASE	Homologous recombination plays a fundamental role in DNA double-strand break repair. Previously, we detected two mammalian nuclear proteins of 100 and 75 kDa (POMp100 and POMp75, respectively) that are able to promote homologous DNA pairing, a key step in homologous recombination. Here me describe the identification of human (h) POMp75 as the pro-oncoprotein TLS/FUS, hPOMp75/TLS binds both single- and double-stranded DNAs and mediates annealing of complementary DNA strands. More important, it promotes the uptake of a single-stranded oligonucleotide into a homologous superhelical DNA to form a D-loop. The formation of a D-loop is an essential step in DNA double-strand break repair through recombination. DNA annealing and D-loop formation catalyzed by hPOMp75/TLS require Mg2+ and are ATP-independent. Interestingly, the oncogenic fusion form TLS-CHOP is not able to promote DNA pairing. These data suggest a possible role for hPOMp75/TLS in maintenance of genomic integrity.	Basel Inst Immunol, CH-4005 Basel, Switzerland; NYU, Med Ctr, Dept Med & Cell Biol, Skirball Inst Biomol Med, New York, NY 10016 USA; NYU, Med Ctr, Kaplan Canc Ctr, New York, NY 10016 USA; CEA, UMR CNRS 217, Direct Sci Vivant, Dept Radiobiol & Radiopathol, F-92265 Fontenay Aux Roses, France	New York University; New York University; CEA; UDICE-French Research Universities; Universite Paris Saclay	Akhmedov, AT (corresponding author), Basel Inst Immunol, Grenzacherstr 487, CH-4005 Basel, Switzerland.		Lopez, Bernard S/O-7308-2017	Lopez, Bernard S/0000-0001-5088-0155; Ron, David/0000-0002-3014-5636	NCI NIH HHS [CA60945] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKHMEDOV AT, 1995, P NATL ACAD SCI USA, V92, P1729, DOI 10.1073/pnas.92.5.1729; Barlow AL, 1997, EMBO J, V16, P5207, DOI 10.1093/emboj/16.17.5207; Baumann P, 1997, EMBO J, V16, P5198, DOI 10.1093/emboj/16.17.5198; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; BERTRAND P, 1993, NUCLEIC ACIDS RES, V21, P3653, DOI 10.1093/nar/21.16.3653; Bertwistle D, 1998, CURR OPIN GENET DEV, V8, P14, DOI 10.1016/S0959-437X(98)80056-7; Borggrefe T, 1998, J BIOL CHEM, V273, P17025, DOI 10.1074/jbc.273.27.17025; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; HALL SD, 1993, J BACTERIOL, V175, P277, DOI 10.1128/JB.175.1.277-287.1993; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; ICHIKAWA H, 1994, CANCER RES, V54, P2865; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1998, ONCOGENE, V16, P1773, DOI 10.1038/sj.onc.1201934; KMIEC EB, 1994, MOL CELL BIOL, V14, P7163, DOI 10.1128/MCB.14.11.7163; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; LEE CG, 1993, J BIOL CHEM, V268, P13472; Li MJ, 1996, P NATL ACAD SCI USA, V93, P10222, DOI 10.1073/pnas.93.19.10222; Li ZF, 1997, P NATL ACAD SCI USA, V94, P11221, DOI 10.1073/pnas.94.21.11221; LUISIDELUCA C, 1994, J MOL BIOL, V236, P124, DOI 10.1006/jmbi.1994.1123; LUISIDELUCA C, 1995, J BACTERIOL, V177, P566, DOI 10.1128/jb.177.3.566-572.1995; MCENTEE K, 1979, P NATL ACAD SCI USA, V76, P2615, DOI 10.1073/pnas.76.6.2615; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; Noirot P, 1998, J BIOL CHEM, V273, P12274, DOI 10.1074/jbc.273.20.12274; Perrotti D, 1998, EMBO J, V17, P4442, DOI 10.1093/emboj/17.15.4442; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; PLUG AW, 1996, NP NATL ACAD SCI US, V93, P5900; Powers CA, 1998, MOL ENDOCRINOL, V12, P4, DOI 10.1210/mend.12.1.0043; PRASAD DDK, 1994, ONCOGENE, V9, P3717; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RADDING CM, 1991, J BIOL CHEM, V266, P5355; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P1638, DOI 10.1073/pnas.76.4.1638; SHIBATA T, 1982, J BIOL CHEM, V257, P3981; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; TRACY RB, 1997, GENE DEV, V11, P2423; WEINSTOCK GM, 1979, P NATL ACAD SCI USA, V76, P126, DOI 10.1073/pnas.76.1.126; Yuan ZM, 1998, J BIOL CHEM, V273, P3799, DOI 10.1074/jbc.273.7.3799; Zhang HB, 1998, CELL, V92, P433, DOI 10.1016/S0092-8674(00)80936-8; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; Zinszner H, 1997, J CELL SCI, V110, P1741	49	120	122	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34337	34342		10.1074/jbc.274.48.34337	http://dx.doi.org/10.1074/jbc.274.48.34337			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567410	hybrid			2022-12-25	WOS:000083857500075
J	De Bleser, PJ; Xu, GX; Rombouts, K; Rogiers, V; Geerts, A				De Bleser, PJ; Xu, GX; Rombouts, K; Rogiers, V; Geerts, A			Glutathione levels discriminate between oxidative stress and transforming growth factor-beta signaling in activated rat hepatic stellate cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER FIBROGENESIS; HYDROGEN-PEROXIDE; REDOX REGULATION; MESANGIAL CELLS; GROWTH-FACTOR-BETA-1; COLLAGEN; FIBROBLASTS; INVOLVEMENT; EXPRESSION; APOPTOSIS	Reactive oxygen species are implicated in the pathogenesis of several diseases, including Alzheimer's disease, multiple sclerosis, human immunodeficiency virus, and liver fibrosis, With respect to liver fibrosis, we have investigated differences in antioxidant enzymes expression in stellate cells (SCs) and parenchymal cells from normal and CCl4-treated rat livers. We observed an increase in the expression of catalase in activated SCs. Treatment with transforming growth factor-beta (TGF-beta) increased the production of H2O2. Treatment with catalase decreased TGF-beta expression. Addition of H2O2 resulted in increased TGF-beta production. 3-Amino-1,2,4-triazole abolished the capacity of SCs to remove H2O2. A paradoxical increase in capacity was observed when the cells were pretreated with diethyl maleate. Treatment with 3-amino-1,2,4-triazole increased TGF-beta production. A paradoxical decrease of TGF-beta production was observed with diethyl maleate. Treatment of the cells with N-acetylcysteine resulted in increased TGF-beta production. TGF-beta decreased the capacity of the SCs to remove H2O2. An increase in the capacity to remove H2O2 was observed when TGF-beta was removed by neutralizing antibodies. In conclusion, our results suggest: 1) a link between cellular GSH levels and TGF-beta production and 2) that cellular GSH levels discriminate whether H2O2 is the result of oxidative stress or acts as second messenger in the TGF-beta signal transduction pathway.	Free Univ Brussels, Cell Biol & Histol Lab, B-1090 Brussels, Belgium; Free Univ Brussels, Toxicol Lab, B-1090 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Geerts, A (corresponding author), Free Univ Brussels, Cell Biol & Histol Lab, Laarbeeklaan 103, B-1090 Brussels, Belgium.		De Bleser, Pieter/C-3489-2011; De Bleser, Pieter/AAB-2968-2021; Rombouts, Krista/ABB-2602-2020; Rombouts, Krista/AAE-8179-2020	De Bleser, Pieter/0000-0003-4762-8770; Rombouts, Krista/0000-0001-9440-0571; Rogiers, Vera/0000-0003-0635-7740				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BACHEM MG, 1992, J CLIN INVEST, V89, P19, DOI 10.1172/JCI115561; Bauer P, 1996, ARCH HISTOL CYTOL, V59, P71, DOI 10.1679/aohc.59.71; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEBLESER P, 1991, CELLS OF THE HEPATIC SINUSOID, VOL 3, P218; Garcia-Trevijano ER, 1999, HEPATOLOGY, V29, P960, DOI 10.1002/hep.510290346; Geerts Albert, 1994, P819; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; GRESSNER AM, 1990, SEMIN LIVER DIS, V10, P30, DOI 10.1055/s-2008-1040455; JIANG ZY, 1990, FEBS LETT, V268, P69, DOI 10.1016/0014-5793(90)80974-N; KAYANOKI Y, 1994, J BIOL CHEM, V269, P15488; LEE KS, 1995, J CLIN INVEST, V96, P2461, DOI 10.1172/JCI118304; MAKINO N, 1994, J BIOL CHEM, V269, P1020; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Pietrangelo A, 1996, SEMIN LIVER DIS, V16, P13, DOI 10.1055/s-2007-1007215; Pitrak DL, 1998, J LAB CLIN MED, V132, P284, DOI 10.1016/S0022-2143(98)90041-5; Reynolds WF, 1999, EXP NEUROL, V155, P31, DOI 10.1006/exnr.1998.6977; ROGIERS V, 1984, PHARM MORPHOLOGICAL, P121; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; SHAN ZH, 1994, KIDNEY INT, V46, P388, DOI 10.1038/ki.1994.286; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; TADA H, 1986, J IMMUNOL METHODS, V93, P157, DOI 10.1016/0022-1759(86)90183-3; THANNICKAL VJ, 1993, AM J PHYSIOL, V265, pL622, DOI 10.1152/ajplung.1993.265.6.L622; TILLY JL, 1995, ENDOCRINOLOGY, V136, P242, DOI 10.1210/en.136.1.242; TSUKAMOTO H, 1995, J GASTROEN HEPATOL, V10, pS50, DOI 10.1111/j.1440-1746.1995.tb01798.x; TSUKAMOTO H, 1993, ALCOHOL, V10, P465, DOI 10.1016/0741-8329(93)90066-W; Vladimirova O, 1998, MULT SCLER, V4, P413, DOI 10.1191/135245898678919456; WHITE SR, 1991, J IMMUNOL METHODS, V144, P257, DOI 10.1016/0022-1759(91)90094-V	29	137	140	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					33881	33887		10.1074/jbc.274.48.33881	http://dx.doi.org/10.1074/jbc.274.48.33881			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567349	hybrid			2022-12-25	WOS:000083857500014
J	Greenfield, JP; Xu, HX; Greengard, P; Gandy, S; Seeger, M				Greenfield, JP; Xu, HX; Greengard, P; Gandy, S; Seeger, M			Generation of the amyloid-beta peptide N terminus in Saccharomyces cerevisiae expressing human Alzheimer's amyloid-beta precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST; PROHORMONE; PROTEASES; DISEASE; CELLS	The Alzheimer's amyloid-beta precursor protein (beta APP) is a type 1 membrane-spanning protein from which the Alzheimer's disease amyloid-beta peptide (A beta) is proteolytically derived. To date, attempts to identify the enzymes responsible for A beta generation have failed. Here we report the accumulation of A beta-immunoreactive peptides in yeast expressing human beta APP. Characterization of these peptides by metabolic labeling, immunoprecipitation with A beta-specific antibodies, and N-terminal radiosequencing indicates that these peptides include the A beta peptide at their N termini. The A beta-like peptides generated in yeast were recovered predominantly as 8- and 12-14-kDa species. A 4-kDa species was recovered either when a protease-deficient strain was used to prevent breakdown or when the 8- and 12-14-kDa species were treated with disaggregating agents. The likely existence in yeast of enzymes generating the A beta N terminus indicates that the molecular identification of yeast beta-secretase-like enzymes may be accomplished using genetic screens or empirical approaches based upon the sequenced genome of Saccharomyces cerevisiae.	NYU, NS Kline Inst, Orangeburg, NY 10962 USA; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA; Rockefeller Univ, Fisher Ctr Res Alzheimer Dis, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, New York, NY 10021 USA	Nathan Kline Institute for Psychiatric Research; New York University; Rockefeller University; Rockefeller University; Cornell University	Gandy, S (corresponding author), NYU, NS Kline Inst, 140 Old Orangeburg Rd, Orangeburg, NY 10962 USA.		Xu, Huaxi/AAV-7177-2021	Greenfield, Jeffrey/0000-0003-1904-1040	NATIONAL INSTITUTE ON AGING [P01AG010491, P01AG009464] Funding Source: NIH RePORTER; NIA NIH HHS [AG09464, AG10491] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HINES V, 1994, CELL MOL BIOL RES, V40, P273; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Komano H, 1998, J BIOL CHEM, V273, P31648, DOI 10.1074/jbc.273.48.31648; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Rose MD., 1990, METHODS YEAST GENETI; THOMAS G, 1988, SCIENCE, V241, P226, DOI 10.1126/science.3291117; ZHANG HY, 1994, J BIOL CHEM, V269, P27799; Zhang W, 1997, BBA-MOL CELL RES, V1359, P110, DOI 10.1016/S0167-4889(97)00082-7	13	17	18	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					33843	33846		10.1074/jbc.274.48.33843	http://dx.doi.org/10.1074/jbc.274.48.33843			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567340	hybrid			2022-12-25	WOS:000083857500005
J	Isotani, S; Hara, K; Tokunaga, C; Inoue, H; Avruch, J; Yonezawa, K				Isotani, S; Hara, K; Tokunaga, C; Inoue, H; Avruch, J; Yonezawa, K			Immunopurified mammalian target of rapamycin phosphorylates and activates p70 S6 kinase alpha in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; EIF-4E BP1; IN-VIVO; SITE; P70(S6K); MTOR; ANTIBODIES	p70 S6 kinase alpha (p70 alpha) is activated in vivo through a multisite phosphorylation in response to mitogens if a sufficient supply of amino acids is available or to high concentrations of amino acids per se. The immunosuppressant drug rapamycin inhibits p70 alpha activation in a manner that can be overcome by coexpression of p70 alpha with a rapamycin-resistant mutant of the mammalian target of rapamycin (mTOR) but only if the mTOR kinase domain is intact. We report here that a mammalian recombinant p70 alpha polypeptide, extracted in an inactive form from rapamycin-treated cells, can be directly phosphorylated by the mTOR kinase in vitro predominantly at the rapamycin-sensitive site Thr-412. mTOR-catalyzed p70 alpha phosphorylation in vitro is accompanied by a substantial restoration in p70 alpha kinase activity toward its physiologic substrate, the 40 S ribosomal protein S6. Moreover, sequential phosphorylation of p70 alpha by mTOR and 3-phosphoinositide-dependent protein kinase 1 in vitro resulted in a synergistic stimulation of p70 alpha activity to levels similar to that attained by serum stimulation in vivo. These results indicate that mTOR is likely to function as a direct activator of p70 in vivo, although the relative contribution of mTOR-catalyzed p70 phosphorylation in each of the many circumstances that engender p70 activation remains to be defined.	Kobe Univ, Biosignal Res Ctr, Nada Ku, Kobe, Hyogo 6518501, Japan; Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02129 USA; Massachusetts Gen Hosp, Med Serv, Boston, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA 02129 USA	Kobe University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Yonezawa, K (corresponding author), Kobe Univ, Biosignal Res Ctr, Nada Ku, 1-1 Rokkodai Cho, Kobe, Hyogo 6518501, Japan.	yonezawa@kobe-u.ac.jp			NATIONAL CANCER INSTITUTE [R01CA073818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK017776, R01DK017776] Funding Source: NIH RePORTER; NCI NIH HHS [CA73818] Funding Source: Medline; NIDDK NIH HHS [DK17776] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Meyuhas Oded, 1996, V30, P363; Moser BA, 1997, MOL CELL BIOL, V17, P5648, DOI 10.1128/MCB.17.9.5648; Nishiuma T, 1998, BIOCHEM BIOPH RES CO, V252, P440, DOI 10.1006/bbrc.1998.9671; Patti ME, 1998, J CLIN INVEST, V101, P1519, DOI 10.1172/JCI1326; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Shigemitsu K, 1999, J BIOL CHEM, V274, P1058, DOI 10.1074/jbc.274.2.1058; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WENG QP, 1995, MOL CELL BIOL, V15, P2333; Ziegler WH, 1999, CURR BIOL, V9, P522, DOI 10.1016/S0960-9822(99)80236-X	23	267	284	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34493	34498		10.1074/jbc.274.48.34493	http://dx.doi.org/10.1074/jbc.274.48.34493			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567431	Green Published, hybrid			2022-12-25	WOS:000083857500096
J	Itoh, Y; Kajita, M; Kinoh, H; Mori, H; Okada, A; Seiki, M				Itoh, Y; Kajita, M; Kinoh, H; Mori, H; Okada, A; Seiki, M			Membrane type 4 matrix metalloproteinase (MT4-MMP, MMP-17) is a glycosylphosphatidylinositol-anchored proteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; UROKINASE PLASMINOGEN-ACTIVATOR; MOLECULAR-CLONING; CELL-SURFACE; TISSUE DISTRIBUTION; RECEPTOR; IDENTIFICATION; DOMAIN; CDNA; EXPRESSION	Among the five membrane-type matrix metalloproteinases (MT-MMPs), MT1-, MT2-, MT3-, and MT5-MMPs have about a 20-amino acid cytoplasmic tail following the transmembrane domain. In contrast, a putative transmembrane domain of MT4-MMP locates at the very C-terminal end, and the expected cytoplasmic tail is very short or nonexistent, Such sequences often act as a glycosylphosphatidylinositol (GPI) anchoring signal rather than as a transmembrane domain, We thus examined the possibility that MT4-MMP is a GPI-anchored proteinase, Our results showed that [H-3]ethanolamine, which can be incorporated into the GPI unit, specifically labeled the MT4-MMP C-terminal end in a sequence-dependent manner. In addition, phosphatidylinositol-specific phospholipase C treatment released the MT4-MMP from the surface of transfected calls. These results indicate that MT4-MMP is the first GPI-anchored proteinase in the MMP family, During cultivation of the transfected cells, MT4-MMP appeared to be shed from the cell surface by the action of an endogenous metalloproteinase. GPI anchoring of MT4-MMP on the cell surface indicates a unique biological function and character for this proteinase.	Univ Tokyo, Inst Med Sci, Dept Canc Cell Res, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Seiki, M (corresponding author), Univ Tokyo, Inst Med Sci, Dept Canc Cell Res, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.		Seiki, Motoharu/K-9443-2015	Itoh, Yoshifumi/0000-0002-2128-2823				BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hoessli DC, 1998, TRENDS CELL BIOL, V8, P87, DOI 10.1016/S0962-8924(98)80018-4; Huang W, 1996, FEBS LETT, V384, P155, DOI 10.1016/0014-5793(96)00304-3; Kajita M, 1999, FEBS LETT, V457, P353, DOI 10.1016/S0014-5793(99)01065-0; KINOH H, 1999, IN PRESS CELL GENET; Llano E, 1997, BIOCHEMISTRY-US, V36, P15101, DOI 10.1021/bi972120y; Llano E, 1999, CANCER RES, V59, P2570; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; Lombard MA, 1998, CANCER RES, V58, P4001; May AE, 1998, J EXP MED, V188, P1029, DOI 10.1084/jem.188.6.1029; MIN HY, 1992, J IMMUNOL, V148, P3636; Movahedi S, 1997, BIOCHEM J, V326, P531, DOI 10.1042/bj3260531; Nagase H, 1997, BIOL CHEM, V378, P151; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Okamoto I, 1999, ONCOGENE, V18, P1435, DOI 10.1038/sj.onc.1202447; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Pendas AM, 1997, J BIOL CHEM, V272, P4281, DOI 10.1074/jbc.272.7.4281; Puente XS, 1996, CANCER RES, V56, P944; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; Simon DI, 1996, BLOOD, V88, P3185, DOI 10.1182/blood.V88.8.3185.bloodjournal8883185; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	34	135	142	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34260	34266		10.1074/jbc.274.48.34260	http://dx.doi.org/10.1074/jbc.274.48.34260			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567400	hybrid			2022-12-25	WOS:000083857500065
J	Maroun, RG; Krebs, D; El Antri, S; Deroussent, A; Lescot, E; Troalen, F; Porumb, H; Goldberg, ME; Fermandjian, S				Maroun, RG; Krebs, D; El Antri, S; Deroussent, A; Lescot, E; Troalen, F; Porumb, H; Goldberg, ME; Fermandjian, S			Self-association and domains of interactions of an amphipathic helix peptide inhibitor of HIV-1 integrase assessed by analytical ultracentrifugation and NMR experiments in trifluoroethanol/H2O mixtures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARTIALLY FOLDED STATE; SECONDARY STRUCTURE FORMATION; NUCLEAR-MAGNETIC-RESONANCE; PREDICTING COILED COILS; ALANINE-BASED PEPTIDES; DNA TOPOISOMERASE-II; EGG-WHITE LYSOZYME; ALPHA-HELIX; EMPIRICAL PARAMETERS; FORMING PROPERTIES	EAA26 (VESMNEELKKIIAQVRAQAEHLKTAY) is a better inhibitor of human immunodeficiency virus, type 1, integrase than its parent Lys-159, reproducing the enzyme segment 147-175 with a nonpolar-polar/charged residue periodicity defined by four helical heptads (abcdefg) prone to collapse into a coiled-coil. Circular dichroism, nuclear magnetic resonance, sedimentation equilibrium, and chemical cross-linking were used to analyze EAA26 in various trifluoroethanol/H2O mixtures. In pure water the helix content is weak but increases regularly up to 50-60% trifluoroethanol. In contrast the multimerization follows a bell-shaped curve with monomers in pure water, tetramers at 10% trifluoroethanol, and dimers at 40% trifluoroethanol, All suggest that interhelical interactions between apolar side chains are required for the coiled-coil formation of EAA26 and subsist at medium trifluoroethanol concentration. The N-H temperature coefficients measured by nuclear magnetic resonance show that at low trifluoroethanol concentration the amide groups buried in the hydrophobic interior of four alpha-helix bundles are weakly accessible to trifluoroethanol and are only weakly subject to its hydrogen bond strengthening effect. The increased accessibility of trifluoroethanol to buried amide groups at higher trifluoroethanol concentration entails the reduction of the hydrophobic interactions and the conversion of helix tetramers into helix dimers, the latter displaying a smaller hydrophobic interface. The better inhibitory activity of EAA26 compared with Lys-159 could arise from its better propensity to form a helix bundle structure with the biologically important helical part of the 147-175 segment in integrase.	Inst Gustave Roussy, Dept Biol & Pharmacol Struct, UMR 8532 CNRS, F-94805 Villejuif, France; IRCOF, UPRES A6014, Lab RMN, F-76821 Mont St Aignan, France; Fac Sci & Tech, Lab Chim Bioorgan & Analyt, Mohamedia, Morocco; Inst Gustave Roussy, UMR 8532 CNRS, Dept Pharmacotoxicol & Pharmacogenet, F-94805 Villejuif, France; Inst Gustave Roussy, Serv Immunol Mol, F-9480 Villejuif, France; Inst Pasteur, CNRS URA 1129, Unite Biochim Cellulaire, Paris, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Fermandjian, S (corresponding author), Inst Gustave Roussy, Dept Biol & Pharmacol Struct, UMR 8532 CNRS, F-94805 Villejuif, France.	sfermand@igr.fr		EL ANTRI, SAID/0000-0003-3534-2476				ALEXANDRESCU AT, 1994, J MOL BIOL, V235, P587, DOI 10.1006/jmbi.1994.1015; ARMSTRONG KM, 1993, P NATL ACAD SCI USA, V90, P11337, DOI 10.1073/pnas.90.23.11337; Aurora R, 1997, J BIOL CHEM, V272, P1413, DOI 10.1074/jbc.272.3.1413; Baldwin RL, 1999, TRENDS BIOCHEM SCI, V24, P77, DOI 10.1016/S0968-0004(98)01345-0; Baldwin RL, 1999, TRENDS BIOCHEM SCI, V24, P26, DOI 10.1016/S0968-0004(98)01346-2; BARLOW DJ, 1983, J MOL BIOL, V168, P867, DOI 10.1016/S0022-2836(83)80079-5; BARSOV EV, 1996, J VIROL, V64, P5617; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BIERZYNSKI A, 1982, P NATL ACAD SCI-BIOL, V79, P2470, DOI 10.1073/pnas.79.8.2470; BIOU V, 1988, PROTEIN ENG, V2, P185, DOI 10.1093/protein/2.3.185; BLANCO FJ, 1994, BIOCHEMISTRY-US, V33, P6004, DOI 10.1021/bi00185a041; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADLEY EK, 1990, J MOL BIOL, V215, P607, DOI 10.1016/S0022-2836(05)80172-X; BRANDEN MR, 1991, INTRO PROTEIN STRUCT, P33; BROWN PO, 1997, RETROVIRUSES, V1, P161; BUCK M, 1995, BIOCHEMISTRY-US, V34, P13219, DOI 10.1021/bi00040a038; BUCK M, 1993, BIOCHEMISTRY-US, V32, P669, DOI 10.1021/bi00053a036; Buckle AM, 1996, BIOCHEMISTRY-US, V35, P4298, DOI 10.1021/bi9524676; CammersGoodwin A, 1996, J AM CHEM SOC, V118, P3082, DOI 10.1021/ja952900z; CHAKRABARTTY A, 1995, ADV PROTEIN CHEM, V46, P141, DOI 10.1016/S0065-3233(08)60334-4; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; Cordes MHJ, 1996, CURR OPIN STRUC BIOL, V6, P3, DOI 10.1016/S0959-440X(96)80088-1; Cordier F, 1999, J AM CHEM SOC, V121, P1601, DOI 10.1021/ja983945d; CORNILESCU G, 1999, NMR PROTEINS NUCL AC, V121, P2949; Drake RR, 1998, P NATL ACAD SCI USA, V95, P4170, DOI 10.1073/pnas.95.8.4170; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; Eckert DM, 1998, J MOL BIOL, V284, P859, DOI 10.1006/jmbi.1998.2214; Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832; FOROOD B, 1993, P NATL ACAD SCI USA, V90, P838, DOI 10.1073/pnas.90.3.838; FRERE V, 1995, J BIOL CHEM, V270, P17502, DOI 10.1074/jbc.270.29.17502; FrereGallois V, 1997, EUR J BIOCHEM, V249, P142, DOI 10.1111/j.1432-1033.1997.t01-1-00142.x; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Gast K, 1997, PROTEIN SCI, V6, P2578; Goldgur Y, 1998, P NATL ACAD SCI USA, V95, P9150, DOI 10.1073/pnas.95.16.9150; GOODMAN EM, 1989, BIOCHEMISTRY-US, V28, P4343, DOI 10.1021/bi00436a033; GOODMAN M, 1962, J AM CHEM SOC, V84, P3770, DOI 10.1021/ja00878a036; Greenwald J, 1999, BIOCHEMISTRY-US, V38, P8892, DOI 10.1021/bi9907173; Harding S. E., 1992, ANAL ULTRACENTRIFUGA; Heuer TS, 1997, BIOCHEMISTRY-US, V36, P10655, DOI 10.1021/bi970782h; HODGES RS, 1973, COLD SPRING HARB SYM, V37, P299, DOI 10.1101/SQB.1973.037.01.040; HOLTZER ME, 1995, BIOPOLYMERS, V36, P365, DOI 10.1002/bip.360360310; JASANOFF A, 1994, BIOCHEMISTRY-US, V33, P2129, DOI 10.1021/bi00174a020; Jenkins TM, 1997, EMBO J, V16, P6849, DOI 10.1093/emboj/16.22.6849; JIMENEZ MA, 1993, EUR J BIOCHEM, V211, P569, DOI 10.1111/j.1432-1033.1993.tb17584.x; Kallenbach N. R., 1996, CIRCULAR DICHROISM C, P201; KAMTEKAR S, 1993, SCIENCE, V262, P1680, DOI 10.1126/science.8259512; Kentsis A, 1998, BIOCHEMISTRY-US, V37, P14613, DOI 10.1021/bi981641y; Krebs D, 1998, EUR J BIOCHEM, V253, P236, DOI 10.1046/j.1432-1327.1998.2530236.x; Krebs D, 1996, EUR J BIOCHEM, V235, P699, DOI 10.1111/j.1432-1033.1996.t01-1-00699.x; LAU SYM, 1984, J BIOL CHEM, V259, P3253; LOCKHART DJ, 1993, SCIENCE, V260, P198, DOI 10.1126/science.8469972; Luo PZ, 1997, BIOCHEMISTRY-US, V36, P8413, DOI 10.1021/bi9707133; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Malashkevich VN, 1996, SCIENCE, V274, P761, DOI 10.1126/science.274.5288.761; Mandell JG, 1998, P NATL ACAD SCI USA, V95, P14705, DOI 10.1073/pnas.95.25.14705; Maroun RG, 1999, EUR J BIOCHEM, V260, P145, DOI 10.1046/j.1432-1327.1999.00130.x; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MERUTKA G, 1991, BIOCHEMISTRY-US, V30, P1591, DOI 10.1021/bi00220a021; MERUTKA G, 1995, J BIOMOL NMR, V5, P14, DOI 10.1007/BF00227466; MONERA OD, 1993, J BIOL CHEM, V268, P19218; MUNOZ V, 1995, J MOL BIOL, V245, P297, DOI 10.1006/jmbi.1994.0024; MUNOZ V, 1994, NAT STRUCT BIOL, V1, P399, DOI 10.1038/nsb0694-399; MUNOZ V, 1995, J MOL BIOL, V245, P275, DOI 10.1006/jmbi.1994.0023; MUNOZ V, 1996, FOLD DES, V1, pR167; Myers JK, 1996, J MOL BIOL, V263, P390, DOI 10.1006/jmbi.1996.0583; Myers JK, 1997, BIOCHEMISTRY-US, V36, P10923, DOI 10.1021/bi9707180; ODONOGHUE SI, 1993, PROTEIN ENG, V6, P557, DOI 10.1093/protein/6.6.557; Padmanabhan S, 1998, BIOCHEMISTRY-US, V37, P17318, DOI 10.1021/bi9813678; PARRY DAD, 1982, BIOSCIENCE REP, V2, P1017, DOI 10.1007/BF01122170; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RamirezAlvarado M, 1996, NAT STRUCT BIOL, V3, P604, DOI 10.1038/nsb0796-604; RASHIN AA, 1984, J MOL BIOL, V173, P515, DOI 10.1016/0022-2836(84)90394-2; Regan L, 1997, P NATL ACAD SCI USA, V94, P2796, DOI 10.1073/pnas.94.7.2796; Reymond MT, 1997, BIOCHEMISTRY-US, V36, P5234, DOI 10.1021/bi970038x; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; Rohl CA, 1996, PROTEIN SCI, V5, P2623, DOI 10.1002/pro.5560051225; Rothemund S, 1996, J BIOMOL NMR, V8, P93, DOI 10.1007/BF00198143; Schafmeister CE, 1997, NAT STRUCT BIOL, V4, P1039, DOI 10.1038/nsb1297-1039; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Scholtz J. Martin, 1995, P171, DOI 10.1016/B978-012310920-0/50005-X; Schonbrunner N, 1996, J MOL BIOL, V260, P432, DOI 10.1006/jmbi.1996.0412; Sourgen F, 1996, EUR J BIOCHEM, V240, P765, DOI 10.1111/j.1432-1033.1996.0765h.x; Thomas M, 1997, TRENDS BIOTECHNOL, V15, P167, DOI 10.1016/S0167-7799(97)01016-0; Turner BG, 1999, J MOL BIOL, V285, P1, DOI 10.1006/jmbi.1998.2354; Vlassi M, 1999, J MOL BIOL, V285, P817, DOI 10.1006/jmbi.1998.2342; WALTHO JP, 1993, BIOCHEMISTRY-US, V32, P6337, DOI 10.1021/bi00076a006; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Yang JX, 1997, PROTEIN SCI, V6, P1264, DOI 10.1002/pro.5560060614; Yi JZ, 1999, BIOCHEMISTRY-US, V38, P8458, DOI 10.1021/bi982870n; ZHONG LX, 1992, P NATL ACAD SCI USA, V89, P4462, DOI 10.1073/pnas.89.10.4462	96	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34174	34185		10.1074/jbc.274.48.34174	http://dx.doi.org/10.1074/jbc.274.48.34174			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567389	hybrid			2022-12-25	WOS:000083857500054
J	Imamura, T; Ishibashi, K; Dalle, S; Ugi, S; Olefsky, JM				Imamura, T; Ishibashi, K; Dalle, S; Ugi, S; Olefsky, JM			Endothelin-l-induced GLUT4 translocation is mediated via G alpha(q/11) protein and phosphatidylinositol 3-kinase in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; DIABETES-MELLITUS; KINASE; MECHANISMS	Endothelin-1 (ET-1) can stimulate insulin-responsive glucose transporter (GLUT4) translocation in 3T3-L1 adipocytes (Wu-Wong, J. R., Berg, C. E,, Wang, J,, Chiou, W, J,, and Fissel, B. (1999) J. Biol. Chem. 274, 8103-8110), and in the current study, we have evaluated the signaling pathway leading to this response. First, we inhibited endogenous Ga-q/11 function by single-cell microinjection using anti-G alpha(q/11) antibody or RGS2 protein (a GTPase activating protein for G alpha(q)) followed by immunostaining to quantitate GLUT4 translocation in 3T3-L1 adipocytes, ET-l-stimulated GLUT4 translocation was markedly decreased by 70 or 75% by microinjection of G alpha(q/11) antibody or RGS2 protein, respectively. Pretreatment of cells with the G alpha(i) inhibitor (pertussis toxin) or microinjection of a G beta gamma inhibitor (glutathione S-transferase-beta-adrenergic receptor kinase (GST-BARK)) did not inhibit ET-1-induced GLUT4 translocation, indicating that G alpha(q/11) mediates ET-1 signaling to GLUT4 translocation. Next, we found that ET-l-induced GLUT4 translocation was inhibited by the phosphatidylinositol (PI) 3-kinase inhibitors wortmannin or LY294002, but not by the phospholipase C inhibitor U-73122. ET-1 stimulated the PI 3-kinase activity of the p110 alpha subunit (5.5-fold), and microinjection of anti-p110 alpha or PKC-lambda antibodies inhibited ET-stimulated GLUT4 translocation, Finally, we found that G alpha(q/11) formed immunocomplexes with the type-A endothelin receptor and the 110 alpha subunit of PI 3-kinase and that ET-1 stimulation enhances tyrosine phosphorylation of G alpha(q/11). These results indicate that: 1) ET-1 signaling to GLUT4 translocation is dependent upon G alpha(q/11) and PI 3-kinase; and 2) G alpha(q/11) can transmit signals from the ET, receptor to the p110 alpha subunit of PI 3-kinase, as does insulin, subsequently leading to GLUT4 translocation.	Univ Calif San Diego, Dept Med 0673, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Olefsky, JM (corresponding author), Univ Calif San Diego, Dept Med 0673, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033651, R01DK033651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-33651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Douglas SA, 1997, J VASC RES, V34, P152, DOI 10.1159/000159219; Egawa K, 1999, J BIOL CHEM, V274, P14306, DOI 10.1074/jbc.274.20.14306; GARCIAHIGUERA I, 1994, J CLIN INVEST, V93, P937, DOI 10.1172/JCI117099; Haruta T, 1998, ENDOCRINOLOGY, V139, P358, DOI 10.1210/en.139.1.358; HARUTA T, 1995, J BIOL CHEM, V270, P27991; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; Imamura T, 1999, MOL CELL BIOL, V19, P6765; Jiang ZY, 1999, DIABETES, V48, P1120, DOI 10.2337/diabetes.48.5.1120; KAWAMURA M, 1992, DIABETES CARE, V15, P1396, DOI 10.2337/diacare.15.10.1396; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Kruszynska YT, 1996, J INVEST MED, V44, P413; Miyauchi T, 1999, TRENDS PHARMACOL SCI, V20, P210, DOI 10.1016/S0165-6147(99)01297-3; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Sarman B, 1998, DIABETES METAB REV, V14, P171, DOI 10.1002/(SICI)1099-0895(199806)14:2<171::AID-DMR207>3.0.CO;2-G; Schiffrin EL, 1998, J CARDIOVASC PHARM, V32, pS2; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Umemori H, 1997, SCIENCE, V276, P1878, DOI 10.1126/science.276.5320.1878; Vollenweider P, 1997, ENDOCRINOLOGY, V138, P4941, DOI 10.1210/en.138.11.4941; Vollenweider P, 1999, MOL CELL BIOL, V19, P1081; Wu-Wong JSR, 1999, J BIOL CHEM, V274, P8103, DOI 10.1074/jbc.274.12.8103	24	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33691	33695		10.1074/jbc.274.47.33691	http://dx.doi.org/10.1074/jbc.274.47.33691			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559259	hybrid			2022-12-25	WOS:000083745200075
J	Kurima, K; Singh, B; Schwartz, NB				Kurima, K; Singh, B; Schwartz, NB			Genomic organization of the mouse and human genes encoding the ATP sulfurylase/adenosine 5 '-phosphosulfate kinase isoform SK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATE-ACTIVATING ENZYMES; SITE-DIRECTED MUTAGENESIS; FATTY-ACID SYNTHASE; HUMAN UMP SYNTHASE; BRACHYMORPHIC MICE; P-LOOP; SACCHAROMYCES-CEREVISIAE; ARABIDOPSIS-THALIANA; MOLECULAR-CLONING; SPONDYLOEPIMETAPHYSEAL DYSPLASIA	Mammalian ATP sulfurylase/adenosine 5'-phosphosulfate (APS) kinase consists of kinase and sulfurylase domains, and catalyzes two sequential reactions to synthesize the universal sulfate donor, phosphoadenosine phosphosulfate (PAPS). In simpler organisms, the ATP sulfurylase and APS kinase reactions are catalyzed by separate enzymes encoded by two or three genes, suggesting that a fusion of separate genes during the course of evolution generated the bifunctional enzyme. We have characterized the genomic structure of the PAPS synthetase SK2 isoform genes for mouse (MSK2) and human (HSK2) and analyzed the possible fusion region. The MSK2 and HSK2 genes exhibit a common structure of 13 exons, including a 15-nucleotide alternatively spliced exon 8. Enzyme activities of several bacterially expressed exon assemblages showed exons 1-6 encode APS kinase, while exons 6-13 encode ATP sulfurylase. The MSK2 construct without the exon 6-encoded peptide showed no kinase or sulfurylase activity, demonstrating that exon 6 encodes sequences required for both activities. Exon 1 and its 5'-flanking sequence are highly divergent between the two species, and intron 1 of the HSK2 gene contains a region similar to the MSK2 promoter sequence, suggesting that it may be the remnant of a now-superceded regulatory region. The HSK2 promoter contains a GC-rich region, not present in the mouse promoter, and has few transcription factor binding sites in common with MSK2. These differences in the two promoter regions suggest that species-specific mechanisms regulate expression of the SK2 isoform.	Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; Univ Chicago, Dept Chem, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	Schwartz, NB (corresponding author), Univ Chicago, Dept Pediat, MC 5058,5825 S Maryland Ave, Chicago, IL 60637 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD017332] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR019622, R01AR019622] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-19622] Funding Source: Medline; NICHD NIH HHS [HD-17332] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ahmad M, 1998, AM J MED GENET, V78, P468; AMY CM, 1992, P NATL ACAD SCI USA, V89, P1105, DOI 10.1073/pnas.89.3.1105; ARZ HE, 1994, BBA-GENE STRUCT EXPR, V1218, P447, DOI 10.1016/0167-4781(94)90203-8; Beaucamp N, 1997, PROTEIN SCI, V6, P2159; BORGESWALMSLEY MI, 1995, MOL GEN GENET, V247, P423; BORK P, 1994, PROTEINS, V20, P347, DOI 10.1002/prot.340200407; CHEN ZD, 1990, P NATL ACAD SCI USA, V87, P3097, DOI 10.1073/pnas.87.8.3097; CHEREST H, 1987, MOL GEN GENET, V210, P307, DOI 10.1007/BF00325699; CRAWFORD IP, 1987, J BIOL CHEM, V262, P239; Deyrup AT, 1998, J BIOL CHEM, V273, P9450, DOI 10.1074/jbc.273.16.9450; Deyrup AT, 1999, J BIOL CHEM, V274, P10751, DOI 10.1074/jbc.274.16.10751; DUNCAN K, 1987, BIOCHEM J, V246, P375, DOI 10.1042/bj2460375; FAURE M, 1989, EUR J BIOCHEM, V179, P345, DOI 10.1111/j.1432-1033.1989.tb14560.x; FOSTER BA, 1994, J BIOL CHEM, V269, P19777; JAIN A, 1994, PLANT PHYSIOL, V105, P771, DOI 10.1104/pp.105.2.771; Jullien D, 1997, MECH DEVELOP, V68, P179, DOI 10.1016/S0925-4773(97)00136-6; KORCH C, 1991, MOL GEN GENET, V229, P96, DOI 10.1007/BF00264218; Kurima K, 1998, P NATL ACAD SCI USA, V95, P8681, DOI 10.1073/pnas.95.15.8681; LANE PW, 1968, J HERED, V65, P297; LEUSTEK T, 1994, PLANT PHYSIOL, V105, P897, DOI 10.1104/pp.105.3.897; LEYH TS, 1988, J BIOL CHEM, V263, P2409; LEYH TS, 1992, J BIOL CHEM, V267, P10405; LI H, 1995, J BIOL CHEM, V270, P29453, DOI 10.1074/jbc.270.49.29453; LIN T, 1995, SOMAT CELL MOLEC GEN, V21, P161, DOI 10.1007/BF02254768; LIN T, 1993, SOMAT CELL MOLEC GEN, V19, P193, DOI 10.1007/BF01233533; LYLE S, 1994, BIOCHEMISTRY-US, V33, P5920, DOI 10.1021/bi00185a032; LYLE S, 1995, BIOCHEMISTRY-US, V34, P940, DOI 10.1021/bi00003a028; MacRae IJ, 1998, J BIOL CHEM, V273, P28583, DOI 10.1074/jbc.273.44.28583; ROSENTHAL E, 1995, GENE, V165, P243, DOI 10.1016/0378-1119(95)00450-K; SAKATA J, 1991, J BIOL CHEM, V266, P15764; Schwartz NB, 1998, CHEM-BIOL INTERACT, V109, P143, DOI 10.1016/S0009-2797(97)00129-4; SCHWARTZ NB, 1978, BIOCHEM BIOPH RES CO, V82, P173, DOI 10.1016/0006-291X(78)90592-2; SCHWEDOCK JS, 1994, J BACTERIOL, V176, P7055, DOI 10.1128/JB.176.22.7055-7064.1994; Smith CA, 1996, BIOPHYS J, V70, P1590, DOI 10.1016/S0006-3495(96)79745-X; Suchi M, 1997, AM J HUM GENET, V60, P525; SUGAHARA K, 1982, ARCH BIOCHEM BIOPHYS, V214, P589, DOI 10.1016/0003-9861(82)90064-9; SUGAHARA K, 1979, P NATL ACAD SCI USA, V76, P6615, DOI 10.1073/pnas.76.12.6615; SUGAHARA K, 1982, ARCH BIOCHEM BIOPHYS, V214, P601; Ul Haque MF, 1998, NAT GENET, V20, P157, DOI 10.1038/2458; Venkatachalam KV, 1999, J BIOL CHEM, V274, P2601, DOI 10.1074/jbc.274.5.2601; Venkatachalam KV, 1998, J BIOL CHEM, V273, P19311, DOI 10.1074/jbc.273.30.19311; WITKOWSKI A, 1991, EUR J BIOCHEM, V198, P571, DOI 10.1111/j.1432-1033.1991.tb16052.x; ZEINER M, 1994, BIOTECHNIQUES, V17, P1051	43	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33306	33312		10.1074/jbc.274.47.33306	http://dx.doi.org/10.1074/jbc.274.47.33306			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559207	hybrid			2022-12-25	WOS:000083745200023
J	Nanduri, J; Mitra, S; Andrei, C; Liu, Y; Yu, YH; Hitomi, M; Tartakoff, AM				Nanduri, J; Mitra, S; Andrei, C; Liu, Y; Yu, YH; Hitomi, M; Tartakoff, AM			An unexpected link between the secretory path and the organization of the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; PORE COMPLEX; SCHIZOSACCHAROMYCES-POMBE; IN-VIVO; YEAST; TRANSPORT; TRANSLOCATION; IMPORT	Yeast sec mutations define the machinery of vesicular traffic. Surprisingly, many of these mutations also inhibit ribosome biogenesis by reducing transcription of rRNA and genes encoding ribosomal proteins. We observe that these mutants reversibly inhibit protein import into the nucleus, with import cargo accumulating at the nucleoplasmic face of nuclear pore complexes, as when Ran-GTP cannot bind importins. They also rapidly and reversibly relocate multiple nucleolar and nucleoplasmic proteins to the cytoplasm. The import block and relocation are antagonized by overexpression of yeast Ran, Hog1p kinase, or Ssa/Hsp70 proteins or by inhibition of protein synthesis. These nucleocytoplasmic signaling events document an extraordinary plasticity of nuclear organization.	Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Cell Biol Program, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Tartakoff, AM (corresponding author), Case Western Reserve Univ, Inst Pathol, 2085 Adelbert Rd, Cleveland, OH 44106 USA.	amt10@po.cwru.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL050160] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK027651] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-50160] Funding Source: Medline; NIDDK NIH HHS [DK-27651-15] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Becker J, 1996, MOL CELL BIOL, V16, P4378; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Bush GL, 1996, J CELL BIOL, V135, P1229, DOI 10.1083/jcb.135.5.1229; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; Chen EJ, 1998, MOL CELL BIOL, V18, P7139, DOI 10.1128/MCB.18.12.7139; CHOW TYK, 1992, J CELL SCI, V101, P709; Corbett AH, 1997, MICROBIOL MOL BIOL R, V61, P193, DOI 10.1128/.61.2.193-211.1997; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; CULBERTSON MR, 1975, GENETICS, V80, P23; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; Eggers DK, 1997, MOL BIOL CELL, V8, P1559, DOI 10.1091/mbc.8.8.1559; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; GONLICH D, 1999, IN PRESS ANN REV CEL, V15; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Her LS, 1997, SCIENCE, V276, P1845, DOI 10.1126/science.276.5320.1845; HICKE L, 1989, EMBO J, V8, P1677, DOI 10.1002/j.1460-2075.1989.tb03559.x; Ho AK, 1998, MOL BIOL CELL, V9, P355, DOI 10.1091/mbc.9.2.355; KADOWAKI T, 1993, EMBO J, V12, P2929, DOI 10.1002/j.1460-2075.1993.tb05955.x; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; Koepp DM, 1996, J CELL BIOL, V133, P1163, DOI 10.1083/jcb.133.6.1163; Lamian V, 1996, EXP CELL RES, V228, P84, DOI 10.1006/excr.1996.0302; Lashkari DA, 1997, P NATL ACAD SCI USA, V94, P13057, DOI 10.1073/pnas.94.24.13057; LegerSilvestre I, 1997, EUR J CELL BIOL, V72, P13; Li BJ, 1999, MOL CELL BIOL, V19, P5393; Li WW, 1997, MOL CELL BIOL, V17, P54, DOI 10.1128/MCB.17.1.54; LIANG S, 1993, EUR J CELL BIOL, V62, P270; Liu Y, 1999, P NATL ACAD SCI USA, V96, P6739, DOI 10.1073/pnas.96.12.6739; Liu Y, 1996, EMBO J, V15, P6750, DOI 10.1002/j.1460-2075.1996.tb01064.x; MIZUTA K, 1994, MOL CELL BIOL, V14, P2493, DOI 10.1128/MCB.14.4.2493; MORELAND RB, 1987, MOL CELL BIOL, V7, P4048, DOI 10.1128/MCB.7.11.4048; NELSON MK, 1993, GENETICS, V134, P159; Nierras CR, 1999, J BIOL CHEM, V274, P13235, DOI 10.1074/jbc.274.19.13235; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; Reiser V, 1999, MOL BIOL CELL, V10, P1147, DOI 10.1091/mbc.10.4.1147; Ren MD, 1996, P NATL ACAD SCI USA, V93, P5151, DOI 10.1073/pnas.93.10.5151; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; Schneiter R, 1996, MOL CELL BIOL, V16, P7161; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; SIKORSKI RS, 1989, GENETICS, V122, P19; Siniossoglou S, 1996, CELL, V84, P265, DOI 10.1016/S0092-8674(00)80981-2; SMITH BJ, 1991, P NATL ACAD SCI USA, V88, P11091, DOI 10.1073/pnas.88.24.11091; SORGER PK, 1990, CELL, V62, P793, DOI 10.1016/0092-8674(90)90123-V; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Turi TG, 1996, J BIOL CHEM, V271, P9166, DOI 10.1074/jbc.271.15.9166; Vithalani KK, 1998, MOL BIOL CELL, V9, P3095, DOI 10.1091/mbc.9.11.3095; WARNER J, 1996, MICROB REV, V53, P256; WENTE SR, 1992, J CELL BIOL, V119, P705, DOI 10.1083/jcb.119.4.705; WOOLFORD JL, 1991, ADV GENET, V29, P63, DOI 10.1016/S0065-2660(08)60107-8; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640	58	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33785	33789		10.1074/jbc.274.47.33785	http://dx.doi.org/10.1074/jbc.274.47.33785			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559272	hybrid			2022-12-25	WOS:000083745200088
J	Saliba, KJ; Kirk, K				Saliba, KJ; Kirk, K			pH regulation in the intracellular malaria parasite, Plasmodium falciparum - H+ extrusion via a V-type H+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROQUINE RESISTANCE; PLASMA-MEMBRANE; ERYTHROCYTIC STAGES; LACTATE PRODUCTION; NA+/H+ EXCHANGERS; STREPTOLYSIN-O; PROTEIN; TRANSPORT; CELLS; IDENTIFICATION	The mechanism by which the intra-erythrocytic form of the human malaria parasite, Plasmodium falciparum, extrudes H+ ions and thereby regulates its cytosolic pH (pH(i)), was investigated using saponin-permeabilized parasitized erythrocytes. The parasite was able both to maintain its resting pH(i) and to recover from an imposed intracellular acidification in the absence of extracellular Na+, thus ruling out the involvement of a Na+/H+ exchanger in both processes. Both phenomena were ATP-dependent. Amiloride and the related compound ethylisopropylamiloride caused a substantial reduction in the resting pH(i) of the parasite, whereas EMD 96785, a potent and allegedly selective inhibitor of Na+/H+ exchange, had relatively little effect. The resting pH(i) of the parasite was also reduced by the sulfhydryl reagent N-ethylmaleimide, by the carboxyl group blocker N,N'-dicyclohexylcarbodiimide, and by bafilomycin A(1), a potent inhibitor of V-type H+-ATPases. Bafilomycin A(1) blocked pH(i) recovery in parasites subjected to an intracellular acidification and reduced the rate of acidification of a weakly buffered solution by parasites under resting conditions. The data are consistent with the hypothesis that the malaria parasite, like other parasitic protozoa, has in its plasma membrane a V-type H+-ATPase, which serves as the major route for the efflux of H+ ions.	Australian Natl Univ, Fac Sci, Div Biochem & Mol Biol, Canberra, ACT 0200, Australia	Australian National University	Kirk, K (corresponding author), Australian Natl Univ, Fac Sci, Div Biochem & Mol Biol, Canberra, ACT 0200, Australia.	kiaran.kirb@anu.edu.au	Saliba, Kevin J/C-9166-2009; Kirk, Kiaran/C-8299-2009	Saliba, Kevin J/0000-0003-3345-8440; Kirk, Kiaran/0000-0002-5613-2622				Ansorge I, 1997, MOL BIOCHEM PARASIT, V84, P259, DOI 10.1016/S0166-6851(96)02806-X; Ansorge I, 1996, BIOCHEM J, V315, P307, DOI 10.1042/bj3150307; BAKKERGRUNWALD T, 1992, J EXP BIOL, V172, P311; Baumgarth M, 1997, J MED CHEM, V40, P2017, DOI 10.1021/jm960768n; Benchimol M, 1998, BIOCHEM J, V332, P695, DOI 10.1042/bj3320695; BIGGS BA, 1991, P NATL ACAD SCI USA, V88, P9171, DOI 10.1073/pnas.88.20.9171; BOSIA A, 1993, J CELL PHYSIOL, V154, P527, DOI 10.1002/jcp.1041540311; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BRAY PG, 1992, BIOCHEM PHARMACOL, V43, P1219, DOI 10.1016/0006-2952(92)90495-5; Bray PG, 1998, MOL PHARMACOL, V54, P170, DOI 10.1124/mol.54.1.170; Bray PG, 1999, J CELL BIOL, V145, P363, DOI 10.1083/jcb.145.2.363; Brown A., 1982, ATP ATPASE DETERMINA, P223; Cranmer SL, 1997, T ROY SOC TROP MED H, V91, P363, DOI 10.1016/S0035-9203(97)90110-3; Desai SA, 1997, P NATL ACAD SCI USA, V94, P2045, DOI 10.1073/pnas.94.5.2045; DESAI SA, 1993, NATURE, V362, P643, DOI 10.1038/362643a0; Fischer H, 1999, J MEMBRANE BIOL, V168, P39, DOI 10.1007/s002329900496; Garcia-Canero R, 1998, HEPATOL RES, V10, P27, DOI 10.1016/S1386-6346(97)00100-9; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; KARCZ SR, 1994, MOL BIOCHEM PARASIT, V65, P123, DOI 10.1016/0166-6851(94)90121-X; KARCZ SR, 1993, MOL BIOCHEM PARASIT, V58, P333, DOI 10.1016/0166-6851(93)90056-4; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; MIKKELSEN RB, 1982, J CELL BIOL, V93, P685, DOI 10.1083/jcb.93.3.685; MIKKELSEN RB, 1986, MOL BIOCHEM PARASIT, V21, P83, DOI 10.1016/0166-6851(86)90082-4; MONK BC, 1994, CRIT REV MICROBIOL, V20, P209, DOI 10.3109/10408419409114555; Moreno SNJ, 1998, BIOCHEM J, V330, P853; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; PFALLER MA, 1982, EXP PARASITOL, V54, P391, DOI 10.1016/0014-4894(82)90048-0; Rowe JA, 1998, MOL BIOCHEM PARASIT, V92, P177, DOI 10.1016/S0166-6851(97)00237-5; Saliba KJ, 1998, J BIOL CHEM, V273, P10190, DOI 10.1074/jbc.273.17.10190; Sanchez CP, 1997, J BIOL CHEM, V272, P2652, DOI 10.1074/jbc.272.5.2652; Sanchez CP, 1998, CELL, V92, P601, DOI 10.1016/S0092-8674(00)81127-7; Sherman Irwin W., 1998, P135; Su XZ, 1997, CELL, V91, P593, DOI 10.1016/S0092-8674(00)80447-X; THOMAS RC, 1984, J PHYSIOL-LONDON, V354, pP3; VANDERJAGT DL, 1990, MOL BIOCHEM PARASIT, V42, P277, DOI 10.1016/0166-6851(90)90171-H; VANKUPPEVELD FJM, 1992, APPL ENVIRON MICROB, V58, P2606, DOI 10.1128/AEM.58.8.2606-2615.1992; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; Wellems TE, 1998, CELL, V94, P285, DOI 10.1016/S0092-8674(00)81471-3; WHITE NJ, 1998, MALARIA PARASITE BIO, P371; WIECZOREK H, 1991, J BIOL CHEM, V266, P15340; Wunsch S, 1998, J CELL BIOL, V140, P335, DOI 10.1083/jcb.140.2.335; Wunsch S, 1997, Behring Inst Mitt, P44; YUN CHC, 1995, AM J PHYSIOL-GASTR L, V269, pG1, DOI 10.1152/ajpgi.1995.269.1.G1	43	146	150	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33213	33219		10.1074/jbc.274.47.33213	http://dx.doi.org/10.1074/jbc.274.47.33213			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559194	hybrid			2022-12-25	WOS:000083745200010
J	Beitz, LO; Fruman, DA; Kurosaki, T; Cantley, LC; Scharenberg, AM				Beitz, LO; Fruman, DA; Kurosaki, T; Cantley, LC; Scharenberg, AM			SYK is upstream of phosphoinositide 3-kinase in B cell receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; C-CBL; REGULATORY SUBUNIT; CA2+ MOBILIZATION; PI 3-KINASE; P85 SUBUNIT; PHOSPHORYLATION; ASSOCIATION; ACTIVATION	We have recently demonstrated that the D3-phosphoinositide phosphatidylinositol 3,4,5-trisphosphate (PtdIns-3,4,5-P-3) is critical for producing sustained calcium signals through its role in promoting the function of TEC family tyrosine kinases such as Bruton's tyrosine kinase. Although PtdIns-3,4,5-P-3 can potentially be synthesized by any of several types of phosphoinositide 3-kinases (PI3Ks), B cell receptor (BCR)-induced PtdIns-3,4,5-P-3 production is thought to occur primarily through the activation of the class Ia (p85/p110) PI3Ks. This process has been proposed to be mediated by an interaction between the Src family kinase LYN and the p85 subunit of FISH and/or through p85 membrane recruitment mediated by CBL and/or CD19. However, calcium signaling and other PI3K-dependent signals are relatively preserved in a LYN kinase-deficient B lymphocyte cell line, suggesting that an alternative pathway for PI3K, activation exists. As SYK/ZAP70 kinases are upstream from many BCR-initiated signaling events, we directly analyzed SYM-dependent accumulation of both PtdIns-3,4,5-P-3 and PtdIns-3,4-P-2 in B cell receptor signaling using both dominant negative and genetic knockout approaches. Both methods indicate that SYK is upstream of, and necessary for, a significant portion of BCR-induced PtdIns-3,4,5-P-3 production. Whereas CD19 does not appear 60 be involved in this SYM-dependent pathway, the SYK substrate CEL is likely involved as the dominant negative SYK markedly attenuates CBL tyrosine phosphorylation and completely blocks the BCR-dependent association of CBL with p85 PI3K.	Harvard Univ, Sch Med, Lab Allergy & Immunol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02215 USA; Kansai Med Univ, Dept Mol Genet, Moriguchi, Osaka 570, Japan	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Kansai Medical University	Scharenberg, AM (corresponding author), Harvard Univ, Sch Med, Lab Allergy & Immunol, Boston, MA 02215 USA.	ascharen@caregroup.harvard.edu	Kurosaki, Tomohiro/D-1306-2009; Cantley, Lewis C/D-1800-2014	Kurosaki, Tomohiro/0000-0002-6352-304X; Cantley, Lewis C/0000-0002-1298-7653	NCI NIH HHS [CA72882] Funding Source: Medline; NICHD NIH HHS [HD34717] Funding Source: Medline; NIGMS NIH HHS [R01 GM041890, GM41890] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R03HD034717] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [K08CA072882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041890, R01GM041890] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Banfic H, 1998, J BIOL CHEM, V273, P13, DOI 10.1074/jbc.273.1.13; Banfic H, 1998, J BIOL CHEM, V273, P11630, DOI 10.1074/jbc.273.19.11630; Beckwith M, 1996, BLOOD, V88, P3502, DOI 10.1182/blood.V88.9.3502.bloodjournal8893502; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; Brown RA, 1997, BIOCHEM BIOPH RES CO, V233, P537, DOI 10.1006/bbrc.1997.6495; Buhl AM, 1999, J IMMUNOL, V162, P4438; Buhl AM, 1997, J EXP MED, V186, P1897, DOI 10.1084/jem.186.11.1897; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Carter RH, 1997, J IMMUNOL, V158, P3062; CHALUPNY NJ, 1995, EUR J IMMUNOL, V25, P2978, DOI 10.1002/eji.1830251040; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Deckert M, 1998, J BIOL CHEM, V273, P8867, DOI 10.1074/jbc.273.15.8867; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Hartley D, 1996, J BIOL CHEM, V271, P21939, DOI 10.1074/jbc.271.36.21939; HOLT KH, 1994, MOL CELL BIOL, V14, P42, DOI 10.1128/MCB.14.1.42; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; JACKSON SP, 1995, EMBO J, V14, P4490, DOI 10.1002/j.1460-2075.1995.tb00128.x; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; KAVANAUGH WM, 1992, MOL CELL BIOL, V12, P3415, DOI 10.1128/MCB.12.8.3415; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; Kurosaki T, 1997, J BIOL CHEM, V272, P15595, DOI 10.1074/jbc.272.25.15595; Li HL, 1999, P NATL ACAD SCI USA, V96, P6890, DOI 10.1073/pnas.96.12.6890; Linassier C, 1997, BIOCHEM J, V321, P849, DOI 10.1042/bj3210849; Macdougall LK, 1995, CURR BIOL, V5, P1404, DOI 10.1016/S0960-9822(95)00278-8; MATZARIS M, 1994, J BIOL CHEM, V269, P3397; Molz L, 1996, J BIOL CHEM, V271, P13892, DOI 10.1074/jbc.271.23.13892; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Ota Y, 1996, J EXP MED, V184, P1713, DOI 10.1084/jem.184.5.1713; PANAYOTOU G, 1992, EMBO J, V11, P4261, DOI 10.1002/j.1460-2075.1992.tb05524.x; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROIFMAN CM, 1993, BIOCHEM BIOPH RES CO, V194, P222, DOI 10.1006/bbrc.1993.1807; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Shepherd PR, 1996, TRENDS CELL BIOL, V6, P92, DOI 10.1016/0962-8924(96)80998-6; STACK JH, 1994, J BIOL CHEM, V269, P31552; STEPHENS L, 1994, CURR BIOL, V4, P203, DOI 10.1016/S0960-9822(00)00049-X; Stephens L, 1996, PHILOS T R SOC B, V351, P211, DOI 10.1098/rstb.1996.0018; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Tang XW, 1997, J BIOL CHEM, V272, P14193, DOI 10.1074/jbc.272.22.14193; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; Ueno H, 1998, BLOOD, V91, P46, DOI 10.1182/blood.V91.1.46.46_46_53; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VANNOESEL CJM, 1993, INT IMMUNOL, V5, P699; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304; YAMAMOTO K, 1990, J BIOL CHEM, V265, P22086; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379; Zhang J, 1998, J BIOL CHEM, V273, P14081, DOI 10.1074/jbc.273.23.14081	59	148	148	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32662	32666		10.1074/jbc.274.46.32662	http://dx.doi.org/10.1074/jbc.274.46.32662			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551821	hybrid			2022-12-25	WOS:000083623000021
J	Shan, XY; Wang, LQ; Hoffmaster, R; Kruger, WD				Shan, XY; Wang, LQ; Hoffmaster, R; Kruger, WD			Functional characterization of human methylenetetrahydrofolate reductase in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETIC RISK FACTOR; COMMON MUTATION; MILD HYPERHOMOCYSTEINEMIA; VASCULAR-DISEASE; YEAST; ADENOSYLMETHIONINE; IDENTIFICATION; DEFICIENCY; INHIBITION; MTHFR	Human methylenetetrahydrofolate reductase (MTHFR, EC 1.5.1.20) catalyzes the reduction of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate. 5-Methyltetrahydrofolate is a major methyl donor in the remethylation of homocysteine to methionine, Impaired MTHFR can cause high levels of homocysteine in plasma, which is an independent risk factor for vascular disease and neural tube defects. We have functionally characterized wildtype and several mutant alleles of human MTHFR in yeast, Saccharomyces cerevisiae. We have shown that yeast MET11 is a functional homologue of human MTHFR. Expression of the human MTHFR cDNA in a yeast strain deleted for MET11 can restore the strain's MTHFR activity in vitro and complement its methionine auxotrophic phenotype in vivo, To understand the domain structure of human MTHFR, we have truncated the C terminus (50%) of the protein and demonstrated that expressing an N-terminal human MTHFR in met11(-) yeast cells rescues the growth phenotype, indicating that this region contains the catalytic domain of the enzyme. However, the truncation leads to the reduced protein levels, suggesting that the C terminus may be important for protein stabilization, We have also functionally characterized four missense mutations identified from patients with severe MTHFB deficiency and two common missense polymorphisms found at high frequency in the general population, Three of the four missense mutations are unable to complement the auxotrophic phenotype of met11(-) yeast cells and show less than 7% enzyme activity of the wild type in vitro, Both of the two common polymorphisms are able to complement the growth phenotype, although one exhibited thermolabile enzyme activity in vitro. These results shall be useful for the functional characterization of MTHFR mutations and analysis structure/function relationship of the enzyme.	Fox Chase Canc Ctr, Div Populat Sci, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Kruger, WD (corresponding author), Fox Chase Canc Ctr, Div Populat Sci, 7701 Burholme Ave, Philadelphia, PA 19111 USA.		kruger, warren/A-6407-2008; Kruger, Warren/Y-2541-2018	kruger, warren/0000-0002-4990-3695; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL057299, R01HL057299] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57299] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMBERG DC, 1995, YEAST, V11, P1275, DOI 10.1002/yea.320111307; Botstein D, 1997, SCIENCE, V277, P1259, DOI 10.1126/science.277.5330.1259; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Christensen B, 1997, ARTERIOSCL THROM VAS, V17, P569, DOI 10.1161/01.ATV.17.3.569; ENGBERSEN AMT, 1995, AM J HUM GENET, V56, P142; Forbes JR, 1998, AM J HUM GENET, V63, P1663, DOI 10.1086/302163; FRIDOVICHKEIL JL, 1995, AM J HUM GENET, V56, P640; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; GOYETTE P, 1995, AM J HUM GENET, V56, P1052; Goyette P, 1996, AM J HUM GENET, V59, P1268; GOYETTE P, 1994, NAT GENET, V7, P195, DOI 10.1038/ng0694-195; Guenther BD, 1999, NAT STRUCT BIOL, V6, P359, DOI 10.1038/7594; ISHIOKA C, 1995, ONCOGENE, V10, P1485; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JENCKS DA, 1987, J BIOL CHEM, V262, P2485; Kim CE, 1997, HUM MOL GENET, V6, P2213, DOI 10.1093/hmg/6.13.2213; Kluijtmans LAJ, 1997, CIRCULATION, V96, P2573, DOI 10.1161/01.CIR.96.8.2573; Kluijtmans LAJ, 1996, AM J HUM GENET, V58, P35; Kokkola T, 1998, BIOCHEM BIOPH RES CO, V249, P531, DOI 10.1006/bbrc.1998.9182; KUTZBACH C, 1971, BIOCHIM BIOPHYS ACTA, V250, P459, DOI 10.1016/0005-2744(71)90247-6; MATTHEWS RG, 1984, J BIOL CHEM, V259, P1647; MILLS JL, 1996, J NUTR, V126, P756; ROSENBLATT DS, 1977, PEDIATR RES, V11, P1137, DOI 10.1203/00006450-197711000-00004; ROSENBLATT DS, 1995, INHERITED DISORDERS, P3111; Rozen R, 1997, THROMB HAEMOSTASIS, V78, P523; Sambrook J., 2002, MOL CLONING LAB MANU; SCHILD D, 1990, P NATL ACAD SCI USA, V87, P2916, DOI 10.1073/pnas.87.8.2916; SHAN XY, 1994, J CELL BIOL, V126, P853, DOI 10.1083/jcb.126.4.853; Shan XY, 1998, NAT GENET, V19, P91, DOI 10.1038/ng0598-91; Sheppard CA, 1999, J BACTERIOL, V181, P718, DOI 10.1128/JB.181.3.718-725.1999; Sherman F., 1986, METHODS YEAST GENETI; van der Put NMJ, 1998, AM J HUM GENET, V62, P1044, DOI 10.1086/301825; VANDERPUT NM, 1997, Q J MED, V90, P11; Xue ZH, 1996, GENETICS, V144, P979	34	37	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32613	32618		10.1074/jbc.274.46.32613	http://dx.doi.org/10.1074/jbc.274.46.32613			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551815	hybrid			2022-12-25	WOS:000083623000015
J	Garrido, C; Bruey, JM; Fromentin, A; Hammann, A; Arrigo, AP; Solary, E				Garrido, C; Bruey, JM; Fromentin, A; Hammann, A; Arrigo, AP; Solary, E			HSP27 inhibits cytochrome c-dependent activation of procaspase-9	FASEB JOURNAL			English	Article						apoptosis; cell death; etoposide; drug resistance; leukemia	HEAT-SHOCK-PROTEIN; INDUCED CELL-DEATH; ETOPOSIDE-INDUCED APOPTOSIS; TNF-ALPHA; DOXORUBICIN RESISTANCE; BREAST-CANCER; BCL-2; EXPRESSION; RELEASE; DNA	We have previously shown that the small heat shock protein HSP27 inhibited apoptotic pathways triggered by a variety of stimuli in mammalian cells. The present study demonstrates that HSP27 overexpression decreases U937 human leukemic cell sensitivity to etoposide-induced cytotoxicity by preventing apoptosis. As observed for Bcl-2, HSP27 overexpression delays poly(ADP-ribose)polymerase cleavage and procaspase-3 activation. In contrast with Bcl-2, HSP27 overexpression does not prevent etoposide-induced cytochrome c release from the mitochondria. In a cell-free system, addition of cytochrome c and dATP to cytosolic extracts from untreated cells induces the proteolytic activation of procaspase-3 in both control and bcl-2-transfected U937 cells but fails to activate procaspase-3 in HSP27-overexpressing cells. Immunodepletion of HSP27 from cytosolic extracts increases cytochrome c/dATP-mediated activation of procaspase-3. Overexpression of HSP27 also prevents procaspase-9 activation. In the cell-free system, immunodepletion of HSP27 increases LEDH-AFC peptide cleavage activity triggered by cytochrome c/dATP treatment. We conclude that HSP27 inhibits etoposide-induced apoptosis by preventing cytochrome c and dATP-triggered activity of caspase-9, downstream of cytochrome c release.-Garrido, C., Bruey, J.-M., Fromentin, A., Hammann, A,, Arrigo, A. P., Solary, E. HSP27 inhibits cytochrome c-dependent activation of procaspase-9.	Fac Med & Pharm Dijon, INSERM U517, Grp Biol & Therapie Canc JE 515, F-21033 Dijon, France; Univ Lyon 1, Stress Lab, CNRS UMR 5534, F-69365 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Garrido, C (corresponding author), Fac Med & Pharm Dijon, INSERM U517, Grp Biol & Therapie Canc JE 515, 7 Blvd Jeanne DArc, F-21033 Dijon, France.	cgarrido@u-bourgogne.fr	Garrido, carmen/G-1633-2018; Garrido, Carolina/GWM-5557-2022	Garrido, carmen/0000-0003-1368-1493; Solary, Eric/0000-0002-8629-1341				ARRIGO AP, 1994, HEAT SHOCK PROTEINS, P335; CHAMPLIN R, 1987, BLOOD, V69, P1551; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Droin N, 1998, ONCOGENE, V16, P2885, DOI 10.1038/sj.onc.1201821; Dubrez L, 1998, BLOOD, V91, P2415, DOI 10.1182/blood.V91.7.2415.2415_2415_2422; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; DUBREZ L, 1995, LEUKEMIA, V9, P1013; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Ellerby HM, 1997, J NEUROSCI, V17, P6165; Garrido C, 1996, EUR J BIOCHEM, V237, P653, DOI 10.1111/j.1432-1033.1996.0653p.x; Garrido C, 1998, CANCER RES, V58, P5495; Garrido C, 1997, CANCER RES, V57, P2661; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; HARRISON JD, 1991, BRIT J SURG, V78, P334, DOI 10.1002/bjs.1800780321; HOUT J, 1992, INT J ONCOL, V1, P31; HOUT J, 1996, CANCER RES, V56, P273; HUOT J, 1991, CANCER RES, V51, P5245; KAMESAKI S, 1993, CANCER RES, V53, P4251; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kim CN, 1997, CANCER RES, V57, P3115; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOVE S, 1994, BRIT J CANCER, V69, P743, DOI 10.1038/bjc.1994.140; Marchetti P, 1996, CANCER RES, V56, P2033; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MEHLEN P, 1995, J IMMUNOL, V154, P363; MEHLEN P, 1993, EUR J BIOCHEM, V215, P277, DOI 10.1111/j.1432-1033.1993.tb18032.x; Mehlen P, 1997, BIOCHEM BIOPH RES CO, V241, P187, DOI 10.1006/bbrc.1997.7635; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MEHLEN P, 1995, BIOCHEM J, V312, P367, DOI 10.1042/bj3120367; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OESTERREICH S, 1993, CANCER RES, V53, P4443; PARSELL DA, 1990, BIOL HEAT SHOCK PROT, P457; Preville X, 1998, J CELL BIOCHEM, V69, P436, DOI 10.1002/(SICI)1097-4644(19980615)69:4<436::AID-JCB5>3.0.CO;2-O; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; SOLARY E, 1991, LEUKEMIA, V5, P592; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; THOR A, 1991, J NATL CANCER I, V83, P170, DOI 10.1093/jnci/83.3.170; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060	51	427	449	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1999	13	14					2061	2070		10.1096/fasebj.13.14.2061	http://dx.doi.org/10.1096/fasebj.13.14.2061			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544189				2022-12-25	WOS:000083660700018
J	Ahn, J; Murphy, M; Kratowicz, S; Wang, A; Levine, AJ; George, DL				Ahn, J; Murphy, M; Kratowicz, S; Wang, A; Levine, AJ; George, DL			Down-regulation of the stathmin/Op18 and FKBP25 genes following p53 induction	ONCOGENE			English	Article						p53; repression; stathmin; FKBP25	TUMOR SUPPRESSION; EXPRESSION; PROTEIN; MDM2; APOPTOSIS; CELLS; PHOSPHORYLATION; IDENTIFICATION; PHOSPHOPROTEIN; DYNAMICS	The p53 tumor suppressor protein can function as an activator and a repressor of gene transcription. Currently, the mechanism of transcriptional repression by p53 is poorly understood. To aid in clarifying this mechanism, we carried out studies designed to identify specific target genes that are down-regulated following p53 induction. Among the negative p53-response genes revealed by our screening protocols are those encoding stathmin (Op18), a tubulin-associated protein implicated in cell signaling pathways, and an FK506/rapamycin-binding protein, FKBP25. Stathmin and FKBP25 exhibit decreased expression in both human and murine immortalized and transformed cell lines following induction of wild-type p53 by several stimuli that result in DNA damage. Candidate p53-repressed genes such as these provide the necessary markers to delineate the mechanism and biological consequences of transcriptional repression mediated by p53.	Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Fox Chase Canc Ctr, Dept Pharmacol, Philadelphia, PA 19111 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	University of Pennsylvania; Fox Chase Cancer Center; Princeton University	George, DL (corresponding author), Univ Penn, Sch Med, Dept Genet, 713 Stellar Chance Bldg,422 Curie Blvd, Philadelphia, PA 19104 USA.			Murphy, Maureen/0000-0001-7644-7296	NATIONAL CANCER INSTITUTE [P01CA041086] Funding Source: NIH RePORTER; NCI NIH HHS [CA466741, CA41086] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; Bieche I, 1998, BRIT J CANCER, V78, P701, DOI 10.1038/bjc.1998.565; BRATTSAND G, 1993, LEUKEMIA, V7, P569; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gopalkrishnan RV, 1998, J BIOL CHEM, V273, P10972, DOI 10.1074/jbc.273.18.10972; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HANASH SM, 1988, J BIOL CHEM, V263, P12813; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Jourdain L, 1997, BIOCHEMISTRY-US, V36, P10817, DOI 10.1021/bi971491b; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Landers JE, 1997, CANCER RES, V57, P3562; Leach SD, 1998, CANCER RES, V58, P3231; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Olmsted JB, 1991, CURR OPIN CELL BIOL, V3, P52, DOI 10.1016/0955-0674(91)90165-U; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; Utrera R, 1998, EMBO J, V17, P5015, DOI 10.1093/emboj/17.17.5015; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang CC, 1998, ONCOGENE, V16, P1617, DOI 10.1038/sj.onc.1201658	34	108	109	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 21	1999	18	43					5954	5958		10.1038/sj.onc.1202986	http://dx.doi.org/10.1038/sj.onc.1202986			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557083				2022-12-25	WOS:000083270700013
J	Kim, AL; Raffo, AJ; Brandt-Rauf, PW; Pincus, MR; Monaco, R; Abarzua, P; Fine, RL				Kim, AL; Raffo, AJ; Brandt-Rauf, PW; Pincus, MR; Monaco, R; Abarzua, P; Fine, RL			Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING FUNCTION; AMINO-ACID-RESIDUES; GROWTH SUPPRESSION; BCL-2 FAMILY; BAX GENE; ACTIVATION; MUTATIONS; DOMAIN; PROTEIN; DEATH	A p53-derived C-terminal peptide induced rapid apoptosis in breast cancer cell lines carrying endogenous p53 mutations or overexpressed wild-type (wt) p53 but was not toxic to nonmalignant human cell lines containing wt p53, Apoptosis occurred through a Fas/APO-1 signaling pathway involving increased extracellular levels of Fas/FasL in the absence of protein synthesis, as well as activation of a Fas/APO-1-specific protease, FLICE, The peptide activity was p53-dependent, and it had no effect in three tumor cell lines with null p53. Furthermore, the C-terminal peptide bound to p53 protein in cell extracts. Thus, p53-dependent, Fas/APO-1 mediated apoptosis can be induced in breast cancer cells with mutant p53 similar to the recently described Fas/APO-1 induced apoptosis by wt p53. However, mutant p53 without p53 peptide does not induce a Fas/APO-1 activation or apoptosis, Docking of the computed low energy conformations for the C-terminal peptide with those for a recently defined proline-rich regulatory region from the N-terminal domain of p53 suggests a unique low energy complex between the two peptide domains. The selective and rapid induction of apoptosis in cancer cells carrying p53 abnormalities may lead to a novel therapeutic modality.	Columbia Univ Coll Phys & Surg, Expt Therapeut Program, Div Med Oncol, New York, NY 10032 USA; Vet Adm Med Ctr, Dept Pathol & Lab Med, Brooklyn, NY 11209 USA; SUNY Hlth Sci Ctr, Brooklyn, NY 11203 USA; Columbia Univ, Sch Publ Hlth, New York, NY 10032 USA; Hoffmann La Roche Inc, Nutley, NJ 07110 USA	Columbia University; US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Columbia University; Roche Holding	Fine, RL (corresponding author), 650 W 168th St, New York, NY 10032 USA.				NATIONAL CANCER INSTITUTE [P30CA013696, R01CA042500] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA13696-26, R01 CA 42500] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABARZUA P, 1996, ONCOGENE, V13, P247; Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BRUGIDOU J, 1995, BIOCHEM BIOPH RES CO, V214, P685, DOI 10.1006/bbrc.1995.2340; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Eischen C M, 1997, Adv Pharmacol, V41, P107, DOI 10.1016/S1054-3589(08)61056-X; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; Gorman AM, 1997, CYTOMETRY, V29, P97; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; INCUS MR, 1976, P NATL ACAD SCI USA, V73, P4261; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Muller-Tiemann BF, 1998, P NATL ACAD SCI USA, V95, P6079, DOI 10.1073/pnas.95.11.6079; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NEMETHY G, 1992, J PHYS CHEM-US, V96, P6472, DOI 10.1021/j100194a068; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Ouyang H, 1998, CLIN CANCER RES, V4, P1071; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PINCUS MR, 1988, INT J QUANTUM CHEM Q, V15, P209; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Selivanova G, 1999, MOL CELL BIOL, V19, P3395; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; SHAH D, 1989, INT J PEPT PROT RES, V34, P325; SOUSSI T, 1990, ONCOGENE, V5, P945; Stefanis L, 1996, J BIOL CHEM, V271, P30663, DOI 10.1074/jbc.271.48.30663; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; VASQUEZ M, 1983, MACROMOLECULES, V16, P1043, DOI 10.1021/ma00241a004; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZIMMERMAN SS, 1977, MACROMOLECULES, V10, P1, DOI 10.1021/ma60055a001	47	106	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34924	34931		10.1074/jbc.274.49.34924	http://dx.doi.org/10.1074/jbc.274.49.34924			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574967	hybrid			2022-12-25	WOS:000083979600061
J	Miller, KD; Guyon, V; Evans, JNS; Shuttleworth, WA; Taylor, LP				Miller, KD; Guyon, V; Evans, JNS; Shuttleworth, WA; Taylor, LP			Purification, cloning, and heterologous expression of a catalytically efficient flavonol 3-O-galactosyltransferase expressed in the male gametophyte of Petunia hybrida	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHALCONE SYNTHASE; UDP-GLUCOSE; POLLEN GERMINATION; YOUNG LEAVES; VIGNA-MUNGO; ZEA-MAYS; GENE; MAIZE; GLUCOSYLTRANSFERASE; SEQUENCE	Flavonols are plant-specific molecules that are required for pollen germination in maize and petunia. They exist in planta as both the aglycone and glycosyl conjugates. We identified a flavonol 3-O-galactosyltransferase (F3GalTase) that is expressed exclusively in the male gametophyte and controls the formation of a pollen-specific class of glycosylated flavonols, Thus an essential step to understanding flavonol-induced germination is the characterization of F3GalTase, Amino acid sequences of three peptide fragments of F3GalTase purified from petunia pollen were used to isolate a full-length cDNA clone. RNA gel blot analysis and enzyme assays confirmed that F3GalTase expression is restricted to pollen. Heterologous expression of the F3GalTase cDNA in Escherichia coli yielded active recombinant enzyme (rF3GalTase) which had the identical substrate specificity as the native enzyme. Unlike the relatively nonspecific substrate usage of flavonoid glycosyltransferases from sporophytic tissues, F3GalTase uses only UDP-galactose and flavonols to catalyze the formation of flavonol 3-O-galactosides. Kinetic analysis showed that the k(cat)/K-m values of rF3GalTase, using kaempferol and quercetin as substrates, approaches that of a catalytically perfect enzyme. rF3GalTase catalyzes the reverse reaction, generation of flavonols from UDP and flavonol 3-O-galactosides, almost as efficiently as the forward reaction. The biochemical characteristics of F3GalTase are discussed in the context of a role in flavonol-induced pollen germination.	Washington State Univ, Program Plant Physiol, Pullman, WA 99164 USA; Washington State Univ, Dept Biochem & Biophys, Pullman, WA 99164 USA; Washington State Univ, Dept Genet & Cell Biol, Pullman, WA 99164 USA	Washington State University; Washington State University; Washington State University	Taylor, LP (corresponding author), Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA.	ltaylor@wsu.edu						Bandurski RS, 1995, PLANT HORMONES, P39, DOI [10.1007/978-94-011-0473-9_3, DOI 10.1007/978-94-011-0473-9_3]; BURN J, 1987, GENE DEV, V1, P456, DOI 10.1101/gad.1.5.456; CHENG GW, 1994, PHYTOCHEMISTRY, V35, P1435, DOI 10.1016/S0031-9422(00)86870-3; DOONER HK, 1977, BIOCHEM GENET, V15, P509, DOI 10.1007/BF00520194; FELDWISCH J, 1994, BIOCHEM J, V302, P15, DOI 10.1042/bj3020015; Ford CM, 1998, J BIOL CHEM, V273, P9224, DOI 10.1074/jbc.273.15.9224; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FURTEK D, 1988, PLANT MOL BIOL, V11, P473, DOI 10.1007/BF00039028; GUSSIN AES, 1969, PLANT PHYSIOL, V44, P1163, DOI 10.1104/pp.44.8.1163; Harborne J. B., 1980, Encyclopedia of Plant Physiology. New Series. Volume 8. Secondary plant products [Bell, A.E.; Charlwood, B.V. (Editors)]., P329; Harborne J. B., 1988, FLAVONOIDS ADV RES 1, P303; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; Heller W., 1993, ADV RES 1986, P499; HOSEL W, 1982, TRENDS BIOCHEM SCI, V7, P219, DOI 10.1016/0968-0004(82)90095-0; Hosel W., 1981, The biochemistry of plants. A comprehensive treatise. Volume 7. Secondary plant products., P725; HUGHES J, 1994, DNA SEQUENCE, V5, P41, DOI 10.3109/10425179409039703; HUNDLE BS, 1992, P NATL ACAD SCI USA, V89, P9321, DOI 10.1073/pnas.89.19.9321; ISHIKURA N, 1994, PHYTOCHEMISTRY, V36, P1139, DOI 10.1016/S0031-9422(00)89627-2; ISHIKURA N, 1993, PLANT CELL PHYSIOL, V34, P329; ISHIKURA N, 1993, Z NATURFORSCH C, V48, P563; KALINOWSKA M, 1978, PHYTOCHEMISTRY, V17, P1533, DOI 10.1016/S0031-9422(00)94637-5; KERNOHAN JC, 1964, BIOCHIM BIOPHYS ACTA, V81, P346, DOI 10.1016/0926-6569(64)90050-1; LARSON RL, 1977, BIOCHEM GENET, V15, P153, DOI 10.1007/BF00484558; LI JY, 1993, PLANT CELL, V5, P171, DOI 10.1105/tpc.5.2.171; Markham KR, 1996, PHYTOCHEMISTRY, V43, P763, DOI 10.1016/0031-9422(96)00286-5; MARRS KA, 1995, NATURE, V375, P397, DOI 10.1038/375397a0; Mato M, 1998, PLANT CELL PHYSIOL, V39, P1145, DOI 10.1093/oxfordjournals.pcp.a029315; MO YY, 1992, P NATL ACAD SCI USA, V89, P7213, DOI 10.1073/pnas.89.15.7213; NAPOLI C, 1990, PLANT CELL, V2, P279, DOI 10.1105/tpc.2.4.279; POLLAK PE, 1993, PLANT PHYSIOL, V102, P925, DOI 10.1104/pp.102.3.925; RALSTON EJ, 1988, GENETICS, V119, P185; SCHULTE S, 1993, P NATL ACAD SCI USA, V90, P10265, DOI 10.1073/pnas.90.21.10265; SEMBDNER G, 1994, PLANT MOL BIOL, V26, P1459, DOI 10.1007/BF00016485; SHARMA S, 1981, PLANT CELL PHYSIOL, V22, P927; SHUTTLEWORTH WA, 1992, PROTEIN ENG, V5, P461, DOI 10.1093/protein/5.5.461; SPARVOLI F, 1994, PLANT MOL BIOL, V24, P743, DOI 10.1007/BF00029856; STAHL N, 1994, J NEUROSCI RES, V38, P234, DOI 10.1002/jnr.490380214; TAYLOR LP, 1992, J HERED, V83, P11, DOI 10.1093/oxfordjournals.jhered.a111149; Taylor LP, 1998, ADV EXP MED BIOL, V439, P35; Taylor LP, 1997, ANNU REV PLANT PHYS, V48, P461, DOI 10.1146/annurev.arplant.48.1.461; TEIPEL JW, 1968, J BIOL CHEM, V243, P5684; VOGT T, 1995, PHYTOCHEMISTRY, V38, P589, DOI 10.1016/0031-9422(94)00703-V; VOGT T, 1995, PLANT PHYSIOL, V108, P903, DOI 10.1104/pp.108.3.903; Wiering H, 1984, PETUNIA, P49; WISE RP, 1990, PLANT MOL BIOL, V14, P277, DOI 10.1007/BF00018568; Xu P, 1997, PLANTA, V202, P257, DOI 10.1007/s004250050127; ZERBACK R, 1989, PHYTOCHEMISTRY, V28, P897, DOI 10.1016/0031-9422(89)80139-6	47	99	111	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34011	34019		10.1074/jbc.274.48.34011	http://dx.doi.org/10.1074/jbc.274.48.34011			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567367	hybrid			2022-12-25	WOS:000083857500032
J	Nicoll, G; Ni, J; Liu, D; Klenerman, P; Munday, J; Dubock, S; Mattei, MG; Crocker, PR				Nicoll, G; Ni, J; Liu, D; Klenerman, P; Munday, J; Dubock, S; Mattei, MG; Crocker, PR			Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; ACID-BINDING-SITE; ADHESION MOLECULE CD22-BETA; SIALIC-ACID; IMMUNOGLOBULIN SUPERFAMILY; DIFFERENTIATION ANTIGEN; SIALOADHESIN; CD22; CD33; OLIGOSACCHARIDES	We describe the characterization of sialic acid-binding Ig-like lectin-7 (siglec-7), a novel member of the siglec subgroup of the immunoglobulin superfamily. A full-length cDNA encoding siglec-7 was isolated from a human primary dendritic cell cDNA library. Siglec-7 is predicted to contain three extracellular immunoglobulin-like domains that comprise an N-terminal V-set domain and two Ca-set domains, a transmembrane region and a cytoplasmic tail containing two tyrosine residues embodied in immunoreceptor tyrosine-based inhibition motif-like motifs. Overall, siglec-7 exhibited a high degree of sequence similarity to genes encoding CD33 (siglec-3), siglec-5, OBBP1/siglec-6, and OBBP-like protein and mapped to the same region on chromosome 19q13.3. When siglec-7 was expressed on COS or Chinese hamster ovary cells, it was able to mediate high levels of sialic acid-dependent binding to human erythrocytes and soluble sialoglycoconjugates, suggesting that it may be involved in cell cell interactions. Among human peripheral blood leukocytes, siglec-7 was found to be present at low levels on granulocytes, intermediate levels on monocytes, and relatively high levels on a major subset of natural killer cells and a minor subset of CD8(+) T cells. Immunoprecipitation experiments indicated that siglec-7 is expressed as a monomer of similar to 65 kDa.	Univ Dundee, Inst Med Sci, Wellcome Trust Bioctr, Dept Biochem, Dundee DD1 5EH, Scotland; Human Genome Sci Inc, Rockville, MD 20850 USA; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England; Fac Med Marseille, INSERM U406, Unite Genet Med & Dev, F-13385 Marseille 5, France	University of Dundee; GlaxoSmithKline; Human Genome Sciences Inc; University of Oxford; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Crocker, PR (corresponding author), Univ Dundee, Inst Med Sci, Wellcome Trust Bioctr, Dept Biochem, Dundee Complex,Dow St, Dundee DD1 5EH, Scotland.	prcrocker@bad.dundee.ac.uk		klenerman, paul/0000-0003-4307-9161; Crocker, Paul/0000-0001-6230-0293				AXBERG I, 1988, SCAND J IMMUNOL, V28, P697, DOI 10.1111/j.1365-3083.1988.tb01503.x; BRAAKMAN E, 1991, INT IMMUNOL, V3, P691, DOI 10.1093/intimm/3.7.691; BRAESCHANDERSEN S, 1994, J BIOL CHEM, V269, P11783; Cornish AL, 1998, BLOOD, V92, P2123, DOI 10.1182/blood.V92.6.2123.418k20_2123_2132; CROCKER PR, 1995, J CLIN INVEST, V95, P635, DOI 10.1172/JCI117708; Crocker PR, 1999, BIOCHEM J, V341, P355, DOI 10.1042/0264-6021:3410355; CROCKER PR, 1994, EMBO J, V13, P4490, DOI 10.1002/j.1460-2075.1994.tb06771.x; Cyster JG, 1997, IMMUNITY, V6, P509, DOI 10.1016/S1074-7613(00)80339-8; Deaglio S, 1998, J IMMUNOL, V160, P395; DORKEN B, 1986, J IMMUNOL, V136, P4470; ELOUAGARI K, 1995, J BIOL CHEM, V270, P26970; Falco M, 1999, J EXP MED, V190, P793, DOI 10.1084/jem.190.6.793; FILBIN MT, 1995, CURR OPIN NEUROBIOL, V5, P588, DOI 10.1016/0959-4388(95)80063-8; FREEMAN SD, 1995, BLOOD, V85, P2005, DOI 10.1182/blood.V85.8.2005.bloodjournal8582005; Frey M, 1998, J IMMUNOL, V161, P400; FUNARO A, 1990, J IMMUNOL, V145, P2390; Gergely J, 1999, IMMUNOL LETT, V68, P3, DOI 10.1016/S0165-2478(99)00024-3; HANASAKI K, 1995, J BIOL CHEM, V270, P7533, DOI 10.1074/jbc.270.13.7533; Harlow E., 1988, ANTIBODIES LAB MANUA; Hashimoto Y, 1998, J BIOCHEM-TOKYO, V123, P468; Hennet T, 1998, P NATL ACAD SCI USA, V95, P4504, DOI 10.1073/pnas.95.8.4504; Hua CT, 1998, J BIOL CHEM, V273, P28332, DOI 10.1074/jbc.273.43.28332; Huber M, 1999, J BIOL CHEM, V274, P335, DOI 10.1074/jbc.274.1.335; KALLI KR, 1991, J EXP MED, V174, P1451, DOI 10.1084/jem.174.6.1451; KANTOR AB, 1997, WEIRS HDB EXPT IMMUN, V2; Kelm S, 1998, EUR J BIOCHEM, V255, P663, DOI 10.1046/j.1432-1327.1998.2550663.x; KELM S, 1994, GLYCOCONJUGATE J, V11, P576, DOI 10.1007/BF00731309; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; Lanier LL, 1998, CELL, V92, P705, DOI 10.1016/S0092-8674(00)81398-7; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; Long EO, 1999, ANNU REV IMMUNOL, V17, P875, DOI 10.1146/annurev.immunol.17.1.875; Lund FE, 1998, IMMUNOL REV, V161, P79, DOI 10.1111/j.1600-065X.1998.tb01573.x; Mandelboim O, 1999, P NATL ACAD SCI USA, V96, P5640, DOI 10.1073/pnas.96.10.5640; May AP, 1998, MOL CELL, V1, P719, DOI 10.1016/S1097-2765(00)80071-4; NAGLER A, 1989, J IMMUNOL, V143, P3183; Ollendorff V, 1998, INT J ONCOL, V13, P1159; Patel N, 1999, J BIOL CHEM, V274, P22729, DOI 10.1074/jbc.274.32.22729; PEIPER SC, 1988, BLOOD, V72, P314; PEIPER SC, 1989, LEUCOCYTE TYPING, V4, P814; POWELL LD, 1993, J BIOL CHEM, V268, P7019; SGROI D, 1993, J BIOL CHEM, V268, P7011; SIMMONS D, 1988, J IMMUNOL, V141, P2797; SJOBERG ER, 1994, J CELL BIOL, V126, P549, DOI 10.1083/jcb.126.2.549; Takei Y, 1997, CYTOGENET CELL GENET, V78, P295, DOI 10.1159/000134676; Tang S, 1997, J CELL BIOL, V138, P1355, DOI 10.1083/jcb.138.6.1355; Taylor VC, 1999, J BIOL CHEM, V274, P11505, DOI 10.1074/jbc.274.17.11505; vanderMerwe PA, 1996, J BIOL CHEM, V271, P9273, DOI 10.1074/jbc.271.16.9273; VANRINSUM J, 1986, INT J CANCER, V38, P915, DOI 10.1002/ijc.2910380620; Vinson M, 1996, J BIOL CHEM, V271, P9267, DOI 10.1074/jbc.271.16.9267; Warren HS, 1999, J IMMUNOL, V162, P735; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Wende H, 1999, MAMM GENOME, V10, P154, DOI 10.1007/s003359900961; YOUSEF GM, 1999, IN PRESS BIOCH BIOPH	53	194	207	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34089	34095		10.1074/jbc.274.48.34089	http://dx.doi.org/10.1074/jbc.274.48.34089			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567377	hybrid			2022-12-25	WOS:000083857500042
J	Oliverio, S; Amendola, A; Rodolfo, C; Spinedi, A; Piacentini, M				Oliverio, S; Amendola, A; Rodolfo, C; Spinedi, A; Piacentini, M			Inhibition of "tissue" transglutaminase increases cell survival by preventing apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; RETINOIC ACID; RAT-LIVER; DEATH; STIMULATION; EXPRESSION	Treatment of the human promonocytic cell line U937 with all-trans-retinoic acid (RA) commits these cells to apoptosis, which can be triggered by simply increasing intracellular calcium levels by the ionophore A23187. RA treatment of U937 cells is characterized by a decrease in Bcl-2 and marked induction of "tissue" transglutaminase (tTG) gene expression. In this study, we show that the inhibition of tTG expression in U937 cells undergoing apoptosis prevents their death. In fact, U937 cell-derived clones transfected with the human tTG gene in the antisense orientation showed a pronounced decrease in apoptosis induced by several stimuli. These findings demonstrate that the Ca2+-dependent irreversible cross-linking of intracellular proteins catalyzed by tTG represents an important biochemical event in the gene-regulated cell death in monoblasts. In addition, our data indicate that the apoptotic program in promonocytic cells is strictly regulated by RA and that a key role is played by the free intracellular calcium concentration.	Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Ist Ricovero & Cura Carattere Sci L Spallanzani, Lab Electron Microscopy & Cell Biol, I-00149 Rome, Italy; Univ Tuscia, Dept Environm Sci, I-01100 Viterbo, Italy	University of Rome Tor Vergata; Tuscia University	Piacentini, M (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via Ric Sci, I-00133 Rome, Italy.		Piacentini, Mauro/I-2411-2016; Amendola, Alessandra/K-8835-2016; Rodolfo, Carlo/H-8953-2019; Amendola, Alessandra/ABC-2753-2021	Piacentini, Mauro/0000-0003-2919-1296; Amendola, Alessandra/0000-0002-7063-0222; Rodolfo, Carlo/0000-0001-7087-545X; Amendola, Alessandra/0000-0002-7063-0222				Amendola A, 1996, P NATL ACAD SCI USA, V93, P11057, DOI 10.1073/pnas.93.20.11057; BERGAMINI A, 1994, IMMUNOL LETT, V42, P35, DOI 10.1016/0165-2478(94)90032-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEFACQUE H, 1995, LEUKEMIA, V9, P1762; FESUS L, 1989, FEBS LETT, V245, P150, DOI 10.1016/0014-5793(89)80210-8; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; Fratazzi C, 1997, J IMMUNOL, V158, P4320; GENTILE V, 1992, J CELL BIOL, V119, P463, DOI 10.1083/jcb.119.2.463; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; Igarashi S, 1998, NAT GENET, V18, P111, DOI 10.1038/ng0298-111; KNIGHT RL, 1993, EUR J CELL BIOL, V60, P210; Melino G, 1998, FEBS LETT, V430, P59, DOI 10.1016/S0014-5793(98)00521-3; MELINO G, 1994, MOL CELL BIOL, V14, P6584, DOI 10.1128/MCB.14.10.6584; Nagy L, 1997, CELL DEATH DIFFER, V4, P534, DOI 10.1038/sj.cdd.4400290; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Oliverio S, 1997, MOL CELL BIOL, V17, P6040, DOI 10.1128/MCB.17.10.6040; PIACENTINI M, 1991, CELL TISSUE RES, V263, P227, DOI 10.1007/BF00318764; Piredda L, 1997, CELL DEATH DIFFER, V4, P463, DOI 10.1038/sj.cdd.4400267; Placido R, 1997, J PATHOL, V181, P31, DOI 10.1002/(SICI)1096-9896(199701)181:1<31::AID-PATH722>3.0.CO;2-G; Singh US, 1996, J BIOL CHEM, V271, P27292, DOI 10.1074/jbc.271.44.27292; Zhuang JG, 1998, J BIOL CHEM, V273, P15628, DOI 10.1074/jbc.273.25.15628	23	100	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34123	34128		10.1074/jbc.274.48.34123	http://dx.doi.org/10.1074/jbc.274.48.34123			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567382	hybrid			2022-12-25	WOS:000083857500047
J	Tang, L; Guo, B; Javed, A; Choi, JY; Hiebert, S; Lian, JB; van Wijnen, AJ; Stein, JL; Stein, GS; Zhou, GW				Tang, L; Guo, B; Javed, A; Choi, JY; Hiebert, S; Lian, JB; van Wijnen, AJ; Stein, JL; Stein, GS; Zhou, GW			Crystal structure of the nuclear matrix targeting signal of the transcription factor acute myelogenous leukemia-1/polyoma enhancer-binding protein 2 alpha B/core binding factor alpha 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; 3-DIMENSIONAL STRUCTURE; MOLECULAR-STRUCTURE; RESOLUTION; GENE; COMPLEX; FAMILY; AML1; REPLICATION; REFINEMENT	Transcription factors of the acute myelogenous leukemia (AML)/polyoma enhancer-binding protein (PEBP2 alpha)/core-binding factor alpha (CBFA) class are key transactivators of tissue-specific genes of the hematopoietic and bone lineages. AML-1/PEBP2 alpha B/CBFA2 proteins participating in transcription are associated with the nuclear matrix, This association is solely dependent on a highly conserved C-terminal protein segment, designated the nuclear matrix targeting signal (NMTS). The NMTS of AML-1 is physically distinct from the nuclear localization signal, operates autonomously, and supports transactivation. Our data indicate that the related AML-3 and AML-2 proteins are also targeted to the nuclear matrix in situ by analogous C-terminal domains. Here we report the first crystal structure of an NMTS in an AML-1 segment fused to glutathione S-transferase. The model of the NMTS consists of two loops connected by a flexible U-shaped peptide chain.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Vanderbilt University	Zhou, GW (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA.		van Wijnen, Andre J./AAG-3578-2019	van Wijnen, Andre J./0000-0002-4458-0946; Javed, Amjad/0000-0002-0847-8266	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045688] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 45688] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aguilar CF, 1997, J MOL BIOL, V271, P789, DOI 10.1006/jmbi.1997.1215; BRABDEN C, 1991, INTRO PROTEIN SCI; BRUNGER AT, 1992, XPLOR MANUAL VERSION; Chen LF, 1998, MOL CELL BIOL, V18, P4165, DOI 10.1128/MCB.18.7.4165; Cook P, 1998, SCIENCE, V281, P1466, DOI 10.1126/science.281.5382.1466; EPP O, 1975, BIOCHEMISTRY-US, V14, P4943, DOI 10.1021/bi00693a025; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; EVANS SV, 1993, J MOL GRAPHICS, V11, P127; FEY EG, 1984, J CELL BIOL, V98, P1973, DOI 10.1083/jcb.98.6.1973; GARCIASAEZ I, 1994, J MOL BIOL, V237, P298, DOI 10.1006/jmbi.1994.1232; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Komori T, 1998, J BONE MINER METAB, V16, P1, DOI 10.1007/s007740050020; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; LANFORD RE, 1986, CELL, V46, P575, DOI 10.1016/0092-8674(86)90883-4; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIM K, 1994, PROTEIN SCI, V3, P2233, DOI 10.1002/pro.5560031209; MARQUART M, 1980, J MOL BIOL, V141, P369, DOI 10.1016/0022-2836(80)90252-1; Meyers S, 1995, CRIT REV EUKAR GENE, V5, P365, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.70; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; Stein Gary S., 1998, Frontiers in Bioscience, V3, pD849; Tang L, 1998, J STRUCT BIOL, V123, P83, DOI 10.1006/jsbi.1998.4016; Wei XY, 1998, SCIENCE, V281, P1502, DOI 10.1126/science.281.5382.1502; Zeng CM, 1998, P NATL ACAD SCI USA, V95, P1585, DOI 10.1073/pnas.95.4.1585; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746	31	66	67	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33580	33586		10.1074/jbc.274.47.33580	http://dx.doi.org/10.1074/jbc.274.47.33580			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559245	hybrid			2022-12-25	WOS:000083745200061
J	Li, J; Kogan, M; Knight, SAB; Pain, D; Dancis, A				Li, J; Kogan, M; Knight, SAB; Pain, D; Dancis, A			Yeast mitochondrial protein, Nfs1p, coordinately regulates iron-sulfur cluster proteins, cellular iron uptake, and iron distribution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPPER TRANSPORT PROTEIN; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SUCCINATE-DEHYDROGENASE; AZOTOBACTER-VINELANDII; GENE; ACONITASE; HOMOLOG; BINDING; INVITRO	Nfs1p is the yeast homolog of the bacterial proteins NifS and IscS, enzymes that release sulfur from cysteine for iron-sulfur cluster assembly. Here we show that the yeast mitochondrial protein Nfs1p regulates cellular and mitochondrial iron homeostasis, A strain of Saccharomyces cerevisiae, MA14, with a missense NFS1 allele (I191S) was isolated in a screen for altered iron-dependent gene regulation. This mutant exhibited constitutive up-regulation of the genes of the cellular iron uptake system, mediated through effects on the aft1p iron-regulatory protein. Iron accumulating in the mutant cells was retained in the mitochondrial matrix while, at the same time, iron-sulfur proteins were deficient, In this work, the yeast protein was localized to mitochondria, and the gene was shown to be essential for viability. Furthermore, Nfs1p in the MA14 mutant was found to be markedly decreased, suggesting that this low protein level produced the observed regulatory effects. This hypothesis was confirmed by experiments in which expression of wild-type Nfs1p from a regulated galactose-induced promoter was turned off, leading to recapitulation of the iron regulatory phenotypes characteristic of the MA14 mutant. These phenotypes include decreases in iron-sulfur protein activities coordinated with increases in cellular iron uptake and iron distribution to mitochondria.	Univ Penn, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Dancis, A (corresponding author), Univ Penn, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA.	adancis@mail.med.upenn.edu		Knight, Simon/0000-0001-7407-3390	NIDDK NIH HHS [DK53953] Funding Source: Medline; NIGMS NIH HHS [GM57067] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK053953, R01DK053953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057067] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Askwith CC, 1996, MOL MICROBIOL, V20, P27, DOI 10.1111/j.1365-2958.1996.tb02485.x; Augeri L, 1997, BIOCHEMISTRY-US, V36, P721, DOI 10.1021/bi9625511; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Beinert H, 1999, CURR OPIN CHEM BIOL, V3, P152, DOI 10.1016/S1367-5931(99)80027-1; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Beinert H, 1976, Adv Exp Med Biol, V74, P137; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; BETTERTO.H, 1968, BIOCHIM BIOPHYS ACTA, V170, P459, DOI 10.1016/0304-4165(68)90036-6; CAMMACK R, 1992, ADV INORG CHEM, V38, P281, DOI 10.1016/S0898-8838(08)60066-5; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; DIS DR, 1994, J BIOL CHEM, V42, P26092; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; Halliwell B., 1991, FREE RADICALS BIOL M; Hidalgo E, 1997, TRENDS BIOCHEM SCI, V22, P207, DOI 10.1016/S0968-0004(97)01068-2; IMLAY JA, 1988, SCIENCE, V240, P640, DOI 10.1126/science.2834821; JACOBSON MR, 1989, MOL GEN GENET, V219, P49, DOI 10.1007/BF00261156; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; Khoroshilova N, 1997, P NATL ACAD SCI USA, V94, P6087, DOI 10.1073/pnas.94.12.6087; Kispal G, 1997, FEBS LETT, V418, P346, DOI 10.1016/S0014-5793(97)01414-2; Knight SAB, 1998, J BIOL CHEM, V273, P18389, DOI 10.1074/jbc.273.29.18389; KOHLHAW GB, 1988, METHOD ENZYMOL, V166, P423; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Land T, 1998, MOL CELL, V2, P807, DOI 10.1016/S1097-2765(00)80295-6; LEIGHTON J, 1995, EMBO J, V14, P188, DOI 10.1002/j.1460-2075.1995.tb06989.x; Leighton J, 1995, METHOD ENZYMOL, V260, P389, DOI 10.1016/0076-6879(95)60152-X; Lesuisse Emmanuel, 1994, V11, P149; Martin H, 1998, ANAL BIOCHEM, V265, P123, DOI 10.1006/abio.1998.2863; Muchmore SW, 1996, ADV INORG BIOCHEM, P111; MUNUJOS P, 1993, ANAL BIOCHEM, V212, P506, DOI 10.1006/abio.1993.1360; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; OUZOUNIS C, 1993, FEBS LETT, V322, P159, DOI 10.1016/0014-5793(93)81559-I; Radisky DC, 1999, J BIOL CHEM, V274, P4497, DOI 10.1074/jbc.274.8.4497; ROBBINS AH, 1989, PROTEINS, V5, P289, DOI 10.1002/prot.340050406; ROBINSON KM, 1994, EUR J BIOCHEM, V222, P983, DOI 10.1111/j.1432-1033.1994.tb18949.x; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; RYAN ED, 1974, J BACTERIOL, V120, P631, DOI 10.1128/JB.120.2.631-637.1974; Schulke N, 1999, J BIOL CHEM, V274, P22847, DOI 10.1074/jbc.274.32.22847; Sherman F, 1986, LAB COURSE MANUAL ME; Shimada Y, 1998, J HUM GENET, V43, P115, DOI 10.1007/s100380050051; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; SINGH A, 1974, J BACTERIOL, V118, P911, DOI 10.1128/JB.118.3.911-918.1974; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; TANGERAS A, 1985, BIOCHIM BIOPHYS ACTA, V843, P199, DOI 10.1016/0304-4165(85)90140-0; Wilson RB, 1997, NAT GENET, V16, P352, DOI 10.1038/ng0897-352; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1997, J BIOL CHEM, V272, P17711, DOI 10.1074/jbc.272.28.17711; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; ZHENG LM, 1994, J BIOL CHEM, V269, P18723; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	62	165	170	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					33025	33034		10.1074/jbc.274.46.33025	http://dx.doi.org/10.1074/jbc.274.46.33025			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551871	hybrid			2022-12-25	WOS:000083623000071
J	Liu, LX; Janvier, K; Berteaux-Lecellier, V; Cartier, N; Benarous, R; Aubourg, P				Liu, LX; Janvier, K; Berteaux-Lecellier, V; Cartier, N; Benarous, R; Aubourg, P			Homo- and heterodimerization of peroxisomal ATP-binding cassette half-transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED ADRENOLEUKODYSTROPHY; CHAIN FATTY-ACIDS; ABC-TRANSPORTER; MEMBRANE-PROTEIN; SACCHAROMYCES-CEREVISIAE; MUTATIONAL ANALYSIS; ALD-GENE; EXPRESSION; ADRENOMYELONEUROPATHY; IDENTIFICATION	Mammalian peroxisomal proteins adrenoleukodystrophy protein (ALDP), adrenoleukodystrophy-related protein (ALDRP), and 70-kDa peroxisomal protein (PMP70) belong to the superfamily of ATP-binding cassette (ABC) transporters. Unlike many ABC transporters that are single functional proteins with two related halves, ALDP, ALDRP, and PMP70 have the structure of ABC half-transporters. The dysfunction of ALDP is responsible for X-linked adrenoleukodystrophy (X-ALD), a neurodegenerative disorder in which saturated very long-chain fatty acids accumulate because of their impaired peroxisomal beta-oxidation. No disease has so far been associated with mutations of adrenoleukodystrophy-related or PMP70 genes. It has been proposed that peroxisomal ABC transporters need to dimerize to exert import functions. Using the yeast two-hybrid system, we show that homo- as well as heterodimerization occur between the carboxyl-terminal halves of ALDP, ALDRP, and PMP70. Two X-ALD disease mutations located in the carboxyl-terminal half of ALDP affect both homo- and heterodimerization of ALDP. Co-immunoprecipitation demonstrated the homodimerization of ALDP, the heterodimerization of ALDP with PMP70 or ALDRP, and the heterodimerization of ALDRP with PMP70. These results provide the first evidence of both homo- and heterodimerization of mammalian ABC half-transporters and suggest that the loss of ALDP dimerization plays a role in X-ALD pathogenesis.	Hop St Vincent de Paul, Inst Cochin Genet Mol, INSERM U342, F-75014 Paris, France; Univ Paris 05, INSERM, Inst Cochin Genet Mol, EPI 9923, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Aubourg, P (corresponding author), Hop St Vincent de Paul, Inst Cochin Genet Mol, INSERM U342, 82 Ave Denfert Rochereau, F-75014 Paris, France.		Janvier, Katy/O-7780-2017; BERTEAUX-LECELLIER, Veronique/P-6456-2019; cartier, nathalie/C-3103-2012	Janvier, Katy/0000-0002-3105-4736; BERTEAUX-LECELLIER, Veronique/0000-0003-2152-6231; cartier, nathalie/0000-0003-2298-5261				Allikmets R, 1999, HUM MOL GENET, V8, P743, DOI 10.1093/hmg/8.5.743; CARTIER N, 1995, P NATL ACAD SCI USA, V92, P1674, DOI 10.1073/pnas.92.5.1674; CHOWERS MY, 1994, J VIROL, V68, P2906, DOI 10.1128/JVI.68.5.2906-2914.1994; Contreras M, 1996, ARCH BIOCHEM BIOPHYS, V334, P369, DOI 10.1006/abbi.1996.0467; Doerflinger N, 1998, HUM GENE THER, V9, P1025, DOI 10.1089/hum.1998.9.7-1025; Dubois-Dalcq M, 1999, TRENDS NEUROSCI, V22, P4, DOI 10.1016/S0166-2236(98)01319-8; EWART GD, 1994, J BIOL CHEM, V269, P10370; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; Flavigny E, 1999, FEBS LETT, V448, P261, DOI 10.1016/S0014-5793(99)00379-8; Fouquet F, 1997, NEUROBIOL DIS, V3, P271, DOI 10.1006/nbdi.1997.0127; FUCHS S, 1994, HUM MOL GENET, V3, P1903, DOI 10.1093/hmg/3.10.1903; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; Hettema EH, 1996, EMBO J, V15, P3813, DOI 10.1002/j.1460-2075.1996.tb00755.x; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Holzinger A, 1997, BIOCHEM BIOPH RES CO, V237, P152, DOI 10.1006/bbrc.1997.7102; Imanaka T, 1999, J BIOL CHEM, V274, P11968, DOI 10.1074/jbc.274.17.11968; KAMIJO K, 1992, BIOCHIM BIOPHYS ACTA, V1129, P323, DOI 10.1016/0167-4781(92)90510-7; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; Kemp S, 1998, NAT MED, V4, P1261, DOI 10.1038/3242; KOK F, 1995, HUM MUTAT, V6, P104, DOI 10.1002/humu.1380060203; Krasemann EW, 1996, HUM GENET, V97, P194, DOI 10.1007/BF02265264; LAGEWEG W, 1991, BIOCHEM J, V276, P53, DOI 10.1042/bj2760053; LAZO O, 1988, P NATL ACAD SCI USA, V85, P7647, DOI 10.1073/pnas.85.20.7647; LAZO O, 1990, BIOCHEMISTRY-US, V29, P3981, DOI 10.1021/bi00468a027; LIGTENBERG MJL, 1995, AM J HUM GENET, V56, P44; LombardPlatet G, 1996, P NATL ACAD SCI USA, V93, P1265, DOI 10.1073/pnas.93.3.1265; Moser HW, 1997, BRAIN, V120, P1485, DOI 10.1093/brain/120.8.1485; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; MOSSER J, 1994, HUM MOL GENET, V3, P265, DOI 10.1093/hmg/3.2.265; Netik A, 1999, HUM MOL GENET, V8, P907, DOI 10.1093/hmg/8.5.907; POLLARD H, 1995, J NEUROSCI RES, V42, P433, DOI 10.1002/jnr.490420318; Shani N, 1997, HUM MOL GENET, V6, P1925, DOI 10.1093/hmg/6.11.1925; SHANI N, 1995, P NATL ACAD SCI USA, V92, P6012, DOI 10.1073/pnas.92.13.6012; SMITH DK, 1999, NEUROCHEM RES, V24, P511; SMITH K, 1999, 2 FEBS ADV LECT COUR; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; Troffer-Charlier N, 1998, EUR J CELL BIOL, V75, P254, DOI 10.1016/S0171-9335(98)80121-0; Verleur N, 1997, EUR J BIOCHEM, V249, P657, DOI 10.1111/j.1432-1033.1997.00657.x; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; WANDERS RJA, 1988, BIOCHEM BIOPH RES CO, V153, P618, DOI 10.1016/S0006-291X(88)81140-9; Yamada T, 1999, NEUROLOGY, V52, P614, DOI 10.1212/WNL.52.3.614	41	115	121	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32738	32743		10.1074/jbc.274.46.32738	http://dx.doi.org/10.1074/jbc.274.46.32738			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551832	hybrid			2022-12-25	WOS:000083623000032
J	Xu, XM; Shi, YC; Wu, X; Gambetti, P; Sui, DX; Cui, MZ				Xu, XM; Shi, YC; Wu, X; Gambetti, P; Sui, DX; Cui, MZ			Identification of a novel PSD-95/Dlg/ZO-1 (PDZ)-like protein interacting with the C terminus of presenilin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; FAMILIAL ALZHEIMERS-DISEASE; SIGNALING COMPLEXES; PDZ DOMAINS; GENE; CELLS; RECOGNITION; PEPTIDE; ELEGANS	Presenilin-1 (PS-l) is the most causative Alzheimer gene product, and its function is not well understood. In an attempt to elucidate the function of PS-l, we screened a human brain cDNA library for PS-l-interacting proteins using the yeast two-hybrid system and isolated a novel protein containing a PSD-95/Dlg/ZO-1 (PDZ)-like domain. This novel PS l-associated protein (PSAP) shares a significant similarity with a Caenorhabditis elegans protein of unknown function. Northern blot analysis revealed that PSAP is predominantly expressed in the brain. Deletion of the first four C-terminal amino acid residues of PS-l, which contain the PDZ domain-binding motif (Gln-Phe-Tyr-Ile), reduced the binding activity of PS-l toward PSAP 4-fold. These data suggest that PS-l may associate with a PDZ-Iike domain-containing protein in vivo and thus may participate in receptor or channel clustering and intracellular signaling events in the brain.	Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA; Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA	Case Western Reserve University; Michigan State University; Cleveland Clinic Foundation	Xu, XM (corresponding author), Univ Tennessee, Dept Pathol, 2407 River Dr, Knoxville, TN 37996 USA.			xu, xuemin/0000-0002-7426-272X; Cui, Mei-Zhen/0000-0003-4745-6999	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R35AG008992, P50AG008012] Funding Source: NIH RePORTER; NIA NIH HHS [AG08992, P50 AG08012] Funding Source: Medline; NINDS NIH HHS [NS-37869-01] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Dewji NN, 1997, P NATL ACAD SCI USA, V94, P14025, DOI 10.1073/pnas.94.25.14025; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Guo Q, 1997, J NEUROSCI, V17, P4212; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kato A, 1998, J BIOL CHEM, V273, P23969, DOI 10.1074/jbc.273.37.23969; Lehmann S, 1997, J BIOL CHEM, V272, P12047, DOI 10.1074/jbc.272.18.12047; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Malin SA, 1998, NEUROBIOL DIS, V4, P398, DOI 10.1006/nbdi.1998.0167; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Ranganathan R, 1997, CURR BIOL, V7, pR770, DOI 10.1016/S0960-9822(06)00401-5; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Smine A, 1998, J BIOL CHEM, V273, P16281, DOI 10.1074/jbc.273.26.16281; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Vito P, 1997, J BIOL CHEM, V272, P28315, DOI 10.1074/jbc.272.45.28315; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Yamamoto A, 1996, BIOCHEM BIOPH RES CO, V226, P536, DOI 10.1006/bbrc.1996.1390	25	43	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32543	32546		10.1074/jbc.274.46.32543	http://dx.doi.org/10.1074/jbc.274.46.32543			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551805	hybrid			2022-12-25	WOS:000083623000005
J	Belman, C; Espinosa, E; Poupot, R; Peyrat, MA; Guiraud, M; Poquet, Y; Bonneville, M; Fournie, JJ				Belman, C; Espinosa, E; Poupot, R; Peyrat, MA; Guiraud, M; Poquet, Y; Bonneville, M; Fournie, JJ			3-formyl-1-butyl pyrophosphate A novel mycobacterial metabolite-activating human gamma delta T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERPENOID BIOSYNTHESIS; NONPEPTIDE ANTIGENS; STIMULATION; 5-PHOSPHATE; LIGANDS; PATHWAY; RECOGNITION; LYMPHOCYTES; PRECURSOR; PYRIDOXOL	Most human blood gamma delta T cells react without major histocompatibility complex restriction to small phosphorylated nonpeptide antigens (phosphoantigens) that are abundantly produced by mycobacteria and several other microbial pathogens. Although isopentenyl pyrophosphate has been identified as a mycobacterial antigen for gamma delta T cells, the structure of several other stimulating compounds with bioactivities around 1000-fold higher than isopentenyl pyrophosphate remains to be elucidated. This paper describes the structural identification of 3-formyl-1-butyl-pyrophosphate as the core of several non-prenyl mycobacterial phosphoantigens bioactive at the nM range. Recognition of this molecule by gamma delta T cells is very selective and relies on its aldehyde and pyrophosphate groups. This novel pyrophosphorylated aldehyde most probably corresponds to a metabolic intermediate of the non-mevalonate pathway of prenyl phosphate biosynthesis in eubacteria and algae. The reactivity to 3-formyl-1-butyl-pyrophosphate supports the view that human gamma delta T cells are physiologically devoted to antimicrobial surveillance.	CHU Purpan, INSERM, U395, F-31024 Toulouse, France; Inst Biol, INSERM, U463, F-44035 Nantes, France; CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Fournie, JJ (corresponding author), CHU Purpan, INSERM, U395, BP3028, F-31024 Toulouse, France.	fournie@purpan.inserm.fr	espinosa, eric/E-4872-2013; Fournie, Jean-Jacques/J-7805-2013	espinosa, eric/0000-0002-3512-0921; Fournie, Jean-Jacques/0000-0001-6542-6908				BELMANT C, 1998, NOUVEAUX COMPOSES PH; BLMANT C, 1998, NOUVEAUX COMPOSES PH; BORCH RF, 1971, J AM CHEM SOC, V93, P2897, DOI 10.1021/ja00741a013; Boullier S, 1998, EUR J IMMUNOL, V28, P3399, DOI 10.1002/(SICI)1521-4141(199811)28:11<3399::AID-IMMU3399>3.0.CO;2-W; Bukowski JF, 1998, J IMMUNOL, V161, P286; BURK MR, 1995, EUR J IMMUNOL, V25, P2052, DOI 10.1002/eji.1830250737; CASORATI G, 1989, J EXP MED, V170, P1521, DOI 10.1084/jem.170.5.1521; CIACHINO C, 1994, EUR J IMMUNOL, V24, P1914; CONSTANT P, 1994, SCIENCE, V264, P267, DOI 10.1126/science.8146660; CONSTANT P, 1995, THESIS U P SABATIER, P168; DAVISSON VJ, 1986, J ORG CHEM, V51, P4768, DOI 10.1021/jo00375a005; DELIBERO G, 1991, CURR TOP MICROBIOL, V173, P235; DeLibero G, 1997, IMMUNOL TODAY, V18, P22, DOI 10.1016/S0167-5699(97)80010-2; Fischer S, 1996, IMMUNOL LETT, V52, P69, DOI 10.1016/0165-2478(96)02584-9; Fournie JJ, 1996, RES IMMUNOL, V147, P338, DOI 10.1016/0923-2494(96)89648-9; Halary F, 1997, EUR J IMMUNOL, V27, P2812, DOI 10.1002/eji.1830271111; HOLOSHITZ J, 1993, INT IMMUNOL, V5, P1437, DOI 10.1093/intimm/5.11.1437; LANG F, 1995, J IMMUNOL, V154, P5986; Lois LM, 1998, P NATL ACAD SCI USA, V95, P2105, DOI 10.1073/pnas.95.5.2105; MINGARI MC, 1989, INT J CANCER, P39; MORITA CT, 1995, IMMUNITY, V3, P495, DOI 10.1016/1074-7613(95)90178-7; NAG B, 1992, J IMMUNOL, V148, P2040; PARKER CM, 1990, J EXP MED, V171, P1597, DOI 10.1084/jem.171.5.1597; Poquet Y, 1996, EUR J IMMUNOL, V26, P2344, DOI 10.1002/eji.1830261011; Poquet Y, 1996, ANAL BIOCHEM, V243, P119, DOI 10.1006/abio.1996.0489; PUTRA SR, 1997, ISOPRENOID BIOSYNTHE; Rohmer M, 1996, J AM CHEM SOC, V118, P2564, DOI 10.1021/ja9538344; ROHMER M, 1993, BIOCHEM J, V295, P517, DOI 10.1042/bj2950517; Sprenger GA, 1997, P NATL ACAD SCI USA, V94, P12857, DOI 10.1073/pnas.94.24.12857; Takahashi S, 1998, P NATL ACAD SCI USA, V95, P9879, DOI 10.1073/pnas.95.17.9879; TANAKA Y, 1995, NATURE, V375, P155, DOI 10.1038/375155a0; Tanaka Y, 1996, J MOL MED-JMM, V74, P223, DOI 10.1007/BF00196576; TANAKA Y, 1994, P NATL ACAD SCI USA, V91, P8175, DOI 10.1073/pnas.91.17.8175	33	95	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32079	32084		10.1074/jbc.274.45.32079	http://dx.doi.org/10.1074/jbc.274.45.32079			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542241	hybrid			2022-12-25	WOS:000083532100049
J	Dodelet, VC; Pazzagli, C; Zisch, AH; Hauser, CA; Pasquale, EB				Dodelet, VC; Pazzagli, C; Zisch, AH; Hauser, CA; Pasquale, EB			A novel signaling intermediate, SHEP1, directly couples Eph receptors to R-Ras and Rap1A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; FOCAL ADHESION KINASE; EXCHANGE FACTOR; VAV PROTOONCOGENE; NEURAL DEVELOPMENT; LIGAND ACTIVATION; GDP/GTP EXCHANGE; SEC7 DOMAIN; IN-VITRO; FAMILY	The Eph family of receptor tyrosine kinases has been implicated in many developmental patterning processes, including cell segregation, cell migration, and axon guidance. The cellular components involved in the signaling pathways of the Eph receptors, however, are incompletely characterized. Using a yeast two-hybrid screen, we have identified a novel signaling intermediate, SHEP1 (SH2 domain-containing Eph receptor-binding protein 1), which is expressed in the embryonic and adult brain. SHEP1 contains an Src homology 2 domain that binds to a conserved tyrosine-phosphorylated motif in the juxtamembrane region of the EphB2 receptor and may itself be a target of EphB2 kinase activity, since it becomes heavily tyrosine-phosphorylated in cells expressing activated EphB2, SHEP1 also contains a domain similar to Ras guanine nucleotide exchange factor domains and binds to the GTPases R-Ras and Rap1A, but not Ha-Ras or Ra1A, Thus, SHEP1 directly links activated, tyrosine-phosphorylated Eph receptors to small Ras superfamily GTPases.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Pasquale, EB (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	elenap@ljcrf.edu			NICHD NIH HHS [HD25938, HD26351] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD026351, P01HD025938, R01HD026351] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P189, DOI 10.1093/nar/24.1.189; Baouz S, 1997, J BIOL CHEM, V272, P6671, DOI 10.1074/jbc.272.10.6671; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Bruckner K, 1998, CURR OPIN NEUROBIOL, V8, P375, DOI 10.1016/S0959-4388(98)80064-0; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Cherfils J, 1998, NATURE, V392, P101, DOI 10.1038/32210; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Collins TL, 1997, IMMUNOL TODAY, V18, P221; Corbalan-Garcia S, 1998, MOL CELL BIOL, V18, P880, DOI 10.1128/MCB.18.2.880; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Drescher U, 1997, CURR BIOL, V7, pR799, DOI 10.1016/S0960-9822(06)00409-X; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Ellis C, 1996, ONCOGENE, V12, P1727; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Flanagan JG, 1997, CELL, V90, P403; Garcia-Guzman M, 1999, J BIOL CHEM, V274, P5762, DOI 10.1074/jbc.274.9.5762; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Huynh-Do U, 1999, EMBO J, V18, P2165, DOI 10.1093/emboj/18.8.2165; Ichiba T, 1999, J BIOL CHEM, V274, P14376, DOI 10.1074/jbc.274.20.14376; Lu YM, 1999, J BIOL CHEM, V274, P10047, DOI 10.1074/jbc.274.15.10047; Meima L, 1997, MOL CELL NEUROSCI, V9, P314, DOI 10.1006/mcne.1997.0621; Meima L, 1997, EUR J NEUROSCI, V9, P177, DOI 10.1111/j.1460-9568.1997.tb01365.x; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; Mossessova E, 1998, CELL, V92, P415, DOI 10.1016/S0092-8674(00)80933-2; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; Nagase T., 1996, DNA RES, V3; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; Pasquale EB, 1997, CURR OPIN CELL BIOL, V9, P608, DOI 10.1016/S0955-0674(97)80113-5; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; SHAO HN, 1994, J BIOL CHEM, V269, P26606; SOANS C, 1994, ONCOGENE, V9, P3353; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; van Agthoven T, 1998, EMBO J, V17, P2799, DOI 10.1093/emboj/17.10.2799; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zisch AH, 1998, ONCOGENE, V16, P2657, DOI 10.1038/sj.onc.1201823; ZMUIDZINAS A, 1995, EMBO J, V14, P1	55	86	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31941	31946		10.1074/jbc.274.45.31941	http://dx.doi.org/10.1074/jbc.274.45.31941			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542222	hybrid			2022-12-25	WOS:000083532100030
J	Han, KH; Green, SR; Tangirala, RK; Tanaka, S; Quehenberger, O				Han, KH; Green, SR; Tangirala, RK; Tanaka, S; Quehenberger, O			Role of the first extracellular loop in the functional activation of CCR2 - The first extracellular loop contains distinct domains necessary for both agonist binding and transmembrane signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; AMINO-TERMINAL DOMAIN; HIGH-AFFINITY BINDING; CHEMOKINE RECEPTOR; MOLECULAR-CLONING; LIGAND-BINDING; INTERLEUKIN-8 RECEPTOR; MULTIPLE DOMAINS; EXPRESSION; IDENTIFICATION	The physiological cellular responses to monocyte che moattractant protein-1 (MCP-1), a potent chemotactic and activating factor for mononuclear leukocytes, are mediated by specific binding to CCR2, The aim of this investigation is to identify receptor microdomains that are involved in high affinity agonist binding and receptor activation, The results from our functional studies in which we utilized neutralizing antisera against CCR2 are consistent with a multidomain binding model, previously proposed by others. The first extracellular loop was of particular interest, because in addition to a ligand-binding domain it contained also information for receptor activation, crucial for transmembrane signaling. Replacement of the first extracellular loop of CCR2 with the corresponding region of CCR1 decreased the MCP-1 binding affinity about 10-fold and prevented transmembrane signaling. A more detailed analysis by site directed mutagenesis revealed that this receptor segment contains two distinct microdomains. The amino acid residues Asn(104) and Glu(105) are. essential for high affinity agonist binding but are not involved in receptor activation. In contrast, the charged amino acid residue His(100) does not contribute to ligand binding but is vital for receptor activation and initiation of transmembrane signaling; We hypothesize that the interaction of agonist with this residue initiates the conformational switch that allows the formation of the functional CCR2-G protein complex.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Quehenberger, O (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	oquehenberger@ucsd.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056989] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI041719] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56989-01] Funding Source: Medline; NIAID NIH HHS [AI41719-01A1] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahuja SK, 1996, J BIOL CHEM, V271, P225, DOI 10.1074/jbc.271.1.225; Arai H, 1996, J BIOL CHEM, V271, P21814, DOI 10.1074/jbc.271.36.21814; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Boring L, 1997, J CLIN INVEST, V100, P2552, DOI 10.1172/JCI119798; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; Frade JMR, 1997, J CLIN INVEST, V100, P497, DOI 10.1172/JCI119558; Gong JH, 1996, J BIOL CHEM, V271, P10521, DOI 10.1074/jbc.271.18.10521; GONG JH, 1995, J EXP MED, V181, P631, DOI 10.1084/jem.181.2.631; Gong JH, 1997, J EXP MED, V186, P131, DOI 10.1084/jem.186.1.131; Han KH, 1999, J LIPID RES, V40, P1053; Han KH, 1998, ARTERIOSCL THROM VAS, V18, P1983, DOI 10.1161/01.ATV.18.12.1983; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Kuang YN, 1996, J BIOL CHEM, V271, P3975; KUNA P, 1992, J EXP MED, V175, P489, DOI 10.1084/jem.175.2.489; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kurihara T, 1997, J EXP MED, V186, P1757, DOI 10.1084/jem.186.10.1757; Kuziel WA, 1997, P NATL ACAD SCI USA, V94, P12053, DOI 10.1073/pnas.94.22.12053; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; Lazareno S, 1997, Methods Mol Biol, V83, P107; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; Monteclaro FS, 1997, J BIOL CHEM, V272, P23186, DOI 10.1074/jbc.272.37.23186; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Prossnitz ER, 1999, BIOCHEMISTRY-US, V38, P2240, DOI 10.1021/bi982274t; QUEHENBERGER O, 1993, J BIOL CHEM, V268, P18167; Quehenberger O, 1997, BIOCHEM BIOPH RES CO, V238, P377, DOI 10.1006/bbrc.1997.7298; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; Tangirala RK, 1997, J BIOL CHEM, V272, P8050, DOI 10.1074/jbc.272.12.8050; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; YAMAGAMI S, 1994, BIOCHEM BIOPH RES CO, V202, P1156, DOI 10.1006/bbrc.1994.2049; YE RD, 1994, CHALL MOD MED, V3, P141; YOSHIMURA T, 1990, J IMMUNOL, V145, P292; YOSHIMURA T, 1989, J EXP MED, V169, P1449, DOI 10.1084/jem.169.4.1449; ZHANG YJ, 1994, J BIOL CHEM, V269, P15918	41	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32055	32062		10.1074/jbc.274.45.32055	http://dx.doi.org/10.1074/jbc.274.45.32055			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542238	hybrid			2022-12-25	WOS:000083532100046
J	Luo, H; Gilinger, G; Mukherjee, D; Bellofatto, V				Luo, H; Gilinger, G; Mukherjee, D; Bellofatto, V			Transcription initiation at the TATA-less spliced leader RNA gene promoter requires at least two DNA-binding proteins and a tripartite architecture that includes an initiator element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINI-EXON GENE; TRYPANOSOMA-BRUCEI; POLYMERASE-II; SMALL NUCLEAR; LEPTOMONAS-SEYMOURI; SNRNA GENES; SL RNA; EXPRESSION; SEQUENCE; U2	Eukaryotic transcriptional regulatory signals, defined as core and activator promoter elements, have yet to be identified in the earliest diverging group of eukaryotes, the primitive protozoans, which include the Trypanosomatidae family of parasites. The divergence within this family is highlighted by the apparent absence of the "universal" transcription factor TATA-binding protein. To understand gene expression in these protists, we have investigated spliced leader RNA gene transcription. The RNA product of this gene provides an m(7)G cap and a 39-nucleotide leader sequence to all cellular mRNAs via a trans-splicing reaction. Regulation of spliced leader RNA synthesis is controlled by a tripartite promoter located exclusively upstream from the transcription start site. Proteins PBP-1 and PBP-2 bind to two of the three promoter elements in the trypanosomatid Leptomonas seymouri, They represent the first trypanosome transcription factors with typical double-stranded DNA binding site recognition. These proteins ensure efficient transcription. However, accurate initiation is determined an initiator element with a a loose consensus of CYAC/AYR (+1), which differs from that found in metazoan initiator elements as well as from that identified in one of the earliest diverging protozoans, Trichomonas vaginalis, Trypanosomes may utilize initiator element-protein interactions, and not TATA sequence-TATA-binding protein interactions, to direct proper transcription initiation by RNA polymerase II.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Bellofatto, V (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, 185 S Orange Ave, Newark, NJ 07103 USA.				NIAID NIH HHS [AI 29478] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029478] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGAMI R, 1994, NUCLEIC ACIDS RES, V22, P1959, DOI 10.1093/nar/22.11.1959; BANGS JD, 1992, J BIOL CHEM, V267, P9805; BELLOFATTO V, 1988, NUCLEIC ACIDS RES, V16, P3455, DOI 10.1093/nar/16.8.3455; BENAMAR MF, 1991, NUCLEIC ACIDS RES, V19, P5857, DOI 10.1093/nar/19.21.5857; CONNELLY S, 1994, MOL CELL BIOL, V14, P5910, DOI 10.1128/MCB.14.9.5910; Crenshaw-Williams K, 1999, PARASITOL RES, V85, P700, DOI 10.1007/s004360050618; Cross GAM, 1998, MOL BIOCHEM PARASIT, V91, P77, DOI 10.1016/S0166-6851(97)00186-2; FURTERGRAVES EM, 1991, MOL CELL BIOL, V11, P4121, DOI 10.1128/MCB.11.8.4121; GIARDINA C, 1993, SCIENCE, V261, P759, DOI 10.1126/science.8342041; GRAHAM SV, 1995, PARASITOL TODAY, V11, P217, DOI 10.1016/0169-4758(95)80081-6; GUNZL A, 1995, J BIOL CHEM, V270, P17287, DOI 10.1074/jbc.270.29.17287; Gunzl A, 1997, MOL BIOCHEM PARASIT, V85, P67, DOI 10.1016/S0166-6851(96)02816-2; HANNON GJ, 1990, EMBO J, V9, P1915, DOI 10.1002/j.1460-2075.1990.tb08318.x; HARTREE D, 1995, MOL BIOCHEM PARASIT, V71, P27, DOI 10.1016/0166-6851(95)00034-X; Huie JL, 1997, MOL BIOCHEM PARASIT, V90, P183, DOI 10.1016/S0166-6851(97)00146-1; Jensen RC, 1998, NUCLEIC ACIDS RES, V26, P616, DOI 10.1093/nar/26.2.616; Lee MGS, 1996, MOL CELL BIOL, V16, P1220; Lemon KP, 1998, SCIENCE, V282, P1516, DOI 10.1126/science.282.5393.1516; Li JM, 1996, MOL CELL BIOL, V16, P1275; Liston DR, 1999, MOL CELL BIOL, V19, P2380; Lo K, 1996, GENE, V182, P13, DOI 10.1016/S0378-1119(96)00438-6; LOBO SM, 1994, TRANSCRIPTION MECH R, V3, P127; Luo H, 1997, J BIOL CHEM, V272, P33344, DOI 10.1074/jbc.272.52.33344; MAICAS E, 1990, NUCLEIC ACIDS RES, V8, P3387; McAndrew M, 1998, EXP PARASITOL, V90, P65, DOI 10.1006/expr.1998.4317; MOSCH HU, 1992, EMBO J, V11, P4583, DOI 10.1002/j.1460-2075.1992.tb05560.x; NAKAAR V, 1994, MOL CELL BIOL, V14, P6736, DOI 10.1128/MCB.14.10.6736; PAYS E, 1993, EUKARYOTIC MICROBIAL, P99; ROSS L, 1995, J BIOL CHEM, V270, P22086; SAITO RM, 1994, EMBO J, V13, P5460, DOI 10.1002/j.1460-2075.1994.tb06881.x; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; Wong MW, 1998, MOL CELL BIOL, V18, P368, DOI 10.1128/MCB.18.1.368; Yoon JB, 1996, MOL CELL BIOL, V16, P1; Yu MC, 1998, MOL BIOCHEM PARASIT, V94, P265, DOI 10.1016/S0166-6851(98)00083-8; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	37	33	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31947	31954		10.1074/jbc.274.45.31947	http://dx.doi.org/10.1074/jbc.274.45.31947			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542223	hybrid			2022-12-25	WOS:000083532100031
J	Cordelier, P; Esteve, JP; Rivard, N; Marletta, M; Vaysse, N; Susini, C; Buscail, L				Cordelier, P; Esteve, JP; Rivard, N; Marletta, M; Vaysse, N; Susini, C; Buscail, L			The activation of neuronal NO synthase is mediated by G-protein beta gamma subunit and the tyrosine phosphatase SHP-2	FASEB JOURNAL			English	Article						cholecystokinin; nitric oxide; cell growth; G beta gamma complex	NITRIC-OXIDE SYNTHASE; PANCREATIC ACINAR-CELLS; SOMATOSTATIN RECEPTOR; L-ARGININE; IN-VIVO; GROWTH; RAT; CHOLECYSTOKININ; PROLIFERATION; STIMULATION	In CHO cells we had found that CCK positively regulated cell proliferation via the activation of a soluble guanylate cyclase, Here we demonstrate that CCK stimulated a nitric oxide synthase (NOS) activity. The production of NO was involved in the proliferative response elicited by CCK regarding the inhibitory effect of NOS inhibitors L-NAME and alpha-guanidinoglutaric acid. We identified the NOS activated by the peptide as the neuronal isoform: the expression of the C415A neuronal NOS mutant inhibited both CCK-induced stimulation of NOS activity and cell proliferation, These two effects were also inhibited after expression of the C459S tyrosine phosphatase SHP-2 mutant and the beta ARK1 (495-689) sequestrant peptide, indicating the requirement of activated SHP-2 and G-beta gamma subunit, Kinetic analysis (Western blot after coimmunoprecipitation and specific SHP-2 activity) revealed that in response to CCK-treatment, SHP-2 associated to G-beta 1 subunit, became activated, and then dephosphorylated the neuronal NOS through a direct association, These data demonstrate that the neuronal NOS is implicated in proliferative effect evoked by CCK, A novel growth signaling pathway is described, involving the activation of neuronal NOS by dephosphorylation of tyrosyl residues.-Cordelier P., Esteve, J.-P., Rivard, N., Marletta, M., Vaysse, N., Susini, C., Buscail, L. The activation of neuronal no synthase is mediated by G-protein beta gamma subunit and the tyrosine phosphatase SHP-2.	CHU Rangueil, INSERM U151, Inst Louis Bugnard, F-31403 Toulouse 4, France; Univ Sherbrooke, Fac Med, Dept Anat & Biol Cellulaire, Sherbrooke, PQ J1K 2R1, Canada; Univ Michigan, Howard Hughes Med Inst, Sch Med, Ann Arbor, MI 48109 USA	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Sherbrooke; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Buscail, L (corresponding author), CHU Rangueil, INSERM U151, Inst Louis Bugnard, 1 Ave J Poulhes,IFR 31, F-31403 Toulouse 4, France.		Cordelier, Pierre/D-1150-2014	Cordelier, Pierre/0000-0003-2096-7967	NCI NIH HHS [CA50414] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050414] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUSCAIL L, 1995, P NATL ACAD SCI USA, V92, P1580, DOI 10.1073/pnas.92.5.1580; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; COLAS B, 1992, EUR J BIOCHEM, V207, P1017, DOI 10.1111/j.1432-1033.1992.tb17138.x; Cordelier P, 1997, P NATL ACAD SCI USA, V94, P9343, DOI 10.1073/pnas.94.17.9343; Cuadra AE, 1998, J NEUROCHEM, V71, P571; Du M, 1997, BIOCHEM MOL BIOL INT, V41, P625; Farinelli SE, 1996, J NEUROSCI, V16, P2325; Fleming I, 1998, CIRC RES, V82, P686, DOI 10.1161/01.RES.82.6.686; Florio T, 1999, MOL ENDOCRINOL, V13, P24, DOI 10.1210/me.13.1.24; FORSTERMANN U, 1994, HYPERTENSION, V23, P1121, DOI 10.1161/01.HYP.23.6.1121; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; HOSHI H, 1993, AM J PHYSIOL, V265, pG1177, DOI 10.1152/ajpgi.1993.265.6.G1177; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; Jaffrey SR, 1995, ANNU REV CELL DEV BI, V11, P417; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Kuzin B, 1996, CELL, V87, P639, DOI 10.1016/S0092-8674(00)81384-7; Lopez F, 1997, J BIOL CHEM, V272, P24448, DOI 10.1074/jbc.272.39.24448; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Matsubara M, 1996, BIOCHEMISTRY-US, V35, P14651, DOI 10.1021/bi9613988; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; POVOSKI SP, 1994, GASTROENTEROLOGY, V107, P1135, DOI 10.1016/0016-5085(94)90239-9; Pueyo ME, 1998, AM J PHYSIOL-CELL PH, V274, pC214, DOI 10.1152/ajpcell.1998.274.1.C214; RICHARDS MK, 1994, BIOCHEMISTRY-US, V33, P14723, DOI 10.1021/bi00253a010; Richards MK, 1996, BIOCHEMISTRY-US, V35, P7772, DOI 10.1021/bi952582g; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; RIVARD N, 1991, ENDOCRINOLOGY, V129, P2867, DOI 10.1210/endo-129-6-2867; RIVARD N, 1994, AM J PHYSIOL, V266, pG1130, DOI 10.1152/ajpgi.1994.266.6.G1130; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SILVENTE-POIROT S, 1993, EUR J BIOCHEM, V215, P513, DOI 10.1111/j.1432-1033.1993.tb18061.x; Thippeswamy T, 1997, BRAIN RES, V774, P116, DOI 10.1016/S0006-8993(97)81694-0; Wang Y, 1995, Curr Opin Nephrol Hypertens, V4, P12, DOI 10.1097/00041552-199501000-00003; Yoshida H, 1997, PFLUG ARCH EUR J PHY, V434, P25, DOI 10.1007/s004240050359; Yu ZB, 1997, J BIOL CHEM, V272, P7519, DOI 10.1074/jbc.272.11.7519; ZICHE M, 1994, J CLIN INVEST, V94, P2036, DOI 10.1172/JCI117557	39	26	26	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1999	13	14					2037	2050		10.1096/fasebj.13.14.2037	http://dx.doi.org/10.1096/fasebj.13.14.2037			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544187	Green Submitted			2022-12-25	WOS:000083660700016
J	Inada, H; Togashi, H; Nakamura, Y; Kaibuchi, K; Nagata, K; Inagaki, M				Inada, H; Togashi, H; Nakamura, Y; Kaibuchi, K; Nagata, K; Inagaki, M			Balance between activities of Rho kinase and type 1 protein phosphatase modulates turnover of phosphorylation and dynamics of desmin/vimentin filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KERATIN INTERMEDIATE FILAMENTS; SERINE-THREONINE KINASE; SMALL GTPASE RHO; MYOSIN PHOSPHATASE; PUTATIVE TARGET; SERINE/THREONINE KINASE; CYTOSKELETAL INTEGRITY; NEURITE RETRACTION; FOCAL ADHESIONS; OKADAIC ACID	To analyze the cell cycle-dependent desmin phosphorylation by Rho kinase, we developed antibodies specifically recognizing the kinase-dependent phosphorylation of desmin at Thr-16, Thr-75, and Thr-76. With these antibodies, phosphorylation of desmin was observed specifically at the cleavage furrow in late mitotic Saos-2 cells. We then found that treatment of the interphase cells with calyculin A revealed phosphorylation at all the three sites of desmin. We also found that an antibody, which specifically recognizes vimentin phosphorylated at Ser-71 by Rho kinase, became immunoreactive after calyculin A treatment. This calyculin A-induced interphase phosphorylation of vimentin at Ser-71 was blocked by Rho kinase inhibitor or by expression of the dominant-negative Rho kinase. Taken together, our results indicate that Rho kinase is activated not only in mitotic cells but also interphase ones, and phosphorylates intermediate filament proteins, although the apparent phosphorylation level is diminished to an undetectable level due to the constitutive action of type 1 protein phosphatase. The balance between intermediate filament protein phosphorylation by Rho kinase and dephosphorylation by type I protein phosphatase may affect the continuous exchange of intermediate filament subunits between a soluble pool and polymerized intermediate filaments.	Aichi Canc Ctr, Res Inst, Div Biochem, Nagoya, Aichi 4648681, Japan; Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Osaka Univ, Sch Med, Dept Neuropsychiat, Suita, Osaka 5650871, Japan; Nara Inst Sci & Technol, Div Signal Transduct, Nara 6300101, Japan	Aichi Cancer Center; Nagoya University; Osaka University; Nara Institute of Science & Technology	Inagaki, M (corresponding author), Aichi Canc Ctr, Res Inst, Div Biochem, 1-1 Chikusa Ku, Nagoya, Aichi 4648681, Japan.		Inagaki, Masaki/B-9920-2016					ALBERS K, 1987, J CELL BIOL, V105, P791, DOI 10.1083/jcb.105.2.791; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1998, GENES CELLS, V3, P177, DOI 10.1046/j.1365-2443.1998.00181.x; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; ERIKSSON J E, 1992, Current Opinion in Cell Biology, V4, P99, DOI 10.1016/0955-0674(92)90065-K; ERIKSSON JE, 1992, P NATL ACAD SCI USA, V89, P11093, DOI 10.1073/pnas.89.22.11093; Foisner R, 1997, BIOESSAYS, V19, P297, DOI 10.1002/bies.950190407; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; Goldman RD, 1996, J CELL BIOL, V134, P971, DOI 10.1083/jcb.134.4.971; Goto H, 1998, J BIOL CHEM, V273, P11728, DOI 10.1074/jbc.273.19.11728; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Inada H, 1998, BIOCHEM BIOPH RES CO, V253, P21, DOI 10.1006/bbrc.1998.9732; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; Inagaki M, 1996, BIOESSAYS, V18, P481, DOI 10.1002/bies.950180610; Inagaki N, 1997, J BIOL CHEM, V272, P25195, DOI 10.1074/jbc.272.40.25195; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; KASIBUCHI K, 1999, ANNU REV BIOCHEM, V68, P459; Katoh H, 1998, J BIOL CHEM, V273, P2489, DOI 10.1074/jbc.273.5.2489; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kimura K, 1998, J BIOL CHEM, V273, P5542, DOI 10.1074/jbc.273.10.5542; Kosako H, 1999, ONCOGENE, V18, P2783, DOI 10.1038/sj.onc.1202633; Kosako H, 1997, J BIOL CHEM, V272, P10333; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; NGAI J, 1990, CELL, V60, P415, DOI 10.1016/0092-8674(90)90593-4; NISHIZAWA K, 1991, J BIOL CHEM, V266, P3074; OGAWARA M, 1995, J CELL BIOL, V131, P1055, DOI 10.1083/jcb.131.4.1055; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; SAITO T, 1995, BIOCHEMISTRY-US, V34, P7376, DOI 10.1021/bi00022a010; SARRIA AJ, 1990, J CELL BIOL, V111, P553, DOI 10.1083/jcb.111.2.553; Sin WC, 1998, MOL CELL BIOL, V18, P6325, DOI 10.1128/MCB.18.11.6325; TAKAI A, 1995, BIOCHEM J, V306, P657, DOI 10.1042/bj3060657; Takai Y, 1996, J CELL BIOL, V133, P141, DOI 10.1083/jcb.133.1.141; Toivola DM, 1998, HEPATOLOGY, V28, P116, DOI 10.1002/hep.510280117; Toivola DM, 1997, J CELL SCI, V110, P23; TSUJIMURA K, 1994, J BIOL CHEM, V269, P31097; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249; [No title captured]	56	77	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34932	34939		10.1074/jbc.274.49.34932	http://dx.doi.org/10.1074/jbc.274.49.34932			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574968	hybrid			2022-12-25	WOS:000083979600062
J	Uitdehaag, JCM; Kalk, KH; van der Veen, BA; Dijkhuizen, L; Dijkstra, BW				Uitdehaag, JCM; Kalk, KH; van der Veen, BA; Dijkhuizen, L; Dijkstra, BW			The cyclization mechanism of cyclodextrin glycosyltransferase (CGTase) as revealed by a gamma-cyclodextrin-CGTase complex at 1.8-angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CIRCULANS STRAIN-251; THERMOANAEROBACTERIUM THERMOSULFURIGENES EM1; ALPHA-AMYLASE FAMILY; X-RAY STRUCTURE; PRODUCT SPECIFICITY; ANGSTROM RESOLUTION; BETA-CYCLODEXTRIN; CATALYTIC MECHANISM; MOLECULAR-DYNAMICS; HISTIDINE-RESIDUES	The enzyme cyclodextrin glycosyltransferase is closely related to alpha-amylases but has the unique ability to produce cyclodextrins (circular alpha(1-->4)-linked glucoses) from starch. To characterize this specificity we determined a 1.8-Angstrom structure of an E257Q/D229N mutant cyclodextrin glycosyltransferase in complex with its product gamma-cyclodextrin, which reveals for the first time how cyclodextrin is competently bound. Across subsites -2, -1, and fl, the cyclodextrin ring binds in a twisted mode similar to linear sugars, giving rise to deformation of its circular symmetry. At subsites -3 and +2, the cyclodextrin binds in a manner different from linear sugars. Sequence comparisons and site-directed mutagenesis experiments support the conclusion that subsites -3 and +2 confer the cyclization activity in addition to subsite -6 and Tyr-195, On this basis, a role of the individual residues during the cyclization reaction cycle is proposed.	Univ Groningen, BIOSON Res Inst, NL-9747 AG Groningen, Netherlands; Univ Groningen, Biophys Chem Lab, Groningen Biomol Sci & Biotechnol Inst, GBB, NL-9747 AG Groningen, Netherlands; Univ Groningen, GBB Inst, Dept Microbiol, NL-9751 NN Haren, Netherlands	University of Groningen; University of Groningen; University of Groningen	Dijkstra, BW (corresponding author), Univ Groningen, BIOSON Res Inst, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.		Dijkstra, Bauke W./H-4308-2019; Dijkhuizen, Lubbert/E-9454-2014; Dijkhuizen, Lubbert/K-3539-2019	Dijkstra, Bauke W./0000-0001-9731-6586; Dijkhuizen, Lubbert/0000-0003-2312-7162				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BENDER H, 1990, CARBOHYD RES, V206, P257, DOI 10.1016/0008-6215(90)80065-B; BENDER H, 1985, CARBOHYD RES, V135, P291, DOI 10.1016/S0008-6215(00)90780-8; BRADY JW, 1993, J PHYS CHEM-US, V97, P958, DOI 10.1021/j100106a024; Brzozowski AM, 1997, BIOCHEMISTRY-US, V36, P10837, DOI 10.1021/bi970539i; FUJIWARA S, 1992, J BACTERIOL, V174, P7478, DOI 10.1128/jb.174.22.7478-7481.1992; GRABB WD, 1997, TRENDS BIOTECHNOL, V15, P349; HARATA K, 1984, CHEM LETT, P641, DOI 10.1246/cl.1984.641; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; HINRICHS W, 1987, SCIENCE, V238, P205, DOI 10.1126/science.238.4824.205; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Janecek S, 1997, PROG BIOPHYS MOL BIO, V67, P67, DOI 10.1016/S0079-6107(97)00015-1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Katsuya Y, 1998, J MOL BIOL, V281, P885, DOI 10.1006/jmbi.1998.1992; Kim YH, 1997, BIOCHEM MOL BIOL INT, V41, P227; KLEIN C, 1991, J MOL BIOL, V217, P737, DOI 10.1016/0022-2836(91)90530-J; KNEGTEL RMK, 1995, J BIOL CHEM, V270, P29256, DOI 10.1074/jbc.270.49.29256; KOEHLER JEH, 1988, J MOL BIOL, V203, P241, DOI 10.1016/0022-2836(88)90105-2; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWSON CL, 1994, J MOL BIOL, V236, P590, DOI 10.1006/jmbi.1994.1168; MATTSSON P, 1995, BBA-PROTEIN STRUCT M, V1247, P97, DOI 10.1016/0167-4838(94)00214-2; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; Meyer JEW, 1997, PROTEIN SCI, V6, P1084, DOI 10.1002/pro.5560060515; Mukai K, 1997, STARCH-STARKE, V49, P26, DOI 10.1002/star.19970490107; NAKAMURA A, 1993, BIOCHEMISTRY-US, V32, P6624, DOI 10.1021/bi00077a015; NAKAMURA A, 1994, BIOCHEMISTRY-US, V33, P9929, DOI 10.1021/bi00199a015; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Parsiegla G, 1998, EUR J BIOCHEM, V255, P710, DOI 10.1046/j.1432-1327.1998.2550710.x; PEDERSEN S, 1995, CHEMTECH, P19; Penninga D, 1996, J BIOL CHEM, V271, P32777, DOI 10.1074/jbc.271.51.32777; PENNINGA D, 1995, BIOCHEMISTRY-US, V34, P3368, DOI 10.1021/bi00010a028; QIAN MX, 1994, BIOCHEMISTRY-US, V33, P6284, DOI 10.1021/bi00186a031; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Schmidt AK, 1998, BIOCHEMISTRY-US, V37, P5909, DOI 10.1021/bi9729918; SIN KA, 1994, J BIOTECHNOL, V32, P283, DOI 10.1016/0168-1656(94)90214-3; STEINER T, 1994, CARBOHYD RES, V259, P1, DOI 10.1016/0008-6215(94)84192-6; Strokopytov B, 1996, BIOCHEMISTRY-US, V35, P4241, DOI 10.1021/bi952339h; STROKOPYTOV B, 1995, BIOCHEMISTRY-US, V34, P2234, DOI 10.1021/bi00007a018; SVENSSON B, 1994, PLANT MOL BIOL, V25, P141, DOI 10.1007/BF00023233; SWIFT HJ, 1991, ACTA CRYSTALLOGR B, V47, P535, DOI 10.1107/S0108768191001970; Terada Y, 1997, J BIOL CHEM, V272, P15729, DOI 10.1074/jbc.272.25.15729; Tewari YB, 1997, CARBOHYD RES, V301, P11, DOI 10.1016/S0008-6215(97)00073-6; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; Uitdehaag JCM, 1999, NAT STRUCT BIOL, V6, P432, DOI 10.1038/8235; Vellieux FMD, 1997, J APPL CRYSTALLOGR, V30, P396, DOI 10.1107/S0021889896012551; VETTER D, 1992, STARCH, V6, P229; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; Wind RD, 1998, J BIOL CHEM, V273, P5771, DOI 10.1074/jbc.273.10.5771; Wind RD, 1998, EUR J BIOCHEM, V253, P598, DOI 10.1046/j.1432-1327.1998.2530598.x	50	112	120	1	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34868	34876		10.1074/jbc.274.49.34868	http://dx.doi.org/10.1074/jbc.274.49.34868			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574960	hybrid, Green Published			2022-12-25	WOS:000083979600054
J	Furge, LL; Chen, K; Cohen, S				Furge, LL; Chen, K; Cohen, S			Annexin VII and annexin XI are tyrosine phosphorylated in peroxovanadate-treated dogs and in platelet-derived growth factor-treated rat vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROVILLAR CORE PROTEIN; NUCLEAR-LOCALIZATION; BINDING-SITE; A-431 CELLS; EZRIN; CLATHRIN; DOMAIN; KINASE; CAP-50; FAMILY	The intraperitoneal administration of peroxovanadate results in the rapid accumulation of many tyrosine-phosphorylated proteins in the liver and kidney of treated animals. The availability of large pools of tyrosine-phosphorylated proteins derived from normal tissues facilitates the purification and identification of previously unknown targets for cellular tyrosine kinases. Using this procedure, we have thus far identified four proteins in the liver and kidney of peroxovanadate-treated dogs. Two of these, annexin VII and annexin XI, were novel and had not been previously reported to be substrates of tyrosine kinases while the remaining two, ezrin and clathrin, have been reported to be tyrosine phosphorylated in some cell culture systems. In the present study, isolated proteins were identified both by sequence analysis and immunological methods. Annexin VII and annexin XI are present in cultured rat vascular smooth muscle cells and both were tyrosine phosphorylated in response to a physiological ligand, platelet-derived growth factor-BB (PDGF-BB). Furthermore, the extent of tyrosine phosphorylation in response to PDGF-BB was augmented by the co-addition of peroxovanadate to cell cultures. In vitro phosphorylation assays showed that PDGF receptor, calcium-dependent tyrosine kinase (CADTK/Pyk-2), Src kinase, and epidermal growth factor receptor all were able to phosphorylate purified annexin VII and XI on tyrosine residues. These findings confirm the usefulness of phosphatase inhibition by peroxovanadate as a tool for identifying previously unknown physiological targets for cellular protein tyrosine kinases.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA	Vanderbilt University	Cohen, S (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 607 Light Hall, Nashville, TN 37232 USA.			Furge, Laura/0000-0003-3593-4770	NCI NIH HHS [P30 CA68485] Funding Source: Medline; NICHD NIH HHS [HD-00700] Funding Source: Medline; NIDDK NIH HHS [T32 DK07061] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007061] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Benz J, 1997, BIOL CHEM, V378, P177; BOUSTEAD CM, 1991, CELLULAR CALCIUM PRA, P247; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; Bretscher A, 1995, BIOCHEMISTRY-US, V34, P16830, DOI 10.1021/bi00051a034; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; EGUCHI S, 1994, ENDOCRINOLOGY, V134, P222, DOI 10.1210/en.134.1.222; FAVA RA, 1984, J BIOL CHEM, V259, P2636; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; Gerke V, 1997, BBA-MOL CELL RES, V1357, P129, DOI 10.1016/S0167-4889(97)00038-4; GOULD KL, 1986, J CELL BIOL, V102, P660, DOI 10.1083/jcb.102.2.660; HOLLENBERG MD, 1994, LIFE SCI, V54, P223, DOI 10.1016/0024-3205(94)00811-6; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; Hung CH, 1996, P NATL ACAD SCI USA, V93, P10797, DOI 10.1073/pnas.93.20.10797; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KRIEG J, 1992, J BIOL CHEM, V267, P19258; Lamb RF, 1997, CURR BIOL, V7, P682, DOI 10.1016/S0960-9822(06)00295-8; MAMIYA N, 1994, BIOCHEM BIOPH RES CO, V202, P403, DOI 10.1006/bbrc.1994.1942; MARTINPEREZ J, 1989, J CELL BIOL, V109, P577, DOI 10.1083/jcb.109.2.577; MISAKI Y, 1994, J BIOL CHEM, V269, P4240; MIZUTANI A, 1993, J BIOL CHEM, V268, P15517; MIZUTANI A, 1995, ARCH BIOCHEM BIOPHYS, V318, P157, DOI 10.1006/abbi.1995.1216; MIZUTANI A, 1992, J BIOL CHEM, V267, P13498; Pollard H B, 1998, Adv Pharmacol, V42, P81; Ruff SJ, 1997, J BIOL CHEM, V272, P1263, DOI 10.1074/jbc.272.2.1263; THUILLIER L, 1994, CELL IMMUNOL, V156, P322, DOI 10.1006/cimm.1994.1178; Thyberg J, 1996, INT REV CYTOL, V169, P183, DOI 10.1016/S0074-7696(08)61987-7; TOKUMITSU H, 1993, ARCH BIOCHEM BIOPHYS, V303, P302, DOI 10.1006/abbi.1993.1287; TOKUMITSU H, 1992, J BIOL CHEM, V267, P8919; TOWLE CA, 1992, J BIOL CHEM, V267, P5416; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; Vaheri A, 1997, CURR OPIN CELL BIOL, V9, P659, DOI 10.1016/S0955-0674(97)80119-6; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635	39	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33504	33509		10.1074/jbc.274.47.33504	http://dx.doi.org/10.1074/jbc.274.47.33504			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559235	hybrid			2022-12-25	WOS:000083745200051
J	Keely, SJ; Barrett, KE				Keely, SJ; Barrett, KE			ErbB2 and ErbB3 receptors mediate inhibition of calcium-dependent chloride secretion in colonic epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	Annual Meeting of the American-Gastroenterological-Association / Digestive Disease Week	MAY 16-22, 1998	NEW ORLEANS, LOUISIANA	Amer Gastroenterol Assoc			EPIDERMAL GROWTH-FACTOR; PROTEIN-COUPLED RECEPTORS; PHOSPHOLIPASE C-GAMMA; PHOSPHATIDYLINOSITOL 3-KINASE; KINASE; EGF; WORTMANNIN; HEREGULIN; ACID; HETERODIMERIZATION	We have previously demonstrated that epidermal growth factor (EGF) inhibits calcium-dependent chloride secretion via a mechanism involving stimulation of phosphatidylinositol 3-kinase (PI3-K). The muscarinic agonist of chloride secretion, carbachol (CCh), also stimulates an antisecretory pathway that involves transactivation of the EGF receptor (EGFR) but does not involve PI3-K. Here, we have examined if ErbB receptors, other than the EGFR, have a role in regulation of colonic secretion and if differential effects on ErbB receptor activation may explain the ability of the EGFR to propagate diverse signaling pathways in response to EGF versus CCh, Basolateral, but not apical, addition of the ErbB3/ErbB4 ligand alpha-heregulin (HRG; 1-100 ng/ml) inhibited secretory responses to CCh (100 mu M) across voltage-clamped T-84 epithelial cells. Immunoprecipitation/Western blot studies revealed that HRG (100 ng/ml) stimulated tyrosine phosphorylation and dimerization of ErbB3 and ErbB2, but had no effect on phosphorylation of the EGFR. HRG also stimulated recruitment of the p85 subunit of PI3-K to ErbB3/ErbB2 receptor dimers, while the PI3-K inhibitor, wortmannin (50 nM), completely reversed the inhibitory effect of HRG on CCh-stimulated secretion. Further studies revealed that, while both EGF (100 ng/ml) and CCh (100 ECM) stimulated phosphorylation of the EGFR, only EGF stimulated phosphorylation of ErbB2, and neither stimulated ErbB3 phosphorylation. EGF, but not CCh, stimulated the formation of EGFR/ErbB2 receptor dimers and the recruitment of p85 to ErbB2. We conclude that ErbE2 and ErbB3 are expressed in T-84 cells and are functionally coupled to inhibition of calcium-dependent chloride secretion, Differential dimerization with other ErbB family members may underlie the ability of the EGFR to propagate diverse inhibitory signals in response to activation by EGF or transactivation by CCh.	Univ Calif San Diego, Med Ctr, Dept Med, San Diego, CA 92103 USA	University of California System; University of California San Diego	Keely, SJ (corresponding author), Univ Calif San Diego, Med Ctr, Dept Med, 8414,200 W Arbor Dr, San Diego, CA 92103 USA.		Barrett, Kim/AAE-2794-2022; Barrett, Kim Elaine/AAE-7762-2019	Barrett, Kim Elaine/0000-0002-6704-998X; Keely, Stephen/0000-0002-6315-3587	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028305] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK28305] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; BARRETT KE, 1993, AM J PHYSIOL, V264, pC446, DOI 10.1152/ajpcell.1993.264.2.C446; BARRETT KE, 1993, AM J PHYSIOL, V265, pC859; Barrett KE, 1997, AM J PHYSIOL-CELL PH, V272, pC1069, DOI 10.1152/ajpcell.1997.272.4.C1069; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; Grasso AW, 1997, ONCOGENE, V15, P2705, DOI 10.1038/sj.onc.1201447; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Hamburger AW, 1997, ANTICANCER RES, V17, P2197; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kataoka H, 1998, LIFE SCI, V63, P553, DOI 10.1016/S0024-3205(98)00306-3; Keely SJ, 1998, J BIOL CHEM, V273, P27111, DOI 10.1074/jbc.273.42.27111; KEELY SJ, 1999, GASTROENTEROLOGY, P326; LAM K, 1994, J BIOL CHEM, V269, P20648; MANDEL KG, 1986, AM J PHYSIOL, V250, pC486, DOI 10.1152/ajpcell.1986.250.3.C486; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; Pinkas-Kramarski R, 1997, J MAMMARY GLAND BIOL, V2, P97, DOI 10.1023/A:1026343528967; PROCACCINO F, 1994, GASTROENTEROLOGY, V107, P12, DOI 10.1016/0016-5085(94)90055-8; Ram TG, 1996, CELL GROWTH DIFFER, V7, P551; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; Ribbons KA, 1997, GROWTH FACTORS, V14, P89, DOI 10.3109/08977199709021513; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; SLIKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Sugden PH, 1997, CELL SIGNAL, V9, P337, DOI 10.1016/S0898-6568(96)00191-X; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Tzahar E, 1998, BBA-REV CANCER, V1377, pM25, DOI 10.1016/S0304-419X(97)00032-2; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; Uribe JM, 1996, AM J PHYSIOL-CELL PH, V271, pC914, DOI 10.1152/ajpcell.1996.271.3.C914; Uribe JM, 1996, J BIOL CHEM, V271, P26588, DOI 10.1074/jbc.271.43.26588; Uribe JM, 1997, GASTROENTEROLOGY, V112, P255; VAJANAPHANICH M, 1993, AM J PHYSIOL, V264, pC1210, DOI 10.1152/ajpcell.1993.264.5.C1210; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; WEYMER A, 1985, J CLIN INVEST, V76, P1828, DOI 10.1172/JCI112175	40	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33449	33454		10.1074/jbc.274.47.33449	http://dx.doi.org/10.1074/jbc.274.47.33449			6	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559227	hybrid			2022-12-25	WOS:000083745200043
J	Powlowski, J; Sahlman, L				Powlowski, J; Sahlman, L			Reactivity of the two essential cysteine residues of the periplasmic mercuric ion-binding protein, MerP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; NUCLEAR MAGNETIC-RESONANCE; ESCHERICHIA-COLI; ACTIVE-SITE; SOLUTION CHEMISTRY; FORMATION INVIVO; REDOX PROPERTIES; METAL-COMPLEXES; RESISTANCE; DSBA	Reactivities of the two essential cysteine residues in the heavy metal binding motif, MTC(14)AAC(17), of the periplasmic Hg2+-binding protein, MerP, have been examined. While Cys-14 and Cys-17 have previously been shown to be Hg2+-binding residues, MerP is readily isolated in an inactive Cys-14-Cys-17 disulfide form, In vivo results demonstrated that these cysteine residues are reduced in the periplasm of Hg2+-resistant Escherichia coli. Denaturation and redox equilibrium studies revealed that reduced MerP is thermodynamically favored over the oxidized form. The relative stability of reduced MerP appears to be related to the lowered thiol pK(a) (5.5) of the Cys-17 side chain. Despite its much lower pK(a), the Cys-17 thiol is far less accessible than Cys-14, reacting 45 times more slowly with iodoacetamide at pH 7.5. This is reminiscent of proteins such as thioredoxin and DsbA, which contain a similar C-X-X-C motif, except in those cases the more exposed thiol has the lowered pK(a). In terms of MerP function, electrostatic attraction between Hg2+ and the buried Cys-17 thiolate may be important for triggering the structural change that MerP has been reported to undergo upon Hg2+ binding. Control of cysteine residue reactivity in heavy metal binding motifs may generally be important in influencing specific metal-binding properties of proteins containing them.	Concordia Univ, Dept Chem & Biochem, Montreal, PQ H3G 1M8, Canada	Concordia University - Canada	Powlowski, J (corresponding author), Concordia Univ, Dept Chem & Biochem, 1455 Maisonneuve Blvd W, Montreal, PQ H3G 1M8, Canada.	powlow@vax2.concordia.ca						ADMAN E, 1975, P NATL ACAD SCI USA, V72, P4854, DOI 10.1073/pnas.72.12.4854; AMES GF, 1984, J BACTERIOL, V160, P1181, DOI 10.1128/JB.160.3.1181-1183.1984; Aronsson G, 1997, FEBS LETT, V411, P359, DOI 10.1016/S0014-5793(97)00730-8; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARRINEAU P, 1984, Journal of Molecular and Applied Genetics, V2, P601; BHRIAIN NNN, 1983, J BACTERIOL, V155, P690, DOI 10.1128/JB.155.2.690-703.1983; BROWN NL, 1985, TRENDS BIOCHEM SCI, V10, P400, DOI 10.1016/0968-0004(85)90069-6; CHEESMAN BV, 1988, J AM CHEM SOC, V110, P6359, DOI 10.1021/ja00227a014; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P4061, DOI 10.1021/bi9628580; DONOHUE J, 1969, J MOL BIOL, V45, P231, DOI 10.1016/0022-2836(69)90102-8; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; FUHR BJ, 1973, J AM CHEM SOC, V95, P6944, DOI 10.1021/ja00802a013; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; Guddat LW, 1998, STRUCT FOLD DES, V6, P757, DOI 10.1016/S0969-2126(98)00077-X; GUILHOT C, 1995, P NATL ACAD SCI USA, V92, P9895, DOI 10.1073/pnas.92.21.9895; HAMLETT NV, 1992, J BACTERIOL, V174, P6377, DOI 10.1128/JB.174.20.6377-6385.1992; HAWKINS HC, 1991, BIOCHEM J, V275, P341, DOI 10.1042/bj2750341; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; KISHIGAMI S, 1995, FEBS LETT, V364, P55, DOI 10.1016/0014-5793(95)00354-C; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN TY, 1989, BIOCHEMISTRY-US, V28, P5282, DOI 10.1021/bi00438a054; LINDLEY H, 1960, BIOCHEM J, V74, P577, DOI 10.1042/bj0740577; MOORE EC, 1964, J BIOL CHEM, V239, P3453; MORBY AP, 1995, MOL MICROBIOL, V17, P25, DOI 10.1111/j.1365-2958.1995.mmi_17010025.x; NELSON JW, 1994, BIOCHEMISTRY-US, V33, P5974, DOI 10.1021/bi00185a039; Nozaki Y, 1972, Methods Enzymol, V26, P43; Pace C.N., 1990, PROTEIN STRUCTURE PR, P311; PACE CN, 1988, J BIOL CHEM, V263, P11820; POLGAR L, 1974, FEBS LETT, V38, P187, DOI 10.1016/0014-5793(74)80110-9; Qian H, 1998, BIOCHEMISTRY-US, V37, P9316, DOI 10.1021/bi9803628; Raina S, 1997, ANNU REV MICROBIOL, V51, P179, DOI 10.1146/annurev.micro.51.1.179; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROST J, 1964, NATURE, V201, P185, DOI 10.1038/201185a0; Sahlman L, 1997, J BIOL CHEM, V272, P29518, DOI 10.1074/jbc.272.47.29518; SAHLMAN L, 1993, BIOCHEM BIOPH RES CO, V196, P583, DOI 10.1006/bbrc.1993.2289; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SERRANO L, 1992, J MOL BIOL, V224, P783, DOI 10.1016/0022-2836(92)90562-X; Steele RA, 1997, BIOCHEMISTRY-US, V36, P6885, DOI 10.1021/bi9631632; STRICKS W, 1953, J AM CHEM SOC, V75, P5673, DOI 10.1021/ja01118a060; SUMMERS AO, 1986, ANNU REV MICROBIOL, V40, P607, DOI 10.1146/annurev.mi.40.100186.003135; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016	49	27	29	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33320	33326		10.1074/jbc.274.47.33320	http://dx.doi.org/10.1074/jbc.274.47.33320			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559209	hybrid			2022-12-25	WOS:000083745200025
J	Estanyol, JM; Jaumot, M; Casanovas, O; Rodriguez-Vilarrupla, A; Agell, N; Bachs, O				Estanyol, JM; Jaumot, M; Casanovas, O; Rodriguez-Vilarrupla, A; Agell, N; Bachs, O			The protein SET regulates the inhibitory effect of p21(Cip1) cyclin E-cyclin-dependent kinase 2 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE UNDIFFERENTIATED LEUKEMIA; CELL-CYCLE; MYELOID LEUKEMOGENESIS; POTENTIAL MEDIATOR; PUTATIVE ONCOGENE; DNA-REPLICATION; P21; CDK4; PROGRESSION; PCNA	The cyclin-dependent kinase (CDK) inhibitor p21(Cip1) has a dual role in the regulation of the cell cycle; it is an activator of cyclin D1-CDK4 complexes and an inhibitor of cyclins E/A-CDK2 activity. By affinity chromatography with p21(Cip1)-Sepharose 4B columns, we purified a 39-kDa protein, which was identified by microsequence analysis as the oncoprotein SET, Complexes containing SET and p21(Cip1) were detected in vivo by immunoprecipitation of Namalwa cell extracts using specific anti-p21(Cip1) antibodies. We found that SET bound directly to p21(Cip1) in vitro by the carboxyl-terminal region of p21(Cip1). SET had no direct effect on cyclin E/A-CDK2 activity, although it reversed the inhibition of cyclin E-CDK2, but not of cyclin A-CDK2, induced by p21(Cip1). This result is specific for p21(Cip1), since SET neither bound to p27(Kip1) nor reversed its inhibitory effect on cyclin E-CDK2 or cyclin A-CDK2, Thus, SET appears to be a modulator of p21(Cip1) inhibitory function. These results suggest that SET can regulate G(1)/S transition by modulating the activity of cyclin E-CDK2.	Univ Barcelona, Fac Med, Inst Invest Biomed August Pi Sunyer, Dept Biol Cellular & Anat Patol, Barcelona 08036, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Bachs, O (corresponding author), Univ Barcelona, Fac Med, Inst Invest Biomed August Pi Sunyer, Dept Biol Cellular & Anat Patol, Casanova 143, Barcelona 08036, Spain.	bachs@medicina.ub.es	Estanyol, Josep M/I-1039-2015; Agell, Neus/E-9640-2016; Jaumot, Montserrat/F-2640-2016; Casanovas, Oriol/L-5210-2014	Estanyol, Josep M/0000-0001-8621-0057; Agell, Neus/0000-0002-1205-6074; Jaumot, Montserrat/0000-0003-2864-357X; Casanovas, Oriol/0000-0002-4298-3995				ADACHI Y, 1994, FEBS LETT, V340, P231, DOI 10.1016/0014-5793(94)80144-4; ADACHI Y, 1994, J BIOL CHEM, V269, P2258; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Cai K, 1998, P NATL ACAD SCI USA, V95, P12254, DOI 10.1073/pnas.95.21.12254; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Dai K, 1996, J BIOL CHEM, V271, P22030, DOI 10.1074/jbc.271.36.22030; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Estanol JM, 1997, CANCER RES, V57, P55; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GRANA X, 1995, ONCOGENE, V11, P211; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; HARPER JW, 1993, CELL, V75, P805; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Jaumot M, 1997, BIOCHEM BIOPH RES CO, V241, P434, DOI 10.1006/bbrc.1997.7787; Kato Akira, 1997, Leukemia (Basingstoke), V11, P361; KELLOGG DR, 1995, J CELL BIOL, V130, P661, DOI 10.1083/jcb.130.3.661; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NAGATA K, 1995, P NATL ACAD SCI USA, V92, P4279, DOI 10.1073/pnas.92.10.4279; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; Parry D, 1999, MOL CELL BIOL, V19, P1775; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Taules M, 1999, J BIOL CHEM, V274, P24445, DOI 10.1074/jbc.274.35.24445; Taules M, 1998, J BIOL CHEM, V273, P33279, DOI 10.1074/jbc.273.50.33279; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANAGIDA M, 1992, CIBA F SYMP, V170, P130	43	76	76	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					33161	33165		10.1074/jbc.274.46.33161	http://dx.doi.org/10.1074/jbc.274.46.33161			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551888	hybrid			2022-12-25	WOS:000083623000088
J	Hood, BD; Garner, B; Truscott, RJW				Hood, BD; Garner, B; Truscott, RJW			Human lens coloration and aging - Evidence for crystallin modification by the major ultraviolet filter, 3-hydroxy-kynurenine O-beta-D-glucoside	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSOLUBLE PROTEIN-FRACTION; FLUORESCENT COMPOUND; NUCLEAR CATARACT; AGE	The human lens becomes increasingly yellow with age and thereby reduces our perception of blue light. This coloration is associated with lens proteins (crystallins), but its molecular basis was unknown. Here we show that the coloration occurs because of the interaction of crystallins with a UV filter compound, 3-hydroxykynurenine glucoside (3-OHKG), Crystallin modification results from deamination of the 3-OHKG amino acid side chain, yielding an unsaturated ketone that is susceptible to nucleophilic attack by cysteine, histidine, and lysine residues. This novel protein modification contributes to age-related lens coloration and may play a role in human nuclear cataractogenesis.	Univ Wollongong, Dept Chem, Australian Cataract Res Fdn, Wollongong, NSW 2522, Australia	University of Wollongong	Truscott, RJW (corresponding author), Univ Wollongong, Dept Chem, Australian Cataract Res Fdn, POB 1144, Wollongong, NSW 2522, Australia.							BANDO M, 1985, EXP EYE RES, V40, P813, DOI 10.1016/0014-4835(85)90126-5; BESSEMS GJH, 1987, INVEST OPHTH VIS SCI, V28, P1157; BLOEMENDAL H, 1977, SCIENCE, V197, P127, DOI 10.1126/science.877544; BOVA LM, 1999, IN PRESS INVESTIGOPH; DAS SK, 1994, BIOORG MED CHEM LETT, V4, P1219; Dickerson JE, 1997, EXP EYE RES, V65, P451, DOI 10.1006/exer.1997.0343; Dillon J, 1999, PHOTOCHEM PHOTOBIOL, V69, P248, DOI 10.1562/0031-8655(1999)069<0248:TPAOTG>2.3.CO;2; FRIEDMAN M, 1964, J AM CHEM SOC, V86, P3735, DOI 10.1021/ja01072a025; Fu SL, 1998, J BIOL CHEM, V273, P28603, DOI 10.1074/jbc.273.44.28603; Garner B, 1999, J BIOL CHEM, V274, P20847, DOI 10.1074/jbc.274.30.20847; INOUE A, 1993, BIOORG MED CHEM LETT, V3, P345, DOI 10.1016/S0960-894X(01)80907-0; LERMAN S, 1976, OPHTHALMIC RES, V8, P335, DOI 10.1159/000264841; Manthey MK, 1999, J ORG CHEM, V64, P3930, DOI 10.1021/jo982321n; STUTCHBURY GM, 1993, EXP EYE RES, V57, P149, DOI 10.1006/exer.1993.1110; Sweeney MHJ, 1998, EXP EYE RES, V67, P587, DOI 10.1006/exer.1998.0549; TOKUYAMA T, 1967, J AM CHEM SOC, V89, P1017, DOI 10.1021/ja00980a046; TOKUYAMA T, 1958, J CHEM SOC JAPAN, V79, P152; TRUSCOTT RJW, 1977, EXP EYE RES, V24, P159, DOI 10.1016/0014-4835(77)90256-1; TRUSCOTT RJW, 1994, FEBS LETT, V348, P173, DOI 10.1016/0014-5793(94)00601-6; VANHEYNI.R, 1971, NATURE, V230, P393, DOI 10.1038/230393a0; WEALE RA, 1988, J PHYSIOL-LONDON, V395, P577, DOI 10.1113/jphysiol.1988.sp016935; WOOD AM, 1993, EXP EYE RES, V56, P317, DOI 10.1006/exer.1993.1041; YAPPERT MC, 1992, INVEST OPHTH VIS SCI, V33, P3555; YU NT, 1989, EXP EYE RES, V49, P189, DOI 10.1016/0014-4835(89)90089-4	24	102	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32547	32550		10.1074/jbc.274.46.32547	http://dx.doi.org/10.1074/jbc.274.46.32547			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551806	hybrid			2022-12-25	WOS:000083623000006
J	Pradhan, S; Bacolla, A; Wells, RD; Roberts, RJ				Pradhan, S; Bacolla, A; Wells, RD; Roberts, RJ			Recombinant human DNA (cytosine-5) methyltransferase I. Expression, purification, and comparison of de novo and maintenance methylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACULOVIRUS-MEDIATED EXPRESSION; ESCHERICHIA-COLI; CDNA; BINDING; MECHANISM; DOMAIN; CELLS; REPLICATION; CLEAVAGE; MUTATION	A method is described to express and purify human DNA (cytosine-5) methyltransferase (human DNMT1) using a protein splicing (intein) fusion partner in a baculovirus expression vector. The system produces similar to 1 mg of intact recombinant enzyme >95% pure per 1.5 x 10(9) insect cells. The protein lacks any affinity tag and is identical to the native enzyme except for the two C-terminal amino acids, proline and glycine, that were substituted for lysine and aspartic acid for optimal cleavage from the intein affinity tag. Human DNMT1 was used for steady-state kinetic analysis with poly(dI-dC).poly(dI-dC) and unmethylated and hemimethylated 36- and 75-mer oligonucleotides. The turnover number (k(cat)) was 131-237 h(-1) on poly(dI-dC).poly(dI-dC), 1.2-2.3 h(-1) on unmethylated DNA, and 8.3-49 h(-1) on hemimethylated DNA. The Michaelis constants for DNA (K-m(CG)) and S-adenosyl-L-methionine (AdoMet) (K-m(AdoMet)) ranged from 0.33-1.32 and 2.6-7.2 mu M, respectively, whereas the ratio of k(cat)/K-m(CG) ranged from 3.9 to 44 (237-336 for poly(dI-dC).poly(dI-dC)) x 10(6) M-1 h(-1). The preference of the enzyme for hemimethylated, over unmethylated, DNA was 7-21-fold. The values of k(cat) on hemimethylated DNAs showed a 2-3-fold difference, depending upon which strand was pre-methylated. Furthermore, human DNMT1 formed covalent complexes with substrates containing 5-fluoro-CNG, indicating that substrate specificity extended beyond the canonical CG dinucleotide. These results show that, in addition to maintenance methylation, human DNMT1 may also carry out de novo and non-CG methyltransferase activities in vivo.	New England Biolabs Inc, Beverly, MA 01915 USA; Texas A&M Univ, Texas Med Ctr, Inst Biosci & Technol, Ctr Genome Res, Houston, TX 77030 USA	Baylor College of Medicine; Texas A&M University System	Roberts, RJ (corresponding author), New England Biolabs Inc, 32 Tozer Rd, Beverly, MA 01915 USA.	roberts@neb.com	Bacolla, Albino/AAP-1727-2020; Bacolla, Albino/N-3877-2013	Bacolla, Albino/0000-0003-0206-8423; Bacolla, Albino/0000-0003-0206-8423; Roberts, Richard/0000-0002-4348-0169	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046127, P01GM052982] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037554] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46127, GM52982] Funding Source: Medline; NINDS NIH HHS [NS37554] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS RLP, 1986, BIOCHIM BIOPHYS ACTA, V868, P9, DOI 10.1016/0167-4781(86)90080-1; Aniello F, 1996, GENE, V178, P57, DOI 10.1016/0378-1119(96)00334-4; Bacolla A, 1999, J BIOL CHEM, V274, P33011, DOI 10.1074/jbc.274.46.33011; BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; BURNS JA, 1991, J ORG CHEM, V56, P2648, DOI 10.1021/jo00008a014; CAROTTI D, 1986, BIOCHIM BIOPHYS ACTA, V866, P135, DOI 10.1016/0167-4781(86)90110-7; Chong SR, 1996, J BIOL CHEM, V271, P22159, DOI 10.1074/jbc.271.36.22159; CHRISTMAN JK, 1995, P NATL ACAD SCI USA, V92, P7347, DOI 10.1073/pnas.92.16.7347; Chuang LSH, 1996, J MOL BIOL, V257, P935, DOI 10.1006/jmbi.1996.0213; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; CLARK SJ, 1995, NAT GENET, V10, P20, DOI 10.1038/ng0595-20; COPELAND RA, 1996, ENZYMES PRACTICAL IN, P93; CZANK A, 1991, GENE, V109, P259, DOI 10.1016/0378-1119(91)90618-L; DAVIS TR, 1992, BIO-TECHNOL, V10, P1148, DOI 10.1038/nbt1092-1148; FINNEGAN EJ, 1993, NUCLEIC ACIDS RES, V21, P2383, DOI 10.1093/nar/21.10.2383; Flynn J, 1996, BIOCHEMISTRY-US, V35, P7308, DOI 10.1021/bi9600512; Flynn J, 1998, J MOL BIOL, V279, P101, DOI 10.1006/jmbi.1998.1761; Glickman JF, 1997, BIOCHEM BIOPH RES CO, V230, P280, DOI 10.1006/bbrc.1996.5943; GLICKMAN JF, 1994, BIOCHEM BIOPH RES CO, V204, P1003, DOI 10.1006/bbrc.1994.2562; Graessmann M, 1993, EXS, V64, P404; HANCK T, 1993, NUCLEIC ACIDS RES, V21, P303, DOI 10.1093/nar/21.2.303; HITT MM, 1988, J BIOL CHEM, V263, P4392; Imbert G, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P27; KEALEY JT, 1994, BIOCHIMIE, V76, P1133, DOI 10.1016/0300-9084(94)90042-6; Kho MR, 1998, J MOL BIOL, V275, P67, DOI 10.1006/jmbi.1997.1430; Kimura H, 1996, J BIOCHEM, V120, P1182; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KUMAR S, 1994, NUCLEIC ACIDS RES, V22, P1, DOI 10.1093/nar/22.1.1; LAAYOUN A, 1995, NUCLEIC ACIDS RES, V23, P1584, DOI 10.1093/nar/23.9.1584; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P124; Pradhan S, 1998, NUCLEIC ACIDS RES, V26, P1214, DOI 10.1093/nar/26.5.1214; Pradhan S, 1997, NUCLEIC ACIDS RES, V25, P4666, DOI 10.1093/nar/25.22.4666; Reale A, 1995, BIOCHEM J, V312, P855, DOI 10.1042/bj3120855; Rein T, 1997, MOL CELL BIOL, V17, P416, DOI 10.1128/MCB.17.1.416; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmutte C, 1998, BIOL CHEM, V379, P377; SEGEL IH, 1975, ENZYME KINETICS, P813; Shapiro H.S., 1970, CRC HDB BIOCH SELECT, P80; TAJIMA S, 1995, J BIOCHEM-TOKYO, V117, P1050, DOI 10.1093/oxfordjournals.jbchem.a124805; TOLLEFSBOL TO, 1995, J BIOL CHEM, V270, P18543, DOI 10.1074/jbc.270.31.18543; TURNBULL JF, 1976, NUCLEIC ACIDS RES, V3, P677, DOI 10.1093/nar/3.3.677; WICKHAM TJ, 1991, BIOTECHNOL LETT, V13, P483, DOI 10.1007/BF01049204; Woodcock DM, 1997, J BIOL CHEM, V272, P7810, DOI 10.1074/jbc.272.12.7810; WU JC, 1987, J BIOL CHEM, V262, P4778; XU GR, 1995, BIOCHEM BIOPH RES CO, V207, P544, DOI 10.1006/bbrc.1995.1222; YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287	51	457	474	0	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					33002	33010		10.1074/jbc.274.46.33002	http://dx.doi.org/10.1074/jbc.274.46.33002			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551868	hybrid			2022-12-25	WOS:000083623000068
J	Schuit, F; Moens, K; Heimberg, H; Pipeleers, D				Schuit, F; Moens, K; Heimberg, H; Pipeleers, D			Cellular origin of hexokinase in pancreatic islets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEVATED GLUCOSE-LEVELS; BETA-CELLS; INSULIN-SECRETION; B-CELLS; GLUCOKINASE ACTIVITY; GENE-EXPRESSION; ALPHA-CELLS; FATTY-ACIDS; RAT ISLETS; METABOLISM	Transgenic or tumoral pancreatic islet beta cells with enhanced expression of low IS, hexokinases (HK) exhibit a leftward shift of the normal dose-response curve for glucose-induced insulin release. Furthermore, HK catalyzes roughly 50% of total glucose phosphorylation measured in extracts from freshly isolated rodent islets, suggesting that HK participates in the process of glucose sensing in beta cells, We previously observed that HK activity represents 20% of total glucose phosphorylation in purified rat beta cell preparations and that HK is not homogenously distributed over these cells. The present study provides several arguments for the idea that HH detected in freshly isolated rat islets or islet cell preparations originates mainly from contaminating exocrine cells. First, reverse transcriptase-polymerase chain reaction using isoform-specific primers allowed detection of hexokinase I and IV mRNA in rat beta cells, whereas the messenger levels encoding the hexokinase II and III isoforms were undetectably low, However, immunoblots indicated that hexokinase I protein was 10-fold more abundant in freshly isolated islets and flow-sorted exocrine cells than in purified rat beta cell preparations. Second, comparison of HII activity in the different pancreatic cell types resulted in 15-25-foId higher values in exocrine than in endocrine cells (acinar cells: 21 +/- 3 pmol of glucose 6-phosphate formed/h/ng of DNA; duct cells: 30 +/- 8 pmol/h/ng of DNA; islet beta cells: 1.2 +/- 0.2 pmol/h/ng DNA; alpha cells: 0.9 +/- 0.4 pmol/h/ng of DNA), Since freshly purified beta cell preparations contain 3 +/- 1% exocrine cells, at least 50% of their HK activity can be accounted for by exocrine contamination, Third, after 5 days of culture of purified islet beta cells, both HK activity and the proportion of exocrine cells decreased by more than 1 order of magnitude, while the ratio of glucokinase over hexokinase activity increased more than 10-fold, Finally, preincubating the cells with 50 mmol/liter 2-deoxyglucose did not affect glucose stimulation of insulin biosynthesis and release, In conclusion, the observation that pancreatic exocrine cells are responsible for a major part of HK activity in islet cell preparations cautions against the use of HK measurements in islet extracts in the study of these enzymes in glucose sensing by pancreatic beta cells.	Free Univ Brussels, Fac Med, Ctr Diabet Res, Dept Biochem, B-1090 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel	Schuit, F (corresponding author), Free Univ Brussels, Fac Med, Ctr Diabet Res, Dept Biochem, Laarbeeklaan 103, B-1090 Brussels, Belgium.			Pipeleers, Daniel/0000-0002-6440-2485; Heimberg, Harry/0000-0003-1954-7375				ASHCROFT SJ, 1970, BIOCHEM J, V119, P5, DOI 10.1042/bj1190005; Becker TC, 1996, J BIOL CHEM, V271, P390, DOI 10.1074/jbc.271.1.390; BONTEMPS F, 1978, BIOCHEM J, V174, P603, DOI 10.1042/bj1740603; BOUWENS L, 1995, J HISTOCHEM CYTOCHEM, V43, P245, DOI 10.1177/43.3.7532655; Detimary P, 1998, J BIOL CHEM, V273, P33905, DOI 10.1074/jbc.273.51.33905; DEVOS A, 1995, J CLIN INVEST, V96, P2489, DOI 10.1172/JCI118308; EFRAT S, 1993, DIABETES, V42, P901, DOI 10.2337/diabetes.42.6.901; EPSTEIN PN, 1992, P NATL ACAD SCI USA, V89, P12038, DOI 10.1073/pnas.89.24.12038; FERBER S, 1994, J BIOL CHEM, V269, P11523; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; GERMAN MS, 1993, P NATL ACAD SCI USA, V90, P1781, DOI 10.1073/pnas.90.5.1781; GIROIX MH, 1984, BIOCHEM J, V223, P447, DOI 10.1042/bj2230447; Glaser B, 1998, NEW ENGL J MED, V338, P226, DOI 10.1056/NEJM199801223380404; GRUPE A, 1995, CELL, V83, P69, DOI 10.1016/0092-8674(95)90235-X; Heimberg H, 1996, P NATL ACAD SCI USA, V93, P7036, DOI 10.1073/pnas.93.14.7036; HEIMBERG H, 1993, EMBO J, V12, P2873, DOI 10.1002/j.1460-2075.1993.tb05949.x; HEIMBERG H, 1995, J BIOL CHEM, V270, P8971, DOI 10.1074/jbc.270.15.8971; Hirose H, 1996, J BIOL CHEM, V271, P5633, DOI 10.1074/jbc.271.10.5633; HOSAKOWA H, 1995, DIABETES, V44, P128; Hosokawa H, 1997, DIABETOLOGIA, V40, P392, DOI 10.1007/s001250050692; ISHIHARA H, 1994, J BIOL CHEM, V269, P3081; IYNEDJIAN PB, 1995, BIOCHEM J, V293, P231; Jonas JC, 1999, J BIOL CHEM, V274, P14112, DOI 10.1074/jbc.274.20.14112; KIEKENS R, 1992, J CLIN INVEST, V89, P117, DOI 10.1172/JCI115551; LIANG Y, 1990, J BIOL CHEM, V265, P16863; Ling ZD, 1996, DIABETES, V45, P1774, DOI 10.2337/diabetes.45.12.1774; Ling ZD, 1996, J CLIN INVEST, V98, P2805, DOI 10.1172/JCI119108; LYNCH RM, 1991, J CELL BIOL, V112, P385, DOI 10.1083/jcb.112.3.385; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MALAISSE WJ, 1976, J BIOL CHEM, V251, P1731; MATSCHIN.FM, 1968, J BIOL CHEM, V243, P2730; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; MILBURN JL, 1995, J BIOL CHEM, V270, P1295, DOI 10.1074/jbc.270.3.1295; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; PIPELEERS D, 1987, DIABETOLOGIA, V30, P277, DOI 10.1007/BF00299019; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; PIPELEERS DG, 1981, DIABETOLOGIA, V20, P654; Piston DW, 1999, J BIOL CHEM, V274, P1000, DOI 10.1074/jbc.274.2.1000; Rabuazzo AM, 1997, DIABETES, V46, P1148, DOI 10.2337/diabetes.46.7.1148; Sakura H, 1998, DIABETOLOGIA, V41, P654, DOI 10.1007/s001250050964; SCHUIT FC, 1991, BIOCHEM BIOPH RES CO, V178, P1182, DOI 10.1016/0006-291X(91)91017-7; SEKINE N, 1994, J BIOL CHEM, V269, P4895; SHIMIZU T, 1988, DIABETES, V37, P1524, DOI 10.2337/diabetes.37.11.1524; Sweet IR, 1996, AM J PHYSIOL-ENDOC M, V271, pE606, DOI 10.1152/ajpendo.1996.271.3.E606; VANSCHAFTINGEN E, 1989, EUR J BIOCHEM, V179, P179; VANSCHAFTINGEN E, 1999, ADV MOL CEL, V29, P199; Weinhaus AJ, 1996, ENDOCRINOLOGY, V137, P1640, DOI 10.1210/en.137.5.1640	47	46	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32803	32809		10.1074/jbc.274.46.32803	http://dx.doi.org/10.1074/jbc.274.46.32803			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551841	hybrid			2022-12-25	WOS:000083623000041
J	Akiyama, H; Hiraki, Y; Noda, M; Shigeno, C; Ito, H; Nakamura, T				Akiyama, H; Hiraki, Y; Noda, M; Shigeno, C; Ito, H; Nakamura, T			Molecular cloning and biological activity of a novel Ha-ras suppressor gene predominantly expressed in skeletal muscle, heart, brain, and bone marrow by differential display using clonal mouse EC cells, ATDC5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINE ATDC5; IN-VITRO; CHONDROGENESIS; CALCIFICATION; RESISTANT; GROWTH	We cloned a cDNA encoding a novel mouse protein, named A-C1, by differential display between two mouse cell lines: embryonic fibroblast C3HIOT1/2 and chondrogenic ATDC5. The deduced amino acid sequence of A-CI consists of 167 amino acids and shows 46% identity with that of a ras-responsive gene, rat Ha-rev107. Northern blot analysis showed a distinct hybridization band of 3.2 kilobases. Expression of A-C1 mRNA was detected in undifferentiated ATDC5 cells and myoblastic C2C12 cells, while none of C3H10T1/2 cells, NIH3T3 fibroblasts, Balb/c 3T3 fibroblasts, osteoblastic MC3T3-E1 cells, and ST2 bone marrow stromal cells expressed A-C1 mRNA in vitro. Moreover, A-CI mRNA was expressed in skeletal muscle, heart, brain, and bone marrow in adult mice. By in situ hybridization, A-C1 gene expression was localized in hippocampus as well as bone marrow cells. By immunocytochemistry, A-C1 protein was detected in the cytoplasm as web as perinuclear region of the cells. Transfection of A-C1 cDNA into Ha-ras-transformed NIH3T3 cell Line caused increase in the number of flat colonies and inhibition of cell growth. Our data indicate that A-C1 is expressed in some specific tissues in vivo and modulates Ba-ras-mediated signaling pathway.	Kyoto Univ, Grad Sch Med, Dept Orthopaed Surg, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Nucl Med & Diagnost Imaging, Calcium Lab, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Kyoto 6068507, Japan; Kyoto Univ, Inst Frontier Med Sci, Dept Mol Interact & Tissue Engn, Kyoto 6068507, Japan	Kyoto University; Kyoto University; Kyoto University; Kyoto University	Akiyama, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Orthopaed Surg, Kyoto 6068507, Japan.							AARONSON SA, 1968, SCIENCE, V162, P1024, DOI 10.1126/science.162.3857.1024; AHRENS M, 1993, DNA CELL BIOL, V12, P871, DOI 10.1089/dna.1993.12.871; Akiyama H, 1996, J BONE MINER RES, V11, P22; Akiyama H, 1997, BIOCHEM BIOPH RES CO, V235, P142, DOI 10.1006/bbrc.1997.6750; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHIU CP, 1984, CELL, V37, P879, DOI 10.1016/0092-8674(84)90423-9; FURTH ME, 1987, ONCOGENE, V1, P47; HAJNAL A, 1994, ONCOGENE, V9, P479; IYAMA K, 1991, ANAT RECORD, V229, P462, DOI 10.1002/ar.1092290405; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; OGAWA M, 1988, EMBO J, V7, P1337, DOI 10.1002/j.1460-2075.1988.tb02949.x; Shukunami C, 1998, EXP CELL RES, V241, P1, DOI 10.1006/excr.1998.4045; Shukunami C, 1997, J BONE MINER RES, V12, P1174, DOI 10.1359/jbmr.1997.12.8.1174; Shukunami C, 1996, J CELL BIOL, V133, P457, DOI 10.1083/jcb.133.2.457; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; ZIPORI D, 1985, J CELL PHYSIOL, V122, P81, DOI 10.1002/jcp.1041220113	23	47	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32192	32197		10.1074/jbc.274.45.32192	http://dx.doi.org/10.1074/jbc.274.45.32192			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542256	hybrid			2022-12-25	WOS:000083532100064
J	Disatnik, MH; Rando, TA				Disatnik, MH; Rando, TA			Integrin-mediated muscle cell spreading - The role of protein kinase C in outside-in and inside-out signaling and evidence of integrin cross-talk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; EXTRACELLULAR-MATRIX; FOCAL ADHESIONS; MUSCULAR-DYSTROPHY; FIBRONECTIN; PHOSPHORYLATION; SURVIVAL; EXPRESSION; TRANSDUCTION; ACTIVATION	Muscle cell survival depends upon the presence of various integrins with affinities for different extracellular matrix proteins. The absence of either alpha(5) or alpha(7) integrins leads to degenerative disorders of skeletal muscle, muscular dystrophies. To understand the cell survival signals that are mediated by integrin engagement with matrix proteins, we studied the early signaling events initiated by the attachment of muscle cells to fibronectin, an interaction that is mediated primarily by alpha(5) integrins, Cells that express alpha(5) integrin rapidly spread on fibronectin, and this process is associated with the phosphorylation of focal adhesion kinase (FAK). Cells deficient in alpha(5) integrin failed to spread or promote FAK phosphorylation when plated on fibronectin, For alpha(5)-expressing cells, both spreading and FAK phosphorylation could be blocked by inhibitors of protein kinase C (PKC), indicating that PKC is necessary for this "outside-in signaling" mediated by alpha(5) integrin. Surprisingly, activators of PKC could promote spreading and FAK phosphorylation in alpha(5)-deficient muscle cells plated on fibronectin, This PKC-induced cell spreading appeared to be due to activation of alpha(4) integrins ("inside-out signaling") since it could be blocked by peptides that specifically inhibit alpha(4) integrin binding to fibronectin, A model of integrin signaling in muscle cells is presented in which there is a positive feedback loop involving PHC in both outside-in and inside-out signaling, and the activation of this cycle is essential for cell spreading and downstream signaling to promote cell survival. In addition, the data indicate a cross-talk that occurs between integrins in which the outside-in signaling via one integrin can promote the activation of another integrin via inside-out signaling.	Stanford Univ, Med Ctr, Dept Neurol & Neurol Sci, Sch Med, Stanford, CA 94305 USA; Vet Affairs Med Ctr, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Rando, TA (corresponding author), Stanford Univ, Med Ctr, Dept Neurol & Neurol Sci, Sch Med, Room A-343, Stanford, CA 94305 USA.	rando@stanford.edu			NINDS NIH HHS [R01 NS-36409] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036409] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BATES RC, 1995, CANCER METAST REV, V14, P191, DOI 10.1007/BF00690291; BROWN PJ, 1988, BIOCHEM BIOPH RES CO, V155, P603, DOI 10.1016/S0006-291X(88)80537-0; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DANILOV YN, 1989, J CELL BIOL, V108, P1925, DOI 10.1083/jcb.108.5.1925; DeNichilo MO, 1996, J BIOL CHEM, V271, P11016, DOI 10.1074/jbc.271.18.11016; Emkey R, 1997, J BIOL CHEM, V272, P31172, DOI 10.1074/jbc.272.49.31172; Faull RJ, 1996, J AM SOC NEPHROL, V7, P1091; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; Haimovich B, 1996, BLOOD, V87, P152, DOI 10.1182/blood.V87.1.152.bloodjournal871152; Haller H, 1998, CIRC RES, V82, P157; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hayashi YK, 1998, NAT GENET, V19, P94, DOI 10.1038/ng0598-94; Hocking DC, 1998, J CELL BIOL, V141, P241, DOI 10.1083/jcb.141.1.241; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ilic D, 1998, J CELL BIOL, V143, P547; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Kolanus W, 1997, CURR OPIN CELL BIOL, V9, P725, DOI 10.1016/S0955-0674(97)80127-5; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; Lichtner RB, 1998, EXP CELL RES, V240, P368, DOI 10.1006/excr.1998.4012; MATSUMURA K, 1994, MUSCLE NERVE, V17, P2, DOI 10.1002/mus.880170103; Mayer U, 1997, NAT GENET, V17, P318, DOI 10.1038/ng1197-318; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Montanaro F, 1999, J CELL BIOL, V145, P1325, DOI 10.1083/jcb.145.6.1325; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; ROSALES C, 1995, BBA-REV CANCER, V1242, P77, DOI 10.1016/0304-419X(95)00005-Z; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; Rozengurt E, 1997, ESSAYS BIOCHEM, V32, P73; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; Short SM, 1998, MOL BIOL CELL, V9, P1969, DOI 10.1091/mbc.9.8.1969; Taverna D, 1998, J CELL BIOL, V143, P849, DOI 10.1083/jcb.143.3.849; Vachon PH, 1997, J CLIN INVEST, V100, P1870, DOI 10.1172/JCI119716; Vachon PH, 1996, J CELL BIOL, V134, P1483, DOI 10.1083/jcb.134.6.1483; VUORI K, 1993, J BIOL CHEM, V268, P21459; WOODS A, 1992, J CELL SCI, V101, P277; YAMADA KM, 1984, J CELL BIOL, V99, P29, DOI 10.1083/jcb.99.1.29; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	41	97	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32486	32492		10.1074/jbc.274.45.32486	http://dx.doi.org/10.1074/jbc.274.45.32486			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542294	hybrid			2022-12-25	WOS:000083532100102
J	Bauman, SJ; Church, FC				Bauman, SJ; Church, FC			Enhancement of heparin cofactor II anticoagulant activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PROTEINASE-INHIBITORS; PROLINE-RICH GLYCOPROTEIN; REACTIVE-SITE; THROMBIN INHIBITION; ESCHERICHIA-COLI; ANTITHROMBIN-III; DERMATAN SULFATE; ACIDIC DOMAIN; HUMAN-PLASMA; C INHIBITOR	Heparin cofactor II (HCII) is a serpin whose thrombin inhibition activity is accelerated by glycosaminoglycans. We describe the novel properties of a carboxyl-terminal histidine-tagged recombinant HCII (rHCII-CHis(6)). Thrombin inhibition by rHCII-CHis(6) was increased >2-fold at similar to 5 mu g/ml heparin compared with wild-type recombinant HCII (wt-rHCII) at 50-100 mu g/ml heparin. Enhanced activity of rHCII-CHis(6) was reversed by treatment with carboxypeptidase A. We assessed the role of the HCII acidic domain by constructing aminoterminal deletion mutants (Delta 1-52, Delta 1-68, and Delta 1-75) in wt-rHCII and rHCII-CHis(6). Without glycosaminoglycan, unlike wt-rHCII deletion mutants, the rHCII-CHis(6) deletion mutants were less active compared with full-length rHCII-CHis(6). With glycosaminoglycans, Delta 1-68 and Delta 1-75 rHCIIs were all less active. We assessed the character of the tag by comparing rHCII-CHis(6), rHCII-CAla(6), and rHCII-CLys(6) to wt-rHCII. Only rHCII-CHis(6) had increased activity with heparin, whereas all three mutants have increased heparin binding. We generated a carboxyl-terminal histidine-tagged recombinant antithrombin III to study the tag on another serpin. Interestingly, this mutant antithrombin III had reduced heparin cofactor activity compared with wild-type protein. In a plasma-based assay, the glycosaminoglycan-dependent inhibition of thrombin by rHCII-CHis(6) was significantly greater compared with wt-rHCII. Thus, HCII variants with increased function, such as rHCII-CHis(6), may offer novel reagents for clinical application.	Univ N Carolina, Sch Med, Dept Med, Div Hematol Oncol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Ctr Thrombosis & Hemostasis, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Church, FC (corresponding author), Univ N Carolina, Sch Med, Dept Med, Div Hematol Oncol, Campus Box 7035,932 Mary Ellen Jones Bldg, Chapel Hill, NC 27599 USA.	fchurch@E-mail.unc.edu			NHLBI NIH HHS [HL-32656] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032656] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLINDER MA, 1988, BIOCHEMISTRY-US, V27, P752, DOI 10.1021/bi00402a039; Borza DB, 1996, BIOCHEMISTRY-US, V35, P1925, DOI 10.1021/bi952061t; Borza DB, 1998, J BIOL CHEM, V273, P5493, DOI 10.1074/jbc.273.10.5493; Chan A, 1997, J BIOL CHEM, V272, P22111, DOI 10.1074/jbc.272.35.22111; CHURCH FC, 1986, ANAL BIOCHEM, V157, P77, DOI 10.1016/0003-2697(86)90198-3; CHURCH FC, 1985, P NATL ACAD SCI USA, V82, P6431, DOI 10.1073/pnas.82.19.6431; CHURCH FC, 1997, ADV EXPT MED BIOL; Ciaccia AV, 1997, J BIOL CHEM, V272, P14074, DOI 10.1074/jbc.272.22.14074; Ciaccia AV, 1997, J BIOL CHEM, V272, P888, DOI 10.1074/jbc.272.2.888; Ciaccia AV, 1995, PROTEIN EXPRES PURIF, V6, P806, DOI 10.1006/prep.1995.0012; Ciaccia AV, 1997, PROTEIN PEPTIDE LETT, V4, P215; COOPER ST, 1995, BIOCHEMISTRY-US, V34, P12991, DOI 10.1021/bi00040a009; Dan JH, 1997, J BIOL CHEM, V272, P8243, DOI 10.1074/jbc.272.13.8243; DERECHIN VM, 1990, J BIOL CHEM, V265, P5623; Desai UR, 1998, J BIOL CHEM, V273, P7478, DOI 10.1074/jbc.273.13.7478; GETTINS P, 1992, HEMATOL ONCOL CLIN N, V6, P1393, DOI 10.1016/S0889-8588(18)30282-X; GRIFFITH MJ, 1985, J BIOL CHEM, V260, P2218; GRIFFITH MJ, 1983, BLOOD, V61, P111; GRIFFITH MJ, 1985, BIOCHEMISTRY-US, V24, P6777, DOI 10.1021/bi00345a008; Grinnell BW, 1998, CORONARY ARTERY DIS, V9, P89; Hall SW, 1997, CELL MOL LIFE SCI, V53, P731, DOI 10.1007/s000180050092; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HOPKINS PCR, 1995, J BIOL CHEM, V270, P11866, DOI 10.1074/jbc.270.20.11866; Hopkins PCR, 1997, J BIOL CHEM, V272, P3905, DOI 10.1074/jbc.272.7.3905; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Kashlev M, 1996, METHOD ENZYMOL, V274, P326; Kounnas MZ, 1996, J BIOL CHEM, V271, P6523, DOI 10.1074/jbc.271.11.6523; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lee GF, 1997, BIOCHEMISTRY-US, V36, P5607, DOI 10.1021/bi970388j; LEUNG L, 1998, HEMATOLOGY, P136; MCGUIRE EA, 1987, J BIOL CHEM, V262, P169; MUELLER RL, 1994, CIRCULATION, V89, P432, DOI 10.1161/01.CIR.89.1.432; Myles T, 1998, J BIOL CHEM, V273, P31203, DOI 10.1074/jbc.273.47.31203; OLSON ST, 1992, J BIOL CHEM, V267, P12528; PARKER KA, 1985, J BIOL CHEM, V260, P3501; PETERS D, 1995, EUR J BIOCHEM, V228, P798, DOI 10.1111/j.1432-1033.1995.tb20325.x; PETERSON CB, 1987, J BIOL CHEM, V262, P7567; PRATT CW, 1992, J BIOL CHEM, V267, P8795; PRATT CW, 1993, BLOOD COAGUL FIBRIN, V4, P479, DOI 10.1097/00001721-199306000-00013; PRATT CW, 1988, ARCH BIOCHEM BIOPHYS, V262, P111, DOI 10.1016/0003-9861(88)90173-7; RAGG H, 1990, J BIOL CHEM, V265, P5211; RAGG H, 1990, J BIOL CHEM, V265, P22386; Robeva AS, 1996, BIOCHEM PHARMACOL, V51, P545, DOI 10.1016/0006-2952(95)02235-X; ROGERS SJ, 1992, J BIOL CHEM, V267, P3613; ROTH M, 1983, CLIN CHIM ACTA, V135, P65, DOI 10.1016/0009-8981(83)90389-3; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; TEIEN AN, 1976, THROMB RES, V8, P859, DOI 10.1016/0049-3848(76)90014-1; TOLLEFSEN DM, 1982, J BIOL CHEM, V257, P2162; TOLLEFSEN DM, 1995, THROMB HAEMOSTASIS, V74, P1209; TOLLEFSEN DM, 1985, BLOOD, V66, P769; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; Weitz JI, 1997, NEW ENGL J MED, V337, P688, DOI 10.1056/NEJM199709043371007; WHINNA HC, 1993, J BIOL CHEM, V268, P3920	55	28	28	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34556	34565		10.1074/jbc.274.49.34556	http://dx.doi.org/10.1074/jbc.274.49.34556			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574918	Green Published, hybrid			2022-12-25	WOS:000083979600012
J	Hiiragi, T; Sasaki, H; Nagafuchi, A; Sabe, H; Shen, SC; Matsuki, M; Yamanishi, K; Tsukita, S				Hiiragi, T; Sasaki, H; Nagafuchi, A; Sabe, H; Shen, SC; Matsuki, M; Yamanishi, K; Tsukita, S			Transglutaminase type 1 and its cross-linking activity are concentrated at adherens junctions in simple epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE UVOMORULIN; TISSUE TRANSGLUTAMINASE; KERATINOCYTE TRANSGLUTAMINASE; E-CADHERIN; TYROSINE PHOSPHORYLATION; TERMINAL DIFFERENTIATION; MICROFILAMENT BUNDLES; CYTOPLASMIC DOMAIN; ENDOTHELIAL-CELLS; BINDING PROTEIN	Transglutaminase type 1 was identified as a tyrosinephosphorylated protein from the isolated junctional fraction of the mouse liver. This enzyme was reported to be involved in the covalent cross-linking of proteins in keratinocytes, but its expression and activity in other cell types have not been examined. Northern blotting revealed that transglutaminase type 1 was expressed in large amounts in epithelial tissues (lung, liver, and kidney), which was also confirmed by immunoblotting with antibodies raised against mouse recombinant protein. Immunoblotting of the isolated junctional fraction revealed that transglutaminase type 1 was concentrated in the fraction not only as a 97-kDa form but also as forms of various molecular masses cross-linked to other proteins. In agreement with this finding, endogenous transglutaminase type 1 was immunofluorescently colocalized with E-cadherin in cultured simple epithelial cells. In the liver and kidney, immunoelectron microscopy revealed that transglutaminase type 1 was concentrated, albeit not exclusively, at cadherin-based adherens junctions. Furthermore, by in vitro and in vivo labeling, transglutaminase cross-linking activity was also shown to be concentrated at intercellular junctions of simple epithelial cells. These findings suggested that the formation of covalently cross-linked multimolecular complexes by transglutaminase type 1 is an important mechanism for maintenance of the structural integrity of simple epithelial cells, especially at cadherin-based adherens junctions.	Kyoto Univ, Fac Med, Dept Cell Biol, Sakyo Ku, Kyoto 6068501, Japan; KAN Res Inst Inc, Cell Biol Lab, Shimogyo Ku, Kyoto 6008317, Japan; Jikei Univ, Sch Med, Dept Mol Cell Biol, Inst DNA Med,Minato Ku, Tokyo 1058461, Japan; Osaka Biosci Inst, Dept Biol Mol, Suita, Osaka 5650874, Japan; Kyoto Prefectural Univ Med, Dept Dermatol, Kamigyo Ku, Kyoto 6028566, Japan	Kyoto University; KAN Research Institute; Jikei University; Kyoto Prefectural University of Medicine	Tsukita, S (corresponding author), Kyoto Univ, Fac Med, Dept Cell Biol, Sakyo Ku, Kyoto 6068501, Japan.		Sabe, Hisataka/A-4066-2012; Yamanishi, Kiyofumi/R-2200-2019; Sabe, Hisataka/GPF-4385-2022	Yamanishi, Kiyofumi/0000-0003-0484-2320; Hiiragi, Takashi/0000-0003-4964-7203				BARSIGIAN C, 1991, J BIOL CHEM, V266, P22501; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BIRCKBICHLER PJ, 1977, BIOCHEM BIOPH RES CO, V78, P1, DOI 10.1016/0006-291X(77)91213-X; BOLLER K, 1985, J CELL BIOL, V100, P327, DOI 10.1083/jcb.100.1.327; Chowdhury ZA, 1997, EXP CELL RES, V231, P38, DOI 10.1006/excr.1996.3448; CLARKE DD, 1959, ARCH BIOCHEM BIOPHYS, V79, P338, DOI 10.1016/0003-9861(59)90413-8; Fesus L, 1996, EXPERIENTIA, V52, P942, DOI 10.1007/BF01920102; FINK ML, 1980, P NATL ACAD SCI-BIOL, V77, P4564, DOI 10.1073/pnas.77.8.4564; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; GEIGER B, 1991, CELL MOTIL CYTOSKEL, V20, P1, DOI 10.1002/cm.970200102; GEIGER B, 1979, CELL, V18, P193, DOI 10.1016/0092-8674(79)90368-4; GENTILE V, 1992, J CELL BIOL, V119, P463, DOI 10.1083/jcb.119.2.463; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; HO KC, 1992, J BIOL CHEM, V267, P12660; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; Jones RA, 1997, J CELL SCI, V110, P2461; KIM HC, 1990, J BIOL CHEM, V265, P21971; KIM SY, 1995, J INVEST DERMATOL, V104, P211, DOI 10.1111/1523-1747.ep12612769; Loewy A G, 1968, Thromb Diath Haemorrh Suppl, V28, P1; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Matsuki M, 1998, P NATL ACAD SCI USA, V95, P1044, DOI 10.1073/pnas.95.3.1044; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Parameswaran KN, 1997, J BIOL CHEM, V272, P10311; PERRY MJM, 1995, NEUROSCIENCE, V65, P1063, DOI 10.1016/0306-4522(94)00556-K; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; PIACENTINI M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P171, DOI 10.1016/0167-4889(92)90134-W; RICE RH, 1978, J CELL BIOL, V76, P705, DOI 10.1083/jcb.76.3.705; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SCHROEDER WT, 1992, J INVEST DERMATOL, V99, P27, DOI 10.1111/1523-1747.ep12611394; SHIBAMOTO S, 1995, J CELL BIOL, V128, P949, DOI 10.1083/jcb.128.5.949; SLIFE CW, 1985, ARCH BIOCHEM BIOPHYS, V241, P329, DOI 10.1016/0003-9861(85)90554-5; Steinert PM, 1997, J BIOL CHEM, V272, P2021, DOI 10.1074/jbc.272.3.2021; TAKATA K, 1988, J CELL BIOL, V106, P1757, DOI 10.1083/jcb.106.5.1757; Takeda H, 1995, J CELL BIOL, V131, P1839, DOI 10.1083/jcb.131.6.1839; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; THOMAZY V, 1989, CELL TISSUE RES, V255, P215; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; TSUKITA S, 1989, J CELL BIOL, V108, P2369, DOI 10.1083/jcb.108.6.2369; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; TSUKITA S, 1989, J CELL BIOL, V109, P2905, DOI 10.1083/jcb.109.6.2905; TSUKITA S, 1989, J CELL BIOL, V108, P31, DOI 10.1083/jcb.108.1.31; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; WARREN SL, 1987, MOL CELL BIOL, V7, P1326, DOI 10.1128/MCB.7.4.1326; YAMADA K, 1997, HUM MOL GENET, V6, P223; Zhang JW, 1998, J BIOL CHEM, V273, P2288, DOI 10.1074/jbc.273.4.2288	55	56	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34148	34154		10.1074/jbc.274.48.34148	http://dx.doi.org/10.1074/jbc.274.48.34148			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567386	Green Submitted, hybrid			2022-12-25	WOS:000083857500051
J	Kanelakis, KC; Morishima, Y; Dittmar, KD; Galigniana, MD; Takayama, S; Reed, JC; Pratt, WB				Kanelakis, KC; Morishima, Y; Dittmar, KD; Galigniana, MD; Takayama, S; Reed, JC; Pratt, WB			Differential effects of the hsp70-binding protein BAG-1 on glucocorticoid receptor folding by the hsp90-based chaperone machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; STEROID-BINDING CONFORMATION; PROGESTERONE-RECEPTOR; MOLECULAR CHAPERONES; INDUCED APOPTOSIS; TERMINAL DOMAIN; CANCER-CELLS; HSP90; HSP70; HETEROCOMPLEX	The heat shock protein hsp70/hsc70 is a required component of a five-protein (hsp90, hsp70, Hop, hsp40, and p23) minimal chaperone system reconstituted from reticulocyte lysate that forms glucocorticoid receptor (GR).hsp90 heterocomplexes. BAG-1 is a cofactor that binds to the ATPase domain of hsp70/hsc70 and that modulates its chaperone activity. Inasmuch as BAG-1 has been found in association with several members of the steroid receptor family, we have examined the effect of BAG-1 on GR folding and GR.hsp90 heterocomplex assembly. BAG-1 was present in reticulocyte lysate at a BAG-1:hsp70/hsc70 molar ratio of similar to 0.03, and its elimination by immunoadsorption did not affect GR folding and GR.hsp90 heterocomplex assembly. At low BAG-1:hsp70/hsc70 ratios, BAG-1 promoted the release of Hop from the hsp90-based chaperone system without inhibiting GR.hsp90 heterocomplex assembly. However, at molar ratios approaching stoichiometry with hsp70, BAG-1 produced a concentration-dependent inhibition of GR folding to the steroid-binding form with corresponding inhibition of GR.hsp90 heterocomplex assembly by the minimal five-protein chaperone system. Also, there was decreased steroid-binding activity in cells that were transiently or stably transfected with BAG-1, These observations suggest that, at physiological concentrations, BAG-1 modulates assembly by promoting Hop release from the assembly complex; but, at concentrations closer to those in transfected cells and some transformed cell lines, hsp70 is continuously bound by BAG-1, and heterocomplex assembly is blocked.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; Burnham Inst, Ctr Canc Res, La Jolla, CA 92037 USA	University of Michigan System; University of Michigan; Sanford Burnham Prebys Medical Discovery Institute	Pratt, WB (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 1301 Med Sci Res Bldg 3, Ann Arbor, MI 48109 USA.			GALIGNIANA, MARIO/0000-0002-9130-8574	NATIONAL CANCER INSTITUTE [R01CA067329] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031573, R01DK031573] Funding Source: NIH RePORTER; NCI NIH HHS [CA67329] Funding Source: Medline; NIDDK NIH HHS [DK31573] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Bimston D, 1998, EMBO J, V17, P6871, DOI 10.1093/emboj/17.23.6871; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Chen SY, 1998, J BIOL CHEM, V273, P35194, DOI 10.1074/jbc.273.52.35194; Demand J, 1998, MOL CELL BIOL, V18, P2023, DOI 10.1128/MCB.18.4.2023; Dittmar KD, 1997, J BIOL CHEM, V272, P13047, DOI 10.1074/jbc.272.20.13047; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; Galigniana MD, 1998, MOL ENDOCRINOL, V12, P1903, DOI 10.1210/me.12.12.1903; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hiromura M, 1998, J BIOL CHEM, V273, P5435, DOI 10.1074/jbc.273.10.5435; Hohfeld J, 1998, BIOL CHEM, V379, P269; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; HUTCHISON KA, 1994, J BIOL CHEM, V269, P27894; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; Kosano H, 1998, J BIOL CHEM, V273, P32973, DOI 10.1074/jbc.273.49.32973; Kullmann M, 1998, J BIOL CHEM, V273, P14620, DOI 10.1074/jbc.273.23.14620; Liu R, 1998, J BIOL CHEM, V273, P16985, DOI 10.1074/jbc.273.27.16985; Pierpaoli EV, 1998, J BIOL CHEM, V273, P6643, DOI 10.1074/jbc.273.12.6643; Pratt WB, 1998, TRENDS ENDOCRIN MET, V9, P244, DOI 10.1016/S1043-2760(98)00059-9; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; Srinivasan G, 1997, J STEROID BIOCHEM, V60, P1, DOI 10.1016/S0960-0760(96)00182-3; Stuart JK, 1998, J BIOL CHEM, V273, P22506, DOI 10.1074/jbc.273.35.22506; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; Takayama S, 1996, GENOMICS, V35, P494, DOI 10.1006/geno.1996.0389; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Takayama S, 1998, CANCER RES, V58, P3116; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Toft DO, 1998, TRENDS ENDOCRIN MET, V9, P238, DOI 10.1016/S1043-2760(98)00060-5; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Yang XL, 1998, ONCOGENE, V17, P981, DOI 10.1038/sj.onc.1202032; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465	49	71	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34134	34140		10.1074/jbc.274.48.34134	http://dx.doi.org/10.1074/jbc.274.48.34134			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567384	hybrid			2022-12-25	WOS:000083857500049
J	Kitchens, RL; Wolfbauer, G; Albers, JJ; Munford, RS				Kitchens, RL; Wolfbauer, G; Albers, JJ; Munford, RS			Plasma lipoproteins promote the release of bacterial lipopolysaccharide from the monocyte cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; SCAVENGER RECEPTOR BI; APOLIPOPROTEIN-A-I; BINDING-PROTEIN; CHLAMYDIA-PNEUMONIAE; CHOLESTEROL EFFLUX; SOLUBLE CD14; WHOLE-BLOOD; ENDOTOXIN; LPS	When bacterial lipopolysaccharide (LPS) enters the bloodstream, it is thought to have two general fates. If LPS binds to circulating leukocytes, it triggers innate host defense mechanisms and often elicits toxic reactions. If instead LPS binds to plasma lipoproteins, its bioactivity is largely neutralized. This study shows that lipoproteins can also take up LPS that has first bound to leukocytes, When monocytes were loaded with [H-3]LPS and then incubated in plasma, they released over 70% of the cell-associated [H-3]LPS into lipoproteins (predominantly high density lipoprotein), whereas in serum-free medium the [H-3]LPS remained tightly associated with the cells. The transfer reaction could be reproduced in the presence of pure native lipoproteins or reconstituted high density lipoprotein. Plasma immunodepletion experiments and experiments using recombinant LPS transfer proteins revealed that soluble CD14 significantly enhances LPS release from the cells, high concentrations of EPS-binding protein have a modest effect, and phospholipid transfer protein is unable to facilitate LPS release, Essentially all of the LPS on the monocyte cell surface can be released. Lipoprotein-mediated LPS release was accompanied by a reduction in several cellular responses to the LPS, suggesting that the movement of LPS from leukocytes into lipoproteins may attenuate host responses to LPS in vivo.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75235 USA; Univ Washington, Dept Med, Seattle, WA USA; Univ Washington, NW Lipid Res Labs, Seattle, WA USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Kitchens, RL (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI018188, R01AI018188, R37AI018188] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30086] Funding Source: Medline; NIAID NIH HHS [AI18188] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; BAUMBERGER C, 1991, PATHOBIOLOGY, V59, P378, DOI 10.1159/000163681; Calvo D, 1998, J LIPID RES, V39, P777; CAVAILLON JM, 1990, INFECT IMMUN, V58, P2375, DOI 10.1128/IAI.58.7.2375-2382.1990; CHEUNG MC, 1996, BIOCHIM BIOPHYS ACTA, V1303, P102; CUE JI, 1994, ARCH SURG-CHICAGO, V129, P193; DEDRICK RL, 1995, INFECT IMMUN, V63, P1362, DOI 10.1128/IAI.63.4.1362-1368.1995; DORAN JE, 1994, OLD HER U M, V5, P106; EDELSTEIN C, 1986, METHOD ENZYMOL, V128, P151; FEINGOLD KR, 1995, INFECT IMMUN, V63, P2041, DOI 10.1128/IAI.63.5.2041-2046.1995; FLEGEL WA, 1993, INFECT IMMUN, V61, P5140, DOI 10.1128/IAI.61.12.5140-5146.1993; FUNK JL, 1993, ATHEROSCLEROSIS, V98, P67, DOI 10.1016/0021-9150(93)90224-I; GALLAY P, 1993, J IMMUNOL, V150, P5086; Grunfeld C, 1999, J LIPID RES, V40, P245; Hailman E, 1996, J BIOL CHEM, V271, P12172, DOI 10.1074/jbc.271.21.12172; Hailman E, 1996, J IMMUNOL, V156, P4384; Hardardottir Ingibjorg, 1994, Current Opinion in Lipidology, V5, P207, DOI 10.1097/00041433-199405030-00008; HARRIS HW, 1993, J CLIN INVEST, V91, P1028, DOI 10.1172/JCI116259; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; Hoshino K, 1999, J IMMUNOL, V162, P3749; Jack RS, 1997, NATURE, V389, P742, DOI 10.1038/39622; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Kalayoglu MV, 1998, INFECT IMMUN, V66, P5067, DOI 10.1128/IAI.66.11.5067-5072.1998; Kalayoglu MV, 1998, J INFECT DIS, V177, P725, DOI 10.1086/514241; Kitchens RL, 1998, J IMMUNOL, V160, P1920; KITCHENS RL, 1995, J BIOL CHEM, V270, P9904, DOI 10.1074/jbc.270.17.9904; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; Lerch PG, 1996, VOX SANG, V71, P155, DOI 10.1046/j.1423-0410.1996.7130155.x; LEVINE DM, 1993, P NATL ACAD SCI USA, V90, P12040, DOI 10.1073/pnas.90.24.12040; Liao W, 1996, J LAB CLIN MED, V128, P452, DOI 10.1016/S0022-2143(96)90042-6; MIIDA T, 1992, BIOCHEMISTRY-US, V31, P11112, DOI 10.1021/bi00160a022; MUNFORD RS, 1992, J IMMUNOL METHODS, V148, P115, DOI 10.1016/0022-1759(92)90164-O; MUNFORD RS, 1986, SCIENCE, V234, P203, DOI 10.1126/science.3529396; MUNFORD RS, 1982, J CLIN INVEST, V70, P877, DOI 10.1172/JCI110684; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; Nanjee MN, 1996, ARTERIOSCL THROM VAS, V16, P1203, DOI 10.1161/01.ATV.16.9.1203; NAVAB M, 1991, J CLIN INVEST, V88, P2039, DOI 10.1172/JCI115532; Pajkrt D, 1996, J EXP MED, V184, P1601, DOI 10.1084/jem.184.5.1601; Park CT, 1996, J BIOL CHEM, V271, P18054, DOI 10.1074/jbc.271.30.18054; PARKER TS, 1995, INFECT IMMUN, V63, P253, DOI 10.1128/IAI.63.1.253-258.1995; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; QUEZADO ZMN, 1995, J PHARMACOL EXP THER, V272, P604; READ TE, 1995, SURGERY, V117, P62, DOI 10.1016/S0039-6060(05)80231-4; READ TE, 1995, J EXP MED, V182, P267, DOI 10.1084/jem.182.1.267; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Roth RI, 1998, J INFECT DIS, V177, P388, DOI 10.1086/514204; Rothblat GH, 1999, J LIPID RES, V40, P781; Schimke J, 1998, P NATL ACAD SCI USA, V95, P13875, DOI 10.1073/pnas.95.23.13875; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Stangl H, 1998, J BIOL CHEM, V273, P31002, DOI 10.1074/jbc.273.47.31002; THEOFAN G, 1994, J IMMUNOL, V152, P3623; Thieblemont N, 1998, IMMUNITY, V8, P771, DOI 10.1016/S1074-7613(00)80582-8; ULEVITCH RJ, 1979, J CLIN INVEST, V64, P1516, DOI 10.1172/JCI109610; VanLenten BJ, 1995, J CLIN INVEST, V96, P2758, DOI 10.1172/JCI118345; Whaley K, 1985, METHODS COMPLEMENT C, P77; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Wurfel MM, 1997, J IMMUNOL, V158, P3925; WURFEL MM, 1994, J EXP MED, V180, P1025, DOI 10.1084/jem.180.3.1025; WURFEL MM, 1995, J EXP MED, V181, P1943; Yokoyama S, 1998, BBA-LIPID LIPID MET, V1392, P1, DOI 10.1016/S0005-2760(98)00032-0	60	104	109	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34116	34122		10.1074/jbc.274.48.34116	http://dx.doi.org/10.1074/jbc.274.48.34116			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567381	hybrid			2022-12-25	WOS:000083857500046
J	Yano, M; Mori, S; Kido, H				Yano, M; Mori, S; Kido, H			Intrinsic nucleoside diphosphate kinase-like activity is a novel function of the 20 S proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MULTICATALYTIC PROTEINASE; MOLECULAR CHAPERONE; CRYSTAL-STRUCTURE; ADENYLATE KINASE; SUBUNIT; IDENTIFICATION; PHOSPHORYLATION; PURIFICATION; COMPLEX	The eukaryotic 20 S proteasome is the prototype of a new family of the N-terminal nucleophil hydrolases and is composed of numerous low molecular mass subunits arranged in a stack of four rings, each containing seven different (alpha- or beta-subunits. Among the beta-type subunits in the yeast proteasome, three proteolytically active ones were identified, although the functions of the other beta- and alpha-type subunits remain to be clarified. We report here that the purified 20 S proteasome exhibits intrinsic nucleoside diphosphate (NDP) kinase-like activity. The proteasome exhibited a preference for ATP and dATP as phosphate donors, and a broad specificity for NDPs, other than GDP, as phosphate accepters, unlike conventional NDP kinase, which catalyzes the transfer of gamma-phosphate between ADPs and nucleoside triphosphates. During the transfer of gamma-phosphate, the proteasome formed acid-labile phosphohistidine as autophosphorylated intermediates, and NDP-dependent dephosphorylation of the latter then occurred. These enzymatic properties are similar to those of the molecular chaperone, Hsp70, which also exhibits intrinsic NDP kinase-like activity, instead of ATPase activity. C5 among the beta-type subunits and Cg among the alpha-type subunits were autophosphorylated during the gamma-phosphate transfer reaction and were photoaffinity labeled with 8-azido-[alpha-P-32]ATP, suggesting that the C5 and C8 subunits of the proteasome are responsible for the NDP kinase-like activity.	Univ Tokushima, Inst Enzyme Res, Div Enzyme Chem, Tokushima 770, Japan	Tokushima University	Kido, H (corresponding author), Univ Tokushima, Inst Enzyme Res, Div Enzyme Chem, Tokushima 770, Japan.	kido@ier.tokushima-u.ac.jp						Agarwal R P, 1978, Methods Enzymol, V51, P376; Arendt CS, 1997, P NATL ACAD SCI USA, V94, P7156, DOI 10.1073/pnas.94.14.7156; Baumeister W, 1997, BIOL CHEM, V378, P121; Biondi RM, 1996, ANAL BIOCHEM, V242, P165, DOI 10.1006/abio.1996.0449; BLACK ME, 1992, J BIOL CHEM, V267, P6801; Castano JG, 1996, BIOCHEMISTRY-US, V35, P3782, DOI 10.1021/bi952540s; CHIN DT, 1988, J BIOL CHEM, V263, P11718; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Czarnecki J, 1979, Methods Enzymol, V56, P642; Dahlmann B, 1999, ARCH BIOCHEM BIOPHYS, V363, P296, DOI 10.1006/abbi.1999.1104; DeMartino GN, 1996, J BIOL CHEM, V271, P3112, DOI 10.1074/jbc.271.6.3112; DevilleBonne D, 1996, BIOCHEMISTRY-US, V35, P14643, DOI 10.1021/bi960945m; DICK LR, 1992, BIOCHEMISTRY-US, V31, P7347, DOI 10.1021/bi00147a020; DUBIEL W, 1995, MOL BIOL REP, V21, P27, DOI 10.1007/BF00990967; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Freije JMP, 1997, J BIOL CHEM, V272, P5525, DOI 10.1074/jbc.272.9.5525; Gerards WLH, 1998, J MOL BIOL, V275, P113, DOI 10.1006/jmbi.1997.1429; Goldberg AL, 1997, BIOL CHEM, V378, P131; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HACHIYA N, 1995, NATURE, V376, P705, DOI 10.1038/376705a0; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HEINEMEYER W, 1994, BIOCHEMISTRY-US, V33, P12229, DOI 10.1021/bi00206a028; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Hiromura M, 1998, J BIOL CHEM, V273, P5435, DOI 10.1074/jbc.273.10.5435; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; INGRAHAM JL, 1978, METHOD ENZYMOL, V52, P371; KIDO H, 1990, J BIOL CHEM, V265, P21979; KIDO H, 1988, J BIOL CHEM, V263, P18104; KOPP F, 1995, J MOL BIOL, V248, P264; KOU, 1996, J BIOL CHEM, V271, P19983; KRISTENSEN P, 1994, BIOCHEM BIOPH RES CO, V205, P1785, DOI 10.1006/bbrc.1994.2876; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leung SM, 1997, J BIOL CHEM, V272, P2607, DOI 10.1074/jbc.272.5.2607; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUDEMANN R, 1993, J BIOL CHEM, V268, P17413; Mason GGF, 1996, EUR J BIOCHEM, V238, P453, DOI 10.1111/j.1432-1033.1996.0453z.x; Miles E W, 1977, Methods Enzymol, V47, P431; MOELLER W, 1985, FEBS LETT, V186, P1; MYLES GM, 1991, BIOCHEMISTRY-US, V30, P3824, DOI 10.1021/bi00230a004; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; REINSTEIN J, 1988, BIOCHEMISTRY-US, V27, P4712, DOI 10.1021/bi00413a020; ROISIN MP, 1978, BIOCHIM BIOPHYS ACTA, V526, P418, DOI 10.1016/0005-2744(78)90133-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schmidtke G, 1997, J MOL BIOL, V268, P95, DOI 10.1006/jmbi.1997.0947; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SHIKATA H, 1989, BIOCHEM INT, V18, P943; TANAKA K, 1988, J MOL BIOL, V203, P985, DOI 10.1016/0022-2836(88)90123-4; TANAKA K, 1988, J BIOL CHEM, V263, P16209; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEI YF, 1991, METHOD ENZYMOL, V200, P388; WILLIAMS RL, 1993, J MOL BIOL, V234, P1230, DOI 10.1006/jmbi.1993.1673; Yano M, 1997, FEBS LETT, V419, P244, DOI 10.1016/S0014-5793(97)01469-5; Yoo SJ, 1997, BIOCHEM BIOPH RES CO, V238, P581, DOI 10.1006/bbrc.1997.7341	57	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34375	34382		10.1074/jbc.274.48.34375	http://dx.doi.org/10.1074/jbc.274.48.34375			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567415	hybrid			2022-12-25	WOS:000083857500080
J	Dorner, C; Ullrich, A; Haring, HU; Lammers, R				Dorner, C; Ullrich, A; Haring, HU; Lammers, R			The kinesin-like motor protein KIF1C occurs in intact cells as a dimer and associates with proteins of the 14-3-3 family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; ANTEROGRADE AXONAL-TRANSPORT; MICROTUBULE-BASED MOTILITY; ADRENAL CHROMAFFIN CELLS; ENDOPLASMIC-RETICULUM; ORGANELLE TRANSPORT; SUPERFAMILY PROTEIN; GOLGI-APPARATUS; MONOMERIC MOTOR; LIGHT-CHAIN	Proteins of the kinesin superfamily are regulated in their motor activity as well as in their ability to bind to their cargo by carboxyl-terminal associating proteins and phosphorylation. KIF1C, a recently identified member of the KIF1/Unc104 family, was shown to be involved in the retrograde vesicle transport from the Golgi-apparatus to the endoplasmic reticulum. In a yeast two-hybrid screen using the carboxyl-terminal 350 amino acids of KIF1C as a bait, we identified as binding proteins 14-3-3 beta, gamma, epsilon, and zeta. In addition, a clone encoding the carboxyl-terminal 290 amino acids of KIF1C was found, indicating a potential for KIF1C to dimerize. Subsequent transient overexpression experiments showed that KIF1C can dimerize efficiently. However, in untransfected cells, only a small portion of KIF1C was detected as a dimer. The association of 14-3-3 proteins with KIF1C could be confirmed in transient expression systems and in untransfected cells and was dependent on the phosphorylation of serine 1092 located in a consensus binding sequence for 14-3-3 ligands. Serine 1092 was a substrate for the protein kinase casein kinase II in vitro, and inhibition of casein kinase II in cells diminished the association of KIF1C with 14-3-3 gamma. Our data thus suggest that KIF1C can form dimers and is associated with proteins of the 14-3-3 family.	Univ Tubingen, Med Clin 4, D-72076 Tubingen, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Eberhard Karls University of Tubingen; Max Planck Society	Lammers, R (corresponding author), Univ Tubingen, Med Clin 4, Otfried Muller Str 10, D-72076 Tubingen, Germany.	rrlammer@med.uni-tuebingen.de						ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Alphey L, 1997, J CELL BIOL, V138, P395, DOI 10.1083/jcb.138.2.395; CELIS A, 1988, FEBS LETT, V227, P14, DOI 10.1016/0014-5793(88)81404-2; CHAMBERLAIN LH, 1995, J CELL BIOL, V130, P1063, DOI 10.1083/jcb.130.5.1063; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Dorner C, 1998, J BIOL CHEM, V273, P20267, DOI 10.1074/jbc.273.32.20267; Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; GELPERIN D, 1995, P NATL ACAD SCI USA, V92, P11539, DOI 10.1073/pnas.92.25.11539; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; JONES BG, 1995, EMBO J, V14, P5869, DOI 10.1002/j.1460-2075.1995.tb00275.x; JONES DHA, 1995, J MOL BIOL, V245, P375, DOI 10.1006/jmbi.1994.0031; Karki S, 1997, J BIOL CHEM, V272, P5887, DOI 10.1074/jbc.272.9.5887; Khodjakov A, 1998, MOL BIOL CELL, V9, P333, DOI 10.1091/mbc.9.2.333; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Lupas A, 1996, METHOD ENZYMOL, V266, P513; Moore JD, 1996, BIOESSAYS, V18, P207, DOI 10.1002/bies.950180308; Morfini G, 1997, J CELL BIOL, V138, P657, DOI 10.1083/jcb.138.3.657; Muresan V, 1998, MOL BIOL CELL, V9, P637, DOI 10.1091/mbc.9.3.637; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; NAKATA T, 1995, J CELL BIOL, V131, P1039, DOI 10.1083/jcb.131.4.1039; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; NODA Y, 1995, J CELL BIOL, V129, P157, DOI 10.1083/jcb.129.1.157; OKADA Y, 1995, J NEUROSCI, V15, P3053; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; ROTH D, 1994, BIOCHEM J, V301, P305, DOI 10.1042/bj3010305; ROTH D, 1993, FEBS LETT, V320, P207, DOI 10.1016/0014-5793(93)80587-K; Santama N, 1998, EMBO J, V17, P5855, DOI 10.1093/emboj/17.20.5855; Scholey JM, 1996, J CELL BIOL, V133, P1, DOI 10.1083/jcb.133.1.1; SEKINE Y, 1994, J CELL BIOL, V127, P187, DOI 10.1083/jcb.127.1.187; SFEIR C, 1995, J BONE MINER RES, V10, P607; Tanaka Y, 1998, CELL, V93, P1147, DOI 10.1016/S0092-8674(00)81459-2; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Verhey KJ, 1998, J CELL BIOL, V143, P1053, DOI 10.1083/jcb.143.4.1053; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; WATANABE M, 1993, MOL BRAIN RES, V17, P135, DOI 10.1016/0169-328X(93)90082-Z; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yamazaki H, 1996, P NATL ACAD SCI USA, V93, P8443, DOI 10.1073/pnas.93.16.8443; YAMAZAKI H, 1995, J CELL BIOL, V130, P1387, DOI 10.1083/jcb.130.6.1387; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414; ZANDOMENI RO, 1989, BIOCHEM J, V262, P469, DOI 10.1042/bj2620469	46	58	60	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33654	33660		10.1074/jbc.274.47.33654	http://dx.doi.org/10.1074/jbc.274.47.33654			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559254	hybrid			2022-12-25	WOS:000083745200070
J	Higashida, H; Egorova, A; Higashida, C; Zhong, ZG; Yokoyama, S; Noda, M; Zhang, JS				Higashida, H; Egorova, A; Higashida, C; Zhong, ZG; Yokoyama, S; Noda, M; Zhang, JS			Sympathetic potentiation of cyclic ADP-ribose formation in rat cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-DINUCLEOTIDE PHOSPHATE; ADENYLATE-CYCLASE; CA2+ RELEASE; SARCOPLASMIC-RETICULUM; VENTRICULAR MYOCYTES; REGULATORY PROTEIN; INTRACELLULAR CA2+; RYANODINE RECEPTOR; CADP-RIBOSE; HEART	We examined the role of cyclic ADP-ribose (cADP-ribose) as a second messenger downstream of adrenergic receptors in the heart after excitation of sympathetic neurons. To address this question, ADP-ribosyl cyclase activity was measured as the rate of [H-3]cADP-ribose formation from [H-3]NAD(+) in a crude membrane fraction of rat ventricular myocytes. Isoproterenol at 1 mu M increased ADP-ribosyl cyclase activity by 1.7-fold in ventricular muscle; this increase was inhibited by propranolol, The stimulatory effect on the cyclase was mimicked by 10 nM GTP and 10 mu M guanosine 5'-3-0(thio)triphosphate, whereas 10 mu M GTP inhibited the cyclase, Cholera toxin blocked the activation of the cyclase by isoproterenol and GTP. The above effects of isoproterenol and GTP in ventricular membranes were confirmed by cyclic GDP-ribose formation fluorometrically, These results demonstrate the existence of a signal pathway from beta-adrenergic receptors to membrane-bound ADP-ribosyl cyclase via G protein in the ventricular muscle cells and suggest that increased cADP-ribose synthesis is involved in up-regulation of cardiac function by sympathetic stimulation.	Kanazawa Univ, Grad Sch Med, Dept Biophys Genet, Kanazawa, Ishikawa 9208640, Japan	Kanazawa University	Higashida, H (corresponding author), Kanazawa Univ, Grad Sch Med, Dept Biophys Genet, 13-1 Takara Machi, Kanazawa, Ishikawa 9208640, Japan.	Haruhiro@med.kaazawa-u.ac.jp	higashida, haruhiro/L-3773-2015	higashida, haruhiro/0000-0002-1779-0606				BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; BRANDT DR, 1985, J BIOL CHEM, V260, P266; Cannell MB, 1998, TRENDS PHARMACOL SCI, V19, P16, DOI 10.1016/S0165-6147(97)01149-8; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; GILL DM, 1978, P NATL ACAD SCI USA, V75, P3050, DOI 10.1073/pnas.75.7.3050; Gomez AM, 1997, SCIENCE, V276, P800, DOI 10.1126/science.276.5313.800; Graeff RM, 1998, J BIOL CHEM, V273, P118, DOI 10.1074/jbc.273.1.118; GRAEFF RM, 1994, J BIOL CHEM, V269, P30260; GRIMALDI JC, 1995, J IMMUNOL, V155, P811; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; HARTZELL HC, 1991, NATURE, V351, P573, DOI 10.1038/351573a0; Higashida H, 1997, J BIOL CHEM, V272, P31272, DOI 10.1074/jbc.272.50.31272; Higashida H, 1997, FEBS LETT, V418, P355, DOI 10.1016/S0014-5793(97)01410-5; Iino S, 1997, CIRC RES, V81, P879; KAMEYAMA M, 1986, PFLUG ARCH EUR J PHY, V407, P123, DOI 10.1007/BF00580662; Kaumann AJ, 1997, TRENDS PHARMACOL SCI, V18, P70, DOI 10.1016/S0165-6147(96)01033-4; KIM H, 1993, SCIENCE, V261, P1330, DOI 10.1126/science.8395705; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; LIEBMANN C, 1990, BIOCHEM BIOPH RES CO, V167, P910, DOI 10.1016/0006-291X(90)90610-Y; LIMBIRD LE, 1980, P NATL ACAD SCI-BIOL, V77, P775, DOI 10.1073/pnas.77.2.775; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; Meszaros LG, 1997, BIOCHEM BIOPH RES CO, V234, P252, DOI 10.1006/bbrc.1997.6620; MESZAROS V, 1995, BIOCHEM BIOPH RES CO, V210, P452, DOI 10.1006/bbrc.1995.1681; Morita K, 1997, J BIOL CHEM, V272, P21002, DOI 10.1074/jbc.272.34.21002; MOSS J, 1994, METHOD ENZYMOL, V235, P44; Noguchi N, 1997, J BIOL CHEM, V272, P3133, DOI 10.1074/jbc.272.6.3133; POHL SL, 1971, J BIOL CHEM, V246, P1849; Rakovic S, 1996, CURR BIOL, V6, P989, DOI 10.1016/S0960-9822(02)00643-7; ROSS EM, 1980, ANNU REV BIOCHEM, V49, P553, DOI 10.1146/annurev.bi.49.070180.002533; SABOL SL, 1979, J BIOL CHEM, V254, P1913; Santana LF, 1998, SCIENCE, V279, P1027, DOI 10.1126/science.279.5353.1027; Sham JSK, 1997, J PHYSIOL-LONDON, V500, P285, DOI 10.1113/jphysiol.1997.sp022020; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P590, DOI 10.1073/pnas.72.2.590; SITSAPESAN R, 1995, TRENDS PHARMACOL SCI, V16, P386, DOI 10.1016/S0165-6147(00)89080-X; Takasawa S, 1998, J BIOL CHEM, V273, P2497, DOI 10.1074/jbc.273.5.2497; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; Tanaka H, 1998, J PHYSIOL-LONDON, V508, P145, DOI 10.1111/j.1469-7793.1998.145br.x; WALSH DA, 1994, FASEB J, V8, P1227, DOI 10.1096/fasebj.8.15.8001734; Wilson HL, 1998, BIOCHEM J, V331, P837, DOI 10.1042/bj3310837; YAMAMURA H, 1977, J BIOL CHEM, V252, P7964; ZAHRADNIKOVA A, 1995, BIOCHEM BIOPH RES CO, V210, P457, DOI 10.1006/bbrc.1995.1682	42	67	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33348	33354		10.1074/jbc.274.47.33348	http://dx.doi.org/10.1074/jbc.274.47.33348			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559213	hybrid			2022-12-25	WOS:000083745200029
J	Urbina, JA; Moreno, B; Vierkotter, S; Oldfield, E; Payares, G; Sanoja, C; Baliey, BN; Yan, W; Scott, DA; Moreno, SNJ; Docampo, R				Urbina, JA; Moreno, B; Vierkotter, S; Oldfield, E; Payares, G; Sanoja, C; Baliey, BN; Yan, W; Scott, DA; Moreno, SNJ; Docampo, R			Trypanosoma cruzi contains major pyrophosphate stores, and its growth in vitro and in vivo is blocked by pyrophosphate analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; CELLS IN-VITRO; TOXOPLASMA-GONDII; DEPENDENT PHOSPHOFRUCTOKINASE; PHOSPHATE DIKINASE; SQUALENE SYNTHASE; POTENT INHIBITOR; MAMMALIAN-CELLS; CALCIUM-PUMP; CA2+ RELEASE	High field P-31 nuclear magnetic resonance spectroscopy showed that inorganic pyrophosphate (P2O74-) is more abundant than ATP in Trypanosoma cruzi, the causative agents of Chagas' disease. These results were confirmed by specific analytical assays, which showed that in epimastigotes, the concentrations of inorganic pyrophosphate and ATP were 194.7 +/- 25.9 and 37.6 +/- 5.5 nmol/mg of protein, respectively, and for the amastigote form, the corresponding concentrations were 358.0 +/- 17.0 and 36.0 +/- 1.9 nmol/mg of protein. High performance liquid chromatographic analysis of perchloric acid extracts of epimastigotes labeled for 3 h with P-32-orthophosphate showed a significant incorporation of the precursor into inorganic pyrophosphate, Inorganic pyrophosphate was not uniformly distributed in T, cruzi but was shown by P-31-NMR and chemical analysis to be particularly associated with acidocalcisomes, organelles shown previously to contain large amounts of phosphorus and various elements. Electron microscopy analysis of pyrophosphatase-treated permeabilized epimastigotes showed disappearance of the electron density of the acidocalcisomes. Nonmetabolizable analogs of pyrophosphate, currently used for the treatment of bone resorption disorders, selectively inhibited the proliferation of intracellular T, cruzi amastigotes and produced a profound suppression in the number of circulating trypomastigotes in mice with an acute infection of T, cruzi, offering a potentially new route to chemotherapy,	Univ Illinois, Dept Pathobiol, Mol Parasitol Lab, Urbana, IL 61802 USA; Univ Illinois, Dept Chem, Urbana, IL 61802 USA; Univ Illinois, Dept Biophys, Urbana, IL 61802 USA; Cent Univ Venezuela, Fac Ciencias, Inst Zool Trop, Dept Parasitol, Caracas 10400, Venezuela	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Central Venezuela	Docampo, R (corresponding author), Univ Illinois, Dept Pathobiol, Mol Parasitol Lab, 2001 S Lincoln Ave, Urbana, IL 61802 USA.			Scott, David/0000-0002-8668-2449	NHLBI NIH HHS [HL-19481] Funding Source: Medline; NIAID NIH HHS [AI-23259] Funding Source: Medline; NIGMS NIH HHS [GM-50694] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI023259, R01AI023259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050694] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMEISEN JC, 1995, CELL DEATH DIFFER, V2, P285; Amin D, 1996, ARZNEIMITTEL-FORSCH, V46, P759; AMIN D, 1992, J LIPID RES, V33, P1657; Berenson JR, 1997, J CLIN PHARMACOL, V37, P285, DOI 10.1002/j.1552-4604.1997.tb04304.x; BLUM JJ, 1989, J PROTOZOOL, V36, P254, DOI 10.1111/j.1550-7408.1989.tb05358.x; Bringaud F, 1998, P NATL ACAD SCI USA, V95, P7963, DOI 10.1073/pnas.95.14.7963; CERDAN S, 1990, ANNU REV BIOPHYS BIO, V19, P43; David P, 1996, J BONE MINER RES, V11, P1498, DOI 10.1002/jbmr.5650111017; Denton H, 1996, MOL BIOCHEM PARASIT, V76, P23, DOI 10.1016/0166-6851(95)02527-8; DESLAURIERS R, 1982, BIOCHIM BIOPHYS ACTA, V720, P329, DOI 10.1016/0167-4889(82)90109-4; DOCAMPO R, 1993, J EUKARYOT MICROBIOL, V40, P311, DOI 10.1111/j.1550-7408.1993.tb04921.x; DOCAMPO R, 1995, BIOCHEM J, V310, P1005, DOI 10.1042/bj3101005; Frith JC, 1997, J BONE MINER RES, V12, P1358, DOI 10.1359/jbmr.1997.12.9.1358; Hensgens CMH, 1996, EUR J BIOCHEM, V242, P327, DOI 10.1111/j.1432-1033.1996.0327r.x; HOULT DI, 1974, NATURE, V252, P285, DOI 10.1038/252285a0; HRDY I, 1993, EXP PARASITOL, V76, P438, DOI 10.1006/expr.1993.1052; HUGHES DE, 1995, J BONE MINER RES, V10, P1478; Lu HG, 1998, MOL CELL BIOL, V18, P2309, DOI 10.1128/MCB.18.4.2309; Lu HG, 1997, J BIOL CHEM, V272, P9464, DOI 10.1074/jbc.272.14.9464; Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MANSUROVA SE, 1989, BIOCHIM BIOPHYS ACTA, V977, P237, DOI 10.1016/S0005-2728(89)80078-7; MARTIN JB, 1987, BIOCHIM BIOPHYS ACTA, V931, P16, DOI 10.1016/0167-4889(87)90045-0; MERTENS E, 1989, MOL BIOCHEM PARASIT, V37, P183, DOI 10.1016/0166-6851(89)90150-3; MERTENS E, 1990, MOL BIOCHEM PARASIT, V40, P147, DOI 10.1016/0166-6851(90)90088-4; MERTENS E, 1993, BIOCHEM J, V292, P797, DOI 10.1042/bj2920797; Moreno SNJ, 1996, BIOCHEM J, V313, P655, DOI 10.1042/bj3130655; MURPHY EJ, 1992, BIOCHIM BIOPHYS ACTA, V1135, P27, DOI 10.1016/0167-4889(92)90162-5; PENG ZY, 1995, BIOCHEM PHARMACOL, V49, P105, DOI 10.1016/0006-2952(94)00437-Q; PENG ZY, 1992, MOL BIOCHEM PARASIT, V54, P223, DOI 10.1016/0166-6851(92)90114-Y; PEREZSALA D, 1994, BIOCHEM BIOPH RES CO, V199, P1209, DOI 10.1006/bbrc.1994.1359; REEVES RE, 1976, J BIOL CHEM, V251, P2958; REEVES RE, 1968, J BIOL CHEM, V243, P5486; REEVES RE, 1975, BIOCHEM BIOPH RES CO, V66, P1389, DOI 10.1016/0006-291X(75)90513-6; REEVES RE, 1970, BIOCHIM BIOPHYS ACTA, V220, P346, DOI 10.1016/0005-2744(70)90021-5; Rodan GA, 1998, ANNU REV PHARMACOL, V38, P375, DOI 10.1146/annurev.pharmtox.38.1.375; Rogers MJ, 1997, CANCER, V80, P1652, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1652::AID-CNCR15>3.0.CO;2-Z; Rogers MJ, 1996, J BONE MINER RES, V11, P1482; ROSENBERG H, 1966, EXP CELL RES, V41, P397, DOI 10.1016/S0014-4827(66)80147-7; ROSENBERG H, 1969, BIOCHIM BIOPHYS ACTA, V184, P191, DOI 10.1016/0304-4165(69)90114-7; Scott DA, 1998, J BIOL CHEM, V273, P22151, DOI 10.1074/jbc.273.34.22151; Scott DA, 1997, J BIOL CHEM, V272, P28020, DOI 10.1074/jbc.272.44.28020; SIANOUDIS J, 1986, ARCH MICROBIOL, V144, P48, DOI 10.1007/BF00454955; STEPHENS L, 1993, J BIOL CHEM, V268, P4009; STITT M, 1990, ANNU REV PLANT PHYS, V41, P153, DOI 10.1146/annurev.pp.41.060190.001101; UGURBIL K, 1979, P NATL ACAD SCI USA, V76, P2227, DOI 10.1073/pnas.76.5.2227; Urbina JA, 1996, SCIENCE, V273, P969, DOI 10.1126/science.273.5277.969; Vercesi AE, 1996, BIOCHEM J, V315, P265, DOI 10.1042/bj3150265; Vercesi AE, 1997, BIOCHEM J, V328, P479; VERCESI AE, 1994, BIOCHEM J, V304, P227, DOI 10.1042/bj3040227; Yan W, 1998, J IMMUNOL METHODS, V220, P123, DOI 10.1016/S0022-1759(98)00155-0; Ylitalo R, 1996, J LAB CLIN MED, V127, P200, DOI 10.1016/S0022-2143(96)90079-7; Yokoyama K, 1998, MOL BIOCHEM PARASIT, V94, P87, DOI 10.1016/S0166-6851(98)00053-X; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; ZHEN RG, 1994, PLANT PHYSIOL, V104, P153, DOI 10.1104/pp.104.1.153	55	140	143	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33609	33615		10.1074/jbc.274.47.33609	http://dx.doi.org/10.1074/jbc.274.47.33609			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559249	hybrid			2022-12-25	WOS:000083745200065
J	Wild, AC; Moinova, HR; Mulcahy, RT				Wild, AC; Moinova, HR; Mulcahy, RT			Regulation of gamma-glutamylcysteine synthetase subunit gene expression by the transcription factor Nrf2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT RESPONSE ELEMENT; SMALL MAF PROTEINS; NAD(P)H-QUINONE OXIDOREDUCTASE GENE; NAPHTHOFLAVONE-INDUCED EXPRESSION; INDUCED OXIDATIVE STRESS; PHENOLIC ANTIOXIDANTS; INDUCIBLE EXPRESSION; MEDIATED EXPRESSION; MAMMALIAN-CELLS; FAMILY PROTEINS	Exposure of HepG2 cells to beta-naphthoflavone (beta-NF) or pyrrolidine dithiocarbamate (PDTC) resulted in the up-regulation of the gamma-glutamylcysteine synthetase catalytic (GCS(h)) and regulatory (GCS(1)) subunit genes. Increased expression was associated with an increase in the binding of Nrf2 to electrophile response elements (EpRE) in the promoters of these genes. Nrf2 overexpression increased the activity of GCS(h) and GCS(1) promoter/reporter transgenes, Overexpression of an MafK dominant negative mutant decreased Nrf2 binding to GCS EpRE sequences, inhibited the inducible expression of GCS, and GCS, promoter/reporter transgenes, and reduced endogenous GCS gene induction. beta-NF and PDTC exposure also increased steady-state levels of MafG mRNA, In addition to Nrf2, small Maf and JunD proteins were detected in GCS(h)EpRE-protein complexes and, to a lesser extent, in GCS(1)EpRE-protein complexes. The Nrf2-associated expression of GCS promoter/reporter transgenes was inhibited by overexpression of MafG, Inhibition of protein synthesis by cycloheximide partially decreased inducibility by PDTC or beta-NF and resulted in significant increases in GCS mRNA at late time points, when GCS mRNA levels are normally declining, We hypothesize that, in response to beta-NF and PDTC, the GCS subunit genes are transcriptionally upregulated by Nrf2-basic leucine zipper complexes, containing either JunD or small Maf protein, depending on the particular GCS EpRE target sequence and the inducer. Following maximal induction, down-regulation of the two genes is mediated via a protein synthesis-dependent mechanism.	Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Mulcahy, RT (corresponding author), Univ Wisconsin, Sch Med, Dept Pharmacol, K4-316,600 Highland Ave, Madison, WI 53792 USA.				NATIONAL CANCER INSTITUTE [R01CA057549, T32CA009471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009749] Funding Source: NIH RePORTER; NCI NIH HHS [5T32-CA09471, CA57549] Funding Source: Medline; NIEHS NIH HHS [ES09749] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BERGELSON S, 1994, BIOCHEM BIOPH RES CO, V200, P290, DOI 10.1006/bbrc.1994.1447; Blank V, 1997, BLOOD, V89, P3925, DOI 10.1182/blood.V89.11.3925; BORROZ KI, 1994, TOXICOL APPL PHARM, V126, P150, DOI 10.1006/taap.1994.1101; Bral CM, 1997, MOL PHARMACOL, V52, P974, DOI 10.1124/mol.52.6.974; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; Crawford DR, 1996, FREE RADICAL BIO MED, V21, P521, DOI 10.1016/0891-5849(96)00160-8; DIGMAN JD, 1983, NUCLEIC ACIDS RES, V11, P1475; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Griffith OW, 1999, ADV ENZYMOL RAMB, V73, P209, DOI 10.1002/9780470123195.ch7; IGARASHI K, 1995, J BIOL CHEM, V270, P7615, DOI 10.1074/jbc.270.13.7615; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; Johnsen O, 1996, NUCLEIC ACIDS RES, V24, P4289, DOI 10.1093/nar/24.21.4289; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; KERPPOLA TK, 1994, ONCOGENE, V9, P3149; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; Lecine P, 1998, J BIOL CHEM, V273, P7572, DOI 10.1074/jbc.273.13.7572; LI Y, 1992, J BIOL CHEM, V267, P15097; LI Y, 1992, BIOCHEM BIOPH RES CO, V188, P992, DOI 10.1016/0006-291X(92)91329-O; LIU S, 1996, TOXICOL APPL PHARM, V141, P59; Liu SX, 1996, BIOCHEMISTRY-US, V35, P11517, DOI 10.1021/bi960572p; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; Marini MG, 1997, J BIOL CHEM, V272, P16490, DOI 10.1074/jbc.272.26.16490; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Moinova HR, 1998, J BIOL CHEM, V273, P14683, DOI 10.1074/jbc.273.24.14683; Moinova HR, 1999, BIOCHEM BIOPH RES CO, V261, P661, DOI 10.1006/bbrc.1999.1109; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; NGUYEN T, 1992, J BIOL CHEM, V267, P13535; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; Oyake T, 1996, MOL CELL BIOL, V16, P6083; PRESTERA T, 1993, ADV ENZYME REGUL, V33, P281; PRESTERA T, 1993, P NATL ACAD SCI USA, V90, P2965, DOI 10.1073/pnas.90.7.2965; PRESTERA T, 1995, MOL MED, V1, P827, DOI 10.1007/BF03401897; Rosl F, 1997, J VIROL, V71, P362; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; Sambrook J., 2002, MOL CLONING LAB MANU; SHI MM, 1994, J BIOL CHEM, V269, P26512; TALALAY P, 1988, P NATL ACAD SCI USA, V85, P8261, DOI 10.1073/pnas.85.21.8261; Toki T, 1997, ONCOGENE, V14, P1901, DOI 10.1038/sj.onc.1201024; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; WANG B, 1994, BBA-GENE STRUCT EXPR, V1219, P645, DOI 10.1016/0167-4781(94)90223-2; Wasserman WW, 1997, ARCH BIOCHEM BIOPHYS, V344, P387, DOI 10.1006/abbi.1997.0215; Wild AC, 1999, BIOCHEM J, V338, P659, DOI 10.1042/0264-6021:3380659; Wild AC, 1998, BIOCHEM J, V332, P373, DOI 10.1042/bj3320373; WOODS JS, 1995, BIOCHEM PHARMACOL, V50, P1719, DOI 10.1016/0006-2952(95)02075-6; XIE T, 1995, J BIOL CHEM, V270, P6894, DOI 10.1074/jbc.270.12.6894; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972	58	496	512	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33627	33636		10.1074/jbc.274.47.33627	http://dx.doi.org/10.1074/jbc.274.47.33627			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559251	hybrid			2022-12-25	WOS:000083745200067
J	Kim, S; Ponka, P				Kim, S; Ponka, P			Control of transferrin receptor expression via nitric oxide-mediated modulation of iron-regulatory protein 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING-PROTEIN; RNA-BINDING; RESPONSIVE ELEMENT; MESSENGER-RNA; ACONITASE ACTIVITY; CYTOSOLIC ACONITASE; DEGRADATION; PROTEASOME; MACROPHAGES; FERRITIN	Cellular iron storage and uptake are coordinately regulated post-transcriptionally by cytoplasmic factors, iron-regulatory proteins 1 and 2 (IRP-1 and IRP-2). When iron in the intracellular transit pool is scarce, IRPs bind to iron-responsive elements (IREs) in the 5'-untranslated region of the ferritin mRNA and 3'-untranslated region of the transferrin receptor (TfR) mRNA Such binding inhibits translation of ferritin mRNA and stabilizes the mRNA for TfR whereas the opposite scenario develops when iron in the transit pool is plentiful, However, we (Richardson, D. R., Neuman-nova, V,, Nagy, E., and Ponka, P. (1995) Blood 86, 3211-3219) and others reported that the binding of IRPs to IREs can also be modulated by nitric oxide (NO). In this study, we showed that a short exposure of RAW 264.7 cells (a murine macrophage cell line) to the NO+ donor, sodium nitroprusside (SNP), caused a significant decrease in IRP-2 binding to the IREs followed by IRP-2 degradation and-that these changes occurred without affecting IRP-1 binding. The SNP-mediated degradation of IRP-2 in RAW 264.7 cells could be prevented by MG;132 or lactacystin, known inhibitors of proteasome dependent protein degradation, A SNP-mediated decrease in IRP-2 binding and-levels was associated with a dramatic decrease in TfR mRNA levels and an increase in ferritin synthesis. Importantly, the proteasome inhibitor MG-132 prevented the SNP-mediated decrease in TfR mRNA levels. These observations suggest that IRP-8 can play an important role in controlling transferrin receptor expression.	McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Physiol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	Ponka, P (corresponding author), McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.		Ponka, Prem/A-4123-2011	Ponka, Prem/0000-0001-5835-1477				Akaike T, 1997, J BIOCHEM-TOKYO, V122, P459; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Gobert AP, 1998, INFECT IMMUN, V66, P4068; GREEN SJ, 1991, J LEUKOCYTE BIOL, V50, P93, DOI 10.1002/jlb.50.1.93; GUO B, 1995, J BIOL CHEM, V270, P16529, DOI 10.1074/jbc.270.28.16529; GUO B, 1994, J BIOL CHEM, V269, P24252; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; Hanson ES, 1998, J BIOL CHEM, V273, P7588, DOI 10.1074/jbc.273.13.7588; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HERLING H, 1994, EMBO J, V13, P453; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; IWAI K, 1995, EMBO J, V14, P5350, DOI 10.1002/j.1460-2075.1995.tb00219.x; KAPTAIN S, 1991, P NATL ACAD SCI USA, V88, P10109, DOI 10.1073/pnas.88.22.10109; Kennedy MC, 1997, J BIOL CHEM, V272, P20340, DOI 10.1074/jbc.272.33.20340; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; McCord JM, 1998, SEMIN HEMATOL, V35, P5; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; OWEN D, 1987, EMBO J, V6, P1287, DOI 10.1002/j.1460-2075.1987.tb02366.x; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PHILPOTT CC, 1993, J BIOL CHEM, V268, P17655; Ponka P, 1999, INT J BIOCHEM CELL B, V31, P1111, DOI 10.1016/S1357-2725(99)00070-9; Ponka P, 1998, SEMIN HEMATOL, V35, P35; RICHARDSON DR, 1995, BLOOD, V86, P3211; Richardson DR, 1997, BBA-REV BIOMEMBRANES, V1331, P1, DOI 10.1016/S0304-4157(96)00014-7; RICHARDSON DR, 1996, METH NEUROSCI, V31, P329; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; ROUAULT TA, 1990, P NATL ACAD SCI USA, V87, P7958, DOI 10.1073/pnas.87.20.7958; Schalinske KL, 1997, P NATL ACAD SCI USA, V94, P10681, DOI 10.1073/pnas.94.20.10681; Simon DI, 1996, P NATL ACAD SCI USA, V93, P4736, DOI 10.1073/pnas.93.10.4736; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; THEIL EC, 1994, BIOCHEM J, V304, P1; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x; ZHENG LM, 1992, ARCH BIOCHEM BIOPHYS, V299, P356, DOI 10.1016/0003-9861(92)90287-7	45	82	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					33035	33042		10.1074/jbc.274.46.33035	http://dx.doi.org/10.1074/jbc.274.46.33035			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551872	hybrid			2022-12-25	WOS:000083623000072
J	Zitzer, H; Honck, HH; Bachner, D; Richter, D; Kreienkamp, HJ				Zitzer, H; Honck, HH; Bachner, D; Richter, D; Kreienkamp, HJ			Somatostatin receptor interacting protein defines a novel family of multidomain proteins present in human and rodent brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; MOLECULAR-CLONING; EXPRESSION; LOCALIZATION; BINDING; PHOSPHORYLATION; REGIONS; DOMAIN; SST2A; CDNA	By using the yeast two-hybrid system we identified a novel protein from-the human brain interacting with the C terminus of somatostatin receptor subtype 2, This protein termed somatostatin receptor interacting protein is characterized by a novel domain structure, consisting of six N-terminal ankyrin repeats followed by SH3 and PDZ domains, several proline-rich regions, and a C-terminal sterile cu motif. It consists of 2185 amino acid residues encoded by a 9-kilobase pair mRNA; several splice variants have been detected in human and rat cDNA libraries. Sequence comparison suggests that the novel multidomain protein, together with cortactin-binding protein, forms a family of cytoskeletal anchoring proteins. Fractionation of rat brain membranes indicated that somatostatin receptor interacting protein is enriched in the postsynaptic density fraction, The interaction of somatostatin receptor subtype 2 with its interacting protein was verified by overlay assays and coimmunoprecipitation experiments from transfected human embryonic kidney cells. Somatostatin receptor subtype 2 and the interacting protein display a striking overlap of their expression patterns in the rat brain. Interestingly, in the hippocampus the mRNA for somatostatin receptor interacting protein was not confined to the cell bodies but was also observed in the molecular layer, suggesting a dendritic localization of this mRNA.	Univ Hamburg, Klinikum Eppendorf, Inst Zellbiochem & Klin Neurobiol, D-20246 Hamburg, Germany	University of Hamburg	Richter, D (corresponding author), Univ Hamburg, Klinikum Eppendorf, Inst Zellbiochem & Klin Neurobiol, Martinistr 52, D-20246 Hamburg, Germany.	richter@uke.uni-hamburg.de						BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; Boeckers TM, 1999, J NEUROSCI, V19, P6506; Boehm S, 1997, J NEUROSCI, V17, P4066; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; BRUNO JF, 1992, P NATL ACAD SCI USA, V89, P11151, DOI 10.1073/pnas.89.23.11151; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; Dournaud P, 1998, J NEUROSCI, V18, P1056; Dournaud P, 1996, J NEUROSCI, V16, P4468; Du YR, 1998, MOL CELL BIOL, V18, P5838, DOI 10.1128/MCB.18.10.5838; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KLUXEN FW, 1992, P NATL ACAD SCI USA, V89, P4618, DOI 10.1073/pnas.89.10.4618; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KREIENKAMP HJ, 1994, J BIOL CHEM, V269, P8108; Krisch J, 1999, CURR OPIN NEUROBIOL, V9, P329, DOI 10.1016/S0959-4388(99)80048-8; KUHSE J, 1995, CURR OPIN NEUROBIOL, V5, P318, DOI 10.1016/0959-4388(95)80044-1; LEFKOWITZ RJ, 1992, COLD SPRING HARB SYM, V57, P127, DOI 10.1101/SQB.1992.057.01.016; MEYERHOF W, 1991, DNA CELL BIOL, V10, P689, DOI 10.1089/dna.1991.10.689; MEYERHOF W, 1992, P NATL ACAD SCI USA, V89, P10267, DOI 10.1073/pnas.89.21.10267; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Roth A, 1997, J BIOL CHEM, V272, P23769, DOI 10.1074/jbc.272.38.23769; Schulz S, 1998, EUR J NEUROSCI, V10, P3700, DOI 10.1046/j.1460-9568.1998.00386.x; Schwartkop CP, 1999, J NEUROCHEM, V72, P1275, DOI 10.1046/j.1471-4159.1999.0721275.x; Stapleton D, 1999, NAT STRUCT BIOL, V6, P44; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Thanos CD, 1999, SCIENCE, V283, P833, DOI 10.1126/science.283.5403.833; Zitzer H, 1999, J BIOL CHEM, V274, P18153, DOI 10.1074/jbc.274.26.18153	28	112	118	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32997	33001		10.1074/jbc.274.46.32997	http://dx.doi.org/10.1074/jbc.274.46.32997			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551867	hybrid			2022-12-25	WOS:000083623000067
J	Dabney-Smith, C; van den Wijngaard, PWJ; Treece, Y; Vredenberg, WJ; Bruce, BD				Dabney-Smith, C; van den Wijngaard, PWJ; Treece, Y; Vredenberg, WJ; Bruce, BD			The C terminus of a chloroplast precursor modulates its interaction with the translocation apparatus and PIRAC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSIT PEPTIDE; PROTEIN-IMPORT; IN-VITRO; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE/OXYGENASE; ENVELOPE MEMBRANES; ESCHERICHIA-COLI; TRANSPORT; IDENTIFICATION; ACCUMULATION; COMPLEXES	The import of proteins into chloroplasts involves a cleavable, N-terminal targeting sequence known as the transit peptide. Although the transit peptide is both necessary and sufficient to direct precursor import into chloroplasts, the mature domain of some precursors has been shown to modulate targeting and translocation efficiency. To test the influence of the mature domain of the small subunit of Rubisco during import in vitro, the precursor (prSSU), the mature domain (mSSU), the transit peptide (SS-tp), and three C-terminal deletion mutants (Delta 52, Delta 67, and Delta 74) of prSSU were expressed and purified from Escherichia coli, Activity was then evaluated by competitive import of S-35-prSSU. Both IC50 and K-i values consistently suggest that removal of C-terminal prSSU sequences inhibits its interaction with the translocation apparatus. Non-competitive import studies demonstrated that prSSU and Delta 52 were properly processed and accumulated within the chloroplast, whereas Delta 67 and Delta 74 were rapidly degraded via a plastid-localized protease, The ability of prSSU-derived proteins to induce inactivation of the protein-import-related anion channel was also evaluated, Although the C-terminal deletion mutants were less effective at inducing channel closure upon import, they did not effect the mean duration of channel closure. Possible mechanisms by which C-terminal residues of prSSU modulate chloroplast targeting are discussed.	Univ Tennessee, Dept Biochem Cellular & Mol Biol, Knoxville, TN 37996 USA; Univ Tennessee, Ctr Legume Res, Knoxville, TN 37996 USA; Wageningen Univ Agr, Lab Plant Physiol, NL-6703 BD Wageningen, Netherlands	University of Tennessee System; University of Tennessee Knoxville; University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture; Wageningen University & Research	Bruce, BD (corresponding author), Univ Tennessee, Dept Biochem Cellular & Mol Biol, Knoxville, TN 37996 USA.	bbruce@utk.edu	Dabney-Smith, Carole/C-2432-2008	Dabney-Smith, Carole/0000-0003-1347-3870				Akita M, 1997, J CELL BIOL, V136, P983, DOI 10.1083/jcb.136.5.983; Bruce B.D., 1994, PLANT MOL BIOL MANUA, VJ1, P1; BRUCE BD, 1994, ADV MOL CELL BIOL MO, V10, P3289; Chen XJ, 1999, TRENDS CELL BIOL, V9, P222, DOI 10.1016/S0962-8924(99)01554-8; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; Colquhoun David, 1995, P483; Halperin T, 1996, PLANT MOL BIOL, V30, P925, DOI 10.1007/BF00020804; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; IVEY R, 2000, IN PRESS CELL STRESS; KAVANAGH TA, 1988, MOL GEN GENET, V215, P38, DOI 10.1007/BF00331300; Kindle KL, 1998, PLANT PHYSIOL, V116, P1179, DOI 10.1104/pp.116.3.1179; KLEIN RR, 1992, PLANT PHYSIOL, V98, P546, DOI 10.1104/pp.98.2.546; KO K, 1992, J BIOL CHEM, V267, P13910; Lawrence SD, 1997, J BIOL CHEM, V272, P20357, DOI 10.1074/jbc.272.33.20357; LUBBEN TH, 1989, PLANT MOL BIOL, V12, P13, DOI 10.1007/BF00017443; MARSHALL JS, 1990, P NATL ACAD SCI USA, V87, P374, DOI 10.1073/pnas.87.1.374; Nielsen E, 1997, EMBO J, V16, P935, DOI 10.1093/emboj/16.5.935; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; PERRY SE, 1991, METHOD CELL BIOL, V34, P327; PILON M, 1992, FEBS LETT, V302, P65, DOI 10.1016/0014-5793(92)80286-P; PILON M, 1995, J BIOL CHEM, V270, P3882, DOI 10.1074/jbc.270.8.3882; Pinnaduwage P, 1996, J BIOL CHEM, V271, P32907, DOI 10.1074/jbc.271.51.32907; Rensink WA, 1998, PLANT PHYSIOL, V118, P691, DOI 10.1104/pp.118.2.691; Schnell DJ, 1997, TRENDS CELL BIOL, V7, P303, DOI 10.1016/S0962-8924(97)01111-2; SHANKLIN J, 1995, PLANT CELL, V7, P1713, DOI 10.1105/tpc.7.10.1713; Taylor TC, 1997, BIOCHEMISTRY-US, V36, P4041, DOI 10.1021/bi962818w; VANDENWIGNGAARD P, 1999, IN PRESS BIOPHYS J; vandenWijngaard PWJ, 1997, J BIOL CHEM, V272, P29430, DOI 10.1074/jbc.272.47.29430; VANTHOF R, 1995, J BIOL CHEM, V270, P22368, DOI 10.1074/jbc.270.38.22368; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1991, PLANT MOL BIOL REP, V9, P104; WASMANN CC, 1986, MOL GEN GENET, V205, P446, DOI 10.1007/BF00338081	33	40	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32351	32359		10.1074/jbc.274.45.32351	http://dx.doi.org/10.1074/jbc.274.45.32351			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542276	hybrid			2022-12-25	WOS:000083532100084
J	Lu, JF; O'Hara, EB; Trieselmann, BA; Romano, PR; Dever, TE				Lu, JF; O'Hara, EB; Trieselmann, BA; Romano, PR; Dever, TE			The interferon-induced double-stranded RNA-activated protein kinase PKR will phosphorylate serine, threonine, or tyrosine at residue 51 in eukaryotic initiation factor 2 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EIF-2-ALPHA KINASE; TRANSLATIONAL CONTROL; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; DEPENDENT KINASE; INSULIN-RECEPTOR; YEAST; GCN2; GENE; FACTOR-2-ALPHA	The family of eukaryotic initiation factor 2 alpha (eIF2 alpha) protein kinases plays an important role in regulating cellular protein synthesis under stress conditions. The mammalian kinases PKR and HRI and the yeast kinase GCN2 specifically phosphorylate Ser-51 on the a subunit of the translation initiation factor eIF2, By using an in vivo assay in yeast, the substrate specificity of these three eIF2 alpha kinases was examined by substituting Ser-51 in eIF2 alpha with Thr or Tyr. In yeast, phosphorylation of eIF2 inhibits general translation but derepresses translation of the GCN4 mRNA. All three kinases phosphorylated Thr in place of Ser-51 and were able to regulate general and GCN4-specific translation. In addition, both PHR and HRI were found to phosphorylate eIF2 alpha-S51Y and stimulate GCN4 expression. Isoelectric focusing analysis of eIF2 alpha followed by detection using anti-eIF2 alpha and anti-phosphotyrosine-specific antibodies demonstrated that PKR and HRI phosphorylated eIF2 alpha-S51Y on Tyr in vivo. These results provide new insights into the substrate recognition properties of the eIF2 alpha kinases, and they are intriguing considering the potential for alternate substrates for PKR in cellular signaling and growth control pathways.	NICHD, Lab Eukaryot Gene Regulat, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Dever, TE (corresponding author), NICHD, Lab Eukaryot Gene Regulat, NIH, Bldg 6A,Rm B1A-02,6 Ctr Dr,MSC 2716, Bethesda, MD 20892 USA.		Dever, Thomas/GSE-0966-2022	Dever, Thomas/0000-0001-7120-9678	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001010] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001010] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abraham N, 1999, J BIOL CHEM, V274, P5953, DOI 10.1074/jbc.274.9.5953; Abraham N, 1998, EXP CELL RES, V244, P394, DOI 10.1006/excr.1998.4201; BARBER GN, 1991, BIOCHEMISTRY-US, V30, P10356, DOI 10.1021/bi00106a038; Brand SR, 1997, J BIOL CHEM, V272, P8388, DOI 10.1074/jbc.272.13.8388; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DER SD, 1995, P NATL ACAD SCI USA, V92, P8841, DOI 10.1073/pnas.92.19.8841; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DOUVILLE E, 1994, CANCER METAST REV, V13, P1, DOI 10.1007/BF00690414; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Hinnebusch Alan G., 1994, Seminars in Cell Biology, V5, P417, DOI 10.1006/scel.1994.1049; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; ICELY PL, 1991, J BIOL CHEM, V266, P16073; KawagishiKobayashi M, 1997, MOL CELL BIOL, V17, P4146, DOI 10.1128/MCB.17.7.4146; KOROMILAS AE, 1995, J BIOL CHEM, V270, P25426, DOI 10.1074/jbc.270.43.25426; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Langland JO, 1999, BIOCHEMISTRY-US, V38, P6361, DOI 10.1021/bi982410u; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; LINDBERG RA, 1993, ONCOGENE, V8, P351; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; MCMILLAN NAJ, 1995, VIROLOGY, V213, P413, DOI 10.1006/viro.1995.0014; MELLOR H, 1991, BIOCHEM BIOPH RES CO, V178, P430, DOI 10.1016/0006-291X(91)90125-Q; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Olsen DS, 1998, GENETICS, V149, P1495; RAMIREZ M, 1992, MOL CELL BIOL, V12, P5801, DOI 10.1128/MCB.12.12.5801; ROMANO PR, 1995, MOL CELL BIOL, V15, P365, DOI 10.1128/MCB.15.1.365; Santoyo J, 1997, J BIOL CHEM, V272, P12544, DOI 10.1074/jbc.272.19.12544; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; WEINMASTER G, 1986, J BIOL CHEM, V261, P328; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; [No title captured]	36	46	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32198	32203		10.1074/jbc.274.45.32198	http://dx.doi.org/10.1074/jbc.274.45.32198			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542257	hybrid			2022-12-25	WOS:000083532100065
J	Masson, L; Tabashnik, BE; Liu, YB; Brousseau, R; Schwartz, JL				Masson, L; Tabashnik, BE; Liu, YB; Brousseau, R; Schwartz, JL			Helix 4 of the Bacillus thuringiensis Cry1Aa toxin lines the lumen of the ion channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORDER MEMBRANE-VESICLES; PLANAR LIPID BILAYERS; PORE-FORMING DOMAIN; DELTA-ENDOTOXIN; SELECTIVE CHANNELS; CRYSTAL-STRUCTURE; RESISTANCE; MUTAGENESIS; BINDING; ORGANIZATION	The mode of action of Bacillus thuringiensis insecticidal proteins is not well understood. Based on analogies with other bacterial toxins and ion channels, we hypothesized that charged amino acids in helix 4 of the Cry1Aa toxin are critical for toxicity and ion channel function. Using Plutella xylostella as a model target, we analyzed responses to Cry1Aa and eight proteins with altered helix 4 residues. Toxicity was abolished in five charged residue mutants (E129K, R131Q, R131D, D136N, D136C), however, two charged (R127E and R127N) and one polar (N138C) residue mutant retained wild-type toxicity. Compared with Cry1Aa and toxic mutants, nontoxic mutants did not show greatly reduced binding to brush border membrane vesicles, but their ion channel conductance was greatly reduced in planar lipid bilayers, Substituted cysteine accessibility tests showed that in situ restoration of the negative charge of D136C restored conductance to wild-type levels, The results imply that charged amino acids on the Asp-136 side of helix 4 are essential for toxicity and passage of ions through the channel. These results also support a refined version of the umbrella model of membrane integration in which the side of helix 4 containing Asp-136 faces the aqueous lumen of the ion channel.	Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; Univ Arizona, Dept Entomol, Tucson, AZ 85721 USA	National Research Council Canada; University of Arizona	Masson, L (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.							AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ARONSON AI, 1995, J BACTERIOL, V177, P4059, DOI 10.1128/jb.177.14.4059-4065.1995; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN XJ, 1995, J BIOL CHEM, V270, P6412, DOI 10.1074/jbc.270.11.6412; CUMMINGS CE, 1994, MOL MEMBR BIOL, V11, P87, DOI 10.3109/09687689409162225; de Maagd RA, 1999, MOL MICROBIOL, V31, P463, DOI 10.1046/j.1365-2958.1999.01188.x; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; GAZIT E, 1995, J BIOL CHEM, V270, P2571, DOI 10.1074/jbc.270.6.2571; Gazit E, 1998, P NATL ACAD SCI USA, V95, P12289, DOI 10.1073/pnas.95.21.12289; GROCHULSKI P, 1995, J MOL BIOL, V254, P447, DOI 10.1006/jmbi.1995.0630; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; Huynh PD, 1997, J GEN PHYSIOL, V110, P229, DOI 10.1085/jgp.110.3.229; James C., 1997, GLOBAL STATUS TRANSG; Jesior J. C., 1994, J APPL CRYSTALLOGR, V27, P1075; Kenyon G L, 1977, Methods Enzymol, V47, P407; KNOWLES BH, 1994, ADV INSECT PHYSIOL, V24, P275, DOI 10.1016/S0065-2806(08)60085-5; LI J, 1996, PROTEIN TOXIN STRUCT, P49; LI JD, 1991, NATURE, V353, P815, DOI 10.1038/353815a0; Liu YB, 1998, J ECON ENTOMOL, V91, P1032, DOI 10.1093/jee/91.5.1032; MASSON L, 1995, J BIOL CHEM, V270, P11887, DOI 10.1074/jbc.270.20.11887; MASSON L, 1989, BIOCHEM J, V269, P507; MAZZA A, 1999, QUANTITATIVE ANAL BI, P163; Montal M, 1996, CURR OPIN STRUC BIOL, V6, P499, DOI 10.1016/S0959-440X(96)80115-1; PARKER MW, 1990, TRENDS BIOCHEM SCI, V15, P126, DOI 10.1016/0968-0004(90)90205-P; PARKER MW, 1993, TRENDS BIOCHEM SCI, V18, P391, DOI 10.1016/0968-0004(93)90096-6; Schwartz JL, 1997, APPL ENVIRON MICROB, V63, P3978, DOI 10.1128/AEM.63.10.3978-3984.1997; Schwartz JL, 1997, FEBS LETT, V410, P397, DOI 10.1016/S0014-5793(97)00626-1; SCHWARTZ JL, 1993, J MEMBRANE BIOL, V132, P53, DOI 10.1007/BF00233051; SCHWARTZ JL, 1999, IN PRESS STRUCTURE F; SLATIN SL, 1990, BIOCHEM BIOPH RES CO, V169, P765, DOI 10.1016/0006-291X(90)90397-6; TABASHNIK BE, 1994, ANNU REV ENTOMOL, V39, P47, DOI 10.1146/annurev.en.39.010194.000403; Tabashnik BE, 1997, P NATL ACAD SCI USA, V94, P12780, DOI 10.1073/pnas.94.24.12780; Tabashnik BE, 1996, APPL ENVIRON MICROB, V62, P2839, DOI 10.1128/AEM.62.8.2839-2844.1996; Tabashnik BE, 1998, PHILOS T R SOC B, V353, P1751, DOI 10.1098/rstb.1998.0327; Uawithya P, 1998, BIOCHEM MOL BIOL INT, V44, P825; WOLFERSBERGER M, 1987, COMP BIOCHEM PHYS A, V86, P301, DOI 10.1016/0300-9629(87)90334-3; WU D, 1992, J BIOL CHEM, V267, P2311	39	95	106	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31996	32000		10.1074/jbc.274.45.31996	http://dx.doi.org/10.1074/jbc.274.45.31996			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542230	hybrid			2022-12-25	WOS:000083532100038
J	Plummer, SM; Holloway, KA; Manson, MM; Munks, RJL; Kaptein, A; Farrow, S; Howells, L				Plummer, SM; Holloway, KA; Manson, MM; Munks, RJL; Kaptein, A; Farrow, S; Howells, L			Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappa B activation via the NIK/IKK signalling complex	ONCOGENE			English	Article						colon cancer; cyclo-oxygenase 2; curcumin; NF-kappa B	PROTEIN-KINASE-C; TRANSCRIPTION FACTOR; ANTIINFLAMMATORY DRUGS; COLORECTAL-CANCER; ENDOTHELIAL-CELLS; GENE-EXPRESSION; CYCLOOXYGENASE-2 EXPRESSION; PROSTAGLANDIN SYNTHASE-2; EPITHELIAL-CELLS; SUPPRESSION	Colorectal cancer is a major cause of cancer deaths in Western countries, but epidemiological data suggest that dietary modification might reduce these by as much as 90%. Cyclo-oxygenase 2 (COX2), an inducible isoform of prostaglandin H synthase, which mediates prostaglandin synthesis during inflammation, and which is selectively overexpressed in colon tumours, is thought to play an important role in colon carcinogenesis. Curcumin, a constituent of turmeric, possesses potent anti-inflammatory activity and prevents colon cancer in animal models. However, its mechanism of action is not fully understood. We found that in human colon epithelial cells, curcumin inhibits COX2 induction by the colon tumour promoters, tumour necrosis factor a or fecapentaene-12. Induction of COX2 by inflammatory cytokines or hypoxia-induced oxidative stress can be mediated by nuclear factor kappa B (NF-kappa B). Since curcumin inhibits NF-kappa B activation, we examined whether its chemopreventive activity is related to modulation of the signalling pathway which regulates the stability of the NF-kappa B-sequestering protein, I kappa B, Recently components of this pathway, NF-kappa B-inducing kinase and I kappa B kinases, IKK alpha and beta, which phosphorylate I kappa B to release NF-kappa B, have been characterised, Curcumin prevents phosphorylation of I kappa B by inhibiting the activity of the IKKs, This property, together with a long history of consumption without adverse health effects, makes curcumin an important candidate for consideration in colon cancer prevention.	Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England; Univ Leicester, Ctr Mech Human Tox, Leicester LE1 9HN, Leics, England; Glaxo Wellcome Res & Dev Ltd, Stevenage SG1 2NY, Herts, England	University of Leicester; University of Leicester; GlaxoSmithKline	Plummer, SM (corresponding author), Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England.							Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bierhaus A, 1997, THROMB HAEMOSTASIS, V77, P772; BRAEGGER CP, 1992, LANCET, V339, P89, DOI 10.1016/0140-6736(92)90999-J; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Crofford LJ, 1997, ARTHRITIS RHEUM-US, V40, P226, DOI 10.1002/art.1780400207; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Du M, 1998, BLOOD, V92, p548A; DuBois RN, 1996, J GASTROENTEROL, V31, P898, DOI 10.1007/BF02358623; EBERHART CE, 1995, GASTROENTEROLOGY, V109, P285, DOI 10.1016/0016-5085(95)90296-1; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; Giardiello FM, 1997, CANCER RES, V57, P199; GIARDIELLO FM, 1995, EUR J CANCER, V31A, P1071, DOI 10.1016/0959-8049(95)00137-8; GYDE SN, 1988, GUT, V29, P206, DOI 10.1136/gut.29.2.206; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; HLA T, 1991, J BIOL CHEM, V266, P24059; Holloway KA, 1998, BRIT J CANCER, V78, P157; HOSHINA S, 1991, BIOCHEM BIOPH RES CO, V176, P505, DOI 10.1016/0006-291X(91)90953-5; HUANG MT, 1992, CANCER CHEMOPREVENTION, P375; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; Jobin C, 1998, IMMUNOLOGY, V95, P537; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kawamori T, 1998, CANCER RES, V58, P409; KELLEY DJ, 1996, P AM ASSOC CANC RES, V37, P909; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Kumar A, 1998, BIOCHEM PHARMACOL, V55, P775, DOI 10.1016/S0006-2952(97)00557-1; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pereira MA, 1996, CARCINOGENESIS, V17, P1305, DOI 10.1093/carcin/17.6.1305; PLUMMER SM, 1994, CARCINOGENESIS, V15, P449, DOI 10.1093/carcin/15.3.449; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RAO CV, 1993, CARCINOGENESIS, V14, P2219, DOI 10.1093/carcin/14.11.2219; ROSENBERG L, 1991, J NATL CANCER I, V83, P355, DOI 10.1093/jnci/83.5.355; Samaha HS, 1997, CANCER RES, V57, P1301; Sanjaya S., 1995, J BIOL CHEM, V270, P24995; SCHIFFMAN MH, 1989, MUTAT RES, V222, P351, DOI 10.1016/0165-1218(89)90111-0; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; SCUDIERO DA, 1988, CANCER RES, V48, P4827; SRIVASTAVA R, 1985, INDIAN J MED RES, V81, P215; Subbaramaiah K, 1998, J BIOL CHEM, V273, P21875, DOI 10.1074/jbc.273.34.21875; Subbaramaiah K, 1997, P SOC EXP BIOL MED, V216, P201; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; TORDJMAN C, 1995, BBA-LIPID LIPID MET, V1256, P249, DOI 10.1016/0005-2760(95)00026-9; TRUJILLO MA, 1994, DIGEST DIS SCI, V39, P2260; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; VAINIO H, 1997, IARC HDB CANC PREVEN, V1; VANE JR, 1995, INFLAMM RES, V44, P1, DOI 10.1007/BF01630479; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; ZARKOVIC M, 1993, CARCINOGENESIS, V14, P1261, DOI 10.1093/carcin/14.7.1261; ZENGGANG L, 1996, CELL, V87, P565	55	528	563	2	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	1999	18	44					6013	6020		10.1038/sj.onc.1202980	http://dx.doi.org/10.1038/sj.onc.1202980			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557090				2022-12-25	WOS:000083359100007
J	Kim, YS; Burns, AL; Goldsmith, PK; Heppner, C; Park, SY; Chandrasekharappa, SC; Collins, FS; Spiegel, AM; Marx, SJ				Kim, YS; Burns, AL; Goldsmith, PK; Heppner, C; Park, SY; Chandrasekharappa, SC; Collins, FS; Spiegel, AM; Marx, SJ			Stable overexpression of MEN1 suppresses tumorigenicity of RAS	ONCOGENE			English	Article						menin; MEN1; RAS; neoplasia; NIH3T3; oncogene; tumor suppressor	ENDOCRINE NEOPLASIA TYPE-1; HUMAN CANCER-CELLS; MUTATION ANALYSIS; GENE; PROTEIN; GROWTH; TRANSFORMATION; ACTIVATION; ONCOGENE; PATHWAY	Although there is indirect genetic evidence that MEN1, the gene for multiple endocrine neoplasia type 1, is a tumor suppressor gene, little is known about the MEN1-encoded protein, menin. Menin was stably overexpressed in a well-characterized murine tumor cell line, (valine-12)-RAS-transformed NTH3T3 cells. Menin overexpression reverted the morphology of the RAS-transformed NIH3T3 cells towards the more flattened and more spread, fibroblastic shape of wild type NIH3T3 cells. The proliferation rate of the RAS-transformed cells in 0.5% calf serum was also slower with menin overexpression. Menin overexpression reduced the RAS-induced clonogenicity in soft agar. Menin also reduced tumor growth after injection of cells in nude mice. In conclusion, stable overexpression of MEN1 suppressed partially the RAS-mediated tumor phenotype in vitro and in vivo. Overexpressed menin protein had biological effects, directly supporting MEN1 gene function as a tumor suppressor.	NIDDK, Metab Dis Branch, Bethesda, MD 20892 USA; NHGRI, Genet & Mol Biol Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Marx, SJ (corresponding author), Bldg 10,Room 9C-101,10 Ctr Dr,MSC 1802, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK043310] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agarwal SK, 1999, CELL, V96, P143, DOI 10.1016/S0092-8674(00)80967-8; Agarwal SK, 1997, HUM MOL GENET, V6, P1169, DOI 10.1093/hmg/6.7.1169; Bassett JHD, 1998, AM J HUM GENET, V62, P232, DOI 10.1086/301729; Boni R, 1998, J INVEST DERMATOL, V111, P539; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; COX DR, 1970, ANAL BINARY DATA, P14; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Debelenko LV, 1997, HUM MOL GENET, V6, P2285, DOI 10.1093/hmg/6.13.2285; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Giraud S, 1998, AM J HUM GENET, V63, P455, DOI 10.1086/301953; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Guru SC, 1997, GENOME RES, V7, P725, DOI 10.1101/gr.7.7.725; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; Heppner C, 1997, NAT GENET, V16, P375, DOI 10.1038/ng0897-375; HOLLANDER M, 1997, NONPARAMETRIC STAT M, P67; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; LUO XN, 1995, ONCOGENE, V11, P743; Marx S, 1998, GENETIC BASIS HUMAN, P489; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; MURRAY MJ, 1981, CELL, V25, P355, DOI 10.1016/0092-8674(81)90054-4; Mutch MG, 1999, HUM MUTAT, V13, P175, DOI 10.1002/(SICI)1098-1004(1999)13:3<175::AID-HUMU1>3.0.CO;2-R; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Poncin J, 1999, HUM MUTAT, V13, P54, DOI 10.1002/(SICI)1098-1004(1999)13:1<54::AID-HUMU6>3.0.CO;2-K; SATOH T, 1992, J BIOL CHEM, V267, P24149; Solanas M, 1996, J PHYSIOL BIOCHEM, V52, P173; Teh BT, 1998, J CLIN ENDOCR METAB, V83, P2621, DOI 10.1210/jc.83.8.2621; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; ZHOU YL, 1994, P NATL ACAD SCI USA, V91, P4165, DOI 10.1073/pnas.91.10.4165; Zhuang ZP, 1997, CANCER RES, V57, P4682	34	92	95	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	1999	18	43					5936	5942		10.1038/sj.onc.1203005	http://dx.doi.org/10.1038/sj.onc.1203005			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557080				2022-12-25	WOS:000083270700010
J	Sanchez-Cespedes, M; Reed, AL; Buta, M; Wu, L; Westra, WH; Herman, JG; Yang, SC; Jen, J; Sidransky, D				Sanchez-Cespedes, M; Reed, AL; Buta, M; Wu, L; Westra, WH; Herman, JG; Yang, SC; Jen, J; Sidransky, D			Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer	ONCOGENE			English	Article						non small cell lung cancer; p16 inactivation; p14(ARF) inactivation; p53 gene mutations	TUMOR-SUPPRESSOR; CPG ISLAND; GENE; P53; METHYLATION; TRANSCRIPT; P19(ARF); PROTEIN; HEAD	Inactivation of the P16 (INK4A)/retinoblastoma (RB) or TP53 biochemical pathway is frequent event in most human cancers. Recent evidence has shown that P14ARF binds to MDM2 leading to an increased availability of wild type T53 protein. Functional studies also support a putative tumor suppressor gene function for p14(ARF) suggesting that p14(ARF) or p53 inactivation may be functionally equivalent in tumorigenesis. To study the relative contribution of each pathway in tumorigenesis, we analysed and compared alterations of the p16, p14(ARF) and p53 genes in 38 primary non-small cell lung cancers (NSCLCs) (19 adenocarcinomas and 19 squamous carcinoma). The p16 tumor suppressor gene was inactivated in 22 of 38 (58%) tumors. Twelve of these samples (31%) had homozygous deletions by microsatellite analysis; eight of them (21%) had p16 promoter hypermethylation detected by Methylation Specific PCR (MSP) and the remaining two (5%) harbored a point mutation in exon 2 by sequence analysis. The absence of P16 protein in every case was confirmed by immunohistochemistry. Fourteen of the 22 tumors with p16 inactivation also inactivated the g14(ARF) gene (12 with homozygous deletions extending into INK4a/ARF and two with exon 2 mutations). Mutations of p53 were found in 18 (47%) of the tumors and nine of them (50%) harbored p14(ARF) inactivation. Thus, an inverse correlation was not found between p14(ARF) and g53 genetic alterations (P = 0.18; Fisher Exact Test). Our data confirm that the p16 gene is frequently inactivated in NSCLC. Assuming that 9p deletion occurs first, the common occurrence of p53 and p14(ARF) alterations suggests that p14(ARF) inactivation is not functionally equivalent to abrogation of the TP53 pathway by p53 mutation.	Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Canc Res, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Sidransky, D (corresponding author), Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Canc Res, 818 Ross Res Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.		Sanchez-Cespedes, Montse/H-8485-2012	Sanchez-Cespedes, Montse/0000-0002-6045-5627	NCI NIH HHS [CA 58184] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058184] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARHRENDT SA, 1999, P NATL ACAD SCI USA, V96, P7382; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; Gazzeri S, 1998, CANCER RES, V58, P3926; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kinoshita I, 1996, CANCER RES, V56, P5557; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kratzke R A, 1992, Cancer Treat Res, V63, P61; Kratzke RA, 1996, CANCER RES, V56, P3415; Larsen CJ, 1996, ONCOGENE, V12, P2041; LING L, 1999, NAT GENET, V21, P128; MAO L, 1995, CANCER RES, V55, P2995; Markl IDC, 1998, CANCER RES, V58, P5348; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MITSUDOMI T, 1996, JAPAN J CANC CHEM, V23, P990; Munro J, 1999, CANCER RES, V59, P2516; Reed AL, 1996, CANCER RES, V56, P3630; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Sidransky D, 1996, CURR BIOL, V6, P523, DOI 10.1016/S0960-9822(02)00532-8; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; STONE S, 1995, CANCER RES, V55, P2988; VANDERRIET P, 1994, CANCER RES, V54, P1156	24	105	106	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 21	1999	18	43					5843	5849		10.1038/sj.onc.1203003	http://dx.doi.org/10.1038/sj.onc.1203003			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557071				2022-12-25	WOS:000083270700001
J	Antil, S; Servent, D; Menez, A				Antil, S; Servent, D; Menez, A			Variability among the sites by which curaremimetic toxins bind to Torpedo acetylcholine receptor, as revealed by identification of the functional residues of alpha-cobratoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; DIRECTED MUTAGENESIS; 3-DIMENSIONAL STRUCTURE; CHEMICAL MODIFICATION; NICOTINIC RECEPTOR; TRYPTOPHAN RESIDUE; SNAKE NEUROTOXINS; HIGH-AFFINITY; PROTON NMR; BUNGAROTOXIN	alpha-Cobratoxin, a long chain curaremimetic toxin from Naja kaouthia venom, was produced recombinantly (r alpha-Cbtx) from Escherichia coli. It was indistinguishable from the snake toxin, Mutations at 8 of the 29 explored toxin positions resulted in affinity decreases for Torpedo receptor with Delta Delta G higher than 1.1 kcal/mol, These are R33E > K49E > D27R > K23E > F29A greater than or equal to W25A > R36A greater than or equal to F65A. These positions cover a homogeneous surface of approximately 880 Angstrom(2) and mostly belong to the second toxin loop, except Lys-49 and Phe-65 which are, respectively, on the third loop and C-terminal tail. The mutations K23E and K49E, and perhaps R33E, induced discriminative interactions at the two toxin-binding sites. When compared with the short toxin erabutoxin a (Ea), a number of structurally equivalent residues are commonly implicated in binding to muscular-type nicotinic acetylcholine receptor. These are Lys-23/Lys-27, Asp-27/Asp-31, Arg-33/Arg-33, Lys-49/Lys-47, and to a lesser and variable extent Trp-25/Trp-29 and Phe-29/Phe-32. In addition, however, the short and long toxins display three major differences. First, Asp-38 is important in Ea in contrast to the homologous Glu-38 in alpha-Cbtx, Second, all of the first loop is insensitive to mutation in alpha-Cbtx, whereas its tip is functionally critical in Ea. Third, the C-terminal tail may be specifically critical in alpha-Cbtx. Therefore, the functional sites of long and short curaremimetic toxins are not identical, but they share common features and marked differences that might reflect an evolutionary pressure associated with a great diversity of prey receptors.	CEA Saclay, Dept Ingn & Etudes Prot, F-91191 Gif Sur Yvette, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Servent, D (corresponding author), CEA Saclay, Dept Ingn & Etudes Prot, F-91191 Gif Sur Yvette, France.			Servent, Denis/0000-0002-0774-1691				Ackermann EJ, 1998, J BIOL CHEM, V273, P10958, DOI 10.1074/jbc.273.18.10958; Ackermann EJ, 1997, BIOCHEMISTRY-US, V36, P12836, DOI 10.1021/bi971513u; BASUS VJ, 1993, BIOCHEMISTRY-US, V32, P12290, DOI 10.1021/bi00097a004; BETZEL C, 1991, J BIOL CHEM, V266, P21530; CHANG CC, 1990, EUR J BIOCHEM, V193, P567, DOI 10.1111/j.1432-1033.1990.tb19373.x; CHANG LS, 1993, BIOCHEM MOL BIOL INT, V29, P435; Charpentier I, 1990, J Mol Recognit, V3, P74, DOI 10.1002/jmr.300030204; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHICHEPORTICHE R, 1975, BIOCHEMISTRY-US, V14, P2081, DOI 10.1021/bi00681a007; Drevet P, 1997, PROTEIN EXPRES PURIF, V10, P293, DOI 10.1006/prep.1997.0740; Ducancel F, 1996, J BIOL CHEM, V271, P31345, DOI 10.1074/jbc.271.49.31345; DUFTON MJ, 1983, CRC CR REV BIOCH MOL, V14, P113, DOI 10.3109/10409238309102792; Endo T., 1991, P165; ENDO T, 1987, BIOCHEMISTRY-US, V26, P4592, DOI 10.1021/bi00388a063; FIORDALISI JJ, 1994, BIOCHEMISTRY-US, V33, P12962, DOI 10.1021/bi00248a004; GROEBE DR, 1995, MOL PHARMACOL, V48, P105; Groebe DR, 1997, BIOCHEMISTRY-US, V36, P6469, DOI 10.1021/bi970195w; Hann RM, 1997, BIOCHEMISTRY-US, V36, P9051, DOI 10.1021/bi970807c; JOHNSON DA, 1990, J BIOL CHEM, V265, P7360; KAMMORGAN LNW, 1993, P NATL ACAD SCI USA, V90, P3958, DOI 10.1073/pnas.90.9.3958; KARLSSON E, 1971, EUR J BIOCHEM, V21, P1, DOI 10.1111/j.1432-1033.1971.tb01433.x; KREIENKAMP HJ, 1994, J BIOL CHEM, V269, P8108; LEGOAS R, 1992, BIOCHEMISTRY-US, V31, P4867, DOI 10.1021/bi00135a018; LIN SR, 1992, BIOCHIM BIOPHYS ACTA, V1159, P255, DOI 10.1016/0167-4838(92)90053-G; Lin SR, 1997, J BIOCHEM-TOKYO, V121, P690, DOI 10.1093/oxfordjournals.jbchem.a021641; LIN SR, 1991, TOXICON, V29, P937, DOI 10.1016/0041-0101(91)90077-5; LOW BW, 1986, EUR J BIOCHEM, V161, P579, DOI 10.1111/j.1432-1033.1986.tb10481.x; Malany S., 1998, Journal of Physiology Paris, V92, P462, DOI 10.1016/S0928-4257(99)80079-5; MARTIN BM, 1983, J BIOL CHEM, V258, P8714; MEBS D, 1972, H-S Z PHYSIOL CHEM, V353, P243, DOI 10.1515/bchm2.1972.353.1.243; PILLET L, 1993, J BIOL CHEM, V268, P909; RODBARD D, 1974, CLIN CHEM, V20, P1255; ROSENTHAL JA, 1994, J BIOL CHEM, V269, P11178; Servent D, 1997, J BIOL CHEM, V272, P24279, DOI 10.1074/jbc.272.39.24279; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; TREMEAU O, 1995, J BIOL CHEM, V270, P9362, DOI 10.1074/jbc.270.16.9362; TSERNOGLOU D, 1977, P NATL ACAD SCI USA, V74, P971, DOI 10.1073/pnas.74.3.971; WALKINSHAW MD, 1980, P NATL ACAD SCI-BIOL, V77, P2400, DOI 10.1073/pnas.77.5.2400; ZINNJUSTIN S, 1992, BIOCHEMISTRY-US, V31, P11335, DOI 10.1021/bi00161a011	39	101	103	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34851	34858		10.1074/jbc.274.49.34851	http://dx.doi.org/10.1074/jbc.274.49.34851			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574958	hybrid			2022-12-25	WOS:000083979600052
J	Bosilevac, JM; Olsen, RJ; Bridge, JA; Hinrichs, SH				Bosilevac, JM; Olsen, RJ; Bridge, JA; Hinrichs, SH			Tumor cell viability in clear cell sarcoma requires DNA binding activity of the EWS/ATF1 fusion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-MELANOMA CELLS; RNA-POLYMERASE-II; MALIGNANT-MELANOMA; SOFT PARTS; CHROMOSOMAL-ABNORMALITIES; TRANSCRIPTIONAL ACTIVATOR; GENE-THERAPY; CREB; EWS; ANTIBODIES	Chimeric proteins resulting from characteristic chromosomal translocations are believed to play a key role in the development of neoplasia. The consistent chromosomal translocation t(12;22) found in Clear Cell sarcoma (CCS) fuses the genes for Ewing's sarcoma protein (EWS) and activating transcription factor 1 (ATF1). Contribution of the chimeric EWS/ATF1 protein to maintenance of the tumor phenotype was investigated using intracellular expression of an inhibitory anti-ATF1 single chain antibody fragment (scFv4). Transfection of scFv4 into a cell line (SU-CCS-1) derived from CCS resulted in a 90% reduction in cyclic AMP response element-driven reporter activity. The delivery of scFv4 into SU-CCS-1 cells by a Moloney sarcoma retroviral vector (SR alpha-Fv4) significantly reduced viability and induced apoptosis as measured by terminal deoxynucleotide-transferase-mediated dUTP-biotin nick end labeling and flow cytometry. Conversely, scFv4 had no effect on viability of HeLa cells. The level of EWS/ATF1 expression was found to be significantly higher in primary tumor tissue than in SU-CCS-1 cells or in 293T cells following introduction of an EWS/ATF1 expression vector. These studies demonstrate a direct role for the EWS/ATF1 fusion protein in maintaining tumor cell viability of Clear Cell sarcoma and indicate that intracellular antibodies may be used to achieve a phenotypic knockout of tumor-related proteins as a method to explore their function.	Univ Nebraska, Med Ctr 986495, Dept Pathol & Microbiol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Orthoped Surg, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Hinrichs, SH (corresponding author), Univ Nebraska, Med Ctr 986495, Dept Pathol & Microbiol, Omaha, NE 68198 USA.	shinric@mail.unmc.edu		Bosilevac, Joseph/0000-0002-0258-6581				Anderson WF, 1998, NATURE, V392, P25; Barr FG, 1997, CURR TOP MICROBIOL, V220, P113; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Boehm JE, 1998, J BIOL CHEM, V273, P7169, DOI 10.1074/jbc.273.12.7169; Bosilevac JM, 1998, J BIOL CHEM, V273, P16874, DOI 10.1074/jbc.273.27.16874; BRIDGE JA, 1991, CANCER GENET CYTOGEN, V52, P101, DOI 10.1016/0165-4608(91)90059-4; BRIDGE JA, 1990, AM J CLIN PATHOL, V93, P26, DOI 10.1093/ajcp/93.1.26; BROWN AD, 1995, ONCOGENE, V10, P1749; Deloulme JC, 1997, J BIOL CHEM, V272, P27369, DOI 10.1074/jbc.272.43.27369; Duan LX, 1995, HUM GENE THER, V6, P1561, DOI 10.1089/hum.1995.6.12-1561; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; EPSTEIN AL, 1984, CANCER RES, V44, P1265; FOULKES N, 1996, ONCOGENE, V10, P1749; Fujimura Y, 1996, ONCOGENE, V12, P159; GILCHRIST C, 1995, J BIOCH SCI, V3, P96; Gilchrist CA, 1995, ANTIBODY IMMUNOCONJ, V8, P281; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GRIFFITHS AD, 1993, EMBO J, V12, P725, DOI 10.1002/j.1460-2075.1993.tb05706.x; Jean D, 1998, J BIOL CHEM, V273, P24884, DOI 10.1074/jbc.273.38.24884; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; LADANYI M, 1995, DIAGN MOL PATHOL, V4, P162, DOI 10.1097/00019606-199509000-00003; Li KKC, 1998, ONCOGENE, V16, P1325, DOI 10.1038/sj.onc.1201649; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; MagnaghiJaulin L, 1996, NUCLEIC ACIDS RES, V24, P1052, DOI 10.1093/nar/24.6.1052; MARASCO WA, 1995, IMMUNOTECHNOLOGY, V1, P1, DOI 10.1016/1380-2933(95)00001-1; MEYER TE, 1993, ENDOCRINOLOGY, V132, P770, DOI 10.1210/en.132.2.770; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; OHNO T, 1994, ONCOGENE, V9, P3087; ORTEN DJ, 1994, J BIOL CHEM, V269, P32254; Pan S, 1998, ONCOGENE, V16, P1625, DOI 10.1038/sj.onc.1201671; PAULA Y, 1999, MOL CELL BIOL, V19, P594; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; Raffray M, 1997, PHARMACOL THERAPEUT, V75, P153, DOI 10.1016/S0163-7258(97)00037-5; SARA AS, 1990, CANCER-AM CANCER SOC, V65, P367, DOI 10.1002/1097-0142(19900115)65:2<367::AID-CNCR2820650232>3.0.CO;2-X; Sassone-Corsi P, 1998, INT J BIOCHEM CELL B, V30, P27, DOI 10.1016/S1357-2725(97)00093-9; Speleman F, 1997, MODERN PATHOL, V10, P496; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TELFORD WG, 1991, CELL PROLIFERAT, V24, P447, DOI 10.1111/j.1365-2184.1991.tb01173.x; TRAVIS JA, 1992, CANCER GENET CYTOGEN, V64, P104, DOI 10.1016/0165-4608(92)90337-8; Wang XW, 1997, J CELL PHYSIOL, V173, P247, DOI 10.1002/(SICI)1097-4652(199711)173:2<247::AID-JCP30>3.0.CO;2-A; Xie SH, 1997, ONCOGENE, V15, P2069, DOI 10.1038/sj.onc.1201358; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	44	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34811	34818		10.1074/jbc.274.49.34811	http://dx.doi.org/10.1074/jbc.274.49.34811			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574952	hybrid			2022-12-25	WOS:000083979600046
J	Pattyn, E; Van Ostade, X; Schauvliege, L; Verhee, A; Kalai, M; Vandekerckhove, J; Tavernier, J				Pattyn, E; Van Ostade, X; Schauvliege, L; Verhee, A; Kalai, M; Vandekerckhove, J; Tavernier, J			Dimerization of the interferon type I receptor IFNaR2-2 is sufficient for induction of interferon effector genes but not for full antiviral activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-BETA RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTIONAL ACTIVATION; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; STAT ACTIVATION; SHARED RECEPTOR; DOWN-REGULATION; CELL-LINE; IFN-ALPHA	We constructed chimeric receptors wherein the extracellular domain of the erythropoietin receptor (EpoR) was fused to the transmembrane and intracellular domains of the interferon (IFN) type I receptor subunits, IFNaR1 or IFNaR2-2. Transfection into 2fTGH and Tyk2-deficient 11,1 cells showed that EpoR/IFNaR2-2 alone was able to transduce a signal upon stimulation with erythropoietin (Epo), as judged by induction of the interferon type I-inducible 6-16 promoter. In contrast, protection against infection with encephalomyocarditis virus or vesicular stomatitis virus was reduced or absent, respectively. To further investigate the role of IFNaR1 in the induction of an antiviral state, we analyzed the Epo- versus IFN alpha-induced transcription of a set of genes, involved in antiviral protection. Up to 24 h after stimulation with Epo or IFN alpha, comparable transcription of the p56, dsRNA-dependent protein kinase, 2'-5'A synthetase, and MxA genes was seen. However, at later time points, only in the case of Epo induction, a sharp decrease of mRNA levels was observed. Western blotting analysis of dsRNA-dependent protein kinase showed a similar pattern at the protein level, Taken together, our results imply a role for IFNaR1 in the induction of sustained mRNA and protein levels that are likely required for optimal antiviral activity.	State Univ Ghent VIB, Dept Med Prot Res, Fac Med, B-9000 Ghent, Belgium; Univ Ghent, Dept Mol Biol, Fac Sci, B-9000 Ghent, Belgium	Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University	Tavernier, J (corresponding author), State Univ Ghent VIB, Dept Med Prot Res, Fac Med, KL Ledeganckstr 35, B-9000 Ghent, Belgium.	jan.tavernier@rug.ac.be	Tavernier, Jan/AAG-3636-2019; Van Ostade, Xaveer/AAG-9587-2020; Van Ostade, Xaveer WMP/D-1702-2015	Van Ostade, Xaveer WMP/0000-0003-4078-3014				Ahmad S, 1997, J BIOL CHEM, V272, P29991, DOI 10.1074/jbc.272.48.29991; Arora T, 1999, J IMMUNOL, V162, P3289; Basu L, 1998, VIROLOGY, V242, P14, DOI 10.1006/viro.1997.9002; Behrmann I, 1997, J BIOL CHEM, V272, P5269, DOI 10.1074/jbc.272.8.5269; BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2846, DOI 10.1128/MCB.13.5.2846; Benkirane M, 1997, EMBO J, V16, P611, DOI 10.1093/emboj/16.3.611; Burfoot MS, 1997, J BIOL CHEM, V272, P24183, DOI 10.1074/jbc.272.39.24183; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CLEARY CM, 1994, J BIOL CHEM, V269, P18747; Croze E, 1996, J BIOL CHEM, V271, P33165, DOI 10.1074/jbc.271.52.33165; Cutrone EC, 1997, FEBS LETT, V404, P197, DOI 10.1016/S0014-5793(97)00129-4; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DEMARCO F, 1995, J GEN VIROL, V76, P445, DOI 10.1099/0022-1317-76-2-445; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; Domanski P, 1998, J BIOL CHEM, V273, P3144, DOI 10.1074/jbc.273.6.3144; EINHORN S, 1977, J GEN VIROL, V35, P573, DOI 10.1099/0022-1317-35-3-573; Fish EN, 1999, J BIOL CHEM, V274, P571, DOI 10.1074/jbc.274.2.571; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gauzzi MC, 1997, P NATL ACAD SCI USA, V94, P11839, DOI 10.1073/pnas.94.22.11839; Gibbs VC, 1996, J BIOL CHEM, V271, P28710, DOI 10.1074/jbc.271.45.28710; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Guo JJ, 1998, EUR CYTOKINE NETW, V9, P325; HILTON DJ, 1994, GUIDEBOOK CYTOKINES, P8; Holland KA, 1997, J BIOL CHEM, V272, P21045, DOI 10.1074/jbc.272.34.21045; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; IMPROTA T, 1994, P NATL ACAD SCI USA, V91, P4776, DOI 10.1073/pnas.91.11.4776; Kim SH, 1997, GENE, V196, P279, DOI 10.1016/S0378-1119(97)00240-0; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Kotenko SV, 1999, P NATL ACAD SCI USA, V96, P5007, DOI 10.1073/pnas.96.9.5007; Lee SB, 1996, J INTERF CYTOK RES, V16, P1073, DOI 10.1089/jir.1996.16.1073; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Lewerenz M, 1998, J MOL BIOL, V282, P585, DOI 10.1006/jmbi.1998.2026; Li XX, 1997, MOL CELL BIOL, V17, P2048, DOI 10.1128/MCB.17.4.2048; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; Lu J, 1998, J IMMUNOL, V160, P1782; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; Means RT, 1996, EXP HEMATOL, V24, P204; MOUCHELVIELH E, 1992, FEBS LETT, V313, P255, DOI 10.1016/0014-5793(92)81204-Y; Nadeau OW, 1999, J BIOL CHEM, V274, P4045, DOI 10.1074/jbc.274.7.4045; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; Petricoin EF, 1997, NATURE, V390, P629, DOI 10.1038/37648; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Platanias LC, 1996, J BIOL CHEM, V271, P23630, DOI 10.1074/jbc.271.39.23630; Rani MRS, 1996, J BIOL CHEM, V271, P22878, DOI 10.1074/jbc.271.37.22878; Richter MF, 1998, J BIOL CHEM, V273, P24723, DOI 10.1074/jbc.273.38.24723; ROSENBLUM MG, 1990, J INTERFERON RES, V10, P141, DOI 10.1089/jir.1990.10.141; Runkel L, 1998, J BIOL CHEM, V273, P8003, DOI 10.1074/jbc.273.14.8003; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; UZE G, 1992, P NATL ACAD SCI USA, V89, P4774, DOI 10.1073/pnas.89.10.4774; WATHELET M, 1986, EUR J BIOCHEM, V155, P11, DOI 10.1111/j.1432-1033.1986.tb09452.x; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; Yang CH, 1998, P NATL ACAD SCI USA, V95, P5568, DOI 10.1073/pnas.95.10.5568; Yang CH, 1996, J BIOL CHEM, V271, P8057, DOI 10.1074/jbc.271.14.8057; Zhou AM, 1999, VIROLOGY, V258, P435, DOI 10.1006/viro.1999.9738	59	23	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34838	34845		10.1074/jbc.274.49.34838	http://dx.doi.org/10.1074/jbc.274.49.34838			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574956	hybrid			2022-12-25	WOS:000083979600050
J	Lee, SK; Anzick, SL; Choi, JE; Bubendorf, L; Guan, XY; Jung, YK; Kallioniemi, OP; Kononen, J; Trent, JM; Azorsa, D; Jhun, BH; Cheong, JH; Lee, YC; Meltzer, PS; Lee, JW				Lee, SK; Anzick, SL; Choi, JE; Bubendorf, L; Guan, XY; Jung, YK; Kallioniemi, OP; Kononen, J; Trent, JM; Azorsa, D; Jhun, BH; Cheong, JH; Lee, YC; Meltzer, PS; Lee, JW			A nuclear factor, ASC-2, as a cancer-amplified transcriptional coactivator essential for ligand-dependent transactivation by nuclear receptors in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; ACTIVATION FUNCTION AF-2; HUMAN BREAST-CANCER; ESTROGEN-RECEPTOR; HISTONE ACETYLTRANSFERASE; MEDIATED TRANSACTIVATIONS; CRYSTAL-STRUCTURE; BINDING DOMAIN; RETINOIC-ACID; CO-REPRESSOR	Many transcription coactivators interact with nuclear receptors in a ligand- and C-terminal transactivation function (AF2)-dependent manner. We isolated a nuclear factor (designated ASC-2) with such properties by using the ligand-binding domain of retinoid X receptor as a bait in a yeast two-hybrid screening. ASC-2 also interacted with other nuclear receptors, including retinoic acid receptor, thyroid hormone receptor, estrogen receptor alpha, and glucocorticoid receptor, basal factors TFIIA and TBP, and transcription integrators CBP/p300 and SRC-1. In transient cotransfections, ASC-2, either alone or in conjunction with CBP/p300 and SRC-1, stimulated ligand dependent transactivation by wild type nuclear receptors but not mutant receptors lacking the AF2 domain. Consistent with an idea that ASC-2 is essential for the nuclear receptor function in vivo, microinjection of anti-ASC-2 antibody abrogated the ligand-dependent transactivation of retinoic acid receptor, and this repression was fully relieved by coinjection of ASC-2-expression vector. Surprisingly, ASC-2 was identical to a gene previously identified during a search for genes amplified and overexpressed in breast and other human cancers. From these results, we concluded that ASC-2 is a bona fide transcription coactivator molecule of nuclear receptors, and its altered expression may contribute to the development of cancers.	NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; Pusan Natl Univ, Coll Pharm, Pusan 609735, South Korea; Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500303, South Korea; Chonnam Natl Univ, Ctr Ligand & Transcript, Kwangju 500757, South Korea; Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Pusan National University; Gwangju Institute of Science & Technology (GIST); Chonnam National University; Chonnam National University	Lee, JW (corresponding author), NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA.	pmeltzer@nhgri.nih.gov; jlee@chonnam.chonnam.ac.kr	Bubendorfl, Lukas/H-5880-2011; Bubendorf, Lukas/G-5299-2015; Kallioniemi, Olli P/H-5111-2011; Guan, Xin-Yuan/A-3639-2009; /A-3639-2009	Bubendorf, Lukas/0000-0001-5970-1803; Kallioniemi, Olli P/0000-0002-3231-0332; Guan, Xin-Yuan/0000-0002-4485-6017; Jung, Yong-Keun/0000-0002-9686-3120; /0000-0003-1874-9805; Kononen, Juha/0000-0002-0157-2137				ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Courjal F, 1997, CANCER RES, V57, P4360; Dallas PB, 1998, MOL CELL BIOL, V18, P3596, DOI 10.1128/MCB.18.6.3596; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Elkahloun AG, 1996, GENE CHROMOSOME CANC, V17, P205, DOI 10.1002/(SICI)1098-2264(199612)17:4<205::AID-GCC2>3.3.CO;2-#; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; Guan XY, 1996, CANCER RES, V56, P3446; GUAN XY, 1994, NAT GENET, V8, P155, DOI 10.1038/ng1094-155; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Harlow E., 1988, ANTIBODIES LAB MANUA; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kim HJ, 1999, MOL CELL BIOL, V19, P6323; Kim HJ, 1998, MOL ENDOCRINOL, V12, P1038, DOI 10.1210/me.12.7.1038; Kim HJ, 1998, J BIOL CHEM, V273, P28564, DOI 10.1074/jbc.273.44.28564; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; Lee SK, 1998, MOL ENDOCRINOL, V12, P1184, DOI 10.1210/me.12.8.1184; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; LEE SK, 1999, IN PRESS MOL ENDOCRI; LEE Y, 1998, J BIOCHEM MOL BIOL, V31, P1; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Moore DD, 1995, GLOB MOB SURV; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Tanner MM, 1996, CANCER RES, V56, P3441; Tirkkonen M, 1998, GENE CHROMOSOME CANC, V21, P177, DOI 10.1002/(SICI)1098-2264(199803)21:3<177::AID-GCC1>3.3.CO;2-C; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3; Zavacki AM, 1997, P NATL ACAD SCI USA, V94, P7909, DOI 10.1073/pnas.94.15.7909; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	76	172	184	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34283	34293		10.1074/jbc.274.48.34283	http://dx.doi.org/10.1074/jbc.274.48.34283			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567404	hybrid			2022-12-25	WOS:000083857500069
J	Trifan, OC; Smith, RM; Thompson, BD; Hla, T				Trifan, OC; Smith, RM; Thompson, BD; Hla, T			Overexpression of cyclooxygenase-2 induces cell cycle arrest - Evidence for a prostaglandin-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ENDOPEROXIDE-H SYNTHASE-1; GROWTH-FACTOR; ENDOTHELIAL-CELLS; ANGIOGENESIS; INTERLEUKIN-1; PROSTACYCLIN; EXPRESSION; INHIBITION; APOPTOSIS	The immediate-early gene cyclooxygenase 2 (Cox-2) is induced in a variety of hyperplastic pathological conditions, including rheumatoid arthritis and colorectal cancer. Although a causal role for Cox-2 has been proposed, mechanisms by which Cox-2 function contributes to the pathogenesis of hyperplastic disease are not well defined. We constructed a green fluorescent protein-tagged Cox-2 (Cox-2-GFP) to examine its effects on a variety of cell types upon overexpression, Subcellular localization and enzymatic and pharmacological properties of Cox-2-GFP polypeptide were indistinguishable from those of the wild-type Cox-2 polypeptide. Overexpression of the Cox-2-GFP or the Cox-2 polypeptide by transient transfection suppressed the population of cells in the S phase of the cell cycle, with a concomitant increase in G(0)/G(1) population. In contrast, transient overexpression of GFP had no effect on cell cycle distribution, whereas endoplasmic reticulum-retained GFP (GFP-KDEL) overexpression was associated with only a minor decrease of cells in S phase. Interestingly, neither NS-398 (a Cox-2-specific inhibitor) nor indomethacin could reverse the effect of Cox-2-GFP overexpression on cell cycle progression. Furthermore, two mutants of Cox-2, S516Q and S516M, which lack the cyclooxygenase activity, exhibited the same effect as Cox-2-GFP. The cell cycle effect of Cox-2-GFP was observed in ECV-304, NIH 3T3, COS-7, bovine microvascular endothelial cells, and human embryonic kidney 293 cells. These findings suggest that Cox-2 inhibits cell cycle progression in a variety of cell types by a novel mechanism that does not require the synthesis of prostaglandins.	Univ Connecticut, Ctr Hlth, Ctr Vasc Biol, Dept Physiol, Farmington, CT 06030 USA	University of Connecticut	Hla, T (corresponding author), Univ Connecticut, Ctr Hlth, Ctr Vasc Biol, Dept Physiol, MC-3505,263 Farmington Ave, Farmington, CT 06030 USA.		Hla, Timothy/G-5873-2012	Hla, Timothy/0000-0001-8355-4065	NHLBI NIH HHS [HL49094, HL54710] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049094, P01HL054710] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAILEY JM, 1985, J LIPID RES, V26, P54; Ballif BA, 1996, P NATL ACAD SCI USA, V93, P5544, DOI 10.1073/pnas.93.11.5544; BENAV P, 1995, FEBS LETT, V372, P83, DOI 10.1016/0014-5793(95)00956-A; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Heinemann FS, 1998, MOL BIOL CELL, V9, P3445, DOI 10.1091/mbc.9.12.3445; HLA T, 1993, ANN NY ACAD SCI, V696, P197; Hla T, 1999, INT J BIOCHEM CELL B, V31, P551, DOI 10.1016/S1357-2725(98)00152-6; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Kawamori T, 1998, CANCER RES, V58, P409; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; LOPEZ S, 1993, BIOCHIM BIOPHYS ACTA, V1170, P17, DOI 10.1016/0005-2760(93)90170-E; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; Munroe DG, 1995, J INFLAMM, V45, P260; Murohara T, 1998, CIRCULATION, V97, P99, DOI 10.1161/01.CIR.97.1.99; Narko K, 1997, J BIOL CHEM, V272, P21455, DOI 10.1074/jbc.272.34.21455; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; Terasaki M, 1996, DEV BIOL, V179, P320, DOI 10.1006/dbio.1996.0263; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563	29	107	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34141	34147		10.1074/jbc.274.48.34141	http://dx.doi.org/10.1074/jbc.274.48.34141			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567385	hybrid			2022-12-25	WOS:000083857500050
J	Ambroziak, W; Izaguirre, G; Pietruszko, R				Ambroziak, W; Izaguirre, G; Pietruszko, R			Metabolism of retinaldehyde and other aldehydes in soluble extracts of human liver and kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOL-BINDING-PROTEIN; RAT-LIVER; DEHYDROGENASE; ACID; OXIDATION; PURIFICATION; IDENTIFICATION; CLONING; BIOSYNTHESIS; RECOGNITION	Purification and characterization of enzymes metabolizing retinaldehyde, propionaldehyde, and octanaldehyde from four human livers and three kidneys were done to identify enzymes metabolizing retinaldehyde and their relationship to enzymes metabolizing other aldehydes, The tissue fractionation patterns from human liver and kidney were the same, indicating presence of the same enzymes in human liver and kidney. Moreover, in both organs the major NAD(+)-dependent retinaldehyde activity copurified with the propionaldehyde and octanaldehyde activities; in both organs the major NAD(+)-dependent retinaldehyde activity was associated with the El isozyme (coded for by aldh1 gene) of human aldehyde dehydrogenase, A small amount of NAD(+)-dependent retinaldehyde activity was associated with the E2 isozyme (product of aldh2 gene) of aldehyde dehydrogenase. Some NAD(+)-independent retinaldehyde activity in both organs was associated with aldehyde oxidase, which could be easily separated from dehydrogenases, Employing cellular retinoid-binding protein (CRBP), purified from human liver, demonstrated that El isozyme (but not E2 isozyme) could utilize CRBP-bound retinaldehyde as substrate, a feature thought to be specific to retinaldehyde dehydrogenases, This is the first report of CRBP-bound retinaldehyde functioning as substrate for aldehyde dehydrogenase of broad substrate specificity. Thus, it is concluded that in the human organism, retinaldehyde dehydrogenase (coded for by raldH1 gene) and broad substrate specificity El (a member of EC 1.2.1.3 aldehyde dehydrogenase family) are the same enzyme. These results suggest that the El isozyme may be more important to alcoholism than the acetaldehyde-metabolizing enzyme, E2, because competition between acetaldehyde and retinaldehyde could result in abnormalities associated with vitamin A metabolism and alcoholism.	Rutgers State Univ, Ctr Alcohol Studies, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick	Pietruszko, R (corresponding author), Rutgers State Univ, Ctr Alcohol Studies, 607 Allison Rd, Piscataway, NJ 08854 USA.				NIAAA NIH HHS [1RO1 AA00186] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA000186] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AMBROZIAK W, 1991, J BIOL CHEM, V266, P13011; Bhat PV, 1995, GENE, V166, P303, DOI 10.1016/0378-1119(96)81752-5; BLISS AF, 1951, ARCH BIOCHEM BIOPHYS, V31, P197, DOI 10.1016/0003-9861(51)90206-8; CAO QN, 1989, BIOCHEM PHARMACOL, V38, P77, DOI 10.1016/0006-2952(89)90152-4; CHEN H, 1995, BIOCHEM PHARMACOL, V50, P1257, DOI 10.1016/0006-2952(95)02005-W; Cleland W W, 1979, Methods Enzymol, V63, P103; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; Dai Y, 1999, J BIOL CHEM, V274, P1193, DOI 10.1074/jbc.274.3.1193; DOCKHAM PA, 1992, BIOCHEM PHARMACOL, V43, P2453, DOI 10.1016/0006-2952(92)90326-E; DUNN TJ, 1989, J BIOL CHEM, V264, P13057; ELDER TD, 1962, BIOCHIM BIOPHYS ACTA, V64, P430, DOI 10.1016/0006-3002(62)90300-1; FEX G, 1982, BIOCHIM BIOPHYS ACTA, V714, P536, DOI 10.1016/0304-4165(82)90165-9; FUTTERMAN S, 1962, J BIOL CHEM, V237, P677; GOA J, 1953, SCAND J CLIN LAB INV, V5, P218, DOI 10.3109/00365515309094189; Goodman AB, 1998, P NATL ACAD SCI USA, V95, P7240, DOI 10.1073/pnas.95.13.7240; GOODMAN DS, 1965, SCIENCE, V149, P879, DOI 10.1126/science.149.3686.879; Graham C, 1996, J BIOL CHEM, V271, P15623, DOI 10.1074/jbc.271.26.15623; GREENFIELD NJ, 1977, BIOCHIM BIOPHYS ACTA, V483, P35, DOI 10.1016/0005-2744(77)90005-5; GUDAS LJ, 1994, J BIOL CHEM, V269, P15399; HEMPEL JD, 1982, ALCOHOL CLIN EXP RES, V6, P417, DOI 10.1111/j.1530-0277.1982.tb05001.x; Hong Waun Ki, 1994, P597; Kathmann EC, 1997, BIOCHEM BIOPH RES CO, V236, P527, DOI 10.1006/bbrc.1997.6998; KURYS G, 1989, J BIOL CHEM, V264, P4715; LABRECQUE J, 1993, BIOCHEM CELL BIOL, V71, P85, DOI 10.1139/o93-013; LEE MO, 1991, BIOCHEM PHARMACOL, V42, P1279, DOI 10.1016/0006-2952(91)90266-8; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; MALPELI G, 1995, EUR J BIOCHEM, V229, P486, DOI 10.1111/j.1432-1033.1995.0486k.x; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; OLSON JA, 1965, P NATL ACAD SCI USA, V54, P1364, DOI 10.1073/pnas.54.5.1364; ONG DE, 1978, J BIOL CHEM, V253, P828; ONG DE, 1982, CANCER RES, V42, P1033; POSCH KC, 1992, J BIOL CHEM, V267, P19676; TOTTMAR SOC, 1973, BIOCHEM J, V135, P577, DOI 10.1042/bj1350577a; VENTEICHER R, 1977, ALCOHOL ALDEHYDE MET, V2, P157; Wang XD, 1996, J BIOL CHEM, V271, P26490, DOI 10.1074/jbc.271.43.26490; Wang XS, 1996, J BIOL CHEM, V271, P16288, DOI 10.1074/jbc.271.27.16288; YOSHIDA A, 1992, ENZYME, V46, P239, DOI 10.1159/000468794; YUN SL, 1977, BIOCHIM BIOPHYS ACTA, V480, P324; Zhao D, 1996, EUR J BIOCHEM, V240, P15, DOI 10.1111/j.1432-1033.1996.0015h.x	39	36	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33366	33373		10.1074/jbc.274.47.33366	http://dx.doi.org/10.1074/jbc.274.47.33366			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559215	hybrid			2022-12-25	WOS:000083745200031
J	Schreiber, V; Richet, E				Schreiber, V; Richet, E			Self-association of the Escherichia coli transcription activator MalT in the presence of maltotriose and ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; KLEBSIELLA-PNEUMONIAE; REGULATORY PROTEIN; PROMOTERS; COMPLEX; SYSTEM; GENE; INITIATION; REGULON; ENZYME	MalT, the transcriptional activator of the Escherichia coli maltose regulon, binds the MalT-dependent promoters and activates transcription initiation only in the presence of maltotriose and ATP (or adenylyl imidodiphosphate (AMP-PNP)). Cooperative binding of MalT to the array of cognate sites present in the MalT-dependent promoters suggests that promoter binding involves MalT oligomerization. Gel filtration and sedimentation experiments were used to analyze the quaternary structure of MalT in solution in the absence or presence of maltotriose and/or AMP-PNP, ATP, or ADP, The protein is monomeric in the absence of ligands and in the presence of ADP, In the presence of maltotriose, AMP-PNP, or ATP only, the protein self-associates, but a large fraction of the protein remains monomeric, In the presence of both maltotriose and AMP-PNP (ATP or ADP), the protein is essentially oligomeric, with the difference being that the oligomerization is less favored in the presence of ADP + maltotriose than in the presence of AMPPNP + maltotriose, We present evidence that the association pathway comprises the following steps: monomers --> dimers --> (MalT)(n) --> aggregates, where 3 less than or equal to n less than or equal to 6, From these data, we conclude that the role of maltotriose and ATP as positive effecters is to induce the multimerization of MalT, and hence its cooperative binding to the mal promoters.	Inst Pasteur, Unite Genet Mol, CNRS, URA 1773, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Richet, E (corresponding author), Inst Pasteur, Unite Genet Mol, CNRS, URA 1773, 25 Rue Dr Roux, F-75724 Paris 15, France.							AMSTERCHODER O, 1992, SCIENCE, V257, P1395, DOI 10.1126/science.1382312; Baikalov I, 1996, BIOCHEMISTRY-US, V35, P11053, DOI 10.1021/bi960919o; Boos W, 1998, MICROBIOL MOL BIOL R, V62, P204, DOI 10.1128/MMBR.62.1.204-229.1998; Danot O, 1996, J MOL BIOL, V262, P1, DOI 10.1006/jmbi.1996.0493; DANOT O, 1994, MOL MICROBIOL, V14, P335, DOI 10.1111/j.1365-2958.1994.tb01294.x; DURSCHLAG H, 1986, THERMODYNAMIC DATA B, P45; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Johansson J, 1998, J BACTERIOL, V180, P6117; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LOHMAN TM, 1989, J BIOL CHEM, V264, P10139; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Panagiotidis CH, 1998, MOL MICROBIOL, V30, P535, DOI 10.1046/j.1365-2958.1998.01084.x; Peist R, 1997, J BACTERIOL, V179, P7679, DOI 10.1128/jb.179.24.7679-7686.1997; Peng HL, 1997, J BACTERIOL, V179, P1497, DOI 10.1128/jb.179.5.1497-1504.1997; PerezMartin J, 1996, CELL, V86, P331, DOI 10.1016/S0092-8674(00)80104-X; PHILO JS, 1995, MODERN ANAL ULTRACEN, P156; RAIBAUD O, 1989, J MOL BIOL, V205, P471, DOI 10.1016/0022-2836(89)90218-0; REIDL J, 1991, J BACTERIOL, V173, P4862, DOI 10.1128/jb.173.15.4862-4876.1991; Richet E, 1996, J MOL BIOL, V264, P852, DOI 10.1006/jmbi.1996.0682; RICHET E, 1991, J MOL BIOL, V218, P529; RICHET E, 1991, CELL, V66, P1185, DOI 10.1016/0092-8674(91)90041-V; RICHET E, 1989, EMBO J, V8, P981, DOI 10.1002/j.1460-2075.1989.tb03461.x; Rippe K, 1998, J MOL BIOL, V278, P915, DOI 10.1006/jmbi.1998.1746; Schwartz M, 1987, ESCHERICHIA COLI SAL, P1482; Tagami H, 1998, EMBO J, V17, P1759, DOI 10.1093/emboj/17.6.1759; VIDALINGIGLIARDI D, 1993, J BIOL CHEM, V268, P24527; VIDALINGIGLIARDI D, 1991, J MOL BIOL, V218, P323, DOI 10.1016/0022-2836(91)90715-I; WILSON TJ, 1994, J MOL BIOL, V238, P309, DOI 10.1006/jmbi.1994.1294; Wubbolts MG, 1994, THESIS U GRONINGEN G	29	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33220	33226		10.1074/jbc.274.47.33220	http://dx.doi.org/10.1074/jbc.274.47.33220			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559195	hybrid			2022-12-25	WOS:000083745200011
J	Severson, W; Partin, L; Schmaljohn, CS; Johnsson, CB				Severson, W; Partin, L; Schmaljohn, CS; Johnsson, CB			Characterization of the hantaan nucleocapsid protein-ribonucleic acid interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR STOMATITIS-VIRUS; INFLUENZA-VIRUS; BINDING-PROPERTIES; RNA-BINDING; INVITRO; NUCLEOPROTEIN; GENOME; TRANSCRIPTION; ENCAPSIDATION; HANTAVIRUSES	The nucleocapsid (N) protein functions in hantavirus replication through its interactions with the viral genomic and antigenomic RNAs. To address the biological functions of the N protein, it was critical to first define this binding interaction. The dissociation constant, K-d, for the interaction of the Hantaan virus (HTNV) N protein and its genomic S segment (vRNA) was measured under several solution conditions. Overall, increasing the NaCl and Mg2+ in these binding reactions had little impact on the K-d. However, the HTNV N protein showed an enhanced specificity for HTNV vRNA as compared with the S segment open reading frame RNA or a nonviral RNA with increasing ionic strength and the presence of Mg2+. In contrast, the assembly of Sin Nombre virus N protein-HTNV vRNA complexes was inhibited by the presence of Mg2+ Or,increase in the ionic strength. The K-d values for HTNV and Sin Nombre virus N proteins were nearly identical for the S segment open reading frame RNA, showing weak affinity over several binding reaction conditions. Our data suggest a model in which specific recognition of the HTNV vRNA by the HTNV N protein resides in the noncoding regions of the HTNV vRNA.	New Mexico State Univ, Dept Chem & Biochem, Las Cruces, NM 88003 USA; New Mexico State Univ, Grad Program Mol Biol, Las Cruces, NM 88003 USA; USA, Med Res Inst Infect Dis, Div Virol, Ft Detrick, MD 21702 USA	New Mexico State University; New Mexico State University	Johnsson, CB (corresponding author), New Mexico State Univ, Dept Chem & Biochem, Box 30001,MSC 3C, Las Cruces, NM 88003 USA.	cjonsson@nmsu.edu	Jonsson, Colleen/GPC-4424-2022	Jonsson, Colleen/0000-0002-2640-7672	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R03AI041114] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM008136] Funding Source: NIH RePORTER; NIAID NIH HHS [R03 AI041114-03, 1RO3AI41114-01] Funding Source: Medline; NIGMS NIH HHS [S06 GM008136-230035, S06 GM008136] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balakrishnan M, 1996, VIROLOGY, V219, P77, DOI 10.1006/viro.1996.0224; BEATON AR, 1986, P NATL ACAD SCI USA, V83, P6282, DOI 10.1073/pnas.83.17.6282; Black DL, 1998, PRACT APPROACH SER, V192, P109; BLUMBERG BM, 1983, CELL, V32, P559, DOI 10.1016/0092-8674(83)90475-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2601, DOI 10.1021/bi00280a002; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2610, DOI 10.1021/bi00280a003; DAS T, 1992, CELL MOL BIOL, V38, P17; Draper D.E., 1994, RNA PROTEIN INTERACT, P82; Draper DE, 1998, NAT STRUCT BIOL, V5, P927, DOI 10.1038/2901; GOTT P, 1993, VIROLOGY, V194, P332, DOI 10.1006/viro.1993.1263; HACKER D, 1989, J VIROL, V63, P5166, DOI 10.1128/JVI.63.12.5166-5174.1989; HEGGENESS MH, 1980, P NATL ACAD SCI-BIOL, V77, P2631, DOI 10.1073/pnas.77.5.2631; HONDA A, 1988, J BIOCHEM-TOKYO, V104, P1021, DOI 10.1093/oxfordjournals.jbchem.a122569; JIN H, 1993, J VIROL, V67, P1396, DOI 10.1128/JVI.67.3.1396-1404.1993; JONSSON CB, 1993, J BIOL CHEM, V268, P1462; KINGSBURY DW, 1987, VIROLOGY, V156, P396, DOI 10.1016/0042-6822(87)90419-3; LI DX, 1995, VIROLOGY, V206, P973, DOI 10.1006/viro.1995.1020; LI R, 1989, VIRUS RES, V12, P97, DOI 10.1016/0168-1702(89)90057-9; MELY Y, 1995, J BIOL CHEM, V270, P1650, DOI 10.1074/jbc.270.4.1650; MOYER SA, 1991, J VIROL, V65, P2170, DOI 10.1128/JVI.65.5.2170-2178.1991; PAN T, 1996, RNA WORLD, P271; PARTIN LR, 1997, THESIS NEW MEXICO ST; PATTON JT, 1984, J VIROL, V49, P303, DOI 10.1128/JVI.49.2.303-309.1984; RAJU R, 1989, J VIROL, V63, P122, DOI 10.1128/JVI.63.1.122-128.1989; Richmond KE, 1998, VIROLOGY, V248, P6, DOI 10.1006/viro.1998.9223; RYAN PC, 1989, BIOCHEMISTRY-US, V28, P9949, DOI 10.1021/bi00452a012; Schmaljohn C., 1996, FIELDS VIROLOGY, V1, P1447; SCHMALJOHN CS, 1986, VIROLOGY, V155, P633, DOI 10.1016/0042-6822(86)90223-0; Serganov A, 1997, EUR J BIOCHEM, V246, P291, DOI 10.1111/j.1432-1033.1997.00291.x; SHAPIRO GI, 1988, J VIROL, V62, P2285, DOI 10.1128/JVI.62.7.2285-2290.1988; SMITH JS, 1993, J VIROL, V67, P4037, DOI 10.1128/JVI.67.7.4037-4049.1993; WANG M, 1993, J GEN VIROL, V74, P1115, DOI 10.1099/0022-1317-74-6-1115; YAMANAKA K, 1990, J BIOL CHEM, V265, P11151; Yang J, 1998, VIROLOGY, V242, P107, DOI 10.1006/viro.1997.9022	35	51	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33732	33739		10.1074/jbc.274.47.33732	http://dx.doi.org/10.1074/jbc.274.47.33732			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559265	hybrid			2022-12-25	WOS:000083745200081
J	You, S; Padmanabhan, R				You, S; Padmanabhan, R			A novel in vitro replication system for dengue virus - Initiation of RNA synthesis at the 3 '-end of exogenous viral RNA templates requires 5 '- and 3 '-terminal complementary sequence motifs of the viral RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEM-LOOP STRUCTURE; YELLOW-FEVER VIRUS; MOUSE HEPATITIS-VIRUS; HOST-CELL PROTEIN; IN-VITRO; SECONDARY STRUCTURE; 3'-UNTRANSLATED REGION; POLIOVIRUS REPLICASE; STRAND RNA; NONSTRUCTURAL PROTEINS	Positive strand viral replicases are membrane-bound complexes of viral and host proteins. The mechanism of viral replication and the role of host proteins are not well understood. To understand this mechanism, a viral replicase assay that utilizes extracts from dengue virus-infected mosquito (C6/36) cells and exogenous viral RNA templates is reported in this study. The 5'- and 3'-terminal regions (TR) of the template RNAs contain the conserved elements including the complementary (cyclization) motifs and stem-loop structures. RNA synthesis in vitro requires both 5'- and 3'-TR present in the same template molecule or when the 5'-TR RNA was added in trans to the 3'-untranslated region (UTR) RNA However, the 3'-UTR RNA alone is not active. RNA synthesis occurs by elongation of the 3'-end of the template RNA to yield predominantly a double-stranded hairpin-like RNA product, twice the size of the template RNA. These results suggest that an interaction between 5'- and 3'-TR of the viral RNA that modulates the 3'-UTR RNA structure is required for RNA synthesis by the viral replicase. The complementary cyclization motifs of the viral genome also seem to play an important role in this interaction.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center	Padmanabhan, R (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.	rpadmana@kumc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI032078, R01AI032078] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-32078] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREWS NC, 1985, J BIOL CHEM, V260, P7628; BARTHOLOMEUSZ AI, 1993, ARCH VIROL, V128, P111, DOI 10.1007/BF01309792; BARTON DJ, 1995, J VIROL, V69, P5516, DOI 10.1128/JVI.69.9.5516-5527.1995; BAZAN JF, 1989, VIROLOGY, V171, P637, DOI 10.1016/0042-6822(89)90639-9; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; Blackwell JL, 1997, J VIROL, V71, P6433, DOI 10.1128/JVI.71.9.6433-6444.1997; BLACKWELL JL, 1995, J VIROL, V69, P5650, DOI 10.1128/JVI.69.9.5650-5658.1995; BLUMENTHAL T, 1979, ANNU REV BIOCHEM, V48, P525, DOI 10.1146/annurev.bi.48.070179.002521; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRINTON MA, 1986, VIROLOGY, V153, P113, DOI 10.1016/0042-6822(86)90012-7; BRINTON MA, 1988, VIROLOGY, V162, P290, DOI 10.1016/0042-6822(88)90468-0; CAHOUR A, 1992, J VIROL, V66, P1535, DOI 10.1128/JVI.66.3.1535-1542.1992; CARPENTER CD, 1995, J MOL BIOL, V245, P608, DOI 10.1006/jmbi.1994.0050; CHAMBERS TJ, 1991, J VIROL, V65, P6042, DOI 10.1128/JVI.65.11.6042-6050.1991; CHAMBERS TJ, 1990, P NATL ACAD SCI USA, V87, P8898, DOI 10.1073/pnas.87.22.8898; CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245; CHU PWG, 1987, VIROLOGY, V157, P330, DOI 10.1016/0042-6822(87)90275-3; CHU PWG, 1985, VIROLOGY, V140, P68, DOI 10.1016/0042-6822(85)90446-5; Clum S, 1997, J BIOL CHEM, V272, P30715, DOI 10.1074/jbc.272.49.30715; DASGUPTA A, 1980, CELL, V19, P423, DOI 10.1016/0092-8674(80)90516-4; ESTEBAN R, 1989, EMBO J, V8, P947, DOI 10.1002/j.1460-2075.1989.tb03456.x; FALGOUT B, 1991, J VIROL, V65, P2467, DOI 10.1128/JVI.65.5.2467-2475.1991; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P3889, DOI 10.1093/nar/17.10.3889; GRUN JB, 1988, J GEN VIROL, V69, P3121, DOI 10.1099/0022-1317-69-12-3121; GRUN JB, 1987, J VIROL, V61, P3641, DOI 10.1128/JVI.61.11.3641-3644.1987; GRUN JB, 1986, J VIROL, V60, P1113, DOI 10.1128/JVI.60.3.1113-1124.1986; GUBLER DJ, 1995, EMERG INFECT DIS, V1, P55; HAHN CS, 1987, J MOL BIOL, V198, P33, DOI 10.1016/0022-2836(87)90455-4; HAYES RJ, 1990, CELL, V63, P363, DOI 10.1016/0092-8674(90)90169-F; HEWLETT MJ, 1977, J VIROL, V21, P1085, DOI 10.1128/JVI.21.3.1085-1093.1977; HEY TD, 1987, J VIROL, V61, P802, DOI 10.1128/JVI.61.3.802-811.1987; HSU MT, 1973, COLD SPRING HARB SYM, V38, P943, DOI 10.1101/SQB.1974.038.01.096; Hsue B, 1997, J VIROL, V71, P7567, DOI 10.1128/JVI.71.10.7567-7578.1997; Hsue B, 1998, ADV EXP MED BIOL, V440, P297; IRIE K, 1989, GENE, V75, P197, DOI 10.1016/0378-1119(89)90266-7; Kadare G, 1997, J VIROL, V71, P2583; Kautner I, 1997, J PEDIATR-US, V131, P516, DOI 10.1016/S0022-3476(97)70054-4; KOONIN EV, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90338-A; LAHSER FC, 1993, J VIROL, V67, P3295, DOI 10.1128/JVI.67.6.3295-3303.1993; Lai MMC, 1998, VIROLOGY, V244, P1, DOI 10.1006/viro.1998.9098; LEATHERS V, 1993, MOL CELL BIOL, V13, P5331, DOI 10.1128/MCB.13.9.5331; Lemm JA, 1998, J VIROL, V72, P6546, DOI 10.1128/JVI.72.8.6546-6553.1998; Li HT, 1999, J VIROL, V73, P3108, DOI 10.1128/JVI.73.4.3108-3116.1999; LUBINSKI JM, 1986, J VIROL, V58, P459, DOI 10.1128/JVI.58.2.459-467.1986; LUO GX, 1991, J VIROL, V65, P2861, DOI 10.1128/JVI.65.6.2861-2867.1991; MARKOFF L, 1989, J VIROL, V63, P3345, DOI 10.1128/JVI.63.8.3345-3352.1989; MOHAN PM, 1991, GENE, V108, P185, DOI 10.1016/0378-1119(91)90433-C; MOLLA A, 1991, SCIENCE, V254, P1647, DOI 10.1126/science.1661029; MONATH TP, 1994, P NATL ACAD SCI USA, V91, P2395, DOI 10.1073/pnas.91.7.2395; Murthy HMK, 1999, J BIOL CHEM, V274, P5573, DOI 10.1074/jbc.274.9.5573; MUSSGAY M, 1975, PROG MED VIROL, V19, P257; NAKHASI HL, 1991, J VIROL, V65, P5961, DOI 10.1128/JVI.65.11.5961-5967.1991; NEUFELD KL, 1991, J BIOL CHEM, V266, P24212; NOWAK T, 1989, VIROLOGY, V169, P365, DOI 10.1016/0042-6822(89)90162-1; O'Reilly EK, 1998, VIROLOGY, V252, P287, DOI 10.1006/viro.1998.9463; Osman TAM, 1996, J VIROL, V70, P6227, DOI 10.1128/JVI.70.9.6227-6234.1996; PARDIGON N, 1992, J VIROL, V66, P1007, DOI 10.1128/JVI.66.2.1007-1015.1992; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; POGUE GP, 1992, J VIROL, V66, P674, DOI 10.1128/JVI.66.2.674-684.1992; PREUGSCHAT F, 1990, J VIROL, V64, P4364, DOI 10.1128/JVI.64.9.4364-4374.1990; QUADT R, 1993, P NATL ACAD SCI USA, V90, P1498, DOI 10.1073/pnas.90.4.1498; QUADT R, 1995, P NATL ACAD SCI USA, V92, P4892, DOI 10.1073/pnas.92.11.4892; RICE CM, 1985, SCIENCE, V229, P726, DOI 10.1126/science.4023707; RICHARDS OC, 1987, J VIROL, V61, P2307, DOI 10.1128/JVI.61.7.2307-2310.1987; ROHLL JB, 1994, J VIROL, V68, P4384, DOI 10.1128/JVI.68.7.4384-4391.1994; ROHLL JB, 1995, J VIROL, V69, P7835, DOI 10.1128/JVI.69.12.7835-7844.1995; Schuppli D, 1998, J MOL BIOL, V283, P585, DOI 10.1006/jmbi.1998.2123; Shi PY, 1996, J VIROL, V70, P6278, DOI 10.1128/JVI.70.9.6278-6287.1996; Siegel RW, 1997, P NATL ACAD SCI USA, V94, P11238, DOI 10.1073/pnas.94.21.11238; Sit TL, 1998, SCIENCE, V281, P829, DOI 10.1126/science.281.5378.829; SMITH TJ, 1970, J VIROL, V5, P524, DOI 10.1128/JVI.5.4.524-532.1970; SONG CZ, 1994, P NATL ACAD SCI USA, V91, P8792, DOI 10.1073/pnas.91.19.8792; SONG CZ, 1995, J MOL BIOL, V254, P6, DOI 10.1006/jmbi.1995.0594; Stewart SR, 1998, NUCLEIC ACIDS RES, V26, P5318, DOI 10.1093/nar/26.23.5318; SVITKIN YV, 1984, VIROLOGY, V135, P536, DOI 10.1016/0042-6822(84)90207-1; Tan BH, 1996, VIROLOGY, V216, P317, DOI 10.1006/viro.1996.0067; WENGLER G, 1991, J GEN VIROL, V72, P851, DOI 10.1099/0022-1317-72-4-851; WERTZ GW, 1994, P NATL ACAD SCI USA, V91, P8587, DOI 10.1073/pnas.91.18.8587; WESTAWAY EG, 1987, ADV VIRUS RES, V33, P45, DOI 10.1016/S0065-3527(08)60316-4; WU SX, 1992, P NATL ACAD SCI USA, V89, P11136, DOI 10.1073/pnas.89.23.11136; WU SX, 1991, VIROLOGY, V183, P392, DOI 10.1016/0042-6822(91)90153-3; YAEGASHI T, 1986, GENE, V46, P257, DOI 10.1016/0378-1119(86)90410-5; YOUNG DC, 1985, J VIROL, V54, P256, DOI 10.1128/JVI.54.2.256-264.1985; Zeng LL, 1998, J VIROL, V72, P7510, DOI 10.1128/JVI.72.9.7510-7522.1998; ZHANG LW, 1992, J VIROL, V66, P7549, DOI 10.1128/JVI.66.12.7549-7554.1992; ZUKER M, 1991, NUCLEIC ACIDS RES, V19, P2707, DOI 10.1093/nar/19.10.2707	87	180	185	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33714	33722		10.1074/jbc.274.47.33714	http://dx.doi.org/10.1074/jbc.274.47.33714			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559263	hybrid			2022-12-25	WOS:000083745200079
J	Low, BC; Lim, YP; Lim, J; Wong, ESM; Guy, GR				Low, BC; Lim, YP; Lim, J; Wong, ESM; Guy, GR			Tyrosine phosphorylation of the Bcl-2-associated protein BNIP-2 by fibroblast growth factor receptor-1 prevents its binding to Cdc42GAP and Cdc42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING-PROTEIN; TUMOR-NECROSIS-FACTOR; RHO-FAMILY GTPASES; BCL-2 PROTEINS; PC12 CELLS; NEURONAL DIFFERENTIATION; SIGNAL-TRANSDUCTION; KINASE; IDENTIFICATION; DOMAIN	Fibroblast growth factor (FGF) receptor tyrosine kinases are involved in the regulation of cell growth, development, and differentiation in a variety of tissues. To isolate potential signaling molecules in the FGF signaling pathway, we have initiated a yeast two-hybrid screening using the cytosolic domain of FGF receptor-1 (Plg). Here we report the identification of BNIP-2, a previously cloned Bcl-2- and adenovirus E1B-associated protein, as a putative substrate of the receptor. When cotransfected in 293T cells, BNIP-2 was tyrosine-phosphorylated via Flg, but their interaction was transient and could only be seen by "capture" experiments with catalytically inert kinase mutants. When responsive cells were challenged with basic FGF, endogenous tyrosine-phosphorylated BNIP-2 could be precipitated with a BNIP-2 antibody. In addition, the recombinant BNIP-2 expressed in bacteria could be phosphorylated by active Flg in vitro. BNIP-2 shares a region of homology with the noncatalytic domain of Cdc42GAP, a GTPase-activating protein for the small GTP-binding molecule, Cdc42, We show here that BNIP-2 and Cdc42GAP could directly bind to each other and they also compete for the binding to the same target, Cdc42. Unexpectedly, BNIP-2, either produced as a bacterial recombinant protein or expressed in 293T cells, could stimulate the intrinsic GTPase activity of Cdc42, In all cases, tyrosine phosphorylation of BNIP-2 severely impaired its association with Cdc42GAP and its induced GTPase-activating protein-like activity toward Cdc42, These findings should allow us to further characterize the integration of signaling between receptor tyrosine kinases, GTP-binding molecules, and apoptotic pathways.	Inst Cell & Mol Biol, Signal Transduct Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Guy, GR (corresponding author), Inst Cell & Mol Biol, Signal Transduct Lab, 30 Med Dr, Singapore 117609, Singapore.	mcbgg@imcb.nus.edu.sg	Low, Boon Chuan/H-8049-2012; Low, Boon Chuan/AAU-7685-2021; Lim, Jormay/A-7257-2011	Low, Boon Chuan/0000-0003-0756-096X; Low, Boon Chuan/0000-0003-0756-096X; Lim, Jormay/0000-0001-7191-545X				Aspenstrom P, 1997, CURR BIOL, V7, P479, DOI 10.1016/S0960-9822(06)00219-3; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Brill S, 1996, MOL CELL BIOL, V16, P4869; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Garnier M, 1997, J NEUROSCI, V17, P4591; Goh KC, 1996, J BIOL CHEM, V271, P5832, DOI 10.1074/jbc.271.10.5832; GOODING LR, 1991, J VIROL, V65, P3083, DOI 10.1128/JVI.65.6.3083-3094.1991; HASHIMOTO S, 1991, INT IMMUNOL, V3, P343, DOI 10.1093/intimm/3.4.343; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; Illenberger D, 1998, EMBO J, V17, P6241, DOI 10.1093/emboj/17.21.6241; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; Leonard DA, 1997, BIOCHEMISTRY-US, V36, P1173, DOI 10.1021/bi9622837; Leung T, 1998, MOL CELL BIOL, V18, P130, DOI 10.1128/MCB.18.1.130; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MUNICIO MM, 1995, J BIOL CHEM, V270, P15884, DOI 10.1074/jbc.270.26.15884; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PAGES F, 1993, J BIOL CHEM, V268, P26358; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Rittinger K, 1998, NATURE, V392, P448, DOI 10.1038/33043; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; SAMBROOK J, 1989, MOL CLONING LABORATO, V1, P53; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Subramanian T, 1995, ONCOGENE, V11, P2403; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Timms JF, 1998, MOL CELL BIOL, V18, P3838, DOI 10.1128/MCB.18.7.3838; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819; Zhang BL, 1998, J BIOL CHEM, V273, P25728, DOI 10.1074/jbc.273.40.25728; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	51	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					33123	33130		10.1074/jbc.274.46.33123	http://dx.doi.org/10.1074/jbc.274.46.33123			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551883	hybrid			2022-12-25	WOS:000083623000083
J	Moussalli, M; Pipe, SW; Hauri, HP; Nichols, WC; Ginsburg, D; Kaufman, RJ				Moussalli, M; Pipe, SW; Hauri, HP; Nichols, WC; Ginsburg, D; Kaufman, RJ			Mannose-dependent endoplasmic reticulum (ER)-Golgi intermediate compartment-53-mediated ER to Golgi trafficking of coagulation factors V and VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPARTMENT PROTEIN ERGIC-53; EARLY SECRETORY PATHWAY; MEMBRANE-PROTEIN; MAMMALIAN-CELLS; B-DOMAIN; TRANSPORT; COPII; EXPRESSION; VESICLES; RETENTION	The endoplasmic reticulum-Golgi intermediate compartment (ERGIC) is the site of segregation of secretory proteins for anterograde transport, via packaging into COPII-coated transport vesicles, ERGIC-53 is a homohexameric transmembrane lectin localized to the ERGIC that exhibits mannose-selective properties in vitro. Null mutations in ERGIC-53 were recently shown to be responsible for the autosomal recessive bleeding disorder, combined deficiency of coagulation factors V and VIII, We have studied the effect of defective ER to Golgi cycling by ERGIC-53 on the secretion of factors V and VIII, The secretion efficiency of factor V and factor VIII was studied in a tetracycline-inducible HeLa cell line overexpressing a wild-type ERGIC-53 or a cytosolic tail mutant of ERGIC-53 (KKAA) that is unable to exit the ER due to mutation of two COOH-terminal phenylalanine residues to alanines, The results show that efficient trafficking of factors V and VIII requires a functional ERGIC-53 cycling pathway and that this trafficking is dependent on post-translational modification of a specific cluster of asparagine (N)-linked oligosaccharides to a fully glucose-trimmed, mannose9 structure.	Univ Michigan, Sch Med, Dept Pediat, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Childrens Hosp, Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA; Univ Basel, Biozentrum, Dept Pharmacol Neurobiol, CH-4056 Basel, Switzerland	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Cincinnati Children's Hospital Medical Center; University of Basel	Kaufman, RJ (corresponding author), 1150 W Med Ctr Dr,MSRB II,Rm 4570, Ann Arbor, MI 48109 USA.	kaufmanr@umich.edu	Pipe, Steven W./ABC-3843-2020	Pipe, Steven W./0000-0003-2558-2089	NHLBI NIH HHS [HL5217302, HL5734601A1] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057346, R01HL052173] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andersson H, 1999, J BIOL CHEM, V274, P15080, DOI 10.1074/jbc.274.21.15080; ARAR C, 1995, J BIOL CHEM, V270, P3551, DOI 10.1074/jbc.270.8.3551; Berntorp E, 1997, THROMB HAEMOSTASIS, V78, P256; Campbell JL, 1997, P NATL ACAD SCI USA, V94, P837, DOI 10.1073/pnas.94.3.837; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; Fiedler K, 1996, J CELL SCI, V109, P271; Hara-Kuge S, 1999, GLYCOBIOLOGY, V9, P833, DOI 10.1093/glycob/9.8.833; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; ITIN C, 1995, BIOCHEM SOC T, V23, P541, DOI 10.1042/bst0230541; KAPPELER F, 1994, J BIOL CHEM, V269, P6279; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Kaufman RJ, 1999, HUM GENE THER, V10, P2091, DOI 10.1089/10430349950017095; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; Lahtinen U, 1996, J BIOL CHEM, V271, P4031; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; Marzioch M, 1999, MOL BIOL CELL, V10, P1923, DOI 10.1091/mbc.10.6.1923; Neerman-Arbez M, 1999, BLOOD, V93, P2253; Nichols WC, 1998, CELL, V93, P61, DOI 10.1016/S0092-8674(00)81146-0; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Pipe SW, 1998, J BIOL CHEM, V273, P8537, DOI 10.1074/jbc.273.14.8537; PITTMAN DD, 1994, BLOOD, V84, P4214, DOI 10.1182/blood.V84.12.4214.bloodjournal84124214; PITTMAN DD, 1993, METHOD ENZYMOL, V222, P236; Powers J, 1998, J CELL BIOL, V142, P1209, DOI 10.1083/jcb.142.5.1209; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SCHINDLER R, 1993, EUR J CELL BIOL, V61, P1; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; Tisdale EJ, 1997, J CELL BIOL, V137, P581, DOI 10.1083/jcb.137.3.581; TOOLE JJ, 1986, P NATL ACAD SCI USA, V83, P5939, DOI 10.1073/pnas.83.16.5939; Vollenweider F, 1998, J CELL BIOL, V142, P377, DOI 10.1083/jcb.142.2.377; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8	36	104	111	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32539	32542		10.1074/jbc.274.46.32539	http://dx.doi.org/10.1074/jbc.274.46.32539			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551804	hybrid			2022-12-25	WOS:000083623000004
J	Tidball, JG; Spencer, MJ; Wehling, M; Lavergne, E				Tidball, JG; Spencer, MJ; Wehling, M; Lavergne, E			Nitric-oxide synthase is a mechanical signal transducer that modulates talin and vinculin expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SKELETAL-MUSCLE; MESSENGER-RNA; SOLEUS MUSCLE; DNA-BINDING; MYOTENDINOUS JUNCTION; HINDLIMB SUSPENSION; ENDOTHELIAL-CELLS; GENE-EXPRESSION; STIMULATION	Mechanical stimuli can cause changes in muscle mass and structure which indicate that mechanisms exist for transducing mechanical stimuli into signals that influence gene expression. Myotendinous junctions show adaptations to modified muscle loading which suggest that these are transcriptionally distinct domains in muscle fibers that may experience local regulation of expression of structural proteins that are concentrated at these sites. Vinculin and talin are cytoskeletal proteins that are highly enriched at myotendinous junctions that we hypothesize to be subject to local transcriptional regulation. Our findings show that mechanical stimulation of muscle cells in vivo and in vitro causes an increase in the expression of vinculin and talin that is mediated by nitric oxide. Furthermore, nitric oxide-stimulated increases in vinculin and talin expression occur through a protein kinase G-dependent pathway and therefore differ from other mechanisms through which nitric oxide has been shown previously to modulate transcription. Analysis of vinculin mRNA distribution in mechanically stimulated muscle fibers shows that the mRNA is highly concentrated at myotendinous junctions, which supports the hypothesis that myotendinous junctions are distinct domains in which the expression of cytoskeletal proteins is modulated by mechanical stimuli through a nitric oxide and protein kinase G-dependent pathway.	Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Tidball, JG (corresponding author), Univ Calif Los Angeles, Dept Physiol Sci, 621 Young Dr, Los Angeles, CA 90095 USA.		Tidball, James/H-7970-2012	Tidball, James/0000-0003-1202-8038	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040343] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40343] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adams JW, 1996, J BIOL CHEM, V271, P1179, DOI 10.1074/jbc.271.2.1179; AWOLESI MA, 1995, J CLIN INVEST, V96, P1449, DOI 10.1172/JCI118181; Baldi JC, 1995, J MUSCLE RES CELL M, V16, P587, DOI 10.1007/BF00130240; BALON TW, 1994, J APPL PHYSIOL, V77, P2519, DOI 10.1152/jappl.1994.77.6.2519; Caiozzo VJ, 1996, J APPL PHYSIOL, V80, P1503, DOI 10.1152/jappl.1996.80.5.1503; Chang WJ, 1996, P NATL ACAD SCI USA, V93, P9142, DOI 10.1073/pnas.93.17.9142; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; DelaTorre A, 1997, BIOCHEM BIOPH RES CO, V238, P703, DOI 10.1006/bbrc.1997.7279; DIKE LE, 1988, P NATL ACAD SCI USA, V85, P6792, DOI 10.1073/pnas.85.18.6792; DIX DJ, 1990, J CELL BIOL, V111, P1885, DOI 10.1083/jcb.111.5.1885; Ezzell RM, 1997, EXP CELL RES, V231, P14, DOI 10.1006/excr.1996.3451; FITTS RH, 1986, J APPL PHYSIOL, V60, P1946, DOI 10.1152/jappl.1986.60.6.1946; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Frenette J, 1998, AM J PHYSIOL-CELL PH, V275, pC818, DOI 10.1152/ajpcell.1998.275.3.C818; HARRINGTON CA, 1983, NUCLEIC ACIDS RES, V11, P3317, DOI 10.1093/nar/11.10.3317; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Hobbs AJ, 1996, METHOD ENZYMOL, V269, P134; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; LOWENSTEIN CJ, 1994, ANN INTERN MED, V120, P227, DOI 10.7326/0003-4819-120-3-199402010-00009; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; MCDONALD KS, 1995, J APPL PHYSIOL, V79, P1796, DOI 10.1152/jappl.1995.79.5.1796; MOREYHOLTON ER, 1981, PHYSIOLOGIST S, V24, P45; Nikitovic D, 1998, BIOCHEM BIOPH RES CO, V242, P109, DOI 10.1006/bbrc.1997.7930; PACIFICI R, 1992, J CLIN INVEST, V89, P61, DOI 10.1172/JCI115586; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; PENG HB, 1995, J BIOL CHEM, V270, P17050, DOI 10.1074/jbc.270.28.17050; Pitsillides AA, 1995, FASEB J, V9, P1614, DOI 10.1096/fasebj.9.15.8529841; Reiser PJ, 1997, J APPL PHYSIOL, V82, P1250, DOI 10.1152/jappl.1997.82.4.1250; SACHS F, 1987, FASEB J, V46, P12; Sharp WW, 1997, AM J PHYSIOL-HEART C, V273, pH546, DOI 10.1152/ajpheart.1997.273.2.H546; SHAW RJ, 1990, J CELL BIOL, V111, P2139, DOI 10.1083/jcb.111.5.2139; SIMON AM, 1992, DEVELOPMENT, V114, P545; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; TEMPLETON GH, 1984, J APPL PHYSIOL, V56, P278, DOI 10.1152/jappl.1984.56.2.278; THOMASON DB, 1987, J APPL PHYSIOL, V63, P130, DOI 10.1152/jappl.1987.63.1.130; THOMASON DB, 1989, AM J PHYSIOL, V257, pR300, DOI 10.1152/ajpregu.1989.257.2.R300; Tidball JG, 1998, AM J PHYSIOL-CELL PH, V275, pC260, DOI 10.1152/ajpcell.1998.275.1.C260; TIDBALL JG, 1991, J BIOMECH, V24, P43, DOI 10.1016/0021-9290(91)90376-X; TIDBALL JG, 1992, J APPL PHYSIOL, V73, P59, DOI 10.1152/jappl.1992.73.1.59; Uematsu M, 1995, AM J PHYSIOL-CELL PH, V269, pC1371, DOI 10.1152/ajpcell.1995.269.6.C1371; VANDENBURGH H, 1979, SCIENCE, V203, P265, DOI 10.1126/science.569901; VANDENBURGH HH, 1989, AM J PHYSIOL, V256, pC674, DOI 10.1152/ajpcell.1989.256.3.C674; VANDENBURGH HH, 1993, J CELL PHYSIOL, V155, P63, DOI 10.1002/jcp.1041550109; WATSON PA, 1991, FASEB J, V5, P2013, DOI 10.1096/fasebj.5.7.1707019	46	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					33155	33160		10.1074/jbc.274.46.33155	http://dx.doi.org/10.1074/jbc.274.46.33155			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551887	hybrid			2022-12-25	WOS:000083623000087
J	Dunn, CA; O'Handley, SF; Frick, DN; Bessman, MJ				Dunn, CA; O'Handley, SF; Frick, DN; Bessman, MJ			Studies on the ADP-ribose pyrophosphatase subfamily of the Nudix hydrolases and tentative identification of trgB, a gene associated with tellurite resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE TRIPHOSPHATE PYROPHOSPHOHYDROLASE; ESCHERICHIA-COLI MUTT; METHANOCOCCUS-JANNASCHII; CATALYTIC DOMAIN; STREPTOCOCCUS-PNEUMONIAE; MOLECULAR-CLONING; PROTEINS; SEQUENCE; PURIFICATION; ENZYMES	Four Nudix hydrolase genes, ysa1 from Saccharomyces cerevisiae, orf209 from Escherichia coli, yqkg from Bacillus subtilis, and hi0398 from Hemophilus influenzae were amplified, cloned into an expression vector, and transformed into E. coli. The expressed proteins were purified and shown to belong to a subfamily of Nudix hydrolases active on ADP-ribose. Comparison with other members of the subfamily revealed a conserved proline 16 amino acid residues downstream of the Nudix box, common to all of the ADP-ribose pyrophosphatase subfamily. In this same region, a conserved tyrosine designates another subfamily, the diadenosine polyphosphate pyrophosphatases, while an array of eight conserved amino acids is indicative of the NADH pyrophosphatases. On the basis of these classifications, the trgB gene, a tellurite resistance factor from Rhodobacter sphaeroides, was predicted to designate an ADP-ribose pyrophosphatase. In support of this hypothesis, a highly specific ADP-ribose pyrophosphatase gene from the archaebacterium, Methanococcus jannaschii, introduced into E, coli, increased the transformant's tolerance to potassium tellurite.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, McCollum Pratt Inst, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Bessman, MJ (corresponding author), Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.	zoot@jhu.edu		Frick, David/0000-0002-2434-7223; Dunn, Christopher/0000-0001-7899-0110; O'Handley, Suzanne/0000-0001-8373-0065	NIGMS NIH HHS [GM 18649] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEYGUNAWARDANA C, 1995, BIOCHEMISTRY-US, V34, P14997, DOI 10.1021/bi00046a006; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMES BN, 1960, J BIOL CHEM, V235, P769; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; Bucala R, 1992, Adv Pharmacol, V23, P1; BULLIONS LC, 1994, J BIOL CHEM, V269, P12339; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Cartwright JL, 1999, J BIOL CHEM, V274, P8604, DOI 10.1074/jbc.274.13.8604; Cartwright JL, 1999, BIOCHEM BIOPH RES CO, V256, P474, DOI 10.1006/bbrc.1999.0354; Churin J, 1998, FEBS LETT, V431, P481, DOI 10.1016/S0014-5793(98)00819-9; Conyers GB, 1999, J BIOL CHEM, V274, P1203, DOI 10.1074/jbc.274.3.1203; FRICK DN, 1995, J BIOL CHEM, V270, P1529, DOI 10.1074/jbc.270.4.1529; FRICK DN, 1995, J BIOL CHEM, V270, P24086, DOI 10.1074/jbc.270.41.24086; Hankin S, 1997, INT J BIOCHEM CELL B, V29, P317, DOI 10.1016/S1357-2725(96)00153-7; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Ingram SW, 1999, BIOCHEMISTRY-US, V38, P3649, DOI 10.1021/bi982951j; JACOBSON EL, 1994, MOL CELL BIOCHEM, V138, P207, DOI 10.1007/BF00928463; JONES WJ, 1983, ARCH MICROBIOL, V136, P254, DOI 10.1007/BF00425213; Kaneto H, 1996, BIOCHEM J, V320, P855, DOI 10.1042/bj3200855; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P4847, DOI 10.1093/nar/21.20.4847; Kroger H, 1997, GEN PHARMACOL, V28, P257, DOI 10.1016/S0306-3623(96)00181-4; Maksel D, 1998, BIOCHEM J, V329, P313, DOI 10.1042/bj3290313; MARKHAM R, 1952, BIOCHEM J, V52, P552, DOI 10.1042/bj0520552; MATHEW N, 1995, BIOCHEM J, V311, P717, DOI 10.1042/bj3110717; MCDONALD LJ, 1994, MOL CELL BIOCHEM, V138, P221, DOI 10.1007/BF00928465; MEJEAN V, 1994, MOL MICROBIOL, V11, P323, DOI 10.1111/j.1365-2958.1994.tb00312.x; MOSS J, 1994, MOL CELL BIOCHEM, V138, P5; O'Handley SF, 1998, J BIOL CHEM, V273, P3192, DOI 10.1074/jbc.273.6.3192; OGara JP, 1997, APPL ENVIRON MICROB, V63, P4713, DOI 10.1128/AEM.63.12.4713-4720.1997; OHandley SF, 1996, J BIOL CHEM, V271, P24649, DOI 10.1074/jbc.271.40.24649; OLIVERA BM, 1989, ADP RIBOSE TRANSFER, P353; Pennisi E, 1999, SCIENCE, V283, P1105, DOI 10.1126/science.283.5405.1105; Ribeiro JM, 1997, BBA-GEN SUBJECTS, V1336, P403, DOI 10.1016/S0304-4165(97)00051-2; Sheikh S, 1998, J BIOL CHEM, V273, P20924, DOI 10.1074/jbc.273.33.20924; Taylor DE, 1999, TRENDS MICROBIOL, V7, P111, DOI 10.1016/S0966-842X(99)01454-7; VLASSARA H, 1985, P NATL ACAD SCI USA, V82, P5588, DOI 10.1073/pnas.82.17.5588	38	133	143	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32318	32324		10.1074/jbc.274.45.32318	http://dx.doi.org/10.1074/jbc.274.45.32318			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542272	hybrid			2022-12-25	WOS:000083532100080
J	Eggleson, KK; Duffin, KL; Goldberg, DE				Eggleson, KK; Duffin, KL; Goldberg, DE			Identification and characterization of falcilysin, a metallopeptidase involved in hemoglobin catabolism within the malaria parasite Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PROCESSING PEPTIDASE; INSULIN-DEGRADING ENZYME; BUD-SITE SELECTION; CYSTEINE PROTEINASE; HUMAN-ERYTHROCYTES; DIGESTIVE VACUOLE; ACTIVE-SITE; DEGRADATION; PURIFICATION; RESIDUES	The malaria parasite Plasmodium falciparum degrades hemoglobin in its acidic food vacuole for use as a major nutrient source. A novel metallopeptidase activity, falcilysin, was purified from food vacuoles and characterized. Falcilysin appears to function downstream of the aspartic proteases plasmepsins I and II and the cysteine protease falcipain in the hemoglobin proteolytic pathway. It is unable to cleave hemoglobin or denatured globin but readily destroys peptide fragments of hemoglobin. Falcilysin cleavage sites along the alpha and beta chains of hemoglobin are polar in character, with charged residues located in the P1 and/or P4' positions. In contrast, plasmepsins I and II and falcipain prefer hydrophobic residues around the scissile bond. The gene encoding falcilysin has been cloned. Its coding sequence exhibits features characteristic of clan ME family M16 metallopeptidases, including an "inverted" HXXEH active site motif, Falcilysin shares primary structural features with M16 family members such as insulysin, mitochondrial processing peptidase, nardilysin, and pitrilysin as well as with data base hypothetical proteins that are potential M16 family members. The characterization of falcilysin increases our understanding of hemoglobin catabolism in P. falciparum and the unusual M16 family of metallopeptidases.	Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Microbiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Med, St Louis, MO 63110 USA; Monsanto Co, Monsanto Corp Res, St Louis, MO 63198 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Monsanto	Goldberg, DE (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Microbiol, Box 8230,660 S Euclid Ave, St Louis, MO 63110 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI031615] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-31615] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMES N, 1995, SCIENCE, V270, P464, DOI 10.1126/science.270.5235.464; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AULS DS, 1995, METHOD ENZYMOL, V248, P2828; BECKER AB, 1992, P NATL ACAD SCI USA, V89, P3835, DOI 10.1073/pnas.89.9.3835; BECKER AB, 1993, BIOCHEM J, V292, P137, DOI 10.1042/bj2920137; CHENG YSE, 1979, J BIOL CHEM, V254, P4698; CHESNEAU V, 1994, J BIOL CHEM, V269, P2056; CLAUSER KR, 1995, P NATL ACAD SCI USA, V92, P5072, DOI 10.1073/pnas.92.11.5072; CURLEY GP, 1994, J EUKARYOT MICROBIOL, V41, P119, DOI 10.1111/j.1550-7408.1994.tb01483.x; DAME JB, 1994, MOL BIOCHEM PARASIT, V64, P177, DOI 10.1016/0166-6851(94)90024-8; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIVO AA, 1985, J PROTOZOOL, V32, P59, DOI 10.1111/j.1550-7408.1985.tb03013.x; Florent I, 1998, MOL BIOCHEM PARASIT, V97, P149, DOI 10.1016/S0166-6851(98)00143-1; FRANCIS SE, 1994, EMBO J, V13, P306, DOI 10.1002/j.1460-2075.1994.tb06263.x; Francis SE, 1996, MOL BIOCHEM PARASIT, V83, P189, DOI 10.1016/S0166-6851(96)02772-7; FUJITA A, 1994, NATURE, V372, P567, DOI 10.1038/372567a0; GEHM BD, 1991, ENDOCRINOLOGY, V128, P1603, DOI 10.1210/endo-128-3-1603; GINSBURG H, 1986, BIOCHIM BIOPHYS ACTA, V886, P337, DOI 10.1016/0167-4889(86)90168-0; GLUZMAN IY, 1994, J CLIN INVEST, V93, P1602, DOI 10.1172/JCI117140; GOLDBERG DE, 1990, P NATL ACAD SCI USA, V87, P2931, DOI 10.1073/pnas.87.8.2931; GOLDBERG DE, 1991, J EXP MED, V173, P961, DOI 10.1084/jem.173.4.961; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; KIRSCHNER RJ, 1983, J BIOL CHEM, V258, P967; KITADA S, 1995, J BIOCHEM-TOKYO, V117, P1148, DOI 10.1093/oxfordjournals.jbchem.a124836; Kitada S, 1998, J BIOL CHEM, V273, P32547, DOI 10.1074/jbc.273.49.32547; Kolakovich KA, 1997, MOL BIOCHEM PARASIT, V87, P123, DOI 10.1016/S0166-6851(97)00062-5; KROGSTAD DJ, 1985, J CELL BIOL, V101, P2302, DOI 10.1083/jcb.101.6.2302; KUROCHKIN IV, 1994, FEBS LETT, V345, P33, DOI 10.1016/0014-5793(94)00387-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Luker KE, 1996, MOL BIOCHEM PARASIT, V79, P71, DOI 10.1016/0166-6851(96)02651-5; Olliaro P, 1996, JAMA-J AM MED ASSOC, V275, P230, DOI 10.1001/jama.275.3.230; PERLMAN RK, 1993, J BIOL CHEM, V268, P21538; RAWLINGS ND, 1998, HDB PROTEOLYTIC ENZY, P1360; ROSENTHAL PJ, 1991, J CLIN INVEST, V88, P1467, DOI 10.1172/JCI115456; ROSENTHAL PJ, 1992, MOL BIOCHEM PARASIT, V51, P143, DOI 10.1016/0166-6851(92)90209-3; ROSENTHAL PJ, 1988, J CLIN INVEST, V82, P1560, DOI 10.1172/JCI113766; ROSENTHAL PJ, 1993, J CLIN INVEST, V91, P1052, DOI 10.1172/JCI116262; SCHNEIDER H, 1990, J BIOL CHEM, V265, P9881; SHII K, 1986, DIABETES, V35, P675, DOI 10.2337/diabetes.35.6.675; Shimokata K, 1998, J BIOL CHEM, V273, P25158, DOI 10.1074/jbc.273.39.25158; Striebel HM, 1996, ARCH BIOCHEM BIOPHYS, V335, P211, DOI 10.1006/abbi.1996.0500; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VANDERJAGT DL, 1984, MOL BIOCHEM PARASIT, V10, P45, DOI 10.1016/0166-6851(84)90017-3; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; Yates JR, 1996, J AM SOC MASS SPECTR, V7, P1089, DOI 10.1016/S1044-0305(96)00079-7; YAYON A, 1984, EMBO J, V3, P2695, DOI 10.1002/j.1460-2075.1984.tb02195.x; YAYON A, 1983, J PROTOZOOL, V30, P642, DOI 10.1111/j.1550-7408.1983.tb05336.x	49	199	204	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32411	32417		10.1074/jbc.274.45.32411	http://dx.doi.org/10.1074/jbc.274.45.32411			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542284	hybrid			2022-12-25	WOS:000083532100092
J	Kuwahara, H; Araki, N; Makino, K; Masuko, N; Honda, S; Kaibuchi, K; Fukunaga, K; Miyamoto, E; Ogawa, M; Saya, H				Kuwahara, H; Araki, N; Makino, K; Masuko, N; Honda, S; Kaibuchi, K; Fukunaga, K; Miyamoto, E; Ogawa, M; Saya, H			A novel NE-dlg/SAP102-associated protein, p51-nedasin, related to the amidohydrolase superfamily, interferes with the association between NE-dlg/SAP102 and N-methyl-D-aspartate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; EFFICIENT GENE ACTIVATION; POSTSYNAPTIC DENSITY; HUMAN HOMOLOG; PDZ DOMAINS; GUANYLATE KINASES; AXONAL GUIDANCE; CRE RECOMBINASE; MEMBRANE; BINDING	The membrane-associated guanylate kinase proteins have been known to interact various membrane receptors with their N-terminal segments designated the PDZ domains and to cluster these receptors at the target site of the cell membrane. NE-dlg/SAP102, a neuronal and endocrine tissue-specific MAGUK family protein, was found to be expressed in both dendrites and cell bodies in neuronal cells. Although NE-dlg/SAP102 localized at dendrites was shown to interact with N-methyl-D-aspartate receptor 2B via the PDZ domains to compose postsynaptic density, the binding proteins existing in the cell body of the neuron are still unknown. Here we report the isolation of a novel NE-dlg/SAP102-associated protein, p51-nedasin. Nedasin has a significant homology with amidohydrolase superfamily proteins and shows identical sequences to a recently identified protein that has guanine aminohydrolase activity. Nedasin has four alternative splice variants (S, Vf, V2, and V3) that exhibited different C-terminal structures. NE-dlg/SAP102 is shown to interact with only the S form of nedasin which is predominantly expressed in brain. The expression of nedasin in neuronal cells increases in parallel with the progress of synaptogenesis and is mainly detected in cell bodies where it co-localizes with NE-dlg/SAP102, Furthermore, nedasin interferes with the association between NE-dlg/SAP102 and NMDA receptor 2B in vitro. These findings suggest that alternative splicing of nedasin may play a role in the formation and/or structural change in synapses during neuronal development by modifying clustering of neurotransmitter receptors at the synaptic sites.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8600811, Japan; Kumamoto Univ, Sch Med, Dept Surg 2, Kumamoto 8600811, Japan; Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 6300101, Japan; Kumamoto Univ, Sch Med, Dept Pharmacol, Kumamoto 8600811, Japan	Kumamoto University; Kumamoto University; Nara Institute of Science & Technology; Kumamoto University	Saya, H (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Honjo, Kumamoto 8600811, Japan.	hsaya@gpo.kumamoto-u.ac.jp	Fukunaga, Kohji/AAI-8811-2021; Saya, Hideyuki/J-4325-2013	Fukunaga, Kohji/0000-0001-8526-2824				ASKANAS V, 1994, AM J PATHOL, V144, P177; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; FUKUNAGA K, 1992, J BIOL CHEM, V267, P22527; Garcia EP, 1998, NEURON, V21, P727, DOI 10.1016/S0896-6273(00)80590-5; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; Holm L, 1997, PROTEINS, V28, P72, DOI 10.1002/(SICI)1097-0134(199705)28:1<72::AID-PROT7>3.0.CO;2-L; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; Hunt CA, 1996, J NEUROSCI, V16, P1380; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; ITO S, 1988, ACTA HISTOCHEM, V83, P99, DOI 10.1016/S0065-1281(88)80078-3; ITO S, 1989, J HISTOCHEM CYTOCHEM, V37, P611, DOI 10.1177/37.5.2649557; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kanegae Y, 1996, GENE, V181, P207, DOI 10.1016/S0378-1119(96)00516-1; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KISTNER U, 1993, J BIOL CHEM, V268, P4580; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LAHEY T, 1994, NEURON, V13, P823, DOI 10.1016/0896-6273(94)90249-6; Lau LF, 1996, J BIOL CHEM, V271, P21622, DOI 10.1074/jbc.271.35.21622; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; LI W, 1992, GENETICS, V132, P675; Makino K, 1997, ONCOGENE, V14, P2425, DOI 10.1038/sj.onc.1201087; Marfatia SM, 1996, J CELL BIOL, V135, P753, DOI 10.1083/jcb.135.3.753; Masuko N, 1999, J BIOL CHEM, V274, P5782, DOI 10.1074/jbc.274.9.5782; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MitraniRosenbaum S, 1996, HUM MOL GENET, V5, P159, DOI 10.1093/hmg/5.1.159; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; NARDIELLO S, 1978, ENZYME, V23, P353, DOI 10.1159/000458600; Niethammer M, 1996, J NEUROSCI, V16, P2157; PERRIMON N, 1988, DEV BIOL, V127, P392, DOI 10.1016/0012-1606(88)90326-0; POLAKIS P, 1995, CURR OPIN GENET DEV, V5, P66, DOI 10.1016/S0959-437X(95)90055-1; Sadowsky MJ, 1998, J BACTERIOL, V180, P152, DOI 10.1128/JB.180.1.152-158.1998; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; TAKESHIMA H, 1994, ONCOGENE, V9, P2135; VANWAEG G, 1986, PURINE PYRIMIDINE ME, P425; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; Yamamoto T, 1995, J BIOL CHEM, V270, P30557, DOI 10.1074/jbc.270.51.30557; Yuan G, 1999, J BIOL CHEM, V274, P8175, DOI 10.1074/jbc.274.12.8175	44	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32204	32214		10.1074/jbc.274.45.32204	http://dx.doi.org/10.1074/jbc.274.45.32204			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542258	hybrid			2022-12-25	WOS:000083532100066
J	Bernhard, D; Ausserlechner, MJ; Tonko, M; Loffler, M; Hartmann, BL; Csordas, A; Kofler, R				Bernhard, D; Ausserlechner, MJ; Tonko, M; Loffler, M; Hartmann, BL; Csordas, A; Kofler, R			Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts	FASEB JOURNAL			English	Article						caspase; c-myc; bcl-2; p16/INK4A; CCRF-CEM	GLUCOCORTICOID-INDUCED APOPTOSIS; CELL-LINE; GENE-EXPRESSION; C-MYC; MYELOGENOUS LEUKEMIA; MAMMALIAN-CELLS; CARCINOMA CELLS; FLOW-CYTOMETRY; TRICHOSTATIN-A; CANCER CELLS	The histone deacetylase inhibitor and potential anti-cancer drug sodium butyrate is a general inducer of growth arrest, differentiation, and in certain cell types, apoptosis. In human CCRF-CEM, acute T lymphoblastic leukemia cells, butyrate, and other histone deacetylase inhibitors caused G2/M cell cycle arrest as well as apoptotic cell death. Forced G0/G1 arrest by tetracycline-regulated expression of transgenic p16/INK4A protected the cells from butyrate-induced cell death without affecting the extent of histone hyperacetylation, suggesting that the latter may be necessary, but not sufficient, for cell death induction. Nuclear apoptosis, but not G2/M arrest, was delayed but not prevented by the tripeptide broad-range caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (zVAD) and, to a lesser extent, by the tetrapeptide 'effector caspase' inhibitors benzyloxycarbonyl-Asp-Glu-Val-Asp.fluoromethylketone (DEVD) and benzyloxycarbonyl-Val-Glu-Ile-Asp.fluoromethyl-ketone (VEID); however, the viral protein inhibitor of 'inducer caspases', crmA, had no effect. Bcl-2 overexpression partially protected stably transfected CCRF-CEM sublines from butyrate-induced apoptosis, but showed no effect on butyrate-induced growth inhibition, further distinguishing these two butyrate effects. c-myc, constitutively expressed in CCRF-CEM cells, was down-regulated by butyrate, but this was not causative for cell death. On the contrary, tetracycline-induced transgenic c-myc sensitized stably transfected CCRF-CEM derivatives to butyrate-induced cell death.-Bernhard, D., Ausserlechner, M. J., Tonko, M., Loffler, M., Hartmann, B. L., Csordas, A., Kofler, R. Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts.	Univ Innsbruck, Inst Gen & Expt Pathol, Div Mol Pathophysiol, Sch Med, A-6020 Innsbruck, Austria; Univ Innsbruck, Inst Med Chem & Biochem, Sch Med, A-6020 Innsbruck, Austria	University of Innsbruck; University of Innsbruck	Kofler, R (corresponding author), Univ Innsbruck, Inst Gen & Expt Pathol, Div Mol Pathophysiol, Sch Med, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.	Reinhard.Kofler@uibk.ac.at		Ausserlechner, Michael/0000-0002-1015-2302; Bernhard, David/0000-0002-2383-6607				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; AUSSERLECHNER MJ, 1999, UNPUB TETRACYCLINE R, P16; BOFFA LC, 1978, J BIOL CHEM, V253, P3364; Buckley AR, 1996, CELL GROWTH DIFFER, V7, P1713; Conley BA, 1998, CLIN CANCER RES, V4, P629; Csordas A., 1995, ROLE GUT BACTERIA HU, P105; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; GarciaBermejo L, 1997, EXP CELL RES, V236, P268, DOI 10.1006/excr.1997.3725; Geley S, 1997, FEBS LETT, V402, P36, DOI 10.1016/S0014-5793(96)01496-2; Geley S, 1997, ONCOGENE, V15, P2429, DOI 10.1038/sj.onc.1201399; Geley S, 1996, CANCER RES, V56, P5033; Geley S, 1997, FEBS LETT, V400, P15, DOI 10.1016/S0014-5793(96)01284-7; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HAGUE A, 1995, INT J CANCER, V60, P400, DOI 10.1002/ijc.2910600322; Hague A, 1997, INT J CANCER, V72, P898, DOI 10.1002/(SICI)1097-0215(19970904)72:5<898::AID-IJC30>3.0.CO;2-2; Hartmann BL, 1999, ONCOGENE, V18, P713, DOI 10.1038/sj.onc.1202339; HERUTH DP, 1993, J BIOL CHEM, V268, P20466; Janson W, 1997, ONCOGENE, V15, P1395, DOI 10.1038/sj.onc.1201304; Kamada S, 1997, CELL DEATH DIFFER, V4, P473, DOI 10.1038/sj.cdd.4400268; Kasukabe T, 1997, BRIT J CANCER, V75, P850, DOI 10.1038/bjc.1997.151; Kruh J., 1995, P275; Loffler M, 1999, ONCOGENE, V18, P4626, DOI 10.1038/sj.onc.1202820; Mandal M, 1996, CELL GROWTH DIFFER, V7, P311; Martin Seamus J., 1996, P107; McBain JA, 1997, BIOCHEM PHARMACOL, V53, P1357, DOI 10.1016/S0006-2952(96)00904-5; McCaffrey PG, 1997, BLOOD, V90, P2075, DOI 10.1182/blood.V90.5.2075; Medina V, 1997, CANCER RES, V57, P3697; MILLER AA, 1987, EUR J CANCER CLIN ON, V23, P1283, DOI 10.1016/0277-5379(87)90109-X; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NORMAN MR, 1977, CANCER RES, V37, P3785; NOVOGRODSKY A, 1983, CANCER-AM CANCER SOC, V51, P9, DOI 10.1002/1097-0142(19830101)51:1<9::AID-CNCR2820510104>3.0.CO;2-4; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OTSUKI T, 1995, CANCER RES, V55, P1436; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PERRINE SP, 1993, NEW ENGL J MED, V328, P81, DOI 10.1056/NEJM199301143280202; QUAN LT, 1995, J BIOL CHEM, V270, P10377, DOI 10.1074/jbc.270.18.10377; RIGGS MG, 1977, NATURE, V268, P462, DOI 10.1038/268462a0; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Soldatenkov VA, 1998, CELL DEATH DIFFER, V5, P307, DOI 10.1038/sj.cdd.4400345; STRASSERWOZAK EMC, 1995, CANCER RES, V55, P348; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Urbano A, 1998, LEUKEMIA, V12, P930, DOI 10.1038/sj.leu.2401031; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Wang XM, 1998, ANN SURG, V227, P922, DOI 10.1097/00000658-199806000-00016; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; Zweidler A, 1978, Methods Cell Biol, V17, P223, DOI 10.1016/S0091-679X(08)61145-0	57	113	123	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1999	13	14					1991	2001		10.1096/fasebj.13.14.1991	http://dx.doi.org/10.1096/fasebj.13.14.1991			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544182	Bronze			2022-12-25	WOS:000083660700011
J	De Jong-Brink, M; Reid, CN; Tensen, CP; Ter Maat, A				De Jong-Brink, M; Reid, CN; Tensen, CP; Ter Maat, A			Parasites flicking the NPY gene on the host's switchboard: why NPY?	FASEB JOURNAL			English	Article						host interaction; LyNPY; reproduction; food intake; glycogen storage	SNAIL LYMNAEA-STAGNALIS; HYPOTHALAMIC NEUROPEPTIDE-Y; FRESH-WATER SNAIL; CILIARY NEUROTROPIC FACTOR; GROWTH-HORMONE SECRETION; CENTRAL-NERVOUS-SYSTEM; PEPTIDE YY; TRICHOBILHARZIA-OCELLATA; PANCREATIC-POLYPEPTIDE; LUTEINIZING-HORMONE	It was investigated whether up-regulation of the NPY gene by the schistosome Trichobilharzia ocellata in its snail host Lymnaea stagnalis redirects the host's energy flows. We cloned the cDNA encoding Lymnaea NPY (LyNPY), purified and sequenced the peptide, and used synthesized peptide for physiological and morphological studies. Increasing the LyNPY titer in nonparasitized snails (mimicking parasitosis) by 1) implantation of slow-release pellets and 2) injections suppressed reproductive activity and reduced growth in a dose- and time-dependent manner without affecting food intake. When the LyNPY titer was back to normal, reproduction and growth were resumed, coinciding with a transient increase of food intake serving to replenish glycogen stores, Observations on double-immunostained whole mount preparations of brains support these data. A close association was found between LyNPY-positive axons and axons both from ovulation hormone-producing neurons and molluscan insulin-like peptide-producing neurons involved in regulation of growth. As no synaptic(-like) contacts were observed, it is supposed that LyNPY acts noasynaptically. No morphological interaction was found between LyNPY-positive axons and motoneurons innervating the feeding apparatus. Our data explain why it is an advantageous strategy for endoparasites to up-regulate the highly conserved NPY gene in their host.-de Jong-Brink, M., Reid, C. N., Tensen, C. P., Ter Maat, A. Parasites flicking the NPY gene on the host's switchboard: why NPY?.	Free Univ Amsterdam, Fac Biol, Dept Dev Neurobiol, NL-1081 HV Amsterdam, Netherlands; Queens Univ Belfast, Sch Biol & Biochem, Ctr Med Biol, Belfast BT7 1NN, Antrim, North Ireland; Vrije Univ Amsterdam, Acad Ziekenhuis, Dept Dermatol, Amsterdam Leiden Inst Immunol, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Queens University Belfast; Vrije Universiteit Amsterdam	De Jong-Brink, M (corresponding author), Free Univ Amsterdam, Fac Biol, Dept Dev Neurobiol, De Boelelaan 1087, NL-1081 HV Amsterdam, Netherlands.	mdejong@bio.vu.nl		Tensen, Cornelis/0000-0002-5325-1888				BAYOMY MFF, 1989, P K NED AKAD C BIOL, V92, P137; Benjamin P.R., 1985, P87; Blomqvist AG, 1997, TRENDS NEUROSCI, V20, P294, DOI 10.1016/S0166-2236(96)01057-0; Bluet-Pajot MT, 1998, CELL MOL NEUROBIOL, V18, P101, DOI 10.1023/A:1022579327647; BRADBURY AF, 1991, TRENDS BIOCHEM SCI, V16, P112, DOI 10.1016/0968-0004(91)90044-V; de Jong-Brink Marijke, 1997, P57; DEJONGBRINK M, 1995, ADV PARASIT, V35, P177, DOI 10.1016/S0065-308X(08)60072-X; DeLange RPJ, 1997, NEUROSCIENCE, V78, P289, DOI 10.1016/S0306-4522(96)00576-3; FRANKISH HM, 1995, PEPTIDES, V16, P757, DOI 10.1016/0196-9781(94)00200-P; Friedman JM, 1997, NATURE, V385, P119, DOI 10.1038/385119a0; GERAERTS WPM, 1981, EXPERIENTIA, V37, P1168, DOI 10.1007/BF01989899; GERAERTS WPM, 1992, GEN COMP ENDOCR, V86, P433, DOI 10.1016/0016-6480(92)90068-U; GERAERTS WPM, 1988, NEUROHORMONES INVERT, P261; Haynes JM, 1997, BRIT J PHARMACOL, V122, P1530, DOI 10.1038/sj.bjp.0701544; HEMMINGA MA, 1985, COMP BIOCHEM PHYS A, V82, P239, DOI 10.1016/0300-9629(85)90733-9; HERMANN PM, 1994, J EXP BIOL, V197, P79; Hoek RM, 1996, EUR J IMMUNOL, V26, P939, DOI 10.1002/eji.1830260433; Hoek RM, 1997, P NATL ACAD SCI USA, V94, P14072, DOI 10.1073/pnas.94.25.14072; HORBURY SR, 1995, J NEUROENDOCRINOL, V7, P867, DOI 10.1111/j.1365-2826.1995.tb00728.x; HORDIJK PL, 1992, NEUROSCI LETT, V136, P193, DOI 10.1016/0304-3940(92)90047-B; Horvath TL, 1999, J NEUROSCI, V19, P1072; Hurd H., 1990, Advances in Parasitology, V29, P271, DOI 10.1016/S0065-308X(08)60108-6; Jansen RF, 1997, J NEUROPHYSIOL, V78, P3415, DOI 10.1152/jn.1997.78.6.3415; JOOSSE J, 1986, EXP PARASITOL, V62, P1, DOI 10.1016/0014-4894(86)90002-0; Judd SJ, 1998, REPROD FERT DEVELOP, V10, P65, DOI 10.1071/R98024; Kalra SP, 1998, NEUROSCI LETT, V240, P45, DOI 10.1016/S0304-3940(97)00896-3; Kalra SP, 1996, FRONT NEUROENDOCRIN, V17, P371, DOI 10.1006/frne.1996.0010; LANGE RPJ, 1998, J COMP NEUROL, V390, P564; Larhammar D, 1996, REGUL PEPTIDES, V65, P165, DOI 10.1016/0167-0115(96)00110-3; Larhammar D, 1996, REGUL PEPTIDES, V62, P1, DOI 10.1016/0167-0115(95)00169-7; Leibowitz SF, 1998, ENDOCRINOLOGY, V139, P1771, DOI 10.1210/en.139.4.1771; LEUNG PS, 1992, REGUL PEPTIDES, V41, P71, DOI 10.1016/0167-0115(92)90515-V; MALVEN PV, 1995, J ANIM SCI, V73, P2105; MAULE AG, 1995, HYDROBIOLOGIA, V305, P297, DOI 10.1007/BF00036410; McShane TM, 1999, J GERONTOL A-BIOL, V54, pB14, DOI 10.1093/gerona/54.1.B14; Morley JE, 1995, AM ZOOL, V35, P437; Phares K, 1996, J PARASITOL, V82, P210, DOI 10.2307/3284147; RAJPARA SM, 1992, NEURON, V9, P505, DOI 10.1016/0896-6273(92)90188-J; ROBERTS HC, 1999, NIPPOSTRONGYLUS BRAS, V118, P117; SAMBROOK J, 1989, MOL CLONING LAB MANA; Sands SA, 1997, PEPTIDES, V18, P1045, DOI 10.1016/S0196-9781(97)00045-4; SCHEERBOOM JEM, 1978, P K NED AKAD C BIOL, V81, P173; Schwartz MW, 1997, J AM DIET ASSOC, V97, P54, DOI 10.1016/S0002-8223(97)00018-7; Sheikh SP, 1998, NEUROSCIENCE, V82, P107; SMELIK WFE, 1995, THESIS U AMSTERDAM N; SMINIA T, 1972, Z ZELLFORSCH MIK ANA, V130, P497, DOI 10.1007/BF00307004; SMIT AB, 1988, NATURE, V331, P535, DOI 10.1038/331535a0; Sonti G, 1996, PEPTIDES, V17, P517, DOI 10.1016/0196-9781(96)00016-2; STEEN WJ, 1969, NETH J ZOOL, V19, P131; TENSEN CP, 1994, P NATL ACAD SCI USA, V91, P4816, DOI 10.1073/pnas.91.11.4816; Tensen CP, 1998, EUR J NEUROSCI, V10, P3409, DOI 10.1046/j.1460-9568.1998.00350.x; ter Maat A., 1987, P255; TERMAAT A, 1992, PROG BRAIN RES, V92, P345, DOI 10.1016/S0079-6123(08)61188-7; VANHEUMEN WRA, 1990, NEUROSCIENCE, V39, P493, DOI 10.1016/0306-4522(90)90285-C; VANMINNEN J, 1988, CELL TISSUE RES, V251, P477, DOI 10.1007/BF00215857; Vuagnat BAM, 1998, NEUROENDOCRINOLOGY, V67, P291, DOI 10.1159/000054326; White BD, 1997, P SOC EXP BIOL MED, V214, P222, DOI 10.3181/00379727-214-44090; WIJSMAN TCM, 1987, INT J INVER REP DEV, V12, P199, DOI 10.1080/01688170.1987.10510317; Xu B, 1998, ENDOCRINOLOGY, V139, P466, DOI 10.1210/en.139.2.466; ZONNEVELD C, 1989, FUNCT ECOL, V3, P269, DOI 10.2307/2389365	60	32	33	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1999	13	14					1972	1984		10.1096/fasebj.13.14.1972	http://dx.doi.org/10.1096/fasebj.13.14.1972			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544180				2022-12-25	WOS:000083660700009
J	Barrett, WC; DeGnore, JP; Keng, YF; Zhang, ZY; Yim, MB; Chock, PB				Barrett, WC; DeGnore, JP; Keng, YF; Zhang, ZY; Yim, MB; Chock, PB			Roles of superoxide radical anion in signal transduction mediated by reversible regulation of protein-tyrosine phosphatase 1B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; HYDROGEN-PEROXIDE; SULFENIC ACID; PHOSPHORYLATION; MECHANISM; H2O2; INACTIVATION; INTERMEDIATE; GENERATION; CELLS	Growth factors induce intracellular production of reactive oxygen species in non-phagocytic cells and elevation of their phosphorylated protein tyrosine level. The latter can be achieved by activating protein-tyrosine kinases and/or inactivating protein-tyrosine phosphatases (PTPs). A highly abundant PTP, PTP-1B, is known to be inactivated by oxidation of its catalytic site Cys-215. We show that O-2 is kinetically more efficient and chemically more specific oxidant than H2O2 for inactivating PTP-1B. The second-order rate constant for the O-2- and H2O2-mediated inactivation is 334 +/- 45 M-1 s(-1) and 42.8 +/- 3.8 M-1 s(-1), respectively. PTP-1B oxidized by H2O2 exhibits significantly more oxidized methionine residues and shows a lower degree of reversibility. The initial oxidative product, the Cys-215 sulfenic derivative, can easily be oxidized further to its irreversible sulfinic and sulfonic derivatives. This step is prevented by glutathionylation of the sulfenic derivative to form a S-glutathionylated PTP-1B, which can be reactivated by dithiothreitol or thioltransferase. Thus, a signal transduction mechanism mediated by the O-2(radical anion) and the participation of glutathione is proposed for the regulation of PTP-1B. This mechanism is supported by the in vivo demonstration that glutathionylated PTP-1B at Cys-215 is formed in A431 cells when they were treated with epidermal growth factor.	NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA; NHLBI, Biophys Chem Lab, NIH, Bethesda, MD 20892 USA; Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Yeshiva University; Albert Einstein College of Medicine	Chock, PB (corresponding author), NHLBI, Biochem Lab, NIH, Bldg 3,Rm 204,3 Ctr Dr,MSC-0342, Bethesda, MD 20892 USA.				NATIONAL CANCER INSTITUTE [R01CA069202] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000202] Funding Source: NIH RePORTER; NCI NIH HHS [CA69202] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v; CHOCK PB, 1996, PR MED BIOL, V4, P201; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P15013, DOI 10.1021/bi972191x; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Gravina Mieyal S.A, 1995, BIOTHIOLS HLTH DIS, P305; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; KNOTT GD, 1979, COMPUT PROG BIOMED, V10, P271, DOI 10.1016/0010-468X(79)90075-8; KWAK HS, 1995, P NATL ACAD SCI USA, V92, P4582, DOI 10.1073/pnas.92.10.4582; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; Lohse DL, 1997, BIOCHEMISTRY-US, V36, P4568, DOI 10.1021/bi963094r; PICK M, 1974, J AM CHEM SOC, V96, P7329, DOI 10.1021/ja00830a026; Qin J, 1997, ANAL CHEM, V69, P3995, DOI 10.1021/ac970488v; QIN SF, 1995, BIOCHEM J, V308, P347, DOI 10.1042/bj3080347; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; YIM MB, 1994, J BIOL CHEM, V269, P1621; ZHANG N, 1991, J PHYS CHEM-US, V95, P4718, DOI 10.1021/j100165a024; Zhang YL, 1998, ANAL BIOCHEM, V261, P139, DOI 10.1006/abio.1998.2738; ZHANG ZY, 1993, ANAL BIOCHEM, V211, P7, DOI 10.1006/abio.1993.1224; ZHANG ZY, 1994, ADV ENZYMOL RAMB, V68, P1; Zhang ZY, 1998, CRIT REV BIOCHEM MOL, V33, P1, DOI 10.1080/10409239891204161; ZICK Y, 1990, BIOCHEMISTRY-US, V29, P10240, DOI 10.1021/bi00496a013	25	288	299	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34543	34546		10.1074/jbc.274.49.34543	http://dx.doi.org/10.1074/jbc.274.49.34543			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574916	hybrid			2022-12-25	WOS:000083979600010
J	Dircks, LK; Ke, JS; Sul, HS				Dircks, LK; Ke, JS; Sul, HS			A conserved seven amino acid stretch important for murine mitochondrial glycerol-3-phosphate acyltransferase activity - Significance of Arginine 318 in catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE ACYLTRANSFERASE; CELLS; SN-GLYCEROL-3-PHOSPHATE; PURIFICATION; EXPRESSION	Glycerol-3-phosphate acyltransferase (GPAT) catalyzes the initial and committed step in glycerolipid biosynthesis. We previously cloned the cDNA sequence to murine mitochondrial GPAT (Yet, S-F., Lee, S., Hahm, Y. T., and Sul, H.S. (1993) Biochemistry 32, 9486-9491). We expressed the protein in insect cells which was targeted to mitochondria, purified, and reconstituted mitochondrial GPAT activity using phospholipids (Yet, S.-F., Moon, Y., and Sul, H. S. (1995) Biochemistry 34, 7303-7310). Deletion of the seven amino acids from mitochondrial GPAT, (312)IFLEGTR(318), which is highly conserved among acyltransferases in glycerolipid biosynthesis, drastically reduced mitochondrial GPAT activity. Treatment of mitochondrial GPAT with arginine-modifying agents, phenylglyoxal and cyclohexanedione, inactivated the enzyme. Two highly conserved arginine residues, Arg-318, in the seven amino stretch, and Arg-278, were identified. Substitution of Arg-318 with either alanine, histidine, or lysine reduced the mitochondrial GPAT activity by over 90%. On the other hand, although substitution of Arg-278 with alanine and histidine decreased mitochondrial GPAT activity by 90%, replacement with lysine reduced activity by only 25%. A substitution of the nonconserved Arg-279 with either alanine, histidine, or lysine did not alter mitochondrial GPAT activity. Moreover, R278K mitochondrial GPAT still showed sensitivity to arginine-modifying agents, as in the case of wild-type mitochondrial GPAT. These results suggest that Arg-318 may be critical for mitochondrial GPAT activity, whereas Arg-278 can be replaced by a basic amino acid. Examination of the other conserved residues in the seven amino acid stretch revealed that Phe-313 and Glu-315 are also important, but conservative substitutions can partially maintain activity; substitution with alanine reduced activity by 83 and 72%, respectively, whereas substituting Phe-313 with tyrosine and Glu-315 with glutamine had even lesser effect. In addition, there was no change in fatty acyl-CoA selectivity. Kinetic analysis of the R318K and R318A mitochondrial GPAT showed an 89 and 95%, respectively, decrease in catalytic efficiency but no major change in substrate binding as indicated by the K-m values for palmitoyl-CoA and glycerol S-phosphate. These studies indicate importance of the conserved seven amino acid stretch for mitochondrial GPAT activity and the significance of Arg-318 for catalysis.	Univ Calif Berkeley, Dept Nutr Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Sul, HS (corresponding author), Univ Calif Berkeley, Dept Nutr Sci, Berkeley, CA 94720 USA.	hsul@nature.berkeley.edu	Han, Zaiqi/AAI-2233-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036264, R01DK052806] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52806, DK36264] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BATES EJ, 1979, BIOCHEM J, V182, P751, DOI 10.1042/bj1820751; BATES EJ, 1977, FEBS LETT, V84, P225, DOI 10.1016/0014-5793(77)80693-5; Bell RM, 1983, ENZYMES, V16, P87; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brindley D. N, 1991, BIOCH LIPIDS LIPOPRO, P171; Dircks LK, 1997, BBA-LIPID LIPID MET, V1348, P17, DOI 10.1016/S0005-2760(97)00106-9; GERARD RD, 1985, MOL CELL BIOL, V5, P3231, DOI 10.1128/MCB.5.11.3231; GREEN PR, 1984, BIOCHIM BIOPHYS ACTA, V795, P348, DOI 10.1016/0005-2760(84)90085-7; Heath RJ, 1998, J BACTERIOL, V180, P1425, DOI 10.1128/JB.180.6.1425-1430.1998; KELKER HC, 1979, J BIOL CHEM, V254, P5364; MATTSON FH, 1958, J BIOL CHEM, V233, P868; MONTFOORT A, 1971, BIOCHIM BIOPHYS ACTA, V231, P335, DOI 10.1016/0005-2760(71)90147-0; SCHLOSSMAN DM, 1976, J BIOL CHEM, V251, P5738; SHANMUGASUNDARAM T, 1989, BIOCHEMISTRY-US, V28, P7112, DOI 10.1021/bi00443a049; STERN W, 1978, J BIOL CHEM, V253, P8047; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; VANCURA A, 1994, J BIOL CHEM, V269, P27209; YET SF, 1995, BIOCHEMISTRY-US, V34, P7303, DOI 10.1021/bi00022a003; YET SF, 1993, BIOCHEMISTRY-US, V32, P9486, DOI 10.1021/bi00087a029	20	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34728	34734		10.1074/jbc.274.49.34728	http://dx.doi.org/10.1074/jbc.274.49.34728			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574940	hybrid			2022-12-25	WOS:000083979600034
J	Kull, F; Ohlson, E; Haeggstrom, JZ				Kull, F; Ohlson, E; Haeggstrom, JZ			Cloning and characterization of a bifunctional leukotriene A(4) hydrolase from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MECHANISM-BASED INACTIVATION; EPOXIDE HYDROLASE; MOLECULAR-CLONING; ZINC METALLOENZYME; PEPTIDASE ACTIVITY; RAINBOW-TROUT; AMINOPEPTIDASE; MUTATION; TYROSINE-383; INFLAMMATION	In mammals, leukotriene A(4) hydrolase is a bifunctional zinc metalloenzyme that catalyzes hydrolysis of leukotriene A(4) into the proinflammatory leukotriene B-4 and also possesses an arginyl aminopeptidase activity. We have cloned, expressed, and characterized a protein from Saccharomyces cerevisiae that is 42% identical to human leukotriene A(4) hydrolase. The purified protein is an anion-activated leucyl aminopeptidase, as assessed by p-nitroanilide substrates, and does not hydrolyze leukotriene A(4) into detectable amounts of leukotriene B-4. However, the S. cerevisiae enzyme can utilize leukotriene A, as substrate to produce a compound identified as 5S,6S-dihydroxy-7,9-trans-11,14-cis-eicosatetraenoic acid. Both catalytic activities are inhibited by 3-(4-benzyloxyphenyl)-2-(R)-amino-1-propanethiol (thioamine), a competitive inhibitor of human leukotriene A(4) hydrolase. Furthermore, the peptide cleaving activity of the S. cerevisiae enzyme was stimulated approximately 10-fold by leukotriene A(4) with kinetics indicating the presence of a lipid binding site. Nonenzymatic hydrolysis products of leukotriene A(4), leukotriene B-4, arachidonic acid, or phosphatidylcholine were without effect. Moreover, leukotriene A(4) could displace the inhibitor thioamine and restore maximal aminopeptidase activity, indicating that the leukotriene A, binding site is located at the active center of the enzyme. Hence, the S. cerevisiae leukotriene A(4) hydrolase is a bifunctional enzyme and appears to be an early ancestor to mammalian leukotriene A(4) hydrolases.	Karolinska Inst, Div Chem 2, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden	Karolinska Institutet	Haeggstrom, JZ (corresponding author), Karolinska Inst, Div Chem 2, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.	jesper.haeggstrom@mbb.ki.se						Andberg MB, 1997, J BIOL CHEM, V272, P23057, DOI 10.1074/jbc.272.37.23057; AUSUBEL FM, 1996, CURRENT PROTOCOLS MO, P1; BARRET AJ, 1998, HDB PROTEOLYTIC ENZY, P994; Baset HA, 1998, J BIOL CHEM, V273, P27978, DOI 10.1074/jbc.273.43.27978; BLOMSTER M, 1995, EUR J BIOCHEM, V231, P528, DOI 10.1111/j.1432-1033.1995.tb20728.x; EVANS JF, 1985, J BIOL CHEM, V260, P966; FORDHUTCHINSON AW, 1990, CRIT REV IMMUNOL, V10, P1; GREEN FA, 1987, BIOCHEM BIOPH RES CO, V142, P309, DOI 10.1016/0006-291X(87)90274-9; HABENICHT AJR, 1989, P NATL ACAD SCI USA, V86, P921, DOI 10.1073/pnas.86.3.921; HAEGGSTROM JZ, 1990, BIOCHEM BIOPH RES CO, V173, P431, DOI 10.1016/S0006-291X(05)81076-9; HAEGGSTROM JZ, 1990, BIOCHEM BIOPH RES CO, V172, P965, DOI 10.1016/0006-291X(90)91540-9; HOGG JH, 1995, BIOORGAN MED CHEM, V3, P1405, DOI 10.1016/0968-0896(95)00128-4; KNIGHT J, 1995, LIPIDS, V30, P451, DOI 10.1007/BF02536304; MCGEE J, 1985, J BIOL CHEM, V260, P2832; MEDINA JF, 1991, BIOCHEM BIOPH RES CO, V176, P1516, DOI 10.1016/0006-291X(91)90459-K; MEDINA JF, 1988, BIOCHIM BIOPHYS ACTA, V961, P203, DOI 10.1016/0005-2760(88)90115-4; MINAMI M, 1990, BIOCHEM BIOPH RES CO, V173, P620, DOI 10.1016/S0006-291X(05)80080-4; MUELLER MJ, 1995, P NATL ACAD SCI USA, V92, P8383, DOI 10.1073/pnas.92.18.8383; Mueller MJ, 1996, P NATL ACAD SCI USA, V93, P5931, DOI 10.1073/pnas.93.12.5931; Nasr F, 1996, YEAST, V12, P493, DOI 10.1002/(SICI)1097-0061(199604)12:5<493::AID-YEA929>3.0.CO;2-W; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; ORNING L, 1992, J BIOL CHEM, V267, P22733; ORNING L, 1994, J BIOL CHEM, V269, P11269; PETTITT TR, 1989, FEBS LETT, V259, P168, DOI 10.1016/0014-5793(89)81520-0; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Stromberg-Kull F, 1998, FEBS LETT, V433, P219, DOI 10.1016/S0014-5793(98)00918-1; WATANABE T, 1993, EUR J BIOCHEM, V212, P605, DOI 10.1111/j.1432-1033.1993.tb17699.x; WEI YA, 1993, J MED CHEM, V36, P211, DOI 10.1021/jm00054a004; WETTERHOLM A, 1992, BIOCHIM BIOPHYS ACTA, V1123, P275, DOI 10.1016/0005-2760(92)90007-I; WETTERHOLM A, 1991, BIOCHIM BIOPHYS ACTA, V1080, P96, DOI 10.1016/0167-4838(91)90134-L; WETTERHOLM A, 1992, P NATL ACAD SCI USA, V89, P9141, DOI 10.1073/pnas.89.19.9141	32	26	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34683	34690		10.1074/jbc.274.49.34683	http://dx.doi.org/10.1074/jbc.274.49.34683			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574934	hybrid			2022-12-25	WOS:000083979600028
J	Civil, A; Rensink, I; Aarden, LA; Verweij, CL				Civil, A; Rensink, I; Aarden, LA; Verweij, CL			Functional disparity of distinct CD28 response elements toward mitogenic responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; B/REL TRANSCRIPTION FACTORS; ACCESSORY MOLECULE CD28; IFN-BETA GENE; C-REL; INTERLEUKIN-2 ENHANCER; SIGNAL-TRANSDUCTION; ACTIVATION PATHWAY; VIRUS INDUCTION; T-CELLS	Activation of T cells through the antigen-specific T-cell receptor in combination with a costimulatory signal results in efficient cytokine gene transcription. The CD28-induced signal represents a major costimulatory signal for T cells. A CD28 response element, named CD28RE, was first identified in the interleukin-2 (IL-2) promoter region, Here we demonstrate that the NF-kappa B sequence in the IL-6 promoter functions as a CD28 response element. Mutations in this sequence rendered the IL-6 promoter unresponsive to CD28 costimulation, Moreover, this element could replace the IL-2 CD28RE in conferring CD28 responsiveness to the IL-2 promoter. In analogy to the known CD28 response elements IL-2 CD28RE, IL-8 CD28RE, and the human immunodeficiency virus-1 (HIV-1) NF-kappa B motif, the IL-6 NF-kappa B motif efficiently bound c-Rel, c-Rel/NFKB1, and the recently identified inducible T-cell factor NF-MATp35, However, the IL-6 NF-kappa B sequence together with the IL-8 CD28RE and HIV-1 NF-kappa B sequence differed from the IL-2 CD28RE in the binding of NF-kappa B/Rel family proteins. Although the IL-2 CD28RE exerted selective binding with c-Rel and c-Rel/NFKB1, the other CD28REs allowed efficient binding of a wide range of NF-kappa B/Rel family proteins. The difference in binding specificity correlated with the capacity of the distinct CD28 response elements to function in the context of the IL-6 promoter in response to T-cell activation. Domain swapping experiments revealed that the IL-8 CD28RE and HIV-1 NF-kappa B motif conferred similar responsiveness as the genuine IL-6 NF-kappa B motif in the transcriptional activation of the IL-6 promoter upon CD28 costimulation, In contrast, replacement of the IL-6 NF-kappa B sequence by the IL-2 CD28RE motif strongly reduced the responsiveness of the IL-6 promoter. These data indicate that despite the sequence similarity, two different classes of CD28 responsive elements exist that differ in their NF-kappa B binding capacity and the ability to confer CD28 costimulatory responsiveness toward a heterologous promoter.	Leiden Univ, Med Ctr, Dept Rheumatol, NL-2300 RC Leiden, Netherlands; Netherlands Red Cross, Blood Transfus Serv, Cent Lab, Dept Autoimmune Dis, NL-1066 CX Amsterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Verweij, CL (corresponding author), Leiden Univ, Med Ctr, Dept Rheumatol, C4-R,POB 9600, NL-2300 RC Leiden, Netherlands.	Verweij_C@RULMAIL.MedFac.LeidenUniv.nl						AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; BRYAN RG, 1994, MOL CELL BIOL, V14, P7933, DOI 10.1128/MCB.14.12.7933; Butscher WG, 1998, J BIOL CHEM, V273, P552, DOI 10.1074/jbc.273.1.552; Civil A, 1996, J BIOL CHEM, V271, P8321, DOI 10.1074/jbc.271.14.8321; CIVIL A, 1992, EUR J IMMUNOL, V22, P3041, DOI 10.1002/eji.1830221142; DENDORFER U, 1994, MOL CELL BIOL, V14, P4443, DOI 10.1128/MCB.14.7.4443; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; FRASER JD, 1992, MOL CELL BIOL, V12, P4357, DOI 10.1128/MCB.12.10.4357; FRASER JD, 1993, IMMUNOL TODAY, V14, P357, DOI 10.1016/0167-5699(93)90236-E; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; Good LF, 1996, EMBO J, V15, P3744, DOI 10.1002/j.1460-2075.1996.tb00744.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Harhaj EW, 1996, MOL CELL BIOL, V16, P6736; Himes SR, 1996, IMMUNITY, V5, P479, DOI 10.1016/S1074-7613(00)80503-8; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; KOOTEN CV, 1991, J IMMUNOL, V146, P2654; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; LI M, 1993, MOL CELL BIOL, V13, P6490, DOI 10.1128/MCB.13.10.6490; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; Maggirwar SB, 1997, MOL CELL BIOL, V17, P2605, DOI 10.1128/MCB.17.5.2605; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; Ruocco MR, 1996, J BIOL CHEM, V271, P22479, DOI 10.1074/jbc.271.37.22479; SEHGAL PB, 1992, RES IMMUNOL, V143, P724, DOI 10.1016/0923-2494(92)80011-9; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; THOMPSON CB, 1989, P NATL ACAD SCI USA, V86, P1333, DOI 10.1073/pnas.86.4.1333; VERWEIJ CL, 1991, J BIOL CHEM, V266, P14179; WECHSLER AS, 1994, J IMMUNOL, V153, P2515	37	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34369	34374		10.1074/jbc.274.48.34369	http://dx.doi.org/10.1074/jbc.274.48.34369			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567414	hybrid			2022-12-25	WOS:000083857500079
J	Deery, WJ; Gomer, RH				Deery, WJ; Gomer, RH			A putative receptor mediating cell-density sensing in Dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; GENE-EXPRESSION; PROTEIN SUBUNITS; CAMP RECEPTORS; BINDING-SITES; DISCOIDEUM; CHEMOATTRACTANT; GROWTH; ACCUMULATION; CYTOKINESIS	When Dictyostelium cells starve, they begin secreting a glycoprotein called conditioned medium factor (CMF). When there is a high density of starved cells, as indicated by a high concentration of CMF, the cells begin expressing some genes and aggregate using pulses of cAMP as a chemoattractant. CMF regulates gene expression via a G protein-independent pathway, whereas CMF regulates cAMP signal transduction via a G protein-dependent pathway. To elucidate receptors mediating cell density sensing, we used CMF-Sepharose to isolate membrane proteins that bind CMF. We identified a 50-kDa protein, CMFR1, that is sensitive to trypsin treatment of whole cells. We obtained partial amino acid sequence of CMFR1 and isolated the cDNA encoding it, The derived amino acid sequence has no significant similarity to known proteins and has two or three predicted transmembrane domains. Expression of CMFR1 in insect cells caused an increase in CMF binding. Repression of CMFR1 in Dictyostelium by gene disruption resulted in a similar to 50% decrease of the CMF binding and a loss of CMF-induced G protein-independent gene expression. The G protein-dependent CMF signal transduction pathways appear to be functional in cmfr1 cells, suggesting that cells sense the density-sensing factor CMF using two or more different receptors.	Rice Univ, Howard Hughes Med Inst, Dept Biochem & Cell Biol, Houston, TX 77005 USA	Howard Hughes Medical Institute; Rice University	Gomer, RH (corresponding author), Rice Univ, Howard Hughes Med Inst, Dept Biochem & Cell Biol, MS-140,6100 S Main St, Houston, TX 77005 USA.			Gomer, Richard/0000-0003-2361-4307				ALEX LA, 1994, TRENDS GENET, V10, P133, DOI 10.1016/0168-9525(94)90215-1; Brazill DT, 1997, FEBS LETT, V404, P100, DOI 10.1016/S0014-5793(97)00104-X; Brazill DT, 1998, J BIOL CHEM, V273, P8161, DOI 10.1074/jbc.273.14.8161; Brock DA, 1999, GENE DEV, V13, P1960, DOI 10.1101/gad.13.15.1960; Clarke M, 1995, EXPERIENTIA, V51, P1124, DOI 10.1007/BF01944730; Clay JL, 1995, DEV BIOL, V172, P665, DOI 10.1006/dbio.1995.8045; DEHOSTOS EL, 1993, J CELL BIOL, V120, P163, DOI 10.1083/jcb.120.1.163; DEWIT RJW, 1985, BIOCHIM BIOPHYS ACTA, V814, P214, DOI 10.1016/0005-2736(85)90439-0; DEWIT RJW, 1985, BIOCHIM BIOPHYS ACTA, V814, P199, DOI 10.1016/0005-2736(85)90438-9; DOTTIN RP, 1991, DEV GENET, V12, P2, DOI 10.1002/dvg.1020120103; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; Elmquist JK, 1999, NEURON, V22, P221, DOI 10.1016/S0896-6273(00)81084-3; Firtel RA, 1996, CURR OPIN GENET DEV, V6, P545, DOI 10.1016/S0959-437X(96)80082-7; Garvey JS, 1977, METHODS IMMUNOLOGY, V3rd; Gomer RH, 1999, ASM NEWS, V65, P23; GOMER RH, 1991, DEVELOPMENT, V112, P269; GOODLOEHOLLAND CM, 1987, METHOD CELL BIOL, V28, P103; HERELD D, 1992, INT REV CYTOL, V137B, P35; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; JAIN R, 1994, J BIOL CHEM, V269, P9128; JAIN R, 1992, GENE DEV, V6, P390, DOI 10.1101/gad.6.3.390; Kim JY, 1998, DEV BIOL, V197, P117, DOI 10.1006/dbio.1998.8882; KUMAGAI A, 1989, CELL, V57, P265, DOI 10.1016/0092-8674(89)90964-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lehmann S, 1997, J BIOL CHEM, V272, P12047, DOI 10.1074/jbc.272.18.12047; LIBELBINAY S, 1995, J IMMUNOL, V55, P101; Lindsey DF, 1998, J BIOL CHEM, V273, P29178, DOI 10.1074/jbc.273.44.29178; MEHDY MC, 1985, MOL CELL BIOL, V5, P705, DOI 10.1128/MCB.5.4.705; MILNE JLS, 1995, J BIOL CHEM, V270, P5926, DOI 10.1074/jbc.270.11.5926; PETERS DJM, 1991, DEV GENET, V12, P25, DOI 10.1002/dvg.1020120107; SEGALL JE, 1995, J CELL BIOL, V128, P405, DOI 10.1083/jcb.128.3.405; SIMON MN, 1992, NATURE, V356, P171, DOI 10.1038/356171a0; Sonnemann J, 1998, FEBS LETT, V436, P271, DOI 10.1016/S0014-5793(98)01139-9; Spann TP, 1996, P NATL ACAD SCI USA, V93, P5003, DOI 10.1073/pnas.93.10.5003; Stock J, 1996, SCIENCE, V274, P370, DOI 10.1126/science.274.5286.370; SUTOH K, 1993, PLASMID, V30, P150, DOI 10.1006/plas.1993.1042; THEIBERT A, 1986, J BIOL CHEM, V261, P5121; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tuxworth RI, 1997, J CELL BIOL, V138, P605, DOI 10.1083/jcb.138.3.605; VANHAASTERT PJM, 1989, BIOCHEM J, V258, P577, DOI 10.1042/bj2580577; VANHAASTERT PJM, 1985, BIOCHIM BIOPHYS ACTA, V845, P254, DOI 10.1016/0167-4889(85)90184-3; VANHAASTERT PJM, 1987, EUR J BIOCHEM, V162, P251; VanHaastert PJM, 1996, J CELL BIOL, V134, P1543, DOI 10.1083/jcb.134.6.1543; Wang N, 1999, MOL CELL BIOL, V19, P4750; YUEN IS, 1995, J CELL BIOL, V129, P1251, DOI 10.1083/jcb.129.5.1251; YUEN IS, 1994, J THEOR BIOL, V167, P273, DOI 10.1006/jtbi.1994.1069; YUEN IS, 1991, DEVELOPMENT, V113, P1375; [No title captured]	49	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34476	34482		10.1074/jbc.274.48.34476	http://dx.doi.org/10.1074/jbc.274.48.34476			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567429	hybrid			2022-12-25	WOS:000083857500094
J	Knoblauch, NTM; Rudiger, S; Schonfeld, HJ; Driessen, AJM; Schneider-Mergener, J; Bukau, B				Knoblauch, NTM; Rudiger, S; Schonfeld, HJ; Driessen, AJM; Schneider-Mergener, J; Bukau, B			Substrate specificity of the SecB chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING PROTEIN; ESCHERICHIA-COLI; SIGNAL SEQUENCE; PHYSIOLOGICAL LIGAND; TERTIARY STRUCTURE; SELECTIVE BINDING; HSP70 CHAPERONES; LEADER PEPTIDE; EXPORT FACTOR; DNAK	The bacterial chaperone SecB assists translocation of proteins across the inner membrane. The mechanism by which it differentiates between secretory and cytosolic proteins is poorly understood. To identify its binding motif, we screened 2688 peptides covering sequences of 23 proteins for SecB binding. The motif is similar to 9 residues long and is enriched in aromatic and basic residues, whereas acidic residues are disfavored. Its identification allows the prediction of binding regions within protein sequences with up to 87% accuracy. SecB-binding regions occur statistically every 20-30 residues. The occurrence and affinity of binding regions are similar in SecB-dependent and -independent secretory proteins and in cytosolic proteins, and SecB lacks specificity toward signal sequences. SecB cannot thus differentiate between secretory and non-secretory proteins via its binding specificity. This conclusion is supported by the finding that SecB binds denatured luciferase, thereby allowing subsequent refolding by the DnaK system. SecB may rather be a general chaperone whose involvement in translocation is mediated by interactions of SecB and signal sequences of SecB-bound preproteins with the translocation apparatus.	Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; F Hoffmann La Roche & Co Ltd, Pharmaceut Res Infect Dis, CH-4070 Basel, Switzerland; Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands; Humboldt Univ, Inst Med Immunol, Klinikum Charite, D-10098 Berlin, Germany	University of Freiburg; Roche Holding; University of Groningen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Bukau, B (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.	bukau@sun2.ruf.uni-freiburg.de	Rüdiger, Stefan GD/G-4906-2012; Driessen, Arnold J.M./D-1876-2012	Rüdiger, Stefan GD/0000-0002-1807-2972; Bukau, Bernd/0000-0003-0521-7199; Driessen, Arnold J.M./0000-0001-9258-9104				ALTMAN E, 1990, J BIOL CHEM, V265, P18154; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; Buchberger A, 1996, J MOL BIOL, V261, P328, DOI 10.1006/jmbi.1996.0465; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; DenBlaauwen T, 1996, ARCH MICROBIOL, V165, P1, DOI 10.1007/s002030050289; DRIESSEN AJM, 1994, J MEMBRANE BIOL, V142, P145; ERNST F, 1994, J BIOL CHEM, V269, P12840; Fekkes P, 1999, BIOCHEMISTRY-US, V38, P5111, DOI 10.1021/bi982818r; Fekkes P, 1998, MOL MICROBIOL, V29, P1179, DOI 10.1046/j.1365-2958.1998.00997.x; FEKKES P, 1995, BIOCHEMISTRY-US, V34, P10078, DOI 10.1021/bi00031a032; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; GANNON PM, 1989, J BACTERIOL, V171, P813, DOI 10.1128/jb.171.2.813-818.1989; HARDY SJS, 1991, SCIENCE, V251, P439, DOI 10.1126/science.1989077; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; Hesterkamp T, 1998, EMBO J, V17, P4818, DOI 10.1093/emboj/17.16.4818; HOFFSCHUTE HK, 1994, J BIOL CHEM, V269, P12833; KHISTY VJ, 1995, J BACTERIOL, V177, P3277, DOI 10.1128/jb.177.11.3277-3282.1995; KHISTY VJ, 1995, J BIOL CHEM, V270, P25920, DOI 10.1074/jbc.270.43.25920; Kramer A, 1999, J PEPT RES, V54, P319, DOI 10.1034/j.1399-3011.1999.00108.x; Kramer Achim, 1994, Methods (Orlando), V6, P388, DOI 10.1006/meth.1994.1039; KUMAMOTO CA, 1990, J BIOENERG BIOMEMBR, V22, P337, DOI 10.1007/BF00763171; KUMAMOTO CA, 1983, J BACTERIOL, V154, P253, DOI 10.1128/JB.154.1.253-260.1983; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; KUMAMOTO CA, 1993, J BACTERIOL, V175, P2184, DOI 10.1128/JB.175.8.2184-2188.1993; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LECKER SH, 1990, EMBO J, V9, P2309, DOI 10.1002/j.1460-2075.1990.tb07402.x; LIU GP, 1989, P NATL ACAD SCI USA, V86, P9213, DOI 10.1073/pnas.86.23.9213; McCarty JS, 1996, J MOL BIOL, V256, P829, DOI 10.1006/jmbi.1996.0129; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; Pautsch A, 1998, NAT STRUCT BIOL, V5, P1013, DOI 10.1038/2983; Randall LL, 1998, PROTEIN SCI, V7, P2384, DOI 10.1002/pro.5560071115; RANDALL LL, 1990, SCIENCE, V248, P860, DOI 10.1126/science.2188362; Randall LL, 1998, PROTEIN SCI, V7, P1195, DOI 10.1002/pro.5560070514; RANDALL LL, 1995, TRENDS BIOCHEM SCI, V20, P65, DOI 10.1016/S0968-0004(00)88959-8; RANDALL LL, 1992, SCIENCE, V257, P241, DOI 10.1126/science.1631545; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; Randall LL, 1997, P NATL ACAD SCI USA, V94, P802, DOI 10.1073/pnas.94.3.802; Reineke U, 1996, MOL DIVERS, V1, P141, DOI 10.1007/BF01544952; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Schonfeld HJ, 1998, METHOD ENZYMOL, V290, P269, DOI 10.1016/S0076-6879(98)90025-8; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SHARFF AJ, 1993, BIOCHEMISTRY-US, V32, P10553, DOI 10.1021/bi00091a004; Smith VF, 1997, PROTEIN SCI, V6, P1746, DOI 10.1002/pro.5560060815; Smith VF, 1996, PROTEIN SCI, V5, P488; Stenberg G, 1997, J MOL BIOL, V274, P268, DOI 10.1006/jmbi.1997.1398; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; TOPPING TB, 1994, PROTEIN SCI, V3, P730; WATANABE M, 1989, P NATL ACAD SCI USA, V86, P2728, DOI 10.1073/pnas.86.8.2728; WATANABE M, 1995, P NATL ACAD SCI USA, V92, P10133, DOI 10.1073/pnas.92.22.10133; WATANABE M, 1989, CELL, V58, P695, DOI 10.1016/0092-8674(89)90104-9; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; Wild J, 1996, J BACTERIOL, V178, P3608, DOI 10.1128/jb.178.12.3608-3613.1996; WILD J, 1992, GENE DEV, V6, P1165, DOI 10.1101/gad.6.7.1165	55	124	125	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34219	34225		10.1074/jbc.274.48.34219	http://dx.doi.org/10.1074/jbc.274.48.34219			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567394	hybrid, Green Published			2022-12-25	WOS:000083857500059
J	Sarma, AD; Serfozo, P; Kahn, K; Tipton, PA				Sarma, AD; Serfozo, P; Kahn, K; Tipton, PA			Identification and purification of hydroxyisourate hydrolase, a novel ureide-metabolizing enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URATE OXIDASE REACTION; PLANTS; TRANSPORT; NITROGEN	We report the identification and purification of a novel enzyme from soybean root nodules that catalyzes the hydrolysis of 5-hydroxyisourate, which is the true product of the urate oxidase reaction. The product of this reaction is 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline, and the new enzyme is designated 5-hydroxyisourate hydrolase, The enzyme was purified from crude extracts of soybean root nodules similar to 100-fold to apparent homogeneity with a final specific activity of 10 mu mol/min/mg, The enzyme exhibited a native molecular mass of similar to 68 kDa by gel filtration chromatography and migrated as a single band on SDS-polyacrylamide gel electrophoresis with a subunit molecular mass of 68 +/- 2 kDa. The purified enzyme obeyed normal Michaelis-Menten kinetics, and the K-m for 5-hydroxyisourate was determined to be 15 mu M The amino terminal end of the purified protein was sequenced, and the resulting sequence was not found in any available data bases, confirming the novelty of the protein. These data suggest the existence of a hitherto unrecognized enzymatic pathway for the formation of allantoin.	Univ Missouri, Dept Biochem, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Tipton, PA (corresponding author), Univ Missouri, Dept Biochem, 117 Schweitzer Hall, Columbia, MO 65211 USA.							BOLAND MJ, 1983, ARCH BIOCHEM BIOPHYS, V222, P435, DOI 10.1016/0003-9861(83)90542-8; Kahn K, 1997, BIOCHEMISTRY-US, V36, P4731, DOI 10.1021/bi963184w; Kahn K, 1997, J AM CHEM SOC, V119, P5435, DOI 10.1021/ja970375t; Kahn K, 1998, BIOCHEMISTRY-US, V37, P11651, DOI 10.1021/bi980446g; KAHN K, 1998, THESIS U MISSOURI; KARR DB, 1984, PLANT PHYSIOL, V75, P1158, DOI 10.1104/pp.75.4.1158; LEE KW, 1964, ARCH BIOCHEM BIOPHYS, V108, P460, DOI 10.1016/0003-9861(64)90427-8; MCCLURE PR, 1979, PLANT PHYSIOL, V64, P411, DOI 10.1104/pp.64.3.411; MODRIC N, 1992, TETRAHEDRON LETT, V33, P6691, DOI 10.1016/S0040-4039(00)61021-3; REYNOLDS PHS, 1982, TRENDS BIOCHEM SCI, V7, P366, DOI 10.1016/0968-0004(82)90116-5; SCHUBERT KR, 1986, ANNU REV PLANT PHYS, V37, P539, DOI 10.1146/annurev.arplant.37.1.539	11	39	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					33863	33865		10.1074/jbc.274.48.33863	http://dx.doi.org/10.1074/jbc.274.48.33863			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567345	hybrid			2022-12-25	WOS:000083857500010
J	Rutz, C; Rosenthal, W; Schulein, R				Rutz, C; Rosenthal, W; Schulein, R			A single negatively charged residue affects the orientation of a membrane protein in the inner membrane of Escherichia coli only when it is located adjacent to a transmembrane domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSERTION ORIENTATION; ALKALINE-PHOSPHATASE; TOPOLOGY; TRANSLOCATION; HYDROPHOBICITY; RECEPTOR; SIGNALS; TAILS; YEAST	The orientation of membrane proteins is determined by the asymmetric distribution of charged residues in the sequences flanking the transmembrane domains. For the inner membrane of Escherichia coli, numerous studies have shown that an excess of positively charged residues defines a cytoplasmic domain of a membrane protein ("positive inside" rule), The role of negatively charged residues in establishing membrane protein topology, however, is not completely understood. To investigate the influence of negatively charged residues on this process in detail, we have constructed a single spanning chimeric receptor fragment comprising the N terminus and first transmembrane domain of the heptahelical G protein-coupled vasopressin V-2 receptor and the first cytoplasmic loop of the beta(2)-adrenergic receptor. When fused to alkaline phosphatase (PhoA), the receptor fragment inserted into the inner membrane off. coli with its N terminus facing the cytoplasm (N-in-C-out orientation), although both membrane-flanking domains had rather similar topogenic determinants. The orientation of the receptor fragment was changed after the introduction of single glutamate residues into the N terminus. Orientation inversion, however, was found to be dependent on the location of the glutamate substitutions, which had to lie within a narrow window up to 6 residues distant from the transmembrane domain. These results demonstrate that a single negatively charged residue can play an active role as a topogenic determinant of membrane proteins in the inner membrane of E. coli, but only if it is located adjacent to a transmembrane domain.	Forschungsinst Mol Pharmakol, D-10315 Berlin, Germany; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany	Free University of Berlin	Schulein, R (corresponding author), Forschungsinst Mol Pharmakol, Alfred Kowalke Str 4, D-10315 Berlin, Germany.							ANDERSSON H, 1994, EMBO J, V13, P2267, DOI 10.1002/j.1460-2075.1994.tb06508.x; ANDERSSON H, 1993, J BIOL CHEM, V268, P21389; ANDERSSON H, 1994, FEBS LETT, V347, P169, DOI 10.1016/0014-5793(94)00530-3; ANDERSSON H, 1992, J BIOL CHEM, V267, P1491; ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; CAO GQ, 1994, EMBO J, V13, P4662, DOI 10.1002/j.1460-2075.1994.tb06789.x; CAO GQ, 1995, EMBO J, V14, P866, DOI 10.1002/j.1460-2075.1995.tb07068.x; Delgado-Partin VM, 1998, J BIOL CHEM, V273, P9927, DOI 10.1074/jbc.273.16.9927; Harley CA, 1998, J BIOL CHEM, V273, P24963, DOI 10.1074/jbc.273.38.24963; Harley CA, 1996, J BIOL CHEM, V271, P24625, DOI 10.1074/jbc.271.40.24625; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HENN DK, 1995, P NATL ACAD SCI USA, V92, P7425, DOI 10.1073/pnas.92.16.7425; KHYSEANDERSON J, 1984, J BIOCHEM BIOPH METH, V10, P203; Kiefer D, 1997, EMBO J, V16, P2197, DOI 10.1093/emboj/16.9.2197; KOSHLAND D, 1980, CELL, V20, P749, DOI 10.1016/0092-8674(80)90321-9; LACATENA RM, 1994, P NATL ACAD SCI USA, V91, P10521, DOI 10.1073/pnas.91.22.10521; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MANOIL C, 1990, J BACTERIOL, V172, P1035, DOI 10.1128/jb.172.2.1035-1042.1990; Miller JH., 1972, EXPT MOL GENETICS; Schulein R, 1996, J BIOL CHEM, V271, P28844, DOI 10.1074/jbc.271.46.28844; SCHULEIN R, 1992, MOL GEN GENET, V234, P155; Sone M, 1997, J BIOL CHEM, V272, P6174, DOI 10.1074/jbc.272.10.6174; SPIESS M, 1995, FEBS LETT, V369, P76, DOI 10.1016/0014-5793(95)00551-J; vanKlompenburg W, 1997, EMBO J, V16, P4261, DOI 10.1093/emboj/16.14.4261; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1994, ANNU REV BIOPH BIOM, V23, P167	27	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33757	33763		10.1074/jbc.274.47.33757	http://dx.doi.org/10.1074/jbc.274.47.33757			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559268	hybrid			2022-12-25	WOS:000083745200084
J	Broad, LM; Armstrong, DL; Putney, JW				Broad, LM; Armstrong, DL; Putney, JW			Role of the inositol 1,4,5-trisphosphate receptor in Ca2+ feedback inhibition of calcium release-activated calcium current (I-crac)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT MAST-CELLS; STORE DEPLETION; ENTRY; TRISPHOSPHATE; CHANNELS; INFLUX; DISSOCIATION; THAPSIGARGIN; INACTIVATION; INSP(3)	We examined the activation and regulation of calcium release-activated calcium current (I-crac) in RBL-1 cells in response to various Ca2+ store-depleting agents. With [Ca2+](i) strongly buffered to 100 nM, I-crac was activated by ionomycin, thapsigargin, inositol 1,4,5-trisphosphate (IP,), and two metabolically stable IP3 receptor agonists, adenophostin A and L-alpha-glycerophospho-D-myoinositol-4,5-bisphosphate (GPIP(2)). With minimal [Ca2+](i) buffering, with [Ca2+](i) free to fluctuate I-crac was activated by ionomycin, thapsigargin, and by the potent IP3 receptor agonist, adenophostin A, but not by GPIP(2) or IP3 itself. Likewise, when [Ca2+](i) was strongly buffered to 500 nM, ionomycin, thapsigargin, and adenophostin A did and GPIP(2) and IP3 did not activate detectable I-crac. However, with minimal [Ca2+](i) buffering, or with [Ca2+](i) buffered to 500 nM, GPIP(2) was able to fully activate detectable I-crac if uptake of Ca2+ intracellular stores was first inhibited. Our findings suggest that when IP3 activates the IP3 receptor, the resulting influx of Ca2+ quickly inactivates the receptor, and Ca2+ is re-accumulated at sites that regulate I-crac. Adenophostin A, by virtue of its high receptor affinity, is resistant to this inactivation, Comparison of thapsigargin-releasabIe Ca2+ pools following activation by different IP3 receptor agonists indicates that the critical regulatory pool of Ca2+ may be very small in comparison to the total IP3-sensitive component of the endoplasmic reticulum, These findings reveal new and important roles for IP3 receptors located on discrete IP3-sensitive Ca2+ pools in calcium feedback regulation of I-crac and capacitative calcium entry.	NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Broad, LM (corresponding author), NIEHS, Lab Signal Transduct, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Putney, James W/F-7247-2019	Putney, James W/0000-0002-3379-4789	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090087, Z01ES090087, Z01ES080043, ZIAES080043] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Barritt GJ, 1998, CELL CALCIUM, V23, P65, DOI 10.1016/S0143-4160(98)90075-6; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRD GS, 1992, J BIOL CHEM, V267, P17722; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANNAERTMERAH Z, 1994, J BIOL CHEM, V269, P29642; Hofer AM, 1998, J CELL BIOL, V140, P325, DOI 10.1083/jcb.140.2.325; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Huang Y, 1998, J BIOL CHEM, V273, P19554, DOI 10.1074/jbc.273.31.19554; Huang Y, 1998, J BIOL CHEM, V273, P31815, DOI 10.1074/jbc.273.48.31815; Hurst RS, 1998, FEBS LETT, V422, P333, DOI 10.1016/S0014-5793(98)00035-0; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov KI, 1999, PFLUG ARCH EUR J PHY, V437, P305, DOI 10.1007/s004240050784; Parekh AB, 1998, J BIOL CHEM, V273, P14925, DOI 10.1074/jbc.273.24.14925; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Parekh AB, 1997, CELL, V89, P973, DOI 10.1016/S0092-8674(00)80282-2; Putney Jr JW, 1997, CAPACITATIVE CALCIUM; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Putney JW, 1997, CELL CALCIUM, V21, P257, DOI 10.1016/S0143-4160(97)90050-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Ribeiro CMP, 1996, J BIOL CHEM, V271, P21522, DOI 10.1074/jbc.271.35.21522; SAGARA Y, 1992, J BIOL CHEM, V267, P12606; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; TAKAHASHI M, 1994, J BIOL CHEM, V269, P369; VACA L, 1995, AM J PHYSIOL-CELL PH, V269, pC733, DOI 10.1152/ajpcell.1995.269.3.C733; WALDRON RT, 1995, J BIOL CHEM, V270, P11955, DOI 10.1074/jbc.270.20.11955; ZHANG L, 1995, J PHYSIOL-LONDON, V483, P59, DOI 10.1113/jphysiol.1995.sp020567; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209; ZWEIFACH A, 1995, J BIOL CHEM, V270, P14445, DOI 10.1074/jbc.270.24.14445	34	61	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32881	32888		10.1074/jbc.274.46.32881	http://dx.doi.org/10.1074/jbc.274.46.32881			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551852	hybrid			2022-12-25	WOS:000083623000052
J	MacLeod, KJ; Vasilyeva, E; Merdek, K; Vogel, PD; Forgac, M				MacLeod, KJ; Vasilyeva, E; Merdek, K; Vogel, PD; Forgac, M			Photoaffinity labeling of wild-type and mutant forms of the yeast V-ATPase A subunit by 2-azido-[P-32]ADP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; PROTON-TRANSLOCATING ATPASE; ESCHERICHIA-COLI F1-ATPASE; SITE-DIRECTED MUTAGENESIS; NUCLEOTIDE-BINDING-SITES; BETA-SUBUNIT; MUTATIONAL ANALYSIS; CATALYTIC SUBUNIT; F1 ATPASE; B-SUBUNIT	Molecular modeling studies have previously suggested the possible presence of four aromatic residues (Phe(452), Tyr(532), Tyr(535), and Phe(538)) near the adenine binding pocket of the catalytic site on the yeast V-ATPase A subunit (MacLeod, K. J., Vasilyeva, E., Baleja, J. D., and Forgac, M. (1998) J. Biol. Chem. 273, 150-156). To test the proximity of these aromatic residues to the adenine ring, the yeast V-ATPase containing wild-type and mutant forms of the A subunit was reacted with 2-azido-[P-32]ADP, a photoaffinity analog that stably modifies tyrosine but not phenylalanine residues. Mutant forms of the A subunit were constructed in which the two endogenous tyrosine residues were replaced with phenylalanine and in which a single tyrosine was introduced at each of the four positions, Strong ATP-protectable labeling of the A subunit was observed for the wild-type and the mutant containing tyrosine at 532, significant ATP-protectable labeling was observed for the mutants containing tyrosine at positions 452 and 538, and only very weak labeling was observed for the mutants containing tyrosine at 535 or in which all four residues were phenylalanine. These results suggest that Tyr532 and possibly Phe(452) and Tyr(538) are in close proximity to the adenine ring of ATP bound to the A subunit, In addition, the effects of mutations at Phe(452), Tyr(532), Tyr(535), and Glu(286) on dissociation of the peripheral V-1 and integral V-0 domains both in vivo and in vitro were examined. The results suggest that in vivo dissociation requires catalytic activity while in vitro dissociation requires nucleotide binding to the catalytic site.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA; Univ Kaiserslautern, Fachbereich Chem, Biochem Abt, D-67653 Kaiserslautern, Germany	Tufts University; University of Kaiserslautern	Forgac, M (corresponding author), Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA.			Vogel, Pia/0000-0002-8135-4649	NIGMS NIH HHS [GM 34478, R01 GM034478] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034478, R37GM034478] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ADACHI I, 1990, J BIOL CHEM, V265, P967; ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; ARAI H, 1989, BIOCHEMISTRY-US, V28, P3075, DOI 10.1021/bi00433a051; ARAI H, 1988, J BIOL CHEM, V263, P8796; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; CHATTERJEE D, 1992, P NATL ACAD SCI USA, V89, P6257, DOI 10.1073/pnas.89.14.6257; CROSS RL, 1987, P NATL ACAD SCI USA, V84, P5715, DOI 10.1073/pnas.84.16.5715; Cross RL, 1996, J BIOENERG BIOMEMBR, V28, P403, DOI 10.1007/BF02113981; CZARNECKI JJ, 1984, BIOCHIM BIOPHYS ACTA, V800, P41, DOI 10.1016/0304-4165(84)90092-8; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; FENG Y, 1992, J BIOL CHEM, V267, P5817; Fillingame RH, 1997, J EXP BIOL, V200, P217; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; GEITZ D, 1992, NUCLEIC ACIDS RES, V20, P1425; GLUCK SL, 1992, J BIOENERG BIOMEMBR, V24, P351, DOI 10.1007/BF00762528; HIRATA R, 1990, J BIOL CHEM, V265, P6726; Kane PM, 1999, J BIOENERG BIOMEMBR, V31, P49, DOI 10.1023/A:1005444513542; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1995, J BIOL CHEM, V270, P17025; KANE PM, 1990, SCIENCE, V250, P561; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu JZ, 1996, BIOCHEMISTRY-US, V35, P10938, DOI 10.1021/bi9608065; Liu Q, 1996, J BIOL CHEM, V271, P2018, DOI 10.1074/jbc.271.4.2018; Liu Q, 1997, J BIOL CHEM, V272, P11750, DOI 10.1074/jbc.272.18.11750; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MacLeod KJ, 1998, J BIOL CHEM, V273, P150, DOI 10.1074/jbc.273.1.150; MANOLSON MF, 1985, J BIOL CHEM, V260, P2273; Margolles-Clark E, 1999, J BIOENERG BIOMEMBR, V31, P29, DOI 10.1023/A:1005440412633; MARTINEZZAGUILAN R, 1993, AM J PHYSIOL, V265, pC1015, DOI 10.1152/ajpcell.1993.265.4.C1015; MELESE T, 1985, J BIOL CHEM, V260, P5398; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1992, J BIOENERG BIOMEMBR, V24, P407, DOI 10.1007/BF00762533; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PARK MY, 1994, J BIOCHEM-TOKYO, V116, P1139, DOI 10.1093/oxfordjournals.jbchem.a124640; Parra KJ, 1998, MOL CELL BIOL, V18, P7064, DOI 10.1128/MCB.18.12.7064; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SENIOR AE, 1992, J BIOL CHEM, V267, P21471; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; Vasilyeva E, 1996, J BIOL CHEM, V271, P12775, DOI 10.1074/jbc.271.22.12775; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; WEBER J, 1993, J BIOL CHEM, V268, P6241; WISE JG, 1987, FEBS LETT, V223, P395, DOI 10.1016/0014-5793(87)80326-5; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; ZHANG JM, 1995, J BIOL CHEM, V270, P15494, DOI 10.1074/jbc.270.26.15494; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102; [No title captured]	56	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32869	32874		10.1074/jbc.274.46.32869	http://dx.doi.org/10.1074/jbc.274.46.32869			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551850	hybrid			2022-12-25	WOS:000083623000050
J	Blair, A; Shaul, PW; Yuhanna, IS; Conrad, PA; Smart, EJ				Blair, A; Shaul, PW; Yuhanna, IS; Conrad, PA; Smart, EJ			Oxidized low density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; CELL-SURFACE; ARTERY ENDOTHELIUM; MA104 CELLS; CHOLESTEROL; MEMBRANE; RECEPTOR; LOCALIZATION; TRANSPORT; ACYLATION	Hypercholesterolemia-induced vascular disease and atherosclerosis are characterized by a decrease in the bioavailability of endothelium-derived nitric oxide. Endothelial nitric-oxide synthase (eNOS) associates with caveolae and is directly regulated by the caveola protein, caveolin. In the present study, we examined the effects of oxidized low density Lipoprotein (oxLDL) on the subcellular location of eNOS, on eNOS activation, and on caveola cholesterol in endothelial cells. We found that treatment with 10 mu g/ml oxLDL for 60 min caused greater than 90% of eNOS and caveolin to leave caveolae, Treatment with oxLDL also inhibited acetylcholine-indnced activation of eNOS but not prostacyclin production. oxLDL did nob affect total cellular eNOS abundance. Oxidized LDL also did not affect the palmitoylation, myristoylation or phosphorylation of eNOS. Oxidized LDL, but not native LDL, or HDL depleted caveolae of cholesterol by serving as an acceptor for cholesterol. Cyclodextrin also depleted caveolae of cholesterol and caused eNOS and caveolin to translocate from caveolae. Furthermore, removal of oxLDL allowed eNOS and caveolin to return to caveolae. We conclude that oxLDL-induced depletion of caveola cholesterol causes eNOS to leave caveolae and inhibits acetylcholine-induced activation of the enzyme. This process may be an important mechanism in the early pathogenesis of atherosclerosis.	Univ Kentucky, Dept Physiol, Sch Med, Lexington, KY 40536 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75235 USA; Bucknell Univ, Dept Biol, Lewisburg, PA 17837 USA	University of Kentucky; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Bucknell University	Smart, EJ (corresponding author), Univ Kentucky, Dept Physiol, Sch Med, 800 Rose St,MS 508 C, Lexington, KY 40536 USA.	ejsmart@pop.uky.edu			NHLBI NIH HHS [HL62844, HL58888, HL58475] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062844, R29HL058475, R01HL058888, R01HL058475] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Buege J A, 1978, Methods Enzymol, V52, P302; CAYATTE AJ, 1994, ARTERIOSCLER THROMB, V14, P753, DOI 10.1161/01.ATV.14.5.753; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; COHEN RA, 1995, PROG CARDIOVASC DIS, V38, P105, DOI 10.1016/S0033-0620(05)80002-7; DAVDA RK, 1993, HYPERTENSION, V21, P939, DOI 10.1161/01.HYP.21.6.939; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Feron O, 1998, BIOCHEMISTRY-US, V37, P193, DOI 10.1021/bi972307p; FISHER WR, 1986, METHOD ENZYMOL, V128, P247; FLAVAHAN NA, 1992, CIRCULATION, V85, P1927, DOI 10.1161/01.CIR.85.5.1927; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Graf GA, 1999, J BIOL CHEM, V274, P12043, DOI 10.1074/jbc.274.17.12043; GRAHAM J, 1993, METHODS MOL BIOL, V19; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GWYNNE JT, 1989, J BIOL CHEM, V264, P8141; HARRISON DG, 1994, BASIC RES CARDIOL, V89, P87; Jun SS, 1998, J CLIN INVEST, V102, P176, DOI 10.1172/JCI2034; KELLEY JL, 1986, METHOD ENZYMOL, V128, P170; KRIEGER M, 1979, J BIOL CHEM, V254, P3845; LantinHermoso RL, 1997, AM J PHYSIOL-LUNG C, V273, pL119, DOI 10.1152/ajplung.1997.273.1.L119; LEFER AM, 1993, ARTERIOSCLER THROMB, V13, P771, DOI 10.1161/01.ATV.13.6.771; LIAO JK, 1995, J BIOL CHEM, V270, P319, DOI 10.1074/jbc.270.1.319; Liu JW, 1997, J CELL BIOL, V137, P1525, DOI 10.1083/jcb.137.7.1525; Liu JW, 1996, BIOCHEMISTRY-US, V35, P13277, DOI 10.1021/bi961720e; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; PLANE F, 1993, ATHEROSCLEROSIS, V103, P73, DOI 10.1016/0021-9150(93)90041-R; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; Sakoda T, 1995, MOL CELL BIOCHEM, V152, P143, DOI 10.1007/BF01076076; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; SHAUL PW, 1994, J CLIN INVEST, V94, P2231, DOI 10.1172/JCI117585; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1996, J CELL BIOL, V134, P1169, DOI 10.1083/jcb.134.5.1169; SMART EJ, 1995, J CELL BIOL, V131, P929, DOI 10.1083/jcb.131.4.929; SMART EJ, 1994, J CELL BIOL, V124, P307, DOI 10.1083/jcb.124.3.307; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; VANE JR, 1990, NEW ENGL J MED, V323, P27; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563	51	283	296	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32512	32519		10.1074/jbc.274.45.32512	http://dx.doi.org/10.1074/jbc.274.45.32512			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542298	hybrid			2022-12-25	WOS:000083532100106
J	Chan, SL; Tan, KO; Zhang, L; Yee, KSY; Ronca, F; Chan, MY; Yu, VC				Chan, SL; Tan, KO; Zhang, L; Yee, KSY; Ronca, F; Chan, MY; Yu, VC			F1A alpha, a death receptor-binding protein homologous to the Caenorhabditis elegans sex-determining protein, FEM-1, is a caspase substrate that mediates apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; SIGNALING COMPLEX DISC; NECROSIS-FACTOR; DETERMINING GENE; TNF RECEPTOR; NEMATODE SEX; C-ELEGANS; INTERACTING PROTEIN; ADAPTER MOLECULE; 2-HYBRID SYSTEM	Apoptosis is an evolutionarily conserved process that is critical for tissue homeostasis and development including sex determination in essentially all multicellular organisms. Here, we report the cloning of an ankyrin repeat-containing protein, termed F1A alpha, in a yeast two-hybrid screen using the cytoplasmic domain of Fas (CD95/APO-1) as bait. Amino acid sequence analysis indicates that F1A alpha has extensive homology to the sex-determining protein FEM-1 of the Caenorhabditis elegans, which is required for the development of all aspects of the male phenotype. F1A alpha associates with the cytoplasmic domains of Fas and tumor necrosis factor receptor 1, two prototype members of the "death receptor" family. The F1A alpha protein also oligomerizes. Overexpression of F1A alpha induces apoptosis in mammalian cells, and co-expression of Bcl-XL or the dominant negative mutants of either FADD or caspase-9 blocks this effect. Deletion analysis revealed the center region of F1A alpha, including a cluster of five ankyrin repeats to be necessary and sufficient for maximum apoptotic activity, and the N-terminal region appears to regulate negatively this activity. Furthermore, F1A alpha is cleaved by a caspase-3-like protease at Asp(342), and the cleavage-resistant mutant is unable to induce apoptosis upon overexpression. F1Aa is therefore a member of a growing family of death receptor-associated proteins that mediates apoptosis.	Inst Mol & Cell Biol, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Yu, VC (corresponding author), Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.		Yu, Victor/A-7899-2015; Chan, S.L./X-4154-2018	Yu, Victor/0000-0003-3270-4734; Chan, S.L./0000-0002-3270-0525; Tan, Kuan/0000-0002-0947-7337; Zhang, Li/0000-0001-7506-8278				Ahmad M, 1997, CANCER RES, V57, P615; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bai C, 1997, METHOD ENZYMOL, V283, P141; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Carmi I, 1998, NATURE, V396, P168, DOI 10.1038/24164; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CHU KT, 1995, P NATL ACAD SCI USA, V92, P11894, DOI 10.1073/pnas.92.25.11894; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; deBono M, 1996, GENETICS, V144, P587; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Gaudet J, 1996, MOL BIOL CELL, V7, P1107, DOI 10.1091/mbc.7.7.1107; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; HODGKIN J, 1990, NATURE, V344, P721, DOI 10.1038/344721a0; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kuwabara PE, 1996, GENETICS, V144, P597; KUWABARA PE, 1992, TRENDS GENET, V8, P164, DOI 10.1016/0168-9525(92)90218-S; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liou ML, 1999, J BIOL CHEM, V274, P10145, DOI 10.1074/jbc.274.15.10145; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Raymond CS, 1998, NATURE, V391, P691, DOI 10.1038/35618; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Ronca F, 1997, J BIOL CHEM, V272, P4252, DOI 10.1074/jbc.272.7.4252; Ronca F, 1999, J BIOL CHEM, V274, P18128, DOI 10.1074/jbc.274.25.18128; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SONG HY, 1994, J BIOL CHEM, V269, P22492; SPENCE AM, 1990, CELL, V60, P981, DOI 10.1016/0092-8674(90)90346-G; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; Tan KO, 1999, J BIOL CHEM, V274, P23687, DOI 10.1074/jbc.274.34.23687; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Ventura-Holman T, 1998, GENOMICS, V54, P221, DOI 10.1006/geno.1998.5569; Wallach D, 1997, FEBS LETT, V410, P96, DOI 10.1016/S0014-5793(97)00553-X; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Yee KSY, 1998, J BIOL CHEM, V273, P5366, DOI 10.1074/jbc.273.9.5366; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	62	35	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32461	32468		10.1074/jbc.274.45.32461	http://dx.doi.org/10.1074/jbc.274.45.32461			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542291	hybrid			2022-12-25	WOS:000083532100099
J	Engelman, JA; Zhang, XL; Razani, B; Pestell, RG; Lisanti, MP				Engelman, JA; Zhang, XL; Razani, B; Pestell, RG; Lisanti, MP			p42/44 MAP kinase-dependent and -independent signaling pathways regulate caveolin-1 gene expression - Activation of Ras-MAP kinase and protein kinase A signaling cascades transcriptionally down-regulates caveolin-1 promoter activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONCOGENICALLY TRANSFORMED-CELLS; HUMAN BREAST-CANCER; IN-VIVO; SCAFFOLDING DOMAIN; MEMBRANE DOMAINS; TYROSINE KINASE; PLASMA-MEMBRANE; SEQUENCE; FAMILY; IDENTIFICATION	Caveolin-1 is a principal component of caveolae membranes in vivo. Caveolin-1 mRNA and protein expression are down-regulated in NIH 3T3 cells in response to transformation by activated oncogenes, such as H-Ras(G12V) and v-Abl, The mechanisms governing this down-regulation event remain unknown. Here, we show that caveolin-1 gene expression is directly regulated by activation of the Ras-p42/44 MAP kinase cascade, Down regulation of caveolin-1 protein expression by Ras is independent of (i) the type of activating mutation (G12V versus Q61L) and (ii) the form of activated Ras transfected (H-Ras versus H-Ras versus N-Ras), Treatment of Ras or Raf-transformed MH 3T3 cells with a well characterized MEK inhibitor (PD 98059) restores caveolin-1 protein expression. In contrast, treatment of v-Src and v-Abl transformed NIH 3T3 cells with PD 98059 does not restore caveolin-1 expression. Thus, there must be at least two pathways for down-regulating caveolin-1 expression: one that is p42/44 MAP kinase-dependent and another that is p42/44 MAP kinase-independent. We focused our efforts on the p42/44 MAP kinase-dependent pathway. The activity of a panel of caveolin-1 promoter constructs was evaluated using transient expression in H-Ras(G12V) transformed MR 3T3 cells. We show that caveolin-1 promoter activity is up-regulated similar to 5-fold by inhibition of the p42/44 MAP kinase cascade. Using electrophoretic mobility shift assays we provide evidence that the caveolin-1 promoter (from -156 to -561) is differentially bound by transcription factors in normal and H-Ras(G12V)-transformed cells. We also show that activation of protein kinase A (PKA) signaling is sufficient to down-regulate caveolin-1 protein expression and promoter activity. Thus, we have identified two signaling pathways (Ras-p42/44MAP kinase and PKA) that transcriptionally down-regulate caveolin-1 gene expression.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Lisanti, MP (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013	Lisanti, Michael/0000-0003-2034-1382; Razani, Babak/0000-0002-7172-9240	NATIONAL CANCER INSTITUTE [R01CA070897, R01CA080250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA-80250, R29-CA70897] Funding Source: Medline; NIGMS NIH HHS [T32-GM07288] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Engelman JA, 1998, FEBS LETT, V429, P330, DOI 10.1016/S0014-5793(98)00619-X; Engelman JA, 1998, FEBS LETT, V436, P403, DOI 10.1016/S0014-5793(98)01134-X; Engelman JA, 1998, AM J HUM GENET, V63, P1578, DOI 10.1086/302172; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GUERRERO I, 1985, P NATL ACAD SCI USA, V82, P7810, DOI 10.1073/pnas.82.23.7810; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PESTELL RG, 1994, J BIOL CHEM, V269, P31090; POLLARD JW, 1979, J CELL PHYSIOL, V98, P571, DOI 10.1002/jcp.1040980315; Razani B, 1999, J BIOL CHEM, V274, P26353, DOI 10.1074/jbc.274.37.26353; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SAGER R, 1994, COLD SPRING HARB SYM, V59, P537, DOI 10.1101/SQB.1994.059.01.060; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SINGH M, 1993, MOL CELL BIOL, V13, P3611, DOI 10.1128/MCB.13.6.3611; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Toya Y, 1998, ENDOCRINOLOGY, V139, P2025, DOI 10.1210/en.139.4.2025; WOOD WM, 1989, J BIOL CHEM, V264, P14840	36	149	154	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32333	32341		10.1074/jbc.274.45.32333	http://dx.doi.org/10.1074/jbc.274.45.32333			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542274	hybrid			2022-12-25	WOS:000083532100082
J	Tichy, M; Vermaas, W				Tichy, M; Vermaas, W			Accumulation of pre-apocytochrome f in a Synechocystis sp PCC 6803 mutant impaired in cytochrome c maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; HEME ATTACHMENT; CHLAMYDOMONAS-REINHARDTII; SACCHAROMYCES-CEREVISIAE; BIOGENESIS; GENE; MITOCHONDRIA; PROTEINS; PATHWAY; IMPORT	Cytochrome c maturation involves heme transport and covalent attachment of heme to the apoprotein, The 5' end of the ccsB gene, which is involved in the maturation process and resembles the ccs1 gene from Chlamydomonas reinhardtii, was replaced by a chloramphenicol resistance cartridge in the cyanobacterium Synechocystis sp. PCC 6803, The resulting Delta(M1-A24) mutant lacking the first 24 ccsB codons grew only under anaerobic conditions. The mutant retained about 20% of the wild-type amount of processed cytochrome f with heme attached, apparently assembled in a functional cytochrome b(6)f complex, Moreover, the mutant accumulated unprocessed apocytochrome f in its membrane fraction. A pseudorevertant was isolated that regained the ability to grow under aerobic conditions. The locus of the second-site mutation was mapped to ccsB, and the mutation resulted in the formation of a new potential start codon in the intergenic region, between the chloramphenicol resistance marker and ccsB, in frame with the remaining part of ccsB. In this pseudorevertant the amount of holocyt f increased, whereas that of unprocessed apocytochrome f decreased. me suggest that the original deletion mutant Delta(M1-A24) expresses an N-terminally truncated version of the protein. The stable accumulation of unprocessed apocytochrome f in membranes of the Delta(M1-A24) mutant may be explained by its association with truncated and only partially functional CcsB protein resulting in protection from degradation. Our attempt to delete the first 244 codons of ccsB in Synechocystis sp, PCC 6803 was not successful, suggesting that this would lead to a lack of functional cytochrome b(6)f complex, The results suggest that the CcsB protein is an apocytochrome chaperone, which together with CcsA may constitute part of cytochrome c lyase.	Arizona State Univ, Dept Plant Biol, Tempe, AZ 85287 USA; Arizona State Univ, Ctr Study Early Events Photosynthesis, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe	Vermaas, W (corresponding author), Arizona State Univ, Dept Plant Biol, Box 871601, Tempe, AZ 85287 USA.		Tichy, Martin/B-6545-2008	Tichy, Martin/0000-0003-2814-1959				DIAZ A, 1994, FEBS LETT, V347, P173, DOI 10.1016/0014-5793(94)00529-X; DUMONT ME, 1987, EMBO J, V6, P235, DOI 10.1002/j.1460-2075.1987.tb04744.x; Gabbert KK, 1997, J BACTERIOL, V179, P5422, DOI 10.1128/jb.179.17.5422-5428.1997; Goldman BS, 1998, P NATL ACAD SCI USA, V95, P5003, DOI 10.1073/pnas.95.9.5003; Goldman BS, 1998, MOL MICROBIOL, V27, P871, DOI 10.1046/j.1365-2958.1998.00708.x; HOWE G, 1995, MOL GEN GENET, V246, P156, DOI 10.1007/BF00294678; Hubschmann T, 1997, FEBS LETT, V408, P201, DOI 10.1016/S0014-5793(97)00421-3; Inoue K, 1997, J BIOL CHEM, V272, P31747, DOI 10.1074/jbc.272.50.31747; Kranz R, 1998, MOL MICROBIOL, V29, P383, DOI 10.1046/j.1365-2958.1998.00869.x; Manna P, 1997, PLANT MOL BIOL, V35, P407, DOI 10.1023/A:1005875124387; MAYER A, 1995, J BIOL CHEM, V270, P12390, DOI 10.1074/jbc.270.21.12390; NICHOLSON DW, 1989, P NATL ACAD SCI USA, V86, P4340, DOI 10.1073/pnas.86.12.4340; NICHOLSON DW, 1989, J BIOL CHEM, V264, P10156; OHASHI A, 1982, J BIOL CHEM, V257, P3042; Page MD, 1997, MICROBIOL-SGM, V143, P3111, DOI 10.1099/00221287-143-10-3111; Page MD, 1998, TRENDS BIOCHEM SCI, V23, P103, DOI 10.1016/S0968-0004(98)01173-6; Pearce DA, 1998, MICROBIOL-SGM, V144, P467, DOI 10.1099/00221287-144-2-467; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; SAMBONGI Y, 1994, FEBS LETT, V340, P65, DOI 10.1016/0014-5793(94)80174-6; SAMBONGI Y, 1994, FEBS LETT, V344, P207, DOI 10.1016/0014-5793(94)00399-8; Schiott T, 1997, J BACTERIOL, V179, P4523, DOI 10.1128/jb.179.14.4523-4529.1997; Steiner H, 1996, J BIOL CHEM, V271, P32605, DOI 10.1074/jbc.271.51.32605; Sussman JK, 1996, MOL MICROBIOL, V21, P347, DOI 10.1046/j.1365-2958.1996.6371354.x; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; THONYMEYER L, 1995, J BACTERIOL, V177, P4321; ThonyMeyer L, 1997, MICROBIOL MOL BIOL R, V61, P337; ThonyMeyer L, 1997, EUR J BIOCHEM, V246, P794, DOI 10.1111/j.1432-1033.1997.t01-1-00794.x; Tichy M, 1998, BIOCHEMISTRY-US, V37, P1523, DOI 10.1021/bi9723818; Xie ZY, 1998, BBA-BIOENERGETICS, V1365, P309, DOI 10.1016/S0005-2728(98)00085-1; Xie ZY, 1996, J BIOL CHEM, V271, P4632; Xie ZY, 1998, GENETICS, V148, P681; ZOLLNER A, 1992, EUR J BIOCHEM, V207, P1093, DOI 10.1111/j.1432-1033.1992.tb17146.x	32	22	24	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32396	32401		10.1074/jbc.274.45.32396	http://dx.doi.org/10.1074/jbc.274.45.32396			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542282	hybrid			2022-12-25	WOS:000083532100090
J	Truant, R; Kang, YB; Cullen, BR				Truant, R; Kang, YB; Cullen, BR			The human tap nuclear RNA export factor contains a novel transportin-dependent nuclear localizatoin signal that lacks nuclear export signal function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; PROTEIN IMPORT; HNRNP A1; MAMMALIAN-CELLS; BINDING-PROTEIN; POLY(A)(+) RNA; ELEMENT; PATHWAY; DOMAIN; BETA	The human Tap protein mediates the sequence specific nuclear export of RNAs containing the constitutive transport element and is likely also critical for general mRNA export. Here, we demonstrate that a previously defined arginine-rich nuclear localization signal (NLS) present in Tap acts exclusively via the transportin import factor. Previously, transportin has been shown to mediate the nuclear import of several heterogeneous nuclear ribonucleoproteins, including heterogeneous nuclear ribonucleoprotein (hnRNP) Al, by binding to a sequence element termed M9. Although the Tap NLS and the hnRNP Al M9 element are shown to compete for transportin binding, they show no sequence homology, and the Tap NLS does not conform to the recently defined M9 consensus. The Tap NLS also differs from M9 in that only the latter is able to act as a nuclear export signal. The Tap NLS is therefore the first member of a novel class of transportin-specific NLSs that lack nuclear export signal function.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Genet, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University	Cullen, BR (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA.	culle002@mc.duke.edu		Kang, Yibin/0000-0002-1626-6730				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; Bogerd HP, 1999, J BIOL CHEM, V274, P9771, DOI 10.1074/jbc.274.14.9771; Bonifaci N, 1997, P NATL ACAD SCI USA, V94, P5055, DOI 10.1073/pnas.94.10.5055; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Englmeier L, 1999, CURR BIOL, V9, P30, DOI 10.1016/S0960-9822(99)80044-X; Fridell RA, 1997, J CELL SCI, V110, P1325; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; GRAUN IC, 1999, EMBO J, V18, P1953; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Kang YB, 1999, GENE DEV, V13, P1126, DOI 10.1101/gad.13.9.1126; Katahira J, 1999, EMBO J, V18, P2593, DOI 10.1093/emboj/18.9.2593; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MICHAEL WM, 1995, CELL, V83, P415; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; Pasquinelli AE, 1997, EMBO J, V16, P7500, DOI 10.1093/emboj/16.24.7500; PinolRoma S, 1997, SEMIN CELL DEV BIOL, V8, P57, DOI 10.1006/scdb.1996.0122; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Ribbeck K, 1999, CURR BIOL, V9, P47, DOI 10.1016/S0960-9822(99)80046-3; Saavedra C, 1997, CURR BIOL, V7, P619, DOI 10.1016/S0960-9822(06)00288-0; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Siomi MC, 1997, J CELL BIOL, V138, P1181, DOI 10.1083/jcb.138.6.1181; Stutz F, 1998, GENE DEV, V12, P3303, DOI 10.1101/gad.12.21.3303; Truant R, 1998, MOL CELL BIOL, V18, P1449, DOI 10.1128/MCB.18.3.1449; Truant R, 1999, MOL CELL BIOL, V19, P1210; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x	33	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32167	32171		10.1074/jbc.274.45.32167	http://dx.doi.org/10.1074/jbc.274.45.32167			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542253	hybrid			2022-12-25	WOS:000083532100061
J	Wang, HY; Malbon, CC				Wang, HY; Malbon, CC			G(s)alpha repression of adipogenesis via Syk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEIN; ADIPOSE CELL LINE; ALPHA-SUBUNIT; CRYSTAL-STRUCTURE; ADENYLYL-CYCLASE; TYROSINE-KINASE; DIFFERENTIATION; ACTIVATION; IDENTIFICATION; ADIPOCYTES	G(s)alpha regulates the differentiation of 3T3-L1 mouse embryonic fibroblasts to adipocytes, a process termed adipogenesis, Inducers of adipogenesis lead to a loss of G(s)alpha and derepress differentiation to adipocytes, The broad spectrum tyrosine kinase inhibitor genistein is shown to block induction of adipogenesis, suggesting an early role of tyrosine phosphorylation in adipogenesis, Staining of phosphotyrosine identified prominent staining of a similar to 70-kDa protein, hypothesized to be the tyrosine kinase Syk, Reverse transcription and polymerase chain reaction amplification established the expression of Syk mRNA in these embryonic fibroblasts. Immunoprecipitations with Syk-specific antibodies demonstrated the presence of Syk in fibroblasts and a rapid increase in the amount of phospho-Syk, peaking at 24 h post induction, Clones constitutively expressing G(s)alpha, which can no longer be induced to differentiate, no longer display increased phospho-Syk levels in response to inducers. The linkage between G(s)alpha and Syk was probed by immunoprecipitations revealing association of Syk with G(s)alpha in the absence of induction. Upon induction of adipogenesis, G(s)alpha levels decline and phospho-Syk levels as well as Syk kinase activity increase, Expression of wildtype Syk both potentiates the ability of inducers to act as well as induces adipogenesis itself. Expression of the kinase-deficient Syk had no such effects on adipogenesis. These data provide a new insight into the control of adipogenesis, suggesting that G(s)alpha represses adipogenesis via Syk, Treatment with the inducers promotes a decline in G(s)alpha, increases in levels of phospho-syk, and adipogenesis.	SUNY Stony Brook, Univ Med Ctr, Diabet & Metab Dis Res Program, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; SUNY Stony Brook, Univ Med Ctr, Diabet & Metab Dis Res Program, Dept Mol Pharmacol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital	Wang, HY (corresponding author), SUNY Stony Brook, Univ Med Ctr, Diabet & Metab Dis Res Program, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.		malbon, craig/ABF-3604-2020		NIDDK NIH HHS [DK30111] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030111] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Cheng AM, 1997, CURR OPIN IMMUNOL, V9, P528, DOI 10.1016/S0952-7915(97)80106-9; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Harnett M, 1996, IMMUNOL TODAY, V17, P4, DOI 10.1016/0167-5699(96)80558-5; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Liu XX, 1998, J BIOL CHEM, V273, P11685, DOI 10.1074/jbc.273.19.11685; MOXHAM CM, 1993, SCIENCE, V260, P991, DOI 10.1126/science.8493537; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; RUSSELL TR, 1976, P NATL ACAD SCI USA, V73, P4516, DOI 10.1073/pnas.73.12.4516; STRITTMATTER SM, 1994, J NEUROSCI, V14, P2327; SU HL, 1993, AM J PHYSIOL, V265, pC1729, DOI 10.1152/ajpcell.1993.265.6.C1729; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; van Oers N S, 1995, Semin Immunol, V7, P227, DOI 10.1006/smim.1995.0027; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Wang HY, 1997, J BIOL CHEM, V272, P1817, DOI 10.1074/jbc.272.3.1817; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; Wang HY, 1996, J BIOL CHEM, V271, P22022, DOI 10.1074/jbc.271.36.22022; WATKINS DC, 1989, BIOCHEM BIOPH RES CO, V165, P929, DOI 10.1016/0006-291X(89)92692-2; WATKINS DC, 1987, J BIOL CHEM, V262, P10651; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234; WATKINS DC, 1989, J BIOL CHEM, V264, P4186	32	35	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32159	32166		10.1074/jbc.274.45.32159	http://dx.doi.org/10.1074/jbc.274.45.32159			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542252	hybrid			2022-12-25	WOS:000083532100060
J	Bin, OY; Li, WQ; Pan, HQ; Meadows, J; Hoffmann, I; Dai, W				Bin, OY; Li, WQ; Pan, HQ; Meadows, J; Hoffmann, I; Dai, W			The physical association and phosphorylation of Cdc25C protein phosphatase by Prk	ONCOGENE			English	Article						Cdc25C; Prk; protein kinase; protein phosphatase; cell cycle	XENOPUS EGG EXTRACTS; SERINE/THREONINE KINASE; DNA-DAMAGE; DROSOPHILA; SERINE-216; CHECKPOINT; HOMOLOG; GENE; CDC5; IDENTIFICATION	prk encodes a protein serine/threonine kinase involved in regulating M phase functions during the cell cycle. We have expressed His6-Prk and His6-Cdc25C proteins using the baculoviral vector expression system. Purified recombinant His6-Prk, but not a kinase-defective mutant His6-Prk(K52R), is capable of strongly phosphorylating His6-Cdc25C in vitro. Co-immunoprecipitation and affinity column chromatography experiments demonstrate that GST-Prk and native Cdc25C interact. When co-infected with His6-Prk and His6-Cdc25C recombinant baculoviruses, sf-9 cells produce His6-Cdc25C antigen with an additional slower mobility band on denaturing polyacrylamide gels compared with cells infected with His6-Cdc25C baculovirus alone. In addition, His6-Cdc25C immunoprecipitated from sf-9 cells co-infected with His6-Prk and His6-Cdc25C baculoviruses, but not with His6-Prk(K52R) and His6-Cdc25C baculoviruses, contains a greatly enhanced kinase activity that phosphorylates His6-Cdc25C in vitro. Moreover, phosphopeptide mapping shows that His6-Prk phosphorylates His6-Cdc25C at two sites in vitro and that the major phosphorylation site co-migrates with the one that is phosphorylated in vivo in asynchonized cells. Further studies reveal that His6-Prk phosphorylates Cdc25C on serine(216), a residue also phosphorylated by Chk1 and Chk2. Together, these observations strongly suggest that Prk's role in mitosis is at least partly mediated through direct regulation of Cdc25C.	Univ Cincinnati, Coll Med, Dept Internal Med, Div Hematol Oncol, Cincinnati, OH 45267 USA; German Canc Res Ctr, D-6900 Heidelberg, Germany	University System of Ohio; University of Cincinnati; Helmholtz Association; German Cancer Research Center (DKFZ)	Dai, W (corresponding author), Univ Cincinnati, Coll Med, Dept Internal Med, Div Hematol Oncol, ML-508,K-pavilion,231 Bethesda Ave, Cincinnati, OH 45267 USA.				PHS HHS [R01-74229] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; FEILOTTER H, 1992, BIOCHEM CELL BIOL, V70, P954, DOI 10.1139/o92-140; FENTON B, 1993, NATURE, V363, P637, DOI 10.1038/363637a0; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; IZUMI T, 1995, MOL BIOL CELL, V6, P215, DOI 10.1091/mbc.6.2.215; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lammer C, 1998, J CELL SCI, V111, P2445; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OGG S, 1994, J BIOL CHEM, V269, P30461; OUYANG B, 1997, J BIOL CHEM, V274, P28646; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X	29	66	70	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	1999	18	44					6029	6036		10.1038/sj.onc.1202983	http://dx.doi.org/10.1038/sj.onc.1202983			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557092				2022-12-25	WOS:000083359100009
J	Foti, M; Cartier, L; Piguet, V; Lew, DP; Carpentier, JL; Trono, D; Krause, KH				Foti, M; Cartier, L; Piguet, V; Lew, DP; Carpentier, JL; Trono, D; Krause, KH			The HIV Nef protein alters Ca2+ signaling in myelomonocytic cells through SH3-mediated protein-protein interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE INHIBITORS; FURA-2-LOADED HUMAN PLATELETS; PROMYELOCYTIC LEUKEMIA-CELLS; VIRUS TYPE-1 INFECTION; FC-GAMMA-RI; IMMUNODEFICIENCY-VIRUS; SRC-FAMILY; ANTIGEN RECEPTOR; CD4 ENDOCYTOSIS; STORE DEPLETION	Human immunodeficiency virus Nef plays an important role in AIDS pathogenesis. In addition to the well known down-regulation of cell surface receptors (CD4, MHCI), Nef is able to alter cellular signaling, Of particular interest for this study is the ability of Nef to bind with a very high affinity to SH3 domains of myelomonocyte-specific protein-tyrosine kinases of the Src family (Src-like PTK). We have therefore investigated Ca2+ signaling in HL60 cells retrovirally transduced with wild type Nef or with a Nef mutant deficient in the SH3-interacting proline-rich motif (Nef((PXXP)4-)). In differentiated HL60 cells, Nef markedly altered cellular Ca2+ signaling; the amount of intracellularly stored Ca2+ was increased, and as a consequence, store-operated Ca2+ influx was decreased. This effect was not observed in undifferentiated HL60 cells or in CEM T-lymphocytes and correlated with the differentiation-induced up-regulation of Src-like PTK, The Nef effect on Ca2+ signaling depended entirely on the integrity of its PXXP motif, The Src-like PTK p56/59(hck) co-immunoprecipitated with both Nef and with the inositol 1,4,5-trisphosphate receptor, providing a possible mechanistic link between the viral protein and intracellular Ca2+ stores of the host cell. Collectively, our results demonstrate that the human immunodeficiency virus 1 Nef protein manipulates intracellular Ca2+ stores through SH3-mediated interactions in myelomonocytic cells.	Univ Geneva, Sch Med, Dept Geriatr, Biol Aging Lab, CH-1225 Geneva, Switzerland; Univ Geneva, Sch Med, Dept Morphol, CH-1225 Geneva, Switzerland; Univ Geneva, Sch Med, Dept Genet & Microbiol, CH-1225 Geneva, Switzerland; Univ Geneva, Sch Med, Div Infect Dis, CH-1225 Geneva, Switzerland	University of Geneva; University of Geneva; University of Geneva; University of Geneva	Krause, KH (corresponding author), Univ Geneva, Sch Med, Dept Geriatr, Biol Aging Lab, 2 Chemin Petit Bel Air, CH-1225 Geneva, Switzerland.	kkrause@cmu.unige.ch	Krause, Karl-Heinz/E-8030-2011	Krause, Karl-Heinz/0000-0002-9033-6768; Foti, Michelangelo/0000-0001-7199-4135	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI034306] Funding Source: NIH RePORTER; NIAID NIH HHS [R37 AI34306] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; AIKEN C, 1995, J VIROL, V69, P5048, DOI 10.1128/JVI.69.8.5048-5056.1995; Aiken C, 1996, VIROLOGY, V217, P293, DOI 10.1006/viro.1996.0116; Alexander L, 1997, J VIROL, V71, P6094, DOI 10.1128/JVI.71.8.6094-6099.1997; Baur AS, 1997, IMMUNITY, V6, P283, DOI 10.1016/S1074-7613(00)80331-3; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; Bian XP, 1997, AM J PHYSIOL-CELL PH, V272, pC1241, DOI 10.1152/ajpcell.1997.272.4.C1241; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; BROWN G, 1994, LEUKEMIA, V8, P806; Collette Y, 1996, J BIOL CHEM, V271, P6333, DOI 10.1074/jbc.271.11.6333; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; COLLINS SJ, 1987, BLOOD, V70, P1233; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DE SK, 1994, J BIOL CHEM, V269, P6656; DURDEN DL, 1995, J IMMUNOL, V154, P4039; ENGLISH BK, 1993, J EXP MED, V178, P1017, DOI 10.1084/jem.178.3.1017; Favre CJ, 1996, J LAB CLIN MED, V128, P19, DOI 10.1016/S0022-2143(96)90110-9; Foti M, 1997, J CELL BIOL, V139, P37, DOI 10.1083/jcb.139.1.37; GREENWAY A, 1995, J VIROL, V69, P1842, DOI 10.1128/JVI.69.3.1842-1850.1995; Hanna Z, 1998, CELL, V95, P163, DOI 10.1016/S0092-8674(00)81748-1; Harris M, 1996, J GEN VIROL, V77, P2379, DOI 10.1099/0022-1317-77-10-2379; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; Iafrate AJ, 1997, EMBO J, V16, P673, DOI 10.1093/emboj/16.4.673; Jayaraman T, 1996, SCIENCE, V272, P1492, DOI 10.1126/science.272.5267.1492; JENNER S, 1994, BIOCHEM J, V303, P337, DOI 10.1042/bj3030337; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; KLOTMAN ME, 1991, P NATL ACAD SCI USA, V88, P5011, DOI 10.1073/pnas.88.11.5011; KRAUSE KH, 1990, CLIN BIOCHEM, V23, P159, DOI 10.1016/0009-9120(90)80030-M; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; LEE KM, 1993, J BIOL CHEM, V268, P9945; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; Lu XB, 1998, IMMUNITY, V8, P647, DOI 10.1016/S1074-7613(00)80569-5; Mandeville J T, 1996, Curr Opin Hematol, V3, P63; Mangasarian A, 1997, IMMUNITY, V6, P67, DOI 10.1016/S1074-7613(00)80243-5; Mariani R, 1996, J VIROL, V70, P7752, DOI 10.1128/JVI.70.11.7752-7764.1996; MEIER RW, 1992, BIOCHEM BIOPH RES CO, V185, P91, DOI 10.1016/S0006-291X(05)80959-3; MIYAURA C, 1981, BIOCHEM BIOPH RES CO, V102, P937, DOI 10.1016/0006-291X(81)91628-4; MUSTELIN T, 1994, IMMUNITY, V1, P351, DOI 10.1016/1074-7613(94)90065-5; Oldridge J, 1998, TRENDS CELL BIOL, V8, P302, DOI 10.1016/S0962-8924(98)01318-X; Pahl HL, 1997, TRENDS BIOCHEM SCI, V22, P63, DOI 10.1016/S0968-0004(96)10073-6; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PerezTerzic C, 1997, BIOESSAYS, V19, P787, DOI 10.1002/bies.950190908; Piguet V, 1999, CELL, V97, P63, DOI 10.1016/S0092-8674(00)80715-1; Piguet V, 1998, EMBO J, V17, P2472, DOI 10.1093/emboj/17.9.2472; RHEE SS, 1994, J VIROL, V68, P5156, DOI 10.1128/JVI.68.8.5156-5163.1994; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; Saksela Kalle, 1997, Frontiers in Bioscience, V2, pD606; Salvi R, 1998, J VIROL, V72, P3646, DOI 10.1128/JVI.72.5.3646-3657.1998; SARGEANT P, 1993, J BIOL CHEM, V268, P18151; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; TSYGANKOV AY, 1993, STEM CELLS, V11, P371, DOI 10.1002/stem.5530110504; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911; WANG AVT, 1994, J EXP MED, V180, P1165, DOI 10.1084/jem.180.3.1165; Welch H, 1997, J BIOL CHEM, V272, P102; WILLMAN CL, 1991, BLOOD, V77, P726; YAMAMOTO T, 1993, IMMUNOL REV, V132, P187, DOI 10.1111/j.1600-065X.1993.tb00843.x; YULE DI, 1994, BIOCHEM BIOPH RES CO, V202, P1697, DOI 10.1006/bbrc.1994.2130; Zhou YP, 1998, J CLIN INVEST, V101, P1623, DOI 10.1172/JCI1245; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	64	31	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34765	34772		10.1074/jbc.274.49.34765	http://dx.doi.org/10.1074/jbc.274.49.34765			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574946	hybrid			2022-12-25	WOS:000083979600040
J	Klein, J; Fasshauer, M; Ito, M; Lowell, BB; Benito, M; Kahn, CR				Klein, J; Fasshauer, M; Ito, M; Lowell, BB; Benito, M; Kahn, CR			beta(3)-adrenergic stimulation differentially inhibits insulin signaling and decreases insulin-induced glucose uptake in brown adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RECEPTOR TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; RAT ADIPOCYTES; 3T3-L1 ADIPOCYTES; C-ALPHA; BETA; TRANSPORT; CELLS; PHOSPHORYLATION	Activity of the sympathetic nervous system is an important factor involved in the pathogenesis of insulin resistance and associated metabolic and vascular abnormalities. In this study, we investigate the molecular basis of cross-talk between beta(2)-adrenergic and insulin signaling systems in mouse brown adipocytes immortalized by SV40 T infection. Insulin-induced tyrosine phosphorylation of the insulin receptor, insulin receptor substrate 1 (IRS-1), and IRS-S was reduced by prestimulation of beta(3)-adrenergic receptors (CL316243). Similarly, insulin-induced IRS-1-associated and phosphotyrosine-associated phosphatidylinositol S-kinase (PI 3-kinase) activity, but not IRS-2-associated PI 3-kinase activity, was reduced by beta(3)-adrenergic prestimulation, Furthermore, insulin-stimulated activation of Akt, but not mitogen-activated protein kinase, was diminished. Insulin-induced glucose uptake was completely inhibited by beta(3)-adrenersc prestimulation. These effects appear to be protein kinase A-dependent. Furthermore inhibition of protein kinase C restored the beta(3)-receptor-mediated reductions in insulin-induced IRS-1 tyrosine phosphorylation and IRS-1-associated PI 3-kinase activity. Together, these findings indicate cross-talk between adrenergic and insulin signaling pathways. This interaction is protein kinase A-dependent and, at least in part, protein kinase C-dependent, and could play an important role in the pathogenesis of insulin resistance associated with sympathetic overactivity and regulation of brown fat metabolism.	Univ Complutense, Fac Farm, E-28040 Madrid, Spain; Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA	Complutense University of Madrid; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Kahn, CR (corresponding author), Univ Complutense, Fac Farm, E-28040 Madrid, Spain.		Kahn, Ronald/AAY-2435-2021; Benito, Manuel/J-5637-2014	Kahn, Ronald/0000-0002-7583-9228; Benito, Manuel/0000-0002-7218-406X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033201, P30DK036836] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 36836, DK 33201] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Bandyopadhyay G, 1999, BIOCHEM J, V337, P461, DOI 10.1042/0264-6021:3370461; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HARING H, 1986, BIOCHEM J, V234, P59; Inoue G, 1998, J BIOL CHEM, V273, P11548, DOI 10.1074/jbc.273.19.11548; ISSAD T, 1995, EUR J BIOCHEM, V234, P108, DOI 10.1111/j.1432-1033.1995.108_c.x; KAHN CR, 1997, INT TXB DIABETES MEL, P437; KAROOR V, 1995, J BIOL CHEM, V270, P25305, DOI 10.1074/jbc.270.43.25305; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; KLEIN HH, 1991, BIOCHEM J, V274, P787, DOI 10.1042/bj2740787; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Levesque L, 1998, J PHARMACOL EXP THER, V287, P425; Lowell BB, 1997, ANNU REV MED, V48, P307; Moyers JS, 1996, J BIOL CHEM, V271, P23111, DOI 10.1074/jbc.271.38.23111; OBERMAIER B, 1987, DIABETOLOGIA, V30, P93; Ohsaka Y, 1997, FEBS LETT, V402, P246, DOI 10.1016/S0014-5793(97)00007-0; Porras A, 1998, MOL ENDOCRINOL, V12, P825, DOI 10.1210/me.12.6.825; Puigserver P, 1996, MOL CELL ENDOCRINOL, V117, P7, DOI 10.1016/0303-7207(95)03727-6; Reaven Gerald M., 1996, New England Journal of Medicine, V334, P374; REHNMARK S, 1990, J BIOL CHEM, V265, P16464; ROHLFS EM, 1995, J BIOL CHEM, V270, P10723, DOI 10.1074/jbc.270.18.10723; Sambrook J., 1990, MOL CLONING LAB MANU, V2nd; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; Shimizu Y, 1998, BIOCHEM J, V330, P397, DOI 10.1042/bj3300397; Shimizu Y, 1996, BIOCHEM J, V314, P485, DOI 10.1042/bj3140485; Shimizu Y, 1997, ENDOCRINOLOGY, V138, P248, DOI 10.1210/en.138.1.248; Singh H, 1997, AM J PHYSIOL-RENAL, V273, pF193, DOI 10.1152/ajprenal.1997.273.2.F193; Strosberg AD, 1997, TRENDS PHARMACOL SCI, V18, P449; Strosberg AD, 1997, J ENDOCRINOL, V155, P221, DOI 10.1677/joe.0.1550221; TANTI JF, 1987, BIOCHEM J, V245, P19, DOI 10.1042/bj2450019; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; Valverde AM, 1998, ENDOCRINOLOGY, V139, P1229, DOI 10.1210/en.139.3.1229; Valverde AM, 1997, MOL ENDOCRINOL, V11, P595, DOI 10.1210/me.11.5.595; Valverde AM, 1998, MOL ENDOCRINOL, V12, P688, DOI 10.1210/me.12.5.688; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wan Y, 1998, J BIOL CHEM, V273, P14533, DOI 10.1074/jbc.273.23.14533; WEBER TM, 1991, CELL SIGNAL, V3, P51, DOI 10.1016/0898-6568(91)90007-H; WHITE MF, 1994, J BIOL CHEM, V269, P1; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619	43	205	209	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34795	34802		10.1074/jbc.274.49.34795	http://dx.doi.org/10.1074/jbc.274.49.34795			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574950	hybrid			2022-12-25	WOS:000083979600044
J	Bennett, MC; Bishop, JF; Leng, Y; Chock, PB; Chase, TN; Mouradian, MM				Bennett, MC; Bishop, JF; Leng, Y; Chock, PB; Chase, TN; Mouradian, MM			Degradation of alpha-synuclein by proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSONS-DISEASE; LEWY BODIES; PROTEIN-DEGRADATION; DEMENTIA; AGGREGATION; UBIQUITIN; MUTATION	Mutations in alpha-synuclein are known to be associated with Parkinson's disease (PD), The coexistence of this neuronal protein with ubiquitin and proteasome subunits in Lewy bodies in sporadic disease suggests that alterations of alpha-synuclein catabolism may contribute to the pathogenesis of PD. The degradation pathway of alpha-synuclein has not been identified nor has the kinetics of this process been described. We investigated the degradation kinetics of both wild-type and A53T mutant 6XHis-tagged alpha-synuclein in transiently transfected SH-SY5Y cells. Degradation of both isoforms followed first-order kinetics over 24 h as monitored by the pulse-chase method. However, the t(1/2) of mutant alpha-synuclein was 50% longer than that of the wild-type protein (p < 0.01). The degradation of both recombinant proteins and endogenous alpha-synuclein in these cells was blocked by the selective proteasome inhibitor beta-lactone (40 mu M), indicating that both wild-type and A53T mutant alpha-synuclein are degraded by the ubiquitin-proteasome pathway. The slower degradation of mutant alpha-synuclein provides a kinetic basis for its intracellular accumulation, thus favoring its aggregation.	NINDS, Expt Therapeut Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Mouradian, MM (corresponding author), NINDS, Expt Therapeut Branch, NIH, 10 Ctr Dr,MSC 1046,Bldg 10,Rm 5C-116, Bethesda, MD 20892 USA.	mmm@helix.nih.gov		Mouradian, M. Maral/0000-0002-9937-412X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002826] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baba M, 1998, AM J PATHOL, V152, P879; BIEDLER JL, 1978, CANCER RES, V38, P3751; CIASSON BI, 1999, J BIOL CHEM, V274, P7619; Ciechanover A, 1995, COLD SPRING HARB SYM, V60, P491, DOI 10.1101/SQB.1995.060.01.053; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Crowther RA, 1998, FEBS LETT, V436, P309, DOI 10.1016/S0014-5793(98)01146-6; Dick LR, 1997, J BIOL CHEM, V272, P182; Franklin JL, 1998, J CELL BIOL, V142, P1313, DOI 10.1083/jcb.142.5.1313; Goldberg AL, 1997, MOL BIOL REP, V24, P69, DOI 10.1023/A:1006860828265; Ii K, 1997, J NEUROPATH EXP NEUR, V56, P125, DOI 10.1097/00005072-199702000-00002; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; KUZUHARA S, 1988, ACTA NEUROPATHOL, V75, P345, DOI 10.1007/BF00687787; LENNOX G, 1989, J NEUROL NEUROSUR PS, V52, P67, DOI 10.1136/jnnp.52.1.67; LOWE J, 1988, J PATHOL, V155, P9, DOI 10.1002/path.1711550105; MARTEGANI E, 1979, J BIOL CHEM, V254, P7047; Mayer R J, 1989, Prog Clin Biol Res, V317, P809; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rivett AJ, 1997, MOL BIOL REP, V24, P99, DOI 10.1023/A:1006814306401; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Trojanowski JQ, 1998, ARCH NEUROL-CHICAGO, V55, P151, DOI 10.1001/archneur.55.2.151; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Weissman AM, 1997, IMMUNOL TODAY, V18, P189, DOI 10.1016/S0167-5699(97)84666-X; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509	23	355	369	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					33855	33858		10.1074/jbc.274.48.33855	http://dx.doi.org/10.1074/jbc.274.48.33855			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567343	hybrid			2022-12-25	WOS:000083857500008
J	Hirota, J; Furuichi, T; Mikoshiba, K				Hirota, J; Furuichi, T; Mikoshiba, K			Inositol 1,4,5-trisphosphate receptor type 1 is a substrate for caspase-3 and is cleaved during apoptosis in a caspase-3-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECONSTITUTED LIPID VESICLES; MONOCLONAL-ANTIBODIES; MORPHOLOGICAL-CHANGES; DNA FRAGMENTATION; ALPHA-FODRIN; CELLS; TRISPHOSPHATE; INVOLVEMENT; DEGRADATION; EXPRESSION	The inositol 1,4,5-trisphosphate (IP3) receptor (IP3R), an IP3-gated Ca2+ channel located on intracellular Ca2+ stores, modulates intracellular Ca2+ signaling. During apoptosis of the human T-cell line, Jurkat cells, as induced by staurosporine or Fas ligation, IP3R type 1 (LP(3)R1) was found to be cleaved. IP(3)R1 degradation during apoptosis was inhibited by pretreatment of Jurkat cells with the caspase-3 (-like protease) inhibitor, AcDEVD-CHO, and the caspases inhibitor, z-VAD-CH2DCB but not by the caspase-1 (-like protease) inhibitor, Ac-YVAD-CHO, suggesting that IP(3)R1 was cleaved by a caspase-3 (-like) protease. The recombinant caspase-3 cleaved IP(3)R1 in vitro to produce a fragmentation pattern consistent with that seen in Jurkat cells undergoing apoptosis. N-terminal amino acid sequencing revealed that the major cleavage site is (DEVD)-D-1888*R-1892 (mouse IP(3)R1), which involves consensus sequence for caspase-3 cleavage (DEVD). To determine whether IP(3)R1 is cleaved by caspase-3 or is proteolyzed in its absence by other caspases, we examined the cleavage of IP(3)R1 during apoptosis in the MCF-7 breast carcinoma cell line, which has genetically lost caspase-3, Tumor necrosis factor-alpha- or staurosporine-induced apoptosis in caspase-3-deficient MCF-7 cells failed to demonstrate cleavage of IP(3)R1, In contrast, MCF-7/Casp-3 cells stably expressing caspase-3 showed IP(3)R1 degradation upon apoptotic stimuli. Therefore IP(3)R1 is a newly identified caspase-3 substrate, and caspase-3 is essential for the cleavage of IP(3)R1 during apoptosis. This cleavage resulted in a decrease in the channel activity as IP(3)R1 was digested, indicating that caspase-3 inactivates IP(3)R1 channel functions.	Univ Tokyo, Inst Med Sci, Dept Mol Neurobiol, Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Corp, Mikoshiba Calciosignal Net Project, Exploratory Res Adv Technol, Bunkyo Ku, Tokyo 1130021, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Hirota, J (corresponding author), Univ Tokyo, Inst Med Sci, Dept Mol Neurobiol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.		Furuichi, Teiichi/B-5086-2014; Hirota, Junji/G-1357-2019; Mikoshiba, Katsuhiko/N-7943-2015; Hirota, Junji/O-9315-2019	Furuichi, Teiichi/0000-0002-9676-1888; Hirota, Junji/0000-0002-5741-0655; Hirota, Junji/0000-0002-5741-0655				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HIROTA J, 1995, J BIOL CHEM, V270, P19046, DOI 10.1074/jbc.270.32.19046; Hirota J, 1998, BIOCHEM J, V333, P615, DOI 10.1042/bj3330615; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Mikoshiba K, 1997, CURR OPIN NEUROBIOL, V7, P339, DOI 10.1016/S0959-4388(97)80061-X; NAKADE S, 1994, J BIOL CHEM, V269, P6735; NAKADE S, 1991, BIOCHEM J, V277, P125, DOI 10.1042/bj2770125; Porter AG, 1997, BIOESSAYS, V19, P501, DOI 10.1002/bies.950190609; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; SUGIYAMA T, 1994, FEBS LETT, V349, P191, DOI 10.1016/0014-5793(94)00662-8; SUGIYAMA T, 1994, FEBS LETT, V354, P149, DOI 10.1016/0014-5793(94)01099-4; Tang D, 1998, J BIOL CHEM, V273, P28549, DOI 10.1074/jbc.273.44.28549; Wojcikiewicz RJH, 1996, J BIOL CHEM, V271, P16652, DOI 10.1074/jbc.271.28.16652; YAMAMOTOHINO M, 1994, RECEPTOR CHANNEL, V2, P9; Yoshikawa F, 1999, J BIOL CHEM, V274, P316, DOI 10.1074/jbc.274.1.316	28	101	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34433	34437		10.1074/jbc.274.48.34433	http://dx.doi.org/10.1074/jbc.274.48.34433			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567423	hybrid			2022-12-25	WOS:000083857500088
J	Zhong, M; Munzer, JS; Basak, A; Benjannet, S; Mowla, SJ; Decroly, E; Chretien, M; Seidah, NG				Zhong, M; Munzer, JS; Basak, A; Benjannet, S; Mowla, SJ; Decroly, E; Chretien, M; Seidah, NG			The prosegments of furin and PC7 as potent inhibitors of proprotein convertases - In vitro and ex vivo assessment of their efficacy and selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENVELOPE GLYCOPROTEIN GP160; ENDOPLASMIC-RETICULUM; PROHORMONE CONVERTASE-1; PRECURSOR PROTEINS; CELL-SURFACE; IN-VITRO; SUBTILISIN; ACTIVATION; CLEAVAGE; PEPTIDE	All proprotein convertases (PCs) of the subtilisin/kexin family contain an N-terminal prosegment that is presumed to act both as an intramolecular chaperone and an inhibitor of its parent enzyme. In this work, we examined inhibition by purified, recombinant bacterial prosegments of furin and PC7 on the in vitro processing of either the fluorogenic peptide pERTKR-MCA or the human immunodeficiency virus envelope glycoprotein gp160. These propeptides are potent inhibitors that display measurable selectivity toward specific proprotein convertases. Small, synthetic decapeptides derived from the C termini of the prosegments are also potent inhibitors, albeit less so than the full-length proteins, and the C-terminal P1 arginine is essential for inhibition. The bacterial, recombinant prosegments were also used to generate specific antisera, allowing us to study the intracellular metabolic fate of the prosegments of furin and PC7 expressed via vaccinia virus constructs. These vaccinia virus recombinants, along with transient transfectants of the preprosegments of furin and PC7, efficiently inhibited the ex vivo processing of the neurotrophins nerve growth factor and brain-derived neurotrophic factor. Thus, we have demonstrated for the first time that PC prosegments, expressed ex vivo as independent domains, can act in trans to inhibit precursor maturation by intracellular PCs.	Univ Montreal, Clin Res Inst Montreal, Biochem Lab, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Clin Res Inst Montreal, Lab Mol Neuroendocrinol, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Clin Res Inst Montreal, Prot Engn Network Ctr Excellence, Montreal, PQ H2W 1R7, Canada; Ottawa Hosp, Loeb Hlth Res Inst, Prot Chem Ctr, Ottawa, ON K1Y 4K9, Canada; Sch Med, Ottawa, ON K1Y 4K9, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Ottawa; Ottawa Hospital Research Institute	Seidah, NG (corresponding author), Univ Montreal, Clin Res Inst Montreal, Biochem Lab, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	mchetien@lri.ca; seidahn@ircm.qc.ca	Seidah, Nabil/I-3596-2013; Mowla, Seyed Javad/B-2242-2009	Seidah, Nabil/0000-0001-6503-9342; DECROLY, Etienne/0000-0002-6046-024X; Mowla, Seyed Javad/0000-0002-3300-6332; CHRETIEN, Michel/0000-0002-8588-4460				Abrami L, 1998, J BIOL CHEM, V273, P32656, DOI 10.1074/jbc.273.49.32656; Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; Apletalina E, 1998, J BIOL CHEM, V273, P26589, DOI 10.1074/jbc.273.41.26589; Basak A, 1997, J PEPT RES, V49, P596; Basak A, 1999, PEPTIDES: FRONTIERS OF PEPTIDES SCIENCE, P676; Benjannet S, 1997, J BIOL CHEM, V272, P26210, DOI 10.1074/jbc.272.42.26210; Boudreault A, 1998, PROTEIN EXPRES PURIF, V14, P353, DOI 10.1006/prep.1998.0964; Boudreault A, 1998, J BIOL CHEM, V273, P31574, DOI 10.1074/jbc.273.47.31574; Campan M, 1996, BIOCHEMISTRY-US, V35, P3797, DOI 10.1021/bi952552d; CHAUDHURI B, 1992, BIOCHEM BIOPH RES CO, V183, P212, DOI 10.1016/0006-291X(92)91630-9; CHIRON MF, 1994, J BIOL CHEM, V269, P18167; CHRETIEN M, 1995, P ASSOC AM PHYSICIAN, V107, P47; CORNISHB.A, 1974, BIOCHEM J, V137, P143, DOI 10.1042/bj1370143; CREEMERS JWM, 1995, J BIOL CHEM, V270, P2695, DOI 10.1074/jbc.270.6.2695; Dahlen JR, 1998, J BIOL CHEM, V273, P1851, DOI 10.1074/jbc.273.4.1851; DAVISON AJ, 1990, NUCLEIC ACIDS RES, V18, P4285, DOI 10.1093/nar/18.14.4285; Decroly E, 1997, FEBS LETT, V405, P68, DOI 10.1016/S0014-5793(97)00156-7; Decroly E, 1996, J BIOL CHEM, V271, P30442, DOI 10.1074/jbc.271.48.30442; DECROLY E, 1994, J BIOL CHEM, V269, P12240; DIXON M, 1953, BIOCHEM J, V55, P161, DOI 10.1042/bj0550161; Fricker LD, 1996, J BIOL CHEM, V271, P30619, DOI 10.1074/jbc.271.48.30619; Hallenberger S, 1997, J VIROL, V71, P1036, DOI 10.1128/JVI.71.2.1036-1045.1997; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HOFFMANN W, 1983, EMBO J, V2, P711, DOI 10.1002/j.1460-2075.1983.tb01489.x; IBRAHIMI IM, 1986, EUR J BIOCHEM, V155, P571, DOI 10.1111/j.1432-1033.1986.tb09526.x; JEAN F, 1995, BIOCHEM J, V307, P689, DOI 10.1042/bj3070689; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; JEAN F, 1995, J BIOL CHEM, V270, P19225, DOI 10.1074/jbc.270.33.19225; Khan AR, 1998, PROTEIN SCI, V7, P815; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; Lei YH, 1999, DNA CELL BIOL, V18, P175, DOI 10.1089/104454999315565; LIU B, 1995, INT J CANCER, V63, P276, DOI 10.1002/ijc.2910630222; LU WY, 1993, J BIOL CHEM, V268, P14583; Marcinkiewicz M, 1998, MOL BRAIN RES, V59, P229, DOI 10.1016/S0169-328X(98)00141-7; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Mowla SJ, 1999, J NEUROSCI, V19, P2069; Munzer JS, 1997, J BIOL CHEM, V272, P19672, DOI 10.1074/jbc.272.32.19672; Nachtigal MW, 1996, P NATL ACAD SCI USA, V93, P7711, DOI 10.1073/pnas.93.15.7711; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; OKUN MM, 1990, J BIOL CHEM, V265, P7478; POWER SD, 1986, P NATL ACAD SCI USA, V83, P3096, DOI 10.1073/pnas.83.10.3096; Powner D, 1998, MOL CELL BIOL, V18, P400, DOI 10.1128/MCB.18.1.400; ROMPAEY LV, 1997, BIOCHEM J, V326, P507; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; Seidah NG, 1998, ANN NY ACAD SCI, V839, P9, DOI 10.1111/j.1749-6632.1998.tb10727.x; Seidah NG, 1996, BIOCHEM J, V314, P951, DOI 10.1042/bj3140951; Seidah NG, 1996, FEBS LETT, V379, P247, DOI 10.1016/0014-5793(95)01520-5; Seidah NG, 1999, P NATL ACAD SCI USA, V96, P1321, DOI 10.1073/pnas.96.4.1321; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; SEIDAH NG, 1995, INTRAMOLECULAR CHAPE, P181; SEIDAH NG, 1998, MOL B INT U, V2, P49; Shinde U., 1995, INTRAMOLECULAR CHAPE, P1; Siezen RJ, 1997, PROTEIN SCI, V6, P501; SIEZEN RJ, 1995, INTRAMOLECULAR CHAPE, P233; SOHL JL, 1995, INTRAMOLECULAR CHAPE, P61; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; STRAUSBERG S, 1993, BIOCHEMISTRY-US, V32, P8112, DOI 10.1021/bi00083a009; vandeLoo JWHP, 1997, J BIOL CHEM, V272, P27116, DOI 10.1074/jbc.272.43.27116; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; Volchkov VE, 1998, P NATL ACAD SCI USA, V95, P5762, DOI 10.1073/pnas.95.10.5762; Vollenweider F, 1996, BIOCHEM J, V314, P521, DOI 10.1042/bj3140521; Zhong M, 1996, FEBS LETT, V396, P31, DOI 10.1016/0014-5793(96)01059-9; ZHOU A, 1995, J BIOL CHEM, V270, P21509, DOI 10.1074/jbc.270.37.21509	65	109	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					33913	33920		10.1074/jbc.274.48.33913	http://dx.doi.org/10.1074/jbc.274.48.33913			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567353	hybrid			2022-12-25	WOS:000083857500018
J	Carmona, M; de Lorenzo, V; Bertoni, G				Carmona, M; de Lorenzo, V; Bertoni, G			Recruitment of RNA polymerase is a rate-limiting step for the activation of the sigma(54) promoter Pu of Pseudomonas putida	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; ENHANCER-BINDING PROTEIN; IN-VITRO ACTIVITIES; ESCHERICHIA-COLI; TRANSCRIPTIONAL ACTIVATOR; TOL PLASMID; DNA; NIFA; XYLR; GENES	The activity of the sigma(54)-promoter Pu of Pseudomonas putida was examined in vitro with a DNA template lacking upstream activating sequences, such that RNA polymerase can be activated by the enhancer-binding protein Xy1R only from solution. Although the transcription activation pathway in this system lacked the step of integration host factor (IHF)-mediated looping of the Xy1R DNA complex toward the prebound RNA polymerase, IHF still stimulated promoter activity. The positive effect of IHF became evident not only with Xy1R from solution, but also with other sigma(54)-dependent activators such as NtrC and NifA Furthermore, an equivalent outcome was shown for the nonspecific DNA-binding protein HU. This stimulation of transcription in the absence of the enhancer was traced to the recruitment of RNA polymerase (i.e. increased efficiency of formation of closed complexes) brought about by IHF or HU binding. Thus, under limiting concentrations of the polymerase, the factor-mediated binding of the enzyme to Pu seems to enter a kinetic checkpoint in the system that prevents the Xy1R-mediated formation of an open complex.	CSIC, Ctr Nacl Biotecnol, Dept Microbial Biotechnol, Madrid 28049, Spain; Univ Milan, Dipartimento Genet & Biol Microirganismi, I-20133 Milan, Italy	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); University of Milan	de Lorenzo, V (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Microbial Biotechnol, Campus Cantoblanco, Madrid 28049, Spain.		BERTONI, GIOVANNI/J-3437-2012	BERTONI, GIOVANNI/0000-0001-5761-9494; Carmona, Manuel/0000-0002-1591-7618; de Lorenzo, Victor/0000-0002-6041-2731				AUSTIN S, 1994, J BACTERIOL, V176, P3460, DOI 10.1128/JB.176.12.3460-3465.1994; BERGER DK, 1994, P NATL ACAD SCI USA, V91, P103, DOI 10.1073/pnas.91.1.103; Bertoni G, 1998, EMBO J, V17, P5120, DOI 10.1093/emboj/17.17.5120; BUCK M, 1992, MOL MICROBIOL, V8, P287; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; Calb R, 1996, J BACTERIOL, V178, P6319, DOI 10.1128/jb.178.21.6319-6326.1996; Carmona M, 1996, J MOL BIOL, V261, P348, DOI 10.1006/jmbi.1996.0468; CLAVERIEMARTIN F, 1992, J MOL BIOL, V227, P996, DOI 10.1016/0022-2836(92)90516-M; CLAVERIEMARTIN F, 1991, P NATL ACAD SCI USA, V88, P1631, DOI 10.1073/pnas.88.5.1631; DeHaseth PL, 1998, J BACTERIOL, V180, P3019, DOI 10.1128/JB.180.12.3019-3025.1998; DELORENZO V, 1991, EMBO J, V10, P1159, DOI 10.1002/j.1460-2075.1991.tb08056.x; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; Dworkin J, 1998, GENE DEV, V12, P894, DOI 10.1101/gad.12.6.894; ELLIOTT T, 1984, CELL, V36, P211, DOI 10.1016/0092-8674(84)90091-6; Farewell A, 1998, MOL MICROBIOL, V29, P1039, DOI 10.1046/j.1365-2958.1998.00990.x; FERNANDEZ S, 1995, MOL MICROBIOL, V16, P205, DOI 10.1111/j.1365-2958.1995.tb02293.x; Geiselmann J, 1997, BIOL CHEM, V378, P599; GOBER JW, 1990, GENE DEV, V4, P1494, DOI 10.1101/gad.4.9.1494; Gralla JD, 1996, ESCHERICHIA COLI SAL, P1232; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; Maxam A M, 1980, Methods Enzymol, V65, P499; MORETT E, 1993, J BACTERIOL, V175, P6067, DOI 10.1128/JB.175.19.6067-6074.1993; North AK, 1997, J MOL BIOL, V267, P17, DOI 10.1006/jmbi.1996.0838; PEREZMARTIN J, 1994, J BIOL CHEM, V269, P22657; PerezMartin J, 1997, ANNU REV MICROBIOL, V51, P593, DOI 10.1146/annurev.micro.51.1.593; PerezMartin J, 1996, J MOL BIOL, V258, P575, DOI 10.1006/jmbi.1996.0270; PEREZMARTIN J, 1995, P NATL ACAD SCI USA, V92, P7277, DOI 10.1073/pnas.92.16.7277; PerezMartin J, 1997, J BACTERIOL, V179, P2757, DOI 10.1128/jb.179.8.2757-2760.1997; PREOBRAJENSKAYA O, 1994, MOL MICROBIOL, V13, P459, DOI 10.1111/j.1365-2958.1994.tb00440.x; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Record Jr MT, 1996, ESCHERICHIA COLI SAL, P792; Sambrook J., 2002, MOL CLONING LAB MANU; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919	34	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33790	33794		10.1074/jbc.274.47.33790	http://dx.doi.org/10.1074/jbc.274.47.33790			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559273	hybrid			2022-12-25	WOS:000083745200089
J	Gerton, JL; Herschlag, D; Brown, PO				Gerton, JL; Herschlag, D; Brown, PO			Stereospecificity of reactions catalyzed by HIV-1 integrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; VIRAL-DNA ENDS; TYPE-1 INTEGRASE; RETROVIRAL DNA; IN-VITRO; V(D)J RECOMBINATION; ESCHERICHIA-COLI; PROTEIN INVITRO; STRAND TRANSFER; TARGET SITE	The retroviral integrase catalyzes two successive chemical reactions essential for integration of the retroviral genome into a host chromosome: 3' end processing, in which a dinucleotide is cleaved from each 3' end of the viral DNA; and the integration reaction itself, in which the resulting recessed 3' ends of the viral DNA are joined to the host DNA. We have examined the stereospecificity of human immunodeficiency virus type 1 integrase for phosphorothioate substrates in these reactions and in a third reaction, disintegration, which is macroscopically the reverse of integration. Integrase preferentially catalyzed end processing and integration of a substrate with the (R-p)-phosphorothioate stereoisomer at the reaction center and disintegration of a substrate with an (S-p)-phosphorothiate at the reaction center. These results suggest a model for the architecture of the active site of integrase, and its interactions with key features of the viral and target DNA.	Stanford Univ, Med Ctr, Dept Biochem, Stanford, CA 94305 USA; Stanford Univ, Med Ctr, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Med Ctr, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Stanford University; Howard Hughes Medical Institute; Stanford University; Stanford University	Brown, PO (corresponding author), Stanford Univ, Med Ctr, Dept Biochem, Stanford, CA 94305 USA.							Acel A, 1998, J VIROL, V72, P2062, DOI 10.1128/JVI.72.3.2062-2071.1998; BOR YC, 1995, P NATL ACAD SCI USA, V92, P10334, DOI 10.1073/pnas.92.22.10334; Brown P. O., 1997, P161; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; BUJACZ G, 1995, J MOL BIOL, V253, P333, DOI 10.1006/jmbi.1995.0556; Bujacz G, 1996, STRUCTURE, V4, P89, DOI 10.1016/S0969-2126(96)00012-3; BURGERS PMJ, 1979, BIOCHEMISTRY-US, V18, P592, DOI 10.1021/bi00571a007; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; CHOW SA, 1994, J VIROL, V68, P3896, DOI 10.1128/JVI.68.6.3896-3907.1994; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; CHOW SA, 1994, J VIROL, V68, P7869, DOI 10.1128/JVI.68.12.7869-7878.1994; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; DENNIS EA, 1966, J AM CHEM SOC, V88, P3432, DOI 10.1021/ja00966a046; DOTAN I, 1995, J VIROL, V69, P456, DOI 10.1128/JVI.69.1.456-468.1995; DRELICH M, 1992, VIROLOGY, V188, P459, DOI 10.1016/0042-6822(92)90499-F; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; ELLISON V, 1994, P NATL ACAD SCI USA, V91, P7316, DOI 10.1073/pnas.91.15.7316; ELLISON V, 1995, J BIOL CHEM, V270, P3320, DOI 10.1074/jbc.270.7.3320; ENGELMAN A, 1995, J VIROL, V69, P5908, DOI 10.1128/JVI.69.9.5908-5911.1995; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; Gerton JL, 1997, J BIOL CHEM, V272, P25809, DOI 10.1074/jbc.272.41.25809; JONSSON CB, 1993, J VIROL, V67, P5562, DOI 10.1128/JVI.67.9.5562-5571.1993; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LAFEMINA RL, 1991, J VIROL, V65, P5624, DOI 10.1128/JVI.65.10.5624-5630.1991; LEAVITT AD, 1992, J VIROL, V66, P2359, DOI 10.1128/JVI.66.4.2359-2368.1992; LEAVITT AD, 1993, J BIOL CHEM, V268, P2113; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MULLER HP, 1994, EMBO J, V13, P4707; POTTER BVL, 1983, BIOCHEMISTRY-US, V22, P1369, DOI 10.1021/bi00275a008; PRUSS D, 1994, J BIOL CHEM, V269, P25031; PRUSS D, 1994, P NATL ACAD SCI USA, V91, P5913, DOI 10.1073/pnas.91.13.5913; PRYCIAK PM, 1992, CELL, V69, P769, DOI 10.1016/0092-8674(92)90289-O; Ramsden DA, 1996, EMBO J, V15, P3197, DOI 10.1002/j.1460-2075.1996.tb00682.x; ROTH MJ, 1989, CELL, V58, P47, DOI 10.1016/0092-8674(89)90401-7; SAVILAHTI H, 1995, EMBO J, V14, P4893, DOI 10.1002/j.1460-2075.1995.tb00170.x; Scottoline BP, 1997, GENE DEV, V11, P371, DOI 10.1101/gad.11.3.371; SHERMAN PA, 1990, P NATL ACAD SCI USA, V87, P5119, DOI 10.1073/pnas.87.13.5119; SHERMAN PA, 1992, J VIROL, V66, P3593, DOI 10.1128/JVI.66.6.3593-3601.1992; VANDENENT FMI, 1994, J VIROL, V68, P7825, DOI 10.1128/JVI.68.12.7825-7832.1994; VANGENT DC, 1992, P NATL ACAD SCI USA, V89, P9598, DOI 10.1073/pnas.89.20.9598; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; VINCENT KA, 1993, J VIROL, V67, P425, DOI 10.1128/JVI.67.1.425-437.1993; VINK C, 1991, NUCLEIC ACIDS RES, V19, P6691, DOI 10.1093/nar/19.24.6691	47	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33480	33487		10.1074/jbc.274.47.33480	http://dx.doi.org/10.1074/jbc.274.47.33480			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559232	hybrid			2022-12-25	WOS:000083745200048
J	Minke, WE; Hong, F; Verlinde, CLMJ; Hol, WGJ; Fan, E				Minke, WE; Hong, F; Verlinde, CLMJ; Hol, WGJ; Fan, E			Using a galactose library for exploration of a novel hydrophobic pocket in the receptor binding site of the Escherichia coli heat-labile enterotoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLERA-TOXIN; CRYSTAL-STRUCTURE; GLYCOSIDES; BOND	The binding of the B subunits of Escherichia coli heat-labile enterotoxin (LT) to epithelial cells lining the intestines is a critical step for the toxin to invade the host. This mechanism suggests that molecules which possess high affinity to the receptor binding site of the toxin would be good leads for the development of therapeutics against LT. The natural receptor for LT is the complex ganglioside GM1, which has galactose as its terminal sugar. A chemical library targeting a novel hydrophobic pocket in the receptor binding site of LT was constructed based on galactose derivatives and screened for high affinity to the receptor binding site of LT. This screening identified compounds that have 2-3 orders of magnitude higher affinity toward the receptor binding site of LT than the parent compound, galactose. The present findings will pave the way for developing simple and easily synthesizable molecules, instead of complex oligosaccharides, as drugs and/or prophylactics against LT caused disease.	Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; Univ Washington, Biomol Struct Ctr, Seattle, WA 98195 USA; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Fan, E (corresponding author), Univ Washington, Dept Biol Struct, Box 357742, Seattle, WA 98195 USA.	erkang@u.washington.edu	VERLINDE, CHRISTOPHE LMJ/J-5796-2013	VERLINDE, CHRISTOPHE LMJ/0000-0002-7790-3203	NIAID NIH HHS [AI34501] Funding Source: Medline; NIGMS NIH HHS [GM54618] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI034501, R01AI034501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054618] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen F.H., 1993, CHEM DESIGN AUTOMATI, V8, P31; APPARU M, 1981, CAN J CHEM, V59, P314, DOI 10.1139/v81-049; Bowen WP, 1995, TRENDS PHARMACOL SCI, V16, P413, DOI 10.1016/S0165-6147(00)89091-4; CHERNYAK AY, 1992, CARBOHYD RES, V223, P303, DOI 10.1016/0008-6215(92)80029-Z; DILLER DJ, 1999, IN PRESS J COMPUT CH; Feil IK, 1996, MOL MICROBIOL, V20, P823, DOI 10.1111/j.1365-2958.1996.tb02520.x; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; GOODSELL DS, 1990, PROTEINS, V8, P195, DOI 10.1002/prot.340080302; HOLMGREN J, 1992, GASTROENTEROL CLIN N, V21, P283; Hooft RWW, 1996, PROTEINS, V26, P363; INAZU T, 1993, SYNLETT, P869; Merritt EA, 1998, J MOL BIOL, V282, P1043, DOI 10.1006/jmbi.1998.2076; Merritt EA, 1997, STRUCTURE, V5, P1485, DOI 10.1016/S0969-2126(97)00298-0; MERRITT EA, 1994, MOL MICROBIOL, V13, P745, DOI 10.1111/j.1365-2958.1994.tb00467.x; Minke WE, 1999, BIOCHEMISTRY-US, V38, P5684, DOI 10.1021/bi982649a; MOOCK TE, 1994, J CHEM INF COMP SCI, V34, P184, DOI 10.1021/ci00017a024; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; SIXMA TK, 1992, NATURE, V355, P561, DOI 10.1038/355561a0; SPANGLER BD, 1992, MICROBIOL REV, V56, P622, DOI 10.1128/MMBR.56.4.622-647.1992; SUGII S, 1989, CAN J MICROBIOL, V35, P670, DOI 10.1139/m89-109; SUSAKI H, 1994, CHEM PHARM BULL, V42, P2090; TVAROSKA I, 1989, ADV CARBOHYD CHEM BI, V47, P45; UESAKA Y, 1994, MICROB PATHOGENESIS, V16, P71, DOI 10.1006/mpat.1994.1007; VandenAkker F, 1997, PROTEIN SCI, V6, P2644; WANKE CA, 1987, BAILLIERE CLIN GASTR, V1, P335, DOI 10.1016/0950-3528(87)90008-X	25	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33469	33473		10.1074/jbc.274.47.33469	http://dx.doi.org/10.1074/jbc.274.47.33469			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559230	hybrid			2022-12-25	WOS:000083745200046
J	Kaluz, S; Kaluzova, M; Opavsky, R; Pastorekova, S; Gibadulinova, A; Dequiedt, F; Kettmann, R; Pastorek, J				Kaluz, S; Kaluzova, M; Opavsky, R; Pastorekova, S; Gibadulinova, A; Dequiedt, F; Kettmann, R; Pastorek, J			Transcriptional regulation of the MN/CA 9 gene coding for the tumor-associated carbonic anhydrase IX - Identification and characterization of a proximal silencer element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL-CELL CARCINOMA; NEGATIVE REGULATION; NUCLEAR FACTOR-1; DIAGNOSTIC BIOMARKER; DOWN-REGULATION; MN ANTIGEN; EXPRESSION; PROMOTER; PROTEIN; ACTIVATION	The MN/CA 9 (MN) gene encodes a tumor-associated isoenzyme of the carbonic anhydrase family. Functional characterization of the 3.5-kilobase pair MN 5' upstream region by deletion analysis led to the identification of the -173 to +31 fragment as the MN promoter. lie vitro DNase I footprinting revealed the presence of five protected regions (PRs) within the MN promoter. Detailed deletion analysis of the promoter identified PR1 and PR2 (numbered from the transcription start) as the most critical for transcriptional activity. PR4 negatively affected transcription, since its deletion led to increased promoter activity and was confirmed to function as a promoter-, position, and orientation-independent silencer element. Mutational analysis indicated that the direct repeat AGGGCacAGGGC is required for efficient repressor binding. Two components of the repressor complex (35 and 42 kDa) were found to be in direct contact with PR4 by UV cross-linking. Increased cell density, known to induce MN expression, did not affect levels of PR4 binding in HeLa cells. Significantly reduced repressor level seems to be responsible for MN up-regulation in the case of tumorigenic CGL3 as compared with nontumorigenic CGL1 HeLa x normal fibroblast hybrid cells.	Slovak Acad Sci, Inst Virol, Bratislava 84246, Slovakia; Fac Agron, Dept Mol Biol, B-5030 Gembloux, Belgium	Slovak Academy of Sciences	Kaluz, S (corresponding author), Slovak Acad Sci, Inst Virol, Dubravska Cesta 9, Bratislava 84246, Slovakia.		Pastorek, Jaromir/AAR-2647-2020; Pastorekova, Silvia/C-6685-2018	Dequiedt, Franck/0000-0003-1234-7477; Kaluz, Stefan/0000-0002-6273-3766				Adam E, 1996, J VIROL, V70, P1990, DOI 10.1128/JVI.70.3.1990-1999.1996; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOAM DSW, 1990, J BIOL CHEM, V265, P8285; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; CHEN JH, 1993, ONCOGENE, V8, P133; CLARK AR, 1993, BIOCHEM J, V296, P521, DOI 10.1042/bj2960521; ELDEIRY WS, 1992, NAT GENET, V1, P44; Furlong EEM, 1996, J BIOL CHEM, V271, P29688, DOI 10.1074/jbc.271.47.29688; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; Ivanov SV, 1998, P NATL ACAD SCI USA, V95, P12596, DOI 10.1073/pnas.95.21.12596; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; LIAO SY, 1994, AM J PATHOL, V145, P598; Liao SY, 1997, CANCER RES, V57, P2827; Lieskovska J, 1998, INT J ONCOL, V13, P1081; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; Malone CS, 1997, P NATL ACAD SCI USA, V94, P12314, DOI 10.1073/pnas.94.23.12314; MATHEYPREVOT B, 1990, P NATL ACAD SCI USA, V13, P5040; McKiernan JM, 1997, CANCER RES, V57, P2362; Morel Y, 1998, J BIOL CHEM, V273, P26969, DOI 10.1074/jbc.273.41.26969; Mukhopadhyay D, 1998, GENE EXPRESSION, V7, P53; Ogbourne S, 1998, BIOCHEM J, V331, P1; Opavsky R, 1996, GENOMICS, V33, P480, DOI 10.1006/geno.1996.0223; PAN WT, 1990, J BIOL CHEM, V265, P7022; PASTOREK J, 1994, ONCOGENE, V9, P2877; PASTOREKOVA S, 1992, VIROLOGY, V187, P620, DOI 10.1016/0042-6822(92)90464-Z; Pastorekova S, 1997, GASTROENTEROLOGY, V112, P398, DOI 10.1053/gast.1997.v112.pm9024293; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Rajas F, 1998, BIOCHEM J, V333, P77, DOI 10.1042/bj3330077; RAMJI DP, 1991, NUCLEIC ACIDS RES, V19, P1139, DOI 10.1093/nar/19.5.1139; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; Sambrook J., 2002, MOL CLONING LAB MANU; SATO K, 1992, MOL CELL BIOL, V12, P2525, DOI 10.1128/MCB.12.6.2525; SAWADA S, 1994, CELL, V77, P917, DOI 10.1016/0092-8674(94)90140-6; SCHMIDTGOFF CM, 1993, J BACTERIOL, V175, P1806, DOI 10.1128/JB.175.6.1806-1813.1993; SIRUMCONNOLLY K, 1991, NUCLEIC ACIDS RES, V19, P335, DOI 10.1093/nar/19.2.335; STANBRIDGE EJ, 1981, SOMAT CELL GENET, V7, P699, DOI 10.1007/BF01538758; Tanaka M, 1996, P NATL ACAD SCI USA, V93, P4311, DOI 10.1073/pnas.93.9.4311; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Tureci O, 1998, P NATL ACAD SCI USA, V95, P7608, DOI 10.1073/pnas.95.13.7608; Turner JR, 1997, HUM PATHOL, V28, P740, DOI 10.1016/S0046-8177(97)90185-4; WANG WD, 1991, MOL CELL BIOL, V11, P4561, DOI 10.1128/MCB.11.9.4561; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; YANG J, 1995, J IMMUNOL, V155, P2498; YE JP, 1994, J BIOL CHEM, V269, P25728; Yeung K, 1997, MOL CELL BIOL, V17, P36, DOI 10.1128/MCB.17.1.36; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; ZAVADA J, 1993, INT J CANCER, V54, P268, DOI 10.1002/ijc.2910540218; ZIEGLER SF, 1991, ONCOGENE, V6, P283	50	51	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32588	32595		10.1074/jbc.274.46.32588	http://dx.doi.org/10.1074/jbc.274.46.32588			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551812	hybrid			2022-12-25	WOS:000083623000012
J	Li, DX; Dobrowolska, G; Aicher, LD; Chen, MZ; Wright, JH; Drueckes, P; Dunphy, EL; Munar, ES; Krebs, EG				Li, DX; Dobrowolska, G; Aicher, LD; Chen, MZ; Wright, JH; Drueckes, P; Dunphy, EL; Munar, ES; Krebs, EG			Expression of the casein kinase 2 subunits in Chinese hamster ovary and 3T3 L1 cells provides information on the role of the enzyme in cell proliferation and the cell cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II ALPHA-SUBUNIT; BETA-SUBUNIT; PROTEIN-KINASES; SACCHAROMYCES-CEREVISIAE; MOLECULAR-COMPLEX; ZEA-MAYS; PHOSPHORYLATION; CK2; CLONING; P34(CDC2)	In order to investigate the in vivo functions of protein kinase CK2 (CK2), the expression of Myc-tagged versions of the subunits, Myc-CK2 alpha and Myc-CK2 beta, was carried out in Chinese hamster ovary cells (CHO cells) and in 3T3 L1 fibroblasts. Cell proliferation in these cells was examined. CHO cells that transiently overexpressed the Myc-CK2 beta subunit exhibited a severe growth defect, as shown by a much lower value of [H-3]thymidine incorporation than the vector controls, and a rounded shrunken morphology. In contrast, cells overexpressing Myc-tagged CK2 alpha showed a slightly but consistently higher value of [H-3]thymidine incorporation than the controls. The defect in cell growth and changes in morphology caused by Myc-CK2 beta overexpression were partially rescued by coexpression of Myc-tagged CK2 alpha. In parallel to the studies in CHO cells, the stable transfection of Myc-CK2 alpha and Myc-CK2 beta subunits was achieved in 3T3 LI fibroblast cells. Similarly, the ectopic expression of Myc-CK2 beta, but not Myc-CK2 alpha, caused a growth defect. By measuring [H-3]thymidine incorporation, it was found that expression of Myc-CK2 beta prolonged the G(1) phase and inhibited up-regulation of cyclin DI expression during G(1). In addition, a lower mitotic index and lower mitotic cyclin-dependent kinase activities were detected in Myc-CK2 beta-expressing cells. Detailed analysis of stable cells that were synchronously released into the cell cycle revealed that the expression of Myc-CK2 beta inhibited cells entering into mitosis and prevented the activation of mitotic cyclin-dependent kinases. Taken together, results from both transient and stable expression of CK2 subunits strongly suggest that CK2 may be involved in the control of cell growth and progression of the cell cycle.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Krebs, EG (corresponding author), Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA.			Dobrowolska, Grazyna/0000-0002-2598-9666	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042528] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42528] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; BOJANOWSKI K, 1993, J BIOL CHEM, V268, P22920; Boldyreff B, 1997, FEBS LETT, V403, P197, DOI 10.1016/S0014-5793(97)00010-0; BOSC DG, 1995, J BIOL CHEM, V270, P25872, DOI 10.1074/jbc.270.43.25872; Chen MZ, 1997, P NATL ACAD SCI USA, V94, P9136, DOI 10.1073/pnas.94.17.9136; Chen MZ, 1997, MOL CELL BIOL, V17, P1904, DOI 10.1128/MCB.17.4.1904; DOBROWOLSKA G, 1991, BIOCHIM BIOPHYS ACTA, V1129, P139, DOI 10.1016/0167-4781(91)90230-J; FILHOL O, 1992, J BIOL CHEM, V267, P20577; GUPTA SK, 1993, GENE, V124, P287, DOI 10.1016/0378-1119(93)90407-T; Hagemann C, 1997, FEBS LETT, V403, P200, DOI 10.1016/S0014-5793(97)00011-2; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HANNA DE, 1995, J BIOL CHEM, V270, P25905, DOI 10.1074/jbc.270.43.25905; HELLERHARRISON RA, 1991, J BIOL CHEM, V266, P14435; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; KIKKAWA U, 1992, MOL CELL BIOL, V12, P5711, DOI 10.1128/MCB.12.12.5711; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; Li DX, 1997, J BIOL CHEM, V272, P3773, DOI 10.1074/jbc.272.6.3773; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; LORENZ P, 1993, J BIOL CHEM, V268, P2733; LOZEMAN FJ, 1990, BIOCHEMISTRY-US, V29, P8436, DOI 10.1021/bi00488a034; LUSCHER B, 1994, EUR J BIOCHEM, V220, P521, DOI 10.1111/j.1432-1033.1994.tb18651.x; MEGGIO F, 1992, EUR J BIOCHEM, V205, P939, DOI 10.1111/j.1432-1033.1992.tb16860.x; MEGGIO F, 1994, BIOCHEMISTRY-US, V33, P4336, DOI 10.1021/bi00180a030; MEISNER H, 1989, BIOCHEMISTRY-US, V28, P4072, DOI 10.1021/bi00435a066; Meisner H, 1991, CURR OPIN CELL BIOL, V3, P474, DOI 10.1016/0955-0674(91)90076-B; Niefind K, 1998, EMBO J, V17, P2451, DOI 10.1093/emboj/17.9.2451; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; Reszka AA, 1997, MOL BIOL CELL, V8, P1219, DOI 10.1091/mbc.8.7.1219; ROUSSOU I, 1994, MOL CELL BIOL, V14, P576, DOI 10.1128/MCB.14.1.576; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; SEGER R, 1994, J BIOL CHEM, V269, P25699; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SNELL V, 1994, EMBO J, V13, P2066, DOI 10.1002/j.1460-2075.1994.tb06481.x; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; TUAZON PT, 1991, ADV 2 MESSENGER PHOS, V23, P126; ULLOA L, 1993, EMBO J, V12, P1633, DOI 10.1002/j.1460-2075.1993.tb05808.x	42	46	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32988	32996		10.1074/jbc.274.46.32988	http://dx.doi.org/10.1074/jbc.274.46.32988			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551866	hybrid			2022-12-25	WOS:000083623000066
J	Liang, SH; Clarke, MF				Liang, SH; Clarke, MF			A bipartite nuclear localization signal is required for p53 nuclear import regulated by a carboxyl-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC SEQUESTRATION; CELL-CYCLE; NUCLEOCYTOPLASMIC TRANSPORT; PROTEIN IMPORT; EXPORT FACTOR; C-MYC; GROWTH; IDENTIFICATION; SEQUENCES; RECEPTOR	Abnormal p53 cellular localization has been considered to be one of the mechanisms that could inactivate p53 function. To understand the regulation of p53 cellular trafficking, we have previously identified two p53 domains involved in its localization. A basic domain, Lys(305)-Arg(306), is required for p53 nuclear import, and a carboxyl-terminal domain, namely the cytoplasmic sequestration domain (CSD) from residues 326-355, could block the nuclear import of Lys(305) Or Arg(306) mutated p53. To characterize further the function of these two domains, we demonstrate in this report that the previously described major nuclear localization signal works together with Lys(305)-Arg(306) to form a bipartite and functional nuclear localization sequence (NLS) for p53 nuclear import. The CSD could block the binding of p53 to the NLS receptor, importin alpha, and reduce the efficiency of p53 nuclear import in MCF-7, H1299, and Saos-2 cells. The blocking effect of the CSD is not due to the enhancement of nuclear export or oligomerization of the p53. These results indicate that the CSD can regulate p53 nuclear import by controlling access of the NLS to importin rw binding.	Univ Michigan, Med Ctr, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Clarke, MF (corresponding author), Univ Michigan, Med Ctr, Dept Internal Med, 4310 CCGC,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.				NATIONAL CANCER INSTITUTE [R55CA067140, R01CA067140] Funding Source: NIH RePORTER; NCI NIH HHS [CA67140] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BOSARI S, 1995, AM J PATHOL, V147, P790; Canman C E, 1997, Adv Pharmacol, V41, P429, DOI 10.1016/S1054-3589(08)61068-6; Carey KL, 1996, J CELL BIOL, V133, P985, DOI 10.1083/jcb.133.5.985; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DANG CV, 1989, J BIOL CHEM, V264, P18019; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; GANNON JV, 1991, NATURE, V349, P802; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Jans DA, 1997, FEBS LETT, V406, P315, DOI 10.1016/S0014-5793(97)00293-7; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Knippschild U, 1996, ONCOGENE, V12, P1755; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liang SH, 1998, J BIOL CHEM, V273, P19817, DOI 10.1074/jbc.273.31.19817; Liang SH, 1999, ONCOGENE, V18, P2163, DOI 10.1038/sj.onc.1202350; Middeler G, 1997, ONCOGENE, V14, P1407, DOI 10.1038/sj.onc.1200949; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MORELAND RB, 1987, MOL CELL BIOL, V7, P4048, DOI 10.1128/MCB.7.11.4048; Mowat MRA, 1998, ADV CANCER RES, V74, P25, DOI 10.1016/S0065-230X(08)60764-2; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; STURZBECHER HW, 1990, ONCOGENE, V5, P795; TAKAHASHI K, 1993, MOL CARCINOGEN, V8, P58, DOI 10.1002/mc.2940080112; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Wang XW, 1997, J CELL PHYSIOL, V173, P247, DOI 10.1002/(SICI)1097-4652(199711)173:2<247::AID-JCP30>3.0.CO;2-A; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Weis K, 1998, TRENDS BIOCHEM SCI, V23, P185, DOI 10.1016/S0968-0004(98)01204-3; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; ZACKSENHAUS E, 1993, MOL CELL BIOL, V13, P4588, DOI 10.1128/MCB.13.8.4588	40	109	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32699	32703		10.1074/jbc.274.46.32699	http://dx.doi.org/10.1074/jbc.274.46.32699			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551826	hybrid			2022-12-25	WOS:000083623000026
J	McMahon, LW; Walsh, CE; Lambert, MW				McMahon, LW; Walsh, CE; Lambert, MW			Human alpha spectrin II and the Fanconi anemia proteins FANCA and FANCC interact to form a nuclear complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENTATION GROUP-A; BETA-SPECTRIN; NONERYTHROID SPECTRINS; XERODERMA-PIGMENTOSUM; MEMBRANE SKELETON; MAMMALIAN-CELLS; DNA-DAMAGE; REPAIR; BRAIN; GENE	Fanconi anemia (FA) is a genetic disorder characterized by bone marrow failure, congenital abnormalities, cancer susceptibility, and a marked cellular hypersensitivity to DNA interstrand cross-linking agents, which correlates with a defect in ability to repair this type of damage, We have previously identified an approximately 230-kDa protein present, in a nuclear protein complex in normal human lymphoblastoid cells that is involved in repair of DNA interstrand cross-links and shows reduced levels in FA-A cell nuclei. The FANCA gene appears to play a role in the stability or expression of this protein. me now show that p230 is a well known structural protein, human ct spectrin II (alpha SpII Sigma*), and that levels of alpha SpII Sigma* are not only significantly reduced in FA-A cells but also in FA-B, FA-C and FA-D cells (i.e. in all FA cell Lines tested), suggesting a role for these FA proteins in the stability or expression of alpha SpII Sigma*. These studies also show that alpha SpII Sigma* forms a complex in the nucleus with the FANCA and FANCC proteins. alpha SpII Sigma* may thus act as a scaffold to align or enhance interactions between FA proteins and proteins involved in DNA repair. These results suggest that FA represents a disorder in which there is a deficiency in alpha SpII Sigma*.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pathol & Lab Med, Newark, NJ 07103 USA; Univ Med & Dent New Jersey Grad Sch Biomed Sci, Newark, NJ 07103 USA; Univ N Carolina, Gene Therapy Ctr, Chapel Hill, NC 27599 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of North Carolina; University of North Carolina Chapel Hill	Lambert, MW (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pathol & Lab Med, 185 S Orange Ave, Newark, NJ 07103 USA.				NATIONAL CANCER INSTITUTE [T32CA009665] Funding Source: NIH RePORTER; NCI NIH HHS [CA09665] Funding Source: Medline; NHLBI NIH HHS [R01 HL54806] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Apostolou S, 1996, NAT GENET, V14, P324, DOI 10.1038/ng1196-324; AUERBACH AD, 1991, CANCER GENET CYTOGEN, V51, P1, DOI 10.1016/0165-4608(91)90002-C; AVERBECK D, 1988, CANCER RES, V48, P2015; BACHS O, 1990, J BIOL CHEM, V265, P18595; Balajee AS, 1998, MUTAT RES-FUND MOL M, V404, P3, DOI 10.1016/S0027-5107(98)00088-8; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; BLOCH RJ, 1989, J CELL BIOL, V108, P481, DOI 10.1083/jcb.108.2.481; Brois DW, 1999, CARCINOGENESIS, V20, P1845, DOI 10.1093/carcin/20.9.1845; Brookman KW, 1996, MOL CELL BIOL, V16, P6553; Buchwald M, 1998, MUTAT RES-DNA REPAIR, V408, P75, DOI 10.1016/S0921-8777(98)00024-X; Cottrell J S, 1996, Methods Mol Biol, V61, P67; de Winter JP, 1998, NAT GENET, V20, P281, DOI 10.1038/3093; Fu KL, 1998, HUM GENET, V102, P166, DOI 10.1007/s004390050671; GLANZ A, 1982, J MED GENET, V19, P412, DOI 10.1136/jmg.19.6.412; GOODMAN SR, 1995, BRAIN RES BULL, V36, P593, DOI 10.1016/0361-9230(94)00264-2; HANG B, 1993, NUCLEIC ACIDS RES, V21, P4187, DOI 10.1093/nar/21.18.4187; HU RJ, 1992, J BIOL CHEM, V267, P18715; Johnston PJ, 1998, RADIAT RES, V149, P533, DOI 10.2307/3579899; Koehler DR, 1996, NUCLEIC ACIDS RES, V24, P2877, DOI 10.1093/nar/24.15.2877; Kupfer GM, 1997, NAT GENET, V17, P487, DOI 10.1038/ng1297-487; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambert M W, 1999, Prog Nucleic Acid Res Mol Biol, V63, P257; LAMBERT MW, 1992, MUTAT RES, V273, P57, DOI 10.1016/0921-8777(92)90050-D; LAMBERT MW, 1988, MUTAT RES, V193, P65, DOI 10.1016/0167-8817(88)90008-9; Lambert MW, 1997, BIOCHEM BIOPH RES CO, V230, P587, DOI 10.1006/bbrc.1996.6008; LETO TL, 1989, J BIOL CHEM, V264, P5826; LoTenFoe JR, 1996, NAT GENET, V14, P320, DOI 10.1038/ng1196-320; MA YP, 1993, MOL BRAIN RES, V18, P87, DOI 10.1016/0169-328X(93)90176-P; MOON RT, 1990, J BIOL CHEM, V265, P4427; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; STRATHDEE CA, 1992, AM J PEDIAT HEMATOL, V14, P177; Thompson LH, 1996, MUTAT RES-DNA REPAIR, V363, P77, DOI 10.1016/0921-8777(96)00008-0; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; WIDADA JS, 1989, J MOL BIOL, V205, P455, DOI 10.1016/0022-2836(89)90355-0; Williams Kenneth R., 1996, P541, DOI 10.1007/978-1-60327-259-9_91; WINKELMANN JC, 1993, BLOOD, V81, P3173; Yamashita T, 1998, P NATL ACAD SCI USA, V95, P13085, DOI 10.1073/pnas.95.22.13085; ZHEN WP, 1993, CARCINOGENESIS, V14, P919, DOI 10.1093/carcin/14.5.919; Ziemnicka-Kotula D, 1998, J BIOL CHEM, V273, P13681, DOI 10.1074/jbc.273.22.13681	41	75	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32904	32908		10.1074/jbc.274.46.32904	http://dx.doi.org/10.1074/jbc.274.46.32904			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551855	hybrid, Green Published			2022-12-25	WOS:000083623000055
J	Zhong, XT; Guidotti, G				Zhong, XT; Guidotti, G			A yeast golgi E-type ATPase with an unusual membrane topology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE TRIPHOSPHATE HYDROLASE; CELL ACTIVATION ANTIGEN; BRAIN ECTO-APYRASE; SACCHAROMYCES-CEREVISIAE; GUANOSINE DIPHOSPHATASE; ENDOPLASMIC-RETICULUM; ALPHA-1,3 MANNOSYLTRANSFERASE; TRANSMEMBRANE DOMAIN; NUCLEOTIDE SULFATE; TOXOPLASMA-GONDII	E-type ATPases are involved in many biological processes such as modulation of neural cell activity, prevention of intravascular thrombosis, and protein glycosylation. In this study, we show that a gene of Saccharomyces cerevisiae, identified by similarity to that of animal ectoapyrase CD39, codes for a new member of the E-type ATPase family (Apy1p). Overexpression of Apy1p in yeast cells causes an increase in intracellular membrane-bound nucleoside di- and triphosphate hydrolase activity. The activity is highest with ADP as substrate and is stimulated similarly by Ca (2+), Mg2+, and Mn2+. The results also indicate that Apy1p is an integral membrane protein located predominantly in the Golgi compartment. Sequence analysis reveals that Apy1p contains one large NH2-terminal hydrophilic apyrase domain, one COOH-terminal hydrophilic domain, and two hydrophobic stretches in the central region of the polypeptide. Although no signal sequence is found at the NH2-terminal portion of the protein and no NH2-terminal cleavage of the protein is oh served, demonstrated by the detection of NH2-terminal tagged Apy1p, the NH2-terminal domain of Apy1p is on the luminal side of the Golgi apparatus, and the COOH-terminal hydrophilic domain binds to the cytoplasmic face of the Golgi membrane. The second hydrophobic stretch of Apy1p is the transmembrane domain. These results indicate that Apy1p is a type III transmembrane protein; however, the size of the Apy1p extracytoplasmic NH, terminus is much larger than those of other type III transmembrane proteins, suggesting that a novel translocation mechanism is utilized.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Guidotti, G (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 7 Divin Ave, Cambridge, MA 02138 USA.	guidotti@fas.harvard.edu			NHLBI NIH HHS [HL08893] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; Abeijon C, 1997, TRENDS BIOCHEM SCI, V22, P203, DOI 10.1016/S0968-0004(97)01053-0; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BERMUDES D, 1994, J BIOL CHEM, V269, P29252; BERNINSONE P, 1994, J BIOL CHEM, V269, P207; CAPASSO JM, 1989, J BIOL CHEM, V264, P5233; Chadwick BP, 1998, GENOMICS, V50, P357, DOI 10.1006/geno.1998.5317; Chadwick BP, 1997, MAMM GENOME, V8, P668, DOI 10.1007/s003359900534; CHAPMAN RE, 1994, EMBO J, V13, P4896, DOI 10.1002/j.1460-2075.1994.tb06817.x; COOPER A, 1989, MOL CELL BIOL, V9, P2706, DOI 10.1128/MCB.9.6.2706; Dean N, 1997, J BIOL CHEM, V272, P31908, DOI 10.1074/jbc.272.50.31908; GRAHAM TR, 1995, MOL BIOL CELL, V6, P809, DOI 10.1091/mbc.6.7.809; GRAHAM TR, 1994, J CELL BIOL, V127, P667, DOI 10.1083/jcb.127.3.667; Handa M, 1996, BIOCHEM BIOPH RES CO, V218, P916, DOI 10.1006/bbrc.1996.0162; Harley CA, 1998, J BIOL CHEM, V273, P24963, DOI 10.1074/jbc.273.38.24963; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; Hegde RS, 1997, CELL, V91, P575, DOI 10.1016/S0092-8674(00)80445-6; Heine P, 1999, EUR J BIOCHEM, V262, P102, DOI 10.1046/j.1432-1327.1999.00347.x; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; Hsieh HL, 1996, PLANT MOL BIOL, V30, P135, DOI 10.1007/BF00017808; HURT EC, 1988, EUR J CELL BIOL, V46, P554; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; KANE SM, 1974, J BACTERIOL, V118, P8, DOI 10.1128/JB.118.1.8-14.1974; Kirley TL, 1997, J BIOL CHEM, V272, P1076, DOI 10.1074/jbc.272.2.1076; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MALISZEWSKI CR, 1994, J IMMUNOL, V153, P3574; Marcus AJ, 1997, J CLIN INVEST, V99, P1351, DOI 10.1172/JCI119294; MILLER JH, 1992, SHORT COURSE BACTERI, P439; Nagy AK, 1998, J BIOL CHEM, V273, P16043, DOI 10.1074/jbc.273.26.16043; Piper P, 1996, Methods Mol Biol, V53, P103; PLESNER L, 1995, INT REV CYTOL, V158, P141; Powers T, 1997, SCIENCE, V278, P2072, DOI 10.1126/science.278.5346.2072; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; ROBERTS CJ, 1992, J CELL BIOL, V119, P69, DOI 10.1083/jcb.119.1.69; ROSE MD, 1991, METHOD ENZYMOL, V194, P195; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Siegel V, 1997, CELL, V90, P5, DOI 10.1016/S0092-8674(00)80307-4; SIKORSKI RS, 1989, GENETICS, V122, P19; Smith TM, 1998, BBA-PROTEIN STRUCT M, V1386, P65, DOI 10.1016/S0167-4838(98)00063-6; Smith TM, 1999, BIOCHEMISTRY-US, V38, P321, DOI 10.1021/bi9820457; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; Thomas C, 1999, PLANT PHYSIOL, V119, P543, DOI 10.1104/pp.119.2.543; Vasconcelos EG, 1996, J BIOL CHEM, V271, P22139, DOI 10.1074/jbc.271.36.22139; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; Vowels JJ, 1998, MOL BIOL CELL, V9, P1351, DOI 10.1091/mbc.9.6.1351; WALLIN E, 1995, PROTEIN ENG, V8, P693, DOI 10.1093/protein/8.7.693; Wang TF, 1997, MOL BRAIN RES, V47, P295, DOI 10.1016/S0169-328X(97)00066-1; Wang TF, 1998, J BIOL CHEM, V273, P11392, DOI 10.1074/jbc.273.18.11392; Wang TF, 1996, J BIOL CHEM, V271, P9898, DOI 10.1074/jbc.271.17.9898; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; ZIMMERMANN H, 1994, TRENDS NEUROSCI, V17, P420, DOI 10.1016/0166-2236(94)90016-7	59	32	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32704	32711		10.1074/jbc.274.46.32704	http://dx.doi.org/10.1074/jbc.274.46.32704			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551827	hybrid, Green Published			2022-12-25	WOS:000083623000027
J	Delgado, M; Ganea, D				Delgado, M; Ganea, D			Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin-12 transcription by regulating nuclear factor kappa B and Ets activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATORY FACTOR INTERLEUKIN-12; NITRIC-OXIDE PRODUCTION; NECROSIS-FACTOR-ALPHA; GENE-EXPRESSION; CYCLIC-AMP; PROINFLAMMATORY CYTOKINE; PERITONEAL-MACROPHAGES; MEDIATED TRANSCRIPTION; MURINE MACROPHAGES; IMMUNE-RESPONSES	The vasoactive intestinal peptide (VIP) and the structurally related neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) act as "macrophage-deactivating factors". We showed previously that VIP and PACAP inhibit the production of macrophage-derived tumor necrosis factor-alpha, interleukin (LL)-6, nitric oxide, and IL-12. This study examines the molecular mechanisms involved in the VIP/PACAP inhibition of IL-12 production. VIP and PACAP inhibit IL-12 (p40) gene expression by affecting both NF-kappa B binding and the composition of the Ets-2 binding complex. Both neuropeptides prevent the activation-induced nuclear translocation of the NF-kappa B components p65 and c-Rel by inhibiting the reduction in cytoplasmic I kappa B alpha, Moreover, VIP and PACAP inhibit the synthesis of the interferon responsive factor-1. The decrease in nuclear interferon responsive factor-1 and c-Rel results in alterations of the Ets-S-binding complex. Two transduction pathways, a cAMP-dependent and a cAMP-independent pathway, are involved in the inhibition of IL-12 gene expression and appear to differentially regulate the transcriptional factors involved. Because IL-12 participates in T cell activation and cytolytic T lymphocyte activity and promotes the differentiation of T helper cells into the Th1 subset, the understanding of the mechanisms that affect IL-12 production in normal and pathological conditions could contribute to immune response-based therapies or vaccine designs.	Rutgers State Univ, Dept Biol Sci, Newark, NJ 07102 USA; Univ Complutense Madrid, Dept Biol Celular, E-28040 Madrid, Spain	Rutgers State University Newark; Rutgers State University New Brunswick; Complutense University of Madrid	Ganea, D (corresponding author), Rutgers State Univ, Dept Biol Sci, 101 Warren St, Newark, NJ 07102 USA.	dganea@andromeda.rutgers.edu	Delgado, Mario/P-1524-2016	Delgado, Mario/0000-0003-1893-5982	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI041786, R01AI041786] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 41786-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aoki Y, 1997, ENDOCRINOLOGY, V138, P1930, DOI 10.1210/en.138.5.1930; Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Bellinger DL, 1996, ADV NEUROIMMUNOL, V6, P5, DOI 10.1016/S0960-5428(96)00008-3; CHEN D, 1994, J EXP MED, V179, P931, DOI 10.1084/jem.179.3.931; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DelaFuente M, 1996, ADV NEUROIMMUNOL, V6, P75, DOI 10.1016/S0960-5428(96)00002-2; Delgado M, 1998, J BIOL CHEM, V273, P31427, DOI 10.1074/jbc.273.47.31427; Delgado M, 1999, J IMMUNOL, V162, P4685; Delgado M, 1999, J IMMUNOL, V162, P2358; Delgado M, 1999, J IMMUNOL, V162, P1707; Delgado M, 1999, J NEUROIMMUNOL, V96, P167, DOI 10.1016/S0165-5728(99)00023-5; Delgado M, 1996, REGUL PEPTIDES, V62, P161, DOI 10.1016/0167-0115(96)00024-9; Delgado M, 1999, J IMMUNOL, V162, P1200; Dewit D, 1998, IMMUNOL LETT, V60, P57, DOI 10.1016/S0165-2478(97)00129-6; DOHERTY GM, 1992, J IMMUNOL, V149, P1666; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; Ganea D, 1996, ADV NEUROIMMUNOL, V6, P61, DOI 10.1016/S0960-5428(96)00007-1; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GOETZL EJ, 1988, ANN NY ACAD SCI, V840, P540; Gourlet P, 1997, PEPTIDES, V18, P1539, DOI 10.1016/S0196-9781(97)00228-3; Gourlet P, 1997, PEPTIDES, V18, P1555, DOI 10.1016/S0196-9781(97)00230-1; GOURLET P, 1995, EUR J PHARMACOL, V287, P7, DOI 10.1016/0014-2999(95)00467-5; Gri G, 1998, J BIOL CHEM, V273, P6431, DOI 10.1074/jbc.273.11.6431; GUBLER U, 1991, P NATL ACAD SCI USA, V88, P4143, DOI 10.1073/pnas.88.10.4143; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARAGUCHI S, 1995, IMMUNOL TODAY, V16, P595, DOI 10.1016/0167-5699(95)80083-2; Harmar AJ, 1998, PHARMACOL REV, V50, P265; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HEINZEL FP, 1994, INFECT IMMUN, V62, P4244, DOI 10.1128/IAI.62.10.4244-4249.1994; Hernanz A, 1996, J NEUROIMMUNOL, V71, P25, DOI 10.1016/S0165-5728(96)00118-X; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Karras JG, 1996, J IMMUNOL, V157, P2299; KincyCain T, 1997, J IMMUNOL, V158, P2334; KRAAN TCTMV, 1995, J EXP MED, V181, P775, DOI 10.1084/jem.181.2.775; KUNKEL SL, 1988, J BIOL CHEM, V263, P5380; LASKIN DL, 1995, ANNU REV PHARMACOL, V35, P655, DOI 10.1146/annurev.pharmtox.35.1.655; Ma XJ, 1997, J BIOL CHEM, V272, P10389; Ma XJ, 1996, J EXP MED, V183, P147, DOI 10.1084/jem.183.1.147; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; Manna SK, 1998, J IMMUNOL, V161, P2873; Martinez C, 1996, J IMMUNOL, V156, P4128; Martinez C, 1998, J LEUKOCYTE BIOL, V63, P591, DOI 10.1002/jlb.63.5.591; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Muchamuel T, 1997, J IMMUNOL, V158, P2898; Muller A, 1998, J NEUROCHEM, V70, P1431; MURPHY TL, 1995, MOL CELL BIOL, V15, P5258; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; Ollivier V, 1996, J BIOL CHEM, V271, P20828, DOI 10.1074/jbc.271.34.20828; PaninaBordignon P, 1997, J CLIN INVEST, V100, P1513, DOI 10.1172/JCI119674; Parry GCN, 1997, J IMMUNOL, V159, P5450; Pozo D, 1997, BBA-MOL CELL RES, V1359, P250, DOI 10.1016/S0167-4889(97)00104-3; Romano MF, 1996, J IMMUNOL, V156, P2119; Said SI, 1996, ANN NY ACAD SCI, V805, P379; Said SI, 1996, J CLIN INVEST, V97, P2163, DOI 10.1172/JCI118655; Said SI, 1998, ANN NY ACAD SCI, V865, P226, DOI 10.1111/j.1749-6632.1998.tb11182.x; SCHOENHAUT DS, 1992, J IMMUNOL, V148, P3433; Schomerus C, 1996, CELL TISSUE RES, V286, P305; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SUZUKI YJ, 1994, J IMMUNOL, V153, P5008; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; Trepicchio WL, 1996, J IMMUNOL, V157, P3627; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; Trinchieri G, 1998, Int Rev Immunol, V16, P365, DOI 10.3109/08830189809043002; Trinchieri G, 1998, IMMUNOL RES, V17, P269, DOI 10.1007/BF02786451; TSUNAWAKI S, 1988, NATURE, V334, P260, DOI 10.1038/334260a0; WANG P, 1995, J BIOL CHEM, V270, P9558, DOI 10.1074/jbc.270.16.9558; WOLF S, 1992, FASEB J, V6, pA1335; Xin ZC, 1998, J NEUROIMMUNOL, V89, P206, DOI 10.1016/S0165-5728(98)00140-4	70	103	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31930	31940		10.1074/jbc.274.45.31930	http://dx.doi.org/10.1074/jbc.274.45.31930			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542221	hybrid			2022-12-25	WOS:000083532100029
J	Jones, PS; Parrott, E; White, INH				Jones, PS; Parrott, E; White, INH			Activation of transcription by estrogen receptor alpha and beta is cell type- and promoter-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUINONE REDUCTASE GENE; NF-KAPPA-B; RESPONSE ELEMENT; BREAST-CANCER; BINDING DOMAIN; TGF-ALPHA; IN-VITRO; ER-ALPHA; EXPRESSION; TAMOXIFEN	Tamoxifen acts as a strong estrogen antagonist in human breast but as an estrogen agonist in the uterus. The action of tamoxifen is mediated through estrogen receptors (ER alpha and ER beta), which bind to a variety of responsive elements, to activate transcription. To examine the role of these varied elements in the response to antiestrogens, we studied the activation of a panel of differing promoters, by these compounds, in human breast, bone, and endometrial derived cell lines. No agonistic activity was observed in breast cells, whereas all antiestrogens, particularly tamoxifen, exhibited agonistic effects in uterine cell lines. All antiestrogens studied were agonistic in co-transfections of a collagenase reporter gene and ER beta, but tamoxifen alone was agonist ic with ER alpha in (uterine) HEC-1-A cells. The ER alpha mediated, agonism of tamoxifen was not observed in primary cultures of human uterine stromal cells, whereas the ER beta-mediated agonism of all selective estrogen receptor modulators was present. This suggests that the two receptors operate by distinct pathways and that the response of cells to antiestrogens is dependent on the ER subtypes expressed.	MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England	University of Leicester	Jones, PS (corresponding author), MRC, Toxicol Unit, Hodgkin Bldg,POB 138,Lancaster Rd, Leicester LE1 9HN, Leics, England.							Anolik JH, 1996, J STEROID BIOCHEM, V59, P413, DOI 10.1016/S0960-0760(96)00129-X; Castro-Rivera E, 1998, J STEROID BIOCHEM, V64, P287, DOI 10.1016/S0960-0760(97)00202-1; CHEN XR, 1994, ONCOGENE, V9, P3179; Chu S, 1997, MOL CELL ENDOCRINOL, V132, P195, DOI 10.1016/S0303-7207(97)00133-0; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; deMedeiros SRB, 1997, J BIOL CHEM, V272, P18250, DOI 10.1074/jbc.272.29.18250; Dowsett M, 1999, ENDOCR-RELAT CANCER, V6, P25, DOI 10.1677/erc.0.0060025; Driscoll MD, 1998, J BIOL CHEM, V273, P29321, DOI 10.1074/jbc.273.45.29321; ElAshry D, 1996, J STEROID BIOCHEM, V59, P261, DOI 10.1016/S0960-0760(96)00118-5; Elgort MG, 1996, MOL ENDOCRINOL, V10, P477, DOI 10.1210/me.10.5.477; Eng FCS, 1998, J BIOL CHEM, V273, P28371, DOI 10.1074/jbc.273.43.28371; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Galien R, 1997, NUCLEIC ACIDS RES, V25, P2424, DOI 10.1093/nar/25.12.2424; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; HEDDEN A, 1995, ANN NY ACAD SCI, V761, P109, DOI 10.1111/j.1749-6632.1995.tb31373.x; Hess RA, 1997, J ANDROL, V18, P602; Ishimitsu T, 1998, BIOCHEM BIOPH RES CO, V243, P463, DOI 10.1006/bbrc.1998.8110; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KRISHNAN V, 1994, J BIOL CHEM, V269, P15912; Kuiper GGJM, 1997, FEBS LETT, V410, P87, DOI 10.1016/S0014-5793(97)00413-4; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; LAFYATIS R, 1990, J BIOL CHEM, V265, P19128; Lazennec G, 1997, MOL ENDOCRINOL, V11, P1375, DOI 10.1210/me.11.9.1375; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; Montano MM, 1997, P NATL ACAD SCI USA, V94, P2581, DOI 10.1073/pnas.94.6.2581; Montano MM, 1998, J BIOL CHEM, V273, P25443, DOI 10.1074/jbc.273.39.25443; NARDULLI AM, 1995, MOL ENDOCRINOL, V9, P1064, DOI 10.1210/me.9.8.1064; Norris JD, 1996, MOL ENDOCRINOL, V10, P1605, DOI 10.1210/mend.10.12.8961270; Ogawa S, 1998, BIOCHEM BIOPH RES CO, V243, P122, DOI 10.1006/bbrc.1997.7893; Ogawa S, 1998, FEBS LETT, V423, P129, DOI 10.1016/S0014-5793(98)00079-9; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Petersen DN, 1998, ENDOCRINOLOGY, V139, P1082, DOI 10.1210/en.139.3.1082; Porter W, 1997, MOL ENDOCRINOL, V11, P1569, DOI 10.1210/me.11.11.1569; RAY A, 1994, J BIOL CHEM, V269, P12940; RISHI AK, 1995, CANCER RES, V55, P4999; RUTQVIST LE, 1995, J NATL CANCER I, V87, P645, DOI 10.1093/jnci/87.9.645; Sathya G, 1997, MOL ENDOCRINOL, V11, P1994, DOI 10.1210/me.11.13.1994; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Sun GL, 1998, MOL ENDOCRINOL, V12, P882, DOI 10.1210/me.12.6.882; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; VIGANO P, 1993, ACTA OBSTET GYN SCAN, V72, P87, DOI 10.3109/00016349309023418; VYHLIDAL C, 1998, TOXICOLOGIST, V42, P160; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; Wood JR, 1998, MOL CELL BIOL, V18, P1927, DOI 10.1128/MCB.18.4.1927; WRENN CK, 1993, J BIOL CHEM, V268, P24089; Yang NN, 1996, ENDOCRINOLOGY, V137, P2075, DOI 10.1210/en.137.5.2075; Yang NN, 1996, SCIENCE, V273, P1222, DOI 10.1126/science.273.5279.1222; Zhao Y, 1998, ONCOGENE, V16, P409, DOI 10.1038/sj.onc.1201768; Zou AH, 1999, MOL ENDOCRINOL, V13, P418, DOI 10.1210/me.13.3.418	53	98	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32008	32014		10.1074/jbc.274.45.32008	http://dx.doi.org/10.1074/jbc.274.45.32008			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542232	hybrid			2022-12-25	WOS:000083532100040
J	Oakley, RH; Laporte, SA; Holt, JA; Barak, LS; Caron, MG				Oakley, RH; Laporte, SA; Holt, JA; Barak, LS; Caron, MG			Association of beta-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; V2 VASOPRESSIN RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; SUBCELLULAR-DISTRIBUTION; WILD-TYPE; AGONIST; INTERNALIZATION; SEQUESTRATION; PHOSPHORYLATION; DESENSITIZATION	Resensitization of G protein-coupled receptors (GPCRs) following agonist-mediated desensitization is a necessary step for maintaining physiological responsiveness. However, the molecular mechanisms governing the nature of GPCR resensitization are poorly understood. Here, we examine the role of beta-arrestin in the resensitization of the beta(2) adrenergic receptor (beta(2)AR), known to recycle and resensitize rapidly, and the vasopressin V2 receptor (V2R), known to recycle and resensitize slowly. Upon agonist activation, both receptors recruit beta-arrestin to the plasma membrane and internalize in a beta-arrestin- and clathrin-dependent manner. However, whereas beta-arrestin dissociates from the beta(2)AR at the plasma membrane, it internalizes with the V2R into endosomes. The differential trafficking of beta-arrestin and the ability of these two receptors to dephosphorylate, recycle, and resensitize is completely reversed when the carboxyl-terminal tails of these two receptors are switched, Moreover, the ability of beta-arrestin to remain associated with desensitized GPCRs during clathrin-mediated endocytosis is mediated by a specific cluster of phosphorylated serine residues in the receptor carboxyl-terminal tail. These results demonstrate that the interaction of beta-arrestin with a specific motif in the GPCR carboxyl-terminal tail dictates the rate of receptor dephosphorylation, recycling, and resensitization, and thus provide direct evidence for a novel mechanism by which beta-arrestins regulate the reestablishment of GPCR responsiveness.	Duke Univ, Med Ctr, Howard Hughes Med Inst Labs, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst Labs, Dept Med, Durham, NC 27710 USA	Duke University; Duke University	Caron, MG (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Box 3287, Durham, NC 27710 USA.		Laporte, Stephane A/F-3282-2012; Laporte, Stephane/ABC-4228-2021	Laporte, Stephane/0000-0002-0633-543X	NHLBI NIH HHS [HL 61365] Funding Source: Medline; NINDS NIH HHS [NS 19576] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BARAK LS, 1994, J BIOL CHEM, V269, P2790; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; BIRNHAUMER M, 1992, J BIOL CHEM, V267, P11786; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; FONSECA MI, 1995, J BIOL CHEM, V270, P8902, DOI 10.1074/jbc.270.15.8902; Garland AM, 1996, MOL PHARMACOL, V49, P438; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUREVICH VV, 1993, J BIOL CHEM, V268, P16879; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HAUSDORFF WP, 1990, J BIOL CHEM, V265, P1388; Innamorati G, 1998, J BIOL CHEM, V273, P7155, DOI 10.1074/jbc.273.12.7155; Innamorati G, 1997, J BIOL CHEM, V272, P2486; Innamorati G, 1998, P NATL ACAD SCI USA, V95, P2222, DOI 10.1073/pnas.95.5.2222; Ishii I, 1998, J BIOL CHEM, V273, P9878, DOI 10.1074/jbc.273.16.9878; KIESELBACH T, 1994, EUR J BIOCHEM, V226, P87, DOI 10.1111/j.1432-1033.1994.tb20029.x; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lazari RDM, 1998, J BIOL CHEM, V273, P18316, DOI 10.1074/jbc.273.29.18316; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; McConalogue K, 1998, MOL BIOL CELL, V9, P2305, DOI 10.1091/mbc.9.8.2305; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Nakamura K, 1998, J BIOL CHEM, V273, P24346, DOI 10.1074/jbc.273.38.24346; PALCZEWSKI K, 1989, J BIOL CHEM, V264, P15770; Pfeiffer R, 1998, EXP CELL RES, V244, P327, DOI 10.1006/excr.1998.4159; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Shih ML, 1999, J BIOL CHEM, V274, P1588, DOI 10.1074/jbc.274.3.1588; SIBLEY DR, 1986, P NATL ACAD SCI USA, V83, P9408, DOI 10.1073/pnas.83.24.9408; Tarasova NI, 1997, J BIOL CHEM, V272, P14817, DOI 10.1074/jbc.272.23.14817; Vogler O, 1998, J BIOL CHEM, V273, P12155, DOI 10.1074/jbc.273.20.12155; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; YU SS, 1993, J BIOL CHEM, V268, P337; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	42	433	441	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32248	32257		10.1074/jbc.274.45.32248	http://dx.doi.org/10.1074/jbc.274.45.32248			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542263	hybrid			2022-12-25	WOS:000083532100071
J	Movilla, N; Crespo, P; Bustelo, XR				Movilla, N; Crespo, P; Bustelo, XR			Signal transduction elements of TC21, an oncogenic member of the R-Ras subfamily of GTP-binding proteins	ONCOGENE			English	Article						TC21; RasGRF; Raf; JNK; MAPK	NUCLEOTIDE-RELEASING FACTOR; VAV PROTOONCOGENE; GDP/GTP EXCHANGE; CELL-LINE; ACTIVATION; TRANSFORMATION; TC21/R-RAS2; PATHWAY; FIBROBLASTS; CLONING	TC21 is a Ras-like GTPase with high oncogenic potential that is found mutated in some human tumors and overexpressed in breast cancer cell lines. We have conducted cellular and biochemical studies in order to understand the role of this protein in signal transduction and to unveil the signaling elements that participate in the TC21 pathway. Using gene transfer experiments, we demonstrate here that the TC21 oncogene can induce both cellular transformation in mouse fibroblasts and neuronal-like differentiation in rat PC12 cells. Interestingly, the proto-oncogenic version of TC21 shows also a lower, but significant, activity in both biological processes. We also demonstrate that the similarity of the cellular responses induced by TC21 and Ras derive from the utilization of overlapping pathways. Thus, the exchange of guanosine nucleotides in wild type TC21 is catalyzed by Ras exchange factors. Moreover, TC21 binds physically to c-Raf-1 in a GTP-dependent manner. Finally, overexpression of TC21(G23V) in NIH3T3 cells results in the activation of c-Raf-1 and the MAPK and the JNK branches of serine/threonine cascades. From these results, we conclude that TC21 promotes Ras-like responses in diverse cell types due to the use of overlapping, if not identical, signaling elements of the Ras oncogenic pathway.	SUNY Stony Brook, Univ Hosp, Dept Pathol, Stony Brook, NY 11794 USA; Univ Cantabria, Dept Biol Mol, E-39005 Santander, Spain	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital; Universidad de Cantabria	Bustelo, XR (corresponding author), SUNY Stony Brook, Univ Hosp, Dept Pathol, Level 2,Room 718-B, Stony Brook, NY 11794 USA.		Bustelo, Xose R./AAD-2081-2022; Bustelo, Xose R./A-9526-2010; Crespo, Piero/M-3273-2014	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072; Crespo, Piero/0000-0003-2825-7783	NCI NIH HHS [CA7373501] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Bustelo XR, 1996, CRIT REV ONCOGENESIS, V7, P65, DOI 10.1615/CritRevOncog.v7.i1-2.50; BUSTELO XR, 1994, ONCOGENE, V9, P2405; CARBONI JM, 1995, ONCOGENE, V10, P1905; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; Clark GJ, 1996, ONCOGENE, V12, P169; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COX AD, 1994, ONCOGENE, V9, P3281; Crespo P, 1996, ONCOGENE, V13, P455; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; CUADRADO A, 1993, ONCOGENE, V8, P2443; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; Graham SM, 1996, MOL CELL BIOL, V16, P6132; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; HUANG Y, 1995, ONCOGENE, V11, P1255; Kozian DH, 1997, FEBS LETT, V414, P239, DOI 10.1016/S0014-5793(97)01038-7; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LopezBarahona M, 1996, ONCOGENE, V12, P463; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MORRISON DK, 1995, METHOD ENZYMOL, V255, P301; Rosario M, 1999, EMBO J, V18, P1270, DOI 10.1093/emboj/18.5.1270; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; SUEN KL, 1995, ONCOGENE, V11, P825; van der Eb A J, 1980, Methods Enzymol, V65, P826	35	36	38	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 21	1999	18	43					5860	5869		10.1038/sj.onc.1202968	http://dx.doi.org/10.1038/sj.onc.1202968			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557073				2022-12-25	WOS:000083270700003
J	Yan, J; Kuroyanagi, H; Tomemori, T; Okazaki, N; Asato, K; Matsuda, Y; Suzuki, Y; Ohshima, Y; Mitani, S; Masuho, Y; Shirasawa, T; Muramatsu, M				Yan, J; Kuroyanagi, H; Tomemori, T; Okazaki, N; Asato, K; Matsuda, Y; Suzuki, Y; Ohshima, Y; Mitani, S; Masuho, Y; Shirasawa, T; Muramatsu, M			Mouse ULK2, a novel member of the UNC-51-like protein kinases: unique features of functional domains	ONCOGENE			English	Article						protein kinase; signal transduction; UNC-51-like kinases; C. elegans; autophosphorylation	CAENORHABDITIS-ELEGANS; C-ELEGANS; SERINE/THREONINE KINASE; AXONAL ELONGATION; SACCHAROMYCES-CEREVISIAE; GENE; EXPRESSION; NEURONS; MUTANTS; IDENTIFICATION	The UNC-51 serine/threonine kinase of C. elegans plays an essential role in axonal elongation, and unc-51 mutants exhibit uncoordinated movements. We have previously identified mouse and human cDNAs encoding UNC-51-like kinase (ULK1), Here we report the identification and characterization of the second murine member of this kinase family, ULK2, Mouse ULK2 cDNA encodes a putative polypeptide of 1033 aa which has an overall 52% and 33% amino acid identity to ULK1 and UNC-51, respectively. ULKs and UNC-51 share a typical domain structure of an amino-terminal kinase domain, a central proline/serine rich (PS) domain, and a carboxy-terminal (C) domain. Northern blot analysis showed that ULK2 mRNA is widely expressed in adult tissues. In situ hybridization analysis indicated that ULK2 mRNA is ubiquitously localized in premature as well as mature neurons in developing nervous system. ULK2 gene was mapped to mouse chromosome 11B1.3 and rat chromosome 10q23 by FISH. HA-tagged ULK2 expressed in COS7 cells had an apparent molecular size of similar to 150 kDa and was autophosphorylated in vitro. Truncation mutants suggested that the autophosphorylation occurs in the PS domain. Although expression of ULK2 failed to rescue unc-51 mutant of C. elegans, a series of ULK2/UNC-51 chimeric kinases revealed that function of the kinase and PS domains are conserved among species, while the C domain acts in a species-specific manner. These results suggest that ULK2 is involved in a previously uncharacterized signaling pathway in mammalian cells.	Helix Res Inst, Chiba 2920812, Japan; Tokyo Metropolitan Inst Gerontol, Dept Mol Genet, Itabashi Ku, Tokyo 1730015, Japan; Univ Tokyo, Inst Mol Biosci, Lab Cellular Biosynth, Bunkyou Ku, Tokyo 1130032, Japan; Nagoya Univ, Sch Agr Sci, Lab Anim Genet, Chikusa Ku, Nagoya, Aichi 46401, Japan; Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 81281, Japan; Tokyo Womens Med Univ, Sch Med, Dept Physiol, Shinjuku Ku, Tokyo 1628666, Japan; Japan Sci & Technol Corp, CREST, Tokyo, Japan	Tokyo Metropolitan Institute of Gerontology; University of Tokyo; Nagoya University; Kyushu University; Tokyo Women's Medical University; Japan Science & Technology Agency (JST)	Muramatsu, M (corresponding author), Helix Res Inst, 1532-3 Yana, Chiba 2920812, Japan.							Chen WN, 1996, J BIOL CHEM, V271, P26362, DOI 10.1074/jbc.271.42.26362; Chervitz SA, 1998, SCIENCE, V282, P2022, DOI 10.1126/science.282.5396.2022; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; GROSS RE, 1990, J BIOL CHEM, V265, P6896; HANKS SK, 1995, FASEB J, V9, P579; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Kuroyanagi H, 1998, GENOMICS, V51, P76, DOI 10.1006/geno.1998.5340; LAND M, 1994, J BIOL CHEM, V269, P9234; MATSUDA Y, 1995, ELECTROPHORESIS, V16, P261, DOI 10.1002/elps.1150160142; MATSUDA Y, 1992, CYTOGENET CELL GENET, V61, P282, DOI 10.1159/000133423; Matsuura A, 1997, GENE, V192, P245, DOI 10.1016/S0378-1119(97)00084-X; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; OGURA K, 1994, GENE DEV, V8, P2389, DOI 10.1101/gad.8.20.2389; Ogura K, 1997, GENE DEV, V11, P1801, DOI 10.1101/gad.11.14.1801; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; SHIRASAWA T, 1993, DEV DYNAM, V198, P1, DOI 10.1002/aja.1001980102; TABUSE Y, 1989, SCIENCE, V243, P1713, DOI 10.1126/science.2538925; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; WatkinsChow D, 1996, MAMM GENOME, V6, pS201; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; YAMADA J, 1994, MAMM GENOME, V5, P63, DOI 10.1007/BF00292332; Yan J, 1998, BIOCHEM BIOPH RES CO, V246, P222, DOI 10.1006/bbrc.1998.8546	29	73	77	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 21	1999	18	43					5850	5859		10.1038/sj.onc.1202988	http://dx.doi.org/10.1038/sj.onc.1202988			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557072				2022-12-25	WOS:000083270700002
J	Bourque, S; Binet, MN; Ponchet, M; Pugin, A; Lebrun-Garcia, A				Bourque, S; Binet, MN; Ponchet, M; Pugin, A; Lebrun-Garcia, A			Characterization of the cryptogein binding sites on plant plasma membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; TOBACCO CELLS; DISEASE RESISTANCE; CLADOSPORIUM-FULVUM; RADIATION INACTIVATION; PROTEINACEOUS ELICITOR; INSULIN-RECEPTOR; CROSS-LINKING; H+-ATPASE; TOMATO	Cryptogein is a 98-amino acid proteinaceous elicitor of tobacco defense reactions. Specific binding of cryptogein to high affinity binding sites on tobacco plasma membranes has been previously reported (K-d = 2 nM; number of binding sites: 220 fmol/mg of protein). In this study, biochemical characterization of cryptogein binding sites reveals that they correspond to a plasma membrane glycoprotein(s) with an N-linked carbohydrate moiety, which is involved in cryptogein binding. Radiation inactivation experiments performed on tobacco plasma membrane preparations indicated that cryptogein bound specifically to a plasma membrane component with an apparent functional molecular mass of 193 kDa. Moreover, using the homobifunctional cross-linking reagent disuccinimidyl suberate and tobacco plasma membranes incubated with I-125-cryptogein, we identified, after SDS-polyacrylamide gel electrophoresis and autoradiography, two I-125-cryptogein linked N-glycoproteins of about 162 and 50 kDa. Similar results were obtained using Arabidopsis thaliana and Acer pseudoplatanus plasma membrane preparations, whereas cryptogein did not induce any effects on the corresponding cell suspensions. These results suggest that either cryptogein binds to nonfunctional binding sites, homologues to those present in tobacco plasma membranes, or that a protein involved in signal transduction after cryptogein recognition is absent or inactive in both A. pseudoplatanus and A. thaliana.	Univ Bourgogne, INRA, UMR, F-21034 Dijon, France; INRA, Stn Botan & Pathol Vegetale, F-06606 Antibes, France	INRAE; Universite de Bourgogne; INRAE	Lebrun-Garcia, A (corresponding author), Univ Bourgogne, INRA, UMR, 17 Rue Sully,BV 1540, F-21034 Dijon, France.	lebrun@dijon.inra.fr	Bourque, Stephane/AAH-4084-2020	Ponchet, Michel/0000-0002-0144-109X				AMIRANOFF B, 1989, J BIOL CHEM, V264, P20714; BARBIERBRYGOO H, 1995, CRIT REV PLANT SCI, V14, P1, DOI 10.1080/713608067; BASSE CW, 1993, J BIOL CHEM, V268, P14724; Bonnet P, 1996, EUR J PLANT PATHOL, V102, P181, DOI 10.1007/BF01877105; Bourque S, 1998, PLANT PHYSIOL, V118, P1317, DOI 10.1104/pp.118.4.1317; BRISKIN DP, 1992, J EXP BOT, V43, P269, DOI 10.1093/jxb/43.3.269; CHANDLER MT, 1972, CAN J BOTANY, V50, P2265, DOI 10.1139/b72-294; COSIO EG, 1992, EUR J BIOCHEM, V204, P1115, DOI 10.1111/j.1432-1033.1992.tb16736.x; COSIO EG, 1990, FEBS LETT, V271, P223, DOI 10.1016/0014-5793(90)80411-B; Ebel J, 1998, BIOESSAYS, V20, P569, DOI 10.1002/(SICI)1521-1878(199807)20:7&lt;569::AID-BIES8&gt;3.0.CO;2-F; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; Giranton JL, 1995, PLANT J, V8, P827, DOI 10.1046/j.1365-313X.1995.8060827.x; Hammond-Kosack KE, 1998, PLANT CELL, V10, P1251, DOI 10.1105/tpc.10.8.1251; HammondKosack KE, 1997, ANNU REV PLANT PHYS, V48, P575, DOI 10.1146/annurev.arplant.48.1.575; HARMON JT, 1980, J BIOL CHEM, V255, P3412; Ito Y, 1997, PLANT J, V12, P347, DOI 10.1046/j.1365-313X.1997.12020347.x; Ji C, 1997, PLANT CELL, V9, P1425, DOI 10.1105/tpc.9.8.1425; Jones DA, 1997, ADV BOT RES, V24, P89; JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631; JUNG CY, 1984, MOL CHEM CHARACTERIZ, P193; KEEN NT, 1992, PLANT MOL BIOL, V19, P109, DOI 10.1007/BF00015609; KEMPNER ES, 1979, ANAL BIOCHEM, V92, P2, DOI 10.1016/0003-2697(79)90617-1; KOGEL G, 1991, PLANTA, V183, P164, DOI 10.1007/BF00197784; Kooman-Gersmann M, 1998, PLANT PHYSIOL, V117, P609, DOI 10.1104/pp.117.2.609; KoomanGersmann M, 1996, PLANT CELL, V8, P929, DOI 10.1105/tpc.8.5.929; Lamb C, 1997, ANNU REV PLANT PHYS, V48, P251, DOI 10.1146/annurev.arplant.48.1.251; Lebrun-Garcia A, 1998, PLANT J, V15, P773, DOI 10.1046/j.1365-313X.1998.00269.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MASSAGUE J, 1980, P NATL ACAD SCI-BIOL, V77, P7137, DOI 10.1073/pnas.77.12.7137; MICHELET B, 1995, PLANT PHYSIOL, V108, P1, DOI 10.1104/pp.108.1.1; NOVICK D, 1987, J BIOL CHEM, V262, P8483; NURNBERGER T, 1995, P NATL ACAD SCI USA, V92, P2338, DOI 10.1073/pnas.92.6.2338; Petitot AS, 1997, PLANT MOL BIOL, V35, P261, DOI 10.1023/A:1005833216479; PUGIN A, 1988, PLANT PHYSIOL BIOCH, V26, P347; Pugin A, 1997, PLANT CELL, V9, P2077, DOI 10.1105/tpc.9.11.2077; RENELT A, 1993, J EXP BOT, V44, P257; RICCI P, 1993, DEV PLANT PATHOL, V2, P121; Scofield SR, 1996, SCIENCE, V274, P2063, DOI 10.1126/science.274.5295.2063; SUTY L, 1995, MOL PLANT MICROBE IN, V8, P644, DOI 10.1094/MPMI-8-0644; Tang XY, 1996, SCIENCE, V274, P2060, DOI 10.1126/science.274.5295.2060; TAVERNIER E, 1995, PLANT PHYSIOL, V109, P1025, DOI 10.1104/pp.109.3.1025; Thomas CM, 1998, PHILOS T ROY SOC B, V353, P1413, DOI 10.1098/rstb.1998.0296; van der Biezen EA, 1998, CURR BIOL, V8, pR226, DOI 10.1016/S0960-9822(98)70145-9; VIARD MP, 1994, PLANT PHYSIOL, V104, P1245, DOI 10.1104/pp.104.4.1245; Wang GL, 1998, PLANT CELL, V10, P765, DOI 10.1105/tpc.10.5.765; WENDEHENNE D, 1995, FEBS LETT, V374, P203, DOI 10.1016/0014-5793(95)01108-Q; YOSHIKAWA M, 1983, PLANT CELL PHYSL, V34, P1229; Zhang SQ, 1998, PLANT CELL, V10, P435, DOI 10.1105/tpc.10.3.435	49	70	82	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34699	34705		10.1074/jbc.274.49.34699	http://dx.doi.org/10.1074/jbc.274.49.34699			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574936	hybrid			2022-12-25	WOS:000083979600030
J	Schultz, SJ; Zhang, MH; Kelleher, CD; Champoux, JJ				Schultz, SJ; Zhang, MH; Kelleher, CD; Champoux, JJ			Polypurine tract primer generation and utilization by moloney murine leukemia virus reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RNASE-H ACTIVITY; PLUS-STRAND DNA; DISPLACEMENT SYNTHESIS; AVIAN-MYELOBLASTOSIS; RIBONUCLEASE-H; CLEAVAGE SPECIFICITY; ANGSTROM RESOLUTION; POLYMERASE DOMAIN; CRYSTAL-STRUCTURE	During reverse transcription, the RNase H activity of reverse transcriptase specifically cleaves the viral genome within the polypurine tract (PPT) to create the primer used for the initiation of plus-strand DNA synthesis and nonspecifically cleaves the viral genome to facilitate synthesis of plus-strand DNA. To understand how primer length and sequence affect generation and utilization of the PPT, we employed short hybrid substrates containing or lacking the PPT to evaluate cleavage, extension, and binding by reverse transcriptase. Substrates containing RNAs with the correct 3' end for initiation of plus-strand synthesis were extended equally well by reverse transcriptase, but primer length affected susceptibility to RNase H cleavage. RNA substrates with 3' ends extending beyond the plus strand initiation site were extended poorly but were specifically cleaved to generate the correct 3' end for initiation of plus-strand synthesis, Substrates containing RNAs lacking the PPT were cleaved nonspecifically and extended inefficiently. Specific cleavages to generate the plus-strand primer and 5'-end-directed cleavages were kinetically favored over cleavages that destroyed the PPT primer or degraded other short RNA fragments. The PPT was not intrinsically resistant to cleavage by the isolated RNase H domain, and the isolated polymerase domain extended RNA primers containing the PPT sequence irrespective of the primer 3' end. These results provide insights into how reverse transcriptase generates and selectively utilizes the PPT primer for initiation of plus strand DNA synthesis.	Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Champoux, JJ (corresponding author), Univ Washington, Sch Med, Dept Microbiol, Box 357242, Seattle, WA 98195 USA.				NATIONAL CANCER INSTITUTE [R37CA051605] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA51605] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENARTZI H, 1993, J BIOL CHEM, V268, P16465; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CHAMPOUX JJ, 1984, J VIROL, V49, P686, DOI 10.1128/JVI.49.3.686-691.1984; DESTEFANO JJ, 1993, BIOCHEMISTRY-US, V32, P6908, DOI 10.1021/bi00078a014; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P7423; DESTEFANO JJ, 1994, NUCLEIC ACIDS RES, V22, P3793, DOI 10.1093/nar/22.18.3793; DESTEFANO JJ, 1995, NUCLEIC ACIDS RES, V23, P3901, DOI 10.1093/nar/23.19.3901; DESTEFANO JJ, 1993, NUCLEIC ACIDS RES, V21, P4330, DOI 10.1093/nar/21.18.4330; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P24295; DIVITA G, 1993, BIOCHEMISTRY-US, V32, P7966, DOI 10.1021/bi00082a018; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; FINSTON WI, 1984, J VIROL, V51, P26, DOI 10.1128/JVI.51.1.26-33.1984; FU TB, 1992, J VIROL, V66, P4271, DOI 10.1128/JVI.66.7.4271-4278.1992; FUENTES GM, 1995, J BIOL CHEM, V270, P28169, DOI 10.1074/jbc.270.47.28169; FURFINE ES, 1991, BIOCHEMISTRY-US, V30, P7041, DOI 10.1021/bi00243a001; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; GUO JH, 1995, BIOCHEMISTRY-US, V34, P5018, DOI 10.1021/bi00015a013; HUBER HE, 1990, J BIOL CHEM, V265, P10565; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kelleher CD, 1998, J BIOL CHEM, V273, P9976, DOI 10.1074/jbc.273.16.9976; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KOTEWICZ ML, 1988, NUCLEIC ACIDS RES, V16, P265, DOI 10.1093/nar/16.1.265; LEVIN JG, 1988, J VIROL, V62, P4376, DOI 10.1128/JVI.62.11.4376-4380.1988; LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990; OYAMA F, 1989, J BIOL CHEM, V264, P18808; Palaniappan C, 1998, J BIOL CHEM, V273, P3808, DOI 10.1074/jbc.273.7.3808; Palaniappan C, 1996, J BIOL CHEM, V271, P2063, DOI 10.1074/jbc.271.47.29605; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; POST K, 1993, BIOCHEMISTRY-US, V32, P5508, DOI 10.1021/bi00072a004; Powell MD, 1996, J VIROL, V70, P5288, DOI 10.1128/JVI.70.8.5288-5296.1996; PULLEN KA, 1993, J BIOL CHEM, V268, P6221; RANDOLPH CA, 1994, J BIOL CHEM, V269, P19207; RATTRAY AJ, 1987, J VIROL, V61, P2843, DOI 10.1128/JVI.61.9.2843-2851.1987; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; Schultz SJ, 1996, J VIROL, V70, P8630, DOI 10.1128/JVI.70.12.8630-8638.1996; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SKALKA AM, 1993, COLD SPRING HARBOR M, V23; SMITH JK, 1984, J VIROL, V52, P314, DOI 10.1128/JVI.52.2.314-319.1984; TANESE N, 1988, P NATL ACAD SCI USA, V85, P1777, DOI 10.1073/pnas.85.6.1777; TANESE N, 1991, J VIROL, V65, P4387, DOI 10.1128/JVI.65.8.4387-4397.1991; TELESNITSKY A, 1993, P NATL ACAD SCI USA, V90, P1276, DOI 10.1073/pnas.90.4.1276; WHITING SH, 1994, J VIROL, V68, P4747, DOI 10.1128/JVI.68.8.4747-4758.1994; WOHRL BM, 1990, BIOCHEMISTRY-US, V29, P10141, DOI 10.1021/bi00496a001; Wohrl BM, 1997, J BIOL CHEM, V272, P17581, DOI 10.1074/jbc.272.28.17581; Zhan XY, 1997, J BIOL CHEM, V272, P22023, DOI 10.1074/jbc.272.35.22023	49	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34547	34555		10.1074/jbc.274.49.34547	http://dx.doi.org/10.1074/jbc.274.49.34547			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574917	hybrid			2022-12-25	WOS:000083979600011
J	Bour, S; Perrin, C; Strebel, K				Bour, S; Perrin, C; Strebel, K			Cell surface CD4 inhibits HTV-1 particle release by interfering with Vpu activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ENVELOPE GLYCOPROTEIN; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE DOMAIN; CYTOPLASMIC DOMAIN; HIV-1 VPU; T-CELL; SUPERINFECTION INTERFERENCE; PERIPHERAL-BLOOD; PLASMA-MEMBRANE	One of the hallmarks of human immunodeficiency virus type I (HIV-1) infection is the rapid removal of the viral receptor CD4 from the cell surface. This remarkably efficient receptor interference requires the activity of three separate viral proteins: Env, Vpu, and Nef. We have investigated whether this unusually tight interference on cell surface CD4 expression had a more essential function during the viral life cycle than simply preventing superinfection. We now report that the removal of cell surface CD4 is required for optimal virus production by HIV-1, Indeed, maintenance of CD4 surface expression in infected cells lead to a 3-5-fold decrease in viral particle production. This effect was not due to the formation of intracellular complexes between CD4 and the gp160 viral envelope precursor but instead required the presence of CD4 at the cell surface and was specifically mediated by CD4 but not closely related plasma membrane receptors. The finding that CD4 had no significant effect on particle release by a Vpu-deficient variant indicates that CD4 acts by inhibiting the particle release-promoting activity of Vpu. Co-immunoprecipitation experiments further showed that CD4 and Vpu physically interact at the cell surface, suggesting that CD4 might inhibit Vpu activity by disrupting its oligomeric structure.	NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Bour, S (corresponding author), NIAID, Mol Microbiol Lab, NIH, Bldg 4,Rm 312,9000 Rockville Pike, Bethesda, MD 20892 USA.			Bour, Stephan/0000-0002-0211-0110	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000669, ZIAAI000669] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; BOUR S, 1995, J VIROL, V69, P1510, DOI 10.1128/JVI.69.3.1510-1520.1995; Bour S, 1996, J VIROL, V70, P8285, DOI 10.1128/JVI.70.12.8285-8300.1996; BOUR S, 1995, MICROBIOL REV, V59, P63, DOI 10.1128/MMBR.59.1.63-93.1995; BOUR S, 1991, J VIROL, V65, P6387, DOI 10.1128/JVI.65.12.6387-6396.1991; Bour S, 1996, J VIROL, V70, P820, DOI 10.1128/JVI.70.2.820-829.1996; BUONOCORE L, 1990, NATURE, V345, P625, DOI 10.1038/345625a0; BUONOCORE L, 1993, P NATL ACAD SCI USA, V90, P2695, DOI 10.1073/pnas.90.7.2695; CRISE B, 1990, J VIROL, V64, P5585, DOI 10.1128/JVI.64.11.5585-5593.1990; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; DELWART EL, 1989, J VIROL, V63, P273, DOI 10.1128/JVI.63.1.273-280.1989; DEROSSI A, 1991, J ACQ IMMUN DEF SYND, V4, P380; DONAHUE PR, 1991, J VIROL, V65, P4461, DOI 10.1128/JVI.65.8.4461-4469.1991; Ewart GD, 1996, J VIROL, V70, P7108, DOI 10.1128/JVI.70.10.7108-7115.1996; GELEZIUNAS R, 1994, FASEB J, V8, P593, DOI 10.1096/fasebj.8.9.8005387; Gonzalez ME, 1998, BIOCHEMISTRY-US, V37, P13710, DOI 10.1021/bi981527f; Grice AL, 1997, FEBS LETT, V405, P299, DOI 10.1016/S0014-5793(97)00198-1; HART AR, 1990, VIROLOGY, V177, P1, DOI 10.1016/0042-6822(90)90454-Y; JABBAR MA, 1990, J VIROL, V64, P6297, DOI 10.1128/JVI.64.12.6297-6304.1990; KIM JH, 1993, AIDS RES HUM RETROV, V9, P875, DOI 10.1089/aid.1993.9.875; KLIMKAIT T, 1990, J VIROL, V64, P621, DOI 10.1128/JVI.64.2.621-629.1990; Lama J, 1999, CURR BIOL, V9, P622, DOI 10.1016/S0960-9822(99)80284-X; LENBURG ME, 1993, J VIROL, V67, P7238, DOI 10.1128/JVI.67.12.7238-7245.1993; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MALDARELLI F, 1993, J VIROL, V67, P5056, DOI 10.1128/JVI.67.8.5056-5061.1993; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; MARSHALL WL, 1992, J VIROL, V66, P5492, DOI 10.1128/JVI.66.9.5492-5499.1992; MITCHELL T, 1992, J VIROL, V66, P5696, DOI 10.1128/JVI.66.9.5696-5702.1992; Moore PB, 1998, FEBS LETT, V431, P143, DOI 10.1016/S0014-5793(98)00714-5; Oldridge J, 1998, TRENDS CELL BIOL, V8, P302, DOI 10.1016/S0962-8924(98)01318-X; Paul M, 1998, J VIROL, V72, P1270, DOI 10.1128/JVI.72.2.1270-1279.1998; PETRY H, 1995, J VIROL, V69, P1564, DOI 10.1128/JVI.69.3.1564-1574.1995; PSALLIDOPOULOS MC, 1989, J VIROL, V63, P4626, DOI 10.1128/JVI.63.11.4626-4631.1989; RAJA NU, 1994, VIROLOGY, V204, P357, DOI 10.1006/viro.1994.1540; REINHART TA, 1993, J VIROL, V67, P5153, DOI 10.1128/JVI.67.9.5153-5162.1993; Ross TM, 1999, CURR BIOL, V9, P613, DOI 10.1016/S0960-9822(99)80283-8; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; Schubert U, 1996, FEBS LETT, V398, P12, DOI 10.1016/S0014-5793(96)01146-5; SCHUBERT U, 1994, J VIROL, V68, P2260, DOI 10.1128/JVI.68.4.2260-2271.1994; SCHUBERT U, 1995, J VIROL, V69, P7699, DOI 10.1128/JVI.69.12.7699-7711.1995; Schubert U, 1996, J VIROL, V70, P809, DOI 10.1128/JVI.70.2.809-819.1996; STEVENSON M, 1988, CELL, V53, P483, DOI 10.1016/0092-8674(88)90168-7; STREBEL K, 1989, J VIROL, V63, P3784, DOI 10.1128/JVI.63.9.3784-3791.1989; Strebel K, 1999, AIDS, V13, pS13; TEMIN HM, 1988, REV INFECT DIS, V10, P399; Tiganos E, 1998, VIROLOGY, V251, P96, DOI 10.1006/viro.1998.9368; WEISS RA, 1985, RNA TUMOR VIRUSES, V1, P209; WELLER SK, 1980, J VIROL, V33, P494, DOI 10.1128/JVI.33.1.494-506.1980; WILLEY RL, 1992, J VIROL, V66, P226, DOI 10.1128/JVI.66.1.226-234.1992; WILLEY RL, 1994, J VIROL, V68, P1207, DOI 10.1128/JVI.68.2.1207-1212.1994; WILLEY RL, 1992, J VIROL, V66, P7193, DOI 10.1128/JVI.66.12.7193-7200.1992	52	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33800	33806		10.1074/jbc.274.47.33800	http://dx.doi.org/10.1074/jbc.274.47.33800			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559275	hybrid			2022-12-25	WOS:000083745200091
J	Condrescu, M; Hantash, BM; Fang, Y; Reeves, JP				Condrescu, M; Hantash, BM; Fang, Y; Reeves, JP			Mode-specific inhibition of sodium-calcium exchange during protein phosphatase blockade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC NA+-CA2+ EXCHANGER; HAMSTER OVARY CELLS; ATP-DEPENDENT REGULATION; CALYCULIN-A; OKADAIC ACID; NA+/CA2+ EXCHANGE; CA2+-BINDING DOMAIN; NA+,CA2+ EXCHANGE; HUMAN PLATELETS; CA2+	The effects of the protein phosphatase inhibitors calyculin A and okadaic acid on Na+/Ca2+ exchange activity were examined in transfected Chinese hamster ovary cells expressing the bovine cardiac Na+/Ca2+ exchanger. Incubating the cells for 5-10 min with 100 nM calyculin A reduced exchange-mediated Ca-45(2+) uptake or Ba2+ influx by 50-75%. Half-maximal inhibition of Ca-45(2+) up-take was observed at 15 nM calyculin A. The nonselective protein kinase inhibitors K252a and staurosporine provided partial protection against the effects of calyculin A. Okadaic acid, another protein phosphatase inhibitor, nearly completely blocked exchange-mediated Ba2+ influx. Chinese hamster ovary cells expressing a mutant exchanger in which 420 out of 520 amino acid residues were deleted from the central hydrophilic domain of the exchanger remained sensitive to the inhibitory effects of calyculin A and okadaic acid. Surprisingly, Na-o(+)-dependent Ca2+ efflux appeared to be only modestly inhibited, if at all, by calyculin A or okadaic acid. We conclude that protein hyperphosphorylation during protein phosphatase blockade selectively inhibits the Ca2+ influx mode of Na+/Ca2+ exchange, probably by an indirect mechanism that does not involve phosphorylation of the exchanger itself.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Reeves, JP (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, 185 S Orange Ave, Newark, NJ 07103 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049932] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49932] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACETO JF, 1992, ARCH BIOCHEM BIOPHYS, V298, P553, DOI 10.1016/0003-9861(92)90449-7; ALMAZAN G, 1993, J NEUROSCI RES, V36, P163, DOI 10.1002/jnr.490360206; BERLIN RD, 1993, CELL CALCIUM, V14, P379, DOI 10.1016/0143-4160(93)90042-5; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Chernaya G, 1996, J BIOL CHEM, V271, P5378, DOI 10.1074/jbc.271.10.5378; COLLINS A, 1992, J PHYSIOL-LONDON, V454, P27, DOI 10.1113/jphysiol.1992.sp019253; Condrescu M, 1997, J GEN PHYSIOL, V109, P41, DOI 10.1085/jgp.109.1.41; CONDRESCU M, 1995, J BIOL CHEM, V270, P9137, DOI 10.1074/jbc.270.16.9137; DIPOLO R, 1979, J GEN PHYSIOL, V73, P91, DOI 10.1085/jgp.73.1.91; Fang Y, 1998, AM J PHYSIOL-CELL PH, V275, pC50, DOI 10.1152/ajpcell.1998.275.1.C50; FANG Y, 1999, IN PRESS CELL CALCIU; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; Georgatos S D, 1996, Int Rev Cytol, V164, P91; GEORGATOS SD, 1985, J CELL BIOL, V100, P1955, DOI 10.1083/jcb.100.6.1955; He SW, 1998, J NEUROSCI, V18, P4833; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; Hilgemann DW, 1996, BIOPHYS J, V71, P759, DOI 10.1016/S0006-3495(96)79275-5; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P905, DOI 10.1085/jgp.100.6.905; Hilgemann DW, 1997, ANNU REV PHYSIOL, V59, P193, DOI 10.1146/annurev.physiol.59.1.193; HIRANO K, 1992, J MUSCLE RES CELL M, V13, P341, DOI 10.1007/BF01766462; Hryshko LV, 1997, BASIC RES CARDIOL, V92, P45, DOI 10.1007/BF00794067; Iwamoto T, 1996, J BIOL CHEM, V271, P22391, DOI 10.1074/jbc.271.37.22391; Iwamoto T, 1996, J BIOL CHEM, V271, P13609, DOI 10.1074/jbc.271.23.13609; KOIKE Y, 1994, CELL CALCIUM, V15, P381, DOI 10.1016/0143-4160(94)90013-2; LEVITSKY DO, 1994, J BIOL CHEM, V269, P22847; LI ZP, 1993, J BIOL CHEM, V268, P11489; LIN LF, 1994, J NEUROCHEM, V63, P1941; MAIER GD, 1995, INT J CANCER, V61, P54, DOI 10.1002/ijc.2910610110; Marriott I, 1996, J BIOL CHEM, V271, P26732, DOI 10.1074/jbc.271.43.26732; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; Matsuoka S, 1997, J GEN PHYSIOL, V109, P273, DOI 10.1085/jgp.109.2.273; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; MENE P, 1993, EXP NEPHROL, V1, P245; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PIJUAN V, 1993, AM J PHYSIOL, V264, pC1066, DOI 10.1152/ajpcell.1993.264.4.C1066; RANDRIAMAMPITA C, 1995, J BIOL CHEM, V270, P29, DOI 10.1074/jbc.270.1.29; Reeves JP, 1998, J BIOENERG BIOMEMBR, V30, P151, DOI 10.1023/A:1020569224915; Sakai T, 1996, AM J PHYSIOL-CELL PH, V271, pC284, DOI 10.1152/ajpcell.1996.271.1.C284; Shigekawa M, 1996, ANN NY ACAD SCI, V779, P249, DOI 10.1111/j.1749-6632.1996.tb44791.x; TAKAI A, 1995, BIOCHEM J, V306, P657, DOI 10.1042/bj3060657; TAKUMA T, 1993, FEBS LETT, V323, P145, DOI 10.1016/0014-5793(93)81467-E; Tojyo Y, 1995, JPN J PHARMACOL, V69, P381, DOI 10.1254/jjp.69.381; Watano T, 1996, BRIT J PHARMACOL, V119, P555, DOI 10.1111/j.1476-5381.1996.tb15708.x; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; YANO Y, 1995, BIOCHEM J, V307, P439, DOI 10.1042/bj3070439	46	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33279	33286		10.1074/jbc.274.47.33279	http://dx.doi.org/10.1074/jbc.274.47.33279			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559203	hybrid			2022-12-25	WOS:000083745200019
J	Yoo, EM; Coloma, MJ; Trinh, KR; Nguyen, TQ; Vuong, LUC; Morrison, SL; Chintalacharuvu, KR				Yoo, EM; Coloma, MJ; Trinh, KR; Nguyen, TQ; Vuong, LUC; Morrison, SL; Chintalacharuvu, KR			Structural requirements for polymeric immunoglobulin assembly and association with J chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHIMERIC ANTIBODIES; CONSTANT-REGION; N-GLYCOSYLATION; IGM; SECRETION; TAILPIECE; DOMAIN; IGA1; MUTAGENESIS; RECEPTOR	Both IgM and IgA exist as polymeric immunoglobulins, IgM is assembled into pentamers with J chain and hexamers lacking J chain. In contrast, polymeric IgA exists mostly as dimers with J chain. Both IgM and IgA possess an 18-amino acid extension of the C terminus (the tail-piece (tp)) that participates in polymerization through a penultimate cysteine residue. The IgM (mu tp) and IgA (alpha tp) tail-pieces differ at seven amino acid positions. However, the tail-pieces by themselves do not determine the extent of polymerization. We now show that the restriction of polymerization to dimers requires both C(alpha)3 and alpha tp and that more efficient dimer assembly occurs when C(alpha)2 is also present; the dimers contain J chain. Formation of pentamers containing J chain requires C(mu)3, C(mu)4, and the mu tp. IgM-alpha tp is present mainly as hexamers lacking J chain, and mu mu gamma mu-mu tp forms tetramers and hexamers lacking J chain, whereas IgA-mu tp is present as high order polymers containing J chain. In addition, there is heterogeneous processing of the N-linked carbohydrate on IgA-mu tp, with some remaining in the high mannose state. These data suggest that in addition to the tail-piece, structural motifs in the constant region domains are critical for polymer assembly and J chain incorporation.	Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Chintalacharuvu, KR (corresponding author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, 405 Hilgard Ave, Los Angeles, CA 90095 USA.				NCI NIH HHS [CA16858] Funding Source: Medline; NIAID NIH HHS [AI08994] Funding Source: Medline; NIDDK NIH HHS [DK41301] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA016858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041301] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atkin JD, 1996, J IMMUNOL, V157, P156; BASTIAN A, 1992, BIOL CHEM H-S, V373, P1255, DOI 10.1515/bchm3.1992.373.2.1255; Brewer JW, 1997, MOL IMMUNOL, V34, P323, DOI 10.1016/S0161-5890(97)00029-1; CHAPUIS RM, 1975, BIOCHEMISTRY-US, V14, P1320, DOI 10.1021/bi00677a034; CHINTALACHARUVU KR, 1994, HEPATOLOGY, V19, P162, DOI 10.1016/0270-9139(94)90068-X; Chuang PD, 1997, J IMMUNOL, V158, P724; DANGL JL, 1988, EMBO J, V7, P1989, DOI 10.1002/j.1460-2075.1988.tb03037.x; DAVIS A, 1989, IMMUNOL TODAY, V4, P118; DAVIS A, 1989, IMMUNOL TODAY, V4, P127; Fazel S, 1997, INT IMMUNOL, V9, P1149, DOI 10.1093/intimm/9.8.1149; HAMILTON RG, 1993, J IMMUNOL METHODS, V158, P107, DOI 10.1016/0022-1759(93)90263-7; Krugmann S, 1997, J IMMUNOL, V159, P244; Mattu TS, 1998, J BIOL CHEM, V273, P2260, DOI 10.1074/jbc.273.4.2260; NILES MJ, 1995, P NATL ACAD SCI USA, V92, P2884, DOI 10.1073/pnas.92.7.2884; POON PH, 1995, J BIOL CHEM, V270, P8571, DOI 10.1074/jbc.270.15.8571; RANDALL TD, 1990, EUR J IMMUNOL, V20, P1971, DOI 10.1002/eji.1830200915; RANDALL TD, 1992, P NATL ACAD SCI USA, V89, P962, DOI 10.1073/pnas.89.3.962; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; SMITH RIF, 1994, BIO-TECHNOL, V12, P683, DOI 10.1038/nbt0794-683; SMITH RIF, 1995, J IMMUNOL, V154, P2226; Sorensen V, 1996, J IMMUNOL, V156, P2858; Sorensen V, 1999, J IMMUNOL, V162, P3448; TAO MH, 1989, J IMMUNOL, V143, P2595; Towbin H, 1992, Biotechnology, V24, P145; Wiersma EJ, 1997, J IMMUNOL, V158, P1719; WORMALD MR, 1991, EUR J BIOCHEM, V198, P131, DOI 10.1111/j.1432-1033.1991.tb15995.x	26	41	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33771	33777		10.1074/jbc.274.47.33771	http://dx.doi.org/10.1074/jbc.274.47.33771			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559270	hybrid			2022-12-25	WOS:000083745200086
J	Chen, L; Molinski, TF; Pessah, IN				Chen, L; Molinski, TF; Pessah, IN			Bastadin 10 stabilizes the open conformation of the ryanodine-sensitive Ca2+ channel in an FKBP12-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM; BINDING-SITES; IANTHELLA-BASTA; CA-2+ RELEASE; RECEPTOR; RAPAMYCIN; COMPLEX; MECHANISM	The marine sponge lanthella basta synthesizes at least 25 tetrameric bromotyrosine structures that possess a stringent structural requirement for modifying the gating behavior of ryanodine-sensitive Ca2+ channels (ryanodine receptors) (RYR). Bastadin 5 (B5) was shown to stabilize open and closed channel states with little influence on the sensitivity of the channel to activation by Ca2+ (Mack, M. M., Molinski, T, F,, Buck, E, D,, and Pessah, I. N. (1994) J. Biol. Chem. 269, 23236-23249), In the present paper, we utilize single channel analysis and measurements of Ca2+ flux across the sarcoplasmic reticulum to identify bastadin 10 (B10) as the structural congener responsible for dramatically stabilizing the open conformation of the RyR channel, possibly by reducing the free energy associated with closed to open channel transitions (Delta G*c --> o), The stability of the channel open state induced by B10 sensitized the channel to activation by Ca2+ to such an extent that it essentially obviated regulation by physiological concentrations of Ca2+ and relieved inhibition by physiological Mg2+. These actions of BIO were produced only on the cytoplasmic face of the channel, were selectively eliminated by pretreatment of channels with FK506 or rapamycin, and were reconstituted by human recombinant FKBP12. The actions of B10 were found to be reversible. A structure-activity model is proposed by which substitutions on the Eastern and Western hemispheres of the bastarane macrocycle may confer specificity toward the RyR1-FKBP12 complex to stabilize either the closed or open channel conformation. These results indicate that RyR1-FKBP12 complexes possesses a novel binding domain for phenoxycatechols and raise the possibility of molecular recognition of an endogenous ligand.	Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Grad Program Neurosci, Davis, CA 95616 USA; Univ Calif Davis, Dept Chem, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Pessah, IN (corresponding author), Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Grad Program Neurosci, 1 Shields Ave, Davis, CA 95616 USA.		Pessah, Isaac N/K-7985-2017; Molinski, Tadeusz F/P-2125-2018	Pessah, Isaac N/0000-0002-8149-588X; 	NIAMS NIH HHS [1RO1AR43140-03] Funding Source: Medline; NIGMS NIH HHS [1RO1 GM 57560-01] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057560] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Ahern GP, 1997, BIOPHYS J, V72, P146, DOI 10.1016/S0006-3495(97)78654-5; BRILLANTES AB, CELL, V77, P513; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; CALLAWAY C, 1994, J BIOL CHEM, V269, P15876; Choi JW, 1996, SCIENCE, V273, P239, DOI 10.1126/science.273.5272.239; CLARDY J, 1995, P NATL ACAD SCI USA, V92, P56, DOI 10.1073/pnas.92.1.56; Franklin MA, 1996, J NAT PROD, V59, P1121, DOI 10.1021/np960507g; FRANKLIN MA, 1995, THESIS U CALIFORNIA; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; KAZLAUSKAS R, 1981, AUST J CHEM, V34, P765, DOI 10.1071/CH9810765; Lamb GD, 1996, J PHYSIOL-LONDON, V494, P569, DOI 10.1113/jphysiol.1996.sp021514; LORENZ MC, 1995, J BIOL CHEM, V270, P27531, DOI 10.1074/jbc.270.46.27531; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACK MM, 1992, J PHARMACOL EXP THER, V262, P1028; MACK MM, 1994, J BIOL CHEM, V269, P23236; Marks AR, 1996, PHYSIOL REV, V76, P631, DOI 10.1152/physrev.1996.76.3.631; Marx SO, 1998, SCIENCE, V281, P818, DOI 10.1126/science.281.5378.818; MAYRLEITNER M, 1994, CELL CALCIUM, V15, P99, DOI 10.1016/0143-4160(94)90048-5; Ondrias K, 1996, SOC GEN PHY, V51, P29; PALADE P, 1987, J BIOL CHEM, V262, P6135; Pessah IN, 1997, AM J PHYSIOL-CELL PH, V272, pC601, DOI 10.1152/ajpcell.1997.272.2.C601; PESSAH IN, 1991, MOL PHARMACOL, V39, P679; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; Schultz LW, 1998, BIOORG MED CHEM LETT, V8, P1; Shou WN, 1998, NATURE, V391, P489, DOI 10.1038/35146; Snyder SH, 1998, TRENDS PHARMACOL SCI, V19, P21, DOI 10.1016/S0165-6147(97)01146-2; Wagenknecht T, 1997, J BIOL CHEM, V272, P32463, DOI 10.1074/jbc.272.51.32463; WITCHER DR, 1994, J BIOL CHEM, V269, P13076; Wong PW, 1997, MOL PHARMACOL, V51, P693, DOI 10.1124/mol.51.5.693; Wong PW, 1996, MOL PHARMACOL, V49, P740; Wong PW, 1997, J BIOL CHEM, V272, P15145, DOI 10.1074/jbc.272.24.15145	35	46	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32603	32612		10.1074/jbc.274.46.32603	http://dx.doi.org/10.1074/jbc.274.46.32603			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551814	hybrid			2022-12-25	WOS:000083623000014
J	Huang, HW; Zoppellaro, G; Sakurai, T				Huang, HW; Zoppellaro, G; Sakurai, T			Spectroscopic and kinetic studies on the oxygen-centered radical formed during the four-electron reduction process of dioxygen by Rhus vernicifera laccase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRACHYDERMA-TSUNODAE K-2593; SATIVUS ASCORBATE OXIDASE; TYPE-3 COPPER CENTERS; LEVEL INTERMEDIATE; BILIRUBIN OXIDASE; CRYSTAL-STRUCTURE; PURIFICATION; PEROXIDE; RESOLUTION; MECHANISM	The oxygen-centered radical bound to the trinuclear copper center was detected as an intermediate during the reoxidation process of the reduced Rhus vernicifera laccase with dioxygen and characterized by using absorption, stopped-flow, and electron paramagnetic resonance (EPR) spectroscopies and by super conducting quantum interface devices measurement. The intermediate bands appeared at 370 nm (is an element of similar to 1000), 420 nm (sh), and 670 nm (weak) within 15 ms, and were observable for similar to 2 min at pH 7.4 but for less than 5 s at pH 4.2. The first-order rate constant for the decay of the intermediate has been determined by stopped-flow spectroscopy, showing the isotope effect, k(H)/K-D of 1.4 in D2O. The intermediate was found to decay mainly from the protonated form by analyzing pH dependences. The enthalpy and entropy of activation suggested that a considerable structure change takes place around the active site during the decay of the intermediate. The EPR spectra at cryogenic temperatures (<27 K) showed two broad signals with g similar to 1.8 and 1.6 depending on pH. We propose an oxygen-centered radical in magnetic interaction with the oxidized type III copper ions as the structure of the three-electron reduced form of dioxygen.	Kanazawa Univ, Grad Sch Nat Sci & Technol, Kanazawa, Ishikawa 9201192, Japan	Kanazawa University	Sakurai, T (corresponding author), Kanazawa Univ, Grad Sch Nat Sci & Technol, Gen Educ Hall, Kanazawa, Ishikawa 9201192, Japan.		Zoppellaro, Giorgio/F-8453-2012; Sakurai, Takeshi/C-3335-2015	Zoppellaro, Giorgio/0000-0003-2304-2564; Sakurai, Takeshi/0000-0002-7989-8882				AASA R, 1976, BIOCHEM BIOPH RES CO, V70, P1204, DOI 10.1016/0006-291X(76)91030-5; ANDREASSON LE, 1976, BIOCHIM BIOPHYS ACTA, V438, P370, DOI 10.1016/0005-2744(76)90254-0; ATKINS PW, 1990, PHYSICAL CHEM, P855; BLEANEY B, 1952, PROC R SOC LON SER-A, V214, P451, DOI 10.1098/rspa.1952.0181; BLIGNY R, 1983, BIOCHEM J, V209, P489, DOI 10.1042/bj2090489; BOUDREAUX EA, 1976, THOERY APPL MOL PARA; BRANDEN R, 1978, BIOCHIM BIOPHYS ACTA, V524, P297, DOI 10.1016/0005-2744(78)90166-3; CALABRESE L, 1988, J BIOL CHEM, V263, P6480; DIXON M, 1971, BIOCHIM BIOPHYS ACTA, V226, P241, DOI 10.1016/0005-2728(71)90092-2; DRAGO RS, 1977, PHYSICAL METHOD CHEM; Ducros V, 1998, NAT STRUCT BIOL, V5, P310, DOI 10.1038/nsb0498-310; Earnshaw A., 1968, INTRO MAGNETOCHEMIST; FESHT A, 1985, ENZYME STRUCTURE MEC, P155; FREEMAN JC, 1993, BIOCHEMISTRY-US, V32, P4826, DOI 10.1021/bi00069a018; FROEHNER SC, 1974, J BACTERIOL, V120, P458, DOI 10.1128/JB.120.1.458-465.1974; GOLDBERG M, 1980, BIOCHEMISTRY-US, V19, P5181, DOI 10.1021/bi00564a005; HIROMI K, 1992, BIOSCI BIOTECH BIOCH, V56, P1349, DOI 10.1271/bbb.56.1349; Hirose J, 1998, INORG CHIM ACTA, V273, P204, DOI 10.1016/S0020-1693(97)06183-5; Huang HW, 1998, BBA-PROTEIN STRUCT M, V1384, P160, DOI 10.1016/S0167-4838(98)00014-4; Huang HW, 1999, J INORG BIOCHEM, V75, P19, DOI 10.1016/S0162-0134(99)00026-4; JONSSON L, 1995, BBA-PROTEIN STRUCT M, V1251, P210, DOI 10.1016/0167-4838(95)00104-3; Karlin KD, 1998, J BIOL INORG CHEM, V3, P172, DOI 10.1007/s007750050218; LANGEN R, 1992, J BIOL CHEM, V267, P25625; MALKIN R, 1970, ADV ENZYMOL REL S BI, V33, P177; MALMSTROM BG, 1994, EUR J BIOCHEM, V223, P711, DOI 10.1111/j.1432-1033.1994.tb19044.x; MESSERSCHMIDT A, 1993, J MOL BIOL, V230, P997, DOI 10.1006/jmbi.1993.1215; MESSERSCHMIDT A, 1992, J MOL BIOL, V224, P179, DOI 10.1016/0022-2836(92)90583-6; MONDOVI B, 1984, COPPER PROTEINS COPP, V3, P161; REIHAMMAR BRM, 1971, EUR J BIOCHEM, V18, P463; REINHAMM.B, 1970, BIOCHIM BIOPHYS ACTA, V205, P35, DOI 10.1016/0005-2728(70)90059-9; REINHAMMAR B, 1985, CHEM SCRIPTA, V25, P172; Rheinhammar B., 1984, COPPER PROTEINS COPP, V3, P1; RNTIE R, 1984, COPPER PROTEINS COPP, V3; Ryden L., 1984, COPP PROTEINS COPP E, V3, P37; SAKURAI T, 1990, J BIOCHEM-TOKYO, V107, P37, DOI 10.1093/oxfordjournals.jbchem.a123008; SAKURAI T, 1995, BBA-PROTEIN STRUCT M, V1248, P143, DOI 10.1016/0167-4838(95)00018-P; SAKURAI T, 1992, BIOCHEMISTRY-US, V31, P9844, DOI 10.1021/bi00155a042; SAKURAI T, 1997, MULTICOPPER OXIDASES, P225; Shimizu A, 1999, BIOCHEMISTRY-US, V38, P3034, DOI 10.1021/bi9819531; Shimizu A, 1999, J BIOCHEM-TOKYO, V125, P662, DOI 10.1093/oxfordjournals.jbchem.a022334; Shin W, 1996, J AM CHEM SOC, V118, P3202, DOI 10.1021/ja953621e; SPIRASOLOMON DJ, 1987, J AM CHEM SOC, V109, P6421, DOI 10.1021/ja00255a031; Sundaram UM, 1997, J AM CHEM SOC, V119, P12525, DOI 10.1021/ja972039i; [No title captured]	44	64	66	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32718	32724		10.1074/jbc.274.46.32718	http://dx.doi.org/10.1074/jbc.274.46.32718			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551829	hybrid			2022-12-25	WOS:000083623000029
J	Zhang, Y; Jiang, J; Kopchick, JJ; Frank, SJ				Zhang, Y; Jiang, J; Kopchick, JJ; Frank, SJ			Disulfide linkage of growth hormone (GH) receptors (GHR) reflects GH-induced GHR dimerization - Association of JAK2 with the GHR is enhanced by receptor dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; EXTRACELLULAR DOMAIN; BETA-CHAIN; ACTIVATION; BINDING; INTERLEUKIN-3; CELLS; HETERODIMERIZATION; IDENTIFICATION; EXPRESSION	The growth hormone (GH) receptor (GHR) binds GH in its extracellular domain and transduces activating signals via its cytoplasmic domain. Both GH-induced GHR dimerization and JAK2 tyrosine kinase activation are critical in initiation of GH signaling We previously described a rapid GH-induced disulfide linkage of GHRs in human IM-9 cells. In this study, three GH-induced phenomena (GHR dimerization, GHR disulfide linkage, and enhanced GHR-JAK2 association) were examined biochemically and immunologically. By using the GH antagonist, G120K; and an antibody recognizing a dimerization-sensitive GHR epitope, we demonstrated that GH-induced GHR disulfide linkage reflects GH-induced GHR dimerization. GH, not G120K, promoted both GHR disulfide linkage and enhanced association with JAK2. Measures that diminished GH-dependent JAK2 and GHR tyrosine phosphorylation diminished neither GH-induced GHR disulfide linkage nor GH-enhanced GHR-JAK2 association. By using both transient and stable expression systems, we determined that cysteine 241 (an unpaired extracellular cysteine) was critical for GH-induced GHR disulfide linkage; however, GH-induced GHR dimerization, GHR-JAK2 interaction, and GHR, JAK2, and STATE tyrosine phosphorylation still proceeded when this cysteine residue was mutated. We conclude GH-induced GHR disulfide linkage is not required for GHR dimerization, and activation and GH-enhanced GHR-JAK2 association depends more on GHR dimerization than on GHR and/or JAK2 tyrosine phosphorylation.	Univ Alabama, Dept Med, Div Endocrinol & Metab, DERB, Birmingham, AL 35294 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Vet Affairs Med Ctr, Birmingham, AL 35294 USA; Ohio Univ, Edison Biotechnol Inst, Athens, OH 45701 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); University System of Ohio; Ohio University	Frank, SJ (corresponding author), Univ Alabama, Dept Med, Div Endocrinol & Metab, DERB, Rm 756,UAB Stn, Birmingham, AL 35294 USA.				NIDDK NIH HHS [DK46395] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046395, R56DK046395, R29DK046395] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alele J, 1998, ENDOCRINOLOGY, V139, P1927, DOI 10.1210/en.139.4.1927; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CarterSu C, 1996, ANNU REV PHYSIOL, V58, P187, DOI 10.1146/annurev.ph.58.030196.001155; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN WY, 1991, MOL ENDOCRINOL, V5, P1845, DOI 10.1210/mend-5-12-1845; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; Flyvbjerg A, 1999, DIABETES, V48, P377, DOI 10.2337/diabetes.48.2.377; Frank SJ, 1999, ADV MOL CELL ENDOCR, V3, P1; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P2228, DOI 10.1210/en.135.5.2228; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P148, DOI 10.1210/en.135.1.148; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; FUH G, 1990, J BIOL CHEM, V265, P3111; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; Goldsmith JF, 1997, AM J PHYSIOL-ENDOC M, V273, pE932, DOI 10.1152/ajpendo.1997.273.5.E932; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; Ihle JN, 1995, ADV IMMUNOL, V60, P1, DOI 10.1016/S0065-2776(08)60582-9; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; Jiang J, 1998, BIOCHEM BIOPH RES CO, V253, P774, DOI 10.1006/bbrc.1998.9793; Kim SO, 1998, J BIOL CHEM, V273, P2344, DOI 10.1074/jbc.273.4.2344; LESNIAK MA, 1974, J BIOL CHEM, V249, P1661; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LI W, 1991, MOL CELL BIOL, V11, P3756, DOI 10.1128/MCB.11.7.3756; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; Liang L, 1999, ENDOCRINOLOGY, V140, P1972, DOI 10.1210/en.140.5.1972; Maru Y, 1996, J BIOL CHEM, V271, P15353, DOI 10.1074/jbc.271.26.15353; Moutoussamy S, 1998, J BIOL CHEM, V273, P15906, DOI 10.1074/jbc.273.26.15906; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Niedziela-Majka A, 1998, PROTEIN EXPRES PURIF, V14, P208, DOI 10.1006/prep.1998.0932; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SOTIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292, DOI 10.1210/en.135.4.1292; Stomski FC, 1998, J BIOL CHEM, V273, P1192, DOI 10.1074/jbc.273.2.1192; Stomski FC, 1996, MOL CELL BIOL, V16, P3035; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; Yi WS, 1996, MOL ENDOCRINOL, V10, P1425, DOI 10.1210/me.10.11.1425; Zhu T, 1998, J BIOL CHEM, V273, P33864, DOI 10.1074/jbc.273.50.33864	42	87	88	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					33072	33084		10.1074/jbc.274.46.33072	http://dx.doi.org/10.1074/jbc.274.46.33072			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551877	hybrid			2022-12-25	WOS:000083623000077
J	Carter, PH; Shimizu, M; Luck, MD; Gardella, TJ				Carter, PH; Shimizu, M; Luck, MD; Gardella, TJ			The hydrophobic residues phenylalanine 184 and leucine 187 in the type-1 parathyroid hormone (PTH) receptor functionally interact with the amino-terminal portion of PTH-(1-34)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; PROTEIN-LINKED RECEPTOR; (PTH)/PTH-RELATED PEPTIDE; TRANSMEMBRANE RESIDUES; EXTRACELLULAR LOOP; BINDING-AFFINITY; CROSS-LINKING; DOMAIN; SITE; MUTAGENESIS	Recent mutagenesis and cross-linking studies suggest that three regions of the PTH-1 receptor play important roles in ligand interaction: (i) the extreme NH2-terminal region, (ii) the juxtamembrane base of the amino-terminal extracellular domain, and (iii) the third extracellular loop. In this report, Re analyzed the second of these segments in the rat PTH-I receptor (residues 182-190) and its role in functional interaction with short PTH fragment analogs. Twenty-eight singly substituted PTH-I receptors were transiently transfected into COS-7 cells and shown to be fully expressed by surface antibody binding analysis, Alanine scanning analysis identified phe(184), Arg(186), Leu(187), and Ile(190) as important determinants of maximum binding of I-125-Iabeled bovine PTH-(1-34) and I-125-labeled bovine PTH-(3-34) and determinants of responsiveness to the NH2-terminal analog, PTH (1-14) in cAMP stimulation assays. Alanine mutations at these four sites augmented the ability of the COOH-terminal peptide [Glu(22),Trp(23)]PTHrP-(15-36) to inhibit the cAMP response induced by PTH-(1-34). At Phe(184) and Leu(187), hydrophobic substitutions (e.g. Ile, Met, or Leu) preserved PTH-(1-34)-mediated cAMP signaling potency, whereas hydrophilic substitutions (e.g. Asp, Glu, Lys, or Arg) weakened this response by 20-fold or more, as compared with the unsubstituted receptor's response. The results suggest that hydrophobicity at positions occupied by phe(184) and Leu(187) in the PTH-1 receptor plays an important role in determining functional interaction with the 3-14 portion of PTH.	Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Gardella, TJ (corresponding author), Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.				NIDDK NIH HHS [DK11794] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK011794] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abell A, 1996, J BIOL CHEM, V271, P4518; Adams AE, 1998, MOL ENDOCRINOL, V12, P1673, DOI 10.1210/me.12.11.1673; Bergwitz C, 1997, J BIOL CHEM, V272, P28861, DOI 10.1074/jbc.272.46.28861; Bergwitz C, 1996, J BIOL CHEM, V271, P26469, DOI 10.1074/jbc.271.43.26469; Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; Bowen WP, 1995, TRENDS PHARMACOL SCI, V16, P413, DOI 10.1016/S0165-6147(00)89091-4; CAO YJ, 1995, BIOCHEM BIOPH RES CO, V212, P673, DOI 10.1006/bbrc.1995.2021; Couvineau A, 1996, J BIOL CHEM, V271, P12795, DOI 10.1074/jbc.271.22.12795; Dautzenberg FM, 1998, P NATL ACAD SCI USA, V95, P4941, DOI 10.1073/pnas.95.9.4941; DeAlmeida VI, 1998, MOL ENDOCRINOL, V12, P750, DOI 10.1210/me.12.5.750; Dong MQ, 1999, J BIOL CHEM, V274, P903, DOI 10.1074/jbc.274.2.903; Gardella TJ, 1996, J BIOL CHEM, V271, P19888, DOI 10.1074/jbc.271.33.19888; GARDELLA TJ, 1994, ENDOCRINOLOGY, V135, P1186, DOI 10.1210/en.135.3.1186; Gardella TJ, 1996, J BIOL CHEM, V271, P12820, DOI 10.1074/jbc.271.22.12820; Holtmann MH, 1996, J PHARMACOL EXP THER, V279, P555; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; KOLAKOWSKI LF, 1994, RECEPTOR CHANNEL, V2, P1; KROEENBERG H, 1997, GENETICS ENDOCRINE M, P389; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE CW, 1995, MOL ENDOCRINOL, V9, P1269, DOI 10.1210/me.9.10.1269; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; Luck MD, 1999, MOL ENDOCRINOL, V13, P670, DOI 10.1210/me.13.5.670; Mannstadt M, 1998, J BIOL CHEM, V273, P16890, DOI 10.1074/jbc.273.27.16890; Nicole P, 1998, J PHARMACOL EXP THER, V284, P744; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Pellegrini M, 1998, BIOCHEMISTRY-US, V37, P12737, DOI 10.1021/bi981265h; ROST B, 1995, PROTEIN SCI, V4, P521; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; STROOP SD, 1995, BIOCHEMISTRY-US, V34, P1050, DOI 10.1021/bi00003a040; Turner PR, 1998, J BIOL CHEM, V273, P3830, DOI 10.1074/jbc.273.7.3830; Zhou AT, 1997, P NATL ACAD SCI USA, V94, P3644, DOI 10.1073/pnas.94.8.3644	32	36	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					31955	31960		10.1074/jbc.274.45.31955	http://dx.doi.org/10.1074/jbc.274.45.31955			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542224	hybrid			2022-12-25	WOS:000083532100032
J	Lausen, M; Lynch, N; Schlosser, A; Tornoe, I; Saekmose, SG; Teisner, B; Willis, AC; Crouch, E; Schwaeble, W; Holmskov, U				Lausen, M; Lynch, N; Schlosser, A; Tornoe, I; Saekmose, SG; Teisner, B; Willis, AC; Crouch, E; Schwaeble, W; Holmskov, U			Microfibril-associated protein 4 is present in lung washings and binds to the collagen region of lung surfactant protein D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE GELS; LECTIN ACTIVITY; GAMMA-CHAIN; CD11B CD18; FIBRINOGEN; RECEPTOR; COLLECTINS; TENASCIN; MOLECULE; CARBOHYDRATE	We have purified a glycoprotein from bovine lung washings using affinity chromatography on a maltose-affinity column. On SDS-polyacrylamide gel electrophoresis the protein showed a molecular mass of 36 kDa in the reduced state and 66 kDa in the unreduced state. On gel permeation chromatography the apparent molecular mass was 250 kDa, N-terminal sequencing showed homology to the human matrix protein microfibril-associated protein (hMFAP4), and the glycoprotein was designated bovine MFAP4 (bMFAP4). Lung surfactant protein D (SP-D) was also purified from lung washings, and calcium-dependent binding was demonstrated between bMFAP4 and SP-D. hMFAP4 was cloned, and recombinant hMFAP4 showed the same binding pattern to SP-D as bMFAP4. No binding was seen to recombinant SP-D composed of the neck region and carbohydrate recognition domain of SP-D, indicating that the interaction between MFAP4 and SP-D is mediated via the collagen region of SP-D. MFAP4 also showed calcium-dependent binding to mannan, which was partially inhibited by maltose. Our findings indicate that MFAP4 has two binding specificities, one for collagen and one for carbohydrate, and we suggest that MFAP4 may fix the collectins in the extracellular compartment during inflammation.	Odense Univ, Univ So Denmark, Inst Mol Biol, Dept Immunol & Microbiol, DK-5000 Odense, Denmark; Univ Leicester, Dept Microbiol & Immunol, Leicester LE1 9HN, Leics, England; Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England; Washington Univ, Dept Pathol, St Louis, MO 63110 USA	University of Southern Denmark; University of Leicester; University of Oxford; Washington University (WUSTL)	Holmskov, U (corresponding author), Odense Univ, Univ So Denmark, Inst Mol Biol, Dept Immunol & Microbiol, DK-5000 Odense, Denmark.		Holmskov, Uffe/AAA-3056-2022	Holmskov, Uffe/0000-0002-2391-9445; Schwaeble, Wilhelm/0000-0001-8927-0864; Lynch, Nicholas/0000-0003-3803-3329; Saekmose, Susanne Gjorup/0000-0002-1346-0052				ALTIERI DC, 1993, J BIOL CHEM, V268, P1847; ALTIERI DC, 1990, J BIOL CHEM, V265, P12119; Botas C, 1998, P NATL ACAD SCI USA, V95, P11869, DOI 10.1073/pnas.95.20.11869; BRISTOW J, 1993, J CELL BIOL, V122, P265, DOI 10.1083/jcb.122.1.265; BrownAugsburger P, 1996, J BIOL CHEM, V271, P18912, DOI 10.1074/jbc.271.31.18912; Cai GZ, 1999, AM J PHYSIOL-LUNG C, V276, pL131, DOI 10.1152/ajplung.1999.276.1.L131; Chroneos ZC, 1996, J BIOL CHEM, V271, P16375, DOI 10.1074/jbc.271.27.16375; Clark RA, 1997, J CELL BIOL, V137, P755, DOI 10.1083/jcb.137.3.755; CRAWFORD C, 1990, BIOCHEM J, V265, P575, DOI 10.1042/bj2650575; Crouch EC, 1998, BBA-MOL BASIS DIS, V1408, P278, DOI 10.1016/S0925-4439(98)00073-8; CROUCH EC, 1995, AM J RESP CELL MOL, V12, P410, DOI 10.1165/ajrcmb.12.4.7695920; DANG CV, 1985, J BIOL CHEM, V260, P9713; Eggleton P, 1999, CURR OPIN IMMUNOL, V11, P28, DOI 10.1016/S0952-7915(99)80006-5; Erickson HP, 1993, CURR OPIN CELL BIOL, V5, P869, DOI 10.1016/0955-0674(93)90037-Q; FISHER JH, 1995, AM J RESP CELL MOL, V12, P13, DOI 10.1165/ajrcmb.12.1.7811466; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; GUESDON JL, 1979, J HISTOCHEM CYTOCHEM, V27, P1131, DOI 10.1177/27.8.90074; Hansen S, 1998, IMMUNOBIOLOGY, V199, P165, DOI 10.1016/S0171-2985(98)80025-9; HENSCHEN A, 1979, THROMB HAEMOSTASIS, V41, P662; Holmskov U, 1997, J BIOL CHEM, V272, P13743, DOI 10.1074/jbc.272.21.13743; HOLMSKOV U, 1996, COLLECTINS INNATE IM, P51; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KOBAYASHI R, 1994, BIOCHEM BIOPH RES CO, V198, P1262, DOI 10.1006/bbrc.1994.1178; KOBAYASHI R, 1989, J BIOL CHEM, V264, P17437; Korfhagen TR, 1998, J BIOL CHEM, V273, P28438, DOI 10.1074/jbc.273.43.28438; Kremlev Sergey G., 1997, American Journal of Physiology, V272, pL1070; KREMLEV SG, 1994, AM J PHYSIOL-LUNG C, V267, pL712, DOI 10.1152/ajplung.1994.267.6.L712; Kremlev SG, 1997, AM J PHYSIOL-LUNG C, V272, pL996, DOI 10.1152/ajplung.1997.272.5.L996; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le Y, 1998, FEBS LETT, V425, P367, DOI 10.1016/S0014-5793(98)00267-1; Lu JH, 1996, BIOCHEM J, V313, P473, DOI 10.1042/bj3130473; Lu JH, 1998, IMMUNOBIOLOGY, V199, P190, DOI 10.1016/S0171-2985(98)80026-0; LUNN CA, 1982, J BIOL CHEM, V257, P1424; MALHOTRA R, 1990, J EXP MED, V172, P955, DOI 10.1084/jem.172.3.955; Matsushita M, 1996, J BIOL CHEM, V271, P2448, DOI 10.1074/jbc.271.5.2448; NAKAJIMA T, 1974, J BIOL CHEM, V249, P7679; Nepomuceno RR, 1997, IMMUNITY, V6, P119, DOI 10.1016/S1074-7613(00)80419-7; NESTERENKO MV, 1994, J BIOCHEM BIOPH METH, V28, P239, DOI 10.1016/0165-022X(94)90020-5; NISHI T, 1991, EUR J BIOCHEM, V202, P643, DOI 10.1111/j.1432-1033.1991.tb16418.x; Ohashi T, 1997, J BIOL CHEM, V272, P14220, DOI 10.1074/jbc.272.22.14220; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; REID KBM, 1996, COLLECTINS INNATE IM, P99; RUBIO S, 1995, J BIOL CHEM, V270, P12162, DOI 10.1074/jbc.270.20.12162; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; VANIWAARDEN JF, 1992, BIOCHEM J, V286, P5, DOI 10.1042/bj2860005; VNIWAARDEN F, 1990, AM J RESP CELL MOL N, V2, P91; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Yee VC, 1997, STRUCTURE, V5, P125, DOI 10.1016/S0969-2126(97)00171-8; ZHAO ZY, 1995, HUM MOL GENET, V4, P589, DOI 10.1093/hmg/4.4.589	50	50	53	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32234	32240		10.1074/jbc.274.45.32234	http://dx.doi.org/10.1074/jbc.274.45.32234			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542261	hybrid			2022-12-25	WOS:000083532100069
J	Raschle, M; Marra, G; Nystrom-Lahti, M; Schar, P; Jiricny, J				Raschle, M; Marra, G; Nystrom-Lahti, M; Schar, P; Jiricny, J			Identification of hMutL beta, a heterodimer of hMLH1 and hPMS1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA MISMATCH REPAIR; NONPOLYPOSIS COLORECTAL-CANCER; TUMOR-CELLS; MICROSATELLITE INSTABILITY; MICE DEFICIENT; COLON-CANCER; MUTL GENE; MUTATIONS; YEAST; PMS1	hMLH1 and hPMS2 function in postreplicative mismatch repair in the form of a heterodimer referred to as hMutL alpha. Tumors or cell Lines lacking this factor display mutator phenotypes and microsatellite instability, and mutations in the hMLH1 and hPMS2 genes predispose to hereditary non-polyposis colon cancer, A third MutL homologue, hPMS1, has also been reported to be mutated in one cancer-prone kindred, but the protein encoded by this locus has so far remained without function. We now show that hPMS1 is expressed in human cells and that it interacts with hMLH1 with high affinity to form the heterodimer hMutL beta. Recombinant hMutL alpha and hMutL beta, expressed in the baculovirus system, were tested for their activity in an in vitro mismatch repair assay. While hMutL alpha could fully complement extracts of mismatch repair-deficient cell lines lacking hMLH1 or hPMS2, hMutL beta failed to do so with any of the different substrates tested in this assay. The involvement of the latter factor in postreplicative mismatch repair thus remains to be demonstrated.	Univ Zurich, Inst Med Radiobiol, CH-8008 Zurich, Switzerland; Paul Scherrer Inst, CH-8008 Zurich, Switzerland	University of Zurich; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Jiricny, J (corresponding author), Univ Zurich, Inst Med Radiobiol, August Forel Str 7, CH-8008 Zurich, Switzerland.		Schär, Primo/G-5967-2012	Schär, Primo/0000-0003-1843-6147; Nystrom, Minna/0000-0003-0827-0243				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Akiyama Y, 1997, CANCER RES, V57, P3920; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Bennett SE, 1997, CANCER RES, V57, P2956; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Drotschmann K, 1998, NUCLEIC ACIDS RES, V26, P948, DOI 10.1093/nar/26.4.948; Drummond JT, 1997, P NATL ACAD SCI USA, V94, P10144, DOI 10.1073/pnas.94.19.10144; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; FISCHEL R, 1993, CELL, V75, P1027; Flores-Rozas H, 1998, P NATL ACAD SCI USA, V95, P12404, DOI 10.1073/pnas.95.21.12404; Glaab WE, 1998, J BIOL CHEM, V273, P26662, DOI 10.1074/jbc.273.41.26662; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; Hampson R, 1997, J BIOL CHEM, V272, P28596, DOI 10.1074/jbc.272.45.28596; HORII A, 1994, BIOCHEM BIOPH RES CO, V204, P1257, DOI 10.1006/bbrc.1994.2598; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JIRICNY J, 1988, P NATL ACAD SCI USA, V85, P8860, DOI 10.1073/pnas.85.23.8860; Johnson RE, 1996, J BIOL CHEM, V271, P7285, DOI 10.1074/jbc.271.13.7285; Kato T, 1998, MUTAT RES-FUND MOL M, V422, P279, DOI 10.1016/S0027-5107(98)00208-5; KOI M, 1994, CANCER RES, V54, P4308; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; Marra G, 1998, P NATL ACAD SCI USA, V95, P8568, DOI 10.1073/pnas.95.15.8568; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NystromLahti M, 1996, HUM MOL GENET, V5, P763, DOI 10.1093/hmg/5.6.763; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; Pang QS, 1997, MOL CELL BIOL, V17, P4465, DOI 10.1128/MCB.17.8.4465; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; RISINGER JI, 1995, J BIOL CHEM, V270, P18183, DOI 10.1074/jbc.270.31.18183; Risinger JI, 1998, CANCER RES, V58, P2978; Sambrook J., 2002, MOL CLONING LAB MANU; Schar P, 1997, GENETICS, V146, P1275; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; Yao X, 1999, P NATL ACAD SCI USA, V96, P6850, DOI 10.1073/pnas.96.12.6850	48	146	150	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32368	32375		10.1074/jbc.274.45.32368	http://dx.doi.org/10.1074/jbc.274.45.32368			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542278	hybrid			2022-12-25	WOS:000083532100086
J	Shaked, Y; Rosenmann, H; Talmor, G; Gabizon, R				Shaked, Y; Rosenmann, H; Talmor, G; Gabizon, R			A C-terminal-truncated PrP isoform is present in mature sperm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCRAPIE PRION PROTEINS; CREUTZFELDT-JAKOB-DISEASE; ASPARAGINE-LINKED GLYCOSYLATION; PHOSPHOLIPASE-C; COPPER-BINDING; CELL-SURFACE; MOUSE SPERM; MICE; RESISTANT; CHOLESTEROL	PrPC, the normal isoform of the prion component PrPSc, is a 33-35-kDa glycophosphatidylinositol-anchored glycoprotein expressed in the plasma membrane of many cells and especially in the brain. The specific role of PrPC is unknown, although lately it has been shown to bind copper specifically. We show here that PrPC is present even in mature sperm cells, a polarized cell that retains only the minimal components required for DNA delivery, movement, and energy production, As opposed to PrPC in other cells, PrP in ejaculated sperm cells was truncated in its C terminus in the vicinity of residue 200, Sperm PrP, although membrane-bound, was not released by phosphatidylinositol phospholipase C as web as not localized in cholesterol-rich microdomains (rafts), Although no infertility was reported for PrP-ablated mice in normal situations, our results suggest that sperm cells originating from PrP-ablated mice were significantly more susceptible to high copper concentrations than sperm from wild type mice, allocating a protective role for PrP in specific stress situations related to copper toxicity. Since the functions performed by proteins in sperm cells are limited, these cells may constitute an ideal system to elucidate the function of PrPC.	Hadassah Univ Hosp, Dept Neurol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Gabizon, R (corresponding author), Hadassah Univ Hosp, Dept Neurol, IL-91120 Jerusalem, Israel.							BALDWIN MA, 1994, PHILOS T ROY SOC B, V343, P435, DOI 10.1098/rstb.1994.0041; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BREUCKER H, 1985, CELL TISSUE RES, V240, P303; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Brown DR, 1998, J NEUROCHEM, V70, P1686; Brown DR, 1999, GLIA, V25, P282, DOI 10.1002/(SICI)1098-1136(19990201)25:3<282::AID-GLIA8>3.0.CO;2-N; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Buschmann A, 1998, BIOCHEM BIOPH RES CO, V253, P693, DOI 10.1006/bbrc.1998.9838; Chan S, 1998, CLIN LAB MED, V18, P673; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; Collinge J, 1998, BRIT MED J, V317, P472; Cross NL, 1998, BIOL REPROD, V59, P7, DOI 10.1095/biolreprod59.1.7; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Gabizon R, 1996, NAT MED, V2, P59, DOI 10.1038/nm0196-59; GAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672; GENNIS R, 1995, SCIENCE, V269, P1063, DOI 10.1126/science.7652553; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; Harris Z. Leah, 1996, American Journal of Clinical Nutrition, V63, p836S; Holada K, 1998, BRIT J HAEMATOL, V103, P276, DOI 10.1046/j.1365-2141.1998.01032.x; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V207, P621, DOI 10.1006/bbrc.1995.1233; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V214, P993, DOI 10.1006/bbrc.1995.2384; Ironside JW, 1998, J PATHOL, V186, P227, DOI 10.1002/(SICI)1096-9896(1998110)186:3&lt;227::AID-PATH174&gt;3.0.CO;2-3; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P2333, DOI 10.1073/pnas.94.6.2333; KASCZAK RJ, 1997, J VIROL, V61, P3688; Kirchhoff C, 1998, ANDROLOGIA, V30, P225; KRETZSCHMAR HA, 1986, DNA-J MOLEC CELL BIO, V5, P315, DOI 10.1089/dna.1986.5.315; Ladha S, 1998, J MEMBRANE BIOL, V165, P1, DOI 10.1007/s002329900415; MANSON JC, 1994, MOL NEUROBIOL, V8, P121, DOI 10.1007/BF02780662; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; Moore HDM, 1998, ANDROLOGIA, V30, P233; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; OVERSTREET JW, 1993, AM J IND MED, V4, P5; PAPA S, 1994, J BIOENERG BIOMEMBR, V26, P609, DOI 10.1007/BF00831535; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Roblero L, 1996, REPROD FERT DEVELOP, V8, P871, DOI 10.1071/RD9960871; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; Shiraishi N, 1998, ARCH BIOCHEM BIOPHYS, V357, P225, DOI 10.1006/abbi.1998.0802; STAHL N, 1990, BIOCHEMISTRY-US, V29, P5405, DOI 10.1021/bi00474a028; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; TAGUCHI F, 1993, ARCH VIROL, V130, P219, DOI 10.1007/BF01319011; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262; Tash JS, 1998, BIOCHEM BIOPH RES CO, V251, P557, DOI 10.1006/bbrc.1998.9516; THALER CD, 1995, BIOCHEMISTRY-US, V34, P7788, DOI 10.1021/bi00024a002; Tobler I, 1996, NATURE, V380, P639, DOI 10.1038/380639a0; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042; Yamamoto Toshinobu, 1998, Journal of Toxicological Sciences, V23, P373	53	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32153	32158		10.1074/jbc.274.45.32153	http://dx.doi.org/10.1074/jbc.274.45.32153			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542251	hybrid			2022-12-25	WOS:000083532100059
J	Stacker, SA; Stenvers, K; Caesar, C; Vitali, A; Domagala, T; Nice, E; Roufail, S; Simpson, RJ; Moritz, R; Karpanen, T; Alitalo, K; Achen, MG				Stacker, SA; Stenvers, K; Caesar, C; Vitali, A; Domagala, T; Nice, E; Roufail, S; Simpson, RJ; Moritz, R; Karpanen, T; Alitalo, K; Achen, MG			Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCHAIN DISULFIDE BONDS; VEGF-C; CRYSTAL-STRUCTURE; TYROSINE KINASES; FACTOR FAMILY; IN-VIVO; RECEPTOR; ANGIOGENESIS; BINDING; EXPRESSION	Vascular endothelial growth factor-D (VEGF-D) binds and activates the endothelial cell tyrosine kinase receptors VEGF receptor-2 (VEGFR-2) and VEGF receptor-3 (VEGFR-3), is mitogenic for endothelial cells, and shares structural homology and receptor specificity with VEGF-C, The primary translation product of VEGF-D has long N- and C-terminal polypeptide extensions in addition to a central VEGF homology domain (VHD). The VHD of VEGF-D is sufficient to bind and activate VEGFR-2 and VEGFR-3. Here we report that VEGF-D is proteolytically processed to release the VHD. Studies in 293EBNA cells demonstrated that VEGF-D undergoes Nand C-terminal cleavage events to produce numerous secreted polypeptides including a fully processed form of M-r similar to 21,000 consisting only of the VHD, which is predominantly a non-covalent dimer. Biosensor analysis demonstrated that the VHD has similar to 290- and similar to 40-fold greater affinity for VEGFR-2 and VEGFR-3, respectively, compared with unprocessed VEGF-D. In situ hybridization demonstrated that embryonic lung is a major site of expression of the VEGF-D gene. Processed forms of VEGF-D were detected in embryonic lung indicating that VEGF-D is proteolytically processed in vivo.	Royal Melbourne Hosp, Ludwig Inst Canc Res, Parkville, Vic 3050, Australia; Ludwig Inst Canc Res, Joint Prot Struct Lab, Parkville, Vic 3050, Australia; Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, SF-00014 Helsinki, Finland	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of Helsinki	Stacker, SA (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, POB 2008, Parkville, Vic 3050, Australia.		Alitalo, Kari K/J-5013-2014; Nice, Edouard C/B-1026-2011	Alitalo, Kari K/0000-0002-7331-0902; Karpanen, Terhi/0000-0002-2803-083X; Achen, Marc/0000-0002-3791-803X; Stacker, Steven/0000-0003-4096-9273; Simpson, Richard/0000-0002-9834-0796				Achen MG, 1998, INT J EXP PATHOL, V79, P255, DOI 10.1046/j.1365-2613.1998.700404.x; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; ANDERSSON M, 1992, J BIOL CHEM, V267, P11260; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Ji H, 1997, ELECTROPHORESIS, V18, P614, DOI 10.1002/elps.1150180345; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; KENNEY WC, 1994, J BIOL CHEM, V269, P12351; Korpelainen EI, 1998, CURR OPIN CELL BIOL, V10, P159, DOI 10.1016/S0955-0674(98)80137-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lints TJ, 1996, DEV DYNAM, V205, P457, DOI 10.1002/(SICI)1097-0177(199604)205:4<457::AID-AJA9>3.0.CO;2-H; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Nice EC, 1999, BIOESSAYS, V21, P339, DOI 10.1002/(SICI)1521-1878(199904)21:4<339::AID-BIES11>3.0.CO;2-C; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Oh SJ, 1997, DEV BIOL, V188, P96, DOI 10.1006/dbio.1997.8639; Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; OSTMAN A, 1988, J BIOL CHEM, V263, P16202; OSTMAN A, 1992, J CELL BIOL, V118, P509, DOI 10.1083/jcb.118.3.509; PARK JE, 1994, J BIOL CHEM, V269, P25646; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; POTGENS AJG, 1994, J BIOL CHEM, V269, P32879; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; STACKER SA, 1991, J IMMUNOL, V146, P648; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071; Witzenbichler B, 1998, AM J PATHOL, V153, P381, DOI 10.1016/S0002-9440(10)65582-4; Yamada Y, 1997, GENOMICS, V42, P483, DOI 10.1006/geno.1997.4774	39	260	281	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32127	32136		10.1074/jbc.274.45.32127	http://dx.doi.org/10.1074/jbc.274.45.32127			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542248	hybrid			2022-12-25	WOS:000083532100056
J	Shack, S; Gorospe, M; Fawcett, TW; Hudgins, WR; Holbrook, NJ				Shack, S; Gorospe, M; Fawcett, TW; Hudgins, WR; Holbrook, NJ			Activation of the cholesterol pathway and Ras maturation in response to stress	ONCOGENE			English	Article						cholesterol; 3-hydroxy-3-methylglutaryl-CoA reductase; ras; stress	MAP KINASE KINASE; PROTEIN-KINASE; P21RAS ISOPRENYLATION; CELLS; TRANSFORMATION; PRENYLATION; EXPRESSION; INHIBITOR; REDUCTASE; PLANTS	All cells depend on sterols and isoprenoids derived from mevalonate (MVA) for growth, differentiation, and maintenance of homeostatic functions. In plants, environmental insults like heat and sunlight trigger the synthesis of isoprene, also derived from MVA, and this phenomenon has been associated with enhanced tolerance to heat. Here, we show that in human prostate adenocarcinoma PC-3M cells heat shock leads to activation of the MVA pathway. This is characterized by a dose- and time-dependent elevation in 3-hydroxy3methylglutaryl-coenzyme A reductase (HMGR) activity; enhanced sterol and isoprenoid synthesis, and increased protein prenylation, Furthermore, prenylation and subsequent membrane localization of Ras, a central player in cell signaling, was rapidly induced following heat stress. These effects were dose-dependent, augmented with repeated insults, and were prevented by culturing cells in the presence of lovastatin, a competitive inhibitor of HMGR, Enhanced Ras maturation by heat stress was also associated with a heightened activation of extracellular signal-regulated kinase (ERK), a key mediator of both mitogenic and stress signaling pathways, in response to subsequent growth factor stimulation. Thus, activation of the MVA pathway may constitute an important adaptive host response to stress, and have significant implications to carcinogenesis.	NIA, Gerontol Res Ctr, Biol Chem Lab, Cell Stress & Aging Sect,NIH, Baltimore, MD 21224 USA; NCI, Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Holbrook, NJ (corresponding author), NIA, Gerontol Res Ctr, Biol Chem Lab, Cell Stress & Aging Sect,NIH, 5600 Nathan Shock Dr,Box 12, Baltimore, MD 21224 USA.							ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; BACH TJ, 1995, LIPIDS, V30, P191, DOI 10.1007/BF02537822; Bernhard EJ, 1998, CANCER RES, V58, P1754; BUCHER NLR, 1958, J BIOL CHEM, V234, P262; CASEY PJ, 1992, J LIPID RES, V33, P1731; CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; FUJII H, 1982, BIOCHIM BIOPHYS ACTA, V712, P716; Gadbut AP, 1997, EMBO J, V16, P7250, DOI 10.1093/emboj/16.24.7250; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRUNLER J, 1994, BBA-LIPID LIPID MET, V1212, P259, DOI 10.1016/0005-2760(94)90200-3; Guyton KZ, 1996, CANCER RES, V56, P3480; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HARDIE DG, 1997, EUR J BIOCHEM, V246, P258; HORIE M, 1993, BIOCHEM PHARMACOL, V46, P297, DOI 10.1016/0006-2952(93)90418-V; KHAN SG, 1994, J INVEST DERMATOL, V102, P754, DOI 10.1111/1523-1747.ep12377020; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KRITCHEVSKY D, 1958, CHOLESTEROL, P139; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Larner J, 1998, AM J CLIN ONCOL-CANC, V21, P579, DOI 10.1097/00000421-199812000-00010; LARSON TR, 1995, J ENDOUROL, V9, P339, DOI 10.1089/end.1995.9.339; Madersbacher S, 1998, PROSTATE, V37, P174; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MILLER AC, 1993, INT J CANCER, V53, P302, DOI 10.1002/ijc.2910530222; MILLER AC, 1995, INT J CANCER, V60, P249; Moriyama T, 1998, J BIOL CHEM, V273, P22037, DOI 10.1074/jbc.273.34.22037; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; OKAZAKI K, 1995, ONCOGENE, V10, P1149; SAMID D, 1991, RADIAT RES, V126, P244, DOI 10.2307/3577825; SERVADIO C, 1991, UROLOGY, V38, P307, DOI 10.1016/0090-4295(91)80140-3; SERVATIUS RJ, 1993, PHYSIOL BEHAV, V53, P1101, DOI 10.1016/0031-9384(93)90365-M; SHAPIRO DJ, 1974, BIOCHIM BIOPHYS ACTA, V370, P369, DOI 10.1016/0005-2744(74)90098-9; SHARKEY TD, 1995, NATURE, V374, P769, DOI 10.1038/374769a0; Sharkey TD, 1996, ENDEAVOUR, V20, P74, DOI 10.1016/0160-9327(96)10014-4; Siddiqui AA, 1998, J BIOL CHEM, V273, P3712, DOI 10.1074/jbc.273.6.3712; SIPERSTEIN MD, 1995, ADV EXP MED BIOL, V369, P155; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; STERMER BA, 1994, J LIPID RES, V35, P1133; TILBROOK PA, 1995, ONCOGENE, V10, P805; Yasuda M, 1932, J CLIN INVEST, V11, P677, DOI 10.1172/JCI100442	43	32	32	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 28	1999	18	44					6021	6028		10.1038/sj.onc.1203002	http://dx.doi.org/10.1038/sj.onc.1203002			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557091				2022-12-25	WOS:000083359100008
J	Doronin, S; Murray, L; Dessauer, CW; Johnson, RA				Doronin, S; Murray, L; Dessauer, CW; Johnson, RA			Covalent labeling of adenylyl cyclase cytosolic domains with gamma-methylimidazole-2 ',5 '-dideoxy-[gamma-P-32]3 '-ATP and the mechanism for P-site-mediated inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AQUEOUS-SOLUTION; 3'-POLYPHOSPHATES; PHOTOCHEMISTRY; REQUIREMENTS; ADENINE	A truncated first cytosolic domain of type V adenylyl cyclase (VC1) and a truncated second cytosolic domain of type II adenylyl cyclase (IIC2) were used alone and in the readily reversible complex (VC1.IIC2) to evaluate interactions with each other and with reversible and irreversible P-site ligands, Enzyme activity was used to assess formation and dissolution of VC1.IIC2. The data suggest that binding of 2',5'-dideoxy-3'-ATP to VC1 and IIC2 prevented formation of VC1.IIC2 and that 2',5'-dideoxy-3'-ATP dissociation occurred slowly. To enable configuration specific cross-linking to the catalytic site, 2',5'-dideoxyadenosine 3'-[gamma-(1-methylimidazole)-triphosphate] (gamma-MetIm-2', 5'-dd-3'-ATP) and 2',5'-dd-adenosine 3'-(gamma-azidoanilido)-triphosphate (gamma-azidoanilido-2',5'-dd-3'-ATP) were synthesized, the former also as its gamma-P-32-labeled analog. gamma-Azidoanilido-2',5'-dd-3'-ATP exhibited an inhibitory potency comparable with that of 2',5'-dd-3'-ATP, gamma-MetIm-2',5'-dd-[gamma-P-32]3'-ATP labeled the individual VC1 and IIC2 domains comparably and covalently to similar to 20% within 1 h. Formation of VC1.IIC2 resulted in reduced labeling of VC1 but enhanced labeling of IIC2. The data imply that formation of the catalytically active VC1.IIC2 complex affects the interaction of each domain with the 2',5'-dd-3'-ATP, the binding of which also affects the interaction between the two cytosolic domains, leading to a pseudo irreversible inhibition.	SUNY Stony Brook, Hlth Sci Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Johnson, RA (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.	rjohnson@ccmail.sunysb.edu	Dessauer, Carmen/N-6933-2018	Dessauer, Carmen/0000-0003-1210-4280	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038828] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-38828] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARCE R, 1993, PHOTOCHEM PHOTOBIOL, V58, P318, DOI 10.1111/j.1751-1097.1993.tb09568.x; Desaubry L, 1996, J BIOL CHEM, V271, P14028, DOI 10.1074/jbc.271.24.14028; Desaubry L, 1996, J BIOL CHEM, V271, P2380, DOI 10.1074/jbc.271.5.2380; Dessauer CW, 1997, J BIOL CHEM, V272, P22272, DOI 10.1074/jbc.272.35.22272; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; Dessauer CW, 1996, J BIOL CHEM, V271, P16967, DOI 10.1074/jbc.271.28.16967; Doronin S, 1998, J BIOL CHEM, V273, P32416, DOI 10.1074/jbc.273.49.32416; ELAD D, 1976, PHOTOCHEM PHOTOBIOL, V1, P357; GRACHEV MA, 1987, EUR J BIOCHEM, V163, P113, DOI 10.1111/j.1432-1033.1987.tb10743.x; GRACHEV MA, 1987, BIOORG KHIM+, V13, P992; IVANCHENKO VA, 1975, NUCLEIC ACIDS RES, V2, P1365, DOI 10.1093/nar/2.8.1365; JOHNSON RA, 1989, MOL PHARMACOL, V35, P681; JOHNSON RA, 1990, J BIOL CHEM, V265, P11595; JOHNSON RA, 1994, METHOD ENZYMOL, V238, P31; Johnson RA, 1998, FASEB J, V12, pA1479; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; MURRAY L, 1998, FASEB J, V12, P1478; Shoshani I, 1999, J BIOL CHEM, V274, P34735, DOI 10.1074/jbc.274.49.34735; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0	22	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34745	34750		10.1074/jbc.274.49.34745	http://dx.doi.org/10.1074/jbc.274.49.34745			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574943	hybrid			2022-12-25	WOS:000083979600037
J	Shoshani, I; Boudou, V; Pierra, C; Gosselin, G; Johnson, RA				Shoshani, I; Boudou, V; Pierra, C; Gosselin, G; Johnson, RA			Enzymatic synthesis of unlabeled and beta-P-32-labeled beta-L-2 ',3 '-dideoxyadenosine-5 '-triphosphate as a potent inhibitor of adenylyl cyclases and its use as reversible binding ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-MEDIATED INHIBITION; NUCLEOSIDE 3'-POLYPHOSPHATES; ATP ANALOGS; ADENOSINE; 2',5'-DIDEOXYADENOSINE; ECTONUCLEOTIDASES; REQUIREMENTS; DOMAINS; METAL; AMP	beta-L-2',3'-Dideoxyadenosine-5'-triphosphate (beta-L-2',3'-dd-5'-ATP) was prepared enzymatically from the corresponding monophosphate by the use of adenylate kinase, creatine phosphate, and creatine kinase in a single step. The beta-P-32-labeled analog was prepared similarly, but in a two step reaction. beta-L-2',3'-dd-5'-ATP inhibited adenylyl cyclase from rat brain competitively with respect to substrate (5'-ATP . Mn2+) and exhibited an IC50 similar to 24 nM. The labeled ligand was used in the development of a reversible binding assay for adenylyl cyclases, Binding of beta-L-2',3'-dd-[beta-P-32]5'-ATP was saturable with increasing concentrations of ligand and increased in proportion to membrane protein, and was enhanced by Mn2+ to a greater extent than by Mg2+. Binding was displaced with adenine nucleotides known to be either competitive or noncompetitive inhibitors but not by agents known not to act on the cyclase, or by 3-isobutyl-1-methylxanthine, creatine phosphate, or creatine kinase, Binding was rapid, with a half-time for the on-rate <1.8 min and for the off-rate <0.8 min. The potency and mechanism of the inhibition of this ligand and the pattern of agents that displace binding suggest an interaction with adenylyl cyclase per se and to a configuration of the enzyme consistent with. an interaction at the catalytic active site. The data suggest that this is a pretransition state inhibitor and contrasts with the equipotent 2',5'-dd-3'ATP, a post-transition state noncompetitive inhibitor.	SUNY Stony Brook, Hlth Sci Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; Univ Montpellier 2, CNRS USTL 5625, UMR, Lab Chim Organ Biomol Synth, F-34095 Montpellier, France	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Universite de Montpellier	Johnson, RA (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038828] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38828] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bolon PJ, 1996, BIOORG MED CHEM LETT, V6, P1657, DOI 10.1016/0960-894X(96)00293-4; Boudou V, 1999, NUCLEOS NUCLEOT, V18, P607, DOI 10.1080/15257779908041512; BOUDOU V, 1997, THESIS U MONTPELLIER; Desaubry L, 1996, J BIOL CHEM, V271, P14028, DOI 10.1074/jbc.271.24.14028; Desaubry L, 1998, J BIOL CHEM, V273, P24972, DOI 10.1074/jbc.273.38.24972; Desaubry L, 1996, J BIOL CHEM, V271, P2380, DOI 10.1074/jbc.271.5.2380; Dessauer CW, 1997, J BIOL CHEM, V272, P22272, DOI 10.1074/jbc.272.35.22272; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; FLORIO VA, 1983, MOL PHARMACOL, V24, P195; GARBERS DL, 1975, J BIOL CHEM, V250, P8449; HASLAM RJ, 1978, BIOCHEM J, V176, P83, DOI 10.1042/bj1760083; Johnson MS, 1994, ISS ENVIR SCI TECHN, P31; JOHNSON RA, 1989, MOL PHARMACOL, V35, P681; JOHNSON RA, 1990, J BIOL CHEM, V265, P11595; Johnson RA, 1997, J BIOL CHEM, V272, P8962; LUDVIG I, 1981, ACTA BIOCH BIOPH SIN, V16, P131; MANSURI MM, 1989, J MED CHEM, V32, P461, DOI 10.1021/jm00122a029; PIERRA C, 1997, THESIS U MONTPELLIER; Shoshani I, 1999, J BIOL CHEM, V274, P34742, DOI 10.1074/jbc.274.49.34742; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; WALSETH TF, 1979, BIOCHIM BIOPHYS ACTA, V562, P11, DOI 10.1016/0005-2787(79)90122-9; WEINRYB I, 1974, BIOCHIM BIOPHYS ACTA, V334, P218, DOI 10.1016/0005-2744(74)90165-X; WELFORD LA, 1987, EUR J PHARMACOL, V141, P123, DOI 10.1016/0014-2999(87)90418-3; WELFORD LA, 1986, EUR J PHARMACOL, V129, P217, DOI 10.1016/0014-2999(86)90431-0; WOLFF J, 1981, ADV CYCL NUCL RES<D>, V14, P199; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0	28	15	16	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34735	34741		10.1074/jbc.274.49.34735	http://dx.doi.org/10.1074/jbc.274.49.34735			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574941	hybrid			2022-12-25	WOS:000083979600035
J	Yabe, I; Horiuchi, K; Nakahara, K; Hiyama, T; Yamanaka, T; Wang, PC; Toda, K; Hirata, A; Ohsumi, Y; Hirata, R; Anraku, Y; Kusaka, I				Yabe, I; Horiuchi, K; Nakahara, K; Hiyama, T; Yamanaka, T; Wang, PC; Toda, K; Hirata, A; Ohsumi, Y; Hirata, R; Anraku, Y; Kusaka, I			Patch clamp studies on V-type ATPase of vacuolar membrane of haploid Saccharomyces cerevisiae - Preparation and utilization of a giant cell containing a giant vacuole	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING POTASSIUM CHANNEL; 2 PORE DOMAINS; PLASMA-MEMBRANE; K+ CHANNEL; H+-ATPASE; ESCHERICHIA-COLI; NA+/H+ EXCHANGER; COMPLETE GENOME; ION-TRANSPORT; YEAST GENE	A method for obtaining giant protoplasts of Escherichia coli (the spheroplast incubation (SI) method: Kuroda ct al. (Kuroda, T., Okuda, N., Saitoh, N., Hiyama, T., Terasaki, Y., Anazawa, H., Hirata, A., Mos, T., Kusaka, I., Tsuchiya, T., and Yabe, I. (1998) J. Biol. Chem. 273, 16897-16904) was adapted to haploid cells of Saccharomyces cerevisiae. The yeast cell grew to become as large as 20 mu m in diameter and to contain an oversized vacuole inside. A patch clamp technique in the whole cell/vacuole recording mode was applied for the vacuole isolated by osmotic shock. At zero membrane potential, ATP induced a strong current (as high as 100 pA; specific activity, 0.1 pA/mu m(2)) toward the inside of the vacuole. Bafilomycin A(1), a specific inhibitor of the V-type ATPase, strongly inhibited the activity (K-i = 10 nM). Complete inhibition at higher concentrations indicated that any other ATP-driven transport systems were not expressed under the present incubation conditions. This current was not observed in the vacuoles prepared from a mutant that disrupted a catalytic subunit of the V-type ATPase (RH105(Delta vma1::TRP)). The K-m value for the ATP dose response of the current was 159 mu M and the H+/ATP ratio estimated from the reversible potential of the V-I curve was 3.5 +/- 0.3. These values agreed well with those previously estimated by measuring the V-type ATPase activity biochemically. This method can potentially be applied to any type of ion channel, ion pump, and ion transporter in S. cerevisiae, and can also be used to investigate gene functions in various organisms by using yeast cells as hosts for homologous and heterogeneous expression systems.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Saitama Univ, Dept Biochem & Mol Biol, Urawa, Saitama 3388570, Japan; Univ Tokyo, Fac Sci, Dept Biol, Tokyo 1130033, Japan; Natl Inst Mat & Chem Res, Dept Polymer Engn, Tsukuba, Ibaraki 305, Japan; Natl Inst Basic Biol, Okazaki, Aichi 4448585, Japan	University of Tokyo; Saitama University; University of Tokyo; National Institute of Advanced Industrial Science & Technology (AIST); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Yabe, I (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan.	yabe@bio.t.u-tokyo.ac.jp	Ohsumi, Yoshinori/C-6449-2009; Hirata, Ryogo/C-7424-2017; Wang, Pa-Chun/AAD-4094-2019	Ohsumi, Yoshinori/0000-0003-2384-2166; 				ALBERTY RA, 1968, J BIOL CHEM, V243, P1337; ANRAKU Y, 1997, HDB BIOL PHYSICS, P93; BENNETT AB, 1984, PLANT PHYSIOL, V74, P545, DOI 10.1104/pp.74.3.545; BERTL A, 1995, P NATL ACAD SCI USA, V92, P2701, DOI 10.1073/pnas.92.7.2701; BERTL A, 1990, P NATL ACAD SCI USA, V87, P7824, DOI 10.1073/pnas.87.20.7824; BERTL A, 1992, J EXP BIOL, V172, P271; Bertl A, 1998, J MEMBRANE BIOL, V162, P67, DOI 10.1007/s002329900343; BERTL A, 1992, SCIENCE, V258, P873, DOI 10.1126/science.1439795; Bertl A, 1998, PFLUG ARCH EUR J PHY, V436, P999, DOI 10.1007/s004240050735; BIELY P, 1974, BIOCHIM BIOPHYS ACTA, V352, P268, DOI 10.1016/0005-2736(74)90218-1; BIELY P, 1971, J BACTERIOL, V107, P121, DOI 10.1128/JB.107.1.121-129.1971; Bihler H, 1998, FEBS LETT, V432, P59, DOI 10.1016/S0014-5793(98)00832-1; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; COURTOY R, 1974, J MICROSC-OXFORD, V100, P199, DOI 10.1111/j.1365-2818.1974.tb03929.x; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; DAVIES JM, 1994, P NATL ACAD SCI USA, V91, P8547, DOI 10.1073/pnas.91.18.8547; DEBONO M, 1994, ANNU REV MICROBIOL, V48, P471, DOI 10.1146/annurev.mi.48.100194.002351; dEnfert C, 1995, METHOD CELL BIOL, V49, P417, DOI 10.1016/S0091-679X(08)61470-3; EILAM Y, 1988, J GEN MICROBIOL, V134, P1063; Goldstein SAN, 1996, P NATL ACAD SCI USA, V93, P13256, DOI 10.1073/pnas.93.23.13256; GUSTIN MC, 1986, SCIENCE, V233, P1195, DOI 10.1126/science.2426783; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HILGEMANN DW, 1991, NATURE, V352, P715, DOI 10.1038/352715a0; HIRATA A, 1992, ARCH MICROBIOL, V158, P249, DOI 10.1007/BF00245240; HIRATA A, 1982, J GEN APPL MICROBIOL, V28, P263, DOI 10.2323/jgam.28.263; HIRATA R, 1992, BIOCHEM BIOPH RES CO, V188, P40, DOI 10.1016/0006-291X(92)92347-Z; Jones EW., 1997, MOL CELLULAR BIOL YE, VIII, P363; KAKINUMA Y, 1981, J BIOL CHEM, V256, P859; KETCHUM KA, 1995, NATURE, V376, P690, DOI 10.1038/376690a0; KITAMOTO K, 1988, J BACTERIOL, V170, P2683, DOI 10.1128/jb.170.6.2683-2686.1988; Kuroda T, 1998, J BIOL CHEM, V273, P16897, DOI 10.1074/jbc.273.27.16897; KUSAKA I, 1967, J BACTERIOL, V94, P884, DOI 10.1128/JB.94.4.884-888.1967; Lesage F, 1996, J BIOL CHEM, V271, P4183; LEW DJ, 1995, J CELL BIOL, V129, P739, DOI 10.1083/jcb.129.3.739; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; LOPRESTI P, 1989, BIOCHIM BIOPHYS ACTA, V998, P317, DOI 10.1016/0167-4838(89)90291-4; Loukin SH, 1997, EMBO J, V16, P4817, DOI 10.1093/emboj/16.16.4817; Lurin C, 1996, PLANT CELL, V8, P701, DOI 10.1105/tpc.8.4.701; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MARTINOIA E, 1981, NATURE, V289, P292, DOI 10.1038/289292a0; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; MISHINA M, 1984, NATURE, V307, P604, DOI 10.1038/307604a0; Nass R, 1997, J BIOL CHEM, V272, P26145, DOI 10.1074/jbc.272.42.26145; Nass R, 1998, J BIOL CHEM, V273, P21054, DOI 10.1074/jbc.273.33.21054; NEHER E, 1976, NATURE, V260, P799, DOI 10.1038/260799a0; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; OHSUMI Y, 1981, J BIOL CHEM, V256, P2079; PARKER I, 1987, PROC R SOC SER B-BIO, V232, P289, DOI 10.1098/rspb.1987.0075; Paulsen IT, 1998, FEBS LETT, V430, P116, DOI 10.1016/S0014-5793(98)00629-2; Pozos TC, 1996, MOL CELL BIOL, V16, P3730; RAMIREZ JA, 1989, P NATL ACAD SCI USA, V86, P7866, DOI 10.1073/pnas.86.20.7866; Reid JD, 1996, RECEPTOR CHANNEL, V4, P51; Sakaguchi S, 1995, PROTOPLASMA, V189, P142, DOI 10.1007/BF01280167; SCHACHTMAN DP, 1992, SCIENCE, V258, P1654, DOI 10.1126/science.8966547; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; Serrano R, 1995, METHOD CELL BIOL, V50, P481, DOI 10.1016/S0091-679X(08)61052-3; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUN GH, 1992, J CELL BIOL, V119, P1625, DOI 10.1083/jcb.119.6.1625; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; Vergani P, 1997, FEBS LETT, V405, P337, DOI 10.1016/S0014-5793(97)00211-1; WADA Y, 1992, BIOCHIM BIOPHYS ACTA, V1101, P296, DOI 10.1016/0005-2728(92)90085-G; WADA Y, 1994, J BIOENERG BIOMEMBR, V26, P631, DOI 10.1007/BF00831538; WADA Y, 1987, J BIOL CHEM, V262, P17260; WICK AN, 1957, J BIOL CHEM, V224, P963; ZHOU XL, 1995, FEBS LETT, V373, P170, DOI 10.1016/0014-5793(95)01035-D	69	28	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34903	34910		10.1074/jbc.274.49.34903	http://dx.doi.org/10.1074/jbc.274.49.34903			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574964	hybrid			2022-12-25	WOS:000083979600058
J	Estape, D; Rinas, U				Estape, D; Rinas, U			Folding kinetics of the all-beta-sheet protein human basic fibroblast growth factor, a structural homolog of interleukin-1 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; TRANSITION-STATE; CHYMOTRYPSIN INHIBITOR-2; SPECTROSCOPY; RESOLUTION; STABILITY; LYSOZYME; 2-STATE; STEP	The refolding and unfolding kinetics of the all-beta-sheet protein human basic fibroblast growth factor (hFGF-2) were studied by fluorescence spectroscopy. The kinetics of the unfolding transition are monophasic. The refolding reaction at high and low guanidinium chloride (GdmCl) concentrations is best described by mono- and biphasic folding, respectively. Refolding and unfolding of hFGF-2 (155 amino acids) is very slow compared with other non-disulfide-bonded monomeric proteins of similar size. For example, the rate constant for unfolding at 4.5 mol.liter(-1) GdmCl is 0.006 s(-1), and the refolding rate constants at 0.4 mol.liter(-1) GdmCl are 0.01 s(-1) and 0.0009 s(-1) (15 degrees C, pH 7.0), A characterization of the thermodynamic nature of the folding process using transition state theory revealed that the slow refolding is almost exclusively controlled by entropic factors, namely the strong loss of conformational freedom during refolding, The rate of the slow unfolding kinetics is mainly land at low denaturant concentrations exclusively) controlled by the large positive change in enthalpy, hFGF-2 shows similar slow folding kinetics to that of its structural homolog interleukin-1 beta. Since both proteins show very little sequence identity, it is suggested that their slow folding kinetics are determined by the complex beta-sheet arrangement of the native molecules.	GBF Natl Res Ctr Biotechnol, Div Biochem Engn, D-38124 Braunschweig, Germany	Helmholtz Association; Helmholtz-Center for Infection Research	Rinas, U (corresponding author), GBF Natl Res Ctr Biotechnol, Div Biochem Engn, Mascheroder Weg 1, D-38124 Braunschweig, Germany.			Rinas, Ursula/0000-0003-4940-5749				ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHEN BL, 1989, BIOCHEMISTRY-US, V28, P691, DOI 10.1021/bi00428a042; CHEN XW, 1994, BIOCHEMISTRY-US, V33, P6356, DOI 10.1021/bi00186a040; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P2315, DOI 10.1021/bi00223a005; CRAIG S, 1987, BIOCHEMISTRY-US, V26, P3570, DOI 10.1021/bi00386a048; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; ERIKSSON AE, 1993, PROTEIN SCI, V2, P1274, DOI 10.1002/pro.5560020810; Estape D, 1998, BIOCHEM J, V335, P343, DOI 10.1042/bj3350343; Eyring H, 1935, J CHEM PHYS, V3, P107, DOI 10.1063/1.1749604; Heidary DK, 1997, NAT STRUCT BIOL, V4, P725, DOI 10.1038/nsb0997-725; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10428, DOI 10.1021/bi00107a010; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10436, DOI 10.1021/bi00107a011; Jennings P, 1998, NAT STRUCT BIOL, V5, P11, DOI 10.1038/nsb0198-11a; MATTHEWS CR, 1987, METHOD ENZYMOL, V154, P498; MEYERINGOLD W, 1993, TRENDS BIOTECHNOL, V11, P387, DOI 10.1016/0167-7799(93)90098-T; Mizuguchi M, 1998, J MOL BIOL, V283, P265, DOI 10.1006/jmbi.1998.2100; OLIVEBERG M, 1995, P NATL ACAD SCI USA, V92, P8926, DOI 10.1073/pnas.92.19.8926; Schmid F X, 1986, Methods Enzymol, V131, P70; Schmid Franz X., 1992, P197; Tan YJ, 1996, J MOL BIOL, V264, P377, DOI 10.1006/jmbi.1996.0647; Utiyama H, 1986, Methods Enzymol, V131, P51; VARLEY P, 1993, SCIENCE, V260, P1110, DOI 10.1126/science.8493553; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446	25	28	29	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34083	34088		10.1074/jbc.274.48.34083	http://dx.doi.org/10.1074/jbc.274.48.34083			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567376	hybrid			2022-12-25	WOS:000083857500041
J	Razin, E; Zhang, ZC; Nechushtan, H; Frenkel, S; Lee, YN; Arudehandran, R; Rivera, J				Razin, E; Zhang, ZC; Nechushtan, H; Frenkel, S; Lee, YN; Arudehandran, R; Rivera, J			Suppression of microphthalmia transcriptional activity by its association with protein kinase C-interacting protein 1 in mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEIN; SECRETORY GRANULE PROTEASES; SERINE PROTEASES; GENE-EXPRESSION; MUTANT MICE; LOCUS; TFE3; POPULATIONS; ACTIVATION; FAMILY	Microphthalmia (mi) is a transcription factor that plays a major role in the regulation of growth and function in mast cells and melanocytes. Association of mi with other proteins is a critical step in the regulation of mi-mediated transcriptional activation We found protein kinase C-interacting protein 1 (PKCI) specifically associated with mi in yeast two-hybrid screening. Immunoprecipitation of mi from quiescent rat basophilic leukemic cells or mouse melanocytes resulted in the specific co-immunoprecipitation of PKCI. This association was significantly reduced on engagement of the surface Fc epsilon RI of mast cells or engagement of the Kit receptor on melanocytes. Hence, cell activation caused disengagement of mi from PKCI. Microphthalmia was previously shown to activate the mouse mast cell protease 6 (mMCP-6) promoter. Cotransfection of mi with PKCI in NIH 3T3 fibroblasts containing an mMCP-6 promoter-luciferase reporter demonstrated an up to 94% inhibition of mi-mediated transcriptional activation PKCI by itself, although localized in the cytosol and nucleus of the cells, has no known physiological function and did not demonstrate transcriptional activity. Its ability to suppres mi transcriptional activity in the transient transfected fibroblast system suggests that it can function in vivo as a negative regulator of mi-induced transcriptional activation.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel; NIAMS, Arthritis & Rheumatism Branch, NIH, Bethesda, MD 20892 USA	Hebrew University of Jerusalem; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Razin, E (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, POB 12272, IL-91120 Jerusalem, Israel.		nechushtan, hovav/Z-3564-2019; Frenkel, Shahar/AAQ-1909-2020; Lee, Yu Nee/T-2360-2017	Frenkel, Shahar/0000-0002-3688-8676; Lee, Yu Nee/0000-0001-8648-5253	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041101, ZIAAR041101] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; DUBREUIL P, 1991, P NATL ACAD SCI USA, V88, P2341, DOI 10.1073/pnas.88.6.2341; Friend DS, 1998, J IMMUNOL, V160, P5537; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Huang CF, 1998, J IMMUNOL, V160, P1910; HUGHES MJ, 1993, J BIOL CHEM, V268, P20687; ISOZAKI K, 1994, AM J PATHOL, V145, P827; Jippo T, 1997, AM J PATHOL, V150, P1373; JIPPO T, 1994, BLOOD, V84, P2977; Klein MG, 1998, EXP CELL RES, V244, P26, DOI 10.1006/excr.1998.4153; Lima CD, 1997, SCIENCE, V278, P286, DOI 10.1126/science.278.5336.286; Lutzelschwab C, 1997, J EXP MED, V185, P13, DOI 10.1084/jem.185.1.13; MCDONALD JR, 1985, BIOCHEM J, V232, P559, DOI 10.1042/bj2320559; MOORE KJ, 1995, TRENDS GENET, V11, P442, DOI 10.1016/S0168-9525(00)89143-X; Morii E, 1996, BLOOD, V88, P2488, DOI 10.1182/blood.V88.7.2488.bloodjournal8872488; Nechushtan H, 1997, BLOOD, V89, P2999, DOI 10.1182/blood.V89.8.2999; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; ROBINSON K, 1994, BIOCHEM J, V304, P661; SELDIN DC, 1985, P NATL ACAD SCI USA, V82, P3871, DOI 10.1073/pnas.82.11.3871; STEVENS RL, 1994, P NATL ACAD SCI USA, V91, P128, DOI 10.1073/pnas.91.1.128; Tachibana M, 1996, NAT GENET, V14, P50, DOI 10.1038/ng0996-50; Weilbaecher KN, 1998, J EXP MED, V187, P775, DOI 10.1084/jem.187.5.775; ZHAO GQ, 1993, MOL CELL BIOL, V13, P4505, DOI 10.1128/MCB.13.8.4505	26	88	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34272	34276		10.1074/jbc.274.48.34272	http://dx.doi.org/10.1074/jbc.274.48.34272			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567402	hybrid			2022-12-25	WOS:000083857500067
J	Salminen, A; Efimova, IS; Parfenyev, AN; Magretova, NN; Mikalahti, K; Goldman, A; Baykov, AA; Lahti, R				Salminen, A; Efimova, IS; Parfenyev, AN; Magretova, NN; Mikalahti, K; Goldman, A; Baykov, AA; Lahti, R			Reciprocal effects of substitutions at the subunit interfaces in hexameric pyrophosphatase of Escherichia coli - Dimeric and monomeric forms of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; INORGANIC PYROPHOSPHATASE; 2.2-ANGSTROM RESOLUTION; POSITIVE COOPERATIVITY; CATALYTIC PROPERTIES; ACTIVE-SITE; LYSINE-104; MUTATION	A homohexameric molecule of Escherichia coli pyrophosphatase is arranged as a dimer of trimers, with an active site present in each of its six monomers. Earlier we reported that substitution of His(136) and His(140) in the intertrimeric subunit interface splits the molecule into active trimers (Velichko, I. S., Mikalahti, K., Kasho, V. N., Dudarenkov, V. Y., Hyytia, T., Goldman, A., Cooperman, B. S., Lahti, R., and Baykov, A. A. (1998) Biochemistry 37, 734-740). Here we demonstrate that additional substitutions of Tyr(77) and Gln(80) in the intratrimeric interface give rise to moderately active dimers or virtually inactive monomers, depending on pH, temperature, and Mg2+ concentration. Successive dissociation of the hexamer into trimers, dimers, and monomers progressively decreases the catalytic efficiency (by 10(6)-fold in total), and conversion of a trimer into dimer decreases the affinity of one of the essential Mg2+-binding sites/monomer. Disruptive substitutions predominantly in the intratrimeric interface stabilize the intertrimeric interface and vice versa, suggesting that the optimal intratrimeric interaction is not compatible with the optimal intertrimeric interaction. Because of the resulting "conformational strain," hexameric wild-type structure appears to be preformed to bind substrate. A hexameric triple variant substituted at Tyr(77), Gln(80), and His(136) exhibits positive cooperativity in catalysis, consistent with this model.	AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia; Moscow State Univ, Sch Chem, Moscow 119899, Russia; Univ Turku, Dept Biochem, FIN-20500 Turku, Finland	Lomonosov Moscow State University; Lomonosov Moscow State University; Finland National Institute for Health & Welfare; University of Turku	Baykov, AA (corresponding author), AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia.		Baykov, Alexander A/C-7981-2012; Baykov, Alexander/AAH-5301-2021	Baykov, Alexander/0000-0002-2495-8200	FIC NIH HHS [TW00407] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW000407] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Baykov A A, 1999, Prog Mol Subcell Biol, V23, P127; Baykov AA, 1999, EUR J BIOCHEM, V260, P308, DOI 10.1046/j.1432-1327.1999.00181.x; BAYKOV AA, 1981, ANAL BIOCHEM, V116, P1, DOI 10.1016/0003-2697(81)90313-4; Baykov AA, 1995, J BIOL CHEM, V270, P30804, DOI 10.1074/jbc.270.51.30804; BORSHCHIK I B, 1986, Biokhimiya, V51, P1484; CHEN J, 1990, J BACTERIOL, V172, P5686, DOI 10.1128/jb.172.10.5686-5689.1990; COOPERMAN BS, 1992, TRENDS BIOCHEM SCI, V17, P262, DOI 10.1016/0968-0004(92)90406-Y; Efimova IS, 1999, J BIOL CHEM, V274, P3294, DOI 10.1074/jbc.274.6.3294; Fabrichniy IP, 1997, BIOCHEMISTRY-US, V36, P7746, DOI 10.1021/bi9629844; FIRST EA, 1993, BIOCHEMISTRY-US, V32, P13651, DOI 10.1021/bi00212a033; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Harutyunyan EG, 1996, KRISTALLOGRAFIYA+, V41, P84; Harutyunyan EH, 1997, BIOCHEMISTRY-US, V36, P7754, DOI 10.1021/bi962637u; Heikinheimo P, 1996, STRUCTURE, V4, P1491, DOI 10.1016/S0969-2126(96)00155-4; Kankare J, 1996, ACTA CRYSTALLOGR D, V52, P551, DOI 10.1107/S0907444996000376; Kankare J, 1996, BIOCHEMISTRY-US, V35, P4670, DOI 10.1021/bi952637e; LAHTI R, 1990, BIOCHEMISTRY-US, V29, P5761, DOI 10.1021/bi00476a017; LUNDIN M, 1991, J BIOL CHEM, V266, P12168; RICCI G, 1995, J BIOL CHEM, V270, P1243, DOI 10.1074/jbc.270.3.1243; Salminen T, 1996, PROTEIN SCI, V5, P1014; SALMINEN T, 1995, BIOCHEMISTRY-US, V34, P782, DOI 10.1021/bi00003a011; Shinoda H, 1999, J BIOCHEM-TOKYO, V125, P58, DOI 10.1093/oxfordjournals.jbchem.a022268; Velichko IS, 1998, BIOCHEMISTRY-US, V37, P734, DOI 10.1021/bi9714823; VELICHKO IV, 1995, FEBS LETT, V359, P20, DOI 10.1016/0014-5793(95)00003-R; Volk SE, 1996, BIOCHEMISTRY-US, V35, P4662, DOI 10.1021/bi952636m; WONG SCK, 1970, J BIOL CHEM, V245, P4335	26	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					33898	33904		10.1074/jbc.274.48.33898	http://dx.doi.org/10.1074/jbc.274.48.33898			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567351	hybrid			2022-12-25	WOS:000083857500016
J	Yu, JH; Schwartzbauer, G; Kazlman, A; Menon, RK				Yu, JH; Schwartzbauer, G; Kazlman, A; Menon, RK			Role of the Sp family of transcription factors in the ontogeny of growth hormone receptor gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-SPECIFIC PROMOTER; GH-BINDING-PROTEIN; 5'-UNTRANSLATED REGIONS; IDENTIFICATION; ACTIVATION; MOUSE; CLONING; DOMAINS	The growth hormone (GH) receptor is essential for the actions of growth hormone on postnatal growth and metabolism. GH receptor transcripts are characterized by the presence of disparate 5'-untranslated exons, Factors regulating the expression of the GC rich L2 transcript of the murine GH receptor gene have hitherto remained unidentified. To characterize the mechanisms regulating expression of the L2 transcript, primer extension and ribonuclease protection assays mere used to identify transcription start sites in RNA from liver of adult mice. Transient transfection experiments revealed that 2.0 kilobase pairs of the L2 5'-flanking sequence exhibited promoter activity in BNL CL.2 (mouse liver) cells, CV-1 (monkey kidney) cells, and HRP.1 trophoblasts, Deletional analysis localized a major regulatory region to within 75 base pairs of the 5' transcription start site. Sequence analysis revealed that the region contained consensus binding sites for the Sp family of transcription factors. Standard gel shift and supershift analysis using liver nuclear extracts established that Sp1 and Sp3 bound this regulatory element, Transfection of wild type but not mutant decoy oligonucleotides into BNL CL.2 cells decreased the activity of the L2 promoter. Overexpression of Sp1 and Sp3 protein in Drosophila Schneider cells established that Sp3 is more potent than Sp1 in transactivating the L2 promoter. Co-transfection experiments further established that Sp1 antagonizes the activity of Sp3 to transactivate the L2 promoter. Western blot analysis of liver nuclear extracts revealed that the levels of Sp3 increase significantly after birth, suggesting a role for the Sp family of transcription factors in controlling the fetal to postnatal increase in GH receptor gene expression.	Univ Pittsburgh, Dept Pediat, Div Endocrinol, Childrens Hosp Pittsburgh,Sch Med, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Menon, RK (corresponding author), Univ Pittsburgh, Dept Pediat, Div Endocrinol, Childrens Hosp Pittsburgh,Sch Med, 3705 5th Ave, Pittsburgh, PA 15213 USA.	menonr@chplink.chp.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK049845, T32DK007729] Funding Source: NIH RePORTER; NIDDK NIH HHS [5T32DK07729, R29-DK49845] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS TE, 1990, MOL CELL ENDOCRINOL, V73, P135, DOI 10.1016/0303-7207(90)90126-S; BAUMBACH WR, 1995, ENDOCRINOLOGY, V136, P749, DOI 10.1210/en.136.2.749; Bigger CB, 1997, J BIOL CHEM, V272, P25976, DOI 10.1074/jbc.272.41.25976; DOMENE HM, 1995, DNA CELL BIOL, V14, P195, DOI 10.1089/dna.1995.14.195; Edens A, 1998, ENDOCR REV, V19, P559, DOI 10.1210/er.19.5.559; GLUCKMAN PD, 1986, REV REPRODUCTIVE BIO, P1; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Jiang HL, 1999, J BIOL CHEM, V274, P7893, DOI 10.1074/jbc.274.12.7893; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kumar AP, 1997, NUCLEIC ACIDS RES, V25, P2012, DOI 10.1093/nar/25.10.2012; Kwon HS, 1999, J BIOL CHEM, V274, P20, DOI 10.1074/jbc.274.1.20; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Liang FQ, 1999, ENDOCRINOLOGY, V140, P1695, DOI 10.1210/en.140.4.1695; MAJELLO B, 1995, ONCOGENE, V10, P1841; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MENON RK, 1995, J BIOL CHEM, V270, P8851, DOI 10.1074/jbc.270.15.8851; Menon RK, 1997, MOL ENDOCRINOL, V11, P1291, DOI 10.1210/me.11.9.1291; MOFFAT JG, 1998, 80 ANN M END SOC NEW; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; OMAHONEY JV, 1994, MOL CELL ENDOCRINOL, V101, P129, DOI 10.1016/0303-7207(94)90227-5; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schwartzbauer G, 1998, MOL GENET METAB, V63, P243, DOI 10.1006/mgme.1998.2685; SMITH WC, 1989, MOL ENDOCRINOL, V3, P984, DOI 10.1210/mend-3-6-984; SOUTHARD JN, 1995, ENDOCRINOLOGY, V136, P2913, DOI 10.1210/en.136.7.2913; ZOU LL, 1995, ENDOCRINOLOGY, V136, P5236, DOI 10.1210/en.136.11.5236; Zou LL, 1997, ENDOCRINOLOGY, V138, P1771, DOI 10.1210/en.138.4.1771	29	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34327	34336		10.1074/jbc.274.48.34327	http://dx.doi.org/10.1074/jbc.274.48.34327			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567409	hybrid			2022-12-25	WOS:000083857500074
J	Baricordi, OR; Melchiorri, L; Adinolfi, E; Falzoni, S; Chiozzi, P; Buell, G; Di Virgilio, F				Baricordi, OR; Melchiorri, L; Adinolfi, E; Falzoni, S; Chiozzi, P; Buell, G; Di Virgilio, F			Increased proliferation rate of lymphoid cells transfected with the P2X(7) ATP receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE 5'-TRIPHOSPHATE ATP; EXTRACELLULAR ATP; MOUSE LYMPHOCYTES; PLASMA-MEMBRANE; T-LYMPHOCYTES; P-2Z RECEPTOR; P2Z RECEPTOR; PERMEABILITY; STIMULATION; MACROPHAGES	Human leukocytes can express the P2X(7) purinergic receptor, an ionic channel gated by extracellular ATP, for which the physiological role is only partially understood. Transfection of P2X(7) cDNA into lymphoid cells that lack this receptor sustains their proliferation in serum-free medium. Increased proliferation of serum-starved P2X(7) transfectants is abolished by the P2X(7) receptor blocker oxidized ATP or by the ATP hydrolase apyrase. Both wild type and P2X(7)-transfected lymphoid cells release large amounts of ATP into the culture medium. These data suggest the operation of an ATP-based autocrine/paracrine loop that supports lymphoid cell growth in the absence of serum-derived growth factors.	Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, I-44100 Ferrara, Italy; Univ Ferrara, Dept Expt & Diagnost Med, Med Genet Sect, I-44100 Ferrara, Italy; Univ Ferrara, Ctr Biotechnol, I-44100 Ferrara, Italy; Ares Serono, CH-1228 Geneva, Switzerland	University of Ferrara; University of Ferrara; University of Ferrara	Di Virgilio, F (corresponding author), Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, Via Borsari 46, I-44100 Ferrara, Italy.		Di Virgilio, Francesco/J-3754-2018; DI VIRGILIO, Francesco/O-4634-2019; Adinolfi, Elena/F-9169-2010	Di Virgilio, Francesco/0000-0003-3566-1362; DI VIRGILIO, Francesco/0000-0003-3566-1362; Adinolfi, Elena/0000-0001-8129-9929; Falzoni, Simonetta/0000-0002-6594-0357; Chiozzi, Paola/0000-0003-4952-334X	Telethon [A.028] Funding Source: Medline	Telethon(Fondazione Telethon)		Baricordi OR, 1996, BLOOD, V87, P682, DOI 10.1182/blood.V87.2.682.bloodjournal872682; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chused TM, 1996, J IMMUNOL, V157, P1371; Chvatchko Y, 1996, IMMUNITY, V5, P275, DOI 10.1016/S1074-7613(00)80322-2; Coutinho-Silva R, 1999, AM J PHYSIOL-CELL PH, V276, pC1139, DOI 10.1152/ajpcell.1999.276.5.C1139; Di Virgilio F, 1998, CELL DEATH DIFFER, V5, P191; DIVIRGILIO F, 1989, J IMMUNOL, V143, P1955; FALZONI S, 1995, J CLIN INVEST, V95, P1207, DOI 10.1172/JCI117770; Ferrari D, 1996, J IMMUNOL, V156, P1531; Ferrari D, 1997, J IMMUNOL, V159, P1451; FERRARI D, 1994, AM J PHYSIOL-CELL PH, V267, pC886, DOI 10.1152/ajpcell.1994.267.4.C886; Freedman BD, 1999, EUR J IMMUNOL, V29, P1635, DOI 10.1002/(SICI)1521-4141(199905)29:05<1635::AID-IMMU1635>3.3.CO;2-2; GREGORY S, 1978, BIOCHEM BIOPH RES CO, V83, P1111, DOI 10.1016/0006-291X(78)91510-3; HUANG NN, 1989, P NATL ACAD SCI USA, V86, P7904, DOI 10.1073/pnas.86.20.7904; IKEHARA S, 1981, J IMMUNOL, V127, P1834; Michel AD, 1998, BRIT J PHARMACOL, V125, P1194, DOI 10.1038/sj.bjp.0702205; Neary JT, 1999, J NEUROSCI, V19, P4211, DOI 10.1523/jneurosci.19-11-04211.1999; PADEH S, 1991, J IMMUNOL, V146, P1626; RAPPOLEE DA, 1989, J CELL BIOCHEM, V39, P1, DOI 10.1002/jcb.240390102; Rassendren F, 1997, J BIOL CHEM, V272, P5482, DOI 10.1074/jbc.272.9.5482; ROZENGURT E, 1977, J BIOL CHEM, V252, P4584; STEINBERG TH, 1987, J BIOL CHEM, V262, P8884; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; WILEY JS, 1989, BLOOD, V73, P1316; ZANOVELLO P, 1990, J IMMUNOL, V145, P1545	25	164	168	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33206	33208		10.1074/jbc.274.47.33206	http://dx.doi.org/10.1074/jbc.274.47.33206			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559192	hybrid			2022-12-25	WOS:000083745200008
J	Reid, T; Bathoorn, A; Ahmadian, MR; Collard, JG				Reid, T; Bathoorn, A; Ahmadian, MR; Collard, JG			Identification and characterization of hPEM-2, a guanine nucleotide exchange factor specific for Cdc42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DBL HOMOLOGY DOMAIN; RAS-BINDING DOMAIN; EPITHELIAL-CELLS; PROTEIN-KINASES; P115 RHOGEF; ACTIVATION; GTPASE; GROWTH; INVASION; VAV	Guanine nucleotide exchange factors of the Dbl family regulate the actin cytoskeleton through activation of Rho-like GTPases, At present the Dbl family consists of more than thirty members; many have not been phenotypically or biochemically characterized. Guanine nucleotide exchange factors universally feature a Dbl homology domain followed by a pleckstrin homology domain. Employing data base screening we identified a recently cloned cDNA, KIAA0424, showing substantial sequence homology with Rac activators such as Tiam1, Sos, Vav, and PIX within the catalytic domain. This cDNA appears to be the human homologue of the Ascidian protein Posterior End Mark-2 (PEM-2). We refer to this exchanger as hPEM-2, hPEM-2 encodes a protein of 70 kDa and features an N-terminal src homology 3 domain, followed by tandem Dbl homology and pleckstrin homology domains. The gene is highly expressed in brain and is localized on the human X-chromosome. Employing biochemical activity assays for Rho-like GTPases we found that hPEM-2 specifically activates Cdc42 and not Rac or RhoA, Ectopic expression of hPEM-2 in NIH3T3 fibroblasts revealed a Cdc42 phenotype featuring filopodia formation, followed by cortical actin polymerization and cell rounding. hPEM-2 represents an exchange factor, which may have a role in the regulation of a number of cellular processes through Cdc42.	Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany	Netherlands Cancer Institute; Max Planck Society	Collard, JG (corresponding author), Netherlands Canc Inst, Div Cell Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	jcoll@nki.nl						ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; Aghazadeh B, 1998, NAT STRUCT BIOL, V5, P1098, DOI 10.1038/4209; Ahmadian MR, 1997, FEBS LETT, V408, P315, DOI 10.1016/S0014-5793(97)00422-5; Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; Clayton L, 1999, DEV BIOL, V205, P322, DOI 10.1006/dbio.1998.9117; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HART MJ, 1994, J BIOL CHEM, V269, P62; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; Johnson LN, 1998, FEBS LETT, V430, P1, DOI 10.1016/S0014-5793(98)00606-1; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Nern A, 1998, NATURE, V391, P195, DOI 10.1038/34458; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rubino D, 1998, ONCOGENE, V16, P2513, DOI 10.1038/sj.onc.1201783; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Satou Y, 1997, DEV BIOL, V192, P467, DOI 10.1006/dbio.1997.8730; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Stam J C, 1999, Prog Mol Subcell Biol, V22, P51; Steven R, 1998, CELL, V92, P785, DOI 10.1016/S0092-8674(00)81406-3; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Threadgill R, 1997, NEURON, V19, P625, DOI 10.1016/S0896-6273(00)80376-1; van Leeuwen FN, 1999, NAT CELL BIOL, V1, P242, DOI 10.1038/12068; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Zhou KM, 1998, J BIOL CHEM, V273, P16782, DOI 10.1074/jbc.273.27.16782	50	93	94	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33587	33593		10.1074/jbc.274.47.33587	http://dx.doi.org/10.1074/jbc.274.47.33587			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559246	hybrid			2022-12-25	WOS:000083745200062
J	San Jose, E; Alarcon, B				San Jose, E; Alarcon, B			Receptor engagement transiently diverts the T cell receptor heterodimer from a constitutive degradation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-CONTAINING MOTIF; AUREUS ENTEROTOXIN-B; TRANS-GOLGI NETWORK; PROTEIN-KINASE-C; DI-LEUCINE MOTIF; ANTIGEN RECEPTOR; DOWN-REGULATION; ENDOPLASMIC-RETICULUM; SIGNAL-TRANSDUCTION; SURFACE EXPRESSION	In the absence of ligand, the T cell receptor (TCR)/CD3 complex is continuously internalized and recycled to the cell surface, whereas receptor engagement results in its down-regulation. The present study shows that the TCR and CD3 components follow different fates accompanying their constitutive internalization. Although the CD3 moiety is recycled to the cell surface, the TCR heterodimer is degraded and replaced by newly synthesized chains, Since the TCR heterodimer cannot reach the cell membrane on its own, we propose a model in which recycling CD3 is transported along a retrograde pathway to the endoplasmic reticulum, where it associates with newly made TCR. Interestingly, engagement of the TCR CDS complex by superantigen resulted not only in the down-regulation of the TCR and CD3 components but also caused a transient stabilization of the TCR heterodimer. This suggests that TCR engagement diverts the TCR heterodimer from a degradation to a recycling pathway. Contrary to CD3, the intracellular fate of the TCR heterodimer is thus regulated, providing a mechanism for rapidly replacing nonfunctional TCR during intrathymic development of T cells.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Alarcon, B (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.	Balarcon@cbm.uam.es	Alarcon, Balbino/N-9648-2016	Alarcon, Balbino/0000-0001-7820-1070; San Jose, Esther/0000-0002-5707-628X				ALARCON B, 1988, J BIOL CHEM, V263, P2953; AlberolaIla J, 1997, ANNU REV IMMUNOL, V15, P125, DOI 10.1146/annurev.immunol.15.1.125; ANDO I, 1985, EUR J IMMUNOL, V15, P196, DOI 10.1002/eji.1830150217; Andre P, 1997, J IMMUNOL, V159, P5253; Bevan AP, 1996, TRENDS ENDOCRIN MET, V7, P13, DOI 10.1016/1043-2760(95)00179-4; BLUMBERG RS, 1990, J BIOL CHEM, V265, P14036; Borroto A, 1999, J IMMUNOL, V163, P25; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; BOYER C, 1991, EUR J IMMUNOL, V21, P1623, DOI 10.1002/eji.1830210707; Cai ZL, 1997, J EXP MED, V185, P641, DOI 10.1084/jem.185.4.641; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Cassard S, 1998, J IMMUNOL, V160, P1767; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; DOro U, 1997, IMMUNITY, V7, P619, DOI 10.1016/S1074-7613(00)80383-0; GEISLER C, 1992, J IMMUNOL, V148, P2437; HEMAR A, 1995, J CELL BIOL, V129, P55, DOI 10.1083/jcb.129.1.55; HEWITT CRA, 1992, J EXP MED, V175, P1493, DOI 10.1084/jem.175.6.1493; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; Johannes L, 1998, TRENDS CELL BIOL, V8, P158, DOI 10.1016/S0962-8924(97)01209-9; Jose ES, 1998, EUR J IMMUNOL, V28, P12; KISHIMOTO H, 1995, J EXP MED, V182, P1997, DOI 10.1084/jem.182.6.1997; KRANGEL MS, 1987, J EXP MED, V165, P1141, DOI 10.1084/jem.165.4.1141; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; Luton F, 1997, J IMMUNOL, V158, P3140; MALEFYT RD, 1990, J IMMUNOL, V145, P2297; MALISSEN B, 1993, CURR OPIN IMMUNOL, V5, P324, DOI 10.1016/0952-7915(93)90049-X; MALLABIABARRENA A, 1995, EMBO J, V14, P2257, DOI 10.1002/j.1460-2075.1995.tb07220.x; MALLABIABARRENA A, 1992, NATURE, V357, P593, DOI 10.1038/357593a0; MIESENBOCK G, 1995, J CELL BIOL, V129, P309, DOI 10.1083/jcb.129.2.309; MINAMI Y, 1987, J BIOL CHEM, V262, P13342; NIEDERGANG F, 1995, J BIOL CHEM, V270, P12839, DOI 10.1074/jbc.270.21.12839; Niedergang F, 1997, RES IMMUNOL, V148, P231, DOI 10.1016/S0923-2494(97)80865-6; ONO S, 1995, IMMUNITY, V2, P639, DOI 10.1016/1074-7613(95)90008-X; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RodriguezTarduchy G, 1996, J BIOL CHEM, V271, P30417, DOI 10.1074/jbc.271.48.30417; Rothenberg EV, 1996, SCIENCE, V273, P78, DOI 10.1126/science.273.5271.78; SANDVIG K, 1992, NATURE, V358, P510, DOI 10.1038/358510a0; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; Seaman MNJ, 1996, CURR OPIN CELL BIOL, V8, P549, DOI 10.1016/S0955-0674(96)80034-2; Shepherd PR, 1996, TRENDS CELL BIOL, V6, P92, DOI 10.1016/0962-8924(96)80998-6; Valitutti S, 1997, IMMUNOL TODAY, V18, P299, DOI 10.1016/S0167-5699(97)01075-X; Valitutti S, 1996, EUR J IMMUNOL, V26, P2012, DOI 10.1002/eji.1830260907; WEGENER AMK, 1995, J BIOL CHEM, V270, P4675, DOI 10.1074/jbc.270.9.4675; ZANDERS ED, 1983, NATURE, V303, P625, DOI 10.1038/303625a0	46	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33740	33746		10.1074/jbc.274.47.33740	http://dx.doi.org/10.1074/jbc.274.47.33740			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559266	hybrid			2022-12-25	WOS:000083745200082
J	Peet, GW; Li, J				Peet, GW; Li, J			I kappa B kinases alpha and beta show a random sequential kinetic mechanism and are inhibited by staurosporine and quercetin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; MULTISUBSTRATE INHIBITORS; ACTIVATION; PHOSPHORYLATION; POTENT; DEGRADATION; SALICYLATE; ASPIRIN; DOMAIN; SIGNAL	Activation of transcription factor NF-kappa B is regulated by phosphorylation and subsequent degradation of its inhibitory subunit I kappa B, The signal-induced phosphorylation of I kappa B involves two I kappa B kinases, IKK alpha and IKK beta, In the present study, we investigated the kinetic mechanisms of IKK alpha and IKK beta by substrate and product inhibition. For both IKK alpha and IKK beta, the product ADP was a competitive inhibitor versus ATP and a non-competitive inhibitor versus I kappa B alpha. An alternative peptide substrate, I kappa B alpha-(21-41), was a competitive inhibitor versus I kappa B alpha: and a non-competitive inhibitor versus ATP for both kinases, These results rigorously eliminate the possibility of an ordered sequential mechanism and demonstrate that both kinases have a random sequential bi bi mechanism, Two natural compounds, quercetin and staurosporine, had previously been shown to inhibit the NF-kappa B pathway, but the molecular target(s) of these compounds in the event had not been established. Here we demonstrate that quercetin and staurosporine potently inhibit both IKK alpha and IKK beta. Daidzein, a quercetin analogue that does not inhibit NF-kappa B activation, showed no significant inhibition of either enzyme. This suggests that the inhibitory properties of quercetin and staurosporine in the NF-kappa B pathway are mediated in part by their inhibition of IKK alpha and IKK beta, Mechanism studies reveal that staurosporine is a competitive inhibitor versus ATP, whereas quercetin serves as a mixed type inhibitor versus ATP, The strong inhibition of IKK beta by staurosporine (K-i = 172 nM) and ADP (K-i = 136 nM) provides a rationale and structural framework for designing potent ATP-site inhibitors of IKK beta, which is an attractive drug target for inflammatory diseases.	Boehringer Ingelheim Pharmaceut, Ctr Res & Dev, Ridgefield, CT 06877 USA	Boehringer Ingelheim	Li, J (corresponding author), Boehringer Ingelheim Pharmaceut, Ctr Res & Dev, 900 Ridgebury Rd, Ridgefield, CT 06877 USA.							Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BHATNAGAR D, 1983, BIOCHEMISTRY-US, V22, P6310, DOI 10.1021/bi00295a042; Burke JR, 1998, J BIOL CHEM, V273, P12041, DOI 10.1074/jbc.273.20.12041; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Cleland W W, 1979, Methods Enzymol, V63, P103; COPELAND RA, 1996, ENZYMES, P263; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DeMedina FS, 1996, J PHARMACOL EXP THER, V278, P771; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; GRAZIANI Y, 1983, EUR J BIOCHEM, V135, P583, DOI 10.1111/j.1432-1033.1983.tb07692.x; Groundwater P W, 1996, Prog Med Chem, V33, P233, DOI 10.1016/S0079-6468(08)70307-2; Hayess K, 1997, BIOCHEM PHARMACOL, V53, P1239, DOI 10.1016/S0006-2952(96)00877-5; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; ISHIKAWA Y, 1995, J BIOL CHEM, V270, P4158, DOI 10.1074/jbc.270.8.4158; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; KRUSE CH, 1988, J MED CHEM, V31, P1768, DOI 10.1021/jm00117a016; KRUSE CH, 1988, J MED CHEM, V31, P1762, DOI 10.1021/jm00117a015; Li J, 1998, J BIOL CHEM, V273, P30736, DOI 10.1074/jbc.273.46.30736; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; LoGrasso PV, 1997, BIOCHEMISTRY-US, V36, P10422, DOI 10.1021/bi9706778; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MEYER T, 1989, INT J CANCER, V43, P851, DOI 10.1002/ijc.2910430519; MIESEL R, 1995, INFLAMMATION, V19, P347, DOI 10.1007/BF01534392; Natarajan K, 1998, ARCH BIOCHEM BIOPHYS, V352, P59, DOI 10.1006/abbi.1998.0576; NIXON JS, 1991, DRUG EXP CLIN RES, V17, P389; O'Connell MA, 1998, J BIOL CHEM, V273, P30410, DOI 10.1074/jbc.273.46.30410; OMURA S, 1977, J ANTIBIOT, V30, P275, DOI 10.7164/antibiotics.30.275; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROMERO J, 1989, OPHTHALMIC RES, V21, P112, DOI 10.1159/000266788; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; Segel I., 1975, ENZYME KINETICS, P170; Segel I. H., 1975, ENZYME KINETICS, p[107, 132]; SEGEL IH, 1975, ENZYME KINETICS, P283; SEGEL IH, 1975, ENZYME KINETICS, P309; SESHADRI TR, 1951, ANNU REV BIOCHEM, V20, P487, DOI 10.1146/annurev.bi.20.070151.002415; SHIBASAKI F, 1993, BIOCHEM J, V289, P227, DOI 10.1042/bj2890227; Singh J, 1997, J MED CHEM, V40, P1130, DOI 10.1021/jm960380s; Srivastava A K, 1986, Prog Clin Biol Res, V213, P315; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	48	88	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32655	32661		10.1074/jbc.274.46.32655	http://dx.doi.org/10.1074/jbc.274.46.32655			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551820	hybrid			2022-12-25	WOS:000083623000020
J	Alirezaei, M; Nairn, AC; Glowinski, J; Premont, J; Marin, P				Alirezaei, M; Nairn, AC; Glowinski, J; Premont, J; Marin, P			Zinc inhibits protein synthesis in neurons - Potential role of phosphorylation of translation initiation factor-2 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; METHYL-D-ASPARTATE; FACTOR-II; CORTICAL-NEURONS; ALPHA-SUBUNIT; METAL-IONS; GLUTAMATE; RECEPTORS; KINASE; BRAIN	In the central nervous system, Zn2+ is concentrated in the cerebral cortex and hippocampus and has been found to be toxic to neurons. In this study, we show that exposure of cultured cortical neurons from mouse to increasing concentrations of Zn2+ (10-300 mu M) induces a progressive decrease in global protein synthesis. The potency of Zn2+ was increased by about 2 orders of magnitude in the presence of Na+-pyrithione, a Zn2+ ionophore. The basal rate of protein synthesis was restored 3 h after Zn2+ removal. Zn2+ induced a sustained increase in phosphorylation of the Lu subunit of the translation eukaryotic initiation factor-2 (eIF-2 alpha), whereas it triggered a transient increase in phosphorylation of eukaryotic elongation factor-2 (eEF-2). Protein synthesis was still depressed 60 min after the onset of Zn2+ exposure while the state of eEF-2 phosphorylation had already returned to its basal level. Moreover, Zn2+ was less effective than glutamate to increase eEF-2 phosphorylation, whereas it induced a more profound inhibition of protein synthesis. These results suggest that Zn2+-induced inhibition of protein synthesis mainly correlates with the increase in eIF-2 alpha phosphorylation. Supporting further that Zn2+ acts at the initiation step of protein synthesis, it strongly decreased the amount of polyribosomes.	Coll France, INSERM, U114, Chaire Neuropharmacol, F-75231 Paris 05, France; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Rockefeller University	Premont, J (corresponding author), Coll France, INSERM, U114, Chaire Neuropharmacol, 11 Pl Marcelin Berthelot, F-75231 Paris 05, France.			Nairn, Angus/0000-0002-7075-0195				ALCAZAR A, 1995, J NEUROCHEM, V65, P754; Ascher P, 1998, NAT NEUROSCI, V1, P173, DOI 10.1038/619; ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTINE CW, 1990, J NEUROSCI, V10, P108; Cuajungco MP, 1997, NEUROBIOL DIS, V4, P137, DOI 10.1006/nbdi.1997.0163; Frederickson C. J., 1994, Biological Signals, V3, P127; GABRIELSSON B, 1986, BRAIN RES, V384, P218, DOI 10.1016/0006-8993(86)91157-1; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; HURST R, 1987, J BIOL CHEM, V262, P15939; KOH JY, 1994, NEUROSCIENCE, V60, P1049, DOI 10.1016/0306-4522(94)90282-8; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUDWIG JC, 1981, AGENTS ACTIONS, V9, P65; Marin P, 1997, J NEUROSCI, V17, P3445; PALFREY HC, 1995, ADV SEC MESS PHOSPH, V30, P191; PRICE NT, 1990, BIOCHIM BIOPHYS ACTA, V1054, P83, DOI 10.1016/0167-4889(90)90208-U; PROSTKO CR, 1995, J BIOL CHEM, V270, P6211, DOI 10.1074/jbc.270.11.6211; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; RASSENDREN FA, 1990, NEURON, V4, P733, DOI 10.1016/0896-6273(90)90199-P; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; RYAZANOV AG, 1993, TRANSLATIONAL REGULA, V2, P433; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; Schinder AF, 1996, J NEUROSCI, V16, P6125; Sensi SL, 1997, J NEUROSCI, V17, P9554; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; SMITH PK, 1985, ANAL BIOCHEM, V150, P6; Spiridon M, 1998, J PHYSIOL-LONDON, V506, P363, DOI 10.1111/j.1469-7793.1998.363bw.x; SRIVASTAVA SP, 1995, J BIOL CHEM, V270, P16619, DOI 10.1074/jbc.270.28.16619; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; WARREN L, 1966, J CELL PHYSIOL, V68, P269, DOI 10.1002/jcp.1040680308; Weiler IJ, 1996, J NEUROCHEM, V66, P197; WEILER IJ, 1993, P NATL ACAD SCI USA, V90, P7168, DOI 10.1073/pnas.90.15.7168; WEISS S, 1986, P NATL ACAD SCI USA, V83, P2238, DOI 10.1073/pnas.83.7.2238; White RJ, 1996, J NEUROSCI, V16, P5688	38	30	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32433	32438		10.1074/jbc.274.45.32433	http://dx.doi.org/10.1074/jbc.274.45.32433			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542287	hybrid			2022-12-25	WOS:000083532100095
J	O'Neill, E; Sze, CC; Shingler, V				O'Neill, E; Sze, CC; Shingler, V			Novel effector control through modulation of a preexisting binding site of the aromatic-responsive sigma(54)-dependent regulator DmpR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING ATP HYDROLYSIS; SP STRAIN CF600; TRANSCRIPTIONAL ACTIVATOR; TRUNCATED FORM; PROTEIN NTRC; IN-VITRO; PSEUDOMONAS-PUTIDA; FUNCTIONAL DOMAINS; GENETIC-EVIDENCE; RNA-POLYMERASE	The Pseudomonas derived sigma(54)-dependent DmpR activator regulates transcription of the (methyl)phenol catabolic dmp-operon, DmpR is constitutively expressed, but its transcriptional promoting activity is positively controlled in direct response to the presence of multiple aromatic effecters. Previous work has led to a model in which effector binding by the amino-terminal region of the protein relieves repression of an intrinsic ATPase activity essential for its transcriptional promoting property. Here, we address whether the observed differences in the potencies of the multiple effecters (i) reside at the level of different aromatic binding sites, or (ii) are mediated through differential binding affinities; furthermore, we address whether binding of distinct aromatic effecters has different functional consequences for DmpR activity. These questions were addressed by comparing wild type and an effector specificity mutant of DmpR with respect to effector binding characteristics and the ability of aromatics to elicit ATPase activity and transcription, The results demonstrate that six test aromatics all share a common binding site on DmpR and that binding affinities determine the concentration at which DmpR responds to the presence of the effector, but not the magnitude of the responses. Interestingly, this analysis reveals that the novel abilities of the effector specificity mutant are not primarily due to acquisition of new binding abilities, but rather, they reside in being able to productively couple ATPase activity to transcriptional activation. The mechanistic implications of these findings in terms of aromatic control of DmpR activity are discussed.	Umea Univ, Dept Cell & Mol Biol, S-90187 Umea, Sweden	Umea University	Shingler, V (corresponding author), Umea Univ, Dept Cell & Mol Biol, S-90187 Umea, Sweden.		Sze, Chun Chau/A-2200-2011	Sze, Chun Chau/0000-0003-2245-9050; Shingler, Victoria/0000-0002-7349-1678				ABRIL MA, 1989, J BACTERIOL, V171, P6782, DOI 10.1128/jb.171.12.6782-6790.1989; AUSTIN S, 1994, J BIOL CHEM, V269, P18141; AUSTIN S, 1992, EMBO J, V11, P2219, DOI 10.1002/j.1460-2075.1992.tb05281.x; BERGER DK, 1994, P NATL ACAD SCI USA, V91, P103, DOI 10.1073/pnas.91.1.103; Byrne AM, 1996, J BACTERIOL, V178, P6327, DOI 10.1128/jb.178.21.6327-6337.1996; DELGADO A, 1994, J BIOL CHEM, V269, P8059; FERNANDEZ S, 1995, MOL MICROBIOL, V16, P205, DOI 10.1111/j.1365-2958.1995.tb02293.x; Gardan R, 1997, MOL MICROBIOL, V24, P825, DOI 10.1046/j.1365-2958.1997.3881754.x; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HOPPER S, 1995, J BACTERIOL, V177, P2798, DOI 10.1128/jb.177.10.2798-2803.1995; HUALA E, 1992, J BACTERIOL, V174, P1428, DOI 10.1128/jb.174.4.1428-1431.1992; LEE JH, 1995, P NATL ACAD SCI USA, V92, P9702, DOI 10.1073/pnas.92.21.9702; LEE JH, 1994, J BIOL CHEM, V269, P20401; METTKE I, 1995, J BACTERIOL, V177, P5056, DOI 10.1128/jb.177.17.5056-5061.1995; MORETT E, 1993, J BACTERIOL, V175, P6067, DOI 10.1128/JB.175.19.6067-6074.1993; Ng LC, 1996, J BIOL CHEM, V271, P17281, DOI 10.1074/jbc.271.29.17281; NG LC, 1995, J BACTERIOL, V177, P1485, DOI 10.1128/jb.177.6.1485-1490.1995; North AK, 1996, J MOL BIOL, V260, P317, DOI 10.1006/jmbi.1996.0403; O'Neill E, 1998, MOL MICROBIOL, V28, P131, DOI 10.1046/j.1365-2958.1998.00780.x; Osuna J, 1997, PROTEIN SCI, V6, P543; PAVEL H, 1994, J BACTERIOL, V176, P7550, DOI 10.1128/JB.176.24.7550-7557.1994; PerezMartin J, 1996, CELL, V86, P331, DOI 10.1016/S0092-8674(00)80104-X; PerezMartin J, 1996, J MOL BIOL, V258, P575, DOI 10.1006/jmbi.1996.0270; PORTER SC, 1993, GENE DEV, V7, P2258, DOI 10.1101/gad.7.11.2258; Porter SC, 1995, 2 COMPONENT SIGNAL T, P147; Salto R, 1998, J BACTERIOL, V180, P600, DOI 10.1128/JB.180.3.600-604.1998; Sambrook J., 2002, MOL CLONING LAB MANU; Schirmer F, 1997, J BACTERIOL, V179, P1329, DOI 10.1128/jb.179.4.1329-1336.1997; Shingler V, 1996, MOL MICROBIOL, V19, P409, DOI 10.1046/j.1365-2958.1996.388920.x; SHINGLER V, 1994, J BACTERIOL, V176, P1555, DOI 10.1128/jb.176.6.1555-1560.1994; SHINGLER V, 1993, J BACTERIOL, V175, P1596, DOI 10.1128/JB.175.6.1596-1604.1993; SHINGLER V, 1995, MOL MICROBIOL, V17, P505, DOI 10.1111/j.1365-2958.1995.mmi_17030505.x; SHINGLER V, 1996, PSEUDOMONAS MOL BIOL, P153; Sze CC, 1996, J BACTERIOL, V178, P3727, DOI 10.1128/jb.178.13.3727-3735.1996; Wang YK, 1997, MOL MICROBIOL, V26, P373, DOI 10.1046/j.1365-2958.1997.5851955.x; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N; Widdick D, 1998, FEBS LETT, V437, P70, DOI 10.1016/S0014-5793(98)01206-X	37	30	32	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32425	32432		10.1074/jbc.274.45.32425	http://dx.doi.org/10.1074/jbc.274.45.32425			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542286	hybrid			2022-12-25	WOS:000083532100094
J	Zhu, HJ; Iaria, J; Sizeland, AM				Zhu, HJ; Iaria, J; Sizeland, AM			Smad7 differentially regulates transforming growth factor beta-mediated signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; MAD-RELATED PROTEIN; TGF-BETA; HETEROOLIGOMERIC COMPLEXES; TUMOR-SUPPRESSOR; RECEPTOR; PHOSPHORYLATION; IDENTIFICATION; ACTIVATION; ANTAGONIST	Smad7 has been identified as a negative regulator of transforming growth factor beta (TGF-beta) signaling by interfering with the phosphorylation of other Smad proteins by TGF-beta receptor type I (T beta RI). me established a mink lung epithelial (Mv1Lu) cell line where ectopic expression of Smad7 is tightly controlled by doxycycline using an improved Tet-on system. Once induced by doxycycline, the recombinant Smad7 was localized predominantly in the perinuclear region and in the cytoplasm, However, the type of culture surface alters the subcellular localization of Smad7: on plastic or on fibronectin-coated glass, Smad7 was localized in the cytoplasm; but when the cells were cultured on glass, nuclear localization was observed. TGF-beta stimulation did not alter substantially the cellular distribution of Smad7. Importantly, the expression of recombinant Smad7 differentially inhibited TGF-beta signaling pathways. Consistent with previous studies, Smad7 inhibited TGF-beta-stimulated induction of type 1 plasminogen activator inhibitor as measured by p3TP-Lux reporter. However, expression of Smad7 had Little effect on TGF-beta-induced growth inhibition.	Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia	Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Zhu, HJ (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, PO, Melbourne, Vic 3050, Australia.			Zhu, Hong-Jian/0000-0002-1478-995X				Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; Attisano Liliana, 1996, Cytokine and Growth Factor Reviews, V7, P327, DOI 10.1016/S1359-6101(96)00042-1; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; CHEN RH, 1995, J BIOL CHEM, V270, P12235, DOI 10.1074/jbc.270.20.12235; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dennler S, 1999, ONCOGENE, V18, P1643, DOI 10.1038/sj.onc.1202729; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HILLEN W, 1994, ANNU REV MICROBIOL, V48, P345, DOI 10.1146/annurev.mi.48.100194.002021; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, J BIOL CHEM, V272, P2896, DOI 10.1074/jbc.272.5.2896; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; RAFTERY LA, 1995, GENETICS, V139, P241; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; tenDijke P, 1996, CURR OPIN CELL BIOL, V8, P139; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Wells RG, 1999, J BIOL CHEM, V274, P5716, DOI 10.1074/jbc.274.9.5716; Wong C, 1999, MOL CELL BIOL, V19, P1821; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3; Zhu HJ, 1999, J BIOL CHEM, V274, P11773, DOI 10.1074/jbc.274.17.11773	41	76	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32258	32264		10.1074/jbc.274.45.32258	http://dx.doi.org/10.1074/jbc.274.45.32258			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542264	hybrid			2022-12-25	WOS:000083532100072
J	Cuzzocrea, S; Tan, DX; Costantino, G; Mazzon, E; Caputi, AP; Reiter, RJ				Cuzzocrea, S; Tan, DX; Costantino, G; Mazzon, E; Caputi, AP; Reiter, RJ			The protective role of endogenous melatonin in carrageenan-induced pleurisy in the rat	FASEB JOURNAL			English	Article						inflammation; nitric oxide; peroxynitrite; superoxide; hydroxyl radical	NITRIC-OXIDE SYNTHASE; ADP-RIBOSE SYNTHETASE; ISCHEMIA-REPERFUSION INJURY; CELLULAR-ENERGY DEPLETION; INDUCED OXIDATIVE DAMAGE; ENDOTOXIC-SHOCK; INDUCED MODELS; IN-VIVO; PEROXYNITRITE; INHIBITOR	Peroxynitrite, a potent cytotoxic oxidant formed by the reaction of nitric oxide (NO) with the superoxide anion, was recently proposed to play a major pathogenic role in the inflammatory process. Here we have investigated the effects of endogenous melatonin, a known scavenger of peroxynitrite, in rats subjected to carrageenan-induced pleurisy. Endogenous melatonin was depleted in rats maintained on 24 h light cycle for 1 wk. lit vivo depletion of endogenous melatonin enhanced the carrageenan-induced degree of pleural exudation and polymorphonuclear leukocyte migration in rats subjected to carrageenan-induced pleurisy. Lung myeloperoxidase activity and lipid peroxidation were significantly increased in melatonin-deprived rats. However, the inducible NO synthase in lung samples was unaffected by melatonin depletion. Immunohistochemical analysis for nitrotyrosine revealed a positive staining in lungs from carrageenan-treated rats that was markedly enhanced in melatonin-deprived rats. Furthermore, melatonin depletion significantly increased peroxynitrite formation as measured by the oxidation of the fluorescent dye dihydrorhodamine 123, enhanced DNA damage and the decrease in mitochondrial respiration and reduced the cellular levels of NAD+ in macrophages harvested from the pleural cavity of rats subjected to carrageenan-induced pleurisy. In vivo treatment with exogenous melatonin (15 mg/kg intraperitoneal) significantly reversed the effects of melatonin depletion. Thus, endogenous melatonin plays an important protective role against carrageenan-induced local inflammation.-Cuzzocrea, S., Tan, D.-X., Costantino, G., Mazzon, E., Caputi, A. P., Reiter, R. J. The protective role of endogenous melatonin in carrageenan-induced pleurisy in the rat.	Univ Messina, Sch Med, Inst Pharmacol, Policlin, I-98100 Messina, Italy; Univ Texas, Ctr Hlth, Dept Cellular & Struct Biol, San Antonio, TX 78285 USA; Univ Messina, Biomorphol Sch Med, I-98100 Messina, Italy	University of Messina; University of Texas System; University of Messina	Cuzzocrea, S (corresponding author), Univ Messina, Sch Med, Inst Pharmacol, Policlin, Via C Valeria, I-98100 Messina, Italy.		Mazzon, Emanuela/AAL-4334-2020; tan, dun-xian/E-3610-2010	mazzon, emanuela/0000-0002-5073-717X				ALVAREZ B, 1995, CHEM RES TOXICOL, V8, P859, DOI 10.1021/tx00048a006; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bertuglia S, 1996, CARDIOVASC RES, V31, P947; Cuzzocrea S, 1998, IMMUNOLOGY, V93, P96; Cuzzocrea S, 1998, FREE RADICAL BIO MED, V24, P450, DOI 10.1016/S0891-5849(97)00280-3; Cuzzocrea S, 1998, BRIT J PHARMACOL, V123, P525, DOI 10.1038/sj.bjp.0701612; Cuzzocrea S, 1999, FREE RADICAL BIO MED, V26, P25, DOI 10.1016/S0891-5849(98)00142-7; Cuzzocrea S, 1998, J PINEAL RES, V25, P78, DOI 10.1111/j.1600-079X.1998.tb00543.x; Cuzzocrea S, 1998, J PINEAL RES, V25, P24, DOI 10.1111/j.1600-079X.1998.tb00382.x; Cuzzocrea S, 1997, BRIT J PHARMACOL, V121, P1065, DOI 10.1038/sj.bjp.0701234; Cuzzocrea S, 1997, J PINEAL RES, V23, P106, DOI 10.1111/j.1600-079X.1997.tb00342.x; DAMOTTA JIB, 1994, BRIT J PHARMACOL, V112, P111; DANIELS WMU, 1996, J PINEAL RES, V19, P1; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; FRASER S, 1983, CLIN CHEM, V29, P396; Giusti P, 1996, FASEB J, V10, P891, DOI 10.1096/fasebj.10.8.8666166; HALLIWELL B, 1995, ANN RHEUM DIS, V54, P505, DOI 10.1136/ard.54.6.505; Karoui H, 1996, J BIOL CHEM, V271, P6000, DOI 10.1074/jbc.271.11.6000; LEE KJ, 1995, P SOC EXP BIOL MED, V209, P178; Marshall KA, 1996, FREE RADICAL BIO MED, V21, P307, DOI 10.1016/0891-5849(96)00046-9; McCord J M, 1993, New Horiz, V1, P70; MELCHIORRI D, 1994, LIFE SCI, V56, P83, DOI 10.1016/0024-3205(94)00928-7; MENENDEZPELAEZ A, 1993, J CELL BIOCHEM, V53, P373, DOI 10.1002/jcb.240530415; MONCADA S, 1991, PHARMACOL REV, V43, P109; MULLANE KM, 1985, J PHARMACOL METHOD, V14, P157, DOI 10.1016/0160-5402(85)90029-4; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Nava F, 1997, EUR J PHARMACOL, V331, P267, DOI 10.1016/S0014-2999(97)01049-2; NEMETH L, 1989, BIOMED BIOCHIM ACTA, V48, pS53; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; PENTNEY PT, 1995, J PINEAL RES, V19, P31, DOI 10.1111/j.1600-079X.1995.tb00168.x; Petit JF, 1996, BIOCHEM PHARMACOL, V52, P205, DOI 10.1016/0006-2952(96)00177-3; PIERPAOLI W, 1994, P NATL ACAD SCI USA, V91, P787, DOI 10.1073/pnas.91.2.787; Pierre C., 1994, LIFE SCI, V55, P271; RADI R, 1991, J BIOL CHEM, V266, P4244; Reiter RJ, 1998, PROG NEUROBIOL, V56, P359, DOI 10.1016/S0301-0082(98)00052-5; REITER RJ, 1991, ENDOCR REV, V12, P151, DOI 10.1210/edrv-12-2-151; REITER RJ, 1995, J PINEAL RES, V18, P1, DOI 10.1111/j.1600-079X.1995.tb00133.x; REITER RJ, 1995, NEUROCHEM INT, V27, P453, DOI 10.1016/0197-0186(95)80002-3; Salvemini D, 1996, BRIT J PHARMACOL, V118, P829, DOI 10.1111/j.1476-5381.1996.tb15475.x; SEWERYNEK E, 1995, J CELL BIOCHEM, V58, P436, DOI 10.1002/jcb.240580406; Sewerynek E, 1996, HEPATO-GASTROENTEROL, V43, P898; SINGH A, 1989, CIRCULATION, V80, P1795, DOI 10.1161/01.CIR.80.6.1795; Stasica P, 1998, J PINEAL RES, V25, P65, DOI 10.1111/j.1600-079X.1998.tb00387.x; Szabo C, 1997, J CLIN INVEST, V100, P723, DOI 10.1172/JCI119585; SZABO C, 1994, P NATL ACAD SCI USA, V91, P271, DOI 10.1073/pnas.91.1.271; Tan DX, 1993, ENDOCR J, V1, P57; TRACEY WR, 1995, J PHARMACOL EXP THER, V273, P1295; WALKER MW, 1995, PEDIATR RES, V37, P41, DOI 10.1203/00006450-199501000-00010; WEBB SM, 1985, NEUROENDOCRINOLOGY, V40, P205, DOI 10.1159/000124076; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; YOUN YK, 1991, CIRC SHOCK, V35, P245; [No title captured]	52	62	67	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1999	13	14					1930	1938		10.1096/fasebj.13.14.1930	http://dx.doi.org/10.1096/fasebj.13.14.1930			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544176				2022-12-25	WOS:000083660700005
J	Capellari, S; Zaidi, SIA; Urig, CB; Perry, G; Smith, MA; Petersen, RB				Capellari, S; Zaidi, SIA; Urig, CB; Perry, G; Smith, MA; Petersen, RB			Prion protein glycosylation is sensitive to redox change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB-DISEASE; DISULFIDE BOND FORMATION; ENDOPLASMIC-RETICULUM; OXIDATIVE STRESS; TRUNCATED FORMS; CELLS; GLYCOPROTEINS; EXPRESSION; COPPER; POLYMORPHISM	The conversion of soluble prion protein into an insoluble, pathogenic, protease-resistant isoform is a key event in the development of prion diseases. Although the mechanism by which the conversion engenders a pathogenic event is unclear, there is increasing evidence to suggest that this may depend on the function of the prion protein in preventing oxidative damage. Therefore, in this study, we assessed the interrelationship between redox-sensitive cysteine, glycosylation, and prion metabolism. Cells were treated with a thioreductant, dithiothreitol, to assess the effect of the cellular oxidation state on the synthesis of the prion protein. This change in redox balance affected the glycosylation of the prion protein, resulting in the sole production of glycosylated forms. The role of the single disulfide bridge in mediating this effect within the prion protein was confirmed by mutating the cysteine residues involved in its formation. These data suggest that conditions that increase the rate of formation of the disulfide bridge favor formation of the unglycosylated prion protein. Thus, since the presence of glycans on the prion protein is protective against its pathogenic conversion, a change in the redox status of the cell would increase the risk of developing a prion disease by favoring the production of the unglycosylated form.	Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA	Case Western Reserve University	Petersen, RB (corresponding author), Case Western Reserve Univ, Inst Pathol, 2085 Adelbert Rd, Cleveland, OH 44106 USA.		Smith, Mark A/A-9053-2009; Perry, George/A-8611-2009; capellari, sabina/F-5545-2012; Petersen, Robert/B-5075-2011	Perry, George/0000-0002-6547-0172; capellari, sabina/0000-0003-1631-1439; Petersen, Robert/0000-0002-3154-0072	NIA NIH HHS [AG08992, AG08155] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG008155, R35AG008992] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLEN S, 1995, J BIOL CHEM, V270, P4797, DOI 10.1074/jbc.270.9.4797; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Brown DR, 1998, J NEUROCHEM, V70, P1686; Brown DR, 1997, EXP NEUROL, V146, P104, DOI 10.1006/exnr.1997.6505; Brown DR, 1997, INT J DEV NEUROSCI, V15, P961, DOI 10.1016/S0736-5748(97)00042-7; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; DeArmond SJ, 1997, NEURON, V19, P1337, DOI 10.1016/S0896-6273(00)80424-9; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; Glombik MM, 1999, EMBO J, V18, P1059, DOI 10.1093/emboj/18.4.1059; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Herrmann LM, 1998, NEUROREPORT, V9, P2457, DOI 10.1097/00001756-199808030-00006; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V207, P621, DOI 10.1006/bbrc.1995.1233; Isidoro C, 1996, J BIOL CHEM, V271, P26138, DOI 10.1074/jbc.271.42.26138; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; KAETZEL CS, 1987, BIOCHEM J, V241, P39, DOI 10.1042/bj2410039; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Kromer A, 1998, J CELL BIOL, V140, P1331, DOI 10.1083/jcb.140.6.1331; Lehmann S, 1997, J BIOL CHEM, V272, P21479, DOI 10.1074/jbc.272.34.21479; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; MONARI L, 1994, P NATL ACAD SCI USA, V91, P2839, DOI 10.1073/pnas.91.7.2839; Muramoto T, 1997, NAT MED, V3, P750, DOI 10.1038/nm0797-750; Nitrini R, 1997, ANN NEUROL, V42, P138, DOI 10.1002/ana.410420203; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; Petersen RB, 1996, J BIOL CHEM, V271, P12661, DOI 10.1074/jbc.271.21.12661; PUIG A, 1994, J BIOL CHEM, V269, P19128; Rizzardini M, 1997, J NEUROCHEM, V68, P715; SHYNG SL, 1993, J BIOL CHEM, V268, P15922; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; STAHL N, 1990, BIOCHEMISTRY-US, V29, P8879, DOI 10.1021/bi00490a001; TATU U, 1993, EMBO J, V12, P2151, DOI 10.1002/j.1460-2075.1993.tb05863.x; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; THOTAKURA NR, 1987, METHOD ENZYMOL, V138, P350; Zanusso G, 1998, P NATL ACAD SCI USA, V95, P8812, DOI 10.1073/pnas.95.15.8812	38	58	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34846	34850		10.1074/jbc.274.49.34846	http://dx.doi.org/10.1074/jbc.274.49.34846			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574957	hybrid			2022-12-25	WOS:000083979600051
J	Shoshani, I; Laux, WHG; Perigaud, C; Gosselin, G; Johnson, RA				Shoshani, I; Laux, WHG; Perigaud, C; Gosselin, G; Johnson, RA			Inhibition of adenylyl cyclase by acyclic nucleoside phosphonate antiviral agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-MEDIATED INHIBITION; IN-VITRO; 9-(2-PHOSPHONYLMETHOXYETHYL)ADENINE PMEA; REVERSE-TRANSCRIPTASE; ORAL BIOAVAILABILITY; RAT CHORIOCARCINOMA; POTENT INHIBITORS; GUANYLYL CYCLASES; ADENINE PMEA; 3'-POLYPHOSPHATES	Acyclic derivatives of adenine, known as highly effective nucleotide analogs with broad spectrum antiviral activity, were evaluated for potential cross-reactivity with adenylyl cyclases, a family of membrane-bound enzymes that share putative topologies at their catalytic sites with oligonucleotide polymerases and reverse transcriptases. A series of derivatives of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) inhibited a preparation of adenylyl cyclase derived from rat brain with IC50 values that ranged from 66 mu M (PMEA) to 175 nM for its diphosphate derivative (PMEApp) and mimics of it. PMEApp mimics included PMEAp(NH)p, PMEAp(CH2)p, PREAp(CX2)p (X = fluorine, chlorine, or bromine), PMEAp(CHX)pp, and PMEAp(C(OH)CH(3)pp. The data suggest that inhibition of adenylyl cyclases may contribute to the therapeutic action of some of these or similar compounds or constitute part of their side effects in therapeutic settings.	SUNY Stony Brook, Hlth Sci Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; Univ Montpellier 2, CNRS USTL 5625, UMR, Lab Organ Biomol Synth, F-34095 Montpellier, France	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Universite de Montpellier	Johnson, RA (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.	rjohnson@ccmail.sunysb.edu		Perigaud, Christian/0000-0003-4631-6927	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038828] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 38828] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Annaert P, 1998, PHARM RES-DORDR, V15, P239, DOI 10.1023/A:1011914618109; Arimilli MN, 1997, ANTIVIR CHEM CHEMOTH, V8, P557, DOI 10.1177/095632029700800610; Artymiuk PJ, 1997, NATURE, V388, P33, DOI 10.1038/40310; Benzaria S, 1996, J MED CHEM, V39, P4958, DOI 10.1021/jm960289o; BLACKBURN GM, 1984, J CHEM SOC PERK T 1, P1119, DOI 10.1039/p19840001119; Bryant SH, 1997, NATURE, V388, P34, DOI 10.1038/40313; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; DECLERCQ E, 1991, BIOCHEM PHARMACOL, V42, P963, DOI 10.1016/0006-2952(91)90276-B; Desaubry L, 1996, J BIOL CHEM, V271, P14028, DOI 10.1074/jbc.271.24.14028; Desaubry L, 1998, J BIOL CHEM, V273, P24972, DOI 10.1074/jbc.273.38.24972; Desaubry L, 1996, J BIOL CHEM, V271, P2380, DOI 10.1074/jbc.271.5.2380; DING J, 1995, STRUCTURE, V3, P365, DOI 10.1016/S0969-2126(01)00168-X; ENGLUND PT, 1969, J BIOL CHEM, V244, P3038; Hatse S, 1998, ADV EXP MED BIOL, V431, P605; Hatse S, 1998, BIOCHEM PHARMACOL, V56, P851, DOI 10.1016/S0006-2952(98)00058-6; Hatse S, 1998, INT J CANCER, V76, P595; HOLY A, 1987, COLLECT CZECH CHEM C, V52, P2801, DOI 10.1135/cccc19872801; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Ibrahimi A, 1999, AM J PHYSIOL-CELL PH, V276, pC487, DOI 10.1152/ajpcell.1999.276.2.C487; JOHNSON RA, 1989, MOL PHARMACOL, V35, P681; JOHNSON RA, 1990, J BIOL CHEM, V265, P11595; Johnson RA, 1997, J BIOL CHEM, V272, P8962; JOHNSON RA, 1991, METHOD ENZYMOL, V195, P3; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; Laux WHG, 1999, NUCLEOS NUCLEOT, V18, P1003, DOI 10.1080/15257779908041629; Liu Y, 1997, P NATL ACAD SCI USA, V94, P13414, DOI 10.1073/pnas.94.25.13414; MOFFATT JG, 1964, CAN J CHEM, V42, P599, DOI 10.1139/v64-087; Naesens L, 1996, ANTIMICROB AGENTS CH, V40, P22, DOI 10.1128/AAC.40.1.22; Naesens L, 1998, ANTIMICROB AGENTS CH, V42, P1568, DOI 10.1128/AAC.42.7.1568; NAESENS L, 1994, REV MED VIROL, V4, P147, DOI 10.1002/rmv.1980040302; Naesens L, 1995, Postepy Biochem, V41, P347; Naesens L, 1997, ANTIVIR CHEM CHEMOTH, V8, P1; Shoshani I, 1999, J BIOL CHEM, V274, P34735, DOI 10.1074/jbc.274.49.34735; Sunahara RK, 1998, J BIOL CHEM, V273, P16332, DOI 10.1074/jbc.273.26.16332; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0	36	26	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34742	34744		10.1074/jbc.274.49.34742	http://dx.doi.org/10.1074/jbc.274.49.34742			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574942	hybrid			2022-12-25	WOS:000083979600036
J	Yan, M; Gralla, JD				Yan, M; Gralla, JD			The use of ATP and initiating nucleotides during postrecruitment steps at the activated adenovirus E4 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTION FACTORS IIE; TERMINAL-DOMAIN KINASE; OPEN COMPLEX-FORMATION; DNA HELICASE; FACTOR-DELTA; RAT-LIVER; IN-VITRO; TFIIH; REQUIREMENT	Permanganate probing has been used to follow the progress and ATP dependence of promoter opening during activated adenovirus E4 initiation and clearance. Using templates designed to restrict synthesis to defined positions, formation of a 3-nucleotide-long RNA was found to be sufficient to trigger expansion of the initial transcription bubble. This occurred by a discrete transition that expanded the downstream limit of melting from position 1 to 15. Subsequent clearance of the bubble from the promoter region also occurred without detectable intermediates. Thus, initial opening, extension, and the clearance of the promoter bubble appear to occur as discrete, unique transitions. The apparent K-m values for these three steps were determined to be near 5, 9, and 50 mu M, respectively. Comparison of these values with ATPase activities within known transcription factors raises the possibility that different activities could be responsible for each step.	Univ Calif Los Angeles, Inst Mol Biol, Dept Chem & Biochem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Gralla, JD (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, Dept Chem & Biochem, Los Angeles, CA 90095 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049048] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49048] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKOULITCHEV S, 1995, NATURE, V377, P557, DOI 10.1038/377557a0; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; Dvir A, 1996, J BIOL CHEM, V271, P23352, DOI 10.1074/jbc.271.38.23352; Dvir A, 1997, J BIOL CHEM, V272, P28175, DOI 10.1074/jbc.272.45.28175; Dvir A, 1997, P NATL ACAD SCI USA, V94, P9006, DOI 10.1073/pnas.94.17.9006; Dvir A, 1996, J BIOL CHEM, V271, P7245, DOI 10.1074/jbc.271.13.7245; Gebara MM, 1997, J CELL BIOCHEM, V64, P390; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; Guo Y, 1998, P NATL ACAD SCI USA, V95, P11655, DOI 10.1073/pnas.95.20.11655; Holstege FCP, 1997, EMBO J, V16, P7468, DOI 10.1093/emboj/16.24.7468; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; JIANG Y, 1995, J BIOL CHEM, V270, P1277, DOI 10.1074/jbc.270.3.1277; Jiang Y, 1996, MOL CELL BIOL, V16, P1614; JIANG Y, 1995, J BIOL CHEM, V270, P27332, DOI 10.1074/jbc.270.45.27332; JIANG Y, 1993, J BIOL CHEM, V268, P6535; KORNBERG A, 1978, J BIOL CHEM, V253, P3298; Kugel JF, 1998, P NATL ACAD SCI USA, V95, P9232, DOI 10.1073/pnas.95.16.9232; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; Ohkuma Y, 1997, J BIOCHEM-TOKYO, V122, P481; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; Wolner BS, 1997, J BIOL CHEM, V272, P32301, DOI 10.1074/jbc.272.51.32301; Yan M, 1997, EMBO J, V16, P7457, DOI 10.1093/emboj/16.24.7457; Yankulov KY, 1996, MOL CELL BIOL, V16, P3291	36	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	1999	274	49					34819	34824		10.1074/jbc.274.49.34819	http://dx.doi.org/10.1074/jbc.274.49.34819			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	260XW	10574953	hybrid			2022-12-25	WOS:000083979600047
J	Hunt, MC; Nousiainen, SEB; Huttunen, MK; Orii, KE; Svensson, LT; Alexson, SEH				Hunt, MC; Nousiainen, SEB; Huttunen, MK; Orii, KE; Svensson, LT; Alexson, SEH			Peroxisome proliferator-induced long chain acyl-CoA thioesterases comprise a highly conserved novel multi-gene family involved in lipid metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-ALPHA; BETA-OXIDATION PATHWAY; RETINOID-X-RECEPTOR; RAT-LIVER; FATTY-ACIDS; MOLECULAR-CLONING; ELEMENT UPSTREAM; HORMONE RECEPTOR; CLOFIBRIC ACID; EXPRESSION	Long chain acyl-CoA esters are important intermediates in degradation and synthesis of fatty acids, as well as having important functions in regulation of intermediary metabolism and gene expression. Although the physiological functions for most acyl-CoA thioesterases have not yet been elucidated, previous data suggest that these enzymes may be involved in lipid metabolism by modulation of cellular concentrations of acyl-CoAs and fatty acids. In line with this, we have cloned four highly homologous acyl-CoA thioesterase genes from mouse, showing multiple compartmental localizations. The nomenclature for these genes has tentatively been assigned as CTE-I (cytosolic), MTE-I (mitochondrial), and PTE-Ia and Ib (peroxisomal), based on the identification of putative targeting signals. Although the various isoenzymes show between 67% and 94% identity at amino acid level, each individual enzyme shows a specific tissue expression. Our data suggest that all four genes are located within a very narrow cluster on chromosome 12 in mouse, similar to a sequence cluster on human chromosome 14, which identified four genes homologous to the mouse thioesterase genes. Four related genes were also identified in Caenorhabditis elegans, all containing putative PTS1 targeting signals, suggesting that the ancestral type I thioesterase gene(s) is/are of peroxisomal origin. All four thioesterases are differentially expressed in tissues examined, but all are inducible at mRNA level by treatment with the peroxisome proliferator clofibrate, or during the physiological condition of fasting, both of which conditions cause a perturbation in overall lipid homeostasis. These results strongly support the existence of a novel multi-gene family cluster of mouse acyl-CoA thioesterases, each with a distinct function in lipid metabolism.	Huddinge Univ Hosp, Karolinska Inst, Dept Med Lab Sci & Technol, Div Clin Chem, S-14186 Huddinge, Sweden; Gifu Univ, Sch Med, Dept Pediat, Gifu 5008705, Japan	Karolinska Institutet; Gifu University	Alexson, SEH (corresponding author), Huddinge Univ Hosp, Karolinska Inst, Dept Med Lab Sci & Technol, Div Clin Chem, S-14186 Huddinge, Sweden.		Orii, Kenji/AAJ-9069-2020	Svensson, Thomas/0000-0002-9190-2979				ALEXSON SEH, 1985, BIOCHIM BIOPHYS ACTA, V834, P149, DOI 10.1016/0005-2760(85)90150-X; ALEXSON SEH, 1989, BIOCHEM J, V262, P41, DOI 10.1042/bj2620041; Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; BERGE RK, 1981, FEBS LETT, V124, P43, DOI 10.1016/0014-5793(81)80050-6; COHEN BI, 1974, BIOCHIM BIOPHYS ACTA, V369, P79; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; DREYER C, 1993, BIOL CELL, V77, P67, DOI 10.1016/S0248-4900(05)80176-5; Finkielstein C, 1998, EUR J BIOCHEM, V256, P60, DOI 10.1046/j.1432-1327.1998.2560060.x; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; Geraghty MT, 1999, P NATL ACAD SCI USA, V96, P2937, DOI 10.1073/pnas.96.6.2937; Goni FM, 1996, FEBS LETT, V390, P1, DOI 10.1016/0014-5793(96)00603-5; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KASE BF, 1989, J BIOL CHEM, V264, P9220; KASE BF, 1991, PEDIATR RES, V29, P64, DOI 10.1203/00006450-199101000-00013; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Kroetz DL, 1998, J BIOL CHEM, V273, P31581, DOI 10.1074/jbc.273.47.31581; KWAKYE JB, 1991, BIOCHEM J, V280, P821, DOI 10.1042/bj2800821; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LEONE TC, 1995, J BIOL CHEM, V270, P16308, DOI 10.1074/jbc.270.27.16308; LI QL, 1993, J CELL BIOCHEM, V51, P458, DOI 10.1002/jcb.2400510411; Lindquist PJG, 1998, EUR J BIOCHEM, V251, P631, DOI 10.1046/j.1432-1327.1998.2510631.x; MIYAZAWA S, 1981, EUR J BIOCHEM, V117, P425, DOI 10.1111/j.1432-1033.1981.tb06356.x; Motojima K, 1998, J BIOL CHEM, V273, P16710, DOI 10.1074/jbc.273.27.16710; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; PAZ C, 1994, EUR J BIOCHEM, V224, P709, DOI 10.1111/j.1432-1033.1994.00709.x; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; Schoonjans K, 1996, J LIPID RES, V37, P907; Schug J., 1997, CBILTR19971001V00 U; STAHLBERG D, 1989, J LIPID RES, V30, P953; SVENSSON LT, 1995, J BIOL CHEM, V270, P12177, DOI 10.1074/jbc.270.20.12177; SVENSSON LT, 1995, EUR J BIOCHEM, V230, P813; Svensson LT, 1998, BIOCHEM J, V329, P601, DOI 10.1042/bj3290601; WAKU K, 1992, BIOCHIM BIOPHYS ACTA, V1124, P101, DOI 10.1016/0005-2760(92)90085-A; WARDEN CH, 1993, GENOMICS, V18, P295, DOI 10.1006/geno.1993.1469; WILCKE M, 1994, EUR J BIOCHEM, V222, P803, DOI 10.1111/j.1432-1033.1994.tb18927.x; Yamada J, 1998, BIOCHEM BIOPH RES CO, V248, P608, DOI 10.1006/bbrc.1998.9048; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541	43	92	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34317	34326		10.1074/jbc.274.48.34317	http://dx.doi.org/10.1074/jbc.274.48.34317			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567408	hybrid			2022-12-25	WOS:000083857500073
J	Wilson, NF; O'Connell, JS; Lu, M; Snell, WJ				Wilson, NF; O'Connell, JS; Lu, M; Snell, WJ			Flagellar adhesion between mt(+) and mt(-) Chlamydomonas gametes regulates phosphorylation of the mt(+)-specific homeodomain protein GSP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATING-TYPE; CYCLIC-AMP; DEPENDENT REGULATION; CELL ADHESION; IN-VITRO; REINHARDTII; FERTILIZATION; ACTIVATION; AGGLUTININS; MEMBRANE	During fertilization in Chlamydomonas, flagellar adhesion between mt(+) and mt(-) gametes induces a cAMP-dependent signal transduction pathway that prepares the gametes for cell fusion and zygote formation. Previously, our laboratory identified a homeodomain protein (GSP1) whose expression was restricted to the cell bodies of mt(+) gametes and whose transcript level was upregulated during flagellar adhesion. In this report, we describe a new form of GSP1 that appears early during gamete interactions, Immunoblot analysis showed that in addition to the 120-kDa form of GSP1 normally present in mt(+) gametes, a 122-kDa form was detected when the cells mere mixed with mt- gametes, The more slowly migrating form of GSP1 was detectable within minutes after gametes were mixed together, and its appearance did not require new protein synthesis. Thus, the 122-kDa form represents a post-translational modification of the pre-existing 120-kDa form of GSP1. Moreover, conversion to the 122-kDa form did not require cell fusion, Although the 120-kDa form was expressed 10 h after vegetative cells were transferred to gametic induction medium, the 122-kDa form was detected only after mt(+) gametes were induced to undergo the sexual signaling that accompanies fertilization. Incubation of mt(+) gametes with dibutyryl cAMP led to the appearance of the 122-kDa form of GSP1, and the cyclic nucleotide-dependent protein kinase inhibitor H-8 inhibited the adhesion-induced conversion. Incubation of GSP1 immunoprecipitated from signaling mt(+) gametes with alkaline phosphatase showed that the conversion was due to phosphorylation, The results indicate that flagellar adhesion induces a rapid, cAMP-dependent phosphorylation of the homeodomain protein GSP1 early during fertilization in Chlamydomonas.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Snell, WJ (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	william.snell@email.swmed.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025661] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25661, R01 GM025661] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAIR WS, 1982, J BIOL CHEM, V257, P4593; AMBRUST EV, 1993, CELL, V74, P801; BUCHANAN MJ, 1989, J CELL BIOL, V108, P199, DOI 10.1083/jcb.108.1.199; Ferris PJ, 1997, GENETICS, V146, P859; Ferris PJ, 1996, MOL BIOL CELL, V7, P1235, DOI 10.1091/mbc.7.8.1235; FORSTER H, 1954, Z NATURFORSCH B, V9, P548; Goodenough U.W., 1991, MICROBIAL CELL CELL, P71; GOODENOUGH UW, 1989, J CELL BIOL, V109, P247, DOI 10.1083/jcb.109.1.247; GOODENOUGH UW, 1982, J CELL BIOL, V92, P378, DOI 10.1083/jcb.92.2.378; Harris E., 1989, CHLAMYDOMONAS SOURCE, P575; HUNNICUTT GR, 1990, J CELL BIOL, V111, P1605, DOI 10.1083/jcb.111.4.1605; HUNNICUTT GR, 1991, DEV BIOL, V47, P216; JOHNSON AD, 1995, CURR OPIN GENET DEV, V5, P552, DOI 10.1016/0959-437X(95)80022-0; King SJ, 1997, J CELL BIOL, V136, P177, DOI 10.1083/jcb.136.1.177; Kurvari V, 1996, P NATL ACAD SCI USA, V93, P39, DOI 10.1073/pnas.93.1.39; Kurvari V, 1995, PLANT MOL BIOL, V29, P1235, DOI 10.1007/BF00020465; Kurvari V, 1998, J CELL BIOL, V143, P1971, DOI 10.1083/jcb.143.7.1971; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PASQUALE SM, 1987, J CELL BIOL, V105, P2279, DOI 10.1083/jcb.105.5.2279; PIJST HLA, 1984, FEBS LETT, V174, P132, DOI 10.1016/0014-5793(84)81091-1; SAGER R, 1954, J GEN PHYSIOL, V37, P729, DOI 10.1085/jgp.37.6.729; Snell WJ, 1990, CURR OPIN CELL BIOL, V2, P821, DOI 10.1016/0955-0674(90)90079-T; SNELL WJ, 1989, J CELL BIOL, V109, P1689, DOI 10.1083/jcb.109.4.1689; SNELL WJ, 1980, J CELL BIOL, V84, P203, DOI 10.1083/jcb.84.1.203; SNELL WJ, 1976, J CELL BIOL, V68, P48, DOI 10.1083/jcb.68.1.48; SNELL WJ, 1993, SIGNAL TRANSDUCTION, P255; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wassarman PM, 1999, CELL, V96, P175, DOI 10.1016/S0092-8674(00)80558-9; Wilson NF, 1997, J CELL BIOL, V137, P1537, DOI 10.1083/jcb.137.7.1537; Xu HL, 1999, P NATL ACAD SCI USA, V96, P2554, DOI 10.1073/pnas.96.5.2554; ZHANG YH, 1991, J BIOL CHEM, V266, P22954; ZHANG YH, 1994, J CELL BIOL, V125, P617, DOI 10.1083/jcb.125.3.617; Zhang YH, 1996, MOL BIOL CELL, V7, P515, DOI 10.1091/mbc.7.4.515	33	18	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					34383	34388		10.1074/jbc.274.48.34383	http://dx.doi.org/10.1074/jbc.274.48.34383			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567416	hybrid			2022-12-25	WOS:000083857500081
J	Zhou, B; Oka, JA; Singh, A; Weigel, PH				Zhou, B; Oka, JA; Singh, A; Weigel, PH			Purification and subunit characterization of the rat liver endocytic hyaluronan receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; ACID; BINDING; IDENTIFICATION; PROTEINS; DISEASE; SURFACE; ICAM-1	The endocytic hyaluronan (HA) receptor of liver sinusoidal endothelial cells (LECs) is responsible for the clearance of HA and other glycosaminoglycans from the circulation in mammals. We report here for the first time the purification of this liver HA receptor. Using lectin and immune-affinity chromatography, two HA receptor species were purified from detergent-solubilized membranes prepared from purified rat LECs. In nonreducing SDS-polyacrylamide gel electrophoresis (PAGE), these two proteins migrated at 175- and similar to 300 kDa corresponding to the two species previously identified by photoaffinity labeling of live cells as the HA receptor (Yannariello-Brown, J., Frost, S, J,, and Weigel, P, H, (1992) J, Biol. Chem, 267, 20451-20456). These two proteins co-purify in a molar ratio of 2:1 (175:300), and both proteins are active, able to bind HA after SDS-PAGE, electrotransfer, and renaturation, After reduction, the 175-kDa protein migrates as a similar to 185-kDa protein and is not able to bind HA The 300s-kDa HA receptor is a complex of three disulfide-bonded subunits that migrate in reducing SDS-PAGE at similar to 260, 230, and 97 kDa. These proteins designated, respectively, the alpha, beta, and gamma subunits are present in a molar ratio of 1:1:1 and are also unable to bind HA when reduced. The 175-kDa protein and all three subunits of the 300-kDa species contain N-linked oligosaccharides, as indicated by increased migration in SDS-PAGE after treatment with N-glycosidase F, Both of the deglycosylated, nonreduced HA receptor proteins still bind HA.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Weigel, PH (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA.				NIGMS NIH HHS [GM35978] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035978] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAGANTINI A, 1994, CURR THER RES CLIN E, V55, P319, DOI 10.1016/S0011-393X(05)80175-4; BURD DAR, 1991, BRIT J PLAST SURG, V44, P579, DOI 10.1016/0007-1226(91)90093-Y; Cook G, 1997, ACTA HAEMATOL-BASEL, V97, P81; EVERED D, 1989, CIBA F SYMP, V143, P1; FORSBERG N, 1991, BIOCHIM BIOPHYS ACTA, V1078, P12, DOI 10.1016/0167-4838(91)90085-E; Fuxe K, 1996, BRAIN RES, V736, P329, DOI 10.1016/S0006-8993(96)00720-2; GOA KL, 1994, DRUGS, V47, P536, DOI 10.2165/00003495-199447030-00009; GUSTAFSON S, 1995, GLYCOCONJUGATE J, V12, P350, DOI 10.1007/BF00731337; KING SR, 1991, SURGERY, V109, P76; KNUDSON CB, 1993, FASEB J, V7, P233; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai KN, 1998, J LAB CLIN MED, V131, P354, DOI 10.1016/S0022-2143(98)90186-X; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; McCourt PAG, 1997, INT J BIOCHEM CELL B, V29, P1179, DOI 10.1016/S1357-2725(97)00058-7; MCCOURT PAG, 1994, J BIOL CHEM, V269, P30081; MCGARY CT, 1989, BIOCHEM J, V257, P875, DOI 10.1042/bj2570875; MCGARY CT, 1993, HEPATOLOGY, V18, P1465, DOI 10.1002/hep.1840180628; OKA JA, 1987, J CELL PHYSIOL, V133, P243, DOI 10.1002/jcp.1041330207; RAJA RH, 1984, ANAL BIOCHEM, V139, P168, DOI 10.1016/0003-2697(84)90402-0; RAJA RH, 1988, J BIOL CHEM, V263, P16661; SMEDSROD B, 1994, GUT, V35, P1509, DOI 10.1136/gut.35.11.1509; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; Toole B. P., 1991, CELL BIOL EXTRACELLU, P305; Yamada M, 1998, ACTA HAEMATOL-BASEL, V99, P212, DOI 10.1159/000040841; YannarielloBrown J, 1997, GLYCOBIOLOGY, V7, P15, DOI 10.1093/glycob/7.1.15; YANNARIELLOBROWN J, 1992, BIOCHEMISTRY-US, V31, P576, DOI 10.1021/bi00117a039; YANNARIELLOBROWN J, 1992, J BIOL CHEM, V267, P20451; Yaron I, 1997, J RHEUMATOL, V24, P2221; YUI N, 1993, J CONTROL RELEASE, V25, P133	31	54	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	1999	274	48					33831	33834		10.1074/jbc.274.48.33831	http://dx.doi.org/10.1074/jbc.274.48.33831			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	258UL	10567337	hybrid			2022-12-25	WOS:000083857500002
J	Grimaldi, M; Favit, A; Alkon, DL				Grimaldi, M; Favit, A; Alkon, DL			cAMP-induced cytoskeleton rearrangement increases calcium transients through the enhancement of capacitative calcium entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORTICAL ASTROCYTES; CELLS; RECEPTOR; CULTURE; STORES; BRADYKININ	In this report we investigated the correlation between cell morphology and regulation of cytosolic calcium homeostasis. Type I astrocytes were differentiated to stellate process-bearing cells by a 100-min exposure to cAMP, Differentiation of cortical astrocytes increased the magnitude and duration of calcium transients elicited by phospholipase C-activating agents as measured by single cell Fura-a-based imaging. Calcium imaging showed differences in the spatial pattern of the response. In both differentiated and the control cells, the response originated in the periphery and gradually extended into the center of the cell. However, the elevation of cytosolic calcium concentration ([Ca2+](i)) was particularly evident within the processes and adjacent to the inner cell membrane of the differentiated astrocytes, In addition, differentiation significantly prolonged the duration of the [Ca2+](i) elevation. Potentiation of the calcium transients was mimicked by forskolin-induced differentiation and abolished by a specific protein kinase-A blocker. Conversely, the enhancement of the calcium transients was not mimicked by brief exposure to cAMP not causing morphological differentiation, and in PC12 cells that did not undergo morphological changes after 100 min of cAMP treatment. Impairing cAMP-induced cytoskeleton re-organization, by means of cytochalasin D and nocodazole, prevented the potentiation of the calcium transients in cAMP-treated astrocytes. Phospholipase C activity and sensitivity to inositol (1,4,5)-trisphosphate were not involved in the enhancement of the calcium responses. Also, potentiation of the calcium transients was dependent on extracellular calcium. Calcium storage and thapsigargin-depletable intracellular calcium reservoirs were analogously not increased in differentiated astrocytes, Rearrangement of the cell shape also caused a condensation of the endoplasmic reticulum and altered the spatial relationship between the endoplasmic reticulum and the cell membrane. In conclusion, morphological rearrangements of type I astrocytes increase the magnitude and the duration of agonist-induced calcium transients via enhancement of capacitative calcium entry and is associated with a spatial reorganization of the relationship between cell membrane and the endoplasmic reticulum structures.	NINDS, Lab Adapt Syst, NIH, Bethesda, MD 20817 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Grimaldi, M (corresponding author), NINDS, Lab Adapt Syst, NIH, 36 Convent Dr,Bldg 36,Rm 4A22, Bethesda, MD 20817 USA.	maurizio@codon.nih.gov		Grimaldi, Maurizio/0000-0002-7331-7055				BARRES BA, 1989, J NEUROSCI, V9, P3169; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Bhat NR, 1995, DEV NEUROSCI-BASEL, V17, P267, DOI 10.1159/000111296; Chen CC, 1996, GLIA, V16, P210, DOI 10.1002/(SICI)1098-1136(199603)16:3<210::AID-GLIA3>3.0.CO;2-5; GOLDMAN JE, 1984, BRAIN RES, V306, P85, DOI 10.1016/0006-8993(84)90358-5; GRIMALDI M, 1994, J NEUROCHEM, V63, P344; Grimaldi M, 1999, EUR J NEUROSCI, V11, P2767, DOI 10.1046/j.1460-9568.1999.00693.x; Hofer AM, 1998, EMBO J, V17, P1986, DOI 10.1093/emboj/17.7.1986; Holda JR, 1997, FEBS LETT, V403, P191, DOI 10.1016/S0014-5793(97)00051-3; Iwasaki H, 1998, EUR J PHARMACOL, V352, P131, DOI 10.1016/S0014-2999(98)00413-0; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; Kovbasnjuk ON, 1998, J MEMBRANE BIOL, V161, P93, DOI 10.1007/s002329900317; Lascola CD, 1996, J NEUROSCI, V16, P2532; Li Y, 1996, J BIOL CHEM, V271, P16862, DOI 10.1074/jbc.271.28.16862; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Putney JW, 1998, SCIENCE, V279, P191, DOI 10.1126/science.279.5348.191; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Putney JW, 1997, CELL CALCIUM, V21, P257, DOI 10.1016/S0143-4160(97)90050-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Ribeiro CMP, 1997, J BIOL CHEM, V272, P26555, DOI 10.1074/jbc.272.42.26555; Rzigalinski BA, 1999, J BIOL CHEM, V274, P175, DOI 10.1074/jbc.274.1.175; SHAO Y, 1993, NEUROSCIENCE, V55, P991, DOI 10.1016/0306-4522(93)90313-5; STEPHENS GJ, 1993, GLIA, V9, P269, DOI 10.1002/glia.440090405; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Zhou YP, 1998, J CLIN INVEST, V101, P1623, DOI 10.1172/JCI1245	25	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33557	33564		10.1074/jbc.274.47.33557	http://dx.doi.org/10.1074/jbc.274.47.33557			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559242	hybrid			2022-12-25	WOS:000083745200058
J	Henderson, JP; Byun, J; Heinecke, JW				Henderson, JP; Byun, J; Heinecke, JW			Molecular chlorine generated by the myeloperoxidase-hydrogen peroxide-chloride system of phagocytes produces 5-chlorocytosine in bacterial RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HUMAN ATHEROSCLEROTIC INTIMA; AQUEOUS HYPOCHLOROUS ACID; HUMAN NEUTROPHILS EMPLOY; L-TYROSINE OXIDATION; NITRIC-OXIDE; P-HYDROXYPHENYLACETALDEHYDE; CATALYZED OXIDATION; REACTIVE ALDEHYDES; MASS-SPECTROMETRY	Myeloperoxidase, a heme enzyme secreted by activated phagocytes, uses H2O2 and Cl- to generate the chlorinating intermediate hypochlorous acid (HOCl), This potent cytotoxic oxidant plays a critical role in host defenses against invading pathogens. In this study, we explore the possibility that myeloperoxidase-derived HOCl might oxidize nucleic acids. When we exposed 2'-deoxycytidine to the myeloperoxidase-H2O2-Cl- system, we obtained a single major product that was identified as 5-chloro-2'-deoxycytidine using mass spectrometry, high performance liquid chromatography, W-visible spectroscopy, and NMR spectroscopy. 5-Chloro-2'-deoxycytidine production by myeloperoxidase required H2O2 and Cl-, suggesting that HOCl is an intermediate in the reaction. However, reagent HOCl failed to generate 5-chloro-2'-deoxycytidine in the absence of Cl-. Moreover, chlorination of 2'-deoxycytidine was optimal under acidic conditions in the presence of Cl-. These results implicate molecular chlorine (Cl-2), which is in equilibrium with HOCl through a reaction requiring Cl- and HC, in the generation of 5-chloro-2'-deoxycytidine, Activated human neutrophils were able to generate 5-chloro-2'-deoxycytidine. Cellular chlorination was blocked by catalase and heme poisons, consistent with a myeloperoxidase-catalyzed reaction. The myeloperoxidase-H2O2-Cl- system generated similar levels of 5-chlorocytosine in RNA and DNA in vitro. In striking contrast, only cell-associated RNA acquired detectable levels of 5-chlorocytosine when intact Escherichia coli was exposed to the myeloperoxidase system. This observation suggests that oxidizing intermediates generated by myeloperoxidase selectively target intracellular RNA for chlorination. Collectively, these results indicate that Cl-2 derived from HOCl generates 5-chloro-2'-deoxycytidine during the myeloperoxidase-catalyzed oxidation of 2'-deoxycytidine, Phagocytic generation of Cl-2 therefore may constitute one mechanism for oxidizing nucleic acids at sites of inflammation.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Heinecke, JW (corresponding author), Div Atherosclerosis Nutr & Lipd Res, Campus Box 8046,660 S Euclid Ave, St Louis, MO 63110 USA.		Henderson, Jeffrey P/D-3337-2015		NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012293, R01AG015013] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00954] Funding Source: Medline; NIA NIH HHS [AG12293, AG15013] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BEERS RF, 1952, J BIOL CHEM, V195, P133; BERNOFSKY C, 1991, FASEB J, V5, P295, DOI 10.1096/fasebj.5.3.1848195; BIRNBOIM HC, 1985, P NATL ACAD SCI USA, V82, P6820, DOI 10.1073/pnas.82.20.6820; BRYANT RE, 1980, J INFECT DIS, V142, P594, DOI 10.1093/infdis/142.4.594; Byun J, 1999, BIOCHEMISTRY-US, V38, P2590, DOI 10.1021/bi9822980; Carr AC, 1997, BIOCHEM J, V327, P275, DOI 10.1042/bj3270275; CHAUDHARY AK, 1994, SCIENCE, V265, P1580, DOI 10.1126/science.8079172; CRAIN PF, 1990, METHOD ENZYMOL, V193, P782, DOI 10.1016/0076-6879(90)93450-Y; Douki T, 1996, CHEM RES TOXICOL, V9, P3, DOI 10.1021/tx950126n; Dunford H. B., 1999, HEME PEROXIDASES; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Eiserich JP, 1996, J BIOL CHEM, V271, P19199, DOI 10.1074/jbc.271.32.19199; FOOTE CS, 1983, NATURE, V301, P715, DOI 10.1038/301715a0; FOX LM, 1982, ANTIMICROB AGENTS CH, V22, P431, DOI 10.1128/AAC.22.3.431; GAJEWSKI E, 1990, BIOCHEMISTRY-US, V29, P7876, DOI 10.1021/bi00486a014; Ghoshal K, 1997, BIOCHEM PHARMACOL, V53, P1569, DOI 10.1016/S0006-2952(97)00040-3; Giese RW, 1996, METHOD ENZYMOL, V271, P504; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; Hazen SL, 1996, J BIOL CHEM, V271, P23080, DOI 10.1074/jbc.271.38.23080; Hazen SL, 1997, J BIOL CHEM, V272, P16990, DOI 10.1074/jbc.272.27.16990; Hazen SL, 1998, J BIOL CHEM, V273, P4997, DOI 10.1074/jbc.273.9.4997; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; Hazen SL, 1996, J BIOL CHEM, V271, P1861, DOI 10.1074/jbc.271.4.1861; HEINECKE JW, 1994, BIOCHEMISTRY-US, V33, P10127, DOI 10.1021/bi00199a041; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; HOYANO Y, 1973, BIOCHEM BIOPH RES CO, V53, P1195, DOI 10.1016/0006-291X(73)90591-3; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; IIZASA T, 1986, BIOCHIM BIOPHYS ACTA, V888, P249, DOI 10.1016/0167-4889(86)90027-3; JACKSON JH, 1989, J CLIN INVEST, V84, P1644, DOI 10.1172/JCI114342; Jacob JS, 1996, J BIOL CHEM, V271, P19950, DOI 10.1074/jbc.271.33.19950; Kettle AJ, 1997, REDOX REP, V3, P3, DOI 10.1080/13510002.1997.11747085; KETTLE AJ, 1988, BIOCHIM BIOPHYS ACTA, V956, P58, DOI 10.1016/0167-4838(88)90297-X; Klebanoff S.J., 1978, NEUTROPHIL FUNCTION; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P1433, DOI 10.1074/jbc.272.3.1433; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; Luo YZ, 1996, J BIOL CHEM, V271, P21167, DOI 10.1074/jbc.271.35.21167; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; Marquez LA, 1995, J BIOL CHEM, V270, P30434, DOI 10.1074/jbc.270.51.30434; MORITA Y, 1986, J BIOCHEM-TOKYO, V99, P761, DOI 10.1093/oxfordjournals.jbchem.a135535; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; MORRIS SM, 1993, MUTAT RES, V297, P39, DOI 10.1016/0165-1110(93)90006-9; ONEILL JP, 1983, MUTAT RES, V109, P259, DOI 10.1016/0027-5107(83)90051-9; PARK EM, 1992, P NATL ACAD SCI USA, V89, P3375, DOI 10.1073/pnas.89.8.3375; PATTON W, 1972, BIOCHEM BIOPH RES CO, V48, P880, DOI 10.1016/0006-291X(72)90690-0; PENMAN BW, 1976, LIFE SCI, V19, P563, DOI 10.1016/0024-3205(76)90237-X; Prutz WA, 1998, ARCH BIOCHEM BIOPHYS, V349, P183, DOI 10.1006/abbi.1997.0440; RAKITA RM, 1990, BIOCHEMISTRY-US, V29, P1075, DOI 10.1021/bi00456a033; RAMACHANDRAN S, 1976, T ROY SOC TROP MED H, V70, P159, DOI 10.1016/0035-9203(76)90180-2; SANTOS O, 1990, INT J RADIAT ONCOL, V19, P357, DOI 10.1016/0360-3016(90)90544-T; SAVENKOVA MI, 1994, J BIOL CHEM, V269, P20394; SHIGENAGA MK, 1989, P NATL ACAD SCI USA, V86, P9697, DOI 10.1073/pnas.86.24.9697; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; STETMASZYNSKA T, 1978, EUR J BIOCHEM, V92, P301; Taddei F, 1997, SCIENCE, V278, P128, DOI 10.1126/science.278.5335.128; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; Tamir S, 1996, CHEM RES TOXICOL, V9, P821, DOI 10.1021/tx9600311; TEST ST, 1984, J CLIN INVEST, V74, P1341, DOI 10.1172/JCI111544; Thomas E L, 1986, Methods Enzymol, V132, P569; THOMAS EL, 1995, J BIOL CHEM, V270, P2906, DOI 10.1074/jbc.270.7.2906; TOBLER A, 1991, BLOOD CELL BIOCH LYM; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; WEITZMAN SA, 1990, BLOOD, V76, P655; Whiteman M, 1997, CHEM RES TOXICOL, V10, P1240, DOI 10.1021/tx970086i; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; WINTERBOURN CC, 1992, ARCH BIOCHEM BIOPHYS, V296, P547, DOI 10.1016/0003-9861(92)90609-Z; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274; YERMILOV V, 1995, FEBS LETT, V376, P207, DOI 10.1016/0014-5793(95)01281-6	71	93	95	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33440	33448		10.1074/jbc.274.47.33440	http://dx.doi.org/10.1074/jbc.274.47.33440			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559226	hybrid			2022-12-25	WOS:000083745200042
J	Suske, WA; van Berkel, WJH; Kohler, HPE				Suske, WA; van Berkel, WJH; Kohler, HPE			Catalytic mechanism of 2-hydroxybiphenyl 3-monooxygenase, a flavoprotein from Pseudomonas azelaica HBP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARA-HYDROXYBENZOATE HYDROXYLASE; 2-METHYL-3-HYDROXYPYRIDINE-5-CARBOXYLIC ACID OXYGENASE; OXIDATIVE HALF-REACTION; PHENOL HYDROXYLASE; CRYSTAL-STRUCTURE; STEADY-STATE; BINDING; SUBSTRATE; FLAVIN; FAD	2-Hydroxybiphenyl 3-monooxygenase (EC 1.14.13.44) from Pseudomonas azelaica HBP1 is an FAD-dependent aromatic hydroxylase that catalyzes the conversion of a-hydroxybiphenyl to 2,3 dihydroxybiphenyl in the presence of NADH and oxygen. The catalytic mechanism of this three-substrate reaction was investigated at 7 degrees C by stopped-flow absorption spectroscopy. Various individual steps associated with catalysis were readily observed at pH 7.5, the optimum pH for enzyme turnover. Anaerobic reduction of the free enzyme by NADH is a biphasic process, most likely reflecting the presence of two distinct enzyme forms. Binding of 2-hydroxybiphenyl stimulated the rate of enzyme reduction by NADH by 2 orders of magnitude. The anaerobic reduction of the enzyme-substrate complex involved the formation of a transient charge-transfer complex between the reduced flavin and NAD(+), A similar transient intermediate was formed when the enzyme was complexed with the substrate analog 2-sec-butylphenol or with the non-substrate effector 2,3-dihydroxybiphenyl. Excess NAD(+) strongly stabilized the charge-transfer complexes but did not give rise to the appearance of any intermediate during the reduction of uncomplexed enzyme. Free reduced 2-hydroxybiphenyl S-monooxygenase reacted rapidly with oxygen to form oxidized enzyme with no appearance of intermediates during this reaction. In the presence of 2-hydroxybiphenyl, two consecutive spectral intermediates were observed which were assigned to the flavin C(4a)-hydroperoxide and the flavin C(4a)hydroxide, respectively. No oxygenated flavin intermediates were observed when the enzyme was in complex with 2,3-dihydroxybiphenyl, Monovalent anions retarded the dehydration of the flavin C(4a)-hydroxide without stabilization of additional intermediates. The kinetic data for 2-hydroxybiphenyl S-monooxygenase are consistent with a ternary complex mechanism in which the aromatic substrate has strict control in both the reductive and oxidative half-reaction in a way that reactions leading to substrate hydroxylation are favored over those leading to the futile formation of hydrogen peroxide. NAD(+) release from the reduced enzyme-substrate complex is the slowest step in catalysis.	Wageningen Univ Agr, Res Ctr, Dept Biomol Sci, Biochem Lab, NL-6703 HA Wageningen, Netherlands; EAWAG, Dept Microbiol, CH-8600 Dubendorf, Switzerland	Wageningen University & Research; Swiss Federal Institutes of Technology Domain; Swiss Federal Institute of Aquatic Science & Technology (EAWAG)	van Berkel, WJH (corresponding author), Wageningen Univ Agr, Res Ctr, Dept Biomol Sci, Biochem Lab, Dreijenlaan 3, NL-6703 HA Wageningen, Netherlands.		Kohler, Hans-Peter/C-1456-2015; van Berkel, Willem J.H./O-2431-2014	Kohler, Hans-Peter/0000-0001-7667-0762; van Berkel, Willem J.H./0000-0002-6551-2782				ANDERSON RF, 1987, J BIOL CHEM, V262, P17475; ARUNACHALAM U, 1994, J BIOL CHEM, V269, P150; ARUNACHALAM U, 1994, J BIOL CHEM, V269, P11795; BEATY NB, 1981, J BIOL CHEM, V256, P4611; Chaiyen P, 1997, BIOCHEMISTRY-US, V36, P13856, DOI 10.1021/bi9715122; Chaiyen P, 1997, BIOCHEMISTRY-US, V36, P8060, DOI 10.1021/bi970089u; Chaiyen PC, 1997, P NATL ACAD SCI USA, V94, P7233, DOI 10.1073/pnas.94.14.7233; CLAIBORNE A, 1983, J BIOL CHEM, V258, P4919; DETMER K, 1984, J BIOL CHEM, V259, P1265; DETMER K, 1985, J BIOL CHEM, V260, P5998; Enroth C, 1998, STRUCTURE, V6, P605, DOI 10.1016/S0969-2126(98)00062-8; ENTSCH B, 1991, J BIOL CHEM, V266, P17341; ENTSCH B, 1995, FASEB J, V9, P476, DOI 10.1096/fasebj.9.7.7737455; ENTSCH B, 1989, BIOCHIM BIOPHYS ACTA, V999, P313, DOI 10.1016/0167-4838(89)90014-9; ENTSCH B, 1976, J BIOL CHEM, V251, P2550; EPPINK MHM, 1995, EUR J BIOCHEM, V231, P157, DOI 10.1111/j.1432-1033.1995.0157f.x; Eppink MHM, 1997, PROTEIN SCI, V6, P2454; Eppink MHM, 1998, J BIOL CHEM, V273, P21031, DOI 10.1074/jbc.273.33.21031; GATTI DL, 1994, SCIENCE, V266, P110, DOI 10.1126/science.7939628; GHISLA S, 1986, BIOCHEM J, V239, P1; Held M, 1998, J MOL CATAL B-ENZYM, V5, P87, DOI 10.1016/S1381-1177(98)00012-5; HOWELL LG, 1972, J BIOL CHEM, V247, P4340; HUSAIN M, 1979, J BIOL CHEM, V254, P6657; KATAGIRI M, 1965, J BIOL CHEM, V240, P3414; KEMAL C, 1976, P NATL ACAD SCI USA, V73, P995, DOI 10.1073/pnas.73.4.995; KOHLER HPE, 1988, APPL ENVIRON MICROB, V54, P2683, DOI 10.1128/AEM.54.11.2683-2688.1988; KOHLER HPE, 1993, J BACTERIOL, V175, P1621, DOI 10.1128/JB.175.6.1621-1628.1993; MAEDAYORITA K, 1993, J BIOL CHEM, V268, P4134; MASSEY V, 1994, J BIOL CHEM, V269, P22459; MASSEY V, 1975, ENZYMES, V12, P191; NEUJAHR HY, 1991, CHEM BIOCH FLAVOENZY, V2, P65; Palfey BA, 1997, BIOCHEMISTRY-US, V36, P15713; POWLOWSKI J, 1989, J BIOL CHEM, V264, P5606; SCHMID A, 1997, THESIS U STUTTGART S; SCHOPFER LM, 1979, J BIOL CHEM, V254, P634; SCHOPFER LM, 1991, J BIOL CHEM, V266, P13080; SCHREUDER HA, 1994, BIOCHEMISTRY-US, V33, P10161, DOI 10.1021/bi00199a044; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; STRICKLAND S, 1973, J BIOL CHEM, V248, P2944; Suske WA, 1997, J BIOL CHEM, V272, P24257, DOI 10.1074/jbc.272.39.24257; TAYLOR MG, 1990, J BIOL CHEM, V265, P13687; van Berkel W.J.H., 1991, CHEM BIOCH FLAVOENZY, P1; VANBERKEL W, 1992, EUR J BIOCHEM, V210, P411; VANBERKEL WJH, 1994, PROTEIN SCI, V3, P2245, DOI 10.1002/pro.5560031210; VERVOORT J, 1991, EUR J BIOCHEM, V200, P731, DOI 10.1111/j.1432-1033.1991.tb16238.x; WESSIAK A, 1984, J BIOL CHEM, V259, P2547; XUN LY, 1991, J BACTERIOL, V173, P4447, DOI 10.1128/JB.173.14.4447-4453.1991	47	36	38	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33355	33365		10.1074/jbc.274.47.33355	http://dx.doi.org/10.1074/jbc.274.47.33355			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559214	Green Published, hybrid			2022-12-25	WOS:000083745200030
J	Tassi, E; Biesova, Z; Di Fiore, PP; Gutkind, JS; Wong, WT				Tassi, E; Biesova, Z; Di Fiore, PP; Gutkind, JS; Wong, WT			Human JIK, a novel member of the STE20 kinase family that inhibits JNK and is negatively regulated by epidermal growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION PATHWAY; N-TERMINAL KINASE; MAP KINASE; C-JUN; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; COUPLED RECEPTORS; PROTEIN-KINASE-1 BMK1; CELLULAR STRESSES	Mammalian members related to Saccharomyces cerevisiae serine/threonine kinase STE20 can be divided into two subfamilies based on their structure and function. The PAK subfamily is characterized by an N-terminal p21-binding domain (also known as CRIB domain), a C-terminal kinase domain, and is regulated by the small GTP-binding proteins Rad and Cdc42Hs. The second group is represented by the GCK-like members, which contain an N-terminal catalytic domain and lack the p21-binding domain. Some of them have been demonstrated to induce c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) cascade, while others have been shown to be activated by a subset of stress conditions or apoptotic agents, although little is known about their specific function. Here, we have identified a novel human STE20-related serine/threonine kinase, belonging to the GCK-like subfamily. This kinase does not induce the JNK/SAPK pathway, but, instead, inhibits the basal activity of JNK/SAPK, and diminishes its activation in response to human epidermal growth factor (EGF). Therefore, we designated this molecule JIK for JNK/SAPK-inhibitory kinase. The inhibition of JNK/SAPK signaling pathway by JIK was found to occur between the EGF receptor and the small GTP-binding proteins Rad and Cdc42Hs. In contrast, JIK does not activate nor does it inhibit ERK2, ERK6, p38, or ERK5. Furthermore, JIK kinase activity is not modulated by any exogenous stimuli, but, interestingly it is dramatically decreased upon EGF receptor activation. Thus, JIK might represent the first member of the STE20 kinase family whose activity can be negatively regulated by tyrosine kinase receptors, and whose downstream targets inhibit, rather than enhance, JNK/SAPK activation.	NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Slovak Acad Sci, Inst Virol, Bratislava 84246, Slovakia; European Inst Oncol, Dept Expt Oncol, I-20140 Milan, Italy; GenoQuest Inc, Germantown, MD 20874 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Slovak Academy of Sciences; IRCCS European Institute of Oncology (IEO)	Wong, WT (corresponding author), NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA.	wwong@genoquest.com	Tassi, Enrico/AAJ-9661-2020; Tassi, Enrico/K-3958-2015; Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016; Di Fiore, Pier Paolo/K-2130-2012	Tassi, Enrico/0000-0002-3335-6500; Gutkind, J. Silvio/0000-0002-5150-4482; Di Fiore, Pier Paolo/0000-0002-2252-0950				Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMMERER G, 1994, CURR OPIN GENET DEV, V4, P90, DOI 10.1016/0959-437X(94)90096-5; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Biesova Z, 1997, ONCOGENE, V14, P233, DOI 10.1038/sj.onc.1200822; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; CASTAGNINO P, 1995, ONCOGENE, V10, P723; Cobb M H, 1996, Adv Pharmacol, V36, P49, DOI 10.1016/S1054-3589(08)60576-1; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; CRESPO P, 1994, J BIOL CHEM, V269, P21103; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HATZ P, 1994, J BIOL CHEM, V269, P16802; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Itoh S, 1997, ARCH BIOCHEM BIOPHYS, V340, P201, DOI 10.1006/abbi.1997.9893; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kuramochi S, 1997, J BIOL CHEM, V272, P22679, DOI 10.1074/jbc.272.36.22679; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEBERER E, 1993, MOL GEN GENET, V241, P241, DOI 10.1007/BF00284675; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARCUS S, 1995, P NATL ACAD SCI USA, V92, P6180, DOI 10.1073/pnas.92.13.6180; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; MIKI T, 1993, PRACT APPROACH SER, P177; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NEIMAN AM, 1993, TRENDS GENET, V9, P390, DOI 10.1016/0168-9525(93)90139-9; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Schinkmann K, 1997, J BIOL CHEM, V272, P28695, DOI 10.1074/jbc.272.45.28695; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Sugden PH, 1997, CELL SIGNAL, V9, P337, DOI 10.1016/S0898-6568(96)00191-X; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; Wang XHS, 1996, J BIOL CHEM, V271, P31607; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; YAN MH, 1994, NATURE, V372, P798; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	91	56	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33287	33295		10.1074/jbc.274.47.33287	http://dx.doi.org/10.1074/jbc.274.47.33287			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559204	hybrid			2022-12-25	WOS:000083745200020
J	Wang, SB; Wang, WH; Wesley, RA; Danner, RL				Wang, SB; Wang, WH; Wesley, RA; Danner, RL			A Sp1 binding site of the tumor necrosis factor alpha promoter functions as a nitric oxide response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	Experimental Biology 98 Meeting	APR 18-22, 1998	SAN FRANCISCO, CALIFORNIA	Amer Soc Exper Biol			TRANSCRIPTION FACTOR SP1; HUMAN MONOCYTIC CELLS; SMOOTH-MUSCLE CELLS; GENE-TRANSCRIPTION; ENDOTHELIAL-CELLS; HUMAN NEUTROPHILS; PROTEIN-KINASE; CYCLIC-AMP; U937 CELLS; EXPRESSION	Regulation of gene transcription is an incompletely understood function of nitric oxide (NO). Human leukocytes produce increased amounts of tumor necrosis factor alpha (TNF-alpha) in response to NO. This effect is associated with decreases in intracellular cAMP, suggesting that NO might regulate gene transcription through promoter sequences sensitive to cAMP such as cAMP response elements (CRE) and Sp1 binding sites. Here we report that a Sp1 binding site in the TNF-alpha promoter conveys NO responsiveness. Human U937 cells were differentiated for TNF-alpha production with phorbol 12-myristate 13-acetate. NO donors and H89, an inhibitor of cAMP-dependent protein kinase increased, while dibutyryl cAMP (Bt(2)cAMP) decreased TNF-alpha promoter activity. Deletion or mutation of the proximal Sp1 site, but not the CRE site, abolished the activating effects of NO donors and H89. Further, NO- and H89-mediated increases in TNF-alpha promoter activity were associated with decreased Sp1 binding. The insertion of Sp1 sites into a minimal cytomegalovirus promoter conferred NO responsiveness, an effect blocked by Bt(2)cAMP, Mutation of these inserted Sp1 sites prevented this heterologous promoter from responding to NO, H89 and Bt(2)cAMP. These results identify the Sp1 binding site as a promoter motif that allows NO to control gene transcription.	NIH, Dept Crit Care Med, Warren Grant Magnuson Clin Ctr, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Danner, RL (corresponding author), NIH, Dept Crit Care Med, Warren Grant Magnuson Clin Ctr, Bldg 10,Rm 7D43, Bethesda, MD 20892 USA.							Berendji D, 1997, FEBS LETT, V405, P37, DOI 10.1016/S0014-5793(97)00150-6; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Cieslik K, 1998, J BIOL CHEM, V273, P14885, DOI 10.1074/jbc.273.24.14885; Corriveau CC, 1998, J INFECT DIS, V177, P116, DOI 10.1086/513829; GRIMALDI P, 1993, MOL ENDOCRINOL, V7, P1217, DOI 10.1210/me.7.9.1217; Hartsfield CL, 1997, AM J PHYSIOL-LUNG C, V273, pL980; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; Ichiki T, 1998, HYPERTENSION, V31, P342, DOI 10.1161/01.HYP.31.1.342; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; LANDER HM, 1993, J IMMUNOL, V150, P1509; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LEITMAN DC, 1992, MOL CELL BIOL, V12, P1352, DOI 10.1128/MCB.12.3.1352; LEITMAN DC, 1991, J BIOL CHEM, V266, P9343; Liu XK, 1998, LIFE SCI, V62, P739, DOI 10.1016/S0024-3205(97)01172-7; Liu YX, 1998, J BIOL CHEM, V273, P15257, DOI 10.1074/jbc.273.24.15257; Madsen CS, 1997, J BIOL CHEM, V272, P6332, DOI 10.1074/jbc.272.10.6332; McClure RF, 1999, J BIOL CHEM, V274, P7756, DOI 10.1074/jbc.274.12.7756; NEWELL CL, 1994, J LEUKOCYTE BIOL, V56, P27, DOI 10.1002/jlb.56.1.27; Ollivier V, 1996, J BIOL CHEM, V271, P20828, DOI 10.1074/jbc.271.34.20828; PENG HB, 1995, J BIOL CHEM, V270, P17050, DOI 10.1074/jbc.270.28.17050; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; ROMAN D, 1990, New Biologist, V2, P642; TABUCHI A, 1994, FEBS LETT, V351, P123, DOI 10.1016/0014-5793(94)00839-6; VANDERVORT AL, 1994, J IMMUNOL, V152, P4102; VENEPALLY P, 1995, J BIOL CHEM, V270, P25402, DOI 10.1074/jbc.270.43.25402; Wang SB, 1997, J BIOL CHEM, V272, P5959, DOI 10.1074/jbc.272.9.5959; Xu QB, 1997, J CLIN INVEST, V100, P1089, DOI 10.1172/JCI119619; Yan L, 1997, BLOOD, V90, P1160, DOI 10.1182/blood.V90.3.1160.1160_1160_1167; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795	32	72	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	1999	274	47					33190	33193		10.1074/jbc.274.47.33190	http://dx.doi.org/10.1074/jbc.274.47.33190			4	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	256UQ	10559188	hybrid			2022-12-25	WOS:000083745200004
J	Hincke, MT; Gautron, J; Tsang, CPW; McKee, MD; Nys, Y				Hincke, MT; Gautron, J; Tsang, CPW; McKee, MD; Nys, Y			Molecular cloning and ultrastructural localization of the core protein of an eggshell matrix proteoglycan, ovocleidin-116	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; EXTRACELLULAR-MATRIX; MINERALIZED TISSUES; SOLUBLE MATRIX; HENS; BIOMINERALIZATION; PEPTIDES; CLEAVAGE; MODEL; CELLS	The role of avian eggshell matrix proteins in shell formation is poorly understood. This calcitic biomaterial forms in a uterine fluid where the protein composition varies during the initial, calcification, and terminal phases of eggshell deposition, A specific antibody was raised to a 116-kDa protein, which is most abundant in uterine fluid during active eggshell calcification. This antiserum was used to expression screen a bacteriophage cDNA library prepared using mRNA extracted from pooled uterine tissue harvested at the midpoint of eggshell calcification. Plasmids containing inserts of differing 5'-lengths were isolated with a maximum cDNA sequence of 2.4 kilobases, Northern blotting and reverse transcriptase-polymerase chain reaction demonstrated that the 2,35-kilobase message was expressed in a uterine-specific manner,. The hypothetical translational product from the open reading frame corresponded to a novel 80-kDa protein, which we have named ovocleidin-116, After removal of the predicted signal peptide, its N-terminal sequence corresponded almost exactly with that determined from direct microsequencing of the 116-kDa uterine protein (this work) and with that previously determined for the core protein of a 120-kDa egg shell dermatan sulfate proteoglycan (Corrino, D. A., Rodriguez, J, P,, and Caplan, A. I. (1997) Connect. Tissue Res. 36, 175-193), Ultrastructural colloidal gold immunocytochemistry of ovocleidin-116 demonstrated its presence in the organic matrix, in small vesicles found throughout the mineralized palisade layer, and the calcium reserve assembly of the mammillary layer. Ovocleidin-116 thus is a candidate molecule for the regulation of calcite growth during eggshell calcification.	Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada; INRA, Rech Avicoles Stn, F-37380 Nouzilly, France; McGill Univ, Fac Dent, Montreal, PQ H3A 2B2, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada; Agr Canada, Ctr Food & Anim Res, Cent Expt Farm, Ottawa, ON K1A 0C6, Canada	University of Ottawa; INRAE; McGill University; McGill University; Agriculture & Agri Food Canada	Hincke, MT (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	mhincke@uottawa.ca	McKee, Marc D/E-2187-2011; GAUTRON, Joël/A-1753-2017	McKee, Marc D/0000-0001-8349-965X; GAUTRON, Joël/0000-0001-7800-0578				ADAIR WS, 1990, P NATL ACAD SCI USA, V87, P7355, DOI 10.1073/pnas.87.19.7355; Addadi L., 1989, Connective Tissue Research, V21, P127, DOI 10.3109/03008208909050003; ADDADI L, 1987, P NATL ACAD SCI USA, V84, P2732, DOI 10.1073/pnas.84.9.2732; ARIAS JL, 1992, ARCH BIOCHEM BIOPHYS, V298, P293, DOI 10.1016/0003-9861(92)90126-H; ARIAS JL, 1993, INT REV CYTOL, V145, P217, DOI 10.1016/S0074-7696(08)60428-3; BOUVIER M, 1990, ARCH ORAL BIOL, V35, P301, DOI 10.1016/0003-9969(90)90047-E; BOUVIER M, 1990, DIFFERENTIATION, V45, P128, DOI 10.1111/j.1432-0436.1990.tb00466.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brinkmann T, 1997, J BIOL CHEM, V272, P11171; Carrino DA, 1996, CONNECT TISSUE RES, V35, P325, DOI 10.3109/03008209609029207; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORRINO DA, 1997, CONNECT TISSUE RES, V36, P175; Fernandez MS, 1997, MATRIX BIOL, V16, P13, DOI 10.1016/S0945-053X(97)90112-8; Fujisawa R, 1998, EUR J ORAL SCI, V106, P249, DOI 10.1111/j.1600-0722.1998.tb02183.x; FUREDIMILHOFER H, 1994, CONNECT TISSUE RES, V30, P251, DOI 10.3109/03008209409015041; Gautron J, 1996, BRIT POULTRY SCI, V37, P853, DOI 10.1080/00071669608417914; Gautron J, 1997, CONNECT TISSUE RES, V36, P195, DOI 10.3109/03008209709160220; GAUTRON J, 1999, IN PRESS P 6 INT C C; Hames B. D., 1981, GEL ELECTROPHORESIS; HAMILTON RMG, 1986, FOOD MICROSTRUCT, V5, P99; Hincke M. T., 1999, Egg nutrition and biotechnology., P447; HINCKE MT, 1995, CALCIFIED TISSUE INT, V56, P578, DOI 10.1007/BF00298593; Hincke MT, 1995, CONNECT TISSUE RES, V31, P227, DOI 10.3109/03008209509010814; HINCKE MT, 1992, BRIT POULTRY SCI, V33, P505, DOI [10.1080/00071669208417489, NO_DOI]; HUNTER GK, 1992, MATRIX, V12, P362, DOI 10.1016/S0934-8832(11)80032-6; HUNTER GK, 1991, CLIN ORTHOP RELAT R, P256; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRUEGER RC, 1990, J BIOL CHEM, V265, P12075; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCKEE MD, 1995, MICROSC RES TECHNIQ, V31, P44, DOI 10.1002/jemt.1070310105; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NYS Y, 1999, IN PRESS POULT AVIAN; OLDBERG A, 1987, BIOCHEM J, V243, P255, DOI 10.1042/bj2430255; Panheleux M, 1999, BRIT POULTRY SCI, V40, P240, DOI 10.1080/00071669987665; PARSONS AH, 1982, POULTRY SCI, V61, P2013, DOI 10.3382/ps.0612013; PINES M, 1996, MATRIX BIOL, V14, P765; Sambrook J., 2002, MOL CLONING LAB MANU; Smith CE, 1998, CRIT REV ORAL BIOL M, V9, P128, DOI 10.1177/10454411980090020101; TERMINE JD, 1984, METHODS CALCIFIED TI, P547; Watanabe H, 1998, J BIOCHEM, V124, P687, DOI 10.1093/oxfordjournals.jbchem.a022166; WU TM, 1992, INT CONGR SER, V1002, P133; WU TM, 1994, MATRIX BIOL, V14, P507; ZHANG LJ, 1994, J BIOL CHEM, V269, P19295	43	125	134	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32915	32923		10.1074/jbc.274.46.32915	http://dx.doi.org/10.1074/jbc.274.46.32915			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551857	Green Published, hybrid			2022-12-25	WOS:000083623000057
J	Kim, DE; Kim, SS				Kim, DE; Kim, SS			The mechanism of ATP hydrolysis at the noncatalytic sites of the transcription termination factor rho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-DNA HELICASE; PROTEIN-RHO; CATALYTIC SITES; BINDING-SITES; MUTANT-RHO; F1-ATPASE; COFACTORS; GEOMETRY; KINETICS	Escherichia coli transcription termination factor rho is a hexamer with three catalytic subunits that turnover ATP at a fast rate and three noncatalytic subunits that turnover ATP at a relatively slow rate. The mechanism of the ATPase reaction at the noncatalytic sites was determined and was compared with the ATPase mechanism at the catalytic sites. A sequential mechanism for ATP binding or hydrolysis that was proposed for the catalytic sites was not observed at the noncatalytic sites. Pre-steady-state pulse-chase experiments showed that three ATPs were tightly bound to the noncatalytic sites and these were simultaneously hydrolyzed at a rate of 1.8 s(-1) at 18 degrees C. The apparent bimolecular rate constant for ATP binding was determined as 5.4 x 10(5) M-1 s(-1) in the presence of poly(C) RNA. The ATP hydrolysis products dissociated from the noncatalytic sites at 0.02 s(-1) The hydrolysis of ATP at the noncatalytic sites was at least 130 times slower, and the overall ATPase turnover was 1500 times slower than that at the catalytic sites. These results from studies of the rho protein are likely to be general to hexameric helicases. We propose that the ATPase activity at the noncatalytic site is too slow to drive translocation of the protein on the nucleic acid or to provide energy for nucleic acid unwinding.	Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Kim, SS (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA.		Kim, Dong-Eun/D-8304-2011	Kim, Dong-Eun/0000-0001-6545-8387	NIGMS NIH HHS [GM55310] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Allison TJ, 1998, NAT STRUCT BIOL, V5, P352, DOI 10.1038/nsb0598-352; BEAR DG, 1988, J MOL BIOL, V199, P623, DOI 10.1016/0022-2836(88)90306-3; BRENNAN CA, 1990, J BIOL CHEM, V265, P5440; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; BUJALOWSKI W, 1993, BIOCHEMISTRY-US, V32, P5888, DOI 10.1021/bi00073a023; CROSS RL, 1982, J BIOL CHEM, V257, P2874; FINGER LR, 1981, BIOCHEMISTRY-US, V20, P1640, DOI 10.1021/bi00509a036; GALLUPPI GR, 1980, J MOL BIOL, V138, P513, DOI 10.1016/S0022-2836(80)80016-7; GEISELMANN J, 1992, PROTEIN SCI, V1, P850, DOI 10.1002/pro.5560010703; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P111, DOI 10.1021/bi00116a017; Hingorani MM, 1997, P NATL ACAD SCI USA, V94, P5012, DOI 10.1073/pnas.94.10.5012; Horiguchi T, 1997, J MOL BIOL, V269, P514, DOI 10.1006/jmbi.1997.1059; Johnson K. A., 1992, ENZYMES, P1; Kim DE, 1999, J BIOL CHEM, V274, P11623, DOI 10.1074/jbc.274.17.11623; LOWERY C, 1977, J BIOL CHEM, V252, P1375; LOWERY C, 1977, J BIOL CHEM, V252, P1381; Matsui T, 1997, J BIOL CHEM, V272, P8215, DOI 10.1074/jbc.272.13.8215; MIWA Y, 1995, J MOL BIOL, V254, P815, DOI 10.1006/jmbi.1995.0658; MORI H, 1989, J MOL BIOL, V210, P39, DOI 10.1016/0022-2836(89)90289-1; O IS, 1994, J BIOL CHEM, V269, P5009; Richardson J. P., 1996, ESCHERICHIA COLI SAL, P822; RICHARDSON JP, 1986, J MOL BIOL, V189, P413, DOI 10.1016/0022-2836(86)90313-X; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5760; ROBERTS JW, 1969, NATURE, V224, P1168, DOI 10.1038/2241168a0; Stitt BL, 1998, J BIOL CHEM, V273, P26477, DOI 10.1074/jbc.273.41.26477; STITT BL, 1988, J BIOL CHEM, V263, P11130; Walstrom KM, 1997, BIOCHEMISTRY-US, V36, P7993, DOI 10.1021/bi963180r; Walstrom KM, 1997, BIOCHEMISTRY-US, V36, P7980, DOI 10.1021/bi963179s; WANG Y, 1993, J BIOL CHEM, V268, P13947	30	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32667	32671		10.1074/jbc.274.46.32667	http://dx.doi.org/10.1074/jbc.274.46.32667			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551822	hybrid			2022-12-25	WOS:000083623000022
J	Zenke, FT; King, CC; Bohl, BP; Bokoch, GM				Zenke, FT; King, CC; Bohl, BP; Bokoch, GM			Identification of a central phosphorylation site in p21-activated kinase regulating autoinhibition and kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; RAC GTPASES; ALPHA-PAK; ACTIVATION; AUTOPHOSPHORYLATION; ACTIN; INHIBITION; CLEAVAGE; REVEALS; FAMILY	p21-activated kinases (Pak)/Ste20 kinases are regulated in vitro and in vivo by the small GTP-binding proteins Rac and Cdc42 and lipids, such as sphingosine, which stimulate autophosphorylation and phosphorylation of exogenous substrates, The mechanism of Pak activation by these agents remains unclear. We investigated Pak kinase activation in more detail to gain insight into the interplay between the GTPase/sphingosine binding, an intramolecular inhibitory interaction, and autophosphorylation, We present biochemical evidence that an autoinhibitory domain (ID) contained within amino acid residues 67-150 of Pak1 interacts with the carboxyl-terminal kinase domain and that this interaction is regulated in a GTPase-dependent fashion. Cdc42- and sphingosine-stimulated Pak1 activity can be inhibited in trans by recombinant ID peptide, indicating similarities in their mode of activation. However, Pak1, which was autophosphorylated in response to either GTPase or sphingosine, is highly active and is insensitive to inhibition by the ID peptide, We identified phospho-acceptor site threonine 423 in the kinase activation loop as a critical determinant for the sensitivity to autoinhibition and enzymatic activity. Phosphorylation studies suggested that the stimulatory effect of both GTPase and sphingosine results in exposure of the activation loop, making it accessible for intermolecular phosphorylation.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Bokoch, GM (corresponding author), Scripps Res Inst, Dept Immunol, Immunobiol IMM14,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		King, Cecile/Q-9794-2019	King, Cecile/0000-0003-2193-2563; Zenke, Frank/0000-0002-2226-3755	NIA NIH HHS [AG15430] Funding Source: Medline; NIGMS NIH HHS [GM 39434] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039434] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015430] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; BENNER GE, 1995, J BIOL CHEM, V270, P21121, DOI 10.1074/jbc.270.36.21121; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Daniels RH, 1999, J BIOL CHEM, V274, P6047, DOI 10.1074/jbc.274.10.6047; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; Knaus UG, 1998, J BIOL CHEM, V273, P21512, DOI 10.1074/jbc.273.34.21512; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Lian JP, 1998, J IMMUNOL, V161, P4375; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; Taylor SS, 1997, CURR OPIN CHEM BIOL, V1, P219, DOI 10.1016/S1367-5931(97)80013-0; Tu H, 1999, MOL CELL BIOL, V19, P602; Walter BN, 1998, J BIOL CHEM, V273, P28733, DOI 10.1074/jbc.273.44.28733; Yu JS, 1998, BIOCHEM J, V334, P121, DOI 10.1042/bj3340121; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	21	201	206	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	1999	274	46					32565	32573		10.1074/jbc.274.46.32565	http://dx.doi.org/10.1074/jbc.274.46.32565			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	254QE	10551809	hybrid			2022-12-25	WOS:000083623000009
J	Alvarez-Gonzalez, R; Spring, H; Muller, M; Burkle, A				Alvarez-Gonzalez, R; Spring, H; Muller, M; Burkle, A			Selective loss of poly(ADP-ribose) and the 85-kDa fragment of poly(ADP-ribose) polymerase in nucleoli during alkylation-induced apoptosis of HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; ADP-RIBOSE; CLEAVAGE; DAMAGE; IDENTIFICATION; CASPASE-3; INHIBITOR; SUBSTRATE; KINETICS; DOMAINS	Alkylation treatment of HeLa cells results in the rapid induction of apoptosis as revealed by DNA laddering and cleavage of poly(ADP-ribose) polymerase (PARP) into the 29-and 85-kDa fragments (Kumari S. R., Mendoza-Alvarez, H. & Alvarez-Gonzalez, R, (1998) Cancer Res. 58, 5075-5078). Here, we performed a time-course analysis of (i) poly(ADP-ribose) synthesis and degradation as well as (ii) the subnuclear localization of PARP and its fragments by using confocal laser scanning immunofluorescence microscopy, PARP was activated within 15 min post-treatment, as revealed by nuclear immunostaining with antibody 10H (recognizing poly(ADP-ribose)), This was followed by a late, time-dependent, progressive decline of 10H signals that coincide with the time of PARP cleavage. Strikingly, nucleolar immunostaining with antibodies 10H and C-LI-IO (recognizing the 85-kDa PARP fragment) was lost by 15 min post-treatment, whereas F-I-23 signals (recognizing the 29-kDa fragment) persisted. We hypothesize that the 85-kDa PARP fragment is translocated, along with covalently bound poly(ADP-ribose), from nucleoli to the nucleoplasm, whereas the 29-kDa fragment is retained, because it binds to DNA strand breaks. Our data (i) provide a Link between the known time-dependent bifunctional role of PARP in apoptosis and the subcellular localization of PARP fragments and also (ii) add to the evidence for early proteolytic changes in nucleoli during apoptosis.	Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA; Univ N Texas, Hlth Sci Ctr, Inst Canc Res, Ft Worth, TX 76107 USA; German Canc Res Ctr, Div Tumor Virol, D-6900 Heidelberg, Germany; German Canc Res Ctr, Biomed Struct Anal Unit, D-6900 Heidelberg, Germany	University of North Texas System; University of North Texas Health Science Center; University of North Texas System; University of North Texas Health Science Center; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Alvarez-Gonzalez, R (corresponding author), Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA.		Gonzalez, Rafael Alvarez/I-4560-2019	Alvarez-Gonzalez, Rafael/0000-0003-1038-7512	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM045451] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45451] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMIETZ P, 1987, EUR J BIOCHEM, V169, P365, DOI 10.1111/j.1432-1033.1987.tb13621.x; ALTHAUS FR, 1997, BASE EXCISION REPAIR, P169; ALVAREZGONZALEZ R, 1989, MUTAT RES, V218, P67, DOI 10.1016/0921-8777(89)90012-8; ALVAREZGONZALEZ R, 1986, BIOCHEM BIOPH RES CO, V138, P1055; BENJAMIN RC, 1980, J BIOL CHEM, V255, P502; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; BUKI KG, 1995, J BIOL CHEM, V270, P3370, DOI 10.1074/jbc.270.7.3370; Burkle A, 1998, EXP GERONTOL, V33, P519, DOI 10.1016/S0531-5565(98)00036-9; BURKLE A, 1993, CARCINOGENESIS, V14, P559, DOI 10.1093/carcin/14.4.559; D'Amours D, 1998, RADIAT RES, V150, P3, DOI 10.2307/3579638; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; Depraetere V, 1997, Semin Immunol, V9, P93, DOI 10.1006/smim.1997.0062; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; KAMESHITA I, 1984, J BIOL CHEM, V259, P4770; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KAWAMITSU H, 1984, BIOCHEMISTRY-US, V23, P3771, DOI 10.1021/bi00311a032; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kumari SR, 1998, CANCER RES, V58, P5075; KUMARI SR, 2000, IN PRESS CANC INVEST, V18; LAMARRE D, 1988, BIOCHIM BIOPHYS ACTA, V950, P147, DOI 10.1016/0167-4781(88)90007-3; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lin WS, 1997, J BIOL CHEM, V272, P11895, DOI 10.1074/jbc.272.18.11895; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; MARSISCHKY GT, 1995, J BIOL CHEM, V270, P3247, DOI 10.1074/jbc.270.7.3247; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Mendoza-Alvarez H, 1999, BIOCHEMISTRY-US, V38, P3948, DOI 10.1021/bi982148p; MENDOZAALVAREZ H, 1993, J BIOL CHEM, V268, P22575; OEI SL, 1997, REV PHYSIOL BIOCHEM, V131, P4135; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Rawling JM, 1997, BIOCHEM J, V324, P249, DOI 10.1042/bj3240249; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Samejima K, 1998, J CELL BIOL, V143, P225, DOI 10.1083/jcb.143.1.225; SCHREIBER V, 1992, EMBO J, V11, P3263, DOI 10.1002/j.1460-2075.1992.tb05404.x; SHALL S, 1984, ADV RADIAT BIOL, V11, P1; Smulson ME, 1998, CANCER RES, V58, P3495; Stegh AH, 1998, EMBO J, V17, P5974, DOI 10.1093/emboj/17.20.5974; STELLER H, 1996, SCIENCE, V275, P1445; WIELCKENS K, 1982, J BIOL CHEM, V257, P2872	40	68	73	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32122	32126		10.1074/jbc.274.45.32122	http://dx.doi.org/10.1074/jbc.274.45.32122			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542247	hybrid			2022-12-25	WOS:000083532100055
J	Booth, JW; Belanger, KD; Sannella, MI; Davis, LI				Booth, JW; Belanger, KD; Sannella, MI; Davis, LI			The yeast nucleoporin Nup2p is involved in nuclear export of importin alpha/Srp1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING PROTEIN RANGAP1; PORE COMPLEX PROTEINS; RAN-BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; LOCALIZATION SIGNAL; TRANSPORT FACTORS; RAN/TC4; HOMOLOG; MUTANTS; DOMAIN	The importin alpha.beta heterodimer mediates nuclear import of proteins containing classical nuclear localization signals, After carrying its cargo into the nucleus, the importin dimer dissociates, and Srp1p (the yeast importin cu subunit) is recycled to the cytoplasm in a complex with Cse1p and RanGTP. Nup2p is a yeast FXFG nucleoporin that contains a Ran-binding domain. We find that export of Srp1p from the nucleus is impaired in Delta nup2 mutants. Also, Srp1p fusion proteins accumulate at the nuclear rim in wild-type cells but accumulate in the nuclear interior in Delta nup2 cells. A deletion of NUP2 shows genetic interactions with mutants in SRP1 and PRP20, which encodes the Ran nucleotide exchange factor. Srp1p binds directly to an N-terminal domain of Nup2p. This region of Nup2p is sufficient to allow accumulation of an Srp1p fusion protein at the nuclear rim, but the C-terminal Ran-binding domain of Nup2p is required for efficient Srp1p export. Formation of the Srp1p Cse1p RanGTP export complex releases Srp1p from its binding site in Nup2p. me propose that Nup2p may act as a scaffold that facilitates formation of the Srp1p export complex.	Brandeis Univ, Rosenstiel Ctr, WM Keck Inst Cellular Visualizat, Waltham, MA 02454 USA; Brandeis Univ, Dept Biol, Waltham, MA 02454 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Brandeis University; Brandeis University; Duke University	Davis, LI (corresponding author), Brandeis Univ, Rosenstiel Ctr, WM Keck Inst Cellular Visualizat, MS 029,415 South St, Waltham, MA 02454 USA.			Belanger, Kenneth/0000-0002-7181-0188	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054768] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-54768-04] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; BECKER J, 1995, J BIOL CHEM, V270, P11860, DOI 10.1074/jbc.270.20.11860; BEDDOW AL, 1995, P NATL ACAD SCI USA, V92, P3328, DOI 10.1073/pnas.92.8.3328; BELANGER KD, 1994, J CELL BIOL, V126, P619, DOI 10.1083/jcb.126.3.619; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; Bischoff FR, 1997, FEBS LETT, V419, P249, DOI 10.1016/S0014-5793(97)01467-1; BOGERD AM, 1994, J CELL BIOL, V127, P319, DOI 10.1083/jcb.127.2.319; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1995, P NATL ACAD SCI USA, V92, P7525, DOI 10.1073/pnas.92.16.7525; Doye V, 1997, CURR OPIN CELL BIOL, V9, P401, DOI 10.1016/S0955-0674(97)80014-2; Floer M, 1997, J BIOL CHEM, V272, P19538, DOI 10.1074/jbc.272.31.19538; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Gorlich D, 1996, CELL, V87, P21, DOI 10.1016/S0092-8674(00)81319-7; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; HARLOW E, 1988, ANTIBODIES LAB MANUA, P547; HIGUCHI R, 1989, PCR TECHNOLOGY PRINC, P65; Hood JK, 1998, J BIOL CHEM, V273, P35142, DOI 10.1074/jbc.273.52.35142; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Izaurralde E, 1998, RNA, V4, P351; KADOWAKI T, 1994, J CELL BIOL, V126, P649, DOI 10.1083/jcb.126.3.649; KAHANA JA, 1995, P NATL ACAD SCI USA, V92, P9707, DOI 10.1073/pnas.92.21.9707; Kehlenbach RH, 1999, J CELL BIOL, V145, P645, DOI 10.1083/jcb.145.4.645; Kenna MA, 1996, MOL CELL BIOL, V16, P2025; Koepp DM, 1996, J CELL BIOL, V133, P1163, DOI 10.1083/jcb.133.6.1163; Kunzler M, 1998, FEBS LETT, V433, P185, DOI 10.1016/S0014-5793(98)00892-8; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; LEE WC, 1989, P NATL ACAD SCI USA, V86, P8808, DOI 10.1073/pnas.86.22.8808; LOEB JDJ, 1993, MOL BIOL CELL, V4, P209, DOI 10.1091/mbc.4.2.209; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; OHASHI A, 1982, J BIOL CHEM, V257, P3042; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLENSTEDT G, 1995, EMBO J, V14, P5367, DOI 10.1002/j.1460-2075.1995.tb00221.x; Seedorf M, 1999, MOL CELL BIOL, V19, P1547; Sherman F, 1986, LAB COURSE MANUAL ME; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DB, 1991, CURRENT PROTOCOLS MO, V2; Solsbacher J, 1998, MOL CELL BIOL, V18, P6805, DOI 10.1128/MCB.18.11.6805; Taura T, 1997, J BIOL CHEM, V272, P31877, DOI 10.1074/jbc.272.50.31877; Taura T, 1998, P NATL ACAD SCI USA, V95, P7427, DOI 10.1073/pnas.95.13.7427; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; WENTE SR, 1992, J CELL BIOL, V119, P705, DOI 10.1083/jcb.119.4.705; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; WILKEN N, 1995, EUR J CELL BIOL, V68, P211; Wozniak RW, 1998, TRENDS CELL BIOL, V8, P184, DOI 10.1016/S0962-8924(98)01248-3; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; XIAO ZX, 1993, MOL CELL BIOL, V13, P4691, DOI 10.1128/MCB.13.8.4691; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; YANO R, 1994, P NATL ACAD SCI USA, V91, P6880, DOI 10.1073/pnas.91.15.6880; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	64	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1999	274	45					32360	32367		10.1074/jbc.274.45.32360	http://dx.doi.org/10.1074/jbc.274.45.32360			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	252ZL	10542277	hybrid			2022-12-25	WOS:000083532100085
J	Retondaro, FC; Costa, PCD; Pedrosa, RC; Kurtenbach, E				Retondaro, FC; Costa, PCD; Pedrosa, RC; Kurtenbach, E			Presence of antibodies against the third intracellular loop of the m2 muscarinic receptor in the sera of chronic chagasic patients	FASEB JOURNAL			English	Article						Trypanosoma cruzi; autoimmune disease; chagasic cardiomyopathy; G-protein-coupled receptors	IDIOPATHIC DILATED CARDIOMYOPATHY; FUNCTIONAL AUTOIMMUNE EPITOPE; PROTEIN-COUPLED RECEPTORS; TRYPANOSOMA-CRUZI; PATHOLOGICAL IMPLICATIONS; DISEASE; IGG	Patients in the chronic phase of Chagas' disease suffer from a slowly evolving inflammatory cardiomyopathy that can lead to severe cardiac dilatation, congestive heart failure, and death. This process appears to be caused by autoimmune recognition of heart tissue by a mononuclear cell infiltrate decades after infection with the parasite Trypanosoma cruzi, Recent evidence suggests that there are circulating antibodies in chronic chagasic patients that alter the physiological behavior of the heart on binding to G-protein-coupled cardiovascular receptors, including beta 1-adrenergic and m2 muscarinic receptors, A 42 kDa fusion protein was constructed that contains the central part of the third intracellular loop (i3; Arg(267)-Arg(381)) of the human m2 muscarinic receptor, linked to glutathione S-transferase, This fusion protein was overexpressed in Escherichia coli and subsequently purified by affinity chromatography, Based on Western blots, the i3 loop is specifically recognized by the sera of chronic chagasic patients who have reached advanced stages of cardiac failure (according to the Los Andes classification). Analysis of the prevalence and distribution of these antibodies shows a strong association between seropositive patients and moderate (group II) to severe (group III) heart dysfunction.-Retondaro, F. C., dos Santos Costa, P. C., Pedrosa, R. C., Kurtenbach, E. Presence of antibodies against the third intracellular loop of the m2 muscarinic receptor in the sera of chronic chagasic patients.	Univ Fed Rio de Janeiro, Dept Bioquim Med, Inst Ciencias Biomed, Ctr Ciencias Saude, BR-21941900 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Hosp Clementino Fraga Filho, Ctr Ciencias Saude, BR-21941900 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro	Kurtenbach, E (corresponding author), Univ Fed Rio de Janeiro, Dept Bioquim Med, Inst Ciencias Biomed, Ctr Ciencias Saude, Cidade Univ, BR-21941900 Rio De Janeiro, Brazil.	kurten@bioqmed.ufrj.br	Costa, Patrícia C dos S/AAL-9975-2020; Kurtenbach, Eleonora/L-4148-2016	Kurtenbach, Eleonora/0000-0002-2141-518X; dos Santos Costa, Patricia Cristina/0000-0003-0111-6980				Bohm SK, 1997, BIOCHEM J, V322, P1; BONNER TI, 1992, TRENDS PHARMACOL SCI, V13, P48, DOI 10.1016/0165-6147(92)90021-W; CARRASCO HA, 1983, TEXTOS U LOS ANDES C; CUNHANETO E, 1995, P NATL ACAD SCI USA, V92, P3541, DOI 10.1073/pnas.92.8.3541; deOliveira SF, 1997, CIRCULATION, V96, P2031, DOI 10.1161/01.CIR.96.6.2031; DOSSANTOS RR, 1992, J EXP MED, V175, P29, DOI 10.1084/jem.175.1.29; FERRARI I, 1995, J EXP MED, V182, P59, DOI 10.1084/jem.182.1.59; FU LX, 1993, J CLIN INVEST, V91, P1964, DOI 10.1172/JCI116416; FU MLX, 1994, CLIN IMMUNOL IMMUNOP, V72, P15, DOI 10.1006/clin.1994.1101; GOIN JC, 1994, J AUTONOM NERV SYST, V47, P45, DOI 10.1016/0165-1838(94)90064-7; GOIN JC, 1991, P SOC EXP BIOL MED, V197, P186, DOI 10.3181/00379727-197-43244; Goin JC, 1997, FASEB J, V11, P77, DOI 10.1096/fasebj.11.1.9034169; Goin Juan Carlos, 1994, Neuroimmunomodulation, V1, P284; Goin Juan Carlos, 1994, Molecular Neuropharmacology, V3, P189; MAGNUSSON Y, 1990, J CLIN INVEST, V86, P1658, DOI 10.1172/JCI114888; PETRY K, 1989, PARASITOL TODAY, V5, P111, DOI 10.1016/0169-4758(89)90052-5; RASSI A, 1982, DOENCAS INFECCIOSAS, V7; ROSENBAUM MB, 1994, J CARDIOVASC ELECTR, V5, P367, DOI 10.1111/j.1540-8167.1994.tb01174.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4	19	25	26	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1999	13	14					2015	2020		10.1096/fasebj.13.14.2015	http://dx.doi.org/10.1096/fasebj.13.14.2015			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	255GG	10544184				2022-12-25	WOS:000083660700013
J	Gazit, A; Yaniv, A; Bafico, A; Pramila, T; Igarashi, M; Kitajewski, J; Aaronson, SA				Gazit, A; Yaniv, A; Bafico, A; Pramila, T; Igarashi, M; Kitajewski, J; Aaronson, SA			Human frizzled 1 interacts with transforming Wnts to transduce a TCF dependent transcriptional response	ONCOGENE			English	Article						frizzled; Hfz; Wnt; TCF	BETA-CATENIN; SIGNALING PATHWAY; NEGATIVE REGULATOR; XENOPUS EMBRYOS; FAMILY; PROTEIN; WINGLESS; AXIN; EXPRESSION; HOMOLOG	The human homologue of fz1 (Hfz1) was cloned from a cDNA library. Hfz1 was shown to couple to Wnt signal transduction pathways by its ability to enhance Wnt induced TCF dependent transcription in both autocrine and paracrine modes. Enhanced TCF dependent signaling was dose dependent with respect to both Wnt-3A and Hfz1. Moreover, Hfz1 deletion mutants with truncated carboxy termini showed markedly reduced capacity to enhance Wnt signal transduction. Specificity was demonstrated with respect to signal transduction by different Wnts. While Wnt-3a, -3, -1 and to a lesser extent Wnt-2 cooperated with Hfz1 in the paracrine assay for TCF dependent signaling, neither Wnt-4, -5a, -5b, -6, -7a nor -7b did so, despite similar levels of expression. However, coimmunoprecipitation of Hfz1 with both Wnt-3a and Wnt-5a indicated that TCF dependent signaling in response to Wnts is not determined solely by their ability to bind the receptor. All of these findings provide strong evidence that Hfz1 is a functional partner for certain Wnts in inducing TCF dependent transcription.	CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Ctr Reprod Sci, New York, NY 10032 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Tel Aviv University; Sackler Faculty of Medicine; Columbia University; Columbia University	Aaronson, SA (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, Box 1130,1 Gustave L Levy Pl, New York, NY 10029 USA.				NCI NIH HHS [R01-CA71672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bafico A, 1998, ONCOGENE, V16, P2819, DOI 10.1038/sj.onc.1201797; Barnes MR, 1998, TRENDS PHARMACOL SCI, V19, P399, DOI 10.1016/S0165-6147(98)01246-2; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bienz M, 1998, CURR OPIN CELL BIOL, V10, P366, DOI 10.1016/S0955-0674(98)80013-6; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; BRADBURY JM, 1994, ONCOGENE, V9, P2597; Bullions Linda C., 1998, Current Opinion in Oncology, V10, P81, DOI 10.1097/00001622-199801000-00013; BURRUS LW, 1995, EXP CELL RES, V220, P363, DOI 10.1006/excr.1995.1327; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; Deardorff' MA, 1998, DEVELOPMENT, V125, P2687; DU SJ, 1995, MOL CELL BIOL, V15, P2625; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; JI TH, 1998, SCIENCE, V280, P1274; KENGAKU M, 1998, J BIOL CHEM, V273, P17299; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, MOL CELL BIOL, V18, P1248, DOI 10.1128/MCB.18.3.1248; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MIKI T, 1995, METHOD ENZYMOL, V254, P196; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; Porfiri E, 1997, ONCOGENE, V15, P2833, DOI 10.1038/sj.onc.1201462; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sagara N, 1998, BIOCHEM BIOPH RES CO, V252, P117, DOI 10.1006/bbrc.1998.9607; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Torres MA, 1996, J CELL BIOL, V133, P1123, DOI 10.1083/jcb.133.5.1123; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; Zhang J, 1998, DEVELOPMENT, V125, P3075	38	76	97	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 28	1999	18	44					5959	5966		10.1038/sj.onc.1202985	http://dx.doi.org/10.1038/sj.onc.1202985			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557084				2022-12-25	WOS:000083359100001
